"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,TW,B,TW I286435 B,053-161-566-811-882,2007-09-01,2007,TW 94131251 A,2005-09-12,TW 94131251 A,2005-09-12,Calibration mechanism of a scanning device,"A calibration mechanism of a scanning device including an assembly of a flexible connecter and a calibration strip and a limiting element is disclosed. The assembly of the flexible connecter and the calibration strip travels reciprocating motion, and the limiting element limits a vertical shift of the calibration strip. Because the calibration strip is placed in an anticipated position, the accuracy and the consistency of the calibration results for a scanning module of the scanner, which acquires data of a plurality of the scanning line of the calibration strip, are greatly improved.",AVISION INC,CHEN CLARK,,https://lens.org/053-161-566-811-882,Granted Patent,no,0,0,4,4,0,H04N1/401;;H04N1/401,,,0,0,,,,INACTIVE
2,WO,A1,WO 2017/134628 A1,198-819-360-934-736,2017-08-10,2017,IB 2017050613 W,2017-02-03,US 201662290737 P,2016-02-03,METHODS AND COMPOSITIONS FOR CULTURING STEM CELLS,The current disclosure relates to methods for isolating and culturing naïve embryonic stem cells that phenotypically resemble pre-implantation-derived stem cells. Also disclosed are therapeutic methods and compositions comprising such cells.,UNIV CALIFORNIA,CLARK AMANDER;;CHEN DI,,https://lens.org/198-819-360-934-736,Patent Application,yes,2,6,1,1,0,C12Q1/24;;C12N5/0606;;C12N2501/115;;C12N2501/16;;C12N2501/235;;C12N2501/727;;C12N2501/999;;G01N33/56966,C12N5/02;;C12N5/071;;C12N5/0735;;C12N5/074;;C12Q1/24;;G01N33/53,,0,0,,,,PENDING
3,CN,U,CN 202562076 U,024-297-076-293-606,2012-11-28,2012,CN 201220070913 U,2012-02-29,US 201161575020 P,2011-08-15,Gravity flow split type solar water heater,"The utility model discloses a gravity flow split type solar water heater, which relates to the technology field of solar industrial application. The gravity flow split type solar water heater comprises at least a heat separator, a plurality of complete glass solar heat collection vacuum tubes connected to the heat separator and an insulation water case connected to the at least one heat separator through at least two insulating pipes. An isolation apparatus is arranged in the cavity of the heat separator, and the cavity of the heat separator is divided into a first water chamber and a second water chamber by the isolation apparatus. According to the gravity flow split type solar water heater provided in the utility model, cold water entering a vacuum tube and hot water leaving the vacuum tube is separated, hot water is driven by the cold-hot water temperature difference water-power head to flow to the water case through the insulating pipes automatically, and no electric pump is required. Cold water in the water case automatically returns back to the cold water entrance of the heat separator through a backwater insulating pipe, and the water flow continuity is maintained.",CHENGJUN CHEN;;CLARK GORDON,CHENGJUN CHEN;;GORDON CLARK,,https://lens.org/024-297-076-293-606,Limited Patent,no,0,1,2,2,0,F28D20/021;;F28D20/021;;F24S10/45;;F24S10/45;;F24S23/74;;F24S23/74;;F24S80/30;;F24S80/30;;F24S90/10;;F24S90/10;;F28D2020/0078;;F28D2020/0078;;Y02E10/40;;Y02E10/44;;Y02E10/44;;Y02E60/14;;Y02E60/14;;Y02E70/30;;Y02E70/30;;Y02P80/20;;Y02P80/20,F24J2/46;;F24S10/30;;F24S10/40;;F24S10/70;;F24S90/00,,0,0,,,,EXPIRED
4,ES,U,ES 1229119 U,014-464-966-454-179,2019-05-07,2019,ES 201930063 U,2019-01-15,TW 107209179 U,2018-07-06,"RAPID RELEASE MECHANISM FOR REMOVABLE CONNECTION OF TWO OBJECTS (Machine-translation by Google Translate, not legally binding)","A quick release mechanism for releasably connecting a first object and a second object, comprising: a first base seat configured to be disposed on the first object and including a mounting portion having a first insertion hole; a second base seat configured to be arranged in the second object and including a fixed plate, and a first coupling rod projecting transversely from said fixed plate and inserted into said first insertion hole, said first coupling rod having one end coupling extending outside said first insertion hole; and a coupling unit including a securing cylinder mounted movably on said first base seat along an securing direction and a rotating member installed rotatably on said securing cylinder and having a first coupling portion, said rotatable member being operable to rotate relative to said securing cylinder between a coupling position, wherein said first coupling portion of said rotating member is coupled to said coupling end of said first coupling rod for connecting the first object and the second object, and a decoupling position, wherein said first coupling portion of said rotary member is decoupled from said coupling end of said first coupling rod to separate the first object and the second object from each other. (Machine-translation by Google Translate, not legally binding)",KARMA MEDICAL PROD CO LTD,CHEN CLARK;;YANG YAO-LUNG,,https://lens.org/014-464-966-454-179,Patent Application,no,0,0,3,3,0,,A61G5/10,,0,0,,,,ACTIVE
5,US,A1,US 2022/0222518 A1,177-076-289-204-792,2022-07-14,2022,US 202217709796 A,2022-03-31,US 202217709796 A,2022-03-31,DYNAMIC COMPENSATION OF ANALOG CIRCUITRY IMPAIRMENTS IN NEURAL NETWORKS,"Dynamic compensation of analog circuitry impairments in ANNs is provided. An example ANN includes an analog circuitry that performs MAC operations based on weights. To compensate analog circuitry impairments, a signal package including a training signal and an input signal, is formed. The training signal is fed into the ANN. The ANN generates an output signal through MAC operations by the analog circuitry with the training signal and the weights. The output signal is compared with a reference signal to determine an error in the output signal. The reference signal may include one or more ground-truth classifications of the training signal. The error is used to compute a compensation coefficient, which compensates impact of analog circuitry impairments on accuracy in outputs of the ANN. The ANN is updated with the compensation coefficient. The analog circuitry performs MAC operations with the input signal, the compensation coefficient, and the set of weights.",INTEL CORP,WANG HECHEN;;CHEN KUILIN CLARK,INTEL CORPORATION (2022-03-09),https://lens.org/177-076-289-204-792,Patent Application,yes,0,0,1,1,0,G06N3/084;;G06N3/065;;G06N3/045;;G06F7/5443;;G06V10/7747;;G06N3/065,G06N3/063;;G06F7/544;;G06V10/774,,0,0,,,,PENDING
6,US,A1,US 2007/0121764 A1,112-382-209-356-188,2007-05-31,2007,US 29036705 A,2005-11-30,US 29036705 A,2005-11-30,Frequency error estimation and correction in a SAIC linear equalizer,"Different from conventional equalizers, the output of an SAIC (Single Antenna Interference Cancellation) linear equalizer in GSM/EDGE wireless communication systems is a real signal combined from two real FIR (Finite Impulse Response) filter outputs. Each of the FIRs separately uses the real and imaginary components of the ½ π de-rotated received signal as input. The real-valued output of the SAIC equalizer creates difficulty to estimate and correct the frequency errors due to receiver LO and Doppler shift. Disclosed is an efficient and effective solution to the estimation and correction of the frequency error through an assistant signal generated by two additional FIR filters. The assistant signal and the SAIC equalizer output are used to estimate the frequency error, which is combined with the SAIC equalizer output and the assistant signal to give the frequency error corrected SAIC equalizer output.",FREESCALE SEMICONDUCTOR INC,CHEN WEIZHONG;;JARVIS CLARK H,APPLE INC (2011-04-11);;FREESCALE SEMICONDUCTOR INC (2005-11-15),https://lens.org/112-382-209-356-188,Patent Application,yes,7,38,2,2,0,H04L27/2271;;H04L27/2271;;H04L2027/0065;;H04L2027/0065,H04L27/06,375/340,0,0,,,,ACTIVE
7,US,B2,US 7539272 B2,176-575-550-581-218,2009-05-26,2009,US 29036705 A,2005-11-30,US 29036705 A,2005-11-30,Frequency error estimation and correction in a SAIC linear equalizer,"Different from conventional equalizers, the output of an SAIC (Single Antenna Interference Cancellation) linear equalizer in GSM/EDGE wireless communication systems is a real signal combined from two real FIR (Finite Impulse Response) filter outputs. Each of the FIRs separately uses the real and imaginary components of the ½ π de-rotated received signal as input. The real-valued output of the SAIC equalizer creates difficulty to estimate and correct the frequency errors due to receiver LO and Doppler shift. Disclosed is an efficient and effective solution to the estimation and correction of the frequency error through an assistant signal generated by two additional FIR filters. The assistant signal and the SAIC equalizer output are used to estimate the frequency error, which is combined with the SAIC equalizer output and the assistant signal to give the frequency error corrected SAIC equalizer output.",FREESCALE SEMICONDUCTOR INC,CHEN WEIZHONG;;JARVIS CLARK H,APPLE INC (2011-04-11);;FREESCALE SEMICONDUCTOR INC (2005-11-15),https://lens.org/176-575-550-581-218,Granted Patent,yes,7,6,2,2,0,H04L27/2271;;H04L27/2271;;H04L2027/0065;;H04L2027/0065,H04L27/06,375/340,0,0,,,,ACTIVE
8,ES,Y,ES 1229119 Y,127-070-095-090-132,2019-07-26,2019,ES 201930063 U,2019-01-15,TW 107209179 U,2018-07-06,MECANISMO DE LIBERACION RAPIDA PARA CONEXION DESMONTABLE DE DOS OBJETOS,,KARMA MEDICAL PROD CO LTD,CHEN CLARK;;YANG YAO-LUNG,,https://lens.org/127-070-095-090-132,Limited Patent,no,0,0,3,3,0,,A61G5/10,,0,0,,,,ACTIVE
9,US,A1,US 2021/0346692 A1,007-303-044-730-260,2021-11-11,2021,US 201917250735 A,2019-08-29,US 201917250735 A;;US 201862724177 P;;US 2019/0048858 W,2018-08-29,DEVICES AND METHODS FOR TREATMENT OF TUMORS USING ELECTROMAGNETIC SIGNAL,"Systems and methods for treating cancerous tumors (including glioblastoma multiforme (GBM)) with electrotherapy, such as deep brain stimulation (DBS) technology, as disclosed herein. One or more configurations can be generated based on a patients tumor characteristics. The selected configurations can be electrode configurations or settings for an electrical source coupled to the electrodes. The one or more configurations can be targeted for inhibiting cell growth process, such as to inhibit mitosis, immune suppression, or to inhibit DNA replication. Inhibition of cell growth processes can initiate death of the cancerous cells.",UNIV MINNESOTA,CHEN CLARK C;;MOLNAR GREGORY FREDERICK,REGENTS OF THE UNIVERSITY OF MINNESOTA (2021-04-08),https://lens.org/007-303-044-730-260,Patent Application,yes,1,1,4,4,0,A61N1/05;;A61B2576/026;;A61B5/4848;;A61B5/4064;;A61B5/0042;;A61B5/6868;;A61B2018/00321;;A61B2018/00482;;A61B2018/00565;;A61B2018/00577;;A61B18/1206;;A61B18/14;;A61N1/40;;G16H30/40;;B33Y80/00;;A61N1/36002;;A61N1/0534;;A61N1/36171;;A61N1/37211;;A61N1/40,A61N1/36;;A61N1/05;;A61N1/372;;A61N1/40;;B33Y80/00,,0,0,,,,ACTIVE
10,WO,A1,WO 2022/051279 A1,055-799-632-448-416,2022-03-10,2022,US 2021/0048444 W,2021-08-31,US 202063073761 P,2020-09-02,PHOTOSENSITIZER COMBINATION,"Methods for making disinfecting compositions based on phototherapy, systems for use in disinfecting with a combination of photosensitizers, and the disinfecting compositions themselves, are described. Concentrations of the photosensitizers can be based on the particular light source and the wavebands or fluence rates emitted by the light source for maximum singlet oxygen generation. Concentrations of the photosensitizers can also be based on the quantum yield of the photosensitizers.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,,https://lens.org/055-799-632-448-416,Patent Application,yes,3,0,2,2,0,A61L2/088;;A61L2/088;;A61L2/26;;A61L2202/11;;G01N21/314;;C09B67/0033,A61K41/00;;A61N5/06;;C09K11/06,,0,0,,,,PENDING
11,WO,A1,WO 2022/040440 A1,175-832-883-925-347,2022-02-24,2022,US 2021/0046722 W,2021-08-19,US 202063068762 P;;US 202063074640 P;;US 202117389936 A,2020-08-21,INVISIBLE SINGLET FILM,"Antimicrobial films for generating singlet oxygen and their use is described. The antimicrobial films are generally thin films having two surfaces or faces. The first surface of the film is adhesive. Various adhesives, including, electrostatic charges, are possible. The second surface faces in a direction opposite from the first surface. The second surface of the film emits singlet oxygen when activated by light or ultrasound. Various photosensitizers can be incorporated onto the second surface of the films for generating the singlet oxygen. The singlet oxygen and other radical species generated from the antimicrobial films diffuses out from and in proximity to the films to form a layer or cloud of singlet oxygen at a concentration sufficient to inactivate microbial particles, e.g., viruses and other pathogens, that come within the singlet oxygen layer to provide a protective zone against microbial particles.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,,https://lens.org/175-832-883-925-347,Patent Application,yes,6,0,2,5,0,A01N25/34;;A61N5/062;;A61N5/0624;;A61N2005/0645;;A61N2005/0647;;A61N2005/0657;;A61N2005/0651;;A61N2005/0654;;A61K9/7007;;A61K41/0057;;A61N7/00;;A61B2017/00154;;A61N2007/0034;;A61L2/0076;;A61L2/088;;A61L2/025;;A61K41/0057;;A61K41/0028;;A61K9/7007;;A61N2007/0004;;A01P1/00;;A61N5/062;;A61N5/0624;;A61N7/00;;A61L2202/26;;A01N25/34,A01N25/34;;A01N31/08,,0,0,,,,PENDING
12,US,A,US 5008824 A,008-994-360-218-05X,1991-04-16,1991,US 36800189 A,1989-06-19,US 36800189 A,1989-06-19,Hybrid air charge calculation system,"A hybrid air charge calculation system for an internal combustion engine in which the air charge is obtained by using either the mass airflow sensor readings or the engine speed and throttle angle information. A decision logic selects either means based on the engine speed, throttle angle, and the mass airflow rate.",FORD MOTOR CO,CLARK WALTER F;;CHEN BOR-DONG,VISTEON GLOBAL TECHNOLOGIES INC (2000-06-15);;FORD MOTOR COMPANY (1989-06-12),https://lens.org/008-994-360-218-05X,Granted Patent,yes,9,15,3,3,0,F02D41/18;;F02D41/187;;F02D41/28;;F02D2200/0402;;F02D2200/0404;;F02D41/28;;F02D41/18;;F02D2200/0404;;F02D2200/0402;;F02D41/187,F02D41/18;;F02D41/24;;F02D45/00,364/431.05;;364/510;;73/118.2,0,0,,,,EXPIRED
13,CN,B,CN 101452317 B,037-314-735-953-393,2012-04-25,2012,CN 200810176672 A,2008-11-14,US 1206407 P,2007-12-07,Foldable electronic apparatus with an enhanced pivotal mechanism,"The present invention provides a foldable electronic apparatus and an actuation structure of dual-mode, the actuation structure is used in the foldable electronic apparatus, the foldable electronic apparatus mainly includes a first casing and a second casing unfolded each other; a pivot pivotally connected to the first casing and the second casing; a first cover pivotally connected to the first casing; a first cam, pivotally connected to the first casing in a place between the first casing and the first cover; and a first driving element, connected to the main pivot and the first cam; wherein, when the first casing is unfolded from the second casing through the main pivot, the main pivot rotates to drive the first driving element to rotate the first cam, and then the first cover is unfolded from the first casing. Thereby the actuation structure may coordinate with unfolding and folding states of the foldable electronic apparatus, correspondingly the cover plate may have two structure states.",ASUSTEK COMP INC,TIMOTHY CLARK PETER;;KUAN-TING CHEN,,https://lens.org/037-314-735-953-393,Granted Patent,no,0,0,6,6,0,G06F1/183;;G06F1/183;;G06F1/1616;;G06F1/1616;;G06F1/1637;;G06F1/1637;;G06F1/166;;G06F1/166;;G06F1/1684;;G06F1/1684,G06F1/16;;H05K5/00,,0,0,,,,ACTIVE
14,US,A1,US 2012/0132195 A1,151-465-657-627-912,2012-05-31,2012,US 201113334404 A,2011-12-22,US 201113334404 A;;US 201161575020 P,2011-08-15,Convection Driven Two-Component Solar Water Heater Using All-Glass Evacuated Tubes with a Heat Separator,"A solar water heater including a heat separator containing either a single partition wall that connects in parallel colder water entering all-glass evacuated tubes with hotter water exiting the same all-glass evacuated tubes, or a number of partition walls that connect in series colder water entering each all-glass evacuated tube with hotter water exiting each all-glass evacuated tube. As water in the evacuated tubes is heated by solar radiation, a hydrodynamic head is created which forces the hot water in the evacuated tubes to flow automatically into the hot water compartment(s) of the heat separator(s) and subsequently through an insulated pipe to a water tank without requiring a pump. The cool water in the water tank flows automatically through an insulated pipe back into the cool water compartment(s) of the heat separator(s) in order to preserve flow continuity.",CHEN CHENGJUN JULIAN;;GORDON CLARK THEODORE,CHEN CHENGJUN JULIAN;;GORDON CLARK THEODORE,CHEN LABORATORIES INC (2012-05-20),https://lens.org/151-465-657-627-912,Patent Application,yes,0,10,2,2,0,F28D20/021;;F28D20/021;;F24S10/45;;F24S10/45;;F24S23/74;;F24S23/74;;F24S80/30;;F24S80/30;;F24S90/10;;F24S90/10;;F28D2020/0078;;F28D2020/0078;;Y02E10/40;;Y02E10/44;;Y02E10/44;;Y02E60/14;;Y02E60/14;;Y02E70/30;;Y02E70/30;;Y02P80/20;;Y02P80/20,F24J2/04;;F24J2/34;;F24S10/30;;F24S10/40;;F24S10/70;;F24S90/00,126/610;;126/640;;126/641;;126/618,0,0,,,,DISCONTINUED
15,EP,A1,EP 0404392 A1,180-349-939-830-461,1990-12-27,1990,EP 90306195 A,1990-06-07,US 36800189 A,1989-06-19,Air charge calculation system.,"An apparatus for determining the amount of air charge in an internal combustion engine including, a memory means (12) including decision logic means (100) for deciding to determine air charge using either a mass airflow sensor mode or a speed throttle mode of calculation, a throttle angle sensor means (15) coupled to said memory means (12), an engine revolution sensor means (16) coupled to said memory means (12), a mass airflow sensor means (17) coupled to said memory means (12), a microprocessor unit (10) coupled to said memory means for using data from said throttle angle sensor means, engine revolution sensor means, and mass airflow means in connection with said decision logic means to determine air charge using either a mass airflow sensor mode or a speed throttle mode of calculation, and a timer means (19) coupled to said microprocessor means. The invention also discloses a method of determining air charge into an internal combustion engine.  ",FORD MOTOR CO;;FORD FRANCE;;FORD WERKE AG,CLARK WALTER FRANKLIN;;CHEN BOR-DONG,,https://lens.org/180-349-939-830-461,Patent Application,yes,4,5,3,3,0,F02D41/18;;F02D41/187;;F02D41/28;;F02D2200/0402;;F02D2200/0404;;F02D41/28;;F02D41/18;;F02D2200/0404;;F02D2200/0402;;F02D41/187,F02D41/18;;F02D41/24;;F02D45/00,,2,0,,,"PATENT ABSTRACTS OF JAPAN, vol. 6, no. 130 (M-143), 16th July 1982; & JP-A-57 056 632 (HITACHI LTD) 05-04-1982;;PATENT ABSTRACTS OF JAPAN, vol. 6, no. 17 (M-109)[895], 30th January 1982; & JP-A-56 135 728 (HITACHI SEISAKUSHO K.K.) 23-10-1981",DISCONTINUED
16,TW,A,TW 200925832 A,190-395-576-342-353,2009-06-16,2009,TW 97143982 A,2008-11-14,US 1206407 P,2007-12-07,Foldable portable electronic device and dual mode enable structure of thereof,"A foldable portable electronic device and a dual mode enable structure of thereof are disclosed. The dual mode enable structure is applied to the foldable portable electronic device, which includes a first body and a second body foldably connected to the first body. When the first body and the second body lifted from each other, a pivotal shaft drives a cam to rotate via a transmission mechanism. A cover is driven to be lifted from the first body or the second body.",ASUSTEK COMP INC,CHEN KUAN-TING;;CLARK PETER TIMOTHY,,https://lens.org/190-395-576-342-353,Patent of Addition,no,0,1,6,6,0,G06F1/183;;G06F1/183;;G06F1/1616;;G06F1/1616;;G06F1/1637;;G06F1/1637;;G06F1/166;;G06F1/166;;G06F1/1684;;G06F1/1684,G06F1/16,,0,0,,,,ACTIVE
17,US,A1,US 2022/0054667 A1,171-615-373-177-821,2022-02-24,2022,US 202117389936 A,2021-07-30,US 202117389936 A;;US 202063074640 P;;US 202063068762 P,2020-08-21,INVISIBLE SINGLET FILM,"Antimicrobial films for generating singlet oxygen and their use is described. The antimicrobial films are generally thin films having two surfaces or faces. The first surface of the film is adhesive. Various adhesives, including, electrostatic charges, are possible. The second surface faces in a direction opposite from the first surface. The second surface of the film emits singlet oxygen when activated by light or ultrasound. Various photosensitizers can be incorporated onto the second surface of the films for generating the singlet oxygen. The singlet oxygen and other radical species generated from the antimicrobial films diffuses out from and in proximity to the films to form a layer or cloud of singlet oxygen at a concentration sufficient to inactivate microbial particles, e.g., viruses and other pathogens, that come within the singlet oxygen layer to provide a protective zone against microbial particles.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/171-615-373-177-821,Patent Application,yes,2,1,2,5,0,A01N25/34;;A61N5/062;;A61N5/0624;;A61N2005/0645;;A61N2005/0647;;A61N2005/0657;;A61N2005/0651;;A61N2005/0654;;A61K9/7007;;A61K41/0057;;A61N7/00;;A61B2017/00154;;A61N2007/0034;;A61L2/0076;;A61L2/088;;A61L2/025;;A61K41/0057;;A61K41/0028;;A61K9/7007;;A61N2007/0004;;A01P1/00;;A61N5/062;;A61N5/0624;;A61N7/00;;A61L2202/26;;A01N25/34,A61L2/00;;A01N25/34;;A01P1/00;;A61K9/70;;A61K41/00;;A61L2/025;;A61L2/08;;A61N5/06;;A61N7/00,,0,0,,,,DISCONTINUED
18,TW,B,TW I352277 B,086-969-477-843-021,2011-11-11,2011,TW 97143982 A,2008-11-14,US 1206407 P,2007-12-07,Foldable portable electronic device and dual mode,,ASUSTEK COMP INC,CHEN KUAN TING;;PETER TIMOTHY CLARK,,https://lens.org/086-969-477-843-021,Granted Patent,no,0,3,6,6,0,G06F1/183;;G06F1/183;;G06F1/1616;;G06F1/1616;;G06F1/1637;;G06F1/1637;;G06F1/166;;G06F1/166;;G06F1/1684;;G06F1/1684,,,0,0,,,,ACTIVE
19,TW,A,TW 201033791 A,139-368-442-243-138,2010-09-16,2010,TW 98108088 A,2009-03-12,TW 98108088 A,2009-03-12,Foldable electronic equipment,"The invention provides a foldable electronic equipment which has a hinge apparatus adapted to pivot a first body and a second body. The hinge apparatus includes a pair of foldable hinge portions where each hinge portion is divided into a first connection portion and a second connection portion by a folded line thereon. The first connection portion connects with the first body, and the second connection portion connects with the second body. The hinge apparatus has a quite simplified structure which reduces fabrication cost effectively and is easy for assembly and maintenance.",ASUSTEK COMP INC,CLARK PETER TIMOTHY;;LIU HUAN-CHEN,,https://lens.org/139-368-442-243-138,Patent of Addition,no,0,1,4,4,0,G06F1/1681;;H04M1/0216;;G06F1/1681;;H04M1/0216,G06F1/16,,0,0,,,,ACTIVE
20,US,B2,US 8134829 B2,029-191-731-107-686,2012-03-13,2012,US 72207510 A,2010-03-11,TW 98108088 A,2009-03-12,Foldable electronic device,"The invention discloses a foldable electronic device having a folding module pivotally connected to a first body and a second body. The folding module has at least one folding member with a first connecting portion and a second connecting portion defined thereon, wherein the first connecting portion and the second connecting portion are foldable along a first folding line defined there between, and the first connecting portion and the second connecting portion are connected to the first body and the second body respectively. With such, the structure of the folding module is simplified, the cost is reduced and the folding module is also easy to be assembled and repaired.",CLARK PETER TIMOTHY;;LIU HUAN-CHEN;;ASUSTEK COMP INC,CLARK PETER TIMOTHY;;LIU HUAN-CHEN,ASUSTEK COMPUTER INC (2010-02-17),https://lens.org/029-191-731-107-686,Granted Patent,yes,11,4,4,4,0,G06F1/1681;;H04M1/0216;;G06F1/1681;;H04M1/0216,G06F1/16,361/679.26;;345/647;;455/575.8;;16/382,0,0,,,,ACTIVE
21,US,A1,US 2009/0032812 A1,166-216-728-445-508,2009-02-05,2009,US 88807207 A,2007-07-31,US 88807207 A,2007-07-31,Microelectronic device,A microelectronic device includes a thin film transistor having an oxide semiconductor channel and an organic polymer passivation layer formed on the oxide semiconductor channel.,HERMAN GREGORY;;CLARK BENJAMIN;;CHEN ZHIZHANG,HERMAN GREGORY;;CLARK BENJAMIN;;CHEN ZHIZHANG,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2007-07-30),https://lens.org/166-216-728-445-508,Patent Application,yes,7,19,2,2,0,H01L21/02554;;H01L21/02565;;H01L21/02631;;H01L21/02667;;H01L29/7869;;H01L21/02118;;H01L21/312;;H01L21/02118;;H01L21/02631;;H01L21/02667;;H01L29/7869;;H01L21/02554;;H01L21/02565,H01L21/34;;H01L29/24,257/43;;438/104;;X257E291;;X257E2146,0,0,,,,ACTIVE
22,US,B2,US 11623085 B2,195-233-358-848-911,2023-04-11,2023,US 201917250735 A,2019-08-29,US 201917250735 A;;US 201862724177 P;;US 2019/0048858 W,2018-08-29,Devices and methods for treatment of tumors using electromagnetic signal,"Systems and methods for treating cancerous tumors (including glioblastoma multiforme (GBM)) with electrotherapy, such as deep brain stimulation (DBS) technology, as disclosed herein. One or more configurations can be generated based on a patients tumor characteristics. The selected configurations can be electrode configurations or settings for an electrical source coupled to the electrodes. The one or more configurations can be targeted for inhibiting cell growth process, such as to inhibit mitosis, immune suppression, or to inhibit DNA replication. Inhibition of cell growth processes can initiate death of the cancerous cells.",UNIV MINNESOTA,CHEN CLARK C;;MOLNAR GREGORY FREDERICK,REGENTS OF THE UNIVERSITY OF MINNESOTA (2021-04-08),https://lens.org/195-233-358-848-911,Granted Patent,yes,20,0,4,4,0,A61N1/05;;A61B2576/026;;A61B5/4848;;A61B5/4064;;A61B5/0042;;A61B5/6868;;A61B2018/00321;;A61B2018/00482;;A61B2018/00565;;A61B2018/00577;;A61B18/1206;;A61B18/14;;A61N1/40;;G16H30/40;;B33Y80/00;;A61N1/36002;;A61N1/0534;;A61N1/36171;;A61N1/37211;;A61N1/40,A61N1/05;;A61N1/36;;A61N1/372;;A61N1/40;;B33Y80/00,,11,9,097-696-132-936-095;;026-236-498-924-897;;098-823-795-161-10X;;141-231-201-541-729;;118-724-956-399-259;;028-981-833-063-784;;071-834-366-473-571;;087-756-699-358-918;;013-555-297-557-652,22608262;;10.1016/j.ejca.2012.04.011;;10.3410/f.717957721.793462124;;28544575;;pmc5463092;;10.1002/cam4.1095;;pmc5467909;;10.1371/journal.pone.0179214;;28604803;;17551011;;pmc1886002;;10.1073/pnas.0702916104;;26059434;;10.18632/oncotarget.3996;;pmc4494902;;26670971;;10.1001/jama.2015.16669;;10.1001/jama.2014.12146;;10.1001/2013.jamaneurol.45;;23407652;;10.21037/cco.2017.06.29;;28841803;;26736813;;10.1109/embc.2015.7318913,"International Preliminary Report on Patentability, International Application No. PCT/US2019/048858, dated Mar. 11, 2021, 9 pages.;;International Search Report, International Application No. PCT/US2019/048858, dated Jan. 2, 2020, 12 pages.;;Stupp et al., “NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.” Eur J Cancer. Sep. 2012;48(14):2192-202. doi: 10.1016/j.ejca.2012.04.011. Epub May 18, 2012.;;Lok et al., “Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma.” Cancer Med. Jun. 2017;6(6): 1286-1300. doi: 10.1002/cam4.1095. Epub May 23, 2017.;;Korshoej Ar “Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study.” PLoS One. Jun. 12, 2017;12(6):e0179214. doi: 10.1371/journal.pone.0179214. eCollection 2017.;;Kirson Ed “Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors.” Proc Natl Acad Sci USA. Jun. 12, 2007; 104(24):10152-7. Epub Jun. 5, 2007.;;Shen Y, “Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition.” Oncotarget. May 20, 2015;6(14):11751-67.;;Stupp, “Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.” JAMA. Dec. 15, 2015;314(23):2535-43. doi: 10.1001/jama.2015.16669.;;Miocinovic S, “History, applications, and mechanisms of deep brain stimulation.” JAMA Neurol. Feb. 2013;70(2):163-71. doi: 10.1001/2013.jamaneurol.45.;;Zhu P, “Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.” Chin Clin Oncol. Aug. 2017;6(4):41. doi: 10.21037/cco.2017.06.29.;;Wenger C, “Modeling Tumor Treating fields (TTFields) application within a realistic human head model.” Conf Proc IEEE Eng Med Biol Soc. 2015;2015:2555-8. doi: 10.1109/EMBC.2015.7318913.",ACTIVE
23,US,B2,US 11612669 B2,002-823-618-608-473,2023-03-28,2023,US 202117405900 A,2021-08-18,US 202117405900 A;;US 202063068762 P;;US 202063074280 P,2020-08-21,Disinfection method and apparatus,"Photosensitizers are incorporated into articles, such a personal protective equipment. A method of applying continuous and consistent light includes fitting the articles with light sources and optical fibers to apply light to the areas of the articles incorporated with the photosensitizers. Photosensitizers can be applied to articles by various applicators in either a gel or solution. A gel can be particularly effective when used on hydrophobic surfaces. Photodynamic reactor systems can be used to determine the effective doses of photosensitizers and the light dosimetry which can then be applied for use with the articles.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/002-823-618-608-473,Granted Patent,yes,90,0,3,5,0,A41D31/30;;A41D13/1192;;A41D13/12;;A41D19/015;;A61L2/088;;A61L2/232;;A61L2202/26;;A61L2/088;;A61L31/12;;A61L31/16;;A41D13/1192;;A41D13/0002;;A41D13/12;;A61L2202/14;;A61L2/28;;A61L2/084;;A61L2101/44;;A61L2202/11;;A61L2202/122;;A61L2202/26;;A61L2/18,A61L2/08;;A41D13/00;;A41D13/11;;A41D13/12;;A61L2/18;;A61L2/28;;A61L31/12;;A61L31/16;;A61L101/44,,73,52,071-315-468-972-414;;055-611-002-759-124;;147-739-746-094-573;;058-214-960-300-659;;032-374-355-070-495;;056-184-862-634-367;;042-023-960-529-83X;;036-999-860-923-650;;000-409-973-377-909;;027-268-121-505-214;;046-415-043-790-959;;033-466-657-266-228;;040-094-909-340-017;;058-131-308-191-718;;017-214-137-653-709;;005-688-265-382-690;;015-383-164-780-775;;046-608-698-175-106;;037-210-407-450-571;;029-694-646-332-779;;041-401-243-694-823;;058-195-152-855-719;;019-980-133-493-942;;115-394-470-241-357;;013-514-292-332-752;;005-146-572-303-773;;004-603-966-374-149;;017-589-172-330-383;;066-896-390-438-883;;024-668-409-019-008;;165-313-740-952-121;;002-076-612-988-747;;027-369-533-036-285;;029-970-078-876-361;;011-091-787-318-51X;;104-735-392-666-045;;021-550-417-090-442;;079-481-920-229-614;;025-362-344-749-265;;091-819-263-711-397;;078-363-993-200-384;;105-490-966-873-865;;013-124-195-476-566;;015-149-066-563-085;;004-618-619-277-709;;058-244-677-368-129;;019-055-342-526-925;;015-986-570-318-191;;033-515-425-498-28X;;006-233-231-990-589;;151-236-689-453-284;;096-826-407-988-334,10.4209/aaqr.2010.12.0105;;10.1172/jci81532;;pmc4563760;;26168222;;10.1039/c2jm31987j;;10.1039/c3sc53186d;;10.1039/b905495b;;10.1001/jama.1969.03150160032007;;10.1001/jama.207.3.520;;5818213;;10.1016/j.pdpdt.2016.06.011;;27375182;;16464894;;10.1093/jac/dkl021;;10.1038/ijos.2012.63;;23222991;;pmc3633065;;10.4103/jisp.jisp_157_17;;pmc5803877;;29440788;;22368354;;pmc3283927;;10.4103/0972-124x.92563;;10.4172/2153-2435.1000403;;30929100;;10.1007/s10103-019-02774-9;;pmc2763101;;10.3390/md7030268;;19841715;;pmc7168192;;31906034;;10.3390/antibiotics9010013;;pmc7139796;;10.3390/cancers12030545;;32120810;;31658786;;pmc6963634;;10.3390/vaccines7040144;;31471148;;10.1016/j.vaccine.2019.08.037;;29678452;;10.1016/j.ajic.2018.02.018;;pmc7115285;;29033339;;10.1016/j.tim.2017.09.007;;pmc5777272;;28724343;;10.1080/14760584.2017.1357471;;pmc4724431;;25595808;;10.1016/bs.pmbts.2014.10.012;;10.1016/j.vaccine.2013.11.036;;24262313;;pmc3906608;;22664163;;10.1016/j.jaci.2012.03.050;;21779206;;pmc3132980;;10.1159/000323786;;pmc2953188;;10.1128/jvi.00502-10;;20739541;;20692307;;pmc2975779;;10.1016/j.jconrel.2010.07.125;;20375174;;pmc2876658;;10.1128/jvi.02690-09;;10.1128/cvi.00353-09;;pmc2815535;;20007362;;19768415;;10.1007/978-3-540-92165-3_18;;pmc2904604;;10.1371/journal.ppat.1000138;;pmc2516931;;18769719;;10.1073/pnas.0601932103;;16617103;;pmc1436023;;8896540;;10.1093/infdis/174.supplement_3.s324;;10.5812/jamm.96149;;10.1111/iej.13057;;30548497;;10.1021/ja00351a001;;17177354;;10.1021/ja066739b;;10.1039/b926014p;;20571680;;24885074;;pmc4234451;;10.1021/jp503149x;;10.1038/s41467-018-05223-3;;30022060;;pmc6052022;;25155698;;10.1039/c4cp02439g;;pmc6698391;;10.1021/acsami.8b09439;;29972022;;10.1155/2019/2584686;;pmc6399532;;30915256;;pmc3812664;;10.1021/es303645n;;23075418;;10.1021/acsabm.0c00114;;35025286;;27069623;;10.1186/s13756-016-0111-x;;pmc4827199;;pmc4187643;;25278571;;10.1128/cmr.00020-14;;10.1186/s40560-015-0120-5;;26693023;;pmc4676153;;24286078;;10.1155/2013/429780;;pmc3830765;;10.1186/2191-0855-3-59;;pmc3851522;;24090112;;10.1155/2012/302029;;22011544;;10.1086/662377,"Chen, James, et al., “Vaccine Generation,” U.S. Appl. No. 17/244,610, filed Apr. 29, 2021, 19 pages.;;Chen, James, et al., “Antimicrobial Preventive Netting,” U.S. Appl. No. 17/244,688, filed Apr. 29, 2021, 35 pages.;;Shen, James, et al., “Photosensitizer Combination,” U.S. Appl. No. 17/463,245, filed Aug. 31, 2021, 46 pages.;;Chen, James, et al., “Invisible Singlet Film,” U.S. Appl. No. 17/389,936, filed Jul. 30, 2021, 33 pages.;;International Search Report and Written Opinion dated Nov. 8, 2021, issued in International Application No. PCT/US2021/046416, filed Aug. 18, 2021, 9 pages.;;Lee, Im-Soon, et al. “Aerosol particle size distribution and genetic characteristics of aerosolized influenza A H1N1 virus vaccine particles.” Aerosol and Air Quality Research 11.3 (2011): 230-237.;;Meyer, Michelle, et al. “Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.” The Journal of clinical investigation 125.8 (2015): 3241-3255.;;Noimark, Sacha, et al. “Incorporation of methylene blue and nanogold into polyvinyl chloride catheters; a new approach for light-activated disinfection of surfaces.” Journal of Materials Chemistry. 2012; 22(30): 15388-15396. <https://doi.org/10.1039/C2JM31987J>, 1 page.;;Noimark, Sacha, Elaine Allan, and Ivan P. Parkin. “Light-activated antimicrobial surfaces with enhanced efficacy induced by a dark-activated mechanism.” Chemical Science 5.6 (2014): 2216-2223.;;Piccirillo, Clara, et al. “Antimicrobial activity of methylene blue and toluidine blue O covalently bound to a modified silicone polymer surface.” Journal of Materials Chemistry 19.34 (2009): 6167-6171.;;Fecht, S., “The First Fully 3-D Printed LEDs Are Here,” 2014, <https://www.popsci.com/article/technology/first-fully-3-d-printed-leds-are-here/> [Accessed Mar. 24, 2020], 8 pages.;;Waldman, Robert H., John J. Mann, and Parker A. Small. “Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine.” Jama 207.3 (1969): 520-524. doi:10.1001/jama.1969.03150160032007, 1 page.;;Fracalossi C, Nagata JY, Pellosi DS, et al. Singlet oxygen production by combining erythrosine and halogen light for photodynamic inactivation of Streptococcus mutans. Photodiagnosis and Photodynamic Therapy. 2016;15:127-132. https://search.datacite.org/works/10.1016/j.pdpdt.2016.06.011. doi: 10.1016/j.pdpdt.2016.06.011, 1 page.;;Wood S, Metcalf D, Devine D, Robinson C. Erythrosine is a potential photosensitizer for the photodynamic therapy of oral plaque biofilms. Journal of antimicrobial chemotherapy. 2006;57(4):680-684.;;Lee Y, Park H, Lee J, Seo H, Lee S. The photodynamic therapy on Streptococcus mutans biofilms using erythrosine and dental halogen curing unit. International journal of oral science. 2012;4(4):196-201.;;Bhat M, Acharya S, Prasad K, Kulkarni R, Bhat A, Bhat D. Effectiveness of erythrosine-mediated photodynamic antimicrobial chemotherapy on dental plaque aerobic microorganisms: A randomized controlled trial. Journal of Indian Society of Periodontology. 2017;21(3):210-215.;;Koshi E, Mohan A, Rajesh S, Philip K. Antimicrobial photodynamic therapy: An overview. Journal of Indian Society of Periodontology. 2011;15(4):323-327.;;Akira Nakatsuma KK. Commentary on the phototoxicity and absorption of vitamin B2 and its degradation product, lumichrome. Pharmaceutica analytica acta. 2015;6(8). doi: 10.4172/2153-2435.1000403.;;Makdoumi K, Hedin M, Bäckman A. Different photodynamic effects of blue light with and without riboflavin on methicillin-resistant Staphylococcus aureus (MRSA) and human keratinocytes in vitro. Lasers Med Sci. 2019;34(9):1799-1805.;;Henneberry, B. How Surgical Masks are Made. Thomas Industry.<https://www.thomasnet.com/articles/other/how-surgical-masks-are-made/>[Accessed Mar. 21, 2020].;;Clear Polypropylene Omnexus: The material selection platform.<https://omnexus.specialchem.com/centers/clear-polypropylene> [Accessed Mar. 21, 2020].;;Almeida, A , et al. “Phage Therapy and Photodynamic Therapy: Low Environmental Impact Approaches to Inactivate Microorganisms in Fish Farming Plants,” Marine Drugs 7(3): pp. 268-313, 2009.;;Hasenleitner, M., et al. “In the Right Light: Photodynamic Inactivation of Microorganisms Using a LED-Based Illumination Device Tailored for the Antimicrobial Application,” Antibiotics 9(1 ): pp. 1-13, 2020.;;Trempolec, N., et al. “Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.” Cancers 12.3 (2020): 545.;;Weaver, E.A. “Dose Effects of Recombinant Adenovirus Immunization in Rodents,” Vaccines 7(4):144 pp. 1-11, 2019.;;Hankaniemi, M.M., et al. “A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a coxsackievirus B1 vaccine,” Vaccine 37: pp. 5962-5971, 2019.;;Mills, D., et al. “Ultraviolet germicidal irradiation of influenza-contaminated N95 filtering facepiece respirators,” AJIC American Journal of Infection Control 46(7): pp. e49-e55, 2018.;;Bull, J.J., et al. “Transmissible Viral Vaccines,” Trends in Microbiology 26(1): pp. 6-15, Jan. 2018.;;Barrett, P.N., et al. “Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases,” Expert Review of Vaccines 16(9): pp. 883-894, 2017.;;Klasse, P.J. “Molecular determinants of the ratio of inert to infectious virus particles,” Progress in Molecular Biology and Translational Science 129: pp. 285-326, 2015.;;Klausberger, M. et al. “One-shot vaccination with an insect cell- derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge,” Vaccine 32(3): pp. 355-362, 2014.;;Mertes, P., et al. “Methylene blue-treated plasma: an increased allergy risk?” The Journal of Allergy and Clinical Immunology 130(3): pp. 808-812, 2012.;;Seghatchian, J_ et al. “Main properties of the THERAFLEX MB-plasma system for pathogen reduction,” Transfusion Medicine and Hemotherapy 38(1): pp. 55-64, 2011.;;Marcus, P. et al. “In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines,” Journal of Virology 84(21): pp. 10974-10981, Nov. 2010.;;Quan, F. et al. “Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles,” Journal of Controlled Release 147(3): pp. 326-332, 2010.;;Victoria, J_ et al. “Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus,” Journal of Virology 84(12): pp. 6033-6040, Jun. 2010.;;Maves, R. et al. “Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.” Clinical and Vaccine Immunology 17(2): pp. 304-306, Feb. 2010.;;Prausnitz, M.R., et al. “Microneedle-based vaccines,” Current Topics in Microbiology and Immunology 333: pp. 369-393, 2009.;;Geeraedts, F., et al. “Superior immunogenicity of inactivated whole virus H5N 1 influenza vaccine is primarily controlled by toll-like receptor signalling,” PLoS Pathogens 4(8): p. e1000138, Aug. 2008.;;Monath, T.P. et al. “A live, attenuated recombinant west nile virus vaccine,” Proceedings of the National Academy of Sciences, USA 103(17): pp. 6694-6699, Apr. 25, 2006.;;Meurice, F. et al. “Immunogenicity and safety of a live attenuated varicella vaccine (oka/SB bio) in healthy children,” The Journal of Infectious Diseases 174(Supplement 3): pp. S324-S329, Nov. 1996.;;THERAFLEX-MB Plasma-Processing Principle, advertisement published by MacoPharma, Sep. 2007.;;“Influenza Vaccine,” Cytiva, https://www.gelifesciences.com/en/us/solutions/bioprocessing/knowledge-center/influenza, vaccine-manufacturing [retrieved Mar. 30, 2020], 10 pages.;;Borkar, T.G., et al. “Techniques Employed in Production of Traditional Vaccines Commonly Used by Military Forces: A Review,” Journal of Archives in Military Medicine 7(102):e96149, pp. 1-12, Jun. 2019.;;Plotino, G., et al. “Photodynamic therapy in endodontics,” International Endodontic Journal (52): pp. 760-774, 2019.;;Meller, D., et al. “Photodisinfection Therapy: Essential Technology for Infection Control,” <https://infectioncontro.tips/2020/01/17/photodisinfection-therapy/> [retrieved Jul. 30, 2020], 20 pages.;;What is Photodisinfection?, Ondine Biomedical, <https://ondinebio.com/technology> [retrieved Aug. 12, 2020], 5 pages.;;Midden, R.W., Wang, S.Y., “Singlet Oxygen Generation for Solution Kinetics: Clean and Simple,” Journal of the American Chemical Society, 105(13):4129-4135, Jun. 29, 1983.;;Naito, K. et al. “Single-molecule detection of airborne singlet oxygen,” Journal of the American Chemical Society 128(51): pp. 16430-16431, 2006.;;Ogilby, P.R. “Singlet oxygen: There is indeed something new under the sun,” Chemical Society reviews 39(8): pp. 3181-3209, 2010.;;Zhao, Y. et al. “Singlet oxygen generation on porous superhydrophobic surfaces: Effect of gas flow and sensitizer wetting on trapping efficiency,” The Journal of Physical Chemistry A 118(45): pp. 10364-10371, 2014.;;Gao, R. et al. “Nano-photosensitizer based on layered double hydroxide and isophthalic acid for singlet oxygenation and photodynamic therapy,” Nature communications 9(1):2798, pp. 1-10, 2018.;;Felgentrager, A., et al. “Singlet oxygen generation in porphyrin-doped polymeric surface coating enables antimicrobial effects on Staphylococcus aureus,” Physical Chemistry Chemical Physics:PCCP, 16(38): pp. 20598-20607, 2014.;;Pushalkar, S. et al. “Superhydrophobic photosensitizers: Airborne 102 killing of an in vitro oral biofilm at the plastron interface,” ACS Applied Materials & Interfaces 10(30): pp. 25819-25829, Jul. 4, 2018.;;Hwang, J. et al. “Study of singlet oxygen dynamics on silicon polymer matrix,” Journal of Analytical Methods in Chemistry vol. 2019 Article ID 2584686, pp. 1-6, Feb. 19, 2019.;;Bartusik, D. et al. “Bacterial inactivation by a singlet oxygen bubbler: Identifying factors controlling the toxicity of 1O2 bubbles,” Environmental Science & Technology 46(21): pp. 12098-12104, Oct. 18, 2012.;;Aebisher, D. el al. “Superhydrophobic surfaces as a source of airborne singlet oxygen through free space for photodynamic therapy,” ACS Applied Bio Materials 3(4): pp. 2370-2377, Mar. 17, 2020.;;Boyce, John M. “Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals.” Antimicrobial Resistance & Infection Control 5.1 (2016): 1-10.;;Dancer, Stephanie J. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews 27.4 (2014): 665-690.;;Pyrek, K. “Portable medical equipment: A significant source of transmission,” Feb. 1, 2018, 16 pages.;;Russotto, V., Cortegiani, A., Raineri, S. M., & Giarratano, A. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. Journal of Intensive Care. 2015;3(1):54, pp. 1-8.;;Gabriele Messina, Emma Ceriale, Daniele Lenzi, Sandra Burgassi, Elena Azzolini, Pietro Manzi. Environmental contaminants in hospital settings and progress in disinfecting techniques. BioMed research international. 2013;2013:429780, 8 pages.;;Bonetta S, Bonetta S, Motta F, Strini A, Carraro E. Photocatalytic bacterial inactivation by TiO2-coated surfaces. AMB Expr. 2013;3(1):1-8. https://www.ncbi.nlm.nih.gov/pubmed/24090112. doi: 10.1186/2191-0855-3-59.;;Air permeable(breathable) film, <http://tamstech.net> [Accessed Mar. 25, 2020], 1 page.;;Siracusa, Valentina. “Food packaging permeability behaviour: A report.” International Journal of Polymer Science 2012 (2012), 2 pages.;;Gahleitner, Markus, et al. Sterilization effects on polypropylene: technology and polymer type effects., Jan. 2003 , <https://www.researchgate.net/publication/288596501>, 3 pages.;;“Cover Picture: Optik & Photonik Apr. 2015,” Abstract, vol. 10, Issue 4, 2015,<https://doi.org/10.1002/opph.201590064>, 2 pages.;;Molitch-Hou, M., “First 3D Printed Fiber Optics Created by University of Sydney researchers with Desktop 3d Printer,” 2015, 3D Printing Industry, The Authority on Additive Manufacturing, <https://3dprintingindustry.com/news/first-3d-printed-fiber-optics-createdby-university-of-sydney-researchers-with-desktop-3d-printer-55047/> [Accessed Mar. 24, 2020], 1 page.;;Ismail, Salim, et al. “Efficacy of a novel light-activated antimicrobial coating for disinfecting hospital surfaces.” Infection Control & Hospital Epidemiology 32.11 (2011): 1130-1132.;;International Search Report and Written Opinion dated Nov. 30, 2021, in International Application PCT/US2021/0046417, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion dated Dec. 6, 2021, in International Application PCT/US2021/046722, filed Aug. 19, 2021, 9 pages.;;International Search Report and Written Opinion dated Feb. 2, 2022, issued in International Application No. PCT/US2021/046419, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion dated Feb. 1, 2022, issued in International Application No. PCT/US2021/048444, filed Aug. 31, 2021, 14 pages.",ACTIVE
24,WO,A1,WO 2022/051090 A1,191-245-031-466-172,2022-03-10,2022,US 2021/0046417 W,2021-08-18,US 202063073652 P;;US 202117244688 A,2020-09-02,ANTIMICROBIAL PREVENTIVE NETTING,"An antimicrobial preventive netting is disclosed that includes one or more photosensitizers that are capable of generating a cloud of singlet oxygen on each surface and openings through the netting in response to incident light. A depth of the singlet oxygen cloud may be less than 0.7 centimeters from a netting surface. The netting may be supported by screens, enclosures or headgear. The netting can be made by dipping or soaking the netting in a solution of one or more photosensitizers.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,,https://lens.org/191-245-031-466-172,Patent Application,yes,5,0,3,3,0,A01P1/00;;A01N59/00;;A61L2209/14;;A61L9/205;;A61L9/22;;E04H1/1277;;A01N25/34;;A01N43/84;;A01N43/16;;A01N43/90;;A61L9/18;;A61L2209/12;;E04H15/54;;A62B18/02;;A62B31/00;;A41D31/305;;A61L2209/14;;E04H15/46,A61L2/08;;A61L2/20,,0,0,,,,PENDING
25,US,A1,US 2022/0062461 A1,012-432-840-435-280,2022-03-03,2022,US 202117463245 A,2021-08-31,US 202117463245 A;;US 202063073761 P,2020-09-02,PHOTOSENSITIZER COMBINATION,"Methods for making disinfecting compositions based on phototherapy, systems for use in disinfecting with a combination of photosensitizers, and the disinfecting compositions themselves, are described. Concentrations of the photosensitizers can be based on the particular light source and the wavebands or fluence rates emitted by the light source for maximum singlet oxygen generation. Concentrations of the photosensitizers can also be based on the quantum yield of the photosensitizers.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/012-432-840-435-280,Patent Application,yes,0,1,2,2,0,A61L2/088;;A61L2/088;;A61L2/26;;A61L2202/11;;G01N21/314;;C09B67/0033,A61L2/08;;A61L2/26;;C09B67/22;;G01N21/31,,0,0,,,,DISCONTINUED
26,US,A1,US 2011/0134590 A1,062-856-052-519-953,2011-06-09,2011,US 72207510 A,2010-03-11,TW 98108088 A,2009-03-12,FOLDABLE ELECTRONIC DEVICE,"The invention discloses a foldable electronic device having a folding module pivotally connected to a first body and a second body. The folding module has at least one folding member with a first connecting portion and a second connecting portion defined thereon, wherein the first connecting portion and the second connecting portion are foldable along a first folding line defined there between, and the first connecting portion and the second connecting portion are connected to the first body and the second body respectively. With such, the structure of the folding module is simplified, the cost is reduced and the folding module is also easy to be assembled and repaired.",ASUSTEK COMP INC,CLARK PETER TIMOTHY;;LIU HUAN CHEN,ASUSTEK COMPUTER INC (2010-02-17),https://lens.org/062-856-052-519-953,Patent Application,yes,7,2,4,4,0,G06F1/1681;;H04M1/0216;;G06F1/1681;;H04M1/0216,H05K5/00,361/679.01,0,0,,,,ACTIVE
27,WO,A1,WO 2022/147232 A1,133-867-189-374-377,2022-07-07,2022,US 2021/0065662 W,2021-12-30,US 202063132194 P,2020-12-30,DEVICE INCLUDING FERROELECTRIC NEMATIC LIQUID CRYSTAL-FORMING MOLECULES AND METHODS OF FORMING AND USING SAME,"Surface polarity of a ferroelectric nematic can be configured to generate vectorial control of the orientation of its bulk polarization field. The contact between a surface with in-plane polarity and a ferroelectric nematic liquid crystal generates preferred in-plane orientation of the ferroelectric polarization field at that interface, which can lead to the formation of fluid or glassy monodomains of high polarization without electric field poling. Materials surfaces can be used as a route to making planar-aligned cells with a variety of azimuthal director/polarization structures, including twisted states, in a π-twist cell, obtained with antiparallel, unidirectional buffing on opposing surfaces, we demonstrate three distinct modes of ferroelectric nematic electro-optic response: intrinsic viscosity-limited field induced molecular reorientation, field-induced motion of domain walls separating twisted states of opposite chirality; and propagation of polarization reorientation solitons from the cell plates to the cell center upon field reversal.",UNIV COLORADO REGENTS,CLARK NOEL;;CHEN XI;;MACLENNAN JOSEPH,,https://lens.org/133-867-189-374-377,Patent Application,yes,3,0,6,6,0,G02F1/141;;G02F1/1337;;G02F1/133788;;G02F1/141;;G02F1/133788,G02F1/141;;G02F1/1337,,0,0,,,,PENDING
28,TW,B,TW I357552 B,194-866-499-027-15X,2012-02-01,2012,TW 98108088 A,2009-03-12,TW 98108088 A,2009-03-12,Foldable electronic equipment,,ASUSTEK COMP INC,CLARK PETER TIMOTHY;;LIU HUAN CHEN,,https://lens.org/194-866-499-027-15X,Granted Patent,no,0,0,4,4,0,G06F1/1681;;H04M1/0216;;G06F1/1681;;H04M1/0216,,,0,0,,,,ACTIVE
29,US,B2,US 8014147 B2,096-687-136-790-766,2011-09-06,2011,US 32742708 A,2008-12-03,US 32742708 A;;US 1206407 P,2007-12-07,Foldable electronic apparatus with an enhanced pivotal mechanism,"A portable electronic apparatus includes a first casing, a second casing, and an enhanced pivotal mechanism for folding/unfolding the second casing with respect to the first casing. The pivotal mechanism further includes a main pivot to pivot the first casing and the second casing; a combination constructed on the first casing and further including a first driving element driven by the main pivot, a first cam driven by the first driving element, and a first cover pivotally rotated by the first cam; and, another combination constructed on the second casing and further including a second driving element driven by the main pivot, a second cam driven by the second driving element, and a second cover pivotally rotated by the second cam.",ASUSTEK COMP INC,CHEN KUAN-TING;;CLARK PETER TIMOTHY,ASUSTEK COMPUTER INC (2008-12-02),https://lens.org/096-687-136-790-766,Granted Patent,yes,12,31,6,6,0,G06F1/183;;G06F1/183;;G06F1/1616;;G06F1/1616;;G06F1/1637;;G06F1/1637;;G06F1/166;;G06F1/166;;G06F1/1684;;G06F1/1684,H05K7/16,361/679.56;;200/61.62;;200/61.7;;361/679.27;;361/679.08;;361/679.09,0,0,,,,ACTIVE
30,US,A1,US 2022/0061318 A1,167-187-240-112-44X,2022-03-03,2022,US 202117244688 A,2021-04-29,US 202117244688 A;;US 202063073652 P,2020-09-02,ANTIMICROBIAL PREVENTIVE NETTING,"An antimicrobial preventive netting is disclosed that includes one or more photosensitizers that are capable of generating a cloud of singlet oxygen on each surface and openings through the netting in response to incident light. A depth of the singlet oxygen cloud may be less than 0.7 centimeters from a netting surface. The netting may be supported by screens, enclosures or headgear. The netting can be made by dipping or soaking the netting in a solution of one or more photosensitizers.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/167-187-240-112-44X,Patent Application,yes,4,1,3,3,0,A01P1/00;;A01N59/00;;A61L2209/14;;A61L9/205;;A61L9/22;;E04H1/1277;;A01N25/34;;A01N43/84;;A01N43/16;;A01N43/90;;A61L9/18;;A61L2209/12;;E04H15/54;;A62B18/02;;A62B31/00;;A41D31/305;;A61L2209/14;;E04H15/46,A01N25/34;;A01N43/16;;A01N43/84;;A01N43/90;;A41D31/30;;A61L9/18;;A62B18/02;;A62B31/00;;E04H15/46;;E04H15/54,,0,0,,,,ACTIVE
31,WO,A1,WO 2022/040258 A1,155-064-704-477-258,2022-02-24,2022,US 2021/0046419 W,2021-08-18,US 202063068762 P;;US 202063074280 P,2020-08-21,DISINFECTION METHOD AND APPARATUS,"Photosensitizers are incorporated into articles, such a personal protective equipment. A method of applying continuous and consistent light includes fitting the articles with light sources and optical fibers to apply light to the areas of the articles incorporated with the photosensitizers. Photosensitizers can 5 be applied to articles by various applicators in either a gel or solution. A gel can be particularly effective when used on hydrophobic surfaces. Photodynamic reactor systems can be used to determine the effective doses of photosensitizers and the light dosimetry which can then be applied for use with the articles.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,,https://lens.org/155-064-704-477-258,Patent Application,yes,7,0,3,5,0,A41D31/30;;A41D13/1192;;A41D13/12;;A41D19/015;;A61L2/088;;A61L2/232;;A61L2202/26;;A61L2/088;;A61L31/12;;A61L31/16;;A41D13/1192;;A41D13/0002;;A41D13/12;;A61L2202/14;;A61L2/28;;A61L2/084;;A61L2101/44;;A61L2202/11;;A61L2202/122;;A61L2202/26;;A61L2/18,A41D13/12;;A41D27/12;;A41D31/30;;A61L2/08;;B32B5/02;;B32B33/00,,0,0,,,,PENDING
32,US,A1,US 2022/0054149 A1,198-244-788-441-866,2022-02-24,2022,US 202117244610 A,2021-04-29,US 202117244610 A;;US 202063068729 P,2020-08-21,VACCINE GENERATION,"An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/198-244-788-441-866,Patent Application,yes,2,1,3,3,0,A61B10/0045;;A61K9/0021;;A61K41/10;;B01L3/5029;;B01L2300/0681;;B01L2300/0841;;B01L2400/0478;;A61K39/00;;C07K14/165;;C07K14/11;;A61B17/20;;A61M5/3145;;A61M5/3293;;A61K9/0021;;A61K39/215;;B01L2300/0681;;A61B10/0045;;A61M2209/04;;A61M2205/7509;;A61M2202/30;;A61K2039/54;;B01L3/02;;A61K41/0057,A61B17/20;;A61K9/00;;A61K39/215;;A61M5/31;;A61M5/32;;B01L3/02,,0,0,,,,ACTIVE
33,US,B2,US 8686412 B2,037-542-637-504-281,2014-04-01,2014,US 88807207 A,2007-07-31,US 88807207 A,2007-07-31,Microelectronic device,A microelectronic device includes a thin film transistor having an oxide semiconductor channel and an organic polymer passivation layer formed on the oxide semiconductor channel.,HERMAN GREGORY;;CLARK BENJAMIN;;CHEN ZHIZHANG;;HEWLETT PACKARD DEVELOPMENT CO,HERMAN GREGORY;;CLARK BENJAMIN;;CHEN ZHIZHANG,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2007-07-30),https://lens.org/037-542-637-504-281,Granted Patent,yes,7,4,2,2,0,H01L21/02554;;H01L21/02565;;H01L21/02631;;H01L21/02667;;H01L29/7869;;H01L21/02118;;H01L21/312;;H01L21/02118;;H01L21/02631;;H01L21/02667;;H01L29/7869;;H01L21/02554;;H01L21/02565,H01L29/12;;H01L29/10,257/43;;438/142;;438/150;;438/151;;X257E21411,2,0,,,"Christiansen et al, Spin-on Glass, Jun. 2000, pp. 1-7.;;Honeywell, Honeywell Electronic Materials, 2000-2009, p. 1.",ACTIVE
34,US,A1,US 2009/0147469 A1,048-718-424-183-694,2009-06-11,2009,US 32742708 A,2008-12-03,US 32742708 A;;US 1206407 P,2007-12-07,FOLDABLE ELECTRONIC APPARATUS WITH AN ENHANCED PIVOTAL MECHANISM,"A portable electronic apparatus includes a first casing, a second casing, and an enhanced pivotal mechanism for folding/unfolding the second casing with respect to the first casing. The pivotal mechanism further includes a main pivot to pivot the first casing and the second casing; a combination constructed on the first casing and further including a first driving element driven by the main pivot, a first cam driven by the first driving element, and a first cover pivotally rotated by the first cam; and, another combination constructed on the second casing and further including a second driving element driven by the main pivot, a second cam driven by the second driving element, and a second cover pivotally rotated by the second cam.",CHEN KUAN-TING;;CLARK PETER TIMOTHY,CHEN KUAN-TING;;CLARK PETER TIMOTHY,ASUSTEK COMPUTER INC (2008-12-02),https://lens.org/048-718-424-183-694,Patent Application,yes,10,36,6,6,0,G06F1/183;;G06F1/183;;G06F1/1616;;G06F1/1616;;G06F1/1637;;G06F1/1637;;G06F1/166;;G06F1/166;;G06F1/1684;;G06F1/1684,H05K7/00,361/679.55,0,0,,,,ACTIVE
35,WO,A1,WO 2022/040256 A1,125-694-900-586-003,2022-02-24,2022,US 2021/0046416 W,2021-08-18,US 202063068729 P;;US 202117244610 A,2020-08-21,VACCINE GENERATION,"An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,,https://lens.org/125-694-900-586-003,Patent Application,yes,5,0,3,3,0,A61B10/0045;;A61K9/0021;;A61K41/10;;B01L3/5029;;B01L2300/0681;;B01L2300/0841;;B01L2400/0478;;A61K39/00;;C07K14/165;;C07K14/11;;A61B17/20;;A61M5/3145;;A61M5/3293;;A61K9/0021;;A61K39/215;;B01L2300/0681;;A61B10/0045;;A61M2209/04;;A61M2205/7509;;A61M2202/30;;A61K2039/54;;B01L3/02;;A61K41/0057,C01B13/02,,0,0,,,,PENDING
36,US,B2,US 11529153 B2,147-759-404-092-12X,2022-12-20,2022,US 202117244610 A,2021-04-29,US 202117244610 A;;US 202063068729 P,2020-08-21,Vaccine generation,"An apparatus for vaccine generation includes a syringe with a cavity that includes a solution with photosensitizers. Microbial particles are added to the solution. A light source is capable of emitting one or more wavebands of light that are effectively absorbed by the one photosensitizers to generate singlet oxygen in the solution and other radical species that rapidly react with and damage lipids, proteins, DNA, and RNA of the microbial particles. This damage produces immunogens that can be applied as a vaccine to viruses and other infectious microbial particles. A plunger that fits within a proximal opening in the syringe is used for forcing the solution including the immunogens through the filter and out of the syringe while the photosensitizers, debris and unwanted microbial particles are trapped within the filter.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/147-759-404-092-12X,Granted Patent,yes,90,0,3,3,0,A61B10/0045;;A61K9/0021;;A61K41/10;;B01L3/5029;;B01L2300/0681;;B01L2300/0841;;B01L2400/0478;;A61K39/00;;C07K14/165;;C07K14/11;;A61B17/20;;A61M5/3145;;A61M5/3293;;A61K9/0021;;A61K39/215;;B01L2300/0681;;A61B10/0045;;A61M2209/04;;A61M2205/7509;;A61M2202/30;;A61K2039/54;;B01L3/02;;A61K41/0057,A61B17/20;;A61B10/00;;A61K9/00;;A61K39/00;;A61K39/215;;A61K41/00;;A61M5/31;;A61M5/32;;B01L3/02,,74,52,058-131-308-191-718;;017-214-137-653-709;;005-688-265-382-690;;015-383-164-780-775;;046-608-698-175-106;;037-210-407-450-571;;029-694-646-332-779;;041-401-243-694-823;;058-195-152-855-719;;019-980-133-493-942;;115-394-470-241-357;;013-514-292-332-752;;005-146-572-303-773;;004-603-966-374-149;;017-589-172-330-383;;066-896-390-438-883;;024-668-409-019-008;;165-313-740-952-121;;002-076-612-988-747;;027-369-533-036-285;;029-970-078-876-361;;011-091-787-318-51X;;058-244-677-368-129;;104-735-392-666-045;;021-550-417-090-442;;079-481-920-229-614;;025-362-344-749-265;;091-819-263-711-397;;078-363-993-200-384;;105-490-966-873-865;;013-124-195-476-566;;015-149-066-563-085;;004-618-619-277-709;;019-055-342-526-925;;015-986-570-318-191;;033-515-425-498-28X;;006-233-231-990-589;;151-236-689-453-284;;040-094-909-340-017;;033-466-657-266-228;;046-415-043-790-959;;027-268-121-505-214;;000-409-973-377-909;;042-023-960-529-83X;;036-999-860-923-650;;096-826-407-988-334;;071-315-468-972-414;;055-611-002-759-124;;147-739-746-094-573;;058-214-960-300-659;;032-374-355-070-495;;056-184-862-634-367,pmc2763101;;10.3390/md7030268;;19841715;;pmc7168192;;31906034;;10.3390/antibiotics9010013;;pmc7139796;;10.3390/cancers12030545;;32120810;;31658786;;pmc6963634;;10.3390/vaccines7040144;;31471148;;10.1016/j.vaccine.2019.08.037;;29678452;;10.1016/j.ajic.2018.02.018;;pmc7115285;;29033339;;10.1016/j.tim.2017.09.007;;pmc5777272;;28724343;;10.1080/14760584.2017.1357471;;pmc4724431;;25595808;;10.1016/bs.pmbts.2014.10.012;;10.1016/j.vaccine.2013.11.036;;24262313;;pmc3906608;;22664163;;10.1016/j.jaci.2012.03.050;;21779206;;pmc3132980;;10.1159/000323786;;pmc2953188;;10.1128/jvi.00502-10;;20739541;;20692307;;pmc2975779;;10.1016/j.jconrel.2010.07.125;;20375174;;pmc2876658;;10.1128/jvi.02690-09;;10.1128/cvi.00353-09;;pmc2815535;;20007362;;19768415;;10.1007/978-3-540-92165-3_18;;pmc2904604;;10.1371/journal.ppat.1000138;;pmc2516931;;18769719;;10.1073/pnas.0601932103;;16617103;;pmc1436023;;8896540;;10.1093/infdis/174.supplement_3.s324;;10.5812/jamm.96149;;10.1111/iej.13057;;30548497;;27069623;;10.1186/s13756-016-0111-x;;pmc4827199;;10.1021/ja00351a001;;17177354;;10.1021/ja066739b;;10.1039/b926014p;;20571680;;24885074;;pmc4234451;;10.1021/jp503149x;;10.1038/s41467-018-05223-3;;30022060;;pmc6052022;;25155698;;10.1039/c4cp02439g;;pmc6698391;;10.1021/acsami.8b09439;;29972022;;10.1155/2019/2584686;;pmc6399532;;30915256;;pmc3812664;;10.1021/es303645n;;23075418;;10.1021/acsabm.0c00114;;35025286;;pmc4187643;;25278571;;10.1128/cmr.00020-14;;10.1186/s40560-015-0120-5;;26693023;;pmc4676153;;24286078;;10.1155/2013/429780;;pmc3830765;;10.1186/2191-0855-3-59;;pmc3851522;;24090112;;10.1155/2012/302029;;30929100;;10.1007/s10103-019-02774-9;;10.4172/2153-2435.1000403;;22368354;;pmc3283927;;10.4103/0972-124x.92563;;10.4103/jisp.jisp_157_17;;pmc5803877;;29440788;;10.1038/ijos.2012.63;;23222991;;pmc3633065;;10.1016/j.pdpdt.2016.06.011;;27375182;;16464894;;10.1093/jac/dkl021;;22011544;;10.1086/662377;;10.4209/aaqr.2010.12.0105;;10.1172/jci81532;;pmc4563760;;26168222;;10.1039/c2jm31987j;;10.1039/c3sc53186d;;10.1039/b905495b;;10.1001/jama.1969.03150160032007;;10.1001/jama.207.3.520;;5818213,"Almeida, A., et al. “Phage Therapy and Photodynamic Therapy: Low Environmental Impact Approaches to Inactivate Microorganisms in Fish Farming Plants,” Marine Drugs 7(3): pp. 268-313, Jun. 30, 2009.;;Hasenleitner, M., et al. “In the Right Light: Photodynamic Inactivation of Microorganisms Using a LED-Based Illumination Device Tailored for the Antimicrobial Application,” Antibiotics 9(1): pp. 1-13, Dec. 30, 2019.;;Trempolec, N., et al. “Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma,” Cancers 12(3): pp. 1-16, Feb. 27, 2020.;;Weaver, E.A. “Dose Effects of Recombinant Adenovirus Immunization in Rodents,” Vaccines 7(4):144 pp. 1-11, Oct. 10, 2019.;;Hankaniemi, M.M., et al. “A comparative study of the effect of UV and formalin inactivation on the stability and immunogenicity of a coxsackievirus B1 vaccine,” Vaccine 37: pp. 5962-5971, Aug. 27, 2019.;;Mills, D., et al. “Ultraviolet germicidal irradiation of influenza-contaminated N95 filtering facepiece respirators,” AJIC: American Journal of Infection Control 46(7): pp. e49-e55, 2018.;;Bull, J.J., et al. “Transmissible Viral Vaccines,” Trends in Microbiology 26(1): pp. 6-15, Jan. 2018.;;Barrett, P.N., et al. “Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases,” Expert Review of Vaccines 16(9): pp. 883-894, Jul. 17, 2017.;;Klasse, P.J. “Molecular determinants of the ratio of inert to infectious virus particles,” Progress in Molecular Biology and Translational Science 129: pp. 285-326, 2015.;;Klausberger, M. et al. “One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge,” Vaccine 32(3): pp. 355-362, Nov. 18, 2013.;;Mertes, P., et al. “Methylene blue-treated plasma: an increased allergy risk?” The Journal of Allergy and Clinical Immunology 130(3): pp. 808-812, Jun. 2, 2012.;;Seghatchian, J. et al. “Main properties of the THERAFLEX MB-plasma system for pathogen reduction,” Transfusion Medicine and Hemotherapy 38(1): pp. 55-64, Jan. 27, 2011.;;Marcus, P. et al. “In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines,” Journal of Virology 84(21): pp. 10974-10981, Aug. 13, 2010.;;Quan, F. et al. “Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles,” Journal of Controlled Release 147(3): pp. 326-332, Aug. 6, 2010.;;Victoria, J. et al. “Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus,” Journal of Virology 84(12): pp. 6033-6040, Mar. 25, 2010.;;Maves, R. et al. “Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.” Clinical and Vaccine Immunology 17(2): pp. 304-306, Feb. 2010.;;Prausnitz, M.R., et al. “Microneedle-based vaccines,” Current Topics in Microbiology and Immunology 333: pp. 369-393, Jul. 15, 2010.;;Geeraedts, F., et al. “Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by toll-like receptor signalling,” PLoS Pathogens 4(8): p. e1000138, Aug. 29, 2008.;;Monath, T.P. et al. “A live, attenuated recombinant west nile virus vaccine,” Proceedings of the National Academy of Sciences, USA 103(17): pp. 6694-6699, Mar. 9, 2006.;;Meurice, F. et al. “Immunogenicity and safety of a live attenuated varicella vaccine (oka/SB bio) in healthy children,” The Journal of Infectious Diseases 174(Supplement 3): pp. S324-S329, Nov. 1996.;;THERAFLEX-MB Plasma-Processing Principle, advertisement published by MacoPharma, Sep. 2007.;;“Influenza Vaccine,” Cytiva, https://www.gelifesciences.com/en/us/solutions/bioprocessing/knowledge-center/influenza-vaccine-manufacturing [retrieved Mar. 30, 2020], 10 pages.;;Borkar, T.G., et al. “Techniques Employed in Production of Traditional Vaccines Commonly Used by Military Forces: A Review,” Journal of Archives in Military Medicine 7(102):e96149, pp. 1-12, Jun. 2019.;;Plotino, G., et al. “Photodynamic therapy in endodontics,” International Endodontic Journal (52): pp. 760-774, 2019.;;Meller, D., et al. “Photodisinfection Therapy: Essential Technology for Infection Control,” <https://infectioncontrol.tips/2020/01/17/photodisinfection-therapy/> [retrieved Jul. 30, 2020], 20 pages.;;Boyce, J.M., “Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals,” © 2016 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827199/> [retrieved Jul. 30, 2020], 20 pages.;;“What is Photodisinfection?,” Ondine Biomedical, <https://ondinebio.com/technology> [retrieved Aug. 12, 2020], 5 pages.;;Henneberry, B. How Surgical Masks are Made. Thomas Industry.<https://www.thomasnet.com/articles/other/how-surgical-masks-are-made/>[Accessed Mar. 21, 2020], 1 page.;;Clear Polypropylene. Omnexus: The material selection platform.<https://omnexus.specialchem.com/centers/clear-polypropylene> [Accessed Mar. 21, 2020], 1 page.;;Midden, R.W., Wang, S.Y., “Singlet Oxygen Generation for Solution Kinetics: Clean and Simple,” Journal of the American Chemical Society, 105(13):4129-4135, Jun. 29, 1983.;;Naito, K. et al. “Single-molecule detection of airborne singlet oxygen,” Journal of the American Chemical Society 128(51): pp. 16430-16431, 2006.;;Ogilby, P.R. “Singlet oxygen: There is indeed something new under the sun,” Chemical Society reviews 39(8): pp. 3181-3209, 2010.;;Zhao, Y. et al. “Singlet oxygen generation on porous superhydrophobic surfaces: Effect of gas flow and sensitizer wetting on trapping efficiency,” The Journal of Physical Chemistry A 118(45): pp. 10364-10371, 2014.;;Gao, R. et al. “Nano-photosensitizer based on layered double hydroxide and isophthalic acid for singlet oxygenation and photodynamic therapy,” Nature communications 9(1):2798, pp. 1-10, 2018.;;Felgentrager, A., et al. “Singlet oxygen generation in porphyrin-doped polymeric surface coating enables antimicrobial effects on Staphylococcus aureus,” Physical Chemistry Chemical Physics:PCCP, 16(38): pp. 20598-20607, 2014.;;Pushalkar, S. et al. “Superhydrophobic photosensitizers: Airborne 102 killing of an in vitro oral biofilm at the plastron interface,” ACS Applied Materials & Interfaces 10(30): pp. 25819-25829, Jul. 4, 2018.;;Hwang, J. et al. “Study of singlet oxygen dynamics on silicon polymer matrix,” Journal of Analytical Methods in Chemistry vol. 2019 Article ID 2584686, pp. 1-6, Feb. 19, 2019.;;Bartusik, D. et al. “Bacterial inactivation by a singlet oxygen bubbler: Identifying factors controlling the toxicity of 1O2 bubbles,” Environmental Science & Technology 46(21): pp. 12098-12104, Oct. 18, 2012.;;Aebisher, D. el al. “Superhydrophobic surfaces as a source of airborne singlet oxygen through free space for photodynamic therapy,” ACS Applied Bio Materials 3(4): pp. 2370-2377, Mar. 17, 2020.;;Dancer, Stephanie J. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews 27.4 (2014): 665-690.;;Pyrek, K. “Portable medical equipment: A significant source of transmission,” Feb. 1, 2018, 16 pages.;;Russotto, V., Cortegiani, A., Raineri, S. M., & Giarratano, A. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. Journal of Intensive Care. 2015;3(1):54, pp. 1-8.;;Gabriele Messina, Emma Ceriale, Daniele Lenzi, Sandra Burgassi, Elena Azzolini, Pietro Manzi. Environmental contaminants in hospital settings and progress in disinfecting techniques. BioMed research international. 2013;2013:429780, 8 pages.;;Bonetta S, Bonetta S, Motta F, Strini A, Carraro E. Photocatalytic bacterial inactivation by TiO2-coated surfaces. AMB Expr. 2013;3(1):1-8. https://www.ncbi.nlm.nih.gov/pubmed/24090112. doi: 10.1186/2191-0855-3-59.;;Air permeable(breathable) film, <http://tamstech.net> [Accessed Mar. 25, 2020], 1 page.;;Siracusa, Valentina. “Food packaging permeability behaviour: A report.” International Journal of Polymer Science 2012 (2012), 2 pages.;;Makdoumi K, Hedin M, Bäckman A. Different photodynamic effects of blue light with and without riboflavin on methicillin-resistant Staphylococcus aureus (MRSA) and human keratinocytes in vitro. Lasers Med Sci. 2019;34(9):1799-1805.;;Kino, K., et al. Commentary on the phototoxicity and absorption of vitamin B2 and its degradation product, lumichrome. Pharmaceutica analytica acta. 2015;6(8). doi: 10.4172/2153-2435.1000403.;;Koshi E, Mohan A, Rajesh S, Philip K. Antimicrobial photodynamic therapy: An overview. Journal of Indian Society of Periodontology. 2011;15(4):323-327, 1 page.;;Bhat M, Acharya S, Prasad K, Kulkarni R, Bhat A, Bhat D. Effectiveness of erythrosine-mediated photodynamic antimicrobial chemotherapy on dental plaque aerobic microorganisms: A randomized controlled trial. Journal of Indian Society of Periodontology. 2017;21(3):210-215.;;Lee Y, Park H, Lee J, Seo H, Lee S. The photodynamic therapy on Streptococcus mutans biofilms using erythrosine and dental halogen curing unit. International journal of oral science. 2012;4(4):196-201.;;Fracalossi C, Nagata JY, Pellosi DS, et al. Singlet oxygen production by combining erythrosine and halogen light for photodynamic inactivation of Streptococcus mutans. Photodiagnosis and Photodynamic Therapy. 2016;15:127-132. https://search.datacite.org/works/10.1016/j.pdpdt.2016.06.011. doi: 10.1016/j.pdpdt.2016.06.011, 1 page.;;Wood S, Metcalf D, Devine D, Robinson C. Erythrosine is a potential photosensitizer for the photodynamic therapy of oral plaque biofilms. Journal of antimicrobial chemotherapy. 2006;57(4):680-684.;;Gahleitner, Markus, et al. Sterilization effects on polypropylene: technology and polymer type effects., Jan. 2003 , <https://www.researchgate.net/publication/288596501>, 3 pages.;;“Cover Picture: Optik & Photonik Apr. 2015,” Abstract, vol. 10, Issue 4, 2015,<https://doi.org/10.1002/opph.201590064>, 2 pages.;;Molitch-Hou, M., “First 3D Printed Fiber Optics Created by University of Sydney researchers with Desktop 3d Printer,” 2015, 3D Printing Industry, The Authority on Additive Manufacturing, <https://3dprintingindustry.com/news/first-3d-printed-fiber-optics-createdby-university-of-sydney-researchers-with-desktop-3d-printer-55047/> [Accessed Mar. 24, 2020], 1 page.;;Ismail, Salim, et al. “Efficacy of a novel light-activated antimicrobial coating for disinfecting hospital surfaces.” Infection Control & Hospital Epidemiology 32.11 (2011): 1130-1132.;;Lee, Im-Soon, et al. “Aerosol particle size distribution and genetic characteristics of aerosolized influenza A H1N1 virus vaccine particles.” Aerosol and Air Quality Research 11.3 (2011): 230-237.;;Meyer, Michelle, et al. “Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.” The Journal of clinical investigation 125.8 (2015): 3241-3255.;;Noimark, Sacha, et al. “Incorporation of methylene blue and nanogold into polyvinyl chloride catheters; a new approach for light-activated disinfection of surfaces.” Journal of Materials Chemistry. 2012; 22(30): 15388-15396. <https://doi.org/10.1039/C2JM31987J>, 1 page.;;Noimark, Sacha, Elaine Allan, and Ivan P. Parkin. “Light-activated antimicrobial surfaces with enhanced efficacy induced by a dark-activated mechanism.” Chemical Science 5.6 (2014): 2216-2223.;;Piccirillo, Clara, et al. “Antimicrobial activity of methylene blue and toluidine blue O covalently bound to a modified silicone polymer surface.” Journal of Materials Chemistry 19.34 (2009): 6167-6171.;;Fecht, S., “The First Fully 3-D Printed LEDs Are Here,” 2014, <https://www.popsci.com/article/technology/first-fully-3-d-printed-leds-are-here/> [Accessed Mar. 24, 2020], 8 pages.;;Waldman, Robert H., John J. Mann, and Parker A. Small. “Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine.” Jama 207.3 (1969): 520-524. doi:10.1001/jama. 1969.03150160032007, 1 page.;;Chen, James, et al., “Disinfection Method and Apparatus,” U.S. Appl. No. 17/405,900, filed Aug. 18, 2021, 55pages.;;Chen, James, et al., “Antimicrobial Preventive Netting,” U.S. Appl. No. 17/244,688, filed Apr. 29, 2021, 35 pages.;;Chen, James, et al., “Photosensitizer Combination,” U.S. Appl. No. 17/463,245, filed Aug. 31, 2021, 46 pages.;;Chen, James, et al., “Invisible Singlet Film,” U.S. Appl. No. 17/389,936, filed Jul. 30, 2021, 33 pages.;;International Search Report and Written Opinion dated Feb. 2, 2022, issued in International Application No. PCT/US2021/046419, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion dated Feb. 1, 2022, issued in International Application No. PCT/US2021/048444, filed Aug. 31, 2021, 14 pages.;;International Search Report and Written Opinion dated Nov. 30, 2021, in International Application PCT/US2021/0046417, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion mailed Dec. 6, 2021, in International Application PCT/JS2021/046722, filed Aug. 19, 2021, 9 pages.;;International Search Report and Written Opinion dated Nov. 8, 2021, issued in International Application No. PCT/US2021/046416, filed Aug. 18, 2021, 9 pages.;;International Search Report and Written Opinion dated Dec. 6, 2021, in International Application PCT/US2021/046722, filed Aug. 19, 2021, 9 pages.",ACTIVE
37,US,A1,US 2023/0201582 A1,024-276-091-318-59X,2023-06-29,2023,US 202318171516 A,2023-02-20,US 202318171516 A;;US 202117250735 A;;US 2019/0048858 W;;US 201862724177 P,2018-08-29,DEVICES AND METHODS FOR TREATMENT OF TUMORS USING ELECTROMAGNETIC SIGNAL,"Systems and methods for treating cancerous tumors (including glioblastoma multiforme (GBM)) with electrotherapy, such as deep brain stimulation (DBS) technology, as disclosed herein. One or more configurations can be generated based on a patients tumor characteristics. The selected configurations can be electrode configurations or settings for an electrical source coupled to the electrodes. The one or more configurations can be targeted for inhibiting cell growth process, such as to inhibit mitosis, immune suppression, or to inhibit DNA replication. Inhibition of cell growth processes can initiate death of the cancerous cells.",UNIV MINNESOTA,CHEN CLARK C;;MOLNAR GREGORY FREDERICK,REGENTS OF THE UNIVERSITY OF MINNESOTA (2021-04-08),https://lens.org/024-276-091-318-59X,Patent Application,yes,0,0,4,4,0,A61N1/05;;A61B2576/026;;A61B5/4848;;A61B5/4064;;A61B5/0042;;A61B5/6868;;A61B2018/00321;;A61B2018/00482;;A61B2018/00565;;A61B2018/00577;;A61B18/1206;;A61B18/14;;A61N1/40;;G16H30/40;;B33Y80/00;;A61N1/36002;;A61N1/0534;;A61N1/36171;;A61N1/37211;;A61N1/40,A61N1/36;;A61N1/05;;A61N1/372;;A61N1/40;;B33Y80/00,,0,0,,,,PENDING
38,US,A1,US 2022/0054672 A1,032-672-291-955-248,2022-02-24,2022,US 202117405900 A,2021-08-18,US 202117405900 A;;US 202063068762 P;;US 202063074280 P,2020-08-21,DISINFECTION METHOD AND APPARATUS,"Photosensitizers are incorporated into articles, such a personal protective equipment. A method of applying continuous and consistent light includes fitting the articles with light sources and optical fibers to apply light to the areas of the articles incorporated with the photosensitizers. Photosensitizers can be applied to articles by various applicators in either a gel or solution. A gel can be particularly effective when used on hydrophobic surfaces. Photodynamic reactor systems can be used to determine the effective doses of photosensitizers and the light dosimetry which can then be applied for use with the articles.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/032-672-291-955-248,Patent Application,yes,0,1,3,5,0,A41D31/30;;A41D13/1192;;A41D13/12;;A41D19/015;;A61L2/088;;A61L2/232;;A61L2202/26;;A61L2/088;;A61L31/12;;A61L31/16;;A41D13/1192;;A41D13/0002;;A41D13/12;;A61L2202/14;;A61L2/28;;A61L2/084;;A61L2101/44;;A61L2202/11;;A61L2202/122;;A61L2202/26;;A61L2/18,A61L2/08;;A41D13/00;;A41D13/11;;A41D13/12;;A61L2/18;;A61L2/28;;A61L31/12;;A61L31/16,,0,0,,,,ACTIVE
39,US,B2,US 11425905 B2,137-798-923-665-689,2022-08-30,2022,US 202117244688 A,2021-04-29,US 202117244688 A;;US 202063073652 P,2020-09-02,Antimicrobial preventive netting,"An antimicrobial preventive netting is disclosed that includes one or more photosensitizers that are capable of generating a cloud of singlet oxygen on each surface and openings through the netting in response to incident light. A depth of the singlet oxygen cloud may be less than 0.7 centimeters from a netting surface. The netting may be supported by screens, enclosures or headgear. The netting can be made by dipping or soaking the netting in a solution of one or more photosensitizers.",UNIV WASHINGTON;;SEATTLE CHILDRENS HOSPITAL,CHEN JAMES;;CLARK TANNER;;LENDVAY THOMAS,SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE) (2021-12-13);;WASHINGTON UNIVERSITY OF (2021-12-10),https://lens.org/137-798-923-665-689,Granted Patent,yes,90,0,3,3,0,A01P1/00;;A01N59/00;;A61L2209/14;;A61L9/205;;A61L9/22;;E04H1/1277;;A01N25/34;;A01N43/84;;A01N43/16;;A01N43/90;;A61L9/18;;A61L2209/12;;E04H15/54;;A62B18/02;;A62B31/00;;A41D31/305;;A61L2209/14;;E04H15/46,A01N25/34;;A01N43/16;;A01N43/84;;A01N43/90;;A41D31/30;;A61L9/18;;A61L9/20;;A62B18/02;;A62B31/00;;E04H15/46;;E04H15/54,,73,52,104-735-392-666-045;;021-550-417-090-442;;079-481-920-229-614;;025-362-344-749-265;;091-819-263-711-397;;078-363-993-200-384;;105-490-966-873-865;;013-124-195-476-566;;015-149-066-563-085;;004-618-619-277-709;;011-091-787-318-51X;;058-244-677-368-129;;005-146-572-303-773;;013-514-292-332-752;;058-131-308-191-718;;017-214-137-653-709;;005-688-265-382-690;;115-394-470-241-357;;015-383-164-780-775;;046-608-698-175-106;;037-210-407-450-571;;029-694-646-332-779;;041-401-243-694-823;;058-195-152-855-719;;019-980-133-493-942;;004-603-966-374-149;;017-589-172-330-383;;066-896-390-438-883;;024-668-409-019-008;;165-313-740-952-121;;002-076-612-988-747;;027-369-533-036-285;;029-970-078-876-361;;019-055-342-526-925;;015-986-570-318-191;;033-515-425-498-28X;;006-233-231-990-589;;151-236-689-453-284;;040-094-909-340-017;;033-466-657-266-228;;046-415-043-790-959;;027-268-121-505-214;;000-409-973-377-909;;042-023-960-529-83X;;036-999-860-923-650;;096-826-407-988-334;;071-315-468-972-414;;055-611-002-759-124;;147-739-746-094-573;;058-214-960-300-659;;032-374-355-070-495;;056-184-862-634-367,10.1021/ja00351a001;;17177354;;10.1021/ja066739b;;10.1039/b926014p;;20571680;;24885074;;pmc4234451;;10.1021/jp503149x;;10.1038/s41467-018-05223-3;;30022060;;pmc6052022;;25155698;;10.1039/c4cp02439g;;pmc6698391;;10.1021/acsami.8b09439;;29972022;;10.1155/2019/2584686;;pmc6399532;;30915256;;pmc3812664;;10.1021/es303645n;;23075418;;10.1021/acsabm.0c00114;;35025286;;10.1111/iej.13057;;30548497;;27069623;;10.1186/s13756-016-0111-x;;pmc4827199;;pmc2953188;;10.1128/jvi.00502-10;;20739541;;21779206;;pmc3132980;;10.1159/000323786;;pmc2763101;;10.3390/md7030268;;19841715;;pmc7168192;;31906034;;10.3390/antibiotics9010013;;pmc7139796;;10.3390/cancers12030545;;32120810;;22664163;;10.1016/j.jaci.2012.03.050;;31658786;;pmc6963634;;10.3390/vaccines7040144;;31471148;;10.1016/j.vaccine.2019.08.037;;29678452;;10.1016/j.ajic.2018.02.018;;pmc7115285;;29033339;;10.1016/j.tim.2017.09.007;;pmc5777272;;28724343;;10.1080/14760584.2017.1357471;;pmc4724431;;25595808;;10.1016/bs.pmbts.2014.10.012;;10.1016/j.vaccine.2013.11.036;;24262313;;pmc3906608;;20692307;;pmc2975779;;10.1016/j.jconrel.2010.07.125;;20375174;;pmc2876658;;10.1128/jvi.02690-09;;10.1128/cvi.00353-09;;pmc2815535;;20007362;;19768415;;10.1007/978-3-540-92165-3_18;;pmc2904604;;10.1371/journal.ppat.1000138;;pmc2516931;;18769719;;10.1073/pnas.0601932103;;16617103;;pmc1436023;;8896540;;10.1093/infdis/174.supplement_3.s324;;10.5812/jamm.96149;;pmc4187643;;25278571;;10.1128/cmr.00020-14;;10.1186/s40560-015-0120-5;;26693023;;pmc4676153;;24286078;;10.1155/2013/429780;;pmc3830765;;10.1186/2191-0855-3-59;;pmc3851522;;24090112;;10.1155/2012/302029;;30929100;;10.1007/s10103-019-02774-9;;10.4172/2153-2435.1000403;;22368354;;pmc3283927;;10.4103/0972-124x.92563;;10.4103/jisp.jisp_157_17;;pmc5803877;;29440788;;10.1038/ijos.2012.63;;23222991;;pmc3633065;;10.1016/j.pdpdt.2016.06.011;;27375182;;16464894;;10.1093/jac/dkl021;;22011544;;10.1086/662377;;10.4209/aaqr.2010.12.0105;;10.1172/jci81532;;pmc4563760;;26168222;;10.1039/c2jm31987j;;10.1039/c3sc53186d;;10.1039/b905495b;;10.1001/jama.1969.03150160032007;;10.1001/jama.207.3.520;;5818213,"Midden, R.W., Wang, S.Y., “Singlet Oxygen Generation for Solution Kinetics: Clean and Simple,” Journal of the American Chemical Society, 105(13):4129-4135, Jun. 29, 1983.;;Naito, K. et al. “Single-molecule detection of airborne singlet oxygen,” Journal of the American Chemical Society 128 (51): p. 16430-16431, Nov. 30, 2006.;;Ogilby, P. R. “Singlet oxygen: There is indeed something new under the sun,” Chemical Society reviews 39(8): pp. 3181-3209, Jun. 22, 2010.;;Zhao, Y. et al. “Singlet oxygen generation on porous superhydrophobic surfaces: Effect of gas flow and sensitizer vetting on trapping efficiency,” The Journal of Physical Chemistry A 118(45): pp. 10364-10371, 2014.;;Gao, R. et al. “Nano-photosensitizer based on layered double hydroxide and isophthalic acid for singlet oxygenation and photodynamic therapy,” Nature communications 9(1):2798, pp. 1-10, 2018.;;Felgenträger, A., et al. “Singlet oxygen generation in porphyrin-doped polymeric surface coating enables antimicrobial effects on staphylococcus aureus,” Physical Chemistry Chemical Physics:PCCP, 16(38): pp. 20598-20607, Aug. 7, 2014.;;Pushalkar, S. et al. “Superhydrophobic photosensitizers: Airborne 1O2 killing of an in vitro oral biofilm at the plastron interface,” ACS Applied Materials & Interfaces 10(30): pp. 25819-25829, Jul. 4, 2018.;;Hwang, J. et al. “Study of singlet oxygen dynamics on silicon polymer matrix,” Journal of Analytical Methods in Chemistry vol. 2019 Article ID 2584686, pp. 1-6, Feb. 19, 2019.;;Bartusik, D. et al. “Bacterial inactivation by a singlet oxygen bubbler: Identifying factors controlling the toxicity of 1O2 bubbles,” Environmental Science & Technology 46(21): pp. 12098-12104, Oct. 18, 2012.;;Aebisher, D. et al. “Superhydrophobic surfaces as a source of airborne singlet oxygen through free space for photodynamic therapy,” ACS Applied Bio Materials 3(4): pp. 2370-2377, Mar. 17, 2020.;;Plotino, G., et al. “Photodynamic therapy in endodontics,” International Endodontic Journal (52): pp. 760-774, 2019.;;Meller, D., et al. “Photodisinfection Therapy: Essential Technology for Infection Control,” <https://infectioncontrol.tips/2020/01/17/photodisinfection-therapy/> [retrieved Jul. 30, 2020], 20 pages.;;Boyce, J.M., “Modern technologies for improving cleaning and disinfection of environmental surfaces in hospitals,” ©2016 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4827199/> [retrieved Jul. 30, 2020], 20 pages.;;“What is Photodisinfection?,” Ondine Biomedical, <https://ondinebio.com/technology> [retrieved Aug. 12, 2020], 5 pages.;;International Search Report and Written Opinion dated Nov. 30, 2021, in International Application PCT/US2021/0046417, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion dated Dec. 6, 2021, in International Application PCT/US2021/046722, filed Aug. 19, 2021, 9 pages.;;International Search Report and Written Opinion dated Nov. 8, 2021, issued in International Application No. PCT/US2021/046416, filed Aug. 18, 2021, 9 pages.;;Chen, James, et al., “Disinfection Method and Apparatus,” U.S. Appl. No. 17/405,900, filed Aug. 18, 2021, 55pages.;;Chen, James, et al., “Photosensitizer Combination,” U.S. Appl. No. 17/463,245, filed Aug. 31, 2021, 46 pages.;;Chen, James, et al., “Invisible Singlet Film,” U.S. Appl. No. 17/389,936, filed Jul. 30, 2021, 33 pages.;;Chen, James, et al., “Vaccine Generation,” U.S. Appl. No. 17/244,610, filed Apr. 29, 2021, 19 pages.;;Marcus, P. et al. “In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines,” Journal of Virology 84(21): pp. 10974-10981, Nov. 2010.;;Seghatchian, J_ et al. “Main properties of the THERAFLEX MB-plasma system for pathogen reduction,” Transfusion Medicine and Hemotherapy 38(1): pp. 55-64, 2011.;;Almeida, A., et al. “Phage Therapy and Photodynamic Therapy: Low Environmental Impact Approaches to Inactivate Microorganisms in Fish Farming Plants,” Marine Drugs 7(3): pp. 268-313, 2009.;;Hasenleitner, M., et al. “In the Right Light: Photodynamic Inactivation of Microorganisms Using a LED-Based Illumination Device Tailored for the Antimicrobial Application,” Antibiotics 9(1 ): pp. 1-13, 2020.;;Trempolec, N., et al. “Photodynamic Therapy-Based Dendritic Cell Vaccination Suited to Treat Peritoneal Mesothelioma.” Cancers 12.3 (2020): 545.;;Mertes, P., et al. “Methylene blue-treated plasma: an increased allergy risk?” The Journal of Allergy and Clinical Immunology 130(3): pp. 808-812, 2012.;;Henneberry, B. How Surgical Masks are Made. Thomas Industry.<https://www.thomasnet.com/articles/other/how-surgical-masks-are-made/>[Accessed Mar. 21, 2020], 1 page.;;Clear Polypropylene Omnexus: The material selection platform.<https://omnexus.specialchem.com/centers/clear-polypropylene> [Accessed Mar. 21, 2020], 1 page.;;Weaver, E.A. “Dose Effects of Recombinant Adenovirus Immunization in Rodents,” Vaccines 7(4):144 pp. 1-11, 2019.;;Hankaniemi, M.M., et al. “A comparative study of the effect of UV and formalin inactivation on the stability and Immunogenicity of a coxsackievirus B1 vaccine,” Vaccine 37: pp. 5962-5971, 2019.;;Mills, D., et al. “Ultraviolet germicidal irradiation of influenza-contaminated N95 filtering facepiece respirators,” AJIC: American Journal of Infection Control 46(7): pp. e49-e55, 2018.;;Bull, J.J., et al. “Transmissible Viral Vaccines,” Trends in Microbiology 26(1): pp. 6-15, Jan. 2018.;;Barrett, P.N., et al. “Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases,” Expert Review of Vaccines 16(9): pp. 883-894, 2017.;;Klasse, P.J. “Molecular determinants of the ratio of inert to infectious virus particles,” Progress in Molecular Biology and Translational Science 129: pp. 285-326, 2015.;;Klausberger, M. et al. “One-shot vaccination with an insect cell- derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge,” Vaccine 32(3): pp. 355-362, 2014.;;Quan, F. et al. “Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles,” Journal of Controlled Release 147(3): pp. 326-332, 2010.;;Victoria, J_ et al. “Viral nucleic acids in live-attenuated vaccines: Detection of minority variants and an adventitious virus,” Journal of Virology 84(12): pp. 6033-6040, Jun. 2010.;;Maves, R. et al. “Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice.” Clinical and Vaccine Immunology 17(2): pp. 304-306, Feb. 2010.;;Prausnitz, M.R., et al. “Microneedle-based vaccines,” Current Topics in Microbiology and Immunology 333: pp. 369-393, 2009.;;Geeraedts, F., et al. “Superior immunogenicity of inactivated whole virus H5N 1 influenza vaccine is primarily controlled by toll-like receptor signalling,” PLoS Pathogens 4(8): p. e1000138, Aug. 2008.;;Monath, T.P. et al. “A live, attenuated recombinant west nile virus vaccine,” Proceedings of the National Academy of Sciences, USA 103(17): pp. 6694-6699, Apr. 25, 2006.;;Meurice, F. et al. “Immunogenicity and safety of a live attenuated varicella vaccine (oka/SB bio) in healthy children,” The Journal of Infectious Diseases 174(Supplement 3): pp. S324-S329, Nov. 1996.;;THERAFLEX-MB Plasma-Processing Principle, advertisement published by MacoPharma, Sep. 2007.;;“Influenza Vaccine,” Cytiva, https://www.gelifesciences.com/en/us/solutions/bioprocessing/knowledge-center/influenza, vaccine-manufacturing [retrieved Mar. 30, 2020], 10 pages.;;Borkar, T.G., et al. “Techniques Employed in Production of Traditional Vaccines Commonly Used by Military Forces: A Review,” Journal of Archives in Military Medicine 7(102):e96149, pp. 1-12, Jun. 2019.;;Dancer, Stephanie J. “Controlling hospital-acquired infection: focus on the role of the environment and new technologies for decontamination.” Clinical microbiology reviews 27.4 (2014): 665-690.;;Pyrek, K. “Portable medical equipment: A significant source of transmission,” Feb. 1, 2018, 16 pages.;;Russotto, V., Cortegiani, A., Raineri, S. M., & Giarratano, A. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. Journal of Intensive Care. 2015;3(1):54, pp. 1-8.;;Gabriele Messina, Emma Ceriale, Daniele Lenzi, Sandra Burgassi, Elena Azzolini, Pietro Manzi. Environmental contaminants in hospital settings and progress in disinfecting techniques. BioMed research international. 2013;2013:429780, 8 pages.;;Bonetta S, Bonetta S, Motta F, Strini A, Carraro E. Photocatalytic bacterial inactivation by TiO2-coated surfaces. AMB Expr. 2013;3(1):1-8. https://www.ncbi.nlm.nih.gov/pubmed/24090112. doi: 10.1186/2191-0855-3-59.;;Air permeable(breathable) film, <http://tamstech.net> [Accessed Mar. 25, 2020], 1 page.;;Siracusa, Valentina. “Food packaging permeability behaviour: A report.” International Journal of Polymer Science 2012 (2012), 2 pages.;;Makdoumi K, Hedin M, Backman A. Different photodynamic effects of blue light with and without riboflavin on methicillin-resistant staphylococcus aureus (MRSA) and human keratinocytes in vitro. Lasers Med Sci. 2019;34(9):1799-1805.;;Kino, K., et al. Commentary on the phototoxicity and absorption of vitamin B2 and its degradation product, lumichrome. Pharmaceutica analytica acta. 2015;6(8) doi: 10.4172/2153-2435. 1000403.;;Koshi E, Mohan A, Rajesh S, Philip K. Antimicrobial photodynamic therapy: An overview. Journal of Indian Society of Periodontology. 2011;15(4):323-327, 1 page.;;Bhat M, Acharya S, Prasad K, Kulkarni R, Bhat A, Bhat D. Effectiveness of erythrosine-mediated photodynamic antimicrobial chemotherapy on dental plaque aerobic microorganisms: A randomized controlled trial. Journal of Indian Society of Periodontology. 2017;21(3):210-215.;;Lee Y, Park H, Lee J, Seo H, Lee S. The photodynamic therapy on streptococcus mutans biofilms using erythrosine and dental halogen curing unit. International journal of oral science 2012;4(4):196-201.;;Fracalossi C, Nagata JY, Pellosi DS, et al. Singlet oxygen production by combining erythrosine and halogen light for photodynamic inactivation of streptococcus mutans. Photodiagnosis and Photodynamic Therapy. 2016;15:127-132. https://search.datacite.org/works/10.1016/j.pdpdt.2016.06.011. doi: 10.1016/j.pdpdt.2016.06.011, 1 page.;;Wood S, Metcalf D, Devine D, Robinson C. Erythrosine is a potential photosensitizer for the photodynamic therapy of oral plaque biofilms. Journal of antimicrobial chemotherapy. 2006;57(4):680-684.;;Gahleitner, Markus, et al. Sterilization effects on polypropylene: technology and polymer type effects., Jan. 2003, <https://www.researchgate.net/publication/288596501>, 3 pages.;;“Cover Picture: Optik & Photonik Apr. 2015,” Abstract, vol. 10, Issue 4, 2015,<https://doi.org/10.1002/opph.201590064>, 2 pages.;;Molitch-Hou, M., “First 3D Printed Fiber Optics Created by University of Sydney researchers with Desktop 3d Printer,” 2015, 3D Printing Industry, The Authority on Additive Manufacturing, <https://3dprintingindustry.com/news/first-3d-printed-fiber-optics-createdby-university-of-sydney-researchers-with-desktop-3d-printer-55047/> [Accessed Mar. 24, 2020], 1 page.;;Ismail, Salim, et al. “Efficacy of a novel light-activated antimicrobial coating for disinfecting hospital surfaces.” Infection Control & Hospital Epidemiology 32.11 (2011): 1130-1132.;;Lee, Im-Soon, et al. “Aerosol particle size distribution and genetic characteristics of aerosolized influenza A H1N1 virus vaccine particles.” Aerosol and Air Quality Research 11.3 (2011): 230-237.;;Meyer, Michelle, et al. “Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.” The Journal of clinical investigation 125.8 (2015): 3241-3255.;;Noimark, Sacha, et al. “Incorporation of methylene blue and nanogold into polyvinyl chloride catheters; a new approach for light-activated disinfection of surfaces.” Journal of Materials Chemistry. 2012; 22(30): 15388-15396. <https://doi.org/10.1039/C2JM31987J>, 1 page.;;Noimark, Sacha, Elaine Allan, and Ivan P. Parkin. “Light-activated antimicrobial surfaces with enhanced efficacy induced by a dark-activated mechanism.” Chemical Science 5.6 (2014): 2216-2223.;;Piccirillo, Clara, et al. “Antimicrobial activity of methylene blue and toluidine blue O covalently bound to a modified silicone polymer surface.” Journal of Materials Chemistry 19.34 (2009): 6167-6171.;;Fecht, S., “The First Fully 3-D Printed LEDs Are Here,” 2014, <https://www.popsci.com/article/technology/first-fully-3-d-printed-leds-are-here/> [Accessed Mar. 24, 2020], 8 pages.;;Waldman, Robert H., John J. Mann, and Parker A. Small. “Immunization against influenza: prevention of illness in man by aerosolized inactivated vaccine.” Jama 207.3 (1969): 520-524 doi:10.1001/jama.1969.03150160032007, 1 page.;;International Search Report and Written Opinion dated Feb. 2, 2022, issued in International Application No. PCT/US2021/046419, filed Aug. 18, 2021, 11 pages.;;International Search Report and Written Opinion dated Feb. 1, 2022, issued in International Application No. PCT/US2021/048444, filed Aug. 31, 2021, 14 pages.",ACTIVE
40,WO,A1,WO 2022/232223 A1,051-281-582-889-448,2022-11-03,2022,US 2022/0026464 W,2022-04-27,US 202163180995 P,2021-04-28,TREATING CANCER,"This document relates to methods and materials for treating cancer. For example, this document provides nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs. In some cases, nanoparticles (e.g., liposomes and LNPs) encapsulating one or more microRNAs and/or one or more anti-microRNAs can be administered to a mammal (e.g., a human) having cancer to treat the mammal.",UNIV JOHNS HOPKINS;;UNIV MINNESOTA,KOKKOLI EFROSINI;;CHEN CLARK C;;SCHNEIDERMAN ZACHARY,,https://lens.org/051-281-582-889-448,Patent Application,yes,4,0,1,1,22,B82Y30/00;;A61K47/42;;C12N15/113;;C12N2320/32;;C12N2310/141;;C12N2310/113;;C12N2320/31;;C12N2310/3231;;A61K47/59;;A61K9/5169;;A61K9/0019;;A61K9/1272,A61K47/42;;B82Y30/00;;C12N15/11;;C12N15/113,,1,1,004-522-111-906-977,34452076;;10.3390/pharmaceutics13081115;;pmc8399469,"SHABANA AHMED M., XU BEIBEI, SCHNEIDERMAN ZACHARY, MA JUN, CHEN CLARK C., KOKKOLI EFROSINI: ""Targeted Liposomes Encapsulating miR-603 Complexes Enhance Radiation Sensitivity of Patient-Derived Glioblastoma Stem-Like Cells"", PHARMACEUTICS, vol. 13, no. 1115, 21 July 2021 (2021-07-21), pages 1 - 12, XP093003083",PENDING
41,US,A1,US 2020/0306313 A1,051-898-745-596-173,2020-10-01,2020,US 202016900178 A,2020-06-12,US 202016900178 A;;US 201615308915 A;;US 2015/0029612 W;;US 201461990698 P;;US 201462061370 P,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2016-11-29),https://lens.org/051-898-745-596-173,Patent Application,yes,0,0,7,7,2,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K35/28;;A61K31/395;;A61K38/19;;A61M1/34;;A61M1/38;;C12N5/0789,,1,1,031-281-625-246-624,pmc3271026;;19895994;;10.1016/j.jaci.2009.08.041,"Patel et al, J. Allergy Clin. Immunol. 124: 1062-1069, 2009",PENDING
42,US,A1,US 2017/0080031 A1,083-621-295-747-964,2017-03-23,2017,US 201515308915 A,2015-05-07,US 201515308915 A;;US 201461990698 P;;US 201462061370 P;;US 2015/0029612 W,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,THE BOARD OF REGENT OF THE UNIV OF TEXAS SYSTEM,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2016-11-29),https://lens.org/083-621-295-747-964,Patent Application,yes,0,6,7,7,2,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K35/28;;A61K31/395;;A61K38/19;;A61M1/34;;A61M1/38;;C12N5/0789,,0,0,,,,DISCONTINUED
43,US,A1,US 2022/0029876 A1,027-756-602-490-861,2022-01-27,2022,US 202016938430 A,2020-07-24,US 202016938430 A,2020-07-24,METHOD AND SYSTEM FOR ROOT CAUSE ANALYSIS OF NETWORK ISSUES,"An event analysis system in a network is provided. During operation, the system can determine a set of monitoring elements in the network. A respective monitoring element can facilitate monitoring of events in the network. The system can then represent a respective monitoring element as a node of a graph. If the corresponding monitoring elements are related based on a relationship definition, the system can connect a node pair of the graph with an edge. The system can activate a set of nodes of the graph corresponding to an issue in the network based on notifications from one or more monitoring agents on one or more switches in the network. Subsequently, the system can determine a root cause of the issue by traversing the set of activated nodes of the graph and determine a recovery action for mitigating the root cause.",HEWLETT PACKARD ENTPR DEV LP,MERCIAN ANU;;CHEN CHINLIN;;CLARK CHARLES F,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2020-07-21),https://lens.org/027-756-602-490-861,Patent Application,yes,15,4,5,5,0,H04L41/0631;;H04L41/0654;;H04L43/08;;H04L43/50;;H04L45/70;;H04L45/12;;G06N3/006;;G06N20/00;;G06N5/02;;H04L41/0631;;H04L41/0654;;H04L43/0817;;H04L41/12;;H04L41/16;;H04L41/0631;;G06N20/00;;H04L49/25;;H04L45/12;;H04L43/12;;H04L41/0654,G06N20/00,,0,0,,,,ACTIVE
44,AU,A1,AU 2021/204760 A1,145-902-372-821-485,2022-07-21,2022,AU 2021/204760 A,2021-07-07,NZ 77165921 A,2021-01-05,CONVERSATION ORCHESTRATION IN INTERACTIVE AGENTS,"Abstract A computer-implemented multi-conversation orchestration system for managing an interactive conversation between a user and a computer system presenting an Agent, including: a set of conversation Rules, each Conversation Rule including a Condition and an Action configured to modify the interactive conversation; and a Router, configured to: receive Input Requests from the user and forward the Input Requests to a Conversation Instance from a set of two or more Conversation Instances, wherein each Conversation Instance is configured to deliver conversational content from at least one Conversation Source; and receive Output Responses from the two or more Conversation Instances and forward the Output Responses to the user; wherein the Router is configured to trigger corresponding Conversation Rule Actions when Conversation Rule Conditions are matched from Input Requests and/or Output Responses. Conversation Controller Input Request Output Response Router Conversation Instance A Conversation Instance B Conversation Instance N 10A 10B 10N",SOUL MACHINES,CHEN JEREMY;;CLARK-YOUNGER HANNAH;;HASLAM ANDREW,,https://lens.org/145-902-372-821-485,Patent Application,no,0,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02,,0,0,,,,PENDING
45,EP,A4,EP 3139913 A4,181-902-578-950-464,2018-04-04,2018,EP 15789962 A,2015-05-07,US 201461990698 P;;US 201462061370 P;;US 2015/0029612 W,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,,https://lens.org/181-902-578-950-464,Search Report,no,1,0,7,7,0,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K31/137;;A61K31/381;;A61K31/395;;A61K35/28;;A61K38/19;;A61M1/34;;A61M1/38;;A61P31/18;;C12N5/0781,,5,5,175-787-819-389-447;;016-176-042-633-245;;030-771-585-823-639;;021-062-731-284-795;;059-067-144-057-67X,20938660;;10.1007/s00277-010-1098-7;;pmc3070880;;10.1159/000354229;;pmc3776405;;24415962;;24151324;;10.1093/infdis/jit382;;pmc3807977;;23587921;;10.1038/mt.2013.65;;pmc3677314;;24381033;;pmc3917431;;10.3390/v6010054,"GRZEGORZ WLADYSLAW BASAK ET AL: ""Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience"", ANNALS OF HEMATOLOGY, SPRINGER, BERLIN, DE, vol. 90, no. 5, 12 October 2010 (2010-10-12), pages 557 - 568, XP019893245, ISSN: 1432-0584, DOI: 10.1007/S00277-010-1098-7;;FRUEHAUF STEFAN: ""Current clinical indications for plerixafor"", TRANSFUSION MEDICINE AND HEMOTHERAPY, KARGER, BASEL, CH, vol. 40, no. 4, 1 August 2013 (2013-08-01), pages 246 - 250, XP002745249, ISSN: 1660-3796, [retrieved on 20130719], DOI: 10.1159/000354229;;U. HOFER ET AL: ""Pre-clinical Modeling of CCR5 Knockout in Human Hematopoietic Stem Cells by Zinc Finger Nucleases Using Humanized Mice"", JOURNAL OF INFECTIOUS DISEASES. JID, vol. 208, no. suppl 2, 22 October 2013 (2013-10-22), CHICAGO, IL., pages S160 - S164, XP055422378, ISSN: 0022-1899, DOI: 10.1093/infdis/jit382;;LI L ET AL: ""Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases"", MOL THER,, vol. 21, no. 6, 1 June 2013 (2013-06-01), pages 1259 - 1269, XP002774948;;BRYAN BURKE ET AL: ""CCR5 as a Natural and Modulated Target for Inhibition of HIV"", VIRUSES, vol. 6, no. 1, 30 December 2013 (2013-12-30), CH, pages 54 - 68, XP055287500, ISSN: 1999-4915, DOI: 10.3390/v6010054",DISCONTINUED
46,CN,A,CN 106470676 A,052-958-478-542-135,2017-03-01,2017,CN 201580036739 A,2015-05-07,US 201461990698 P;;US 201462061370 P;;US 2015/0029612 W,2014-05-08,Methods and compositions for non-cytotoxic stem cell transplantation,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,,https://lens.org/052-958-478-542-135,Patent Application,no,2,0,7,7,0,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K31/137;;A61K31/381;;A61K31/395,,0,0,,,,DISCONTINUED
47,US,B2,US 11349703 B2,094-870-699-689-306,2022-05-31,2022,US 202016938430 A,2020-07-24,US 202016938430 A,2020-07-24,Method and system for root cause analysis of network issues,"An event analysis system in a network is provided. During operation, the system can determine a set of monitoring elements in the network. A respective monitoring element can facilitate monitoring of events in the network. The system can then represent a respective monitoring element as a node of a graph. If the corresponding monitoring elements are related based on a relationship definition, the system can connect a node pair of the graph with an edge. The system can activate a set of nodes of the graph corresponding to an issue in the network based on notifications from one or more monitoring agents on one or more switches in the network. Subsequently, the system can determine a root cause of the issue by traversing the set of activated nodes of the graph and determine a recovery action for mitigating the root cause.",HEWLETT PACKARD ENTPR DEV LP,MERCIAN ANU;;CHEN CHINLIN;;CLARK CHARLES F,HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP (2020-07-21),https://lens.org/094-870-699-689-306,Granted Patent,yes,22,2,5,5,0,H04L41/0631;;H04L41/0654;;H04L43/08;;H04L43/50;;H04L45/70;;H04L45/12;;G06N3/006;;G06N20/00;;G06N5/02;;H04L41/0631;;H04L41/0654;;H04L43/0817;;H04L41/12;;H04L41/16;;H04L41/0631;;G06N20/00;;H04L49/25;;H04L45/12;;H04L43/12;;H04L41/0654,H04L41/0631;;G06N20/00;;H04L41/0654;;H04L43/12;;H04L45/12;;H04L49/25,,2,2,052-876-563-303-21X;;131-536-973-114-107,10.1007/978-3-030-45778-5_10;;10.1109/comst.2018.2866942,"Salaün, A. et al., “Space-time Pattern Extraction in Alarm Logs for Network Diagnosis,” 2nd IFIP International Conference on Machine Learning for Networking, Dec. 2019, pp. 1-20.;;Xie, J. et al., “A Survey of Machine Learning Techniques Applied to Software Defined Networking (SDN): Research Issues and Challenges,” IEEE Communications Surveys & Tutorials, Aug. 23, 2018, vol. 21, No. 1, pp. 393-430.",ACTIVE
48,DE,A1,DE 102021109228 A1,044-557-810-238-753,2022-01-27,2022,DE 102021109228 A,2021-04-13,US 202016938430 A,2020-07-24,VERFAHREN UND SYSTEM ZUR URSACHENANALYSE VON NETZWERKPROBLEMEN,"Ein System zur Ereignisanalyse in einem Netzwerk wird bereitgestellt. Während des Betriebs kann das System einen Satz von Überwachungselementen in dem Netzwerk bestimmen. Ein jeweiliges Überwachungselement kann die Überwachung von Ereignissen im Netzwerk ermöglichen. Das System kann dann ein jeweiliges Überwachungselement als einen Knoten eines Graphen darstellen. Wenn die entsprechenden Überwachungselemente auf der Grundlage einer Beziehungsdefinition miteinander in Beziehung stehen, kann das System ein Knotenpaar des Graphen mit einer Kante verbinden. Das System kann einen Satz von Knoten des Graphen aktivieren, der einem Problem im Netz entspricht, und zwar auf der Grundlage von Benachrichtigungen von einem oder mehreren Überwachungsagenten auf einem oder mehreren Schaltern im Netz. Anschließend kann das System eine Grundursache des Problems bestimmen, indem es die Menge der aktivierten Knoten des Graphen durchläuft, und eine Wiederherstellungsmaßnahme zur Abschwächung der Grundursache bestimmen.",HEWLETT PACKARD ENTPR DEV LP,MERCIAN ANU;;CHEN CHINLIN;;CLARK CHARLES F,"HEWLETT PACKARD ENTERPRISE DEVELOPMENT LP, SPR, US (2022-10-07)",https://lens.org/044-557-810-238-753,Patent Application,no,0,0,5,5,0,H04L41/0631;;H04L41/0654;;H04L43/08;;H04L43/50;;H04L45/70;;H04L45/12;;G06N3/006;;G06N20/00;;G06N5/02;;H04L41/0631;;H04L41/0654;;H04L43/0817;;H04L41/12;;H04L41/16;;H04L41/0631;;G06N20/00;;H04L49/25;;H04L45/12;;H04L43/12;;H04L41/0654,H04L43/00,,0,0,,,,PENDING
49,US,B1,US 10652380 B1,173-001-757-686-744,2020-05-12,2020,US 201816218790 A,2018-12-13,US 201816218790 A;;US 201715720994 A,2017-09-29,Techniques to manage contact records,"Exemplary embodiments relate to techniques for managing contact information received in the context of a messaging system. Messages may be received from known contacts which contain user contact records for third parties. Based on the trust relationship with the known contacts, the user contact record is placed in a contact record repository for later retrieval. When another message is received which either references the user contact record or is from the third party referenced in the user contact record, a dialog box is presented offering the user the opportunity to add the user contact record as an address entry in the address book of the device.",WHATSAPP INC,DONOHUE MICHAEL B;;CHEN CLARK;;LIU ALAN,WHATSAPP LLC (2017-10-11),https://lens.org/173-001-757-686-744,Granted Patent,yes,7,0,4,4,0,H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/216;;H04L51/56;;H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/56;;H04L51/212;;H04L51/216;;H04L51/224,H04M1/2745;;H04L12/58;;H04M1/7243;;H04M1/72484,,0,0,,,,ACTIVE
50,WO,A3,WO 2015/171852 A3,189-173-634-070-124,2016-07-07,2016,US 2015/0029612 W,2015-05-07,US 201462061370 P;;US 201461990698 P,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,,https://lens.org/189-173-634-070-124,Search Report,yes,2,0,7,7,2,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K31/137;;A61K31/381;;A61K31/395,,0,0,,,,PENDING
51,CN,A,CN 1331702 A,007-344-752-431-051,2002-01-16,2002,CN 99814884 A,1999-11-23,US 19764498 A,1998-11-23,Reduced molecular weight native gellan gum,,CP CALCO AMERICA INC,CLARK R;;MORRISON N;;YOU-LUNG CHEN,,https://lens.org/007-344-752-431-051,Patent Application,no,0,7,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A23C9/152;;A21D13/08;;A23G9/32;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,,0,0,,,,DISCONTINUED
52,CN,A,CN 113973042 A,035-999-898-515-840,2022-01-25,2022,CN 202110420913 A,2021-04-19,US 202016938430 A,2020-07-24,METHOD AND SYSTEM FOR ROOT CAUSE ANALYSIS OF NETWORK ISSUES,"The invention relates to a method and system for root cause analysis of network issues. An event analysis system in a network is provided. During operation, the system can determine a set of monitoring elements in the network. A respective monitoring element can facilitate monitoring of events in the network. The system can then represent a respective monitoring element as a node of a graph. If the corresponding monitoring elements are related based on a relationship definition, the system can connect a node pair of the graph with an edge. The system can activate a set of nodes of the graph corresponding to an issue in the network based on notifications from one or more monitoring agents on one or more switches in the network. Subsequently, the system can determine a root cause of the issue by traversing the set of activated nodes of the graph and determine a recovery action for mitigating the root cause.",HEWLETT PACKARD ENTPR DEV LP,MERCIAN ANU;;CHEN CHINLIN;;CLARK CHARLES F,,https://lens.org/035-999-898-515-840,Patent Application,no,5,0,5,5,0,H04L41/0631;;H04L41/0654;;H04L43/08;;H04L43/50;;H04L45/70;;H04L45/12;;G06N3/006;;G06N20/00;;G06N5/02;;H04L41/0631;;H04L41/0654;;H04L43/0817;;H04L41/12;;H04L41/16;;H04L41/0631;;G06N20/00;;H04L49/25;;H04L45/12;;H04L43/12;;H04L41/0654,H04L41/0631;;H04L41/0654;;H04L43/08;;H04L43/50,,0,0,,,,ACTIVE
53,US,A1,US 2014/0274668 A1,098-363-796-169-264,2014-09-18,2014,US 201414293468 A,2014-06-02,US 201414293468 A;;US 65103209 A;;US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",GRACE W R & CO,GONZALEZ KELLY;;WILLIAMS CLARK C;;CHEN LINFENG,W. R. GRACE & CO.-CONN (2013-10-10),https://lens.org/098-363-796-169-264,Patent Application,yes,6,1,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F10/06,502/127,0,0,,,,ACTIVE
54,US,B1,US 10194010 B1,025-282-605-023-180,2019-01-29,2019,US 201715720994 A,2017-09-29,US 201715720994 A,2017-09-29,Techniques to manage contact records,"Exemplary embodiments relate to techniques for managing contact information received in the context of a messaging system. Messages may be received from known contacts which contain user contact records for third parties. Based on the trust relationship with the known contacts, the user contact record is placed in a contact record repository for later retrieval. When another message is received which either references the user contact record or is from the third party referenced in the user contact record, a dialog box is presented offering the user the opportunity to add the user contact record as an address entry in the address book of the device.",WHATSAPP INC,DONOHUE MICHAEL B;;CHEN CLARK;;LIU ALAN,WHATSAPP LLC (2017-10-11),https://lens.org/025-282-605-023-180,Granted Patent,yes,9,5,4,4,0,H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/216;;H04L51/56;;H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/56;;H04L51/212;;H04L51/216;;H04L51/224,H04M1/2745;;H04L12/58;;H04M1/7243;;H04M1/72484,,0,0,,,,ACTIVE
55,EP,A2,EP 3139913 A2,126-295-039-220-394,2017-03-15,2017,EP 15789962 A,2015-05-07,US 201461990698 P;;US 201462061370 P;;US 2015/0029612 W,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,,https://lens.org/126-295-039-220-394,Patent Application,yes,0,0,7,7,2,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,A61K31/137;;A61K31/381;;A61K31/395,,0,0,,,,DISCONTINUED
56,WO,A2,WO 2015/171852 A2,198-053-371-820-527,2015-11-12,2015,US 2015/0029612 W,2015-05-07,US 201462061370 P;;US 201461990698 P,2014-05-08,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG,,https://lens.org/198-053-371-820-527,Patent Application,yes,0,4,7,7,2,A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K38/193;;A61P31/18;;A61K31/395;;A61M1/38;;C12N5/0647;;A61M2202/0437;;A61K31/395;;A61K35/28;;A61K38/193;;A61M1/3496;;C12N2510/00,C12N5/078,,0,0,,,,PENDING
57,US,B2,US 9464144 B2,053-053-467-040-375,2016-10-11,2016,US 201414293468 A,2014-06-02,US 201414293468 A;;US 65103209 A;;US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,Enhanced procatalyst composition and process,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",W R GRACE & CO —CONN,GONZALEZ KELLY;;WILLIAMS CLARK C;;CHEN LINFENG,W. R. GRACE & CO.-CONN (2013-10-10),https://lens.org/053-053-467-040-375,Granted Patent,yes,104,1,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F10/06;;C08F110/06;;C08F210/06,,29,17,157-075-458-519-227;;054-988-098-086-780;;028-058-204-006-569;;000-564-102-869-246;;117-317-490-852-933;;131-439-169-675-785;;096-277-516-411-420;;065-043-441-103-290;;065-043-441-103-290;;043-304-176-025-459;;065-043-441-103-290;;001-066-237-416-732;;041-477-728-822-273;;071-802-167-990-705;;040-987-453-097-466;;017-175-501-878-113;;105-647-274-528-780,10.1021/jo00195a008;;10.1016/0022-328x(95)06035-u;;10.1002/bscb.19830921112;;10.1016/j.jcat.2004.10.024;;10.1002/app.1984.070291211;;10.1055/s-1997-1281;;10.1002/chin.200841080;;10.1002/jlac.19656880116;;10.1002/jlac.19656880116;;10.1515/znb-1963-1202;;10.1002/jlac.19656880116;;10.1002/jps.2600781006;;2600785;;12945691;;10.1039/b303060c;;10.1021/ma60022a030;;10.1135/cccc19661839;;10.1002/ardp.19262642606;;10.1021/je60022a029,"Adam et al., ""Synthesis, Thermal stability, and Chemilumimescence Properties of he Dioxetanes derived from 1 ,4-Dioxins"" J. Org. Chem., vol. 49, 1984, pp. 3920-3928, XP002585185.;;Barnier et al., Journal of Organometallic Chemistry 514 (1996), 67-71.;;English translation of Mueller et al. (Justus Liebigs Annalen der Chemie, 1965, 688, 134).;;Falshaw, et al., Journal of the Chemical Society, Chemical Society, Letchworth, GB, Jan. 1, 1963, 2422-2428.;;Hanselaer, R., L. D'Haenens, M. Martens, H. Van Nieuwenhuyse, and C.F. Van Sumere. ""N-Acylamino Acids and Peptides. VII. Synthesis ofOxygen-Sensitive N-Acylglycines (N-Caffeoylglycine, N-Protocatechuoylglycin E and N-Galloylglycine) and a N-Acyldipeptide (N-Caffeoylglycyl-L-Phenylalanin."" Bulletin Des societies Chimiques Belges. 92.11-12 (1983): 1029-1038.;;Veldurthy, Bhaskar, Jean-Marc Clacens, and Francois Figueras. ""Correlation Between the Basicity of Solid Bases and their Catalytic Activity Towards the Synthesis of Unsymmetrical Organic Carbonates."" Jornal of Catalysis. 229.1 (2005): 237-42.;;Th.G. Scholte et al., J. Appl. Polym. Sci., 29, 3763-3782 (1984).;;International Search Report corresponding to PCT/US20091069895, dated Mar. 23, 2010, 3 pgs.;;International Search Report corresponding to PCT/US20091069896, dated Mar. 24, 2010, 3 pgs.;;International Search Report corresponding to PCT/US20091069901, dated Jan. 4, 2010, 3 pgs.;;International Search Report corresponding to PCT/US20091069942, dated Nov. 24, 2010, 4 pgs.;;International Search Report corresponding to PCT/US2011/040536, dated Sep. 9, 2011, 4 pgs.;;International Search Report for Application No. PCT/US2010/058262 dated Apr. 26, 2011.;;International Search Report for PCT/US2010/058273, dated Apr. 26, 2011, 3 pgs.;;Kiji, Jitsuo, Tamon Okano, Eiichi Fujii, and Jiro Tsuji. ""A Simple Synthetic Method to Bis(Methylene)Butanedioates."" Synthesis. (1997): 869-70.;;Kuwano, Ryoichi, and Hiroki Kusano. ""Benzyl Protection of Phenols under Neutral Conditions: Palladium-Catalyzed Benzylations of Phenols."" Organic Letters. 10.10 (2008): 1979-82.;;Muller E et al: ""Stabile ortho-Semichinonsalze"" Justus Liebigs Annalen Der Chemie, Verlag Chemie GMBH, Weinheim; DE, vol. 688, Jan. 1, 1965, pp. 134-149.;;Muller et al., Liebigs Ann. Chem., vol. 688, 1965, pp. 134-149.;;Muller et al., Zur Kenntnis neuer Brenzcatechine and orthe-chinone, Z. Naturforschg., vol. 18b, 1963, p. 1002-1009.;;Muller, et al., Stabile Semichinonsalze, Liebigs Ann. Chem., vol. 688, 1965, p. 134-149.;;Murata, Kazuo, Kazuo Noda, Keiichi Kohno, and Masayoshi Samejima. ""Bioavailabilty and Pharmacokinetics of an Oral Dopamine Prodrug in Dogs."" Journal of Pharmaceutical Sciences. 78.10 (1989): 812-14.;;Nakamatsu et al., ""Isolation of an inclusion complex of naphthol and its benzoate as an intermidiate in the solvent-free benzoylation reaction of naphthol"" Org. Biomol. Chem., vol. 1, 2003, pp. 2231-2234, XP002585186.;;Otocka, E.P., et al., Macromolecules, 4, 507-514 (1971).;;Pospisil et al., ""Antioxydation Agents and Stabilizers. XI. The Synthesis of 1,1 ,3,3,5,5-Hexamethylhexylphenols"" Collection of Czechoslovak Chemical Communications, Institute of Organic Chemistry & Biochemistry, Prague; CZ, vol. 31, Jan. 1, 1996, pp. 1839-1847, XP0090513151SSN: 0010-0765.;;Raiford et al. (J. Amer. Chem. Soc., 1933, 55, 4288).;;Rosemund and Theodor Boehm K. W: ""Zur Kenntnis der Polyoxy-Benzylalkohole, insbesondere des Gallusalkohols and eines daraus gewonnenen Gerbstoffes"", Archiv Der Pharmazie, Wiley-VCH Verlag GMBH & Co. KGAA, DE, vol. 264, No. 26-43, Jan. 1, 1926, pp. 448-459.;;Schneider et al. (European Journal of Organic Chemistry, 2001, (16), 3055).;;Scholte, Th. G., et al., J. Appl. Polym. Sci., 29, 3763-3782 (1982).;;Stenseth, Raymond E., Robert M. Schisla, and Joseph W. Baker. ""Halophenyl and 8-Quinolyl Carbonates."" Journal of Chemical and Engineering Data. 9.3 (1964): 390-97.",ACTIVE
58,US,B2,US 8778826 B2,165-592-370-015-425,2014-07-15,2014,US 65103209 A,2009-12-31,US 65103209 A;;US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,Enhanced procatalyst composition and process,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",GONZALEZ KELLY;;WILLIAMS CLARK C;;CHEN LINFENG;;GRACE W R & CO,GONZALEZ KELLY;;WILLIAMS CLARK C;;CHEN LINFENG,DOW GLOBAL TECHNOLOGIES LLC (2010-12-31);;W. R. GRACE & CO. CONN (2014-03-24),https://lens.org/165-592-370-015-425,Granted Patent,yes,9,15,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/16,502/107;;502/103;;502/116;;502/118;;502/158;;526/351;;526/352;;526/65,0,0,,,,ACTIVE
59,US,B1,US 11165899 B1,112-510-145-162-977,2021-11-02,2021,US 202016752777 A,2020-01-27,US 202016752777 A;;US 201816218790 A;;US 201715720994 A,2017-09-29,Techniques to manage contact records,"Exemplary embodiments relate to techniques for managing contact information received in the context of a messaging system. Messages may be received from known contacts which contain user contact records for third parties. Based on the trust relationship with the known contacts, the user contact record is placed in a contact record repository for later retrieval. When another message is received which either references the user contact record or is from the third party referenced in the user contact record, a dialog box is presented offering the user the opportunity to add the user contact record as an address entry in the address book of the device.",WHATSAPP INC;;WHATSAPP LLC,DONOHUE MICHAEL B;;CHEN CLARK;;LIU ALAN,WHATSAPP LLC (2017-10-11),https://lens.org/112-510-145-162-977,Granted Patent,yes,7,0,4,4,0,H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/216;;H04L51/56;;H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/56;;H04L51/212;;H04L51/216;;H04L51/224,H04M1/27457;;H04L12/58;;H04M1/7243;;H04M1/72484,,0,0,,,,ACTIVE
60,BR,A8,BR PI0918697 A8,028-435-281-372-459,2017-10-03,2017,BR PI0918697 A,2009-12-31,US 14190208 P;;US 2009/0069929 W;;US 14195908 P,2008-12-31,PROCESSO PARA MELHORAR AS PROPRIEDADES DE UM PROCATALISADOR E COMPOSIÇÃO DE PROCATALISADOR,"PROCESSO PARA MELHORAR AS PROPRIEDADES DE UM PROCATALISADOR E COMPOSIÇÃO DE PROCATALISADOR. São divulgados aqui processos para preparar composições de procatalisador e polímeros, i.é, polímeros baseados em propileno, produzidos a partir dos mesmos. As presentes composições de procatalisador melhoram a seletividade do catalisador e também aumentam o peso específico aparente do polímero em formação.",DOW GLOBAL TECHNOLOGIES LLC;;GRACE W R & CO,KELLY A GONZALEZ;;CLARK C WILLIAMS;;LINFENG CHEN,W. R. GRACE AND CO. -CONN. (US) (2017-10-03),https://lens.org/028-435-281-372-459,Patent Application,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651,,0,0,,,,DISCONTINUED
61,EP,A1,EP 2373701 A1,034-122-118-764-014,2011-10-12,2011,EP 09796286 A,2009-12-31,US 2009/0069929 W;;US 14195908 P;;US 14190208 P,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,,DOW GLOBAL TECHNOLOGIES LLC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,W.R. GRACE & CO.-CONN. (2014-05-28),https://lens.org/034-122-118-764-014,Patent Application,yes,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651;;C08F4/654,,0,0,,,,ACTIVE
62,US,A1,US 2017/0241661 A1,144-474-353-053-64X,2017-08-24,2017,US 201715405249 A,2017-01-12,US 201715405249 A;;US 201414524103 A;;US 87460710 A;;US 23419909 P;;US 201662277883 P,2009-08-14,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,OPTIMUM ENERGY LLC (2017-06-01),https://lens.org/144-474-353-053-64X,Patent Application,yes,5,16,1,16,0,F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/56;;F24F11/46;;F24F11/76;;H04L12/2814;;H04L2012/285;;F24F2011/0006;;Y02B30/54;;F24F11/523;;F24F11/63;;G05B19/048;;F24F2011/0006;;G05B2219/2614;;F24F2110/10;;F24F2110/12;;F24F11/30;;F24F11/46;;F24F11/62;;F24F11/76;;F24F2140/60;;F24F11/56;;F24F11/64;;F24F2130/00;;F24F2130/10;;H04L2012/285;;H04L12/2814;;Y02B30/54;;F24F11/63;;F24F11/523,F24F11/00;;F24F11/76;;G05B19/048,,0,0,,,,DISCONTINUED
63,US,B2,US 9967107 B2,036-629-999-062-922,2018-05-08,2018,US 201414582732 A,2014-12-24,US 201414582732 A,2014-12-24,Intelligent equipment sequencing,"Systems and methods for sequencing HVAC equipment of an HVAC system using data recorded in situ to build a model capable of making predictions about equipment efficiency and using that information, in combination with predictions about building load, to produce an operational sequence for the HVAC equipment that promotes an improved or optimized overall energy efficiency for the HVAC system. In one embodiment, the process is automated and utilizes Bayesian computational models or algorithms to generate are initial sequence. The process reduces engineering hours and may advantageously provide a means to predict potential sequencing problems for similar types of HVAC equipment.",OPTIMUM ENERGY LLC,JONES THOMAS;;DEMPSTER IAN;;MATTHYS CLARK;;CHEN PENG,OPTIMUM ENERGY LLC (2018-01-25),https://lens.org/036-629-999-062-922,Granted Patent,yes,18,6,4,4,0,F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64;;H04L12/2816;;F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64,G05B21/00;;G01M1/38;;G05B13/00;;G05B15/00;;G05D23/00;;H04L12/28,,1,1,131-674-888-192-384,10.1016/j.enbuild.2011.07.003,"Chan, A.L.S., “Developing future hourly weather files for studying the impact of climate change on building energy performance in Hong Kong,” Energy and Buildings 43 (2011), pp. 2860-2868.",ACTIVE
64,EP,B1,EP 2722556 B1,040-380-743-471-910,2016-09-21,2016,EP 14151196 A,2010-02-25,US 15604209 P;;EP 10706869 A,2009-02-27,Vehicle and method of operating the same,,NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,"HYSTER-YALE GROUP, INC. (2017-05-03)",https://lens.org/040-380-743-471-910,Granted Patent,yes,4,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/10;;F16H3/089,,0,0,,,,ACTIVE
65,US,B2,US 11294343 B2,051-452-688-173-45X,2022-04-05,2022,US 201715405194 A,2017-01-12,US 201715405194 A;;US 201662277883 P,2016-01-12,Predictive free cooling,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,OPTIMUM ENERGY LLC (2017-06-01),https://lens.org/051-452-688-173-45X,Granted Patent,yes,53,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B19/042;;F24F11/00;;F24F11/30;;F24F11/46;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/76;;F24F110/10;;F24F110/12;;F24F130/00;;F24F130/10;;F24F140/60,,8,1,158-819-572-824-239,10.1109/iciafs.2010.5715685,"International Search Report and Written Opinion for PCT Application No. PCT/US2017/013254, dated Apr. 4, 2017, 8 pages.;;Pawlish, M. et al., “Free Cooling: A Paradigm Shift in Data Centers,” Information and Automation for Sustainability; 347-352, 2010. [retrieved on Feb. 20, 2017]. Retrieved from the Internet. <URL: http://www.cs.montclair.edu/˜greenit/papers/Sri%20Lanka.pdf>. entire document.;;International Search Report and Written Opinion for PCT/US2018/013667, dated Apr. 4, 2018, 10 pages.;;Extended European Search Report for European Application No. 17738973.1, dated Nov. 25, 2019, 5 pages.;;Japanese Office Action, dated Feb. 9, 2021, for Japanese Application No. 2018-536852, 5 pages.;;Extended European Search Report, dated Dec. 12, 2019, for European Application No. 17738973.1, 10 pages.;;Extended European Search Report, dated Jan. 10, 2020, for European Application No. 18739049.7, 8 pages.;;Office Action, dated Apr. 14, 2021, for Chinese Patent Application No. 201780012622.8. (3 pages) (with English Translation).",ACTIVE
66,US,A1,US 2014/0052354 A1,120-539-349-359-551,2014-02-20,2014,US 201314067091 A,2013-10-30,US 201314067091 A;;US 201113202173 A;;US 2010/0025408 W;;US 15604209 P,2009-02-27,Vehicle Transmission With Clutch Pack Overrun,"A drive system ( 14, 34 ) comprising an input shaft ( 112 ); a first clutch ( 114 ) configured to selectively couple a first gear ( 116 ) to the input shaft ( 112 ); an output shaft ( 126 ); a second gear ( 138 ) engaging with the first gear ( 116 ); and a drive axle clutch system ( 142 ) having different travel direction clutches.",CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/120-539-349-359-551,Patent Application,yes,5,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,B60W10/02;;B60W10/11,701/53,0,0,,,,ACTIVE
67,RU,C2,RU 2522435 C2,189-379-631-329-00X,2014-07-10,2014,RU 2011132147 A,2009-12-31,US 14195908 P;;US 14190208 P;;US 2009/0069929 W,2008-12-31,IMPROVED PROCATALYST COMPOSITION AND METHOD FOR PRODUCTION THEREOF,"FIELD: chemistry.SUBSTANCE: invention relates to olefin polymerisation catalysts. Disclosed is a method of halogenating an olefin polymerisation procatalyst precursor which involves halogenating a procatalyst precursor in the presence of a substituted aromatic phenylene diether at temperature ranging from about 90°C to less than or equal to about 100°C. The aromatic phenylene diether has the structure,wherein groups R-Rare identical or different, each group from R-Ris selected from a group consisting of a hydrogen atom, halogen, a hydrocarbon group containing 1-20 carbon atoms and an alkoxy group containing 1-20 carbon atoms and combinations thereof, and where at least one of the groups R-Ris not hydrogen. The Ziegler-Natta procatalyst composition has selectivity index less than 2.5 and has a magnesium component, a titanium component and a substituted aromatic phenylene diether. Also disclosed is a procatalyst composition obtained using said method.EFFECT: present procatalyst composition increases catalyst selectivity and increases apparent density of the formed polymer.8 cl, 6 tbl, 10 ex",DOW GLOBAL TECHNOLOGIES LLC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/189-379-631-329-00X,Granted Patent,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,B01J37/22;;C08F4/654;;C08F110/06,,0,0,,,,INACTIVE
68,US,A1,US 2020/0355503 A1,003-803-545-258-190,2020-11-12,2020,US 201916960693 A,2019-01-10,GR 20180100008 A;;GB 201804079 A;;GB 2019050056 W,2018-01-10,DETERMINING THE LOCATION OF A MOBILE DEVICE,"A computer-implemented method of determining a location of a mobile device, the method comprising receiving inertial data generated at the mobile device, the inertial data comprising a plurality of samples taken at different times, segmenting the inertial data into pseudo-independent windows, wherein each pseudo-independent window comprises a plurality of the samples and wherein one or more initial states for each pseudo-independent window are treated as unknown, estimating a change in navigation state over each pseudo-independent window using the samples of inertial data, and summing the changes in the navigation states over the pseudo-independent windows so as to determine the location of the mobile device.",UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,OXFORD UNIVERSITY INNOVATION LIMITED (2020-07-12),https://lens.org/003-803-545-258-190,Patent Application,yes,12,9,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C19/00;;G01C21/20;;G01P15/08,,0,0,,,,ACTIVE
69,US,A1,US 2016/0187896 A1,087-068-837-058-253,2016-06-30,2016,US 201414582732 A,2014-12-24,US 201414582732 A,2014-12-24,INTELLIGENT EQUIPMENT SEQUENCING,"Systems and methods for sequencing HVAC equipment of an HVAC system using data recorded in situ to build a model capable of making predictions about equipment efficiency and using that information, in combination with predictions about building load, to produce an operational sequence for the HVAC equipment that promotes an improved or optimized overall energy efficiency for the HVAC system. In one embodiment, the process is automated and utilizes Bayesian computational models or algorithms to generate are initial sequence. The process reduces engineering hours and may advantageously provide a means to predict potential sequencing problems for similar types of HVAC equipment.",JONES THOMAS;;DEMPSTER IAN;;MATTHYS CLARK;;CHEN PENG,JONES THOMAS;;DEMPSTER IAN;;MATTHYS CLARK;;CHEN PENG,OPTIMUM ENERGY LLC (2018-01-25),https://lens.org/087-068-837-058-253,Patent Application,yes,13,20,4,4,0,F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64;;H04L12/2816;;F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64,G05D23/19;;H04L12/28,,0,0,,,,ACTIVE
70,US,B2,US 8233939 B2,130-132-058-496-271,2012-07-31,2012,US 5937508 A,2008-03-31,US 5937508 A,2008-03-31,Multiuser sector micro diversity system,Embodiments of methods and apparatus for a multiuser sector micro diversity system are described herein. Other embodiments may be described and claimed.,LI LI;;CHEN CLARK;;LI GUANGJIE;;WU MAY;;INTEL CORP,LI LI;;CHEN CLARK;;LI GUANGJIE;;WU MAY,INTEL CORPORATION (2008-04-06),https://lens.org/130-132-058-496-271,Granted Patent,yes,11,17,2,2,0,H04B7/0452;;H04B7/0491;;H04B7/0632;;H04L5/0023;;H04L5/0037;;H04L5/0044;;H04L5/006;;H04L25/03343;;H04B7/0465;;H04L5/0023;;H04B7/0491;;H04B7/0452;;H04B7/0632;;H04L5/0044;;H04L5/0037;;H04L25/03343;;H04L5/006;;H04B7/0465,H04B1/38;;H04B15/00;;H04W4/00,455/561;;455/422.1;;455/450;;455/509;;455/500;;455/502;;370/329,7,3,076-427-017-794-485;;034-380-203-569-901;;002-316-458-238-197,10.1049/el:19950051;;10.1109/49.864018;;10.1109/pimrc.2004.1368288,"Brandao et al., ""Base station macro-diversity combining merge cells in mobile systems,"" IEEE Electronics Letters, Jan. 5, 1995, vol. 31, No. 1, pp. 12-13, Middletown, PA.;;3GPP, TSGR1#3(99)187, Motorola, ""Improvements to Site Selection Diversity Transmission (SSDT),"" TSG-RAN Working Group 1 meeting #3, Mar. 22-26, 1999, 5 pages, Stockholm, Sweeden.;;EGPP TSG-RAN WG1 #46big, R1-062778, ""Further System-Level Simulation Results for Downlink Inter-Sector Macro Diversity,"" Chunghwa Telecom Laboratories (CHTTL), 6.6.4, 5 pages, Oct. 13, 2006, Seoul, Korea.;;Furukawa et al., ""SSDT-Site Selection Diversity Transmission Power Control for CDMA Forward Link,"" IEEE Journal on Selected Areas in Communications, vol. 18, No. 8, Aug. 2000, pp. 1546-1554.;;Morimoto et al., ""Experiments on Fast Sector Selection with Entire-Bandwidth Assignment in Forward Link for OFCDM Broadband Packet Wireless Access,"" IEEE 2004, IP Radio Network Development Department, NTT DoCoMo, Inc., pp. 1689-1694, Kanagawa-ken, Japan.;;3GPP TR 25.814, V7.1.0, 3rd Generation Partnership Project, ""Technical Specification Group Radio Access Network; Physical layer aspects for evolved Universal Terrestrial Radio Access (UTRA),"" Release 7, (Sep. 2006), 132 pages.;;3GPP TSG RAN WG1 Ad Hoc on LTE, R1-050615, NTT DoCoMo, 4.3, ""Investigations on Inter-Sector Diversity in Evolved UTRA Downlink,"" Jun. 20-21, 2005, Sophia Antipolis, France, 7 pages.",ACTIVE
71,KR,A,KR 20180100230 A,018-814-261-390-93X,2018-09-07,2018,KR 20187023265 A,2017-01-12,US 201662277883 P;;US 2017/0013254 W,2016-01-12,예측적 자유-냉각,"HVAC(heating, ventilation and air conditioning) 시스템을 갖는 소정의 지리적 위치에 위치한 빌딩에 대한 환경 제어 시스템으로서, 상기 환경 제어 시스템은, 외부 애플리케이션과 통신하는 적어도 하나의 처리 장치에 의해 실행될 때, 적어도 하나의 처리 장치로 하여금, 상기 지리적 위치에 대하여 미리 결정된 시간 주기 동안 기상 예보를 특성화하는 기상 데이터를 수신할 수 있게 하고, 자유-냉각 구간 데이터를 수신할 수 있게 하며, 기상 데이터 및 자유-냉각 구간 데이터에 기초하여, 가용한 자유-냉각 시간 구간을 결정할 수 있게 하고, 가용한 자유-냉각 시간 구간 동안 자유-냉각 모드에 진입하도록 HVAC 시스템으로의 실행가능 명령을 외부 애플리케이션에 발급할 수 있게 하는, 명령어를 저장한 적어도 하나의 컴퓨터-판독가능 매체를 포함한다.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/018-814-261-390-93X,Patent Application,no,0,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,F24F11/64;;F24F11/00;;F24F11/46;;F24F11/65;;F24F11/76;;F24F110/12;;F24F130/10;;F24F140/60;;G05B19/042,,0,0,,,,PENDING
72,WO,A1,WO 2017/123810 A1,012-283-659-066-066,2017-07-20,2017,US 2017/0013254 W,2017-01-12,US 201662277883 P,2016-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/012-283-659-066-066,Patent Application,yes,11,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B21/00;;F24F11/76;;G05D23/00;;G05D23/19;;G06F19/00;;H05K7/20,,2,0,,,"PAWLISH ET AL.: ""Free cooling: A paradigm shift in data centers"", INFORMATION AND AUTOMATION FOR SUSTAINABILITY, 2010, pages 347 - 352, XP031979706, Retrieved from the Internet <URL:http://www.cs.montclair.edu/~greenit/papers/Sri%20Lanka.pdf> [retrieved on 20170220];;See also references of EP 3403151A4",PENDING
73,US,A1,US 2009/0247148 A1,030-697-767-447-07X,2009-10-01,2009,US 5745208 A,2008-03-28,US 5745208 A,2008-03-28,TECHNIQUES FOR FEEDBACK IN CELLULAR SYSTEMS TO MITIGATE INTERFERENCE IN DOWNLINK,"An embodiment of the present invention provides a method, comprising broadcasting base station (BS) channel allocation methods and supported interference mitigation techniques in a whole cell by the base station and reporting classification information by mobile stations (MSs) within the cell to said base station about their preferred interference mitigation (IM) techniques.",CHEN CLARK;;YIN HUJUN;;SUN HONGMEI;;YANG HUA,CHEN CLARK;;YIN HUJUN;;SUN HONGMEI;;YANG HUA,INTEL CORPORATION (2008-03-31),https://lens.org/030-697-767-447-07X,Patent Application,yes,5,28,2,2,0,H04W72/27;;H04W72/541;;H04W72/542;;H04W72/21;;H04W72/21;;H04W72/27;;H04W72/541;;H04W72/542,H04B15/00,455/422.1;;455/63.1,0,0,,,,ACTIVE
74,EP,B1,EP 2373701 B1,053-312-924-623-829,2016-03-09,2016,EP 09796286 A,2009-12-31,US 2009/0069929 W;;US 14195908 P;;US 14190208 P,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,,GRACE W R & CO,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,W.R. GRACE & CO.-CONN. (2014-05-28),https://lens.org/053-312-924-623-829,Granted Patent,yes,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651;;C08F4/654,,1,0,,,"DATABASE WPI Week 200754, Derwent World Patents Index; AN 2007-552455",ACTIVE
75,US,A1,US 2009/0208488 A1,076-537-694-469-521,2009-08-20,2009,US 80535007 A,2007-05-22,US 80535007 A;;US 4861005 A,2005-01-31,Regulation of dendritic cell functions by the DCAL-2 receptor,"This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.",UNIV WASHINGTON,CLARK EDWARD A;;CHEN CHANG HUNG;;FLOYD HELEN,,https://lens.org/076-537-694-469-521,Patent Application,yes,4,1,2,2,12,A61K38/177;;A61K38/178;;A61P37/00;;C07K16/28;;C07K16/28;;C07K2317/77;;C07K2317/77;;G01N33/505;;G01N33/505,A61K39/395;;A61K35/12;;A61P37/00,424/133.1;;424/139.1;;424/93.7,0,0,,,,DISCONTINUED
76,WO,A1,WO 2010/078503 A1,128-468-198-128-283,2010-07-08,2010,US 2009/0069929 W,2009-12-31,US 14190208 P;;US 14195908 P,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",DOW GLOBAL TECHNOLOGIES INC;;GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/128-468-198-128-283,Patent Application,yes,4,3,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651,,0,0,,,,PENDING
77,CA,A1,CA 3049884 A1,144-233-010-127-419,2018-07-19,2018,CA 3049884 A,2018-01-12,US 201715405249 A;;US 2018/0013667 W,2017-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC;;ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/144-233-010-127-419,Patent Application,no,0,0,5,16,0,F24F2110/12;;F24F2110/22;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;G05B15/02;;G05B2219/2642;;Y02B30/54,F24F11/00,,0,0,,,,DISCONTINUED
78,CN,A,CN 108700871 A,156-401-263-218-824,2018-10-23,2018,CN 201780012622 A,2017-01-12,US 201662277883 P;;US 2017/0013254 W,2016-01-12,Predictive free cooling,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/156-401-263-218-824,Patent Application,no,3,1,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B21/00;;F24F11/76;;G05D23/00;;G05D23/19;;H05K7/20,,0,0,,,,DISCONTINUED
79,MX,B,MX 342632 B,199-527-620-659-77X,2016-10-07,2016,MX 2014008822 A,2009-12-31,US 14195908 P;;US 14190208 P;;US 2009/0069929 W,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS.,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",W R GRACE & CO -CONN,LINFENG CHEN;;CLARK C WILLIAMS;;KELLY A GONZALEZ,,https://lens.org/199-527-620-659-77X,Granted Patent,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F4/06;;C08F4/10;;C08F4/654,,0,0,,,,ACTIVE
80,SG,A1,SG 172819 A1,084-196-132-298-182,2011-08-29,2011,SG 2011048097 A,2009-12-31,US 14190208 P;;US 14195908 P;;US 2009/0069929 W,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",DOW GLOBAL TECHNOLOGIES LLC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/084-196-132-298-182,Patent Application,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,,,0,0,,,,PENDING
81,CN,A,CN 103502280 A,128-593-169-452-466,2014-01-08,2014,CN 201280020995 A,2012-02-29,US 2012/0027086 W;;US 201161447800 P,2011-03-01,Process for improving bulk density with multi-contact procatalyst and product,"Disclosed herein are processes for preparing procatalyst compositions which include multiple contact steps in the presence of a substituted phenylene aromatic diester and at least one other internal electron donor. The multi-contact procatalyst compositions produced from the present processes improve polymer properties and polymerization parameters. In particular, the present multi-contact procatalyst compositions improve polymer bulk density.",DOW GLOBAL TECHNOLOGIES LLC,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,,https://lens.org/128-593-169-452-466,Patent Application,no,5,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F110/06,,0,0,,,,DISCONTINUED
82,US,B2,US 10461954 B2,014-935-017-290-561,2019-10-29,2019,US 201815942306 A,2018-03-30,US 201815942306 A;;US 201414582732 A,2014-12-24,Intelligent equipment sequencing,"Systems and methods for sequencing HVAC equipment of an HVAC system using data recorded in situ to build a model capable of making predictions about equipment efficiency and using that information, in combination with predictions about building load, to produce an operational sequence for the HVAC equipment that promotes an improved or optimized overall energy efficiency for the HVAC system. In one embodiment, the process is automated and utilizes Bayesian computational models or algorithms to generate an initial sequence. The process reduces engineering hours and may advantageously provide a means to predict potential sequencing problems for similar types of HVAC equipment.",OPTIMUM ENERGY LLC,JONES THOMAS;;DEMPSTER IAN;;MATTHYS CLARK;;CHEN PENG,OPTIMUM ENERGY LLC (2018-01-25),https://lens.org/014-935-017-290-561,Granted Patent,yes,18,0,4,4,0,F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64;;H04L12/2816;;F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64,G05B21/00;;F24F11/30;;F24F11/46;;F24F11/62;;G01M1/38;;G05B13/00;;G05B15/00;;G05D23/00;;H04L12/28,,1,1,131-674-888-192-384,10.1016/j.enbuild.2011.07.003,"Chan, A.L.S., “Developing future hourly weather tiles for studying the impact of climate change on building energy performance in Hong Kong,” Energy and Buildings 43 (2011), pp. 2860-2868.",ACTIVE
83,AU,A1,AU 2019/207463 A1,056-077-514-623-617,2020-07-23,2020,AU 2019/207463 A,2019-01-10,GB 201804079 A;;GR 20180100008 A;;GB 2019050056 W,2018-01-10,Determining the location of a mobile device,"A computer-implemented method of determining a location of a mobile device, the method comprising receiving inertial data generated at the mobile device, the inertial data comprising a plurality of samples taken at different times, segmenting the inertial data into pseudo-independent windows, wherein each pseudo-independent window comprises a plurality of the samples and wherein one or more initial states for each pseudo-independent window are treated as unknown, estimating a change in navigation state over each pseudo-independent window using the samples of inertial data, and summing the changes in the navigation states over the pseudo-independent windows so as to determine the location of the mobile device.",UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,,https://lens.org/056-077-514-623-617,Patent Application,no,0,0,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C21/20;;G01C22/00,,0,0,,,,DISCONTINUED
84,US,A1,US 2006/0171929 A1,127-167-580-544-768,2006-08-03,2006,US 4861005 A,2005-01-31,US 4861005 A,2005-01-31,Regulation of dendritic cell functions by the DCAL-2 receptor,"This invention provides antibodies that specifically bind to DCAL-2 and other DCAL-2 reagents that modulate dendritic cell function. Modulators of the receptor, including modulators that alter DCAL-2 associated signals to and from DCs, can be used to alter dendritic cell function and to enhance or inhibit immune responses to cancer antigens, autoantigens, or pathogens.",UNIV WASHINGTON,CLARK EDWARD A;;CHEN CHANG HUNG;;FLOYD HELEN,WASHINGTON UNIVERSITY OF THE (2005-06-15),https://lens.org/127-167-580-544-768,Patent Application,yes,3,10,2,2,12,A61K38/177;;A61K38/178;;A61P37/00;;C07K16/28;;C07K16/28;;C07K2317/77;;C07K2317/77;;G01N33/505;;G01N33/505,G01N33/567;;A61K35/14;;A61K39/395,424/93.7;;424/144.1;;435/7.21,0,0,,,,DISCONTINUED
85,TW,B,TW I410478 B,168-890-604-651-630,2013-10-01,2013,TW 97101597 A,2008-01-15,US 88500507 P,2007-01-15,Liquid crystal composite and device with faster electro-optical response characteristics,,UNIV CHUNG YUAN CHRISTIAN,LEE WEI;;CHEN HUI YU;;CLARK NOEL ANTHONY,,https://lens.org/168-890-604-651-630,Granted Patent,no,2,0,2,2,0,,,,0,0,,,,INACTIVE
86,EP,A1,EP 3403151 A1,034-854-940-765-031,2018-11-21,2018,EP 17738973 A,2017-01-12,US 201662277883 P;;US 2017/0013254 W,2016-01-12,PREDICTIVE FREE COOLING,,OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/034-854-940-765-031,Patent Application,yes,0,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B21/00;;F24F11/76;;G05D23/00;;G05D23/19;;G06F19/00;;H05K7/20,,0,0,,,,PENDING
87,WO,A1,WO 2019/138225 A1,114-881-386-488-084,2019-07-18,2019,GB 2019050056 W,2019-01-10,GR 20180100008 A;;GB 201804079 A,2018-01-10,DETERMINING THE LOCATION OF A MOBILE DEVICE,"A computer-implemented method of determining a location of a mobile device, the method comprising receiving inertial data generated at the mobile device, the inertial data comprising a plurality of samples taken at different times, segmenting the inertial data into pseudo-independent windows, wherein each pseudo-independent window comprises a plurality of the samples and wherein one or more initial states for each pseudo-independent window are treated as unknown, estimating a change in navigation state over each pseudo-independent window using the samples of inertial data, and summing the changes in the navigation states over the pseudo-independent windows so as to determine the location of the mobile device.",UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,,https://lens.org/114-881-386-488-084,Patent Application,yes,2,2,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C21/20;;G01C22/00,,2,1,136-774-932-884-776,10.1007/978-3-030-01261-8_38,"""Serious Games"", vol. 11217, 31 December 2017, SPRINGER INTERNATIONAL PUBLISHING, Cham, ISBN: 978-3-642-38979-5, ISSN: 0302-9743, article HANG YAN ET AL: ""RIDI: Robust IMU Double Integration : 15th European Conference, Munich, Germany, September 8-14, 2018, Proceedings, Part XIII"", pages: 641 - 656, XP055568708, 032682, DOI: 10.1007/978-3-030-01261-8_38;;CHANGHAO CHEN ET AL: ""IONet: Learning to Cure the Curse of Drift in Inertial Odometry"", 30 January 2018 (2018-01-30), Thirty-Second AAAI Conference on Artificial Intelligence, XP055568599, Retrieved from the Internet <URL:https://www.cs.ox.ac.uk/files/9853/Learning%20to%20Cure%20the%20Curse%20of%20Drift%20in%20Inertial%20Odometry.pdf> [retrieved on 20190315]",PENDING
88,WO,A1,WO 2008/000045 A1,167-493-839-719-411,2008-01-03,2008,AU 2007/000913 W,2007-06-29,AU 2006/903544 A,2006-06-30,NANOSTRUCTURED COMPOSITES,"The present invention relates to nanostructured composites, in particular nanotube/ substrate composites for use in the fields of biomedical materials and devices as well as energy conversion and storage, ion transport and liquid and gas separation. The use of such composites as biomaterials are of particular interest.",UNIV WOLLONGONG;;WALLACE GORDON GEORGE;;CHEN JUN;;CLARK GRAEME MILBOURNE,WALLACE GORDON GEORGE;;CHEN JUN;;CLARK GRAEME MILBOURNE,,https://lens.org/167-493-839-719-411,Patent Application,yes,7,27,4,4,0,B81C1/00111;;Y10T428/24479;;Y10T428/24479;;B81C1/00111,B82B1/00,,0,0,,,,PENDING
89,BR,A2,BR 112013020713 A2,185-867-602-678-291,2016-10-18,2016,BR 112013020713 A,2012-02-29,US 2012/0027086 W;;US 201161447800 P,2011-03-01,"processo para produzir uma composição de procatalisador, composição de catalisador e processo de polimerização",,DOW GLOBAL TECHNLOGIES INC,WILLIAMS CLARK C;;COALTER JOSEPH N;;CHEN LINFENG,DOW GLOBAL TECHNLOGIES INC (US) (2018-05-02),https://lens.org/185-867-602-678-291,Patent Application,no,0,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F110/06,,0,0,,,,DISCONTINUED
90,SG,A1,SG 192716 A1,191-858-785-446-700,2013-09-30,2013,SG 2013060934 A,2012-02-29,US 201161447800 P;;US 2012/0027086 W,2011-03-01,PROCESS FOR IMPROVING BULK DENSITY WITH MULTI-CONTACT PROCATALYST AND PRODUCT,"Disclosed herein are processes for preparing procatalyst compositions which include multiple contact steps in the presence of a substituted phenylene aromatic diester and at least one other internal electron donor. The multi-contact procatalyst compositions produced from the present processes improve polymer properties and polymerization parameters. In particular, the present multi-contact procatalyst compositions improve polymer bulk density.",DOW GLOBAL TECHNOLOGIES LLC,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,,https://lens.org/191-858-785-446-700,Patent Application,no,0,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,,,0,0,,,,PENDING
91,US,B2,US 11788843 B2,039-407-030-397-388,2023-10-17,2023,US 201916960693 A,2019-01-10,GR 20180100008 A;;GB 201804079 A;;GB 2019050056 W,2018-01-10,Determining the location of a mobile device,"A computer-implemented method of determining a location of a mobile device is provided. The method can include receiving inertial data generated at the mobile device, the inertial data including a plurality of samples taken at different times, segmenting the inertial data into pseudo-independent windows, wherein each pseudo-independent window can include a plurality of the samples and wherein one or more initial states for each pseudo-independent window are treated as unknown, estimating a change in navigation state over each pseudo-independent window using the samples of inertial data, and summing the changes in the navigation states over the pseudo-independent windows so as to determine the location of the mobile device.",UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,OXFORD UNIVERSITY INNOVATION LIMITED (2020-07-12),https://lens.org/039-407-030-397-388,Granted Patent,yes,20,0,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C19/00;;G01C21/20;;G01C22/00;;G01P15/08,,7,5,136-774-932-884-776;;084-922-488-818-410;;027-834-538-968-330;;095-328-609-336-870;;067-695-217-484-523,10.1007/978-3-030-01261-8_38;;10.1609/aaai.v32i1.12102;;10.1109/icra.2017.7989236;;10.1177/0278364917734298;;10.1609/aaai.v31i1.11215,"International Search Report and Written Opinion for PCT/GB2019/050056, dated Apr. 12, 2019, pp. 1-13.;;UK Search Report for GB 1804079.0, dated Sep. 17, 2018, pp. 1-4.;;Hang Yan et al: “RID !: Robust IMU Double Integration : 15th European Conference, Munich, Germany, Sep. 8-14, 2018, Proceedings, Part XIII” In: “Serious Games”, Dec. 31, 2017 (Dec. 31, 2017), Springer International Publishing, Cham 032682, XP055568708, ISSN: 0302-9743 ISBN: 978-3-642-38979-5 vol. 11217, pp. 641-656.;;Changhao Chen et al: “IONet: Learning to Cure the Curse of Drift in Inertial Odometry”, Jan. 30, 2018 (Jan. 30, 2018), XP055568599, Thirty-Second AAAI Conference on Artificial Intelligence.;;“DeepVO: Towards End-to-End Visual Odometry with Deep Recurrent Convolutional Neural Networks”, Sen Wang, Ronald Clark, Hongkai Wen and Niki Trigoni, 2017 IEEE International Conference on Robotics and Automation (ICRA) Singapore, May 29-Jun. 3, 2017.;;“End-to-end, sequence-to-sequence probabilistic visual odometry through deep neural networks”, Sen Wang, Ronald Clark, Hongkai Wen and Niki Trigoni, The International Journal of Robotics Research2018, vol. 37 (4-5) 513-542© The Author(s) 2017 Reprints and permissions:sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0278364917734298 journals.sagepub.com/home/ijr.;;“VINet: Visual-Inertial Odometry as a Sequence-to-Sequence Learning Problem”, Ronald Clark, Sen Wang, Hongkai Wen, Andrew Markham and Niki Trigoni, Department of Computer Science, University of Oxford, United Kingdom, Department of Computer Science, University of Warwick, United Kingdom, Apr. 2, 2017.",ACTIVE
92,KR,A,KR 20110110270 A,077-657-385-680-916,2011-10-06,2011,KR 20117017808 A,2009-12-31,US 14190208 P;;US 14195908 P;;US 2009/0069929 W,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS,,DOW GLOBAL TECHNOLOGIES LLC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/077-657-385-680-916,Patent Application,no,4,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F4/651;;B01J31/02;;C08F10/06;;C08K5/10,,0,0,,,,ACTIVE
93,KR,A,KR 20140007411 A,161-237-093-199-913,2014-01-17,2014,KR 20137022715 A,2012-02-29,US 201161447800 P;;US 2012/0027086 W,2011-03-01,PROCESS FOR IMPROVING BULK DENSITY WITH MULTI-CONTACT PROCATALYST AND PRODUCT,,DOW GLOBAL TECHNOLOGIES LLC,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,,https://lens.org/161-237-093-199-913,Patent Application,no,0,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F2/00;;C08F10/06,,0,0,,,,DISCONTINUED
94,JP,A,JP 2016172868 A,007-775-929-328-91X,2016-09-29,2016,JP 2016093313 A,2016-05-06,US 14195908 P;;US 14190208 P,2008-12-31,ENHANCED PROCATALYST COMPOSITION,"PROBLEM TO BE SOLVED: To provide procatalyst compositions that improve procatalyst selectivity and also increase the bulk density of the formant polymer.SOLUTION: Particles comprise a magnesium moiety, a titanium moiety, and a substituted phenylene aromatic diester. The substituted phenylene aromatic diester is a compound represented by the structure (I). The particles have a D50 from 10 μm to 25 μm. The procatalyst compositions are Ziegler-Natta procatalyst compositions for the production of propylene-based polymers having less than 2.5 wt.% xylene solubles.SELECTED DRAWING: None",WR GRACE & CO CONNECTICUT,KELLY A GONZALEZ;;CLARK C WILLIAMS;;CHEN LINFENG,,https://lens.org/007-775-929-328-91X,Patent Application,no,8,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F4/654,,0,0,,,,INACTIVE
95,US,B2,US 8596156 B2,135-203-818-678-447,2013-12-03,2013,US 201013202173 A,2010-02-25,US 201013202173 A;;US 15604209 P;;US 15599509 P;;US 2010/0025408 W,2009-02-27,Vehicle transmission with clutch pack overrun,"A transmission system ( 14 ) comprising an input shaft ( 112 ); a first clutch ( 114 ) configured to selectively couple a first gear ( 116 ) to the input shaft ( 112 ); an output shaft ( 126 ); a second gear ( 138 ) engaging with the first gear ( 116 ), —and a second clutch ( 136 ) configured to couple the second gear ( 138 ) to the output shaft ( 126 ) when the first gear ( 116 ) rotates the second gear ( 138 ) faster than the output shaft ( 126 ).",CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,NACCO MATERIALS HANDLING GROUP INC (2010-02-24);;HYSTER-YALE GROUP INC (2016-05-20),https://lens.org/135-203-818-678-447,Granted Patent,yes,41,5,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,B60W10/10,74/325;;74/335;;477/115;;477/176,4,0,,,"European Patent Office; ""PCT International Search Report and Written Opinion of the International Searching Authority"" for PCT/US2010/025324, filed Feb. 25, 2010; mailed Jun. 16, 2010; 9 pages.;;European Patent Office; ""PCT International Search Report and Written Opinion of the International Searching Authority"" for PCT/US2010/025408, filed Feb. 25, 2010; mailed Jul. 13, 2010; 16 pages.;;Stolowitz Ford Cowger LLC, ""Listing of Related Cases"", Aug. 18, 2011, 1 page.;;Stolowitz Ford Cowger LLP, ""Listing of Related Cases"", Feb. 6, 2013, 1 page.",ACTIVE
96,CN,A,CN 111566444 A,180-486-275-130-016,2020-08-21,2020,CN 201980007844 A,2019-01-10,GB 201804079 A;;GR 20180100008 A;;GB 2019050056 W,2018-01-10,Determining the location of a mobile device,"A computer-implemented method of determining a location of a mobile device, the method comprising receiving inertial data generated at the mobile device, the inertial data comprising a plurality of samples taken at different times, segmenting the inertial data into pseudo-independent windows, wherein each pseudo-independent window comprises a plurality of the samples and wherein one or more initial states for each pseudo-independent window are treated as unknown, estimating a change in navigation state over each pseudo-independent window using the samples of inertial data, and summing the changes in the navigation states over the pseudo-independent windows so as to determine the location of the mobile device.",UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,,https://lens.org/180-486-275-130-016,Patent Application,no,6,0,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C21/20;;G01C22/00,,2,0,,,"刘猛;李光春;高延滨;李莹;王帝;: ""基于伪地球坐标系的惯导系统全球导航算法"", 中国惯性技术学报, no. 04;;程传奇;郝向阳;李建胜;刘智伟;胡鹏;: ""基于非线性优化的单目视觉/惯性组合导航算法"", 中国惯性技术学报, no. 05",PENDING
97,EP,A4,EP 3568646 A4,032-129-454-589-517,2020-11-04,2020,EP 18739049 A,2018-01-12,US 201715405249 A;;US 2018/0013667 W,2017-01-12,PREDICTIVE FREE COOLING,,OPTIMUM ENERGY LLC;;ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/032-129-454-589-517,Search Report,no,3,0,5,16,0,F24F11/62;;F24F11/46;;F24F11/64;;F24F11/65;;F24F2110/12;;F24F2110/22;;F24F2130/10;;G05B15/02;;G05B2219/2642;;Y02B30/54,F24F11/46;;F24F11/62;;F24F11/64;;F24F11/65;;G05B15/02,,1,0,,,See also references of WO 2018132770A1,DISCONTINUED
98,MX,A,MX 2011007151 A,045-872-552-380-103,2011-09-26,2011,MX 2011007151 A,2009-12-31,US 14195908 P;;US 14190208 P;;US 2009/0069929 W,2008-12-31,ENHANCED PROCATALYST COMPOSITION AND PROCESS.,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",DOW GLOBAL TECHNOLOGIES LLC,CHEN LINFENG;;GONZALEZ KELLY A;;WILLIAMS CLARK C,W. R. GRACE & CO.-CONN. (2014-10-14),https://lens.org/045-872-552-380-103,Patent Application,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651,,0,0,,,,DISCONTINUED
99,WO,A1,WO 2010/099315 A1,060-622-114-951-502,2010-09-02,2010,US 2010/0025408 W,2010-02-25,US 15604209 P,2009-02-27,POWER SHIFT TRANSMISSION WITH CLUTCH PACK OVERRUN,"A transmission system (14) comprising an input shaft (112); a first clutch (114) configured to selectively couple a first gear (116) to the input shaft (112); an output shaft (126); a second gear (138) engaging with the first gear (116),- and a second clutch (136) configured to couple the second gear (138) to the output shaft (126) when the first gear (116) rotates the second gear (138) faster than the output shaft (126).",NACCO MATERIALS HANDLING GROUP;;CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/060-622-114-951-502,Patent Application,yes,6,4,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/089;;F16H3/10,,0,0,,,,PENDING
100,CN,A,CN 102325809 A,080-717-179-542-993,2012-01-18,2012,CN 200980157206 A,2009-12-31,US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,Enhanced procatalyst composition and process,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",DOW GLOBAL TECHNOLOGIES INC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/080-717-179-542-993,Patent Application,no,2,6,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651,,0,0,,,,ACTIVE
101,TW,A,TW 200838991 A,045-703-732-385-078,2008-10-01,2008,TW 97101597 A,2008-01-15,US 88500507 P,2007-01-15,Liquid crystal composite and device with faster electro-optical response characteristics,"The present invention discloses a liquid crystal composite comprising a liquid crystal composition as a host and a plurality of carbon nanotubes as a dopant, wherein the carbon nanotubes are dispersed in the liquid crystal composition. The average length of the carbon nanotubes is equal to or less than 1 μm. The present invention also discloses a device comprising the mentioned liquid crystal composite.",UNIV CHUNG YUAN CHRISTIAN,LEE WEI;;CHEN HUI-YU;;CLARK NOEL ANTHONY,,https://lens.org/045-703-732-385-078,Patent of Addition,no,0,3,2,2,0,,C09K19/58,,0,0,,,,INACTIVE
102,EP,A1,EP 2401524 A1,058-988-059-550-056,2012-01-04,2012,EP 10706869 A,2010-02-25,US 2010/0025408 W;;US 15604209 P,2009-02-27,Transmission system and method for operating a transmission system,,NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/058-988-059-550-056,Patent Application,yes,0,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/089;;F16H3/10,,0,0,,,,ACTIVE
103,EP,A4,EP 3403151 A4,051-659-013-119-840,2019-12-25,2019,EP 17738973 A,2017-01-12,US 201662277883 P;;US 2017/0013254 W,2016-01-12,PREDICTIVE FREE COOLING,,OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/051-659-013-119-840,Search Report,no,5,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B21/00;;F24F11/00;;F24F11/30;;F24F11/62;;F24F11/76;;F24F110/10;;F24F110/12;;F24F130/00;;F24F130/10;;F24F140/60;;G05B19/042;;G05D23/00;;G05D23/19;;H05K7/20,,1,0,,,See also references of WO 2017123810A1,PENDING
104,WO,A1,WO 2018/132770 A1,061-086-225-904-311,2018-07-19,2018,US 2018/0013667 W,2018-01-12,US 201715405249 A,2017-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC;;ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/061-086-225-904-311,Patent Application,yes,5,5,5,16,0,F24F11/62;;F24F11/46;;F24F11/64;;F24F11/65;;F24F2110/12;;F24F2110/22;;F24F2130/10;;G05B15/02;;G05B2219/2642;;Y02B30/54,F24F11/00,,1,0,,,See also references of EP 3568646A4,PENDING
105,US,B2,US 8140068 B2,188-371-452-999-064,2012-03-20,2012,US 5745208 A,2008-03-28,US 5745208 A,2008-03-28,Techniques for feedback in cellular systems to mitigate interference in downlink,"An embodiment of the present invention provides a method, comprising broadcasting base station (BS) channel allocation methods and supported interference mitigation techniques in a whole cell by the base station and reporting classification information by mobile stations (MSs) within the cell to said base station about their preferred interference mitigation (IM) techniques.",CHEN CLARK;;YIN HUJUN;;SUN HONGMEI;;YANG HUA;;INTEL CORP,CHEN CLARK;;YIN HUJUN;;SUN HONGMEI;;YANG HUA,INTEL CORPORATION (2008-03-31),https://lens.org/188-371-452-999-064,Granted Patent,yes,5,1,2,2,0,H04W72/27;;H04W72/541;;H04W72/542;;H04W72/21;;H04W72/21;;H04W72/27;;H04W72/541;;H04W72/542,H04W24/00,455/423;;455/63.1;;455/114.2;;455/278.1;;455/296,0,0,,,,ACTIVE
106,US,A1,US 2011/0303505 A1,075-035-963-834-165,2011-12-15,2011,US 201013202173 A,2010-02-25,US 201013202173 A;;US 15604209 P;;US 15599509 P;;US 2010/0025408 W,2009-02-27,VEHICLE TRANSMISSION WITH CLUTCH PACK OVERRUN,"A transmission system ( 14 ) comprising an input shaft ( 112 ); a first clutch ( 114 ) configured to selectively couple a first gear ( 116 ) to the input shaft ( 112 ); an output shaft ( 126 ); a second gear ( 138 ) engaging with the first gear ( 116 ), —and a second clutch ( 136 ) configured to couple the second gear ( 138 ) to the output shaft ( 126 ) when the first gear ( 116 ) rotates the second gear ( 138 ) faster than the output shaft ( 126 ).",CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE;;NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,NACCO MATERIALS HANDLING GROUP INC (2010-02-24);;HYSTER-YALE GROUP INC (2016-05-20),https://lens.org/075-035-963-834-165,Patent Application,yes,5,7,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/10;;F16D13/00,192 82 R;;74/325,0,0,,,,ACTIVE
107,CN,A,CN 110651156 A,072-496-783-725-618,2020-01-03,2020,CN 201880012244 A,2018-01-12,US 201715405249 A;;US 2018/0013667 W,2017-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC;;ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/072-496-783-725-618,Patent Application,no,3,0,5,16,0,F24F11/62;;F24F11/46;;F24F11/64;;F24F11/65;;F24F2110/12;;F24F2110/22;;F24F2130/10;;G05B15/02;;G05B2219/2642;;Y02B30/54,F24F11/61;;F24F11/54;;F24F11/56;;F24F11/64;;F24F11/84;;F24F130/10;;F24F140/20,,0,0,,,,DISCONTINUED
108,ES,T3,ES 2513315 T3,090-709-775-820-825,2014-10-24,2014,ES 10706869 T,2010-02-25,US 15604209 P;;US 2010/0025408 W,2009-02-27,Sistema de transmisión y método para hacer funcionar un sistema de transmisión,"Sistema de transmisión para ser usado en un vehículo que tiene un árbol (112) de entrada acoplado operativamente a un árbol (126) de salida mediante una pluralidad de conjuntos de engranajes, que comprende: un primer conjunto de engranajes que incluye un primer engranaje conductor (116) acoplado con un primer engranaje conducido (138), en donde el primer engranaje conductor (116) está dispuesto giratoriamente en el árbol (112) de entrada y acoplado selectivamente al mismo por un primer embrague (114) provisto de una válvula electro-hidráulica proporcional y de un sensor para proporcionar un control de bucle cerrado de retroalimentación, y en donde el primer engranaje conducido (138) está dispuesto giratoriamente en el árbol (126) de salida y acoplado al mismo con un primer cojinete unidireccional (136); un segundo conjunto de engranajes que incluye un segundo engranaje conductor (120) acoplado con un segundo engranaje conducido (134), en donde el segundo engranaje conductor (120) está dispuesto giratoriamente en el árbol (112) de entrada y acoplado selectivamente al mismo mediante un segundo embrague (118) provisto de una válvula electro-hidráulica proporcional y de un sensor para proporcionar un control de bucle de retroalimentación cerrado, y en donde el segundo engranaje conducido (134) está dispuesto giratoriamente en el árbol (126) de salida y acoplado al mismo con un segundo cojinete unidireccional (132); y un tercer conjunto de engranajes que incluye un tercer engranaje conductor (122) acoplado con un tercer engranaje conducido (128), en donde el tercer engranaje conductor (122) está acoplado rígidamente al árbol (112) de entrada, y en donde el tercer engranaje conducido (128) está dispuesto giratoriamente en el árbol (126) de salida y acoplado selectivamente al mismo mediante un tercer embrague (130) provisto de una válvula electro-hidráulica proporcional y de un sensor para proporcionar un control de bucle cerrado de retroalimentación, en donde el árbol (112) de entrada está configurado para acoplarse a un motor (12) de vehículo sin ningún convertidor de par intermedio, y en donde el árbol (126) de salida está configurado para acoplarse a un conjunto (34) de eje motor.",NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/090-709-775-820-825,Granted Patent,no,0,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/089;;F16H3/10,,0,0,,,,ACTIVE
109,MX,A,MX 2013010015 A,104-861-201-014-616,2013-10-25,2013,MX 2013010015 A,2012-02-29,US 201161447800 P;;US 2012/0027086 W,2011-03-01,PROCESS FOR IMPROVING BULK DENSITY WITH MULTI-CONTACT PROCATALYST AND PRODUCT.,"Disclosed herein are processes for preparing procatalyst compositions which include multiple contact steps in the presence of a substituted phenylene aromatic diester and at least one other internal electron donor. The multi-contact procatalyst compositions produced from the present processes improve polymer properties and polymerization parameters. In particular, the present multi-contact procatalyst compositions improve polymer bulk density.",DOW GLOBAL TECHNOLOGIES LLC,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,W. R. GRACE & CO.-CONN. (2014-10-14),https://lens.org/104-861-201-014-616,Patent Application,no,0,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F110/06,,0,0,,,,ACTIVE
110,CN,B,CN 102325809 B,161-508-281-803-796,2014-04-09,2014,CN 200980157206 A,2009-12-31,US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,Enhanced procatalyst composition and process,,DOW GLOBAL TECHNOLOGIES INC,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,,https://lens.org/161-508-281-803-796,Granted Patent,no,0,0,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,C08F110/06;;C08F4/651,,0,0,,,,ACTIVE
111,US,A1,US 2004/0218752 A1,062-193-047-763-383,2004-11-04,2004,US 42809003 A,2003-05-02,US 42809003 A,2003-05-02,Conference speakerphone,"
   A conference speakerphone comprises a conference telephone host and a plurality of separate microphones. A DSP, a control unit, a telephone interface and a microphone interface are disposed in the conference telephone host. The telephone interface is used to achieve signal connection with a telecommunications network. The control unit is responsible for control of interface and logic action. The DSP is used to cancel echo signals of communication and detect the loss of echo signals. The DSP will send an indication signal to the control unit once detecting abnormal echoes. The control unit will then send out a control command to the microphone via the microphone interface for adjusting the microphone according to the control command. Thereby, automatic detection of abnormal echoes and maintenance of communication quality can be accomplished, and the cost can also be lowered. 
",HUANG WESLEY;;CHEN TOM;;HUANG CLARK C. M.,HUANG WESLEY;;CHEN TOM;;HUANG CLARK C M,TECOM CO. LTD (2003-03-14),https://lens.org/062-193-047-763-383,Patent Application,yes,4,13,1,1,0,H04M1/6033;;H04M1/6033,H04M1/60,379/387.01;;379/207.02,0,0,,,,DISCONTINUED
112,EP,A3,EP 2722556 A3,128-199-350-497-09X,2014-11-26,2014,EP 14151196 A,2010-02-25,US 15604209 P;;EP 10706869 A,2009-02-27,Vehicle and method of operating the same,"The present invention provides a vehicle and a method of operating the same. The vehicle comprises an engine (12), a transmission (14) comprising an input shaft (112) operably connected to the engine (12) for receiving torque, and an output shaft (126) operably connected to a drive axle (34) for transferring the torque to the drive axle (34), a drive gear connected to either the input shaft (112) or to the output shaft (126) for rotation therewith, a driven gear connected to the other of the input shaft (112) or the output shaft (126) for selective rotation therewith via operation of a first clutch (114) such that the driven gear engages the drive gear, and a processor (40) configured to operate the first clutch (114) to modulate transmission of the torque from the input shaft (112) to the output shaft (126). The drive axle (34) comprises a first clutch system (142) operably connected to a first drive wheel (39). The processor (40) is further configured to operate a second clutch of the first clutch system (142) to modulate transmission of the torque to rotate the drive wheel (39) in a first rotational direction, and to operate a third clutch of the first clutch system (142) to modulate transmission of the torque to rotate the drive wheel (39) in a second rotational direction that is opposite the first rotational direction.
",NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,"HYSTER-YALE GROUP, INC. (2017-05-03)",https://lens.org/128-199-350-497-09X,Search Report,yes,0,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/10;;F16H3/089,,1,0,,,No Search,ACTIVE
113,EP,A1,EP 3737912 A1,148-141-517-908-211,2020-11-18,2020,EP 19700992 A,2019-01-10,GR 20180100008 A;;GB 201804079 A;;GB 2019050056 W,2018-01-10,DETERMINING THE LOCATION OF A MOBILE DEVICE,,UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,,https://lens.org/148-141-517-908-211,Patent Application,yes,0,0,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C21/20;;G01C22/00,,0,0,,,,ACTIVE
114,EP,B1,EP 2401524 B1,153-880-295-935-838,2014-07-02,2014,EP 10706869 A,2010-02-25,US 2010/0025408 W;;US 15604209 P,2009-02-27,Transmission system and method for operating a transmission system,,NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/153-880-295-935-838,Granted Patent,yes,3,0,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/089;;F16H3/10,,0,0,,,,ACTIVE
115,US,B2,US 9114800 B2,166-196-266-301-669,2015-08-25,2015,US 201314067091 A,2013-10-30,US 201314067091 A;;US 201113202173 A;;US 2010/0025408 W;;US 15604209 P,2009-02-27,Vehicle transmission with clutch pack overrun,"A drive system ( 14, 34 ) comprising an input shaft ( 112 ); a first clutch ( 114 ) configured to selectively couple a first gear ( 116 ) to the input shaft ( 112 ); an output shaft ( 126 ); a second gear ( 138 ) engaging with the first gear ( 116 ); and a drive axle clutch system ( 142 ) having different travel direction clutches.",CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE;;NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,,https://lens.org/166-196-266-301-669,Granted Patent,yes,51,1,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H59/36;;B60W10/02;;B60W10/11;;F16H3/10;;F16H61/02;;F16H61/684,,2,0,,,"European Patent Office; ""PCT International Search Report and Written Opinion of the International Searching Authority"" for PCT/US2010/025324, filed Feb. 25, 2010; mailed Jun. 16, 2010; 9 pages.;;European Patent Office; ""PCT International Search Report and Written Opinion of the International Searching Authority"" for PCT/US2010/025408, filed Feb. 25, 2010; mailed Jul. 13, 2010; 16 pages.",ACTIVE
116,CA,A1,CA 3011094 A1,015-229-428-346-265,2017-07-20,2017,CA 3011094 A,2017-01-12,US 201662277883 P;;US 2017/0013254 W,2016-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY LLC,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/015-229-428-346-265,Patent Application,no,0,0,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,G05B21/00;;F24F11/76;;G05D23/00;;G05D23/19;;G06F19/00;;H05K7/20,,0,0,,,,PENDING
117,US,A1,US 2009/0245153 A1,010-687-393-297-85X,2009-10-01,2009,US 5937508 A,2008-03-31,US 5937508 A,2008-03-31,MULTIUSER SECTOR MICRO DIVERSITY SYSTEM,Embodiments of methods and apparatus for a multiuser sector micro diversity system are described herein. Other embodiments may be described and claimed.,LI LI;;CHEN CLARK;;LI GUANGJIE;;WU MAY,LI LI;;CHEN CLARK;;LI GUANGJIE;;WU MAY,INTEL CORPORATION (2008-04-06),https://lens.org/010-687-393-297-85X,Patent Application,yes,10,151,2,2,0,H04B7/0452;;H04B7/0491;;H04B7/0632;;H04L5/0023;;H04L5/0037;;H04L5/0044;;H04L5/006;;H04L25/03343;;H04B7/0465;;H04L5/0023;;H04B7/0491;;H04B7/0452;;H04B7/0632;;H04L5/0044;;H04L5/0037;;H04L25/03343;;H04L5/006;;H04B7/0465,H04J15/00,370/312,0,0,,,,ACTIVE
118,EP,A1,EP 2681248 A1,027-216-985-830-722,2014-01-08,2014,EP 12709212 A,2012-02-29,US 201161447800 P;;US 2012/0027086 W,2011-03-01,PROCESS FOR IMPROVING BULK DENSITY WITH MULTI-CONTACT PROCATALYST AND PRODUCT,,DOW GLOBAL TECHNOLOGIES LLC,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,W.R. GRACE & CO.-CONN. (2014-06-25),https://lens.org/027-216-985-830-722,Patent Application,yes,0,0,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F110/06,,0,0,,,,DISCONTINUED
119,EP,A2,EP 2722556 A2,046-118-752-186-315,2014-04-23,2014,EP 14151196 A,2010-02-25,US 15604209 P;;EP 10706869 A,2009-02-27,Vehicle and method of operating the same,"The present invention provides a vehicle and a method of operating the same. The vehicle comprises an engine (12), a transmission (14) comprising an input shaft (112) operably connected to the engine (12) for receiving torque, and an output shaft (126) operably connected to a drive axle (34) for transferring the torque to the drive axle (34), a drive gear connected to either the input shaft (112) or to the output shaft (126) for rotation therewith, a driven gear connected to the other of the input shaft (112) or the output shaft (126) for selective rotation therewith via operation of a first clutch (114) such that the driven gear engages the drive gear, and a processor (40) configured to operate the first clutch (114) to modulate transmission of the torque from the input shaft (112) to the output shaft (126). The drive axle (34) comprises a first clutch system (142) operably connected to a first drive wheel (39). The processor (40) is further configured to operate a second clutch of the first clutch system (142) to modulate transmission of the torque to rotate the drive wheel (39) in a first rotational direction, and to operate a third clutch of the first clutch system (142) to modulate transmission of the torque to rotate the drive wheel (39) in a second rotational direction that is opposite the first rotational direction.
",NACCO MATERIALS HANDLING GROUP INC,CLARK ROBERT DAVID;;CHEN CHENYAO;;CHESS ROBERT LEE,"HYSTER-YALE GROUP, INC. (2017-05-03)",https://lens.org/046-118-752-186-315,Patent Application,yes,0,1,11,11,0,F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;Y10T74/19251;;Y10T74/19219;;Y10T74/19251;;Y10T74/19219;;F16H3/10;;F16H61/0246;;F16H61/684;;F16H2200/0039;;B60W10/02;;B60W10/11,F16H3/10;;F16H3/089,,0,0,,,,ACTIVE
120,EP,B1,EP 3737912 B1,043-552-864-530-865,2022-08-10,2022,EP 19700992 A,2019-01-10,GR 20180100008 A;;GB 201804079 A;;GB 2019050056 W,2018-01-10,DETERMINING THE LOCATION OF A MOBILE DEVICE,,UNIV OXFORD INNOVATION LTD,CHEN CHANGHAO;;CLARK RONALD;;MARKHAM ANDREW;;TRIGONI AGATHONIKI,,https://lens.org/043-552-864-530-865,Granted Patent,yes,2,0,8,8,0,G01C21/206;;G01C22/006;;G01C21/185;;G01C19/00;;G01C21/206;;G01P15/08;;G01C21/185,G01C21/16;;G01C21/20;;G01C22/00,,2,0,,,"Hang Yan ET AL: ""RIDI: Robust IMU Double Integration : 15th European Conference, Munich, Germany, September 8-14, 2018, Proceedings, Part XIII"" In: ""Serious Games"", 31 December 2017 (2017-12-31), Springer International Publishing, Cham 032682, XP055568708, ISSN: 0302-9743 ISBN: 978-3-642-38979-5 vol. 11217, pages 641-656, DOI: 10.1007/978-3-030-01261-8_38, sections 4, 5;;Changhao Chen ET AL: ""IONet: Learning to Cure the Curse of Drift in Inertial Odometry"", , 30 January 2018 (2018-01-30), XP055568599, Thirty-Second AAAI Conference on Artificial Intelligence Retrieved from the Internet: URL:https://www.cs.ox.ac.uk/files/9853/Lea rning%20to%20Cure%20the%20Curse%20of%20Dri ft%20in%20Inertial%20Odometry.pdf [retrieved on 2019-03-15]",ACTIVE
121,US,A1,US 2010/0173769 A1,053-115-527-756-158,2010-07-08,2010,US 65103209 A,2009-12-31,US 65103209 A;;US 2009/0069929 W;;US 14190208 P;;US 14195908 P,2008-12-31,Enhanced Procatalyst Composition and Process,"Disclosed herein are processes for preparing procatalyst compositions and polymers, i.e., propylene-based polymers, produced therefrom. The present procatalyst compositions improve catalyst selectivity and also increase the bulk density of the formant polymer.",GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,GONZALEZ KELLY A;;WILLIAMS CLARK C;;CHEN LINFENG,DOW GLOBAL TECHNOLOGIES LLC (2010-12-31);;W. R. GRACE & CO. CONN (2014-03-24),https://lens.org/053-115-527-756-158,Patent Application,yes,7,6,96,146,0,C08F110/06;;C08F210/06;;C07C37/02;;C07C37/14;;C07C37/16;;C07C37/50;;C07C37/56;;C07C37/60;;C07C67/14;;C08F10/06;;C08F2410/06;;C07C37/02;;C07C37/14;;C07C67/14;;C08F10/06;;B01J31/02;;C08F4/32;;C08F4/64;;C08F4/651;;C08F4/653;;C08F4/654;;C08K5/10;;C08F2/00;;C08F210/02;;C08F210/06;;C08L23/16;;C08L23/10;;C08F4/42;;C08F110/06;;C08F110/06;;C08F210/06;;C07C67/14;;C07C37/50;;C07C37/60;;C07C37/16;;C07C37/02;;C07C37/14;;C07C37/56;;C08F10/06,B01J31/38;;B01J31/02,502/107;;502/126,0,0,,,,ACTIVE
122,WO,A1,WO 2012/118883 A1,125-482-446-235-814,2012-09-07,2012,US 2012/0027086 W,2012-02-29,US 201161447800 P,2011-03-01,PROCESS FOR IMPROVING BULK DENSITY WITH MULTI-CONTACT PROCATALYST AND PRODUCT,"Disclosed herein are processes for preparing procatalyst compositions which include multiple contact steps in the presence of a substituted phenylene aromatic diester and at least one other internal electron donor. The multi-contact procatalyst compositions produced from the present processes improve polymer properties and polymerization parameters. In particular, the present multi-contact procatalyst compositions improve polymer bulk density.",DOW GLOBAL TECHNOLOGIES LLC;;COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,COALTER JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,,https://lens.org/125-482-446-235-814,Patent Application,yes,12,2,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/651;;C08F110/06,,1,0,,,"""Periodic Table of the Elements"", 2003, CRC PRESS, INC.",PENDING
123,US,A1,US 2018/0323994 A1,113-233-365-983-893,2018-11-08,2018,US 201815942306 A,2018-03-30,US 201815942306 A;;US 201414582732 A,2014-12-24,INTELLIGENT EQUIPMENT SEQUENCING,"Systems and methods for sequencing HVAC equipment of an HVAC system using data recorded in situ to build a model capable of making predictions about equipment efficiency and using that information, in combination with predictions about building load, to produce an operational sequence for the HVAC equipment that promotes an improved or optimized overall energy efficiency for the HVAC system. In one embodiment, the process is automated and utilizes Bayesian computational models or algorithms to generate an initial sequence. The process reduces engineering hours and may advantageously provide a means to predict potential sequencing problems for similar types of HVAC equipment.",OPTIMUM ENERGY LLC,JONES THOMAS;;DEMPSTER IAN;;MATTHYS CLARK;;CHEN PENG,OPTIMUM ENERGY LLC (2018-01-25),https://lens.org/113-233-365-983-893,Patent Application,yes,0,0,4,4,0,F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64;;H04L12/2816;;F24F11/30;;F24F11/62;;F24F11/46;;F24F11/64,H04L12/28;;F24F11/30;;F24F11/46;;F24F11/62,,0,0,,,,ACTIVE
124,EP,A1,EP 3568646 A1,105-734-732-675-389,2019-11-20,2019,EP 18739049 A,2018-01-12,US 201715405249 A;;US 2018/0013667 W,2017-01-12,PREDICTIVE FREE COOLING,,OPTIMUM ENERGY LLC;;ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,,https://lens.org/105-734-732-675-389,Patent Application,yes,0,0,5,16,0,F24F11/62;;F24F11/46;;F24F11/64;;F24F11/65;;F24F2110/12;;F24F2110/22;;F24F2130/10;;G05B15/02;;G05B2219/2642;;Y02B30/54,F24F11/00,,0,0,,,,DISCONTINUED
125,US,A1,US 2017/0198933 A1,188-822-213-824-208,2017-07-13,2017,US 201715405194 A,2017-01-12,US 201715405194 A;;US 201662277883 P,2016-01-12,PREDICTIVE FREE COOLING,"An environmental control system for a building in a geographic location and having a heating, ventilation and air-conditioning (HVAC) system includes at least one computer-readable medium having instructions stored thereon that, when executed by at least one processing device in communication with the external application, enables the at least one processing device to receive weather data characterizing a weather forecast over a predetermined time period for the geographic location, receive free-cooling window data, determine, based on the weather data and free-cooling window data, an available free-cooling time window, and issue to the external application an executable command to the HVAC system to enter free-cooling mode during the available free-cooling time window.",OPTIMUM ENERGY,ERPELDING BEN;;DEMPSTER IAN;;CHEN PENG;;MATTHYS CLARK,OPTIMUM ENERGY LLC (2017-06-01),https://lens.org/188-822-213-824-208,Patent Application,yes,7,15,10,16,0,G05B19/0426;;F24F11/30;;F24F2110/10;;F24F2110/12;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F11/62;;F24F11/64;;F24F11/65;;F24F11/46;;F24F11/76;;F24F2011/0002;;G05B2219/2614;;Y02B30/54;;F24F11/523;;F24F11/64;;F24F11/46;;F24F11/65;;F24F11/76;;G05B19/0426;;F24F2140/60;;F24F2130/00;;F24F2130/10;;F24F2110/10;;F24F2110/12;;F24F2011/0002;;G05B2219/2614;;F24F11/523;;F24F2011/0002;;G05B2219/2614;;G05B19/0426;;F24F2140/60;;F24F2130/10;;F24F2110/12;;F24F11/65;;F24F11/62;;F24F2110/10;;F24F11/76;;F24F11/46;;F24F2130/00;;F24F11/30;;F24F11/64;;Y02B30/54;;F24F11/523,F24F11/00;;F24F11/76;;G05B19/048,,0,0,,,,ACTIVE
126,US,A1,US 2006/0089804 A1,131-354-813-136-860,2006-04-27,2006,US 22268905 A,2005-09-09,US 22268905 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling methodology for determining earth formation characteristics and other useful information based upon streaming potential measurements,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/131-354-813-136-860,Patent Application,yes,72,31,5,5,0,E21B47/10;;G01V3/265;;G01V3/265;;E21B47/10,G01V3/00;;G06F19/00;;G01V3/08;;G01V3/18;;G01V3/26,702/1,0,0,,,,INACTIVE
127,US,B2,US 7466136 B2,144-808-368-367-964,2008-12-16,2008,US 22268905 A,2005-09-09,US 22268905 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling methodology for determining earth formation characteristics and other useful information based upon streaming potential measurements,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/144-808-368-367-964,Granted Patent,yes,76,7,5,5,0,E21B47/10;;G01V3/265;;G01V3/265;;E21B47/10,G01V3/20;;G01V3/00;;G01V3/08;;G01V3/18;;G01V3/26,324/369;;324/347;;324/354;;324/355;;324/356;;324/366;;175/50,9,4,160-919-555-206-025;;144-289-954-649-970;;023-324-612-587-38X;;065-784-698-904-809,10.1029/1999gl011099;;10.1029/2001gl013483;;10.1190/1.1443533;;10.2118/77522-ms,"Hunt, et al. ""Borehole Electrokinetic Responses in Fracture Dominated Hydraulically Conductive Zones."" Geophysical Research Letters, May 1, 2000, vol. 27, No. 9, pp. 1315-1318.;;Fordham, E.J., and H.K.J. Ladva, ""Cross-flow Filtration of Bentonite Suspensions"", PhysicoChemical Hydrodynamics, 11(4), 411-439 (1989).;;Hovhannissian et al. ""Transient electric phenomena observed during fluid circulation in unsaturated porous media."" Geophysical Research Letters, vol. 29, No. 1, pp. 5-1 to 5-4.;;Wurmstich et al. ""Modeling of streaming potential responses caused by oil well pumping."" Geophysics, vol. 59, No. 1 (Jan. 1994), pp. 46-56.;;International Search Report for PCT/US2006/034526 mailed Mar. 14, 2007.;;International Search Report for PCT/US2006/034160 mailed Jan. 19, 2007.;;Bryant et al. ""Real-Time Monitoring and Control of Water Influx to a Horizontal Well Using Advanced Completion Equipped with Permanent Sensors."" SPE 77522 SPE Annual Technical Conference and Exhibition, San Antonio, Texas (Sep. 29 - Oct. 2, 2002).;;International Search Report and Written Opinion for PCT/US2006/034159 mailed May 29, 2007.;;International Search Report and Written Opinion for PCT/US2006/034291 mailed Jun. 19, 2007.",INACTIVE
128,US,A1,US 2007/0170924 A1,058-254-860-321-395,2007-07-26,2007,US 22364405 A,2005-09-09,US 22364405 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling apparatus for measuring streaming potentials and determining earth formation characteristics and other useful information,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/058-254-860-321-395,Patent Application,yes,69,13,4,4,0,G01V3/265;;G01V3/265,G01V3/00,324/347,0,0,,,,ACTIVE
129,WO,A1,WO 2020/047285 A1,090-590-146-749-012,2020-03-05,2020,US 2019/0048858 W,2019-08-29,US 201862724177 P,2018-08-29,DEVICES AND METHODS FOR TREATMENT OF TUMORS USING ELECTROMAGNETIC SIGNAL,"Systems and methods for treating cancerous tumors (including glioblastoma multiforme (GBM)) with electrotherapy, such as deep brain stimulation (DBS) technology, as disclosed herein. One or more configurations can be generated based on a patient's tumor characteristics. The selected configurations can be electrode configurations or settings for an electrical source coupled to the electrodes. The one or more configurations can be targeted for inhibiting cell growth processes, such as to inhibit mitosis, immune suppression, or to inhibit DNA replication. Inhibition of cell growth processes can initiate death of the cancerous cells.",UNIV MINNESOTA,CHEN DR CLARK;;MOLNAR DR GREGORY FREDERICK;;DHAWAN SANJAY,,https://lens.org/090-590-146-749-012,Patent Application,yes,4,2,4,4,0,A61N1/05;;A61B2576/026;;A61B5/4848;;A61B5/4064;;A61B5/0042;;A61B5/6868;;A61B2018/00321;;A61B2018/00482;;A61B2018/00565;;A61B2018/00577;;A61B18/1206;;A61B18/14;;A61N1/40;;G16H30/40;;B33Y80/00;;A61N1/36002;;A61N1/0534;;A61N1/36171;;A61N1/37211;;A61N1/40,A61B18/12;;A61B5/05;;A61N1/05,,0,0,,,,PENDING
130,AU,A,AU 1986/054111 A,126-717-056-201-889,1986-09-04,1986,AU 1986/054111 A,1986-02-26,US 70696485 A,1985-02-28,WATER RESISTANT LATEX SEALANT,,BEECHAM HOME IMPROV PROD,CHEN FUNG-BOR;;WILLITTS CLARK M;;CLUTTER EDWARD T,,https://lens.org/126-717-056-201-889,Patent Application,no,0,0,4,4,0,C09D133/064;;C08L83/08;;C09D133/066,C08L83/08;;C09D133/06,,0,0,,,,EXPIRED
131,CA,C,CA 1340267 C,137-499-135-958-771,1998-12-15,1998,CA 502863 A,1986-02-27,US 70696485 A,1985-02-28,WATER RESISTANT LATEX SEALANT,"An acrylic copolymer latex sealant composition, which comprises an acrylic copolymer having a glass transition temperature not exceeding about -10.degree.C, a hydrolyzed organoaminosilane, inorganic filler, an anionic, non-ionic or amphoteric surfactant, and water, the weight ratio of said filler to said acrylic copolymer being from about 1:1 to about 1.8:1.",DAP INC,CHEN FUNG-BOR;;WILLITTS CLARK M;;CLUTTER EDWARD T,,https://lens.org/137-499-135-958-771,Granted Patent,no,0,1,4,4,0,C09D133/064;;C08L83/08;;C09D133/066,C08L83/08;;C09D133/06,D14005344    M,0,0,,,,EXPIRED
132,WO,A1,WO 2007/032929 A1,173-890-398-390-986,2007-03-22,2007,US 2006/0034160 W,2006-09-01,US 22364405 A,2005-09-09,WHILE-DRILLING APPARATUS FOR MEASURING STREAMING POTENTIALS AND DETERMINING EARTH FORMATION CHARACTERISTICS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/173-890-398-390-986,Patent Application,yes,4,0,4,4,0,G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,PENDING
133,WO,A3,WO 2007/032928 A3,067-702-388-665-428,2007-07-26,2007,US 2006/0034159 W,2006-09-01,US 22367605 A,2005-09-09,WHILE-DRILLING APPARATUS FOR MEASURING STREAMING POTENTIALS AND DETERMINING EARTH FORMATION CHARACTERISTICS AND OTHER USEFUL INFORMATION,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/067-702-388-665-428,Search Report,yes,4,0,5,5,0,G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,PENDING
134,US,A1,US 2016/0312767 A1,115-252-499-303-693,2016-10-27,2016,US 201615138303 A,2016-04-26,IB 2015001448 W;;DK PA201570888 A,2015-04-27,METHOD FOR OPERATING A WIND TURBINE BASED ON DEGRADATION OF WIND TURBINE BLADE,A control method and a wind turbine for adaptively adjusting the operation of the wind turbine to maintain maximum power production during degraded conditions. The control system has an estimator module that determines a scaling factor based on the current set of control signals and at least the current set of measurement of the operating parameters. The scaling factor is transmitted to a control module which scales at least one aerodynamic property of the rotor based on this scaling factor. The control module further determines the ideal settings for the control signals based on the scaled aerodynamic properties. The present control method scales the aerodynamic properties to provide a better representation of the actual degraded aerodynamic properties.,ENVISION ENERGY (JIANGSU) CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,ENVISION ENERGY (JIANGSU) CO. LTD (2016-05-10),https://lens.org/115-252-499-303-693,Patent Application,yes,10,13,6,8,0,F03D7/0224;;F03D7/044;;F03D7/046;;F03D7/0224;;F03D7/043;;F03D7/044;;F03D7/046;;F03D9/25;;F03D9/25;;F03D17/00;;F03D80/40;;F03D80/40;;F05B2270/1033;;F05B2270/20;;F05B2270/20;;F05B2270/30;;F05B2270/336;;F05B2270/336;;F05B2270/602;;F05B2270/705;;Y02E10/72;;Y02E10/72,F03D7/04;;F03D7/02;;F03D9/00;;F03D17/00,,0,0,,,,ACTIVE
135,WO,A2,WO 2007/032938 A2,039-550-009-625-827,2007-03-22,2007,US 2006/0034291 W,2006-09-05,US 22268905 A,2005-09-09,WHILE-DRILLING METHODOLOGY FOR DETERMINING EARTH FORMATION CHARACTERISTICS AND OTHER USEFUL INFORMATION BASED UPON STREAMING POTENTIAL MEASUREMENTS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/039-550-009-625-827,Patent Application,yes,0,0,5,5,0,E21B47/10;;G01V3/265;;G01V3/265;;E21B47/10,G01V3/00;;G01V3/08;;G01V3/18;;G01V3/26,,0,0,,,,PENDING
136,JP,A,JP 2020075356 A,051-080-754-730-337,2020-05-21,2020,JP 2019232190 A,2019-12-24,JP 2019232190 A;;JP 2018526711 A,2016-02-29,FLUID PROPULSION DEVICE INCLUDING HEAT SINK,"To provide a fluid propulsion device that allows reduction in an amount of silicon in a device and can efficiently release heat from a MEMS.SOLUTION: A fluid propulsion device comprises: a plastic compound structure 9 comprising a first fluid channel 3; a MEMS 5 which is embedded in the compound 9, the MEMS 5 comprising a substrate, a second fluid channel 7 fluid-connected to the first fluid channel 3, and a fluid propulsion actuator 13 in the second fluid channel 7; and a heat sink 15 which lies adjacent to the MEMS 5 for releasing heat from the MEMS 5. The heat sink 15 is surrounded at least partially by the compound 9. The MEMS 5 has a width of less than 2.3 mm and a thickness of less than 0.8 mm, and the MEMS 5 has an average density of at least 300 pieces/inch per row of actuators.SELECTED DRAWING: Figure 1",HEWLETT PACKARD DEVELOPMENT CO,GARRETT E CLARK;;MICHAEL W CUMBIE;;CHEN CHIEN-HUA,,https://lens.org/051-080-754-730-337,Patent Application,no,9,0,2,2,0,,B81B3/00;;B41J2/14,,0,0,,,,ACTIVE
137,DE,A1,DE 102022130131 A1,116-193-346-502-21X,2023-06-22,2023,DE 102022130131 A,2022-11-15,US 202117553918 A,2021-12-17,VERFAHREN UND VORRICHTUNGEN ZUR GEMEINSAMEN VERARBEITUNG IN MASSIVE-MIMO-SYSTEMEN,"Eine verteilte Einheit (DU) kann einen Transceiver beinhalten, der konfiguriert ist, um mit einer Vielzahl von Funkeinheiten (RUs) zu kommunizieren, die konfiguriert sind, um mehrere Benutzergeräte (UEs) zu bedienen. Die DU kann einen Prozessor beinhalten, der konfiguriert ist, um RU-Vorcodierungsparameter für UEs zu bestimmen, die von einem ersten RU-Satz der Vielzahl von RUs bedient werden, basierend auf geschätzten Kanalparametern für Kommunikationskanäle zwischen dem ersten RU-Satz und mindestens einem der interferierenden UEs, die von anderen RUs der Vielzahl von RUs bedient werden; Informationen, die bestimmte Vorcodierungsparameter für Downlink-Übertragungen an den ersten RU-Satz angeben, zu codieren und DU-Vorcodierungsparameter für Downlink-Übertragungen an die UEs zu bestimmen, die von dem ersten RU-Satz bedient werden, basierend auf den bestimmten RU-Vorcodierungsparametern; und/oder Kommunikationssignale basierend auf den bestimmten DU-Vorcodierungsparametern vorzucodieren.",INTEL CORP,LU LU;;KRISHNAMURTHY SUNDAR;;CHEN KUILIN CLARK;;HEWAVITHANA THUSHARA,,https://lens.org/116-193-346-502-21X,Patent Application,no,0,0,2,2,0,H04B17/391;;H04L25/03343;;H04L25/0256;;H04B17/391;;H04L25/0252;;H04L25/025;;H04L25/0258,H04B7/0413,,0,0,,,,PENDING
138,BR,A2,BR PI0615890 A2,131-261-366-557-82X,2011-05-31,2011,BR PI0615890 A,2006-09-01,US 22367605 A;;US 2006/0034159 W,2005-09-09,aparelho para investigação de uma formação terrestre atravessada por um furo,"APARELHO PARA INVESTIGAR UMA FORMAçãO TERRESTRE ATRAVESSADA POR UM FURO São fornecidos um aparelho e metodologias de perfuração com perfilagem para medir potencial de escoamento em uma formação terrestre. O aparelho e metodologias podem ser utilizados para localizar informações relevantes sobre as operações de perfuração. De modo particular, visto que a medição do potencial de escoamento se refere diretamente ao fluxo de fluido, as medições do potencial de escoamento podem ser usadas, para localizar informações relevantes sobre as operações de perfuração, tais como condições de perfuração sub- balanceada, pressões anormais na formação, fraturas abertas, a permeabilidade da formação, e pressão da formação.",PRAD RES & DEV NV,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/131-261-366-557-82X,Patent Application,no,0,0,5,5,0,G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,DISCONTINUED
139,AU,B2,AU 579713 B2,054-700-622-163-231,1988-12-08,1988,AU 1986/054111 A,1986-02-26,US 70696485 A,1985-02-28,WATER RESISTANT LATEX SEALANT,,BEECHAM HOME IMPROVEMENT PRODU,CHEN FUNG-BOR;;WILLITTS CLARK M;;CLUTTER EDWARD T,,https://lens.org/054-700-622-163-231,Granted Patent,no,1,0,4,4,0,C09D133/064;;C08L83/08;;C09D133/066,C08L83/08;;C09D133/06,,0,0,,,,EXPIRED
140,WO,A1,WO 2018/045266 A1,140-501-732-585-692,2018-03-08,2018,US 2017/0049815 W,2017-09-01,US 201662382872 P,2016-09-02,METHODS AND COMPOSITIONS FOR TREATING CHRONIC GRANULOMATOUS DISEASE,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation for the treatment of chronic granulomatous disease,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;LI YANG,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;LI YANG,,https://lens.org/140-501-732-585-692,Patent Application,yes,3,3,3,3,40,A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;C12N15/86,A61K35/28;;A61K48/00;;A61M1/38;;C12N5/071;;C12N5/0783;;C12N5/0789;;C12N15/86,,2,2,019-572-121-670-064;;075-103-788-296-727,10.1016/j.jaci.2011.03.028;;pmc3133927;;21497887;;28077679;;10.1126/scitranslmed.aah3480,"KANG, EM ET AL.: ""Chronic Granulomatous Disease: Overview and Hematopoietic Stem Cell Transplant"", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 127, no. 6, June 2011 (2011-06-01), pages 1319 - 1326, XP028385467;;RAVIN, SSD ET AL.: ""CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease"", SCIENCE TRANSLATIONAL MEDICINE, vol. 9, no. 372, 11 January 2017 (2017-01-11), pages 1 - 10, XP055471976, Retrieved from the Internet <URL:DOI:10.1126/scitranslmed.aah3480>",PENDING
141,CN,A,CN 108367909 A,161-990-609-958-520,2018-08-03,2018,CN 201680069872 A,2016-02-29,US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,"A fluid propelling apparatus, including a plastic compound, a MEMS at least partially surrounded by the compound, and a heat sink next to the MEMS, to transfer heat away from the MEMS, wherein the heat sink is at least partly surrounded by the compound.",HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,,https://lens.org/161-990-609-958-520,Patent Application,no,4,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B81B7/02;;B81B3/00,,0,0,,,,DISCONTINUED
142,US,A1,US 2023/0198815 A1,046-115-930-100-497,2023-06-22,2023,US 202117553918 A,2021-12-17,US 202117553918 A,2021-12-17,METHODS AND DEVICES FOR JOINT PROCESSING IN MASSIVE MIMO SYSTEMS,A distributed unit (DU) may include a transceiver configured to communicate with a plurality of radio units (RUs) that are configured to serve a plurality of user equipments (UEs). The DU may include a processor configured to determine RU precoding parameters for UEs served by a first RU set from the plurality of RUs based on estimated channel parameters for communication channels between the first RU set and at least one of interfering UEs served by other RUs from the plurality of RUs; to encode information indicating the determined precoding parameters for downlink transmissions to the first RU set and determine DU precoding parameters for downlink transmissions to the UEs served by the first RU set based on the determined RU precoding parameters; and/or precode communication signals based on the determined DU precoding parameters.,INTEL CORP,LU LU;;KRISHNAMURTHY SUNDAR;;CHEN KUILIN CLARK;;HEWAVITHANA THUSHARA,INTEL CORPORATION (2021-12-07),https://lens.org/046-115-930-100-497,Patent Application,yes,0,0,2,2,0,H04B17/391;;H04L25/03343;;H04L25/0256;;H04B17/391;;H04L25/0252;;H04L25/025;;H04L25/0258,H04L25/02;;H04B17/391,,0,0,,,,PENDING
143,US,B1,US 9112484 B1,069-166-858-517-267,2015-08-18,2015,US 201314136258 A,2013-12-20,US 201314136258 A;;US 201261740339 P,2012-12-20,Integrated circuit process and bias monitors and related methods,"An integrated circuit device can include at least one oscillator stage having a current mirror circuit comprising first and second mirror transistors of a first conductivity type, and configured to mirror current on two mirror paths, at least one reference transistor of a second conductivity type having a source-drain path coupled to a first of the mirror paths, and a switching circuit coupled to a second of the mirror paths and configured to generate a transition in a stage output signal in response to a stage input signal received from another oscillator stage, wherein the channel lengths of the first and second mirror transistors are larger than that of the at least one reference transistor.",MIE FUJITSU SEMICONDUCTOR LTD,CLARK LAWRENCE T;;KIDD DAVID A;;CHEN CHAO-WU,SUVOLTA INC (2013-12-19);;MIE FUJITSU SEMICONDUCTOR LIMITED (2015-03-03),https://lens.org/069-166-858-517-267,Granted Patent,yes,104,21,3,3,0,G01R31/2884;;H01L22/34;;H03K3/0315;;G05F3/262;;G05F3/205;;H01L29/7851;;H03K3/0315;;H03K3/011;;G05F3/262;;G05F3/205;;H01L22/34;;G01R31/2884,H03K3/03,,44,27,064-735-181-181-671;;176-034-520-459-930;;116-323-438-999-844;;021-680-905-582-417;;157-354-250-886-679;;173-501-876-729-218;;018-385-851-474-68X;;062-487-330-942-241;;168-629-837-711-367;;101-593-457-781-889;;043-110-693-882-533;;041-586-532-565-175;;150-260-890-760-298;;015-093-657-307-147;;032-553-133-830-958;;110-642-117-637-519;;011-900-260-029-102;;001-947-888-041-487;;126-540-642-620-903;;017-208-359-250-402;;058-472-243-648-742;;030-155-185-671-921;;179-841-142-977-561;;057-884-966-335-103;;060-779-596-368-736;;026-606-955-791-598;;119-578-504-667-48X,10.1016/j.sse.2005.10.048;;10.1109/5.752515;;10.1109/cicc.2006.320869;;10.1109/ted.2003.815371;;10.1109/iedm.1993.347253;;10.1109/vlsit.1996.507784;;10.1109/ted.2006.884070;;10.1109/isqed.2012.6187559;;10.1109/iscas.2010.5537410;;10.1145/1973009.1973037;;10.3745/jips.2011.7.1.093;;10.1109/jssc.2002.803949;;10.1109/aspdac.2011.5722162;;10.1109/vlsit.1995.520841;;10.1149/1.2356293;;10.1149/1.2355889;;10.1109/vlsit.2008.4588583;;10.1109/iedm.2009.5424250;;10.1109/iedm.1996.553626;;10.4028/www.scientific.net/ssp.82-84.189;;10.1109/16.662780;;10.1109/16.772479;;10.1063/1.1489715;;10.1063/1.120684;;10.1063/1.123081;;10.1063/1.122483;;10.1109/16.141237,"Komaragiri, R. et al., ""Depletion-Free Poly Gate Electrode Architecture for Sub 100 Nanometer CMOS Devices with High-K Gate Dielectrics"", IEEE IEDM Tech Dig., San Francisco CA, 833-836, Dec. 13-15, 2004.;;Samsudin, K et al., Integrating Intrinsic Parameter Fluctuation Description into BSIMSOI to Forecast sub-15 nm UTB SOI based 6T SRAM Operation, Solid-State Electronics (50), pp. 86-93, (2005).;;Wong, H et al., ""Nanoscale CMOS"", Proceedings of the IEEE, Vo. 87, No. 4, pp. 537-570, Apr. 11, 1999.;;Machine Translation of KR 10-0794094.;;Banerjee et al., ""Compensating Non-Optical Effects using Electrically-Driven Optical Proximity Correction"", Proc. of SPIE, vol. 7275, 2009.;;Cheng et al., ""Extremely Thin SOI (ETSOI) CMOS with Record Low Variability for Low Power System-on-Chip Applications"", IEDM 2009, Dec. 2009.;;Cheng et al., ""Fully Depleted Extremely Thin SOI Technology Fabricated by a Novel Integration Scheme Featuring Implant-Free, Zero-Silicon-Loss, and Faceted Raised Source/Drain"", 2009 Symposium on VLSI Technology Digest of Technical Papers, 2009.;;Drennan et al., ""Implications of Proximity Effects for Analog Design"", Custom Integrated Circuits Conference, 2006, CICC '06, IEEE, Sep. 10-13, 2006, pp. 169-176.;;Hook et al., ""Lateral Ion Implant Straggle and Mask Proximity Effect"", IEEE Transactions on Electron Devices, vol. 50, No. 9, Sep. 2003.;;Hori et al., ""A 0.1 um CMOS with a Step Channel Profile Formed by Ultra High Vacuum CVD and In-Situ Doped Ions"", IEDM 1993, May 12, 1993.;;Matsuhashi et al., ""High-Performance Double-Layer Epitaxial-Channel PMOSFET Compatible with a Single Gate CMOSFET"", 1996 Symposium on VLSI Technology Digest of Technical Papers, 1996.;;Shao et al., ""Boron diffusion in silicon: the anomalies and control by point defect engineering"", Materials Science and Engineering R 42 (2003), Nov. 2003, pp. 65-114.;;Sheu et al., ""Modeling the Well-Edge Proximity Effect in Highly Scaled MOSFETs"", IEEE Transactions on Electron Devices, vol. 53, No. 11, Nov. 2006, pp. 2792-2798.;;Chan et al., ""DDRO: A Novel Performance Monitoring Methodology Based on Design-Dependent Ring Oscillators"", IEEE International Symposium on Quality Electronic Design, Mar. 19, 2012.;;Chen et al., ""Fully On-Chip Temperature, Process, and Voltage Sensors"", ISCAS, IEEE, 2010.;;Datta, Basab and Burleson, Wayne et al., ""A 45.6u2 13.4uW 7.1V/V Resolution Sub-Threshold Based Digital Process-Sensing Circuit in 45nm CMOS"", GLSVLSI '11, Lausanne, Switzerland, May 2-14, 2011.;;Ghosh, et al., ""On-Chip Negative Bias Temperature Instability Sensor Using Slew Rate Monitoring Circuitry"", IEEE International Symposium on Circuits and Systems, May 24-27, 2009.;;Ghosh, et al., ""On-Chip Process Variation Detection and Compensation for Parametric Yield Enhancement in Sub-100nm CMOS Technology"", IEEE International Symposium on Circuits and Systems, IBM Austin Center for Advanced Studies, 2007.;;Nan et al., ""Dynamic Voltage and Frequency Scaling for Power-Constrained Design using Process Voltage and Temperature Sensor Circuits"", Journal of Information Processing Systems, vol. 7, No. 1, Mar. 2011.;;Tschanz, et al., ""Adaptive Body Bias for Reducing Impacts of Die-to-Die and Within-Die Parameter Variations on Microprocessor Frequency and Leakage"", IEEE Journal of Solid-State Circuits, vol. 37, No. 11, Nov. 2002.;;Zhang et al., ""An On-Chip Characterizing System for Within-Die Delay Variation Measurement of Individual Standard Cells in 65-nm CMOS"", Design Automation Conference, Jan. 25-28, 2011.;;Saxena et al., ""Variation in Transistor Performance and Leakage in Nanometer-Scale Technologies"", IEEE Transactions on Electron Devices, vol. 55, No. 1, Jan. 2008.;;English Translation of JP 8153873.;;Abiko, H et al., ""A Channel Engineering Combined with Channel Epitaxy Optimization and TED Suppression for 0.15mum n-n Gate CMOS Technology"", 1995 Symposium on VLSI Technology Digest of Technical Papers, 1995, pp. 23-24.;;Chau, R et al., ""A 50nm Depleted-Substrate CMOS Transistor (DST)"", Electron Device Meeting 2001, IEDM Technical Digest, IEEE International, 2001, pp. 29.1.1-29.1.4.;;Ducroquet, F et al. ""Fully Depleted Silicon-On-Insulator nMOSFETs with Tensile Strained High Carbon Content Si1-yCy Channel"", 2006, ECS 210th Meeting, Abstract 1033.;;Ernst, T et al., ""Nanoscaled MOSFET Transistors on Strained Si, SiGe, Ge Layers: Some Integration and Electrical Properties Features"", 2006, ECS Trans. 2006, vol. 3, Issue 7, pp. 947-961.;;Goesele, U et al., Diffusion Engineering by Carbon in Silicon, 2000, Mat. Res. Soc. Symp. vol. 610.;;Hokazono, A et al., ""Steep Channel & Halo Profiles Utilizing Boron-Diffusion-Barrier Layers (Si:C) for 32 nm Node and Beyond"", 2008, 2008 Symposium on VLSI Technology Digest of Technical Papers, pp. 112-113.;;Hokazono, A et al., ""Steep Channel Profiles in n/pMOS Controlled by Boron-Doped Si:C Layers for Continual Bulk-CMOS Scaling"", 2009, IEDM09-676 Symposium, pp. 29.1.1-29.1.4.;;Holland, OW and Thomas, DK ""A Method to Improve Activation of Implanted Dopants in SiC"", 2001, Oak Ridge National Laboratory, Oak Ridge, TN.;;Kotaki, H., et al., ""Novel Bulk Dynamic Threshold Voltage MOSFET (B-DTMOS) with Advanced Isolation (SITOS) and Gate to Shallow-Well Contact (SSS-C) Processes for Ultra Low Power Dual Gate CMOS"", 1996, IEDM 96, pp. 459-462.;;Lavéant, P. ""Incorporation, Diffusion and Agglomeration of Carbon in Silicon"", 2002, Solid State Phenomena, vols. 82-84, pp. 189-194.;;Noda, K et al., ""A 0.1-mum Delta-Doped MOSFET Fabricated with Post-Low-Energy Implanting Selective Epitaxy"", Apr. 1998, IEEE Transactions on Electron Devices, vol. 45, No. 4, pp. 809-814.;;Ohguro, Tet al., ""An 0.18-mum CMOS for Mixed Digital and Analog Aplications with Zero-Volt-Vth Epitaxial-Channel MOSFET's"", Jul. 1999, IEEE Transactions on Electron Devices, vol. 46, No. 7, pp. 1378-1383.;;Pinacho, R et al., ""Carbon in Silicon: Modeling of Diffusion and Clustering Mechanisms"", Aug. 2002, Journal of Applied Physics, vol. 92, No. 3, pp. 1582-1588.;;Robertson, Ls et al., ""The Effect of Impurities on Diffusion and Activation of Ion Implanted Boron in Silicon"", 2000, Mat. Res. Soc. Symp. vol. 610.;;Scholz, R et al., ""Carbon-Induced Undersaturation of Silicon Self-Interstitials"", Jan. 1998, Appl. Phys. Lett. 72(2), pp. 200-202.;;Scholz, RF et al., ""The Contribution of Vacancies to Carbon Out-Diffusion in Silicon"", Jan. 1999,Appl. Phys. Lett., vol. 74, No. 3, pp. 392-394.;;Stolk, PA et al., ""Physical Mechanisms of Transient Enhanced Dopant Diffusion in Ion-Implanted Silicon"", May 1997, J. Appl. Phys. 81(9), pp. 6031-6050.;;Thompson, S et al., ""MOS Scaling: Transistor Challenges for the 21st Century"", 1998, Intel Technology Journal Q3' 1998, pp. 1-19.;;Wann, C. et al., ""Channel Profile Optimization and Device Design for Low-Power High-Performance Dynamic-Threshold MOSFET"", 1996, IEDM 96, pp. 113-116.;;Werner, P et al., ""Carbon Diffusion in Silicon"", Oct. 1998, Applied Physics Letters, vol. 73, No. 17, pp. 2465-2467.;;Yan, Ran-Hong et al., ""Scaling the Si MOSFET: From Bulk to SOI to Bulk"", Jul. 1992, IEEE Transactions on Electron Devices, vol. 39, No. 7.",ACTIVE
144,CA,A1,CA 2171032 A1,139-833-226-640-113,1996-09-07,1996,CA 2171032 A,1996-03-05,US 40005595 A,1995-03-06,DUST PROTECTION FOR PCMCIA CARD AND SOCKET,A compliant boot (30) for protecting the electrical connection between a PCMCIA card (14) and receiving socket (18) from dust and other contaminants when used in a harsh or dusty environment such as on-board a refuse collection vehicle.,EATON CORP,CHEN YUE-MING;;FORTUNE G CLARK;;STOUT DONALD M,,https://lens.org/139-833-226-640-113,Patent Application,no,0,0,2,2,0,H01R12/721;;H01R12/721;;H01R13/52;;H01R13/52,H01R13/52,,0,0,,,,DISCONTINUED
145,US,B2,US 7586310 B2,138-819-860-262-060,2009-09-08,2009,US 22367605 A,2005-09-09,US 22367605 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling apparatus for measuring streaming potentials and determining earth formation characteristics and other useful information,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-07),https://lens.org/138-819-860-262-060,Granted Patent,yes,76,7,5,5,0,G01V3/265;;G01V3/265,G01V3/00;;G01V3/18,324/347;;324/351,9,4,160-919-555-206-025;;065-784-698-904-809;;144-289-954-649-970;;023-324-612-587-38X,10.1029/1999gl011099;;10.2118/77522-ms;;10.1029/2001gl013483;;10.1190/1.1443533,"Hunt and Worthington, Borehole electrokinetic response in fracture dominated hydraulically conductive zones, May 2000, Geophysical research letters, vol. 27, No. 9, pp. 1315-1318.;;Bryant et al. ""Real-Time Monitoring and Control of Water Influx to a Horizontal Well Using Advanced Completion Equipped with Permanent Sensors."" SPE 77522 SPE Annual Technical Conference and Exhibition, San Antonio, Texas (Sep. 29-Oct. 2, 2002).;;Hovhannissian et al. ""Transient electric phenomena observed during fluid circulation in unsaturated porous media."" Geophysical Research Letters, vol. 29, No. 1, pp. 5-1 to 5-4, Undated.;;Wurmstich et al. ""Modeling of streaming potential responses caused by oil well pumping."" Geophysics, vol. 59, No. 1 (Jan. 1994), pp. 46-56.;;International Search Report for PCT/US2006/034526 mailed Mar. 14, 2007.;;International Search Report for PCT/US2006/034160 mailed Jan. 19, 2007.;;Fordham, E.J., and H.K.J. Ladva, ""Cross-flow Filtration of Bentonite Suspensions"", PhysicoChemical Hydrodynamics, 11(4), 411-439 (1989).;;International Search Report and Written Opinion for PCT/US2006/034159 mailed May 29, 2007.;;International Search Report and Written Opinion for PCT/US2006/034291 mailed Jun. 19, 2007.",INACTIVE
146,US,S,US D0446213 S,198-449-863-406-411,2001-08-07,2001,US 13503301 F,2001-01-04,US 13503301 F,2001-01-04,Stylus,,INTEL CORP,CHEN CLARK;;BROWN STEPHEN R;;CHO MASAHITO;;VALENTINE CHRISTOPHER,INTEL CORPORATION (2001-02-12),https://lens.org/198-449-863-406-411,Design Right,yes,10,7,1,1,0,,,D14/411;;1402,0,0,,,,EXPIRED
147,EP,A1,EP 3088733 A1,072-877-100-026-826,2016-11-02,2016,EP 16165950 A,2016-04-19,IB 2015001448 W;;DK PA201570888 A,2015-04-27,Method for operating a wind turbine based on degradation of wind turbine blade,"The present invention relates to a control method and a wind turbine for adaptively adjusting the operation of the wind turbine to maintain maximum power production during degraded conditions. The control system comprises an estimator module that determines a scaling factor based on the current set of control signals and at least the current set of measurement of the operating parameters. The scaling factor is transmitted to a control module which scales at least one aerodynamic property of the rotor based on this scaling factor. The control module further determines the ideal settings for the control signals based on the scaled aerodynamic properties. The present control method scales the aerodynamic properties to provide a better representation of the actual degraded aerodynamic properties.
",ENVISION ENERGY JIANGSU CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,,https://lens.org/072-877-100-026-826,Patent Application,yes,4,14,6,8,0,F03D7/0224;;F03D7/044;;F03D7/046;;F03D7/0224;;F03D7/043;;F03D7/044;;F03D7/046;;F03D9/25;;F03D9/25;;F03D17/00;;F03D80/40;;F03D80/40;;F05B2270/1033;;F05B2270/20;;F05B2270/20;;F05B2270/30;;F05B2270/336;;F05B2270/336;;F05B2270/602;;F05B2270/705;;Y02E10/72;;Y02E10/72,F03D7/04;;F03D80/40,,0,0,,,,ACTIVE
148,BR,A2,BR PI0615864 A2,132-071-330-838-362,2011-05-31,2011,BR PI0615864 A,2006-09-05,US 22268905 A;;US 2006/0034291 W,2005-09-09,método para investigar uma formação terrestre atravessada por um furo durante operações de perfuração,"MéTODO PARA INVESTIGAR UMA FORMAçãO TERRESTRE ATRAVESSADAPOR UM FURO DURANTE OPERAçõES DE PERFURAçãO São fornecidos um aparelho e metodologias de perfuração com perfilagem para medir potencial de escoamento em uma formação terrestre. O aparelho e metodologias podem ser utilizados para localizar informações relevantes sobre as operações de perfuração. De modo particular, visto que a medição do potencial de escoamento se refere diretamente ao fluxo de fluido, as medições do potencial de escoamento podem ser usadas, para localizar informações relevantes sobre as operações deperfuração, tais como condições de perfuração subbalanceada, pressões anormais na formação, fraturas abertas, a permeabilidade da formação, e pressão da formação.",PRAD RES & DEV NV,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/132-071-330-838-362,Patent Application,no,0,0,5,5,0,E21B47/10;;G01V3/265;;G01V3/265;;E21B47/10,G01V3/26;;G01V3/00;;G01V3/08;;G01V3/18,,0,0,,,,DISCONTINUED
149,US,A1,US 2022/0111645 A1,180-394-639-210-837,2022-04-14,2022,US 202117560994 A,2021-12-23,US 202117560994 A;;US 201815772377 A;;US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,"A fluid propelling apparatus, including a plastic compound, a MEMS at least partially surrounded by the compound, and a heat sink next to the MEMS, to transfer heat away from the MEMS, wherein the heat sink is at least partly surrounded by the compound.",HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-02-29),https://lens.org/180-394-639-210-837,Patent Application,yes,0,1,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B01L3/00;;B41J2/14;;B81B1/00;;B81B7/00;;B81C1/00;;F04B19/00;;F04B43/04,,0,0,,,,PENDING
150,US,A1,US 2024/0031466 A1,035-132-459-844-712,2024-01-25,2024,US 202117516876 A,2021-11-02,US 202117516876 A;;US 202016752777 A;;US 201816218790 A;;US 201715720994 A,2017-09-29,TECHNIQUES TO MANAGE CONTACT RECORDS,"Exemplary embodiments relate to techniques for managing contact information received in the context of a messaging system. Messages may be received from known contacts which contain user contact records for third parties. Based on the trust relationship with the known contacts, the user contact record is placed in a contact record repository for later retrieval. When another message is received which either references the user contact record or is from the third party referenced in the user contact record, a dialog box is presented offering the user the opportunity to add the user contact record as an address entry in the address book of the device.",WHATSAPP LLC,DONOHUE MICHAEL B;;CHEN CLARK;;LIU ALAN CHUN TUNG,WHATSAPP LLC (2017-10-11),https://lens.org/035-132-459-844-712,Patent Application,yes,0,0,4,4,0,H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/216;;H04L51/56;;H04L51/046;;H04M1/27457;;H04M1/2757;;H04M1/7243;;H04M1/72484;;H04L51/56;;H04L51/212;;H04L51/216;;H04L51/224,H04M1/27457;;H04L51/00;;H04L51/046;;H04L51/224;;H04L51/56,,0,0,,,,DISCONTINUED
151,US,A1,US 2018/0319655 A1,044-076-754-202-256,2018-11-08,2018,US 201615772377 A,2016-02-29,US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,"A fluid propelling apparatus, including a plastic compound, a MEMS at least partially surrounded by the compound, and a heat sink next to the MEMS, to transfer heat away from the MEMS, wherein the heat sink is at least partly surrounded by the compound.",HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-02-29),https://lens.org/044-076-754-202-256,Patent Application,yes,0,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B81B7/00;;B01L3/00;;B41J2/14;;B81B1/00;;B81C1/00,,0,0,,,,ACTIVE
152,BR,A2,BR PI0615891 A2,056-035-297-507-373,2011-05-31,2011,BR PI0615891 A,2006-09-01,US 22364405 A;;US 2006/0034160 W,2005-09-09,aparelho para investigar uma formação de terrestre atravessada por um furo de poço,"APARELHO PARA INVESTIGAR UMA FORMAçàO TERRESTRE ATRAVESSADA POR UM FURO DE POçO São fornecidos um aparelho e metodologias de perfuração com perfilagem para medir potencial de escoamento em uma formação terrestre. O aparelho e metodologias podem ser utilizados para localizar informações relevantes sobre as operações de perfuração. De modo particular, visto que a medição do potencial de escoamento se refere diretamente ao fluxo de fluido, as medições do potencial de escoamento podem ser usadas, para localizar informações relevantes sobre as operações de perfuração, tais como condições de perfuração sub- balanceada, pressões anormais na formação, fraturas abertas, a permeabilidade da formação, e pressão da formação.",PRAD RES & DEV NV,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/056-035-297-507-373,Patent Application,no,0,0,4,4,0,G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,DISCONTINUED
153,EP,B1,EP 3088733 B1,120-573-874-012-379,2018-10-17,2018,EP 16165950 A,2016-04-19,IB 2015001448 W;;DK PA201570888 A,2015-04-27,Method for operating a wind turbine based on degradation of wind turbine blade,,ENVISION ENERGY JIANGSU CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,,https://lens.org/120-573-874-012-379,Granted Patent,yes,4,0,6,8,0,F03D7/0224;;F03D7/043;;F03D7/044;;F05B2270/30;;F05B2270/1033;;F05B2270/602;;F05B2270/705;;F03D9/25;;F03D80/40;;F03D7/046;;F05B2270/20;;F05B2270/336;;Y02E10/72;;F03D9/25;;F03D80/40;;F03D7/046;;F05B2270/20;;F05B2270/336;;Y02E10/72;;F03D17/00;;F03D7/0224;;F03D7/044,F03D80/40;;F03D7/04,,0,0,,,,ACTIVE
154,US,B2,US 11235574 B2,152-061-426-256-259,2022-02-01,2022,US 201615772377 A,2016-02-29,US 2016/0020041 W,2016-02-29,Fluid propelling apparatus including a heat sink,"A fluid propelling apparatus, including a plastic compound, a MEMS at least partially surrounded by the compound, and a heat sink next to the MEMS, to transfer heat away from the MEMS, wherein the heat sink is at least partly surrounded by the compound.",HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2016-02-29),https://lens.org/152-061-426-256-259,Granted Patent,yes,30,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B01L99/00;;B01L3/00;;B41J2/05;;B41J2/14;;B81B1/00;;B81B7/00;;B81C1/00;;F04B19/00;;F04B43/04,,1,1,111-510-529-583-504,10.1109/jmems.2008.2009847,"Shen, S-C. et al., “Manufacture of an Integrated Three-dimensional Structure Nozzle Plate Using Microinjection Molding for a 1200-dpi Inkjet Printhead”, Journal of Microelectromechanical Systems, Feb. 2009, 12 pages, vol. 18, No. 1.",ACTIVE
155,WO,A1,WO 2017/151091 A1,198-279-006-290-355,2017-09-08,2017,US 2016/0020041 W,2016-02-29,US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,"A fluid propelling apparatus, including a plastic compound, a MEMS at least partially surrounded by the compound, and a heat sink next to the MEMS, to transfer heat away from the MEMS, wherein the heat sink is at least partly surrounded by the compound.",HEWLETT PACKARD DEVELOPMENT CO LP,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,,https://lens.org/198-279-006-290-355,Patent Application,yes,7,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B81B7/02;;B81B3/00,,1,0,,,See also references of EP 3423397A4,PENDING
156,US,A1,US 2006/0125474 A1,098-761-703-408-486,2006-06-15,2006,US 22388305 A,2005-09-09,US 22388305 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,WHILE-DRILLING METHODOLOGY FOR ESTIMATING FORMATION PRESSURE BASED UPON STREAMING POTENTIAL MEASUREMENTS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/098-761-703-408-486,Patent Application,yes,93,6,5,5,0,E21B47/06;;E21B47/06;;G01V3/265;;G01V3/265,G01R33/02,324/247,0,0,,,,INACTIVE
157,DK,A1,DK 201570888 A1,109-178-911-808-82X,2016-11-07,2016,DK PA201570888 A,2015-12-29,IB 2015001448 W,2015-04-27,Method for operating a wind turbine based on degradation of wind turbine blade,The present invention relates to a control method and a wind turbine for adaptively adjusting the operation of the wind turbine to maintain maximum power production during degraded conditions. The control system comprises an estimator module that determines a scaling factor based on the current set of control signals and at least the current set of measurement of the operating parameters. The scaling factor is transmitted to a control module which scales at least one aerodynamic property of the rotor based on this scaling factor. The control module further determines the ideal settings for the control signals based on the scaled aerodynamic properties. The present control method scales the aerodynamic properties to provide a better representation of the actual degraded aerodynamic properties.,ENVISION ENERGY (JIANGSU) CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,,https://lens.org/109-178-911-808-82X,Unknown,no,7,0,2,8,0,Y02E10/74;;Y02E10/72,F03D3/00;;F03D80/00;;F03D7/00,,0,0,,,,ACTIVE
158,US,B2,US 11738053 B2,134-282-705-401-507,2023-08-29,2023,US 201716329915 A,2017-09-01,US 201716329915 A;;US 201662382872 P;;US 2017/0049815 W,2016-09-02,Methods and compositions for treating chronic granulomatous disease,The invention relates to a method of treating chronic granulomatous disease through Hematopoietic stem cell (HSC) transplantation. The method comprises the steps of administering stem cell mobilization agent to human such that the target stem cell population migrates from host niches into the subject's blood. The target stem cells are removed from blood and administering the therapeutic stem cells to human and said therapeutic stem cells are engineered to express gp91 phox . The steps are repeated multiple times i.e. at least four times. The mobilization agents used in the invention are granulocyte-colony stimulating factor and AMD3100. The method of HSC transplantation is effective in treatment of chronic granulomatous disease.,UNIV TEXAS;;UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;LI YANG,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2016-11-29),https://lens.org/134-282-705-401-507,Granted Patent,yes,3,0,3,3,40,A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;C12N15/86,A01N63/00;;A01K67/027;;A61K35/28;;A61K38/19;;C07H21/04;;C12N15/63;;C12N15/86,,88,82,019-593-784-930-333;;002-073-883-535-981;;007-434-408-121-387;;056-365-393-069-459;;028-599-334-857-97X;;014-257-271-444-423;;064-515-530-692-564;;015-473-125-658-784;;031-468-349-017-875;;002-563-934-956-252;;042-257-300-825-467;;035-142-480-664-379;;048-850-770-633-692;;019-589-349-676-199;;049-709-867-052-126;;043-736-301-626-683;;007-517-251-129-332;;005-522-787-285-556;;019-456-390-173-973;;006-961-504-788-331;;044-580-059-391-000;;079-766-037-510-078;;090-111-294-541-044;;069-602-982-707-779;;004-012-901-878-35X;;065-954-491-771-569;;032-705-731-140-711;;118-749-969-411-668;;019-886-178-828-311;;102-554-594-818-881;;056-629-724-273-320;;046-326-042-367-556;;024-188-874-869-363;;019-572-121-670-064;;001-370-831-964-703;;165-490-291-458-319;;076-455-555-254-329;;022-109-542-633-994;;013-826-367-001-88X;;045-546-316-218-119;;021-881-244-636-959;;029-206-480-539-896;;039-996-379-471-665;;014-259-076-861-642;;005-229-073-760-041;;024-990-081-709-632;;061-443-275-484-215;;097-414-789-320-385;;002-364-003-029-643;;005-472-252-642-534;;017-347-414-978-712;;050-207-507-785-970;;144-798-327-115-342;;046-032-837-397-704;;049-602-884-011-406;;049-860-540-752-579;;002-785-368-586-122;;075-103-788-296-727;;031-670-911-796-255;;139-359-219-687-209;;007-674-568-239-977;;031-532-439-308-661;;009-592-093-695-162;;042-028-037-177-386;;021-293-350-908-670;;020-349-455-860-064;;039-755-342-956-928;;091-620-831-666-216;;064-227-086-891-172;;002-632-656-059-119;;032-330-914-541-050;;115-431-247-252-811;;053-284-544-058-922;;016-969-047-418-878;;027-795-210-920-676;;020-828-661-613-628;;143-102-619-689-677;;062-154-144-576-705;;053-240-900-376-931;;056-650-636-588-484;;010-292-558-154-069;;006-308-943-185-16X,pmc3047684;;21181320;;10.1007/s12265-010-9253-z;;10.1016/j.arr.2011.06.002;;21736956;;27967247;;10.1080/17425247.2017.1272569;;10.1111/pai.12527;;26680691;;10.1016/j.ijsu.2015.06.068;;26159291;;pmc4684773;;10.1182/blood-2003-01-0318;;12714498;;10.1073/pnas.101505898;;pmc33250;;11331784;;10.1182/blood.v85.4.1017.bloodjournal8541017;;7849290;;12473664;;10.1074/jbc.c200613200;;10615049;;10.1126/science.287.5450.138;;17347493;;10.1634/stemcells.2006-0808;;10.1182/blood.v89.1.41.41_41_48;;8978275;;10196526;;10.1038/1584;;10.1016/s0167-4889(03)00024-7;;12676350;;11376945;;10.1016/s0378-1119(01)00449-8;;3031060;;10.1016/s0021-9258(18)61312-2;;2161041;;10.1093/infdis/161.6.1140;;10.1002/jlb.63.2.153;;9468274;;18033883;;pmc2527021;;10.1126/science.1149726;;10419882;;10.1182/blood.v94.3.914.415a11_914_922;;10.1182/blood.v97.12.3738;;11389011;;10.1182/blood.v85.2.319.bloodjournal852319;;10.1182/blood.v85.2.319.319;;7811988;;11668682;;10.1002/gene.10007;;11892251;;10.1007/978-3-642-56114-6_13;;10.1074/jbc.m301289200;;12657628;;10.1097/00043426-200212000-00026;;12468930;;11012609;;pmc1905749;;10.1046/j.1365-2249.2000.01314.x;;pmc24544;;10.1073/pnas.95.25.14880;;9843984;;pmc6793059;;9671653;;10.1523/jneurosci.18-15-05614.1998;;11259721;;10.1056/nejm200103223441203;;12730498;;10.1126/science.1083452;;7650482;;pmc2192153;;10.1084/jem.182.3.751;;12077603;;10.1038/nature00870;;10.1016/j.jaci.2011.03.028;;pmc3133927;;21497887;;10.1146/annurev.immunol.21.120601.141007;;12615892;;12359866;;10.1146/annurev.pharmtox.43.100901.140257;;10695656;;10.1067/mlc.2000.104458;;11271792;;10.1136/jcp.54.1.7;;pmc1731272;;10.1016/s0301-472x(02)00883-4;;12225788;;11106721;;10.1056/nejm200012073432307;;12036891;;10.1182/blood.v99.12.4578;;10.1074/jbc.274.45.32453;;10542290;;11483614;;10.1074/jbc.m106111200;;10.1074/jbc.272.28.17802;;9211934;;10096290;;10.1038/6981;;10081502;;10.1086/513852;;10.1182/blood.v86.8.2993.2993;;10.1182/blood.v86.8.2993.bloodjournal8682993;;7579392;;8639760;;9116268;;10.1182/blood.v89.7.2268;;10894546;;10.1038/35017565;;2196089;;10.1182/blood.v76.2.271.271;;10.1182/blood.v76.2.271.bloodjournal762271;;10.1128/jvi.72.10.8150-8157.1998;;9733856;;pmc110156;;10.1055/s-0037-1615879;;12095299;;10.1006/mthe.2002.0630;;10.1182/blood-2003-05-1595;;14604975;;11743206;;10.1126/science.1065806;;pmc33980;;10805762;;10.1073/pnas.97.10.5022;;28077679;;10.1126/scitranslmed.aah3480;;2165113;;10.1093/infdis/162.2.523;;10.1182/blood.v96.6.2108;;10.1182/blood.v96.6.2108.h8002108_2108_2115;;10979955;;10.1182/blood.v79.3.586.bloodjournal793586;;10.1182/blood.v79.3.586.586;;1531036;;10.1182/blood-2001-12-0165;;12393624;;10.1182/blood-2012-07-443713;;23412092;;10954613;;pmc110717;;10.1093/nar/28.17.e80;;10.1097/00005792-200005000-00004;;10844936;;12393596;;10.1182/blood-2002-02-0583;;10.2144/01306st06;;11414219;;8639758;;10.1182/blood.v87.10.4025.bloodjournal87104025;;10.1038/43459;;10485709;;9600921;;10.1073/pnas.95.11.6085;;pmc27589;;16904174;;10.1016/j.cell.2006.07.024;;12716910;;10.1074/jbc.m212856200;;9226149;;10.1182/blood.v90.2.489.489_489_519;;10.1182/blood.v90.2.489;;11863414;;10.1006/mthe.2002.0542;;7829869;;10.1016/0022-1759(94)00247-t;;10865962;;10.1038/sj.leu.2401808;;pmc280133;;2834728;;10.1073/pnas.85.9.3014;;10844935;;10.1097/00005792-200005000-00003;;10.1038/sj.leu.2402447;;11960333;;11729320;;10.1126/science.1064081;;20813896;;10.1182/blood-2010-07-295949;;pmc3012550;;10.1006/mthe.2002.0558;;11945076,"Dib et al., 2011, J. of Cardiovasc. Trans. Res., 4:177-181.;;Wu et al., 2012, Aging Research reviews, vol. 11, p. 32-40.;;Agrahari et al., 2017, Expert Opinion on Drug Delivery, vol. 14, No. 10, p. 1145-1162.;;Ikonomou et al., 2017, Am J Respir Crit Care Med, vol. 195, p. 13-14.;;Chiriaco et al., 2016, Pediatric Allergy and Immunology, vol. 27, issue 3, p. 242-253, Published on Dec. 17, 2015.;;Ikehara et al., 2013, Frontier in Cell and Developmental Biology, vol. 1, Article 2, p. 1-2.;;Cooper et al., 2015, International Journal of Surgery, vol. 23, p. 211-216.;;Liu et al., 2017, Frontiers in Immunology, vol. 8, article 645, p. 1-6.;;Abkowitz et al., “Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure,” Blood, 2003; 102: 1249-53.;;Arnold et al., “Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1” Proc. Natl. Acad Sci USA, 2001; 98: 5550-5555.;;Back et al., “Leukocyte integrin CD11b promoter directs expression in lymphocytes and granulocytes in transgenic mice,” Blood, 1995; 85: 1017-24.;;Banfi et al. “Two novel proteins activate superoxide generation by the NADPH oxidase NOX1,” J. Biol. Chem., 2003; 278: 3510-3513.;;Banfi et al. “A Mammalian H+ Channel Generated Through Alternative Splicing of the NADPH Oxidase Homolog NOH-1” Science, 2000; 287: 138-142.;;Barese et al. “Granulocyte colony-stimulating factor prior to nonmyeloablative irradiation decreases murine host hematopoietic stem cell function and increases engraftment of donor marrow cells,” Stem Cells, 2007; 25(6)1578-85.;;Bjorgvinsdottir et al. “Retroviral-Mediated Gene Transfer of gp91 phox Into Bone Marrow Cells Rescues Defect in Host Defense Against Aspergillus fumigatus in Murine X-Linked Chronic Granulomatous Disease” Blood, 1997; 89: 41-48.;;Blum, “A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra,” Nat Neurosci, 1998; 1: 374-77.;;Brenner and Malech, “Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy,” Biochim Biophys Acta, 2003; 1640: 1-24.;;Cheng et al. “Homologs of gp91phox: cloning and tissue expression of Nox3, Nox4, and Nox5,” Gene, 2001; 269: 131-140.;;Clark et al.,“ NADPH oxidase of human neutrophils. Subcellular localization and characterization of an arachidonate-activatable superoxide-generating system,” J. Biol. Chem, 1987; 262: 4065-74.;;Clark, “The Human Neutrophil Respiratory Burst Oxidase,” J. Infect. Dis, 1990; 161: 1140-1147.;;Clarke and Gordon, “Myeloid-specific gene expression” J. Leukoc. Biol. 1998; 63: 153-168.;;Czechowicz et al. “Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches,” Science 2007; 318(5854): 1296-99.;;Dinauer et al. “Long-Term Correction of Phagocyte NADPH Oxidase Activity by Retroviral-Mediated Gene Transfer in Murine X-Linked Chronic Granulomatous Disease,” Blood, 1999; 94:914-922.;;Dinauer et al. “Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease,” Blood, 2001; 97:3738-3745.;;Dziennis et al., “The CD11b Promoter Directs High-Level Expression of Reporter Genes in Macrophages in Transgenic Mice,” Blood, 1995; 85: 319-329.;;Fedorov et al., “Generation dependent reduction of tTA expression in double transgenic NZL-2/tTACMV mice,” Genesis, 2001; 31: 78-84.;;Galimi and Verma, “Opportunities for the use of lentiviral vectors in human gene therapy” Curr. Top Microbiol. Immunol. 2002; 261: 245-254.;;Geiszt et al., “Proteins Homologous to p47phox and p67phox Support Superoxide Production by NAD(P)H Oxidase 1 in Colon Epithelial Cells,” J. Biol. Chem., 2003; 278: 20006-20012.;;Goebel and Dinauer, “Retroviral-Mediated Gene Transfer and Nonmyeloablative Conditioning: Studies in a Murine X-Linked Chronic Granulomatous Disease Model,” J. Pediatr. Hematol. Oncol., 2002; 24: 787-790.;;Goldblatt and Thrasher, “Chomic Granulomatous Disease” Clin Exp. Immunol., 2000; 122: 1-9.;;Hahn et al., “Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter,” PNAS USA, 1998; 95: 14880-85.;;Ho and Blum, “Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease,” J. Neurosci, 1998; 18: 5614-29.;;Horwitz et al. “Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.,” N. Engl. J. Med., 2001; 344: 881-888.;;Hubner et al.,“Derivation of oocytes from mouse embryonic stem cells,” Science, 2003; 300: 1251-56.;;Imren et al., “Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells,” Proc Natl Acad Sci USA, 2002; 99: 14380-14385.;;International Preliminary Report on Patentability in application No. PCT/US2017/049815, dated Mar. 5, 2019.;;International Search Report and Written Opinion in application No. PCT/US2017/049815, dated Nov. 3, 2017.;;Jackson et al.,“The p47phox mouse knock-out model of chronic granulomatous disease,” J. Exp. Med., 1995; 182: 751-58.;;Jiang et al., “Pluripotency of mesenchymal stem cells derived from adult marrow,” Nature, 2002; 418: 41-49.;;Kang et al. “Chronic granulomatous disease: overview and hematopoietic stem cell transplant,” Journal of Allergy and Clinical Immunology, 2011; 127(6): 1319-1326.;;Kondo et al., “Biology of hematopoietic stem cells and progenitors: implications for clinical application,” Annu Rev. Immunol., 2003; 21: 759-806.;;Koostra and Verma, “Gene therapy with viral vectors,” Annu Rev Pharmacol. Toxicol, 2003; 43: 413-439.;;Kume and Dinauer, “Gene therapy for chronic granulomatous disease” J. Lab Clin Med. 2000, 135: 122-128.;;Lakshman and Finn, “Neutrophil disorders and their management” J. Clin. Pathol. 2001, 54: 7-19.;;Lapidot and Petit, “Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells,” Exp. Hematol, 2002; 30: 973-81.;;Lekstrom-Himes and Gallin, “Immunodeficiency diseases caused by defects in phagocytes,” N. Engl. J. Med., 2000; 343: 1703-1714.;;Li et al. “Multiple PU.1 sites cooperate in the regulation ofp40 phox transcription during granulocytic differentiation of myeloid cells,” Blood, 2002; 99: 4578-4587.;;Li et al. “Critical Flanking Sequences of PU.1 Binding Sites in Myeloid-specific Promoters” J. Biol. Chem. 1999; 274-32453-32460.;;Li et al. “Transcriptional Regulation of the p67phox Gene Role of AP-1 In Concert With Myeloid-Specific Transcription Factors,” J. Biol. Chem. 2001; 39368-39378.;;Li et al., “PU.1 Is Essential for p47phox Promoter Activity in Myeloid Cells,” J. Biol. Chem. 1997; 272: 17802-17809.;;Li et al., “Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences” Nat. Biotechnol., 1999; 17: 241-245.;;Malech, “Progress in Gene Therapy for Chronic Granulomatous Disease,” J. Infect Dis., 1999, 179 Suppl 2: S318-325.;;Malik, “Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters,” Blood, 1995; 86; 2993-3005.;;Mardiney and Malech, “Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy,” Blood, 1996 87(10): 4049-56.;;Mardiney et al., “Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease,” Blood, 1997; 89: 2268-75.;;May et al. “Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin,” Nature, 2000; 406: 82-86.;;Miller, “Progress Toward Human Gene Therapy,” Blood, 1990; 76: 271-78.;;Miyoshi et al.,“Development of a Self-Inactivating Lentivirus Vector,” J. Virol. 1998; 72: 8150-8157.;;Naldini, “In Vivo Gene Delivery by Lentiviral Vectors,” Thromb. Haemost, 1999; 82: 552-554.;;Pan et al. “Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow,” Mol. Ther., 2002; 6: 19-29.;;Papayannopoulou, “Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization,” Blood, 2004; 103: 1580-85.;;Pawliuk et al., “Correction of sickle cell disease in transgenic mouse models by gene therapy,” Science, 2001; 294: 2368-2371.;;Persons and Nienhuis, “Gene therapy for the hemoglobin disorders: past, present, and future,” Proc Natl Acad Sci USA, 2000; 97: 5022-24.;;Ravin et al. “CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease,” Science Translational Medicine, 2017; 9(372): 1-10.;;Rex et al.“Normal and Deficient Neutrophils Can Cooperate to Damage Aspergillus fumigatus Hyphae,” J. Infect. Dis, 1990; 162: 523-528.;;Rhoades et al., “Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model” Blood, 2000; 96: 2108-15.;;Roberts et al., “Transcription of the Human Colony-Stimulating Factor-1 Receptor Gene Is Regulated by Separate Tissue-Specific Promoters,” Blood, 1992; 79: 586-593.;;Roesler et al., “Third-generation, self-inactivating gp91phoxlentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease,” Blood, 2002; 100: 4381-4390.;;Sato et al. “Novel interferon-based pre-transplantation conditioning in the treatment of a congenital metabolic disorder,” Blood, 2013; 121(16): 3267-73.;;Sclimenti et al., “An extrachromosomal tetracycline-regulatable system for mammalian cells,” Nucleic Acids Res., 2000; 28:E80.;;Segal et al. “Genetic, biochemical, and clinical features of chronic granulomatous disease” Medicine (Baltimore), 2000; 79: 170-200.;;Seger et al. “Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000” Blood, 2002; 100: 4344-4350.;;Shariatmadari et al., “Improved technique for detection of enhanced green fluorescent protein in transgenic mice,” Biotechniques, 2001; 30: 1282-85.;;Shivdasani and Orkin, “The Transcriptional Control of Hematopoiesis” Blood, 1996; 87: 4025-4039.;;Suh et al. “Cell transformation by the superoxide-generating oxidase Mox1,” Nature, 1999; 401: 79-82.;;Suzuki et al. “PU.1 as an essential activator for the expression of gp91phox gene in human peripheral neutrophils, monocytes, and B lymphocytes” Proc. Natl. Acad Sci USA, 1998; 95: 6085-6090.;;Takahashi et al., “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors” Cell, 2006; 126: 663-76.;;Takeya et al. “Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases” J. Biol. Chem., 2003; 25: 25.;;Tenen et al., “Transcription factors, normal myeloid development, and leukemia,” Blood, 1997; 90: 489-519.;;Vigna et al., “Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors.” Mol. Ther., 2002; 5: 252-261.;;Vowells et al., “Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes,” J. Immunol. Methods, 1995; 178: 89-97.;;Ward et al., “Regulation of granulopoiesis by transcription factors and cytokine signals,” Leukemia, 2000; 14: 973-990.;;Wilson et al., “Retrovirus-mediated transduction of adult hepatocytes” PNAS 1988; 85(9): 3014-18.;;Winkelstein et al. “Chronic granulomatous disease. Report on a national registry of 368 patients,” Medicine (Baltimore) 2000, 79(3): 155-169.;;Woods et al., “Development of gene therapy for hematopoietic stem cells using lentiviral vectors,” Leukemia, 2002; 16: 563-569.;;Wright et al., “Physiological Migration of Hematopoietic Stem and Progenitor Cells,” Science 2001; 294: 1933-36.;;Xue et al. “Antibody targeting KIT as pretransplantation conditioning in immunocompetent mice,” Blood, 2010; 116:5419-22.;;Yam et al., “Design of HIV vectors for efficient gene delivery into human hematopoietic cells” Mol. Ther., 2002; 5: 479-484.",ACTIVE
159,DK,B1,DK 178737 B1,169-433-564-017-119,2016-12-12,2016,DK PA201570888 A,2015-12-29,IB 2015001448 W,2015-04-27,Method for operating a wind turbine based on degradation of wind turbine blade,The present invention relates to a control method and a wind turbine for adaptively adjusting the operation of the wind turbine to maintain maximum power production during degraded conditions. The control system comprises an estimator module that determines a scaling factor based on the current set of control signals and at least the current set of measurement of the operating parameters. The scaling factor is transmitted to a control module which scales at least one aerodynamic property of the rotor based on this scaling factor. The control module further determines the ideal settings for the control signals based on the scaled aerodynamic properties. The present control method scales the aerodynamic properties to provide a better representation of the actual degraded aerodynamic properties.,ENVISION ENERGY (JIANGSU) CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,,https://lens.org/169-433-564-017-119,Granted Patent,no,0,1,2,8,0,Y02E10/74;;Y02E10/72,F03D3/00;;F03D80/00;;F03D7/00,,0,0,,,,ACTIVE
160,EP,A1,EP 3423397 A1,171-110-909-508-032,2019-01-09,2019,EP 16892842 A,2016-02-29,US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,,HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/171-110-909-508-032,Patent Application,yes,0,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B81B7/02;;B81B3/00,,0,0,,,,DISCONTINUED
161,US,B2,US 7388380 B2,170-983-982-923-79X,2008-06-17,2008,US 22364405 A,2005-09-09,US 22364405 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling apparatus for measuring streaming potentials and determining earth formation characteristics and other useful information,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/170-983-982-923-79X,Granted Patent,yes,73,27,4,4,0,G01V3/265;;G01V3/265,G01V3/22;;E21B47/00;;G01V3/24;;G01V3/40,324/347;;324/366;;175/50,7,2,144-289-954-649-970;;023-324-612-587-38X,10.1029/2001gl013483;;10.1190/1.1443533,"Fordham, E.J., and H.K.J. Ladva, ""Cross-flow Filtration of Bentonite Suspensions"", PhysicoChemical Hydrodynamics, 11(4), 411-439 (1989).;;International Search Report and Written Opinion for PCT/US2006/034159 mailed May 29, 2007.;;International Search Report and Written Opinion for PCT/US2006/034291 mailed Jun. 19, 2007.;;Hovhannissian et al. ""Transient electric phenomena observed during fluid circulation in unsaturated porous media."" Geophysical Research Letters, vol. 29, No. 1, pp. 5-1 to 5-4.;;Wurmstich et al. ""Modeling of streaming potential responses caused by oil well pumping."" Geophysics, vol. 59, No. 1 (Jan. 1994), pp. 46-56.;;International Search Report for PCT/US2006/034526 mailed Mar. 14, 2007.;;International Search Report for PCT/US2006/034160 mailed Jan. 19, 2007.",ACTIVE
162,US,A1,US 2013/0338321 A1,032-179-114-519-26X,2013-12-19,2013,US 201214002019 A,2012-02-29,US 201214002019 A;;US 201161447800 P;;US 2012/0027086 W,2011-03-01,Process for Improving Bulk Density with Multi-Contact Procatalyst and Product,"Disclosed herein are processes for preparing procatalyst compositions which include multiple contact steps in the presence of a substituted phenylene aromatic diester and at least one other internal electron donor. The multi-contact procatalyst compositions produced from the present processes improve polymer properties and polymerization parameters. In particular, the present multi-contact procatalyst compositions improve polymer bulk density.",COALTER III JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,COALTER III JOSEPH N;;CHEN LINFENG;;WILLIAMS CLARK C,DOW GLOBAL TECHNOLOGIES LLC (2011-08-30);;W. R. GRACE & CO. CONN (2014-03-24),https://lens.org/032-179-114-519-26X,Patent Application,yes,2,7,10,10,0,C08F110/06;;C08F10/00;;C08F4/651;;C08F10/06;;C08F2/00;;C08F110/06;;C08F10/00;;C08F4/10;;C08F4/52,C08F4/52;;C08F4/10,526/125.7;;502/104;;502/152;;526/124.2;;526/185,0,0,,,,DISCONTINUED
163,US,A1,US 2007/0057674 A1,096-324-088-272-717,2007-03-15,2007,US 22367605 A,2005-09-09,US 22367605 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling apparatus for measuring streaming potentials and determining earth formation characteristics and other useful information,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-07),https://lens.org/096-324-088-272-717,Patent Application,yes,25,16,5,5,0,G01V3/265;;G01V3/265,G01V3/02,324/347,0,0,,,,INACTIVE
164,US,B2,US 10184450 B2,117-356-138-710-743,2019-01-22,2019,US 201615138303 A,2016-04-26,IB 2015001448 W;;DK PA201570888 A,2015-04-27,Method for operating a wind turbine based on degradation of wind turbine blade,A control method and a wind turbine for adaptively adjusting the operation of the wind turbine to maintain maximum power production during degraded conditions. The control system has an estimator module that determines a scaling factor based on the current set of control signals and at least the current set of measurement of the operating parameters. The scaling factor is transmitted to a control module which scales at least one aerodynamic property of the rotor based on this scaling factor. The control module further determines the ideal settings for the control signals based on the scaled aerodynamic properties. The present control method scales the aerodynamic properties to provide a better representation of the actual degraded aerodynamic properties.,ENVISION ENERGY JIANGSU CO LTD;;ENVISION ENERGY JIANGSU CO LTD,WILSON KITCHENER CLARK;;ZHANG FENG;;CHEN LIN;;SUN YUPING,ENVISION ENERGY (JIANGSU) CO. LTD (2016-05-10),https://lens.org/117-356-138-710-743,Granted Patent,yes,27,5,6,8,0,F03D7/0224;;F03D7/044;;F03D7/046;;F03D7/0224;;F03D7/043;;F03D7/044;;F03D7/046;;F03D9/25;;F03D9/25;;F03D17/00;;F03D80/40;;F03D80/40;;F05B2270/1033;;F05B2270/20;;F05B2270/20;;F05B2270/30;;F05B2270/336;;F05B2270/336;;F05B2270/602;;F05B2270/705;;Y02E10/72;;Y02E10/72,F03D7/04;;F03D7/02;;F03D9/00;;F03D9/25;;F03D17/00;;F03D80/40,,0,0,,,,ACTIVE
165,WO,A3,WO 2007/032956 A3,165-893-818-026-181,2007-05-03,2007,US 2006/0034526 W,2006-09-05,US 22388305 A,2005-09-09,WHILE-DRILLING METHODOLOGY FOR ESTIMATING FORMATION PRESSURE BASED UPON STREAMING POTENTIAL MEASUREMENTS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/165-893-818-026-181,Search Report,yes,5,0,5,5,0,E21B47/06;;E21B47/06;;G01V3/265;;G01V3/265,G01V3/26,,2,2,144-289-954-649-970;;023-324-612-587-38X,10.1029/2001gl013483;;10.1190/1.1443533,"HOVHANNISSIAN G.M., POZZI J.P., BERNARD P., TABBAGH A.: ""Transient electric phenomena observed during fluid circulation in unsaturated porous media"", GEOPHYSICAL RESEARCH LETTERS, vol. 29, no. 1, 3 January 2002 (2002-01-03), pages 5-1 - 5-4, XP009076787;;WURMSTICH BURKHARD ET AL: ""Modeling of streaming potential responses caused by oil well pumping"", GEOPHYSICS, SOCIETY OF EXPLORATION GEOPHYSICISTS, TULSA, OK, US, vol. 59, no. 1, January 1994 (1994-01-01), pages 46 - 56, XP002378946, ISSN: 0016-8033",PENDING
166,WO,A2,WO 2007/032956 A2,187-550-792-794-302,2007-03-22,2007,US 2006/0034526 W,2006-09-05,US 22388305 A,2005-09-09,WHILE-DRILLING METHODOLOGY FOR ESTIMATING FORMATION PRESSURE BASED UPON STREAMING POTENTIAL MEASUREMENTS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/187-550-792-794-302,Patent Application,yes,0,4,5,5,0,E21B47/06;;E21B47/06;;G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,PENDING
167,US,A1,US 2019/0201449 A1,109-280-917-503-26X,2019-07-04,2019,US 201716329915 A,2017-09-01,US 201716329915 A;;US 201662382872 P;;US 2017/0049815 W,2016-09-02,METHODS AND COMPOSITIONS FOR TREATING CHRONIC GRANULOMATOUS DISEASE,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation for the treatment of chronic granulomatous disease,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;LI YANG;;UNIV TEXAS,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;LI YANG,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2016-11-29),https://lens.org/109-280-917-503-26X,Patent Application,yes,0,0,3,3,40,A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;A61K38/193;;A01K67/0276;;A01K2227/105;;A01K2267/0306;;C12N2740/16043;;A61K35/28;;C12N15/86,A61K35/28;;A01K67/027;;A61K38/19;;C12N15/86,,0,0,,,,ACTIVE
168,WO,A2,WO 2007/032928 A2,165-056-716-932-636,2007-03-22,2007,US 2006/0034159 W,2006-09-01,US 22367605 A,2005-09-09,WHILE-DRILLING APPARATUS FOR MEASURING STREAMING POTENTIALS AND DETERMINING EARTH FORMATION CHARACTERISTICS AND OTHER USEFUL INFORMATION,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/165-056-716-932-636,Patent Application,yes,0,0,5,5,0,G01V3/265;;G01V3/265,,,0,0,,,,PENDING
169,US,B2,US 9276561 B2,140-033-506-563-079,2016-03-01,2016,US 201514808358 A,2015-07-24,US 201514808358 A;;US 201314136258 A;;US 201261740339 P,2012-12-20,Integrated circuit process and bias monitors and related methods,"An integrated circuit device can include at least one oscillator stage having a current mirror circuit comprising first and second mirror transistors of a first conductivity type, and configured to mirror current on two mirror paths, at least one reference transistor of a second conductivity type having a source-drain path coupled to a first of the mirror paths, and a switching circuit coupled to a second of the mirror paths and configured to generate a transition in a stage output signal in response to a stage input signal received from another oscillator stage, wherein the channel lengths of the first and second mirror transistors are larger than that of the at least one reference transistor.",MIE FUJITSU SEMICONDUCTOR LTD,CLARK LAWRENCE T;;KIDD DAVID A;;CHEN CHAO-WU,SUVOLTA INC (2013-12-19);;MIE FUJITSU SEMICONDUCTOR LIMITED (2015-02-27),https://lens.org/140-033-506-563-079,Granted Patent,yes,102,1,3,3,0,G01R31/2884;;H01L22/34;;H03K3/0315;;G05F3/262;;G05F3/205;;H01L29/7851;;H03K3/0315;;H03K3/011;;G05F3/262;;G05F3/205;;H01L22/34;;G01R31/2884,H03K3/03;;G05F3/20;;G05F3/26;;H03K3/011,,45,28,116-323-438-999-844;;021-680-905-582-417;;157-354-250-886-679;;173-501-876-729-218;;078-444-251-719-309;;018-385-851-474-68X;;064-735-181-181-671;;176-034-520-459-930;;015-093-657-307-147;;032-553-133-830-958;;110-642-117-637-519;;011-900-260-029-102;;001-947-888-041-487;;126-540-642-620-903;;017-208-359-250-402;;058-472-243-648-742;;030-155-185-671-921;;179-841-142-977-561;;057-884-966-335-103;;060-779-596-368-736;;026-606-955-791-598;;119-578-504-667-48X;;062-487-330-942-241;;168-629-837-711-367;;101-593-457-781-889;;043-110-693-882-533;;041-586-532-565-175;;150-260-890-760-298,10.1109/cicc.2006.320869;;10.1109/ted.2003.815371;;10.1109/iedm.1993.347253;;10.1109/vlsit.1996.507784;;10.1016/j.mser.2003.08.002;;10.1109/ted.2006.884070;;10.1016/j.sse.2005.10.048;;10.1109/5.752515;;10.1109/vlsit.1995.520841;;10.1149/1.2356293;;10.1149/1.2355889;;10.1109/vlsit.2008.4588583;;10.1109/iedm.2009.5424250;;10.1109/iedm.1996.553626;;10.4028/www.scientific.net/ssp.82-84.189;;10.1109/16.662780;;10.1109/16.772479;;10.1063/1.1489715;;10.1063/1.120684;;10.1063/1.123081;;10.1063/1.122483;;10.1109/16.141237;;10.1109/isqed.2012.6187559;;10.1109/iscas.2010.5537410;;10.1145/1973009.1973037;;10.3745/jips.2011.7.1.093;;10.1109/jssc.2002.803949;;10.1109/aspdac.2011.5722162,"Banerjee, et al. ""Compensating Non-Optical Effects using Electrically-Driven Optical Proximity Correction"", Proc. of SPIE vol. 7275 7275OE, 2009.;;Cheng, et al. ""Extremely Thin SOI (ETSOI) CMOS with Record Low Variability for Low Power System-on-Chip Aoolications"", Electron Devices Meeting (IEDM), Dec. 2009.;;Machine Translation of KR 10-0794094 submitted herewith.;;Cheng, et al. ""Fully Depleted Extremely Thin SOI Technology Fabricated by a Novel Integration Scheme Feturing Implant-Free, Zero-Silicon-Loss, and Faceted Raised Source/Drain"", Symposium on VLSI Technology Digest of Technical Papers, pp. 212-213, 2009.;;Drennan, et al. ""Implications of Proximity Effects for Analog Design"", Custom Integrated Circuits Conference, pp. 169-176, Sep. 2006.;;Hook, et al. ""Lateral Ion Implant Straggle and Mask Proximity Effect"", IEEE Transactions on Electron Devices, vol. 50, No. 9, pp. 1946-1951, Sep. 2003.;;Hori, et al., ""A 0.1 mum CMOS with a Step Channel Profile Formed by Ultra High Vacuum CVD and In-Situ Doped Ions"", Proceedings of the International Electron Devices Meeting, New York, IEEE, US, pp. 909-911, Dec. 5, 1993.;;Matshuashi, et al. ""High-Performance Double-Layer Epitaxial-Channel PMOSFET Compatible with a Single Gate CMOSFET"", Symposium on VLSI Technology Digest of Technical Papers, pp. 36-37, 1996.;;Shao, et al., ""Boron Diffusion in Silicon: The Anomalies and Control by Point Defect Engineering"", Materials Science and Engineering R: Reports, vol. 42, No. 3-4, pp. 65-114, Nov. 1, 2003.;;Sheu, et al. ""Modeling the Well-Edge Proximity Effect in Highly Scaled MOSFETs"", IEEE Transactions on Electron Devices, vol. 53, No. 11, Nos. 2792-2798, Nov. 2006.;;Komaragiri, R. et al., ""Depletion-Free Poly Gate Electrode Architecture for Sub 1 00 Nanometer CMOS Devices with High-K Gate Dielectrics"", IEEE IEDM Tech Dig., San Francisco CA, 833-836, Dec. 13-15, 2004.;;Samsudin, K et al., ""Integrating Intrinsic Parameter Fluctuation Description into BSIMSOI to Forecast sub-15nm UTB SOI based 6T SRAM Operation"", Solid-State Electronics (50), pp. 86-93, 2006.;;Wong, H et al., ""Nanoscale CMOS"", Proceedings of the IEEE, Vo. 87, No. 4, pp. 537-570, Apr. 1999.;;Abiko, H et al., ""A Channel Engineering Combined with Channel Epitaxy Optimization and TED Suppression for 0.15mum n-n Gate CMOS Technology"", 1995 Symposium on VLSI Technology Digest of Technical Papers, pp. 23-24, 1995.;;Chau, R et al., ""A 50nm Depleted-Substrate CMOS Transistor (DST)"", Electron Device Meeting 2001, IEDM Technical Digest, IEEE International, pp. 29.1.1-29.1.4, 2001.;;Ducroquet, F et al. ""Fully Depleted Silicon-on-Insulator nMOSFETs with Tensile Strained High Carbon Content Si i-vCv Channel"", ECS 210th Meeting, Abstract 1033, 2006.;;Ernst, I et al., ""Nanoscaled MOSFET Transistors on Strained Si, SiGe, Ge Layers: Some Integration and Electrical Properties Features"", ECS Trans. 2006, vol. 3, Issue 7, pp. 947-961, 2006.;;Goesele, U et al., ""Diffusion Engineering by Carbon in Silicon"", Mat. Res. Soc. Symp. vol. 610, 2000.;;Hokazono, A et al., ""Steep Channel & Halo Profiles Utilizing Boron-Diffusion-Barrier Layers (Si:C) for 32 nm Node and Beyond"", 2008 Symposium on VLSI Technology Digest of Technical Papers, pp. 112-113, 2008.;;Hokazono, A et al., ""Steep Channel Profiles in n/pMOS Controlled by Boron-Doped Si:C Layers for Continual Bulk-CMOS Scaling"", IEDM09-676 Symposium, pp. 29.1.1-29.1.4, 2009.;;Holland, OW and Thomas, DK ""A Method to Improve Activation of Implanted Dopants in SiC"", Oak Ridge National Laboratory, Oak Ridge, TN, 2001.;;Kotaki, H., et al., ""Novel Bulk Dynamic Threshold Voltage MOSFET (B-DTMOS) with Advanced Isolation (SITOS) and Gate to Shallow-Well Contact (SSS-C) Processes for Ultra Low Power Dual Gate CMOS"", IEDM 96, Po. 459-462, 1996.;;Laveant, P. ""Incorporation, Diffusion and Agglomeration of Carbon in Silicon"", Solid State Phenomena, vols. 82-84, pp. 189-194, 2002.;;Noda, K et al., ""A 0.1-mum Delta-Doped MOSFET Fabricated with Post-Low-Energy Implanting Selective Epitaxy"" IEEE Transactions on Electron Devices, vol. 45, No. 4, pp. 809-814, Apr. 1998.;;Ohguro, T et al., ""An 0.18-mum CMOS for Mixed Digital and Analog Applications with Zero- Volt-Vth Epitaxial-Channel MOSFET's"", IEEE Transactions on Electron Devices, vol. 46, No. 7, pp. 1378-1383, Jul. 1999.;;Pinacho, R et al., ""Carbon in Silicon: Modeling of Diffusion and Clustering Mechanisms"", Journal of Applied Physics, vol. 92, No. 3, pp. 1582-1588, Aug. 2002.;;Robertson, LS et al., ""The Effect of Impurities on Diffusion and Activation of Ion Implanted Boron in Silicon"", Mat. Res. Soc. Symp. vol. 610, 2000.;;Scholz, R et al., ""Carbon-Induced Undersaturation of Silicon Self-Interstitials"", Appl. Phys. Lett. 72(2), pp. 200-202, Jan. 1998.;;Scholz, RF et al., ""The Contribution of Vacancies to Carbon Out-Diffusion in Silicon"", Appl. Phys. Lett., vol. 74, No. 3, pp. 392-394, Jan. 1999.;;Stolk PA et al., ""Physical Mechanisms of Transient Enhanced Dopant Diffusion in Ion-Implanted Silicon"", J. Appl. Phys. 81(9), pp. 6031-6050, May 1997.;;Thompson, S et al., ""MOS Scaling: Transistor Challenges for the 21st Century"", Intel Technology Journal Q3' 1998, pp. 1-19, 1998.;;Wann, C. et al., ""Channel Profile Optimization and Device Design for Low-Power High-Performance Dynamic-Threshold MOSFET"", IEDM 96, pp. 113-116, 1996.;;Werner, P. et al., ""Carbon Diffusion in Silicon"", Applied Physics Letters, vol. 73, No. 17, pp. 2465-2467, Oct. 1998.;;Yan, Ran-Hong et al., ""Scaling the Si MOSFET: From Bulk to SOI to Bulk"", IEEE Transactions on Electron Devices, vol. 39, No. 7, Jul. 1992.;;Final Office Action issued in U.S. Appl. No. 13/469,201; 10 pgs, Apr. 9, 2015.;;English Translation of JP 8153873 submitted herewith.;;Chan et al., ""DDRO: A Novel Performance Monitoring Methodology Based on Design-Dependent Ring Oscillators"", IEEE International Symposium on Quality Electronic Design, Mar. 19, 2012.;;Chen et al., ""Fully On-Chip Temperature, Process, and Voltage Sensors"", ISCAS, IEEE, 2010.;;Datta, Basab and Burleson, Wayne et al., ""A 45.6u2 13.4uW 7.1V/V Resolution Sub-Threshold Based Digital Process-Sensing Circuit in 45nm CMOS"", GLSVLSI '11, Lausanne, Switzerland, May 2-14, 2011.;;Ghosh, et al., ""On-Chip Negative Bias Temperature Instability Sensor Using Slew Rate Monitoring Circuitry"", IEEE International Symposium on Circuits and Systems, May 24-27, 2009.;;Ghosh, et al., ""On-Chip Process Variation Detection and Compensation for Parametric Yield Enhancement in Sub-100nm CMOS Technology"", IEEE International Symposium on Circuits and Systems, IBM Austin Center for Advanced Studies, 2007.;;Nan et al., ""Dynamic Voltage and Frequency Scaling for Power-Constrained Design using Process Voltage and Temperature Sensor Circuits"", Journal of Information Processing Systems, vol. 7, No. 1, Mar. 2011.;;Tschanz, et al., ""Adaptive Body Bias for Reducing Impacts of Die-to-Die and Within-Die Parameter Variations on Microprocessor Frequency and Leakage"", IEEE Journal of Solid-State Circuits, vol. 37, No. 11, Nov. 2002.;;Zhang et al., ""An On-Chip Characterizing System for Within-Die Delay Variation Measurement of Individual Standard Cells in 65-nm CMOS"", Design Automation Conference, Jan. 25-28, 2011.;;Saxena et al., ""Variation in Transistor Performance and Leakage in Nanometer-Scale Technologies"", IEEE Transactions on Electron Devices, vol. 55, No. 1, Jan. 2008.",ACTIVE
170,US,B2,US 7301345 B2,009-698-670-922-376,2007-11-27,2007,US 22388305 A,2005-09-09,US 22388305 A;;US 87185604 A;;US 87185404 A;;US 87144604 A;;US 87211204 A,2004-06-18,While-drilling methodology for estimating formation pressure based upon streaming potential measurements,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER TECHNOLOGY CORP,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,SCHLUMBERGER TECHNOLOGY CORPORATION (2005-10-20),https://lens.org/009-698-670-922-376,Granted Patent,yes,73,11,5,5,0,E21B47/06;;E21B47/06;;G01V3/265;;G01V3/265,G01V3/18;;G01V1/40,324/347;;324/351;;702/11,8,3,065-784-698-904-809;;144-289-954-649-970;;023-324-612-587-38X,10.2118/77522-ms;;10.1029/2001gl013483;;10.1190/1.1443533,"Bryant et al. ""Real-Time Monitoring and Control of Water Influx to a Horizontal Well Using Advanced Completion Equipped with Permanent Sensors."" SPE 77522 SPE Annual Technical Conference and Exhibition, San Antonio, Texas (Sep. 29-Oct. 2, 2002).;;Fordham, E.J., and H.K.J. Ladva, ""Cross-flow Filtration of Bentonite Suspensions"", PhysicoChemical Hydrodynamics, 11(4), 411-439 (1989).;;Hovhannissian et al. ""Transient electric phenomena observed during fluid circulation in unsaturated porous media."" Geophysical Research Letters, vol. 29, No. 1, pp. 5-1 to 5-4.;;Wurmstich et al. ""Modeling of streaming potential reponses caused by oil well pumping."" Geophysics, vol. 59, No. 1 (Jan. 1994), pp. 46-56.;;International Search Report for PCT/US2006/034526 mailed Mar. 14, 2007.;;International Search Report for PCT/US2006/034160 mailed Jan. 19, 2007.;;International Search Report and Written Opinion for PCT/US2006/034159 mailed May 29, 2007.;;International Search Report and Written Opinion for PCT/US2006/034291 mailed Jun. 19, 2007.",INACTIVE
171,US,A,US 5575670 A,034-931-876-728-338,1996-11-19,1996,US 40005595 A,1995-03-06,US 40005595 A,1995-03-06,Dust protection for PCMCIA card and socket,A compliant boot (30) for protecting the electrical connection between a PCMCIA card (14) and receiving socket (18) from dust and other contaminants when used in a harsh or dusty environment such as on-board a refuse collection vehicle.,EATON CORP,CHEN YUE-MING;;FORTUNE G CLARK;;STOUT DONALD M,EATON CORPORATION (1995-03-02),https://lens.org/034-931-876-728-338,Granted Patent,yes,6,5,2,2,0,H01R12/721;;H01R12/721;;H01R13/52;;H01R13/52,H01R13/52,439/138;;439/278;;439/374,1,0,,,"IBM Technical Disclosure Bulletin, vol. 33, No. 9, Feb. 1991, p. 33.",EXPIRED
172,EP,A4,EP 3423397 A4,080-436-519-331-711,2019-07-10,2019,EP 16892842 A,2016-02-29,US 2016/0020041 W,2016-02-29,FLUID PROPELLING APPARATUS INCLUDING A HEAT SINK,,HEWLETT PACKARD DEVELOPMENT CO,CLARK GARRETT E;;CUMBIE MICHAEL W;;CHEN CHIEN-HUA,"HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (2019-05-15)",https://lens.org/080-436-519-331-711,Search Report,no,4,0,9,9,0,B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L3/502784;;F04B43/046;;B01L2300/0867;;B01L2300/087;;B01L2300/088;;B01L2300/1827;;B01L2300/1894;;B01L2400/0442;;B01L2400/046;;B41J2202/12;;B41J2/1404;;B41J2/1408;;B41J2/1603;;B41J2/1637;;B01L3/502707;;B01L3/50273;;F04B43/046;;B01L2300/1894;;B01L2400/046;;B01L2300/087;;B01L2300/088;;B01L3/502784;;B01L2300/1827;;B01L2300/0867;;B01L2400/0442;;B01L3/5027;;B41J2/1404;;B41J2/1433;;B81B1/006;;B81B7/0083;;B81B2203/0338;;B81C1/00119;;F04B19/006,B01L3/00;;B81B7/02;;B41J2/14;;B81B1/00;;B81B3/00;;B81B7/00;;B81C1/00;;F04B19/00;;F04B43/04,,1,0,,,See also references of WO 2017151091A1,DISCONTINUED
173,BR,A2,BR PI0615867 A2,096-226-096-631-602,2011-05-31,2011,BR PI0615867 A,2006-09-05,US 22388305 A;;US 2006/0034526 W,2005-09-09,"método para caracterizar uma pressão de uma formação terrestre atravessada por um furo, durante a perfuração do furo, método para determinar uma pressão de uma formação subsuperficial envolvendo um furo de poço, e método para detectar influxo de fluxo para dentro de um furo de poço a partir de uma formação terrestre envolvendo o furo de poço","MéTODO PARA CARACTERIZAR UMA PRESSãO DE UMA FORMAçãO TERRESTRE ATRAVESSADA POR UM FURO, DURANTE A PERFURAçãO DO FURO, MéTODO PARA DETERMINAR UMA PRESSãO DE UMA FORMAçãO SUBSUPERFICIAL ENVOLVENDO UM FURO DE POçO, E MéTODO PARA DETECTAR INFLUXO DE FLUXO PARA DENTRO DE UM FURO DE POçO A PARTIR DE UMA FORMAçãO TERRESTRE ENVOLVENDO O FURO DE POçO São fornecidos um aparelho e metodologias de perfuração com perfilagem para medir potencial de escoamento em uma formaçào terrestre. O aparelho e metodologias podem ser utilizados para localizar informações relevantes sobre as operações de perfuração. De modo particular, visto que a medição do potencial de escoamento se refere diretamente ao fluxo de fluido, as medições do potencial de escoamento podem ser usadas, para rastrear fluxos de fluidos na formação. Por sua vez, essas informações podem ser usadas para localizar informações relevantes sobre as operações de perfuração, tais corno condições de perfuração sub-balanceada, pressões anormais na formação, fraturas abertas, a permeabilidade da formação, e pressão da formação.",PRAD RES & DEV NV,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/096-226-096-631-602,Patent Application,no,0,0,5,5,0,E21B47/06;;E21B47/06;;G01V3/265;;G01V3/265,G01V3/26,,0,0,,,,DISCONTINUED
174,US,A1,US 2015/0333738 A1,129-874-480-469-073,2015-11-19,2015,US 201514808358 A,2015-07-24,US 201514808358 A;;US 201314136258 A;;US 201261740339 P,2012-12-20,Integrated Circuit Process and Bias Monitors and Related Methods,"An integrated circuit device can include at least one oscillator stage having a current mirror circuit comprising first and second mirror transistors of a first conductivity type, and configured to mirror current on two mirror paths, at least one reference transistor of a second conductivity type having a source-drain path coupled to a first of the mirror paths, and a switching circuit coupled to a second of the mirror paths and configured to generate a transition in a stage output signal in response to a stage input signal received from another oscillator stage, wherein the channel lengths of the first and second mirror transistors are larger than that of the at least one reference transistor.",MIE FUJITSU SEMICONDUCTOR LTD,CLARK LAWRENCE T;;KIDD DAVID A;;CHEN CHAO-WU,SUVOLTA INC (2013-12-19);;MIE FUJITSU SEMICONDUCTOR LIMITED (2015-02-27),https://lens.org/129-874-480-469-073,Patent Application,yes,0,7,3,3,0,G01R31/2884;;H01L22/34;;H03K3/0315;;G05F3/262;;G05F3/205;;H01L29/7851;;H03K3/0315;;H03K3/011;;G05F3/262;;G05F3/205;;H01L22/34;;G01R31/2884,G05F3/20;;H03K3/011;;G05F3/26;;H03K3/03,,0,0,,,,ACTIVE
175,WO,A3,WO 2007/032938 A3,188-320-550-142-187,2007-08-02,2007,US 2006/0034291 W,2006-09-05,US 22268905 A,2005-09-09,WHILE-DRILLING METHODOLOGY FOR DETERMINING EARTH FORMATION CHARACTERISTICS AND OTHER USEFUL INFORMATION BASED UPON STREAMING POTENTIAL MEASUREMENTS,"Logging-while-drilling apparatus and methodologies for measuring streaming potential in an earth formation are provided. The apparatus and methodologies can be utilized to find information relevant to the drilling operations. In particular, since the streaming potential measurement relates directly to fluid flow, the streaming potential measurements can be used to track flow of fluids in the formation. In turn, this information may be used to find information relevant to the drilling operations, such as under-balanced drilling conditions, abnormal formation pressures, open fractures, the permeability of the formation, and formation pressure.",SCHLUMBERGER SERVICES PETROL;;SCHLUMBERGER CA LTD;;SCHLUMBERGER HOLDINGS;;SCHLUMBERGER TECHNOLOGY BV;;PRAD RES & DEV NV;;CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,CHEN MIN-YI;;CLARK BRIAN;;COLLINS ANTHONY;;TARVIN JEFFREY,,https://lens.org/188-320-550-142-187,Search Report,yes,5,0,5,5,0,E21B47/10;;G01V3/265;;G01V3/265;;E21B47/10,G01V3/26;;G01V3/00;;G01V3/08;;G01V3/18,,0,0,,,,PENDING
176,EP,A1,EP 3438325 A1,026-905-191-762-796,2019-02-06,2019,EP 18184877 A,2018-07-23,US 201715664446 A,2017-07-31,IMPROVED ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE,"A coated component (10) is generally provided, along with methods of forming such a coating system (20). The coated component (10) includes a substrate having a surface (25,27) with a coating system (20) thereon. The coating system (20) may include a columnar thermal barrier coating (TBC) (24) over the surface (25,27) of the substrate, with the columnar TBC (24) including surface-connected voids (30). An intermediate layer (26) is over the columnar TBC layer. The intermediate layer (26) has a surface (25,27) opposite of the columnar TBC (24) that is rougher than the surface (25,27) of the columnar TBC (24). A second TBC (28) is over the intermediate layer (26).
",GEN ELECTRIC,CHEN DIANYING;;FU MING;;CLARK MICHAEL DAVID;;KONITZER DOUGLAS GERARD,,https://lens.org/026-905-191-762-796,Patent Application,yes,3,2,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,C23C28/04;;C23C4/134;;C23C28/00;;F01D5/28,,0,0,,,,DISCONTINUED
177,WO,A2,WO 2023/250192 A2,033-568-166-403-045,2023-12-28,2023,US 2023/0026151 W,2023-06-23,US 202263354991 P,2022-06-23,"FERROELECTRIC SMECTIC A PHASE MATERIALS, DEVICES INCLUDING THE MATERIALS, AND METHODS OF FORMING AND USING SAME",Devices including a volume comprising ferroelectric smectic A (SmAF) liquid crystal-forming fluid and methods of forming and using such devices are disclosed. Exemplary devices include one or more surfaces and one or more electrodes thereon for application of an electric field to the volume.,UNIV COLORADO REGENTS,MACLENNAN JOSEPH;;CLARK NOEL;;GLASER MATTHEW;;CHEN XI;;MARTINEZ VIKINA,,https://lens.org/033-568-166-403-045,Patent Application,yes,0,0,2,2,0,G02F1/141,G09G3/36,,0,0,,,,PENDING
178,CN,A,CN 108290879 A,037-486-831-446-974,2018-07-17,2018,CN 201680066898 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/037-486-831-446-974,Patent Application,no,9,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,1,0,,,"GEORGE M. BUCKLEY，等: ""IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》",ACTIVE
179,WO,A1,WO 2017/049069 A1,045-786-386-127-653,2017-03-23,2017,US 2016/0052107 W,2016-09-16,US 201562220358 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH;;JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/045-786-386-127-653,Patent Application,yes,8,4,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,21,15,003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033;;088-902-381-301-89X;;048-216-169-484-878;;018-960-566-924-993;;027-013-467-518-974;;095-716-273-533-92X;;013-862-057-494-226;;007-364-858-655-289;;051-933-822-151-495;;003-604-589-168-97X;;026-362-629-080-389;;011-166-598-579-298;;077-295-491-167-117,10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8;;10.1016/j.cyto.2007.12.012;;pmc2377356;;18249132;;10.1126/science.271.5252.1128;;8599092;;10.1126/science.278.5343.1612;;9374458;;10383454;;10.1074/jbc.274.27.19403;;pmc122810;;11960013;;10.1073/pnas.082100399;;10.1016/j.bmcl.2008.04.042;;18501603;;10.1002/jps.2600660104;;833720;;10.1021/jo00300a010;;10.1021/jo00391a029;;8130206;;10.1021/bi00176a024;;10.1093/carcin/16.4.683;;7728943;;10.1002/0471220574,"DING K. ET AL.: ""Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 24, 14 May 2014 (2014-05-14), pages 3113 - 3117, XP002762798;;HRANJEC ET AL.: ""Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: mechanisms and determination of crystal structure"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 16 November 2012 (2012-11-16), pages 111 - 119, XP002762799;;SOVIC IRENA ET AL: ""Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis, and biological tests"", MONATSHEFTE FÜR CHEMIE = CHEMICAL MONTHLY, SPRINGER VIENNA, VIENNA, vol. 146, no. 9, 29 April 2015 (2015-04-29), pages 1503 - 1517, XP035525720, ISSN: 0026-9247, [retrieved on 20150429], DOI: 10.1007/S00706-015-1478-8;;COHEN, CURRENT OPINION IN CELL BIOLOGY, vol. 21, 2009, pages 1 - 8;;RINGWOOD; LI, CYTOKINE, vol. 42, 2008, pages 1 - 7;;CAO ET AL., SCIENCE, vol. 271, no. 5252, 1996, pages 1128 - 31;;MUZIO ET AL., SCIENCE, vol. 278, no. 5343, 1997, pages 1612 - 5;;WESCHE ET AL., J. BIOL. CHEM., vol. 274, no. 27, 1999, pages 19403 - 10;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, no. 8, 2002, pages 5567 - 5572;;BUCKLEY ET AL., BIOORG MED CHEM LETT., vol. 18, no. 12, 2008, pages 3656 - 60;;.: ""Handbook of Chemistry and Physics, 75th Ed."", article ""Periodic Table of the Elements, CAS version"";;THOMAS SORRELL: ""Organic Chemistry"", 1999, UNIVERSITY SCIENCE BOOKS;;SMITH, M.B.; MARCH, J.: ""March's Advanced Organic Chemistry, 5th Ed.,"", 2001, JOHN WILEY & SONS;;S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19;;HANZLIK ET AL., J. ORG. CHEM., vol. 55, 1990, pages 3992 - 3997;;REIDER ET AL., J. ORG. CHEM., vol. 52, 1987, pages 3326 - 3334;;FOSTER, ADV. DRUG RES., vol. 14, 1985, pages 1 - 40;;GILLETTE ET AL., BIOCHEMISTRY, vol. 33, no. 10, 1994, pages 2927 - 2937;;JARMAN ET AL., CARCINOGENESIS, vol. 16, no. 4, 1993, pages 683 - 688;;PHILIP J. KOCIENSKI: ""Protecting Groups"", 1994, GEORG THIEME VERLAG;;THEODORA W. GREENE; PETER G. M. WUTS: ""Protective Groups in Organic Synthesis, 3rd Edition"", 1999, WILEY INTERSCIENCE",PENDING
180,KR,A,KR 20220103204 A,049-776-888-465-528,2022-07-21,2022,KR 20227023776 A,2014-03-10,US 201361776710 P;;US 201361776715 P;;US 201361776724 P;;KR 20157027621 A;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"카바트 넘버링에 따른 아미노산 위치 (114)에 조작된 N-연결 글리코실화 부위를 갖는 CH1 도메인 (예를 들어, 인간 IgG1 CH1 도메인)을 포함하는 결합 폴리펩티드 (예를 들어, 항체) 및 그의 이펙터 모이어티 접합체를 제공한다. 또한, 항원-결합 폴리펩티드를 코딩하는 핵산, 상기 항원-결합 폴리펩티드를 제조하기 위한 재조합 발현 벡터 및 숙주 세포를 제공한다. 질환을 치료하기 위해 본원에 개시된 항원-결합 폴리펩티드를 사용하는 방법을 또한 제공한다.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/049-776-888-465-528,Patent Application,no,0,0,88,165,82,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K39/00,,0,0,,,,DISCONTINUED
181,US,A1,US 2017/0147908 A1,058-946-523-861-881,2017-05-25,2017,US 201515323530 A,2015-07-07,US 201515323530 A;;US 201462021532 P;;US 2015/0039385 W,2014-07-07,Automatic Segmentation And Quantitative Parameterization Of Brain Tumors In MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-07-05),https://lens.org/058-946-523-861-881,Patent Application,yes,0,15,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G01R33/56;;G06T7/00;;G06T7/11;;G06T7/187;;G06V10/764,,0,0,,,,ACTIVE
182,US,A1,US 2017/0081307 A1,111-431-719-036-004,2017-03-23,2017,US 201615267606 A,2016-09-16,US 201615267606 A;;US 201562220358 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2016-10-17),https://lens.org/111-431-719-036-004,Patent Application,yes,4,4,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,,0,0,,,,ACTIVE
183,US,B2,US 10392375 B2,168-435-476-145-666,2019-08-27,2019,US 201815959686 A,2018-04-23,US 201815959686 A;;US 201615267565 A;;US 201562220307 P,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/168-435-476-145-666,Granted Patent,yes,8,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,A01N43/00;;A61K31/397;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D498/08,,23,15,088-902-381-301-89X;;053-041-511-200-033;;088-902-381-301-89X;;048-216-169-484-878;;018-960-566-924-993;;027-013-467-518-974;;095-716-273-533-92X;;013-862-057-494-226;;007-364-858-655-289;;051-933-822-151-495;;003-604-589-168-97X;;026-362-629-080-389;;011-166-598-579-298;;077-295-491-167-117;;165-533-825-286-740,10.1016/j.cyto.2007.12.012;;pmc2377356;;18249132;;19217767;;10.1016/j.ceb.2009.01.015;;10.1016/j.cyto.2007.12.012;;pmc2377356;;18249132;;10.1126/science.271.5252.1128;;8599092;;10.1126/science.278.5343.1612;;9374458;;10383454;;10.1074/jbc.274.27.19403;;pmc122810;;11960013;;10.1073/pnas.082100399;;10.1016/j.bmcl.2008.04.042;;18501603;;10.1002/jps.2600660104;;833720;;10.1021/jo00300a010;;10.1021/jo00391a029;;8130206;;10.1021/bi00176a024;;10.1093/carcin/16.4.683;;7728943;;10.1002/0471220574;;10.1111/j.1349-7006.2003.tb01343.x,"Ringwood et al. (Cytokine, 2008, 42, 1-7) (Year: 2008).;;STN compound 509094-23-9 (May 2, 2003) (Year: 2003).;;Cohen, Current Opinion in Cell Biology 21, 317-324 (2009).;;Ringwood and Li, Cytokine 42, 1-7 (2008).;;Cao et al., Science 271(5252): 1128-31 (1996).;;Muzio et al., Science 278(5343): 1612-5 (1997).;;Wesche et al. J. Biol. Chem. 274(27): 19403-10 (1999).;;Li et al. Proc. Natl. Acad. Sci. USA 99(8):5567-5572 (2002).;;Buckley et al. Bioorg Med Chem Lett. 18(12):3656-60 (2008).;;Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed.;;Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito (1999).;;“March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: (2001).;;S. M. Berge et al., J. Pharmaceutical Sciences, 66, 1-19 (1977).;;Hanzlik et al., J. Org. Chem. 55, 3992-3997 (1990).;;Reider et al., J. Org. Chem. 52, 3326-3334 (1987).;;Foster, Adv. Drug Res. 14, 1-40 (1985).;;Gillette et al., Biochemistry 33(10) 2927-2937 (1994).;;Jarman et al., Carcinogenesis 16(4), 683-688 (1993).;;Philip J. Kocienski, “Protecting Groups”, Georg Thieme Verlag Stuttgart, New York, (1994).;;Theodora W. Greene and Peter G. M. Wuts, “Protective Groups in Organic Synthesis”, Wiley Interscience, 3rd Edition (1999).;;Ito et al., Cancer Science, 2003, 94(1): 3-8.;;STN registry database compound 509094-21-7 (Entered STN May 2, 2003).;;STN registry database compound 509094-23-9 (Entered STN May 2, 2003).",ACTIVE
184,US,A1,US 2017/0081317 A1,178-321-709-153-809,2017-03-23,2017,US 201615267565 A,2016-09-16,US 201615267565 A;;US 201562220307 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2016-10-17),https://lens.org/178-321-709-153-809,Patent Application,yes,0,6,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D401/04;;C07D413/14;;C07D403/04;;C07D413/04;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08,,3,1,165-533-825-286-740,10.1111/j.1349-7006.2003.tb01343.x,"STN registry database compound 509094-21-7 (Entered STN 2 May 2003);;Ito et al. (Cancer Science, 2003, 94(1), 3-8);;STN registry database compound 509094-23-9 (Entered STN 2 May 2003)",ACTIVE
185,EP,B1,EP 3350177 B1,178-825-167-463-480,2021-07-07,2021,EP 16778936 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2022-05-04),https://lens.org/178-825-167-463-480,Granted Patent,yes,8,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,1,0,,,"BUCKLEY G M ET AL: ""IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 12, 15 June 2008 (2008-06-15) , pages 3656-3660, XP022707452, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.04.042 [retrieved on 2008-04-24] cited in the application",ACTIVE
186,EP,A1,EP 3350170 A1,007-498-904-091-167,2018-07-25,2018,EP 16770654 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2022-05-04),https://lens.org/007-498-904-091-167,Patent Application,yes,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,ACTIVE
187,ZA,B,ZA 201801056 B,034-659-252-260-677,2020-05-27,2020,ZA 201801056 A,2018-02-15,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,CATHERINE JORAND-LEBRUN;;RUOXI LAN;;AUSTIN CHEN;;RYAN C CLARK,,https://lens.org/034-659-252-260-677,Granted Patent,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,,,0,0,,,,ACTIVE
188,MX,A,MX 2015012527 A,038-669-426-196-658,2016-05-26,2016,MX 2015012527 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES.,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,QIU HUAWEI;;PAN CLARK;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/038-669-426-196-658,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,ACTIVE
189,US,B2,US 10169685 B2,035-107-321-183-072,2019-01-01,2019,US 201515323530 A,2015-07-07,US 201515323530 A;;US 201462021532 P;;US 2015/0039385 W,2014-07-07,Automatic segmentation and quantitative parameterization of brain tumors in MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2015-07-05),https://lens.org/035-107-321-183-072,Granted Patent,yes,7,5,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G06T7/11;;G01R33/56;;G06T7/00;;G06T7/187;;G06V10/764,,43,42,067-084-615-211-43X;;025-606-207-383-613;;008-401-964-610-216;;046-790-993-975-302;;032-042-147-850-410;;080-513-827-971-661;;002-796-015-264-48X;;081-816-662-743-699;;114-556-826-062-660;;123-008-616-569-550;;050-541-732-697-786;;031-818-054-450-257;;062-836-401-504-605;;008-714-661-490-12X;;043-099-997-684-689;;010-663-283-182-094;;003-735-461-355-696;;039-197-603-248-580;;004-348-623-369-422;;002-034-769-416-645;;000-125-181-498-310;;011-543-929-020-220;;011-312-511-703-704;;085-656-742-202-556;;095-773-278-696-411;;184-446-291-593-247;;000-679-757-085-450;;031-136-752-436-374;;023-459-652-549-183;;046-019-657-946-925;;056-180-494-985-439;;000-211-465-944-790;;002-015-261-929-841;;056-967-412-924-149;;107-231-653-430-242;;020-391-746-039-013;;024-900-976-807-186;;026-223-754-328-507;;028-984-112-805-307;;091-712-215-361-775;;062-797-804-086-955;;028-519-256-561-598,pmc3866108;;24358132;;10.1371/journal.pone.0081895;;18091357;;10.1203/pdr.0b013e31815ed071;;16019235;;10.1016/j.neuroimage.2005.05.046;;15006671;;10.1016/j.neuroimage.2003.10.012;;pmc3910500;;24120142;;10.1016/j.cell.2013.09.034;;10.1371/journal.pone.0008918;;20169195;;pmc2820542;;9931268;;10.1006/nimg.1998.0395;;21725140;;pmc3153124;;10.1088/0031-9155/56/14/021;;24110443;;10.1109/embc.2013.6610256;;10.2307/1932409;;10.1073/pnas.0801279105;;18362333;;pmc2278224;;10.1016/s0896-6273(02)00569-x;;11832223;;10.1016/s0933-3657(00)00073-7;;11154873;;23790354;;10.1016/j.mri.2013.05.002;;17354756;;10.1007/11866763_8;;10.1148/radiol.13120118;;23392431;;pmc3632807;;21601840;;10.1016/j.compbiomed.2011.04.010;;10.1016/j.neuroimage.2009.11.044;;pmc2819607;;19944768;;21880566;;10.1109/tmi.2011.2138152;;10.1016/s1361-8415(01)00036-6;;11516708;;10.1006/nimg.2002.1132;;10.1016/s1053-8119(02)91132-8;;12377157;;21979382;;10.1016/j.neuroimage.2011.09.015;;16300968;;10.1016/j.neuroimage.2005.09.046;;20044633;;10.1001/jama.2013.280319;;24193082;;10.1109/tsmc.1979.4310076;;14697002;;10.1016/s1076-6332(03)00506-3;;pmc2430604;;15501092;;10.1016/j.neuroimage.2004.07.051;;10.1002/hbm.10062;;pmc6871816;;12391568;;10.1016/j.nicl.2013.10.003;;pmc3830067;;24273728;;10.3174/ajnr.a4171;;25414001;;pmc7964326;;10.1016/0730-725x(95)00012-6;;8569446;;10.1016/j.ccr.2009.12.020;;10.3410/f.718384247.793495043;;pmc2818769;;20129251;;pmc3049580;;21119666;;10.1038/sj.bjc.6606031;;11410304;;10.1016/s0167-8140(01)00371-1;;10.1056/nejmra0708126;;18669428;;10.1016/j.neuroimage.2008.10.055;;19059349;;pmc3705006;;10.1007/s10278-012-9568-1;;23319111;;11293691;;10.1109/42.906424;;pmc3515056;;22591720;;10.1016/j.acra.2012.03.026;;10.1007/978-3-642-33454-2_46;;23286152;;10.1371/journal.pone.0025451;;21998659;;pmc3187774,"Anbeek et al., “Automatic segmentation of eight tissue classes in neonatal brain MRI”, PloS one 2013, 8, e81895.;;Anbeek et al., “Probabilistic brain tissue segmentation in neonatal magnetic resonance imaging”, Pediatric research 2008, 63, pp. 158-163.;;Anbeek et al., “Probabilistic segmentation of brain tissue in MR imaging”, NeuroImage 2005, 27, pp. 795-804.;;Anbeek et al., “Probabilistic segmentation of white matter lesions in MR imaging”, NeuroImage 2004, 21, pp. 1037-1044.;;Brennan et al., “The somatic genomic landscape of glioblastoma”, Cell 2013, 155, pp. 462-477.;;Cerami et al., “Automated network analysis identities core pathways in glioblastoma”, PLoS One 2010, 5, e8918.;;Dale et al., “Cortical surface-based analysis I. Segmentation and surface reconstruction”, NeuroImage 1999, 9, pp. 179-194.;;Deeley et al., “Comparison of manual and automatic segmentation methods for brain structures in the presence of space-occupying lesions: a multi-expert study”, Physics in Medicine and Biology 2011, 56, pp. 4557-4577.;;Diaz et al., “An automatic brain tumor segmentation tool. Conference proceedings”, Annual International Conference Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society 2013, pp. 3339-3342.;;Dice, L.R., “Measures of the Amount of Ecologic Association Between Species”, Ecology 1945, 26, pp. 297-302.;;Diehn et al., “Identification of noninvasive imaging surrogates for brain tumor gene-expression modules”, Proc Natl Acad Sci U S A 2008, 105, pp. 5213-5218.;;Fischl et al., “Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain”, Neuron 2002, 33, pp. 341-355.;;Fletcher-Heath et al., “Automatic segmentation of non-enhancing brain tumors in magnetic resonance images”, Artificial Intelligence in Medicine 2001, 21, pp. 43-63.;;Gordillo et al., “State of the art survey on MRI brain tumor segmentation”, Magnetic resonance imaging 2013, 31, pp. 1426-1438.;;Grabner et al., “Symmetric atlasing and model based segmentation: an application to the hippocampus in older adults”, Medical image computing and computer-assisted intervention: MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention 2006, 9, pp. 58-66.;;Gutman et al., “MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set”, Radiology 2013, 267, pp. 560-569.;;Harati et al., “Fully automated tumor segmentation based on improved fuzzy connectedness algorithm in brain MR images”, Computers in Biology and Medicine 2011, 41, pp. 483-492.;;Holland et al., “Efficient correction of inhomogeneous static magnetic field-induced distortion in Echo Planar Imaging”, NeuroImage 2010, 50, pp. 175-183.;;Iglesias et al., “Robust brain extraction across datasets and comparison with publicly available methods”, IEEE transactions on medical imaging 2011, 30, pp. 1617-1634.;;Jenkinson et al., “A global optimisation method for robust affine registration of brain images”, Medical image analysis 2001, 5, pp. 143-156.;;Jenkinson et al., “Improved optimization for the robust and accurate linear registration and motion correction of brain images”, NeuroImage 2002, 17, pp. 825-841.;;Jenkinson et al., FSL, NeuroImage 2012, 62, pp. 782-790.;;Jovicich et al., “Reliability in multi-site structural MRI studies: effects of gradient non-linearity correction on phantom and human data”, NeuroImage 2006, 30, pp. 436-443.;;Minniti et al., “Chemotherapy for glioblastoma: current treatment and future perspectives for cytotoxic and targeted agents”, Anticancer research 2009, 29, pp. 5171-5184.;;Omuro et al., “Glioblastoma and other malignant gliomas: a clinical review”, JAMA: The journal of the American Medical Association 2013, 310, pp. 1842-1850.;;Otsu, “A Threshold Selection Method from Gray-Level Histograms.” Systems, Man and Cybernetics, IEEE Transactions on Systems, Man and Cybernetics, 1979, 9, pp. 62-66.;;Prastawa et al., “Automatic brain tumor segmentation by subject specific modification of atlas priors”, Academic Radiology 2003, 10, pp. 1341-1348.;;Smith et al., “Advances in functional and structural MR image analysis and implementation as FSL”, NeuroImage 2004, 23 Suppl 1, pp. S208-S219.;;Smith, S.M., “Fast robust automated brain extraction”, Human brain mapping 2002, 17, pp. 143-155.;;Steenwijk et al., “Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs)”, NeuroImage Clinical 2013, 3, pp. 462-469.;;Steed et al., “Iterative Probabilistic Voxel Labeling: Automated Segmentation for Analysis of the Cancer Imaging Archive Glioblastoma Images”, Original Research Brain, 2015, pp. 678-685.;;Vaidyanathan et al., “Comparison of supervised MRI segmentation methods for tumor volume determination during therapy”, Magnetic Resonance Imaging 1995, 13, pp. 719-728.;;Verhaak et al., “Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1”, Cancer Cell 2010, 17, pp. 98-110.;;Vitucci et al., “Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy”, Br J Cancer 2011, 104, pp. 545-553.;;Weltens et al. “Interobserver variations in gross tumor volume delineation of brain tumors on computed tomography and impact of magnetic resonance imaging”, Radiotherapy and Oncology, 2001, 60, pp. 49-59.;;Wen et al., “Malignant gliomas in adults”, The New England Journal of Medicine 2008, 359, pp. 492-507.;;Woolrich et al., “Bayesian analysis of neuroimaging data in FSL”, NeuroImage 2009, 45, pp. S173-S186.;;Wu et al., “Semi-automatic segmentation of brain tumors using population and individual information”, Journal of Digital Imaging 2013, 26, pp. 786-796.;;Zhang et al., “Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm”, IEEE transactions on medical imaging 2001, 20, pp. 45-57.;;Zhu et al., “Semi-automatic segmentation software for quantitative clinical brain glioblastoma evaluation”, Academic Radiology 2012, 19, pp. 977-985.;;Zikic et al., “Decision forests for tissue-specific segmentation of high-grade gliomas in multi-channel MR”, MICCAI International Conference on Medical Image Computing and Computer-Assisted Intervention 2012;15:369-76.;;Zinn et al., “Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme”, PloS one 2011, 6, e25451.;;International Search Report and Written Opinion of International Application No. PCT/US2015/039385; dated Sep. 29, 2015.",ACTIVE
190,MX,A,MX 2018002986 A,111-089-030-251-66X,2018-05-02,2018,MX 2018002986 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF.,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,RUOXI LAN;;CATHERINE JORAND-LEBRUN;;AUSTIN CHEN;;RYAN C CLARK,,https://lens.org/111-089-030-251-66X,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D233/88;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,PENDING
191,WO,A3,WO 2023/133356 A3,108-321-665-361-518,2023-08-24,2023,US 2023/0010510 W,2023-01-10,US 202263298116 P,2022-01-10,COMPOSITE MATERIALS BASED ON FERROELECTRIC NEMATIC LIQUID CRYSTALS AND DEVICES INCLUDING SAME,"Composite materials and devices including composite materials are disclosed. Exemplary composite materials include a porous material and ferroelectric nematic liquid crystal within pores of the porous material. The composite materials can be used in a variety of applications, such as capacitors, information storage and processing, actuators, sensors, electro-caloric devices, energy storage and/or conversion devices utilizing piezoelectric effects. The porous material can be a solid, a polymer, glassy, crystalline, amorphous, foam, an aerogel or ceramic.",UNIV COLORADO REGENTS,GLASER MATTHEW A;;CLARK NOEL;;MACLENNAN JOSEPH E;;CHEN XI,,https://lens.org/108-321-665-361-518,Search Report,yes,7,0,2,2,0,C09K19/0225;;C09K2019/521;;G02F1/141;;G02F1/1334,G02F1/141;;E06B9/24;;G02F1/1333;;G02F1/135;;G02F1/136;;G06F17/00,,1,1,000-709-885-359-625,10.1098/rspa.1954.0273,"R. DE P. DAUBENY, CHARLES WILLIAM BUNN AND C. J. BROWN: ""The crystal structure of polyethylene terephthalate"", PROCEEDINGS OF THE ROYAL SOCIETY OF LONDON. SERIES A, MATHEMATICAL AND PHYSICAL SCIENCES., ROYAL SOCIETY OF LONDON, LONDON., GB, vol. 226, no. 1167, 7 December 1954 (1954-12-07), GB , pages 531 - 542, XP009548287, ISSN: 0080-4630, DOI: 10.1098/rspa.1954.0273",PENDING
192,US,A1,US 2015/0079070 A1,131-388-299-774-805,2015-03-19,2015,US 201414203438 A,2014-03-10,US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/131-388-299-774-805,Patent Application,yes,5,17,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K47/48;;C07K16/28,424/130.1;;530/389.1;;530/391.7;;536/23.53;;435/320.1;;435/326,5,4,004-272-966-072-139;;100-801-934-296-913;;008-019-042-176-997;;013-142-717-038-23X,10.1038/nbt832;;12778055;;18234994;;10.1167/iovs.07-1175;;15185369;;10.1002/cbic.200300806;;10556035;;10.1006/jmbi.1999.3141,"Doronina et al., Nat Biotech 21(7): 778-784, Epub June 1, 2003.;;Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527, February 2008.;;Winkler et al., J. Imm., 265:4505-4514, 2000.;;Piatesi et al., ChemBio Chem 5: 460-466, 2004.;;Wu et al., J. Mol. Biol. 294: 151-162, 1999.",ACTIVE
193,EP,B1,EP 3350170 B1,157-415-091-314-548,2022-01-26,2022,EP 16770654 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2022-05-04),https://lens.org/157-415-091-314-548,Granted Patent,yes,8,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D235/30;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,3,0,,,"DING K. ET AL.: ""Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 24, 14 May 2014 (2014-05-14), pages 3113-3117, XP002762798,;;HRANJEC ET AL.: ""Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: mechanisms and determination of crystal structure"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, 16 November 2012 (2012-11-16), pages 111-119, XP002762799,;;SOVIC IRENA ET AL: ""Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis, and biological tests"", MONATSHEFTE FÜR CHEMIE = CHEMICAL MONTHLY, SPRINGER VIENNA, VIENNA, vol. 146, no. 9, 29 April 2015 (2015-04-29), pages 1503-1517, XP035525720, ISSN: 0026-9247, DOI: 10.1007/S00706-015-1478-8 [retrieved on 2015-04-29]",ACTIVE
194,TW,A,TW 202344707 A,172-990-646-212-874,2023-11-16,2023,TW 112107737 A,2023-03-03,US 202263316956 P,2022-03-04,Process for preparing silicon-rich silicon nitride films,"In summary, the invention provides a process for depositing a silicon nitride film onto a microelectronic device substrate. The process utilizes precursors and co-reactants chosen from a halosilane compound, a compound of the formula R2NH, an amino-silane, and hydrogen. The silicon nitride films so formed have increased proportions of silicon, while providing uniform thickness films, i.e., high conformality, even in high aspect 3D NAND structures.",ENTEGRIS INC,CHEN PHILIP S H;;NGUYEN SHAWN DUC;;HENDRIX BRYAN CLARK,,https://lens.org/172-990-646-212-874,Patent of Addition,no,0,0,3,3,0,C23C16/345;;C23C16/45536;;C23C16/45553;;H01L21/0217;;H01L21/02211;;H01L21/02274;;H01L21/0228;;H01L21/02219;;H01L21/02126;;C23C16/045;;C23C16/45527;;C23C16/45553;;H01L21/0217;;C23C16/345;;H01L21/02271;;C23C16/45536;;H01L21/02211,C23C16/34;;B81C1/00;;C23C16/455;;C23C16/50;;H01L21/02,,0,0,,,,PENDING
195,CN,A,CN 111875705 A,019-873-809-792-448,2020-11-03,2020,CN 202010633677 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;CN 201480014449 A,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linkedglycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/019-873-809-792-448,Patent Application,no,2,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/40;;A61K47/54;;A61K47/68;;A61P35/00;;A61P43/00;;C07K16/28;;C07K16/32;;C12N15/13,,1,0,,,"QU Z等: ""Carbohydrate engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates.""",PENDING
196,WO,A1,WO 2018/187469 A1,022-905-546-582-407,2018-10-11,2018,US 2018/0026082 W,2018-04-04,US 201762481779 P,2017-04-05,METHODS AND COMPOSITIONS FOR NON-CYTOTOXIC STEM CELL TRANSPLANTATION,Certain embodiments are directed to compositions and methods to enhance non-cytotoxic hematopoietic stem cell transplantation.,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,,https://lens.org/022-905-546-582-407,Patent Application,yes,4,1,1,1,2,A61M1/38;;A61K31/616;;A61K35/28;;A61K38/193;;A61K45/06,A61K35/28;;A61K35/14;;A61K38/19;;A61M1/34;;A61M1/38;;C12N5/071;;C12N5/0775;;C12N5/0783;;C12N5/0789,,2,2,044-499-228-080-273;;106-028-365-026-94X,pmc3514440;;21886173;;10.1038/leu.2011.197;;10.22038/ijbms.2016.7918;;pmc5220237;;28096964,"RETTIG, MP ET AL.: ""Mobilization of Hematopoietic Stem and Progenitor Cells Using Inhibitors of CXCR4 and VLA-4"", LEUKEMIA, vol. 26, no. 1, January 2012 (2012-01-01), pages 34 - 53, XP055543545;;SAFARI, M ET AL.: ""G-CSF for mobilizing transplanted bone marrow stem cells in rat model of Parkinson's disease"", IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES, vol. 19, no. 12, December 2016 (2016-12-01), pages 1318 - 1324, XP055543549",PENDING
197,KR,A,KR 20180064382 A,172-276-828-229-468,2018-06-14,2018,KR 20187007194 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,IRAK 억제제로서의 헤테로아릴 화합물 및 이의 용도,"화학식 I의 화합물 이의 약제학적으로 허용가능한 조성물에 관한 것으로, IRAK 억제제로서 유용하다.",MERCK PATENT GMBH,JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/172-276-828-229-468,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D417/04,,0,0,,,,DISCONTINUED
198,EP,B1,EP 2970469 B1,044-975-571-182-626,2018-10-03,2018,EP 14714881 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,,GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2018-07-18),https://lens.org/044-975-571-182-626,Granted Patent,yes,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,8,0,,,"QU Z ET AL: ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 213, no. 2, 15 April 1998 (1998-04-15), pages 131-144, XP002103672, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(97)00192-0;;LEUNG S O ET AL: ""The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH OCT 1999, vol. 5, no. 10 Suppl, October 1999 (1999-10), pages 3106s-3117s, XP002727052, ISSN: 1078-0432;;WANG M ET AL: ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules"", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 12, 1 January 1998 (1998-01-01), pages 1277-1283, XP002345837, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.12.1277;;JAGATH R JUNUTULA ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 26, no. 8, 1 August 2008 (2008-08-01) , pages 925-932, XP002623992, ISSN: 1087-0156, DOI: 10.1038/NBT.1480 [retrieved on 2008-07-20];;JUNUTULA JAGATH R ET AL: ""Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OCT 2010, vol. 16, no. 19, 1 October 2010 (2010-10-01), pages 4769-4778, XP002727053, ISSN: 1078-0432;;CARTER PAUL J ET AL: ""Antibody-drug conjugates for cancer therapy"", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 14, no. 3, 1 May 2008 (2008-05-01), pages 154-169, XP009146579, ISSN: 1528-9117, DOI: 10.1097/PPO.0B013E318172D704;;RAVI V J CHARI: ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"", ACCOUNTS OF CHEMICAL RESEARCH, ACS, WASHINGTON, DC, US, vol. 41, no. 1, 1 January 2008 (2008-01-01), pages 98-107, XP008146241, ISSN: 0001-4842, DOI: 10.1021/AR700108G [retrieved on 2007-08-12];;POLAKIS ET AL: ""Arming antibodies for cancer therapy"", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 382-387, XP027625386, ISSN: 1471-4892 [retrieved on 2005-08-01]",ACTIVE
199,IL,B,IL 258082 B,038-976-723-222-488,2022-10-01,2022,IL 25808218 A,2018-03-13,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Bezimidazole derivatives and pharmaceutical compositions containing them,,MERCK PATENT GMBH;;JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/038-976-723-222-488,Unknown,no,9,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,A61K31/4184;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00,,0,0,,,,PENDING
200,CN,A,CN 109317376 A,050-463-829-107-147,2019-02-12,2019,CN 201810844643 A,2018-07-27,US 201715664446 A,2017-07-31,IMPROVED ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE,"A coated component is generally provided, along with methods of forming such a coatin`g system. The coated component includes a substrate having a surface with a coating system thereon. The coating system may include a columnar thermal barrier coating (TBC) over the surface of the substrate, with the columnar TBC including surface-connected voids. An intermediate layer is over the columnar TBC layer. The intermediate layer has a surface opposite of the columnar TBC that is rougher than the surface of the columnar TBC. A second TBC is over the intermediate layer.",GEN ELECTRIC,CHEN DIANYING;;FU MING;;CLARK MICHAEL DAVID;;KONITZER DOUGLAS GERARD,,https://lens.org/050-463-829-107-147,Patent Application,no,2,0,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,B05D5/00;;B05D7/00,,2,0,,,"[美] C.T. 西姆斯等: ""《高温合金 —宇航和工业动力用的高温材料》"", 29 February 1992, 大连理工大学出版社;;孙家枢等: ""《热喷涂科学与技术》"", 31 October 2013, 冶金工业出版社",DISCONTINUED
201,IL,A,IL 258082 A,070-058-503-399-22X,2018-05-31,2018,IL 25808218 A,2018-03-13,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Heteroaryl compounds and pharmaceutical compositions containing them,,JORAND LEBRUN CATHERINE;;LAN RUOXI;;MERCK PATENT GMBH;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/070-058-503-399-22X,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,,,0,0,,,,PENDING
202,US,B2,US 9701753 B2,080-603-416-698-647,2017-07-11,2017,US 201414203438 A,2014-03-10,US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/080-603-416-698-647,Granted Patent,yes,86,11,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;C07K16/32;;C07K16/40,,70,54,004-272-966-072-139;;100-801-934-296-913;;008-019-042-176-997;;013-142-717-038-23X;;136-414-621-541-929;;046-783-448-716-481;;033-955-564-406-161;;083-071-649-888-913;;062-544-695-545-247;;060-056-896-118-940;;058-985-409-440-786;;003-338-632-019-904;;074-787-113-780-602;;013-977-769-158-191;;143-862-943-589-725;;032-476-801-692-751;;028-456-569-502-585;;016-716-200-807-517;;042-233-175-582-26X;;058-270-451-857-914;;111-625-445-280-864;;013-157-274-165-126;;025-805-731-142-930;;153-263-439-316-208;;032-870-057-378-750;;011-629-800-752-356;;013-795-151-218-458;;005-218-993-322-382;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;015-623-518-697-144;;076-152-531-431-484;;113-720-510-689-403;;047-364-936-221-939;;075-912-302-795-48X;;028-401-996-299-149;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X;;048-510-345-009-61X;;013-885-021-097-853;;032-720-983-972-675;;037-751-049-527-007;;039-183-048-383-873;;058-270-451-857-914;;018-007-265-921-231;;045-974-352-776-610;;058-543-894-773-905,10.1038/nbt832;;12778055;;18234994;;10.1167/iovs.07-1175;;15185369;;10.1002/cbic.200300806;;10556035;;10.1006/jmbi.1999.3141;;pmc3464487;;10.1021/bc900103p;;19425533;;18536555;;10.1097/ppo.0b013e318172d704;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;8623165;;10.1097/00007890-199603270-00018;;10.1097/00007890-199601270-00032;;8600649;;10.4049/jimmunol.148.12.3768;;1376340;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;18577454;;10.1016/j.coi.2008.05.010;;10541351;;10.1021/bc400505q;;24533768;;10.1111/j.1432-2277.2012.01456.x;;22420711;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;7879044;;10.4049/jimmunol.147.12.4366;;1836485;;9930678;;10.1093/protein/11.12.1277;;1476621;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;10.1002/bit.21598;;17680659;;9780179;;10.4049/jimmunol.161.8.4083;;17041261;;10.1385/1-59745-187-8:95;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;389741;;10.1016/0378-1119(79)90029-5;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;388229;;10.1038/282039a0;;6248420;;10.1016/0378-1119(80)90133-x;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;10.1021/ja00119a001;;10.1006/jmbi.1997.1354;;9367782;;21632778;;10.1101/pdb.prot5633;;pmc3065967;;21035459;;10.1016/j.jmb.2010.10.030;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;10.1002/anie.199612301;;10.1021/ja038545r;;14692737;;10.1039/b604391g;;16791327,"Doronina et al., Nat Biotech 21(7): 778-784, Epub Jun. 1, 2003.;;Yu et al., Investigative Ophthalmology & Visual Science 49(2): 522-527, Feb. 2008.;;Winkler et al., J. Imm., 265:4505-4514, 2000.;;Piatesi et al., ChemBio Chem 5: 460-466, 2004.;;Wu et al., J. Mol. Biol. 294: 151-162, 1999.;;Boeggeman et al. (2009) “Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection,” Bioconjugate Chemistry. 20:1228-1236.;;Carter et al. (2008) “Antibody-drug conjugates for cancer therapy,” Caner Journal. 14:154-169.;;Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” The Journal of Immunology. 10:301-316.;;Chari (2008) “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs,” Accounts of Chemical Research. 41:98-107.;;Heidecke et al. (1996) “Alpha-Beta T Cell Receptor-Directed Therapy in Rat Allograft Recipients,” Transplantation. 61:948-956.;;Heidecke et al. (1996) “Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-A/B-Targeted Therapy,” Transplantation 61:336-339.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/003819, mailed Jul. 17, 2013.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/059481, mailed Feb. 7, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022623, mailed Jul. 31, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022728, mailed Oct. 9, 2014.;;Jassal et al. (2001) “Sialylation of Human IgG-Fc Carbohydrate by Transfected Rat α2,6-Sialyltransferase,” Biochemical and Biophysical Research Communications. 286:243-249.;;Jung et al. (1992) “Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta,” Journal of Immunology. 148:3768-3775.;;Junutula et al. (2008) “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” Nat. Biotechnol. 26:925-932.;;Junutula et al. (2010) “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer,” Clin. Cancer Res. 16:4769-4778.;;Labrijn et al. (2008) “When binding is enough: nonactivating antibody formats,” Curr. Opin. Immunol. 20:479-485.;;Leung et al. (1999) “The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments,” Clin. Cancer Res. 5:3106s-3117s.;;Zhou et al. (2014) “Site-Specific Antibody—Drug Conjugation through Glycoengineering,” Bioconjugate Chemistry. 25:510-520.;;Page et al. (2012) “Biologics in Organ Transplant,” Transplant International. 25:707-719.;;Polakis (2005) “Arming antibodies for cancer therapy,” Current Opinion in Pharmacology. 5:382-387.;;Qu et al. (1998) “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,” Journal of Immunological Methods. 213:131-144.;;Roche Diagnostics (May 2013) “Alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data Sheet),” XP002727803. Retrieved from Internet: URL: https://cssportal.roche.com/LFR—PublicDocs/ras/07012250103—en—02.pdf. [retrieved on Jul. 25, 2014].;;Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,” Proc. Natl. Acad. Sci. USA. 105(51): 20167-20172.;;Scharpf et al. (2006) “Immunomodulation with anti-αβ T-cell receptor monoclonal antibodies in combination with cyclosporine a improves regeneration in nerve allografts,” Microsurgery. 26:599-607.;;Schorlemmer et al. (1995) “Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats,” Transplantation Proceedings. 27:414-416.;;Shearman et al. (1991) “Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor,” The Journal of Immunology. 147:4366-4373.;;Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,” J. Biol. Chem. 276:6591-6604.;;Wang et al. (1998) “Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules,” Protein Engineering. 11:1277-1283.;;Wright et al. (1992) “Genetically Engineered Antibodies: Progress and Prospects,” Critical Reviews in Immunology. 12:125-168.;;Yamagami et al. (1999) “Suppression of Allograft Rejection with Anti-Aβ T Cell Receptor Antibody in Rat Corneal Transplantation,” Transplantation. 67:600-604.;;Yoshino et al. (1992) “Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats.,” J. Exp. Med. 175:907-915.;;Zhou et al. (2008) “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,” Biotechnol. Bioeng. 99:652-665.;;Zhou et al. (2011) “Strategies for Neoglycan Conjugation to Human Acid α-Glucosidase,” Bioconjugate Chemistry. 22:741-751.;;Roux et al. ‘Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry’. Journal of Immunology. 1998, vol. 161, No. 8, pp. 4083-4090.;;Koide et al. ‘Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain’. Methods in Molecular Biology. 2007, vol. 352, pp. 95-109.;;Stumpp et al. ‘DARPins: A New Generation of Protein Therpeutics’. Drug Discovery Today. 2008, vol. 13, No. 15-16, pp. 695-670.;;Nygren et al. ‘Alternative Binding Proteins: Affibody Binding Proteins Devloped from a Small Three-helix Bundle Scaffold’. The FEBS Journal. 2008, vol. 275, No. 11, pp. 2668-2676.;;Skerra et al. ‘Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activites’. The FEBS Journal. 2008, vol. 275, No. 11, pp. 2677-2683.;;Ebersbach et al. ‘Affilin-Novel Binding Molecules Based on Humans γ-B-Crystallin, an All β-Sheet Protein’. Journal of Molecular Biology. 2007, vol. 372, No. 1, pp. 172-185.;;Krehenbrink et al. ‘Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PulD’. Journal of Molecular Biology. 2008, vol. 383, No. 5, pp. 1058-1068.;;Silverman et al. ‘Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains’. Nature Biotechnology. 2005, vol. 23, No. 12, pp. 1556-1561.;;Grabulovski et al. ‘A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Proteins’. The Journal of Biological Chemistry. 2007, vol. 282, No. 5, pp. 3196-3204.;;Nixon et al. ‘Engineered Protein Inhibitors of Proteases’. Current Opinion in Drug Discovery & Development. 2006, vol. 9, No. 2, pp. 261-268.;;Guan et al. ‘Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization’. PNAS. 1998, vol. 95, No. 22, pp. 13206-13210.;;Kingsman et al. ‘Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trpl Region’. Gene. 1979, vol. 7, pp. 141-152.;;Carrasquillo et al. Improved imaging of metastatic melanoma with high dose 9.2.27 In-11 1 monoclonal antibody. J. Nuc. Med. 1985. vol. 26, pp. 67, Abstract No. 276.;;Cobos-Correa et. al. ‘Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation’. Nature Chemical Biology. 2009, vol. 5, No. 9, pp. 628-663.;;Gehrig et.al. ‘Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters’. Angewandte Chemie International Edition. 2012, vol. 51, No. 25, pp. 6258-6261.;;Stinchcomb et al. ‘Isolation and Characterization of a Yeast Chromosomal Replicator’. Nature. 1979, vol. 282, pp. 39-43.;;Tschumper et al. ‘Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene’. Gene. 1980, vol. 10, pp. 157-166.;;Jones. ‘Proteinase Mutants of Saccharomyces cerevisiae’. Genetics. 1977, vol. 85, pp. 23-33.;;Kaneko et al. ‘Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation’. Science. 2006, vol. 313, No. 5787, pp. 670-673.;;Wang et al. ‘Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies’. Molecular Immunology. 2011, vol. 48, No. 6, pp. 860-866.;;Teicher. ‘Antibody-drug conjugate targets’. Current Cancer Drug Targets. 2009, vol. 9, No. 8, pp. 982-1004.;;Axup, J.Y. et al., “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids”, PNAS 2012, vol. 109, No. 40, pp. 16101-16106.;;Shao, J. et al., “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages” Journal of the American Chemical Society, vol. 117, No. 14, Apr. 12, 1995.;;International Search Report and Written Opinion, Application No. PCT/US2015/021342 mailed Jun. 8, 2015, 20 pages.;;Al-Lazikani et al. (1997) “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol. 273:927-948.;;Giudicelli et al. (Jun. 1, 2011) “IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences,” Cold Springs Harbor Protocols. pp. 58-78.;;Martin (2010) “Protein Sequencing and Structure Analysis of Antibody Variable Domains,” Ch. 3 In; Antibody Engineering. vol. 2. Eds: Kontermann et al. Springer-Verlag Berlin. Heidelberg, Germany. pp. 33-51.;;North et al. (Oct. 28, 2010) “A new clustering of antibody CDR loop conformations,” J. Mol. Biol. 406:228-256.;;Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,” Proc. Natl. Scad. Sci. USA. 105(51):20167-20172.—with Supplementary Information.;;Williams et al. (2010) “Humanising Antibodies by CDR Grafting,” Ch. 21 In; Antibody Engineering. vol. 1. Eds: Kontermann et al. Springer-Verlag Berlin. Heidelberg, Germany. pp. 319-339.;;Cervigni et al. (1996) “Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation,” Angew. Chem., Int. Ed. 35(11):1230-1232.;;Khidekel et al. (2003) “A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications,” J. Am. Chem. Soc. 125:16162-16163.;;Renaudet et al. (2006) “On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides,” Org. Biomol. Chem. 4:2628-2636.",ACTIVE
203,US,A1,US 2009/0268508 A1,085-954-849-064-152,2009-10-29,2009,US 14921708 A,2008-04-29,US 14921708 A,2008-04-29,Reverse leakage reduction and vertical height shrinking of diode with halo doping,"One embodiment of the invention provides a semiconductor diode device including a first conductivity type region, a second conductivity type region, where the second conductivity type is different from the first conductivity type, an intrinsic region located between the first conductivity type region and the second conductivity type region; a first halo region of the first conductivity type located between the second conductivity type region and the intrinsic region, and optionally a second halo region of the second conductivity type located between the first conductivity type region and the intrinsic region.",SANDISK 3D LLC,CHEN XIYING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY,SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2008-04-28),https://lens.org/085-954-849-064-152,Patent Application,yes,50,32,4,4,0,H01L29/1606;;H01L29/8615;;H01L29/868;;H01L29/868;;H01L29/8615;;H01L29/1606,G11C11/00;;G11C11/34;;H01L21/34;;H01L29/868,365/148;;257/656;;365/174;;438/510;;X257E21459;;X257E29336,0,0,,,,ACTIVE
204,CA,A1,CA 2996318 A1,101-028-395-644-499,2017-03-23,2017,CA 2996318 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/101-028-395-644-499,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,PENDING
205,EP,A1,EP 4098663 A1,172-785-421-020-334,2022-12-07,2022,EP 22171935 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;EP 18187892 A;;EP 14714881 A;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CHI domain (e.g., a human IgGl CHI domain), wherein the CHI domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/172-785-421-020-334,Patent Application,yes,53,0,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,27,26,042-233-175-582-26X;;143-862-943-589-725;;025-805-731-142-930;;003-338-632-019-904;;074-787-113-780-602;;046-783-448-716-481;;083-071-649-888-913;;016-716-200-807-517;;081-762-551-590-027;;005-218-993-322-382;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;076-152-531-431-484;;113-720-510-689-403;;047-364-936-221-939;;015-623-518-697-144;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X,10.1016/s0022-1759(97)00192-0;;9692846;;10541351;;9930678;;10.1093/protein/11.12.1277;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;18536555;;10.1097/ppo.0b013e318172d704;;10.1021/ar700108g;;17705444;;10.1016/j.coph.2005.04.008;;15951239;;10.1006/meth.1995.9996;;17041261;;10.1385/1-59745-187-8:95;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;388229;;10.1038/282039a0;;389741;;10.1016/0378-1119(79)90029-5;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365,"QU Z ET AL: ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 213, no. 2, 15 April 1998 (1998-04-15), pages 131 - 144, XP002103672, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(97)00192-0;;LEUNG S-O ET AL: ""THE EFFECTS OF DOMAIN DELETION, GLYCOSYLATION, AND LONG IGG3 HINGE ON THE BIODISTRUBUTION AND SERUM STABILITY PROPERTIES OF A HUMANIZED IGG1 IMMUNOGLOBULIN, HLL2, AND ITS FRAGMENTS"", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 10, SUPPL, 1 October 1999 (1999-10-01), pages 3106S - 3117S, XP001149244, ISSN: 1078-0432;;WANG M ET AL: ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules"", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 12, 1 January 1998 (1998-01-01), pages 1277 - 1283, XP002345837, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.12.1277;;JAGATH R JUNUTULA ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 26, no. 8, 1 August 2008 (2008-08-01), pages 925 - 932, XP002623992, ISSN: 1087-0156, [retrieved on 20080720], DOI: 10.1038/NBT.1480;;JUNUTULA J R ET AL: ""Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer"", CLINICAL CANCER RESEARCH, ASSOCIATION FOR CANCER RESEARCH, US, vol. 16, no. 19, 1 October 2010 (2010-10-01), pages 4769 - 4778, XP002727053, ISSN: 1078-0432, [retrieved on 20100830], DOI: 10.1158/1078-0432.CCR-10-0987;;PAUL J CARTER ET AL: ""Antibody-Drug Conjugates for Cancer Therapy"", CANCER JOURNAL, vol. 14, no. 3, 1 May 2008 (2008-05-01), US, pages 154 - 169, XP055549236, ISSN: 1528-9117, DOI: 10.1097/PPO.0b013e318172d704;;RAVI V J CHARI: ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"", ACCOUNTS OF CHEMICAL RESEARCH, ACS , WASHINGTON , DC, US, vol. 41, no. 1, 1 January 2008 (2008-01-01), pages 98 - 107, XP008146241, ISSN: 0001-4842, [retrieved on 20070812], DOI: 10.1021/AR700108G;;POLAKIS ET AL: ""Arming antibodies for cancer therapy"", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 382 - 387, XP027625386, ISSN: 1471-4892, [retrieved on 20050801];;ASHKENAZI ET AL., METHODS, vol. 8, no. 2, 1995, pages 104 - 115;;KOIDE ET AL., METHODS MOL. BIOL., vol. 352, 2007, pages 95 - 109;;STUMPP ET AL., DRUG DISCOV, 2008, pages 695 - 701;;NYGREN ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2668 - 76;;SKERRA ET AL., FEBS J, vol. 275, no. 11, 2008, pages 2677 - 83;;EBERSBACH ET AL., J. MOL. BIOL., vol. 372, no. 1, 2007, pages 172 - 85;;KREHENBRINK ET AL., J. MOL. BIOL., vol. 383, no. 5, 2008, pages 1058 - 68;;SILVERMAN ET AL., NAT. BIOTECHNOL., vol. 23, no. 12, 2005, pages 1556 - 61;;GRABULOVSKI ET AL., J BIOL CHEM, vol. 282, no. 5, 2007, pages 3196 - 3204;;NIXON ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, no. 2, 2006, pages 261 - 8;;GUAN ET AL., PNAS, vol. 95, 1998, pages 13206 - 10;;A. COBOS-CORREA: ""Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation"", NATURE CHEMICAL BIOLOGY, vol. 5, no. 9, 2009, pages 628 - 63;;S. GEHRIG: ""Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters"", ANGEW. CHEM. INT. ED., vol. 51, 2012, pages 6258 - 6261;;STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39;;KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141;;TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157;;KANEKO, Y.NIMMERJAHN, F.RAVETCH, J. V.: ""Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"", SCIENCE, vol. 313, 2006, pages 670 - 3, XP008076047, DOI: 10.1126/science.1129594;;WANG, W. ET AL.: ""Impact of methionine oxidation in human IgGl Fc on serum half-life of monoclonal antibodies"", MOL IMMUNOL, vol. 48, 2011, pages 860 - 6, XP028143840, DOI: 10.1016/j.molimm.2010.12.009;;TEICHER, B. A.: ""Antibody-drug conjugate targets"", CURR CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004",PENDING
206,AU,A1,AU 2016/323612 A1,196-940-368-951-540,2018-02-22,2018,AU 2016/323612 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/196-940-368-951-540,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,ACTIVE
207,US,A1,US 2020/0224165 A1,018-649-448-032-829,2020-07-16,2020,US 201716319517 A,2017-07-07,US 201716319517 A;;US 201662365492 P;;US 2017/0041088 W,2016-07-22,METHODS AND COMPOSITIONS FOR REJUVENATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (2016-10-03),https://lens.org/018-649-448-032-829,Patent Application,yes,4,0,2,2,0,C12N5/0647;;C12N2501/22;;C12N5/0647;;C12N2501/22;;A61K38/193;;A61M1/3496;;A61K31/395;;A61K2035/124;;A61M1/38;;A61K35/28,C12N5/0789,,9,9,039-627-843-244-690;;055-862-358-315-66X;;000-862-479-142-907;;025-365-599-694-183;;037-476-829-034-648;;016-847-831-571-176;;134-582-783-288-663;;068-983-930-323-787;;031-710-621-857-375,21934652;;10.1038/mt.2011.181;;pmc3255589;;17046578;;10.1016/j.exphem.2006.06.012;;8831605;;10.1016/s0016-5085(96)70078-1;;10.1038/74731;;10742157;;10.1182/blood-2005-02-0468;;15890685;;15665846;;10.1038/sj.bmt.1704805;;10.1007/s12026-009-8107-8;;19224139;;16761001;;10.1038/nm0606-610;;10.1158/1078-0432.ccr-10-2505;;21676926;;pmc3593121,"Nitahara et alLong-term Engraftment of Multipotent Mesenchymal Stromal Cells That Differentiate to Form Myogenic Cells in Dogs With Duchenne Muscular Dystrophy, Molecular Therapy 20(1): 168-177, 2012;;Yannaki et al, Exp. Hematol. 34: 1583-1587, 2006;;Rajvanshi et al, Gastroenterology 111: 1092-1102, 1996;;Wekerle et al, Nature 6(4): 464-469, 2000;;Flomenberg et al, Blood 106(5): 1867-1874, 2005;;Milone et al, Bone Marrow Transplantation 35: 521-522, 2005;;Aiuti et al, Immunol. Res. 44: 150-159, 2009;;Purton et al, Nature Medicine 12(6): 610-611, 2006;;Shiozawa et al, Clin. Cancer Res. 17(17): 5553-5558, 2011",DISCONTINUED
208,WO,A1,WO 2016/007518 A1,051-976-515-123-187,2016-01-14,2016,US 2015/0039385 W,2015-07-07,US 201462021532 P,2014-07-07,AUTOMATIC SEGMENTATION AND QUANTITATIVE PARAMETERIZATION OF BRAIN TUMORS IN MRI,"Techniques, systems, and devices are described for implementing automatic segmentation and quantitative parameterization of MRI images. For example, the disclosed method includes processing the MRI image to correct any distortions; performing a preliminary segmentation of the MRI image to assign a tissue label of a set of tissue labels to one or more preliminary volumes of voxels of the MRI image; comparing each voxel of the MRI image with the one or more preliminary volumes of voxels with an assigned tissue label and assigning each voxel of the MRI image a probability of being associated with each tissue label of the set of tissue labels; and assigning each voxel of the MRI image a tissue label according to its greatest probability among probabilities for each voxel being associated with the set of tissue labels.",UNIV CALIFORNIA,CHEN CLARK;;STEED TYLER;;CARTER BOB S;;DALE ANDERS M,,https://lens.org/051-976-515-123-187,Patent Application,yes,7,10,3,3,0,G01R33/5608;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G06V2201/03;;G06V10/764;;G06V10/7788;;G06T7/0012;;G06T2207/10088;;G06T2207/20128;;G06T2207/30016;;G06T7/11;;G01R33/5608;;G06V2201/03;;G06V2201/031;;G06F18/24147;;G06F18/41;;G06F18/2415;;G06V10/764;;G06V10/7788;;G06T7/187;;G06T2207/20081;;G06T2207/30096,G06V10/764,,0,0,,,,PENDING
209,ZA,B,ZA 201800975 B,064-585-900-045-270,2020-05-27,2020,ZA 201800975 A,2018-02-13,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,CATHERINE JORAND-LEBRUN;;RUOXI LAN;;AUSTIN CHEN;;RYAN C CLARK,,https://lens.org/064-585-900-045-270,Granted Patent,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,,,0,0,,,,ACTIVE
210,SG,A,SG 11201506088R A,068-971-386-147-346,2015-09-29,2015,SG 11201506088R A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,,GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/068-971-386-147-346,Unknown,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,PENDING
211,DE,D1,DE 60303567 D1,080-068-709-787-043,2006-04-20,2006,DE 60303567 T,2003-06-12,US 39155702 P,2002-06-25,Herstellungsverfahren eines unterstützten Mischoxidkatalysators durch physikalische oder chemikalische Dampfphasenabscheidung,,ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE;;GAFFNEY ANNE MAE,,https://lens.org/080-068-709-787-043,Granted Patent,no,0,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J23/00;;B01J37/00;;B01J23/20;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,EXPIRED
212,WO,A1,WO 2014/164503 A1,141-661-085-154-093,2014-10-09,2014,US 2014/0022623 W,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/141-661-085-154-093,Patent Application,yes,55,18,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,38,27,042-233-175-582-26X;;143-862-943-589-725;;025-805-731-142-930;;003-338-632-019-904;;074-787-113-780-602;;046-783-448-716-481;;083-071-649-888-913;;016-716-200-807-517;;013-795-151-218-458;;081-762-551-590-027;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;076-152-531-431-484;;113-720-510-689-403;;064-343-550-244-269;;047-364-936-221-939;;015-623-518-697-144;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X,10.1016/s0022-1759(97)00192-0;;9692846;;10541351;;9930678;;10.1093/protein/11.12.1277;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;18536555;;10.1097/ppo.0b013e318172d704;;10.1021/ar700108g;;17705444;;10.1016/j.coph.2005.04.008;;15951239;;9780179;;10.4049/jimmunol.161.8.4083;;10.1006/meth.1995.9996;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;3061521;;10.1016/b978-0-409-90042-2.50030-1;;388229;;10.1038/282039a0;;389741;;10.1016/0378-1119(79)90029-5;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365,"QU Z ET AL: ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 213, no. 2, 15 April 1998 (1998-04-15), pages 131 - 144, XP002103672, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(97)00192-0;;LEUNG S O ET AL: ""The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH OCT 1999, vol. 5, no. 10 Suppl, October 1999 (1999-10-01), pages 3106s - 3117s, XP002727052, ISSN: 1078-0432;;WANG M ET AL: ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules"", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 12, 1 January 1998 (1998-01-01), pages 1277 - 1283, XP002345837, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.12.1277;;JAGATH R JUNUTULA ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 26, no. 8, 1 August 2008 (2008-08-01), pages 925 - 932, XP002623992, ISSN: 1087-0156, [retrieved on 20080720], DOI: 10.1038/NBT.1480;;JUNUTULA JAGATH R ET AL: ""Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OCT 2010, vol. 16, no. 19, 1 October 2010 (2010-10-01), pages 4769 - 4778, XP002727053, ISSN: 1078-0432;;CARTER PAUL J ET AL: ""Antibody-drug conjugates for cancer therapy"", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 14, no. 3, 1 May 2008 (2008-05-01), pages 154 - 169, XP009146579, ISSN: 1528-9117, DOI: 10.1097/PPO.0B013E318172D704;;RAVI V J CHARI: ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"", ACCOUNTS OF CHEMICAL RESEARCH, ACS, WASHINGTON, DC, US, vol. 41, no. 1, 1 January 2008 (2008-01-01), pages 98 - 107, XP008146241, ISSN: 0001-4842, [retrieved on 20070812], DOI: 10.1021/AR700108G;;POLAKIS ET AL: ""Arming antibodies for cancer therapy"", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 382 - 387, XP027625386, ISSN: 1471-4892, [retrieved on 20050801];;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th edition,"", 1991, U.S. DEPT. HEALTH AND HUMAN SERVICES;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ASHKENAZI ET AL., METHODS, vol. 8, no. 2, 1995, pages 104 - 115;;KOIDE ET AL., METHODS MOL. BIOI., vol. 352, 2007, pages 95 - 109;;STUMPP ET AL., DRUG DISCOV. TODAY, vol. 13, no. 15-16, 2008, pages 695 - 701;;NYGREN ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2668 - 76;;SKERRA ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2677 - 83;;EBERSBACH ET AL., J. MOL. BIOD., vol. 372, no. 1, 2007, pages 172 - 85;;KREHENBRINK ET AL., J. MOL. BIOI., vol. 383, no. 5, 2008, pages 1058 - 68;;SILVERMAN ET AL., NAT. BIOTECHNOL., vol. 23, no. 12, 2005, pages 1556 - 61;;GRABULOVSKI ET AL., J BIOL CHEM, vol. 282, no. 5, 2007, pages 3196 - 3204;;NIXON ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, no. 2, 2006, pages 261 - 8;;DRICKAMER K; TAYLOR ME: ""Introduction to Glycobiology 2nd ed."", 2006;;GUAN ET AL., PNAS, vol. 95, 1998, pages 13206 - 10;;MURRAY, J. NUC. MED., vol. 26, 1985, pages 3328;;CARRAGUILLO ET AL., J. NUC. MED., vol. 26, 1985, pages 67;;A. COBOS-CORREA: ""Membrane-bound FRETprobe visualizes MMP12 activity in pulmonary inflammation"", NATURE CHEMICAL BIOLOGY, vol. 5, no. 9, 2009, pages 628 - 63;;S. GEHRIG: ""Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters"", ANGEW. CHEM. INT. ED., vol. 51, 2012, pages 6258 - 6261;;HERMANSON, G.T.: ""Bioconjugate Techniques"", 1996, ACADEMIC PRESS;;ARNOLD S. FREEDMAN; LEE M. NADLER ET AL.: ""HARRISON'S PRINCIPLES OF INTERNAL MEDICINE"", 1994, article ""Malignant Lymphomas"", pages: 1774 - 1788;;BRUCE A CHABNER ET AL.: ""GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS"", 1996, article ""Antineoplastic Agents"", pages: 1233 - 1287;;RIDGWAY, A. A. G.: ""Mammalian Expression Vectors"", 1988, BUTTERWORTHS, pages: 470 - 472;;STINCHCOMB, NATURE, vol. 282, 1979, pages 39;;KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141;;TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157;;JONES, GENETICS, vol. 85, 1977, pages 12;;KANEKO, Y.; NIMMERJAHN, F.; RAVETCH, J. V.: ""Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"", SCIENCE, vol. 313, 2006, pages 670 - 3, XP008076047, DOI: doi:10.1126/science.1129594;;WANG, W. ET AL.: ""Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies"", MOLIMMUNOL, vol. 48, 2011, pages 860 - 6, XP028143840, DOI: doi:10.1016/j.molimm.2010.12.009;;STEFANO ET AL., METHODS IN MOLECULAR BIOLOGY, 2013;;TEICHER, B. A.: ""Antibody-drug conjugate targets"", CURR CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004",PENDING
213,CA,C,CA 2996318 C,181-367-320-693-171,2023-10-10,2023,CA 2996318 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/181-367-320-693-171,Granted Patent,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,PENDING
214,CN,A,CN 106089578 A,032-968-838-231-183,2016-11-09,2016,CN 201610270968 A,2016-04-27,DK PA201570888 A;;IB 2015001448 W,2015-04-27,Method for operating wind turbine based on degeneration of wind turbine blades,"The invention discloses a method for operating a wind turbine based on degeneration of wind turbine blades. The invention relates to a control method and a wind turbine for adaptively adjusting operation of the wind turbine, thereby sustaining maximal electric power production in a degeneration period. A control system comprises an estimator module. The estimator module determines a proportion factor based on a set of current control signals and the measured value of at least one current operation parameters. The proportion factor is transmitted to a control module. The control module performs conversion based on the proportion factor for obtaining at least oen air dynamics performance of a rotor. The control module furthermore determines an ideal setting of the control signal based on the converted air dynamics performance. According to the control method, the air dynamics performance is obtained through conversion, thereby representing better actually degenerated air dynamics performance.",ENVISION ENERGY (JIANGSU) CO LTD,KITCHENER CLARK WILSON(US);;LIN CHEN;;YUPING SUN;;FENG ZHANG,,https://lens.org/032-968-838-231-183,Patent Application,no,6,6,6,8,0,F03D7/0224;;F03D7/044;;F03D7/046;;F03D7/0224;;F03D7/043;;F03D7/044;;F03D7/046;;F03D9/25;;F03D9/25;;F03D17/00;;F03D80/40;;F03D80/40;;F05B2270/1033;;F05B2270/20;;F05B2270/20;;F05B2270/30;;F05B2270/336;;F05B2270/336;;F05B2270/602;;F05B2270/705;;Y02E10/72;;Y02E10/72,F03D7/02;;F03D7/04,,0,0,,,,ACTIVE
215,KR,A,KR 20150126023 A,084-465-091-725-565,2015-11-10,2015,KR 20157027621 A,2014-03-10,US 201361776710 P;;US 201361776715 P;;US 201361776724 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"카바트 넘버링에 따른 아미노산 위치 (114)에 조작된 N-연결 글리코실화 부위를 갖는 CH1 도메인 (예를 들어, 인간 IgG1 CH1 도메인)을 포함하는 결합 폴리펩티드 (예를 들어, 항체) 및 그의 이펙터 모이어티 접합체를 제공한다. 또한, 항원-결합 폴리펩티드를 코딩하는 핵산, 상기 항원-결합 폴리펩티드를 제조하기 위한 재조합 발현 벡터 및 숙주 세포를 제공한다. 질환을 치료하기 위해 본원에 개시된 항원-결합 폴리펩티드를 사용하는 방법을 또한 제공한다.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/084-465-091-725-565,Patent Application,no,0,1,88,165,82,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/10;;C07K16/28;;C07K16/32,,2,0,,,"J.R. Junutula 등, Nature Biotechnology, Vol.26, No.8, p.925-932 (2008.08.)*;;Z. Qu 등, Journal of Immunological Methods, Vol.213, p.131-144 (1998)*",ACTIVE
216,CN,A,CN 1231663 A,092-550-350-568-207,1999-10-13,1999,CN 97198356 A,1997-07-24,US 2293396 P,1996-08-01,Arthropodicidal and fungicidal cyclic amides,,DU PONT,BROWN R J;;CHEN D M-T;;CLARK D A,,https://lens.org/092-550-350-568-207,Patent Application,no,0,2,7,7,0,A01N43/653;;A01N43/78;;A01N43/80;;A01N43/82;;C07D401/04;;C07D249/12;;C07D261/12;;C07D401/12;;C07D403/04;;C07D403/12;;C07D403/14;;C07D413/12;;C07D417/12;;C07D417/14;;C07F7/0812;;C07F7/1804,A01N43/653;;A01N43/78;;A01N43/80;;A01N43/82;;A01N43/836;;A01N43/84;;C07D249/12;;C07D261/12;;C07D401/04;;C07D401/12;;C07D403/04;;C07D403/10;;C07D403/12;;C07D403/14;;C07D405/12;;C07D413/12;;C07D417/12;;C07D417/14;;C07F7/08;;C07F7/18;;C07F7/30,,0,0,,,,DISCONTINUED
217,CN,A,CN 115413222 A,143-423-798-455-637,2022-11-29,2022,CN 202180025237 A,2021-04-21,US 202063014232 P;;US 2021/0028283 W,2020-04-23,Soybean promoter and application thereof,"Provided herein are promoters and related compositions and methods of use. Such promoters are useful in expression cassettes in plants such as soybean. Such expression cassettes are useful, for example, to drive expression of trait genes in plants such as soybean. In some aspects, the disclosure provides expression cassettes comprising a promoter, a 5 'UTR, and an intron.",SYNGENTA PARTICIPATIONS AG,CHEN ZHONGYING;;ZHOU NAN;;CLARK V JAMES D;;QUE QIUDENG,,https://lens.org/143-423-798-455-637,Patent Application,no,6,0,5,5,0,C12N15/8216;;Y02A40/146;;C12N15/8205;;C12N15/8261,A01H6/54;;C07K14/415;;C12N15/11,,0,0,,,,PENDING
218,US,B2,US 9969710 B2,157-533-694-844-449,2018-05-15,2018,US 201615267606 A,2016-09-16,US 201615267606 A;;US 201562220358 P,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2016-10-17),https://lens.org/157-533-694-844-449,Granted Patent,yes,12,22,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,A61K31/4439;;A61K31/4184;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;C07D471/08,,21,16,053-041-511-200-033;;088-902-381-301-89X;;048-216-169-484-878;;018-960-566-924-993;;027-013-467-518-974;;095-716-273-533-92X;;013-862-057-494-226;;007-364-858-655-289;;051-933-822-151-495;;003-604-589-168-97X;;026-362-629-080-389;;011-166-598-579-298;;077-295-491-167-117;;003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033,19217767;;10.1016/j.ceb.2009.01.015;;10.1016/j.cyto.2007.12.012;;pmc2377356;;18249132;;10.1126/science.271.5252.1128;;8599092;;10.1126/science.278.5343.1612;;9374458;;10383454;;10.1074/jbc.274.27.19403;;pmc122810;;11960013;;10.1073/pnas.082100399;;10.1016/j.bmcl.2008.04.042;;18501603;;10.1002/jps.2600660104;;833720;;10.1021/jo00300a010;;10.1021/jo00391a029;;8130206;;10.1021/bi00176a024;;10.1093/carcin/16.4.683;;7728943;;10.1002/0471220574;;10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8,"Cohen, Current Opinion in Cell Biology 21, 317-324 (2009.;;Ringwood and Li, Cytokine 42, 1-7 (2008).;;Cao et al., Science 271(5252): 1128-31 (1996).;;Muzio et al., Science 278(5343): 1612-5 (1997).;;Wesche et al. J. Biol. Chem. 274(27): 19403-10 (1999).;;Li et al. Proc. Natl. Acad. Sci. USA 99(8):5567-5572 (2002).;;Buckley et al. Bioorg Med Chem Lett. 18(12):3656-60 (2008).;;Periodic Table of the Elements, CAS Version, Handbook of Chemistry and Physics, 75th Ed.;;“Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito (1999).;;“March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: (2001).;;S. M. Berge et al., J. Pharmaceutical Sciences, 66, 1-19 (1977).;;Hanzlik et al., J. Org. Chem. 55, 3992-3997 (1990).;;Reider et al., J. Org. Chem. 52, 3326-3334 (1987).;;Foster, Adv. Drug Res. 14, 1-40 (1985).;;Gillette et al., Biochemistry 33(10) 2927-2937 (1994).;;Jarman et al., Carcinogenesis 16(4), 683-688 (1993).;;Philip J. Kocienski, “Protecting Groups”, Georg Thieme Verlag Stuttgart, New York, (1994).;;Theodora W. Greene and Peter G. M. Wuts, “Protective Groups in Organic Synthesis”, Wiley Interscience, 3rd Edition (1999).;;Ding et al., Bioorganic and Medicinal Chemistry Letters, (24):3113-3117 (2014).;;Hranjec et al., European Journal of Medicinal Chemistry, 59:111-119 (2012).;;Sovic et al., Chemical Monthly, Vienna 146(9):1503-1517 (2015).",ACTIVE
219,AU,A1,AU 2016/323613 A1,015-475-153-682-043,2018-03-01,2018,AU 2016/323613 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/015-475-153-682-043,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,ACTIVE
220,WO,A1,WO 2023/150066 A1,024-889-758-167-454,2023-08-10,2023,US 2023/0011779 W,2023-01-27,US 202263306287 P,2022-02-03,PROCESS FOR SELECTIVELY DEPOSITING HIGHLY-CONDUCTIVE METAL FILMS,"Provided is a process comprising a selective ruthenium seed layer deposition with oxygen-free ruthenium precursors, followed by bulk deposition of metal-containing precursors such as tungsten, molybdenum, cobalt, ruthenium, and/or copper-containing precursors. The ruthenium seed layer deposition is highly selective for the conducting portions of the microelectronic device substrate while minimizing deposition onto the insulating surfaces of the microelectronic device substrate. In certain embodiments, the conducting portions of the substrate is chosen from titanium nitride, tungsten nitride, tantalum nitride, tungsten, cobalt, molybdenum, aluminum, and copper.",ENTEGRIS INC,CHEN PHILIP S H;;HENDRIX BRYAN CLARK;;CAMERON THOMAS M,,https://lens.org/024-889-758-167-454,Patent Application,yes,5,0,3,3,0,C23C16/18;;C23C16/45553;;H01L21/28562;;H01L21/28556;;H01L21/76876;;H01L21/28568;;H01L21/76843;;C23C16/14;;C23C16/45523;;C23C16/0281;;C23C16/04;;C23C16/045;;H01L21/28568;;H01L21/76843;;H01L21/76876;;C23C16/14,C23C16/06;;C23C16/04;;C23C16/455;;C23C16/515;;C23C16/52,,0,0,,,,PENDING
221,DE,T2,DE 60303567 T2,110-131-748-611-222,2006-09-21,2006,DE 60303567 T,2003-06-12,US 39155702 P,2002-06-25,Herstellungsverfahren eines unterstützten Mischoxidkatalysators durch physikalische oder chemische Dampfphasenabscheidung,,ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE;;GAFFNEY ANNE MAE,,https://lens.org/110-131-748-611-222,Granted Patent,no,0,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J23/00;;B01J37/00;;B01J23/20;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,EXPIRED
222,ES,T3,ES 2911524 T3,142-632-832-328-928,2022-05-19,2022,ES 16778936 T,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Compuestos heteroarilo como inhibidores de IRAK y sus usos,"Compuesto de fórmula I, **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, donde: **(Ver fórmula)** se selecciona entre **(Ver fórmula)** cada Ra es independientemente -R, halógeno, -haloalquilo C1-6, -OR, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R o -N(R)2; El anillo X es un arilo C3-10; un anillo heteroarilo monocíclico de 5-6 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre; un arilo C3-10 fusionado, un anillo carbocíclico fusionado de 5- 10 átomos saturado o parcialmente insaturado, un anillo heterocíclico fusionado de 5-10 átomos que tiene 1-4 hetero- átomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico fu- sionado de 5-10 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; R1 es -R, halógeno, -haloalquilo C1-6, -OR, - SR, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R o -N(R)2; -CN, R2 es -R, halógeno, -haloalquilo C1-6, -OR, -SR, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R o -N(R)2; -CN, R3 es - R o -haloalquilo C1-6; R4 es -R, halógeno, -haloalquilo C1-6, -OR, -SR, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R o -N(R)2; -CN, Z es N o CR; cada R es independientemente hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, arilo C3-10, un anillo carbocíclico de 3-8 átomos saturado o parcialmente insaturado, un anillo heterocíclico de 3-7 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5-6 áto- mos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; o se toman dos grupos R del mismo átomo junto con el átomo al que están unidos para formar un arilo C3-10, un anillo carbocíclico de 3-8 átomos saturado o parcialmente insaturado, un anillo heterocíclico de 3-7 átomos que tiene 1- 4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocí- clico de 5-6 átomos que tiene 1-4 heteroátomos, seleccionados independientemente entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; y p es 0, 1, 2, 3, 4 o 5; donde cuando un grupo está «opcionalmente sustituido» significa la sustitución de uno, dos, tres o más de los átomos de hidrógeno de los mismos con uno o más sustituyentes seleccionados independientemente entre el grupo com- puesto por: -F, -Cl, -Br, -I, deuterio, -OH, hidroxi protegido, alcoxi, oxo, tiooxo, -NO2, -CN, CF3, N3, -NH2, amino prote- gido, -NH-alquilo, -NH-alquenilo, -NH-alquinilo, - NH-cicloalquilo, -NH-arilo, -NH-heteroarilo, -NH-heterocíclico, -dial- quilamino, -diarilamino, -diheteroarilamino, -O-alquilo, -O-alquenilo, -O-alquinilo, -O-cicloalquilo, -O-arilo, -O-heteroa- rilo, -O-heterocíclico, -C(O)-alquilo, -C(O)-alquenilo, -C(O)-alquinilo, -C(O)-carbociclilo, -C(O)-arilo, -C(O)-heteroa- rilo, -C(O)-heterociclilo, -CONH2, -CONH-alquilo, -CONH-alquenilo, -CONH-alquinilo, -CONH-carbociclilo, -CONH- arilo, -CONH-heteroarilo, -CONH-heterociclilo, -OCO2-alquilo, -OCO2-alquenilo, -OCO2-alquinilo, -OCO2-carboci- clilo, -OCO2-arilo, -OCO2-heteroarilo, -OCO2-heterociclilo, -OCONH2, -OCONH-alquilo, -OCONH-alquenilo, -OCONH- alquinilo, -OCONH-carbociclilo, -OCONH-arilo, -OCONH-heteroarilo, -OCONH-heterociclilo, -NHC(O)-al- quilo, -NHC(O)-alquenilo, -NHC(O)-alquinilo, -NHC(O)-carbociclilo, -NHC(O)-arilo, -NHC(O)-heteroarilo, -NHC(O)-he- terociclilo, -NHCO2-alquilo, -NHCO2-alquenilo, -NHCO2-alquinilo, -NHCO2-carbociclilo, -NHCO2-arilo, -NHCO2-hete- roarilo, -NHCO2-heterociclilo, -NHC(O)NH2, -NHC(O)NH-alquilo, -NHC(O)NH-alquenilo, -NHC(O)NH-alqui- nilo, -NHC(O)NH-carbociclilo, -NHC(O)NH-arilo, -NHC(O)NH-heteroarilo, -NHC(O)NH-heterociclilo, NHC(S)NH2, -NHC(S)NH-alquilo, -NHC(S)NH-alquenilo, -NHC(S)NH-alquinilo, -NHC(S)NH-carbociclilo, -NHC(S)NH- arilo, -NHC(S)NH-heteroarilo, -NHC(S)NH-heterociclilo, -NHC(NH)NH2, -NHC(NH)NH-alquilo, -NHC(NH)NH-alque- nilo, -NHC(NH)NH-alquenilo, -NHC(NH)NH-carbociclilo, -NHC(NH)NH-arilo, -NHC(NH)NH-heteroarilo, -NHC(NH)NH- heterociclilo, -NHC(NH)-alquilo, -NHC(NH)-alquenilo, -NHC(NH)-alquinilo, -NHC(NH)-carbociclilo, -NHC(NH)- arilo, -NHC(NH)-heteroarilo, -NHC(NH)-heterociclilo, -C(NH)NH-alquilo, -C(NH)NH-alquenilo, -C(NH)NH-alqui- nilo, -C(NH)NH-carbociclilo, -C(NH)NH-arilo, -C(NH)NH-heteroarilo, -C(NH)NH-heterociclilo, -S(O)-alquilo, -S(O)-al- quenilo, -S(O)-alquinilo, -S(O)-carbociclilo, -S(O)-arilo, - S(O)-heteroarilo, -S(O)-heterociclilo -SO2NH2, -SO2NH-al- quilo, -SO2NH-alquenilo, -SO2NH-alquinilo, -SO2NH-carbociclilo, -SO2NH-arilo, -SO2NH-heteroarilo, -SO2NH-hetero- coclilo, -NHSO2-alquilo, -NHSO2-alquenilo, -NHSO2-alquinilo, -NHSO2-carbociclilo, -NHSO2-arilo, -NHSO2-heteroa- rilo, -NHSO2-heterociclilo, -CH2NH2, -CH2SO2CH3, -mono-, di- o tri-alquil sililo, -alquilo, - alquenilo, -alquinilo, -arilo, -ari- lalquilo, -heteroarilo, -heteroarilalquilo, -heterocicloalquilo, -cicloalquilo, -carbocíclico, -heterocíclico, polialcoxialquilo, polialcoxi, -metoximetoxi, -metoxietoxi, -SH, -S-alquilo, -S-alquenilo, -S-alquinilo, -S-carbociclilo, -S-arilo, -S-heteroa- rilo, -S-heterociclilo o metiltiometilo.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/142-632-832-328-928,Granted Patent,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,ACTIVE
223,CA,C,CA 2996316 C,156-776-109-346-191,2023-10-17,2023,CA 2996316 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"Disclosed are compounds of Formula I (see formula I) and pharmaceutically acceptable salts thereof. Selected compounds are useful as IRAK inhibitors including diseases and disorders affected by IRAK inhibition, which may include, but are not limited to, forms of arthritis, forms of Lupus, forms of sclerosis, diabetes, gastrointestinal disorders, Alzheimer's disease, Parkinson's disease and cancer.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/156-776-109-346-191,Granted Patent,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,PENDING
224,SG,A,SG 10201806033T A,018-277-954-130-400,2019-02-27,2019,SG 10201806033T A,2018-07-13,US 201715664446 A,2017-07-31,IMPROVED ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE,"IMPROVED ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE OF THE DISCLOSURE A coated component is generally provided, along with methods of forming such a coating system. The coated component includes a substrate having a surface with a coating system thereon. The coating system may include a columnar thermal barrier coating (TBC) over the surface of the substrate, with the columnar TBC including surface-connected voids. An intermediate layer is over the columnar TBC layer. The intermediate layer has a surface opposite of the columnar TBC that is rougher than the surface of the columnar TBC. A second TBC is over the intermediate layer. [Figure 1]",GEN ELECTRIC,CHEN DIANYING;;FU MING;;CLARK MICHAEL DAVID;;KONITZER DOUGLAS GERARD,,https://lens.org/018-277-954-130-400,Unknown,no,0,0,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,,,0,0,,,,PENDING
225,CN,A,CN 108602776 A,035-366-091-400-401,2018-09-28,2018,CN 201680065303 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/035-366-091-400-401,Patent Application,no,8,1,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,3,0,,,"KEJIA DING等: ""Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site"", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》;;MARIJANA HRANJEC等: ""Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: Cell death mechanisms and determination of crystal structure"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》;;IRENA SOVIC等: ""Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis, and biological tests"", 《MONATSH CHEM》",ACTIVE
226,US,B2,US 11555200 B2,030-779-740-674-976,2023-01-17,2023,US 201916405105 A,2019-05-07,US 201916405105 A;;US 201113132186 A;;US 2009/0066560 W;;US 12027308 P,2008-12-05,Regulation of cotton fiber growth by extracellular nucleotides and ectoapyrases,"The present invention includes compositions and methods of modulating the length of one or more cotton fibers in a plant by contacting the plant or tissue derived therefrom with at least one of: a nucleotide; a modulator of ectoapyrase gene transcription; or an anti-ectoapyrase antibody or fragments thereof, at a concentration that modulates growth of one or more cotton fibers.",UNIV TEXAS,ROUX STANLEY J;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY,,https://lens.org/030-779-740-674-976,Granted Patent,yes,10,0,5,5,4,C12N9/14;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N9/14,C12N15/82;;C12N9/14,,74,66,016-348-047-424-854;;006-181-967-002-57X;;000-047-739-257-25X;;058-032-369-859-095;;081-108-383-235-766;;036-778-709-216-823;;029-003-834-392-079;;019-876-688-940-996;;068-644-293-733-399;;052-550-347-907-422;;054-525-689-639-366;;120-105-695-732-576;;019-782-939-356-878;;027-125-197-437-82X;;068-161-445-618-853;;074-961-646-672-111;;044-708-170-990-212;;044-315-528-175-267;;048-716-004-650-277;;010-628-065-087-300;;056-791-889-923-18X;;070-047-330-919-747;;036-778-709-216-823;;062-945-046-727-283;;077-142-740-872-291;;008-590-281-641-131;;121-256-667-721-76X;;018-953-374-470-872;;015-442-533-126-611;;110-213-864-658-852;;036-256-831-736-269;;029-879-944-027-992;;065-286-086-202-871;;000-844-913-606-809;;001-651-428-677-983;;002-847-968-000-261;;149-359-421-826-949;;035-898-799-654-500;;059-279-138-190-727;;058-586-846-368-059;;053-320-807-975-913;;108-992-060-441-74X;;027-105-286-561-998;;012-109-108-492-364;;032-758-645-130-356;;104-112-393-718-758;;051-275-984-945-528;;019-876-688-940-996;;029-003-834-392-079;;044-511-245-341-155;;016-553-029-865-659;;088-332-023-656-728;;015-097-046-748-742;;042-751-225-249-722;;005-738-433-372-41X;;039-333-580-937-562;;133-554-075-235-611;;030-618-957-547-92X;;008-349-154-640-514;;137-815-281-701-984;;005-930-167-858-854;;028-544-000-539-877;;001-859-255-429-393;;008-186-751-659-690;;008-382-403-384-086;;017-841-618-351-392,10.1111/j.1365-313x.2008.03733.x;;18980645;;10.1073/pnas.182204199;;pmc129380;;12181491;;10.1046/j.1365-313x.2001.00976.x;;11260498;;10.1038/nbt936;;14758366;;pmc3002239;;10.1093/molbev/msq204;;20736450;;11743074;;pmc1540163;;10.1104/pp.010724;;10.1104/pp.127.4.1361;;17928260;;10.1016/j.tplants.2007.09.003;;10.1104/pp.107.097568;;pmc1914212;;17434987;;pmc1276027;;10.1105/tpc.105.036806;;16199612;;10.1016/j.jmb.2004.05.028;;15223320;;pmc1221403;;10.1042/0264-6021:3510639;;10.1042/bj3510639;;11042118;;16414200;;10.1016/j.neuroscience.2005.11.039;;10.1111/jpi.12129;;24571270;;pmc2151711;;18056866;;10.1104/pp.107.107672;;10.1007/pl00006994;;25017166;;10.1016/j.plantsci.2014.06.002;;10.1104/pp.114.1.295;;9159952;;pmc158305;;23758901;;10.1111/jipb.12077;;10.1006/bbrc.1996.0162;;8579614;;23349362;;pmc3585596;;10.1104/pp.112.203760;;10.1105/tpc.104.023945;;15367717;;pmc520962;;pmc2254475;;10.1007/s11302-005-3981-6;;18404482;;11743074;;pmc1540163;;10.1104/pp.010724;;10.1104/pp.127.4.1361;;pmc1630726;;16963521;;10.1104/pp.106.085670;;10.1007/s11302-010-9214-7;;pmc3083126;;21484095;;pmc2759220;;10.1093/aob/mcm232;;17905721;;10.1007/s00425-010-1246-2;;20711605;;10.1111/j.1469-8137.2007.02120.x;;17635221;;pmc3982762;;10.1104/pp.113.233429;;24550243;;10.1111/j.1365-313x.2007.03144.x;;17565582;;pmc2151707;;17951461;;10.1104/pp.107.105676;;10.1038/447138a;;17495900;;7721538;;10.1016/s0074-7696(08)62487-0;;10.1007/bf00193840;;27301434;;10.1038/srep27883;;pmc4908599;;10.1007/s00344-012-9260-1;;10.3389/fpls.2013.00214;;23805149;;pmc3690342;;10.1139/b95-081;;10.1073/pnas.171304098;;11504909;;pmc56987;;10.2144/02335st02;;12449379;;12640467;;10.1038/nbt809;;10.1007/s11103-007-9184-5;;17534719;;10.1016/j.plaphy.2013.04.022;;23728389;;10.1016/j.bbamcr.2008.01.024;;18302942;;10.1007/s002100000309;;11111825;;10.1104/pp.103.027052;;pmc219034;;12972649;;pmc166876;;12644663;;10.1104/pp.102.010926;;10.1104/pp.107.097568;;pmc1914212;;17434987;;17928260;;10.1016/j.tplants.2007.09.003;;10.1042/bj20150235;;26338998;;10.1104/pp.111.193151;;pmc3375956;;22430844;;10.1007/s11302-006-9003-5;;18404480;;pmc2254478;;10.1098/rstb.2003.1441;;15253361;;pmc1693356;;19036836;;10.1104/pp.108.128728;;pmc2633840;;11043467;;10.1094/mpmi.2000.13.10.1053;;12972043;;10.1016/s1369-5266(03)00081-5;;10.1093/pcp/pcs131;;23034877;;10.1016/j.bbagen.2004.09.006;;15652174;;16179357;;10.1093/pcp/pci201;;16461577;;pmc1383640;;10.1105/tpc.105.040303;;10.1186/1471-2229-12-123;;pmc3511161;;22849572;;pmc1906782;;10.1186/1471-2229-7-22;;17506877;;10.1104/pp.013672;;12529523;;pmc166795;;pmc32131;;10.1104/pp.119.2.543;;9952450;;pmc4379058;;25822168;;10.1371/journal.pone.0115832;;pmc161145;;8672885;;10.2307/3870289;;10.1105/tpc.8.5.873,"Kondou et al. (2009) Plant J 57(5):883-94.;;Klahre et al. (2002) Proc Nat'l Acad Sci 99:11981-86.;;Thomas et al. (2001) Plant J 25:417-25.;;Reynolds et al. (2004) Nature Biotech 22(3):326-30.;;Hanada et al. (2011) Mol Biol Evol 28(1):377-82.;;Kim & Triplett (2001) Plant Physiol 127:1361-66.;;Roux & Steinebruner (2007) Trends Plant Sci 12(11):522-27.;;Wu et al. (2007) Plant Physiol 144:961-75.;;Chivasa et al. (2005) Plant Cell 17:3019-34.;;Cai et al. (2011) Textil Res J 81:239-46.;;Bendtsen, Jannick Dyrlov, et al., Improved Prediction of Signal Peptides—Signal P 3.0, J. Mol. Biol., (2004), 22 pages.;;Braun et al., “Sequencing, functional expression and characterization of rat NTPDase6, a nucleoside diphosphatase and novel member of the ecto-nucleoside triphosphate diphosohohydrolase family,” Biochem J. 351:639-647, 2000.;;Wink et al., “Nucleoside Triphosphate Diphosphohydrolase-2 (Ntpdase2/Cd39I1) is the Dominant Ectonucleotidase Expressed by Rat Astrocytes,” Neuroscience 138:421-432, 2006.;;Byeon et al., An increase in melatonin in transgenic rice causes pleiotropic phenotypes, including enhanced seedling growth, delayed flowering, and low grain yield, J. Pineal Res. 56:408-414, 2014.;;Chen, et al., “Toward Sequencing Cotton (Gossypium) Genomes,” Plant Physiology, Dec. 2007, vol. 145, pp. 1303-1310.;;Chen, J. G., et al., “Levels of Cytokinins in the Ovules of Cotton Mutants with Altered Fiber Development”, Journal of Plant Growth Regulation (1997) 16:181-185.;;Clark et al., “Breakthroughs spotlighting roles for extracellular nucleotides and apyrases in stress responses and growth and development,” Plant Science 225:107-116, 2014.;;Clark et al., “Extracellular ATP levels are higher in growth of primary roots of wild-type Arabidopsis seedlings and are changed by altered expression of apyrase enzymes and auxin transporters,” abstract 600:020, ASPB Plant Biology Meeting, Jun. 2017, Honolulu.;;Gendreau et al., “Cellular Basis of Hypocotyl Growth in Arabidopsis thaliana,” Plant Physiol. 114:295-305, 1997.;;Gu et al., “Targeting and Regulation of Cell Wall Synthesis During Tip Growth in Plants,” Journal of Integrative Plant Biology 55(9):835-846, 2013.;;Handa et al., “Purification and Cloning of a Soluble ATP-Diphosphohydrolase (Apyrase) from Potato Tubers (Solanum tuberosum),” Biochemical and Biophysical Research Communications 218:916-923, 1996.;;Huang, G., et al., A Fasciclin-Like Arabinogalactan Protein, GhFLA1, Is Involved in Fiber Initiation and Elongation of Cotton1[C][W][OA], Plant Physiology, Mar. 2013, vol. 161, pp. 1278-1290.;;International Search Report and Written Opinion for PCT/US2009/066560, dated Aug. 18, 2010, 14 pages.;;Jeter, Collene R., et al., “Evidence of a Novel Cell Signaling Role for Extracellular Adenosine Triphosphates and Diphosphates in Arabidopsis,” The Plant Cell, vol. 16, Oct. 2004, pp. 2652-2664.;;Jeter, Collene R., et al., “Plant Responses to Extracellular Nucleotides: Cellular Processes and Biological Effects,” Purinergic Signalling, (2006), vol. 2, pp. 443-449.;;Kim, Hee Jin, et al., “Cotton Fiber Growth in Planta and in Vitro. Models for Plant Cell Elongation and Cell Wall Biogenesis,” Plant Physiology, Dec. 2001, vol. 127, pp. 1361-1366.;;Kim, Sung-Yong, et al., “Extracellular ATP in Plants. Visualization, Localization, and Analysis of Physiological Significance in Growth and Signaling,” Plant Physiology, Nov. 2006, vol. 142, pp. 984-992.;;Knowles, “The GDA1_CD39 superfamily: NTPDases with diverse functions,” Purinergic Signaling 7:21-45, 2011.;;Lee, Jinsuk J., et al., “Gene Expression Changes and Early Events in Cotton Fibre Development,” Annals. of Botany, (2007), vol. 100, pp. 1391-1401.;;Lee, Joohyun, et al., “Xyloglucan endotransglycosylase/hydrolase genes in cotton and their role in fiber elongation”, Planta (2010) 232:1191-1205 DOI 10.1007/s00425-010-1246-2.;;Li, Hong-Bin, et al., “A Cotton Ascorbate Peroxidase is Involved in Hydrogen Peroxide Homeostasis During Fibre Cell Development,” New Phytologist, (2007), vol. 175, pp. 462-471.;;Lim et al., “Apyrase Suppression Raises Extracellular ATP Levels and Induces Gene Expression and Cell Wall Changes Characteristic of Stress Responses,” Plant Physiology 164:2054-2067, 2014.;;Luo, Ming, et al., “GhDET2, a Steriod 5a-Reductase, Plays an Important Role in Cotton Fiber Cell Initiation and Elongation,” The Plant Journal, (2007), vol. 51, pp. 419-430.;;Panikashvili, David, et al., “The Arabidopsis Desperado/AtWBC11 Transporter is Required for Cutin and Wax Secreation,” Plant Physiology, Dec. 2007, vol. 145, pp. 1345-1360.;;Pearson, “The Good, the Bad and the Ugly,” Nature 447:138-140, 2007.;;Plesner, “Ecto-ATPases: Identities and Functions,” Int. Rev. Cytol. 158:141-214, 1995.;;Ravnikar, M., et al., “Stimulatory Effects of Jasmonic Acid on Potato Stem Node and Protoplast Culture”, Journal of Plant Growth Regulation (1992) 11:29-33.;;Stiff et al., “Cotton fiber tips have diverse morphologies and show evidence of apical cell wall synthesis,” Scientific Reports 6:27883, 2016.;;Tan, J., et al., “Exogenous Jasmonic Acid Inhibits Cotton Fiber Elongation”, Journal Plant Growth Regulation (2012) 31:599-605 DOI 10.1007/s00344-012-9260-1.;;Tanz et al., “Fluorescent protein tagging as a tool to define the subcellular distribution of proteins in plants,” Frontiers in Plant Science 4:1-9, 2013.;;Tiwari et al., “Cotton (Gossypium hirsutum) seed trichomes expand via diffuse growing mechanism,” Can. J. Bot. 73:746-757, 1995.;;Werner, T., et al., “Regulation of plant growth by cytokinin”, PNAS, Aug. 28, 2001, vol. 98, No. 18, 10489.;;Windsor, J.B., et al., “Automated Colorimetric Screen for Apyrase Inhibitors,” BioTechniques, Nov. 2002, vol. 33, pp. 1024-1030.;;Windsor, Brian, et al., “Multiherbicide Tolerance Conferred by AtPgp1 and Apyrase Overexpression in Arabidopsis Thaliana,” Nature Biotechnology, Apr. 2003, vol. 21, pp. 428-433.;;Wolf, Carolin, et al., “Developmental Defects and Seedling Lethality in Apyrase AtAPY1 and AtAPY2 Double Knockout Mutants,” Plant Mol. Biol., (2007), vol. 64, pp. 657-672.;;Yang et al., “Co-regulation of exine wall patterning, pollen fertility and anther dehiscence by Arabidopsis apyrases 6 and 7,” Plant Physiology and Biochemistry 69:62-73, 2013.;;Yegutkin, “Nucleotide- and nucleoside-converting extoenzymes: Important modulators of purinergic signalling cascade,” Biochimica et Biophysica Acta 1783:673-694, 2008.;;Zimmerman, Naunyn Schmiedebergs Arch Pharmacol 362:299-309 (2000).;;Zhu, Yong-Qing, et al., “An ATP-Binding Cassette Transporter GhWBC1 From Elongating Cotton Fibers,” Plant Physiology, Oct. 2003, vol. 133, pp. 580-588.;;Navarro-Gochicoa et al., Plant Physiol 131:1124-36 (2003).;;Wu, Functional analyses of two Arabidopsis apyrases. Doctoral Dissertation. p. 1-98. Univ. Texas, Austin (Dec. 2007).;;Wu, Jian, et al., “Apyrases (Nucleoside Triphosphate-Diphosphohydrolases) Play a Key Role in Growth Control in Arabidopsis,” Plant Physiology, Jun. 2007, vol. 144, pp. 961-975.;;Roux, Stanley J., et al., “Extracellular ATP: An Unexpected Role as a Signaler in Plants,” Trends in Plant Science, vol. 12, No. 11, 2007, pp. 522-527.;;Chiu et al., Biochem J 472:43-54 (2015).;;Parsons et al., Plant Physiol 159:12-26 (2012).;;Steinebrunner et al., Plant Physiol Biochem 38:912-22, 914 (2000).;;Robson et al., Purinergic Signal 2:409-30 (2006).;;Crane, Phil Trans Biol Sci 359(1444):735-37 (2004).;;Govindarajula et al., Plant Physiol 149:994-1004 (2009).;;Day et al., MPMI 13(10) 153-70 (2000).;;Zhang, Curr Opin Plant Biol 6:430-40 (2003).;;Chiu et al., Plant Cell Physiol 53:1913-25, 1915 (2012).;;Chapman, Numbers Living Species in Australia and the World, 2nd ed. (2009).;;Leal et al., Biochim Biophys Acta 1721:9-15 (2005).;;He et al., Plant Cell Physiol. 46(11):1848-1854 (2005).;;Shi, Yong-Hui, et al., “Transcriptome Profiling, Molecular Biological, and Physiological Studies Reveal a Major Role for Ethylene in Cotton Fiber Cell Elongation,” The Plant Cell, Mar. 2006, vol. 18, pp. 651-664.;;Shiller et al., BMC Plant Biol 12:123 (2012).;;Taliercio, Earl W., et al., “Analysis of Gene Expression in Cotton Fiber Initials,” BMC Plant Biology, (2007).;;Tang, Wenqiang, et al., “Extracellular ATP Inhibits Root Gravitropism at Concentrations that Inhibit Polar Auxin Transport,” Plant Physiology, Jan. 2003, vol. 131, pp. 147-154.;;Thomas, Collin, et al., “Apyrase Functions in Plant Phosphate Nutrition and Mobilizes Phosphate from Extracellular ATP,” Plant Physiology, Feb. 1999, vol. 119, pp. 543-551.;;Massalski et al., PLOS One 10:e0115832 (2015).;;Stoynova-Bakalova et al., New Physiol 62:471-79 (2004).;;GenBank, Accession GU365147.1. p. 1-2.;;Narasimhulu et al., Early transcription of Agrobacterium T-DNA genes in tobacco and maize. 1996. Plant Cell. 8:873-886.",ACTIVE
227,US,A1,US 2003/0236163 A1,075-196-111-097-502,2003-12-25,2003,US 46073003 A,2003-06-12,US 46073003 A;;US 39155702 P,2002-06-25,PVD supported mixed metal oxide catalyst,"
   A supported catalyst comprising a mixed metal oxide is useful for the vapor phase oxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated carboxylic acid and for the vapor phase ammoxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated nitrile. 
",CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE;;GAFFNEY ANNE MAE,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE;;GAFFNEY ANNE MAE,ROHM AND HAAS COMPANY (2003-04-14),https://lens.org/075-196-111-097-502,Patent Application,yes,22,30,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J23/00;;B01J37/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,502/305;;502/304;;502/308;;502/309;;502/325;;502/326;;502/334;;502/335;;502/336;;502/337;;502/338;;502/339;;502/202,0,0,,,,EXPIRED
228,IL,B2,IL 258082 B2,093-798-255-920-730,2023-02-01,2023,IL 25808218 A,2018-03-13,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Bezimidazole derivatives and pharmaceutical compositions containing them,,MERCK PATENT GMBH;;JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/093-798-255-920-730,Unknown,no,9,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,A61K31/4184;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/16;;A61P25/28;;A61P35/00,,0,0,,,,PENDING
229,NZ,A,NZ 739742 A,136-921-419-063-691,2022-03-25,2022,NZ 73974216 A,2016-09-16,US 2016/0052107 W;;US 201562220358 P,2015-09-18,Heteroaryl compounds as irak inhibitors and uses thereof,"The present invention relates to benzimidazole derivatives of Formula (I) and pharmaceutically acceptable compositions thereof, useful as interleukin-1 receptor-associated kinase (IRAK) inhibitors.",MERCK PATENT GMBH,LAN RUOXI;;JORAND-LEBRUN CATHERINE;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/136-921-419-063-691,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,PENDING
230,EP,A1,EP 3424956 A1,174-539-885-433-507,2019-01-09,2019,EP 18187892 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;EP 14714881 A;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/174-539-885-433-507,Patent Application,yes,55,3,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,36,26,042-233-175-582-26X;;143-862-943-589-725;;025-805-731-142-930;;003-338-632-019-904;;074-787-113-780-602;;046-783-448-716-481;;083-071-649-888-913;;016-716-200-807-517;;081-762-551-590-027;;005-218-993-322-382;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;076-152-531-431-484;;113-720-510-689-403;;047-364-936-221-939;;015-623-518-697-144;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X,10.1016/s0022-1759(97)00192-0;;9692846;;10541351;;9930678;;10.1093/protein/11.12.1277;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;18536555;;10.1097/ppo.0b013e318172d704;;10.1021/ar700108g;;17705444;;10.1016/j.coph.2005.04.008;;15951239;;10.1006/meth.1995.9996;;17041261;;10.1385/1-59745-187-8:95;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;388229;;10.1038/282039a0;;389741;;10.1016/0378-1119(79)90029-5;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365,"QU Z ET AL: ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 213, no. 2, 15 April 1998 (1998-04-15), pages 131 - 144, XP002103672, ISSN: 0022-1759, DOI: 10.1016/S0022-1759(97)00192-0;;LEUNG S O ET AL: ""The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH OCT 1999, vol. 5, no. 10 Suppl, October 1999 (1999-10-01), pages 3106s - 3117s, XP002727052, ISSN: 1078-0432;;WANG M ET AL: ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules"", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 12, 1 January 1998 (1998-01-01), pages 1277 - 1283, XP002345837, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.12.1277;;JAGATH R JUNUTULA ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 26, no. 8, 1 August 2008 (2008-08-01), pages 925 - 932, XP002623992, ISSN: 1087-0156, [retrieved on 20080720], DOI: 10.1038/NBT.1480;;JUNUTULA JAGATH R ET AL: ""Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer."", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 OCT 2010, vol. 16, no. 19, 1 October 2010 (2010-10-01), pages 4769 - 4778, XP002727053, ISSN: 1078-0432;;CARTER PAUL J ET AL: ""Antibody-drug conjugates for cancer therapy"", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 14, no. 3, 1 May 2008 (2008-05-01), pages 154 - 169, XP009146579, ISSN: 1528-9117, DOI: 10.1097/PPO.0B013E318172D704;;RAVI V J CHARI: ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"", ACCOUNTS OF CHEMICAL RESEARCH, ACS, WASHINGTON, DC, US, vol. 41, no. 1, 1 January 2008 (2008-01-01), pages 98 - 107, XP008146241, ISSN: 0001-4842, [retrieved on 20070812], DOI: 10.1021/AR700108G;;POLAKIS ET AL: ""Arming antibodies for cancer therapy"", CURRENT OPINION IN PHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 5, no. 4, 1 August 2005 (2005-08-01), pages 382 - 387, XP027625386, ISSN: 1471-4892, [retrieved on 20050801];;ASHKENAZI ET AL., METHODS, vol. 8, no. 2, 1995, pages 104 - 115;;KOIDE ET AL., METHODS MOL. BIOL., vol. 352, 2007, pages 95 - 109;;STUMPP ET AL., DRUG DISCOV. TODAY, vol. 13, no. 15-16, 2008, pages 695 - 701;;NYGREN ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2668 - 76;;SKERRA ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2677 - 83;;EBERSBACH ET AL., J. MOL. BIOL., vol. 372, no. 1, 2007, pages 172 - 85;;KREHENBRINK ET AL., J. MOL. BIOL., vol. 383, no. 5, 2008, pages 1058 - 68;;SILVERMAN ET AL., NAT. BIOTECHNOL., vol. 23, no. 12, 2005, pages 1556 - 61;;GRABULOVSKI ET AL., J BIOL CHEM, vol. 282, no. 5, 2007, pages 3196 - 3204;;NIXON ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, no. 2, 2006, pages 261 - 8;;DRICKAMER K; TAYLOR ME: ""Introduction to Glycobiology, 2nd ed"", 2006;;GUAN ET AL., PNAS, vol. 95, 1998, pages 13206 - 10;;MURRAY, J. NUC. MED., vol. 26, 1985, pages 3328;;CARRAGUILLO ET AL., J. NUC. MED., vol. 26, 1985, pages 67;;A. COBOS-CORREA: ""Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation"", NATURE CHEMICAL BIOLOGY, vol. 5, no. 9, 2009, pages 628 - 63;;GEHRIG: ""Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters"", ANGEW. CHEM. INT. ED., vol. 51, 2012, pages 6258 - 6261;;HERMANSON, G.T.: ""Bioconjugate Techniques"", 1996, ACADEMIC PRESS;;KURT J. ISSELBACHER ET AL: ""HARRISON'S PRINCIPLES OF INTERNAL MEDICINE, 13th ed"", 1994, article ARNOLD S. FREEDMAN; LEE M. NADLER ET AL.: ""Malignant Lymphomas"", pages: 1774 - 1788;;JOEL G. HARDMAN ET AL: ""GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 9th ed."", 1996, article BRUCE A CHABNER ET AL.: ""Antineoplastic Agents"", pages: 1233 - 1287;;RODRIGUEZ AND DENHARDT: ""Mammalian Expression Vectors"", 1988, article RIDGWAY, A. A. G.: ""Chapter 24.2"", pages: 470 - 472;;STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39;;KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141;;TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157;;JONES, GENETICS, vol. 85, 1977, pages 12;;KANEKO, Y.; NIMMERJAHN, F.; RAVETCH, J. V.: ""Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"", SCIENCE, vol. 313, 2006, pages 670 - 3, XP008076047, DOI: doi:10.1126/science.1129594;;WANG, W. ET AL.: ""Impact of methionine oxidation in human IgGl Fc on serum half-life of monoclonal antibodies"", MOL IMMUNOL, vol. 48, 2011, pages 860 - 6, XP028143840, DOI: doi:10.1016/j.molimm.2010.12.009;;STEFANO ET AL., METHODS IN MOLECULAR BIOLOGY, 2013;;TEICHER, B. A.: ""Antibody-drug conjugate targets"", CURR CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004",DISCONTINUED
231,US,A1,US 2018/0237426 A1,187-263-055-616-555,2018-08-23,2018,US 201815959686 A,2018-04-23,US 201815959686 A;;US 201615267565 A;;US 201562220307 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/187-263-055-616-555,Patent Application,yes,0,3,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D498/08,,0,0,,,,ACTIVE
232,CA,C,CA 2902525 C,055-745-579-912-190,2023-12-05,2023,CA 2902525 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/055-745-579-912-190,Granted Patent,no,0,0,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,PENDING
233,EP,A1,EP 2970469 A1,126-866-481-245-099,2016-01-20,2016,EP 14714881 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,,GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2018-07-18),https://lens.org/126-866-481-245-099,Patent Application,yes,0,3,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,ACTIVE
234,US,B2,US 8078185 B2,197-038-211-317-453,2011-12-13,2011,US 41592409 A,2009-03-31,US 41592409 A,2009-03-31,User group-based adaptive soft frequency reuse method to mitigate downlink interference for wireless cellular networks,"A novel soft fractional frequency reuse (FFR) technique is disclosed. The novel FFR technique includes reuse partition and power restriction, dynamic user grouping, channel quality indicator feedback based on reuse, and a user group-based interference aware scheduler. The FFR technique reduces co-channel interference for cell edge users.",SUN HONGMEI;;YANG HUA;;TALWAR SHILPA;;HIMAYAT NAGEEN;;CHEN CLARK;;INTEL CORP,SUN HONGMEI;;YANG HUA;;TALWAR SHILPA;;HIMAYAT NAGEEN;;CHEN CLARK,INTEL CORPORATION (2009-03-31),https://lens.org/197-038-211-317-453,Granted Patent,yes,6,26,2,2,0,H04W16/10;;H04W16/10,H04W72/00;;H04B1/00;;H04B1/38;;H04B7/00;;H04B7/212;;H04J1/00;;H04L5/22;;H04L12/16;;H04L27/28,455/450;;375/147;;375/141;;375/260;;370/330;;370/329;;370/260;;370/343;;455/452.1;;455/452.2;;455/561;;455/522,0,0,,,,INACTIVE
235,BR,A,BR 0301955 A,014-041-979-031-218,2004-08-24,2004,BR 0301955 A,2003-06-20,US 39155702 P,2002-06-25,"Processo para a preparação de um catalisador suportado, catalisador, e, processo catalìtico","""PROCESSO PARA A PREPARAçãO DE UM CATALISADOR SUPORTADO, CATALISADOR, E, PROCESSO CATALìTICO"". Um catalisador suportado compreendendo um óxido de metal misturado é útil para a oxidação de fase de vapor de um alcano ou uma mistura de um alcano e um alqueno em um ácido carboxílico insaturado e para a amoxidação de fase de vapor de um alcano ou uma mistura de um alcano e um alqueno em uma nitrila insaturada.",ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE;;GAFFNEY ANNE MAE,,https://lens.org/014-041-979-031-218,Patent Application,no,0,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,DISCONTINUED
236,US,B2,US 10494439 B2,035-401-636-167-074,2019-12-03,2019,US 201715614015 A,2017-06-05,US 201715614015 A;;US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/035-401-636-167-074,Granted Patent,yes,112,4,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K47/54;;A61K47/68;;C07K16/28;;C07K16/30;;C07K16/32;;C07K16/40;;C12N15/09;;C12N15/11;;C12N15/63,,100,89,027-477-313-726-928;;013-142-717-038-23X;;013-452-637-389-025;;010-673-495-194-66X;;017-882-810-578-23X;;092-890-446-683-93X;;075-912-302-795-48X;;025-805-731-142-930;;050-877-021-901-567;;002-771-789-858-985;;153-263-439-316-208;;013-142-717-038-23X;;036-975-782-541-190;;032-870-057-378-750;;100-801-934-296-913;;011-629-800-752-356;;084-230-129-207-67X;;032-476-801-692-751;;075-192-332-107-331;;024-566-886-688-557;;156-222-375-677-941;;012-014-436-857-578;;045-729-053-464-650;;042-810-773-450-504;;056-471-233-133-22X;;093-834-126-228-444;;136-900-289-011-574;;026-844-281-977-583;;005-237-901-039-197;;060-802-427-932-669;;039-987-734-111-45X;;143-883-026-349-057;;021-635-324-390-465;;023-084-573-306-134;;001-738-124-789-726;;088-402-699-481-535;;013-688-922-444-741;;103-031-843-607-684;;109-417-981-751-748;;066-847-171-955-046;;003-339-819-702-214;;087-412-910-091-181;;032-720-983-972-675;;048-510-345-009-61X;;136-414-621-541-929;;046-783-448-716-481;;018-007-265-921-231;;033-955-564-406-161;;083-071-649-888-913;;076-152-531-431-484;;004-272-966-072-139;;023-630-635-437-312;;113-720-510-689-403;;037-751-049-527-007;;080-596-177-983-981;;001-329-438-412-588;;062-544-695-545-247;;060-056-896-118-940;;038-305-867-383-662;;028-401-996-299-149;;058-985-409-440-786;;003-338-632-019-904;;074-787-113-780-602;;023-249-219-470-807;;045-974-352-776-610;;015-623-518-697-144;;005-218-993-322-382;;015-458-200-457-953;;013-977-769-158-191;;143-862-943-589-725;;143-898-600-120-153;;039-183-048-383-873;;043-016-539-897-20X;;028-456-569-502-585;;008-019-042-176-997;;016-716-200-807-517;;042-233-175-582-26X;;058-543-894-773-905;;013-795-151-218-458;;058-270-451-857-914;;106-158-572-918-727;;111-625-445-280-864;;013-885-021-097-853;;013-157-274-165-126;;004-458-031-333-650;;079-000-142-364-026;;006-053-610-642-017;;047-364-936-221-939;;039-331-124-493-196,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10556035;;10.1006/jmbi.1999.3141;;8943402;;10.4049/jimmunol.157.11.4963;;10.1023/a:1007533121682;;10870990;;10.1016/j.addr.2013.05.007;;23727341;;20025606;;10.2174/156800909790192365;;6248420;;10.1016/0378-1119(80)90133-x;;9930678;;10.1093/protein/11.12.1277;;21256596;;10.1016/j.molimm.2010.12.009;;10.4049/jimmunol.165.8.4505;;11035090;;1476621;;10556035;;10.1006/jmbi.1999.3141;;10.1097/00007890-199902270-00019;;10071034;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;18234994;;10.1167/iovs.07-1175;;10.1002/bit.21598;;17680659;;10.1021/bc1005416;;21417264;;10.1021/bc400505q;;24533768;;19036920;;10.1073/pnas.0810163105;;pmc2604916;;pmc2409116;;18420934;;10.1126/science.1154315;;17370997;;10.1021/bc060341n;;pmc3534963;;pmc2890185;;10.1182/blood-2009-12-257386;;20181615;;pmc3197974;;10.3109/10428194.2011.604755;;21756025;;10.1016/j.jmb.2009.06.048;;19559712;;pmc3182912;;21980295;;10.1371/journal.ppat.1002281;;pmc3241764;;10.1073/pnas.1105057108;;22114188;;14695221;;20684602;;10.1021/jm100612r;;pmc3651435;;23610394;;10.1073/pnas.1219888110;;10.2210/pdb1h3v/pdb;;10.2210/pdb1h3w/pdb;;10.1016/s0022-2836(02)01250-0;;12527303;;10.1002/anie.201402606;;24862406;;pmc4128391;;15791258;;10.1038/nature03408;;10.1007/s10719-013-9490-x;;23949787;;21429574;;10.1016/j.biomaterials.2010.11.068;;pmc3740328;;23787467;;pmc6557662;;10.1515/cclm-2013-0174;;10.1021/bi010475i;;11467948;;18771295;;pmc2628294;;10.1021/bi800874y;;23957305;;10.1021/ja407739y;;pmc3812917;;pmc2835178;;19277015;;10.1038/mt.2009.37;;520572;;10.1016/0014-5793(79)80559-1;;10.1021/bp050228w;;16321047;;10.1016/j.jim.2007.12.011;;18230399;;10.1006/jmbi.1997.1354;;9367782;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;pmc3464487;;10.1021/bc900103p;;19425533;;18536555;;10.1097/ppo.0b013e318172d704;;10.1002/anie.199612301;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;10.1038/nchembio.196;;19648933;;10.1038/nbt832;;12778055;;17628592;;10.1016/j.jmb.2007.06.045;;10.1002/anie.201109226;;22555935;;21632778;;10.1101/pdb.prot5633;;10.1074/jbc.m609211200;;17130124;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;8623165;;10.1097/00007890-199603270-00018;;10.1097/00007890-199601270-00032;;8600649;;10.1006/bbrc.2001.5382;;11500028;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.4049/jimmunol.148.12.3768;;1376340;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;10.1126/science.1129594;;16888140;;10.1021/ja038545r;;14692737;;389741;;10.1016/0378-1119(79)90029-5;;17041261;;10.1385/1-59745-187-8:95;;18822295;;10.1016/j.jmb.2008.09.016;;18577454;;10.1016/j.coi.2008.05.010;;10541351;;16566296;;pmc3065967;;21035459;;10.1016/j.jmb.2010.10.030;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1432-2277.2012.01456.x;;22420711;;15185369;;10.1002/cbic.200300806;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;10.1039/b604391g;;16791327;;9780179;;10.4049/jimmunol.161.8.4083;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;10.1002/micr.20294;;17066409;;7879044;;10.1021/ja00119a001;;10.4049/jimmunol.147.12.4366;;1836485;;11096108;;10.1074/jbc.m009483200;;10.1038/nbt1166;;16299519;;10.1111/j.1742-4658.2008.06439.x;;18435758;;388229;;10.1038/282039a0;;10.1016/j.drudis.2008.04.013;;18621567,"Rudikoff et al., PNAS 79: 1979-1983 (Year: 1982).;;Wu et al., J Mol Biol 294: 151-162 (Year: 1999).;;Lund et al., The Journal of Immunology 157:4963-4969 (Year: 1996).;;Anwer et al. (2000) “Synthetic Glycopeptide-Based Delivery Systems for Systemic Gene Targeting to Hepatocytes,” Pharm. Res. 17:451-459.;;Lepenies et al. (2013) “Targeting C-type lectin receptors with multivalent carbohydrate ligands,” Adv. Drug Delivery Rev. 65:1271-1281.;;Teicher (2009) “Antibody-drug conjugate targets,” Current Cancer Drug Targets. 9(8):982-1004.;;Tschumper et al. (1980) “Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene,” Gene. 10:157-166.;;Wang et al. (1998) “Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules,” Protein Engineering. 11:1277-1283.;;Wang et al. (2011) “Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies,” Molecular Immunology. 48(6):860-866.;;Williams et al. (2010) “Humanising Antibodies by CDR Grafting,” Ch. 21 In; Antibody Engineering. vol. 1. Eds: Kontermann et al. Springer-Verlag Berlin. Heidelberg, Germany. pp. 319-339.;;Winkler et al. (2000) “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,” J. Immunol. 265:4505-4514.;;Wright et al. (1992) “Genetically Engineered Antibodies: Progress and Prospects,” Critical Reviews in Immunology. 12:125-168.;;Wu et al. (1999) “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,” J. Mol. Biol. 294:151-162.;;Yamagami et al. (1999) “Suppression of Allograft Rejection with Anti-A8 T Cell Receptor Antibody in Rat Corneal Transplantation,” Transplantation. 67:600-604.;;Yoshino et al. (1992) “Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats.,” J. Exp. Med. 175:907-915.;;Yu et al. (2008) “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Investigative Ophthalmology & Visual Science. 49(2):522-527.;;Zhou et al. (2008) “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,” Biotechnol. Bioeng. 99:652-665.;;Zhou et al. (2011) “Strategies for Neoglycan Conjugation to Human Acid a-Glucosidase,” Bioconjugate Chemistry. 22:741-751.;;Zhou et al. (2014) “Site-Specific Antibody—Drug Conjugation through Glycoengineering,” Bioconjugate Chemistry. 25:510-520.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/003819, dated Jul. 17, 2013.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/059481, dated Feb. 7, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022623, dated Jul. 31, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022728, dated Oct. 9, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/021342, dated Jun. 8, 2015.;;Anthony et al. (2008) “Identification of a receptor required for the anti-inflammatory activity of IVIG,” Proc. Natl. Acad. Sci. USA. 105:19571-19578.;;Anthony et al. (2008) “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science. 320:373-376.;;Boeggeman et al. (2007) “Direct Identification of Nonreducing GlcNAc Residues on N-Glycans of Glycoproteins Using a Novel Chemoenzymatic Method,” Bioconjugate Chemistry. 18(3):806-814.;;Chen et al. (2010) “In vivo targeting of B-cell lymphoma with glycan ligands of CD22,” Blood. 115:4778-4786.;;Chen et al. (2012) “Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22,” Leukemia and Lymphoma. 53:208-210.;;Feige et al. (2009) “Structure of the murine unglycosylated IgG1 Fc fragment,” J. Mol Biol. 391:599-508.;;Ganesan et al. (2011) “Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium,” PLoS Pathogens. 7(9):e1002281. pp. 1-11.;;Hatekeyama et al. (2011) “Targeted Drug Delivery to Tumor Vasculature by a Carbohydrate Mimetic Peptide,” Proc. Natl. Acad. Sci. USA. 108:19587-19592.;;Hong et al. (2003) “Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells,” Cancer Res. 23:9023-9031.;;Hosoguchi (2010) “An efficient approach to the discovery of potent inhibitors against glycosyltransferases,” J. Med. Chem. 53:5607-5619.;;Kawasaki et al. (2013) “Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation,” Proc. Natl. Acad. Sci. USA. 110:7826-7831.;;Krapp et al. (2003) “Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity,” J. Mol. Biol. 325:979-898.;;Li et al. (May 23, 2014) “The Preparation of Well-Defined Antibody-Drug Conjugates Through Glycan Remodeling and Strain Promoted Azide-Alkyne Cycloadditions,” Angew. Chem., Int. Ed. 53(28):7179-7182.;;Mattner et al. (2005) “Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections,” Nature. 434:525-529.;;McCarthy (Aug. 16, 2013) “Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates,” Glycoconj. J. 30:857-870.;;Medina et al. (2011) “N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers,” Biomaterials. 32:4118-4129.;;Monnier et al. (2014) “Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications,” Clin. Chem. Lab. Med. 52:21-32.;;Murray (1985) “Imaging Findings and Pharmacaokinetics of 111-Indium ZME-018 Monoclonal Antibodies,” J. Nuc. Med. 26:P16. Abstract No. 55.;;Raju et al. (2011) “Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues,” Biochem. 40(30):8868-8876.;;Wei et al. (2008) “Glyco-engineering of human IgG1-Fc through combined yeast expression and in vitro chemoenzymatic glycosylation,” Biochem. 47(39):10294-10304.;;Zhou (Aug. 22, 2013) “Bioconjugation by native chemical tagging of C—H bonds.,” J. Am. Chem. Soc. 135:12994-12997.;;Zhu et al. (2009) “Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease,” Mol. Ther. 17(6):954-963.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/054651, dated Apr. 20, 2016.;;Bause et al. (1979) “Primary structural requirements for N-glycosylation of peptides in rat liver,” FEBS Letters. 108(2):341-344.;;Hodoniczky et al. (2005) “Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro,” Biotechnol. Prog. 21:1644-1652.;;Junutula et al. (2008) “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs,” Journal of Immunological Methods. 332:41-52.;;Al-Lazikani et al. (1997) “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol. 273:927-948.;;Axup et al. (Sep. 17, 2012) “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids,” Proc. Natl. Acad. Sci. USA. 109(40):16101-16106.;;Boeggeman et al. (2009) “Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection,” Bioconjugate Chemistry. 20:1228-1236.;;Carrasquillo et al. (1985) “Improved imaging of metastatic melanoma with high dose 9.2.27 In-11 1 monoclonal antibody,” J. Nuc. Med. 26:67. Abstract No. 276.;;Carter et al. (2008) “Antibody-drug conjugates for cancer therapy,” Caner Journal. 14:154-169.;;Cervigni et al. (1996) “Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation,” Angew. Chem., Int. Ed. 35(11):1230-1232.;;Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” The Journal of Immunology. 10:301-316.;;Chari (2008) “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs,” Accounts of Chemical Research. 41:98-107.;;Cobos-Correa et al. (2009) “Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation,” Nature Chemical Biology. 5(9):628-663.;;Doronina et al. (2003) “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nat. Biotech. 21(7):778-784.;;Ebersbach et al. (2007) “Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein,” Journal of Molecular Biology. 372(1):172-185.;;Gehrig et.al. (May 3, 2012) “Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters,” Angewandte Chemie International Edition. 51(25):6258-6261.;;Giudicelli et al. (Jun. 1, 2011) “IMGTN-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences,” Cold Springs Harbor Protocols. pp. 58-78.;;Grabulovski et al. (2007) “A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Proteins,” The Journal of Biological Chemistry. 282(5):3196-3204.;;Guan et al. (1998) “Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization,” Proc. Natl. Acad. Sci. USA. 95(22):13206-13210.;;Heidecke et al. (1996) “Alpha-Beta T Cell Receptor-Directed Therapy in Rat Allograft Recipients,” Transplantation. 61:948-956.;;Heidecke et al. (1996) “Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-NB-Targeted Therapy,” Transplantation 61:336-339.;;Jassal et al. (2001) “Sialylation of Human IgG-Fc Carbohydrate by Transfected Rat a2,6-Sialyltransferase,” Biochemical and Biophysical Research Communications. 286:243-249.;;Jones (1977) “Proteinase Mutants of Saccharomyces cerevisiae,” Genetics. 85:23-33.;;Jung et al. (1992) “Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta,” Journal of Immunology. 148:3768-3775.;;Junutula et al. (2008) “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” Nat. Biotechnol. 26:925-932.;;Junutula et al. (2010) “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer,” Clin. Cancer Res. 16:4769-4778.;;Kaneko et al. (2006) “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science. 313 (5787):670-673.;;Khidekel et al. (2003) “A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications,” J. Am. Chem. Soc. 125:16162-16163.;;Kingsman et al. (1979) “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trpl Region,” Gene. 7:141-152.;;Koide et al. (2007) “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain,” Methods in Molecular Biology. 352:95-109.;;Krehenbrink et al. (2008) “Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PuID,” Journal of Molecular Biology. 383(5):1058-1068.;;Labrijn et al. (2008) “When binding is enough: nonactivating antibody formats,” Curr. Opin. Immunol. 20:479-485.;;Leung et al. (1999) “The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments,” Clin. Cancer Res. 5:3106s-3117s.;;Martin (2010) “Protein Sequencing and Structure Analysis of Antibody Variable Domains,” Ch. 3 in; Antibody Engineenng. vol. 2. Eds: Kontermann et al. Springer-Verlag Berlin. Heidelberg, Germany. pp. 33-51.;;Nixon et al. (2006) “Engineered Protein Inhibitors of Proteases,” Current Opinion in Drug Discovery & Development. 9(2):261-268.;;North et al. (Oct. 28, 2010) “A new clustering of antibody CDR loop conformations,” J. Mol. Biol. 406:228-256.;;Nygren et al. (2008) “Alternative Binding Proteins: Affibody Binding Proteins Devloped from a Small Three-helix Bundle Scaffold,” The FEBS Journal. 275(11):2668-2676.;;Page et al. (2012) “Biologics in Organ Transplant,” Transplant International. 25:707-719.;;Piatesi et al. (2004) “Immunological optimization of a generic hydrophobic pocket for high affinity hapten binding and Diels-Alder activity,” ChemBio Chem 5:460-466.;;Polakis (2005) “Arming antibodies for cancer therapy,” Current Opinion in Pharmacology. 5:382-387.;;Qu et al. (1998) “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,” Journal of Immunological Methods. 213:131-144.;;Renaudet et al. (2006) “On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides,” Org. Biomol. Chem. 4:2628-2636.;;Roche Diagnostics (May 2013) “Alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data Sheet),” XP002727803. Retrieved from Internet: URL: hftps://cssportal.roche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf. [retrieved on Jul. 25, 2014].;;Roux et al. (1998) “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, 19E, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” Journal of Immunology. 161(8):4083-4090.;;Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,” Proc. Natl. Acad. Sci. USA. 105(51):20167-20172.—with supplementary information.;;Scharpf et al. (2006) “Immunomodulation with anti-anti-a[3T-cell receptor monoclonal antibodies in combination with cyclosporine a improves regeneration in nerve allografts,” Microsurgery. 26:599-607.;;Schorlemmer et al. (1995) “Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats,” Transplantation Proceedings. 27:414-416.;;Shao et al. (1995) “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages,” Journal of the American Chemical Society. 117(14):3893-3899.;;Shearman et al. (1991) “Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor,” The Journal of Immunology. 147:4366-4373.;;Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR,” J. Biol. Chem. 276:6591-6604.;;Silverman et al. (2005) “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains,” Nature Biotechnology. 23(12):1556-1561.;;Skerra et al. (2008) “Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activites,” The FEBS Journal. 275(11):2677-2683.;;Stinchcomb et al. (1979) “Isolation and Characterization of a Yeast Chromosomal Replicator,” Nature. 282:39-43.;;Stumpp et al. (2008) “DARPins: A New Generation of Protein Therpeutics,” Drug Discovery Today. 13(15-16):695-670.",ACTIVE
237,WO,A3,WO 2023/034628 A3,064-102-175-144-030,2023-04-13,2023,US 2022/0042586 W,2022-09-05,US 202163240666 P;;US 202163278039 P,2021-09-03,MIXTURE INCLUDING FERROELECTRIC NEMATIC PHASE AND METHODS OF FORMING AND USING SAME,"Material comprising a ferroelectric nematic phase, the material are disclosed. The material can include a mixture comprising first molecules and second molecules. At least one of a fluid of the first molecules and a fluid of the second molecules exhibits a ferroelectric nematic phase. The first molecules and second molecules are miscible. The first molecules can induce a polar orientational order of said second molecules.",UNIV COLORADO REGENTS,MACLENNAN JOSEPH;;CLARK NOEL;;GLASER MATTHEW;;CHEN XI;;SMITH GREGORY,,https://lens.org/064-102-175-144-030,Search Report,yes,2,0,2,2,0,C09K19/0225;;C09K2019/2078;;C09K2019/3422,G02F1/141;;C07C25/00;;C09K19/42;;G02F1/135;;G02F1/139,,1,1,198-022-728-942-50X,10.1080/02678292.2022.2058101,"ZHU, ZHECONG ; PARK, CHEOL ; CHEN, XI ; KORBLOVA, EVA ; GLASER, MATTHEW ; MACLENNAN, JOSEPH ; WALBA, DAVID ; CLARK, NOEL: ""Electro-optic study of the phase behavior of mixtures of two ferroelectric nematic liquid crystals"", APS MARCH MEETING 2021; MARCH 15–19, 2021, 30 November 2020 (2020-11-30), US, pages 1 - 1, XP009546676",PENDING
238,US,A1,US 2019/0032189 A1,080-850-105-188-162,2019-01-31,2019,US 201715664446 A,2017-07-31,US 201715664446 A,2017-07-31,ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE,"A coated component is generally provided, along with methods of forming such a coating system. The coated component includes a substrate having a surface with a coating system thereon. The coating system may include a columnar thermal barrier coating (TBC) over the surface of the substrate, with the columnar TBC including surface-connected voids. An intermediate layer is over the columnar TBC layer. The intermediate layer has a surface opposite of the columnar TBC that is rougher than the surface of the columnar TBC. A second TBC is over the intermediate layer.",GEN ELECTRIC,CHEN DIANYING;;FU MING;;CLARK MICHAEL DAVID;;KONITZER DOUGLAS GERARD,GENERAL ELECTRIC COMPANY (2017-07-27),https://lens.org/080-850-105-188-162,Patent Application,yes,0,2,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,C23C4/134;;C23C4/04,,0,0,,,,DISCONTINUED
239,US,B2,US 11807690 B2,087-531-618-220-152,2023-11-07,2023,US 201916655500 A,2019-10-17,US 201916655500 A;;US 201715614015 A;;US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/087-531-618-220-152,Granted Patent,yes,190,1,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,198,124,032-427-821-815-367;;027-880-661-246-429;;006-007-491-725-663;;052-467-514-351-787;;042-601-433-468-58X;;086-617-534-349-291;;077-406-419-134-117;;077-950-844-586-930;;032-720-983-972-675;;024-566-886-688-557;;075-192-332-107-331;;010-673-495-194-66X;;048-510-345-009-61X;;066-847-171-955-046;;136-414-621-541-929;;156-222-375-677-941;;041-863-374-864-841;;046-783-448-716-481;;018-007-265-921-231;;033-955-564-406-161;;083-071-649-888-913;;045-729-053-464-650;;012-014-436-857-578;;076-152-531-431-484;;004-272-966-072-139;;038-611-663-646-681;;023-630-635-437-312;;042-810-773-450-504;;056-471-233-133-22X;;113-720-510-689-403;;012-795-649-239-671;;037-751-049-527-007;;080-596-177-983-981;;001-329-438-412-588;;024-645-922-183-894;;093-834-126-228-444;;062-544-695-545-247;;003-339-819-702-214;;026-844-281-977-583;;066-983-118-990-009;;106-775-004-854-415;;028-401-996-299-149;;058-985-409-440-786;;003-338-632-019-904;;087-412-910-091-181;;074-787-113-780-602;;023-249-219-470-807;;005-237-901-039-197;;045-974-352-776-610;;015-623-518-697-144;;005-218-993-322-382;;060-802-427-932-669;;015-458-200-457-953;;013-977-769-158-191;;108-189-657-649-284;;017-882-810-578-23X;;143-862-943-589-725;;039-987-734-111-45X;;103-311-396-038-390;;143-883-026-349-057;;021-635-324-390-465;;023-084-573-306-134;;001-738-124-789-726;;131-466-064-832-733;;143-898-600-120-153;;039-183-048-383-873;;043-016-539-897-20X;;028-456-569-502-585;;008-019-042-176-997;;016-716-200-807-517;;042-233-175-582-26X;;071-306-244-240-05X;;088-402-699-481-535;;058-543-894-773-905;;013-795-151-218-458;;027-477-313-726-928;;058-270-451-857-914;;111-625-445-280-864;;015-134-258-276-433;;013-885-021-097-853;;013-157-274-165-126;;065-341-725-220-179;;004-458-031-333-650;;079-000-142-364-026;;006-053-610-642-017;;047-364-936-221-939;;039-331-124-493-196;;092-890-446-683-93X;;075-912-302-795-48X;;025-805-731-142-930;;050-877-021-901-567;;013-688-922-444-741;;097-207-733-781-885;;002-771-789-858-985;;153-263-439-316-208;;013-142-717-038-23X;;032-870-057-378-750;;100-801-934-296-913;;019-737-890-459-231;;066-795-715-073-024;;103-031-843-607-684;;011-629-800-752-356;;032-476-801-692-751;;109-417-981-751-748;;032-566-016-820-34X;;011-639-763-090-400;;119-478-163-586-308;;032-550-451-050-056;;118-842-100-913-06X;;004-989-332-514-167;;034-100-369-734-330;;039-987-734-111-45X;;003-740-674-013-733;;090-065-894-166-909;;012-850-592-077-235;;017-641-935-143-857;;008-912-660-885-354;;016-005-182-044-630;;120-563-486-439-523;;132-319-124-196-043;;028-562-361-664-672;;024-197-815-015-477;;077-056-641-270-884;;012-268-510-926-843,18974080;;10.1093/protein/gzn058;;10.1016/j.jmb.2003.09.054;;14596803;;10.1080/19420862.2017.1389355;;pmc5800364;;28991504;;10.1016/j.chembiol.2013.01.010;;23438745;;15520207;;10.1158/0008-5472.can-04-1722;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.1016/j.jim.2004.01.024;;15099763;;10.1016/j.molimm.2004.11.003;;15829301;;10.1006/jmbi.1997.1354;;9367782;;pmc2409116;;18420934;;10.1126/science.1154315;;19036920;;10.1073/pnas.0810163105;;pmc2604916;;10.1023/a:1007533121682;;10870990;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;520572;;10.1016/0014-5793(79)80559-1;;pmc3464487;;10.1021/bc900103p;;19425533;;17370997;;10.1021/bc060341n;;pmc3534963;;10.1016/0022-1759(95)00016-4;;7769243;;18536555;;10.1097/ppo.0b013e318172d704;;10.1002/anie.199612301;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;pmc3197974;;10.3109/10428194.2011.604755;;21756025;;pmc2890185;;10.1182/blood-2009-12-257386;;20181615;;10.1038/nchembio.196;;19648933;;10.1038/nbt832;;12778055;;10.1021/bc9002019;;19769391;;17628592;;10.1016/j.jmb.2007.06.045;;10.1016/j.jmb.2009.06.048;;19559712;;pmc3182912;;21980295;;10.1371/journal.ppat.1002281;;10.1002/anie.201109226;;22555935;;23774760;;pmc3906313;;10.4161/mabs.25161;;21632778;;10.1101/pdb.prot5633;;10.1074/jbc.m609211200;;17130124;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;17411062;;10.1021/ol0704946;;pmc3241764;;10.1073/pnas.1105057108;;22114188;;8623165;;10.1097/00007890-199603270-00018;;10.1021/bp050228w;;16321047;;20684602;;10.1021/jm100612r;;21866965;;10.1021/ja206023e;;pmc3187659;;22465822;;10.1016/j.abb.2012.03.021;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.4049/jimmunol.148.12.3768;;1376340;;10.1038/nbt.1480;;18641636;;10.1016/j.jim.2007.12.011;;18230399;;20805300;;10.1158/1078-0432.ccr-10-0987;;10.1126/science.1129594;;16888140;;pmc3651435;;23610394;;10.1073/pnas.1219888110;;10.1021/ja038545r;;14692737;;389741;;10.1016/0378-1119(79)90029-5;;17041261;;10.1385/1-59745-187-8:95;;10.2210/pdb1h3v/pdb;;10.2210/pdb1h3w/pdb;;10.1016/s0022-2836(02)01250-0;;12527303;;18822295;;10.1016/j.jmb.2008.09.016;;18577454;;10.1016/j.coi.2008.05.010;;10.1021/jm00123a007;;2783975;;10.1016/j.addr.2013.05.007;;23727341;;10541351;;10.1002/anie.201402606;;24862406;;pmc4128391;;10.1007/978-3-642-01147-4_3;;15791258;;10.1038/nature03408;;10.1007/s10719-013-9490-x;;23949787;;21429574;;10.1016/j.biomaterials.2010.11.068;;pmc3740328;;23787467;;pmc6557662;;10.1515/cclm-2013-0174;;10.1002/cbic.201100117;;pmc3151320;;21661087;;16566296;;pmc3065967;;21035459;;10.1016/j.jmb.2010.10.030;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1432-2277.2012.01456.x;;22420711;;15185369;;10.1002/cbic.200300806;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;10.1074/jbc.m100350200;;11297532;;10.1021/bi010475i;;11467948;;10.1039/b604391g;;16791327;;9780179;;10.4049/jimmunol.161.8.4083;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;7879044;;10.1016/0022-1759(87)90120-7;;3035026;;10.1021/ja00119a001;;10.4049/jimmunol.147.12.4366;;1836485;;1824850;;10.4049/jimmunol.146.3.928;;11096108;;10.1074/jbc.m009483200;;10.1038/nbt1166;;16299519;;10.1111/j.1742-4658.2008.06439.x;;18435758;;388229;;10.1038/282039a0;;10.1016/j.drudis.2008.04.013;;18621567;;20025606;;10.2174/156800909790192365;;6248420;;10.1016/0378-1119(80)90133-x;;9930678;;10.1093/protein/11.12.1277;;21256596;;10.1016/j.molimm.2010.12.009;;18771295;;pmc2628294;;10.1021/bi800874y;;10.1007/978-3-642-01144-3_21;;10.4049/jimmunol.165.8.4505;;11035090;;1476621;;10556035;;10.1006/jmbi.1999.3141;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;18234994;;10.1167/iovs.07-1175;;22052803;;10.1002/psc.1415;;23783454;;pmc6269833;;10.3390/molecules18067145;;23957305;;10.1021/ja407739y;;pmc3812917;;10.1002/bit.21598;;17680659;;10.1021/bc400505q;;24533768;;pmc2835178;;19277015;;10.1038/mt.2009.37;;pmc3661573;;10.1371/journal.pone.0063625;;23717456;;1547823;;10.1002/eji.1830220326;;10.1172/jci19836;;15146247;;10.1172/jci200419836;;pmc406524;;10.2217/imt.11.61;;21751954;;pmc3666312;;24441081;;10.4161/mabs.27876;;pmc3984323;;10.1097/00007890-199457110-00008;;10.1097/00007890-199406150-00008;;8009591;;10.1111/j.1399-3089.2004.00174.x;;15479462;;10.1002/anie.201402606;;24862406;;pmc4128391;;10.1080/19420862.2018.1548233;;30526254;;pmc6343770;;10.1002/art.1780370315;;8129796;;15681752;;10.1196/annals.1309.030;;17312017;;10.1124/dmd.106.013490;;10.1371/journal.pone.0100736;;24959685;;pmc4069079;;10.4161/mabs.1.3.8035;;20065649;;pmc2726584;;10.1002/ibd.20053;;17206665;;10.1021/bi00374a001;;3030393;;10.1271/nogeikagaku1924.72.1171;;21185301;;10.1016/j.jim.2010.12.014;;21614585;;10.1007/s10545-011-9337-1;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007,"Lloyd et al. Protein Engineering, Design & Selection 22:159-168 (Year: 2009).;;Edwards et al., J Mol Biol. 334(1): 103-118 (Year: 2003).;;Piche-Nicholas et al., MABS 10(1): 81-94 (Year: 2018).;;Strop et al., Chemistry and Biology 20: 161-167 (Year: 2013).;;Henry et al., Cancer Res. 64: 7995-8001 (Year: 2004).;;Stancovski et al., Proceedings of the National Academy of Science USA 88: 8691-8695 (Year: 1991).;;Cochran et al., J. Immunol. Meth. 287: 147-158 (Year: 2004).;;Riemer et al., Mol. Immunol. 42: 1121-1124 (Year: 2005).;;Al-Lazikani, et al. (Nov. 7, 1997) “Standard Conformations for the Canonical Structures of Immunoglobulins”, Journal of Molecular Biology, vol. 273, No. 4, pp. 927-948.;;Anthony, et al. (Apr. 18, 2018) “Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc”, Science, vol. 320, No. 5874, pp. 373-376.;;Anthony, et al. (Dec. 16, 2008) “Identification of a Receptor Required for the Anti-Inflammatory Activity of IVIG”, Proceedings of the National Academy of Sciences, vol. 105, No. 50, pp. 19571-19578.;;Anwer, et al. (Apr. 1, 2000) “Synthetic Glycopeptide-Based Delivery Systems for Systemic Gene Targeting to Hepatocytes”, Pharmaceutical Research, vol. 17, No. 4, pp. 451-459.;;Axup, et al. (Oct. 2, 2012) “Synthesis of Site-Specific Antibody-Drug Conjugates Using Unnatural Amino Acids”, Proceedings of the National Academy of Sciences, vol. 109, No. 40, pp. 16101-16106.;;Bause, et al. (1979) “Primary Structural Requirements for N-Glycosylation of Peptides in Rat Liver”, FEBS Letters, vol. 108, No. 2, pp. 341-344.;;Boeggeman, et al. (Jun. 17, 2009) “Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection”, Bioconjugate Chemistry, vol. 20, No. 6, pp. 1228-1236.;;Boeggeman, et al. (Mar. 20, 2007) “Direct Identification of Nonreducing GlcNAc Residues on N-Glycans of Glycoproteins Using a Novel Chemoenzymatic Method”, Bioconjugate Chemistry, vol. 18, No. 3, pp. 806-814.;;Brinkmann et al., “Phage Display Of Disulfide-Stabilized Fv Fragments”, Journal of Immunological Methods, 1995, vol. 182, No. 1, pp. 41-50.;;Carey et al., “Advanced Organic Chemistry”, Plenum Press, New York and London, 1978, p. 21.;;Carrasquillo, et al. (1985) “Improved Imaging of Metastatic Melanoma with High Dose 9.2. 27 In-111 Monoclonal Antibody”, Abstract No. 276, Journal of Nuclear Medicine, vol. 26, No. 5, pp. 67.;;Carter, et al. (May 1, 2008) “Antibody-Drug Conjugates for Cancer Therapy”, The Cancer Journal, vol. 14, No. 3, pp. 154-169.;;Cervigni, et al. (Jun. 17, 1996) “Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation”, Angewandte Chemie International Edition in English, vol. 35, No. 11, pp. 1230-1232.;;Chan, et al. (May 1, 2010) “Therapeutic Antibodies for Autoimmunity and Inflammation”, Nature Reviews Immunology, vol. 10, No. 5, pp. 301-316.;;Chari, Ravi V.J. (Jan. 1, 2008) “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs”, Accounts of Chemical Research, vol. 41, No. 1, pp. 98-107.;;Chen, et al. (Feb. 1, 2012) “Targeting B Lymphoma with Nanoparticles Bearing Glycan Ligands of CD22”, Leukemia & Lymphoma, vol. 53, No. 2, pp. 208-210.;;Chen, et al. (Jun. 10, 2010) “In Vivo Targeting of B-Cell Lymphoma with Glycan Ligands of CD22”, Blood, vol. 115, No. 23, pp. 4778-4786.;;Cobos-Correa, et al. (Sep. 2009) “Membrane-Bound FRET Probe Visualizes MMP12 Activity in Pulmonary Inflammation”, Nature Chemical Biology, vol. 5, No. 9, pp. 628-663.;;Doronina, et al. (Jul. 2003) “Development of Potent Monoclonal Antibody Auristatin Conjugates for Cancer Therapy”, Nature Biotechnology, vol. 21, No. 7, pp. 778-784.;;Ducry et al., (2010) “Antibody-conjugates: Linking Cytotoxic to Monoclonal Antibodies,” Bioconjugate Chem., 21:5-13.;;Ebersbach, et al. (2007) “Affilin-Novel Binding Molecules Based on Human Gamma-B-crystallin, An All Beta-Sheet Protein”, Journal on Molecular Biology, vol. 372, No. 1, pp. 172-185.;;Extended European Search Report received for European Patent Application No. 18166377.4, dated May 16, 2018, 7 Pages.;;Extended European Search Report received for European Patent Application No. 18187892.7, dated Nov. 19, 2018, 9 Pages.;;Feige, et al. (Aug. 21, 2009) “Structure of the Murine Unglycosylated IgG1 Fc Fragment”, Journal of Molecular Biology, vol. 391, Issue 3, pp. 599-608.;;Ganesan, et al. (Sep. 29, 2011) “Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium”, PLoS Pathogens, vol. 7, No. 9, e1002281, pp. 1-11.;;Gehrig, et al. (May 3, 2012) “Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters”, Angewandte Chemie International Edition, vol. 51, No. 25, pp. 6258-6261.;;Gion, et al. (May 31, 2013) “Expression of antibodies using single open reading frame (sORF) vector design: Demonstration of manufacturing feasibility.”, mAbs, vol. 5, No. 4, XP055258379, pp. 595-607.;;Giudicelli, et al. (Jun. 1, 2011) “IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences”, Cold Spring Harbor Protocols, vol. 6, pp. 58-78.;;Grabulovski, et al. (2007) “A Novel Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Properties”, Journal of Biological Chemistry, vol. 282, No. 5, pp. 3196-3204.;;Guan, et al. (Oct. 2, 1998) “Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization”, Proceedings of the National Academy of Sciences vol. 95, No. 22, pp. 13206-13210.;;Hanashima et al. (2007) “Syntheis of a Sialic Acid r(2-3) Galactose Building Block and Its Use in a Linear Synthesis of Sialyl Lewis X.,” Organic Letters, 9(9):1777-1779.;;Hatakeyama, et al. (Dec. 6, 2011) “Targeted Drug Delivery to Tumor Vasculature by A Carbohydrate Mimetic Peptide”, Proceedings of the National Academy of Sciences, vol. 108, No. 49, pp. 19587-19592.;;He, et al. (Jan. 1, 2009) Chemoenzymatic Synthesis of New Fluorescent Sialyl Conjugates Poster, Biotrans, InstitutfurOrganische Chemie und Biochemie, Technische Universitat Darmstadt, 1 Page.;;Heidecke, et al. (1996) “Alpha-beta T Cell Receptor-directed Therapy in Rat Allograft Recipients”, Transplantation, vol. 61, No. 6, pp. 948-956.;;Heidecke, et al. (1996) “Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-α/β-Targeted Therapy”, Transplantation, vol. 61, No. 2, pp. 336-339.;;Hodoniczky, et al. (Nov.-Dec. 2005) “Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-glycan Remodeling in Vitro”, Biotechnology Progress, vol. 21, No. 6, pp. 1644-1652.;;Hong, et al. (Dec. 15, 2003) “β-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells”, Cancer Research, vol. 63, No. 24, pp. 9023-9031.;;Hosoguchi, et al. (Jul. 2010) “An Efficient Approach to the Discovery of Potent Inhibitors Against Glycosyltransferases”, Journal of Medicinal Chemistry vol. 53, No. 15, pp. 5607-5619.;;Hudak et al., “Protein Glycoengineering Enabled by the Versatile Synthesis of Aminooxy Glycans and the Genetically Encoded Aldehyde Tag”, Journal of the American Chemical Society, 2011, vol. 133, No. 40, pp. 16127-16135.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/EP2012/003819, dated Jul. 17, 2013, 20 Pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/022623, dated Jul. 31, 2014, 11 Pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/022728, dated Oct. 9, 2014, 11 Pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2013/059481, dated Feb. 7, 2014, 11 Pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/021342, dated Jun. 8, 2015, 11 Pages.;;International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2015/054651, dated Apr. 20, 2016, 16 Pages.;;Jassal, et al. (Aug. 17, 2001) “Sialylation of Human IgG-Fc Carbohydrate by Transfected Rat α2,6-Sialyltransferas”, Biochemical and Biophysical Research Communications, vol. 286, Issue 2, pp. 243-249.;;Jefferis, (Oct. 15, 2012) “Isotype and Glycoform Selection for Antibody Therapeutics”, Archives of Biochemistry and Biophysics, vol. 526, Issue 2, pp. 159-166.;;Jones, et al. (Jan. 1977) “Proteinase mutants of Saccharomyces cerevisiae”, Genetics, vol. 85, No. 1, pp. 23-33.;;Jung, et al. (1992) “Prevention and Therapy of Experimental Autoimmune Neuritis by An Antibody Against T Cell Receptors-Alpha/Beta”, The Journal of Immunology, vol. 148, No. 12, pp. 3768-3775.;;Junutula, et al. (Aug. 1, 2008) “Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index”, Nature Biotechnology, vol. 26, No. 8, pp. 925-932.;;Junutula, et al. (Mar. 20, 2008) “Rapid Identification of Reactive Cysteine Residues for Site-Specific Labeling of Antibody-Fabs”, Journal of Immunological Methods, vol. 332, Issues 1-2, pp. 41-52.;;Junutula, et al. (Oct. 1, 2010) “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Indexto Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer”, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, abstract, pp. 4769-4778.;;Kaneko, et al. (Aug. 4, 2006) “Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation”, Science, vol. 313, No. 5787, pp. 670-673.;;Kawasaki, et al. (May 7, 2013) “Targeted Delivery of Lipid Antigen to Macrophages via the CD169/sialoadhesin Endocytic Pathway Induces Robust Invariant Natural Killer T Cell Activation”, Proceedings of the National Academy of Sciences, vol. 110, No. 19, pp. 7826-7831.;;Khidekel, et al. (Dec. 31, 2015) “A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of 0-GicNAc Posttranslational Modifications”, Journal of the American Chemical Society, vol. 125, No. 52, pp. 16162-16163.;;Kingsman, et al. (1979) “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA From the Yeast trpl Region”, Gene, vol. 7, No. 2, pp. 141-152.;;Koide, et al. (2007) “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain”, Methods in Molecular Biology, vol. 352, pp. 95-109.;;Krapp, et al. (Jan. 31, 2003) “Structural Analysis of Human IgG-Fc Glycoforms Reveals a Correlation Between Glycosylation and Structural Integrity”, Journal of Molecular Biology, vol. 325, Issue 5, pp. 979-989.;;Krehenbrink, et al. (2008) “Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PuID”, Journal of Molecular Biology, vol. 383, No. 5, pp. 1058-1068.;;Labrijn, et al. (Aug. 2008) “When Binding is Enough: Nonactivating Antibody Formats”, Current Opinion in Immunology, vol. 20, Issue 4, pp. 479-485.;;Laguzza, et al. (Mar. 1989) “New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Representative In Vivo Activity”, Journal of Medicinal Chemistry, vol. 32, No. 3, pp. 548-555.;;Lepenies, et al. (Aug. 1, 2013) “Targeting C-Type Lectin Receptors with Multivalent Carbohydrate Ligands”, Advanced Drug Delivery Reviews, vol. 65, No. 9, pp. 1271-1281.;;Leung, et al. (Oct. 1999) “The Effects of Domain Deletion, Glycosylation, and Long IgG 3 Hinge on the Biodistribution and Serum Stability Properties of a Humanized IgG Immunoglobulin, hLL2, and Its Fragments”, Clinical Cancer Research, vol. 5, No. 10, pp. 3106s-3117s.;;Li, et al. (May 23, 2014) “The Preparation of Well-Defined Antibody-Drug Conjugates Through Glycan Remodeling and Strain Promoted Azide-Alkyne Cycloadditions”, Angewandte Chemie International Edition, vol. 53, No. 2, pp. 7179-7182.;;Lund, et al. (Dec. 1, 1996) “Multiple Interactions of IgG With Its Core Oligosaccharide Can Modulate Recognition by Complement and Human Fcγ Receptor I And Influence the Synthesis of Its Oligosaccharide Chains”, The Journal of Immunology, vol. 157, Issue 11, pp. 4963-4969.;;Martin, Andrew C.R. (2010) “Protein Sequence and Structure Analysis of Antibody Variable Domains”, Chapter 3 of Antibody Engineering, vol. 2, Kontermann and Dubel Eds., Springer-Verlag Berlin Heidelberg, pp. 33-51.;;Mattner, et al. (Mar. 2005) “Exogenous and Endogenous Glycolipid Antigens Activate NKT Cells During Microbial Infections”, Nature 434, No. 7032, pp. 525-529.;;McCarthy, et al. (Dec. 2013) “Chemoenzymatic Synthesis of Immunogenic Meningococcal Group C Polysialic Acid-Tetanus Hc Fragment Glycoconjugates”, Glycoconjugate Journal, vol. 30, Issue 9, pp. 857-870.;;Medina, et al. (Jun. 1, 2011) “N-Acetylgalactosamine-Functionalized Dendrimers as Hepatic Cancer Cell-Targeted Carriers”, Biomaterials, vol. 32, No. 17, pp. 4118-4129.;;Monnier, et al. (Jan. 1, 2014) “Glucosepane: A Poorly Understood Advanced Glycation End Product of Growing Importance for Diabetes and its Complications”, Clinical Chemistry and Laboratory Medicine, vol. 52, No. 1, pp. 21-32.;;Murray, et al. (May 1, 1985) “Imaging Findings and Pharmacokinetics of 111-Indium ZME-018 Monoclonal Antibody (MoAb) in Malignant Melanoma”, Journal of Nuclear Medicine, vol. 26, No. 5, Abstract No. 55, p. 16.;;Ngalle, et al. (Aug. 16, 2011) “Strain-Promoted Alkyne-Azide Cycloadditions (SPAAC) Reveal New Features of Glycoconjugate Biosynthesis”, ChemBioChem, vol. 12, No. 12, XP055182162, pp. 1912-1921.;;Nippon Nogeikagaku Kaishi, 1998, vol. 72, No. 10, pp. 9-18.;;Nixon, et al. (2006) “Engineered Protein Inhibitors of Proteases”, Current Opinion in Drug Discovery and Development, vol. 9, No. 2, pp. 261-268.;;North, et al. (2011) “A New Clustering of Antibody CDR Loop Conformations”, Journal of Molecular Biology, vol. 406, No. 2, pp. 228-256.;;Nygren, et al. (2008) “Alternative Binding Proteins: Affibody Binding Proteins Developed from a Small Three-Helix Bundle Scaffold”, vol. 275, No. 11, pp. 2668-2676.;;Page, et al. (2012) “Biologies in Organ Transplantation”, Transplant International, vol. 25, No. 7, pp. 707-719.;;Piatesi, et al. (Apr. 2, 2004) “Immunological Optimization of a Generic Hydrophobic Pocket for High Affinity Hapten Binding and Diels-Alder Activity”, ChemBioChem, vol. 5, Issue 4, pp. 460-466.;;Polakis, Paul et al. (Aug. 2005) “Arming Antibodies for Cancer Therapy”, Current Opinion in Pharmacology, vol. 5, Issue 4, pp. 382-387.;;Qu, et al. (Jun. 1998) “Carbohydrates Engineered at Antibody Constant Domains can be used for Site-Specific Conjugation of Drugs and Chelates”, Journal of Immunological Methods, vol. 213, Issue 2, pp. 131-144.;;Radaev, et al. (May 11, 2001) “The Structure of a Human Type III Fcg Receptor in Complex with Fc”, Journal of Biological Chemistry, vol. 276, No. 19, pp. 16469-16477.;;Raju, et al. (Jul. 31, 2001) “Glycoengineering of Therapeutic Glycoproteins: In Vitro Galactosylation and Sialylation of Glycoproteins with Terminal N-acetylglucosamine and Galactose Residues”, Biochemistry, vol. 40, No. 30, (Abstract), pp. 8868-8876.;;Renaudet, et al. (2006) “On-Bead Synthesis and Binding Assay of Chemoselectively Template-Assembled Multivalent Neoglycopeptides”, Organic and Biomolecular Chemistry, vol. 4, No. 13, pp. 2628-2636.;;Ridgeway, “Introduction of Vector into Host Cells”, Mammalian Expression Vectors, 1988, Chapter 24.2, pp. 470-472.;;Roche Diagnostics (May 2013) “Alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data sheet)”, XP002727803, Retrieved From URL: https://cssportal.roche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf.;;Roux, et al. (Oct. 15, 1998) “Comparisons of the Ability of Human lgG3 Hinge Mutants, IgM, IgE, and lgA2, to form Small Immune Complexes: A Role for Flexibility and Geometry”, Journal of Immunology, vol. 161, No. 8, pp. 4083-4090.;;Rudikoff, et al. (Mar. 1, 1982) “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Proceedings of the National Academy of Sciences of the United States of America, vol. 79, pp. 1979-1983.;;Sakarellos-Kaitsiotisa et al., (2012) “Design, synthesis and binding assays of sialic acid and sialyl-saccharide conjugates to lectins and influenza H1N1 virus,” J. Pep. Sci., 18(Supp 1):S52, Abstract No. 069.;;Sazinsky, et al. (Dec. 23, 2008) “Aglycosylated Immunoglobulin G1 Variants Productively Engage Activating Fc Receptors”, Proceedings of the National Academy of Sciences of the United States of America, vol. 105, No. 51, pp. 20167-20172.;;Scharpf, et al. (2006) “Immunomodulation with Anti-αβ T-Cell Receptor Monoclonal Antibodies in Combination with Cyclosporine A Improves Regeneration in Nerve Allografts”, Microsurgery: Official Journal of the International Microsurgical Society and the European Federation of Societies for Microsurgery, vol. 26, No. 8, pp. 599-607.;;Schorlemmer, et al. (1995) “Synergistic Effects Of 15-Deoxyspergualin With Cyclosporine and the TCR-Targeted Monoclonal Antibody R73 To Induce Specific Unresponsiveness to Skin Allografts in Rats”, Transplantation Proceedings, vol. 27, No. 1, pp. 414-416.;;Schroeder, et al. (2010) “Structure and Function of Immunoglobulins”, The Journal of Allergy and Clinical Immunology, vol. 125, No. 2, Supplement 2, pp. 841-852.;;Shannessy, et al. (May 20, 1987) “Labeling of the Oligosaccharide Moieties of Immunoglobulins”, Journal of Immunological Methods, vol. 99, Issue 2, pp. 153-161.;;Shao, et al. (Apr. 1995) “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages”, Journal of the American Chemical Society, vol. 117, No. 14, pp. 3893-3899.;;Shearman, et al. (1991) “Construction, Expression and Characterization of Humanized Antibodies Directed Against the Human Alpha/Beta T Cell Receptor”, The Journal of Immunology, vol. 147, No. 12, pp. 4366-4373.;;Shearman, et al. (Feb. 1, 1991) “Construction, Expression, and Biologic Activity of Murine/Human Chimeric Antibodies with Specificity for the Human Alpha/Beta T Cell Receptor”, The Journal of Immunology, vol. 146, No. 3, pp. 928-935.;;Shields, et al. (Mar. 2, 2001) “High Resolution Mapping of The Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to The Fc Gamma R”, Journal of Biological Chemistry, vol. 276, No. 9, pp. 6591-6604.;;Silverman, et al. (2005) “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains”, Nature Biotechnology, vol. 23, No. 12, pp. 1556-1561.;;Skerra, et al. (2008) “Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activities”, The FEBS Journal, vol. 275, No. 11, pp. 2677-2683.;;Stinchcomb, et al. (Nov. 1, 1979) “Isolation and Characterisation of a Yeast Chromosomal Replicator”, Nature, vol. 282, No. 5734, pp. 39-43.;;Stumpp, et al. (pp. 695-701.) “DARPins: A New Generation of Protein Therapeutics”, Drug Discovery Today, vol. 13, pp. 15-16.;;Teicher, B A. (Dec. 9, 2009) “Antibody-Drug Conjugate Targets”, Current Cancer Drug Targets, vol. 9, No. 8, pp. 982-1004.;;The Research on the Functional Expression and Many-Sided Control of the Homo sapiens Antibody, Journal of the Japan Society for Bioscience, Biotechnology, and Agrochemistry, 1998, vol. 72, No. 10, pp. 1171-1180.;;Tschumper, et al. (Jul. 1980) “Sequence of A Yeast DNA Fragment Containing A Chromosomal Replicator and The TRP1 Gene”, Gene, vol. 10, No. 2, pp. 157-166.;;Wang, et al. (Jan. 1, 1998) “Single-Chain Fv With Manifold N-Glycans as Bifunctional Scaffolds for Immunomolecules”, Protein Engineering, vol. 11, No. 12, pp. 1277-1283.;;Wang, et al. (Mar. 1, 2011) “Impact of Methionine Oxidation in Human lgG1 Fc on Serum Half-Life of Monoclonal Antibodies”, Immunology, vol. 48, No. 6, pp. 860-866.;;Wei, et al. (Sep. 2008) “Glycoengineering of Human IgG1-Fc Through Combined Yeast Expression and In Vitro Chemoenzymatic Glycosylation”, Biochemistry, vol. 47, No. 39, pp. 10294-10304.;;Williams, et al. (2010) “Humanising Antibodies by CDR Grafting”, Antibody Engineering, pp. 319-339.;;Winkler, K., et al. (Oct. 15, 2000) “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-A21) antibody”, Journal of Immunology, vol. 165, No. 8, pp. 4505-4514.;;Wright, et al. (1992) “Genetically Engineered Antibodies: Progress and Prospects”, Critical Reviews in Immunology, vol. 12, No. 3-4, pp. 125-168.;;Wu, et al. (Nov. 19, 1999) “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues”, Journal of Molecular Biology, vol. 294, No. 1, pp. 151-162.;;Yamagami, et al. (1999) “Suppression of Allograft Rejection with Anti-αβ T Cell Receptor Antibody in Rat Corneal Transplantation1”, Transplantation, vol. 67, No. 4, pp. 600-604.;;Yoshino, et al. (1992) “Depletion of Alpha/Beta T Cells by a Monoclonal Antibody Against the Alpha/Beta T Cell Receptor Suppresses Established Adjuvant Arthritis, But Not Established Collagen-Induced Arthritis in Rats”, Journal of Experimental Medicine, vol. 175, No. 4, pp. 907-915.;;Yu, et al. (Feb. 2008) “Interaction between Bevacizumab and Murine VEGF-A: A Reassessment”, Investigative Ophthalmology & Visual Science, vol. 49, No. 2, pp. 522-527.;;Zevgiti et al. (2011) “Sialic acid and sialyl-lactose glyco-conjugates: design, synthesis and binding assays to lectins and swine influenza H1N1 virus,” J. Pep. Sci., 18:52-58.;;Zhang, et al. (Jun. 19, 2013) “Applications of Azide-Based Biorthogonal Click Chemistry in Glycobiology”, Molecules, vol. 18, No. 6, XP055507949, pp. 7145-7159.;;Zhou, et al. (Apr. 20, 2011) “Strategies for Neoglycan Conjugation to Human Acid α-Glucosidase”, Bioconjugate Chemistry, vol. 22, No. 4, pp. 741-751.;;Zhou, et al. (Aug. 22, 2013) “Bioconjugation by Native Chemical Tagging of C—H Bonds”, Journal of the American Chemical Society, vol. 13 5, No. 35, pp. 12994-12997.;;Zhou, et al. (Feb. 15, 2008) “Development of A Simple and Rapid Method for Producing Non-Fucosylated Oligomannose Containing Antibodies with Increased Effector Function”, Biotechnology and Bioengineering, vol. 99, No. 3, pp. 652-665.;;Zhou, et al. (Mar. 19, 2014) “Site-Specific Antibody-Drug Conjugation through Glycoengineering”, Bioconjugate Chemistry, vol. 25, No. 3, pp. 510-520.;;Zhu, et al. (Jun. 2009) “Glycoengineered Acid Alpha-Glucosidase with Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease”, Molecular Therapy, vol. 17, Issue 6, pp. 954-963.;;Armour, et al., “Recombinant human IgG molecules lacking Fcγ receptor I binding and monocyte triggering activities”, European Journal of Immunology 29(8): 2613-2624 (Aug. 1, 1999).;;Ashkenazi, et al., “Pancreatic Islet Xenograft Survival in Mice is Extended by a Combination of Alpha-1-Antitrypsin and Single-Dose Anti-CD4/CD8 Therapy”, PLOS One, vol. 8, Issue 5, e63625, 10 pages (May 1, 2013).;;Chen, et al., “Tolerance in the Mouse to Major Histocompatibility Complex-Mismatched Heart Allografts, and to Rat Heart Xenografts, using Monoclonal Antibodies to CD4 and CD8”, European Journal of Immunology 22(3):805-810 (Mar. 1, 1992).;;Extended European Search Report for European Patent Application No. 21207026.2, dated May 10, 2022.;;Fuss, et al., “Nonclassical CD1d-Restricted NK Cells that Produce IL-13 Characterize an Atypical Th2 Response in Ulcerative Colitis”, The Journal of Clinical Investigation 113(10):1490-1497 (May 15, 2004).;;Genbank, “Immunoglobulin Heavy Chain, Partial [Homo sapiens]”, GenBank Accession No. BAF64538.1, Retrieved from: <<https://www.ncbi.nlm.nih.gov/protein/BAF64538.1>> (Dec. 27, 2006).;;Getts, et al., “Current landscape for T-cell targeting in autoimmunity and transplantation”, Immunotherapy 3(7):853-870 (Jul. 1, 2011).;;Haberger, et al., “Assessment of Chemical Modifications of Sites in the CDRs of Recombinant Antibodies”, MAbs, 6(2):327-339 (Mar. 2014).;;International Search Report and Written Opinion for PCT International Patent Application No. PCT/US2020/026304, dated Jul. 20, 2020.;;Knight, et al., “Clinical Evaluation Of Induction Immunosuppression With A Murine Igg2b Monoclonal Antibody (BMA 031) Directed Toward The Human Alpha/Beta-T Cell Receptor”, Transplantation 57(11):1581-1588 (Jan. 1, 1994).;;Koulmanda, et al., “Prolonged Survival of Fetal Pig Islet Xenografts in Mice Lacking the Capacity for an Indirect Response”, Xenotransplantation 11(6):525-530 (Nov. 11, 2004).;;Lavasani, et al., “Monoclonal Antibody against T-Cell Receptor αβ Induces Self-Tolerance in Chronic Experimental Autoimmune Encephalomyelitis”, Scandinavian Journal of Immunology 65(1):39-47 (Jan. 1, 2007).;;Li, et al., “The Preparation of Well-Defined Antibody-Drug Conjugates through Glycan Remodeling and Strain-Promoted Azide-Alkyne Cycloadditions (Supplementary Information)”, Angewandte Chemie, Retrieved from: https//onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002/ange.201402606&file=ange_201402606_sm_miscellaneous_information.pdf, pp. S1-S22 (May 23, 2014).;;Lu, et al., “Deamidation and Isomerization Liability Analysis of 131 Clinical-stage Antibodies”, In MAbs, 11(1):45-57 (Dec. 10, 2018).;;Maeda, et al., “Exacerbation of Established Collagen-Induced Arthritis in Mice Treated with an Anti-T Cell Receptor Antibody”, Arthritis & Rheumatism 37(3):406-413 (Mar. 1994).;;National Institute of Health (NIH), “Chain B, 6-26 Fab Heavy chain”, Protein Databank Accession No. 4HFW_B, Retrieved from:<<https://www.ncbi.nlm.nih.gov/protein/4HFW_B>> (Oct. 5, 2012).;;Powrie, “Immune Regulation in the Intestine: A Balancing Act between Effector and Regulatory T Cell Responses”, Annals of the New York Academy of Sciences, 1029(1):132-141 (2004).;;Rachmawati, et al., “Chemical Modification of Interleukin-10 with Mannose 6-Phosphate Groups Yields a Liver-Selective Cytokine”, Drug Metabolism and Disposition 35(5):814-821 (2007).;;Roitt, et al., Immunology—Sixth Edition Mosby—Harcourt Publishers Limited, pp. 110-111 (2001).;;Sempe, et al., “Anti-α/β T Cell Receptor Monoclonal Antibody Provides an Efficient Therapy for Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice”, European Journal of Immunology, 21 (5):1163-1169 (May 1, 1991).;;Sydow, et al., “Structure-Based Prediction of Asparagine and Aspartate Degradation Sites in Antibody Variable Regions”, PLOS One 9(6):1-13 (Jun. 24, 2014).;;Wang, et al., “Potential Aggregation Prone Regions in Biotherapeutics”, MAbs, 1(3):254-267 (May 1, 2009).;;Yu, et al., “Expression and Functional Characterization of FOXP3+ CD4+ Regulatory T CeHs in Ulcerative Colitis”, Inflammatory Bowel Diseases 13(2):191-199 (Feb. 1, 2007).;;U.S. Appl. No. 14/203,438 2015/0079070 U.S. Pat. No. 9,701,753, filed Mar. 10, 2014 Mar. 19, 2015 Jul. 11, 2017, Clark Pan.;;U.S. Appl. No. 15/614,015 2017/0369584 U.S. Pat. No. 10,494,439, filed Jun. 5, 2017 Dec. 28, 2017 Dec. 3, 2019, Clark Pan.;;U.S. Appl. No. 14/241,099 2015/0099861 U.S. Pat. No. 10,017,573, filed Nov. 18, 2014 Apr. 9, 2015 Jul. 10, 2018, Daniel Snell.;;U.S. Appl. No. 15/867,364 2018/0237522 U.S. Pat. No. 11,186,638, filed Jan. 10, 2018 Aug. 23, 2018 Nov. 30, 2021, Daniel Snell.;;U.S. Appl. No. 17/511,218 2022/0153841, filed Oct. 26, 2021 May 19, 2022 Daniell Snell.;;U.S. Appl. No. 14/203,479 2014/0294867 U.S. Pat. No. 9,580,511, filed Mar. 10, 2014 Oct. 2, 2014 Feb. 28, 2017, Clark Pan.;;U.S. Appl. No. 15/417,648 2017/0267774 U.S. Pat. No. 10,214,589, filed Jan. 27, 2017 Sep. 21, 2017 Feb. 26, 2019, Clark Pan.;;U.S. Appl. No. 16/238,932 2019/0233531 U.S. Pat. No. 11,130,816, filed Jan. 3, 2019 Aug. 1, 2019 Sep. 28, 2021, Clark Pan.;;U.S. Appl. No. 17/404,412 2022/0089763, filed Aug. 17, 2021 Mar. 24, 2022, Clark Pan.;;U.S. Appl. No. 14/205,264 2014/0271676 U.S. Pat. No. 9,790,268, filed Mar. 11, 2014 Sep. 18, 2014 Oct. 17, 2017, Clark Pan.;;U.S. Appl. No. 15/702,368 2018/0100010 U.S. Pat. No. 10,836,813, filed Sep. 12, 2017 Apr. 12, 2018 Nov. 17, 2020, Clark Pan.;;U.S. Appl. No. 17/065,729 2021/0147524, filed Oct. 8, 2020 May 20, 2021, Clark Pan.;;U.S. Appl. No. 14/662,187 2016/0060354 U.S. Pat. No. 10,995,148, filed Mar. 18, 2015 Mar. 3, 2016 May 4, 2021, Luis Avila.;;U.S. Appl. No. 17/215,674 2022/0119547, filed Mar. 29, 2021 Apr. 21, 2022, Luis Avila.;;U.S. Appl. No. 14/878,444 2016/0136299 U.S. Pat. No. 10,064,952, filed Oct. 8, 2015 May 19, 2016 Sep. 4, 2018, Luis Avila.;;U.S. Appl. No. 16/055,661 2019/0060481 U.S. Pat. No. 11,160,874, filed Aug. 6, 2018 Feb. 28, 2019 Nov. 2, 2021, Luis Avila.;;U.S. Appl. No. 17/403,592 2022/0088214, filed Aug. 16, 2021 Mar. 24, 2022, Luis Avila.;;U.S. Appl. No. 17/441,028 2022/0153840, filed Sep. 20, 2021 May 19, 2022, Huawei Qiu.;;U.S. Appl. No. 17/441,028 2022/0153840, filed Sep. 20, 2021 May 19, 2022, Huawei Qiu, Anti-Alpha Beta TCR Binding Polypeptides With Reduced Fragmentation.;;Eaton, “Construction And Characterization of An Active Factor VIII Variant Lacking the Central One-Third of the Molecule”, Biochemistry, Dec. 30, 1986, 25(26): 8343-8347.;;Extended European Search Report for European Patent Application No. 22151876.4, dated Nov. 30, 2022.;;Extended European Search Report for European Patent Application No. 22171935.4, dated Aug. 24, 2022.;;Extended European Search Report received for European Patent Application No. 20192498.2, dated Mar. 3, 2021.;;Onitsuka et al., “Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of α2,6-sialyltransferase derived from Chinese hamster ovary cells”, Biotechnological products and process engineering, Dec. 29, 2011, 94: 69-80.;;Tachibana, “Study on functional expression of human antibody and its multifaceted control”, Journal of the Agricultural Chemical Society of Japan, 72 (10): 1171-1180 (1998).;;Lu et al., “Identification of IgG1 variants with increased affinity to FcyRllla and unaltered affinity to FcyRI and FcRn: Comparison of soluble receptor-based and cell-based binding assays”, Journal of Immunological Methods, 365(1-2): 132-141, Feb. 28, 2011.;;Mohorko et al. (2011) “Oligosaccharyltansferase: the Central Enzyme of N-linked Protein Glycosylation,” J. Inherit. Metab. Dis., 34: 869-878.;;Okazaki et al., “Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and Fcyllla”, Journal of Molecular Biology, 336(5): 1239-1249, Mar. 5, 2004.;;U.S. Appl. No. 14/203,438 2015/0079070 U.S. Pat. No. 9,701,753, filed Mar. 10, 2014 Mar. 19, 2015 Jul. 11, 2017, Clark Pan, Hyperglycosylated Binding Polypeptides.;;U.S. Appl. No. 15/614,015 2017/0369584 U.S. Pat. No. 10,494,439, filed Jun. 5, 2017 Dec. 28, 2017 Dec. 3, 2019, Clark Pan, Hyperglycosylated Binding Polypeptides.;;U.S. Appl. No. 16/655,500 2020/0140564, filed Oct. 17, 2019 May 7, 2020, Clark Pan, Hyperglycosylated Binding Polypeptides.;;U.S. Appl. No. 14/241,099 2015/0099861 U.S. Pat. No. 10,017,573, filed Nov. 18, 2014 Apr. 9, 2015 Jul. 10, 2018, Daniel Snell, Anti-Alpha Beta TCR Antibodies.;;U.S. Appl. No. 15/867,364 2018/0237522 U.S. Pat. No. 11,186,638, filed Jan. 10, 2018 Aug. 23, 2018 Nov. 30, 2021, Daniel Snell, Anti-Alpha Beta TCR Antibodies.;;U.S. Appl. No. 17/511,218 2022/0153841, filed Oct. 26, 2021 May 19, 2022, Daniel Snell, Anti-Alpha Beta TCR Antibodies.;;U.S. Appl. No. 14/203,479 2014/0294867 U.S. Pat. No. 9,580,511, filed Mar. 10, 2014 Oct. 2, 2014 Feb. 28, 2017, Clark Pan, Site-Specific Antibody-Drug Conjugation Through Glycoengineering.;;U.S. Appl. No. 15/417,648 2017/0267774 U.S. Pat. No. 10,214,589, filed Jan. 27, 2017 Sep. 21, 2017 Feb. 26, 2019, Clark Pan, Site-Specific Antibody-Drug Conjugation Through Glycoengineering.;;U.S. Appl. No. 16/238,932 2019/0233531 U.S. Pat. No. 11,130,816, filed Jan. 3, 2019 Aug. 1, 2019 Sep. 28, 2021, Clark Pan, Site-Specific Antibody-Drug Conjugation Through Glycoengineering.;;U.S. Appl. No. 17/404,412 2022/0089763, filed Aug. 17, 2021 Mar. 24, 2022, Clark Pan, Site-Specific Antibody-Drug Conjugation Through Glycoengineering. et al.",ACTIVE
240,AU,A1,AU 2014/249290 A1,123-471-991-357-44X,2015-09-24,2015,AU 2014/249290 A,2014-03-10,US 201361776715 P;;US 201361776710 P;;US 201361776724 P;;US 2014/0022623 W,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/123-471-991-357-44X,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,ACTIVE
241,CN,A,CN 105189555 A,123-678-605-575-325,2015-12-23,2015,CN 201480014449 A,2014-03-10,US 2014/0022623 W;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/123-678-605-575-325,Patent Application,no,2,1,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,2,0,,,"QU Z等: ""Carbohydrate engineered at antibody constant domains can be used fro site-specific conjugation of drugs and chelates"", 《J IMMUNOL METH》;;WANG M等: ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules"", 《PROT ENGINEERING》",ACTIVE
242,CA,A1,CA 3011841 A1,164-115-432-739-667,2019-01-31,2019,CA 3011841 A,2018-07-19,US 201715664446 A,2017-07-31,IMPROVED ADHESION OF THERMAL SPRAY COATINGS OVER A SMOOTH SURFACE,"A coated component is generally provided, along with methods of forming such a coating system. The coated component includes a substrate having a surface with a coating system thereon. The coating system may include a columnar thermal barrier coating (TBC) over the surface of the substrate, with the columnar TBC including surface-connected voids. An intermediate layer is over the columnar TBC layer. The intermediate layer has a surface opposite of the columnar TBC that is rougher than the surface of the columnar TBC. A second TBC is over the intermediate layer.",GEN ELECTRIC,CHEN DIANYING;;FU MING;;CLARK MICHAEL DAVID;;KONITZER DOUGLAS GERARD,,https://lens.org/164-115-432-739-667,Patent Application,no,0,0,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,C23C4/134;;C23C4/02;;C23C4/10,,0,0,,,,DISCONTINUED
243,US,A1,US 2017/0369584 A1,017-818-412-212-56X,2017-12-28,2017,US 201715614015 A,2017-06-05,US 201715614015 A;;US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/017-818-412-212-56X,Patent Application,yes,1,5,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/68;;C07K16/32;;C07K16/40,,3,3,013-452-637-389-025;;027-477-313-726-928;;013-142-717-038-23X,8943402;;10.4049/jimmunol.157.11.4963;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;10556035;;10.1006/jmbi.1999.3141,"Lund et al., The Journal of Immunology 157:4963-4969 (Year: 1996);;Rudikoff et al., PNAS 79: 1979-1983 (Year: 1982);;Wu et al., J Mol Biol 294: 151-162 (Year: 1999)",ACTIVE
244,MX,A,MX 2018003130 A,043-363-183-953-501,2018-05-16,2018,MX 2018003130 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF.,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,RUOXI LAN;;CATHERINE JORAND-LEBRUN;;AUSTIN CHEN;;RYAN C CLARK,,https://lens.org/043-363-183-953-501,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,PENDING
245,US,B2,US 10059701 B2,114-884-237-267-61X,2018-08-28,2018,US 201615267565 A,2016-09-16,US 201615267565 A;;US 201562220307 P,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2016-10-17),https://lens.org/114-884-237-267-61X,Granted Patent,yes,8,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,A01N43/00;;A61K31/397;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D498/08,,21,14,165-533-825-286-740;;053-041-511-200-033;;088-902-381-301-89X;;048-216-169-484-878;;018-960-566-924-993;;027-013-467-518-974;;095-716-273-533-92X;;013-862-057-494-226;;007-364-858-655-289;;051-933-822-151-495;;003-604-589-168-97X;;026-362-629-080-389;;011-166-598-579-298;;077-295-491-167-117,10.1111/j.1349-7006.2003.tb01343.x;;19217767;;10.1016/j.ceb.2009.01.015;;10.1016/j.cyto.2007.12.012;;pmc2377356;;18249132;;10.1126/science.271.5252.1128;;8599092;;10.1126/science.278.5343.1612;;9374458;;10383454;;10.1074/jbc.274.27.19403;;pmc122810;;11960013;;10.1073/pnas.082100399;;10.1016/j.bmcl.2008.04.042;;18501603;;10.1002/jps.2600660104;;833720;;10.1021/jo00300a010;;10.1021/jo00391a029;;8130206;;10.1021/bi00176a024;;10.1093/carcin/16.4.683;;7728943;;10.1002/0471220574,"STN registry database compound 509094-21-7 (Entered STN May 2, 2003).;;Ito et al. (Cancer Science, 2003, 94(1), 3-8).;;STN registry database compound 509094-23-9 (Entered STN May 2, 2003).;;Cohen, Current Opinion in Cell Biology 21, 317-324 (2009).;;Ringwood and Li, Cytokine 42, 1-7 (2008).;;Cao et al., Science 271(5252): 1128-31 (1996).;;Muzio et al., Science 278(5343): 1612-5 (1997).;;Wesche et al. J. Biol. Chem. 274(27): 19403-10 (1999).;;Li et al. Proc. Natl. Acad. Sci. USA 99(8):5567-5572 (2002).;;Buckley et al. Bioorg Med Chem Lett. 18(12):3656-60 (2008).;;Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th Ed.;;Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito (1999).;;“March's Advanced Organic Chemistry”, 5th Ed., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: (2001).;;S. M. Berge et al., J. Pharmaceutical Sciences, 66, 1-19 (1977).;;Hanzlik et al., J. Org. Chem. 55, 3992-3997 (1990).;;Reider et al., J. Org. Chem. 52, 3326-3334 (1987).;;Foster, Adv. Drug Res. 14, 1-40 (1985).;;Gillette et al., Biochemistry 33(10) 2927-2937 (1994).;;Jarman et al., Carcinogenesis 16(4), 683-688 (1993).;;Philip J. Kocienski, “Protecting Groups”, Georg Thieme Verlag Stuttgart, New York, (1994).;;Theodora W. Greene and Peter G. M. Wuts, “Protective Groups in Organic Synthesis”, Wiley Interscience, 3rd Edition (1999).",ACTIVE
246,IL,A,IL 258081 A,133-044-524-043-210,2018-05-31,2018,IL 25808118 A,2018-03-13,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Heteroaryl compounds and pharmaceutical compositions cotaining them,,JORAND LEBRUN CATHERINE;;LAN RUOXI;;MERCK PATENT GMBH;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/133-044-524-043-210,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,,,0,0,,,,PENDING
247,BR,A2,BR 112018003812 A2,197-952-649-131-72X,2018-09-25,2018,BR 112018003812 A,2016-09-16,US 2016/0052104 W;;US 201562220307 P,2015-09-18,compostos de heteroarila como inibidores de irak e usos dos mesmos,"a presente invenção refere-se a compostos de fórmula i e composições farmaceuticamente aceitáveis dos mesmos, úteis como inibidores de irak.",MERCK PATENT GMBH,AUSTIN CHEN;;CATHERINE JORAND-LEBRUN;;RUOXI LAN;;RYAN C CLARK,,https://lens.org/197-952-649-131-72X,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D403/04;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D413/04;;C07D413/14;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,PENDING
248,WO,A3,WO 2023/250192 A3,031-079-328-129-115,2024-02-08,2024,US 2023/0026151 W,2023-06-23,US 202263354991 P,2022-06-23,"FERROELECTRIC SMECTIC A PHASE MATERIALS, DEVICES INCLUDING THE MATERIALS, AND METHODS OF FORMING AND USING SAME",Devices including a volume comprising ferroelectric smectic A (SmAF) liquid crystal-forming fluid and methods of forming and using such devices are disclosed. Exemplary devices include one or more surfaces and one or more electrodes thereon for application of an electric field to the volume.,UNIV COLORADO REGENTS,MACLENNAN JOSEPH;;CLARK NOEL;;GLASER MATTHEW;;CHEN XI;;MARTINEZ VIKINA,,https://lens.org/031-079-328-129-115,Search Report,yes,0,0,2,2,0,G02F1/141,C09K19/02;;G02F1/13;;C09K19/10;;G02F1/133;;G02F1/141,,0,0,,,,PENDING
249,WO,A1,WO 2009/134324 A1,123-232-020-471-233,2009-11-05,2009,US 2009/0002402 W,2009-04-17,US 14921708 A,2008-04-29,REDUCTION OF LEAKAGE CURRENT IN A VERTICAL DIODE,"One embodiment of the invention provides a semiconductor diode device including a first conductivity type region, a second conductivity type region, where the second conductivity type is different from the first conductivity type, an intrinsic region located between the first conductivity type region and the second conductivity type region; a first halo region of the first conductivity type located between the second conductivity type region and the intrinsic region, and optionally a second halo region of the second conductivity type located between the first conductivity type region and the intrinsic region.",SANDISK 3D LLC;;CHEN XIYING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY,CHEN XIYING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY,,https://lens.org/123-232-020-471-233,Patent Application,yes,3,0,4,4,0,H01L29/1606;;H01L29/8615;;H01L29/868;;H01L29/868;;H01L29/8615;;H01L29/1606,H01L29/861;;H01L29/868,,2,2,018-087-265-263-382;;077-656-265-724-625,10.1557/proc-467-943;;10.1109/msmw.2001.947308,"CAPUTO D ET AL: ""EVIDENCE OF HYSTERESIS IN A NEW P-I-N-I-P-I-N AMORPHOUS SILICON DEVICE"", AMORPHOUS AND MICROCRYSTALLINE SILICON TECHNOLOGY - 1997. SAN FRANCISCO, CA, MARCH 31 - APRIL 4, 1997; [MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS. VOL. 467], PITTSBURGH, PA : MRS, US, 31 March 1997 (1997-03-31), pages 943 - 948, XP000905800, ISBN: 978-1-55899-371-6;;MAKSYMOV P P: ""Static electrical fields of reverse-biased GaAs- and Ge-pnipn structures"", PHYSICS AND ENGINEERING OF MILLIMETER AND SUB-MILLIMETER WAVES, 2001. THE FOURTH INTERNATIONAL KHARKOV SYMPOSIUM ON JUNE 4-9, 2001, PISCATAWAY, NJ, USA,IEEE, vol. 2, 4 June 2001 (2001-06-04), pages 777 - 779, XP010555457, ISBN: 978-0-7803-6473-8",PENDING
250,IL,B,IL 258081 B,187-477-951-578-298,2022-10-01,2022,IL 25808118 A,2018-03-13,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Benzimidazole derivatives and their use,,MERCK PATENT GMBH;;JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/187-477-951-578-298,Unknown,no,7,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,A61K31/4184;;A61K31/4439;;A61K31/506,,3,3,003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033,10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8,"DING, KEJIA, ET AL., ARYL-SUBSTITUTED AMINOBENZIMIDAZOLES TARGETING THE HEPATITIS C VIRUS INTERNAL RIBOSOME ENTRY SITE, 14 May 2014 (2014-05-14);;HRANJEC, MARIJANA, ET AL., ANTIPROLIFERATIVE POTENCY OF NOVEL BENZOFURAN-2-CARBOXAMIDES ON TUMOUR CELL LINES: CELL DEATH MECHANISMS AND DETERMINATION OF CRYSTAL STRUCTURE., 16 November 2012 (2012-11-16);;SOVIC, IRENA, ET AL., EXPLORING ANTIPROLIFERATIVE ACTIVITY OF HETEROAROMATIC AMIDES AND THEIR FUSED DERIVATIVES USING 3D-QSAR, SYNTHESIS, AND BIOLOGICAL TESTS., 29 April 2015 (2015-04-29)",PENDING
251,US,A1,US 2023/0245894 A1,188-911-460-633-681,2023-08-03,2023,US 202318102641 A,2023-01-27,US 202318102641 A;;US 202263306287 P,2022-02-03,PROCESS FOR SELECTIVELY DEPOSITING HIGHLY-CONDUCTIVE METAL FILMS,"Provided is a process comprising a selective ruthenium seed layer deposition with oxygen-free ruthenium precursors, followed by bulk deposition of metal-containing precursors such as tungsten, molybdenum, cobalt, ruthenium, and/or copper-containing precursors. The ruthenium seed layer deposition is highly selective for the conducting portions of the microelectronic device substrate while minimizing deposition onto the insulating surfaces of the microelectronic device substrate. In certain embodiments, the conducting portions of the substrate is chosen from titanium nitride, tungsten nitride, tantalum nitride, tungsten, cobalt, molybdenum, aluminum, and copper.",ENTEGRIS INC,CHEN PHILIP S H;;HENDRIX BRYAN CLARK;;CAMERON THOMAS M,ENTEGRIS INC (2022-11-30),https://lens.org/188-911-460-633-681,Patent Application,yes,0,0,3,3,0,C23C16/18;;C23C16/45553;;H01L21/28562;;H01L21/28556;;H01L21/76876;;H01L21/28568;;H01L21/76843;;C23C16/14;;C23C16/45523;;C23C16/0281;;C23C16/04;;C23C16/045;;H01L21/28568;;H01L21/76843;;H01L21/76876;;C23C16/14,H01L21/285;;C23C16/14,,0,0,,,,PENDING
252,US,A1,US 2010/0248728 A1,192-781-226-900-085,2010-09-30,2010,US 41592409 A,2009-03-31,US 41592409 A,2009-03-31,USER GROUP-BASED ADAPTIVE SOFT FREQUENCY REUSE METHOD TO MITIGATE DOWNLINK INTERFERENCE FOR WIRELESS CELLULAR NETWORKS,"A novel soft fractional frequency reuse (FFR) technique is disclosed. The novel FFR technique includes reuse partition and power restriction, dynamic user grouping, channel quality indicator feedback based on reuse, and a user group-based interference aware scheduler. The FFR technique reduces co-channel interference for cell edge users.",SUN HONGMEI;;YANG HUA;;TALWAR SHILPA;;HIMAYAT NAGEEN;;CHEN CLARK,SUN HONGMEI;;YANG HUA;;TALWAR SHILPA;;HIMAYAT NAGEEN;;CHEN CLARK,INTEL CORPORATION (2009-03-31),https://lens.org/192-781-226-900-085,Patent Application,yes,6,41,2,2,0,H04W16/10;;H04W16/10,H04W72/00,455/450,0,0,,,,INACTIVE
253,US,B2,US 8608566 B2,023-492-029-063-194,2013-12-17,2013,US 10367508 A,2008-04-15,US 10367508 A,2008-04-15,Music video game with guitar controller having auxiliary palm input,"A music based video game provides an auxiliary palm input on an associated guitar shaped video game controller. In some embodiments, the auxiliary palm input is positioned near a strum input on a body of the guitar shaped video game controller, allowing for simultaneous operation of both the strum input and the auxiliary palm input with one hand. In some embodiments, the auxiliary palm input modifies audio outputs generated in the music based video game. In some embodiments, the auxiliary palm input triggers an alternate game mode, for example, a bonus mode, during video game play of the music based video game.",GUINCHARD LEE;;CHEN TRAVIS;;BRIGHT BRIAN;;WEN CLARK;;CHRZANOWSKI MICHAEL;;ACTIVISION PUBLISHING INC,GUINCHARD LEE;;CHEN TRAVIS;;BRIGHT BRIAN;;WEN CLARK;;CHRZANOWSKI MICHAEL,ACTIVISION PUBLISHING INC (2008-05-20),https://lens.org/023-492-029-063-194,Granted Patent,yes,40,5,2,2,0,A63F2300/1043;;A63F2300/1062;;A63F2300/1068;;A63F2300/305;;A63F2300/6063;;A63F2300/638;;A63F2300/8047;;A63F13/814;;A63F2300/61;;A63F13/5375;;A63F2300/64;;A63F13/44;;A63F13/63;;A63F13/245;;A63F13/46;;A63F2300/6081;;A63F2300/6018;;A63F13/57;;A63F2300/1031;;A63F13/54;;A63F13/214;;A63F13/235;;A63F13/814;;A63F13/245;;A63F13/235;;A63F2300/1068;;A63F2300/305;;A63F2300/8047;;A63F2300/1062;;A63F2300/6063;;A63F2300/1043;;A63F2300/638,A63F9/24;;A63F13/02;;G06F17/00,463/38;;463/7;;463/36;;463/37;;463/47,1,0,,,"""Power Tour Electric Guitar"", User's Guide, Tiger Electronics, 2007 (12 pgs.).",ACTIVE
254,AU,B2,AU 2014/249290 B2,064-449-959-973-147,2018-11-22,2018,AU 2014/249290 A,2014-03-10,US 201361776715 P;;US 201361776710 P;;US 201361776724 P;;US 2014/0022623 W,2013-03-11,Hyperglycosylated binding polypeptides,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/064-449-959-973-147,Granted Patent,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,2,2,042-233-175-582-26X;;003-338-632-019-904,10.1016/s0022-1759(97)00192-0;;9692846;;10.1038/nbt.1480;;18641636,"QU Z ET AL, ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates"", JOURNAL OF IMMUNOLOGICAL METHODS (1998-04-15), vol. 213, no. 2 pages 131 -144;;JUNUTULA JAGATH R ET AL, ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index."", NATURE BIOTECHNOLOGY, (2008-08), vol. 26, no. 8, ISSN 1546-1696, pages 925 - 932",ACTIVE
255,WO,A2,WO 2023/133356 A2,113-596-519-529-566,2023-07-13,2023,US 2023/0010510 W,2023-01-10,US 202263298116 P,2022-01-10,COMPOSITE MATERIALS BASED ON FERROELECTRIC NEMATIC LIQUID CRYSTALS AND DEVICES INCLUDING SAME,"Composite materials and devices including composite materials are disclosed. Exemplary composite materials include a porous material and ferroelectric nematic liquid crystal within pores of the porous material. The composite materials can be used in a variety of applications, such as capacitors, energy storage and/or conversion devices.",UNIV COLORADO REGENTS,GLASER MATTHEW A;;CLARK NOEL;;MACLENNAN JOSEPH E;;CHEN XI,,https://lens.org/113-596-519-529-566,Patent Application,yes,0,0,2,2,0,C09K19/0225;;C09K2019/521;;G02F1/141;;G02F1/1334,H10K10/10,,0,0,,,,PENDING
256,RU,C2,RU 2743360 C2,143-559-308-732-164,2021-02-17,2021,RU 2018113451 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USE THEREOF,"FIELD: chemical engineering.SUBSTANCE: present invention relates to compound of formula IIor pharmaceutically acceptable salt thereof. In formula I:represents 3- to 7-membered heterocyclic ring, having 1 to 3 heteroatoms independently selected from nitrogen or oxygen; each Ra independently represents C1-C3 alkyl, -(CH2)-cycloalkyl or -C(O)C1-C3alkyl; Rb represents -ОН or C1-C3 alkyl; or Rb is absent; ring X represents phenil; R1 represents haloalkyl; R2 represents hydrogen; R3 represents C1-C6 alkyl or C2-C6 alkenyl, each unnecessarily and independently repaced by groups 1-3 selected independently from –OH and halogen; R4 represents hydrogen; and p equals to 0, 1, 2 or 3. Disclosed are also a pharmaceutic composition, a method for inhibition of IRAK or its mutant in patient or in biological sample and a method for treating IRAK-caused disorder.EFFECT: suggested compounds have inhibitory activity in relation to IRAK and may be useful when treating IRAK-caused disorder.14 cl, 2 tbl, 64 ex",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/143-559-308-732-164,Granted Patent,no,9,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61K35/00;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,3,3,003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033,10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8,"DING K. et al. Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site, Bioorg. Med. Chem. Let., 2014, v. 24, p. 3113-3117.;;HRANJEC M. et al. Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: cell death mechanisms and determination of crystal structure, Eur. J. Med. Chem., 2013, v. 59, p. 111-119.;;SOVIC I. et al. Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis, and biological tests, Monatch. Chem., 29.04.2015, v. 146, p. 1503-1517.",ACTIVE
257,CA,A1,CA 2996316 A1,149-317-438-840-848,2017-03-23,2017,CA 2996316 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/149-317-438-840-848,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,PENDING
258,IL,B2,IL 258081 B2,153-464-335-477-921,2023-02-01,2023,IL 25808118 A,2018-03-13,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Benzimidazole derivatives and their use,,MERCK PATENT GMBH;;JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/153-464-335-477-921,Unknown,no,7,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,A61K31/4184;;A61K31/4439;;A61K31/506,,3,3,003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033,10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8,"DING, KEJIA, ET AL., ARYL-SUBSTITUTED AMINOBENZIMIDAZOLES TARGETING THE HEPATITIS C VIRUS INTERNAL RIBOSOME ENTRY SITE, 14 May 2014 (2014-05-14);;HRANJEC, MARIJANA, ET AL., ANTIPROLIFERATIVE POTENCY OF NOVEL BENZOFURAN-2-CARBOXAMIDES ON TUMOUR CELL LINES: CELL DEATH MECHANISMS AND DETERMINATION OF CRYSTAL STRUCTURE., 16 November 2012 (2012-11-16);;SOVIC, IRENA, ET AL., EXPLORING ANTIPROLIFERATIVE ACTIVITY OF HETEROAROMATIC AMIDES AND THEIR FUSED DERIVATIVES USING 3D-QSAR, SYNTHESIS, AND BIOLOGICAL TESTS., 29 April 2015 (2015-04-29)",PENDING
259,HK,A1,HK 1213271 A1,154-777-329-797-527,2016-06-30,2016,HK 16101117 A,2016-02-01,US 2014/0022623 W;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,,GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/154-777-329-797-527,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K/,,0,0,,,,PENDING
260,US,A1,US 2009/0258705 A1,000-453-825-391-854,2009-10-15,2009,US 10367508 A,2008-04-15,US 10367508 A,2008-04-15,MUSIC VIDEO GAME WITH GUITAR CONTROLLER HAVING AUXILIARY PALM INPUT,"A music based video game provides an auxiliary palm input on an associated guitar shaped video game controller. In some embodiments, the auxiliary palm input is positioned near a strum input on a body of the guitar shaped video game controller, allowing for simultaneous operation of both the strum input and the auxiliary palm input with one hand. In some embodiments, the auxiliary palm input modifies audio outputs generated in the music based video game. In some embodiments, the auxiliary palm input triggers an alternate game mode, for example, a bonus mode, during video game play of the music based video game.",GUINCHARD LEE;;CHEN TRAVIS;;BRIGHT BRIAN;;WEN CLARK;;CHRZANOWSKI MICHAEL,GUINCHARD LEE;;CHEN TRAVIS;;BRIGHT BRIAN;;WEN CLARK;;CHRZANOWSKI MICHAEL,ACTIVISION PUBLISHING INC (2008-05-20),https://lens.org/000-453-825-391-854,Patent Application,yes,40,48,2,2,0,A63F2300/1043;;A63F2300/1062;;A63F2300/1068;;A63F2300/305;;A63F2300/6063;;A63F2300/638;;A63F2300/8047;;A63F13/814;;A63F2300/61;;A63F13/5375;;A63F2300/64;;A63F13/44;;A63F13/63;;A63F13/245;;A63F13/46;;A63F2300/6081;;A63F2300/6018;;A63F13/57;;A63F2300/1031;;A63F13/54;;A63F13/214;;A63F13/235;;A63F13/814;;A63F13/245;;A63F13/235;;A63F2300/1068;;A63F2300/305;;A63F2300/8047;;A63F2300/1062;;A63F2300/6063;;A63F2300/1043;;A63F2300/638,A63F9/24,463/37;;463/25,0,0,,,,ACTIVE
261,JP,A,JP 2023099146 A,010-730-354-061-247,2023-07-11,2023,JP 2023075428 A,2023-05-01,JP 2021068088 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"To provide new engineered binding polypeptides which allow for stoichiometrically constant conjugation.SOLUTION: The present disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. The present disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.SELECTED DRAWING: None",GENZYME CORP,CLARK PAN;;QIU HUAWEI;;PRADEEP DHAL;;CHEN BO;;DIEGO GIANOLIO,,https://lens.org/010-730-354-061-247,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C12N15/13;;A61K39/395;;A61K47/68;;A61K50/00;;A61K51/10;;A61P29/00;;A61P31/00;;A61P35/00;;C07K16/00;;C07K19/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/62;;C12N15/63;;C12P21/02,,0,0,,,,PENDING
262,US,A1,US 2018/0237413 A1,019-258-191-343-776,2018-08-23,2018,US 201815954759 A,2018-04-17,US 201815954759 A;;US 201615267606 A;;US 201562220358 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/019-258-191-343-776,Patent Application,yes,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D401/04;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;C07D471/08,,0,0,,,,DISCONTINUED
263,AU,B2,AU 2016/323612 B2,076-858-489-031-376,2021-04-08,2021,AU 2016/323612 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/076-858-489-031-376,Granted Patent,no,7,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,2,0,,,"CAS Registry Number 509094-23-9; STN Entry Date 2 May 2003; Benzamide, N-[5-(2-oxo-1-piperidinyl)-1-phenyl-1H-benzimidazol-2-yl]-3-(trifluoromethyl)-;;CAS Registry Number 509094-21-7; STN Entry Date 2 May 2003; Benzamide, N-[1-(trans-4-hydroxycyclohexyl)-5-(2-oxo-1-pyrrolidinyl)-1H-benzimidazol-2-yl]-3-(trifluoromethyl)-",ACTIVE
264,WO,A8,WO 2022/147232 A8,157-132-169-764-806,2023-08-10,2023,US 2021/0065662 W,2021-12-30,US 202063132194 P,2020-12-30,DEVICE INCLUDING FERROELECTRIC NEMATIC LIQUID CRYSTAL-FORMING MOLECULES AND METHODS OF FORMING AND USING SAME,"Surface polarity of a ferroelectric nematic can be configured to generate vectorial control of the orientation of its bulk polarization field. The contact between a surface with in-plane polarity and a ferroelectric nematic liquid crystal generates preferred in-plane orientation of the ferroelectric polarization field at that interface, which can lead to the formation of fluid or glassy monodomains of high polarization without electric field poling. Materials surfaces can be used as a route to making planar-aligned cells with a variety of azimuthal director/polarization structures, including twisted states, in a π-twist cell, obtained with antiparallel, unidirectional buffing on opposing surfaces, we demonstrate three distinct modes of ferroelectric nematic electro-optic response: intrinsic viscosity-limited field induced molecular reorientation, field-induced motion of domain walls separating twisted states of opposite chirality; and propagation of polarization reorientation solitons from the cell plates to the cell center upon field reversal.",UNIV COLORADO REGENTS,CLARK NOEL A;;CHEN XI;;MACLENNAN JOSEPH;;GLASER MATTHEW A,,https://lens.org/157-132-169-764-806,Amended Application,yes,0,0,6,6,0,G02F1/141;;G02F1/1337;;G02F1/133788;;G02F1/141;;G02F1/133788,G02F1/141;;G02F1/1337,,0,0,,,,PENDING
265,CN,A,CN 112969813 A,173-027-510-726-738,2021-06-15,2021,CN 201980073756 A,2019-11-04,US 201862757356 P;;US 2019/0059694 W,2018-11-08,CHEMICAL VAPOR DEPOSITION PROCESSES USING RUTHENIUM PRECURSOR AND REDUCING GAS,"The invention describes a chemical vapor deposition (CVD) processes which use a ruthenium precursor of formula R1R2Ru(0), wherein R1 is an aryl group-containing ligand, and R2 is a diene group-containing ligand and a reducing gas a described. The CVD can include oxygen after an initial deposition period using the ruthenium precursor and reducing gas. The method can provide selective Ru deposition on conductive materials while minimizing deposition on non-conductive or less conductive materials. Further, the subsequent use of oxygen can significantly improve deposition rate while minimizing or eliminating oxidative damage of the substrate material. The method can be used to form Ru-containing layers on integrated circuits and other microelectronic devices.",ENTEGRIS INC,CHEN PHILIP S H;;HENDRIX BRYAN CLARK;;BAUM THOMAS H,,https://lens.org/173-027-510-726-738,Patent Application,no,13,0,10,10,0,C23C16/18;;H01L21/28556;;H01L21/76849;;H01L21/76843;;C23C16/18;;C07F15/0046;;H01L21/28568;;C23C16/18;;C23C18/42;;C23C18/44;;C23C16/02;;C23C16/06,C23C16/18;;C07F15/00,,0,0,,,,PENDING
266,KR,A,KR 20180063145 A,031-751-956-069-590,2018-06-11,2018,KR 20187010914 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,IRAK 억제제로서의 헤테로아릴 화합물 및 이의 용도,"본 발명은 IRAK 억제제로서 유용한, 화학식 I 및 이의 약제학적으로 허용가능한 염에 대한 것이다.",MERCK PATENT GMBH,JORAND LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/031-751-956-069-590,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D235/30;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P19/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08,,0,0,,,,ACTIVE
267,US,A1,US 2020/0087674 A1,046-570-884-963-236,2020-03-19,2020,US 201916405105 A,2019-05-07,US 201916405105 A;;US 201113132186 A;;US 2009/0066560 W;;US 12027308 P,2008-12-05,Regulation of Cotton Fiber Growth by Extracellular Nucleotides and Ectoapyrases,"The present invention includes compositions and methods of modulating the length of one or more cotton fibers in a plant by contacting the plant or tissue derived therefrom with at least one of: a nucleotide; a modulator of ectoapyrase gene transcription; or an anti-ectoapyrase antibody or fragments thereof, at a concentration that modulates growth of one or more cotton fibers.",UNIV TEXAS,ROUX STANLEY J;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY,,https://lens.org/046-570-884-963-236,Patent Application,yes,0,0,5,5,4,C12N9/14;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N9/14,C12N15/82;;C12N9/14,,0,0,,,,ACTIVE
268,TW,A,TW 202338022 A,050-037-363-849-955,2023-10-01,2023,TW 112103769 A,2023-02-03,US 202263306287 P,2022-02-03,Process for selectively depositing highly-conductive metal films,"Provided is a process comprising a selective ruthenium seed layer deposition with oxygen-free ruthenium precursors, followed by bulk deposition of metal-containing precursors such as tungsten, molybdenum, cobalt, ruthenium, and/or copper-containing precursors. The ruthenium seed layer deposition is highly selective for the conducting portions of the microelectronic device substrate while minimizing deposition onto the insulating surfaces of the microelectronic device substrate. In certain embodiments, the conducting portions of the substrate is chosen from titanium nitride, tungsten nitride, tantalum nitride, tungsten, cobalt, molybdenum, aluminum, and copper.",ENTEGRIS INC,CHEN PHILIP S H;;HENDRIX BRYAN CLARK;;CAMERON THOMAS M,,https://lens.org/050-037-363-849-955,Patent of Addition,no,0,0,3,3,0,C23C16/18;;C23C16/45553;;H01L21/28562;;H01L21/28556;;H01L21/76876;;H01L21/28568;;H01L21/76843;;C23C16/14;;C23C16/45523;;C23C16/0281;;C23C16/04;;C23C16/045;;H01L21/28568;;H01L21/76843;;H01L21/76876;;C23C16/14,C09D11/52;;H01B1/00;;H01B1/22;;H01B13/00,,0,0,,,,PENDING
269,JP,A,JP 2019065384 A,056-326-339-232-807,2019-04-25,2019,JP 2018140845 A,2018-07-27,US 201715664446 A,2017-07-31,ADHESION IMPROVED BY THERMAL SPRAY COATING ON SMOOTH SURFACE,"To provide a coated component, a method for forming the same and a method for using the coated component.SOLUTION: A coated component (10) is generally provided together with a method for forming such a coating system (20). The coated component (10) includes a base material having surfaces (25 and 27) having a coating system (20) thereon; the coating system (20) may include a columnar thermal barrier coating (TBC) (24) on the surfaces (25 and 27) of the base material, and the columnar TBC (24) includes a gap (30) connected on the surfaces; an intermediate layer (26) is on the columnar TBC layer and has surfaces (25, 27) rougher than the surfaces (25, 27) of the columnar TBC (24) on the side opposite to the columnar TBC (24); and a second TBC (28) is on the intermediate layer (26).SELECTED DRAWING: Figure 1",GENERAL ELECTRIC CO GE,CHEN DIANYING;;FU MING;;MICHAEL DAVID CLARK;;KONITZER DOUGLAS GERARD,,https://lens.org/056-326-339-232-807,Patent Application,no,6,1,6,6,0,B05D5/00;;B05D7/54;;C23C28/042;;C23C28/048;;C23C28/44;;F01D5/288;;C23C4/134;;F05D2230/90;;F05D2230/312;;F05D2230/313;;F05D2230/31;;F05D2300/21;;F05D2300/2118;;F05D2250/63;;C23C4/134;;C23C4/04;;F01D5/288;;C23C28/048;;C23C28/042;;C23C28/44,C23C4/11;;C23C4/134;;F02C7/00,,0,0,,,,PENDING
270,ES,T3,ES 2911888 T3,091-946-801-759-198,2022-05-23,2022,ES 16770654 T,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos,"Un compuesto de fórmula I, **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo, donde: **(Ver fórmula)** se selecciona entre **(Ver fórmula)** el anillo X es **(Ver fórmula)** R3 es -R o -haloalquilo; R4 es -R, halógeno, -haloalquilo, -OR, -SR, -CN, -NO2, -SO2R, -SOR, -C(O)R, -CO2R, -C(O)N(R)2, -NRC(O)R, -NRC(O)N(R)2, -NRSO2R o -N(R)2; y cada R es independientemente hidrógeno, grupo alifático C1-6, arilo C3-10, un anillo carbocíclico de 3-8 átomos saturado o parcialmente insaturado, un anillo heterocíclico de 3-7 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5-6 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido; o se toman dos grupos R del mismo átomo junto con el átomo al que están unidos para formar un arilo C3-10, un anillo carbocíclico de 3-8 átomos saturado o parcialmente insaturado, un anillo heterocíclico de 3-7 átomos que tiene 1-4 heteroátomos seleccionados independientemente entre nitrógeno, oxígeno o azufre, o un anillo heteroarilo monocíclico de 5-6 átomos que tiene 1-4 heteroátomos, seleccionados independientemente entre nitrógeno, oxígeno o azufre; cada uno de los cuales está opcionalmente sustituido.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/091-946-801-759-198,Granted Patent,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D235/30;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,ACTIVE
271,BR,A2,BR 112015020885 A2,141-372-799-184-365,2017-10-10,2017,BR 112015020885 A,2014-03-10,US 2014/0022623 W;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,polipeptídeos de ligação hiperglicosilados,"resumo patente de invenção: ""polipeptídeos de ligação hiperglicosilados"". são fornecidos polipeptídeos de ligação (por exemplo, anticorpos), e conjugados de porção efetora dos mesmos, compreendendo um domínio de ch1 (por exemplo, um domínio de ch1 de igg1 humano), em que o domínio de ch1 tem um sítio de glicosilação n-ligado construído na posição de aminoácido (114), de acordo com a numeração de kabat. da mesma forma são fornecidos ácidos nucleicos que codificam os polipeptídeos de ligação de antígeno, vetores de expressão recombinantes e células hospedeiras para preparar tais polipeptídeos de ligação de antígeno. métodos de usar os polipeptídeos de ligação de antígeno aqui descritos para tratar doença são da mesma forma fornecidos. 1/1",GENZYME CORP,BO CHEN;;CLARK PAN;;DIEGO GIANOLIO;;HUAWEI QIU;;PRADEEP DHAL,,https://lens.org/141-372-799-184-365,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,DISCONTINUED
272,US,A1,US 2020/0140564 A1,153-992-613-239-78X,2020-05-07,2020,US 201916655500 A,2019-10-17,US 201916655500 A;;US 201715614015 A;;US 201414203438 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,GENZYME CORPORATION (2013-09-05),https://lens.org/153-992-613-239-78X,Patent Application,yes,10,2,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,4,4,042-601-433-468-58X;;086-617-534-349-291;;077-406-419-134-117;;077-950-844-586-930,15520207;;10.1158/0008-5472.can-04-1722;;pmc52575;;10.1073/pnas.88.19.8691;;1717984;;10.1016/j.jim.2004.01.024;;15099763;;10.1016/j.molimm.2004.11.003;;15829301,"Henry et al., Cancer Res. 64: 7995-8001 (Year: 2004);;Stancovski et al., Proceedings of the National Academy of Science USA 88: 8691-8695 (Year: 1991);;Cochran et al., J. Immunol. Meth. 287: 147-158 (Year: 2004);;Riemer et al., Mol. Immunol. 42: 1121-1124 (Year: 2005)",ACTIVE
273,WO,A1,WO 2018/017341 A1,199-401-799-950-669,2018-01-25,2018,US 2017/0041088 W,2017-07-07,US 201662365492 P,2016-07-22,METHODS AND COMPOSITIONS FOR REJUVENATION,Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,LI SENLIN;;CLARK ROBERT A;;CHEN CANG;;GUDERYON MICHAEL J,,https://lens.org/199-401-799-950-669,Patent Application,yes,4,0,2,2,0,C12N5/0647;;C12N2501/22;;C12N5/0647;;C12N2501/22;;A61K38/193;;A61M1/3496;;A61K31/395;;A61K2035/124;;A61M1/38;;A61K35/28,C12N5/00;;C12N5/0735;;C12N5/074;;C12N5/0789;;C12N5/16;;C12N9/02,,1,1,019-820-814-326-119,pmc2213145;;15837815;;10.1084/jem.20041385,"BROXMEYER ET AL.: ""Rapid Mobilization of Murine and Human Hematopoietic Stem and Progenitor Cells with AMD3100, a CXCR4 Antagonist"", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 201, no. 8, 18 April 2005 (2005-04-18), pages 1307 - 1318, XP009076434",PENDING
274,BR,A2,BR 112018003343 A2,001-471-048-544-259,2018-09-25,2018,BR 112018003343 A,2016-09-16,US 2016/0052107 W;;US 201562220358 P,2015-09-18,compostos heteroarila como inibidores de irak e usos dos mesmos,"a presente invenção refere-se a compostos de fórmula i e suas composições farmaceuticamente aceitáveis, úteis como inibidores de irak.",MERCK PATENT GMBH,AUSTIN CHEN;;CATHERINE JORAND-LEBRUN;;RUOXI LAN;;RYAN C CLARK,,https://lens.org/001-471-048-544-259,Patent Application,no,0,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,0,0,,,,PENDING
275,EP,A1,EP 3350177 A1,015-282-896-226-697,2018-07-25,2018,EP 16778936 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,,MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,MERCK PATENT GMBH (2022-05-04),https://lens.org/015-282-896-226-697,Patent Application,yes,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,ACTIVE
276,WO,A1,WO 2017/049068 A1,033-391-112-846-333,2017-03-23,2017,US 2016/0052104 W,2016-09-16,US 201562220307 P,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH;;JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/033-391-112-846-333,Patent Application,yes,8,21,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,1,1,013-862-057-494-226,10.1016/j.bmcl.2008.04.042;;18501603,"BUCKLEY G M ET AL: ""IRAK-4 inhibitors. Part III: A series of imidazo[1,2-a]pyridines"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 18, no. 12, 15 June 2008 (2008-06-15), pages 3656 - 3660, XP022707452, ISSN: 0960-894X, [retrieved on 20080424], DOI: 10.1016/J.BMCL.2008.04.042",PENDING
277,JP,A,JP 2019103514 A,036-927-161-435-399,2019-06-27,2019,JP 2019040108 A,2019-03-06,US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"To provide novel modified binding polypeptides that enable constant conjugation, since the capability to attach a molecule(s) reliably and efficiently to one or more defined site(s) of an antibody is highly desirable in conjugation of a drug to a monoclonal antibody or other polypeptides.SOLUTION: The invention provides a binding polypeptide, for example, an antibody comprising a CH1 domain (e.g., a human CH1 domain) having a modified N-linked glycosylation site at amino acid position 114 according to Kabat numbering, as well as a conjugate between the binding polypeptide and an effector moiety. Also disclosed are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells to prepare such antigen-binding polypeptides. Methods for treating disease using the antigen-binding polypeptide are also disclosed.SELECTED DRAWING: None",GENZYME CORP,CLARK PAN;;QIU HUAWEI;;PRADEEP DHAL;;CHEN BO;;DIEGO GIANOLIO,,https://lens.org/036-927-161-435-399,Patent Application,no,4,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C12N15/13;;A61K39/395;;A61K45/00;;A61P43/00;;C07K16/00;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/08,,5,1,087-412-910-091-181,10.1016/j.jim.2007.12.011;;18230399,"JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, JPN6017050905, 1998, pages 131 - 144, ISSN: 0004406331;;FEBS LETTERS, vol. 108, no. 2, JPN6017050906, 1979, pages 341 - 344, ISSN: 0004406332;;BIOTECHNOL. PROG., vol. 21, JPN6017025072, 2005, pages 1644 - 1652, ISSN: 0004406333;;JOURNAL OF IMMUNOLOGICAL METHODS, vol. 332, JPN6017050908, 2008, pages 41 - 52, ISSN: 0004406334;;MOLECULAR THERAPY, vol. 17, no. 6, JPN6017050909, 2009, pages 954 - 963, ISSN: 0004406335",ACTIVE
278,WO,A1,WO 2023/086522 A1,042-175-129-077-42X,2023-05-19,2023,US 2022/0049620 W,2022-11-10,US 202163278047 P,2021-11-10,CHARGE-CONTROLLED DEVICES AND METHODS OF FORMING AND USING SAME,"Devices including a volume containing a ferroelectric nematic liquid crystalline material, a dielectric layer overlying a portion of the volume, and a charge-bearing substrate or layer are disclosed. Methods of forming and using such devices are also disclosed.",UNIV COLORADO REGENTS,GLASER MATTHEW A;;CLARK NOEL;;MACLENNAN JOSEPH E;;CHEN XI,,https://lens.org/042-175-129-077-42X,Patent Application,yes,3,0,1,1,0,G02F1/141;;G02F1/133723,G02F1/141;;G02F1/1333;;G02F1/136;;G02F1/166,,0,0,,,,PENDING
279,AU,B2,AU 2016/323613 B2,045-677-025-174-304,2020-12-10,2020,AU 2016/323613 A,2016-09-16,US 201562220358 P;;US 2016/0052107 W,2015-09-18,Heteroaryl compounds as IRAK inhibitors and uses thereof,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/045-677-025-174-304,Granted Patent,no,7,0,26,26,0,C07D235/30;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02;;A61P1/00;;A61P1/04;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/10;;A61P3/10;;Y02A50/30;;C07D235/30;;C07D403/04;;C07D451/02;;A61K31/4439;;C07D401/04;;C07D413/04;;A61K31/4184;;C07D405/04;;A61K31/506;;A61P19/00;;A61K31/4184;;A61K31/4439;;A61K31/506;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D471/08;;A61K31/4184;;A61K31/4439;;A61K31/506;;A61P1/00;;A61P1/04;;A61P3/00;;A61P3/10;;A61P9/10;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;C07D235/30;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08;;A61K31/4439;;A61K31/506;;A61K31/4184;;C07D235/30;;C07D471/08;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D451/02,C07D233/88;;A61K31/4184;;A61K31/454;;A61P1/00;;A61P3/00;;A61P17/00;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D405/04;;C07D413/04;;C07D471/08,,3,3,003-250-925-861-330;;004-979-586-257-050;;045-057-900-438-033,10.1016/j.bmcl.2014.05.009;;pmc4096041;;24856063;;23220640;;10.1016/j.ejmech.2012.11.009;;10.1007/s00706-015-1478-8,"DING K. ET AL., ""Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site"", BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2014-05-14), vol. 24, pages 3113 - 3117;;HRANJEC ET AL., ""Antiproliferative potency of novel benzofuran-2-carboxamides on tumour cell lines: mechanisms and determination of crystal structure"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2012-11-16), vol. 59, pages 111 - 119;;SOVIC IRENA ET AL, ""Exploring antiproliferative activity of heteroaromatic amides and their fused derivatives using 3D-QSAR, synthesis and biological tests"", MONATSHEFTE FÜR CHEMIE, vol. 146, no 9, doi:10.1007/S00706-015-1478-8, pp 1503-17",ACTIVE
280,JP,A,JP 2021106600 A,080-258-640-232-425,2021-07-29,2021,JP 2021068088 A,2021-04-14,JP 2019040108 A;;US 201361776724 P;;US 201361776715 P;;US 201361776710 P,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDE,"To provide new engineered binding polypeptides which allow for stoichiometrically constant conjugation.SOLUTION: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.SELECTED DRAWING: None",GENZYME CORP,CLARK PAN;;QIU HUAWEI;;PRADEEP DHAL;;CHEN BO;;DIEGO GIANOLIO,,https://lens.org/080-258-640-232-425,Patent Application,no,4,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C12N15/13;;A61K39/395;;A61K47/64;;A61K47/68;;A61K51/10;;A61P43/00;;C07K16/00;;C12P21/08,,5,0,,,"JOURNAL OF IMMUNOLOGICAL METHODS, vol. 213, JPN6017050905, 1998, pages 131 - 144, ISSN: 0004955860;;FEBS LETTERS, vol. 108, no. 2, JPN6017050906, 1979, pages 341 - 344, ISSN: 0004955861;;BIOTECHNOL. PROG., vol. 21, JPN6017025072, 2005, pages 1644 - 1652, ISSN: 0004955862;;JOURNAL OF IMMUNOLOGICAL METHODS, vol. 332, JPN6017050908, 2008, pages 41 - 52, ISSN: 0004955863;;MOLECULAR THERAPY, vol. 17, no. 6, JPN6017050909, 2009, pages 954 - 963, ISSN: 0004955864",ACTIVE
281,MX,B,MX 370679 B,117-939-030-652-443,2019-12-19,2019,MX 2015012527 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES.,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,HUAWEI QIU;;CLARK PAN;;PRADEEP DHAL;;BO CHEN;;DIEGO GIANOLIO,,https://lens.org/117-939-030-652-443,Granted Patent,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/68;;C07K16/32;;C07K16/40,,0,0,,,,ACTIVE
282,WO,A2,WO 2023/034628 A2,117-077-054-333-934,2023-03-09,2023,US 2022/0042586 W,2022-09-05,US 202163240666 P;;US 202163278039 P,2021-09-03,MIXTURE INCLUDING FERROELECTRIC NEMATIC PHASE AND METHODS OF FORMING AND USING SAME,"Material comprising a ferroelectric nematic phase, the material are disclosed. The material can include a mixture comprising first molecules and second molecules. At least one of a fluid of the first molecules and a fluid of the second molecules exhibits a ferroelectric nematic phase. The first molecules and second molecules are miscible. The first molecules can induce a polar orientational order of said second molecules.",UNIV COLORADO REGENTS,MACLENNAN JOSEPH;;CLARK NOEL;;GLASER MATTHEW;;CHEN XI;;SMITH GREGORY,,https://lens.org/117-077-054-333-934,Patent Application,yes,0,0,2,2,0,C09K19/0225;;C09K2019/2078;;C09K2019/3422,C09K19/02,,0,0,,,,PENDING
283,CA,A1,CA 2902525 A1,143-328-954-537-795,2014-10-09,2014,CA 2902525 A,2014-03-10,US 201361776724 P;;US 201361776715 P;;US 201361776710 P;;US 2014/0022623 W,2013-03-11,HYPERGLYCOSYLATED BINDING POLYPEPTIDES,"Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position (114), according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;QIU HUAWEI;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO,,https://lens.org/143-328-954-537-795,Patent Application,no,0,0,88,165,41,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,0,0,,,,PENDING
284,RU,C2,RU 2743716 C2,177-396-544-235-637,2021-02-24,2021,RU 2018114017 A,2016-09-16,US 201562220307 P;;US 2016/0052104 W,2015-09-18,HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND THEIR APPLICATION,"FIELD: chemistry.SUBSTANCE: present invention relates to a compound of formula Ior its pharmaceutically acceptable salt. According to formula I,is pyrrolidinone, oxazolidinone, imidazolidinone, dihydrotriazolone, piperidinone, tetrahydropyrimidinone, morpholinone, oxazinanone, piperazinone, thiomorpholinone, thiazinane dioxide, pyridinone, pyridazinone, oxazepanone, diazepanone, diazabicyclo[3.1.1]heptanone, diazabicyclo[3.2.1]octanone, diazabicyclo[3.2.2]nonanone or oxaazabicyclo[3.2.1]octanone where each ring represented bycontains an alpha carbonyl with respect to the nitrogen atom that connects the ring to the backbone to form a cyclic amide; ring X is phenyl, a 5-6 membered monocyclic heteroaryl ring containing 1-4 heteroatoms independently selected from nitrogen and oxygen, fused with a 9-10 membered heterocyclic ring containing 1-3 heteroatoms independently selected from nitrogen and oxygen, or a condensed 9-10 membered heteroaryl ring containing 1-3 heteroatoms independently selected from nitrogen and sulfur; Z is N or CH; the values ​​of Ra, R1, R2, R3, R4and p are as defined in the claims. Also provided are a pharmaceutical composition, a method for inhibiting IRAK and a method for treating an IRAK-mediated disorder.EFFECT: proposed compounds display inhibitory activity against IRAK and can be used for the treatment of IRAK-mediated disorders.11 cl, 2 tbl, 234 ex",MERCK PATENT GMBH,JORAND-LEBRUN CATHERINE;;LAN RUOXI;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/177-396-544-235-637,Granted Patent,no,9,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D401/04;;C07D403/04;;C07D413/14;;C07D417/04;;C07D417/14;;C07D487/08;;C07D491/08;;C07D498/08,,1,1,013-862-057-494-226,10.1016/j.bmcl.2008.04.042;;18501603,"BUCKLEY G.M. et al, IRAK-4 inhibitors. Part III: A series of imidazole[1,2-a]pyridines, Bioorg. Med. Chem. Lett., 2008, p. 3656-3660.",ACTIVE
285,NZ,A,NZ 739676 A,175-130-879-862-754,2022-02-25,2022,NZ 73967616 A,2016-09-16,US 2016/0052104 W;;US 201562220307 P,2015-09-18,Heteroaryl compounds as irak inhibitors and uses thereof,"The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.",MERCK PATENT GMBH,LAN RUOXI;;JORAND-LEBRUN CATHERINE;;CHEN AUSTIN;;CLARK RYAN C,,https://lens.org/175-130-879-862-754,Patent Application,no,0,0,27,27,0,C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61P1/04;;A61P13/10;;A61P13/12;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P31/04;;A61P35/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D413/14;;A61P1/04;;A61P3/10;;C07D403/04;;A61P25/28;;A61K31/4184;;C07D491/08;;C07D413/04;;C07D498/08;;A61P19/02;;C07D487/08;;A61P25/16;;C07D417/04;;A61P35/00;;C07D401/04;;A61P17/06;;A61P19/10;;C07D471/08;;A61P19/00;;A61P25/00;;A61P35/00;;A61K31/4184;;A61K31/5377;;C07D401/04;;C07D403/04;;C07D413/04;;C07D417/04;;A61K31/4184;;A61K31/5377;;A61P19/00;;A61P25/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D491/08;;C07D491/08;;C07D401/04;;C07D403/04;;C07D413/04;;C07D413/14;;C07D417/04;;C07D471/08;;C07D487/08;;C07D498/08;;A61K31/4184,C07D413/14;;A61K31/4184;;A61P29/00;;A61P35/00;;C07D403/04;;C07D413/04;;C07D417/04;;C07D487/08;;C07D491/08,,0,0,,,,PENDING
286,US,B2,US 8450835 B2,193-540-020-170-258,2013-05-28,2013,US 14921708 A,2008-04-29,US 14921708 A,2008-04-29,Reverse leakage reduction and vertical height shrinking of diode with halo doping,"One embodiment of the invention provides a semiconductor diode device including a first conductivity type region, a second conductivity type region, where the second conductivity type is different from the first conductivity type, an intrinsic region located between the first conductivity type region and the second conductivity type region; a first halo region of the first conductivity type located between the second conductivity type region and the intrinsic region, and optionally a second halo region of the second conductivity type located between the first conductivity type region and the intrinsic region.",CHEN XIYING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY;;SANDISK 3D LLC,CHEN XIYING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY,SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2008-04-28),https://lens.org/193-540-020-170-258,Granted Patent,yes,53,1,4,4,0,H01L29/1606;;H01L29/8615;;H01L29/868;;H01L29/868;;H01L29/8615;;H01L29/1606,H01L29/06,257/656;;257/104;;257/109;;X257E21459,19,1,077-656-265-724-625,10.1109/msmw.2001.947308,"U.S. Appl. No. 10/095,962, filed Mar. 13, 2002, Herner et al.;;U.S. Appl. No. 10/185,507, filed Jun. 27, 2002, Vyvoda et al.;;U.S. Appl. No. 10/440,882, filed May 19, 2003, Vyvoda et al.;;U.S. Appl. No. 10/728,436, filed Dec. 5, 2003, Chen.;;U.S. Appl. No. 10/728,451, filed Dec. 5, 2003, Cleeves et al.;;U.S. Appl. No. 10/815,312, filed Apr. 1, 2004, Chen.;;U.S. Appl. No. 10/883,417, filed Jun. 30, 2004, Raghuram et al.;;U.S. Appl. No. 10/954,510, filed Sep. 29, 2004, Herner.;;U.S. Appl. No. 11/148,530, filed Jun. 8, 2006, Herner et al.;;U.S. Appl. No. 11/395,995, filed Mar. 31, 2006, Herner et al.;;U.S. Appl. No. 11/444,936, filed May 31, 2006, Radigan et al.;;U.S. Appl. No. 11/693,858, filed Mar. 30, 2007, Kumar et al.;;U.S. Appl. No. 11/819,078, filed Jun. 25, 2007, Herner.;;U.S. Appl. No. 12/007,780, filed Jan. 15, 2008, Herner et al.;;U.S. Appl. No. 12/007,781, filed Jan. 15, 2008, Vance et al.;;International Search Report and Written Opinion mailed Jul. 2, 2009, received in International Application No. PCT/US2009/002402.;;D. Caputo et al., ""Evidence of Hysteresis in a New p-i-n-i-p-i-n Amorphous Silicon Device,"" Materials Research Society Symposium Proceedings, vol. 467, (1997), pp. 943-948.;;P.P. Maksymov, ""Static electrical fields of reverse-biased GaAs- and Ge-pnipn structures,"" Physics and Engineering of Millimeter and Sub-Millimeters Waves, 2001, The Fourth International Kharkov Symposium, Jun. 4-9, 2001, pp. 777-779.;;International Bureau of WIPO. International Preliminary Report on Patentability, Intl. Application PCT/US09/02402. Nov. 11, 2010. 10 pages.",ACTIVE
287,US,A1,US 2022/0122880 A1,078-489-342-218-437,2022-04-21,2022,US 202016949214 A,2020-10-20,US 202016949214 A,2020-10-20,TRENCH ISOLATION PROCESS,"One or more semiconductor processing tools may form a deep trench within a silicon wafer. The one or more semiconductor processing tools may deposit a first insulating material within the deep trench. The one or more semiconductor processing tools may form, after forming the deep trench with the silicon wafer, a shallow trench above the deep trench. The one or more semiconductor processing tools may deposit a second insulating material within the shallow trench.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;CHEN CHENG-HSIN;;TING CHUNG CHIEH;;LIN CHE-YI;;LEE CLARK,TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LIMITED (2020-09-28),https://lens.org/078-489-342-218-437,Patent Application,yes,8,2,6,6,0,H01L21/76224;;H01L21/76224;;H01L21/02123;;H01L21/30625;;H01L21/31133;;H01L21/76224,H01L21/762;;H01L21/02;;H01L21/311,,0,0,,,,ACTIVE
288,TW,B,TW I782363 B,111-552-794-915-827,2022-11-01,2022,TW 109143098 A,2020-12-07,US 202016949214 A,2020-10-20,Method of providing trench isolation and semiconductor device,,TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;CHEN CHENG-HSIN;;TING CHUNG CHIEH;;LIN CHE-YI;;LEE CLARK,,https://lens.org/111-552-794-915-827,Granted Patent,no,3,0,6,6,0,H01L21/76224;;H01L21/76224;;H01L21/02123;;H01L21/30625;;H01L21/31133;;H01L21/76224,,,0,0,,,,ACTIVE
289,US,B2,US 11443976 B2,162-767-737-191-47X,2022-09-13,2022,US 202016949214 A,2020-10-20,US 202016949214 A,2020-10-20,Trench isolation process,"One or more semiconductor processing tools may form a deep trench within a silicon wafer. The one or more semiconductor processing tools may deposit a first insulating material within the deep trench. The one or more semiconductor processing tools may form, after forming the deep trench with the silicon wafer, a shallow trench above the deep trench. The one or more semiconductor processing tools may deposit a second insulating material within the shallow trench.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;CHEN CHENG-HSIN;;TING CHUNG CHIEH;;LIN CHE-YI;;LEE CLARK,TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LIMITED (2020-09-28),https://lens.org/162-767-737-191-47X,Granted Patent,yes,13,0,6,6,0,H01L21/76224;;H01L21/76224;;H01L21/02123;;H01L21/30625;;H01L21/31133;;H01L21/76224,H01L21/762;;H01L21/02;;H01L21/306;;H01L21/311,,0,0,,,,ACTIVE
290,US,A1,US 2022/0392799 A1,193-746-421-552-111,2022-12-08,2022,US 202217818497 A,2022-08-09,US 202217818497 A;;US 202016949214 A,2020-10-20,TRENCH ISOLATION PROCESS,"One or more semiconductor processing tools may form a deep trench within a silicon wafer. The one or more semiconductor processing tools may deposit a first insulating material within the deep trench. The one or more semiconductor processing tools may form, after forming the deep trench with the silicon wafer, a shallow trench above the deep trench. The one or more semiconductor processing tools may deposit a second insulating material within the shallow trench.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;CHEN CHENG-HSIN;;TING CHUNG CHIEH;;LIN CHE-YI;;LEE CLARK,TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LIMITED (2020-09-28),https://lens.org/193-746-421-552-111,Patent Application,yes,3,0,6,6,0,H01L21/76224;;H01L21/76224;;H01L21/02123;;H01L21/30625;;H01L21/31133;;H01L21/76224,H01L21/02;;H01L21/762;;H01L21/306;;H01L21/311,,0,0,,,,PENDING
291,DE,D1,DE 69905041 D1,004-116-426-303-034,2003-02-27,2003,DE 69905041 T,1999-05-21,EP 98870131 A;;EP 9903499 W,1998-06-10,"ZUSAMMENSETZUNG AUF BASIS VON MODIFIZIERTEM GELLANGUMMI, VERFAHREN ZU DESSEN HERSTELLUNG UND SEINE VERWENDUNG",,CP KELCO APS LILLE SKENSVED,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISSON A;;TALASHEK TODD;;CLARK ROSS,,https://lens.org/004-116-426-303-034,Granted Patent,no,0,0,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,0,0,,,,EXPIRED
292,KR,A,KR 20040002671 A,035-246-887-124-100,2004-01-07,2004,KR 20030041369 A,2003-06-25,US 39155702 P,2002-06-25,PVD SUPPORTED MIXED METAL OXIDE CATALYST,"PURPOSE: An improved catalyst for the oxidation of alkanes, or a mixture of alkanes and alkenes, to their corresponding unsaturated carboxylic acids by vapor phase catalytic partial oxidation, a method of making and supporting the catalyst, and a process for the vapor phase catalytic partial oxidation of alkanes, or a mixture of alkanes and alkenes, to their corresponding unsaturated carboxylic acids are provided. CONSTITUTION: The process for the preparation of a supported catalyst comprises the steps of (a) providing a catalyst support; (b) sequentially depositing on the support a catalyst composition comprising, in random order, as essential elements, at least one layer comprising Mo, at least one layer comprising V, at least one layer comprising Te, and at least one layer comprising X, wherein X is at least one element selected from the group consisting of Nb, Ta, W, Ti, Al, Zr, Cr, Mn, Fe, Ru, Co, Rh, Ni, Pd, Pt, Sb, Bi, B, In and Ce, to form a loaded support, the sequential vapor deposition providing relative amounts of the elements such that, after a calcination of the loaded support, the relative amounts of the elements satisfy the following expression: MoaVbTecXd, wherein a, b, c and d are the relative atomic amounts of the essential elements Mo, V, Te and X, respectively, and, when a=1, b=0.01 to 1.0, c=0.01 to 1.0 and d=0.01 to 1.0; and (c) calcining the loaded support. The catalytic process comprises the steps of (a) providing a catalyst support; (b) sequentially depositing on the support a catalyst composition comprising, in random order, as essential elements, at least one layer comprising Mo, at least one layer comprising V, at least one layer comprising Te, and at least one layer comprising X, wherein X is at least one element selected from the group consisting of Nb, Ta, W, Ti, Al, Zr, Cr, Mn, Fe, Ru, Co, Rh, Ni, Pd, Pt, Sb, Bi, B, In and Ce, to form a loaded support, the sequential vapor deposition providing relative amounts of the elements such that, after a calcination of the loaded support, the relative amounts of the elements satisfy the following expression: MoaVbTecXd, wherein a, b, c and d are the relative atomic amounts of the essential elements Mo, V, Te and X, respectively, and, when a=1, b=0.01 to 1.0, c=0.01 to 1.0 and d=0.01 to 1.0; (c) calcining the loaded support; and (d) subjecting a feed including an alkane or a mixture of an alkane and an alkene to a vapor phase catalytic partial oxidation reaction in the presence of the calcined loaded support.",ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE JR;;GAFFNEY ANNE MAE,,https://lens.org/035-246-887-124-100,Patent Application,no,0,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,DISCONTINUED
293,US,B2,US 11640405 B2,079-273-583-932-715,2023-05-02,2023,US 202017108372 A,2020-12-01,US 202017108372 A;;US 201715929318 A;;US 201916570219 A;;US 201916255762 A;;US 201615083058 A;;US 2014/0059103 W;;US 201361886555 P,2013-10-03,Methods for analyzing genotypes,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,CHANDRATILLAKE GEMMA L;;GARCIA SARAH K;;CHEN RICHARD;;CLARK MICHAEL JAMES,PERSONALIS INC (2014-10-01),https://lens.org/079-273-583-932-715,Granted Patent,yes,138,0,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G06F16/2457;;G06F16/248;;G16B20/00;;G16B20/20;;G16B50/00;;G16B50/10,,177,153,026-129-645-699-551;;078-381-584-206-039;;089-584-029-489-307;;111-093-078-328-445;;103-261-559-380-762;;017-055-400-864-20X;;027-897-404-212-931;;026-414-906-566-910;;042-694-322-554-974;;002-118-289-687-006;;041-683-581-320-013;;007-521-351-630-687;;025-700-520-358-36X;;060-299-231-241-596;;076-393-133-359-189;;045-057-747-010-726;;015-040-005-933-987;;051-699-500-456-576;;054-927-332-780-887;;007-768-658-124-927;;043-187-090-326-20X;;052-058-972-976-357;;065-793-135-853-15X;;063-760-585-710-590;;042-028-784-421-776;;063-775-792-131-091;;030-275-384-700-023;;061-092-625-394-817;;001-085-626-560-547;;007-165-296-236-346;;003-566-546-374-656;;017-824-739-633-316;;018-565-258-437-405;;018-636-083-256-332;;085-278-198-162-742;;065-805-607-470-014;;041-326-786-817-693;;032-214-438-107-967;;040-114-686-060-186;;098-890-110-994-679;;034-060-335-674-727;;010-062-796-785-17X;;107-437-565-404-97X;;042-917-117-756-310;;047-145-677-909-324;;047-145-677-909-324;;072-952-674-340-512;;124-140-657-602-876;;060-936-041-911-404;;003-373-615-033-396;;037-630-631-091-922;;043-604-184-975-184;;132-706-623-273-568;;035-148-355-352-744;;072-830-000-427-894;;095-968-551-297-877;;015-770-886-648-944;;040-240-771-908-767;;046-677-294-561-843;;032-755-081-651-733;;114-624-174-153-410;;088-719-963-098-347;;018-313-456-950-874;;038-216-767-939-171;;091-697-722-033-845;;128-964-301-556-474;;025-893-710-899-136;;012-334-909-741-704;;023-643-023-712-451;;097-695-465-307-188;;050-947-334-853-640;;036-636-356-364-148;;062-534-143-598-528;;086-716-470-307-458;;037-329-311-896-147;;029-520-048-641-520;;014-650-477-193-51X;;021-052-954-181-321;;040-795-607-538-396;;067-994-956-829-337;;017-623-124-216-873;;071-688-664-127-164;;139-420-082-283-78X;;111-775-049-884-731;;049-160-266-173-648;;026-752-236-646-779;;010-866-139-512-319;;068-350-822-632-910;;045-368-569-060-947;;037-520-423-993-289;;133-948-236-374-084;;008-914-701-728-582;;058-229-811-685-892;;068-791-812-448-670;;099-331-387-163-267;;020-459-844-094-161;;106-850-251-926-014;;038-944-728-272-47X;;060-394-055-163-837;;042-495-096-503-295;;051-180-976-921-647;;051-180-976-921-647;;015-828-439-921-354;;067-938-552-932-390;;026-315-603-754-419;;006-349-136-605-392;;017-113-088-272-404;;006-128-543-521-322;;056-195-908-415-906;;017-172-604-440-583;;045-826-674-589-143;;045-826-674-589-143;;045-826-674-589-143;;015-453-955-064-354;;000-353-138-882-418;;021-630-366-628-950;;043-885-019-636-545;;056-660-935-780-678;;045-597-414-145-558;;021-037-752-940-187;;061-666-906-572-608;;013-679-252-116-102;;009-324-197-806-807;;107-619-298-099-831;;030-148-170-747-844;;092-028-711-773-790;;056-686-969-336-01X;;053-364-733-637-579;;027-960-730-645-117;;087-515-645-050-945;;041-235-295-588-781;;006-960-435-136-406;;006-960-435-136-406;;046-595-083-143-730;;072-679-325-248-561;;089-592-031-511-745;;041-734-358-076-414;;010-952-167-077-087;;053-790-819-891-510;;007-006-686-100-737;;028-221-653-792-750;;003-152-050-269-49X;;045-613-896-389-439;;056-577-106-186-228;;168-150-402-262-991;;058-566-181-175-739;;104-399-284-573-562;;039-949-677-071-780;;134-662-531-406-256;;130-419-098-423-040;;076-254-297-138-905;;076-254-297-138-905;;078-075-819-222-215,pmc2768590;;19861545;;10.1073/pnas.0910672106;;10.1038/nature08250;;pmc2844771;;19684571;;24702956;;10.1016/j.ajhg.2014.03.010;;pmc3980410;;10.1038/sj.ejhg.5201585;;16493445;;10.1093/nar/28.20.e87;;pmc110803;;11024189;;17934467;;10.1038/nmeth1111;;10.1186/gb-2011-12-9-r95;;pmc3308058;;21955857;;pmc2911110;;10.1186/gb-2010-11-6-r62;;20565776;;10.3233/cbm-2009-0144;;20938087;;21946919;;10.1038/nrg3031;;19181738;;10.1373/clinchem.2008.113597;;22750103;;10.1016/j.ab.2012.06.018;;23535274;;10.1016/j.ab.2013.03.008;;10.1038/nrg3424;;23594909;;10.1093/humupd/8.6.493;;12498419;;10.1016/s0021-9258(18)81883-x;;2498321;;10.1371/journal.pone.0039630;;22815712;;pmc3399827;;21642682;;10.1001/jama.2011.743;;19259405;;pmc2623308;;10.4137/cin.s408;;12651960;;10.1073/pnas.0230489100;;pmc153030;;10.4161/epi.6.12.18280;;22139572;;10.1196/annals.1368.045;;17108229;;pmc3248619;;22120468;;10.1038/nmeth.1781;;pmc2952975;;20930075;;10.1128/cmr.00012-10;;11514393;;10.1093/clinchem/47.9.1607;;10.1038/nbt.1975;;21947028;;pmc4127531;;10.1038/nmeth.1251;;18794863;;pmc3171277;;22440735;;pmc3589570;;10.1126/scitranslmed.3003451;;19262088;;10.4161/cam.1.1.4082;;10.4161/cam.4082;;pmc2633676;;16136383;;10.1007/s10689-004-5811-3;;23712187;;10.1038/nrclinonc.2013.80;;10.1042/bse0390105;;14585077;;10.1073/pnas.1133470100;;pmc166396;;12857956;;19892942;;10.1126/science.1181498;;10.1016/j.urolonc.2009.05.010;;19762255;;10.1186/1471-2164-13-500;;22994565;;pmc3534403;;24065096;;pmc3794814;;10.3390/ijms140918925;;10.1101/gr.1.1.25;;1842917;;17463023;;10.1093/bioinformatics/btm149;;10.1002/9780470649367;;pmc1274291;;10.1371/journal.pcbi.0010050;;16261192;;19182786;;10.1038/nbt.1523;;pmc2663421;;pmc3282406;;22383754;;10.1101/cshperspect.a007260;;9150167;;pmc1712429;;10.1186/1471-2164-13-194;;22607156;;pmc3416685;;10.1186/1471-2164-13-194;;22607156;;pmc3416685;;10.1371/journal.pone.0034150;;22529906;;pmc3328481;;pmc2677117;;10.1016/j.gde.2009.02.002;;19345088;;10.1056/nejm196011242632102;;13714615;;pmc3653748;;10.1186/1471-2164-14-319;;23663360;;20688053;;10.1016/j.cca.2010.07.032;;10.1371/journal.pone.0016486;;21347407;;pmc3036585;;21586637;;pmc3111315;;10.1073/pnas.1105422108;;19542151;;10.1093/bioinformatics/btp373;;pmc2734323;;8923873;;10.1210/jcem.81.11.8923873;;10.1210/jc.81.11.4144;;23176822;;10.1016/j.ajhg.2012.10.018;;pmc3516607;;22585873;;10.1101/gr.138115.112;;pmc3409265;;pmc3881822;;10.1590/s1678-77572012000400013;;23032210;;15251964;;10.1196/annals.1318.034;;10.1373/49.8.1286;;12881444;;10.1093/bioinformatics/btr665;;22155872;;pmc3268238;;4009718;;10.1016/0022-2836(85)90276-1;;10.1002/elps.200305646;;14613204;;pmc3641759;;23197571;;10.1126/scitranslmed.3004742;;pmc2784330;;19835606;;10.1186/gb-2009-10-10-r115;;10.1093/bioinformatics/btp352;;pmc2723002;;19505943;;18405373;;pmc2396641;;10.1186/1471-2105-9-191;;10.1038/898;;9662393;;10.1016/s0140-6736(97)02174-0;;9274585;;10.1086/302205;;9915961;;pmc1377720;;10.1158/0008-5472.can-07-6471;;pmc2662593;;18451182;;24025639;;pmc3946645;;10.1038/ki.2013.338;;10.1038/nature03959;;16056220;;pmc1464427;;10.1371/journal.pbio.0000016;;14551913;;pmc212695;;17185754;;10.1385/1-59745-377-3:15;;10.1136/jmg.2003.015784;;15060106;;pmc1735725;;pmc3712641;;10.1016/j.cell.2012.11.019;;23260136;;pmc2772365;;10.1128/cmr.00019-09;;19822891;;10.1093/nar/27.24.e34;;pmc148757;;10572186;;14338235;;pmc336977;;10.1073/pnas.53.3.564;;12036944;;10.1093/nar/17.21.8889;;2587244;;pmc335081;;10.1038/ng.499;;pmc2847889;;19915526;;10.1093/genetics/120.3.621;;2852134;;pmc1203539;;19776739;;10.1038/nature08390;;22610117;;pmc3400344;;10.1038/ng.2283;;17876077;;10.1007/978-1-59745-298-4_7;;22658618;;pmc3391416;;10.1016/j.jmoldx.2012.03.002;;10.1371/journal.pone.0012517;;20838621;;pmc2935889;;18629393;;pmc2661269;;10.1155/2008/761208;;21615730;;10.1111/j.1399-0004.2011.01713.x;;10.1016/j.ajhg.2008.09.017;;pmc2668030;;18950739;;10.1038/88732;;11376340;;20488869;;10.1093/nar/gkq408;;pmc2952858;;17720704;;10.1093/bioinformatics/btm344;;3785382;;10.1038/324163a0;;10.1016/0014-5793(95)00908-r;;7589485;;pmc3437896;;10.1073/pnas.1208715109;;22853953;;18837946;;10.1196/annals.1448.025;;pmc3266030;;10.1101/gr.123497.111;;21990379;;10.1038/srep02161;;pmc3703611;;23831772;;10.1038/srep02161;;pmc3703611;;23831772;;10.1007/0-387-29362-0_23;;17890440;;10.1373/clinchem.2007.091231;;10.1016/j.cell.2005.04.028;;16009139;;7590320;;10.1016/0378-1119(95)00511-4;;838129;;10.1016/0012-1606(77)90158-0;;6684600;;10.1016/0012-1606(83)90201-4;;10.1093/hmg/ddq333;;pmc2953745;;20705737;;19881494;;10.1038/nbt.1583;;pmc2779736;;22183965;;pmc3266028;;10.1101/gr.125591.111;;22183965;;pmc3266028;;10.1101/gr.125591.111;;22183965;;pmc3266028;;10.1101/gr.125591.111;;17486113;;10.1038/ncb1596;;10.1161/circulationaha.104.482570;;16702488;;9008165;;10.1016/s0092-8674(00)81845-0;;10.1126/science.270.5235.484;;7570003;;10.1038/sj.embor.7400200;;15247927;;pmc1249482;;10.1093/nar/23.21.4407;;pmc307397;;7501463;;10.1093/nar/20.7.1691;;1579461;;pmc312258;;21589938;;pmc3092772;;10.1371/journal.pone.0019816;;18398465;;10.1371/journal.pone.0001939;;pmc2276688;;10.1038/72658;;10657128;;23056502;;pmc3467276;;10.1371/journal.pone.0046874;;10.1158/1078-0432.ccr-12-2861;;23401227;;pmc3618546;;20595611;;pmc3711608;;10.1126/science.1190371;;10.1186/cc4932;;16719935;;pmc1550959;;10.1038/sj.ejhg.5200619;;11313774;;pmc3960862;;10.3390/genes1010038;;24710010;;23065472;;10.1373/clinchem.2012.196014;;19307238;;10.1093/bioinformatics/btp156;;22649089;;10.1126/scitranslmed.3003726;;22649089;;10.1126/scitranslmed.3003726;;10.1016/j.eururo.2014.11.021;;25760253;;20371490;;pmc2858564;;10.1126/scitranslmed.3000702;;18987736;;10.1038/nature07485;;pmc2603574;;10.1373/clinchem.2010.154336;;21078840;;10.1038/nmeth.1419;;20111037;;10.1093/bfgp/elr033;;pmc3245553;;22121152;;pmc3711268;;10.1016/j.tig.2012.01.003;;22342180;;23115052;;10.1373/clinchem.2012.197053;;10.1158/2159-8290.cd-11-0184;;22585170;;pmc3353152;;10.1056/nejmoa1306555;;24088041;;pmc4211433;;16825431;;10.1136/jmg.2006.043257;;pmc2597904;;18987734;;pmc2581791;;10.1038/nature07517;;24048066;;10.1038/nature12625;;18162237;;10.1016/j.bbmt.2007.10.024;;23822788;;10.1056/nejmc1306040;;23822789;;23822790;;10.1038/leu.2008.143;;18528419;;9680114;;10.1016/s0145-2126(98)00056-3;;24705333;;pmc4016134;;10.1038/nm.3519;;24705333;;pmc4016134;;10.1038/nm.3519;;22118887;;10.1016/j.ctrv.2011.11.002,"ARUP's product “Exome Sequencing Symptom-Guided Analysis”. http://www.aruplab.com/guides/ug/tests/2006332.jsp. Accessed Oct. 1, 2014.;;Choi, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. Nov. 10, 2009;106(45):19096-101. doi: 10.1073/pnas.0910672106. Epub Oct. 27, 2009.;;Co-pending U.S. Appl. No. 15/929,318, inventors Chandratillakegemma; L. et al., filed Apr. 24, 2020.;;Co-pending U.S. Appl. No. 16/255,762, inventors Chandratillakegemma; L. et al., filed Jan. 23, 2019.;;Co-pending U.S. Appl. No. 16/570,219, inventors Chandratillakegemma; L. et al., filed Sep. 13, 2019.;;International search report and written opinion dated Jan. 8, 2015 for PCT Application No. US2014/059103.;;Ng, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. Sep. 10, 2009;461(7261):272-6. doi: 10.1038/nature08250. Epub Aug. 16, 2009.;;Singleton, et al. Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. Am J Hum Genet. Apr. 3, 2014;94(4):599-610. doi: 10.1016/j.ajhg.2014.03.010.;;SVBio's services, http://www.svbio.com/service-offerings/current-services. Accessed Oct. 1, 2014.;;U.S. Appl. No. 15/083,058 Notice of Allowance dated Dec. 10, 2018.;;U.S. Appl. No. 15/083,058 Notice of Allowance dated Feb. 6, 2019.;;U.S. Appl. No. 15/083,058 Office Action dated Mar. 21, 2018.;;Van Driel, et al. A text-mining analysis of the human phenome. Eur J Hum Genet. May 2006;14(5):535-42.;;Adessi, et al. Solid phase DNA amplification: characterisation of primer attachment and amplification mechanisms. Nucleic Acids Res. Oct. 15, 2000;28(20):E87.;;Albert, et al. Direct selection of human genomic loci by microarray hybridization. Nat Methods. Nov. 2007;4(11):903-5. Epub Oct. 14, 2007.;;Asan, et al. Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol. Sep. 28, 2011;12(9):R95. doi: 10.1186-gb-2011-12-9-r95.;;Ausubel, et al. eds. Current Protocols in Molecular Biology. United States. Greene Publishing Associates and Wiley-Interscience. 1987. (Table of Contents).;;Baingridge, et al. Whole exome capture in solution with 3 Gbp of data. Genome Biol. 2010;11(6):R62. doi: 10.1186-gb-2010-11-6-r62. Epub Jun. 17, 2010.;;Baird, et al. Developing recombinant antibodies for biomarker detection. Cancer Biomark. 2010;6(5-6):271-9. doi: 10.3233-CBM-2009-0144.;;Bamshad., “Exome sequencing as a tool for Mendelian disease gene discovery”, Nature Reviews Genetics, Nov. 2011, 12, 745-755.;;Beck, et al. Profile of the circulating DNA in apparently healthy individuals. Clin Chem. Apr. 2009;55(4):730-8. doi: 10.1373-clinchem.2008.113597. Epub Jan. 30, 2009.;;Benesova et al., “Mutation-based detection and monitoring of cell-free tumor Dna in peripheral blood of cancer patients”, Analytical Biochemistry vol. 433, Issue 2, Feb. 15, 2013, pp. 227-234.;;ZACHARY W. BENT, MARY B. TRAN-GYAMFI, STANLEY A. LANGEVIN, DAVID M. BRAZEL, RACHELLE Y. HAMBLIN, STEVEN S. BRANDA, KAMLESH D. PATE: ""Enriching pathogen transcripts from infected samples: A capture-based approach to enhanced host–pathogen RNA sequencing"", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, AMSTERDAM, NL, vol. 438, no. 1, 1 July 2013 (2013-07-01), Amsterdam, NL , pages 90 - 96, XP055220731, ISSN: 0003-2697, DOI: 10.1016/j.ab.2013.03.008;;Biesecker, et al. A genomic view of mosaicism and human disease. Nat Rev Genet. May 2013;14(5):307-20. doi: 10.1038-nrg3424.;;Bischoff, et al. Cell-free fetal DNA and intact fetal cells in maternal blood circulation: implications for first and second trimester non-invasive prenatal diagnosis. Hum Reprod Update. Nov.-Dec. 2002;8(6):493-500.;;Blanco et al., “Highly Efficient DNA Synthesis by the Phage phi 29 DNA polymerase”, Journal of Biological Chemistry, vol. 264, No. 15, pp. 8935-8940, May 25, 1989.;;Blaschko. The nerve distribution in the skin in their relation to the diseases of the skin: a report to the VII Congress of the German Society of Dermatology, held at Wroclaw 28-30. May 1901. (in German with English abstract).;;Boers et al., “High-Throughput Multilocus Sequence Typing: Bringing Molecular Typing to the Next Level,” PLoS One 2012; 7(7):e39630.;;Bonadona, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. Jun. 8, 2011;305(22):2304-10. doi: 10.1001-jama.2011.743.;;Boulesteix, et al. Evaluating microarray-based classifiers: an overview. Cancer Inform. 2008;6:77-97. Epub Feb. 29, 2008.;;Braslavsky, et al. Sequence information can be obtained from single DNA molecules. Proc Natl Acad Sci USA. Apr. 1, 2003;100(7):3960-4. Epub Mar. 21, 2003.;;Browne, et al. Increased promoter methylation in exfoliated breast epithelial cells in women with a previous breast biopsy. Epigenetics. Dec. 2011;6(12):1425-35. doi: 10.4161-epi.6.12.18280.;;Bryzgunova, et al. Isolation and comparative study of cell-free nucleic acids from human urine. Ann NY Acad Sci. Sep. 2006;1075:334-40.;;Carlson, et al. Decoding cell lineage from acquired mutations using arbitrary deep sequencing. Nat Methods. Nov. 27, 2011;9(1):78-80. doi: 10.1038-nmeth.1781.;;Chang, et al., Role of Bacteria in Oncogenesis. Clinical Microbiology Reviews, Oct. 2010; vol. 23 No. 4: p. 837-857.;;Chiu, et al. Effects of blood-processing protocols on fetal and total DNA quantification in maternal plasma. Clin Chem. Sep. 2001;47(9):1607-13.;;Clark, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. Sep. 25, 2011;29(10):908-14. doi: 10.1038-nbt.1975.;;Craig, et al. Identification of genetic variants using bar-coded multiplexed sequencing. Nat Methods. Oct. 2008;5(10):887-93. Epub Sep. 14, 2008.;;Damani, et al. Characterization of circulating endothelial cells in acute myocardial infarction. Sci Transl Med. Mar. 21, 2012 ;4(126):126ra33. doi: 10.1126-scitranslmed.3003451.;;Dawe, et al. Cell migration from baby to mother. Cell Adh Migr. Jan.-Mar. 2007;1(1):19-27. Epub Jan. 28, 2007.;;De La Chapelle. The incidence of Lynch syndrome. Fam Cancer. 2005;4(3):233-7.;;De Mattos-Aruda et al., Circulating tumor cells and cell-free DNA as tools for managing breast cancer, Nat. Rev. Clin. Oncol 10, 377-389 (2013); published online May 28, 2013 doi:10.1038-nrclinonc.2013.80.;;De Cathelineau, et al. The final step in programmed cell death: phagocytes carry apoptotic cells to the grave. Essays Biochem. 2003;39:105-17.;;Dressman, et al. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. Jul. 22, 2003;100(15):8817-22. Epub Jul. 11, 2003.;;Drmanac et al., “Human Genome Sequencing Using Unchained Base Reads on Self-Assembling DNA Nanoarrays”, Science, 327(5961), pp. 78-81, Nov. 5, 2009.;;Ellinger et al., “The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer”, Urologic Oncology 29:124-129 (2009), 124-129.;;Elsharawy et al., “Accurate variant detection across non-amplified and whole genome amplified DNA using targeted next generation sequencing”, BMC Genomics 13(500), pp. 1-14, Sep. 20, 2012.;;Elshimali, et al. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci. Sep. 13, 2013;14(9):18925-58. doi: 10.3390-ijms140918925.;;Fahy, et al. Self-sustained sequence replication (3SR): an isothermal transcription-based amplification system alternative to PCR. PCR Methods Appl. Aug. 1991;1 (1):25-33.;;Fishel, et al. Meta-analysis of gene expression data: a predictor-based approach. Bioinformatics. Jul. 1, 2007;23(13):1599-606. Epub Apr. 26, 2007.;;Freshney. Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications. 6th Edition. 2010.;;Frumkin, et al. Genomic variability within an organism exposes its cell lineage tree. PLoS Comput Biol. Oct. 2005;1 (5):e50. Epub Oct. 28, 2005.;;Gnirke, et al. Solution Hybrid Selection with Ultra-long Oligonucleotides for Massively Parallel Targeted Sequencing. Nat. Biotechnol. (Feb. 1, 2009), 27(2):182-9.;;Golob, Mechanisms of cell fate acquisition in the differentiation of pluripotent stem cells. Dissertation. University of Washington. 2009; 110 pages.;;Goris; et al., “The Immunogenetic Architecture of Autoimmune Disease”, Cold Spring Harbor Perspectives in Biology, 2012, 4:a007260, 1-15.;;Gottlieb, et al. The DiGeorge syndrome minimal critical region contains a goosecoid-like (GSCL) homeobox gene that is expressed early in human development. Am J Hum Genet. May 1997;60(5):1194-201.;;Guo et al., “Exome sequencing generates high quality data in non-target regions”, BMC Genomics 13(194), pp. 1-10, May 20, 2012. Main text.;;Guo et al., “Exome sequencing generates high quality data in non-target regions”, BMC Genomics 13(194), pp. 1-10, May 20, 2012. Supplementary Tables.;;Hamfjord et al., Plos ONE at www.plosone.org Apr. 2012, vol. 7, Issue 4, e34150.;;Hiratani, et al., Replication timing and transcriptional control: beyond cause and effect—part II. Curr Opin Genet Dev. Apr. 2009;19(2):142-9. doi: 10.1016-j.gde.2009.02.002. Epub Apr. 1, 2009.;;Hirschhorn, et al. Human intersex with chromosome mosaicism of type XY-XO. Report of a case. N Engl J Med. Nov. 24, 1960;263:1044-8.;;Huang, et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics. May 10, 2013;14:319. doi: 10.1186-1471-2164-14-319.;;Human Genome Overview GRCh37. Genome Reference Consortium, Feb. 27, 2009. 1 Page.;;Human Genome Overview GRCh37.p13. Genome Reference Consortium, Jun. 28, 2013. 2 Pages.;;Illumina., “Interpreting Infinium Assay Data for Whole-Genome Structural Variation”, Technical Note: DNA Analysis, 2010. Website, 1-8.;;Jung et al., “Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature”, Clinica Chimica Acta 411 :1611-1624 (2010).;;Karam, et al. Apoptosis in Carcinogenesis and Chemotherapy. Published by Springer in 2009 ISBN: 978-1-4020-9596-2.;;Kiialainen, et al. Performance of microarray and liquid based capture methods for target enrichment for massively parallel sequencing and SNP discovery. PLoS One. Feb. 9, 2011;6(2):e16486. doi: 10.1371-journal.pone.0016486.;;Kinde, et al. Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci US A. Jun. 7, 2011;108(23):9530-5. doi: 10.1073-pnas.1105422108. Epub May 17, 2011.;;Koboldt et al., “VarScan: variant detection in massively parallel sequencing of individual and pooled samples”, Bioinformatics, 25(17), pp. 2283-2285, Jun. 19, 2009.;;Kokawa, et al. Apoptosis in the human uterine endometrium during the menstrual cycle. J Clin Endocrinol Metab. Nov. 1996;81 (11):4144-7.;;Koren, et al. Differential relationship of DNA replication timing to different forms of human mutation and variation. Am J Hum Genet. Dec. 7, 2012;91 (6):1033-40. doi: 10.1016-j.ajhg.2012.10.018. Epub Nov. 21, 2012.;;Krumm et al., “Copy number variation detection and genotyping from exome sequence data”, Genome Research, 22(8), pp. 1525-1532, May 14, 2012.;;Kuchler, et al. Buccal cells DNA extraction to obtain high quality human genomic DNA suitable for polymorphism genotyping by PCR-RFLP and Real-Time PCR. J Appl Oral Sci. Jul.-Aug. 2012;20(4):467-71.;;Laktionov et al. “Cell-surface-bound nucleic acids: Free and cell-surface-bound nucleic acids in blood of healthy donors and breast cancer patients”, Ann. NY Acad Sci 1022:221-227 (2004).;;Lam, et al. Time course of early and late changes in plasma DNA in trauma patients. Clin Chem. Aug. 2003;49(8):1286-91.;;Larson et al., “SomaticSniper: identification of somatic point mutations in whole genome sequencing data”, Bioinformatics, 28(3), pp. 311-317, Dec. 6, 2011.;;Lathe, R., Synthetic oligonucleotide probes deduced from amino acid sequence data: Theoretical and practical considerations. Journal of Molecular Biology, May 5, 1985; 183(1): 1-12.;;Leamon, et al. A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis. Nov. 2003; 24(21):3769-77.;;Leary, et al. Detection of chromosomal alterations in the circulation of cancer patients with whole genome-sequencing. Sci Transl Med. Nov. 28, 2012;4(162):162ra154. doi: 10.1126-scitranslmed.3004 742.;;Levin, et al., Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biology, 2009. 10:R115.;;Li et al., “The Sequence Alignment/MAP format and SAMtools”, Bioinformatics, 25(16), pp. 2078-2079, Jun. 8, 2009.;;Li, et al., “Novel computational methods for increasing PCR primer design effectiveness in directed sequencing”, BMC Bioinformatics. Apr. 11, 2008;9:191. doi: 10.1186-1471-2105-9-191.;;Lizardi, et al. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat Genet. Jul. 1998;19(3):225-32.;;Lo et al., “Presence of fetal DN in maternal plasma and serum”, Lancet 1997 350 485-87.;;Lo, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. Jan. 1999;64(1):218-24.;;Madeleine et al., “Comprehensive Analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 Loci and Squamous Cell Cervical Cancer Risk”, Cancer Res 2008; 68 (9), May 1, 2008.;;DANIEL G. MALUF, CATHERINE I. DUMUR, JIHEE L. SUH, MARIANO J. SCIAN, ANNE L. KING, HELEN CATHRO, JAE K. LEE, RICARDO C. GEHRAU, KE: ""The urine microRNA profile may help monitor post-transplant renal graft function"", KIDNEY INTERNATIONAL, NATURE PUBLISHING GROUP, LONDON, GB, vol. 85, no. 2, 1 January 2014 (2014-01-01), GB , pages 439 - 449, XP055442385, ISSN: 0085-2538, DOI: 10.1038/ki.2013.338;;Margulies, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature. Sep. 15, 2005;437(7057):376-80. Epub Jul. 31, 2005.;;Market, et al., V(D)J Recombination and the Evolution of the Adaptive Immune System. Plos Biol. 2003; 1(1):e16. https:--doi.org-10.1371-journal.pbio.0000016.;;Marsh. Pyrosequencing applications. Methods Mol Biol. 2007;373:15-24.;;Masuzaki, et al. Detection of cell free placental DNA in maternal plasma: direct evidence from three cases of confined placental mosaicism. J Med Genet. Apr. 2004; 41 (4):289-92.;;Michaelson, et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell. Dec. 21, 2012;151(7):1431-42. doi: 10.1016-j.cell.2012.11.019.;;Miller, et al., Basic concepts of microarrays and potential applications in clinical microbiology. Clinical Microbiology Reviews, Oct. 2009, p. 611-633.;;Mitra, et al. In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res. Dec. 15, 1999;27(24):e34.;;Moudrianakis, et al. Base sequence determination in nucleic acids with the electron microscope. 3. Chemistry and microscope of guanine-labeled DNA. Proc Natl Acad Sci U S A. Mar. 1965;53:564-71.;;Muniappan, et al. The DNA polymerase beta replication error spectrum in the adenomatous polyposis coli gene contains human colon tumor mutational hotspots. Cancer Res. Jun. 1, 2002; 62(11 ):3271-5.;;Murray, et al., Improved double-stranded DNA sequencing using the linear polymerase chain reaction. Nucleic Acids Research, vol. 17, No. 21. p. 8889. Nov. 11, 1989.;;Ng et al., “Exome sequencing identifies the cause of a mendelian disorder”, Nature Genetics, 42(1), pp. 30-35, Nov. 13, 2009.;;Nucleosome Position by MNase-seq from ENCODE-Stanford-BYU. track settings from the UC Santa Cruz Genome Browser. 2011-2012. http:--hgdownload.cse.ucsc.edu-goldenPath-hg19-encodeDCC-wgEncodeSydhNsome-.;;Ochman, et al. Genetic applications of an inverse polymerase chain reaction. Genetics. Nov. 1988;120(3):621-3.;;Ozsolak, et al. Direct RNA sequencing. Nature. Oct. 8, 2009;461(7265):814-8. doi: 10.1038-nature08390. Epub Sep. 23, 2009.;;Park. Scientists Devise a Blood Test to Predict Heart Attack. Time Magazine. Mar. 22, 2012. 2 pages.;;Pasaniuc, et al. Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet. May 20, 2012;44(6):631-5. doi: 10.1038-ng.2283. With Supplementary Information.;;Pierce, et al. Linear-after-the-exponential polymerase chain reaction and allied technologies. Real-time detection strategies for rapid, reliable diagnosis from single cells. Methods Mol Med. 2007;132:65-85.;;Pritchard et al., “ColoSeq Provides Comprehensive Lynch and Polyposis Syndrome Mutational Analysis Using Massively Parallel Sequencing”, Journal of Molecular Diagnostics, vol. 14, No. 4, Jul. 2012.;;Punnoose, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. Sep. 8, 2010;5(9):e12517. doi: 10.1371-journal.pone.0012517.;;Richter. Fecal DNA screening in colorectal cancer. Can J Gastroenterol. Jul. 2008;22(7):631-3.;;Robinson, et al. Strategies for exome and genome sequence data analysis in disease gene discovery projects. Clinical Genetics, vol. 80, No. 2, pp. 127-132 (2011) See the whole document.;;Robinson; et al., “The Human Phenotype Ontology: A Tool for Annotating and Analyzing Human Hereditary Disease”, The American Journal of Human Genetics, Nov. 7, 2008, 83, 610-615.;;Rogozin, et al. Somatic mutation hotspots correlate with DNA polymerase eta error spectrum. Nat Immunol. Jun. 2001;2(6):530-6.;;Rosenfeld, et al. Novel multi-nucleotide polymorphisms in the human genome characterized by whole genome and exome sequencing. Nucleic Acids Research, Article No. gkq408, pp. 1-10 (2010) See abstract; and pp. 8-9.;;Ross, et al. Characterizing and measuring bias in sequence data. Genome Biology, vol. 14, No. 5, Article No. R51, pp. 1-20 (e-pub, May 29, 2013) See the whole document.;;Ross. Introduction to Oncogenes and Molecular Cancer Medicine. Copyright 1998 Springer-Verlag New York, Inc. ISBN : 0-387-98392-9.;;Saeys, et al. A review of feature selection techniques in bioinformatics. Bioinformatics. Oct. 1, 2007;23(19):2507-17. Epub Aug. 24, 2007.;;Saiki, et al. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allelespecific oligonucleotide probes. Nature. Nov. 13-19, 1986;324(6093):163-6.;;Sambrook, et al. Molecular Cloning: A Laboratory Manual. 4th Edition, 2012.;;Sandri, et al. Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. FEBS Lett. Oct. 16, 1995;373(3):291-5.;;Schmitt, et al. Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sei US A. Sep. 4, 2012;109(36):14508-13. doi: 10.1073-pnas.1208715109. Epub Aug. 1, 2012.;;Schwarzenbach, et al. Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci. Aug. 2008;1137:190-6. doi: 10.1196-annals.1448.025.;;Shaw et al. Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Research 22(2):220-231 (Feb. 2012).;;Shigemizu et al., “A practical method to detect SNVs and indels from whole genome and exome sequencing data”, Scientific Reports, 3(1), pp. 1-6, Jul. 8, 2013. Main Text.;;Shigemizu et al., “A practical method to detect SNVs and indels from whole genome and exome sequencing data”, Scientific Reports, 3(1), pp. 1-6, Jul. 8, 2013; Supplementary Information.;;Smyth. Limma: linear models for microarray data. In: Bioinformatics and Computational Biology Solutions using R and Bioconductor. R. Gentleman, V. Carey, S. Dudoit, R. Irizarry, W. Huber (eds.), 2007, Springer, New York, pp. 397-420.;;Soni, et al. Progress toward ultrafast DNA sequencing using solid-state nanopores. din Chem. Nov. 2007;53(11):1996-2001. Epub Sep. 21, 2007.;;Spalding, et al. Retrospective birth dating of cells in humans. Cell. Jul. 15, 2005;122(1):133-43.;;Stemmer, et al. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene. Oct. 16, 1995; 164(1):49-53.;;Sulston, et al. Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. Dev Biol. Mar. 1977;56(1):110-56.;;Sulston, et al. The embryonic cell lineage of the nematode Caenorhabditis elegans. Dev Biol. Nov. 1983;100(1):64-119.;;Teer et al., “Exome sequencing: the sweet spot before whole genomes”, Human Molecular Genetics, 19(R2), R145-R151, Aug. 12, 2010.;;Tewhey, et al. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat Biotechnol. Nov. 2009;27(11):1025-31. doi: 10.1038-nbt.1583. Epub Nov. 1, 2009.;;The Human Cell Lineage Flagship Initiative. Last updated Nov. 10, 2010. 1 page. http:--www. lineage-flagsh ip.eu-.;;Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012. Main document.;;Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012. Supplementary Figures.;;Turajilic et al., “Whole genome sequencing of matched primary and metastatic acral melanomas”, Genome Research, 22(2), pp. 196-207, Feb. 22, 2012. Supplementary Tables.;;Valadi, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. Jun. 2007;9(6):654-9. Epub May 7, 2007.;;VarScan. (2009). Retrieved from http:--varscan.sourceforge.net-.;;Vasan, Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. May 16, 2006;113(19):2335-62.;;Velculescu, et al. Characterization of the yeast transcriptome. Cell. Jan. 24, 1997;88(2):243-51.;;Velculescu, et al. Serial analysis of gene expression. Science. Oct. 20, 1995;270(5235):484-7.;;Vincent, et al. Helicase-dependent isothermal DNA amplification. EMBO Rep. Aug. 2004;5(8):795-800. Epub Jul. 9, 2004.;;Vos, et al. AFLP: a new technique for DNA fingerprinting. Nucleic Acids Res. Nov. 11, 1995; 23(21):4407-14.;;Walker, et al. Strand displacement amplification—an isothermal, in vitro DNA amplification technique. Nucleic Acids Res. Apr. 11, 1992 ;20(7):1691-6.;;Wang, K. (2010). Annovar Documentation. Retrieved from http:--annovar.openbioinformatics.org-.;;RENÉ L. WARREN, ROBERT A. HOLT: ""Targeted Assembly of Short Sequence Reads"", PLOS ONE, vol. 6, no. 5, pages e19816, XP055347747, DOI: 10.1371/journal.pone.0019816;;Wasserstrom, et al. Reconstruction of cell lineage trees in mice. PLoS One. Apr. 9, 2008;3(4):e1939. doi: 10.1371-journal.pone.0001939.;;Westin, et al. Anchored multiplex amplification on a microelectronic chip array. Nat Biotechnol. Feb. 2000;18(2):199-204.;;Xiao, et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One. 2012;7(10):e46874. doi: 10.1371-journal.pone.0046874. Epub Oct. 9, 2012.;;Yeung et al., “LOH in the HLA Class I Region at 6p21 is Associated with Shorter Survival in Newly Diagnosed Glioblastoma”, Clinical Cancer Research, pp. 1816-1826, Apr. 1, 2013.;;Yi et al., “Sequencing of Fifty Human Exomes Reveals Adaptation to High Altitude”, Science, 329(5987), pp. 75-78, Jul. 2, 2010.;;Zeerleder. The struggle to detect circulating DNA. Crit Care. 2006;10(3):142. Epub May 16, 2006.;;Akey et al., “Haplotypes vs. single marker linkage disequilibrium tests: what do we gain?”, European Journal of Human Genetics, Apr. 20, 2001, vol. 8, pp. 291-300.;;Anderson et al., “Next Generation DNA Sequencing and the Future of Genomic Medicine”, Genes 2010, 38-69; doi:10.3390/genes1010038.;;Chan et al., “Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing”, Clinical Chemistry 59:1, 211-224 (2013).;;Chu, Tianjiao et al., “Statistical model for whole genome sequencing and its application to minimally invasive diagnosis of fetal genetic disease”, Bioinformatics, vol. 25, No. 10, 2009, pp. 1244-1250.;;Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA”, Science Translational Medicine, May 30, 2012, vol. 4, Issue 136, 136ra68; DOI: 10.1126/scitranslmed.3003726.;;Forshew et al., “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA”, Supplementary Materials, Science Translational Medicine, May 30, 2012, vol. 4, Issue 136, 136ra68; DOI: 10.1126/scitranslmed.3003726.;;Guo et al., “Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation”, nature Genetics, Letters, vol. 45, No. 12, Dec. 2013. Published online Oct. 13, 2013.;;Leary et al., “Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing”, Science Translational Medicine, Feb. 24, 2010; 2(20): 20ra14.;;Ley et al., “DNA Sequencing of a cytogenetically normal acute myeloid leukemia genome”, Nature, vol. 456|6 Nov. 2008.;;Liao et al., “Targeted Massively Parallel Sequencing of Maternal Plasma DNA Permits Efficient and Unbiased Detection of Fetal Alleles”, Clinical Chemistry 57:1, 92-101 (2011).;;Mamanova et al., “Target-enrichment strategies for next-generation sequencing”, Nature Methods, vol. 7, No. 2, Feb. 2010.;;Mertes et al., “Targeted enrichment of genomic DNA regions for next-generation sequencing”, Briefings in Functional Genomics, vol. 10, No. 6, 374-386, Nov. 26, 2011.;;Podlaha, Ondrej et al., “Evolution of the cancer genome”, Trends Genet. Apr. 2012 ; 28(4): 155-163. doi:10.1016/j.tig.2012.01.003.;;Swanton, Charles, “Plasma-derived Tumor DNA Analysis at Whole-Genome Resolution,” Editorials, Clinical Chemistry 59:1, 6-8; 2013.;;Wagle, Nikhil et al., “High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing”, Cancer Discovery, Jan. 2012.;;Yang, Yaping et al., “Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders”, New England Journal of Medicine, 369;16, Oct. 2, 2013.;;Alter et al., “Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2,” Journal of Medical Genetics 2007;44:1-9. doi: 10.1136/jmg.2006.043257.;;Bentley, et al., “Accurate whole human genome sequencing using reversible terminator chemistry,” Nature. Nov. 6, 2008; 456(7218): 53-59. doi:10.1038/nature07517.;;Burrell et al., “The causes and consequences of genetic heterogeneity in cancer evolution” Nature. Sep. 19, 2013;501(7467):338-45. doi: 10.1038/nature12625.;;Davies, et al., “Indications for Hematopoietic Cell Transplantation in Acute Leukemia,” Biology of Blood and Marrow Transplantation 14:154-164 (2008). doi:10.1016/j.bbmt.2007.10.024.;;Dawson, et al. “Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer,” New England Journal of Medicine, 2013;368:1199-209; DOI:10.1056/NEJMoa1213261. Published online Mar. 13, 2013.;;Haferlach et al., “Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype”, Leukemia. Aug. 2008;22(8):1539-41. doi: 10.1038/leu.2008.143. Epub Jun. 5, 2008.;;Misawa et al., “Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia”, Leuk Res. Jul. 1998;22(7):631-7. doi: 10.1016/s01452126(98)00056-3.;;Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nat Med. May 2014 ; 20(5) 548-554. doi:10.1038/nm.3519.;;Newman et al., “An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage”, Nat Med. May 2014 ; 20(5) 548-554. Supplementary Excel Spreadsheets.;;Vale et al., “Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis”, Cancer Treatment Reviews 38 (2012) 618-625.",ACTIVE
294,EP,B1,EP 3684198 B1,076-913-951-363-872,2021-07-14,2021,EP 19708712 A,2019-02-12,US 201862644031 P;;US 2019/0017653 W,2018-03-16,FOAM CONTROL,,DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,,https://lens.org/076-913-951-363-872,Granted Patent,yes,0,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,A23L29/00;;A23L29/10,,2,0,,,"""POLYOXYALKYLENE GLYCEROL ETHER FATTY ACID ESTER PREPN. - INVOLVES REACTING MIXT. OF NATURAL FATS AND OILS AND HYDROXYALKYL:AMINE WITH ALKYLENE OXIDE, USEFUL AS AN EMULSIFIER, DISPERSANT, CLEANING AGENT OR ANTIFOAMING AGENT"", WPI/DERWENT, 2 March 1993 (1993-03-02), XP002901290,;;DATABASE WPI Week 201501 Thomson Scientific, London, GB; AN 2014-W66530 XP002790405, & CN 104 073 446 A (XUZHOU LVWEI MODERN AGRIC SCI & TECHNOLO) 1 October 2014 (2014-10-01)",ACTIVE
295,US,A1,US 2021/0098516 A1,062-170-277-850-624,2021-04-01,2021,US 202016894901 A,2020-06-08,US 202016894901 A;;US 201962906750 P,2019-09-27,IMAGE SENSOR AND MANUFACTURING METHOD THEREOF,"An image sensor includes a storage device, where the storage device includes a memory element, a first dielectric layer and a light shielding element. The memory element includes a storage node and a storage transistor gate, where the storage transistor gate is located over the storage node. The first dielectric layer is located over a portion of the storage transistor gate. The light shielding element is located on the first dielectric layer and includes a semiconductor layer. The semiconductor layer is electrically isolated from the memory element, where the light shielding element is overlapped with at least a part of a perimeter of the storage transistor gate in a vertical projection on a plane along a stacking direction of the memory element and the light shielding element, and the stacking direction is normal to the plane.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK;;WANG WEN-SHENG;;KUO CHIEN-LI,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-14),https://lens.org/062-170-277-850-624,Patent Application,yes,0,1,2,7,0,H01L27/14623;;H01L27/14614;;H01L27/14603;;H01L27/14689;;H01L27/14643;;H01L27/14614;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14623,H01L27/146,,0,0,,,,ACTIVE
296,US,A1,US 2016/0283484 A1,091-196-380-923-649,2016-09-29,2016,US 201615083058 A,2016-03-28,US 201615083058 A;;US 2014/0059103 W;;US 201361886555 P,2013-10-03,METHODS FOR ANALYZING GENOTYPES,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,CHANDRATILLAKE GEMMA L;;GARCIA SARAH K;;CHEN RICHARD;;CLARK MICHAEL JAMES,PERSONALIS INC (2014-10-01),https://lens.org/091-196-380-923-649,Patent Application,yes,0,18,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G06F17/30;;G16B20/00;;G16B20/20;;G16B50/10,,0,0,,,,ACTIVE
297,US,A1,US 2010/0332422 A1,178-358-048-316-832,2010-12-30,2010,US 26619808 A,2008-11-06,US 26619808 A,2008-11-06,Policy Evolution With Machine Learning,"A method for constructing a classifier which maps an input vector to one of a plurality of pre-defined classes, the method steps includes receiving a set of training examples as input, wherein each training example is an exemplary input vector belonging to one of the pre-defined classes, learning a plurality of functions, wherein each function maps the exemplary input vectors to a numerical value, and determining a class for the input vector by combining numerical outputs of the functions determined for the input vector.",CHENG PAU-CHEN;;CLARK JOHN ANDREW;;LIM YOW TZU;;ROHATGI PANKAJ,CHENG PAU-CHEN;;CLARK JOHN ANDREW;;LIM YOW TZU;;ROHATGI PANKAJ,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-09-19),https://lens.org/178-358-048-316-832,Patent Application,yes,4,7,2,2,0,G06N20/00;;G06N20/00,G06N20/00,706/12,4,4,135-076-315-653-775;;076-075-935-246-254;;168-390-118-438-745;;014-234-232-836-510,10.1109/ijcnn.2005.1555963;;10.1007/3-540-44794-6_26;;10.1007/s10044-004-0213-6;;10.1007/978-3-540-74829-8_20,"Yi Liu; Zheng, Y.F.; , ""One-against-all multi-class SVM classification using reliability measures,"" Neural Networks, 2005. IJCNN '05. Proceedings. 2005 IEEE International Joint Conference on , vol.2, no., pp. 849- 854 vol. 2, 31 July-4 Aug. 2005;;Mendes, Roberto; de Voznika, Fabricio; Freitas, Alex; Nievola, Julio. ""Discovering Fuzzy Classification Rules with Genetic Programming and Co-evolution,"" Principles of Data Mining and Knowledge Discovery pp. 314-325 (2001);;Debnath, R.; Takahide, N.; Takahashi, H.. ""A decision based one-against-one method for multi-class support vector machine,"" Pattern Analysis & Applications vol. 7, no. 2 pp. 164-175 (2004);;C. Thiel, S. Scherer, and F. Schwenker, ""Fuzzy-input fuzzy-output one against-all support vector machines,"" in Proc. 11th Int. Conf. Knowledge-Based Intell. Inf. Eng. Syst., 2007, vol. 4694, pp. 156-165.",INACTIVE
298,WO,A1,WO 2019/178306 A1,005-901-459-253-854,2019-09-19,2019,US 2019/0022172 W,2019-03-14,US 201862644024 P;;US 201862644038 P,2018-03-16,FOAM CONTROL IN FOOD,"A method for controlling foam comprising providing food composition comprising a foam control agent and a foodstuff, the foam control agent comprising a Mono glycidyl ether adduct or a Diglycidyl ether adduct. A composition useful for foam control comprising a mono glycidyl ether adduct, a diglycidyl ether adduct or combination thereof.",DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,,https://lens.org/005-901-459-253-854,Patent Application,yes,3,1,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/10;;A23L19/12,,2,2,023-468-009-807-678;;044-917-850-121-10X,10.1002/hlca.201200438;;10.1021/la049676o;;15491178,"AYTEKIN KOSE ET AL: ""Nucleophilic Reactivity of Ethers Against Terminal Epoxides in the Presence of BF 3 : A Mechanistic Study"", HELVETICA CHIMICA ACTA, vol. 96, no. 7, 1 July 2013 (2013-07-01), pages 1325 - 1330, XP055587023, ISSN: 0018-019X, DOI: 10.1002/hlca.201200438;;N. D. DENKOV: ""Mechanisms of Foam Destruction by Oil-Based Antifoams"", LANGMUIR, vol. 20, no. 22, 2004, pages 9463 - 9505, XP002468579, DOI: doi:10.1021/la049676o",PENDING
299,CN,A,CN 116981992 A,038-162-974-118-084,2023-10-31,2023,CN 202180094544 A,2021-12-30,US 202063132194 P;;US 2021/0065662 W,2020-12-30,Devices including ferroelectric nematic liquid crystal forming molecules and methods of forming and using same,"The surface polarity of the ferroelectric nematic can be configured to generate vector control of the orientation of its bulk polarization field. Contact between the surface having in-plane polarity and the ferroelectric nematic liquid crystal generates a preferred in-plane orientation of the ferroelectric polarization field at the interface, which may result in the formation of highly polarized fluid or glassy single domains without electric field polarization. The material surface can be used as a way to make planar alignment cells with various azimuthal director/polarization structures, including a twisted state in a pi-twisted cell obtained by antiparallel, unidirectional rubbing on opposing surfaces, we exhibit three different modes of ferroelectric nematic electro-optical response: intrinsic viscosity limited field-induced molecular redirection, field-induced motion of a domain wall in a twisted state that separates relative chirality, and propagation of polarization redirection solitons from a cell plate to a cell center upon field inversion.",UNIV COLORADO REGENTS,CLARK NATHAN A;;CHEN XI;;MCLENNAN JOHN E;;GLASER MATTHIAS A,,https://lens.org/038-162-974-118-084,Patent Application,no,0,0,6,6,0,G02F1/141;;G02F1/1337;;G02F1/133788;;G02F1/141;;G02F1/133788,G02F1/141,,0,0,,,,PENDING
300,EP,A4,EP 3473027 A4,041-022-759-363-478,2020-01-01,2020,EP 17814094 A,2017-06-15,US 201662350523 P;;US 201662368723 P;;US 201662421088 P;;US 2017/0037680 W,2016-06-15,SERVICES PROVISIONING FOR INTERNET-OF-THINGS DEVICES IN CELLULAR NETWORKS,,INTEL CORP,LIAO CHING-YU;;CHEN KUILIN CLARK;;MACIOCCO CHRISTIAN;;SUNDER RAJAN ASHOK,APPLE INC. (2020-12-16),https://lens.org/041-022-759-363-478,Search Report,no,6,0,5,5,0,H04W8/26;;H04W12/06;;H04W88/14;;H04W4/50;;H04W4/70;;H04W60/04;;H04W12/35,H04W4/50;;H04W4/70;;H04W8/26;;H04W12/00;;H04W12/06;;H04W60/04;;H04W88/14,,1,0,,,See also references of WO 2017218775A1,ACTIVE
301,US,B2,US 11478005 B2,048-597-748-952-56X,2022-10-25,2022,US 201916636231 A,2019-03-14,US 201916636231 A;;US 201862644024 P;;US 201862644038 P;;US 2019/0022172 W,2018-03-16,Foam control,"A method for controlling foam comprising providing food composition comprising a foam control agent and a foodstuff, the foam control agent comprising a Mono glycidyl ether adduct or a Diglycidyl ether adduct. A composition useful for foam control comprising a mono glycidyl ether adduct, a diglycidyl ether adduct or combination thereof.",DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,DOW GLOBAL TECHNOLOGIES LLC (2018-06-25),https://lens.org/048-597-748-952-56X,Granted Patent,yes,6,0,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/12,,3,2,023-468-009-807-678;;044-917-850-121-10X,10.1002/hlca.201200438;;10.1021/la049676o;;15491178,"Aytekin, “Nucleophilic Reactivity of Ethers Against Terminal Epoxides in the Presence of BF 3: A Mechanistic Study” Helvetica Chimica Acta. 2013, p. 1325-1330, vol. 96.;;Denkov, “Mechanisms of Foam Destruction by Oil-Based Antifoams” 2004, p. 9463-9509, vol. 22.;;PCT/US2019/022172 , International Search Report and Written Opinion dated May 20, 2019.",ACTIVE
302,US,A1,US 2022/0359591 A1,159-341-525-362-138,2022-11-10,2022,US 202217874321 A,2022-07-27,US 202217874321 A;;US 202016894901 A;;US 201962906750 P,2019-09-27,IMAGE SENSOR AND MANUFACTURING METHOD THEREOF,"An image sensor includes a storage device, where the storage device includes a memory element, a first dielectric layer and a light shielding element. The memory element includes a storage node and a storage transistor gate, where the storage transistor gate is located over the storage node. The first dielectric layer is located over a portion of the storage transistor gate. The light shielding element is located on the first dielectric layer and includes a semiconductor layer. The semiconductor layer is electrically isolated from the memory element, where the light shielding element is overlapped with at least a part of a perimeter of the storage transistor gate in a vertical projection on a plane along a stacking direction of the memory element and the light shielding element, and the stacking direction is normal to the plane.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK;;WANG WEN-SHENG;;KUO CHIEN-LI,,https://lens.org/159-341-525-362-138,Patent Application,yes,0,0,5,7,0,H01L27/14614;;H01L27/14623;;H01L27/14625;;H01L27/14643;;H01L27/14685;;H01L27/14689;;H01L27/14603;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14685;;H01L27/14689,H01L27/146,,0,0,,,,PENDING
303,EP,A1,EP 4272031 A1,050-687-492-059-962,2023-11-08,2023,EP 21916483 A,2021-12-30,US 202063132194 P;;US 2021/0065662 W,2020-12-30,DEVICE INCLUDING FERROELECTRIC NEMATIC LIQUID CRYSTAL-FORMING MOLECULES AND METHODS OF FORMING AND USING SAME,,UNIV COLORADO REGENTS,CLARK NOEL A;;CHEN XI;;MACLENNAN JOSEPH E;;GLASER MATTHEW A,,https://lens.org/050-687-492-059-962,Patent Application,yes,0,0,6,6,0,G02F1/141;;G02F1/1337;;G02F1/133788;;G02F1/141;;G02F1/133788,G02F1/141;;G02F1/1337,,0,0,,,,PENDING
304,US,A1,US 2023/0253425 A1,063-984-819-452-946,2023-08-10,2023,US 202318302004 A,2023-04-18,US 202318302004 A;;US 202016894901 A;;US 201962906750 P,2019-09-27,IMAGE SENSOR AND MANUFACTURING METHOD THEREOF,"An image sensor includes a storage device, where the storage device includes a memory element, a first dielectric layer and a light shielding element. The memory element includes a storage node and a storage transistor gate, where the storage transistor gate is located over the storage node. The first dielectric layer is located over a portion of the storage transistor gate. The light shielding element is located on the first dielectric layer and includes a semiconductor layer. The semiconductor layer is electrically isolated from the memory element, where the light shielding element is overlapped with at least a part of a perimeter of the storage transistor gate in a vertical projection on a plane along a stacking direction of the memory element and the light shielding element, and the stacking direction is normal to the plane.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK;;WANG WEN-SHENG;;KUO CHIEN-LI,,https://lens.org/063-984-819-452-946,Patent Application,yes,0,0,5,7,0,H01L27/14614;;H01L27/14623;;H01L27/14625;;H01L27/14643;;H01L27/14685;;H01L27/14689;;H01L27/14603;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14685;;H01L27/14689,H01L27/146,,0,0,,,,PENDING
305,CA,A1,CA 2351319 A1,088-247-507-197-496,2000-06-02,2000,CA 2351319 A,1999-11-23,US 19764498 A;;US 9927655 W,1998-11-23,REDUCED MOLECULAR WEIGHT NATIVE GELLAN GUM,"This invention provides reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention generally have a weight average molecular weight less than about 1.7 X 106, and typically in a range of about 1.2 X 106 to about 9.3 X 105. This invention also provides compositions, e.g., solutions and gels, comprising reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention may be prepared by any method which reduces the molecular weight of polymers. Such methods include homogenization, sonication, radiation, oxidation and hydrolysis.",CP KELCO US INC,MORRISON NEIL;;CLARK ROSS;;BURGUM DAN;;TALASHEK TODD;;CHEN YOU-LUNG,,https://lens.org/088-247-507-197-496,Patent Application,no,0,0,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A23C9/152;;A21D13/08;;A23G9/32;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,,0,0,,,,DISCONTINUED
306,WO,A1,WO 2017/218775 A1,167-947-189-989-041,2017-12-21,2017,US 2017/0037680 W,2017-06-15,US 201662350523 P;;US 201662368723 P;;US 201662421088 P,2016-06-15,SERVICES PROVISIONING FOR INTERNET-OF-THINGS DEVICES IN CELLULAR NETWORKS,"Methods and apparatus are described by which a network controller receives an attach request from a first user equipment (UE). The attach request including a requested IP service. A group of IP addresses for the IP service is allocated. A routing policy is configured for the group of IP addresses. The routing policy is sent to a RAN node and a data gateway. The routing policy indicates a route for data packets, from UEs using the requested IP service, received at the RAN node to the data gateway. A mapping between the service identifier and the group of IP addresses is stored.",INTEL CORP,LIAO CHING-YU;;CHEN KUILIN CLARK;;MACIOCCO CHRISTIAN;;SUNDER RAJAN ASHOK,,https://lens.org/167-947-189-989-041,Patent Application,yes,9,15,5,5,0,H04W8/26;;H04W12/06;;H04W88/14;;H04W4/50;;H04W4/70;;H04W60/04;;H04W12/35,H04W8/26;;H04W12/06;;H04W40/24;;H04W60/00;;H04W88/14,,2,0,,,"""Intra-domaIn connection ot Kadio Access Network (RAN) nodes to multiple Core Network (CN) nodes (Release 13"", 3GPP IS 23.236, 21 June 2015 (2015-06-21), XP051294228, Retrieved from the Internet <URL:https://portal.3gpp.org/desktopmodules/Specifications/SpecificationDetails.pspx?specificationId=825>;;See also references of EP 3473027A4",PENDING
307,WO,A1,WO 2000/031146 A1,008-200-676-174-623,2000-06-02,2000,US 9927655 W,1999-11-23,US 19764498 A,1998-11-23,REDUCED MOLECULAR WEIGHT NATIVE GELLAN GUM,"This invention provides reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention generally have a weight average molecular weight less than about 1.7 X 106, and typically in a range of about 1.2 X 106 to about 9.3 X 105. This invention also provides compositions, e.g., solutions and gels, comprising reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention may be prepared by any method which reduces the molecular weight of polymers. Such methods include homogenization, sonication, radiation, oxidation and hydrolysis.",MONSANTO CO,CLARK ROSS;;MORRISON NEIL;;CHEN YOU-LUNG;;TALASHEK TODD;;BURGUM DAN,,https://lens.org/008-200-676-174-623,Patent Application,yes,1,25,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A21D13/08;;A23G9/32;;A23C9/152;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,,2,1,075-120-400-064-212,10.1006/abbi.1996.9851;;9056228,"CHEMICAL ABSTRACTS, vol. 131, no. 4, 26 July 1999, Columbus, Ohio, US; abstract no. 44062, ""Grease-like gel food"" XP002134675;;W. HASHIMOTO ET AL.: ""Microbial system for polysaccharide depolymerization: Enzymatic route for Gellan depolymerization by Bacillus sp. GL1"", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 339, no. 1, 1 March 1997 (1997-03-01), pages 17 - 23, XP000901105",PENDING
308,US,B2,US 7897453 B2,049-402-510-292-075,2011-03-01,2011,US 33641008 A,2008-12-16,US 33641008 A,2008-12-16,Dual insulating layer diode with asymmetric interface state and method of fabrication,"An integrated circuit including vertically oriented diode structures between conductors and methods of fabricating the same are provided. The diode is a metal-insulator diode having a first metal layer, a first insulating layer, a second insulating layer and a second metal layer. At least one asymmetric interface state is provided at the intersection of at least two of the layers to increase the ratio of the diode's on-current to its reverse bias leakage current. In various examples, the asymmetric interface state is formed by a positive or negative sheet charge that alters the barrier height and/or electric field at one or more portions of the diode. Two-terminal devices such as passive element memory cells can utilize the diode as a steering element in series with a state change element. The devices can be formed using pillar structures at the intersections of upper and lower conductors.",SANDISK 3D LLC,CHEN XIYING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2008-12-02),https://lens.org/049-402-510-292-075,Granted Patent,yes,45,19,4,4,0,H10B63/22;;H10B63/84;;H10N70/00;;H10B63/22;;H10B63/80;;H10B63/84;;H10N70/231;;H10N70/20;;H10N70/063;;H10N70/245;;H10N70/826;;H10N70/881;;H10N70/8828;;H10N70/8833;;H10N70/8836;;H10N70/8845,H01L21/8234,438/237;;257/656;;257/4;;X257E29331,10,3,047-181-506-118-737;;065-658-930-885-415;;000-783-177-455-275,10.1109/led.2005.851232;;10.1109/vlsit.2004.1345471;;10.1109/rfic.2007.380858,"Jammy, et al., ""Synthesis and Characterization of TiO2 Films for Deep Trench Capacitor Applications,"" Proceedings of the 2000 12th IEEE International Symposium on Ferroelectrics, Jul. 21, 2000, pp. 147-150.;;Lu, et al., ""Characteristics and Mechanism of Tunable Work Function Gate Electrodes Using a Bilayer Metal Structure on SiO2 and HfO2,"" IEEE Electron Device Letters, vol. 26, Issue 7, Jul. 2005, pp. 445-447.;;Bae, et al., ""Laminated Metal Gate Electrode With Tunable Work Function for Advanced CMOS,"" 2004 Symposium on VLSI Technology Digest of Technical Papers, Jun. 2004, pp. 188-189.;;Rockwell, et al., ""Characterization and Modeling of Metal/Double-Insulator/Metal Diodes for Millimeter Wave Wireless Receiver Applications,"" 2007 IEEE Radio Frequency Integrated Circuits Symposium, Jun. 2007, pp. 171-174.;;Brown, Chappell, ""Metal diode enables terahertz transceiver,"" EE Times, [http://www.eetimes.com/showArticle.jhtml?articleID=160502202], Apr. 11, 2005, 2 pages.;;International Search Report & The Written Opinion of the International Searching Authority dated Jan. 29, 2010, Patent Cooperation Treaty, International Application No. PCT/US2009/058858 filed Sep. 29, 2009.;;U.S. Appl. No. 12/240,785, filed Sep. 29, 2008.;;U.S. Appl. No. 12/240,766, filed Sep. 29, 2008.;;English translation of Abstract of Japanese Publication No. 3045930, published on Feb. 27, 1991.;;English translation of Abstract of Japanese Publication No. 3051823, published on Jun. 3, 1991.",INACTIVE
309,US,B2,US 11107377 B2,072-526-290-548-187,2021-08-31,2021,US 201916658609 A,2019-10-21,US 201916658609 A,2019-10-21,Projected information display for IT equipment environments,"A system, method, and computer-readable medium are disclosed for performing a projected equipment information operation within an IT environment. In various embodiments, the projected equipment information operation includes: receiving equipment information regarding an information handling system within the IT environment; identifying AR content associated with the equipment information regarding the information handling system within the IT environment; and, projecting the AR content associated with the equipment information onto a physical device within the IT environment, a combination of the AR content and the physical device providing a composite view, the composite view providing a hands free and device free provision of the equipment information.",DELL PRODUCTS LP,CHEN ZHAO;;CLARK PETER TIMOTHY;;HUNG HSIANG-YIN;;KUO WEI-TI,DELL PRODUCTS L.P (2019-10-17),https://lens.org/072-526-290-548-187,Granted Patent,yes,7,0,2,2,0,G06Q10/20;;G09G3/001;;G06Q10/20;;G06T11/00;;G06T11/00;;G06T19/006;;G09G2354/00;;H04N9/3179;;H04N9/3194,G06T19/00;;G06Q10/00;;G06T11/00;;G09G3/00,,1,0,,,"NPL_BMW_AR_Frames.pdf, https://www.youtube.com/watch?v=P9KPJIA5yds Oct. 3, 2007 (Year: 2007).",ACTIVE
310,TW,B,TW I753547 B,104-727-731-021-517,2022-01-21,2022,TW 109129070 A,2020-08-26,US 201962906750 P;;US 202016894901 A,2019-09-27,IMAGE SENSOR AND MANUFACTURING METHOD THEREOF,,TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK;;WANG WEN-SHENG;;KUO CHIEN-LI,,https://lens.org/104-727-731-021-517,Granted Patent,no,5,0,5,7,0,H01L27/14614;;H01L27/14623;;H01L27/14625;;H01L27/14643;;H01L27/14685;;H01L27/14689;;H01L27/14603;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14685;;H01L27/14689,,,0,0,,,,ACTIVE
311,WO,A1,WO 2019/177727 A1,133-850-478-793-85X,2019-09-19,2019,US 2019/0017653 W,2019-02-12,US 201862644031 P,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing a food composition comprising a foam control agent and a foodstuff, and processing the food composition, wherein the foodstuff comprises potato derivatives or beet derivatives. A food composition comprising a foodstuff and a foam control agent, and wherein the foodstuff comprises potato derivatives or beet derivatives.",DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,,https://lens.org/133-850-478-793-85X,Patent Application,yes,2,2,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,A23L29/00;;A23L29/10,,3,1,044-917-850-121-10X,10.1021/la049676o;;15491178,"""POLYOXYALKYLENE GLYCEROL ETHER FATTY ACID ESTER PREPN. - INVOLVES REACTING MIXT. OF NATURAL FATS AND OILS AND HYDROXYALKYL:AMINE WITH ALKYLENE OXIDE, USEFUL AS AN EMULSIFIER, DISPERSANT, CLEANING AGENT OR ANTIFOAMING AGENT"", WPI/DERWENT, 2 March 1993 (1993-03-02), XP002901290;;DATABASE WPI Week 201501, Derwent World Patents Index; AN 2014-W66530, XP002790405;;N. D. DENKOV: ""Mechanisms of Foam Destruction by Oil-Based Antifoams"", LANGMUIR, vol. 20, no. 22, 2004, pages 9463 - 9505, XP002468579, DOI: doi:10.1021/la049676o",PENDING
312,WO,A1,WO 2013/116443 A1,164-174-603-853-799,2013-08-08,2013,US 2013/0024016 W,2013-01-31,US 201261593656 P,2012-02-01,MICRO-DISPENSING MULTI-LAYERED 3D OBJECTS WITH CURING STEPS,"A method of building a three dimensional (3D) structure includes micro-dispensing a layer comprising a material using a syringe-based micro-dispensing tool, curing the layer, and repeating the steps of micro-dispensing and curing a plurality of times in order to build the three-dimensional structure. The material may be loaded with nano to micron sized particles, tubes, or strings.",NSCRYPT INC;;CHURCH KENNETH H;;NEWTON CHARLES M;;CHEN XUDONG;;CLARK PATRICK A,CHURCH KENNETH H;;NEWTON CHARLES M;;CHEN XUDONG;;CLARK PATRICK A,,https://lens.org/164-174-603-853-799,Patent Application,yes,5,0,3,3,0,H05K3/1241;;H05K2203/0126;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;B29C64/165;;B29C64/188;;B29C64/209;;B33Y40/20;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;H05K3/1241;;H05K2203/0126;;B29C64/106;;B33Y40/20;;B29C64/165,H05K3/00,,0,0,,,,PENDING
313,TW,A,TW 200400851 A,162-010-776-654-882,2004-01-16,2004,TW 92115843 A,2003-06-11,US 39155702 P,2002-06-25,PVD supported mixed metal oxide catalyst,A supported catalyst comprising a mixed metal oxide is useful for the vapor phase oxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated carboxylic acid and for the vapor phase ammoxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated nitrile.,ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE JR;;GAFFNEY ANNE MAE,,https://lens.org/162-010-776-654-882,Patent of Addition,no,0,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,PENDING
314,EP,A1,EP 3684198 A1,191-138-895-836-157,2020-07-29,2020,EP 19708712 A,2019-02-12,US 201862644031 P;;US 2019/0017653 W,2018-03-16,FOAM CONTROL,,DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,,https://lens.org/191-138-895-836-157,Patent Application,yes,0,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,A23L29/00;;A23L29/10,,0,0,,,,ACTIVE
315,US,B2,US 8606724 B2,016-110-103-462-290,2013-12-10,2013,US 26619808 A,2008-11-06,US 26619808 A,2008-11-06,Policy evolution with machine learning,"A method for constructing a classifier which maps an input vector to one of a plurality of pre-defined classes, the method steps includes receiving a set of training examples as input, wherein each training example is an exemplary input vector belonging to one of the pre-defined classes, learning a plurality of functions, wherein each function maps the exemplary input vectors to a numerical value, and determining a class for the input vector by combining numerical outputs of the functions determined for the input vector.",CHENG PAU-CHEN;;CLARK JOHN ANDREW;;LIM YOW TZU;;ROHATGI PANKAJ;;IBM,CHENG PAU-CHEN;;CLARK JOHN ANDREW;;LIM YOW TZU;;ROHATGI PANKAJ,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-09-19),https://lens.org/016-110-103-462-290,Granted Patent,yes,4,5,2,2,0,G06N20/00;;G06N20/00,G06N20/00;;G06F17/00;;G06N3/00;;G06N3/12;;G06N5/00,706/12;;706/13;;706/45,4,4,135-076-315-653-775;;076-075-935-246-254;;168-390-118-438-745;;014-234-232-836-510,10.1109/ijcnn.2005.1555963;;10.1007/3-540-44794-6_26;;10.1007/s10044-004-0213-6;;10.1007/978-3-540-74829-8_20,"Yi Liu; Zheng, Y.F.; , ""One-against-all multi-class SVM classification using reliability measures,"" Neural Networks, 2005. IJCNN '05. Proceedings. 2005 IEEE International Joint Conference on , vol. 2, No., pp. 849-854 vol. 2, Jul. 31-Aug. 4, 2005.;;Mendes, Roberto; de Voznika, Fabricio; Freitas, Alex; Nievola, Julio. ""Discovering Fuzzy Classification Rules with Genetic Programming and Co-evolution,"" Principles of Data Mining and Knowledge Discovery pp. 314-325 (2001).;;Debnath, R.; Takahide, N.; Takahashi, H.. ""A decision based one-against-one method for multi-class support vector machine,"" Pattern Analysis & Applications vol. 7, No. 2 pp. 164-175 (2004).;;C. Thiel, S. Scherer, and F. Schwenker, ""Fuzzy-input fuzzy-output one against-all support vector machines,"" in Proc. 11th Int. Conf. Knowledge-Based Intell. Inf. Eng. Syst., 2007, vol. 4694, pp. 156-165.",INACTIVE
316,US,B2,US 10255330 B2,036-458-851-828-457,2019-04-09,2019,US 201615083058 A,2016-03-28,US 201615083058 A;;US 2014/0059103 W;;US 201361886555 P,2013-10-03,Methods for analyzing genotypes,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,CHANDRATILLAKE GEMMA L;;GARCIA SARAH K;;CHEN RICHARD;;CLARK MICHAEL JAMES,PERSONALIS INC (2014-10-01),https://lens.org/036-458-851-828-457,Granted Patent,yes,16,7,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G16B20/00;;G16B20/20;;G16B50/10,,7,4,026-129-645-699-551;;078-381-584-206-039;;089-584-029-489-307;;111-093-078-328-445,pmc2768590;;19861545;;10.1073/pnas.0910672106;;10.1038/nature08250;;pmc2844771;;19684571;;24702956;;10.1016/j.ajhg.2014.03.010;;pmc3980410;;10.1038/sj.ejhg.5201585;;16493445,"Arup's product “Exome Sequencing Symptom-Guided Analysis”. http://www.aruplab.com/guides/ug/tests/2006332.jsp. Accessed Oct. 1, 2014.;;Choi, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci U S A. Nov. 10, 2009;106(45):19096-101. doi: 10.1073/pnas.0910672106. Epub Oct. 27, 2009.;;International search report and written opinion dated Jan. 8, 2015 for PCT Application No. US2014/059103.;;Ng, et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature. Sep. 10, 2009;461(7261):272-6. doi: 10.1038/nature08250. Epub Aug. 16, 2009.;;Singleton, et al. Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. Am J Hum Genet. Apr. 3, 2014;94(4):599-610. doi: 10.1016/j.ajhg.2014.03.010.;;SVBio's services. http://www.svbio.com/service-offerings/current-services. Accessed Oct. 1, 2014.;;Van Driel, et al. A text-mining analysis of the human phenome. Eur J Hum Genet. May 2006;14(5):535-42.",ACTIVE
317,US,A1,US 2024/0077778 A1,077-984-902-589-01X,2024-03-07,2024,US 18270637,2021-12-30,,,DEVICE INCLUDING FERROELECTRIC NEMATIC LIQUID CRYSTAL-FORMING MOLECULES AND METHODS OF FORMING AND USING SAME,"Surface polarity of a ferroelectric nematic can be configured to generate vectorial control of the orientation of its bulk polarization field. The contact between a surface with in-plane polarity and a ferroelectric nematic liquid crystal generates preferred in-plane orientation of the ferroelectric polarization field at that interface, which can lead to the formation of fluid or glassy monodomains of high polarization without electric field poling. Materials surfaces can be used as a route to making planar-aligned cells with a variety of azimuthal director/polarization structures, including twisted states, in a π-twist cell, obtained with antiparallel, unidirectional buffing on opposing surfaces, we demonstrate three distinct modes of ferroelectric nematic electro-optic response: intrinsic viscosity-limited field induced molecular reorientation, field-induced motion of domain walls separating twisted states of opposite chirality; and propagation of polarization reorientation solitons from the cell plates to the cell center upon field reversal.","The Regents of the University of Colorado, a body corporate",Noel A. Clark;;Xi Chen;;Joseph E. Maclennan;;Matthew A. Glaser,,https://lens.org/077-984-902-589-01X,Patent Application,yes,0,0,1,1,0,G02F1/141;;G02F1/133788,G02F1/141;;G02F1/1337,,0,0,,,,UNKNOWN
318,US,A1,US 2021/0294810 A1,123-586-937-049-972,2021-09-23,2021,US 202017108372 A,2020-12-01,US 202017108372 A;;US 201715929318 A;;US 201916570219 A;;US 201916255762 A;;US 201615083058 A;;US 2014/0059103 W;;US 201361886555 P,2013-10-03,METHODS FOR ANALYZING GENOTYPES,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,CHANDRATILLAKE GEMMA L;;GARCIA SARAH K;;CHEN RICHARD;;CLARK MICHAEL JAMES,PERSONALIS INC (2014-10-01),https://lens.org/123-586-937-049-972,Patent Application,yes,4,0,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G06F16/2457;;G06F16/248;;G16B20/00;;G16B20/20;;G16B50/00;;G16B50/10,,0,0,,,,ACTIVE
319,EP,B1,EP 1374992 B1,164-365-479-751-454,2006-02-15,2006,EP 03253743 A,2003-06-12,US 39155702 P,2002-06-25,Process for preparing a supported catalyst by physical or chemical vapour deposition,,ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK JR MICHAEL BRUCE;;GAFFNEY ANNE MAE,,https://lens.org/164-365-479-751-454,Granted Patent,yes,6,3,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J23/00;;B01J37/00;;B01J23/20;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,EXPIRED
320,US,B2,US 6476527 B2,014-827-144-878-968,2002-11-05,2002,US 81573301 A,2001-03-23,US 81573301 A;;US 31739599 A,1999-05-24,Alternator system,"
    An improved alternator system for replacing an OEM Ford IAR alternator system. The improved alternator system includes a rectifier with increased heat dissipation qualities and decreased heat generation qualities and configured to maintain secure electrical connections. The alternator system is further configured to provide optimum electrical output by providing the rotor and the stator with additional turns or windings of heavier gauge wire whereby the alternator is capable of inducing a stabilized output current of at least about 52 amperes of current at about 1600 revolutions per minute of the rotor. 
",UNIT PARTS COMPANY,BALLARD MICHAEL D;;CHEN JIANING;;CLARK DANIEL JOSEPH;;MADDOX LARRY JOE,,https://lens.org/014-827-144-878-968,Granted Patent,yes,13,25,4,4,0,H02K3/12;;H02K3/18;;H02K5/225;;H02K15/0006;;H02K19/22;;H02K11/05;;H02K15/0006;;H02K19/22;;H02K3/12;;H02K5/225;;H02K3/18;;H02K11/05,H02K3/12;;H02K3/18;;H02K5/22;;H02K11/04;;H02K15/00;;H02K19/22,310 68D;;310/71;;363/142;;363/145,0,0,,,,EXPIRED
321,US,A1,US 2021/0118342 A1,158-088-710-559-984,2021-04-22,2021,US 201916658609 A,2019-10-21,US 201916658609 A,2019-10-21,Projected Information Display for IT Equipment Environments,"A system, method, and computer-readable medium are disclosed for performing a projected equipment information operation within an IT environment. In various embodiments, the projected equipment information operation includes: receiving equipment information regarding an information handling system within the IT environment; identifying AR content associated with the equipment information regarding the information handling system within the IT environment; and, projecting the AR content associated with the equipment information onto a physical device within the IT environment, a combination of the AR content and the physical device providing a composite view, the composite view providing a hands free and device free provision of the equipment information.",DELL PRODUCTS LP,CHEN ZHAO;;CLARK PETER TIMOTHY;;HUNG HSIANG-YIN;;KUO WEI-TI,DELL PRODUCTS L.P (2019-10-17),https://lens.org/158-088-710-559-984,Patent Application,yes,0,6,2,2,0,G06Q10/20;;G09G3/001;;G06Q10/20;;G06T11/00;;G06T11/00;;G06T19/006;;G09G2354/00;;H04N9/3179;;H04N9/3194,G09G3/00;;G06Q10/00;;G06T11/00,,0,0,,,,ACTIVE
322,WO,A1,WO 2010/074785 A1,185-387-848-663-353,2010-07-01,2010,US 2009/0058858 W,2009-09-29,US 33641008 A,2008-12-16,DUAL INSULATING LAYER DIODE WITH ASYMMETRIC INTERFACE STATE AND METHOD OF FABRICATION,"An integrated circuit including vertically oriented diode structures between conductors and methods of fabricating the same are provided. The diode is a metal-insulator diode having a first metal layer, a first insulating layer, a second insulating layer and a second metal layer. At least one asymmetric interface state is provided at the intersection of at least two of the layers to increase the ratio of the diode's on-current to its reverse bias leakage current. In various examples, the asymmetric interface state is formed by a positive or negative sheet charge that alters the barrier height and/or electric field at one or more portions of the diode. Two-terminal devices such as passive element memory cells can utilize the diode as a steering element in series with a state change element. The devices can be formed using pillar structures at the intersections of upper and lower conductors.",SANDISK 3D LLC;;CHEN XIYING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,CHEN XIYING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,,https://lens.org/185-387-848-663-353,Patent Application,yes,4,0,4,4,0,H10B63/22;;H10B63/84;;H10N70/00;;H10B63/22;;H10B63/80;;H10B63/84;;H10N70/231;;H10N70/20;;H10N70/063;;H10N70/245;;H10N70/826;;H10N70/881;;H10N70/8828;;H10N70/8833;;H10N70/8836;;H10N70/8845,H01L45/00;;H01L27/24,,0,0,,,,PENDING
323,EP,B1,EP 3473027 B1,062-468-834-777-40X,2021-09-22,2021,EP 17814094 A,2017-06-15,US 201662350523 P;;US 201662368723 P;;US 201662421088 P;;US 2017/0037680 W,2016-06-15,SERVICES PROVISIONING FOR INTERNET-OF-THINGS DEVICES IN CELLULAR NETWORKS,,APPLE INC,LIAO CHING-YU;;CHEN KUILIN CLARK;;MACIOCCO CHRISTIAN;;SUNDER RAJAN ASHOK,APPLE INC. (2020-12-16),https://lens.org/062-468-834-777-40X,Granted Patent,yes,10,0,5,5,0,H04W8/26;;H04W12/06;;H04W88/14;;H04W4/50;;H04W4/70;;H04W60/04;;H04W12/35,H04W4/50;;H04W4/70;;H04W8/26;;H04W12/06;;H04W60/04;;H04W88/14,,1,0,,,"'Intra-domaIn connection ot Kadio Access Network (RAN) nodes to multiple Core Network (CN) nodes (Release 13' 3GPP IS 23.236, [Online] 21 June 2015, XP051294228 Retrieved from the Internet: <URL:https://portal.3gpp.org/desktopmodules /Specifications/SpecificationDetails. pspx?specificationId=825>",ACTIVE
324,CN,A,CN 101312713 A,060-757-885-234-50X,2008-11-26,2008,CN 200680008772 A,2006-03-08,AU 2005/901355 A,2005-03-18,Inhalable drug,"A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.",NANOMATERIALS TECH PTE LTD,CLARK CHIOU HERBERT;;FENG CHEN JIAN;;TING HU TING;;JIMMY YUN,,https://lens.org/060-757-885-234-50X,Patent Application,no,0,8,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61J3/02;;B01J13/00,,0,0,,,,DISCONTINUED
325,EP,A1,EP 3923607 A1,111-044-004-485-164,2021-12-15,2021,EP 21187383 A,2017-06-15,US 201662350523 P;;US 201662368723 P;;US 201662421088 P;;EP 17814094 A;;US 2017/0037680 W,2016-06-15,SERVICES PROVISIONING FOR INTERNET-OF-THINGS DEVICES IN CELLULAR NETWORKS,"Methods and apparatus are described by which a network controller receives an attach request from a first user equipment (UE). The attach request including a requested IP service. A group of IP addresses for the IP service is allocated. A routing policy is configured for the group of IP addresses. The routing policy is sent to a RAN node and a data gateway. The routing policy indicates a route for data packets, from UEs using the requested IP service, received at the RAN node to the data gateway. A mapping between the service identifier and the group of IP addresses is stored.
",APPLE INC,LIAO CHING-YU;;CHEN KUILIN CLARK;;MACIOCCO CHRISTIAN;;SUNDER RAJAN ASHOK,,https://lens.org/111-044-004-485-164,Patent Application,yes,7,0,5,5,0,H04W8/26;;H04W12/06;;H04W88/14;;H04W4/50;;H04W4/70;;H04W60/04;;H04W12/35,H04W4/50;;H04W4/70;;H04W8/26;;H04W12/06;;H04W12/30;;H04W60/04;;H04W88/14,,2,0,,,"""3rd Generation Partnership Project; Technical Specification Group Services and System Aspects; Study on Architecture for Next Generation System (Release 14)"", 3GPP STANDARD; 3GPP TR 23.799, 3RD GENERATION PARTNERSHIP PROJECT (3GPP), MOBILE COMPETENCE CENTRE ; 650, ROUTE DES LUCIOLES ; F-06921 SOPHIA-ANTIPOLIS CEDEX ; FRANCE, vol. SA WG2, no. V0.5.0, 8 June 2016 (2016-06-08), pages 1 - 191, XP051123270;;CATT: ""Service Triggered Network Slicing Selection Procedure"", vol. SA WG2, no. Nanjing, P.R. China; 20160523 - 20160527, 23 May 2016 (2016-05-23), XP051109386, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings_3GPP_SYNC/SA2/Docs/> [retrieved on 20160523]",PENDING
326,WO,A1,WO 2015/051275 A1,105-030-438-116-724,2015-04-09,2015,US 2014/0059103 W,2014-10-03,US 201361886555 P,2013-10-03,METHODS FOR ANALYZING GENOTYPES,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,CHANDRATILLAKE GEMMA L;;GARCIA SARAH K;;CHEN RICHARD;;CLARK MICHAEL JAMES,,https://lens.org/105-030-438-116-724,Patent Application,yes,5,16,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G16B20/00;;G16B20/20;;G16B50/10,,0,0,,,,PENDING
327,TW,A,TW 200952183 A,120-570-754-569-857,2009-12-16,2009,TW 98114087 A,2009-04-28,US 14921708 A,2008-04-29,Reverse leakage reduction and vertical height shrinking of diode with halo doping,"One embodiment of the invention provides a semiconductor diode device including a first conductivity type region, a second conductivity type region, where the second conductivity type is different from the first conductivity type, an intrinsic region located between the first conductivity type region and the second conductivity type region; a first halo region of the first conductivity type located between the second conductivity type region and the intrinsic region, and optionally a second halo region of the second conductivity type located between the first conductivity type region and the intrinsic region.",SANDISK 3D LLC,CHEN XI-YING;;CLARK MARK H;;HERNER S BRAD;;KUMAR TANMAY,,https://lens.org/120-570-754-569-857,Patent of Addition,no,0,0,4,4,0,H01L29/1606;;H01L29/8615;;H01L29/868;;H01L29/868;;H01L29/8615;;H01L29/1606,H01L29/861;;H01L21/8229;;H01L27/112;;H01L27/24,,0,0,,,,PENDING
328,US,B2,US 8351659 B2,126-998-755-153-445,2013-01-08,2013,US 13743508 A,2008-06-11,US 13743508 A;;US 93473207 P,2007-06-14,Eye detection system,"An eye detection system, method, and apparatus are disclosed. The eye detection apparatus includes illuminator, receiver, processor, and memory elements. The illuminator emits radiation at predetermined wavelengths from the eye detection apparatus toward an area of interest. Radiation from the area of interest is detected at the receiver which, in turn, provides sensor data to the processor. The processor is coupled to the illuminator and receiver and controls their respective operations. The processor detects a pattern representative of a human eye in the sensor data and determines coordinates of an object corresponding to the pattern. The memory stores the coordinates of the object. Optionally, the eye detection apparatus communicates the coordinates of the object to a wireless device and directs countermeasures to the object's coordinates in response to commands from the wireless device.",CUBIC CORP;;D SOUZA CLARK;;CHEN IRENE;;LEE SHINHAK;;RIPINGILL JR ALLEN E,D SOUZA CLARK;;CHEN IRENE;;LEE SHINHAK;;RIPINGILL JR ALLEN E,CUBIC CORPORATION (2008-06-10),https://lens.org/126-998-755-153-445,Granted Patent,yes,10,1,3,3,0,G06V40/18;;G06V20/52;;G06V40/18;;G06V20/52,G06K9/00,382/117;;382/103;;382/106;;382/107;;382/115;;382/181;;382/190;;382/191;;382/291;;382/313,1,0,,,"Hampapur, A. et al., ""Smart surveillance: applications, technologies and implications,"" Information, Communications and Signal Processing, 2003 and Fourth Pacific Rim Conference on Multimedia. Proceedings of the 2003 Joint Conference of the Fourth International Conference on Singapore, Dec. 15-18, 2003, Piscataway, NJ, USA, IEEE, pp. 1133-1138, XP010702808, ISBN: 978-0-7803-8185-8 abstract.",INACTIVE
329,US,A1,US 2021/0000153 A1,014-984-013-158-599,2021-01-07,2021,US 201916636231 A,2019-03-14,US 201916636231 A;;US 201862644024 P;;US 201862644038 P;;US 2019/0022172 W,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing food composition comprising a foam control agent and a foodstuff, the foam control agent comprising a Mono glycidyl ether adduct or a Diglycidyl ether adduct. A composition useful for foam control comprising a mono glycidyl ether adduct, a diglycidyl ether adduct or combination thereof.",DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,DOW GLOBAL TECHNOLOGIES LLC (2018-06-25),https://lens.org/014-984-013-158-599,Patent Application,yes,0,0,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/12,,0,0,,,,ACTIVE
330,US,A1,US 2021/0244060 A1,021-943-874-808-613,2021-08-12,2021,US 201916636005 A,2019-02-12,US 201916636005 A;;US 201862644031 P;;US 2019/0017653 W,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing a food composition comprising a foam control agent and a food-stuff, and processing the food composition, wherein the foodstuff comprises potato derivatives or beet derivatives. A food composition comprising a foodstuff and a foam control agent, and wherein the foodstuff comprises potato derivatives or beet derivatives.",DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,DOW GLOBAL TECHNOLOGIES LLC (2018-06-25),https://lens.org/021-943-874-808-613,Patent Application,yes,0,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/12,,0,0,,,,ACTIVE
331,WO,A8,WO 2008/000045 A8,032-225-278-530-750,2009-06-18,2009,AU 2007/000913 W,2007-06-29,AU 2006/903544 A,2006-06-30,NANOSTRUCTURED COMPOSITES,"The present invention relates to nanostructured composites, in particular nanotube/ substrate composites for use in the fields of biomedical materials and devices as well as energy conversion and storage, ion transport and liquid and gas separation. The use of such composites as biomaterials are of particular interest.",UNIV WOLLONGONG;;WALLACE GORDON GEORGE;;CHEN JUN;;MINETT ANDREW IAN;;CLARK GRAEME MILBOURNE,WALLACE GORDON GEORGE;;CHEN JUN;;MINETT ANDREW IAN;;CLARK GRAEME MILBOURNE,,https://lens.org/032-225-278-530-750,Amended Application,yes,0,0,4,4,0,B81C1/00111;;Y10T428/24479;;Y10T428/24479;;B81C1/00111,B82B1/00,,0,0,,,,PENDING
332,GB,A,GB 2535066 A,084-061-552-395-597,2016-08-10,2016,GB 201607223 A,2014-10-03,US 201361886555 P;;US 2014/0059103 W,2013-10-03,Methods for analyzing genotypes,"The disclosure provides methods and systems for analyzing genotype data. In some embodiments, a computer-implemented method comprises receiving data relating to one or more phenotypes of a subject or family members thereof, and ranking genes based on their association score with one or more phenotypes. Next, an output of the data is generated, the output comprising a comparison of the data based on the association score. The comparison can be in at least one of numeric and graphic form.",PERSONALIS INC,GEMMA L CHANDRATILLAKE;;SARAH K GARCIA;;RICHARD CHEN;;MICHAEL JAMES CLARK,,https://lens.org/084-061-552-395-597,Patent Application,no,5,0,6,6,0,G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20;;G16B20/00;;G16B50/10;;G16B20/20;;G06F16/24578;;G06F16/248;;G16B20/00;;G16B50/00;;G16B50/10;;G16B20/20,G16B20/00;;G16B20/20;;G16B50/10,,0,0,,,,DISCONTINUED
333,US,B2,US 11510429 B2,139-828-439-497-115,2022-11-29,2022,US 201916585514 A,2019-09-27,US 201916585514 A;;US 201862738309 P,2018-09-28,Cyclic ketal compounds having long side chains useful as foam control agents in the manufacture of food and beverage products,"Cyclic ketal compounds provide excellent foam protection when having at least one moiety of a threshold size (comprising 4 or more carbon atoms) pendant from a ketal carbon. The carbons in such moieties may be present in one or more chains. The cyclic ketal compounds of the present invention are compatible with foodstuff manufacturing. In particular, it has been discovered that the cyclic ketal compounds of the present invention exhibit excellent foam control performance in both potato and sugar beet processing systems.",DOW GLOBAL TECHNOLOGIES LLC,TULCHINSKY MICHAEL L;;CHEN XUE;;CUMMINS CLARK H;;KING STEPHEN W,DOW GLOBAL TECHNOLOGIES LLC (2018-10-19),https://lens.org/139-828-439-497-115,Granted Patent,yes,3,0,2,2,0,A23L2/52;;A23L2/54;;A23L29/035;;A23V2002/00;;B01D19/0404;;B01D19/0463;;A23L29/035;;B01D19/0404;;A23L2/54,A23L29/00;;A23L2/54;;B01D19/04,,1,1,036-378-537-819-472,10.1021/la010494t,"Iyer, M.; Hayes, D. G.; Harris, J. M., Synthesis of pH-degradable nonionic surfactants and their applications in microemulsions. Langmuir 2001, 17, (22), 6816-6821.",ACTIVE
334,US,A1,US 2013/0193619 A1,191-044-272-282-226,2013-08-01,2013,US 201313755076 A,2013-01-31,US 201313755076 A;;US 201261593656 P,2012-02-01,MICRO-DISPENSING MULTI-LAYERED 3D OBJECTS WITH CURING STEPS,"A method of building a three dimensional (3D) structure includes micro-dispensing a layer comprising a material using a syringe-based micro-dispensing tool, curing the layer, and repeating the steps of micro-dispensing and curing a plurality of times in order to build the three-dimensional structure. The material may be loaded with nano to micron sized particles, tubes, or strings.",NSCRYPT INC;;NSCRYPT INC,CHURCH KENNETH H;;NEWTON CHARLES M;;CHEN XUDONG;;CLARK PATRICK A,NSCRYPT INC (2013-01-28),https://lens.org/191-044-272-282-226,Patent Application,yes,4,45,3,3,0,H05K3/1241;;H05K2203/0126;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;B29C64/165;;B29C64/188;;B29C64/209;;B33Y40/20;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;H05K3/1241;;H05K2203/0126;;B29C64/106;;B33Y40/20;;B29C64/165,H05K3/30;;B29C67/00,264/400;;264/109;;264/463;;264/104;;264/497;;264/40.1;;425/375;;29/832,0,0,,,,ACTIVE
335,SA,B1,SA 520411335 B1,014-759-555-620-142,2022-08-24,2022,SA 520411335 A,2020-02-20,US 2019/0017653 W;;US 201862644031 P,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing a food composition comprising a foam control agent and a foodstuff, and processing the food composition, wherein the foodstuff comprises potato derivatives or beet derivatives. A food composition comprising a foodstuff and a foam control agent, and wherein the foodstuff comprises potato derivatives or beet derivatives.",DOW GLOBAL TECHNOLOGIES LLC,CHEN XUE;;TULCHINSKY MICHAEL L;;CUMMINS CLARK H;;KING STEPHEN W,,https://lens.org/014-759-555-620-142,Granted Patent,no,0,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,,,0,0,,,,ACTIVE
336,US,A1,US 2010/0068461 A1,098-649-569-272-118,2010-03-18,2010,US 30701707 A,2007-06-29,AU 2006/903544 A;;AU 2007/000913 W,2006-06-30,NANOSTRUCTURED COMPOSITES,"The present invention relates to nanostructured composites, in particular nanotube/substrate composites for use in the fields of biomedical materials and devices as well as energy conversion and storage, ion transport and liquid and gas separation. The use of such composites as biomaterials are of particular interest.",UNIV WOLLONGONG,WALLACE GORDON GEORGE;;CHEN JU;;MINETT ANDREW IAN;;CLARK GRAEME MILBOURNE,WOLLONGONG UNIVERSITY (2009-05-01),https://lens.org/098-649-569-272-118,Patent Application,yes,13,49,4,4,0,B81C1/00111;;Y10T428/24479;;Y10T428/24479;;B81C1/00111,B32B3/10;;B29C39/02,428/156;;264/299,0,0,,,,DISCONTINUED
337,US,A1,US 2010/0148324 A1,120-440-459-994-484,2010-06-17,2010,US 33641008 A,2008-12-16,US 33641008 A,2008-12-16,Dual Insulating Layer Diode With Asymmetric Interface State And Method Of Fabrication,"An integrated circuit including vertically oriented diode structures between conductors and methods of fabricating the same are provided. The diode is a metal-insulator diode having a first metal layer, a first insulating layer, a second insulating layer and a second metal layer. At least one asymmetric interface state is provided at the intersection of at least two of the layers to increase the ratio of the diode's on-current to its reverse bias leakage current. In various examples, the asymmetric interface state is formed by a positive or negative sheet charge that alters the barrier height and/or electric field at one or more portions of the diode. Two-terminal devices such as passive element memory cells can utilize the diode as a steering element in series with a state change element. The devices can be formed using pillar structures at the intersections of upper and lower conductors.",CHEN XIYING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,CHEN XIYING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2008-12-02),https://lens.org/120-440-459-994-484,Patent Application,yes,41,20,4,4,0,H10B63/22;;H10B63/84;;H10N70/00;;H10B63/22;;H10B63/80;;H10B63/84;;H10N70/231;;H10N70/20;;H10N70/063;;H10N70/245;;H10N70/826;;H10N70/881;;H10N70/8828;;H10N70/8833;;H10N70/8836;;H10N70/8845,H01L29/868,257/656;;X257E29336,0,0,,,,INACTIVE
338,WO,A2,WO 2010/065725 A2,168-279-542-872-860,2010-06-10,2010,US 2009/0066560 W,2009-12-03,US 12027308 P,2008-12-05,REGULATION OF COTTON FIBER GROWTH BY EXTRACELLULAR NUCLEOTIDES AND ECTOAPYRASES,"The present invention includes compositions and methods of modulating the length of one or more cotton fibers in a plant by contacting the plant or tissue derived therefrom with at least one of: a nucleotide; a modulator of ectoapyrase gene transcription; or an anti-ectoapyrase antibody or fragments thereof, at a concentration that modulates growth of one or more cotton fibers.",UNIV TEXAS;;ROUX STANLEY;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK,ROUX STANLEY;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK,,https://lens.org/168-279-542-872-860,Patent Application,yes,0,3,5,5,0,C12N9/14;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N9/14,C12N5/04;;A01H1/00;;C12N5/02;;C12N5/10;;C12N15/11;;C12N15/52,,0,0,,,,PENDING
339,US,A1,US 2023/0195754 A1,174-091-745-777-188,2023-06-22,2023,US 202117555645 A,2021-12-20,US 202117555645 A,2021-12-20,DECENTRALIZED DATA BROADCASTING IN A DISTRIBUTED NETWORK,A method for publishing a data message to shared storage includes receiving an action targeting a user associated with a distributed network having a plurality of service providers. Each service provider includes a private storage system and has access to a shared storage system. The method also includes parsing data elements of the action into a first set of data elements and a second set of data elements. The method further includes classifying the first set of data elements into categories of a data taxonomy. The method additionally includes generating a message for the action where the message includes the first set of data elements. The method also includes publishing the message to the shared storage system using a first identifier indicating the user and a second identifier that indicates that a respective service provider associated with the action has authority to publish the message to the shared storage system.,EVERNORTH STRATEGIC DEV INC,PATEL HARSHIL;;MUELLER REMIK;;CLARK JONATHAN;;DAMANIA PRASHANT M;;CHEN MICHAEL,EVERNORTH STRATEGIC DEVELOPMENT INC (2021-12-17),https://lens.org/174-091-745-777-188,Patent Application,yes,6,0,1,1,0,G06Q30/0283;;G06F16/285;;G06Q30/0283;;G06F16/285,G06F16/28;;G06Q30/02,,1,0,,,"Lindsay Kolowich Cox, ""How to Send Group Direct Messages on Twitter"", https://blog.hubspot.com/marketing/twitter-group-direct-message (Year: 2015)",PENDING
340,CN,A,CN 111050571 A,170-785-214-545-696,2020-04-21,2020,CN 201980003944 A,2019-02-12,US 201862644031 P;;US 2019/0017653 W,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing a food composition comprising a foam control agent and a foodstuff, and processing the food composition, wherein the foodstuff comprises potato derivatives or beet derivatives. A food composition comprising a foodstuff and a foam control agent, and wherein the foodstuff comprises potato derivatives or beet derivatives.",DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,,https://lens.org/170-785-214-545-696,Patent Application,no,5,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,A23L29/00;;A23L29/10,,1,0,,,"孙传尧: ""《选矿工程师手册 第1册 上 选矿通论》"", 北京：冶金工业出版社",PENDING
341,CN,A,CN 111031809 A,034-173-038-925-324,2020-04-17,2020,CN 201980003915 A,2019-03-14,US 201862644024 P;;US 201862644038 P;;US 2019/0022172 W,2018-03-16,FOAM CONTROL IN FOOD,"A method for controlling foam comprising providing food composition comprising a foam control agent and a foodstuff, the foam control agent comprising a Mono glycidyl ether adduct or a Diglycidyl ether adduct. A composition useful for foam control comprising a mono glycidyl ether adduct, a diglycidyl ether adduct or combination thereof.",DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,,https://lens.org/034-173-038-925-324,Patent Application,no,1,2,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/10;;A23L19/12,,1,0,,,"AYTEKIN KÖSE等: ""Nucleophilic Reactivity of Ethers Against Terminal Epoxides in the Presence of BF3: A Mechanistic Study""",PENDING
342,EP,A1,EP 1144457 A1,193-967-983-641-81X,2001-10-17,2001,EP 99961752 A,1999-11-23,US 9927655 W;;US 19764498 A,1998-11-23,REDUCED MOLECULAR WEIGHT NATIVE GELLAN GUM,,CP KELCO US INC,CLARK ROSS;;MORRISON NEIL;;CHEN YOU-LUNG;;TALASHEK TODD;;BURGUM DAN,,https://lens.org/193-967-983-641-81X,Patent Application,yes,0,0,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A23C9/152;;A21D13/08;;A23G9/32;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,,0,0,,,,DISCONTINUED
343,US,B2,US 6984750 B2,094-509-561-204-575,2006-01-10,2006,US 46073003 A,2003-06-12,US 46073003 A;;US 39155702 P,2002-06-25,PVD supported mixed metal oxide catalyst,A supported catalyst comprising a mixed metal oxide is useful for the vapor phase oxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated carboxylic acid and for the vapor phase ammoxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated nitrile.,ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK JR MICHAEL BRUCE;;GAFFNEY ANNE MAE,ROHM AND HAAS COMPANY (2003-04-14),https://lens.org/094-509-561-204-575,Granted Patent,yes,30,14,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;C07C253/00;;B01J20/00;;B01J21/02;;B01J21/08;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,558/323;;558/321;;558/322;;558/324;;558/325;;501/206;;501/248;;501/311;;501/312;;501/322;;501/323;;501/215;;502/255;;502/415;;502/439;;502/527.12;;502/527.15;;502/527.2;;502/527.24,4,1,061-504-494-028-128,10.1201/9781420028003.pt4,"Abstract of Japanese Laid-Open Patent Application No. 6-228073 (1994);;Abstract of Japanese Laid-Open Patent Application No. 07-53448 (1995).;;Abstract of Japanese Laid-Open Patent Application No. 2000-037623(Feb. 8, 2000).;;A. Cybulski and J.A. Moulijn (Eds.), ""Structured Catalysts and Reactors"", Marcel Dekker, Inc., 1998, pp. 599-615 (Ch. 21X, Xu and J.A. Moulijn, Transformation of a Structured Carrier into Structured Catalyst).",EXPIRED
344,US,A1,US 2001/0010436 A1,157-895-422-975-267,2001-08-02,2001,US 81573301 A,2001-03-23,US 81573301 A;;US 31739599 A,1999-05-24,Alternator system,"
   An improved alternator system for replacing an OEM Ford IAR alternator system. The improved alternator system includes a rectifier with increased heat dissipation qualities and decreased heat generation qualities and configured to maintain secure electrical connections. The alternator system is further configured to provide optimum electrical output by providing the rotor and the stator with additional turns or windings of heavier gauge wire whereby the alternator is capable of inducing a stabilized output current of at least about 52 amperes of current at about 1600 revolutions per minute of the rotor. 
",BALLARD MICHAEL D.;;CHEN JIANING;;CLARK DANIEL JOSEPH;;MADDOX LARRY JOE,BALLARD MICHAEL D;;CHEN JIANING;;CLARK DANIEL JOSEPH;;MADDOX LARRY JOE,,https://lens.org/157-895-422-975-267,Patent Application,yes,0,19,4,4,0,H02K3/12;;H02K3/18;;H02K5/225;;H02K15/0006;;H02K19/22;;H02K11/05;;H02K15/0006;;H02K19/22;;H02K3/12;;H02K5/225;;H02K3/18;;H02K11/05,H02K3/12;;H02K3/18;;H02K5/22;;H02K11/04;;H02K15/00;;H02K19/22,310/68,0,0,,,,EXPIRED
345,WO,A3,WO 2010/065725 A3,154-182-296-503-816,2010-10-14,2010,US 2009/0066560 W,2009-12-03,US 12027308 P,2008-12-05,REGULATION OF COTTON FIBER GROWTH BY EXTRACELLULAR NUCLEOTIDES AND ECTOAPYRASES,"The present invention includes compositions and methods of modulating the length of one or more cotton fibers in a plant by contacting the plant or tissue derived therefrom with at least one of: a nucleotide; a modulator of ectoapyrase gene transcription; or an anti-ectoapyrase antibody or fragments thereof, at a concentration that modulates growth of one or more cotton fibers.",UNIV TEXAS;;ROUX STANLEY;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK,ROUX STANLEY;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK,,https://lens.org/154-182-296-503-816,Search Report,yes,2,0,5,5,0,C12N9/14;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N9/14,C12N5/04;;A01H1/00;;C12N5/02;;C12N5/10;;C12N15/11;;C12N15/52,,2,1,070-047-330-919-747,pmc2254475;;10.1007/s11302-005-3981-6;;18404482,"PLANT PHYSIOLOGY, vol. 119, 1999, pages 543 - 551;;PURINERGIC SIGNALLING, vol. 2, 2006, pages 443 - 449",PENDING
346,JP,A,JP 2004025178 A,197-532-491-101-481,2004-01-29,2004,JP 2003174262 A,2003-06-19,US 39155702 P,2002-06-25,PHYSICAL VAPOR DEPOSITITED SUPPORTED CARRIED MIXED METAL OXIDE CATALYST,"<P>PROBLEM TO BE SOLVED: To provide a physical-vapor-deposited supported mixed metal oxide catalyst for oxidizing alkane or a mixture of alkane and alkene to the corresponding unsaturated carboxylic acid by vapor phase catalyst partial oxidation. <P>SOLUTION: The supported catalyst containing the mixed metal oxide is useful for vapor phase oxidation of the alkane or the mixture of alkane and alkene to the unsaturated carboxylic acid and vapor phase ammo-oxidation of the alkane or the mixture of alkane and alkene to unsaturated nitrile. <P>COPYRIGHT: (C)2004,JPO",ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK MICHAEL BRUCE JR;;GAFFNEY ANNE MAE,,https://lens.org/197-532-491-101-481,Patent Application,no,0,10,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,PENDING
347,US,B1,US 6252320 B1,022-504-732-685-509,2001-06-26,2001,US 37680099 A,1999-08-18,US 37680099 A;;US 31739599 A,1999-05-24,Alternator system,An improved alternator system for replacing an OEM Ford IAR alternator system. The improved alternator system includes a rectifier with increased heat dissipation qualities and decreased heat generation qualities and configured to maintain secure electrical connections. The alternator system is further configured to provide optimum electrical output by providing the rotor and the stator with additional turns or windings of heavier gauge wire whereby the alternator is capable of inducing a stabilized output current of at least about 52 amperes of current at about 1600 revolutions per minute of the rotor.,UNIT PARTS COMPANY,BALLARD MICHAEL D;;CHEN JIANING;;CLARK DANIEL JOSEPH;;MADDOX LARRY JOE,,https://lens.org/022-504-732-685-509,Granted Patent,yes,11,21,4,4,0,H02K3/12;;H02K3/18;;H02K5/225;;H02K15/0006;;H02K19/22;;H02K11/05;;H02K15/0006;;H02K19/22;;H02K3/12;;H02K5/225;;H02K3/18;;H02K11/05,H02K3/12;;H02K3/18;;H02K5/22;;H02K11/04;;H02K15/00;;H02K19/22,310 68D;;363/144;;363/145,0,0,,,,EXPIRED
348,SG,A1,SG 107149 A1,028-693-058-387-502,2004-11-29,2004,SG 200303996 A,2003-06-20,US 39155702 P,2002-06-25,PVD SUPPORTED MIXED METAL OXIDE CATALYST,,ROHM & HAAS,SANJAY CHATURVEDI;;JINGGUANG CHEN;;MICHAEL BRUCE CLARK JR;;ANNE MAE GAFFNEY,,https://lens.org/028-693-058-387-502,Patent Application,no,8,0,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,PENDING
349,US,B2,US 10059056 B2,055-432-619-533-957,2018-08-28,2018,US 201313755076 A,2013-01-31,US 201313755076 A;;US 201261593656 P,2012-02-01,Micro-dispensing multi-layered 3D objects with curing steps,"A method of building a three dimensional (3D) structure includes micro-dispensing a layer comprising a material using a syringe-based micro-dispensing tool, curing the layer, and repeating the steps of micro-dispensing and curing a plurality of times in order to build the three-dimensional structure. The material may be loaded with nano to micron sized particles, tubes, or strings.",NSCRYPT INC,CHURCH KENNETH H;;NEWTON CHARLES M;;CHEN XUDONG;;CLARK PATRICK A,NSCRYPT INC (2013-01-28),https://lens.org/055-432-619-533-957,Granted Patent,yes,16,1,3,3,0,H05K3/1241;;H05K2203/0126;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;B29C64/165;;B29C64/188;;B29C64/209;;B33Y40/20;;Y10T29/4913;;B33Y30/00;;B33Y40/00;;H05K3/1241;;H05K2203/0126;;B29C64/106;;B33Y40/20;;B29C64/165,B29C64/106;;B29C67/00;;B33Y30/00;;B33Y40/00;;H05K3/12,,1,0,,,"Nscrypt, Inc., PCT/US2013/024016 filed Jan. 31, 2013, “Notification of Transmittal of the International Search Report and The Written Opinion of the International Searching Authority, or the Declaration” dated Apr. 5, 2013.",ACTIVE
350,EP,A1,EP 1374992 A1,065-572-312-501-122,2004-01-02,2004,EP 03253743 A,2003-06-12,US 39155702 P,2002-06-25,Process for preparing a supported catalyst by physical or chemical vapour deposition,"A supported catalyst comprising a mixed metal oxide is useful for the vapor phase oxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated carboxylic acid and for the vapor phase ammoxidation of an alkane or a mixture of an alkane and an alkene to an unsaturated nitrile. 
The mixed oxide catalyst is prepared by depositing a plurality of films of different elements using physical or chemical vapor deposition.",ROHM & HAAS,CHATURVEDI SANJAY;;CHEN JINGGUANG;;CLARK JR MICHAEL BRUCE;;GAFFNEY ANNE MAE,,https://lens.org/065-572-312-501-122,Patent Application,yes,6,4,13,13,0,B01J23/002;;B01J23/28;;B01J23/6525;;B01J27/0576;;B01J37/0228;;B01J37/0238;;B01J37/0244;;B01J37/34;;B01J2523/00;;C07C51/215;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J35/58;;B01J35/56;;B01J37/00;;C07C51/252;;B01J37/0244;;B01J23/6525;;B01J37/0228;;B01J23/28;;B01J2523/00;;B01J37/34;;B01J23/002;;C07C253/24;;C07C51/215;;B01J27/0576;;B01J37/0238;;Y02P20/52;;B01J35/56;;B01J35/58,B01J37/00;;B01J23/00;;B01J23/28;;B01J23/652;;B01J27/057;;B01J35/04;;B01J35/06;;B01J37/02;;B01J37/34;;C07B61/00;;C07C51/215;;C07C51/25;;C07C253/24;;C07C255/08;;C23C14/06,,0,0,,,,EXPIRED
351,US,B1,US 6242035 B1,070-578-458-854-797,2001-06-05,2001,US 19764498 A,1998-11-23,US 19764498 A,1998-11-23,Reduced molecular weight native gellan gum,"This invention provides reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention generally have a weight average molecular weight less than about 1.7.times.10.sup.6, and typically in a range of about 1.2.times.10.sup.6 to about 9.3.times.10.sup.5. This invention also provides compositions, e.g., solutions and gels, comprising reduced molecular weight gellan gums. The reduced molecular weight gellan gums of this invention may be prepared by any method which reduces the molecular weight of polymers. Such methods include homogenization, sonication, radiation, oxidation and hydrolysis.",CP KELCO US INC,CLARK ROSS;;MORRISON NEIL;;CHEN YOU-LUNG;;TALASHEK TODD;;BURGUM DAN,MONSANTO COMPANY (1998-11-06);;PHARMACIA CORPORATION (2000-03-31);;CP KELCO U.S. INC (2000-09-28),https://lens.org/070-578-458-854-797,Granted Patent,yes,4,51,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A21D13/08;;A23C9/152;;A23G9/32;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,426/573;;536/123,3,1,075-120-400-064-212,10.1006/abbi.1996.9851;;9056228,"Kerkenaar et al., J. Chem. Technol. Biotech., 56(4):414-415, 1993.*;;Hashimoto et al. Arch. Biochem. Biophys., vol. 339(1), pp. 17-23, Mar. 1997.*;;Chemical Abstracts, vol. 131, No. 4 (Jul. 1999) 44062.",EXPIRED
352,US,A1,US 2023/0041935 A1,079-293-997-630-950,2023-02-09,2023,US 202217947525 A,2022-09-19,US 202217947525 A;;US 202016636231 A;;US 2019/0022172 W;;US 201862644024 P;;US 201862644038 P,2018-03-16,FOAM CONTROL,"A method for controlling foam comprising providing food composition comprising a foam control agent and a foodstuff, the foam control agent comprising a Mono glycidyl ether adduct or a Diglycidyl ether adduct. A composition useful for foam control comprising a mono glycidyl ether adduct, a diglycidyl ether adduct or combination thereof.",DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,,https://lens.org/079-293-997-630-950,Patent Application,yes,1,0,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/12,,0,0,,,,PENDING
353,AU,A,AU 2000/018268 A,107-727-702-476-597,2000-06-13,2000,AU 2000/018268 A,1999-11-23,US 19764498 A;;US 9927655 W,1998-11-23,Reduced molecular weight native gellan gum,,MONSANTO CO,CLARK ROSS;;MORRISON NEIL;;CHEN YOU-LUNG;;TALASHEK TODD;;BURGUM DAN,,https://lens.org/107-727-702-476-597,Patent Application,no,0,0,7,7,0,C08B37/0024;;C08B37/006;;C08L5/00;;C08B37/006;;C08B37/0024;;C08L5/00,A23C9/152;;A21D13/08;;A23G9/32;;A23G9/44;;A23G9/52;;A23L21/10;;A23L29/20;;C08B37/00;;C08L5/00,,0,0,,,,DISCONTINUED
354,EP,A1,EP 3473027 A1,186-181-781-977-202,2019-04-24,2019,EP 17814094 A,2017-06-15,US 201662350523 P;;US 201662368723 P;;US 201662421088 P;;US 2017/0037680 W,2016-06-15,SERVICES PROVISIONING FOR INTERNET-OF-THINGS DEVICES IN CELLULAR NETWORKS,,INTEL CORP,LIAO CHING-YU;;CHEN KUILIN CLARK;;MACIOCCO CHRISTIAN;;SUNDER RAJAN ASHOK,APPLE INC. (2020-12-16),https://lens.org/186-181-781-977-202,Patent Application,yes,0,1,5,5,0,H04W8/26;;H04W12/06;;H04W88/14;;H04W4/50;;H04W4/70;;H04W60/04;;H04W12/35,H04W8/26;;H04W12/06;;H04W40/24;;H04W60/00;;H04W88/14,,0,0,,,,ACTIVE
355,KR,A,KR 20230125828 A,009-087-844-737-013,2023-08-29,2023,KR 20237026081 A,2021-12-30,US 202063132194 P;;US 2021/0065662 W,2020-12-30,강유전성 네마틱 액정 형성 분자들을 포함하는 디바이스및 그를 형성 및 사용하는 방법들,"강유전성 네마틱의 표면 극성은 그의 벌크 분극 필드의 배향의 벡터 제어를 생성하도록 구성될 수 있다. 평면내 극성을 갖는 표면과 강유전성 네마틱 액정 사이의 접촉은 그 계면에서 강유전성 분극 필드의 바람직한 평면내 배향을 생성하며, 이는 전기장 폴링 없이 높은 분극의 유체 또는 유리질(glassy) 모노도메인들의 형성을 초래할 수 있다. 재료 표면들은, 트위스티드 상태를 포함하는 다양한 방위각 디렉터/분극 구조들을 갖는 평면정렬된 셀들을 만드는 경로로서 사용될 수 있고, 대향 표면들 상의 역평행, 단방향 버핑으로 획득된 π 트위스트 셀에서, 강유전성 네마틱 전기광학 응답의 3 가지 상이한 모드들을 입증한다: 고유 점도-제한 필드-유도 분자 재배향, 반대 키랄성의 트위스티드 상태들을 분리하는 도메인 벽들의 필드-유도 모션; 및 필드 역전 시에 셀 플레이트들로부터 셀 중심으로의 분극 재배향 솔리톤들의 전파.",UNIV COLORADO REGENTS,CLARK NOEL A;;CHEN XI;;MACLENNAN JOSEPH E;;GLASER MATTHEW A,,https://lens.org/009-087-844-737-013,Patent Application,no,0,0,6,6,0,G02F1/141;;G02F1/1337;;G02F1/133788;;G02F1/141;;G02F1/133788,G02F1/141;;G02F1/1337,,0,0,,,,PENDING
356,US,B2,US 11419357 B2,071-058-003-760-062,2022-08-23,2022,US 201916636005 A,2019-02-12,US 201916636005 A;;US 201862644031 P;;US 2019/0017653 W,2018-03-16,Foam control,"A method for controlling foam comprising providing a food composition comprising a foam control agent and a food-stuff, and processing the food composition, wherein the foodstuff comprises potato derivatives or beet derivatives. A food composition comprising a foodstuff and a foam control agent, and wherein the foodstuff comprises potato derivatives or beet derivatives.",DOW GLOBAL TECHNOLOGIES LLC,CUMMINS CLARK H;;KING STEPHEN W;;CHEN XUE;;TULCHINSKY MICHAEL L,DOW GLOBAL TECHNOLOGIES LLC (2018-06-25),https://lens.org/071-058-003-760-062,Granted Patent,yes,10,0,8,8,0,A23L29/00;;A23L29/03;;A23L29/10;;A23L19/12;;A23L29/035,C11D7/26;;A23L19/12;;A23L29/00,,4,1,044-917-850-121-10X,10.1021/la049676o;;15491178,"Translation of JPH-05049896-A (Year: 1993).;;Translation of JP-2012082357-A (Year: 2012).;;Denkov., Mechanisms of Foam Destruction by Oil Based Anti foams. 2004, 9463-9505.;;PCT/US2019/017653, International Search Report and Written Opinion dated Apr. 4, 2019.",ACTIVE
357,US,B2,US 11664398 B2,077-938-630-049-652,2023-05-30,2023,US 202016894901 A,2020-06-08,US 202016894901 A;;US 201962906750 P,2019-09-27,Image sensor and manufacturing method thereof,"An image sensor includes a storage device, where the storage device includes a memory element, a first dielectric layer and a light shielding element. The memory element includes a storage node and a storage transistor gate, where the storage transistor gate is located over the storage node. The first dielectric layer is located over a portion of the storage transistor gate. The light shielding element is located on the first dielectric layer and includes a semiconductor layer. The semiconductor layer is electrically isolated from the memory element, where the light shielding element is overlapped with at least a part of a perimeter of the storage transistor gate in a vertical projection on a plane along a stacking direction of the memory element and the light shielding element, and the stacking direction is normal to the plane.",TAIWAN SEMICONDUCTOR MFG CO LTD;;TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK;;WANG WEN-SHENG;;KUO CHIEN-LI,TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD (2020-05-14),https://lens.org/077-938-630-049-652,Granted Patent,yes,29,0,2,7,0,H01L27/14623;;H01L27/14614;;H01L27/14603;;H01L27/14689;;H01L27/14643;;H01L27/14614;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14623,H01L27/146,,1,0,,,"“Office Action of Taiwan Counterpart Application”, dated Apr. 13, 2021, p. 1-p. 7.",ACTIVE
358,US,A1,US 2020/0100531 A1,137-205-088-070-844,2020-04-02,2020,US 201916585514 A,2019-09-27,US 201916585514 A;;US 201862738309 P,2018-09-28,CYCLIC KETAL COMPOUNDS HAVING LONG SIDE CHAINS USEFUL AS FOAM CONTROL AGENTS IN THE MANUFACTURE OF FOOD AND BEVERAGE PRODUCTS,"Cyclic ketal compounds provide excellent foam protection when having at least one moiety of a threshold size (comprising 4 or more carbon atoms) pendant from a ketal carbon. The carbons in such moieties may be present in one or more chains. The cyclic ketal compounds of the present invention are compatible with foodstuff manufacturing. In particular, it has been discovered that the cyclic ketal compounds of the present invention exhibit excellent foam control performance in both potato and sugar beet processing systems.",DOW GLOBAL TECHNOLOGIES LLC,TULCHINSKY MICHAEL L;;CHEN XUE;;CUMMINS CLARK H;;KING STEPHEN W,DOW GLOBAL TECHNOLOGIES LLC (2018-10-19),https://lens.org/137-205-088-070-844,Patent Application,yes,0,0,2,2,0,A23L2/52;;A23L2/54;;A23L29/035;;A23V2002/00;;B01D19/0404;;B01D19/0463;;A23L29/035;;B01D19/0404;;A23L2/54,A23L29/00;;A23L2/54;;B01D19/04,,0,0,,,,ACTIVE
359,US,A1,US 2009/0080712 A1,174-690-540-176-201,2009-03-26,2009,US 13743508 A,2008-06-11,US 13743508 A;;US 93473207 P,2007-06-14,Eye Detection System,"An eye detection system, method, and apparatus are disclosed. The eye detection apparatus includes illuminator, receiver, processor, and memory elements. The illuminator emits radiation at predetermined wavelengths from the eye detection apparatus toward an area of interest. Radiation from the area of interest is detected at the receiver which, in turn, provides sensor data to the processor. The processor is coupled to the illuminator and receiver and controls their respective operations. The processor detects a pattern representative of a human eye in the sensor data and determines coordinates of an object corresponding to the pattern. The memory stores the coordinates of the object. Optionally, the eye detection apparatus communicates the coordinates of the object to a wireless device and directs countermeasures to the object's coordinates in response to commands from the wireless device.",CUBIC CORP,D SOUZA CLARK;;CHEN IRENE;;LEE SHINHAK;;RIPINGILL JR ALLEN E,CUBIC CORPORATION (2008-06-10),https://lens.org/174-690-540-176-201,Patent Application,yes,8,14,3,3,0,G06V40/18;;G06V20/52;;G06V40/18;;G06V20/52,G06K9/00;;G06K9/46,382/117;;382/190,0,0,,,,INACTIVE
360,WO,A1,WO 2008/154637 A1,049-140-224-469-020,2008-12-18,2008,US 2008/0066734 W,2008-06-12,US 93473207 P;;US 13743508 A,2007-06-14,EYE DETECTION SYSTEM,"An eye detection system, method, and apparatus are disclosed. The eye detection apparatus includes illuminator, receiver, processor, and memory elements. The illuminator emits radiation at predetermined wavelengths from the eye detection apparatus toward an area of interest. Radiation from the area of interest is detected at the receiver which, in turn, provides sensor data to the processor. The processor is coupled to the illuminator and receiver and controls their respective operations. The processor detects a pattern representative of a human eye in the sensor data and determines coordinates of an object corresponding to the pattern. The memory stores the coordinates of the object. Optionally, the eye detection apparatus communicates the coordinates of the object to a wireless device and directs countermeasures to the object's coordinates in response to commands from the wireless device.",CUBIC CORP;;D SOUZA CLARK;;CHEN IRENE;;LEE SHINHAK;;RIPINGILL ALLEN E JR,D SOUZA CLARK;;CHEN IRENE;;LEE SHINHAK;;RIPINGILL ALLEN E JR,,https://lens.org/049-140-224-469-020,Patent Application,yes,4,0,3,3,0,G06V40/18;;G06V20/52;;G06V40/18;;G06V20/52,G06K9/00,,1,0,,,"HAMPAPUR A ET AL: ""Smart surveillance: applications, technologies and implications"", INFORMATION, COMMUNICATIONS AND SIGNAL PROCESSING, 2003 AND FOURTH PAC IFIC RIM CONFERENCE ON MULTIMEDIA. PROCEEDINGS OF THE 2003 JOINT CONFE RENCE OF THE FOURTH INTERNATIONAL CONFERENCE ON SINGAPORE 15-18 DEC. 2003, PISCATAWAY, NJ, USA,IEEE, vol. 2, 15 December 2003 (2003-12-15), pages 1133 - 1138, XP010702808, ISBN: 978-0-7803-8185-8",PENDING
361,EP,A1,EP 3764816 A1,080-985-093-734-039,2021-01-20,2021,EP 19713976 A,2019-03-14,US 201862644024 P;;US 201862644038 P;;US 2019/0022172 W,2018-03-16,FOAM CONTROL IN FOOD,,DOW GLOBAL TECHNOLOGIES LLC,KING STEPHEN W;;CUMMINS CLARK H;;TULCHINSKY MICHAEL L;;CHEN XUE,,https://lens.org/080-985-093-734-039,Patent Application,yes,0,0,7,7,0,A23L19/10;;A23L19/12;;A23L29/035;;A23V2002/00;;A23L19/12;;A23L29/035,A23L29/00;;A23L19/10;;A23L19/12,,0,0,,,,PENDING
362,US,A,US 5918225 A,114-069-287-227-965,1999-06-29,1999,US 82086497 A,1997-03-20,US 82086497 A;;US 57018395 A;;US 4863793 A,1993-04-16,SQL-based database system with improved indexing methodology,"A Client/Server Database System with improved methods for performing database queries, particularly DSS-type queries, is described. The system includes one or more Clients (e.g., Terminals or PCs) connected via a Network to a Server. In general operation, Clients store data in and retrieve data from one or more database tables resident on the Server by submitting SQL commands, some of which specify ""queries""--criteria for selecting particular records of a table. The system implements methods for storing data vertically (i.e., by column), instead of horizontally (i.e., by row) as is traditionally done. Each column comprises a plurality of ""cells"" (i.e., column value for a record), which are arranged on a data page in a contiguous fashion. The system builds the value lookup table for tracking unique values in the cells. As additional unique values are inserted into the column of the user's table (i.e., maintained as the row-ordered cell array), the system assigns a small unique integer value to each unique user value. Instead of storing the original (wide) data value into the row-ordered array, the system instead stores the new (narrow) integer number into the row-ordered array. In response to a user request to retrieve a value for a given row number, the system fetches the appropriate chunk of the row-ordered array and retrieves the small integer value. This small integer value is then used to index into the value lookup table, for reconstituting the actual user data.",SYBASE INC,WHITE PETER W;;FRENCH CLARK D;;CHEN YONG MIN;;YACH DAVID,SYBASE INC (1997-07-17),https://lens.org/114-069-287-227-965,Granted Patent,yes,18,673,1,5,0,G06F16/2237;;G06F16/30;;G06F16/30;;Y10S707/99933;;Y10S707/99931;;Y10S707/99934;;Y10S707/99942;;G06F16/2237,G06F17/30,707/3;;707/1;;707/4;;707/101;;707/103;;707/10,9,4,126-524-394-847-323;;052-980-896-523-624;;040-708-594-969-024;;014-065-969-285-659,10.1016/b978-0-934613-53-8.50006-6;;10.1109/32.238583;;10.1109/soac.1991.143840;;10.1109/icde.1991.131498,"Sybase Sq Server Release: Sql Server Transact Sql User s Guide, pp. v xv, 1 5 to 1 9, 3 1 to 3 3, 3 19 to 3 29, 6 13 to 3 29, 6 13 to 3 29, 6 13 to 6 22, 6 48 to 6 51, 7 23 and 10 5, Feb. 1994.;;Reinartz, K., Aspects of vertical mode in multiprocessor systems, unconventional computation on conventional processors, Second International Specialist Seminar on the Design and Application of Parallel Digital Processors, IEEE, 1991, pp. 48 54.;;Brodie, M. and Manola, F., Database Management: A Survey, May 1987, pp. 1 24.;;Hanson Smith, Ltd., Advantage Series System Overview, Ver. 2.0, 1990, pp. 1 132.;;Chu et al., A Transaction Based Approach to Vertical Partitioning for Relational Database Systems, IEEE, v19, n8, IEEE Transactions on Software Engineering, Aug. 1993, pp. 804 812.;;Naecker, P., RDBMS Maturity, DEC Professional, v10, n12, p. 44(6) Available Online; DIALOG File 275 , Nov. 1991, pp. 1 7;;Snellen, D., Ingres Table Structures DBMS, v5, n8, p60(3) Available: On Line; DIALOG File 275 , Jul. 1992, pp. 1 4.;;Graefe et al., Data Compression and Database Performance, IEEE, Applied Computing Symposium, 1991, pp. 22 27.;;Perrizo et al., Domain Vector Accelerator (DVA): A Query Accelerator for Relational Operations, IBM Corp., Rochester, MN, IEEE, Data Engineering, 7th Annual International Conference, 1991, pp. 491 498.",EXPIRED
363,WO,A2,WO 2009/110953 A2,077-546-308-824-195,2009-09-11,2009,US 2009/0000283 W,2009-02-13,US 6762608 P,2008-02-29,SYSTEM AND METHOD FOR METERING AND ANALYZING USAGE AND PERFORMANCE DATA OF A VIRTUALIZED COMPUTE AND NETWORK INFRASTRUCTURE,"A method and system for metering and analyzing usage and performance data of virtualized compute and network infrastructures is disclosed. The processing functions of the metered data are divided into 'processing units' that are configured to execute on a server (or plurality of interconnected servers). Each processing unit receives input from an upstream processing unit, and processes the metered data to produce output for a downstream processing unit. The types of processing units, as well as the order of the processing units is user-configurable (e.g. via XML file), thus eliminating the need to modify source code of the data processing application itself, thereby saving considerable time, money, and development resources required to manage the virtualized compute and network infrastructure.",EVIDENT SOFTWARE INC;;CLARK JOHN M;;FRENKIEL SCOTT T;;CHEN CHING-CHEN;;HO IVAN C;;JEFFERY DONALD C,CLARK JOHN M;;FRENKIEL SCOTT T;;CHEN CHING-CHEN;;HO IVAN C;;JEFFERY DONALD C,,https://lens.org/077-546-308-824-195,Patent Application,yes,0,0,3,3,0,G06F11/3404;;G06F11/3409;;G06F2201/815;;G06F2201/865;;G06F2201/875;;G06F2201/88;;G06F2201/885;;H04L41/142;;H04L41/5009;;H04L43/0847;;H04L43/024;;H04L41/40;;G06F11/3404;;G06F2201/88;;H04L43/0847;;G06F2201/865;;H04L41/142;;H04L41/5009;;G06F2201/875;;G06F11/3409;;G06F2201/815;;G06F2201/885;;H04L43/024,G06F15/16,,0,0,,,,PENDING
364,WO,A3,WO 2009/110953 A3,144-497-520-310-044,2009-10-29,2009,US 2009/0000283 W,2009-02-13,US 6762608 P,2008-02-29,SYSTEM AND METHOD FOR METERING AND ANALYZING USAGE AND PERFORMANCE DATA OF A VIRTUALIZED COMPUTE AND NETWORK INFRASTRUCTURE,"A method and system for metering and analyzing usage and performance data of virtualized compute and network infrastructures is disclosed. The processing functions of the metered data are divided into 'processing units' that are configured to execute on a server (or plurality of interconnected servers). Each processing unit receives input from an upstream processing unit, and processes the metered data to produce output for a downstream processing unit. The types of processing units, as well as the order of the processing units is user-configurable (e.g. via XML file), thus eliminating the need to modify source code of the data processing application itself, thereby saving considerable time, money, and development resources required to manage the virtualized compute and network infrastructure.",EVIDENT SOFTWARE INC;;CLARK JOHN M;;FRENKIEL SCOTT T;;CHEN CHING-CHEN;;HO IVAN C;;JEFFERY DONALD C,CLARK JOHN M;;FRENKIEL SCOTT T;;CHEN CHING-CHEN;;HO IVAN C;;JEFFERY DONALD C,,https://lens.org/144-497-520-310-044,Search Report,yes,5,0,3,3,0,G06F11/3404;;G06F11/3409;;G06F2201/815;;G06F2201/865;;G06F2201/875;;G06F2201/88;;G06F2201/885;;H04L41/142;;H04L41/5009;;H04L43/0847;;H04L43/024;;H04L41/40;;G06F11/3404;;G06F2201/88;;H04L43/0847;;G06F2201/865;;H04L41/142;;H04L41/5009;;G06F2201/875;;G06F11/3409;;G06F2201/815;;G06F2201/885;;H04L43/024,G06F9/44;;G06F15/16;;G06F17/00;;G06F19/00,,0,0,,,,PENDING
365,US,A1,US 2021/0068925 A1,037-737-828-968-492,2021-03-11,2021,US 202016951624 A,2020-11-18,US 202016951624 A;;US 202017085583 A;;US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,"TACTILE OBJECTS FOR ORTHODONTICS, SYSTEMS AND METHODS","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/037-737-828-968-492,Patent Application,yes,0,0,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14,,0,0,,,,ACTIVE
366,TW,A,TW 201029189 A,091-764-200-635-715,2010-08-01,2010,TW 98142769 A,2009-12-14,US 33641008 A,2008-12-16,Dual insulating layer diode with asymmetric interface state and method of fabrication,"An integrated circuit including vertically oriented diode structures between conductors and methods of fabricating the same are provided. The diode is a metal-insulator diode having a first metal layer, a first insulating layer, a second insulating layer and a second metal layer. At least one asymmetric interface stale is provided at the intersection of at least two of the layers to increase the ratio of the diode's on-current to its reverse bias leakage current. In various examples, the asymmetric interface state is formed by a positive or negative sheet charge that alters the barrier height and/or electric field at one or more portions of the diode. Two-terminal devices such as passive element memory cells can utilize the diode as a steering element in series with a state change element. The devices can be formed using pillar structures at the intersections of upper and lower conductors.",SANDISK 3D LLC,CHEN XI-YING;;SEKAR DEEPAK CHANDRA;;CLARK MARK;;NGUYEN DAT;;KUMAR TANMAY,,https://lens.org/091-764-200-635-715,Patent of Addition,no,0,2,4,4,0,H10B63/22;;H10B63/84;;H10N70/00;;H10B63/22;;H10B63/80;;H10B63/84;;H10N70/231;;H10N70/20;;H10N70/063;;H10N70/245;;H10N70/826;;H10N70/881;;H10N70/8828;;H10N70/8833;;H10N70/8836;;H10N70/8845,H01L29/861;;H01L21/329,,0,0,,,,PENDING
367,US,B2,US 11547533 B2,134-205-786-034-657,2023-01-10,2023,US 202016951624 A,2020-11-18,US 202016951624 A;;US 202017085583 A;;US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,"Tactile objects for orthodontics, systems and methods","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/134-205-786-034-657,Granted Patent,yes,235,0,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14;;B33Y80/00,,156,79,066-282-335-791-995;;025-616-909-029-765;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;059-588-461-518-39X;;005-024-996-709-894;;052-731-758-553-641;;081-328-802-841-096;;009-638-995-800-030;;008-744-219-127-384;;083-235-787-432-859;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;114-408-402-448-688;;007-458-121-098-163;;048-527-821-955-377;;052-763-059-483-265;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;021-018-768-707-650;;000-494-525-786-513;;034-464-951-348-782;;013-689-140-672-656;;150-267-339-118-983;;006-370-362-381-143;;099-384-176-695-780;;056-064-135-529-61X;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973;;138-684-123-834-414;;056-383-866-369-582;;123-028-396-811-269;;112-073-423-851-594;;021-881-631-200-08X;;043-213-859-914-534;;058-953-285-075-855;;004-945-615-972-614;;007-791-552-338-375;;036-191-696-513-286;;025-329-363-440-138;;006-539-396-314-679;;129-709-346-949-085;;051-296-399-382-894;;069-298-082-055-441;;021-507-277-374-529;;053-048-658-252-470;;031-271-546-068-031;;049-407-482-660-143;;042-526-631-078-104;;027-754-365-457-953;;030-427-969-872-795;;064-378-232-278-762;;046-665-331-726-574;;055-477-823-513-100;;027-316-381-573-41X;;000-788-861-492-825;;055-418-850-870-066;;088-958-363-169-71X,10.1117/12.7972842;;10.1117/12.957387;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1016/0002-9416(72)90076-0;;4501183;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;6937139;;10.1016/0002-9416(81)90310-9;;298295;;298302;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;1777659;;3058771;;10.14219/jada.archive.1988.0096;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;271471;;10.1016/0002-9416(78)90100-8;;10.2334/josnusd1959.26.11;;6589367;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;21027613;;10.1016/0096-6347(46)90053-1;;10.1016/0096-6347(45)90101-3;;10356517;;10.1145/964965.808575;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387;;2132100;;10.2334/josnusd1959.19.93;;294475;;10.1109/iecon.1998.724103;;5276727;;10.1016/0002-9416(71)90099-6;;10.1016/s0889-5406(00)70049-7;;10672223;;1591643;;10.1016/0022-3913(87)90285-x;;3312586;;1783723;;10.14219/jada.archive.1991.0205;;10.1109/10.133223;;1855790;;10.1093/ejo/14.2.125;;1582457;;10.1016/0889-5406(87)90412-4;;3477086;;10.1093/ejo/3.4.279;;7028491;;1539546;;10.1016/0889-5406(92)70089-s;;10.1001/archotol.1988.01860160082026;;3348899;;10.1016/0002-9416(71)90006-6;;5280427;;2269115;;1452058;;4504704;;10.1177/00220345720510042301;;4504700;;10.1177/00220345720510041901;;20830889;;10.1016/s0010-4485(96)00054-1;;9874310;;10.1109/42.736056;;2718969;;10.1016/0889-5406(89)90300-4;;2639882;;5272402;;10.1016/0002-9416(70)90106-5;;3553441;;3473186;;10.1109/4233.924800;;11420997;;2486752,"AADR. American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Alcaniz, et al., “An Advanced System for the Simulation and Planning of Orthodontic Treatments,” Karl Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Intl. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;Alexander et al., “The DigiGraph Work Station Part 2 Clinical Management,” JCO, pp. 402-407 (Jul. 1990).;;Altschuler, “3D Mapping of Maxillo-Facial Prosthesis,” AADR Abstract #607, 2 pages total, (1980).;;Altschuler et al., “Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures,” IADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., “Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,” Optical Engineering, 20(6):953-961 (1981).;;Altschuler et al., “Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,” SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Andersson et al., “Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,” Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapters, pp. 13-24 (1989).;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind, “A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,” an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of Ill., Aug. 26-30, 1975, pp. 142-166.;;Baumrind et al., “A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,” NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., “Mapping the Skull in 3-D,” reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, “Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,” Semin. in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., “A Computer System for the Analysis of Dental Casts,” The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al.,“Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,” Abstract, J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., “A Computer-Aided Design for Orthognathic Surgery,” Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff, “Computerized Diagnostic Setups and Simulations,” Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biggerstaff et al., “Computerized Analysis of Occlusion in the Postcanine Dentition,” Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890, 20 pages total (1990).;;Blu, et al., “Linear interpolation revitalized”, IEEE Trans. Image Proc., 13(5):710-719 (May 2004.;;Bourke, “Coordinate System Transformation,” (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL http://astronomy.swin.edu.au/—pbourke/prolection/coords.;;Boyd et al., “Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalign Appliance,” Semin. Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., “Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,” J. Dent. Res. Special Issue, Abstract 305, vol. 64, p. 208 (1985).;;Brook et al., “An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: Comparison with Manual Measurements of Mesio-distal Diameter,” J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form IN Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Burstone (interview), “Dr. Charles J. Burstone on The Uses of the Computer in Orthodontic Practice (Part 1),” J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), “Dr. Charles J. Burstone on The Uses of the Computer in Orthodontic Practice (Part 2),” J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Cardinal Industrial Finishes, Powder Coatings information posted at http://www.cardinalpaint.com on Aug. 25, 2000, 2 pages.;;Carnaghan, “An Alternative to Holograms for the Portrayal of Human Teeth,” 4th Int'l. Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., “The DigiGraph Work Station, Part 1, Basic Concepts,” JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., “Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,” Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, “CAD/CAM in the Dental Office: Does It Work?”, Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crawford, “Computers in Dentistry: Part 1 CAD/CAM: The Computer Moves Chairside, Part 2 F. Duret—A Man with a Vision, Part 3 The Computer Gives New Vision—Literally, Part 4 Bytes 'N Bites—The Computer Moves from the Front Desk to the Operatory,” Canadian Dental Journal, vol. 54 (9), pp. 661-666 (1988).;;Crooks, “CAD/CAM Comes to USC,” USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., “Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,” Semin. Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et a/., “Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,” Plast. 77(6):877-885 (Jun. 1986).;;DCS Dental AG, “The CAD/CAM ‘DCS Titan System’ for Production of Crowns/Bridges,” DSC Production AG, pp. 1-7 (Jan. 1992.;;Definition for gingiva. Dictionary.com p. 1-3. Retrieved from the internet Nov. 5, 2004 http://reference.com/search/search?q=gingiva.;;Defranco et al., “Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,” J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium JD on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13 (1992).;;DENT-X posted on Sep. 24, 1998 at http://www.dent-x.com/DentSim.htm, 6 pages.;;Doyle, “Digital Dentistry,” Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClearTM product information, Allesee Orthodontic Appliances—Pro Lab, 1 page (1997).;;Duret et al., “CAD/CAM Imaging in Dentistry,” Curr. Opin. Dent., 1:150-154 (1991).;;Duret et al., “CAD-CAM in Dentistry,” J. Am. Dent. Assoc. 117:715-720 (Nov. 1988).;;Duret, “The Dental CAD/CAM, General Description of the Project,” Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,“Vers Une Prosthese Informatisee,” (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, “The Microcomputer in the Orthodontic Office,” JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Felton et al., “A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,” Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., “Accuracy of Cephalometric Prediction in Orthognathic Surgery,” Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Futterling et al., “Automated Finite Element Modeling of a Human Mandible with Dental Implants,” JS WSCG '98—Conference Program, retrieved from the Internet: http://wscg.zcu.cz/wscg98/papers98/Strasser98.pdf, 8 pages.;;Gao et al., “3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,” Proc. Intl Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, “Das DUX System: Die Technik,” 2 pages total (2002).;;Gottleib et al., “JCO Interviews Dr. James A. McNamura, Jr., on the Frankel Appliance: Part 2: Clinical 1-1 Management, ”J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, “New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: JW Computerized Facial Imaging in Oral and Maxillofacial Surgery,” AAOMS, 3 pages total, (Sep. 13, 1990).;;Guess et al., “Computer Treatment Estimates In Orthodontics and Orthognathic Surgery,” JCO, pp. 262-28 (Apr. 1989).;;Heaven et al., “Computer-Based Image Analysis of Artificial Root Surface Caries,” Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, “Simulating Stress Put on Jaw,” Tooling & Production [online], Nov. 1996, n pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL http://static.highbeam.com/t/toolingampproduction/november011996/simulatingstressputonfa . . . .;;Hikage, “Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning”, Journal of Japan KA Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., “Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,” (Article Summary in English, article in German), Informationen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., “Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,” J. Biomech., 23(11):1157-1166 (1990).;;Huckins, “CAD-CAM Generated Mandibular Model Prototype from MRI Data,” AAOMS, p. 96 (1999).;;Important Tip About Wearing the Red White & Blue Active Clear Retainer System. Allesee Orthodontic Appliances-Pro Lab. 1 page (1998).;;JCO Interviews, “Craig Andreiko , DDS, MS on the Elan and Orthos Systems,” JCO, pp. 459-468 (Aug. 1994).;;JCO Interviews, “Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2,” JCO. 1997; 1983:819-831.;;Jerrold, “The Problem, Electronic Data Transmission and the Law,” AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., “An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,” Br. J. Orthod., 16:85-93 (1989).;;JP Faber et al., “Computerized Interactive Orthodontic Treatment Planning,” Am. J. Orthod., 73(1):36-46 (Jan. 1978).;;Kamada et.al., Case Reports On Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;Kamada et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case KJ Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., “Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,” J. Dent Res., 63(11):1298-1301 (Nov. 1984).;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, KN Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Journal of Orthodontics and Oral surgery. 1945; 31:297-304.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kochanek, “Interpolating Splines with Local Tension, Continuity and Bias Control,” Computer Graphics, ri 18(3):33-41 (Jul. 1984). KM Oral Surgery (1945) 31 :297-30.;;Kunii et al., “Articulation Simulation for an Intelligent Dental Care System,” Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laminated, (n.d.). Dictionary.com Unabridged. Retrieved Apr. 28, 2010, from Dictionary.com website: http://dictionary.reference.com/browse/LAMINATED.;;Laurendeau, et al., “A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of 7 KR Dental Imprints: An Application in Orthodontics,” IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991.;;Leinfelder, et al., “A New Method for Generating Ceramic Restorations: a CAD-CAM System,” J. Am. 1-1 Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., “Computer-Aided Cefalometry and New Mechanics in Orthodontics,” (Article Summary in English, article in German), Fortschr Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, “Inside the ADA,” J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., “Invisible Retainers,” J. Clin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., “Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,” IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, “Correcting Mild Malalignments—As Easy As One, Two, Three,” AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mormann et al., “Marginale Adaptation von adhasuven Porzellaninlays in vitro,” Separatdruck aus: Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.;;Nahoum, “The Vacuum Formed Dental Contour Appliance,” N. Y. State Dent. J., 30(9):385-390 (Nov. 1964).;;Nash, “CEREC CAD/CAM Inlays: Aesthetics and Durability in a Single Appointment,” Dent. Today, 9(8):20, 22-23 (Oct. 1990).;;Nishiyama et al., “A New Construction of Tooth Repositioner by LTV Vinyl Silicone Rubber,” J. Nihon Univ. Sch. Dent., 19(2):93-102 (1977).;;Paul et al., “Digital Documentation of Individual Human Jaw and Tooth Forms for Applications in Orthodontics, Oral Surgery and Forensic Medicine” Proc. of the 24th Annual Conf. of the IEEE Industrial Electronics Society (IECON '98), Sep. 4, 1998, pp. 2415-2418.;;Pinkham, “Foolish Concept Propels Technology,” Dentist, 3 pages total, Jan./Feb. 1989.;;Pinkham, “Inventor's CAD/CAM May Transform Dentistry,” Dentist, 3 pages total, Sep. 1990.;;Ponitz, “Invisible Retainers,” Am. J. Orthod., 59(3):266-272 (Mar. 1971).;;PROCERA Research Projects, “PROCERA Research Projects 1993—Abstract Collection,” pp. 3-7; 28 (1993).;;Proffit et al., Contemporary Orthodontics, (Second Ed.), Chapter 15, Mosby Inc., pp. 470-533 (Oct. 1993.;;Raintree Essix & ARS Materials, Inc., Raintree Essix, Technical Magazine Table of contents and Essix Appliances, http://www.essix.com/magazine/defaulthtml Aug. 13, 1997.;;Redmond et al., “Clinical Implications of Digital Orthodontics,” Am. J. Orthod. Dentofacial Orthop., 117(2):240-242 (2000).;;Rekow, “A Review of the Developments in Dental CAD/CAM Systems,” (contains references to Japanese efforts and content of the papers of particular interest to the clinician are indicated with a one line summary of their content in the bibliography), Curr. Opin. Dent., 2:25-33 (Jun. 1992).;;Rekow, “CAD/CAM in Dentistry: A Historical Perspective and View of the Future,” J. Can. Dent. Assoc., 58(4):283, 287-288 (Apr. 1992).;;Rekow, “Computer-Aided Design and Manufacturing in Dentistry: A Review of the State of the Art,” J. Prosthet. Dent., 58(4):512-516 (Oct. 1987).;;Rekow, “Dental CAD-CAM Systems: What is the State of the Art?”, J. Amer. Dent. Assoc., 122:43-48 1991.;;Rekow et al., “CAD/CAM for Dental Restorations—Some of the Curious Challenges,” IEEE Trans. Biomed. Eng., 38(4):314-318 (Apr. 1991).;;Rekow et al., “Comparison of Three Data Acquisition Techniques for 3-D Tooth Surface Mapping,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 13(1):344-345 1991.;;Rekow, “Feasibility of an Automated System for Production of Dental Restorations, Ph.D. Thesis,” Univ. of Minnesota, 244 pages total, Nov. 1988.;;Richmond et al., “The Development of a 3D Cast Analysis System,” Br. J. Orthod., 13(1):53-54 (Jan. 1986).;;Richmond et al., “The Development of the PAR Index (Peer Assessment Rating): Reliability and Validity,” Eur. J. Orthod., 14:125-139 (1992).;;Richmond, “Recording The Dental Cast In Three Dimensions,” Am. J. Orthod. Dentofacial Orthop., 92(3):199-206 (Sep. 1987).;;Rudge, “Dental Arch Analysis: Arch Form, A Review of the Literature,” Eur. J. Orthod., 3(4):279-284 1981.;;Sakuda et al., “Integrated Information-Processing System In Clinical Orthodontics: An Approach with Use of a Computer Network System,” Am. J. Orthod. Dentofacial Orthop., 101(3): 210-220 (Mar. 1992).;;Schellhas et al., “Three-Dimensional Computed Tomography in Maxillofacial Surgical Planning,” Arch. Otolaryngol Head Neck Surg., 114:438-442 (Apr. 1988).;;Schroeder et al., Eds. The Visual Toolkit, Prentice Hall PTR, New Jersey (1998) Chapters 6, 8 & 9, (pp. 153-210,309-354, and 355-428, respectively.;;Shilliday, (1971). Minimizing finishing problems with the mini-positioner, Am. J. Orthod. 59:596-599.;;Siemens, “Cerec—Computer-Reconstruction,” High Tech in der Zahnmedizin, 14 pages total (2004).;;Sinclair, “The Readers' Corner,” J. Clin. Orthod., 26(6):369-372 (Jun. 1992).;;Sirona Dental Systems GmbH, CEREC 3D, Manuel utilisateur, Version 2.0X (in French), 2003, 114 pages total.;;Stoll et al., “Computer-aided Technologies in Dentistry,” (article summary in English, article in German), Dtsch Zahna'rztl Z 45, pp. 314-322 (1990).;;Sturman, “Interactive Keyframe Animation of 3-D Articulated Models,” Proceedings Graphics Interface '84, May-Jun. 1984, pp. 35-40.;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee Orthodontic Appliances—Pro Lab product information, 6 pages (2003).;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HI Orthodontic Appliances—Pro Lab product information for doctors. http://ormco.com/aoa/appliancesservices/RWB/doctorhtml, 5 pages (May 19, 2003).;;The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HJ Orthodontic Appliances—Pro Lab product information for patients, (http://ormco.com/aoa/appliancesservices/RWB/patients.html), 2 pages (May 19, 2003).;;The Red, White & Blue Way to Improve Your Smile!, Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages (1992).;;Truax L., “Truax Clasp-Less(TM) Appliance System,” Funct. Orthod., 9(5):22-4, 26-8 (Sep.-Oct. 1992).;;Tru-Tain Orthodontic & Dental Supplies, Product Brochure, Rochester, Minnesota 55902, 16 pages total (1996).;;U.S. Department of Commerce, National Technical Information Service, “Automated Crown Replication Using Solid Photography SM,” Solid Photography Inc., Melville NY, Oct. 1977, 20 pages total.;;U.S. Department of Commerce, National Technical Information Service, “Holodontography: An Introduction to Dental Laser Holography,” School of Aerospace Medicine Brooks AFB Tex, Mar. 1973, 37 pages total.;;Provisional U.S. Appl. No. 60/050,342, filed Jun. 20, 1997, 41 pages total.;;Van Der Linden, “A New Method to Determine Tooth Positions and Dental Arch Dimensions,” J. Dent. Res., 51(4):1104 (Jul.-Aug. 1972).;;Van Der Linden et al., “Three-Dimensional Analysis of Dental Casts by Means of the Optocom,” J. Dent. Res., p. 1100 (Jul.-Aug. 1972).;;Van Der Zel, “Ceramic-Fused-to-Metal Restorations with a New CAD/CAM System,” Quintessence Int., 24(11):769-778 (1993.;;Varady et al., “Reverse Engineering Of Geometric Models—An Introduction,” Computer-Aided Design, 29(4):255-268, 1997.;;Verstreken et al., “An Image-Guided Planning System for Endosseous Oral Implants,” IEEE Trans. Med. Imaging, 17(5):842-852 (Oct. 1998).;;Warunek et al., Physical and Mechanical Properties of Elastomers in Orthodonic Positioners, Am J. Orthod. Dentofac. Orthop, vol. 95, No. 5, (May 1989) pp. 388-400.;;Warunek et.al., Clinical Use of Silicone Elastomer Applicances, JCO (1989) XXIII(10):694-700.;;Wells, Application of the Positioner Appliance in Orthodontic Treatment, Am. J. Orthodont. (1970) 58:351-366.;;Williams, “Dentistry and CAD/CAM: Another French Revolution,” J. Dent. Practice Admin., pp. 2-5 (Jan./Mar. 1987).;;Williams, “The Switzerland and Minnesota Developments in CAD/CAM,” J. Dent. Practice Admin., pp. 50-55 (Apr./Jun. 1987).;;Wishan, “New Advances in Personal Computer Applications for Cephalometric Analysis, Growth Prediction, Surgical Treatment Planning and Imaging Processing,” Symposium: Computerized Facial Imaging in Oral and Maxilofacial Surgery Presented on Sep. 13, 1990.;;WSCG'98—Conference Program, “The Sixth International Conference in Central Europe on Computer Graphics and Visualization '98,” Feb. 9-13, 1998, pp. 1-7, retrieved from the Internet on Nov. 5, 2004, URL(http://wscg.zcu.cz/wscg98/wscg98.h).;;Xia et al., “Three-Dimensional Virtual-Reality Surgical Planning and Soft-Tissue Prediction for Orthognathic Surgery,” IEEE Trans. Inf. Technol. Biomed., 5(2):97-107 (Jun. 2001).;;Yamamoto et al., “Optical Measurement of Dental Cast Profile and Application to Analysis of Three-Dimensional Tooth Movement in Orthodontics,” Front. Med. Biol. Eng., 1(2):119-130 (1988).;;Yamamoto et al., “Three-Dimensional Measurement of Dental Cast Profiles and Its Applications to Orthodontics,” Conf. Proc. IEEE Eng. Med. Biol. Soc., 12(5):2051-2053 (1990).;;Yamany et al., “A System for Human Jaw Modeling Using Intra-Oral Images,” Proc, of the 20th Annual Conf. of the IEEE Engineering in Medicine and Biology Society, Nov. 1, 1998, vol. 2, pp. 563-566.;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); I. The D.P. Concept and Implementation of Transparent Silicone Resin (Orthocon),” Nippon Dental Review, 452:61-74 (Jun. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); II. The D.P. Manufacturing Procedure and Clinical Applications,” Nippon Dental Review, 454:107-130 (Aug. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III. The General Concept of the D.P. Method and Its Therapeutic Effect, Part 1, Dental and Functional Reversed Occlusion Case Reports,” Nippon Dental Review, 457:146-164 (Nov. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III.—The General Concept of the D.P. Method and Its Therapeutic Effect, Part 2. Skeletal Reversed Occlusion Case Reports,” Nippon Dental Review, 458:112-129 (Dec. 1980).;;You May Be A Candidate For This Invisible No-Braces Treatment, Allesee Orthodontic Appliances—Pro Lab product information for patients, 2 pages (2002).;;Co-pending U.S. Appl. No. 17/085,583, inventors Li; Chunhua et al., filed on Oct. 30, 2020.",ACTIVE
368,US,B1,US 6602996 B1,127-393-520-436-162,2003-08-05,2003,US 71918700 A,2000-12-08,EP 98870131 A;;EP 9903499 W,1998-06-10,Modified gellan gum composition process for preparation of same and use thereof,"
    The invention relates to a modified gellan gum in which the total acyl content as well as the ratio of acyl substituent groups to glycerate substituent groups per linear saccharide repeat unit is altered to be higher than 1. The invention further relates to a process for the modification of a gellan gum to alter its acyl content in which the gum is treated with a weak base such as sodium or potassium carbonate or a suitable phosphate. The process enables tailor made gums having appropriate setting temperatures and theological properties to be made. Novel compositions containing them are also claimed. 
",CP KELCO US INC,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISON NEIL A;;TALASHEK TODD;;CLARK ROSS,CP KELCO U.S. INC (2003-07-07),https://lens.org/127-393-520-436-162,Granted Patent,yes,10,30,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,536/114;;426/573;;426/575;;536/18.5;;536/52;;536/115;;536/123.1;;536/124,9,7,002-053-925-059-154;;011-909-976-673-80X;;007-356-459-262-218;;017-337-058-242-426;;020-105-423-411-810;;053-069-245-347-845;;074-653-404-534-387,10.1016/s0144-8617(96)00059-8;;16346007;;10.1128/aem.43.5.1086-1091.1982;;pmc244190;;10.1016/0008-6215(83)88360-8;;10.1016/0008-6215(83)88361-x;;10.1016/0144-8617(87)90004-x;;10.1016/0008-6215(88)80151-4;;10.1016/s0144-8617(97)00241-5,"Morris, E.R. et al., ""Conformational and rheological transitions of welan, rhamsan and acylated gellan"", Carbohydrate Polymers, 30, (1996), pp. 165-175.;;Kang, Kenneth S. et al., ""Agar-Like Polysaccharide Produced by a Pseudomonas Species: Production and Basic Properties, Applied and Environmental Microbiology"", May 1982, pp. 1086-1091, vol. 43, No. 5.;;O'Neill, Malcolm A. et al., ""Structure of the Acidic Extracellular Gelling Polysaccharide Produced by Pseudomonas elodea"", Carbohydrate Research, 124, (1983), pp. 123-133.;;Jannson, Per-Erik et al., ""Structural Studies of GellanGum, an Extracellular Polysaccharide Elaborated by Pseudomonas elodea"", Carbohydrate Research, 124, (1983) pp. 135-139.;;Grasdalen, Hans et al., ""Gelation of Gellan Gum"", Carbohydrate Polymers, 7, (1987) pp. 371-393.;;Chandrasekaran, Rengaswam et al., ""The Crystal Structure of Gellan"", Carbohydrate Research, 175, (1988) pp. 1-15.;;Baird, J.K. et al., Proc. 6th International Conference on Gums and Stabilisers for the Food Industry, Wrexham, Clwyd, Wales, Jul. 1991- Edited Phillips G.O., et al., published by IRL Press at OUP (1992), pp. 479-487.;;Bourne, Malcolm C., (1978), ""Texture Profile Analysis"", Food Technology, Jul., 1978, 32, pp. 67-72.;;Jay, A.J. et al., Analysis of structure and function of gellans with different substitution patterns:, Carbohydrate Polymers, 35, (1998), pp. 179-188.",EXPIRED
369,US,A1,US 2023/0095713 A1,097-225-745-793-823,2023-03-30,2023,US 202218062489 A,2022-12-06,US 202218062489 A;;US 202016951624 A;;US 202017085583 A;;US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,ORTHODONTIC APPLIANCES WITH ELONGATE TACTILE OBJECTS,"Appliances for orthodontic treatment are provided. In some embodiments, an orthodontic appliance includes a shell having a plurality of teeth-receiving cavities shaped to reposition a patient’s teeth from a first arrangement toward a second arrangement. The shell can have a first elasticity. The appliance can include an attachment-receiving well formed in the shell. The attachment-receiving well can be configured to engage an attachment coupled to a tooth of the patient. The appliance can further include at least one tactile object coupled to the attachment-receiving well. The at least one tactile object can include an elongate body that extends toward the attachment when the shell is worn on the patient’s teeth. The at least one tactile object can have a second elasticity greater than the first elasticity.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/097-225-745-793-823,Patent Application,yes,0,0,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14;;B33Y80/00,,0,0,,,,PENDING
370,US,B2,US 9056910 B2,094-613-592-652-936,2015-06-16,2015,US 201313873462 A,2013-04-30,US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,Anti-PMEL17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,GENENTECH INC (2013-07-17),https://lens.org/094-613-592-652-936,Granted Patent,yes,108,13,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K39/395;;A61K45/06;;A61K47/48;;A61K51/10;;C07K16/28;;C07K16/30;;G01N33/60,,105,99,027-477-313-726-928;;014-113-432-888-031;;045-942-104-775-903;;062-170-867-080-500;;051-707-000-800-833;;110-132-259-167-081;;103-834-230-679-860;;051-208-529-712-079;;068-257-624-898-885;;086-569-845-269-420;;015-395-754-996-662;;051-576-528-777-865;;036-923-658-847-622;;003-984-734-905-938;;005-112-559-456-657;;017-695-622-077-055;;033-564-353-488-242;;046-783-448-716-481;;009-483-512-107-343;;012-344-084-965-349;;065-684-269-783-203;;083-071-649-888-913;;020-126-164-125-029;;125-541-153-996-289;;001-779-867-387-972;;049-134-753-209-354;;036-000-628-772-935;;034-331-211-704-877;;008-274-774-541-556;;013-584-945-188-940;;013-954-482-377-715;;085-634-291-486-854;;018-694-084-068-187;;006-338-973-732-491;;004-272-966-072-139;;025-595-011-959-317;;120-079-078-809-391;;018-221-719-733-102;;011-842-849-963-456;;039-981-636-470-013;;002-490-451-363-036;;033-261-430-402-230;;080-360-276-571-359;;014-234-489-298-615;;039-841-667-603-953;;036-144-129-406-781;;070-280-057-407-994;;113-394-540-007-150;;035-796-690-562-525;;083-501-514-901-399;;008-587-496-850-953;;005-813-390-127-218;;072-378-691-723-546;;035-232-534-898-963;;068-264-897-850-380;;066-617-857-912-127;;095-843-764-156-972;;016-951-682-761-012;;049-755-438-917-969;;072-389-563-856-866;;019-662-268-310-070;;116-831-294-654-564;;022-725-321-473-914;;002-495-630-767-098;;073-809-444-186-075;;066-749-017-721-197;;061-423-230-346-240;;032-071-991-081-664;;034-345-578-106-977;;089-461-397-670-986;;051-719-785-727-477;;107-783-742-795-839;;009-709-621-617-333;;054-717-629-774-351;;117-747-013-490-001;;079-144-966-327-175;;060-301-220-665-473;;009-275-403-380-31X;;064-667-501-146-970;;030-386-438-509-753;;117-906-457-481-371;;116-075-018-919-051;;009-746-604-420-355;;047-094-213-620-162;;041-208-252-232-319;;104-212-297-137-759;;048-564-471-521-204;;061-970-204-106-123;;069-314-605-679-999;;054-876-950-584-376;;079-666-119-599-514;;071-273-910-767-454;;011-012-284-651-080;;000-325-449-181-936;;015-197-766-709-993;;170-311-024-328-514;;124-805-115-929-413;;032-110-387-855-191;;037-531-283-684-284,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;10.4049/jimmunol.156.9.3285;;8617951;;12079396;;10.1016/s0022-2836(02)00264-4;;11069223;;10.1016/j.cbpa.2010.06.170;;20643572;;17981654;;10.2741/2786;;10.1021/jo00310a019;;20218628;;10.1021/jm901722v;;9099717;;10.1074/jbc.272.16.10678;;10.1007/978-94-009-7630-6_8;;10.1083/jcb.200302072;;pmc2172928;;12732614;;10.4049/jimmunol.147.1.86;;2051030;;10.1126/science.3925553;;3925553;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;10.1200/jco.2010.29.5865;;21172893;;18536555;;10.1097/ppo.0b013e318172d704;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;22509309;;pmc3317983;;10.1371/journal.pone.0034479;;1727373;;10.1021/ar700108g;;17705444;;14970501;;10.1385/1-59259-666-5:245;;10.1074/jbc.m112.361485;;pmc3397835;;22613716;;10.1006/jmbi.1999.3192;;10543973;;10.1016/0022-2836(87)90412-8;;3681981;;12412475;;10.1385/1-59259-334-8:179;;10.1038/352624a0;;1907718;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;10.1182/blood-2002-06-1761;;12393541;;10.1097/00001813-199506000-00006;;7670137;;7680699;;10.1016/0022-1759(93)90011-u;;10.1126/science.2471267;;2471267;;15848074;;10.1016/j.ymeth.2005.01.005;;10.1038/nbt832;;12778055;;10.1021/bc0502917;;16417259;;10.1021/bc0502917.s001;;10.1016/s0040-4039(97)01158-1;;10.1016/s0960-894x(02)00194-4;;12031335;;3258649;;10.1038/332738a0;;15306681;;10.1073/pnas.0401786101;;pmc515084;;17161664;;10.1016/j.jchromb.2006.11.018;;1560463;;10.1016/0022-2836(92)91010-m;;637870;;10.1016/0006-291x(78)91322-0;;10.1182/blood-2003-01-0039;;12714494;;8983339;;10.1021/bc950092v;;21557708;;10.1517/14712598.2011.582464;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1021/bc00014a008;;1325188;;10.1038/nbt1028;;15529166;;16380412;;10.1200/jco.2005.03.8471;;886304;;10.1099/0022-1317-36-1-59;;10.1016/0305-7372(90)90037-g;;2272029;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.4049/jimmunol.152.11.5368;;8189055;;10.4049/jimmunol.117.2.587;;950463;;10.1517/13543776.15.9.1087;;10.1158/1078-0432.ccr-04-0789;;15501986;;17991747;;pmc2430631;;10.1074/jbc.m708007200;;10.1158/0008-5472.can-10-0790;;20660714;;pmc3533126;;10.1016/s0960-894x(99)00381-9;;10465553;;12621449;;10.1038/sj.gt.3301983;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;8324745;;pmc2830135;;10.1096/fj.09-140921;;19884326;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;0001350381;;10.1126/science.256.5060.1205;;1350381;;10.1016/0022-2836(92)90894-p;;1404359;;11968478;;10.1385/1-59259-240-6:001;;11001403;;10.1089/027245700429855;;10.1016/j.bmcl.2009.09.012;;19811912;;12514726;;10.1038/nm0103-129;;10.1021/ar00128a001;;10.4049/jimmunol.164.8.4178;;10754313;;21843648;;10.1016/j.vascn.2011.07.005;;10.1016/j.bmcl.2005.09.081;;16275070;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;16609957;;10.1002/bit.20880;;15848072;;10.1016/j.ymeth.2005.01.003;;7925571;;10.1002/eji.1830241025;;12213074;;10.1021/jm020149g;;6387121;;10.1021/jm00377a012;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;15264863;;10.1021/bc049969t;;18387968;;10.1093/hmg/ddn095;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.133.6.3001;;6092464;;10.2174/092986706776055751;;16515518;;19047044;;10.1074/jbc.m808904200;;pmc2629115;;14736422;;10.1016/j.jim.2003.11.001;;15236968;;10.1016/j.jmb.2004.05.051;;10.1021/ja00952a050;;5845427;;10.1021/ja00952a051;;5845428;;10.1074/jbc.m110.168088;;pmc3059051;;21247888;;pmc2871485;;10.1074/jbc.m109.097725;;20231267;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;10.1038/nbt1178;;16429149;;17196977;;10.1016/j.jmb.2006.11.021;;pmc38722;;10.1073/pnas.93.16.8618;;8710920,"Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Rudikoff et al(Proc. Natl. Acad. Sci. USA 1982 vol. 79: p. 1979).;;Pascalis et al (The Journal of Immunology (2002) 169, 3076-3084).;;Casset et al. (2003) BBRC 307, 198-205.;;Brown et al (J. Immunol. May 1996; 156(9):3285-3291.;;Vajdos et al (J. Mol. Biol. Jul. 5, 2002,;320(2); 415-428).;;Ajani et al., ""A Multi-Institutional Phase II Study of BMS-182248-01 (BR96-Doxorubicin Conjugate) Administered Every 21 Days in Patients with Advanced Gastric Adenocarcinoma"" Cancer Journal 6:78-81 (2000).;;Alley et al., ""Antibody-drug conjugates: targeted drug delivery for cancer"" Current Opinion in Chemical Biology 14:529-537 (2010).;;Alley, S.C. et al., ""Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR"" 45:52 (2004).;;Almagro et al., ""Humanization of antibodies"" Frontiers in Bioscience 13:1619-1633 (Jan. 2008).;;Amsberry et al., ""The lactonization of 2'-hydroxyhydrocinnamic acid amides: A potential prodrug for amines"" J Org Chem 55:5867-5877 (1990).;;Antonow et al., ""Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents"" J Med Chem(53):2927-2941 (2010).;;Baca et al., ""Antibody humanization using monovalent phage display"" J Biol Chem 272(16):10678-10684, (1997).;;Bachur Anthracycline Antibiotics in Cancer Therapy ""Free Radical Damage"" Muggia et al., The Hague:Martinus Nijhoff,:97-102 (1981).;;Berson et al., ""Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis,"" J Cell Biol, 2003, 161:521-533.;;Boerner et al., ""Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes"" J Immunol 147(1):86-95 (Jul. 1991).;;Brennan et al., ""Preparation of Biospecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments"" Science 229(4708):81-83 (Jul. 5, 1985).;;Brodeur et al., ""Mouse-human myeloma partners for the production of heterohybridomas"" Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (New York: Marcel Dekker, Inc.), (1987).;;Brueggemann et al., ""Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies"" J. Exp. Med. 166:1351-1361 (1987).;;Burris et al., ""Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy,"" J Clin Oncol, 2011, 29:398-405.;;Carter and Senter, ""Antibody-drug conjugates for cancer therapy"" Cancer J 14(3):154-169 (2008).;;Carter et al., ""Humanization of an anti-p185 HER2 antibody for human cancer therapy"" P Natl Acad Sci USA 89:4285-4289 (May 1992).;;Chandra et al., ""A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation"" PLoS One 7(4):e34479 (Apr. 3, 2012).;;Chari et al., ""Immunoconjugates containing novel maytansinoids: Promising anticancer drugs"" Cancer Res 52:127-131 (1992).;;Chari, ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"" Accounts of Chemical Research 41(1):98-107 ( 2008).;;Charlton, K.A., ""Expression and isolation of recombinant antibody fragments in E. coli"" Method Molec Biol 248:245-254 (2003).;;Chen et al., ""The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma,"" Biol Chem, 2012, 287:24082-24091.;;Chen et al., ""Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen"" J Mol Biol. 293(4):865-81 (1999).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J Mol Biol 196(4):901-917 (1987).;;Chowdhury, ""Engineering hot spots for affinity enhancement of antibodies"" Methods Molec Biol 207:179-196 (2008).;;Clackson et al., ""Making antibody fragments using phage display libraries"" Nature 352:624-628 (Aug. 1991).;;Clynes et al., ""Fc receptors are required in passive and active immunity to melanoma"" Proc. Natl. Acad. Sci. USA 95:652-656 (Jan. 1998).;;Cragg et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts"" Blood 101(3):1045-1052 (2003).;;Cree et al., ""Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay"" Anticancer Drugs 6:398-404 (1995).;;Crouch et al., ""The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity"" J Immunol Methods 160:81-88 (1993).;;Cunningham and Wells, ""High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis"" Science 24:1081-1085 (Jun. 2, 1989).;;Dall'Acqua et al., ""Antibody humanization by framework shuffling"" Methods 36:43-60 ( 2005).;;Doronina et al., ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"" Nat Biotechnol 21(7):778-784 (Jul. 2003).;;Doronina et al., ""Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity"" Bioconjug Chem 17(1):114-124 (Jan. 2006).;;Dubowchik and Radia, ""Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles"" Tetrahedron Lett 38(30):5257-5260 (1997).;;Dubowchik et al., ""Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages"" Bioorg Med Chem Lett 12:1529-32 (2002).;;Duncan et al., ""The binding site for Clq on IgG"" Nature 322:738-740 (1988).;;Fellouse et al., ""Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition"" P Natl Acad Sci USA 101(34):12467-12472 (Aug. 24, 2004).;;Flatman et al., ""Process analytics for purification of monoclonal antibodies"" J Chromatogr 848:79-87 (2007).;;Foote et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"" J Mol Biol 224:487-499 (1992).;;Fraker and Speck, ""Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril"" Biochem Bioph Res Co 80(4):849-857 (1978).;;Francisco et al., ""cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity"" Blood 102(4):1458-1465 (Aug. 15, 2003).;;Frisch et al., ""Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes"" Bioconj Chem 7:180-186 (1996).;;Garrett and Eng, ""Cetuximab in the treatment of patients with colorectal cancer,"" Expert Opin Biol Ther., 2001, 11:937-949.;;Gazzano-Santoro et al., ""A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody"" J Immunol Methods 202(2):163-171 (Mar. 28, 1997).;;Geoghegan and Stroh, ""Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine"" Bioconjugate Chem. 3:138-146 (1992).;;Gerngross, T. U, ""Advances in the production of human therapeutic proteins in yeasts and filamentous fungi"" Nat Biotech 22(11):1409-1414 (Nov. 2004).;;Goldenberg et al., ""Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy,"" J Clin Oncol, 2006, 24:823-834.;;Graham et al., ""Characteristics of a human cell line transformed by DNA from human adenovirus type 5"" J Gen Virol 36(1):59-72 (Jul. 1977).;;Grandi et al., ""Novel anthracycline analogs"" Cancer Treatment Reviews 17:133-138 (1990).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries"" Embo J 12(2):725-735 ( 1993).;;Gruber et al., ""Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli"" J Immunol 152:5368-5374 (1994).;;Guyer et al., ""Immunoglobulin binding by mouse intestinal epithelial cell receptors"" J Immunol 117(2):587-593 (Aug. 1976).;;Hamann, ""Monoclonal antibody-drug conjugates"" Expert Opin Ther Patents 15(9):1087-1103 (2005).;;Hamblett et al., ""Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate,"" Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the AACR' 45:52 (2004).;;Hamblett et al., ""Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate"" Clin Cancer Res 10:7063-7070 (2004).;;Harper et al., ""Premelanosome amyloid-like fibrils are composed of only golgi-processed forms of Pmel17 that have been proteolytically processed in endosomes,"" J Biol Chem, 2008, 283:2307-2322.;;Hartley et al., ""SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity"" Cancer Res. 70(17):6849-6858 (2010).;;Hay et al., ""A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindo1-2-YL)carbonyl]-1,2-dihydro-3H-benz[E]indole(amino-seco-DB1-TMI) for use with ADEPT and GDEPT"" Bioorg Med Chem Lett 9:2237-2242 (1999).;;Herweijer and Wolff, ""Progress and prospects: naked DNA gene transfer and therapy,"" Gene Ther., 2003, 10:453-458.;;Hellstrom et al., ""Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas"" P Natl Acad Sci USA 83:7059-7063 (Sep. 1986).;;Hellstrom et al., ""Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside"" P Natl Acad Sci USA 82:1499-1502 (Mar. 1985).;;Hinman et al., ""Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics"" Cancer Res 53:3336-3342 (1993).;;Hoashi et al., ""The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding,"" FASEB J, 2010, 24:916-930.;;Hollinger et al., """"Diabodies"": Small Bivalent and Bispecific Antibody Fragments"" Proc. Natl. Acad. Sci. USA 90:6444-6448 (Jul. 1993).;;Holmes et al., ""Identification of Heregulin, a Specific Activator of p185erbB2"" Science 256:1205-1210 (May 22, 1992).;;Hoogenboom et al., ""By-passing Immunisation; Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro"" J Mol Biol 227:381-388 (1992).;;Hoogenboom et al., ""Overview of antibody phage-display technology and its applications"" Methods Mol Biol 178:1-37 ( 2002).;;Hongo et al., ""Characterization of novel neutralizing monoclonal antibodies specific to human neurturin"" Hybridoma, 2000, 19:303-315.;;Howard et al., ""Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate"" Bioorg Med Chem Lett 19(22):6463-6466 (2009).;;Hudson et al., ""Engineered antibodies"" Nature Medicine 9(1):129-134 (Jan. 2003).;;Hurley et al., ""Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines"" Acc Chem Res 19:230-237 ( 1986).;;Idusogie et al., ""Mapping of the Clq Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc"" J Immunol 164(8):4178-4184 (2000).;;Iyer & Kadambi, ""Antibody drug conjugates-Trojan horses in the war on cancer"" Journal of Pharmacological and Toxicological Methods 64:207-212 (2011).;;Jeffrey et al., ""Dipeptide-based highly potent doxorubicin antibody conjugates"" Bioorganic Med Chem Letters 16:358-362 (2006).;;Kam et al., ""Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction"" P Natl Acad Sci USA 102(33):11600-11605 (Aug. 2005).;;Kanda et al., ""Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC"" Biotechnol Bioeng 94(4):680-688 (Jul. 5, 2006).;;Kashmiri et al., ""SDR grafting-a new approach to antibody humanization"" Methods 36:25-34 (2005).;;Kim et al., ""Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor"" Eur. J. Immunol 24:2429-2434 (1994).;;Kindt et al. Kuby Immunology ""Antigens and Antibodies Chapter 4"" 6th ed edition, N.Y.:W.H. Freeman and Co,:p. 91 (2007).;;King et al., ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains"" Journal of Medical Chemistry 45:4336-4343 (2002).;;Kingsbury et al., ""A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil"" J Med Chem 27:1447-1451 (1984).;;Klimka et al., ""Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning""Br J Cancer 83(2):252-260 (2000).;;Klussman et al., ""Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway"" Bioconjugate Chem 15:765-773 (2004).;;Kohler et al., ""Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours"" Hum Mol Genet 17(13):1978-1987 (2008).;;Kohn Antibiotics ""Anthramycin"" Corcoran et al., New York, NY: Springer-Verlag, vol. 3:3-11 (1975).;;Kostelny et al., ""Formation of a bispecific antibody by the use of leucine zippers"" J Immunol. 148:1547-1553 (Mar. 1, 1992).;;Kozbor et al., ""A human hybrid myeloma for production of human monoclonal antibodies"" J Immunol 133(6):3001-3005 (Dec. 1984).;;Kratz et al., ""Prodrugs of anthracyclines in cancer chemotherapy"" Curr Med Chem 13:477-523 (2006).;;Kummer et al., ""Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase,"" J Biol Chem., 2009, 284:2296-2306.;;Lee et al., ""Bivalent antibody phage display mimics natural immunoglobulin"" J Immunol Methods 284(1-2):119-132 ( 2004).;;Lee et al., ""High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold"" J Mol Biol 340(5):1073-1093 (2004).;;Leimgruber et al., ""Isolation and characterization of anthramycin, a new antitumor antibiotic"" J Am Chem Soc 87(24):5791-5793 (1965).;;Leimgruber et al., ""The structure of anthramycin"" J Am Chem Soc 87(24):5793-5795 (1965).;;Leonhardt et al., ""Proprotein convertases process Pmel17 during secretion,"" J Biol Chem., 2011, 286:9321-9337.;;Leonhardt et al., ""Endoplasmic reticulum export, subcellular distribution, and fibril formation by Pmel17 require an intact N-terminal domain junction"" J Biol Chem, 2010, 285:16166-1683.;;Li et al., ""Human antibodies for immunotherapy development generated via a human B cell hybridoma technology"" Proc Natl Acad Sci USA 103:3557-3562 (2006).;;Li et al., ""Optimization of humanized IgGs in glycoengineered Pichia pastoris"" Nat Biotechnol 24(2):210-215 (Feb. 2006).;;Liang et al., ""Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library"" J. Mol. Biol. 366:815-829 (2007).;;Liu et al., ""Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids."" P Natl Acad Sci USA 93:8618-8623 (1996).",ACTIVE
371,US,B2,US 10661567 B2,197-670-202-135-454,2020-05-26,2020,US 201515748848 A,2015-10-26,US 2015/0057389 W,2015-10-26,Printheads and methods of fabricating a printhead,"Printheads and methods of fabricating printheads are disclosed. An example printhead includes a substrate and a printhead die disposed on a surface of the substrate, where a top surface of the printhead die projects a first distance from the surface of the substrate. The example printhead also includes a barrier at least partially surrounding the printhead die. A top surface of the barrier projects a second distance from the surface of the substrate, where the first distance is less than the second distance.",HEWLETT PACKARD DEVELOPMENT CO,CUMBIE MICHAEL W;;CHEN CHIEN-HUA;;MACKENZIE MARK H;;CLARK GARRETT E,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2015-10-21),https://lens.org/197-670-202-135-454,Granted Patent,yes,14,0,5,5,0,B41J2/1637;;B41J2/1637;;B41J2/155;;B41J2/155;;B41J2/16;;B41J2/16;;B41J2/1623;;B41J2/1632;;B41J2/1632;;B41J2/1635;;B41J2/1635;;B41J2/175;;B41J2202/20;;B41J2202/20,B41J2/16;;B41J2/155;;B41J2/175,,1,0,,,"Matsushita, N. et al., “Elaborate Precision Machining Technologies for Creating High Added Value at Low Cost”, Fujitsu Sci. Tech. J., 43,1, p. 67-75, Jan. 2007.",ACTIVE
372,TW,A,TW 201402609 A,120-080-784-042-018,2014-01-16,2014,TW 102115510 A,2013-04-30,US 201261641074 P;;US 201261678911 P,2012-05-01,Anti-PMEL17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/120-080-784-042-018,Patent of Addition,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/28;;A61K47/48;;A61K51/10;;A61K103/30;;A61P35/00,,0,0,,,,PENDING
373,AU,A1,AU 2013/256596 A1,046-492-597-046-266,2014-10-09,2014,AU 2013/256596 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,Anti-PMEL17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/046-492-597-046-266,Patent Application,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/28;;A61K47/48;;C07K16/30,,0,0,,,,DISCONTINUED
374,BR,A2,BR 112014027166 A2,084-684-056-536-400,2017-06-27,2017,BR 112014027166 A,2013-04-30,US 2013/0038742 W;;US 201261641074 P;;US 201261678911 P,2012-05-01,"anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.",,GENENTECH INC,CHRISTINE TAN;;JYOTI ASUNDI;;PAUL POLAKIS;;SUZANNA CLARK;;WILLIAM MALLET;;YOUJUN CHEN,,https://lens.org/084-684-056-536-400,Patent Application,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/28;;C07K16/30,,0,0,,,,DISCONTINUED
375,US,B2,US 9597164 B2,091-008-911-868-52X,2017-03-21,2017,US 201414206836 A,2014-03-12,US 201414206836 A;;US 63371509 A,2009-12-08,"Tactile objects for orthodontics, systems and methods","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/091-008-911-868-52X,Granted Patent,yes,100,11,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08,,99,54,066-282-335-791-995;;025-616-909-029-765;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;005-024-996-709-894;;059-588-461-518-39X;;052-731-758-553-641;;081-328-802-841-096;;008-744-219-127-384;;083-235-787-432-859;;009-638-995-800-030;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;007-458-121-098-163;;114-408-402-448-688;;048-527-821-955-377;;052-763-059-483-265;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;049-270-017-771-054;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;021-018-768-707-650;;034-464-951-348-782;;013-689-140-672-656;;006-370-362-381-143;;150-267-339-118-983;;000-494-525-786-513;;099-384-176-695-780;;056-064-135-529-61X;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973;;138-684-123-834-414;;056-383-866-369-582;;123-028-396-811-269,10.1117/12.7972842;;10.1117/12.957387;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1016/0002-9416(72)90076-0;;4501183;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;298295;;298302;;6937139;;10.1016/0002-9416(81)90310-9;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;3058771;;10.14219/jada.archive.1988.0096;;1777659;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;10.14219/jada.archive.1989.0240;;2918147;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;271471;;10.1016/0002-9416(78)90100-8;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;10.1016/0096-6347(45)90101-3;;21027613;;10.1016/0096-6347(46)90053-1;;10.2334/josnusd1959.26.11;;6589367;;10356517;;10.1145/964965.808575;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387;;2132100;;10.2334/josnusd1959.19.93;;294475;;10.1109/iecon.1998.724103,"AADR. American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Alcaniz, et al, ""An Advanced System for the Simulation and Planning of Orthodontic Treatments,"" Karl HF Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Intl. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;Alexander et al., ""The DigiGraph Work Station Part 2 Clinical Management,"" JCO, pp. 402-407 (Jul. 1990).;;Altschuler et al., ""Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures, "" AADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR HP Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., ""Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,"" Optical Engineering, 20(6):953-961 (1981).;;Altschuler et al., ""Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,"" SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Altschuler, ""3D Mapping of Maxillo-Facial Prosthesis,"" AADR Abstract #607, 2 pages total, (1980).;;Andersson et al., ""Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,"" Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapter 3, pp. 13-24 (1989).;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind et al., ""A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,"" NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., ""Mapping the Skull in 3-D,"" reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, ""A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,"" an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of III., Aug. 26-30, 1975, pp. 142-166.;;Baumrind, ""Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,"" Semin in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., ""A Computer System for the Analysis of Dental Casts,"" The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al., ""Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,"" Abstract, J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., ""A Computer-Aided Design for Orthognathic Surgery,"" Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff et al., ""Computerized Analysis of Occlusion in the Postcanine Dentition,"" Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biggerstaff, ""Computerized Diagnostic Setups and Simulations,"" Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890, 20 pages total (1990).;;Blu, et al., ""Linear interpolation revitalized"", IEEE Trans. Image Proc., 13(5):710-719 (May 2004).;;Bourke, ""Coordinate System Transformation,"" (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL .;;Boyd et al., ""Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalign Appliance,"" Semin Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., ""Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,"" J. Dent. Res. Special Issue, Abstract 305, vol. 64, p. 208 (1985).;;Brook et al., ""An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: IK Comparison with Manual Measurements of Mesio-distal Diameter,"" J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone (interview), ""Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 1),"" J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), ""Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 2),"" J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form in Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Cardinal Industrial Finishes, Powder Coatings information posted at on Aug. 25, 2000, 2 pages.;;Carnaghan, ""An Alternative to Holograms for the Portrayal of Human Teeth,"" 4th Int'l. Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., ""The DigiGraph Work Station, Part 1, Basic Concepts,"" JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., ""Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,"" Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, ""CAD/CAM in the Dental Office: Does It Work?"", Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crawford, ""Computers in Dentistry: Part 1: CAD/CAM: The Computer Moves Chairside,"" ""Part 2: F. Duret-A Man With a Vision,"" ""Part 3: The Computer Gives New Vision-Literally,"" ""Part 4: Bytes 'N Bites"" The Computer Moves From the Front Desk to the Operatory, Canadian Dental Journal, vol. 54(9), pp. 661-666 (1988).;;Crooks, ""CAD/CAM Comes to USC,"" USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., ""Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,"" Semin Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et al., ""Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,"" Plast. 77(6):877-885 (Jun. 1986).;;DCS Dental AG, ""The CAD/CAM 'DCS Titan System' for Production of Crowns/Bridges,"" DSC Production AG, pp. 1-7 (Jan. 1992.;;Definition for gingiva. Dictionary.com p. 1-3. Retrieved from the internet Nov. 5, 2004 .;;DeFranco et al., ""Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,"" J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium JD on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13 (1992).;;DENT-X posted on Sep. 24, 1998 at , 6 pages.;;Doyle, ""Digital Dentistry,"" Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClearTM product information, Allesee Orthodontic Appliances-Pro Lab, 1 page (1997).;;Duret et al, ""CAD-CAM in Dentistry,"" J. Am. Dent. Assoc. 117:715-720 (Nov. 1988).;;Duret et al., ""CAD/CAM Imaging in Dentistry,"" Curr. Opin. Dent., 1:150-154 (1991).;;Duret, ""The Dental CAD/CAM, General Description of the Project,"" Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,""Vers Une Prosthese Informatisee,"" (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, ""The Microcomputer in the Orthodontic Office,"" JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Felton et al., ""A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,"" Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., ""Accuracy of Cephalometric Prediction in Orthognathic Surgery,"" Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Futterling et a/., ""Automated Finite Element Modeling of a Human Mandible with Dental Implants,"" JS WSCG '98-Conference Program, retrieved from the Internet: , 8 pages.;;Gao et al., ""3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,"" Proc. Intl Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, ""Das DUX System: Die Technik,"" 2 pages total (2002).;;Gottleib et al., ""JCO Interviews Dr. James A. McNamara, Jr., on the Frankel Appliance: Part 2: Clinical 1-1 Management, ""J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, ""New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: JW Computerized Facial Imaging in Oral and Maxiiofacial Surgery,"" AAOMS, 3 pages total, (Sep. 13, 1990).;;Guess et al., ""Computer Treatment Estimates in Orthodontics and Orthognathic Surgery,"" JCO, pp. 262-28 (Apr. 1989).;;Heaven et al. ""Computer-Based Image Analysis of Artificial Root Surface Caries,"" Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, ""Simulating Stress Put on Jaw,"" Tooling & Production [online], Nov. 1996, n pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL http://static .highbeam.com/t/toolingampproduction/november011996/simulatingstressputonfa . . .>.;;Hikage, ""Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning"", Journal of Japan KA Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., ""Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,"" 0 (Article Summary in English, article in German), lnformatbnen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., ""Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,"" J. Biomech., 23(11):1157-1166 (1990).;;Huckins, ""CAD-CAM Generated Mandibular Model Prototype from MRI Data,"" AAOMS, p. 96 (1999).;;Important Tip About Wearing the Red White & Blue Active Clear Retainer System, Allesee Orthodontic Appliances-Pro Lab, 1 page 1998).;;Inside the ADA, JADA, 118:286-294 (Mar. 1989).;;JCO Interviews, Craig Andreiko , DDS, MS on the Elan and Orthos Systems, JCO, pp. 459-468 (Aug. 1994).;;JCO Interviews, Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2, JCO. 1997; 1983:819-831.;;Jerrold, ""The Problem, Electronic Data Transmission and the Law,"" AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., ""An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,"" Br. J. Orthod., 16:85-93 (1989).;;JP Faber et al., ""Computerized Interactive Orthodontic Treatment Planning,"" Am. J. Orthod., 73(1):36-46. Jan. 1978.;;Kamada et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case KJ Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., ""Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,"" J. Dent Res., 63(11):1298-1301 (Nov. 1984).;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Journal of Orthodontics and Oral surgery. 1945; 31:297-304.;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, KN Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Ki Kamada et.al., Case Reports on Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kochanek, ""Interpolating Splines with Local Tension, Continuity and Bias Control,"" Computer Graphics, ri 18(3):33-41 (Jul. 1984). KM Oral Surgery (1945) 31 :297-30.;;Kunii et al., ""Articulation Simulation for an Intelligent Dental Care System,"" Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laminated. (n.d.). Dictionary.com Unabridged. Retrieved Apr. 28, 2010, from Dictionary.com website: http://dictionary.reference.com/browse/Laminated.;;Laurendeau, et al., ""A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of 7 KR Dental Imprints: An Application in Orthodontics,"" IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991).;;Leinfelder, et al., ""A New Method for Generating Ceramic Restorations: a CAD-CAM System,"" J. Am. 1-1 Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., ""Computer-Aided Cefalometry and New Mechanics in Orthodontics,"" (Article Summary in English, article in German), Fortschr Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, ""Inside the ADA,"" J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., ""Invisible Retainers,"" J. Cfin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., ""Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,"" IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, ""Correcting Mild Malalignments-As Easy as One, Two, Three,"" AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mormann et al., ""Marginale Adaptation von adhasuven Porzellaninlays in vitro,"" Separatdruck aus:Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.;;Nahoum, ""The Vacuum Formed Dental Contour Appliance,"" N. Y. State Dent. J., 30(9):385-390 (Nov. 1964).;;Nash, ""CEREC CAD/CAM Inlays: Aesthetics and Durability in a Single Appointment,"" Dent. Today, 9(8):20, 22-23 (Oct. 1990).;;Nishiyama et al., ""A New Construction of Tooth Repositioner by LTV Vinyl Silicone Rubber,"" J. Nihon Univ. Sch. Dent., 19(2):93-102 (1977).;;Paul et al., ""Digital Documentation of Individual Human Jaw and Tooth Forms for Applications in Orthodontics, Oral Surgery and Forensic Medicine"" Proc. of the 24th Annual Conf. of the IEEE Industrial Electronics Society (IECON '98), Sep. 4, 1998, pp. 2415-2418.",ACTIVE
376,SG,A,SG 11201407106X A,102-271-803-158-892,2014-11-27,2014,SG 11201407106X A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/102-271-803-158-892,Unknown,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48;;C07K16/28;;C07K16/30,,0,0,,,,PENDING
377,US,A1,US 2017/0240645 A1,136-133-914-928-317,2017-08-24,2017,US 201715425527 A,2017-02-06,US 201715425527 A;;US 201514705525 A;;US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/136-133-914-928-317,Patent Application,yes,0,0,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/30;;A61K31/5383,,0,0,,,,ACTIVE
378,US,A,US 5852821 A,152-171-208-144-088,1998-12-22,1998,US 88267897 A,1997-06-25,US 88267897 A;;US 62706096 A;;US 4863793 A;;US 57018395 A;;US 82086497 A,1993-04-16,High-speed data base query method and apparatus,"A server performing an indexing method of data management to create and maintain indexes more efficiently than existing indexing approaches is described. The server is disposed between an application program and a DBMS and is coupled to a data base located within the DBMS. The data base has an ordered set of data values stored in memory. Each data value has a bit pattern and an identifier associated therewith. The server creates a plurality of bit vectors such that the number of bit vectors created equals the longest length bit pattern for the values. The server accesses one of the values stored in the data base. Each bit of the bit pattern for the value is then assigned by the server to a unique position in successive bit vectors. The bits are assigned to identical unique positions in each of the successive bit vectors. The server repeats the above-described accessing and assigning steps for each remaining value of the set to form an index of bit vectors for the values. Methods are provided for improving the performance of database queries when using bit-vector or HighNonGroup (HNG) indexes. Such queries include, for instance, aggregate operations specified in an SQL statement, such as SUM, MAX, MIN, and AVG operations. Specific methods described include optimizing ""range"" comparisons by reducing bit operations, optimization of MAX and MIN operations, optimization of SUM and AVG operations, implementation of a ""Datepart"" index, and execution of SUBSTRING predicates in an HNG index.",SYBASE INC,CHEN YONG MIN;;KIRK STEVEN A;;WHITE PETER W;;FRENCH CLARK D,SYBASE INC (1997-10-16),https://lens.org/152-171-208-144-088,Granted Patent,yes,12,115,1,5,0,G06F16/2237;;G06F16/24556;;G06F16/24556;;Y10S707/99932;;Y10S707/99933;;G06F16/2237,G06F17/30,707/2;;707/3;;707/10,9,2,014-065-969-285-659;;052-980-896-523-624,10.1109/icde.1991.131498;;10.1109/32.238583,"Perrizo et al., Domain Vector Accelerator (DVA): A Query Accelerator for Relational Operations IBM Corp., Rochester, MN, IEEE, Data Engineering, 1991 7 th Int l, Dec. 1990, pp. 491 498.;;Brodie, M. and Manola, F., Database Management: A Survey, Computer Corporation of America, May 1987, pp. 1 24.;;Hanson Smith, Ltd., Advantage Series System Overview, Version 2.0, Computer Corporation of America, 1990, pp. 1 132.;;Reinartz, K., Aspects of vertical mode in multiprocessor systems, unconventional computation on conventional processors, Second International Specialist Seminar on the Design and Application of Parallel Digital Processors, IEEE, 1991, ppp. 48 54.;;Chu et al., A Transaction Based Approach to Vertical Partitioning for Relational Database Systems, IEEE, IEEE Transactions on Software Engineering, v19, n8, Aug. 1993, pp. 804 812.;;Naecker, P., RDBMS Maturity, DEC Professional, v10, n12, Nov. 1991, p. 44(6) Available: On Line; DIALOG File 275 .;;Snellen, D., Ingres Table Structures, DBMS, v5, n8, Jul. 1992, p. 60(3) Available: On Line; DIALOG File 275 .;;Riding High on Expressway 103, Steve Roti, DBMS, v7, n8, p. 90 93.;;Faster Data Warehouses, Herb Edelstein, InformationWeek, n 556m p. 77, retrieved from Dialog File 647 (6 pages) at http:/www.dialogweb.com on Sep. 5, 1998.",EXPIRED
379,MY,A,MY 181149 A,189-825-448-598-700,2020-12-19,2020,MY PI2012003806 A,2011-02-24,US 30854310 P,2010-02-26,AMIDE ESTER INTERNAL ELECTRON DONOR AND PROCESS,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,GRACE W R & CO,LEUNG TAK W;;WILLIAMS CLARK C;;TAO TAO;;GAO KUANQIANG;;CHEN LINFENG,,https://lens.org/189-825-448-598-700,Granted Patent,no,0,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,,,0,0,,,,ACTIVE
380,US,A1,US 2014/0193767 A1,002-028-221-419-25X,2014-07-10,2014,US 201414206836 A,2014-03-12,US 201414206836 A;;US 63371509 A,2009-12-08,"TACTILE OBJECTS FOR ORTHODONTICS, SYSTEMS AND METHODS","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/002-028-221-419-25X,Patent Application,yes,1,37,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08,433/6;;433/24,0,0,,,,ACTIVE
381,US,B2,US 10196454 B2,196-132-869-230-316,2019-02-05,2019,US 201715425527 A,2017-02-06,US 201715425527 A;;US 201514705525 A;;US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,Anti-PMEL17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/196-132-869-230-316,Granted Patent,yes,242,1,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K39/395;;A61K31/5383;;A61K45/06;;A61K47/68;;A61K51/10;;C07K16/28;;C07K16/30;;G01N33/58;;G01N33/60,,205,188,110-132-259-167-081;;103-834-230-679-860;;051-208-529-712-079;;068-257-624-898-885;;086-569-845-269-420;;015-395-754-996-662;;051-576-528-777-865;;036-923-658-847-622;;003-984-734-905-938;;005-112-559-456-657;;017-695-622-077-055;;033-564-353-488-242;;046-783-448-716-481;;009-483-512-107-343;;012-344-084-965-349;;065-684-269-783-203;;083-071-649-888-913;;020-126-164-125-029;;125-541-153-996-289;;001-779-867-387-972;;049-134-753-209-354;;036-000-628-772-935;;034-331-211-704-877;;008-274-774-541-556;;013-584-945-188-940;;013-954-482-377-715;;085-634-291-486-854;;018-694-084-068-187;;006-338-973-732-491;;004-272-966-072-139;;025-595-011-959-317;;120-079-078-809-391;;018-221-719-733-102;;011-842-849-963-456;;039-981-636-470-013;;002-490-451-363-036;;033-261-430-402-230;;080-360-276-571-359;;014-234-489-298-615;;039-841-667-603-953;;036-144-129-406-781;;070-280-057-407-994;;113-394-540-007-150;;035-796-690-562-525;;083-501-514-901-399;;008-587-496-850-953;;005-813-390-127-218;;072-378-691-723-546;;035-232-534-898-963;;068-264-897-850-380;;066-617-857-912-127;;095-843-764-156-972;;016-951-682-761-012;;049-755-438-917-969;;072-389-563-856-866;;019-662-268-310-070;;116-831-294-654-564;;022-725-321-473-914;;002-495-630-767-098;;073-809-444-186-075;;066-749-017-721-197;;061-423-230-346-240;;032-071-991-081-664;;034-345-578-106-977;;089-461-397-670-986;;051-719-785-727-477;;107-783-742-795-839;;009-709-621-617-333;;054-717-629-774-351;;117-747-013-490-001;;079-144-966-327-175;;060-301-220-665-473;;009-275-403-380-31X;;064-667-501-146-970;;030-386-438-509-753;;117-906-457-481-371;;116-075-018-919-051;;009-746-604-420-355;;047-094-213-620-162;;041-208-252-232-319;;104-212-297-137-759;;048-564-471-521-204;;061-970-204-106-123;;069-314-605-679-999;;054-876-950-584-376;;079-666-119-599-514;;071-273-910-767-454;;011-012-284-651-080;;000-325-449-181-936;;015-197-766-709-993;;170-311-024-328-514;;124-805-115-929-413;;032-110-387-855-191;;037-531-283-684-284;;049-691-363-334-629;;027-670-963-287-976;;003-570-249-164-056;;010-953-281-569-514;;029-806-225-784-498;;095-334-545-560-259;;018-526-825-169-143;;093-015-402-032-976;;020-544-118-938-442;;020-855-322-534-259;;002-017-073-771-118;;021-430-782-622-770;;065-430-968-783-392;;030-630-100-818-462;;060-265-896-490-751;;117-775-899-628-564;;030-607-398-087-475;;065-996-283-702-791;;016-599-925-793-124;;091-742-909-539-31X;;004-601-819-239-79X;;022-023-983-891-895;;020-126-213-879-311;;056-118-200-157-615;;003-280-353-877-595;;022-932-029-853-743;;023-254-173-733-304;;110-088-048-889-302;;016-716-200-807-517;;015-239-659-590-870;;069-144-826-896-138;;044-522-255-085-902;;030-323-674-660-051;;071-328-232-469-698;;086-821-259-912-358;;010-578-924-151-778;;156-501-805-490-709;;066-253-491-333-192;;042-204-626-457-327;;016-155-290-797-107;;037-445-639-149-821;;090-045-691-092-964;;106-032-800-597-23X;;001-887-288-192-781;;003-886-611-489-779;;004-458-031-333-650;;005-283-943-871-819;;093-067-181-692-392;;038-587-785-866-538;;139-827-026-879-372;;023-607-007-385-464;;061-295-123-907-192;;092-890-446-683-93X;;024-993-224-552-040;;052-478-885-325-397;;072-607-648-399-88X;;080-617-841-244-635;;031-120-105-336-16X;;006-520-672-611-427;;031-063-853-127-197;;022-375-749-274-329;;147-222-052-301-820;;051-940-176-386-905;;033-801-581-665-913;;111-654-430-040-748;;001-256-484-369-395;;011-249-580-357-420;;090-760-098-651-81X;;107-330-806-519-859;;006-895-260-696-111;;105-030-562-969-986;;086-168-816-828-53X;;149-071-995-255-492;;019-837-369-326-225;;078-905-907-694-204;;022-133-574-143-973;;093-183-016-210-781;;028-754-368-865-035;;043-114-291-493-998;;041-041-611-414-017;;024-929-137-199-30X;;069-699-907-490-85X;;043-044-953-372-634;;103-603-300-564-578;;000-009-458-425-897;;018-284-584-600-035;;099-070-305-531-124;;041-984-511-767-425;;027-477-313-726-928;;014-113-432-888-031;;045-942-104-775-903;;062-170-867-080-500;;051-707-000-800-833;;019-308-704-101-581,11069223;;10.1016/j.cbpa.2010.06.170;;20643572;;17981654;;10.2741/2786;;10.1021/jo00310a019;;20218628;;10.1021/jm901722v;;9099717;;10.1074/jbc.272.16.10678;;10.1007/978-94-009-7630-6_8;;10.1083/jcb.200302072;;pmc2172928;;12732614;;10.4049/jimmunol.147.1.86;;2051030;;10.1126/science.3925553;;3925553;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;10.1200/jco.2010.29.5865;;21172893;;18536555;;10.1097/ppo.0b013e318172d704;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;22509309;;pmc3317983;;10.1371/journal.pone.0034479;;1727373;;10.1021/ar700108g;;17705444;;14970501;;10.1385/1-59259-666-5:245;;10.1074/jbc.m112.361485;;pmc3397835;;22613716;;10.1006/jmbi.1999.3192;;10543973;;10.1016/0022-2836(87)90412-8;;3681981;;12412475;;10.1385/1-59259-334-8:179;;10.1038/352624a0;;1907718;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;10.1182/blood-2002-06-1761;;12393541;;10.1097/00001813-199506000-00006;;7670137;;7680699;;10.1016/0022-1759(93)90011-u;;10.1126/science.2471267;;2471267;;15848074;;10.1016/j.ymeth.2005.01.005;;10.1038/nbt832;;12778055;;10.1021/bc0502917;;16417259;;10.1021/bc0502917.s001;;10.1016/s0040-4039(97)01158-1;;10.1016/s0960-894x(02)00194-4;;12031335;;3258649;;10.1038/332738a0;;15306681;;10.1073/pnas.0401786101;;pmc515084;;17161664;;10.1016/j.jchromb.2006.11.018;;1560463;;10.1016/0022-2836(92)91010-m;;637870;;10.1016/0006-291x(78)91322-0;;10.1182/blood-2003-01-0039;;12714494;;8983339;;10.1021/bc950092v;;21557708;;10.1517/14712598.2011.582464;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1021/bc00014a008;;1325188;;10.1038/nbt1028;;15529166;;16380412;;10.1200/jco.2005.03.8471;;886304;;10.1099/0022-1317-36-1-59;;10.1016/0305-7372(90)90037-g;;2272029;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.4049/jimmunol.152.11.5368;;8189055;;10.4049/jimmunol.117.2.587;;950463;;10.1517/13543776.15.9.1087;;10.1158/1078-0432.ccr-04-0789;;15501986;;17991747;;pmc2430631;;10.1074/jbc.m708007200;;10.1158/0008-5472.can-10-0790;;20660714;;pmc3533126;;10.1016/s0960-894x(99)00381-9;;10465553;;12621449;;10.1038/sj.gt.3301983;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;8324745;;pmc2830135;;10.1096/fj.09-140921;;19884326;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;0001350381;;10.1126/science.256.5060.1205;;1350381;;10.1016/0022-2836(92)90894-p;;1404359;;11968478;;10.1385/1-59259-240-6:001;;11001403;;10.1089/027245700429855;;10.1016/j.bmcl.2009.09.012;;19811912;;12514726;;10.1038/nm0103-129;;10.1021/ar00128a001;;10.4049/jimmunol.164.8.4178;;10754313;;21843648;;10.1016/j.vascn.2011.07.005;;10.1016/j.bmcl.2005.09.081;;16275070;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;16609957;;10.1002/bit.20880;;15848072;;10.1016/j.ymeth.2005.01.003;;7925571;;10.1002/eji.1830241025;;12213074;;10.1021/jm020149g;;6387121;;10.1021/jm00377a012;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;15264863;;10.1021/bc049969t;;18387968;;10.1093/hmg/ddn095;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.133.6.3001;;6092464;;10.2174/092986706776055751;;16515518;;19047044;;10.1074/jbc.m808904200;;pmc2629115;;14736422;;10.1016/j.jim.2003.11.001;;15236968;;10.1016/j.jmb.2004.05.051;;10.1021/ja00952a050;;5845427;;10.1021/ja00952a051;;5845428;;10.1074/jbc.m110.168088;;pmc3059051;;21247888;;pmc2871485;;10.1074/jbc.m109.097725;;20231267;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;10.1038/nbt1178;;16429149;;17196977;;10.1016/j.jmb.2006.11.021;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;10.1038/sj.gt.3300947;;10455434;;9679947;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;22208984;;10.1016/b978-0-12-416039-2.00006-9;;10.1006/jmbi.1996.0548;;8876650;;11018093;;10.1093/jnci/92.19.1573;;12121134;;10.1021/bc010124g;;10.1016/s0960-894x(00)00155-4;;10843208;;1748994;;10.1016/0022-2836(91)90498-u;;10.1385/1-59259-666-5:161;;14970495;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1095/biolreprod23.1.243;;6774781;;10.1038/348552a0;;2247164;;16644914;;10.1093/protein/gzl013;;10.1038/305537a0;;6137772;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;10639165;;10.1073/pnas.97.2.829;;pmc15416;;10.1038/312604a0;;6095112;;14632201;;10.1046/j.1523-1747.2003.12474.x;;pmc2793674;;15848075;;10.1016/j.ymeth.2005.01.006;;10.1016/0161-5890(91)90163-e;;1905784;;17077181;;10.1093/intimm/dxl110;;10.1039/p19960000859;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1021/ja00196a061;;10.1055/s-1996-4296;;10.1007/978-3-642-78432-3_11;;10.1016/j.coph.2005.04.008;;15951239;;10.4049/jimmunol.150.3.880;;8423344;;8360482;;10.4049/jimmunol.151.5.2623;;9377574;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;10.1158/1078-0432.ccr-04-1845;;15746066;;11266471;;10.1083/jcb.152.4.809;;pmc2195785;;pmc2786984;;17878918;;10.1038/nrm2258;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1038/ncponc0774;;17392715;;3127726;;10.1038/332323a0;;1586598;;pmc1977399;;10.1038/bjc.1992.148;;10.1016/0003-9861(86)90031-7;;2428310;;pmc2659719;;19017974;;10.4049/jimmunol.181.11.7843;;10.1074/jbc.271.37.22611;;8798431;;10.1200/jco.2000.18.11.2282;;10829049;;18177348;;10.1111/j.1600-0625.2007.00675.x;;11096108;;10.1074/jbc.m009483200;;15066433;;10.1016/j.jmb.2004.02.050;;7688398;;10.4049/jimmunol.151.4.2296;;7984244;;10.1038/372478a0;;10.1021/ja00771a046;;10.1016/s0968-0896(03)00057-9;;12659762;;10.1016/s0960-894x(02)00361-x;;12127540;;20025606;;10.2174/156800909790192365;;16162173;;pmc2788625;;10.1111/j.1600-0749.2005.00269.x;;16760433;;pmc1525253;;10.1091/mbc.e06-01-0081;;10.1021/cr00026a006;;17062682;;10.1158/1078-0432.ccr-06-0910;;10.1021/jo016187+;;11895404;;10080588;;10.1200/jco.1999.17.2.478;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;1675655;;10.4049/jimmunol.147.1.60;;pmc2783760;;19795394;;10.1002/jcp.21935;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1111/j.1600-0625.2009.01053.x;;20201954;;16492709;;10.1242/jcs.02804;;pmc4629779;;11470598;;10.1016/s1367-5931(00)00216-7;;18165614;;10.1634/theoncologist.12-12-1379;;12902418;;10.1358/mf.2005.27.3.890876;;15834451;;15944943;;10.14670/hh-20.927;;10.1021/jo00121a070;;19840945;;pmc2790984;;10.1074/jbc.m109.047449;;21104470;;10.4414/smw.2010.13112;;16821799;;10.1021/jm060319f;;10.1007/978-1-61779-400-1_3;;22130872;;pmc3341798;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9032990;;10.1016/s0167-7799(96)10062-7;;pmc2138737;;5508247;;10.1084/jem.132.2.211;;pmc2793097;;19449448;;10.1002/biof.29;;10.1002/bit.20151;;15352059;;15096515;;10.1074/jbc.m401269200;;10.1385/1-59259-666-5:255;;14970502;;21047225;;10.1056/nejmoa1002965;;22212672;;10.1038/nrd3629;;pmc3343383;;22043994;;10.2174/187152012799014968;;10.1073/pnas.092697199;;pmc123004;;12060743;;10.1089/10430349950017734;;10428218;;10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;10.4049/jimmunol.156.9.3285;;8617951;;12079396;;10.1016/s0022-2836(02)00264-4;;10.4161/mabs.22771;;pmc3564883;;23211638,"Ajani et al., “A Multi-Institutional Phase II Study of BMS-182248-01 (BR96-Doxorubicin Conjugate) Administered Every 21 Days in Patients with Advanced Gastric Adenocarcinoma” Cancer Journal 6:78-81 (2000).;;Alley et al., “Antibody-drug conjugates: targeted drug delivery for cancer” Current Opinion in Chemical Biology 14:529-537 (2010).;;Alley, S.C. et al., “Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR” 45:52 (2004).;;Almagro et al., “Humanization of antibodies” Frontiers in Bioscience 13:1619-1633 (Jan. 2008).;;Amsberry et al., “The lactonization of 2′-hydroxyhydrocinnamic acid amides: A potential prodrug for amines” J Org Chem 55:5867-5877 (1990).;;Antonow et al., “Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents” J Med Chem(53):2927-2941 (2010).;;Baca et al., “Antibody humanization using monovalent phage display” J Biol Chem 272(16):10678-10684 (1997).;;Bachur Anthracycline Antibiotics in Cancer Therapy “Free Radical Damage” Muggia et al., The Hague:Martinus Nijhoff,:97-102 (1981).;;Berson et al., “Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis,” J Cell Biol, 2003, 161:521-533.;;Boerner et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes” J Immunol 147(1):86-95 (Jul. 1991).;;Brennan et al., “Preparation of Biospecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments” Science 229(4708):81-83 (Jul. 5, 1985).;;Brodeur et al., “Mouse-human myeloma partners for the production of heterohybridomas” Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (New York: Marcel Dekker, Inc.), (1987).;;Brueggemann et al., “Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies” J. Exp. Med. 166:1351-1361 (1987).;;Burris et al., “Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy,” J Clin Oncol, 2011, 29:398-405.;;Carter and Senter, “Antibody-drug conjugates for cancer therapy” Cancer J 14(3):154-169 (2008).;;Carter et al., “Humanization of an anti-p185 HER2 antibody for human cancer therapy” P Natl Acad Sci USA 89:4285-4289 (May 1992).;;Chandra et al., “A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation” PLoS One 7(4):e34479 (Apr. 3, 2012).;;Chari et al., “Immunoconjugates containing novel maytansinoids: Promising anticancer drugs” Cancer Res 52:127-131 (1992).;;Chari, “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs” Accounts of Chemical Research 41(1):98-107 (2008).;;Charlton, K.A., “Expression and isolation of recombinant antibody fragments in E. coli” Method Molec Biol 248:245-254 (2003).;;Chen et al., “The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma,” J Biol Chem, 2012, 287:24082-24091.;;Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen” J Mol Biol. 293(4):865-81 (1999).;;Chothia and Lesk, “Canonical structures for the hypervariable regions of immunoglobulins” J Mol Biol 196(4):901-917 (1987).;;Chowdhury, “Engineering hot spots for affinity enhancement of antibodies” Methods Molec Biol 207:179-196 (2008).;;Clackson et al., “Making antibody fragments using phage display libraries” Nature 352:624-628 (Aug. 1991).;;Clynes et al., “Fc receptors are required in passive and active immunity to melanoma” Proc. Natl. Acad. Sci. USA 95:652-656 (Jan. 1998).;;Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts” Blood 101(3):1045-1052 (2003).;;Cree et al., “Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay” Anticancer Drugs 6:398-404 (1995).;;Crouch et al., “The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity” J Immunol Methods 160:81-88 (1993).;;Cunningham and Wells, “High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis” Science 24:1081-1085 (Jun. 2, 1989).;;Dall'Acqua et al., “Antibody humanization by framework shuffling” Methods 36:43-60 ( 2005).;;Doronina et al., “Development of potent monoclonal antibody auristatin conjugates for cancer therapy” Nat Biotechnol 21(7):778-784 (Jul. 2003).;;Doronina et al., “Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity” Bioconjug Chem 17(1):114-124 (Jan. 2006).;;Dubowchik and Radia, “Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles” Tetrahedron Lett 38(30):5257-5260 (1997).;;Dubowchik et al., “Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages” Bioorg Med Chem Lett 12:1529-32 (2002).;;Duncan et al., “The binding site for Clq on IgG” Nature 322:738-740 (1988).;;Fellouse et al., “Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition” P Natl Acad Sci USA 101(34):12467-12472 (Aug. 24, 2004).;;Flatman et al., “Process analytics for purification of monoclonal antibodies” J Chromatogr 848:79-87 (2007).;;Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops” J Mol Biol 224:487-499 (1992).;;Fraker and Speck, “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril” Biochem Bioph Res Co 80(4):849-857 (1978).;;Francisco et al., “cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity” Blood 102(4):1458-1465 (Aug. 15, 2003).;;Frisch et al., “Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes” Bioconj Chem 7:180-186 (1996).;;Garrett and Eng, “Cetuximab in the treatment of patients with colorectal cancer,” Expert Opin Biol Ther., 2001, 11:937-949.;;Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody” J Immunol Methods 202(2):163-171 (Mar. 28, 1997).;;Geoghegan and Stroh, “Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine” Bioconjugate Chem. 3:138-146 (1992).;;Gerngross, T. U, “Advances in the production of human therapeutic proteins in yeasts and filamentous fungi” Nat Biotech 22(11):1409-1414 (Nov. 2004).;;Goldenberg et al., “Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy,” J Clin Oncol, 2006, 24:823-834.;;Graham et al., “Characteristics of a human cell line transformed by DNA from human adenovirus type 5” J Gen Virol 36(1):59-72 (Jul. 1977).;;Grandi et al., “Novel anthracycline analogs” Cancer Treatment Reviews 17:133-138 (1990).;;Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries” EMBO J 12(2):725-735 (1993).;;Gruber et al., “Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli” J Immunol 152:5368-5374 (1994).;;Guyer et al., “Immunoglobulin binding by mouse intestinal epithelial cell receptors” J Immunol 117(2):587-593 (Aug. 1976).;;Hamann, “Monoclonal antibody—drug conjugates” Expert Opin Ther Patents 15(9):1087-1103 (2005).;;Hamblett et al., “Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate,” Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the AACR' 45:52 (2004).;;Hamblett et al., “Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate” Clin Cancer Res 10:7063-7070 (2004).;;Harper et al., “Premelanosome amyloid-like fibrils are composed of only golgi-processed forms of Pmel17 that have been proteolytically processed in endosomes,” J Biol Chem, 2008, 283:2307-2322.;;Hartley et al., “SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity” Cancer Res. 70(17):6849-6858 (2010).;;Hay et al., “A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-YL)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-DB1-TMI) for use with ADEPT and GDEPT” Bioorg Med Chem Lett 9:2237-2242 (1999).;;Herweijer and Wolff, “Progress and prospects: naked DNA gene transfer and therapy,” Gene Ther., 2003, 10:453-458.;;Hellstrom et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas” P Natl Acad Sci USA 83:7059-7063 (Sep. 1986).;;Hellstrom et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside” P Natl Acad Sci USA 82:1499-1502 (Mar. 1985).;;Hinman et al., “Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics” Cancer Res 53:3336-3342 (1993).;;Hoashi et al., “The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding,” FASEB J, 2010, 24:916-930.;;Hollinger et al., ““Diabodies”: Small Bivalent and Bispecific Antibody Fragments” Proc. Natl. Acad. Sci. USA 90:6444-6448 (Jul. 1993).;;Holmes et al., “Identification of Heregulin, A Specific Activator of p185erbB2” Science 256:1205-1210 (May 22, 1992).;;Hoogenboom et al., “By-passing Immunisation; Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro” J Mol Biol 227:381-388 (1992).;;Hoogenboom et al., “Overview of antibody phage-display technology and its applications” Methods Mol Biol 178:1-37 ( 2002).;;Hongo et al., “Characterization of novel neutralizing monoclonal antibodies specific to human neurturin” Hybridoma, 2000, 19:303-315.;;Howard et al., “Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate” Bioorg Med Chem Lett 19(22):6463-6466 (2009).;;Hudson et al., “Engineered antibodies” Nature Medicine 9(1):129-134 (Jan. 2003).;;Hurley et al., “Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines” Acc Chem Res 19:230-237 ( 1986).;;Idusogie et al., “Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc” J Immunol 164(8):4178-4184 (2000).;;Iyer & Kadambi, “Antibody drug conjugates—Trojan horses in the war on cancer” Journal of Pharmacological and Toxicological Methods 64:207-212 (2011).;;Jeffrey et al., “Dipeptide-based highly potent doxorubicin antibody conjugates” Bioorganic Med Chem Letters 16:358-362 (2006).;;Kam et al., “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction” P Natl Acad Sci USA 102(33):11600-11605 (Aug. 2005).;;Kanda et al., “Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC” Biotechnol Bioeng 94(4):680-688 (Jul. 5, 2006).;;Kashmiri et al., “SDR grafting—a new approach to antibody humanization” Methods 36:25-34 (2005).;;Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor” Eur. J. Immunol. 24:2429-2434 (1994);;Kindt et al. Kuby Immunology “Antigens and Antibodies Chapter 4” 6th ed edition, N.Y.:W.H. Freeman and Co,:p. 91 (2007).;;King et al., “Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains” Journal of Medical Chemistry 45:4336-4343 (2002).;;Kingsbury et al., “A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil” J Med Chem 27:1447-1451 (1984).;;Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning” Br J Cancer 83(2):252-260 (2000).;;Klussman et al., “Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway” Bioconjugate Chem 15:765-773 (2004).;;Kohler et al., “Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours” Hum Mol Genet 17(13):1978-1987 (2008).;;Kohn Antibiotics “Anthramycin” Corcoran et al., New York, NY:Springer-Verlag, vol. 3:3-11 (1975).;;Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers” J Immunol. 148:1547-1553 (Mar. 1, 1992).;;Kozbor et al., “A human hybrid myeloma for production of human monoclonal antibodies” J Immunol 133(6):3001-3005 (Dec. 1984).;;Kratz et al., “Prodrugs of anthracyclines in cancer chemotherapy” Curr Med Chem 13:477-523 (2006).;;Kummer et al., “Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase,” J Biol Chem., 2009, 284:2296-2306.;;Lee et al., “Bivalent antibody phage display mimics natural immunoglobulin” J Immunol Methods 284(1-2):119-132 ( 2004).;;Lee et al., “High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold”J Mol Biol 340(5):1073-1093 (2004).;;Leimgruber et al., “Isolation and characterization of anthramycin, a new antitumor antibiotic” J Am Chem Soc 87(24):5791-5793 (1965).;;Leimgruber et al., “The structure of anthramycin” J Am Chem Soc 87(24):5793-5795 (1965).;;Leonhardt et al., “Proprotein convertases process Pmel17 during secretion,” J Biol Chem., 2011, 286:9321-9337.;;Leonhardt et al., “Endoplasmic reticulum export, subcellular distribution, and fibril formation by Pmel17 require an intact N-terminal domain junction” J Biol Chem, 2010, 285:16166-1683.;;Li et al., “Human antibodies for immunotherapy development generated via a human B cell hybridoma technology” Proc Natl Acad Sci USA 103:3557-3562 (2006).;;Li et al., “Optimization of humanized IgGs in glycoengineered Pichia pastoris” Nat Biotechnol 24(2):210-215 (Feb. 2006).;;Liang et al., “Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library” J. Mol. Biol. 366:815-829 (2007).;;Liu et al., “Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids.” P Natl Acad Sci USA 93:8618-8623 (1996).;;Liu et al., “Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA,” Gene Ther, 1999, 6:1258-1266.;;Lode et al., “Targeted therapy with a novel enediyene antibiotic calicheamicin V11 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma” Cancer Res 58:2925-2928 (1998).;;Lonberg, “Fully human antibodies from transgenic mouse and phage display platforms” Current Opin Immunol 20:450-459 (2008).;;Lonberg, N., “Human antibodies from transgenic animals” Nat Biotechnol 23(9):1117-11125 (2005).;;Lyon et al., “Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues” Methods Enzymol 502:123-138 (2012).;;MacCallum et al. et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography” J Mol Biol 262:732-745 (1996).;;Mandler et al., “Immunoconjugates of geldanamycin and Anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines” J National Cancer Institute 92(19):1573-1581 (Oct. 4, 2000).;;Mandler et al., “Modifications in synthesis strategy improve the yield and efficacy of geldanamycin—herceptin immunoconjugates” Bioconjugate Chem 13:786-791 (2002).;;Mandler et al., “Synthesis and Evaluation of Antiproliferative Activity of a Geldanamycin-Herceptin(tm) Immunoconjugate” Bioorg Med Chem Lett 10:1025-1028 (2000).;;Marks et al., “By-passing immunization, Human antibodies from V-gene libraries displayed on phage” J. Mol. Biol. 222:581-597 (1991).;;Marks et al., “Selection of human antibodies from phage display libraries” Methods Mol Biol. 248:161-76 (2004).;;Mather et al., “Culture of testicular cells in hormone-supplemented serum-free medium” Ann NY Acad Sci 383:44-68 (1982).;;Mather, “Establishment and characterization of two distinct mouse testicular epithelial cell lines” Biol Reprod 23:243-252 (1980).;;McCafferty et al., “Phage Antibodies: Filamentous Phage Displaying Antibody Variable Domains” Nature 348:552-554 (Dec. 1990).;;McDonagh et al., “Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment” Protein Eng Des Sel. 19(7):299-307 (2006).;;Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry” Nature 305:537-540 (Oct. 6, 1983).;;Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains” P Natl Acad Sci USA 81:6851-6855 (Nov. 1984).;;Nagy et al., “Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: implications for the design of preclinical studies” P Natl Acad Sci USA 97(2):829-34 (Jan. 18, 2000).;;Neuberger et al., “Recombinant Antibodies Possessing Novel Effector Functions” Nature 312:604-608 (Dec. 13, 1984).;;Ni, “Research progress and future perspectives in antibodomics and antibodomic drugs” Xiandai Mianyixue ((Abstract only)), 26(4):265-168 (2006).;;Nichols et al., “A Novel Splice Variant of Pmel17 Expressed by Human Melanocytes and Melanoma Cells Lacking Some of the Internal Repeats,” J Invest Dermatol, 2003, 121:821-830.;;Okazaki et al., “Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FycγRIIIa” J Molec Biol 336:1239-1249 (2004).;;Osbourn et al., “From rodent reagents to human therapeutics using antibody guided selection” Methods 36:61-68 (2005).;;Pacciarini et al., “Phase I/II trial of nemorubicin hydrochloride in combination with cisplatin is supported by new preclinical evidences of its mechanism of action” J Clin Oncol (Abstract from 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)), 24( Suppl 185):14116 (Jun. 20, 2006).;;Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties” Mol Immunol 28(4/4):489-498 (1991).;;Peterson et al. Anthracycline Antibiotics in Cancer Therapy “Transport and Storage of Anthracyclines in Experimental Systems and Human Leukemia” Muggia et al., The Hague:Martinus Nijhoff,:132-146 (1981).;;Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease” Int Immunol 18(12):1759-69 (Dec. 2006).;;Pettit et al., “Dolastatins 24: synthesis of (−)-dolastatin 101 X-ray molecular structure of N,N-dimethylvalyl-valyl-dolaisoleuine tert-butyl ester” J Chem Soc Perkins Trans 1:859-863 (1996).;;Pettit et al., “Specific activities of dolastatin 10 and peptide derivatives against cryptococcus neoformans” Antimicrob Agents and Chemotherapy 42(11):2961-2965 (Nov. 1998).;;Pettit et al., “The absolute configuration and synthesis of natural (−)-Dolastatin 101” J Am Chem Soc 111:5463-5465 (1989).;;Pettit et al., “The dolastatins; 18: stereospecific synthesis of dolaproine” Synthesis:719-725 (Jun. 1996).;;Pluckthun, A. The Pharmacology of Monoclonal Antibodies: Handbook of Pharmacology “Antibodies from Escherichia coli” (Chapter 11), Rosenberg and Moore, eds., Berlin:Springer-Verlag, vol. 113:269-315 (1994).;;Polakis, “Arming antibodies for cancer therapy” Curr Opin Pharm 5:382-387 (2005).;;Portolano et al., “Lack of promiscuity in autoantigen-specific H and L chain combinations as revealed by human H and L chain ‘Roulette’” J Immunol 150(3):880-887 (Feb. 1993).;;Presta et al., “Humanization of an Antibody Directed Against IgE” J Immunol 151(5):2623-2632 (Sep. 1, 1993).;;Presta et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders” Cancer Res 57:4593-4599 (Oct. 1997).;;Queen et al., “A humanized antibody that binds to the interleukin 2 receptor” P Natl Acad Sci USA 86(24):10029-10033 (Dec. 1989).;;Quintieri et al., “Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes” Clin Cancer Res 11:1608-17 (Feb. 15, 2005).;;Quintieri et al., “In vitro cytotoxicity, cell cycle effects and DNA-binding properties of PNU-159682” Abstract (Abs #4649) Proceedings of the American Association of Cancer Research, pp. 925 (2003).;;Raposo et al., “Distinct protein sorting and localization to premelanosomes, melanosomes, and lysosomes in pigmented melanocytic cells,” J Biol Chem, 2001, 152:809-824.;;Raposo and Marks, “Melanosomes—dark organelles enlighten endosomal membrane transport,” Nat Rev Mol Cell Biol, 2007, 8:786-797.;;Ravetch and Kinet, “Fc receptors” Ann Rev Immunol 9:457-492 (1991).;;Remington's Pharmaceutical Sciences (Table of Contents), Osol, 16 edition, Easton, PA:Mack Publishing Company,:TOC (1980).;;Ricart & Tolcher, “Technology Insight: cytotoxic drug immunoconjugates for cancer therapy” Nature Clinical Practice 4(4):245-255 (2007).;;Riechmann et al., “Reshaping human antibodies for therapy” Nature 332:323-327 (Mar. 1988).;;Ripamonti et al., “In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells” Br J Cancer 65(5):703-707 (1992).;;Ripka et al., “Two chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose” Arch Biochem Biophys 249(2):533-545 (Sep. 1986).;;Rodrigues et al., “Synthesis and β-lactamase-mediated activation of a cephalosporin-taxol prodrug” Chem Biol 2:223-227 (Apr. 1995).;;Robila et al., “MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes,” J Immunol, 2008, 181:7843-7852.;;Rosok et al., “A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab” J Biol Chem 271(37):22611-22618 (Sep. 13, 1996).;;Saleh et al., “Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors” J Clin Oncol 18(11):2282-2292 (2000).;;Schallreuter et al., “Regulation of melanogenesis—controversies and new concepts,” Exper Dermatol, 2008, 17:395-404.;;Shields et al. et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R” J Biol Chem 276(9):6591-6604 (Mar. 2, 2001).;;Sidhu et al., “Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions” J Mol Biol 338(2):299-310 (2004).;;Sims et al., “A Humanized CD18 Antibody Can Block Function without Cell Destruction” J. Immunol. 151(4):2296-2308 (Aug. 1993).;;Somers et al., “The X-ray structure of a growth hormone-prolactin receptor complex” Nature 372:478-481 (1994).;;Storm et al., “Effect of small changes in orientation on reaction rate” J Am Chem Soc 94:5815-5825 (1972).;;Sun et al., “Enabling ScFvs as multi-drug carriers: a dendritic approach” Bioorg Med Chem 11:1761-1768 (2003).;;Sun et al., “Phase I and pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unrestectable hepatocellular carcinoma (HCC)” Abstract (Abs #1448) 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, pp. 361 (May 31, 2003).;;Sun et al., “Syntheses of dendritic linkers containing chlorambucil residues for the preparation of antibody-multidrug immunoconjugates” Bioorg Med Chem Lett 12:2213-2215 (2002).;;Teicher, “Antibody-Drug Conjugate Targets” Current Cancer Drug Targets 9:982-1004 (2009).;;Theos et al. “The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function,” Pigment Cell Res., 2005, 18:322-336.;;Theos et al., “Dual loss of ER export and endocytic signals with altered melanosome morphology in the silver mutation of Pmel17,” Mol Biol Cell, 2006, 17:3598-3612.;;Thurston and Bose, “Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines” Chem Rev 94:433-465 (1994).;;Tijink et al., “A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus,” Clin Cancer Res, 2006, 12:6064-6072.;;Toki et al., “Protease-mediated fragmentation of p-amidobenzyl ethers: A new strategy for the activation of anticancer prodrugs” J Org Chem 67:1866-1872 (2002).;;Tolcher et al., “Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer” J Clin Oncol 17(2):478-484 (1999).;;Torgov et al., “Generation of an intensely potent anthracycline by a monoclonal antibody—β-galactosidase conjugate” Bioconjugate Chem 16:717-21 (2005).;;Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells” EMBO J 10(12):3655-3659 (1991).;;Tutt et al., “Trispecific F(ab′) 3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells” J Immunol 147(1):60-69 (Jul. 1991).;;Uong and Zon, “Melanocytes in development and cancer,” J Cell Physiol, 2010, 222:38-41.;;Urlaub et al., “Isolation of chinese hamster cell mutants deficient in dihydrofolate reductase activity” P Natl Acad Sci USA 77(7):4216 (Jul. 1980).;;Vachtenheim and Borovansky, “‘Transcription physiology’ of pigment formation in melanocytes: central role of MITF,” Exp Dermatol, 2010, 19:617-627.;;Valencia et al., “Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes,” J Cell Sci, 2006, 119:1080-1091.;;Van Dijk and van de Winkel, “Human antibodies as next generation therapeutics” Curr Opin Chem Biol 5(4):368-74 (Aug. 2001).;;Van Dongen et al., “Immuno-PET: A navigator in monoclonal antibody development and applications” Oncologist 12:1379-1389 (2007).;;Verel et al., “89Zr Immuno-PET: Comprehensive Procedures for the production of 89Zr-labeled monoclonal antibodies” J Nucl Med 44(8):1271-1281 (Aug. 2003).;;Vollmers and Brandlein, “Death by stress: natural IgM-induced apoptosis” Methods Find Exp Clin Pharmacol 27(3):185-191 (2005).;;Vollmers and Brandlein, “The ‘early birds’: Natural IgM antibodies and immune surveillance” Histol Histopathol 20:927-937 (2005).;;Walker, M., “A high yielding synthesis of N-Alkyl maleimides using a novel modification of the Mitsunobu reaction” J Org Chem 60:5352-5355 (1995).;;Watt et al., “N-terminal domains elicit formation of functional Pmel17 amyloid fibrils,” J Biol Chem, 2009, 284:35543-35555.;;Wicki et al., “Kras in metastatic colorectal cancer” Swiss Med Wkly 140:w13112 (2010).;;Widdison et al., “Semisynthetic Maytansine Analogues for the Targeted Treatment of Cancer” J Med Chem 49:4392-4408 (2006).;;Wilhite and Barrett, “Strategies to explore functional genomics data sets in NCBI's GEO database,” Methods Mol Biol., 2012, 802:41-53.;;Winter et al., “Making antibodies by phage display technology” Annu Rev Immunol 12:433-455 (1994).;;Woyke et al., “In vitro activities and postantifungal effects of the potent dolastatin 10 derivative auristatin PHE” Antimicrob Agents Chemother 45(12):3580-3584 (Dec. 2001).;;Wright and Morrison, “Effect of glycosylation on antibody function: Implications for genetic engineering” Trends Biotechnol 15:26-32 (1997).;;Wu and Kabat, “An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity” J Exp Med 132(2):211-250 (1970).;;Yamaguchi and Hearing, “Physiological factors that regulate skin pigmentation,” Biofactors, 2009, 35:193-199.;;Yamane-Ohnuki et al., “Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity” Biotechnol Bioeng 87(5):614-622 (Sep. 5, 2004).;;Yasumoto et al., “Epitope mapping of the melanosomal matrix protein gp100 (PMEL17): rapid processing in the endoplasmic reticulum and glycosylation in the early Golgi compartment” J Biol Chem., 2004, 279:28330-28338.;;Yazaki and Wu Methods in Molecular Biology Lo, B.K.C. (ed.), Totowa, Nj:Humana Press, vol. 248:255-268 (2004).;;Younes et al., “Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas,” N Engl J Med., 2010, 363:1812-1821.;;Younes et al., “Brentuximab vedotin,” Nat Rev Drug Discov, 2012, 11:19-20.;;Yokota, “Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?” Anticancer Agents Med Chem 12(2):163-171 (2012).;;Yu et al., “The biosynthetic gene cluster of the maytansinoid antitumor agent ansamitocin from Actinosynnema pretiosum” P Natl Acad Sci USA 99(12):7968-7973 (Jun. 11, 2002).;;Zhang et al., “High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA,” Hum Gene Ther, 1999, 10:1735-1737.;;Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, for PCT/US2013/038742, dated Jul. 15, 2013, 8 pages.;;International Search Report and Written Opinion for PCT/US2013/038742, dated Sep. 23, 2013, 19 pages.;;Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295.;;Rudikoff et al., Proc. Natl. Acad. Sci. USA, 1982 vol. 79, p. 1979.;;Pascalis et al., The Journal of Immunology, 2002, 169, 3076-3084.;;Casset et al. (2003) BBRC 307, 198-205.;;Brown et al., J. Immunol., May 1996; 156(9): 3285-3291.;;Vajdos et al., J. Mol. Biol., Jul. 5, 2002; 320(2): 415-428.;;Klein et al., “Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties,” mAbs, 5(1): 22-33 (2013).",ACTIVE
382,WO,A1,WO 2013/165940 A1,008-350-488-667-301,2013-11-07,2013,US 2013/0038742 W,2013-04-30,US 201261641074 P;;US 201261678911 P,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC;;CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/008-350-488-667-301,Patent Application,yes,169,64,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48;;C07K16/28;;C07K16/30,,184,144,069-699-907-490-85X;;091-742-909-539-31X;;111-654-430-040-748;;125-541-153-996-289;;049-134-753-209-354;;051-208-529-712-079;;002-490-451-363-036;;015-239-659-590-870;;001-779-867-387-972;;044-522-255-085-902;;107-783-742-795-839;;030-607-398-087-475;;042-204-626-457-327;;030-323-674-660-051;;064-667-501-146-970;;022-023-983-891-895;;006-338-973-732-491;;004-601-819-239-79X;;009-746-604-420-355;;093-067-181-692-392;;009-483-512-107-343;;069-144-826-896-138;;015-395-754-996-662;;106-032-800-597-23X;;003-570-249-164-056;;010-953-281-569-514;;048-564-471-521-204;;003-984-734-905-938;;170-311-024-328-514;;006-895-260-696-111;;107-330-806-519-859;;034-345-578-106-977;;030-630-100-818-462;;034-331-211-704-877;;020-855-322-534-259;;005-283-943-871-819;;079-666-119-599-514;;039-981-636-470-013;;054-876-950-584-376;;022-133-574-143-973;;072-378-691-723-546;;032-071-991-081-664;;117-775-899-628-564;;031-063-853-127-197;;005-112-559-456-657;;104-212-297-137-759;;035-232-534-898-963;;022-375-749-274-329;;018-694-084-068-187;;012-268-510-926-843;;037-445-639-149-821;;009-275-403-380-31X;;156-501-805-490-709;;116-831-294-654-564;;022-725-321-473-914;;017-695-622-077-055;;008-274-774-541-556;;070-280-057-407-994;;013-584-945-188-940;;012-900-923-946-056;;020-126-213-879-311;;054-717-629-774-351;;068-264-897-850-380;;011-842-849-963-456;;060-301-220-665-473;;020-126-164-125-029;;035-796-690-562-525;;008-587-496-850-953;;065-430-968-783-392;;021-430-782-622-770;;051-940-176-386-905;;016-716-200-807-517;;092-890-446-683-93X;;046-783-448-716-481;;083-071-649-888-913;;029-806-225-784-498;;047-094-213-620-162;;065-684-269-783-203;;004-272-966-072-139;;066-617-857-912-127;;072-389-563-856-866;;023-343-819-824-657;;068-257-624-898-885;;116-075-018-919-051;;061-295-123-907-192;;023-607-007-385-464;;017-653-724-773-187;;031-120-105-336-16X;;120-079-078-809-391;;105-030-562-969-986;;039-841-667-603-953;;099-070-305-531-124;;065-684-269-783-203;;037-531-283-684-284;;019-837-369-326-225;;065-684-269-783-203;;093-183-016-210-781;;003-280-353-877-595;;004-272-966-072-139;;014-234-489-298-615;;025-595-011-959-317;;017-653-724-773-187;;022-932-029-853-743;;088-507-053-804-367;;023-254-173-733-304;;056-118-200-157-615;;004-272-966-072-139;;004-272-966-072-139;;002-495-630-767-098;;027-670-963-287-976;;011-012-284-651-080;;071-273-910-767-454;;009-709-621-617-333;;049-755-438-917-969;;086-569-845-269-420;;051-719-785-727-477;;051-576-528-777-865;;061-970-204-106-123;;079-144-966-327-175;;004-850-131-529-307;;065-996-283-702-791;;018-221-719-733-102;;117-906-457-481-371;;001-887-288-192-781;;110-132-259-167-081;;006-520-672-611-427;;071-328-232-469-698;;005-813-390-127-218;;016-155-290-797-107;;018-526-825-169-143;;020-544-118-938-442;;093-015-402-032-976;;016-599-925-793-124;;060-265-896-490-751;;095-843-764-156-972;;113-394-540-007-150;;011-249-580-357-420;;090-760-098-651-81X;;085-634-291-486-854;;013-954-482-377-715;;019-662-268-310-070;;049-691-363-334-629;;041-984-511-767-425;;089-461-397-670-986,15096515;;10.1074/jbc.m401269200;;14632201;;10.1046/j.1523-1747.2003.12474.x;;pmc2793674;;16492709;;10.1242/jcs.02804;;pmc4629779;;10.1074/jbc.m112.361485;;pmc3397835;;22613716;;10.1016/0022-2836(87)90412-8;;3681981;;17981654;;10.2741/2786;;17161664;;10.1016/j.jchromb.2006.11.018;;10.4049/jimmunol.150.3.880;;8423344;;10.1006/jmbi.1999.3192;;10543973;;9377574;;12514726;;10.1038/nm0103-129;;pmc392030;;10.1073/pnas.81.21.6851;;6436822;;3127726;;10.1038/332323a0;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;15848072;;10.1016/j.ymeth.2005.01.003;;10.1016/0161-5890(91)90163-e;;1905784;;15848074;;10.1016/j.ymeth.2005.01.005;;15848075;;10.1016/j.ymeth.2005.01.006;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;7688398;;10.4049/jimmunol.151.4.2296;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;8360482;;10.4049/jimmunol.151.5.2623;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;18606226;;10.1016/j.coi.2008.06.004;;10.1038/nbt1135;;16151405;;10.4049/jimmunol.133.6.3001;;6092464;;10.4049/jimmunol.147.1.86;;2051030;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;15944943;;10.14670/hh-20.927;;10.1358/mf.2005.27.3.890876;;15834451;;11968478;;10.1385/1-59259-240-6:001;;10.1038/348552a0;;2247164;;10.1038/352624a0;;1907718;;1748994;;10.1016/0022-2836(91)90498-u;;15066433;;10.1016/j.jmb.2004.02.050;;15236968;;10.1016/j.jmb.2004.05.051;;15306681;;10.1073/pnas.0401786101;;pmc515084;;14736422;;10.1016/j.jim.2003.11.001;;10.1146/annurev.iy.12.040194.002245;;10.1146/annurev.immunol.12.1.433;;8011287;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.1016/0022-2836(92)90894-p;;1404359;;10.1038/305537a0;;6137772;;pmc453097;;1834458;;10.1002/j.1460-2075.1991.tb04932.x;;10.1126/science.3925553;;3925553;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.152.11.5368;;8189055;;1675655;;10.4049/jimmunol.147.1.60;;10.1126/science.2471267;;2471267;;15037082;;10.3410/f.1020100.229441;;10.1016/j.jmb.2004.01.007;;10.1016/0003-9861(86)90031-7;;2428310;;16609957;;10.1002/bit.20880;;10.1146/annurev.immunol.9.1.457;;10.1146/annurev.iy.09.040191.002325;;1910686;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1182/blood-2002-06-1761;;12393541;;14551143;;10.1182/blood-2003-06-2031;;17077181;;10.1093/intimm/dxl110;;10.4049/jimmunol.164.8.4178;;10754313;;10.4049/jimmunol.117.2.587;;950463;;3258649;;10.1038/332738a0;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;14970501;;10.1385/1-59259-666-5:245;;10.1038/nbt1028;;15529166;;886304;;10.1099/0022-1317-36-1-59;;10.1095/biolreprod23.1.243;;6774781;;10.1111/j.1749-6632.1982.tb23161.x;;7046561;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;10.1016/j.coph.2005.04.008;;15951239;;20025606;;10.2174/156800909790192365;;18536555;;10.1097/ppo.0b013e318172d704;;10.1021/ar700108g;;17705444;;22208984;;10.1016/b978-0-12-416039-2.00006-9;;15264863;;10.1021/bc049969t;;1727373;;10.1038/nbt832;;12778055;;10.1517/13543776.15.9.1087;;10.1016/s0960-894x(99)00381-9;;10465553;;9383424;;10.1016/1074-5521(95)90272-4;;10.1021/jo00310a019;;6387121;;10.1021/jm00377a012;;10.1016/s0960-894x(02)00361-x;;12127540;;10.1016/s0968-0896(03)00057-9;;12659762;;10.1016/b978-1-4832-2819-8.50009-x;;10.1021/jo016187+;;11895404;;10.1016/s0040-4039(97)01158-1;;10.1021/jo00121a070;;8983339;;10.1021/bc950092v;;10.1073/pnas.092697199;;pmc123004;;12060743;;1727373;;pmc38722;;10.1073/pnas.93.16.8618;;8710920;;16821799;;10.1021/jm060319f;;1727373;;11709343;;pmc90872;;10.1128/aac.45.12.3580-3584.2001;;9797233;;pmc105973;;10.1128/aac.42.11.2961;;10.1038/nbt832;;12778055;;10.1182/blood-2003-01-0039;;12714494;;10.1021/bc0502917;;16417259;;10.1021/bc0502917.s001;;10.1016/b978-1-4832-2819-8.50009-x;;10.1021/ja00196a061;;9627667;;10.1055/s-1996-4296;;10.1039/p19960000859;;10.1038/nbt832;;12778055;;10.1038/nbt832;;12778055;;8324745;;9679947;;10.1021/ja00952a051;;5845428;;10.1021/ja00952a050;;5845427;;10.1021/ar00128a001;;10.1158/0008-5472.can-10-0790;;20660714;;pmc3533126;;20218628;;10.1021/jm901722v;;10.1016/j.bmcl.2009.09.012;;19811912;;10.1007/978-94-009-7630-6_8;;10.2174/092986706776055751;;16515518;;10.1016/j.bmcl.2005.09.081;;16275070;;10.1021/bc050039z;;15898742;;10639165;;10.1073/pnas.97.2.829;;pmc15416;;10.1016/s0960-894x(02)00194-4;;12031335;;12213074;;10.1021/jm020149g;;10.1200/jco.2000.18.11.2282;;10829049;;11069223;;10080588;;10.1200/jco.1999.17.2.478;;10.1158/1078-0432.ccr-04-1845;;15746066;;10.1016/0305-7372(90)90037-g;;2272029;;1586598;;pmc1977399;;10.1038/bjc.1992.148;;11018093;;10.1093/jnci/92.19.1573;;10.1016/s0960-894x(00)00155-4;;10843208;;12121134;;10.1021/bc010124g;;10.1038/312604a0;;6095112;;16644914;;10.1093/protein/gzl013;;10.1158/1078-0432.ccr-04-0789;;15501986;;10.1021/bc00014a008;;1325188;;18165614;;10.1634/theoncologist.12-12-1379;;12902418;;7680699;;10.1016/0022-1759(93)90011-u;;10.1097/00001813-199506000-00006;;7670137;;12621449;;10.1038/sj.gt.3301983;;10.1038/sj.gt.3300947;;10455434;;10.1089/10430349950017734;;10428218;;11001403;;10.1089/027245700429855,"K.-I. YASUMOTO: ""Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17): RAPID PROCESSING IN THE ENDOPLASMIC RETICULUM AND GLYCOSYLATION IN THE EARLY GOLGI COMPARTMENT"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 27, 27 April 2004 (2004-04-27), pages 28330 - 28338, XP055068483, ISSN: 0021-9258, DOI: 10.1074/jbc.M401269200;;SARAH E. NICHOLS ET AL: ""A Novel Splice Variant of Pmel17 Expressed by Human Melanocytes and Melanoma Cells Lacking Some of the Internal Repeats"", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 121, no. 4, 1 October 2003 (2003-10-01), pages 821 - 830, XP055068530, ISSN: 0022-202X, DOI: 10.1046/j.1523-1747.2003.12474.x;;VALENCIA J C ET AL: ""Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes"", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 119, 1 March 2006 (2006-03-01), pages 1080 - 1091, XP002480326, ISSN: 0021-9533, DOI: 10.1242/JCS.02804;;Y. CHEN ET AL: ""The Melanosomal Protein PMEL17 as a Target for Antibody Drug Conjugate Therapy in Melanoma"", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 29, 13 July 2012 (2012-07-13), pages 24082 - 24091, XP055068112, ISSN: 0021-9258, DOI: 10.1074/jbc.M112.361485;;AGNEW, CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;KABAT ET AL.: ""Sequences ofProteins of Immunological Interest, 5th Ed."", 1991, NATIONAL INSTITUTES OF HEALTH;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th Ed."", vol. 1-3, 1991, NIH PUBLICATION 91-3242;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;KABAT ET AL.: ""Sequences of Proteins of Immunological Interest, 5th Ed."", 1991, NATIONAL INSTITUTES OF HEALTH;;ALMAGRO; FRANSSON, FRONT. BIOSCI., vol. 13, 2008, pages 1619 - 1633;;FLATMAN ET AL., J. CHROMATOGR. B, vol. 848, 2007, pages 79 - 87;;KINDT ET AL.: ""Kuby Immunology, 6th ed.,"", 2007, W.H. FREEMAN AND CO., pages: 91;;PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887;;CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;PAQUETTE, LEO A.: ""Principles of Modern Heterocyclic Chemistry"", 1968, W.A. BENJAMIN;;""The Chemistry of Heterocyclic Compounds, A series of Monographs"", vol. 13, 14,, 1950, JOHN WILEY & SONS;;J. AM. CHEM. SOC., vol. 82, 1960, pages 5566;;S. P. PARKER,: ""McGraw-Hill Dictionary of Chemical Terms"", 1984, MCGRAW-HILL BOOK COMPANY;;ELIEL, E.; WILEN, S.: ""Stereochemistry of Organic Compounds"", 1994, JOHN WILEY & SONS, INC.;;T. W. GREENE: ""Protective Groups in Organic Synthesis"", 1991, JOHN WILEY & SONS;;CHEN ET AL., J. MOL. BIOL., vol. 293, 1999, pages 865 - 881;;PRESTA ET AL., CANCER RES., vol. 57, 1997, pages 4593 - 4599;;HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134;;PLUCKTHIIN: ""The Pharmacology of Monoclonal Antibodies"", vol. 113, 1994, SPRINGER-VERLAG, pages: 269 - 315;;HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448;;MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;QUEEN ET AL., PROC. NAT'1 ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033;;KASHMIRI ET AL., METHODS, vol. 36, 2005, pages 25 - 34;;PADLAN, MOL. IMMUNOL., vol. 28, 1991, pages 489 - 498;;DALL'ACQUA ET AL., METHODS, vol. 36, 2005, pages 43 - 60;;OSBOURN ET AL., METHODS, vol. 36, 2005, pages 61 - 68;;KLIMKA ET AL., BR. J. CANCER, vol. 83, 2000, pages 252 - 260;;SIMS ET AL., J IMMUNOL., vol. 151, 1993, pages 2296;;CARTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285;;PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623;;BACA ET AL., J. BIOL. CHEM., vol. 272, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 22611 - 22618;;VAN DIJK AND VAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 74;;LONBERG, CURR. OPIN. IMMUNOL., vol. 20, 2008, pages 450 - 459;;LONBERG, NAT. BIOTECH., vol. 23, 2005, pages 1117 - 1125;;KOZBORJ., IMMUNOL., vol. 133, 1984, pages 3001;;BRODEUR ET AL.: ""Monoclonal Antibody Production Techniques and Applications"", 1987, MARCEL DEKKER, INC., pages: 51 - 63;;BOERNER ET AL., J. IMMUNOL., vol. 1'47, 1991, pages 86;;LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562;;NI, XIANDAI MIANYIXUE, vol. 26, no. 4, 2006, pages 265 - 268;;VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, vol. 20, no. 3, 2005, pages 927 - 937;;VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol. 27, no. 3, 2005, pages 185 - 91;;HOOGENBOOM ET AL.: ""Methods in Molecular Biology"", vol. 178, 2001, HUMAN PRESS, pages: 1 - 37;;MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554;;CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628;;MARKS ET AL., J. MOL. BIOL., vol. 222, 1992, pages 581 - 597;;MARKS; BRADBURY: ""Methods in Molecular Biology"", vol. 248, 2003, HUMAN PRESS, pages: 161 - 175;;SIDHU ET AL., J. MOL. BIOL., vol. 338, no. 2, 2004, pages 299 - 310;;LEE ET AL., J. MOL. BIOL., vol. 340, no. 5, 2004, pages 1073 - 1093;;FELLOUSE, PROC. NATL. ACAD. SCI. USA, vol. 101, no. 34, 2004, pages 12467 - 12472;;LEE ET AL., J. IMMUNOL. METHODS, vol. 284, no. 1-2, 2004, pages 119 - 132;;WINTER ET AL., ANN. REV. IMMUNOL., vol. 12, 1994, pages 433 - 455;;GRIFFITHS ET AL., EMBO J, vol. 12, 1993, pages 725 - 734;;HOOGENBOOM; WINTER, J. MOL. BIOL., vol. 227, 1992, pages 381 - 388;;MILSTEIN; CUELLO, NATURE, vol. 305, 1983, pages 537;;TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655;;BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81;;KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553;;GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368;;TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60;;CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196;;CUNNINGHAM; WELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085;;WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32;;OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249;;YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614;;RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS, vol. 249, 1986, pages 533 - 545;;KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688;;RAVETCH; KINET, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 457 - 492;;HELLSTROM, I. ET AL., PROC. NAT'L ACAD SCI. USA, vol. 83, 1986, pages 7059 - 7063;;HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502;;BRUGGEMANN, M. ET AL., J. EXP. MED, vol. 166, 1987, pages 1351 - 1361;;CLYNES ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 95, 1998, pages 652 - 656;;GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163;;CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052;;CRAGG, M.S.; M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743;;PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769;;SHIELDS ET AL., J. BIOL. CHEM., vol. 9, no. 2, 2001, pages 6591 - 6604;;IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184;;GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587;;KIM ET AL., J. IMMUNOL., vol. 24, 1994, pages 249;;DUNCAN; WINTER, NATURE, vol. 322, 1988, pages 738 - 40;;KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605;;CHARLTON: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 245 - 254;;GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414;;LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215;;GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59;;MATHER, BIOL. REPROD, vol. 23, 1980, pages 243 - 251;;MATHER ET AL., ANNALS N Y ACAD. SCI., vol. 383, 1982, pages 44 - 68;;URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216;;YAZAKI; WU: ""Methods in Molecular Biology"", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268;;MORRIS: ""Methods in Molecular Biology"", vol. 66, 1996, HUMANA PRESS, article ""Epitope Mapping Protocols"";;HARLOW; LANE: ""Antibodies: A Laboratory Manual"", 1988, COLD SPRING HARBOR LABORATORY;;POLAKIS P., CURRENT OPINION IN PHARMACOLOGY, vol. 5, 2005, pages 382 - 387;;TEICHER, B.A., CURRENT CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004;;CARTER, P.J.; SENTER P.D., THE CANCER JOUR., vol. 14, no. 3, 2008, pages 154 - 169;;CHARI, RV., ACC. CHEM. RES., vol. 41, 2008, pages 98 - 107;;LYON, R. ET AL., METHODS IN ENZYM., vol. 502, 2012, pages 123 - 138;;KLUSSMAN ET AL., BIOCONJUGATE CHEMISTRY, vol. 15, no. 4, 2004, pages 765 - 773;;CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 131;;DORONINA ET AL., NAT. BIOTECHNOL., vol. 21, 2003, pages 778 - 784;;HAMANN ET AL., EXPERT OPIN. THER. PATENTS, vol. 15, 2005, pages 1087 - 1103;;HAY ET AL., BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2237;;RODRIGUES ET AL., CHEMISTRY BIOLOGY, vol. 2, 1995, pages 223;;STORM ET AL., J AMER. CHEM. SOC., vol. 94, 1972, pages 5815;;AMSBERRY ET AL., J ORG. CHEM., vol. 55, 1990, pages 5867;;KINGSBURY ET AL., J MED. CHEM., vol. 27, 1984, pages 1447;;SUN ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 2213 - 2215;;SUN ET AL., BIOORGANIC & MEDICINAL CHEMISTRY, vol. 11, 2003, pages 1761 - 1768;;E. SCHRODER; K. LÜBKE: ""The Peptides"", vol. 1, 1965, ACADEMIC PRESS, pages: 76 - 136;;TOKI ET AL., J. ORG. CHEM., vol. 67, 2002, pages 1866 - 1872;;DUBOWCHIK ET AL., TETRAHEDRON LETTERS, vol. 38, 1997, pages 5257 - 60;;WALKER, M.A., J ORG. CHEM., vol. 60, 1995, pages 5352 - 5355;;FRISCH ET AL., BIOCONJUGATE CHEM., vol. 7, 1996, pages 180 - 186;;YU ET AL., PNAS, vol. 99, 2002, pages 7968 - 7973;;CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131;;LIU ET AL., PROC. NATL. ACAD. SCI USA, vol. 93, 1996, pages 8618 - 8623;;WIDDISON ET AL., J. MED. CHEM., vol. 49, 2006, pages 4392 - 4408;;LIU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 93, 1996, pages 8618 - 8623;;CHARI ET AL., CANCER RESEARCH, vol. 52, 1992, pages 127 - 13;;WOYKE ET AL., ANTIMICROB. AGENTS AND CHEMOTHER., vol. 45, no. 12, 2001, pages 3580 - 3584;;PETTIT ET AL., ANTIMICROB. AGENTS CHEMOTHER., vol. 42, 1998, pages 2961 - 2965;;DORONINA ET AL., NATURE BIOTECHNOLOGY, vol. 21, no. 7, 2003, pages 778 - 784;;FRANCISCO ET AL., BLOOD, vol. 102, no. 4, 2003, pages 1458 - 1465;;DORONINA ET AL., BIOCONJUGATE CHEM., vol. 17, 2006, pages 114 - 124;;E. SCHRODER; K. LUBKE: ""The Peptides"", vol. 1, 1965, ACADEMIC PRESS, pages: 76 - 136;;PETTIT ET AL., J. AM. CHEM. SOC., vol. 111, 1989, pages 5463 - 5465;;PETTIT ET AL., ANTI-CANCER DRUG DESIGN, vol. 13, 1998, pages 243 - 277;;PETTIT, G.R ET AL., SYNTHESIS, 1996, pages 719 - 725;;PETTIT ET AL., J CHEM. SOC. PERKIN TRANS., vol. 1, no. 5, 1996, pages 859 - 863;;DORONINA, NAT. BIOTECHNOL., vol. 21, no. 7, 2003, pages 778 - 784;;DORONINA ET AL., NAT. BIOTECH., vol. 21, 2003, pages 778 - 784;;HINMAN ET AL., CANCER RESEARCH, vol. 53, 1993, pages 3336 - 3342;;LODE ET AL., CANCER RESEARCH, vol. 58, 1998, pages 2925 - 2928;;LEIMGRUBER ET AL., J AM. CHEM. SOC., vol. 87, 1965, pages 5793 - 5795;;LEIMGRUBER ET AL., J AM. CHEM. SOC., vol. 87, 1965, pages 5791 - 5793;;THURSTON ET AL., CHEM. REV., 1994, pages 433 - 465;;KOHN: ""In Antibiotics III"", 1975, SPRINGER-VERLAG, pages: 3 - 11;;HURLEY; NEEDHAM-VANDEVANTER, ACC. CHEM. RES., vol. 19, 1986, pages 230 - 237;;HARTLEY ET AL., CANCER RES., vol. 70, no. 17, 2010, pages 6849 - 6858;;ANTONOW, J. MED. CHEM., vol. 53, no. 7, 2010, pages 2927 - 2941;;HOWARD ET AL., BIOORGANIC AND MED. CHEM. LETTERS, vol. 19, no. 22, 2009, pages 6463 - 6466;;C. PETERSON ET AL.: ""Transport And Storage Of Anthracycline In Experimental Systems And Human Leukemia"", ANTHRACYCLINE ANTIBIOTICS IN CANCER THERAPY;;N.R BACHUR, FREE RADICAL DAMAGE, pages 97 - 102;;P.H- WIERNIK, ANTHRACYCLINE: CURRENT STATUS AND NEW DEVELOPMENTS, pages 11;;KRATZ ET AL., CURRENT MED. CHEM., vol. 13, 2006, pages 477 - 523;;JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 16, 2006, pages 358 - 362;;TORGOV ET AL., BIOCONJ. CHEM., vol. 16, 2005, pages 717 - 721;;NAGY ET AL., PROC. NATL. ACAD. SCI. USA, vol. 97, 2000, pages 829 - 834;;DUBOWCHIK ET AL., BIOORG. & MED CHEM. LETTERS, vol. 12, 2002, pages 1529 - 1532;;KING ET AL., J. MED. CHEM., vol. 45, 2002, pages 4336 - 4343;;SALEH ET AL., J. CLIN. ONCOLOGY, vol. 18, 2000, pages 2282 - 2292;;AJANI ET AL., CANCER JOUR., vol. 6, 2000, pages 78 - 81;;TOLCHER ET AL., J. CLIN. ONCOLOGY, vol. 17, 1999, pages 478 - 484;;QUINTIERI ET AL., CLINICAL CANCER RESEARCH, vol. 11, no. 4, 2005, pages 1608 - 1617;;GRANDI ET AL., CANCER TREAT. REV., vol. 17, 1990, pages 133;;RIPAMONTI ET AL., BRIT. J. CANCER, vol. 65, 1992, pages 703;;SUN ET AL., PROCEEDINGS OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY, vol. 22, 2003, pages 1448;;QUINTIERI: ""Proceedings of the American Association of Cancer Research"", vol. 44, 2003, pages: 4649;;PACCIARINI ET AL., JOUR. CLIN. ONCOLOGY, vol. 24, 2006, pages 14116;;MANDLER ET AL., J NAT. CANCER INST., vol. 92, no. 19, 2000, pages 1573 - 1581;;MANDLER ET AL., BIOORGANIC & MED. CHEM. LETTERS, vol. 10, 2000, pages 1025 - 1028;;MANDLER ET AL., BIOCONJUGATE CHEM., vol. 13, 2002, pages 786 - 791;;FRAKER ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 80, 1978, pages 49 - 57;;NEUBERGER ET AL., NATURE, vol. 312, 1984, pages 604 - 608;;MCDONAGH ET AL., PROT. ENGR. DESIGN & SELECTION, vol. 19, no. 7, 2006, pages 299 - 307;;HAMBLETT ET AL., CLIN. CANCER RES., vol. 10, 2004, pages 7063 - 7070;;HAMBLETT, K.J. ET AL.: ""Proceedings of the AACR"", vol. 45, March 2004, AMERICAN ASSOCIATION FOR CANCER RESEARCH, article ""Effect of drug loading on the pharmacology, pharmacokinetics, and toxicity of an anti-CD30 antibody-drug conjugate"";;ALLEY, S.C. ET AL.: ""Proceedings of the AACR"", vol. 45, March 2004, AMERICAN ASSOCIATION FOR CANCER RESEARCH, article ""Controlling the location of drug attachment in antibody-drug conjugates"";;GEOGHEGAN; STROH, BIOCONJUGATE CHEM., vol. 3, 1992, pages 138 - 146;;VAN DONGEN ET AL., THE ONCOLOGIST, vol. 12, 2007, pages 1379 - 1389;;VEREL ET AL., J. NUCL. MED., vol. 44, 2003, pages 1271 - 1281;;OSOL, A.: ""Remington's Pharmaceutical Sciences 16th edition,"", 1980;;CROUCH ET AL., J. IMMUNOL. METH., vol. 160, 1993, pages 81 - 88;;CREE ET AL., ANTICANCER DRUGS, vol. 6, 1995, pages 398 - 404;;HERWEIJER, H.; WOLFF, J. A., GENE THER, vol. 10, no. 6, 2003, pages 453 - 458;;LIU, F.; SONG, Y.; LIU, D., GENE THER, vol. 6, no. 7, 1999, pages 1258 - 1266;;ZHANG ET AL., HUM GENE THER, vol. 10, no. 10, 1999, pages 1735 - 1737;;HONGO ET AL., HYBRIDOMA, vol. 19, no. 4, 2000, pages 303 - 315",PENDING
383,US,A1,US 2011/0136072 A1,039-605-336-826-306,2011-06-09,2011,US 63371509 A,2009-12-08,US 63371509 A,2009-12-08,"TACTILE OBJECTS FOR ORTHODONTICS, SYSTEMS AND METHODS","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGAN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-04),https://lens.org/039-605-336-826-306,Patent Application,yes,104,88,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/00;;B23P13/00,433/18;;433/24;;29/896.11,0,0,,,,ACTIVE
384,CA,A1,CA 2334635 A1,055-933-880-810-984,1999-12-16,1999,CA 2334635 A,1999-05-21,EP 98870131 A;;EP 9903499 W,1998-06-10,MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF,"The invention relates to a modified gellan gum in which the total acyl conte nt as well as the ratio of acyl substituent groups to glycerate substituent groups per linear saccharide repeat unit is altered to be higher than 1. The invention further relates to a process for the modification of a gellan gum to alter its acyl content in which the gum is treated with a weak base such as sodium or potassium carbonate or a suitable phosphate. The process enables ""tailor made"" gums having appropriate setting temperatures and rheological properties to be made. Novel compositions containing them are also claimed.< /SDOAB>",MONSANTO PLC,MORRISSON NEIL A;;TALASHEK TODD;;CHEN YOU-LUNG;;SWORN GRAHAM;;CLARK ROSS,,https://lens.org/055-933-880-810-984,Patent Application,no,0,1,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,0,0,,,,DISCONTINUED
385,WO,A1,WO 2020/123426 A1,174-348-225-756-739,2020-06-18,2020,US 2019/0065341 W,2019-12-10,EP 2018084377 W;;US 201962939853 P,2018-12-11,AMINOAZINE AMIDES,"The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds.",HOFFMANN LA ROCHE;;HOFFMANN LA ROCHE,BACCEI JILL;;BRAVO YALDA;;CHEN AUSTIN;;CLARK RYAN;;STEARNS BRIAN;;TRUONG YEN,,https://lens.org/174-348-225-756-739,Patent Application,yes,3,6,6,7,0,C07D491/10;;C07D403/06;;C07D471/10;;C07D471/04;;C07D487/10;;C07D495/10;;C07D491/048;;C07D491/107;;A61P1/16;;A61P11/00;;A61P3/00;;A61P9/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07D401/06;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D491/107;;C07D495/10,A61K31/505;;A61K31/506;;C07D239/42,,1,0,,,See also references of EP 3873473A4,PENDING
386,US,A1,US 2015/0374847 A1,195-935-442-618-146,2015-12-31,2015,US 201514705525 A,2015-05-06,US 201514705525 A;;US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/195-935-442-618-146,Patent Application,yes,4,0,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48,,0,0,,,,ACTIVE
387,HK,A1,HK 1207987 A1,021-721-461-091-657,2016-02-19,2016,HK 15108726 A,2015-09-08,US 2013/0038742 W;;US 201261641074 P;;US 201261678911 P,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES PMEL17,,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/021-721-461-091-657,Patent Application,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K/;;A61K/,,0,0,,,,PENDING
388,CA,A1,CA 2867824 A1,057-924-879-710-028,2013-11-07,2013,CA 2867824 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/057-924-879-710-028,Patent Application,no,0,0,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48;;C07K16/28;;C07K16/30,,0,0,,,,DISCONTINUED
389,EP,B1,EP 1086140 B1,160-999-040-905-196,2003-01-22,2003,EP 99925025 A,1999-05-21,EP 99925025 A;;EP 9903499 W;;EP 98870131 A,1998-06-10,MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF,,CP KELCO APS,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISSON NEIL A;;TALASHEK TODD;;CLARK ROSS,CP KELCO APS (2002-03-06),https://lens.org/160-999-040-905-196,Granted Patent,yes,2,0,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,4,0,,,"E.R.MORRIS ET AL.: ""Conformational and rheological transitions of welan, rhamsan and acylated gellan."" CARBOHYDRATE POLYMERS., vol. 30, 1996, pages 165-175, XP002085626 BARKING GB cited in the application;;PATENT ABSTRACTS OF JAPAN vol. 14, no. 390 (C-751), 23 August 1990 (1990-08-23) & JP 02 145159 A (SAN EI CHEM IND LTD) & DATABASE WPI Week 9028 Derwent Publications Ltd., London, GB; AN 214226;;PATENT ABSTRACTS OF JAPAN vol. 14, no. 497 (C-774), 30 October 1990 (1990-10-30) & JP 02 207769 A (NICHIEI CHEM KK), 17 August 1990 (1990-08-17) & DATABASE WPI Week 9040 Derwent Publications Ltd., London, GB; AN 300319;;A.J.JAY ET AL.: ""Analysis of structure and function of gellans with different substitution patterns."" CARBOHYDRATE POLYMERS., vol. 35, 4 March 1998 (1998-03-04), pages 179-188, XP004126931 APPLIED SCIENCE PUBLISHERS LTD. BARKING., GB ISSN: 0144-8617",EXPIRED
390,CN,A,CN 113039309 A,177-389-951-111-724,2021-06-25,2021,CN 201980074867 A,2019-11-06,US 201862767967 P;;US 2019/0060068 W,2018-11-15,PEALD PROCESSES USING RUTHENIUM PRECURSOR,"Plasma enhanced atomic layer deposition (PEALD) processes which use a ruthenium precursor of formula RARBRu(0), wherein RA is an aryl group-containing ligand, and RB is a diene group-containing ligand, along with a reducing plasma applied at greater than 200W are described. Use of the RARBRu(0) ruthenium precursors in PEALD with +200W reducing plasma such as ammonia plasma, can provide very good rates of deposition of Ru, have lower carbon and less resistivity, and provide very dense Ru films. The method can be used to form well-formed Ru film with high conformality on integrated circuits and other microelectronic devices.",ENTEGRIS INC,CHEN PHILIP S H;;HENDRIX BRYAN CLARK;;BAUM THOMAS H;;CONDO ERIC,,https://lens.org/177-389-951-111-724,Patent Application,no,4,1,8,8,0,C23C16/18;;C23C16/45536;;C23C16/45553;;C23C16/45553;;C23C16/45536;;C23C16/18;;C23C16/45536;;C07F15/0046;;C23C16/06,C23C16/455;;C23C16/18,,0,0,,,,PENDING
391,CN,A,CN 104470544 A,187-350-919-815-857,2015-03-25,2015,CN 201380022616 A,2013-04-30,US 2013/0038742 W;;US 201261641074 P;;US 201261678911 P,2012-05-01,Anti-pmel17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,Y CHEN;;MALLET WILLIAM;;POLAKIS PAUL;;C TAN;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/187-350-919-815-857,Patent Application,no,1,4,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/28;;A61K47/48;;C07K16/30,,2,2,111-654-430-040-748;;069-699-907-490-85X,16492709;;10.1242/jcs.02804;;pmc4629779;;15096515;;10.1074/jbc.m401269200,"JULIO C. VALENCIA ET AL.: ""《Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes》"", 《JOURNAL OF CELL SCIENCE》;;KEN-ICHI YASUMOTO ET AL.: ""《Epitope Mapping of the Melanosomal Matrix Protein gp100 (PMEL17)》"", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》",ACTIVE
392,EP,A1,EP 2539379 A1,038-666-278-474-674,2013-01-02,2013,EP 11707529 A,2011-02-24,US 30854310 P;;US 2011/0026036 W,2010-02-26,AMIDE ESTER INTERNAL ELECTRON DONOR AND PROCESS,,DOW GLOBAL TECHNOLOGIES LLC;;SHU JAMES X,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG,"SHU, JAMES X. (2014-07-02);;W.R. GRACE & CO.-CONN. (2014-07-23)",https://lens.org/038-666-278-474-674,Patent Application,yes,0,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F10/06;;C08F4/651;;C08F4/654;;C08F110/06,,0,0,,,,ACTIVE
393,US,B2,US 10820967 B2,061-860-458-491-597,2020-11-03,2020,US 201715423418 A,2017-02-02,US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,"Tactile objects for orthodontics, systems and methods","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/061-860-458-491-597,Granted Patent,yes,196,4,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14;;B33Y80/00,,154,78,066-282-335-791-995;;025-616-909-029-765;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;059-588-461-518-39X;;005-024-996-709-894;;052-731-758-553-641;;081-328-802-841-096;;009-638-995-800-030;;008-744-219-127-384;;083-235-787-432-859;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;114-408-402-448-688;;007-458-121-098-163;;048-527-821-955-377;;052-763-059-483-265;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;021-018-768-707-650;;000-494-525-786-513;;034-464-951-348-782;;013-689-140-672-656;;150-267-339-118-983;;006-370-362-381-143;;099-384-176-695-780;;056-064-135-529-61X;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973;;138-684-123-834-414;;056-383-866-369-582;;123-028-396-811-269;;112-073-423-851-594;;021-881-631-200-08X;;043-213-859-914-534;;058-953-285-075-855;;004-945-615-972-614;;007-791-552-338-375;;036-191-696-513-286;;025-329-363-440-138;;006-539-396-314-679;;129-709-346-949-085;;051-296-399-382-894;;069-298-082-055-441;;021-507-277-374-529;;053-048-658-252-470;;031-271-546-068-031;;049-407-482-660-143;;042-526-631-078-104;;027-754-365-457-953;;030-427-969-872-795;;064-378-232-278-762;;055-477-823-513-100;;027-316-381-573-41X;;000-788-861-492-825;;055-418-850-870-066;;088-958-363-169-71X,10.1117/12.7972842;;10.1117/12.957387;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1016/0002-9416(72)90076-0;;4501183;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;6937139;;10.1016/0002-9416(81)90310-9;;298295;;298302;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;1777659;;3058771;;10.14219/jada.archive.1988.0096;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;271471;;10.1016/0002-9416(78)90100-8;;10.2334/josnusd1959.26.11;;6589367;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;21027613;;10.1016/0096-6347(46)90053-1;;10.1016/0096-6347(45)90101-3;;10356517;;10.1145/964965.808575;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387;;2132100;;10.2334/josnusd1959.19.93;;294475;;10.1109/iecon.1998.724103;;5276727;;10.1016/0002-9416(71)90099-6;;10.1016/s0889-5406(00)70049-7;;10672223;;1591643;;10.1016/0022-3913(87)90285-x;;3312586;;1783723;;10.14219/jada.archive.1991.0205;;10.1109/10.133223;;1855790;;10.1093/ejo/14.2.125;;1582457;;10.1016/0889-5406(87)90412-4;;3477086;;10.1093/ejo/3.4.279;;7028491;;1539546;;10.1016/0889-5406(92)70089-s;;10.1001/archotol.1988.01860160082026;;3348899;;10.1016/0002-9416(71)90006-6;;5280427;;2269115;;1452058;;4504704;;10.1177/00220345720510042301;;4504700;;10.1177/00220345720510041901;;20830889;;10.1016/s0010-4485(96)00054-1;;9874310;;10.1109/42.736056;;2718969;;10.1016/0889-5406(89)90300-4;;5272402;;10.1016/0002-9416(70)90106-5;;3553441;;3473186;;10.1109/4233.924800;;11420997;;2486752,"AADR. American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Alcaniz, et aL, “An Advanced System for the Simulation and Planning of Orthodontic Treatments,” Karl Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Intl. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;Alexander et al., “The DigiGraph Work Station Part 2 Clinical Management,” JCO, pp. 402-407 (Jul. 1990).;;Altschuler, “3D Mapping of Maxillo-Facial Prosthesis,” AADR Abstract #607, 2 pages total, (1980).;;Altschuler et al., “Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures,” AADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR HP Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., “Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,” Optical Engineering, 20(6):953-961 (1981).;;Altschuler et al., “Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,” SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Andersson et al., “Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,” Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapter 3, pp. 13-24 (1989).;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind, “A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,” an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of Ill., Aug. 26-30, 1975, pp. 142-166.;;Baumrind et al., “A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,” NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., “Mapping the Skull in 3-D,” reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, “Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,” Semin. in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., “A Computer System for the Analysis of Dental Casts,” The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al.,“Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,” Abstract, J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., “A Computer-Aided Design for Orthognathic Surgery,” Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff, “Computerized Diagnostic Setups and Simulations,” Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biggerstaff et al., “Computerized Analysis of Occlusion in the Postcanine Dentition,” Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890, 20 pages total (1990).;;Blu, et al., “Linear interpolation revitalized”, IEEE Trans. Image Proc., 13(5):710-719 (May 2004.;;Bourke, “Coordinate System Transformation,” (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL< http://astronomy.swin.edu.au/-pbourke/prolection/coords>.;;Boyd et al., “Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalipn Appliance,” Semin. Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., “Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,” J. Dent. Res. Special Issue, Abstract 305, vol. 64, p. 208 (1985).;;Brook et al., “An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: Comparison with Manual Measurements of Mesio-distal Diameter,” J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form in Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Burstone (interview), “Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 1),” J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), “Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 2),” J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Cardinal Industrial Finishes, Powder Coatings information posted at<http://www.cardinalpaint.com> on Aug. 25, 2000, 2 pages.;;Carnaghan, “An Alternative to Holograms for the Portrayal of Human Teeth,” 4th Int'l Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., “The DigiGraph Work Station, Part 1, Basic Concepts,” JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., “Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,” Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, “CAD/CAM in the Dental Office: Does It Work?”, Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crawford, “Computers in Dentistry: Part 1 CAD/CAM: The Computer Moves Chairside,” Part 2 F. Duret—A Man with a Vision,“Part 3 The Computer Gives New Vision—Literally,” Part 4 Bytes 'N Bites—The Computer Moves from the Front Desk to the Operatory, Canadian Dental Journal, vol. 54 (9), pp. 661-666 (1988).;;Crooks, “CAD/CAM Comes to USC,” USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., “Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,” Semin. Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et a/., “Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,” Plast. 77(6):877-885 (Jun. 1986).;;DCS Dental AG, “The CAD/CAM ‘DCS Titan System’ for Production of Crowns/Bridges,” DSC Production AG, pp. 1-7 (Jan. 1992.;;Definition for gingiva. Dictionary.com p. 1-3. Retrieved from the internet Nov. 5, 2004<http://reference.com/search/search?q=gingiva>.;;DeFranco et al., “Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,” J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium JD on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13 (1992).;;Dent-X posted on Sep. 24, 1998 at< http://www.dent-x.com/DentSim.htm>, 6 pages.;;Doyle, “Digital Dentistry,” Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClearTM product information, Allesee Orthodontic Appliances—Pro Lab, 1 page (1997).;;Duret et al., “CAD/CAM Imaging in Dentistry,” Curr. Opin. Dent., 1:150-154 (1991).;;Duret et al, “CAD-CAM in Dentistry,” J. Am. Dent. Assoc. 117:715-720 (Nov. 1988).;;Duret, “The Dental CAD/CAM, General Description of the Project,” Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,“Vers Une Prosthese Informatisee,” (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, “The Microcomputer in the Orthodontic Office,” JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Felton et al., “A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,” Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., “Accuracy of Cephalometric Prediction in Orthognathic Surgery,” Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Futterling et a/., “Automated Finite Element Modeling of a Human Mandible with Dental Implants,” JS WSCG '98—Conference Program, retrieved from the Internet<http://wscg.zcu.cz/wscg98/papers98/Strasser 98.pdf>, 8 pages.;;Gao et al., “3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,” Proc. Intl Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, “Das DUX System: Die Technik,” 2 pages total (2002).;;Gottleib et al., “JCO Interviews Dr. James A. McNamura, Jr., on the Frankel Appliance: Part 2: Clinical 1-1 Management,” J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, “New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: JW Computerized Facial Imaging in Oral and Maxiiofacial Surgery,” AAOMS, 3 pages total, (Sep. 13, 1990).;;Guess et al., “Computer Treatment Estimates in Orthodontics and Orthognathic Surgery,” JCO, pp. 262-228 (Apr. 1989).;;Heaven et a/., “Computer-Based Image Analysis of Artificial Root Surface Caries,” Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, “Simulating Stress Put on Jaw,” Tooling & Production [online], Nov. 1996, n pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL http://static.highbeam.com/t/toolingampproduction/november011996/simulatingstressputonfa . . . >.;;Hikage, “Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning”, Journal of Japan KA Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., “Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,” (Article Summary in English, article in German), Informatbnen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., “Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,” J. Biomech., 23(11):1157-1166 (1990).;;Huckins, “CAD-CAM Generated Mandibular Model Prototype from MRI Data,” AAOMS, p. 96 (1999).;;Important Tip About Wearing the Red White & Blue Active Clear Retainer System, Allesee Orthodontic Appliances—Pro Lab, 1 p. 1998).;;JCO Interviews, Craig Andreiko , DDS, MS on the Elan and Orthos Systems, JCO, pp. 459-468 (Aug. 1994).;;JCO Interviews, Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2, JCO. 1997; 1983:819-831.;;Jerrold, “The Problem, Electronic Data Transmission and the Law,” AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., “An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,” Br. J. Orthod., 16:85-93 (1989).;;JP Faber et al., “Computerized Interactive Orthodontic Treatment Planning,” Am. J. Orthod., 73(1):36-46 (Jan. 1978).;;Kamada et.al., Case Reports on Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;Kamada et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case KJ Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., “Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,” J. Dent Res., 63(11):1298-1301 (Nov. 1984).;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, KN Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Journal of Orthodontics and Oral surgery. 1945; 31:297-304.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kochanek, “Interpolating Splines with Local Tension, Continuity and Bias Control,” Computer Graphics, ri 18(3):33-41 (Jul. 1984). KM Oral Surgery (1945) 31 :297-30.;;Kunii et al., “Articulation Simulation for an Intelligent Dental Care System,” Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laurendeau, et al., “A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of 7 KR Dental Imprints: An Application in Orthodontics,” IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991.;;Leinfelder, et al., “A New Method for Generating Ceramic Restorations: a CAD-CAM System,” J. Am. 1-1 Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., “Computer-Aided Cefalometry and New Mechanics in Orthodontics,” (Article Summary in English, article in German), Fortschr Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, “Inside the ADA,” J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., “Invisible Retainers,” J. Cfin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., “Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,” IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, “Correcting Mild Malalignments—As Easy As One, Two, Three,” AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mormann et al., “Marginale Adaptation von adhasuven Porzellaninlays in vitro,” Separatdruck aus: Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.;;Nahoum, “The Vacuum Formed Dental Contour Appliance,” N. Y. State Dent. J., 30(9):385-390 (Nov. 1964).;;Nash, “CEREC CAD/CAM Inlays: Aesthetics and Durability in a Single Appointment,” Dent. Today, 9(8):20, 22-23 (Oct. 1990).;;Nishiyama et al., “A New Construction of Tooth Repositioner by LTV Vinyl Silicone Rubber,” J. Nihon Univ. Sch. Dent., 19(2):93-102 (1977).;;Paul et al., “Digital Documentation of Individual Human Jaw and Tooth Forms for Applications in Orthodontics, Oral Surgery and Forensic Medicine” Proc. of the 24th Annual Conf. of the IEEE Industrial Electronics Society (IECON '98), Sep. 4, 1998, pp. 2415-2418.;;Pinkham, “Foolish Concept Propels Technology,” Dentist, 3 pages total, Jan./Feb. 1989.;;Pinkham, “Inventor's CAD/CAM May Transform Dentistry,” Dentist, 3 pages total, Sep. 1990.;;Ponitz, “Invisible Retainers,” Am. J. Orthod., 59(3):266-272 (Mar. 1971).;;Procera Research Projects, “PROCERA Research Projects 1993—Abstract Collection,” pp. 3-7; 28 (1993).;;Proffit et al., Contemporary Orthodontics, (Second Ed.), Chapter 15, Mosby Inc., pp. 470-533 (Oct. 1993.;;Raintree Essix & ARS Materials, Inc., Raintree Essix, Technical Magazine Table of contents and Essix Appliances,< http:// www.essix.com/magazine/defaulthtml> Aug. 13, 1997.;;Redmond et al., “Clinical Implications of Digital Orthodontics,” Am. J. Orthod. Dentofacial Orthop., 117(2):240-242 (2000).;;Rekow, “A Review of the Developments in Dental CAD/CAM Systems,” (contains references to Japanese efforts and content of the papers of particular interest to the clinician are indicated with a one line summary of their content in the bibliography), Curr. Opin. Dent., 2:25-33 (Jun. 1992).;;Rekow, “CAD/CAM in Dentistry: A Historical Perspective and View of the Future,” J. Can. Dent. Assoc., 58(4):283, 287-288 (Apr. 1992).;;Rekow, “Computer-Aided Design and Manufacturing in Dentistry: A Review of the State of the Art,” J. Prosthet. Dent., 58(4):512-516 (Oct. 1987).;;Rekow, “Dental CAD-CAM Systems: What is the State of the Art?”, J. Amer. Dent. Assoc., 122:43-48 1991.;;Rekow et al., “CAD/CAM for Dental Restorations—Some of the Curious Challenges,” IEEE Trans. Biomed. Eng., 38(4):314-318 (Apr. 1991).;;Rekow et al., “Comparison of Three Data Acquisition Techniques for 3-D Tooth Surface Mapping,” Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 13(1):344-345 1991.;;Rekow, “Feasibility of an Automated System for Production of Dental Restorations, Ph.D. Thesis,” Univ. of Minnesota, 244 pages total, Nov. 1988.;;Richmond et al., “The Development of a 3D Cast Analysis System,” Br. J. Orthod., 13(1):53-54 (Jan. 1986).;;Richmond et al., “The Development of the PAR Index (Peer Assessment Rating): Reliability and Validity,” Eur. J. Orthod., 14:125-139 (1992).;;Richmond, “Recording the Dental Cast in Three Dimensions,” Am. J. Orthod. Dentofacial Orthop., 92(3):199-206 (Sep. 1987).;;Rudge, “Dental Arch Analysis: Arch Form, A Review of the Literature,” Eur. J. Orthod., 3(4):279-284 1981.;;Sakuda et al., “Integrated Information-Processing System in Clinical Orthodontics: An Approach with Use of a Computer Network System,” Am. J. Orthod. Dentofacial Orthop., 101(3): 210-220 (Mar. 1992).;;Schellhas et al., “Three-Dimensional Computed Tomography in Maxillofacial Surgical Planning,” Arch. Otolamp!. Head Neck Sur9., 114:438-442 (Apr. 1988).;;Schroeder et al., Eds. The Visual Toolkit, Prentice Hall PTR, New Jersey (1998) Chapters 6, 8 & 9, (pp. 153-210,309-354, and 355-428, respectively.;;Shilliday, (1971). Minimizing finishing problems with the mini-positioner, Am. J. Orthod. 59:596-599.;;Siemens, “CEREC—Computer-Reconstruction,” High Tech in der Zahnmedizin, 14 pages total (2004).;;Sinclair, “The Readers' Corner,” J. Clin. Orthod., 26(6):369-372 (Jun. 1992).;;Sirona Dental Systems GmbH, CEREC 3D, Manuel utiiisateur, Version 2.0X (in French), 2003,114 pages total.;;Stoll et al., “Computer-aided Technologies in Dentistry,” (article summary in English, article in German), Dtsch Zahna'rztl Z 45, pp. 314-322 (1990).;;Sturman, “Interactive Keyframe Animation of 3-D Articulated Models,” Proceedings Graphics Interface '84, May-Jun. 1984, pp. 35-40.;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HI Orthodontic Appliances—Pro Lab product information for doctors. http://ormco.com/aoa/appliancesservices/RWB/doctorhtml>, 5 pages (May 19, 2003).;;The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee HJ Orthodontic Appliances—Pro Lab product information for patients,<http://ormco.com/aoa/appliancesservices/RWB/patients.html>, 2 pages (May 19, 2003).;;The Choice Is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment, Allesee Orthodontic Appliances—Pro Lab product information, 6 pages (2003).;;The Red, White & Blue Way to Improve Your Smile! Allesee Orthodontic Appliances—Pro Lab product information for patients, 2 pages 1992.;;Truax L., “Truax Clasp-Less(TM) Appliance System,” Funct. Orthod., 9(5):22-4, 26-8 (Sep.-Oct. 1992).;;Tru-Tain Orthodontic & Dental Supplies, Product Brochure, Rochester, Minnesota 55902, 16 pages total (1996).;;U.S. Department of Commerce, National Technical Information Service, “Automated Crown Replication Using Solid Photography SM,” Solid Photography Inc., Melville NY, Oct. 1977, 20 pages total.;;U.S. Department of Commerce, National Technical Information Service, “Holodontography: An Introduction to Dental Laser Holography,” School of Aerospace Medicine Brooks AFB Tex, Mar. 1973, 37 pages total.;;U.S. Appl. No. 60/050,342, filed Jun. 20,1997, 41 pages total.;;Van Der Linden, “A New Method to Determine Tooth Positions and Dental Arch Dimensions,” J. Dent. Res., 51(4):1104 (Jul.-Aug. 1972).;;Van Der Linden et al., “Three-Dimensional Analysis of Dental Casts by Means of the Optocom,” J. Dent. Res., p. 1100 (Jul.-Aug. 1972).;;Van Der Zel, “Ceramic-Fused-to-Metal Restorations with a New CAD/CAM System,” Quintessence Int., 24(11):769-778 (1993.;;Varady et al., “Reverse Engineering of Geometric Models—An Introduction,” Computer-Aided Design, 29(4):255-268,1997.;;Verstreken et al., “An Image-Guided Planning System for Endosseous Oral Implants,” IEEE Trans. Med. Imaging, 17(5):842-852 (Oct. 1998).;;Warunek et al., Physical and Mechanical Properties of Elastomers in Orthodonic Positioners, Am J. Orthod. Dentofac. Orthop, vol. 95, No. 5, (May 1989) pp. 399-400.;;Warunek et.al., Clinical Use of Silicone Elastomer Applicances, JCO (1989) XXII1(10):694-700.;;Wells, Application of the Positioner Appliance in Orthodontic Treatment, Am. J. Orthodont. (1970) 58:351-366.;;Williams, “Dentistry and CAD/CAM: Another French Revolution,” J. Dent. Practice Admin., pp. 2-5 (Jan./Mar. 1987).;;Williams, “The Switzerland and Minnesota Developments in CAD/CAM,” J. Dent. Practice Admin., pp. 50-55 (Apr./Jun. 1987.;;Wishan, “New Advances in Personal Computer Applications for Cephalometric Analysis, Growth Prediction, Surgical Treatment Planning and Imaging Processing,” Symposium: Computerized Facial Imaging in Oral and Maxilofacial Surgery Presented on Sep. 13, 1990.;;WSCG'98—Conference Program, “The Sixth International Conference in Central Europe on Computer Graphics and Visualization '98,” Feb. 9-13, 1998, pp. 1-7, retrieved from the Internet on Nov. 5, 2004, URL<http://wscg.zcu.cz/wscg98/wscg98.h>.;;Xia et al., “Three-Dimensional Virtual-Reality Surgical Planning and Soft-Tissue Prediction for Orthognathic Surgery,” IEEE Trans. Inf. Technol. Biomed., 5(2):97-107 (Jun. 2001).;;Yamamoto et al., “Optical Measurement of Dental Cast Profile and Application to Analysis of Three-Dimensional Tooth Movement in Orthodontics,” Front. Med. Biol. Eng., 1(2):119-130 (1988).;;Yamamoto et al., “Three-Dimensional Measurement of Dental Cast Profiles and Its Applications to Orthodontics,” Conf. Proc. IEEE Eng. Med. Biol. Soc., 12(5):2051-2053 (1990).;;Yamany et al., “A System for Human Jaw Modeling Using Intra-Oral Images,” Proc. of the 20th Annual Conf. of the IEEE Engineering in Medicine and Biology Society, Nov. 1, 1998, vol. 2, pp. 563-566.;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); I. The D.P. Concept and Implementation of Transparent Silicone Resin (Orthocon),” Nippon Dental Review, 452:61-74 (Jun. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); II. The D.P. Manufacturing Procedure and Clinical Applications,” Nippon Dental Review, 454:107-130 (Aug. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III. The General Concept of the D.P. Method and Its Therapeutic Effect, Part 1, Dental and Functional Reversed Occlusion Case Reports,” Nippon Dental Review, 457:146-164 (Nov. 1980).;;Yoshii, “Research on a New Orthodontic Appliance: The Dynamic Positioner (D.P.); III.—The General Concept of the D.P. Method and Its Therapeutic Effect, Part 2. Skeletal Reversed Occlusion Case Reports,” Nippon Dental Review, 458:112-129 (Dec. 1980).;;You May Be a Candidate for This Invisible No-Braces Treatment, Allesee Orthodontic Appliances—Pro Lab product information for patients, 2 pages (2002).",ACTIVE
394,AU,A,AU 1999/041456 A,077-802-120-937-921,1999-12-30,1999,AU 1999/041456 A,1999-05-21,EP 98870131 A;;EP 9903499 W,1998-06-10,Modified gellan gum composition process for preparation of same and use thereof,,MONSANTO PLC,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISSON NEIL A;;TALASHEK TODD;;CLARK ROSS,,https://lens.org/077-802-120-937-921,Patent Application,no,0,0,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,0,0,,,,DISCONTINUED
395,US,A1,US 2011/0283419 A1,157-136-940-912-816,2011-11-17,2011,US 200913132186 A,2009-12-03,US 200913132186 A;;US 12027308 P;;US 2009/0066560 W,2008-12-05,Regulation of Cotton Fiber Growth by Extracellular Nucleotides and Ectoapyrases,"The present invention includes compositions and methods of modulating the length of one or more cotton fibers in a plant by contacting the plant or tissue derived therefrom with at least one of: a nucleotide; a modulator of ectoapyrase gene transcription; or an anti-ectoapyrase antibody or fragments thereof, at a concentration that modulates growth of one or more cotton fibers.",ROUX STANLEY J;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK;;BOARD OR REGENTS THE UNIVERSITY OF TEXAS SYSTEM,ROUX STANLEY J;;CLARK GREG;;TORRES JONATHAN;;CHEN ZENGJIAN JEFFREY;;LEE JINSUK,BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (2009-03-05),https://lens.org/157-136-940-912-816,Patent Application,yes,3,5,5,5,4,C12N9/14;;C12N15/8261;;Y02A40/146;;C12N15/8261;;C12N9/14,A01H5/00;;A01H5/10;;A01N57/16;;C07K16/40;;C12N5/00;;C12N5/10;;C12N9/99;;C12N15/113;;C12N15/82,800/290;;435/427;;800/298;;435/184;;536/24.1;;530/389.1;;536/24.5;;504/196;;435/410,42,29,088-332-023-656-728;;008-349-154-640-514;;029-003-834-392-079;;039-333-580-937-562;;042-751-225-249-722;;005-930-167-858-854;;016-553-029-865-659;;008-590-281-641-131;;030-618-957-547-92X;;044-511-245-341-155;;005-738-433-372-41X;;051-275-984-945-528;;015-097-046-748-742;;008-349-154-640-514;;017-841-618-351-392;;008-349-154-640-514;;051-275-984-945-528;;029-003-834-392-079;;016-553-029-865-659;;015-097-046-748-742;;088-332-023-656-728;;042-751-225-249-722;;005-738-433-372-41X;;030-618-957-547-92X;;039-333-580-937-562;;008-590-281-641-131;;044-511-245-341-155;;005-930-167-858-854;;008-382-403-384-086,10.1007/s11302-006-9003-5;;18404480;;pmc2254478;;16179357;;10.1093/pcp/pci201;;17928260;;10.1016/j.tplants.2007.09.003;;12972043;;10.1016/s1369-5266(03)00081-5;;19036836;;10.1104/pp.108.128728;;pmc2633840;;10.1186/1471-2229-12-123;;pmc3511161;;22849572;;10.1104/pp.111.193151;;pmc3375956;;22430844;;pmc2759220;;10.1093/aob/mcm232;;17905721;;10.1016/j.bbagen.2004.09.006;;15652174;;10.1042/bj20150235;;26338998;;11043467;;10.1094/mpmi.2000.13.10.1053;;pmc166876;;12644663;;10.1104/pp.102.010926;;10.1098/rstb.2003.1441;;15253361;;pmc1693356;;16179357;;10.1093/pcp/pci201;;pmc161145;;8672885;;10.2307/3870289;;10.1105/tpc.8.5.873;;16179357;;10.1093/pcp/pci201;;pmc166876;;12644663;;10.1104/pp.102.010926;;17928260;;10.1016/j.tplants.2007.09.003;;10.1104/pp.111.193151;;pmc3375956;;22430844;;10.1098/rstb.2003.1441;;15253361;;pmc1693356;;10.1007/s11302-006-9003-5;;18404480;;pmc2254478;;19036836;;10.1104/pp.108.128728;;pmc2633840;;11043467;;10.1094/mpmi.2000.13.10.1053;;10.1016/j.bbagen.2004.09.006;;15652174;;12972043;;10.1016/s1369-5266(03)00081-5;;pmc2759220;;10.1093/aob/mcm232;;17905721;;10.1042/bj20150235;;26338998;;10.1186/1471-2229-12-123;;pmc3511161;;22849572;;pmc4379058;;25822168;;10.1371/journal.pone.0115832,"Robson et al., Purinergic Signal 2:409-30 (2006);;He et al., Plant Cell Physiol. 46(11 ):1848-1854 (2005);;Robson et al., Purin Sig 2:409-30 (2006);;Roux & Steinebrunner, Trends Plant Sci 12(11):522-27 (2007);;Zhang, Curr Opin Plant Biol 6:430-40 (2003);;Govindarajula et al., Plant Physiol 149:994-1004 (2009);;Stoynova-Bakalova et al., New Physiol 62:471-79 (2004);;Chapman, Numbers Living Species in Australia and the World, 2nd ed. (2009);;Schiller et al., BMC Plant Biol 12:123 (2012);;Parsons et al., Plant Physiol 159:12-26 (2012);;Lee et al., Ann. Bot 100:1391-401 (2007);;Wu, Doctoral Dissertation. Univ. Texas, Austin (2007);;Leal et al., Biochim Biophys Acta 1721:9-15 (2005);;Chiu et al., Biochem J 472:43-54 (2015);;Day et al., MPMI 13(10) 1053-70 (2000);;Navarro-Gochicoa et al., Plant Physiol 131:1124-36 (2003);;Steinebrunner et al., Plant Physiol Biochem 38:912-22 (2000);;Crane, Phil Trans Biol Sci 359(1444):735-37 (2004);;He et al. Expression of an Arabidopsis vacuolar sodium/proton antiporter gene in cotton improves photosynthetic performance under salt conditions and increases fiber yield in the field. 2005. Plant Cell Physiology. 46(11):1848-1854.;;Jian Wu. Functional analyses of two Arabidopsis apyrases. December 2007. U. Texas, Austin. Dissertation. pg 1-98.;;GenBank. Accession GU365147.1. pg 1-2.;;Narasimhulu et al. Early transcription of Agrobacterium T-DNA genes in tobacco and maize. 1996. Plant Cell. 8:873-886.;;Stoynova-Bakalova et al., New Physiol 62:471-79 (2004);;He et al., Plant Cell Physiol. 46(11 ):1848-1854 (2005);;Wu, Doctoral Dissertation. Univ. Tx, Austin (2007);;Navarro-Gochicoa et al., Plant Physiol 131:1124-36 (2003);;Roux & Steinebrunner, Trends Plant Sci 12(11):522-27 (2007);;Parsons et al., Plant Physiol 159:12-26 (2012);;Crane, Phil Trans Biol Sci 359(1444):735-37 (2004);;Robson et al., Purin Sig 2:409-30 (2006);;Robson et al., Purinergic Signal 2:409-30 (2006);;Steinebrunner et al., Plant Physiol Biochem 38:912-22 (2000);;Chapman, Numbers Living Species in Australia and the World, 2nd ed. (2009);;Govindarajula et al., Plant Physiol 149:994-1004 (2009);;Day et al., MPMI 13(10) 1053-70 (2000);;Leal et al., Biochim Biophys Acta 1721:9-15 (2005);;Wu, Doctoral Dissertation. Univ. Texas, Austin (2007);;Zhang, Curr Opin Plant Biol 6:430-40 (2003);;Lee et al., Ann. Bot 100:1391-401 (2007);;Chiu et al., Biochem J 472:43-54 (2015);;Schiller et al., BMC Plant Biol 12:123 (2012);;Massalski et al., PLOS One 10:e0115832 (2015)",DISCONTINUED
396,WO,A1,WO 2019/112592 A1,178-438-677-267-535,2019-06-13,2019,US 2017/0065124 W,2017-12-07,US 2017/0065124 W,2017-12-07,REMOTE AUTOMATED DEPLOYMENT OF HVAC OPTIMIZATION SOFTWARE,"Computer-implemented methods and structures deploy a heating ventilation and air conditioning (HVAC) energy optimization program. A standard operating control platform (OCP) is deployed in an energy optimization control engine (EOCE) computing system communicatively coupled to a plurality of HVAC components via a building automation system (BAS). An energy optimization portal (EOP), which receives from the EOCE computing system a first data set identifying the plurality of HVAC components, a second data set including operational control parameters for each of the plurality of HVAC components, and a third data set including measured operations data associated with each of the plurality of HVAC components. The EOP generates an energy optimized operating control platform based on the first, second, and third data sets, which is automatically communicated from the EOP to the EOCE computing system.",OPTIMUM ENERGY LLC,MATTHYS CLARK;;DEMPSTER IAN;;CHEN PENG;;CARTER CHRIS;;BOSCOLO CHRIS;;LECHNER ANDREW,,https://lens.org/178-438-677-267-535,Patent Application,yes,8,0,6,6,0,G05B15/02;;H04L12/2803;;H04L12/4625;;G05B2219/2642;;F24F11/30;;F24F2110/00;;F24F2130/10;;F24F11/54;;F24F11/58;;F24F11/46;;F24F11/64;;F24F2130/10;;F24F11/46;;F24F11/65;;F24F2110/00;;F24F11/30;;F24F11/54;;F24F11/58;;G05B19/042;;G05B2219/2614,F24F11/30;;F24F11/46;;F24F11/54;;F24F11/58;;F24F110/00;;F24F130/10;;G05B15/02;;H04L12/28,,0,0,,,,PENDING
397,DE,D1,DE 69830739 D1,032-136-433-966-251,2005-08-04,2005,DE 69830739 T,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-0-SUBSTITUIERTE KETOLIDE DERIVATE,,ABBOTT LAB,PHAN TAM;;OR SUN;;CHU T;;PLATTNER J;;CHEN YAN;;CLARK F,,https://lens.org/032-136-433-966-251,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
398,CN,A,CN 107531051 A,055-470-194-804-586,2018-01-02,2018,CN 201580079490 A,2015-10-26,US 2015/0057389 W,2015-10-26,Printheads and methods of fabricating a printhead,"Printheads and methods of fabricating printheads are disclosed. An example printhead includes a substrate and a printhead die disposed on a surface of the substrate, wherein a top surface of the printhead die projects a first distance from the surface of the substrate. The example printhead also includes a barrier at least partially surrounding the printhead die. A top surface of the barrier projects a second distance from the surface of the substrate, wherein the first distance is less than the second distance.",HEWLETT PACKARD DEVELOPMENT CO,CUMBIE MICHAEL W;;CHEN CHIEN-HUA;;MACKENZIE MARK H;;CLARK GARRETT E,,https://lens.org/055-470-194-804-586,Patent Application,no,5,1,5,5,0,B41J2/1637;;B41J2/1637;;B41J2/155;;B41J2/155;;B41J2/16;;B41J2/16;;B41J2/1623;;B41J2/1632;;B41J2/1632;;B41J2/1635;;B41J2/1635;;B41J2/175;;B41J2202/20;;B41J2202/20,B41J2/04;;B41J2/14;;B41J2/145,,0,0,,,,ACTIVE
399,DE,T2,DE 69830739 T2,083-350-173-263-740,2006-04-20,2006,DE 69830739 T,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-O-SUBSTITUIERTE KETOLIDE DERIVATE,,ABBOTT LAB,PHAN TAM;;OR SUN;;CHU T;;PLATTNER J;;CHEN YAN;;CLARK F,,https://lens.org/083-350-173-263-740,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,C07H17/08;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61P31/04,,0,0,,,,EXPIRED
400,US,B2,US 9597411 B2,130-213-062-413-349,2017-03-21,2017,US 201514705525 A,2015-05-06,US 201514705525 A;;US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,Anti-PMEL17 antibodies and immunoconjugates,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/130-213-062-413-349,Granted Patent,yes,103,1,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K39/395;;A61K45/06;;A61K51/10;;C07K16/28;;C07K16/30;;G01N33/60,,99,94,110-132-259-167-081;;103-834-230-679-860;;051-208-529-712-079;;068-257-624-898-885;;086-569-845-269-420;;015-395-754-996-662;;051-576-528-777-865;;036-923-658-847-622;;003-984-734-905-938;;005-112-559-456-657;;017-695-622-077-055;;033-564-353-488-242;;046-783-448-716-481;;009-483-512-107-343;;012-344-084-965-349;;065-684-269-783-203;;083-071-649-888-913;;020-126-164-125-029;;125-541-153-996-289;;001-779-867-387-972;;049-134-753-209-354;;036-000-628-772-935;;034-331-211-704-877;;008-274-774-541-556;;013-584-945-188-940;;013-954-482-377-715;;085-634-291-486-854;;018-694-084-068-187;;006-338-973-732-491;;004-272-966-072-139;;025-595-011-959-317;;120-079-078-809-391;;018-221-719-733-102;;011-842-849-963-456;;039-981-636-470-013;;002-490-451-363-036;;033-261-430-402-230;;080-360-276-571-359;;014-234-489-298-615;;039-841-667-603-953;;036-144-129-406-781;;070-280-057-407-994;;113-394-540-007-150;;035-796-690-562-525;;083-501-514-901-399;;008-587-496-850-953;;005-813-390-127-218;;072-378-691-723-546;;035-232-534-898-963;;068-264-897-850-380;;066-617-857-912-127;;095-843-764-156-972;;016-951-682-761-012;;049-755-438-917-969;;072-389-563-856-866;;019-662-268-310-070;;116-831-294-654-564;;022-725-321-473-914;;002-495-630-767-098;;073-809-444-186-075;;066-749-017-721-197;;061-423-230-346-240;;032-071-991-081-664;;034-345-578-106-977;;089-461-397-670-986;;051-719-785-727-477;;107-783-742-795-839;;009-709-621-617-333;;054-717-629-774-351;;117-747-013-490-001;;079-144-966-327-175;;060-301-220-665-473;;009-275-403-380-31X;;064-667-501-146-970;;030-386-438-509-753;;117-906-457-481-371;;116-075-018-919-051;;009-746-604-420-355;;047-094-213-620-162;;041-208-252-232-319;;104-212-297-137-759;;048-564-471-521-204;;061-970-204-106-123;;069-314-605-679-999;;054-876-950-584-376;;079-666-119-599-514;;071-273-910-767-454;;011-012-284-651-080;;000-325-449-181-936;;015-197-766-709-993;;170-311-024-328-514;;124-805-115-929-413;;032-110-387-855-191;;037-531-283-684-284,11069223;;10.1016/j.cbpa.2010.06.170;;20643572;;17981654;;10.2741/2786;;10.1021/jo00310a019;;20218628;;10.1021/jm901722v;;9099717;;10.1074/jbc.272.16.10678;;10.1007/978-94-009-7630-6_8;;10.1083/jcb.200302072;;pmc2172928;;12732614;;10.4049/jimmunol.147.1.86;;2051030;;10.1126/science.3925553;;3925553;;3500259;;pmc2189658;;10.1084/jem.166.5.1351;;10.1200/jco.2010.29.5865;;21172893;;18536555;;10.1097/ppo.0b013e318172d704;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;22509309;;pmc3317983;;10.1371/journal.pone.0034479;;1727373;;10.1021/ar700108g;;17705444;;14970501;;10.1385/1-59259-666-5:245;;10.1074/jbc.m112.361485;;pmc3397835;;22613716;;10.1006/jmbi.1999.3192;;10543973;;10.1016/0022-2836(87)90412-8;;3681981;;12412475;;10.1385/1-59259-334-8:179;;10.1038/352624a0;;1907718;;9435247;;pmc18475;;10.1073/pnas.95.2.652;;10.1182/blood-2002-06-1761;;12393541;;10.1097/00001813-199506000-00006;;7670137;;7680699;;10.1016/0022-1759(93)90011-u;;10.1126/science.2471267;;2471267;;15848074;;10.1016/j.ymeth.2005.01.005;;10.1038/nbt832;;12778055;;10.1021/bc0502917;;16417259;;10.1021/bc0502917.s001;;10.1016/s0040-4039(97)01158-1;;10.1016/s0960-894x(02)00194-4;;12031335;;3258649;;10.1038/332738a0;;15306681;;10.1073/pnas.0401786101;;pmc515084;;17161664;;10.1016/j.jchromb.2006.11.018;;1560463;;10.1016/0022-2836(92)91010-m;;637870;;10.1016/0006-291x(78)91322-0;;10.1182/blood-2003-01-0039;;12714494;;8983339;;10.1021/bc950092v;;21557708;;10.1517/14712598.2011.582464;;9107305;;10.1016/s0022-1759(97)00002-1;;10.1021/bc00014a008;;1325188;;10.1038/nbt1028;;15529166;;16380412;;10.1200/jco.2005.03.8471;;886304;;10.1099/0022-1317-36-1-59;;10.1016/0305-7372(90)90037-g;;2272029;;10.1002/j.1460-2075.1993.tb05706.x;;pmc413258;;7679990;;10.4049/jimmunol.152.11.5368;;8189055;;10.4049/jimmunol.117.2.587;;950463;;10.1517/13543776.15.9.1087;;10.1158/1078-0432.ccr-04-0789;;15501986;;17991747;;pmc2430631;;10.1074/jbc.m708007200;;10.1158/0008-5472.can-10-0790;;20660714;;pmc3533126;;10.1016/s0960-894x(99)00381-9;;10465553;;12621449;;10.1038/sj.gt.3301983;;10.1073/pnas.83.18.7059;;pmc386652;;3462743;;pmc397290;;3856277;;10.1073/pnas.82.5.1499;;8324745;;pmc2830135;;10.1096/fj.09-140921;;19884326;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;0001350381;;10.1126/science.256.5060.1205;;1350381;;10.1016/0022-2836(92)90894-p;;1404359;;11968478;;10.1385/1-59259-240-6:001;;11001403;;10.1089/027245700429855;;10.1016/j.bmcl.2009.09.012;;19811912;;12514726;;10.1038/nm0103-129;;10.1021/ar00128a001;;10.4049/jimmunol.164.8.4178;;10754313;;21843648;;10.1016/j.vascn.2011.07.005;;10.1016/j.bmcl.2005.09.081;;16275070;;16087878;;pmc1187972;;10.1073/pnas.0502680102;;16609957;;10.1002/bit.20880;;15848072;;10.1016/j.ymeth.2005.01.003;;7925571;;10.1002/eji.1830241025;;12213074;;10.1021/jm020149g;;6387121;;10.1021/jm00377a012;;10.1054/bjoc.2000.1226;;10901379;;pmc2363493;;15264863;;10.1021/bc049969t;;18387968;;10.1093/hmg/ddn095;;10.4049/jimmunol.148.5.1547;;1531669;;10.4049/jimmunol.133.6.3001;;6092464;;10.2174/092986706776055751;;16515518;;19047044;;10.1074/jbc.m808904200;;pmc2629115;;14736422;;10.1016/j.jim.2003.11.001;;15236968;;10.1016/j.jmb.2004.05.051;;10.1021/ja00952a050;;5845427;;10.1021/ja00952a051;;5845428;;10.1074/jbc.m110.168088;;pmc3059051;;21247888;;pmc2871485;;10.1074/jbc.m109.097725;;20231267;;16505368;;10.1073/pnas.0511285103;;pmc1383494;;10.1038/nbt1178;;16429149;;17196977;;10.1016/j.jmb.2006.11.021;;pmc38722;;10.1073/pnas.93.16.8618;;8710920,"Ajani et al., ""A Multi-Institutional Phase II Study of BMS-182248-01 (BR96-Doxorubicin Conjugate) Administered Every 21 Days in Patients with Advanced Gastric Adenocarcinoma"" Cancer Journal 6:78-81 (2000).;;Alley et al., ""Antibody-drug conjugates: targeted drug delivery for cancer"" Current Opinion in Chemical Biology 14:529-537 (2010).;;Alley, S.C. et al., ""Controlling the location of drug attachment in antibody-drug conjugates, Abstract No. 627, American Association for Cancer Research, 2004 Annual Meeting, Mar. 27-31, 2004 Proceedings of the AACR"" 45:52 (2004).;;Almagro et al., ""Humanization of antibodies"" Frontiers in Bioscience 13:1619-1633 (Jan. 2008).;;Amsberry et al., ""The lactonization of 2'-hydroxyhydrocinnamic acid amides: a potential prodrug for amines"" J Org Chem 55:5867-5877 (1990).;;Antonow et al., ""Structure-Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents"" J Med Chem(53):2927-2941 (2010).;;Baca et al., ""Antibody humanization using monovalent phage display"" J Biol Chem 272(16):10678-10684 (1997).;;Bachur Anthracycline Antibiotics in Cancer Therapy ""Free Radical Damage"" Muggia et al., The Hague:Martinus.Nijhoff,:97-102 (1981).;;Berson et al., ""Proprotein convertase cleavage liberates a fibrillogenic fragment of a resident glycoprotein to initiate melanosome biogenesis,"" J Cell Biol, 2003, 161:521-533.;;Boerner et al., ""Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes"" J Immunol 147(1):86-95 (Jul. 1991).;;Brennan et al., ""Preparation of Biospecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments"" Science 229(4708):81-83 (Jul. 5, 1985).;;Brodeur et al., ""Mouse-human myeloma partners for the production of heterohybridomas"" Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (New York: Marcel Dekker, Inc.), (1987).;;Brueggemann et al., ""Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies"" J. Exp. Med. 166:1351-1361 (1987).;;Burris et al., ""Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy,"" J Clin Oncol, 2011, 29:398-405.;;Carter and Senter, ""Antibody-drug conjugates for cancer therapy"" Cancer J 14(3):154-169 (2008).;;Carter et al., ""Humanization of an anti-p185 HER2 antibody for human cancer therapy"" P Natl Acad Sci USA 89:4285-4289 (May 1992).;;Chandra et al., ""A common role for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin activity and cell proliferation"" PLoS One 7(4):e34479 (Apr. 3, 2012).;;Chari et al., ""Immunoconjugates containing novel maytansinoids: Promising anticancer drugs"" Cancer Res 52:127-131 (1992).;;Chari, ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs"" Accounts of Chemical Research 41(1):98-107 ( 2008).;;Charlton, K.A., ""Expression and isolation of recombinant antibody fragments in E. coli"" Method Molec Biol 248:245-254 (2003).;;Chen et al., ""The melanosomal protein PMEL17 as a target for antibody drug conjugate therapy in melanoma,"" J Biol Chem, 2012, 287:24082-24091.;;Chen et al., ""Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen"" J Mol Biol. 293(4):865-81 (1999).;;Chothia and Lesk, ""Canonical structures for the hypervariable regions of immunoglobulins"" J Mol Biol 196(4):901-917 (1987).;;Chowdhury, ""Engineering hot spots for affinity enhancement of antibodies"" Methods Molec Biol 207:179-196 (2008).;;Clackson et al., ""Making antibody fragments using phage display libraries"" Nature 352:624-628 (Aug. 1991).;;Clynes et al., ""Fc receptors are required in passive and active immunity to melanoma"" Proc. Natl. Acad. Sci. USA 95:652-656 (Jan. 1998).;;Cragg et al., ""Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts"" Blood 101(3):1045-1052 (2003).;;Cree et al., ""Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay"" Anticancer Drugs 6:398-404 (1995).;;Crouch et al., ""The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity"" J Immunol Methods 160:81-88 (1993).;;Cunningham and Wells, ""High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis"" Science 24:1081-1085 (Jun. 2, 1989).;;Dall'Acqua et al., ""Antibody humanization by framework shuffling"" Methods 36:43-60 ( 2005).;;Doronina et al., ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy"" Nat Biotechnol 21(7):778-784 (Jul. 2003).;;Doronina et al., ""Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity"" Bioconjug Chem 17(1):114-124 (Jan. 2006).;;Dubowchik and Radia, ""Monomethoxytrityl (MMT) as a versatile amino protecting group for complex prodrugs of anticancer compounds sensitive to strong acids, bases and nucleophiles"" Tetrahedron Lett 38(30):5257-5260 (1997).;;Dubowchik et al., ""Doxorubicin immunoconjugates containing bivalent, lysosomally-cleavable dipeptide linkages"" Bioorg Med Chem Lett 12:1529-32 (2002).;;Duncan et al., ""The binding site for C1q on IgG"" Nature 322:738-740 (1988).;;Fellouse et al., ""Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition"" P Natl Acad Sci USA 101(34):12467-12472 (Aug. 24, 2004).;;Flatman et al., ""Process analytics for purification of monoclonal antibodies"" J Chromatogr 848:79-87 (2007).;;Foote et al., ""Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops"" J Mol Biol 224:487-499 (1992).;;Fraker and Speck, ""Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril"" Biochem Bioph Res Co 80(4):849-857 (1978).;;Francisco et al., ""cAC10-vcMMAE, an anti-CD30 monomethyl auristatin E conjugate with potent and selective antitumor activity"" Blood 102(4):1458-1465 (Aug. 15, 2003).;;Frisch et al., ""Synthesis of short polyoxyethylene-based heterobifunctional cross-linking reagents. Application to the coupling of peptides to liposomes"" Bioconj Chem 7:180-186 (1996).;;Garrett and Eng, ""Cetuximab in the treatment of patients with colorectal cancer,"" Expert Opin Biol Ther., 2001, 11:937-949.;;Gazzano-Santoro et al., ""A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody"" J Immunol Methods 202(2):163-171 (Mar. 28, 1997).;;Geoghegan and Stroh, ""Site-directed conjugation of nonpeptide groups to peptides and proteins via periodate oxidation of a 2-amino alcohol. Application to modification at N-terminal serine"" Bioconjugate Chem. 3:138-146 (1992).;;Gerngross, T. U, ""Advances in the production of human therapeutic proteins in yeasts and filamentous fungi"" Nat Biotech 22(11):1409-1414 (Nov. 2004).;;Goldenberg et al., ""Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy,"" J Clin Oncol, 2006,24:823-834.;;Graham et al., ""Characteristics of a human cell line transformed by DNA from human adenovirus type 5"" J Gen Virol 36(1):59-72 (Jul. 1977).;;Grandi et al., ""Novel anthracycline analogs"" Cancer Treatment Reviews 17:133-138 (1990).;;Griffiths et al., ""Human anti-self antibodies with high specificity from phage display libraries"" EMBO J 12(2):725-735 (1993).;;Gruber et al., ""Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli"" J Immunol 152:5368-5374 (1994).;;Guyer et al., ""Immunoglobulin binding by mouse intestinal epithelial cell receptors"" J Immunol 117(2):587-593 (Aug. 1976).;;Hamann, ""Monoclonal antibody-drug conjugates"" Expert Opin Ther Patents 15(9):1087-1103 (2005).;;Hamblett et al., ""Effect of drug loading on the pharmacology, pharmacokinetics and toxicity of an anti-CD30 antibody-drug conjugate,"" Abstract No. 624, American Association for Cancer Research; 2004 Annual Meeting, Mar. 27-31, 2004, Proceedings of the AACR' 45:52 (2004).;;Hamblett et al., ""Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate"" Clin Cancer Res 10:7063-7070 (2004).;;Harper et al., ""Premelanosome amyloid-like fibrils are composed of only golgi-processed forms of Pme117 that have been proteolytically processed in endosomes,"" J Biol Chem, 2008, 283:2307-2322.;;Hartley et al., ""SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity"" Cancer Res. 70(17):6849-6858 (2010).;;Hay et al., ""A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-YL)carbonyl]-1,2-dihydro-3H-benz[E]indole (amino-seco-DB1-TMI) for use with ADEPT and GDEPT"" Bioorg Med Chem Lett 9:2237-2242 (1999).;;Herweijer and Wolff, ""Progress and prospects: naked DNA gene transfer and therapy,"" Gene Ther., 2003, 10:453-458.;;Hellstrom et al., ""Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas"" P Natl Acad Sci USA 83:7059-7063 (Sep. 1986).;;Hellstrom et al., ""Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside"" P Natl Acad Sci USA 82:1499-1502 (Mar. 1985).;;Hinman et al., ""Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics"" Cancer Res 53:3336-3342 (1993).;;Hoashi et al., ""The secreted form of a melanocyte membrane-bound glycoprotein (Pme117/gp100) is released by ectodomain shedding,"" FASEB J, 2010, 24:916-930.;;Hollinger et al., """"Diabodies"": Small Bivalent and Bispecific Antibody Fragments"" Proc. Natl. Acad. Sci. USA 90:6444-6448 (Jul. 1993).;;Holmes et al., ""Identification of Heregulin, a Specific Activator of p185erbB2"" Science 256:1205-1210 (May 22, 1992).;;Hoogenboom et al., ""By-passing Immunisation; Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro"" J Mol Biol 227:381-388 (1992).;;Hoogenboom et al., ""Overview of antibody phage-display technology and its applications"" Methods Mol Biol 178:1-37 ( 2002).;;Hongo et al., ""Characterization of novel neutralizing monoclonal antibodies specific to human neurturin"" Hybridoma, 2000, 19:303-315.;;Howard et al., ""Synthesis of a novel C2/C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate"" Bioorg Med Chem Lett 19(22):6463-6466 (2009).;;Hudson et al., ""Engineered antibodies"" Nature Medicine 9(1):129-134 (Jan. 2003).;;Hurley et al., ""Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines"" Acc Chem Res 19:230-237 ( 1986).;;Idusogie et al., ""Mapping of the C1q Binding Site on Rituxan, A Chimeric Antibody with a Human IgG1 Fc"" J Immunol 164(8):4178-4184 (2000).;;Iyer & Kadambi, ""Antibody drug conjugates-Trojan horses in the war on cancer"" Journal of Pharmacological and Toxicological Methods 64:207-212 (2011).;;Jeffrey et al., ""Dipeptide-based highly potent doxorubicin antibody conjugates"" Bioorganic Med Chem Letters 16:358-362 (2006).;;Kam et al., ""Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction"" P Natl Acad Sci USA 102(33):11600-11605 (Aug. 2005).;;Kanda et al., ""Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC"" Biotechnol Bioeng 94(4):680-688 (Jul. 5, 2006).;;Kashmiri et al., ""SDR grafting-a new approach to antibody humanization"" Methods 36:25-34 (2005).;;Kim et al., ""Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor"" Eur. J. Immunol. 24:2429-2434 (1994).;;Kindt et al. Kuby Immunology ""Antigens and Antibodies Chapter 4"" 6th ed edition, N.Y.:W.H. Freeman and Co,:p. 91 (2007).;;King et al., ""Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: Inhibition of aggregation by methoxytriethyleneglycol chains"" Journal of Medical Chemistry 45:4336-4343 (2002).;;Kingsbury et al., ""A novel peptide delivery system involving peptidase activated prodrugs as antimicrobial agents. Synthesis and biological activity of peptidyl derivatives of 5-fluorouracil"" J Med Chem 27:1447-1451 (1984).;;Klimka et al., ""Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning"" BR J Cancer 83(2):252-260 (2000).;;Klussman et al., ""Secondary mAb-vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway"" Bioconjugate Chem 15:765-773 (2004).;;Kohler et al., ""Functional definition of the mutation cluster region of adenomatous polyposis coli in colorectal tumours"" Hum Mol Genet 17(13):1978-1987 (2008).;;Kohn Antibiotics ""Anthramycin"" Corcoran et al., New York, NY:Springer-Verlag, vol. 3:3-11 (1975).;;Kostelny et al., ""Formation of a bispecific antibody by the use of leucine zippers"" J Immunol. 148:1547-1553 (Mar. 1, 1992).;;Kozbor et al., ""A human hybrid myeloma for production of human monoclonal antibodies"" J Immunol 133(6):3001-3005 (Dec. 1984).;;Kratz et al., ""Prodrugs of anthracyclines in cancer chemotherapy"" Curr Med Chem 13:477-523 (2006).;;Kummer et al., ""Formation of Pme117 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase,"" J Biol Chem., 2009, 284:2296-2306.;;Lee et al., ""Bivalent antibody phage display mimics natural immunoglobulin"" J Immunol Methods 284(1-2):119-132 (2004).;;Lee et al., ""High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold"" J Mol Biol 340(5):1073-1093 (2004).;;Leimgruber et al., ""Isolation and characterization of anthramycin, a new antitumor antibiotic"" J Am Chem Soc 87(24):5791-5793 (1965).;;Leimgruber et al., ""The structure of anthramycin"" J Am Chem Soc 87(24):5793-5795 (1965).;;Leonhardt et al., ""Proprotein convertases process Pme117 during secretion,"" J Biol Chem., 2011, 286:9321-9337.;;Leonhardt et al., ""Endoplasmic reticulum export, subcellular distribution, and fibril formation by Pme117 require an intact N-terminal domain junction"" J Biol Chem, 2010, 285:16166-1683.;;Li et al., ""Human antibodies for immunotherapy development generated via a human B cell hybridoma technology"" Proc Natl Acad Sci USA 103:3557-3562 (2006).;;Li et al., ""Optimization of humanized IgGs in glycoengineered Pichia pastoris"" Nat Biotechnol 24(2):210-215 (Feb. 2006).;;Liang et al., ""Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library"" J. Mol. Biol. 366:815-829 (2007).;;Liu et al., ""Eradication of Large Colon Tumor Xenografts by Targeted Delivery of Maytansinoids."" P Natl Acad Sci USA 93:8618-8623 (1996).",ACTIVE
401,US,A1,US 2013/0295007 A1,129-965-105-369-023,2013-11-07,2013,US 201313873462 A,2013-04-30,US 201313873462 A;;US 201261641074 P;;US 201261678911 P,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA;;GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,GENENTECH INC (2013-07-17),https://lens.org/129-965-105-369-023,Patent Application,yes,9,46,24,24,51,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/30;;A61K39/395;;A61K45/06;;A61K51/10;;G01N33/60,424/1.49;;530/387.9;;530/387.3;;536/23.53;;435/69.6;;530/391.9;;424/181.1;;435/375;;435/7.23,6,5,027-477-313-726-928;;014-113-432-888-031;;045-942-104-775-903;;062-170-867-080-500;;051-707-000-800-833,10.1073/pnas.79.6.1979;;pmc346105;;6804947;;12218124;;10.4049/jimmunol.169.6.3076;;12850000;;10.1016/s0006-291x(03)01131-8;;10.4049/jimmunol.156.9.3285;;8617951;;12079396;;10.1016/s0022-2836(02)00264-4,"Paul, Fundamental Immunology, 3rd Edition, 1993, pp. 292-295;;Rudikoff et al(Proc. Natl. Acad. Sci. USA 1982 Vol. 79: page 1979);;Pascalis et al (The Journal of Immunology (2002) 169, 3076-3084);;Casset et al. (2003) BBRC 307, 198-205;;Brown et al (J. Immunol. 1996 May; 156(9):3285-3291;;Vajdos et al (J. Mol. Biol. 2002, Jul 5;320(2); 415-428)",ACTIVE
402,EP,A1,EP 1086140 A1,111-951-879-225-401,2001-03-28,2001,EP 99925025 A,1999-05-21,EP 99925025 A;;EP 9903499 W;;EP 98870131 A,1998-06-10,MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF,,MONSANTO PLC,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISSON NEIL A;;TALASHEK TODD;;CLARK ROSS,CP KELCO APS (2002-03-06),https://lens.org/111-951-879-225-401,Patent Application,yes,0,0,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,0,0,,,,EXPIRED
403,US,A1,US 2017/0143452 A1,183-749-148-146-315,2017-05-25,2017,US 201715423418 A,2017-02-02,US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,"TACTILE OBJECTS FOR ORTHODONTICS, SYSTEMS AND METHODS","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/183-749-148-146-315,Patent Application,yes,6,1,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14,,0,0,,,,ACTIVE
404,MX,A,MX 2014012889 A,188-230-638-560-43X,2014-11-14,2014,MX 2014012889 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES.,The invention provides anti-PMEL17 antibodies and immunoconjugates and methods of using the same.,GENENTECH INC,POLAKIS PAUL;;MALLET WILLIAM;;ASUNDI JYOTI;;CLARK SUZANNA;;CHEN YOUJUN;;TAN CHRISTINE,,https://lens.org/188-230-638-560-43X,Patent Application,no,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48;;C07K16/28;;C07K16/30,,0,0,,,,PENDING
405,EP,B1,EP 2539379 B1,034-519-615-768-10X,2017-09-06,2017,EP 11707529 A,2011-02-24,US 30854310 P;;US 2011/0026036 W,2010-02-26,AMIDE ESTER INTERNAL ELECTRON DONOR AND PROCESS,,W R GRACE & CO -CONN,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG,"SHU, JAMES X. (2014-07-02);;W.R. GRACE & CO.-CONN. (2014-07-23)",https://lens.org/034-519-615-768-10X,Granted Patent,yes,2,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F10/06;;C08F4/651;;C08F4/654;;C08F110/06,,1,0,,,"DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GAO, MINGZHI ET AL: ""Amino ester solid catalyst components for polymerization of olefin and the catalyst containing the same"", XP002639888, retrieved from STN Database accession no. 2008:81707 & CN 101 104 656 A (CHINA PETROLEUM AND CHEMICAL CORPORATION, PEOP. REP. CHINA; BEIJING RE) 16 January 2008 (2008-01-16)",ACTIVE
406,US,A1,US 2018/0222201 A1,056-138-877-131-773,2018-08-09,2018,US 201515748848 A,2015-10-26,US 2015/0057389 W,2015-10-26,PRINTHEADS AND METHODS OF FABRICATING A PRINTHEAD,"Printheads and methods of fabricating printheads are disclosed. An example printhead includes a substrate and a printhead die disposed on a surface of the substrate, where a top surface of the printhead die projects a first distance from the surface of the substrate. The example printhead also includes a barrier at least partially surrounding the printhead die. A top surface of the barrier projects a second distance from the surface of the substrate, where the first distance is less than the second distance.",HEWLETT PACKARD DEVELOPMENT CO,CUMBIE MICHAEL W;;CHEN CHIEN-HUA;;MACKENZIE MARK H;;CLARK GARRETT E,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2015-10-21),https://lens.org/056-138-877-131-773,Patent Application,yes,1,1,5,5,0,B41J2/1637;;B41J2/1637;;B41J2/155;;B41J2/155;;B41J2/16;;B41J2/16;;B41J2/1623;;B41J2/1632;;B41J2/1632;;B41J2/1635;;B41J2/1635;;B41J2/175;;B41J2202/20;;B41J2202/20,B41J2/16;;B41J2/155;;B41J2/175,,0,0,,,,ACTIVE
407,SG,A1,SG 183813 A1,076-579-633-274-419,2012-10-30,2012,SG 2012062998 A,2011-02-24,US 30854310 P;;US 2011/0026036 W,2010-02-26,AMIDE ESTER INTERNAL ELECTRON AND PROCESS,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,DOW GLOBAL TECHNOLOGIES LLC;;SHU JAMES X,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG,,https://lens.org/076-579-633-274-419,Patent Application,no,0,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,,,0,0,,,,PENDING
408,KR,A,KR 20150006000 A,097-465-462-596-208,2015-01-15,2015,KR 20147032847 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/097-465-462-596-208,Patent Application,no,0,0,24,24,102,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,C07K16/28;;A61K47/48;;A61K51/10;;A61K103/30;;A61P35/00,,0,0,,,,DISCONTINUED
409,EP,A1,EP 2844300 A1,188-419-580-281-778,2015-03-11,2015,EP 13721529 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/188-419-580-281-778,Patent Application,yes,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/48;;C07K16/28;;C07K16/30,,0,0,,,,ACTIVE
410,WO,A1,WO 1999/064468 A1,141-298-904-884-097,1999-12-16,1999,EP 9903499 W,1999-05-21,EP 98870131 A,1998-06-10,MODIFIED GELLAN GUM COMPOSITION PROCESS FOR PREPARATION OF SAME AND USE THEREOF,The invention relates to a modified gellan gum in which the total acyl content as well as the ratio of acyl substituent groups to glycerate substituent groups per linear saccharide repeat unit is altered to be higher than 1. The invention further relates to a process for the modification of a gellan gum to alter its acyl content in which the gum is treated with a weak base such as sodium or potassium carbonate or a suitable phosphate. The process enables 'tailor made' gums having appropriate setting temperatures and rheological properties to be made. Novel compositions containing them are also claimed.,MONSANTO PLC;;SWORN GRAHAM;;CHEN YOU LUNG;;MORRISSON NEIL A;;TALASHEK TODD;;CLARK ROSS,SWORN GRAHAM;;CHEN YOU-LUNG;;MORRISSON NEIL A;;TALASHEK TODD;;CLARK ROSS,,https://lens.org/141-298-904-884-097,Patent Application,yes,2,9,10,10,0,C08B37/006;;A23L29/272;;C08B37/006;;A23L29/272,A23L29/20;;A23L29/269;;C08B37/00,,4,2,002-053-925-059-154;;074-653-404-534-387,10.1016/s0144-8617(96)00059-8;;10.1016/s0144-8617(97)00241-5,"E.R.MORRIS ET AL.: ""Conformational and rheological transitions of welan, rhamsan and acylated gellan."", CARBOHYDRATE POLYMERS., vol. 30, 1996, BARKING GB, pages 165 - 175, XP002085626;;PATENT ABSTRACTS OF JAPAN vol. 14, no. 390 (C - 751) 23 August 1990 (1990-08-23);;PATENT ABSTRACTS OF JAPAN vol. 14, no. 497 (C - 774) 30 October 1990 (1990-10-30);;A.J.JAY ET AL.: ""Analysis of structure and function of gellans with different substitution patterns."", CARBOHYDRATE POLYMERS., vol. 35, 4 March 1998 (1998-03-04), APPLIED SCIENCE PUBLISHERS LTD. BARKING., GB, pages 179 - 188, XP004126931, ISSN: 0144-8617",PATENTED
411,EP,B1,EP 2844300 B1,041-978-650-801-32X,2018-10-17,2018,EP 13721529 A,2013-04-30,US 201261641074 P;;US 201261678911 P;;US 2013/0038742 W,2012-05-01,ANTI-PMEL17 ANTIBODIES AND IMMUNOCONJUGATES,,GENENTECH INC,CHEN YOUJUN;;MALLET WILLIAM;;POLAKIS PAUL;;TAN CHRISTINE;;ASUNDI JYOTI;;CLARK SUZANNA,,https://lens.org/041-978-650-801-32X,Granted Patent,yes,0,0,24,24,0,C07K16/2854;;C07K2317/34;;C07K2317/77;;A61K47/6889;;A61K47/6809;;A61K47/6849;;G01N33/58;;A61K45/06;;C07K16/3053;;A61K31/5383;;C07K2317/33;;A61P35/00;;A61K47/50;;A61K51/10;;C07K16/28;;Y10S530/809;;A61K47/6889;;A61K47/6809;;A61K47/6849;;C07K16/2854;;C07K2317/34;;C07K2317/77;;G01N33/58;;A61K39/39558;;A61K45/06;;A61K51/1093;;C07K16/30;;G01N33/60;;C07K16/3053;;A61K31/5383;;C07K2317/33;;C07K2317/56,A61K47/68;;C07K16/28;;C07K16/30,,1,1,019-308-704-101-581,10.4161/mabs.22771;;pmc3564883;;23211638,"CHRISTIAN KLEIN ET AL: ""Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties"", MABS, vol. 5, no. 1, 1 January 2013 (2013-01-01), pages 22 - 33, XP055117097, ISSN: 1942-0862, DOI: 10.4161/mabs.22771",ACTIVE
412,US,A1,US 2022/0243935 A1,100-540-961-163-857,2022-08-04,2022,US 202117164267 A,2021-02-01,US 202117164267 A,2021-02-01,BEZEL WITH AIR FILTRATION AND CABLE MANAGEMENT FOR AN INFORMATION HANDLING SYSTEM,"An information handling system includes a server and a bezel. The server includes multiple external ports and a mounting bracket. Multiple cables are connected to the external ports. The external ports are located within an air inlet surface of the server. The mounting bracket extends from the air inlet surface. The bezel includes a main frame and a filter. When the main frame is connected with the mounting bracket, the main frame covers the external ports and the cables. The cables extend through the cable router of the mounting bracket to exit an area between the main frame and the air inlet surface. The filter snap fits within the main frame, and provides air filtration to an airflow prior to the airflow being pulled into the server.",DELL PRODUCTS LP,CHEN JULIAN YU-HAO;;HUANG CHIN-AN;;CLARK PETER;;MAGUIRE AMRITA SIDHU,DELL PRODUCTS LP (2021-01-18),https://lens.org/100-540-961-163-857,Patent Application,yes,6,0,2,2,0,H05K7/20727;;F24F8/108;;H05K7/1489;;H05K7/20145;;H05K7/20736,F24F8/108;;H05K7/14;;H05K7/20,,0,0,,,,ACTIVE
413,US,B2,US 11525590 B2,057-823-392-159-454,2022-12-13,2022,US 202117164267 A,2021-02-01,US 202117164267 A,2021-02-01,Bezel with air filtration and cable management for an information handling system,"An information handling system includes a server and a bezel. The server includes multiple external ports and a mounting bracket. Multiple cables are connected to the external ports. The external ports are located within an air inlet surface of the server. The mounting bracket extends from the air inlet surface. The bezel includes a main frame and a filter. When the main frame is connected with the mounting bracket, the main frame covers the external ports and the cables. The cables extend through the cable router of the mounting bracket to exit an area between the main frame and the air inlet surface. The filter snap fits within the main frame, and provides air filtration to an airflow prior to the airflow being pulled into the server.",DELL PRODUCTS LP;;DELL PRODUCTS LP,CHEN JULIAN YU-HAO;;HUANG CHIN-AN;;CLARK PETER;;MAGUIRE AMRITA SIDHU,DELL PRODUCTS LP (2021-01-18),https://lens.org/057-823-392-159-454,Granted Patent,yes,7,1,2,2,0,H05K7/20727;;F24F8/108;;H05K7/1489;;H05K7/20145;;H05K7/20736,H05K7/14;;F24F8/108;;H05K7/20,,1,0,,,"Quick Installation Guide for the SmartEdge 1200 Front Bezel 220-0884-R2A, www.rbman.ito.expert/en_tzn7830002_r6a/6_15330-CRA1191170_1UenA.html, Telefonaktiebolaget LM Ericsson; Nov. 30, 2020; 12 pages.",ACTIVE
414,US,A1,US 2021/0045846 A1,088-874-949-978-815,2021-02-18,2021,US 202017085583 A,2020-10-30,US 202017085583 A;;US 201715423418 A;;US 201414206836 A;;US 63371509 A,2009-12-08,"TACTILE OBJECTS FOR ORTHODONTICS, SYSTEMS AND METHODS","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-05),https://lens.org/088-874-949-978-815,Patent Application,yes,3,0,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08;;A61C7/14,,0,0,,,,PENDING
415,US,B2,US 8708697 B2,095-332-542-682-905,2014-04-29,2014,US 63371509 A,2009-12-08,US 63371509 A,2009-12-08,"Tactile objects for orthodontics, systems and methods","Methods, systems, and apparatus's for improving orthodontic treatments. In an embodiment, an orthodontic system including a tactile object is provided for modulating an engagement between a tooth attachment and an orthodontic appliance.",LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG;;ALIGN TECHNOLOGY INC,LI CHUNHUA;;CHEN JENNIFER;;MORTON JOHN;;MOSS JON;;KAUFHARDT CLARK;;CAO HENG,ALIGN TECHNOLOGY INC (2010-01-04),https://lens.org/095-332-542-682-905,Granted Patent,yes,106,80,10,10,0,A61C7/08;;Y10T29/49568;;B33Y80/00;;Y10T29/49568;;B33Y80/00;;A61C7/08;;A61C7/14,A61C7/08,433/6;;433/18,99,51,049-270-017-771-054;;025-616-909-029-765;;066-282-335-791-995;;012-349-279-389-292;;012-109-303-347-357;;107-771-608-717-858;;062-739-307-619-727;;005-024-996-709-894;;059-588-461-518-39X;;052-731-758-553-641;;081-328-802-841-096;;008-744-219-127-384;;083-235-787-432-859;;009-638-995-800-030;;006-548-225-912-257;;008-400-662-682-578;;008-334-069-985-364;;106-143-739-919-771;;041-946-650-568-904;;026-672-240-066-566;;010-426-032-640-987;;082-594-697-736-865;;007-458-121-098-163;;114-408-402-448-688;;048-527-821-955-377;;052-763-059-483-265;;021-018-768-707-650;;048-656-201-606-564;;042-727-167-432-165;;109-794-479-707-999;;158-570-183-388-081;;046-112-675-259-076;;046-223-741-691-636;;053-649-857-143-596;;053-005-861-291-15X;;011-087-626-493-243;;007-221-538-620-409;;000-494-525-786-513;;034-464-951-348-782;;013-689-140-672-656;;056-064-135-529-61X;;006-370-362-381-143;;150-267-339-118-983;;099-384-176-695-780;;054-749-861-626-632;;136-362-268-202-528;;002-943-783-913-03X;;002-001-653-775-549;;049-270-017-771-054;;114-349-043-008-578;;027-822-397-122-973,10.14219/jada.archive.1989.0240;;2918147;;10.1117/12.957387;;10.1117/12.7972842;;2686338;;10.3109/00016358909007713;;4511478;;6943954;;10.1043/0003-3219(1981)051<0252:acsfta>2.0.co;2;;10.1016/0266-4356(84)90080-9;;6235838;;10.1016/0002-9416(72)90076-0;;4501183;;10.1043/0003-3219(1970)040<0028:cdsas>2.0.co;2;;5262685;;10.1109/tip.2004.826093;;15376602;;10.1177/00220345860650031101;;3457048;;298295;;298302;;6937139;;10.1016/0002-9416(81)90310-9;;2089065;;4064420;;6935222;;5248055;;10.1016/s0002-9416(69)90171-7;;2021892;;10356486;;3714886;;10.1097/00006534-198606000-00001;;1022792;;10.1016/0021-9290(76)90187-1;;3058771;;10.14219/jada.archive.1988.0096;;1777659;;298289;;15419274;;10.1016/0002-9416(50)90076-5;;271471;;10.1016/0002-9416(78)90100-8;;3479893;;10.1016/0889-5406(87)90229-0;;3476699;;10.1016/0278-2391(87)90195-9;;6960008;;2613889;;3333504;;2277050;;10.1016/0021-9290(90)90008-q;;8617829;;6584438;;9563366;;10.1016/s0889-5406(98)80024-3;;10.1179/bjo.16.2.85;;2673344;;10.2334/josnusd1959.26.11;;6589367;;6956677;;10.2334/josnusd1959.24.1;;6594373;;10.1177/00220345840630110901;;10.1145/964965.808575;;10.1016/0096-6347(45)90101-3;;21027613;;10.1016/0096-6347(46)90053-1;;10356517;;10.1016/0141-9382(94)90007-8;;10.1016/s0889-5406(96)70036-7;;8876485;;10.1109/42.97596;;18222848;;2738247;;10.14219/jada.archive.1989.0156;;10.14219/jada.archive.1989.0240;;2918147;;3862671;;3911387,"Alcaniz, et al., ""An Advanced System for the Simulation and Planning of Orthodontic Treatments,"" Karl Heinz Hohne and Ron Kikinis (eds.), Visualization in Biomedical Computing, 4th Int'l. Conf., VBC '96, Hamburg, Germany, Sep. 22-25, 1996, Springer-Verlag, pp. 511-520.;;""Important Tip About Wearing the Red White & Blue Active Clear Retainer System,"" Allesee Orthodontic Appliances-Pro Lab, 1 page.;;""Inside the ADA,"" JADA, 118:286-294 (Mar. 1989).;;""The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment,"" Allesee Orthodontic Appliances-Pro Lab product information for doctors, , 5 pages. (May 19, 2003).;;""The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment,"" Allesee Orthodontic Appliances-Pro Lab product information for patients, , 2 pages. (May 19, 2003).;;""The Choice is Clear: Red, White & Blue . . . The Simple, Affordable, No-Braces Treatment,"" Allesee Orthodontic Appliances-Pro Lab product information, 6 pages (2003).;;""The Red, White & Blue Way to Improve Your Smile!"" Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages.;;""You May Be a Candidate for This Invisible No-Braces Treatment,"" Allesee Orthodontic Appliances-Pro Lab product information for patients, 2 pages.;;Alexander et al., ""The DigiGraph Work Station Part 2 Clinical Management,"" JCO, pp. 402-407 (Jul. 1990).;;Altschuler et al., ""Measuring Surfaces Space-Coded by a Laser-Projected Dot Matrix,"" SPIE Imaging Applications for Automated Industrial Inspection and Assembly, vol. 182, p. 187-191 (1979).;;Altschuler et al., ""Analysis of 3-D Data for Comparative 3-D Serial Growth Pattern Studies of Oral-Facial Structures,"" AADR Abstracts, Program and Abstracts of Papers, 57th General Session, IADR Annual Session, Mar. 29, 1979-Apr. 1, 1979, New Orleans Marriot, Journal of Dental Research, vol. 58, Jan. 1979, Special Issue A, p. 221.;;Altschuler et al., ""Laser Electro-Optic System for Rapid Three-Dimensional (3D) Topographic Mapping of Surfaces,"" Optical Engineering, 20(6):953-961 (1981).;;Altschuler, ""3D Mapping of Maxillo-Facial Prosthesis,"" AADR Abstract #607, 2 pages total, (1980).;;American Association for Dental Research, Summary of Activities, Mar. 20-23, 1980, Los Angeles, CA, p. 195.;;Andersson et al., ""Clinical Results with Titanium Crowns Fabricated with Machine Duplication and Spark Erosion,"" Acta. Odontol. Scand., 47:279-286 (1989).;;Andrews, The Six Keys to Optimal Occlusion Straight Wire, Chapter 3, pp. 13-24.;;Bartels, et al., An Introduction to Splines for Use in Computer Graphics and Geometric Modeling, Morgan Kaufmann Publishers, pp. 422-425 (1987).;;Baumrind et al., ""A Stereophotogrammetric System for the Detection of Prosthesis Loosening in Total Hip Arthroplasty,"" NATO Symposium on Applications of Human Biostereometrics, Jul. 9-13, 1978, SPIE, vol. 166, pp. 112-123.;;Baumrind et al., ""Mapping the Skull in 3-D,"" reprinted from J. Calif. Dent. Assoc., 48(2), 11 pages total, (1972 Fall Issue).;;Baumrind, ""A System for Craniofacial Mapping Through the Integration of Data from Stereo X-Ray Films and Stereo Photographs,"" an invited paper submitted to the 1975 American Society of Photogram Symposium on Close-Range Photogram Systems, University of Ill., Aug. 26-30, 1975, pp. 142-166.;;Baumrind, ""Integrated Three-Dimensional Craniofacial Mapping: Background, Principles, and Perspectives,"" Semin. in Orthod., 7(4):223-232 (Dec. 2001).;;Begole et al., ""A Computer System for the Analysis of Dental Casts,"" The Angle Orthod., 51(3):253-259 (Jul. 1981).;;Bernard et al.,""Computerized Diagnosis in Orthodontics for Epidemiological Studies: A Progress Report,"" Abstract,J. Dental Res. Special Issue, vol. 67, p. 169, paper presented at International Association for Dental Research 66th General Session, Mar. 9-13, 1988, Montreal, Canada.;;Bhatia et al., ""A Computer-Aided Design for Orthognathic Surgery,"" Br. J. Oral Maxillofac. Surg., 22:237-253 (1984).;;Biggerstaff et al., ""Computerized Analysis of Occlusion in the Postcanine Dentition,"" Am. J. Orthod., 61(3): 245-254 (Mar. 1972).;;Biggerstaff, ""Computerized Diagnostic Setups and Simulations,"" Angle Orthod., 40(1):28-36 (Jan. 1970).;;Biostar Opeation & Training Manual. Great Lakes Orthodontics, Ltd. 199 Fire Tower Drive, Tonawanda, New York. 14150-5890. 20 pages total.;;Blu, et al., ""Linear interpolation revitalized"", IEEE Trans. Image Proc., 13(5):710-719 (May 2004).;;Bourke, ""Coordinate System Transformation,"" (Jun. 1996), p. 1, retrieved from the Internet Nov. 5, 2004, URL .;;Boyd et al., ""Three Dimensional Diagnosis and Orthodontic Treatment of Complex Malocclusions With the Invisalign Appliance,"" Semin. Orthod., 7(4):274-293 (Dec. 2001).;;Brandestini et al., ""Computer Machined Ceramic Inlays: In Vitro Marginal Adaptation,"" J. Dent. Res. Special Issue, Abstracts, vol. 64, p. 208 (1985).;;Brook et al., ""An Image Analysis System for the Determination of Tooth Dimensions from Study Casts: Comparison with Manual Measurements of Mesio-distal Diameter,"" J. Dent. Res., 65(3):428-431 (Mar. 1986).;;Burstone (interview), ""Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 1),"" J. Clin. Orthod., 13(7):442-453 (Jul. 1979).;;Burstone (interview), ""Dr. Charles J. Burstone on the Uses of the Computer in Orthodontic Practice (Part 2),"" J. Clin. Orthod., 13(8):539-551 (Aug. 1979).;;Burstone et al., Precision Adjustment of the Transpalatal Lingual Arch: Computer Arch Form Predetermination, Am, Journal of Orthodontics, vol. 79, No. 2 (Feb. 1981), pp. 115-133.;;Cardinal Industrial Finishes, Powder Coatings information posted at on Aug. 25, 2000, 2 pages.;;Carnaghan, ""An Alternative to Holograms for the Portrayal of Human Teeth,"" 4th Int'l. Conf. on Holographic Systems, Components and Applications, Sep. 15, 1993, pp. 228-231.;;Chaconas et al., ""The DigiGraph Work Station, Part 1, Basic Concepts,"" JCO, pp. 360-367 (Jun. 1990).;;Chafetz et al., ""Subsidence of the Femoral Prosthesis, A Stereophotogrammetric Evaluation,"" Clin. Orthop. Relat. Res., No. 201, pp. 60-67 (Dec. 1985).;;Chiappone, (1980). Constructing the Gnathologic Setup and Positioner, J. Clin. Orthod, vol. 14, pp. 121-133.;;Cottingham, (1969). Gnathologic Clear Plastic Positioner, Am. J. Orthod, vol. 55, pp. 23-31.;;Crawford, ""Computers in Dentistry: Part 1: CAD/CAM: The Computer Moves Chairside,"" ""Part 2: F. Duret-A Man With a Vision,"" ""Part 3: The Computer Gives New Vision-Literally,"" ""Part 4: Bytes 'N Bites"" The Computer Moves From the Front Desk to the Operatory, Canadian Dental Journal, vol. 54(9), pp. 661-666 (1988).;;Crawford, ""CAD/CAM in the Dental Office: Does It Work?"", Canadian Dental Journal, vol. 57, No. 2, pp. 121-123 (Feb. 1991).;;Crooks, ""CAD/CAM Comes to USC,"" USC Dentistry, pp. 14-17 (Spring 1990).;;Cureton, Correcting Malaligned Mandibular Incisors with Removable Retainers, J. Clin. Orthod, vol. 30, No. 7 (1996) pp. 390-395.;;Curry et al., ""Integrated Three-Dimensional Craniofacial Mapping at the Craniofacial Research Instrumentation Laboratory/University of the Pacific,"" Semin. Orthod., 7(4):258-265 (Dec. 2001).;;Cutting et al., ""Three-Dimensional Computer-Assisted Design of Craniofacial Surgical Procedures: Optimization and Interaction with Cephalometric and CT-Based Models,"" Plast. Reconstr. Surg., 77(6):877-885 (Jun. 1986).;;DCS Dental AA, ""The CAD/CAM 'DCS Titan System' for Production of Crowns/Bridges,"" DSC Production AG, pp. 1-7 (Jan. 1992).;;Definition for ""Gingiva,"" Dictionary.com, pp. 1-3, retrieved from the Internet on Nov. 5, 2004, URL .;;Defranco et al., ""Three-Dimensional Large Displacement Analysis of Orthodontic Appliances,"" J. Biomechanics, 9:793-801 (1976).;;Dental Institute University of Zurich Switzerland, Program for International Symposium on Computer Restorations: State of the Art of the CEREC-Method, May 1991, 2 pages total.;;Dentrac Corporation, Dentrac document, pp. 4-13.;;Dent-X posted on Sep. 24, 1998 at , 6 pages.;;Doyle, ""Digital Dentistry,"" Computer Graphics World, pp. 50-52, 54 (Oct. 2000).;;DuraClear(TM) product information, Allesee Orthodontic Appliances-Pro Lab, 1 page.;;Duret et al, ""CAD-CAM in Dentistry,"" J. Am. Dent. Assoc., 117:715-720 (Nov. 1988).;;Duret et al., ""CAD/CAM Imaging in Dentistry,"" Curr. Opin. Dent., 1:150-154 (1991).;;Duret, ""The Dental CAD/CAM, General Description of the Project,"" Hennson International Product Brochure, 18 pages total, Jan. 1986.;;Duret,""Vers Une Prosthese Informatisee,"" (English translation attached), Tonus, vol. 75, pp. 55-57 (Nov. 15, 1985).;;Economides, ""The Microcomputer in the Orthodontic Office,"" JCO, pp. 767-772 (Nov. 1979).;;Elsasser, Some Observations on the History and Uses of the Kesling Positioner, Am. J. Orthod. (1950) 36:368-374.;;English translation of Japanese Laid-Open Publication No. 63-11148 to inventor T. Ozukuri (Laid-Open on Jan. 18, 1998) pp. 1-7.;;Faber et al., ""Computerized Interactive Orthodontic Treatment Planning,"" Am. J. Orthod., 73(1):36-46 (Jan. 1978).;;Felton et al., ""A Computerized Analysis of the Shape and Stability of Mandibular Arch Form,"" Am. J. Orthod. Dentofacial Orthop., 92(6):478-483 (Dec. 1987).;;Friede et al., ""Accuracy of Cephalometric Prediction in Orthognathic Surgery,"" Abstract of Papers, J. Dent. Res., 70:754-760 (1987).;;Fütterling et al., ""Automated Finite Element Modeling of a Human Mandible with Dental Implants,"" WSCG '98-Conference Program, retrieved from the Internet: , 8 pages.;;Gao et al., ""3-D element Generation for Multi-Connected Complex Dental and Mandibular Structure,"" Proc. Int'l. Workshop on Medical Imaging and Augmented Reality, pp. 267-271 (Jun. 12, 2001).;;Gim-Alldent Deutschland, ""Das DUX System: Die Technik,"" 2 pages total.;;Gottleib et al., ""JCO Interviews Dr. James A. McNamura, Jr., on the Frankel Appliance: Part 2: Clinical Management,""J. Clin. Orthod., 16(6):390-407 (Jun. 1982).;;Grayson, ""New Methods for Three Dimensional Analysis of Craniofacial Deformity, Symposium: Computerized Facial Imaging in Oral and Maxiiofacial Surgery,"" AAOMS, 3 pages total, (Sep 13, 1990).;;Guess et al., ""Computer Treatment Estimates in Orthodontics and Orthognathic Surgery,"" JCO, pp. 262-228 (Apr. 1989).;;Heaven et al., ""Computer-Based Image Analysis of Artificial Root Surface Caries,"" Abstracts of Papers, J. Dent. Res., 70:528 (Apr. 17-21, 1991).;;Highbeam Research, ""Simulating Stress Put on Jaw,"" Tooling & Production [online], Nov. 1996, pp. 1-2, retrieved from the Internet on Nov. 5, 2004, URL .;;Hikage, ""Integrated Orthodontic Management System for Virtual Three-Dimensional Computer Graphic Simulation and Optical Video Image Database for Diagnosis and Treatment Planning"", Journal of Japan Orthodontic Society, Feb. 1987, English translation, pp. 1-38, Japanese version, 46(2), pp. 248-269 (60 pages total).;;Hoffmann, et al., ""Role of Cephalometry for Planning of Jaw Orthopedics and Jaw Surgery Procedures,"" (Article Summary in English, article in German), Informatbnen, pp. 375-396 (Mar. 1991).;;Hojjatie et al., ""Three-Dimensional Finite Element Analysis of Glass-Ceramic Dental Crowns,"" J. Biomech., 23(11):1157-1166 (1990).;;Huckins, ""CAD-CAM Generated Mandibular Model Prototype from MRI Data,"" AAOMS, p. 96 (1999).;;""JCO Interviews, Craig Andreiko , DDS, MS on the Elan and Orthos Systems,"" JCO, pp. 459-468 (Aug. 1994).;;""JCO Interviews, Dr. Homer W. Phillips on Computers in Orthodontic Practice, Part 2,"" JCO, pp. 819-831 (Dec. 1983).;;Jerrold, ""The Problem, Electronic Data Transmission and the Law,"" AJO-DO, pp. 478-479 (Apr. 1988).;;Jones et al., ""An Assessment of the Fit of a Parabolic Curve to Pre- and Post-Treatment Dental Arches,"" Br. J. Orthod, 16:85-93 (1989).;;Kamada et.al., Case Reports on Tooth Positioners Using LTV Vinyl Silicone Rubber, J. Nihon University School of Dentistry (1984) 26(1): 11-29.;;Kamada et.al., Construction of Tooth Positioners with LTV Vinyl Silicone Rubber and Some Case Reports, J. Nihon University School of Dentistry (1982) 24(1):1-27.;;Kanazawa et al., ""Three-Dimensional Measurements of the Occlusal Surfaces of Upper Molars in a Dutch Population,"" J. Dent Res., 63(11):1298-1301 (Nov. 1984).;;Kochanek, ""Interpolating Splines with Local Tension, Continuity and Bias Control,"" Computer Graphics, 18(3):33-41 (Jul. 1984).;;Kesling et al., The Philosophy of the Tooth Positioning Appliance, American Joumal of Orthodontics and Oral Surgery (1945) 31:297-304.;;Kesling, Coordinating the Predetermined Pattern and Tooth Positioner with Conventional Treatment, Am. J. Orthod. Oral Surg. (1946) 32:285-293.;;Kleeman et al., The Speed Positioner, J. Clin. Orthod. (1996) 30:673-680.;;Kunii et al., ""Articulation Simulation for an Intelligent Dental Care System,"" Displays 15:181-188 (1994).;;Kuroda et al., Three-Dimensional Dental Cast Analyzing System Using Laser Scanning, Am. J. Orthod. Dentofac. Orthop. (1996) 110:365-369.;;Laurendeau, et al., ""A Computer-Vision Technique for the Acquisition and Processing of 3-D Profiles of Dental Imprints: An Application in Orthodontics,"" IEEE Transactions on Medical Imaging, 10(3):453-461 (Sep. 1991).;;Leinfelder, et al., ""A New Method for Generating Ceramic Restorations: a CAD-CAM System,"" J. Am. Dent. Assoc., 118(6):703-707 (Jun. 1989).;;Manetti, et al., ""Computer-Aided Cefalometry and New Mechanics in Orthodontics,"" (Article Summary in English, article in German), Fortschr. Kieferorthop. 44, 370-376 (Nr. 5), 1983.;;McCann, ""Inside the ADA,"" J. Amer. Dent. Assoc., 118:286-294 (Mar. 1989).;;McNamara et al., ""Invisible Retainers,"" J. Clin. Orthod., pp. 570-578 (Aug. 1985).;;McNamara et al., Orthodontic and Orthopedic Treatment in the Mixed Dentition, Needham Press, pp. 347-353 (Jan. 1993).;;Moermann et al., ""Computer Machined Adhesive Porcelain Inlays: Margin Adaptation after Fatigue Stress,"" IADR Abstract 339, J. Dent. Res., 66(a):763 (1987).;;Moles, ""Correcting Mild Malalignments-As Easy As One, Two, Three,"" AOA/Pro Corner, vol. 11, No. 1, 2 pages (2002).;;Mörmann et al., ""Marginale Adaptation von adhäsuven Porzellaninlays in vitro,"" Separatdruck aus: Schweiz. Mschr. Zahnmed. 95: 1118-1129, 1985.",ACTIVE
416,WO,A1,WO 2017/074302 A1,162-389-900-090-877,2017-05-04,2017,US 2015/0057389 W,2015-10-26,US 2015/0057389 W,2015-10-26,PRINTHEADS AND METHODS OF FABRICATING A PRINTHEAD,"Printheads and methods of fabricating printheads are disclosed. An example printhead includes a substrate and a printhead die disposed on a surface of the substrate, where a top surface of the printhead die projects a first distance from the surface of the substrate. The example printhead also includes a barrier at least partially surrounding the printhead die. A top surface of the barrier projects a second distance from the surface of the substrate, where the first distance is less than the second distance.",HEWLETT PACKARD DEVELOPMENT CO LP,CUMBIE MICHAEL W;;CHEN CHIEN-HUA;;MACKENZIE MARK H;;CLARK GARRETT E,,https://lens.org/162-389-900-090-877,Patent Application,yes,5,0,5,5,0,B41J2/155;;B41J2/16;;B41J2/1632;;B41J2/1635;;B41J2202/20;;B41J2/1637;;B41J2/155;;B41J2/1632;;B41J2/1635;;B41J2202/20;;B41J2/16;;B41J2/1637;;B41J2/1623;;B41J2/175,B41J2/14;;B41J2/04;;B41J2/145,,0,0,,,,PENDING
417,WO,A1,WO 2012/139295 A1,165-813-048-264-34X,2012-10-18,2012,CN 2011072802 W,2011-04-14,CN 2011072802 W,2011-04-14,METHOD AND APPARATUS FOR IMPLEMENTING HIGH-ORDER MODULATION SCHEMES USING LOW-ORDER MODULATORS,"A processing device includes a plurality of modulators, the plurality of modulators performing modulation according to a first modulation scheme, a combiner configured to combine outputs from the plurality of modulators, and a signal processor configured to receive a bit stream and convert the bit stream into a plurality of input signals for the plurality of modulators such that the combiner generates a modulated output according to a second modulation scheme. The plurality of modulators may be low order modulators and a modulation schemes of the modulated output may include, for example, rotated quadrature phase shift keying (QPSK), pulse amplitude modulation (PAM), high order quadrature amplitude modulation (QAM), and multi-resolution high order quadrature amplitude modulation (M-QAM).",ALCATEL LUCENT;;ALCATEL LUCENT SHANGHAI BELL;;LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,,https://lens.org/165-813-048-264-34X,Patent Application,yes,6,2,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H04L27/36,,2,0,,,"""Power-and Bandwidth-Efficient Diversity Technique for the Rayleigh Fading Channel"", IEEE TRANS ON INFOR THEORY, vol. 44, no. 4, July 1998 (1998-07-01);;See also references of EP 2697948A4",PENDING
418,US,A1,US 2014/0035693 A1,088-201-717-431-195,2014-02-06,2014,US 201114111582 A,2011-04-14,CN 2011072802 W,2011-04-14,METHOD AND APPARATUS FOR IMPLEMENTING HIGH-ORDER MODULATION SCHEMES USING LOW-ORDER MODULATORS,"A processing device includes a plurality of modulators, the plurality of modulators performing modulation according to a first modulation scheme, a combiner configured to combine outputs from the plurality of modulators, and a signal processor configured to receive a bit stream and convert the bit stream into a plurality of input signals for the plurality of modulators such that the combiner generates a modulated output according to a second modulation scheme. The plurality of modulators may be low order modulators and a modulation schemes of the modulated output may include, for example, rotated quadrature phase shift keying (QPSK), pulse amplitude modulation (PAM), high order quadrature amplitude modulation (QAM), and multi-resolution high order quadrature amplitude modulation (M-QAM).",LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC;;ALCATEL LUCENT,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,ALCATEL LUCENT (2013-09-11),https://lens.org/088-201-717-431-195,Patent Application,yes,1,7,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H03C5/00,332/103,0,0,,,,DISCONTINUED
419,TW,A,TW 202218044 A,084-261-247-172-924,2022-05-01,2022,TW 109143098 A,2020-12-07,US 202016949214 A,2020-10-20,Method of providing trench isolation and semiconductor device,"A method of providing trench isolation includes the following steps. One or more semiconductor processing tools may form a deep trench within a silicon wafer. The one or more semiconductor processing tools may deposit a first insulating material within the deep trench. The one or more semiconductor processing tools may form, after forming the deep trench within the silicon wafer, a shallow trench above the deep trench. The one or more semiconductor processing tools may deposit a second insulating material within the shallow trench. A semiconductor device including a deep trench and a shallow trench is further provided.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;CHEN CHENG-HSIN;;TING CHUNG-CHIEH;;LIN CHE-YI;;LEE CLARK CHENG-ZONG,,https://lens.org/084-261-247-172-924,Patent of Addition,no,0,0,6,6,0,H01L21/76224;;H01L21/76224;;H01L21/02123;;H01L21/30625;;H01L21/31133;;H01L21/76224,H01L21/76;;H01L21/31,,0,0,,,,ACTIVE
420,CN,A,CN 103493454 A,091-321-993-274-24X,2014-01-01,2014,CN 201180070077 A,2011-04-14,CN 2011072802 W,2011-04-14,Method and apparatus for implementing high-order modulation schemes using low-order modulators,"A processing device includes a plurality of modulators, the plurality of modulators performing modulation according to a first modulation scheme, a combiner configured to combine outputs from the plurality of modulators, and a signal processor configured to receive a bit stream and convert the bit stream into a plurality of input signals for the plurality of modulators such that the combiner generates a modulated output according to a second modulation scheme. The plurality of modulators may be low order modulators and a modulation schemes of the modulated output may include, for example, rotated quadrature phase shift keying (QPSK), pulse amplitude modulation (PAM), high order quadrature amplitude modulation (QAM), and multi-resolution high order quadrature amplitude modulation (M-QAM).",ALCATEL LUCENT INC;;ALCATEL LUCENT SHANGHAI BELL,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,,https://lens.org/091-321-993-274-24X,Patent Application,no,3,12,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H04L27/36,,1,0,,,"雷维嘉: ""无线通信系统中的编码写作分集与中继技术研究"", 《中国博士学位论文全文数据库信息科技辑》",DISCONTINUED
421,EP,A1,EP 2697948 A1,021-817-999-468-205,2014-02-19,2014,EP 11863578 A,2011-04-14,CN 2011072802 W,2011-04-14,METHOD AND APPARATUS FOR IMPLEMENTING HIGH-ORDER MODULATION SCHEMES USING LOW-ORDER MODULATORS,,ALCATEL LUCENT,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,ALCATEL LUCENT (2014-08-20),https://lens.org/021-817-999-468-205,Patent Application,yes,0,0,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H03C5/00;;H04L27/00;;H04L27/20;;H04L27/32,,0,0,,,,DISCONTINUED
422,KR,A,KR 20130138323 A,061-175-732-135-208,2013-12-18,2013,KR 20137029147 A,2011-04-14,CN 2011072802 W,2011-04-14,METHOD AND APPARATUS FOR IMPLEMENTING HIGH-ORDER MODULATION SCHEMES USING LOW-ORDER MODULATORS,,ALCATEL LUCENT,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,,https://lens.org/061-175-732-135-208,Patent Application,no,0,0,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H04L27/36,,0,0,,,,DISCONTINUED
423,EP,A4,EP 2697948 A4,178-265-273-608-548,2014-09-10,2014,EP 11863578 A,2011-04-14,CN 2011072802 W,2011-04-14,METHOD AND APPARATUS FOR IMPLEMENTING HIGH-ORDER MODULATION SCHEMES USING LOW-ORDER MODULATORS,,ALCATEL LUCENT,LI ZHENG;;ZHANG RONG;;CHEN GUOYONG;;CLARK DOUG;;CHEN HAI;;WAN YU;;LENG JIAGUAN;;SHELTON MARC,ALCATEL LUCENT (2014-08-20),https://lens.org/178-265-273-608-548,Search Report,no,5,0,7,7,0,H04L27/20;;H04L27/32;;H04L27/0008;;H04L27/20;;H04L27/32;;H04L27/0008;;H03C5/00,H04L27/00;;H03C5/00;;H04L27/20;;H04L27/32,,2,1,070-085-655-243-13X,10.1109/wocc.2011.5872287,"ZHENG LI ET AL: ""High-order modulation scheme based on combinational QPSK accelerators for HSPA evolution in UE"", WIRELESS AND OPTICAL COMMUNICATIONS CONFERENCE (WOCC), 2011 20TH ANNUAL, IEEE, 15 April 2011 (2011-04-15), pages 1 - 4, XP032208521, ISBN: 978-1-4577-0453-6, DOI: 10.1109/WOCC.2011.5872287;;See also references of WO 2012139295A1",DISCONTINUED
424,US,A1,US 2011/0002372 A1,003-066-436-734-162,2011-01-06,2011,US 88295710 A,2010-09-15,US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/003-066-436-734-162,Patent Application,yes,4,4,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04K1/10;;H04B17/00,375/227;;375/260,0,0,,,,ACTIVE
425,US,B2,US 11426373 B2,093-094-141-019-236,2022-08-30,2022,US 202017131418 A,2020-12-22,US 202017131418 A;;US 201916575213 A;;US 201715709262 A;;US 201762473232 P,2017-03-17,Gamma-hydroxybutyrate compositions and their use for the treatment of disorders,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK,JAZZ PHARMACEUTICALS INC (2017-07-31);;JAZZ PHARMACEUTICALS IRELAND LIMITED (2018-03-15),https://lens.org/093-094-141-019-236,Granted Patent,yes,243,0,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61P25/20,,146,82,003-974-588-505-653;;124-875-834-903-459;;019-749-312-714-235;;023-137-217-763-01X;;024-272-763-359-32X;;003-974-588-505-653;;031-263-913-335-411;;145-653-484-736-088;;080-496-076-280-55X;;085-355-647-680-219;;171-520-562-358-558;;014-102-610-862-536;;149-981-625-199-350;;015-234-856-714-307;;102-899-202-637-947;;002-133-868-099-167;;082-516-623-800-461;;002-456-281-571-430;;010-682-458-523-318;;020-085-704-761-512;;018-012-288-721-765;;046-368-296-007-863;;018-750-113-533-732;;024-011-296-277-222;;172-372-589-987-05X;;015-727-310-665-481;;065-910-111-913-752;;095-180-557-299-845;;088-062-036-648-244;;051-213-157-572-605;;114-626-463-876-50X;;037-121-151-148-672;;010-823-624-643-865;;004-006-455-390-942;;045-816-277-025-820;;025-911-372-636-486;;033-971-442-961-757;;028-166-057-824-390;;031-624-652-745-244;;067-954-938-579-884;;055-113-427-061-977;;021-950-272-011-792;;118-444-399-679-429;;056-785-398-853-921;;018-051-671-082-718;;079-676-865-061-504;;021-012-980-011-063;;088-837-947-994-464;;039-091-327-430-806;;076-892-282-478-970;;099-425-313-501-806;;016-420-804-774-83X;;125-702-998-664-408;;021-408-061-057-66X;;006-315-038-449-896;;000-397-376-273-399;;012-715-646-097-951;;004-607-295-264-405;;139-898-841-231-714;;074-976-826-866-732;;126-920-528-243-192;;142-814-723-360-651;;031-425-175-318-845;;045-566-373-797-573;;078-557-772-461-105;;046-413-156-119-935;;098-242-263-277-974;;025-901-684-956-56X;;000-571-340-663-935;;051-240-227-350-906;;070-696-832-625-626;;051-960-555-783-976;;081-765-993-885-23X;;064-220-053-202-690;;105-650-780-806-12X;;055-156-128-870-846;;111-277-949-911-481;;123-705-321-811-93X;;064-998-466-553-357;;007-173-895-633-271;;189-752-100-048-834;;004-428-730-717-330,12520629;;10.1177/0091270002239707;;10.5664/jcsm.2048;;22893778;;pmc3407266;;10.1016/s1359-6446(01)01922-5;;11522519;;11067777;;10.1006/rtph.2000.1421;;10.1016/s0939-6411(96)00028-8;;12520629;;10.1177/0091270002239707;;7388696;;10.1016/j.ijpharm.2013.10.034;;24177314;;10.1172/jci109985;;6777399;;pmc371618;;15986420;;10.1002/mds.20605;;7803523;;10.1007/bf02191883;;8397726;;10.1038/npp.1993.45;;10.1007/s40261-013-0158-x;;24307430;;21760777;;10.1155/2011/783196;;pmc3132498;;11515679;;10.1007/s003840100299;;10.1093/sleep/4.1.105;;7232968;;3704454;;10.1093/sleep/9.1.285;;10.1300/j094v01n03_05;;169541;;10.1097/00006842-197507000-00008;;15964179;;10.1016/j.ejps.2005.05.002;;10.1007/s11894-006-0046-0;;16888867;;32651734;;10.1007/s11910-020-01057-z;;10.1016/j.colsurfa.2015.01.027;;28731350;;10.1021/acs.molpharmaceut.7b00252;;10.1016/0006-3223(89)90047-4;;2765597;;1985252;;10.1056/nejm199101243240416;;10.1246/bcsj.39.776;;9647355;;10.1023/a:1011976615750;;10.3329/jsr.v2i3.4991;;pmc2850459;;20300894;;10.1208/s12249-010-9406-z;;10.1007/s40263-019-00689-1;;pmc6982634;;31953791;;10.1136/gut.12.7.544;;pmc1411855;;5559143;;pmc2409176;;10.1080/03639040701377292;;17882730;;7381722;;10.1002/jps.2600690331;;2713866;;10.1097/00002826-198902000-00004;;10.4088/jcp.v69n0522a;;18681764;;10.1111/j.1651-2227.1994.tb13113.x;;7919772;;10.1017/s0317167100119304;;264152;;pmc1381393;;1389947;;10.1111/j.1365-2125.1992.tb04129.x;;10.1016/j.forsciint.2011.09.014;;22014974;;16267211;;16382538;;10.1212/01.wnl.0000188670.38576.bd;;1326902;;10.1111/j.1530-0277.1992.tb00658.x;;2571021;;7814832;;10.1097/00004850-199409000-00011;;10.1097/00002826-199201001-00157;;1498849;;10.1016/0924-977x(93)90038-n;;5550840;;10.1093/bja/43.2.110;;5550841;;10.1093/bja/43.2.113;;4061802;;10.1111/j.1365-2044.1985.tb10552.x;;7449723;;10.1016/0301-0082(73)90014-2;;6843688;;10.1007/bf00649351;;8506453;;10.1093/sleep/16.3.216;;2406848;;10.1093/sleep/13.1.24;;10.1016/0006-2944(77)90034-5;;869940;;725311;;4124818;;10.1016/s0149-7634(89)80053-3;;2691926;;192353;;9277127;;18852348;;10.1001/archneur.65.10.1337;;10.1007/bf00265954;;8299669;;4293055;;10.1016/0028-3908(66)90007-4;;10.1016/0006-2952(66)90045-1;;19116896;;10.1002/art.24142;;9779855;;3888969;;12734908;;2669980;;10.1016/0006-3223(89)90048-6;;10.1093/sleep/13.6.479;;2281247;;1596007;;10.1164/ajrccm/145.6.1378;;7260659;;10.1111/j.1528-1157.1988.tb03732.x;;3391142;;4269968;;10.1007/bf00501479;;6145018;;9383489;;10.1111/j.1553-2712.1997.tb03677.x;;9365423;;10.3109/15563659709001236;;10.1007/978-3-642-66925-5_7;;10.1097/00004311-196900710-00007;;5392628;;4164970;;10.1016/0013-4694(67)90064-8;;10.1016/j.sleep.2019.11.179;;20868750;;10.1016/j.ejpb.2010.09.004,"“Guidance for Industry. Food-Effect Bioavailability and Fed Bioequivalence Studies.” U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Dec. 2002. (Year: 2002).;;Borgen et al. (The Influence of Gender and Food on the Pharmacokinetics of Sodium Oxybate Oral Solution in Healthy Subjects. Journal of Clinical Pharmacology, 2003;43:59-65). (Year: 2003).;;“HIB-IMUNE,” Physicians Desk Reference (41st ed.), (1987), 1095-1096.;;“HibVAX,” Physicians Desk Reference (41st ed.), (1987), 870.;;“Phospholine Iodide,” Physicians Desk Reference (50th ed.), (1996), 2784.;;“Taxotere,” Physicians Desk Reference (51st ed.), (1997), 2204-2207.;;21 C.F.R. 184, Food and Drug Administration, HHS, (1998), pp. 441-535.;;Activase, Physicians Desk Reference (50th ed.), (1996), pp. 312,1058-1061.;;Akifuddin et al. “Preparation, characterization and in-vitro evaluation of microcapsules for controlled release of Diltiazem hydrochloride by Ionotropic gelation technique.” Journal of Applied Pharmaceutical Science (2013); 3.4: 35-42.;;Alshaikh et al., “Sodium Oxybate for Narcolepsy with Cataplexy: Systematic Review and Meta-Analysis,” Journal of Clinical Sleep Medicine, 2012, vol. 8, No. 4, 451-458.;;Anand et al. “Ion-exchange resins: carrying drug delivery forward.” Drug Discovery Today (2001); 6.17: 905-914.;;Baldrick, P., “Pharmaceutical Excipient Development: The Need for Preclinical Guidance,” Regul. Toxicol. Pharmacol. Oct. 2000 32(2):210-218.;;Bodmeier, R., “Tableting of coated pellets,” European Journal of Pharmaceutics and Biopharmaceutics, (1997) 43(1), 1-8.;;Borgen et al., “The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects.” J Clin Pharmacol. (2003); 43(1): 59-65.;;Borgen, L., et al. “Xyrem® (sodium oxybate): A Study of Dose Proportionality in Healthy Human Subjects.” J. Clin. Pharmacol. (2000); 40:1053.;;Broughton, et al. “Effects of Nocturnal Gamma-Hydroxybutyrate on Spell/Waking Patterns in Narcolepsy-Cataplexy.” Can J. Neural Sci (1980); 7 (1): 23-31.;;Broughton, et al. “Gamma-Hydroxy-Butyrate in the Treatment of Narcolepsy: a Preliminary Report.” (1976) Narcolepsy, Ny, N.Y., Spectrum Publications, Inc. 659-668.;;Caballero et al. “Characterization of alginate beads loaded with ibuprofen lysine salt and optimization of the preparation method.” International Journal of Pharmaceutics (2014); 460.1: 181-188.;;Chern Abstract ES302338, SciFinder®, (1964), 1 pg.;;Chemical Abstracts: Seventh Collective Index, vols. 56-65, (1962-1966), 4 pgs.;;Davis et al. “Active chloride secretion in the normal human jejunum.” J Clin Invest. (1980); 66(6): 1326-1333.;;Frucht, et al. “A pilot Tolerability and Efficacy Trial of Sodium Oxybate in Ethanol-Responsive Movement Disorders.” Movement Disorders (2005); 20 (10): 1330-1337.;;Gallimberti et al., “Clinical efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal,” EurArch Psychiatry Clin Neurosci. 1994;244(3):113-114.;;Gallimberti et al., “Gamma-Hydroxybutyric Acid for Treatment of Opiate Withdrawal Syndrome,” Neuropsychopharmacology, 1993, vol. 9, No. 1, pp. 77-81.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2019/062237, dated Mar. 31, 2020, 11 pages.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2020/066561, dated Apr. 13, 2021, 12 pages.;;Jazz Pharmaceuticals, “Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness,” Mar. 26, 2019, 2 pages, retrieved from https://investor.jazzpharma.com/node/16206/pdf.;;Keating, GM, “Sodium Oxybate: A Review of Its Use in Alcohol Withdrawal Syndrome and in the Maintenance of Abstinence in Alcohol Dependence,” Clinical Drug Investigation (2014) 34, 63-80.;;Khediri et al., “Efficacy of Diosmectite (Smecta)® in the Treatment of Acute Watery Diarrhea in Adults: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study,” Hindawi Publishing Corporation, Gastroenterology Research and Practice, 2011, vol. 2011, Article ID 783196, 8 pages.;;Lapierre et al., “The Effect of Gamma-Hydroxybutyrate: A Double-Blind Study of Normal Subjects,” Sleep Research (1988); 17:99, 1988, 6 pages. (Abstract Only).;;Lubrano, et al. “Fibromyalgia in Patients with Irritable Bowel Syndrome. An Association with the Severity of the Intestinal Disorder.” Int J Colorectal Dis. (2001); 16 (4): 211-215.;;Luhn, O., “Using Excipients in Powder Formulations,” Pharmaceutical Technology Europe, Jan. 7, 2011, vol. 23, Issue 1, 6 pages, retrieved from https://www.pharmtech.com/view/using-excipients-powder-formulations.;;Mahore et al. “Ion exchange resins: pharmaceutical applications and recent advancement.” Int J Pharm Sci Rev Res (2010); 1.2: 8-13.;;Mamelak, M., et al., “Treatment of Narcolepsy and Sleep Apnea with Gammahydroxybutyrate: A clinical and polysomnographic case study.” Sleep (1981); 4 (1): 105-111.;;Mamelak, M., et al., “Treatment of Narcolepsy with y-hydroxybutyrate. A review of Clinical and Sleep Laboratory Findings.” Sleep (1986); 9 (1): 285-290.;;Medicines for Children, “Oral Rehydration Salts,” Leaflet information published Jul. 25, 2013, by Neonatal and Paediatric Pharmacists Group (NPPG), 6 pages, retrieved from https://www.medicinesforchildren.org.uk/oral-rehyd ration-salts.;;Moldofsky et al. “A Chronobiologic Theory of Fibromyalgia.” J. Muscoloskel. Pain, 1, 49 (1993).;;Moldofsky, et al. “Musculoskeletal Symptoms and Non-REM Sleep Disturbance in Patients with ‘Fibrositis Syndrome’ and Healthy Subjects.” Psychosom. Med. (1975); 37 (4): 341-351.;;Morrison, Robert Thornton, et al., Organic Chemistry, 3rd Edition, (1973), pp. 672-677.;;Ohta et al. “Development of a simple method for the preparation of a silica gel based controlled delivery system with a high drug content.” European Journal of Pharmaceutical Sciences (2005); 26.1: 87-96.;;Outlaw, et al. “Dyspepsia and its Overlap with Irritable Bowel Syndrome.” Curr Gastroenterol Rep. (2006); 8 (4): 266-272.;;Parmar et al., “Clinical Characteristics of Cataplectic Attacks in Type 1 Narcolepsy,” Current Neurology and Neuroscience Reports (2020) 20:38, 9 pages.;;Patil et al. “A review on ionotropic gelation method: novel approach for controlled gastroretentive gelispheres.” International Journal of Pharmacy and Pharmaceutical Sciences (2012); 4.4: 27-32.;;Puguan et al. “Diffusion characteristics of different molecular weight solutes in Ca-alginate gel beads.” Colloids and Surfaces A: Physicochemical and Engineering Aspects (2015); 469:158-165.;;Remington. The Science and Practice of Pharmacy. 20th Edition, Gennaro, Ed,. Lippincott Williams & Wilkins (2000). (See e.g. p. 861).;;Remington. The Science and Practice of Pharmacy. 20th Edition, Gennaro, Ed,. Lippincott Williams & Wilkins. Chapter 45 (Oral Solid Dosage Forms) (2000) pp. 889-928.;;Rohm and Haas. “Duolite AP143/1083 Pharmaceutical Grade Anion Exchange Resin.” Feb. 2006, 4 pages.;;Roxane Laboratories, Inc.'s Answer and Affirmative Defenses to Plaintiff's Complaint, (Jan. 4, 2013), 8 pages.;;Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint, (Dec. 29, 2010), 21 pages.;;Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint, (Jun. 1, 2011), 12 pages.;;Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint, (Mar. 9, 2011), 13 pages.;;Roxane Laboratories, Inc.'s Answer, Affirmative Defenses and Counterclaims to Plaintiff's Complaint, (Nov. 9, 2012), 18 pages.;;Roxane Laboratories, Inc.'s Initial Invalidity and Noninfringement Contentions Pursuant to Local Patent Rule 3.6, (Apr. 14, 2011), 317 pages.;;Rubbens et al., “Gastric and Duodenal Ethanol Concentrations after intake of Alcoholic Beverages in Postprandial Conditions,” Molecular Pharmaceutics, (2017) 14(12):4202-4208.;;Scharf, M. B., et al., “GHB—New Hope for Narcoleptics?” Biol Psychiatry (1989); 26 (4): 329-330.;;Scrima, L., et al., “Narcolepsy.” New England J. Med. (1991); 324 (4): 270-272.;;Seno and Yamabe. “The Rheological Behavior of Suspensions of Ion-exchange Resin Particles.” Bulletin of the Chemical Society of Japan (1966); 39.4: 776-778.;;Shah et al., “In vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2,” Pharm Research, (1998) 15(6):889-896.;;Singh et al. “Ion exchange resins: drug delivery and therapeutic applications.” Fabad J. Pharm. Sci (2007); 32: 91-100.;;Srikanth et al., “Ion-exchange resins as controlled drug delivery carriers.” Journal of Scientific Research (2010); 2.3: 597-611.;;Takka and Gürel. “Evaluation of chitosan/alginate beads using experimental design: formulation and in vitro characterization.” AAPS PharmSciTech (2010); 11.1: 460-466.;;The Dow Chemical Company, Product Data Sheet for AMBERLITE™ IRN78 Resin. Form No. 177-02230-0311, Rev. 0, 3 pages.;;Thorpy, M.J., “Recently Approved and Upcoming Treatments for Narcolepsy,” CNS Drugs (2020) 34:9-27.;;Transcript of a Markman Hearing, dated Apr. 26, 2012, in the case of Jazz Pharmaceuticals, Inc., Plaintiff, v. Roxane Laboratories, Inc., Defendant (United States District Court for the District of New Jersey, Civil 106108 ES), (Apr. 26, 2012).;;Turnberg, L.A. “Abnormalities in intestinal electrolyte transport in congenital chloridorrhoea.” Gut. (1971); 12(7): 544-551.;;U.S. Department of Health and Human Services et al., “Dissolution Testing of Immediate Release Solid Oral Dosage Forms,” Food and Drug Administration, CDER, Aug. 1997, 17 pages.;;U.S. Department of Health and Human Services et al., “Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations”, Food and Drug Administration, CDER, Sep. 1997, 27 pages.;;Unknown author, title: definition of biotransformation; Medical dictionary; downloaded Jun. 21, 18 (Year: 2018), 3 pages.;;Walden et al., “The Effect of Ethanol on the Release of Opioids 30 from Oral Sustained-Release Preparations,” Drug Development and Industrial Pharmacy, 2007, 33:10,1101-1111.;;Wermuth (Ed.), The Practice of Medicinal Chemistry, Academic Press, Third Edition, “Preparation of Water-Soluble Compounds Through Salt Formulation,” Chapter 37, 2008, p. 758, 6 pages.;;World Health Organization, “Annex 7: Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability,” WHO Expert Committee on Specifications for Pharmaceutical Preparations Fortieth Report, pp. 347-390, 2006, retrieved from http://apps.who.int/prequal/info_general/documents/TRS937/WHO_TRS_937_eng.pdf#page=359.;;Zheng (Ed.), “Formulation and Analytical Development for Low-Dose Oral Drug Products,” John Wiley & Sons, Inc., Hoboken, New Jersey, Table 4.1, p. 65, 2009, 3 pages.;;Arena, C., et al., “Absorption of Sodium Gamma-Hydroxybutyrate and its Prodrug Gamma-Butyrolactone: Relationship Between In Vitro Transport and In Vivo Absorption,” Journal of Pharmaceutical Sciences, 1980, 69(3): 356-358.;;Bédard, M.A., et al., “Nocturnal Gamma-Hydroxybutyrate—Effect on Periodic Leg Movements and Sleep Organization of Narcoleptic Patients”, Clin Neuropharmacol., 1989, 12(1): 29-36.;;Berner, Jon E., “A Case of Sodium Oxybate Treatment of Tardive Dyskinsela and Bipolar Diorder,” J. Clin Psychiatry, 2008, 69: 862.;;Berthier, M, et al., “Possible Involvement of a Gamma-Hydroxybutyric Acid Receptor in Startle Disease”, Acta Paediatr, 1994, 83(6): 678-680.;;Broughton, Roger, et al., “The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate”, Le Journal Canadien des Sciences Neurologiques, 1979, 6(1): 285-289.;;Erowid, “Gamma-hydroxybutyrate (GHB) Basic Synthesis Procedure,” http://www.crowid.ondchemicals/ghb/ghb svnthcsis.shtm (as downloaded on Aug. 8, 2013).;;European Patent Office, European Search Report for European Application Serial No. 03075658.9, dated Apr. 11, 2003, 5 pg.;;Ferrara, S.D., et al., “Pharmacokinetics of Gamma-Hydroxybutyric Acid in Alcohol Dependent Patients After Single and Repeated Oral Doses”, Br. J. Clin. Pharmaca., 1992, 34(3): 231-235.;;Ferris, Trevor J., et al., “Synthesis, characterisation and detection of gamma-hydroxybutyrate salts”, Forensic Science International, 2012, 216: 158-162.;;Fides, “Solutions of 4-hydroxybutyric acid salts for injection,” Chem Abstract ES302338, Laboratorio M. Cuatecases, S.A., 2011, 2 pp.;;Frucht, S.J., et al., “A Single-Blind, Open-Label Trial of Sodium Oxybate for Myoclonus and Essential Tremor,” Neurology, 2005, 65: 1967-1970.;;Gallimberti, L., et al., “Gamma-Hydroxybutric Acid in the Treatment of Alcohol Dependence: A Double-Blind Study”, Alcohol Clin. Exp. Res., 1992, 16(4): 673-676.;;Gallimberti, L., et al., “Gamma-hydroxybutyric Acid for Treatment of Alcohol Withdrawal Syndrome”, Clinical Pharmacology, 1989, 2(8666): 787-789.;;Geekwench et al., “Title: Does anyone know why Jazz choose to make sodium oxybate?”, Sep. 14, 2010; downloaded from http://www.talkaboutsleep.com/message/boards/topic/does-anybody-know-why-jazz-chose-to-make-sodium-oxybate/#sthash.no0PSCkL.dpuf on Jan. 21, 2015.;;Geekwench et al., “Title: Does anyone know why Jazz choose to make sodium oxybate?”, Sep. 14, 2010; downloaded from http://www.talkaboutsleep.com/message-boards/topic/does-anybody-know-why-jazz-chose-to-make-sodium-oxybate/ on Nov. 13, 2017 (30 pages).;;Gerra, G., et al., “Flumazenil effects on growth hormone response to gammahydroxybutyric acid”, Int Clin Psychopharmacol., 1994, 9(3): 211-215.;;Gessa, G.L., “Gamma-Hydroxybutyric Acid in the Treatment of Alcohol Dependence”, Clin. Neuropharm., 15 Suppl. 1, Pt. A, (1992), 303a-304a.;;Gessa, Gian Luigi, et al., “Gamma-hydroxybutyric acid (GHB) for treatment of ethanol dependence”, European Neuropsychopharmacology, 1993, 3(3): 224-225.;;Grove-White, I.G., et al., “Critical Flicker Frequency after Small Doses of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate”, Brit. J. Anaesth, 1971, 43(2): 110-112.;;Grove-White, I.G., et al., “Effect of Methohexitone, Diazepam and Sodium 4-Hydroxybutyrate on Short-Term Memory”, Brit. J. Anaesth., 1971, 43: 113-116.;;Hasenbos, M A, “Anaesthesia for bullectomy. A technique with spontaneous ventilation and extradural blockade”, Anaesthesia, 1985, 40(10): 977-980.;;Hoes, M.J.A.J.M., et al., “Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man”, Encephale, 1980, 6(1): 93-99.;;International Searching Authority, “International Search Report, dated Apr. 15, 2014, for Internaitonal Patent Application No. PCT/US2013/074954”.;;International Searching Authority, “Written Opinion, dated Apr. 15, 2014, for International Patent Application No. PCT/US2013/074954”.;;International Searching Authority, International Search Report and Written Opinion, dated Jun. 27, 2018, for International Patent Application No. PCT/EP2018/056745 (12 pages).;;International Searching Authority, International Search Report for International Application Serial No. PCT/US99/30740, dated Jul. 21, 2000, 1 pg.;;Jazz Pharmaceuticals, Inc., “XYREM® (sodium oxybate) oral solution Prescribing Information,” XYREM® US Package Insert available at http://pp.jazzpharma.com/pi/xyrem.en.USPI.pdf (downloaded Sep. 12, 2017).;;Jurkovich, Patti, Amendment filed in response to Written Opinion, International Application Serial No. PCT/US99/30740, filed Feb. 16, 2001, 9 pg.;;Laborit, H., “Gamma-Hydroxybutyrate, Succinic Semialdehyde and Sleep,” Laboratoire d'Eutonologie, 1973, 8: 257-274.;;Ladinsky, Herbert, et al., “Mode of Action of Gamma-Butyrolactone on the Central Cholinergic System,” Naunyn-Schmiedeberg's Arch. Pharmacal., 1983, 322: 42-48.;;Lammers, G.J., et al., “Gammahydroxybutyrate and Narcolepsy: A Double-Blind Placebo-Controlled Study,” Sleep, 1993, 16(3): 216-220.;;Lapierre, O., et al., “The Effect of Gamma-Hydroxybutyrate on Nocturnal and Diurnal Sleep of Normal Subjects: Further Considerations on REM Sleep-Triggering Mechanisms,” Sleep, 1990, 13(1): 24-30.;;Lee, C.R., “Evidence for the Beta-Oxidation of Orally Administered 4-Hydroxybutyrate in Humans”, Biochemical Medicine, 1977, 17(3): 284-291.;;Lettieri, John, et al., “Improved Pharmacological Activity via Pro-Drug Modification: Comparative Pharmacokinetics of Sodium Gamm-Hydroxybutyrate and Gamma-Butyrolactone”, Research Communications in Chemical Pathology and Pharmacology, 1978, 22(1): 107-118,.;;Lynch, M., “Malic Acid”, The Handbook of Pharmaceutical Excipients, 2nd Ed., 1994, 63 3: 285-286.;;Mamelak, M., et al., “Sleep-Inducing Effects of Gammahydroxybutyrate”, The Lancet, 1973, 2(7824): 328-329.;;Mamelak, Mortimer, “Gammahydroxybutyrate: An Endogenous Regulator of Energy Metabolism”, Neuroscience and Biobehavioral Reviews, 1989, 13(4): 187-198.;;Mamelak, Morty, et al., “The Effects of Gamma-Hydroxybutyrate on Sleep”, Biological Psychiatry, 1977, 12(2): 273-288.;;Morrison, Robert T., et al., “Organic Chemistry”, Chapter 20: “Functional Derivatives of Carboxylic Acids,” 3rd Edition, 1973, pp. 658-700.;;Nema, Sandeep, et al., “Excipients and Their Use in Injectable Products”, PDA J. Pharm. Sci. Technol, 1997, 51(4): 166-171.;;Neuman, Ariel, “GHB's Path to Legitimacy: An Administrative and Legislative History of Xyrem”, paper submitted to Harvard Law School, 2004, 1-39.;;Ondo, William G., et al., “Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson Disease,” Arch. Neural., 2008, 65(10): 1337-1340.;;Palatini, P., et al., “Dose-Dependent Absorption and Elimination of Gamma-Hydroxybutyric Acid in Healthy Volunteers”, Eur. J. Clin Pharmacal., 1993, 45(4): 353-356.;;Roth, R. H., et al., “Gamma-Butyrolactone and Gamma-Hydroxybutyric Acid-II. The Pharmacologically Active Form”, J. Neuropharmacol. 1966, 5: 421-428.;;Roth, Robert H., et al., “Gamma-Butyrolactone and Gamma-Hydroxybutyric Acid-I, Distribution and Metabolism”, Biochemical Pharmacology, 1966, 15: 1333-1348.;;Russel, I. Jon, et al., “Sodium Oxybate Relieves Pain and Improves Function in Fibromyaligia Syndrome,” Arthritis. Rheum , 2009, 60: 299-309.;;Scharf et al., “Effect of Gamma-Hydroxybutyrate on Pain, Fatigue, and the Alpha Sleep Anomaly in Patients with Fibromyalgia. Preliminary Report”, The Journal of Rheumatology, 25(10): 1986-1990 (1998).;;Scharf, M.B., et al., “The Effects and Effectiveness of Gamma-Hydroxybutyrate in Patients with Narcolepsy”, J. Clin. Psychiatry, 1985, 46(6): 222-225.;;Scharf, Martin B., et al., The Effects of Sodium Oxybate on Clinical Symptoms and Sleep Patterns in Patients with Fibromyalgia, J. Rheumatol, 2003, 30(5): 1070-1074.;;Scrima, et al., “Effect of High Altitude on a Patient with Obstructive Sleep Apnea”, Sleep Research, Abstract, 1987, 16: 427.;;Scrima, et al., “Effects of Gamma-Hydroxybutyrate (GHB) on Narcolepsy-Cataplexy Symptoms and MSLT Results in Male and Female Patients”, Association of Professional Sleep Societies, Abstract, 1988, 251.;;Scrima, et al., “Gamma-Hydroxybutyrate Effects on Cataplexy and Sleep Attacks in Narcoleptics”, Sleep Research, Abstract, 1987, 16: 134.;;Scrima, L, et al., “Efficacy of Gamma-Hydroxybutyrate Versus Placebo in Treating Narcolepsy-Cataplexy: Double-Blind Subjective Measures”, Biol. Psychiatry, 1989, 26(4): 331-343.;;Scrima, L. et al., “Effect of Gamma-Hydroxybutyrate on a Patient with Obstructive Sleep Apnea,” Sleep Research, Abstract, 1987, 16: 137.;;Scrima, Lawrence, et al., “The Effects of Gamma-Hydroxybutyrate on the Sleep of Narcolepsy Patients: A Double-Blind Study”, Sleep, 1990, 13(6): 479-490.;;Sériès, F., et al., “Effects of Enhancing Slow-Wave Sleep by Gamma-Hydroxybutyrate on Obstructive Sleep Apnea”, Am. Rev. Respir. Dis., 1992, 145(6): 1378-1383.;;Snead, O. Carter et al., “Ontogeny of Gamma-Hydroxybutyric Acid. I. Regional Concentration in Developing Rat, Money and Human Brain,” Brain Res., 1981, 227(4): 579-589.;;Snead, O. Carter, “Gamma-Hydroxybutyrate Model of Generalized Absence Seizures: Further Characterization and Comparison with Other Absence Models,” Epilepsia, 1988, 29(4): 361-368.;;Stock, Günter, et al., “Increase in Brain Dopamine after Axotomy or Treatment with Gammahydroxybutyric Acid Due to Elimination of the Nerve Impulse Flow”, Naunyn-Schmiedeberg's Arch, Pharmacal., 1973, 278(4): 347-361,.;;Strong, A. J., “Gamma-Hydroxybutyric Acid and Intracranial Pressure”, The Lancet, 1984, 1(8389): 1304.;;Suner, S., et al., “Pediatric Gamma Hydroxybutyrate Intoxication”, Acad. Emerg. Med., 1997, 4(11): 1041-1045.;;Tunnicliff, Godfrey, “Sites of Action of Gamma-Hydroxybutyrate (GHB)—A Neuroactive Drug with Abuse Potential”, Clinical Toxicology, 1997, 35(6): 581-590.;;United States District Court, “Opinion,” Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., Markman Hearing, No. 10-6108 (ES), (Sep. 14, 2012), 43 pg.;;United States District Court, “Order,” Jazz Pharmaceuticals, Inc. v. Roxane Laboratories, Inc., Markman Hearing, No. 10-6108 (ES), (Sep. 14, 2012), 1 pg.;;United States Pharmacopeia (USP), Pharmaceutic Ingredients, 23/NF18, 1995, p. 2205.;;Van Den Bogert, et al., “Placentatransfer of 4-Hydroxybutyric Acid in Man”, Anaesthesiology and Intensive Care Medicine, 1978, 110: 55-64.;;Vickers, M.D., “Gammahydroxybutyric Acid”, Int. Anesth. Clinic, 1969, 7(1): 75-89.;;Vogel et al., 2018, “Toxicologic/transport properties of NCS-382, a γ-hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder,” Toxicol In Vitro, 46:203-212 (Epub 2017),.;;Yamada, Y., et al., “Effect of Butyrolactone and Gamma-Hydroxybutyrate on the EEG and Sleep Cycle in Man”, Electroenceph. clin. Neurophysiol., 1967, 22: 558-562.;;Chen et al., “Pharmacokinetics, relative bioavailability and food effect of JZP-258 and sodium oxybate: results of two phase 1, open-label, randomised crossover studies in healthy volunteers,” Sleep Medicine, Abstracts, 2019, vol. 64, pp. S65-S66.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2021/019024, dated Jun. 2, 2021, 10 pages.;;Jha, M.K, “Modified release formulations to achieve the quality target product profile (QTPP),” IJPSR, 2012; vol. 3(8): 2376-2386.;;Rujivipat et al., “Improved drug delivery to the lower intestinal tract with tablets compression-coated with enteric/nonenteric polymer powder blends,” European Journal of Pharmaceutics and Biopharmaceutics (2010) 76: 486-492.;;Non-Final Office Action dated Aug. 25, 2021, for U.S. Appl. No. 17/222,579, 14 pages.",ACTIVE
426,EP,A2,EP 2238769 A2,178-948-887-835-641,2010-10-13,2010,EP 08866054 A,2008-12-17,US 2008/0087072 W;;US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,,MOTOROLA INC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC (2016-06-01);;MOTOROLA MOBILITY LLC (2012-09-05)",https://lens.org/178-948-887-835-641,Patent Application,yes,0,0,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;H04B1/40;;H04M1/03;;H04R1/02;;H04R1/28;;H04R5/00,,0,0,,,,ACTIVE
427,US,A1,US 2012/0275497 A1,004-228-500-436-502,2012-11-01,2012,US 201213543371 A,2012-07-06,US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/004-228-500-436-502,Patent Application,yes,0,5,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04B17/00;;H04B1/38,375/219;;375/224;;375/227,0,0,,,,ACTIVE
428,US,A1,US 2009/0006227 A1,003-950-630-027-231,2009-01-01,2009,US 13918008 A,2008-06-13,US 13918008 A;;US 94404907 P,2007-06-14,SYSTEM AND METHOD FOR GENERATING CONSOLIDATION INDICATORS,"A investment portfolio accounting system and method are provided. The system determines the percentage ownership in a number of investment securities. The system flags securities according to predetermined accounting and business rules. Consolidating or derecognizing the security with others interests is also determined by the system in accordance with predetermined rules. In one example, the accounting system flags (or communicates) a determination to consolidate according to percentage ownership. System reports generated by the accounting system are chronicled in a reporting database for downstream accounting systems.",CHEN-YOUNG MICHAEL P;;CLARK LINDSAY NICOLE;;DAMICO DAWN R;;PIZZINO JEFF LEE,CHEN-YOUNG MICHAEL P;;CLARK LINDSAY NICOLE;;DAMICO DAWN R;;PIZZINO JEFF LEE,,https://lens.org/003-950-630-027-231,Patent Application,yes,2,8,1,1,0,G06Q10/00;;G06Q10/00;;G06Q40/00;;G06Q40/00;;G06Q40/12;;G06Q40/12,G06Q10/00;;G06Q40/00,705/30,0,0,,,,DISCONTINUED
429,CN,A,CN 111517009 A,075-039-751-184-015,2020-08-11,2020,CN 202010078558 A,2020-02-03,US 201962800095 P,2019-02-01,SMART AIRFLOW DISTRIBUTION SYSTEM,"A shipping container is provided and includes a structural frame defining an interior, a transport refrigeration unit (TRU) and a control system. The TRU includes an inlet through which air is drawn from a lower region of the interior, a refrigeration unit configured to cool the air drawn from the lower region of the interior through the inlet and an outlet through which air cooled by the refrigeration unit is exhausted toward an upper region of the interior. The control system is configured to control an exhaustion of the air cooled by the refrigeration unit toward the upper region of the interior to maintain a predefined environmental condition within the interior.",CARRIER CORP,CHEN YU;;TAECKENS JAMES;;CLARK RICHARD;;CHIOU FUN SIN;;ELZINGA RENZE;;SAU TERRY,,https://lens.org/075-039-751-184-015,Patent Application,no,6,0,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,B65D88/74;;B65D88/12;;F25D17/08;;F25D29/00,,0,0,,,,ACTIVE
430,US,B2,US 9597332 B2,146-629-097-058-236,2017-03-21,2017,US 201514957020 A,2015-12-02,US 201514957020 A;;US 201462086323 P,2014-12-02,Sulfide alkyl compounds for HBV treatment,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/146-629-097-058-236,Granted Patent,yes,5,1,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,A61K31/5375;;A61K31/18;;A61K31/196;;A61K31/24;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/397;;A61K31/4453;;A61K31/495;;A61K45/06;;C07C323/62;;C07D295/155;;C07D295/192;;C07D305/06;;C07D307/16;;C07D309/08;;C07D487/10,,3,1,018-584-171-893-938,3005577;;10.1021/jm00153a018,"Ogata et al. (1986) ""Synthesis and Antiviral Activity of Sulfonamidobenzophenone Oximes and Sulfonamidobenzamides"" J. Med. Chem., vol. 29, pp. 417-423.;;International Search Report for International Patent Application No. PCT/US2015/063417 mailed Mar. 2, 2016.;;Written Opinion of the International Searching Authority for International Patent Application No. PCT/US2015/063417 dated Feb. 11, 2016.",ACTIVE
431,US,A1,US 2007/0254601 A1,194-818-662-488-76X,2007-11-01,2007,US 61731306 A,2006-12-28,US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,SYNCHRONOSS TECHNOLOGIES INC (2011-01-03);;APPLE INC (2019-11-30);;INTEL CORPORATION (2007-02-12),https://lens.org/194-818-662-488-76X,Patent Application,yes,2,16,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04B1/40,455/88,0,0,,,,ACTIVE
432,US,B2,US 7818013 B2,049-969-330-074-334,2010-10-19,2010,US 61731306 A,2006-12-28,US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,SYNCHRONOSS TECHNOLOGIES INC (2011-01-03);;APPLE INC (2019-11-30);;INTEL CORPORATION (2007-02-12),https://lens.org/049-969-330-074-334,Granted Patent,yes,2,19,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04W72/00,455/452.2;;455/450;;455/451;;455/452.1;;370/310;;370/322;;370/338;;370/339;;370/341,3,3,030-902-043-921-565;;007-655-844-257-212;;016-098-506-857-239,10.1016/s1403-3664(02)00118-4;;10.1109/pimrc.2004.1368736;;10.1109/pimrc.2004.1373821,"Martin Haardt et al., ""Smart antennas for wireless communications beyond the third generation,"" Computer Communications, vol. 26, Issue 1, Jan. 1, 2003, pp. 41-45.;;Vishakan Ponnampalam et al., ""MIMO Processing for HSDPA in UTRA TDD,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 4, pp. 2333-2336.;;Antti Tolli et al., ""Compensation of interference non-reciprocity in adaptive TDD MIMO-OFDM systems,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 2, pp. 859-863.",ACTIVE
433,TW,A,TW 202114196 A,073-520-019-817-588,2021-04-01,2021,TW 109129070 A,2020-08-26,US 201962906750 P;;US 202016894901 A,2019-09-27,Image sensor and manufacturing method thereof,"An image sensor includes a storage device, where the storage device includes a memory element, a first dielectric layer and a light shielding element. The memory element includes a storage node and a storage transistor gate, where the storage transistor gate is located over the storage node. The first dielectric layer is located over a portion of the storage transistor gate. The light shielding element is located on the first dielectric layer and includes a semiconductor layer. The semiconductor layer is electrically isolated from the memory element, where the light shielding element is overlapped with at least a part of a perimeter of the storage transistor gate in a vertical projection on a plane along a stacking direction of the memory element and the light shielding element, and the stacking direction is normal to the plane.",TAIWAN SEMICONDUCTOR MFG CO LTD,CHEN CHUNG-LEI;;LEE CLARK CHENG-ZONG;;WANG WEN-SHENG;;KUO CHIEN-LI,,https://lens.org/073-520-019-817-588,Patent of Addition,no,0,0,5,7,0,H01L27/14614;;H01L27/14623;;H01L27/14625;;H01L27/14643;;H01L27/14685;;H01L27/14689;;H01L27/14603;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14689;;H01L27/14685;;H01L27/14614;;H01L27/14623;;H01L27/14643;;H01L27/14685;;H01L27/14689,H01L27/146;;H01L21/302;;H01L21/3205;;H01L21/336,,0,0,,,,ACTIVE
434,WO,A2,WO 2009/085785 A2,016-600-942-677-219,2009-07-09,2009,US 2008/0087072 W,2008-12-17,US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,"Disclosed is a portable audio device and a quick-disconnect passive acoustic cover. The portable audio device includes a housing and a speaker supported by the housing that have a first system frequency response. The speaker of the portable audio device has a first side and a second side associated with a first audio port and a second audio port, associated with a first acoustic load and a second acoustic load respectively. The housing is configured to removably receive the cover which is configured to redefine at least one of the first acoustic load and the second acoustic load to replace the first system frequency response with a second system frequency response. The cover provides one or more additional surrounding structures, which replace the inherent frequency response with an improved frequency response. Different embodiments of the disclosed cover provide a plurality of sound quality enhancement options to a user.",MOTOROLA INC;;ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,,https://lens.org/016-600-942-677-219,Patent Application,yes,4,2,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;H04B1/40;;H04R5/00,,1,0,,,See also references of EP 2238769A4,PENDING
435,US,A1,US 2016/0277080 A1,038-255-632-419-779,2016-09-22,2016,US 201615169247 A,2016-05-31,US 201615169247 A;;US 201314108207 A;;US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/038-255-632-419-779,Patent Application,yes,2,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04B7/04;;H04B7/06;;H04L5/00;;H04W72/12,,0,0,,,,ACTIVE
436,US,B2,US 6823222 B2,085-019-215-051-141,2004-11-23,2004,US 87018501 A,2001-05-30,US 87018501 A,2001-05-30,Portable processor-based system,"
    A portable processor-based system may include a display that is controlled by a scroll wheel. The scroll wheel extends completely through the display housing so that it can be manipulated between the thumb and forefinger of the user. This scrolling operation may be done at the same time the display itself is held in the user's hand. 
",INTEL CORP,CHEN CLARK;;WHITE PHILIP;;CHO MASAHITO;;BROWN STEPHEN R;;RODDEN STEVEN;;JELI RICHARD,INTEL CORPORATION (2001-05-21),https://lens.org/085-019-215-051-141,Granted Patent,yes,8,2,2,2,0,G06F1/1626;;G06F1/169;;G06F2200/1632;;G06F1/169;;G06F1/1626;;G06F2200/1632,G06F1/16,700/83;;700/17;;345/184,0,0,,,,EXPIRED
437,US,B2,US 8611918 B2,119-650-543-545-614,2013-12-17,2013,US 201213543371 A,2012-07-06,US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY;;INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/119-650-543-545-614,Granted Patent,yes,11,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04W72/00,455/452.2;;455/450;;455/451;;455/452.1;;370/310;;370/322;;370/338;;370/339;;370/341,15,4,030-902-043-921-565;;007-655-844-257-212;;016-098-506-857-239;;111-442-997-617-646,10.1016/s1403-3664(02)00118-4;;10.1109/pimrc.2004.1368736;;10.1109/pimrc.2004.1373821;;10.1109/78.905894,"Office Action issued Jun. 26, 2012 in Japanese Patent Application No. 2009-510012.;;Huawei, ""Downlink Adaptation/schedulign guided by an efficient CQI-feedback scheme,"" TSG RAN WG1 meeting 44bis, R1-060821, Mar. 27-31, 2006, Athens, pp. 1-6.;;Chaliste et al., ""Uplink to Downlink Spatial Coverage Martix Transformation Concepts for Downlink Beamforming,"" University Duisburg-Essen, Department of Communication Systems, Duisburg, Germany, pp. 568-571.;;Hata et al., ""Experimental Evaluation on E-SDM with Channel Estimation Error Compensation,"" The Institute of Electronics Information and Communication Engineers, IEICE Technical Report, RCS2005-38 (Jun. 2005), Graduate School of Information Science and Technology, Hokkaido University, Sapporo, Japan, pp. 1-7.;;International Search Report mailed Sep. 28, 2007 from International Application No. PCT/US2007/067889.;;Office Action issued Oct. 23, 2012 from Chinese Patent Application No. 200780015620.0.;;Martin Haardt et al., ""Smart antennas for wireless communications beyond the third generation,"" Computer Communications, vol. 26, Issue 1, Jan. 1, 2003, pp. 41-45.;;Vishakan Ponnampalam et al., ""MIMO Processing for HSDPA in UTRA TDD,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 4, pp. 2333-2336.;;Antti Tolli et al., ""Compensation of interference non-reciprocity in adaptive TDD MIMO-OFDM systems,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 2, pp. 859-863.;;Office Action issued Aug. 12, 2011 in Japanese Application No. 2009-510012.;;Office Action issued Jan. 18, 2012 in Chinese Application No. 2007-80015620.0.;;Hochwald et al., ""Adapting a Downlink Array from Uplink Measurements,"" IEEE Transactions on Signal Processing, vol. 49, No. 3, Mar. 2001, pp. 642-653.;;Office Action issued May 14, 2013 from Japanese Patent Application No. 2009-510012.;;Office Action issued Jul. 29, 2013 from Chinese Patent Application No. 200780015620.0.;;3GPP, ""Views on the High Level Principles of MIMO for unicast traffic in E-UTRA downlink,"" 3GPP TSG RAN WG1 Meeting #44, R1-060521, Feb. 13-17, 2006, Denver, Colorado, USA, 9 pages.",ACTIVE
438,US,A1,US 2014/0185542 A1,112-600-628-378-034,2014-07-03,2014,US 201314108207 A,2013-12-16,US 201314108207 A;;US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 78441806 P;;US 79704206 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,,https://lens.org/112-600-628-378-034,Patent Application,yes,0,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04L5/00;;H04B7/04,370/329,0,0,,,,ACTIVE
439,EP,B1,EP 3689649 B1,052-428-390-122-613,2023-04-05,2023,EP 20153945 A,2020-01-27,US 201962800095 P,2019-02-01,SHIPPING CONTAINER,,CARRIER CORP,CHEN YU;;TAECKENS JAMES;;CLARK RICHARD;;CHIOU FUN SIN;;ELZINGA RENZE;;SAU TERRY,,https://lens.org/052-428-390-122-613,Granted Patent,yes,4,0,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,B60H1/00;;B60H1/32;;B60P3/20;;F25D11/00;;F25D17/00;;F25D17/04;;F25D17/06,,0,0,,,,ACTIVE
440,US,A9,US 2015/0358141 A9,025-523-748-270-212,2015-12-10,2015,US 201314108207 A,2013-12-16,US 201314108207 A;;US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 78441806 P;;US 79704206 P,2006-03-20,DOWNLINK CHANNEL PARAMETERS DETERMINATION FOR A MULTIPLE-INPUT-MULTIPLE-OUTPUT (MIMO) SYSTEM,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/025-523-748-270-212,Amended Application,yes,0,1,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04L5/00;;H04B7/04,,0,0,,,,ACTIVE
441,US,B2,US 10320451 B2,126-293-289-403-602,2019-06-11,2019,US 201615169247 A,2016-05-31,US 201615169247 A;;US 201314108207 A;;US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/126-293-289-403-602,Granted Patent,yes,28,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04B7/0413;;H04B7/0417;;H04B7/0426;;H04B7/06;;H04B17/24;;H04B17/26;;H04B17/309;;H04L5/00;;H04W72/12,,32,4,030-902-043-921-565;;007-655-844-257-212;;016-098-506-857-239;;111-442-997-617-646,10.1016/s1403-3664(02)00118-4;;10.1109/pimrc.2004.1368736;;10.1109/pimrc.2004.1373821;;10.1109/78.905894,"Office Action dated Sep. 13, 2016 in Japanese Application No. 2014-104931; 12 pages.;;Martin Haardt et al., “Smart antennas for wireless communications beyond the third generation,” Computer Communications, vol. 26, Issue 1, Jan. 1, 2003, pp. 41-45.;;Vishakan Ponnampalam et al., “MIMO Processing for HSDPA in UTRA TDD,” Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 4, pp. 2333-2336.;;Antti Tolli et al., “Compensation of interference non-reciprocity in adaptive TDD MIMO-OFDM systems,” Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 2, pp. 859-863.;;Office Action dated Aug. 12, 2011 in Japanese Application No. 2009-510012.;;Office Action dated Jan. 18, 2012 in Chinese Application No. 2007-80015620.0.;;Hochwald et al., “Adapting a Downlink Array from Uplink Measurements,” IEEE Transactions on Signal Processing, vol. 49, No. 3, Mar. 2001, pp. 642-653.;;Chaliste et al., “Uplink to Downlink Spatial Coverage Martix Transformation Concepts for Downlink Beamforming,” University Duisburg-Essen, Department of Communication Systems, Duisburg, Germany, pp. 568-571.;;Hata et al., “Experimental Evaluation on E-SDM with Channel Estimation Error Compensation,” The Institute of Electronics Information and Communication Engineers, IEICE Technical Report, RCS2005-38 (Jun. 2005), Graduate School of Information Science and Technology, Hokkaido University, Sapporo, Japan, pp. 1-7.;;International Search Report dated Sep. 28, 2007 from International Application No. PCT/US2007/067889.;;Office Action dated Jun. 26, 2012 in Japanese Patent Application No. 2009-510012.;;Huawei, “Downlink Adaptation/schedulign guided by an efficient CQI-feedback scheme,” TSG RAN WG1 meeting 44bis, R1-060821, Mar. 27-31, 2006, Athens, pp. 1-6.;;Office Action dated Oct. 23, 2012 from Chinese Patent Application No. 200780015620.0.;;Office Action dated May 14, 2013 from Japanese Patent Application No. 2009-510012.;;Office Action dated Jul. 29, 2013 from Chinese Patent Application No. 200780015620.0.;;3GPP, “Views on the High Level Principles of MIMO for unicast traffic in E-UTRA downlink,” 3GPP TSG RAN WG1 Meeting #44, R1-060521, Feb. 13-17, 2006, Denver, Colorado, USA, 9 pages.;;Extended Search Report dated Dec. 20, 2012 from European Patent Application No. 07761649.8.;;Office Action dated Jul. 29, 2013 from Japanese Patent Divisional Application No. 2012-210604.;;Office Action dated Jul. 28, 2015 from Japanese Patent Application No. 2014-104931.;;Huawei, “Downlink adaptation/scheduling guided by an efficient CQI-feedback scheme,” TSG RAN WG1 meeting 44bis, R1-060821, Agenda Item: 10.1.6, Mar. 27-31, 2006, Athens, 6 pages.;;3GPP, website: www.3gpp.org-/ftp/tsg_ran/WG1_RL1/TSGR1_44bis/Docs/ (Document date ranges from Mar. 15, 2006 to May 3, 2006), Dec. 29, 2015, 6 pages.;;3GPP, “The Mobile Broadband Standard,” 3GPP FAQ's, Lte Advanced Pro, website: http://www.3gpp.org/contact/3gpp-faqs, Dec. 29, 2015, 3 pages.;;Notification of Reexamination dated Mar. 16, 2016 from Chinese Patent Application No. 200780015620.0, 6 pages.;;Partial European Search Report dated Feb. 2, 2016 from European Divisional Patent Application No. 15160616.7, 10 pages.;;Office Action dated Feb. 9, 2016 from Japanese Divisional Application No. 2014-104931, 14 pages.;;Huawei, “Initial Performance Evaluation of Multi-user MIMO Scheme, ” 3GPP TSG RAN WG1, R1-051094, Agenda Item: 8.6, Oct. 10-14, 2005, San Diego, USA, 8 pages.;;Office Action dated Feb. 23, 2016 from Japanese Divisional Application No. 2015-071652, 9 pages.;;Extended European Search Report dated Apr. 28, 2016 from European Divisional Patent Application No. 15160616.7, 18 pages.;;First Office Action dated Aug. 2, 2017 from Chinese Divisional Application No. 201510175513.0, 17 pages.;;Article 94(3) issued Jan. 15, 2018 from European Patent Application No. 07761649.8, 8 pages.;;Chinese Patent Office; Second Office Action dated May 25, 2018 from Chinese Divisional Application No. 201510175513.0, 7 pages.;;Japanese Patent Office; Notice of Reason(s) for Rejection issued for Patent Application No. 2014-104931 dated Mar. 20, 2018; 19 pages.",ACTIVE
442,CN,A,CN 104753650 A,155-047-199-919-881,2015-07-01,2015,CN 201510175513 A,2007-05-01,US 79704206 P;;US 61731306 A;;CN 200780015620 A,2006-05-01,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LI GUANGJIE;;LIN XINTIAN E;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,,https://lens.org/155-047-199-919-881,Patent Application,no,6,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04L1/16;;H04L5/00,,0,0,,,,ACTIVE
443,EP,A1,EP 3689649 A1,058-457-878-621-687,2020-08-05,2020,EP 20153945 A,2020-01-27,US 201962800095 P,2019-02-01,SHIPPING CONTAINER,"A shipping container (101) including a structural frame (110) defining an interior (111), a transport refrigeration unit (130) and a control system (601), wherein the transport refrigeration unit (130) includes an inlet (131) through which air is drawn from a lower region of the interior (1112), a refrigeration unit (132) configured to cool the air drawn from the lower region of the interior (1112) through the inlet (131) and an outlet (133) through which air cooled by the refrigeration unit (132) is exhausted toward an upper region of the interior (1111), the control system (601) is configured to control an exhaustion of the air cooled by the refrigeration unit (132) toward the upper region of the interior (1111) to maintain a predefined environmental condition within the interior (111).
",CARRIER CORP,CHEN YU;;TAECKENS JAMES;;CLARK RICHARD;;CHIOU FUN SIN;;ELZINGA RENZE;;SAU TERRY,,https://lens.org/058-457-878-621-687,Patent Application,yes,4,0,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,B60H1/00;;B60H1/32;;B60P3/20;;F25D11/00,,0,0,,,,ACTIVE
444,US,B2,US 9379875 B2,084-106-071-017-663,2016-06-28,2016,US 201314108207 A,2013-12-16,US 201314108207 A;;US 201213543371 A;;US 88295710 A;;US 61731306 A;;US 78441806 P;;US 79704206 P,2006-03-20,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,INTEL CORP,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/084-106-071-017-663,Granted Patent,yes,22,0,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04W72/00;;H04B7/04;;H04B7/06;;H04B17/24;;H04B17/26;;H04B17/309;;H04L5/00,,27,4,030-902-043-921-565;;007-655-844-257-212;;016-098-506-857-239;;111-442-997-617-646,10.1016/s1403-3664(02)00118-4;;10.1109/pimrc.2004.1368736;;10.1109/pimrc.2004.1373821;;10.1109/78.905894,"Martin Haardt et al., ""Smart antennas for wireless communications beyond the third generation,"" Computer Communications, vol. 26, Issue 1, Jan. 1, 2003, pp. 41-45.;;Vishakan Ponnampalam et al., ""MIMO Processing for HSDPA in UTRA TDD,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 4, pp. 2333-2336.;;Antti Tolli et al., ""Compensation of interference non-reciprocity in adaptive TDD MIMO-OFDM systems,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 2, pp. 859-863.;;Office Action issued Aug. 12, 2011 in Japanese Application No. 2009-510012.;;Office Action issued Jan. 18, 2012 in Chinese Application No. 2007-80015620.0.;;Hochwald et al., ""Adapting a Downlink Array from Uplink Measurements,"" IEEE Transactions on Signal Processing, vol. 49, No. 3, Mar. 2001, pp. 642-653.;;Chaliste et al., ""Uplink to Downlink Spatial Coverage Martix Transformation Concepts for Downlink Beamforming,"" University Duisburg-Essen, Department of Communication Systems, Duisburg, Germany, pp. 568-571.;;Hata et al., ""Experimental Evaluation on E-SDM with Channel Estimation Error Compensation,"" The Institute of Electronics Information and Communication Engineers, IEICE Technical Report, RCS2005-38 (Jun. 2005), Graduate School of Information Science and Technology, Hokkaido University, Sapporo, Japan, pp. 1-7.;;International Search Report mailed Sep. 28, 2007 from International Application No. PCT/US2007/067889.;;Office Action issued Jun. 26, 2012 in Japanese Patent Application No. 2009-510012.;;Huawei, ""Downlink Adaptation/schedulign guided by an efficient CQI-feedback scheme,"" TSG RAN WG1 meeting 44bis, R1-060821, Mar. 27-31, 2006, Athens, pp. 1-6.;;Office Action issued Oct. 23, 2012 from Chinese Patent Application No. 200780015620.0.;;Office Action issued May 14, 2013 from Japanese Patent Application No. 2009-510012.;;Office Action issued Jul. 29, 2013 from Chinese Patent Application No. 200780015620.0.;;3GPP, ""Views on the High Level Principles of MIMO for unicast traffic in E-UTRA downlink,"" 3GPP TSG RAN WG1 Meeting #44, R1-060521, Feb. 13-17, 2006, Denver, Colorado, USA, 9 pages.;;Extended Search Report issued Dec. 20, 2012 from European Patent Application No. 07761649.8.;;Office Action issued Jul. 29, 2013 from Japanese Patent Divisional Application No. 2012-210604.;;3GPP, website: www.3gpp.org-/ftp/tsg-ran/WG1-RL1/TSGR1-44bis/Docs/ (Document date ranges from Mar. 15, 2006 to May 3, 2006), Dec. 29, 2015, 6 pages.;;3GPP, ""The Mobile Broadband Standard,"" 3GPP FAQ's, Lte Advanced Pro, website: http://www.3gpp.org/contact/3gpp-faqs, Dec. 29, 2015, 3 pages.;;Office Action issued Jul. 28, 2015 from Japanese Patent Application No. 2014-104931.;;Huawei, ""Downlink adaptation/scheduling guided by an efficient CQI-feedback scheme,"" TSG RAN WG1 meeting 44bis, R1-060821, Agenda Item: 10.1.6, Mar. 27-31, 2006, Athens, 6 pages.;;Notification of Reexamination issued Mar. 16, 2016 from Chinese Patent Application No. 200780015620.0, 6 pages.;;Partial European Search Report issued Feb. 2, 2016 from European Divisional Patent Application No. 15160616.7, 10 pages.;;Office Action issued Feb. 9, 2016 from Japanese Divisional Application No. 2014-104931, 14 pages.;;Huawei, ""Initial Performance Evaluation of Multi-user MIMO Scheme,"" 3GPP TSG RAN WG1, R1-051094, Agenda Item: 8.6, Oct. 10-14, 2005, San Diego, USA, 8 pages.;;Office Action issued Feb. 23, 2016 from Japanese Divisional Application No. 2015-071652, 9 pages.;;Extended European Search Report issued Apr. 28, 2016 from European Divisional Patent Application No. 15160616.7, 18 pages.",ACTIVE
445,US,B2,US 8229452 B2,017-441-478-282-352,2012-07-24,2012,US 88295710 A,2010-09-15,US 88295710 A;;US 61731306 A;;US 79704206 P;;US 78441806 P,2006-03-20,Downlink channel parameters determination for a multiple-input-multiple-output (MIMO) system,Embodiments of methods and apparatus for providing downlink channel parameters determination for downlink channels associated with a multiple-input-multiple-output (MIMO) system are generally described herein. Other embodiments may be described and claimed.,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,LI QINGHUA;;LIN XINTIAN E;;LI GUANGJIE;;CHEN KUILIN CLARK;;WU XIAOYUN MAY,APPLE INC (2019-11-30),https://lens.org/017-441-478-282-352,Granted Patent,yes,5,8,36,36,0,H04B17/24;;H04B17/26;;H04B17/309;;H04B7/043;;H04B7/0632;;H04B7/0639;;H04B7/0634;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/0417;;H04L5/0058;;H04B17/24;;H04B17/26;;H04B17/309;;H04B7/0632;;H04B7/043;;H04B7/0634;;H04B7/0639;;H04B7/0417;;H04L5/0058;;H04B7/0413;;H04W72/1273,H04W72/00,455/452.2;;455/450;;455/451;;455/452.1;;370/310;;370/322;;370/338;;370/339;;370/341,8,4,030-902-043-921-565;;007-655-844-257-212;;016-098-506-857-239;;111-442-997-617-646,10.1016/s1403-3664(02)00118-4;;10.1109/pimrc.2004.1368736;;10.1109/pimrc.2004.1373821;;10.1109/78.905894,"Martin Haardt et al., ""Smart antennas for wireless communications beyond the third generation,"" Computer Communications, vol. 26, Issue 1, Jan. 1, 2003, pp. 41-45.;;Vishakan Ponnampalam et al., ""MIMO Processing for HSDPA in UTRA TDD,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 4, pp. 2333-2336.;;Antti Tolli et al., ""Compensation of interference non-reciprocity in adaptive TDD MIMO-OFDM systems,"" Personal, Indoor and Mobile Radio Communications, 2004, PIMRC 2004, 15th IEEE International Symposium on Sep. 5-8, 2004, vol. 2, pp. 859-863.;;Office Action issued Aug. 12, 2011 in Japanese Application No. 2009-510012.;;Office Action issued Jan. 18, 2012 in Chinese Application No. 2007-80015620.0.;;Hochwald et al., ""Adapting a Downlink Array from Uplink Measurements,"" IEEE Transactions on Signal Processing, vol. 49, No. 3, Mar. 2001, pp. 642-653.;;Chaliste et al., ""Uplink to Downlink Spatial Coverage Martix Transformation Concepts for Downlink Beamforming,"" University Duisburg-Essen, Department of Communication Systems, Duisburg, Germany, pp. 568-571.;;Hata et al., ""Experimental Evaluation on E-SDM with Channel Estimation Error Compensation,"" The Institute of Electronics Information and Communication Engineers, IEICE Technical Report, RCS2005-38 (Jun. 2005), Graduate School of Information Science and Technology, Hokkaido University, Sapporo, Japan, pp. 1-7.",ACTIVE
446,US,A1,US 2002/0183862 A1,086-669-293-925-618,2002-12-05,2002,US 87018501 A,2001-05-30,US 87018501 A,2001-05-30,Portable processor-based system,"
   A portable processor-based system may include a display that is controlled by a scroll wheel. The scroll wheel extends completely through the display housing so that it can be manipulated between the thumb and forefinger of the user. This scrolling operation may be done at the same time the display itself is held in the user's hand. 
",CHEN CLARK;;WHITE PHILIP;;CHO MASAHITO;;BROWN STEPHEN R.;;RODDEN STEVEN;;JELI RICHARD,CHEN CLARK;;WHITE PHILIP;;CHO MASAHITO;;BROWN STEPHEN R;;RODDEN STEVEN;;JELI RICHARD,INTEL CORPORATION (2001-05-21),https://lens.org/086-669-293-925-618,Patent Application,yes,8,16,2,2,0,G06F1/1626;;G06F1/169;;G06F2200/1632;;G06F1/169;;G06F1/1626;;G06F2200/1632,G06F1/16,700/1;;361/681,0,0,,,,EXPIRED
447,EP,B1,EP 2238769 B1,097-874-147-873-874,2017-08-16,2017,EP 08866054 A,2008-12-17,US 2008/0087072 W;;US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,,GOOGLE TECHNOLOGY HOLDINGS LLC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC (2016-06-01);;MOTOROLA MOBILITY LLC (2012-09-05)",https://lens.org/097-874-147-873-874,Granted Patent,yes,9,0,10,10,0,H04R1/023;;H04R1/2819;;H04R1/2842;;H04R2499/11;;H04M1/035;;H04R1/2826;;H04M1/0254;;H04R1/2826;;H04R1/2842;;H04R1/2819;;H04R2499/11;;H04R1/023;;H04M1/035;;H04M1/0254,H04R1/20;;H04B1/40;;H04M1/03;;H04R1/02;;H04R1/28;;H04R5/00,,0,0,,,,ACTIVE
448,US,B2,US 10710959 B2,181-996-286-203-213,2020-07-14,2020,US 201816235167 A,2018-12-28,US 201816235167 A;;US 201715416222 A;;US 201514957020 A;;US 201462086323 P,2014-12-02,Sulfide alkyl compounds for HBV treatment,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/181-996-286-203-213,Granted Patent,yes,7,0,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,C07C323/53;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/196;;A61K31/216;;A61K31/24;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/397;;A61K31/44;;A61K31/4412;;A61K31/4453;;A61K31/495;;A61K31/5375;;A61K45/06;;C07C323/22;;C07C323/23;;C07C323/25;;C07C323/52;;C07C323/62;;C07D213/81;;C07D213/82;;C07D295/084;;C07D295/155;;C07D295/192;;C07D305/06;;C07D307/10;;C07D307/16;;C07D307/18;;C07D309/04;;C07D309/08;;C07D487/10,,5,1,018-584-171-893-938,3005577;;10.1021/jm00153a018,"Database accession No. 1280388-44-4, (Apr. 15, 2011) “Benzamide, N-(4-fluorophenyl)-3-[(2-thienylsulfonyl)amino]-”, Registry, Chemical Abstracts Service, Columbus, OH, US.;;Ogata et al. (1986) “Synthesis and Antiviral Activity of Sulfonamidobenzophenone Oximes and Sulfonamidobenzamides” J. Med. Chem. 29:417-423.;;International Search Report corresponding to International Patent Application No. PCT/US2015/063417, dated Mar. 2, 2016.;;Written Opinion corresponding to International Patent Application No. PCT/US2015/063417, dated Feb. 11, 2016.;;Registry No. 896341-85-8, File Registry on STN, Jul. 27, 2006.",ACTIVE
449,WO,A3,WO 2009/085785 A3,062-553-376-937-491,2009-09-17,2009,US 2008/0087072 W,2008-12-17,US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,"Disclosed is a portable audio device and a quick-disconnect passive acoustic cover. The portable audio device includes a housing and a speaker supported by the housing that have a first system frequency response. The speaker of the portable audio device has a first side and a second side associated with a first audio port and a second audio port, associated with a first acoustic load and a second acoustic load respectively. The housing is configured to removably receive the cover which is configured to redefine at least one of the first acoustic load and the second acoustic load to replace the first system frequency response with a second system frequency response. The cover provides one or more additional surrounding structures, which replace the inherent frequency response with an improved frequency response. Different embodiments of the disclosed cover provide a plurality of sound quality enhancement options to a user.",MOTOROLA INC;;ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,,https://lens.org/062-553-376-937-491,Search Report,yes,5,0,10,10,0,H04R1/023;;H04R1/2819;;H04R1/2842;;H04R2499/11;;H04M1/035;;H04R1/2826;;H04M1/0254;;H04R1/2826;;H04R1/2842;;H04R1/2819;;H04R2499/11;;H04R1/023;;H04M1/035;;H04M1/0254,H04R1/20;;H04B1/40;;H04R5/00,,0,0,,,,PENDING
450,BG,B1,BG 64707 B1,084-310-544-275-696,2005-12-30,2005,BG 10443400 A,2000-05-15,US 95988197 A;;US 15423998 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,"The invention relates to novel 2-halo-6-O-substituted ketolide derivatives with the formula to their pharmaceutically acceptable salts having antibacterial activity, to pharmaceutical compositions comprising a therapeutically effective amount of a compound according to the invention in combination with a pharmaceutically acceptable carrier, as well as to the utilization of the compounds or their pharmaceutically acceptable salt for the preparation of a medicament for treating bacterial infections in mammals. The invention also relates to the preparation of the compounds.",ABBOTT LAB,PHAN LY;;OR YAT SUN;;CHU DANIEL;;PLATTNER JACOB;;CHEN YAN;;CLARK RICHARD,,https://lens.org/084-310-544-275-696,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
451,US,A1,US 2016/0151375 A1,105-839-545-718-380,2016-06-02,2016,US 201514957020 A,2015-12-02,US 201514957020 A;;US 201462086323 P,2014-12-02,SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/105-839-545-718-380,Patent Application,yes,0,13,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,A61K31/5375;;A61K31/18;;A61K31/196;;A61K31/24;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/397;;A61K31/4453;;A61K31/495;;A61K45/06;;C07C323/63;;C07C323/67;;C07D295/155;;C07D295/192;;C07D305/06;;C07D307/16;;C07D309/08;;C07D487/10,,1,0,,,no references cited,ACTIVE
452,US,B2,US 11383923 B2,047-005-496-863-836,2022-07-12,2022,US 202016778639 A,2020-01-31,US 202016778639 A;;US 201962800095 P,2019-02-01,Smart airflow distribution system,"A shipping container is provided and includes a structural frame defining an interior, a transport refrigeration unit (TRU) and a control system. The TRU includes an inlet through which air is drawn from a lower region of the interior, a refrigeration unit configured to cool the air drawn from the lower region of the interior through the inlet and an outlet through which air cooled by the refrigeration unit is exhausted toward an upper region of the interior. The control system is configured to control an exhaustion of the air cooled by the refrigeration unit toward the upper region of the interior to maintain a predefined environmental condition within the interior.",CARRIER CORP,CHEN YU;;TAECKENS JAMES;;CLARK RICHARD;;CHIOU FUN SIN;;ELZINGA RENZE;;SAU TERRY,CARRIER CORPORATION (2019-02-22),https://lens.org/047-005-496-863-836,Granted Patent,yes,6,0,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,F25D17/00;;B65D88/74;;F25D17/04,,1,0,,,"European Search Report Application No. 20153945; dated Jul. 2, 2020; pp. 6.",ACTIVE
453,KR,A,KR 20100091230 A,060-599-203-375-073,2010-08-18,2010,KR 20107014100 A,2008-12-17,US 2008/0087072 W;;US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,,MOTOROLA INC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,,https://lens.org/060-599-203-375-073,Patent Application,no,0,0,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R5/00;;H04B1/40;;H04R1/20,,0,0,,,,ACTIVE
454,US,A1,US 2017/0298014 A1,092-772-305-313-84X,2017-10-19,2017,US 201715416222 A,2017-01-26,US 201715416222 A;;US 201514957020 A;;US 201462086323 P,2014-12-02,SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/092-772-305-313-84X,Patent Application,yes,0,0,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,C07C323/53;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/44;;A61K31/4412;;A61K31/5375;;A61K45/06;;C07C323/22;;C07C323/25;;C07C323/52;;C07D213/81;;C07D213/82;;C07D295/084;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D309/08,,0,0,,,,INACTIVE
455,US,B2,US 8712086 B2,001-298-180-799-834,2014-04-29,2014,US 96507707 A,2007-12-27,US 96507707 A,2007-12-27,Acoustic reconfiguration devices and methods,"Disclosed is a portable audio device and a quick-disconnect passive acoustic cover. The portable audio device includes a housing and a speaker supported by the housing that have a first system frequency response. The speaker of the portable audio device has a first side and a second side associated with a first audio port and a second audio port, associated with a first acoustic load and a second acoustic load respectively. The housing is configured to removably receive the cover which is configured to redefine at least one of the first acoustic load and the second acoustic load to replace the first system frequency response with a second system frequency response. The cover provides one or more additional surrounding structures, which replace the inherent frequency response with an improved frequency response. Different embodiments of the disclosed cover provide a plurality of sound quality enhancement options to a user.",ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES;;MOTOROLA MOBILITY LLC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,MOTOROLA MOBILITY INC (2010-07-31);;MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2007-12-27),https://lens.org/001-298-180-799-834,Granted Patent,yes,47,2,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;G10K11/16;;H04R1/02;;H04R25/00,381/345;;381/386;;381/71.6;;381/71.7;;381/370,11,1,113-580-148-279-265,10.1109/joe.2003.811888,"Andrey K. Morozov, Douglas C. Webb; ""A Sound Projector for Acoustic Tomography and Global Ocean Monitoring""; p. 174-185; Apr. 2003.;;Patent Cooperation Treaty, ""PCT Search Report and Written Opinion of the International Searching Authority"" for international Application No. PCT/US2008/087072 Jul. 28, 2009, 11 pages.;;Patent Cooperation Treaty, ""PCT Search Report and Written Opinion of the International Searching Authority"" for International Application No. PCT/US2008/087102 Sep. 22, 2009, 11 pages.;;European Patent Office, ""Extended European Search Report"" for Application No. 08869181.1-2225 Apr. 20, 2001, 8 pages.;;Korean Itellectual Property Office, ""Notice of Preliminary Rejection"", Oct. 6, 2011, pp. 1-3, Korean Pat Appln. No. 10-2010-7014100.;;Rospatent The Federal State Institute, ""The Federal Institute for Industrial Property of the Federal Service for the Intellectual Property Patent and Trademarks"", Sep. 23, 2011, 6 pages, Russian Pat. Appl. No. 201031197/28.;;The Federal Service for Intellectual Property, Patents and Trademarks, ""Decision on Grant Patent for Invention"". Apr. 2, 2012, Russian Pat. Appln. No. 2010131197, 6 pages.;;The State Intellectual Property Office of the People'S Republic of China, ""Notification of the First Office Action"" for Chinese Patent Application No. 200880123216.x dated Nov. 5, 2012, 17 pages.;;United State Patent and Trademark Office, ""Non-Final Office Action"" for U.S. Appl. No. 11/965,022 Mar. 8, 2012, 23 pages.;;United State Patent and Trademark Office, ""Non-Final Office Action"" for U.S. Appl. No. 13/103,416 Feb. 22, 2013, 7 pages.;;European Patent Office, ""Extended European Search Report"" for Application No. 08866054.3-1910, Jul. 10, 2013, 9 pages.",INACTIVE
456,US,A1,US 2009/0169041 A1,010-438-988-000-990,2009-07-02,2009,US 96507707 A,2007-12-27,US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,"Disclosed is a portable audio device and a quick-disconnect passive acoustic cover. The portable audio device includes a housing and a speaker supported by the housing that have a first system frequency response. The speaker of the portable audio device has a first side and a second side associated with a first audio port and a second audio port, associated with a first acoustic load and a second acoustic load respectively. The housing is configured to removably receive the cover which is configured to redefine at least one of the first acoustic load and the second acoustic load to replace the first system frequency response with a second system frequency response. The cover provides one or more additional surrounding structures, which replace the inherent frequency response with an improved frequency response. Different embodiments of the disclosed cover provide a plurality of sound quality enhancement options to a user.",MOTOROLA INC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,MOTOROLA MOBILITY INC (2010-07-31);;MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2007-12-27),https://lens.org/010-438-988-000-990,Patent Application,yes,31,50,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;H04R1/02,381/345,0,0,,,,INACTIVE
457,CN,A,CN 101919265 A,062-849-915-491-795,2010-12-15,2010,CN 200880123216 A,2008-12-17,US 2008/0087072 W;;US 96507707 A,2007-12-27,Acoustic reconfiguration devices and methods,"Disclosed is a portable audio device and a quick-disconnect passive acoustic cover. The portable audio device includes a housing and a speaker supported by the housing that have a first system frequency response. The speaker of the portable audio device has a first side and a second side associated with a first audio port and a second audio port, associated with a first acoustic load and a second acoustic load respectively. The housing is configured to removably receive the cover which is configured to redefine at least one of the first acoustic load and the second acoustic load to replace the first system frequency response with a second system frequency response. The cover provides one or more additional surrounding structures, which replace the inherent frequency response with an improved frequency response. Different embodiments of the disclosed cover provide a plurality of sound quality enhancement options to a user.",MOTOROLA INC,ZUREK ROBERT A;;SHAOHAI CHEN;;CLARK JOEL A;;STEUER PAUL R;;GILES DAVIS,"MOTOROLA MOBILE CO., LTD. (2011-01-07)",https://lens.org/062-849-915-491-795,Patent Application,no,2,2,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;H04B1/40;;H04R5/00,,0,0,,,,DISCONTINUED
458,US,A1,US 2020/0247606 A1,181-425-009-821-022,2020-08-06,2020,US 202016778639 A,2020-01-31,US 202016778639 A;;US 201962800095 P,2019-02-01,SMART AIRFLOW DISTRIBUTION SYSTEM,"A shipping container is provided and includes a structural frame defining an interior, a transport refrigeration unit (TRU) and a control system. The TRU includes an inlet through which air is drawn from a lower region of the interior, a refrigeration unit configured to cool the air drawn from the lower region of the interior through the inlet and an outlet through which air cooled by the refrigeration unit is exhausted toward an upper region of the interior. The control system is configured to control an exhaustion of the air cooled by the refrigeration unit toward the upper region of the interior to maintain a predefined environmental condition within the interior.",CARRIER CORP,CHEN YU;;TAECKENS JAMES;;CLARK RICHARD;;CHIOU FUN SIN;;ELZINGA RENZE;;SAU TERRY,CARRIER CORPORATION (2019-02-22),https://lens.org/181-425-009-821-022,Patent Application,yes,0,6,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,B65D88/74;;F25D17/04,,0,0,,,,ACTIVE
459,US,A1,US 2019/0202780 A1,052-989-337-415-951,2019-07-04,2019,US 201816235167 A,2018-12-28,US 201816235167 A;;US 201715416222 A;;US 201514957020 A;;US 201462086323 P,2014-12-02,SULFIDE ALKYL COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/052-989-337-415-951,Patent Application,yes,0,0,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,C07C323/53;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/196;;A61K31/216;;A61K31/24;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/397;;A61K31/44;;A61K31/4412;;A61K31/4453;;A61K31/495;;A61K31/5375;;A61K45/06;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/62;;C07D213/81;;C07D213/82;;C07D295/084;;C07D295/155;;C07D295/192;;C07D305/06;;C07D307/10;;C07D307/16;;C07D307/18;;C07D309/04;;C07D309/08;;C07D487/10,,0,0,,,,ACTIVE
460,SG,A,SG 10202000788Q A,074-561-401-018-186,2020-09-29,2020,SG 10202000788Q A,2020-01-29,US 201962800095 P,2019-02-01,SMART AIRFLOW DISTRIBUTION SYSTEM,,CARRIER CORP,YU CHEN;;JAMES TAECKENS;;RICHARD CLARK;;FUN SIN CHIOU;;RENZE ELZINGA;;TERRY SAU,,https://lens.org/074-561-401-018-186,Unknown,no,0,0,7,7,0,B65D88/744;;B65D88/121;;F25D17/08;;F25D29/00;;B60H1/00014;;B60H1/3232;;B60H1/00835;;B60P3/20;;F25D11/003;;F25D17/005;;F25D17/06;;F25D17/045;;F25D2700/123;;B65D88/745;;B65D2588/743;;F25D17/045;;F25D2700/12,,,0,0,,,,PENDING
461,EP,A4,EP 2238769 A4,085-552-125-015-855,2013-08-07,2013,EP 08866054 A,2008-12-17,US 2008/0087072 W;;US 96507707 A,2007-12-27,ACOUSTIC RECONFIGURATION DEVICES AND METHODS,,MOTOROLA MOBILITY LLC,ZUREK ROBERT A;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;DAVIS GILES,"MOTOROLA MOBILITY, INC. (2011-03-02);;GOOGLE TECHNOLOGY HOLDINGS LLC (2016-06-01);;MOTOROLA MOBILITY LLC (2012-09-05)",https://lens.org/085-552-125-015-855,Search Report,no,4,0,10,10,0,H04R1/2826;;H04R1/2826;;H04M1/0254;;H04M1/0254;;H04M1/035;;H04M1/035;;H04R1/023;;H04R1/023;;H04R1/2819;;H04R1/2819;;H04R1/2842;;H04R1/2842;;H04R2499/11;;H04R2499/11,H04R1/20;;H04B1/40;;H04M1/03;;H04R1/02;;H04R1/28;;H04R5/00,,1,0,,,See also references of WO 2009085785A2,ACTIVE
462,US,A1,US 2022/0362185 A1,084-153-170-445-593,2022-11-17,2022,US 202217860498 A,2022-07-08,US 202217860498 A;;US 202017131418 A;;US 201916575213 A;;US 201715709262 A;;US 201762473232 P,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK,JAZZ PHARMACEUTICALS INC (2017-07-17),https://lens.org/084-153-170-445-593,Patent Application,yes,0,0,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19,,0,0,,,,PENDING
463,US,B2,US 10196351 B2,129-517-483-014-490,2019-02-05,2019,US 201715416222 A,2017-01-26,US 201715416222 A;;US 201514957020 A;;US 201462086323 P,2014-12-02,Sulfide alkyl compounds for HBV treatment,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C,NOVIRA THERAPEUTICS INC (2015-12-14),https://lens.org/129-517-483-014-490,Granted Patent,yes,5,1,6,22,0,C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04;;A61K31/5375;;A61K31/196;;C07D309/08;;A61K31/351;;C07D295/155;;C07D307/16;;A61K31/341;;A61K31/24;;C07D305/06;;A61K31/337;;A61K31/18;;C07D295/192;;A61K31/4453;;A61K31/495;;C07D487/10;;A61K31/397;;A61K45/06;;C07C323/62;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;C07C2602/20;;A61K31/167;;A61K31/192;;A61K31/216;;A61K31/44;;A61K31/4412;;C07C323/22;;C07C323/25;;C07C323/52;;C07C323/53;;C07D213/81;;C07D213/82;;C07D295/084;;C07D307/10;;C07D307/18;;C07D309/04,C07C323/22;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/196;;A61K31/216;;A61K31/24;;A61K31/337;;A61K31/341;;A61K31/351;;A61K31/397;;A61K31/44;;A61K31/4412;;A61K31/4453;;A61K31/495;;A61K31/5375;;A61K45/06;;C07C323/25;;C07C323/52;;C07C323/53;;C07C323/62;;C07D213/81;;C07D213/82;;C07D295/084;;C07D295/155;;C07D295/192;;C07D305/06;;C07D307/10;;C07D307/16;;C07D307/18;;C07D309/04;;C07D309/08;;C07D487/10,,4,1,018-584-171-893-938,3005577;;10.1021/jm00153a018,"Registry No. 896341-85-8, File Registry on STN, Jul. 27, 2006.;;Ogata et al. (1986) “Synthesis and Antiviral Activity of Sulfonamidobenzophenone Oximes and Sulfonamidobenzamides” J. Med. Chem. 29:417-423.;;International Search Report corresponding to International Patent Application No. PCT/US2015/063417, dated Mar. 2, 2016.;;Written Opinion corresponding to International Patent Application No. PCT/US2015/063417, dated Feb. 11, 2016.",INACTIVE
464,PT,A,PT 80569 A,140-699-076-856-533,1985-06-01,1985,PT 8056985 A,1985-05-31,US 61632384 A;;US 61632584 A;;US 61632684 A;;US 61632784 A,1984-05-31,APPARATUS FOR MICROINDUCTIVE INVESTIGATION OF EARTH FORMATIONS,,SCHLUMBERGER LTD,KLEINBERG ROBERT L;;CHEN WENG CHO;;CLARK BRIAN;;GRIFFIN DOUGLAS D;;DUDLEY DONALD G,,https://lens.org/140-699-076-856-533,Patent Application,no,0,0,25,37,0,G01V3/28,G01V3/28,,0,0,,,,EXPIRED
465,US,A1,US 2005/0048597 A1,050-068-471-209-156,2005-03-03,2005,US 89921704 A,2004-07-26,US 89921704 A;;US 49776703 P,2003-08-26,Apparatus and method for liquid sample testing,"There is provided a device for partitioning a liquefied sample into discrete volumes. The device includes a bottom member; a top member disposed adjacent the bottom member; and at least one channel member disposed between the top and bottom members. The at least one channel member is at least partially defined by the top and bottom members and has first and second end portions. The first end portion of the at least one channel has an opening to receive liquid and the second end portion of the at least one channel has a reaction compartment and a vent opening. Accordingly, when the liquefied sample is introduced to the first end portion, capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion and at least a portion of the liquefied sample is caused to remain in the reaction compartment.",SMITH KENNETH E.;;GU HAOYI;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHEN CHUN-MING,SMITH KENNETH E;;GU HAOYI;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHEN CHUN-MING,IDEXX LABORATORIES INC (2004-07-20),https://lens.org/050-068-471-209-156,Patent Application,yes,52,27,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,435 3;;X435 4;;435/288.5,0,0,,,,ACTIVE
466,WO,A3,WO 2009/151777 A3,110-457-486-318-770,2010-04-01,2010,US 2009/0040566 W,2009-04-14,US 10370208 A,2008-04-15,MUSIC VIDEO GAME WITH CONFIGURABLE INSTRUMENTS AND RECORDING FUNCTIONS,"Music video games provide configurable instruments and/or recording functions. In some embodiments users may select an instrument or play, and also select desired characteristics of the instrument. The desired characteristics may include selection of a chord or selection of effects associated with the type of musical instrument. In some embodiments users may record tracks of music using their simulated musical instrument controllers.",ACTIVISION PUBLISHING INC;;BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,,https://lens.org/110-457-486-318-770,Search Report,yes,4,0,3,3,0,A63F13/10;;A63F2300/8047;;G10H1/368;;G10H2220/135;;A63F13/45;;A63F13/245;;A63F13/44;;A63F13/814;;A63F2300/8047;;G10H1/368;;G10H2220/135,G06Q50/00,,0,0,,,,PENDING
467,WO,A1,WO 2005/021157 A1,119-830-196-834-283,2005-03-10,2005,US 2004/0027659 W,2004-08-25,US 49776703 P;;US 89921704 A,2003-08-26,APPARATUS AND METHOD FOR LIQUID SAMPLE PARTITIONING,"There is provided a device (100) for partitioning a liquefied sample into discrete volumes. The device (100) includes a bottom member (110); a top member (112) disposed adjacent the bottom member (110); and at least one channel member (120) is at least partially defined by the top and bottom members and has first and second end portions. The first end portion (118) of the at least one channel has an opening to receive liquid and the second end portion of the at least one channel has a reaction compartment (122) and a vent opening. Accordingly, when the liquefied sample is introduced to the first end portion (118), capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion and at least a portion of the liquefied sample is caused to remain in the reaction compartment (122).",IDEXX LAB INC;;GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,,https://lens.org/119-830-196-834-283,Patent Application,yes,18,3,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,,2,0,,,"RECLES ET AL.: ""Compendium of Methods for the Microbiological Examination of Foods, 3rd ed."", 1992, article ""Most Probable Number Techniques"", pages: 105 - 199;;GREENBERG ET AL.: ""Standard Methods For the Examination of Water and Wastewater"", 1992",PENDING
468,BR,A2,BR PI1004270 A2,107-737-657-334-125,2015-01-20,2015,BR PI1004270 A,2010-07-14,US 22561109 P;;US 78961310 A,2009-07-15,TRANSFERIDOR SEM FIO DE FORÇA E DADOS ENTRE UM FURO DE POÇO MÃE E UM FURO DE POÇO LATERAL,"SiSTEMA PARA TRANSFERIR ENERGIA SEM FiO EM UM POÇO, METODO PARA FACILITAR UMA TRANSFERÊNCIA DE ENERGIA OU DADOS ENIRE UM POÇO PRINCIPAL E PELO MENOS UM POÇO LATERAIã, MÉTÇDO, E SISTEMA. Uma técnica permite comunicação sem fio de sinais em um poço. A técnica é empregada para comunicâçao de sinais de energia e/ou sinais de dados entre um poço principal e pelo menos um poço lateal. Um primeiro dispositivo sem fio é posicionado em um poço principal próximo a um poço lateral., e um segundo dispositivo sem fio é posicionado no poço lateral. O sinal de enerqia e/ou de dados é transferido sem fio entre os primeiro e segundo dispositivos sem fio via campos magnéticos. Uma pluralidade dos primeiro e segundo dispositivos sem fio pode ser empregada em pares cooperantes, para permitir comunircação entre o poço principal e uma pluralidade de poços laterais.",PRAD RES & DEV LTD,CLARK BRIAN;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;RIOUFOL EMMANUEL;;ALGEROY JOHN;;MCKINLEY PATRICK,,https://lens.org/107-737-657-334-125,Patent Application,no,0,0,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B47/12,,0,0,,,,INACTIVE
469,US,A1,US 2009/0258700 A1,118-896-693-424-125,2009-10-15,2009,US 10370208 A,2008-04-15,US 10370208 A,2008-04-15,MUSIC VIDEO GAME WITH CONFIGURABLE INSTRUMENTS AND RECORDING FUNCTIONS,"Music video games provide configurable instruments and/or recording functions. In some embodiments users may select an instrument or play, and also select desired characteristics of the instrument. The desired characteristics may include selection of a chord or selection of effects associated with the type of musical instrument. In some embodiments users may record tracks of music using their simulated musical instrument controllers.",BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,ACTIVISION PUBLISHING INC (2008-05-28),https://lens.org/118-896-693-424-125,Patent Application,yes,10,97,3,3,0,A63F13/10;;A63F2300/8047;;G10H1/368;;G10H2220/135;;A63F13/45;;A63F13/245;;A63F13/44;;A63F13/814;;A63F2300/8047;;G10H1/368;;G10H2220/135,A63F13/00;;A63F9/24,463/31;;463/35,13,1,158-391-019-718-428,10.1145/1242421.1242435,"""Creating songs with MIDI files"", 17 March 2008, Frets On Fire Wiki, available at .;;""Custom Songs"", 13 March 2008, Frets On Fire Wiki, available at .;;""Hering Mod"", 15 March 2008, Frets On Fire Wiki, available at .;;""fretsonfire.ini"", 10 April 2008, Frets On Fire Wiki, available at .;;""FoF - Song Manager"", 9 April 2008, Frets On Fire Wiki, available at .;;""Adding Downloaded Songs"", 25 March 2008, Frets On Fire Wiki, available at .;;""Freetar Editor"", 3 April 2008, Frets On Fire, available at .;;Hell_Ashes, ""Freetar Editor Tutorial"", 17 July 2006, downloaded on 26 March 2014 from >.;;""Freetar Hero"", 3 April 2008, downloaded on 27 March 2014 from >.;;Screenshots from ""Freetar Hero Editor Demonstration"", 15 May 2006, downloaded on 26 March 2014 from >.;;Screenshots from ""Freetar Hero - Tribute by Tenacious D"", 10 December 2006, downloaded on 26 March 2014 from >.;;Guitar Hero II Magazine, 2007, Activision.;;Guitar Hero II (Game & Guitar Controller Bundle), Apr. 3, 2007, IGN.com, available at >.",DISCONTINUED
470,EP,A1,EP 4115237 A1,174-290-654-356-443,2023-01-11,2023,EP 21765112 A,2021-03-03,US 202062984739 P;;US 2021/0020741 W,2020-03-03,DEVICES INCLUDING FERROELECTRIC NEMATIC MATERIAL AND METHODS OF FORMING AND USING SAME,,UNIV COLORADO REGENTS;;UNIV UTAH RES FOUND,CLARK NOEL;;CHEN XI;;GLASER MATTHEW A;;MACLENNAN JOSEPH E;;DONG DENGPAN;;BEDROV DIMITRY,,https://lens.org/174-290-654-356-443,Patent Application,yes,0,0,5,5,0,G02F1/141;;G02F1/141;;G02F2202/01;;G16C10/00;;G16C20/20;;G02F1/0045;;G02F1/0136;;G02F1/1358;;G02F1/141;;G02F2202/01;;G21K1/00,G02F1/141;;G02F1/1337,,0,0,,,,PENDING
471,WO,A1,WO 2010/028020 A1,180-815-856-279-876,2010-03-11,2010,US 2009/0055699 W,2009-09-02,US 9364508 P,2008-09-02,DISPENSING PATTERNS INCLUDING LINES AND DOTS AT HIGH SPEEDS,"A method for depositing a material on a substrate includes providing an apparatus with at least one material dispenser. The method further includes positioning the pen tip at a predetermined writing gap where the predetermined writing gap is a distance of more than 75 micrometers above the substrate. The method also provides for controlling velocity of the flow of material through the outlet and dispense speed based on dispensed line height and dispensed line width parameters. An apparatus for depositing a material on a substrate is also provided which may have one or more mechanical vibrators, a pen tip with a hydrophobic surface, or multiple nozzles and pen tips on a single pump.",NSCRYPT INC;;CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,,https://lens.org/180-815-856-279-876,Patent Application,yes,5,0,6,6,0,H05K3/1241;;H05K3/1241;;H01L21/67126;;H01L21/67126;;H01L21/6715;;H01L21/6715;;H05K2203/0126;;H05K2203/0126,B05D1/26,,1,0,,,See also references of EP 2321068A4,PENDING
472,CA,A1,CA 2535524 A1,028-777-477-636-102,2005-03-10,2005,CA 2535524 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,APPARATUS AND METHOD FOR LIQUID SAMPLE PARTITIONING,"There is provided a device (100) for partitioning a liquefied sample into discrete volumes. The device (100) includes a bottom member (110); a top member (112) disposed adjacent the bottom member (110); and at least one channel member (120) is at least partially defined by the top and bottom members and has first and second end portions. The first end portion (118) o f the at least one channel has an opening to receive liquid and the second end portion of the at least one channel has a reaction compartment (122) and a vent opening. Accordingly, when the liquefied sample is introduced to the first end portion (118), capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion and at least a portion of the liquefied sample is caused to remain in the reaction compartment (122).",IDEXX LAB INC,CHUN-MING CHEN;;CLARK SCOTT MARSHALL;;WAGNER SCOTT WILLIAM;;SMITH KENNETH E;;GU HAOYI,,https://lens.org/028-777-477-636-102,Patent Application,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00;;C12M1/20;;G01N1/18,,0,0,,,,INACTIVE
473,BR,B1,BR PI1004270 B1,067-220-418-914-324,2020-04-07,2020,BR PI1004270 A,2010-07-14,US 22561109 P;;US 78961310 A,2009-07-15,"sistema para transferir energia sem fio em um poço, método para facilitar uma transferência de energia ou dados entre um poço principal e pelo menos um poço lateral, método, e sistema","sistema para transferir energia sem fio em um poço, metodo para facilitar uma transferência de energia ou dados enire um poço principal e pelo menos um poço lateraiã, métçdo, e sistema. uma técnica permite comunicação sem fio de sinais em um poço. a técnica é empregada para comunicâçao de sinais de energia e/ou sinais de dados entre um poço principal e pelo menos um poço lateal. um primeiro dispositivo sem fio é posicionado em um poço principal próximo a um poço lateral., e um segundo dispositivo sem fio é posicionado no poço lateral. o sinal de enerqia e/ou de dados é transferido sem fio entre os primeiro e segundo dispositivos sem fio via campos magnéticos. uma pluralidade dos primeiro e segundo dispositivos sem fio pode ser empregada em pares cooperantes, para permitir comunircação entre o poço principal e uma pluralidade de poços laterais.",PRAD RES & DEVELOPMENT LTD,BRIAN CLARK;;EMMANUEL RIOUFOL;;JOHN ALGEROY;;KUO-CHIANG CHEN;;PATRICK MCKINLEY;;THOMAS H ZIMMERMAN,,https://lens.org/067-220-418-914-324,Granted Patent,no,0,0,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B47/12,,0,0,,,,INACTIVE
474,EP,A4,EP 2321068 A4,106-040-100-300-511,2012-01-18,2012,EP 09812150 A,2009-09-02,US 2009/0055699 W;;US 9364508 P,2008-09-02,DISPENSING PATTERNS INCLUDING LINES AND DOTS AT HIGH SPEEDS,,NSCRYPT INC,CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,,https://lens.org/106-040-100-300-511,Search Report,no,4,0,6,6,0,H05K3/1241;;H05K3/1241;;H01L21/67126;;H01L21/67126;;H01L21/6715;;H01L21/6715;;H05K2203/0126;;H05K2203/0126,B05D1/26;;B05C5/02;;H05K3/12,,1,0,,,See also references of WO 2010028020A1,ACTIVE
475,CN,A,CN 112889132 A,167-257-028-120-806,2021-06-01,2021,CN 201980069107 A,2019-10-16,US 201862749823 P;;US 2019/0056435 W,2018-10-24,METHOD FOR FORMING MOLYBDENUM FILMS ON A SUBSTRATE,"A process for forming a molybdenum-containing material on a substrate is described, in which the substrate is contacted with molybdenum dioxydichloride (MoO<2>Cl<2>) vapor under vapor deposition conditions, to deposit the molybdenum-containing material on the substrate. Advantageously, the robust process does not require pre-treatment of the substrate with a nucleating agent. In certain embodiments, the process results in the bulk deposition of molybdenum, e.g., by chemical vapor deposition (CVD) techniques such as pulsed CVD or ALD.",ENTEGRIS INC,BAUM THOMAS H;;HENDRIX BRYAN CLARK;;CHEN PHILIP S H;;WRIGHT JR;;WOECKENER JAMES,,https://lens.org/167-257-028-120-806,Patent Application,no,4,0,9,9,0,H01L21/28556;;H01L21/76843;;H01L21/76877;;C23C16/45523;;C23C16/06;;H01L21/28556;;H01L21/28194;;H01L21/02271;;H01L21/02178;;H01L21/324;;H01L21/02164;;H01L2924/01042;;H01L2924/01017;;H01L2924/04941;;C23C16/405;;C23C16/45523;;H01L21/0228;;H01L21/02414;;H01L21/02389;;H01L21/28556,H01L21/285;;H01L21/02;;H01L21/28;;H01L21/324,,0,0,,,,PENDING
476,AU,A1,AU 2004/268618 A1,157-337-821-327-463,2005-03-10,2005,AU 2004/268618 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,Apparatus and method for liquid sample partitioning,,IDEXX LAB INC,CHUN-MING CHEN;;SMITH KENNETH E;;CLARK SCOTT MARSHALL;;GU HAOYI;;WAGNER SCOTT WILLIAM,,https://lens.org/157-337-821-327-463,Patent Application,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00;;C12M1/20;;G01N1/18,,0,0,,,,INACTIVE
477,KR,A,KR 20230011915 A,189-841-268-746-411,2023-01-25,2023,KR 20227034533 A,2021-03-03,US 202062984739 P;;US 2021/0020741 W,2020-03-03,강유전성 네마틱 재료를 포함하는 디바이스들 및 그것들을 형성하고 사용하는 방법들,네마틱 액정 형성 분자들을 포함하는 디바이스들이 개시된다. 분자들은 하나 이상의 쌍극자를 포함하고 강유전성 네마틱 상태로 존재한다. 예시적인 디바이스들은 예를 들어 면내 방향으로 전기장을 인가하기 위한 전극을 더 포함할 수 있다.,UNIV COLORADO REGENTS;;UNIV UTAH RES FOUND,CLARK NOEL;;CHEN XI;;GLASER MATTHEW A;;MACLENNAN JOSEPH E;;DONG DENGPAN;;BEDROV DIMITRY,,https://lens.org/189-841-268-746-411,Patent Application,no,0,0,5,5,0,G02F1/141;;G02F1/141;;G02F2202/01;;G16C10/00;;G16C20/20;;G02F1/0045;;G02F1/0136;;G02F1/1358;;G02F1/141;;G02F2202/01;;G21K1/00,G02F1/141,,0,0,,,,PENDING
478,NO,B1,NO 344537 B1,096-787-543-801-571,2020-01-27,2020,NO 20101004 A,2010-07-14,US 22561109 P;;US 78961310 A,2009-07-15,Trådløs overføring av kraft mellom et moderbrønnhull og et sidebrønnhull,,SCHLUMBERGER TECHNOLOGY BV,CLARK BRIAN;;RIOUFOL EMMANUEL;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;ALGEROY JOHN;;MCKINLEY PATRICK,,https://lens.org/096-787-543-801-571,Granted Patent,no,3,0,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B47/12,,0,0,,,,INACTIVE
479,CA,A1,CA 2369623 A1,113-384-312-967-222,2000-06-29,2000,CA 2369623 A,1999-12-17,US 21533098 A;;US 9929849 W,1998-12-18,GELATIN REPLACEMENT COMPOSITION,"A gelling composition comprising a blend of an alginate (A), a hydrocolloid (B) and a galactomannan (C), wherein the ratio by weight of A:(B+C) is about 0.1:1 to about 1.5:1 and the ratio by weight of B:C is about 0.8:1 to about 1.2:1. A gel composition employing the gelling composition of this invention and a food product comprising one or more food ingredients and the gelling composition described above is also disclosed.",CP KELCO US INC,CLARK ROSS C;;CHEN YOU-LUNG;;MORRISON NEIL A;;TALASHEK TODD;;BURGUM DANIEL R,,https://lens.org/113-384-312-967-222,Patent Application,no,0,0,6,6,0,A23C9/154;;A23C13/16;;A23G3/346;;A23G3/38;;A23G3/42;;A23G2200/06;;A23V2002/00;;A23K20/163;;A23K50/48;;A23L29/238;;A23L29/256;;A23L29/27;;A23L9/12,A23C9/123;;A23C9/154;;A23C13/14;;A23C13/16;;A23G3/00;;A23G3/34;;A23G3/38;;A23G3/42;;A23K1/10;;A23K1/16;;A23K1/18;;A23L1/30;;A23L9/10;;A23L23/00;;A23L27/60;;A23L29/20;;A23L29/238;;A23L29/256;;A23L29/269,,0,0,,,,DISCONTINUED
480,AU,A,AU 2000/021877 A,003-962-458-713-130,2000-07-12,2000,AU 2000/021877 A,1999-12-17,US 21533098 A;;US 9929849 W,1998-12-18,Gelatin replacement composition,,MONSANTO CO,MORRISON NEIL A;;CLARK ROSS C;;CHEN YOU-LUNG;;BURGUM DANIEL R;;TALASHEK TODD,,https://lens.org/003-962-458-713-130,Patent Application,no,0,0,6,6,0,A23G3/42;;A23C9/154;;A23C13/16;;A23G3/346;;A23G3/38;;A23G2200/06;;A23K20/163;;A23K50/48;;A23L9/12;;A23L29/238;;A23L29/256;;A23L29/27;;A23V2002/00,A23C9/123;;A23C9/154;;A23C13/14;;A23C13/16;;A23G3/00;;A23G3/34;;A23G3/38;;A23G3/42;;A23K1/10;;A23K1/16;;A23K1/18;;A23L1/30;;A23L9/10;;A23L23/00;;A23L27/60;;A23L29/20;;A23L29/238;;A23L29/256;;A23L29/269,,0,0,,,,DISCONTINUED
481,EP,A1,EP 1658141 A1,031-373-509-555-372,2006-05-24,2006,EP 04782202 A,2004-08-25,US 2004/0027659 W;;US 49776703 P;;US 89921704 A,2003-08-26,APPARATUS AND METHOD FOR LIQUID SAMPLE PARTITIONING,,IDEXX LAB INC,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,,https://lens.org/031-373-509-555-372,Patent Application,yes,3,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,,0,0,,,,DISCONTINUED
482,WO,A1,WO 2023/167962 A1,136-174-189-451-130,2023-09-07,2023,US 2023/0014320 W,2023-03-02,US 202263316208 P,2022-03-03,OCCLUSIVE IMPLANT SYSTEM,"An occlusive implant system may include an access device including a handle and an access sheath extending distally therefrom. The access device includes a working lumen extending longitudinally therethrough. A proximal portion of the working lumen defines a garage section and a distal portion of the working lumen extends distally of the garage section. The occlusive implant system may include an occlusive implant device including a delivery sheath configured to be received within the garage section, the delivery sheath having a delivery lumen, a core wire disposed therein, and an occlusive implant releasably attached to the core wire. The garage section has a first inner diameter and the distal portion of the working lumen has a second inner diameter less than the first inner diameter. The delivery sheath has an outer diameter less than the first inner diameter and greater than the second inner diameter.",BOSTON SCIENT SCIMED INC,CHEN JAN-HUNG;;ONUSHKO DAVID JOHN;;TASSONI NICHOLAS LEE;;CLARK CHRISTOPHER J;;NATESAN HARISHANKAR,,https://lens.org/136-174-189-451-130,Patent Application,yes,4,0,2,2,0,A61B17/12031;;A61B17/12122;;A61B17/12172;;A61B2017/1205;;A61B17/12177;;A61B2017/00327;;A61B17/12022;;A61B2017/1205,A61B17/12,,0,0,,,,PENDING
483,ZA,B,ZA 200601608 B,145-329-032-791-284,2007-05-30,2007,ZA 200601608 A,2006-02-23,US 49776703 P,2003-08-26,Apparatus and method for liquid sample partitioning,,IDEXX LAB INC,HAOYI GU;;WILLIAM WAGNER SCOTT;;CHEN CHUN-MING;;SMIT KENNETH E;;MARSHALL CLARK SCOTT,,https://lens.org/145-329-032-791-284,Granted Patent,no,0,0,1,15,0,,B01L/;;C12M/;;G01N/,,0,0,,,,ACTIVE
484,US,A1,US 2023/0277182 A1,155-276-707-844-863,2023-09-07,2023,US 202318116406 A,2023-03-02,US 202318116406 A;;US 202263316208 P,2022-03-03,OCCLUSIVE IMPLANT SYSTEM,"An occlusive implant system may include an access device including a handle and an access sheath extending distally therefrom. The access device includes a working lumen extending longitudinally therethrough. A proximal portion of the working lumen defines a garage section and a distal portion of the working lumen extends distally of the garage section. The occlusive implant system may include an occlusive implant device including a delivery sheath configured to be received within the garage section, the delivery sheath having a delivery lumen, a core wire disposed therein, and an occlusive implant releasably attached to the core wire. The garage section has a first inner diameter and the distal portion of the working lumen has a second inner diameter less than the first inner diameter. The delivery sheath has an outer diameter less than the first inner diameter and greater than the second inner diameter.",BOSTON SCIENT SCIMED INC,CHEN JAN-HUNG;;ONUSHKO DAVID JOHN;;TASSONI NICHOLAS LEE;;CLARK CHRISTOPHER J;;NATESAN HARISHANKAR,BOSTON SCIENTIFIC SCIMED INC (2023-02-22),https://lens.org/155-276-707-844-863,Patent Application,yes,0,0,2,2,0,A61B17/12031;;A61B17/12122;;A61B17/12172;;A61B2017/1205;;A61B17/12177;;A61B2017/00327;;A61B17/12022;;A61B2017/1205,A61B17/12,,0,0,,,,PENDING
485,EP,B1,EP 2321068 B1,113-740-133-682-908,2013-01-16,2013,EP 09812150 A,2009-09-02,US 2009/0055699 W;;US 9364508 P,2008-09-02,DISPENSING PATTERNS INCLUDING LINES AND DOTS AT HIGH SPEEDS,,NSCRYPT INC,CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,,https://lens.org/113-740-133-682-908,Granted Patent,yes,9,0,6,6,0,H05K3/1241;;H05K3/1241;;H01L21/67126;;H01L21/67126;;H01L21/6715;;H01L21/6715;;H05K2203/0126;;H05K2203/0126,B05D1/26;;B05C5/02;;H01L21/67;;H05K3/12,,0,0,,,,ACTIVE
486,EP,A1,EP 2321068 A1,182-417-021-579-685,2011-05-18,2011,EP 09812150 A,2009-09-02,US 2009/0055699 W;;US 9364508 P,2008-09-02,DISPENSING PATTERNS INCLUDING LINES AND DOTS AT HIGH SPEEDS,,NSCRYPT INC,CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,,https://lens.org/182-417-021-579-685,Patent Application,yes,0,0,6,6,0,H05K3/1241;;H05K3/1241;;H01L21/67126;;H01L21/67126;;H01L21/6715;;H01L21/6715;;H05K2203/0126;;H05K2203/0126,B05D1/26;;B05C5/02;;H01L21/67;;H05K3/12,,0,0,,,,ACTIVE
487,US,A1,US 2011/0011580 A1,176-530-066-140-753,2011-01-20,2011,US 78961310 A,2010-05-28,US 78961310 A;;US 22561109 P,2009-07-15,WIRELESS TRANSFER OF POWER AND DATA BETWEEN A MOTHER WELLBORE AND A LATERAL WELLBORE,"A technique enables wireless communication of signals in a well. The technique is employed for communication of power signals and/or data signals between a mother wellbore and at least one lateral wellbore. A first wireless device is positioned in a mother wellbore proximate a lateral wellbore, and a second wireless device is positioned in the lateral wellbore. The power and/or data signal is transferred wirelessly between the first and second wireless devices via magnetic fields. A plurality of the first and second wireless devices may be employed in cooperating pairs to enable communication between the mother wellbore and a plurality of lateral wellbores.",SCHLUMBERGER TECHNOLOGY CORP,CLARK BRIAN;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;RIOUFOL EMMANUEL;;ALGEROY JOHN;;MCKINLEY PATRICK,SCHLUMBERGER TECHNOLOGY CORPORATION (2010-05-18),https://lens.org/176-530-066-140-753,Patent Application,yes,9,51,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B31/06,166/244.1;;166/66.5,0,0,,,,INACTIVE
488,WO,A1,WO 2000/036930 A1,070-998-797-952-333,2000-06-29,2000,US 9929849 W,1999-12-17,US 21533098 A,1998-12-18,GELATIN REPLACEMENT COMPOSITION,"A gelling composition comprising a blend of an alginate (A), a hydrocolloid (B) and a galactomannan (C), wherein the ratio by weight of A:(B+C) is about 0.1:1 to about 1.5:1 and the ratio by weight of B:C is about 0.8:1 to about 1.2:1. A gel composition employing the gelling composition of this invention and a food product comprising one or more food ingredients and the gelling composition described above is also disclosed.",MONSANTO CO,MORRISON NEIL A;;CLARK ROSS C;;CHEN YOU-LUNG;;BURGUM DANIEL R;;TALASHEK TODD,,https://lens.org/070-998-797-952-333,Patent Application,yes,2,25,6,6,0,A23G3/42;;A23C9/154;;A23C13/16;;A23G3/346;;A23G3/38;;A23G2200/06;;A23K20/163;;A23K50/48;;A23L9/12;;A23L29/238;;A23L29/256;;A23L29/27;;A23V2002/00,A23C9/123;;A23C9/154;;A23C13/14;;A23C13/16;;A23G3/00;;A23G3/34;;A23G3/38;;A23G3/42;;A23K1/10;;A23K1/16;;A23K1/18;;A23L1/30;;A23L9/10;;A23L23/00;;A23L27/60;;A23L29/20;;A23L29/238;;A23L29/256;;A23L29/269,,1,0,,,"PATENT ABSTRACTS OF JAPAN vol. 017, no. 030 (C - 1018) 20 January 1993 (1993-01-20)",PENDING
489,US,B2,US 8551903 B2,090-337-407-116-506,2013-10-08,2013,US 201113580414 A,2011-02-24,US 201113580414 A;;US 30854310 P;;US 2011/0026036 W,2010-02-26,Amide ester internal electron donor and process,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG;;SHU JAMES X;;DOW GLOBAL TECHNOLOGIES LLC,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG;;HUANG XIAODONG,DOW GLOBAL TECHNOLOGIES LLC (2011-02-23);;W.R. GRACE & CO. - CONN (2013-12-02),https://lens.org/090-337-407-116-506,Granted Patent,yes,15,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,B01J27/24;;B01J31/00;;C08F2/00;;C08F4/00;;C08F4/06;;C08F4/44,502/127;;502/123;;502/167;;502/200;;526/141;;526/147;;526/215;;526/217;;526/236,2,0,,,English translation of CN 101104656 A.;;English translation of CN 101104589 A.,ACTIVE
490,BR,A,BR PI0413891 A,002-197-305-167-042,2006-10-24,2006,BR PI0413891 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,"dispositivo para dividir uma amostra liquefeita em volumes discretos, método para dividir uma amostra liquefeita, dispositivo e método para realizar um teste de amostra de lìquido","""DISPOSITIVO PARA DIVIDIR UMA AMOSTRA LIQUEFEITA EM VOLUMES DISCRETOS, MéTODO PARA DIVIDIR UMA AMOSTRA LIQUEFEITA, DISPOSITIVO E MéTODO PARA REALIZAR UM TESTE DE AMOSTRA DE LìQUIDO"". é provido um dispositivo (100) para dividir uma amostra liquefeita em volumes discretos. O dispositivo (100) inclui um elemento inferior (100), um elemento superior (112) disposto adjacente ao elemento inferior (110) e pelo menos um elemento de canal (120) é definido pelo menos parcialmente pelos elementos superior e inferior e tem primeira e segunda partes. A primeira parte de extremidade (118) do pelo menos um canal tem uma abertura para receber líquido e a segunda parte de extremidade do pelo menos um canal tem um compartimento de reação (122) e uma abertura de exaustão. Dessa maneira, quando a amostra liquefeita for introduzida na primeira parte de extremidade (118), a ação capilar auxiliar a fazer com que a amostra liquefeita se desloque da primeira parte de extremidade para a segunda parte de extremidade e que pelo menos uma parte da amostra liquefeita seja forçada a permanecer no compartimento de reação (122).",IDEXX LAB INC,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,,https://lens.org/002-197-305-167-042,Patent Application,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,,0,0,,,,DISCONTINUED
491,NO,L,NO 20060925 L,049-690-970-083-484,2006-03-24,2006,NO 20060925 A,2006-02-24,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,Apparat og metode for a dele opp en vaeskeprove,"Der er tilveiebrakt en anordning (100) for å fordele en flytende prøve i adskilte volumer. Anordningen (100) inkluderer et bunnelement (110), et toppelement (112) som er anbrakt i umiddelbar nærhet av bunnelementet (110), og minst ett kanalelement (120) som i det minste delvis er definert ved hjelp av topp- og bunnelementene og som har første og andre endedeler. Den første endedelen (118) av den i det minste ene kanalen har en åpning for å motta væsker og den andre endedelen av den i det minste ene kanalen har et reaksjonskammer (122) og en lufteåpning. Følgelig, når den flytende prøven innføres i den første endedelen (118), vil kapillarvirkning hjelpe til med å bevirke at den flytende prøven beveger seg fra den første endedelen til den andre endedelen og i det minste en del av den flytende prøven bevirkes til å forbli i reaksjonskammeret (122).",IDEXX LAB INC,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,,https://lens.org/049-690-970-083-484,Abstract,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00;;C12M1/00,,0,0,,,,DISCONTINUED
492,NO,A1,NO 20101004 A1,089-570-339-597-269,2011-01-17,2011,NO 20101004 A,2010-07-14,US 22561109 P;;US 78961310 A,2009-07-15,Tradlos overforing av kraft mellom et moderbronnhull og et sidebronnhull,En teknikk muliggjør trådløs kommunikasjon av signaler i en brønn. Teknikken benyttes tilkommunikasjon av kraftsignaler og/eller datasignaler mellom et moderbrønnhull og minst ett sidebrønnhull. En første trådløs innretning er plassert i et moderbrønnhull i nærheten av et sidebrønnhull og en andre trådløs innretning er plassert i sidebrønnhullet. Kraft- og/eller datasignalene overføres trådløst mellom de første og andre trådløse innretningene via magnetiske felt. Et antall av de første og andre trådløse innretningene kan benyttes i samvirkende par for å muliggjøre kommunikasjon mellom moderbrønnhullet og et antall sidebrønnhull.,SCHLUMBERGER TECHNOLOGY BV,CLARK BRIAN;;RIOUFOL EMMANUEL;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;ALGEROY JOHN;;MCKINLEY PATRICK,,https://lens.org/089-570-339-597-269,Patent Application,no,0,0,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B47/12,,0,0,,,,INACTIVE
493,CN,A,CN 102170976 A,108-181-124-740-556,2011-08-31,2011,CN 200980138918 A,2009-09-02,US 2009/0055699 W;;US 9364508 P,2008-09-02,Dispensing patterns including lines and dots at high speeds,"A method for depositing a material on a substrate includes providing an apparatus with at least one material dispenser. The method further includes positioning the pen tip at a predetermined writing gap where the predetermined writing gap is a distance of more than 75 micrometers above the substrate. The method also provides controlling of velocity of the flow of material through the outlet and dispense speed based on dispensed line height and dispensed line width parameters. An apparatus for depositing a material on a substrate is also provided which may have one or more mechanical vibrators, a pen tip with a hydrophobic surface, or multiple nozzles and pen tips on a single pump.",NSCRYPT INC,CHURCH KENNETH H;;CLARK PATRICK A;;XUDONG CHEN;;OWENS MICHAEL W;;STONE KELLY M,,https://lens.org/108-181-124-740-556,Patent Application,no,0,3,6,6,0,H05K3/1241;;H05K3/1241;;H01L21/67126;;H01L21/67126;;H01L21/6715;;H01L21/6715;;H05K2203/0126;;H05K2203/0126,B05D1/26,,0,0,,,,DISCONTINUED
494,BR,B1,BR 112012021519 B1,150-482-658-387-832,2019-12-17,2019,BR 112012021519 A,2011-02-24,US 2011/0026036 W;;US 30854310 P,2010-02-26,"proccesso, composição de procatalisador, composição catalítica e processo para produzir um polímero a base de olefina","processo, composição de pro-catalisador, composição de catalisador e processo para produzir um polímero à base de olefina divulga-se um processo para produzir uma composição de pro-catalisador tendo um doador de elétrons interno de éster amida. o processo inclui pré-halogenar um precursor de pro-catalisador antes da reação com o éster amida e formar a composição de pro-catalisador. composições de catalisadores ziegler-natta contendo a presente composição de pro-catalisador exibem atividade catalítica melhorada e/ou seletividade catalítica melhorada, e produzem olefinas a base de propileno com distribuição de peso molecular ampla.",DOW GLOBAL TECHNOLOGIES LLC;;GRACE W R & CO,CLARK C WILLIAMS;;KUANQIANG GAO;;LINFENG CHEN;;TAK W LEUNG;;TAO TAO;;XIAODONG HUANG,DOW GLOBAL TECHNOLOGIES LLC (US) (2018-03-06);;W. R. GRACE AND CO. - CONN (US) (2018-06-19),https://lens.org/150-482-658-387-832,Granted Patent,no,0,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F4/651;;C08F4/654;;C08F10/06,,0,0,,,,ACTIVE
495,AU,B2,AU 2004/268618 B2,059-504-274-162-825,2009-10-08,2009,AU 2004/268618 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,Apparatus and method for liquid sample partitioning,,IDEXX LAB INC,CHUN-MING CHEN;;SMITH KENNETH E;;CLARK SCOTT MARSHALL;;GU HAOYI;;WAGNER SCOTT WILLIAM,,https://lens.org/059-504-274-162-825,Granted Patent,no,6,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,,0,0,,,,INACTIVE
496,WO,A1,WO 2011/106500 A1,019-099-167-467-044,2011-09-01,2011,US 2011/0026036 W,2011-02-24,US 30854310 P,2010-02-26,AMIDE ESTER INTERNAL ELECTRON AND PROCESS,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,DOW GLOBAL TECHNOLOGIES LLC;;CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG;;SHU JAMES X,CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG;;HUANG XIAODONG,,https://lens.org/019-099-167-467-044,Patent Application,yes,5,31,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F4/651;;C08F10/06;;C08F4/654,,2,0,,,"DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GAO, MINGZHI ET AL: ""Amino ester solid catalyst components for polymerization of olefin and the catalyst containing the same"", XP002639888, retrieved from STN Database accession no. 2008:81707;;ZEICHNER GR, PATEL PD: ""A comprehensive Study of Polypropylene Melt Rheology"", 1981, PROC. OF THE 2ND WORLD CONGRESS OF CHEMICAL ENG.",PENDING
497,CA,C,CA 2535524 C,097-156-244-754-037,2010-03-23,2010,CA 2535524 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,APPARATUS AND METHOD FOR LIQUID SAMPLE PARTITIONING,"There is provided a device (100) for partitioning a liquefied sample into discrete volumes. The device (100) includes a bottom member (110); a top member (112) disposed adjacent the bottom member (110); and at least one channel member (120) is at least partially defined by the top and bottom members and has first and second end portions. The first end portion (118) of the at least one channel has an opening to receive liquid and the second end portion of the at least one channel has a reaction compartment (122) and a vent opening. Accordingly, when the liquefied sample is introduced to the first end portion (118), capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion and at least a portion of the liquefied sample is caused to remain in the reaction compartment (122).",IDEXX LAB INC,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHEN CHUN-MING,,https://lens.org/097-156-244-754-037,Granted Patent,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00;;C12M1/20;;G01N1/18,,0,0,,,,INACTIVE
498,US,B2,US 6867134 B2,012-723-076-990-755,2005-03-15,2005,US 39350803 A,2003-03-20,US 39350803 A;;US 36599102 P,2002-03-20,Adherent all-gold electrode structure for lithium niobate based devices and the method of fabrication,"An electrode structure wherein galvanic corrosion at adhesion layers formed between electrodes and electronic or electro-optic substrates is eliminated. The electrode structure includes an electro-optic crystalline substrate, an amorphous layer disposed on the crystalline substrate, the amorphous layer having a composition substantially similar to a composition of the crystalline substrate, and a gold layer disposed directly on the amorphous layer. The amorphous layer is created using ion sputtering etching techniques that clean and activate the surface of the crystalline substrate such that the gold layer is able to adhere to it.",JDS UNIPHASE CORP,CHEN XINGFU;;LYNCH DANIEL;;MARK NELSON;;BOSENBERG WALTER;;XU JASON;;BRODSKY LAWRENCE;;CLARK JOHN,LUMENTUM OPERATIONS LLC (2015-07-31);;JDS UNIPHASE CORPORATION (2003-06-18),https://lens.org/012-723-076-990-755,Granted Patent,yes,3,12,2,2,0,G02F1/0316;;H10N30/06;;G02F1/0316;;H10N30/06,G02F1/03,438/686,2,0,,,"Robert F.Pierret, Field Effect Devices, 1983, Addison-Wesley Publishing Company , Inc, vol. IV, cover and pp. 63 and 82.*;;U.S. patent application Ser. No. 10/261,877, Chen, filed Oct. 1, 2002.",EXPIRED
499,CN,A,CN 102918068 A,074-809-391-336-557,2013-02-06,2013,CN 201180020873 A,2011-02-24,US 2011/0026036 W;;US 30854310 P,2010-02-26,Amide ester internal electron and process,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,DOW GLOBAL TECHNOLOGIES LLC,HUANG XIAODONG;;CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG,W.R. GRACE L CO. (2015-09-06),https://lens.org/074-809-391-336-557,Patent Application,no,3,9,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F10/06;;C08F4/651;;C08F4/654,,0,0,,,,ACTIVE
500,KR,A,KR 20130020771 A,092-073-838-213-523,2013-02-28,2013,KR 20127025017 A,2011-02-24,US 30854310 P;;US 2011/0026036 W,2010-02-26,AMIDE ESTER INTERNAL ELECTRON AND PROCESS,,DOW GLOBAL TECHNOLOGIES LLC,HUANG XIAODONG;;CHEN LINFENG;;WILLIAMS CLARK C;;LEUNG TAK W;;TAO TAO;;GAO KUANQIANG,,https://lens.org/092-073-838-213-523,Patent Application,no,0,3,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F4/651;;C08F4/654;;C08F10/06,,0,0,,,,ACTIVE
501,NZ,A,NZ 545350 A,090-502-403-828-430,2009-02-28,2009,NZ 54535004 A,2004-08-25,US 49776703 P;;US 89921704 A;;US 2004/0027659 W,2003-08-26,Apparatus and method for liquid sample partitioning,"This discloses a device for partitioning a liquefied sample into discrete volumes comprising: a bottom member 110 having a number of discrete reaction compartments 122; a sample receiving well 118 disposed in the bottom member 110; a top member 112 disposed adjacent to the bottom member 110 and a number of channels 120 which are at least partially defined by at least one of the top 112 and bottom members 110, each channel 120 having a first end portion in direct fluid communication with the sample receiving well 118 and a second end portion in direct fluid communication with a respective discrete reaction compartment 122; an overflow well 124 in direct fluid communication with each of the discrete reaction compartments 122; and a vent opening. When the liquefied sample is introduced to the sample receiving well 118, capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion of the channel, where at least a portion of the liquefied sample is subsequently partitioned into and remains in the discrete reaction compartment 122.",IDEXX LAB INC,GU HAOYI;;SMITH KENNETH E;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHUN-MING CHEN,,https://lens.org/090-502-403-828-430,Patent Application,no,0,0,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,B01L3/00,,0,0,,,,DISCONTINUED
502,US,A1,US 2004/0002205 A1,056-358-318-668-157,2004-01-01,2004,US 39350803 A,2003-03-20,US 39350803 A;;US 36599102 P,2002-03-20,Adherent all-gold electrode structure for lithium niobate based devices and the method of fabrication,"
   An electrode structure wherein galvanic corrosion at adhesion layers formed between electrodes and electronic or electro-optic substrates is eliminated. The electrode structure includes an electro-optic crystalline substrate, an amorphous layer disposed on the crystalline substrate, the amorphous layer having a composition substantially similar to a composition of the crystalline substrate, and a gold layer disposed directly on the amorphous layer. The amorphous layer is created using ion sputtering etching techniques that clean and activate the surface of the crystalline substrate such that the gold layer is able to adhere to it. 
",JDS UNIPHASE CORP,CHEN XINGFU;;LYNCH DANIEL;;MARK NELSON;;BOSENBERG WALTER;;XU JASON;;BRODSKY LAWRENCE;;CLARK JOHN,LUMENTUM OPERATIONS LLC (2015-07-31);;JDS UNIPHASE CORPORATION (2003-06-18),https://lens.org/056-358-318-668-157,Patent Application,yes,3,13,2,2,0,G02F1/0316;;H10N30/06;;G02F1/0316;;H10N30/06,G02F1/03,438/597,0,0,,,,EXPIRED
503,US,B2,US 8469084 B2,073-054-145-148-519,2013-06-25,2013,US 78961310 A,2010-05-28,US 78961310 A;;US 22561109 P,2009-07-15,Wireless transfer of power and data between a mother wellbore and a lateral wellbore,"A technique enables wireless communication of signals in a well. The technique is employed for communication of power signals and/or data signals between a mother wellbore and at least one lateral wellbore. A first wireless device is positioned in a mother wellbore proximate a lateral wellbore, and a second wireless device is positioned in the lateral wellbore. The power and/or data signal is transferred wirelessly between the first and second wireless devices via magnetic fields. A plurality of the first and second wireless devices may be employed in cooperating pairs to enable communication between the mother wellbore and a plurality of lateral wellbores.",CLARK BRIAN;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;RIOUFOL EMMANUEL;;ALGEROY JOHN;;MCKINLEY PATRICK;;SCHLUMBERGER TECHNOLOGY CORP,CLARK BRIAN;;ZIMMERMAN THOMAS H;;CHEN KUO-CHIANG;;RIOUFOL EMMANUEL;;ALGEROY JOHN;;MCKINLEY PATRICK,SCHLUMBERGER TECHNOLOGY CORPORATION (2010-05-18),https://lens.org/073-054-145-148-519,Granted Patent,yes,9,39,6,6,0,E21B33/124;;E21B47/12;;E21B47/13;;E21B47/13;;E21B33/124;;E21B41/0035;;E21B41/0035;;E21B47/13;;E21B47/13,E21B17/003,166/65.1;;340/854.6;;340/854.8,0,0,,,,INACTIVE
504,WO,A2,WO 2009/151777 A2,105-628-901-484-008,2009-12-17,2009,US 2009/0040566 W,2009-04-14,US 10370208 A,2008-04-15,MUSIC VIDEO GAME WITH CONFIGURABLE INSTRUMENTS AND RECORDING FUNCTIONS,"Music video games provide configurable instruments and/or recording functions. In some embodiments users may select an instrument or play, and also select desired characteristics of the instrument. The desired characteristics may include selection of a chord or selection of effects associated with the type of musical instrument. In some embodiments users may record tracks of music using their simulated musical instrument controllers.",ACTIVISION PUBLISHING INC;;BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,BRIGHT BRIAN;;CHEN TRAVIS;;WEN CLARK;;PEASE SCOTT;;PEASE JOE;;DEVECKA JOHN;;CHRZANOWSKI MICHAEL,,https://lens.org/105-628-901-484-008,Patent Application,yes,0,2,3,3,0,A63F13/10;;A63F2300/8047;;G10H1/368;;G10H2220/135;;A63F13/45;;A63F13/245;;A63F13/44;;A63F13/814;;A63F2300/8047;;G10H1/368;;G10H2220/135,G06Q50/00,,0,0,,,,PENDING
505,US,A1,US 2010/0055299 A1,113-941-055-712-921,2010-03-04,2010,US 55244809 A,2009-09-02,US 55244809 A;;US 9364508 P,2008-09-02,DISPENSING PATTERNS INCLUDING LINES AND DOTS AT HIGH SPEEDS,"A method for depositing a material on a substrate includes providing an apparatus with at least one material dispenser. The method further includes positioning the pen tip at a predetermined writing gap where the predetermined writing gap is a distance of more than 75 micrometers above the substrate. The method also provides for controlling velocity of the flow of material through the outlet and dispense speed based on dispensed line height and dispensed line width parameters. An apparatus for depositing a material on a substrate is also provided which may have one or more mechanical vibrators, a pen tip with a hydrophobic surface, or multiple nozzles and pen tips on a single pump.",NSCRYPT INC,CHURCH KENNETH H;;CLARK PATRICK A;;CHEN XUDONG;;OWENS MICHAEL W;;STONE KELLY M,NSCRYPT INC (2009-09-08),https://lens.org/113-941-055-712-921,Patent Application,yes,43,12,6,6,0,H01L21/67126;;H01L21/6715;;H05K3/1241;;H05K2203/0126;;H05K3/1241;;H05K2203/0126;;H01L21/6715;;H01L21/67126,B05D5/12;;B05C5/00;;B05C11/00,427/58;;118/300;;118/663;;118/664,0,0,,,,PENDING
506,CA,A1,CA 2209577 A1,150-941-405-492-431,1998-01-24,1998,CA 2209577 A,1997-07-02,US 2257896 P,1996-07-24,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE PH, OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY","Aspergillus awamori glucoamylase ¢1,4-.alpha.-D-glucan glucohydrolase, EC 3.2:1.3! (GA) catalyzes the release of glucose from the non-reducing ends of starch and related oligosaccharides. GA is used in, and defines the rate limiting step of, the commercial production of high glucose syrups. GA is rapidly and irreversibly inactivated at temperatures above 65.degree.C. Based on the known GA structure and homology with other GA's, four proline substitution mutations were constructed and expressed in Saccharomyces cerevisiae. These mutations were designed to increase GA thermal stability by decreasing conformational entropy of unfolding. None of the mutations decreased enzyme activity. Three of the mutations, Asp293-Pro, Asp345-Pro and Glu408-Pro, either decreased or did not significantly alter GA. However, one of the mutations, Ser30-Pro, significantly decreased the rate of irreversible thermal inactivation when analyzed between 65.degree. and 80.degree.C. At 70.degree.C a 1.9-fold decrease in thermal inactivation rate coefficients was seen and the activation energy for thermal inactivation (.DELTA..DELTA.G~) was increased by 2.2 kJ/mol. relative to wild-type GA. Additionally, when the Ser30-Pro mutation was combined with a previously characterized stabilizing mutation (Gly137-Ala, which increased the.DELTA..DELTA.G~ by 1.3 kJ/mol. at 70.degree.C) a 4.0 kJ/mol increase in .DELTA..DELTA.G~ relative to wild-type GA at 70.degree.C was seen without loss of enzyme activity.",UNIV IOWA STATE RES FOUND INC,FORD CLARK F;;COUTINHO PEDRO M;;LI YUXING;;ALLEN MARTIN J;;CHEN HSIU-MEI,,https://lens.org/150-941-405-492-431,Patent Application,no,0,0,1,7,0,,C12N9/34;;C12N15/56;;C12S3/12;;C13K1/06,,0,0,,,,DISCONTINUED
507,US,B1,US 11445290 B1,160-649-005-172-302,2022-09-13,2022,US 202017027258 A,2020-09-21,US 202017027258 A;;US 201962907376 P,2019-09-27,Feedback acoustic noise cancellation tuning,A method performed by an in-ear headphone that includes a speaker and an internal microphone. The method receives a microphone signal from the internal microphone that indicates a current sound pressure level (SPL) in an ear canal of a user. The current SPL is a result of a control leak from the in-ear headphone into an ambient environment that reduces a SPL in the ear canal between 2 dB and 25 dB at a frequency within a frequency range than if otherwise not present. The method determines an active noise cancellation (ANC) filter based on the microphone signal and generates an anti-noise signal using the ANC filter. The method drives the speaker using the anti-noise signal to reduce the current SPL in the ear canal of the user as much as 25 dB at a frequency within the frequency range.,APPLE INC,GRINKER SCOTT C;;BAJIC VLADAN;;CLARK BRIAN D;;SAUX TOM-DAVY W;;CHEN HANCHI,APPLE INC (2020-09-09),https://lens.org/160-649-005-172-302,Granted Patent,yes,5,0,1,1,0,H04R1/1016;;H04R1/1083;;H04R2460/01;;G10K2210/1081;;G10K11/17875;;G10K2210/3023;;G10K2210/3025;;G10K2210/3215;;G10K11/17825;;G10K2210/3214;;G10K11/17857;;G10K2210/3028;;G10K11/17881;;H04R1/1083;;H04R1/1016;;H04R2460/01;;G10K2210/1081;;G10K11/178,G10K11/178;;H04R1/10,,0,0,,,,ACTIVE
508,BR,A2,BR 112012021519 A2,090-606-305-552-297,2016-07-05,2016,BR 112012021519 A,2011-02-24,US 2011/0026036 W;;US 30854310 P,2010-02-26,"proccesso, composição de procatalisador, composição catalítica e processo para produzir um polímero a base de olefina",,DOW GLOBAL TECHNOLOGIES LLC,WILLIAMS CLARK C;;GAO KUANQIANG;;CHEN LINFENG;;LEUNG TAK W;;TAO TAO;;HUANG XIAODONG,DOW GLOBAL TECHNOLOGIES LLC (US) (2018-03-06);;W. R. GRACE AND CO. - CONN (US) (2018-06-19),https://lens.org/090-606-305-552-297,Patent Application,no,0,0,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F4/651;;C08F4/654;;C08F10/06,,0,0,,,,ACTIVE
509,US,B2,US 7582472 B2,145-785-027-232-508,2009-09-01,2009,US 89921704 A,2004-07-26,US 89921704 A;;US 49776703 P,2003-08-26,Apparatus and method for liquid sample testing,"There is provided a device for partitioning a liquefied sample into discrete volumes. The device includes a bottom member; a top member disposed adjacent the bottom member; and at least one channel member disposed between the top and bottom members. The at least one channel member is at least partially defined by the top and bottom members and has first and second end portions. The first end portion of the at least one channel has an opening to receive liquid and the second end portion of the at least one channel has a reaction compartment and a vent opening. Accordingly, when the liquefied sample is introduced to the first end portion, capillary action assists in causing the liquefied sample to travel from the first end portion to the second end portion and at least a portion of the liquefied sample is caused to remain in the reaction compartment.",SMITH KENNETH E;;GU HAOYI;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHEN CHUN-MING,SMITH KENNETH E;;GU HAOYI;;WAGNER SCOTT WILLIAM;;CLARK SCOTT MARSHALL;;CHEN CHUN-MING,IDEXX LABORATORIES INC (2004-07-20),https://lens.org/145-785-027-232-508,Granted Patent,yes,55,5,14,15,0,B01L3/5025;;B01L3/5027;;B01L3/502707;;B01L3/50273;;B01L2300/0803;;B01L2300/0864;;B01L2400/0406;;B01L3/5025;;B01L3/502707;;B01L2300/0803;;B01L3/50273;;B01L2400/0406;;B01L2300/0864;;B01L3/5027,C12M1/34;;B01L3/00;;C12M3/00,435/288.4;;435/30;;435/40;;435/288.5,2,0,,,"Meathrel W. G., Hand H. M. and Su Li-Hung. The effect of hydrophilic adhesives on sample flow. Jul./Aug. 2001. IVD Technology, pp. 1-13.;;International Search Report, PCT/US2004/027659, Aug. 25, 2004.",ACTIVE
510,EP,A1,EP 1139788 A1,152-698-079-457-512,2001-10-10,2001,EP 99966307 A,1999-12-17,US 9929849 W;;US 21533098 A,1998-12-18,GELATIN REPLACEMENT COMPOSITION,,CP KELCO US INC,MORRISON NEIL A;;CLARK ROSS C;;CHEN YOU-LUNG;;BURGUM DANIEL R;;TALASHEK TODD,,https://lens.org/152-698-079-457-512,Patent Application,yes,0,0,6,6,0,A23G3/42;;A23C9/154;;A23C13/16;;A23G3/346;;A23G3/38;;A23G2200/06;;A23K20/163;;A23K50/48;;A23L9/12;;A23L29/238;;A23L29/256;;A23L29/27;;A23V2002/00,A23C9/123;;A23C9/154;;A23C13/14;;A23C13/16;;A23G3/00;;A23G3/34;;A23G3/38;;A23G3/42;;A23K1/10;;A23K1/16;;A23K1/18;;A23L1/30;;A23L9/10;;A23L23/00;;A23L27/60;;A23L29/20;;A23L29/238;;A23L29/256;;A23L29/269,,1,0,,,See references of WO 0036930A1,DISCONTINUED
511,WO,A1,WO 2022/149076 A1,005-417-166-535-095,2022-07-14,2022,IB 2022050071 W,2022-01-05,NZ 77165921 A,2021-01-05,CONVERSATION ORCHESTRATION IN INTERACTIVE AGENTS,"Embodiments described herein relate to methods and systems for animating (bringing to life) an Agent, which may be a virtual object, digital entity, and/or robot. A Router enables seamless interactions between a user and the Agent via multiple Skill Modules. Skill Modules may include conversation corpora and/or other applications. Embodiments described herein may improve Conversation Orchestration in Interactive Agents in the context of multi-modal human-computer interactions.",SOUL MACHINES LTD,CHEN JEREMY;;CLARK-YOUNGER HANNAH;;HASLAM ANDREW;;AYYAD NADER;;PLETKA JOHN;;MASSERINI MAURO;;POOL LIAM,,https://lens.org/005-417-166-535-095,Patent Application,yes,5,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,H04L51/02;;G06F16/248;;G06F16/332;;G10L15/22;;H04L51/00,,0,0,,,,PENDING
512,US,A1,US 2012/0316299 A1,031-234-705-559-960,2012-12-13,2012,US 201113580414 A,2011-02-24,US 201113580414 A;;US 30854310 P;;US 2011/0026036 W,2010-02-26,Amide Ester Internal Electron Donor and Process,Disclosed is a process for producing a procatalyst composition having an amide ester internal electron donor. The process includes pre-halogenating a procatalyst precursor before reaction with the amide ester and forming the procatalyst composition. Ziegler-Natta catalyst compositions containing the present procatalyst composition exhibit improved catalyst activity and/or improved catalyst selectivity and produce propylene-based olefins with broad molecular weight distribution.,CHEN LINFENG;;LEUNG TAK W;;TAO TAO;;SHU JAMES X;;GAO KUANQIANG;;WILLIAMS CLARK C,CHEN LINFENG;;LEUNG TAK W;;TAO TAO;;SHU JAMES X;;GAO KUANQIANG;;WILLIAMS CLARK C,DOW GLOBAL TECHNOLOGIES LLC (2011-02-23);;W.R. GRACE & CO. - CONN (2013-12-02),https://lens.org/031-234-705-559-960,Patent Application,yes,5,5,17,17,0,C08F10/06;;C08F110/06;;C08F4/651;;C08F4/654;;C08F10/06;;C08F2500/04;;C08F10/06;;C08F110/06;;C08F2500/04;;C08F2500/18;;C08F10/06;;C08F110/06,C08F4/649;;C08F10/06,526/123.1;;502/167,2,0,,,English translation of CN 101104656 A;;English translation of CN 101104589 A,ACTIVE
513,WO,A1,WO 2016/089990 A1,053-122-891-970-578,2016-06-09,2016,US 2015/0063417 W,2015-12-02,US 201462097854 P;;US 201462086323 P,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,,https://lens.org/053-122-891-970-578,Patent Application,yes,5,62,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C321/28;;A61K31/10;;A61K31/166;;A61K31/167;;A61P31/00;;A61P31/12;;C07C321/30;;C07C323/62,,13,7,018-584-171-893-938;;077-295-491-167-117;;012-180-065-013-539;;029-641-974-701-191;;102-071-695-047-127;;007-636-465-196-321;;016-798-690-810-744,3005577;;10.1021/jm00153a018;;10.1002/0471220574;;10.2165/00003088-198106060-00002;;7032803;;10.1007/bf01952257;;6382953;;10.1016/0065-2571(84)90007-4;;10.1021/jo01344a001;;10.1021/jo00158a014,"MASARU OGATA ET AL.: ""Synthesis an Antiviral Activity of Sulfonamidobenzophen -one Oximes and Sulfonamidobenzamides"", J. MED. CHEM., vol. 29, 1986, pages 417 - 423, XP002096176;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;""Fieser and Fieser's Reagents for Organic Synthesis"", vol. 1-40, 1991, JOHN WILEY AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1-5, 1989, ELSEVIER SCIENCE PUBLISHERS;;CAREYSUNDBERG: ""Advanced Organic Chemistry"", vol. A, B, 2000, PLENUM;;GREENWUTS: ""Protective Groups in Organic Synthesis"", 1999, WILEY;;HOLFORDSCHEINER, CLIN. PHARMACOKINET., vol. 6, pages 429 - 453;;LOEWEMUISCHNEK, ARCH. EXP. PATHOL PHARMACOL., vol. 114, 1926, pages 313 - 326;;CHOUTALALAY, ADV. ENZYME REGUL., vol. 22, 1984, pages 27 - 55;;E.J. COREY, J. ORG. CHEM., vol. 31, 1966, pages 1663;;HOUSE, H. O., J. ORG. CHEM., vol. 48, 1983, pages 1643;;BASKIN, J. M.WANG, Z., TET. LETT., vol. 43, 2002, pages 8479",PENDING
514,EP,A1,EP 4275348 A1,065-980-408-665-255,2023-11-15,2023,EP 22736690 A,2022-01-05,NZ 77165921 A;;IB 2022050071 W,2021-01-05,CONVERSATION ORCHESTRATION IN INTERACTIVE AGENTS,,SOUL MACHINES LTD,CHEN JEREMY;;CLARK-YOUNGER HANNAH;;HASLAM ANDREW;;AYYAD NADER;;PLETKA JOHN;;MASSERINI MAURO;;POOL LIAM,,https://lens.org/065-980-408-665-255,Patent Application,yes,0,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,H04L51/02;;G06F16/248;;G06F16/332;;G10L15/22;;H04L51/00,,0,0,,,,PENDING
515,CN,A,CN 107406378 A,109-942-642-653-698,2017-11-28,2017,CN 201580075330 A,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,,https://lens.org/109-942-642-653-698,Patent Application,no,2,2,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C321/30;;A61K31/10;;A61K31/166;;A61K31/167;;A61K45/06;;A61P31/20;;C07C311/03;;C07C311/29;;C07C321/28;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12,,1,0,,,"REGISTRY数据库: ""Registry数据库"", 《REGISTRY数据库》",DISCONTINUED
516,CA,A1,CA 3203835 A1,158-300-194-431-866,2022-07-14,2022,CA 3203835 A,2022-01-05,NZ 77165921 A;;IB 2022050071 W,2021-01-05,CONVERSATION ORCHESTRATION IN INTERACTIVE AGENTS,"Embodiments described herein relate to methods and systems for animating (bringing to life) an Agent, which may be a virtual object, digital entity, and/or robot. A Router enables seamless interactions between a user and the Agent via multiple Skill Modules. Skill Modules may include conversation corpora and/or other applications. Embodiments described herein may improve Conversation Orchestration in Interactive Agents in the context of multi-modal human-computer interactions.",SOUL MACHINES LTD,CHEN JEREMY;;CLARK-YOUNGER HANNAH;;HASLAM ANDREW;;AYYAD NADER;;PLETKA JOHN;;MASSERINI MAURO;;POOL LIAM,,https://lens.org/158-300-194-431-866,Patent Application,no,0,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,H04L51/02;;G06F16/248;;G06F16/332;;G10L15/22;;H04L51/00,,0,0,,,,PENDING
517,KR,A,KR 20230129249 A,061-896-484-494-77X,2023-09-07,2023,KR 20237026198 A,2022-01-05,NZ 77165921 A;;IB 2022050071 W,2021-01-05,상호작용형 에이전트들에서의 대화 오케스트레이션,"본 명세서에 설명된 실시예들은 가상 객체, 디지털 엔티티, 및/또는 로봇일 수 있는, 에이전트를 의인화하기 위한(생동감있게 하는) 방법들 및 시스템들에 관한 것이다. 라우터는 다수의 스킬 모듈들을 통해 사용자와 에이전트 사이의 매끄러운 상호작용들을 가능하게 한다. 스킬 모듈들은 대화 코퍼스들 및/또는 다른 애플리케이션들을 포함할 수 있다. 본 명세서에 설명된 실시예들은 다양한 인간-컴퓨터 상호작용들의 맥락에서 상호작용형 에이전트들에서의 대화 오케스트레이션을 개선할 수 있다.",SOUL MACHINES LTD,CHEN JEREMY;;CLARK YOUNGER HANNAH;;HASLAM ANDREW;;AYYAD NADER;;PLETKA JOHN;;MASSERINI MAURO;;POOL LIAM,,https://lens.org/061-896-484-494-77X,Patent Application,no,0,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,H04L51/02;;G06F16/332;;G06F40/35;;H04L51/214,,0,0,,,,PENDING
518,CA,A1,CA 2969557 A1,135-672-739-979-550,2016-06-09,2016,CA 2969557 A,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,,https://lens.org/135-672-739-979-550,Patent Application,no,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C323/62,,0,0,,,,DISCONTINUED
519,TW,B,TW I812557 B,021-362-777-303-335,2023-08-11,2023,TW 111146727 A,2018-03-16,US 201762473232 P;;US 201715709262 A,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,,JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/021-362-777-303-335,Granted Patent,no,1,0,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,,,0,0,,,,ACTIVE
520,WO,A1,WO 2018/167303 A1,062-231-017-610-022,2018-09-20,2018,EP 2018056745 W,2018-03-16,US 201762473232 P;;US 201715709262 A,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/062-231-017-610-022,Patent Application,yes,28,11,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61P25/00,,11,7,025-901-684-956-56X;;055-113-427-061-977;;025-911-372-636-486;;051-960-555-783-976;;071-484-919-859-603;;007-364-858-655-289;;067-954-938-579-884,12734908;;16267211;;16382538;;10.1212/01.wnl.0000188670.38576.bd;;10.4088/jcp.v69n0522a;;18681764;;7260659;;12180542;;10.1023/a:1016473601633;;10.1002/jps.2600660104;;833720;;10.1016/j.forsciint.2011.09.014;;22014974,"SCHARF ET AL., J. RHEUMATOL., vol. 30, 2003, pages 1070;;RUSSELL ET AL., ARTHRITIS. RHEUM., vol. 60, 2009, pages 299;;ONDO ET AL., ARCH. NEURAL., vol. 65, 2008, pages 1337;;FRUCHT ET AL., NEUROLOGY, vol. 65, 1967;;BERNER, J. CLIN. PSYCHIATRY, vol. 69, 2008, pages 862;;SNEAD; MORLEY, BRAIN RES., vol. 227, no. 4, 1981, pages 579 - 89;;YU ET AL., PHARM. RES., vol. 19, no. 7, pages 921 - 925;;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1;;""Remington, The Science and Practice of Pharmacy"", 2013;;""Remington's Pharmaceutical Sciences"", pages: 1035 - 1038,1570-1580;;FERRIS; WENT, FORENSIC SCIENCE INTERNATIONAL, vol. 216, 2012, pages 158 - 162",PENDING
521,CN,A,CN 111448427 A,065-640-717-376-683,2020-07-24,2020,CN 201780097505 A,2017-12-07,US 2017/0065124 W,2017-12-07,Remote automated deployment of HVAC optimization software,"Computer-implemented methods and structures deploy a heating ventilation and air conditioning (HVAC) energy optimization program. A standard operating control platform (OCP) is deployed in an energy optimization control engine (EOCE) computing system communicatively coupled to a plurality of HVAC components via a building automation system (BAS). An energy optimization portal (EOP), which receivesfrom the EOCE computing system a first data set identifying the plurality of HVAC components, a second data set including operational control parameters for each of the plurality of HVAC components,and a third data set including measured operations data associated with each of the plurality of HVAC components. The EOP generates an energy optimized operating control platform based on the first, second, and third data sets, which is automatically communicated from the EOP to the EOCE computing system.",OPTIMUM ENERGY LLC,MATTHYS CLARK RICHARD;;DEMPSTER IAN ROBERT;;CHEN PENG;;CARTER CHRIS;;BOSCOLO CHRIS;;LECHNER ANDREW ALEXANDER,,https://lens.org/065-640-717-376-683,Patent Application,no,15,0,6,6,0,G05B15/02;;H04L12/2803;;H04L12/4625;;G05B2219/2642;;F24F11/30;;F24F2110/00;;F24F2130/10;;F24F11/54;;F24F11/58;;F24F11/46;;F24F11/64;;F24F2130/10;;F24F11/46;;F24F11/65;;F24F2110/00;;F24F11/30;;F24F11/54;;F24F11/58;;G05B19/042;;G05B2219/2614,F24F11/30;;F24F11/46;;F24F11/54;;F24F11/58;;F24F110/00;;F24F130/10;;G05B15/02;;H04L12/28,,0,0,,,,ACTIVE
522,US,A1,US 2020/0113853 A1,087-569-439-712-788,2020-04-16,2020,US 201916575213 A,2019-09-18,US 201916575213 A;;US 201715709262 A;;US 201762473232 P,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/087-569-439-712-788,Patent Application,yes,0,12,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19,,0,0,,,,DISCONTINUED
523,EP,A1,EP 3721146 A1,014-707-165-024-383,2020-10-14,2020,EP 17823274 A,2017-12-07,US 2017/0065124 W,2017-12-07,REMOTE AUTOMATED DEPLOYMENT OF HVAC OPTIMIZATION SOFTWARE,,OPTIMUM ENERGY LLC,MATTHYS CLARK RICHARD;;DEMPSTER IAN ROBERT;;CHEN PENG;;CARTER CHRIS;;BOSCOLO CHRIS;;LECHNER ANDREW ALEXANDER,,https://lens.org/014-707-165-024-383,Patent Application,yes,0,0,6,6,0,G05B15/02;;H04L12/2803;;H04L12/4625;;G05B2219/2642;;F24F11/30;;F24F2110/00;;F24F2130/10;;F24F11/54;;F24F11/58;;F24F11/46;;F24F11/64;;F24F2130/10;;F24F11/46;;F24F11/65;;F24F2110/00;;F24F11/30;;F24F11/54;;F24F11/58;;G05B19/042;;G05B2219/2614,F24F11/30;;F24F11/46;;F24F11/54;;F24F11/58;;F24F110/00;;F24F130/10;;G05B15/02;;H04L12/28,,0,0,,,,PENDING
524,US,A1,US 2009/0222506 A1,048-090-304-574-286,2009-09-03,2009,US 32128209 A,2009-01-20,US 32128209 A;;US 6762608 P,2008-02-29,System and method for metering and analyzing usage and performance data of a virtualized compute and network infrastructure,"A method and system for metering and analyzing usage and performance data of virtualized compute and network infrastructures is disclosed. The processing functions of the metered data are divided into “processing units” that are configured to execute on a server (or plurality of interconnected servers). Each processing unit receives input from an upstream processing unit, and processes the metered data to produce output for a downstream processing unit. The types of processing units, as well as the order of the processing units is user-configurable (e.g. via XML file), thus eliminating the need to modify source code of the data processing application itself, thereby saving considerable time, money, and development resources required to manage the virtualized compute and network infrastructure.",EVIDENT SOFTWARE INC,JEFFERY DONALD C;;CLARK JOHN M;;FRENKIEL SCOTT T;;CHEN CHING-CHENG;;HO IVAN C,,https://lens.org/048-090-304-574-286,Patent Application,yes,13,21,3,3,0,G06F11/3404;;G06F11/3409;;G06F2201/815;;G06F2201/865;;G06F2201/875;;G06F2201/88;;G06F2201/885;;H04L41/142;;H04L41/5009;;H04L43/0847;;H04L43/024;;H04L41/40;;G06F11/3404;;G06F2201/88;;H04L43/0847;;G06F2201/865;;H04L41/142;;H04L41/5009;;G06F2201/875;;G06F11/3409;;G06F2201/815;;G06F2201/885;;H04L43/024,G06F15/16,709/202;;709/201,0,0,,,,DISCONTINUED
525,TW,A,TW 201836596 A,151-055-173-762-526,2018-10-16,2018,TW 107109130 A,2018-03-16,US 201762473232 P;;US 201715709262 A,2017-03-17,Gamma-hydroxybutyrate compositions and their use for the treatment of disorders,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/151-055-173-762-526,Patent of Addition,no,0,11,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61K9/08,,0,0,,,,PENDING
526,CA,A1,CA 3056316 A1,166-383-308-416-848,2018-09-20,2018,CA 3056316 A,2018-03-16,US 201762473232 P;;US 201715709262 A;;EP 2018056745 W,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/166-383-308-416-848,Patent Application,no,0,10,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61P25/00,,0,0,,,,PENDING
527,US,A1,US 2020/0386428 A1,058-925-720-782-047,2020-12-10,2020,US 201716770449 A,2017-12-07,US 2017/0065124 W,2017-12-07,REMOTE AUTOMATED DEPLOYMENT OF HVAC OPTIMIZATION SOFTWARE,"Computer-implemented methods and structures deploy a heating ventilation and air conditioning (HVAC) energy optimization program. A standard operating control platform (OCP) is deployed in an energy optimization control engine (EOCE) computing system communicatively coupled to a plurality of HVAC components via a building automation system (BAS). An energy optimization portal (EOP), which receives from the EOCE computing system a first data set identifying the plurality of HVAC components, a second data set including operational control parameters for each of the plurality of HVAC components, and a third data set including measured operations data associated with each of the plurality of HVAC components. The EOP generates an energy optimized operating control platform based on the first, second, and third data sets, which is automatically communicated from the EOP to the EOCE computing system.",OPTIMUM ENERGY LLC,MATTHYS CLARK RICHARD;;DEMPSTER IAN ROBERT;;CHEN PENG;;CARTER CHRIS;;BOSCOLO CHRIS;;LECHNER ANDREW ALEXANDER,OPTIMUM ENERGY LLC (2017-11-14),https://lens.org/058-925-720-782-047,Patent Application,yes,4,2,6,6,0,G05B15/02;;H04L12/2803;;H04L12/4625;;G05B2219/2642;;F24F11/30;;F24F2110/00;;F24F2130/10;;F24F11/54;;F24F11/58;;F24F11/46;;F24F11/64;;F24F2130/10;;F24F11/46;;F24F11/65;;F24F2110/00;;F24F11/30;;F24F11/54;;F24F11/58;;G05B19/042;;G05B2219/2614,F24F11/30;;F24F11/46;;F24F11/54;;F24F11/58;;F24F11/64;;F24F11/65;;G05B19/042,,0,0,,,,PENDING
528,EP,A1,EP 3227262 A1,078-292-043-968-714,2017-10-11,2017,EP 15864386 A,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,,NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,NOVIRA THERAPEUTICS INC. (2019-04-10),https://lens.org/078-292-043-968-714,Patent Application,yes,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C321/28;;A61K31/10;;A61K31/166;;A61K31/167;;A61P31/00;;A61P31/12;;C07C321/30;;C07C323/62,,0,0,,,,ACTIVE
529,US,A1,US 2021/0121423 A1,101-395-699-390-322,2021-04-29,2021,US 202017131418 A,2020-12-22,US 202017131418 A;;US 201916575213 A;;US 201715709262 A;;US 201762473232 P,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,JAZZ PHARMACEUTICALS INC (2017-07-31);;JAZZ PHARMACEUTICALS IRELAND LIMITED (2018-03-15),https://lens.org/101-395-699-390-322,Patent Application,yes,0,14,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19,,0,0,,,,ACTIVE
530,US,A1,US 2018/0263936 A1,192-283-391-539-682,2018-09-20,2018,US 201715709262 A,2017-09-19,US 201715709262 A;;US 201762473232 P,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,JAZZ PHARMACEUTICALS INC (2017-07-31);;JAZZ PHARMACEUTICALS IRELAND LIMITED (2018-03-15),https://lens.org/192-283-391-539-682,Patent Application,yes,0,28,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19,,0,0,,,,DISCONTINUED
531,US,A1,US 2023/0093063 A1,003-577-908-263-173,2023-03-23,2023,US 202117909276 A,2021-03-03,US 202117909276 A;;US 202062984739 P;;US 2021/0020741 W,2020-03-03,DEVICES INCLUDING FERROELECTRIC NEMATIC MATERIAL AND METHODS OF FORMING AND USING SAME,"Devices including nematic liquid crystal-forming molecules are disclosed. The molecules include one or more dipoles and exist in a ferroelectric nematic state. Exemplary devices can further include an electrode for applying an electric field in, for example, and in-plane direction.",UNIV COLORADO REGENTS;;UNIV UTAH RES FOUND,CLARK NOEL A;;CHEN XI;;GLASER MATTHEW A;;MACLENNAN JOSEPH E;;DONG DENGPAN;;BEDROV DIMITRY,,https://lens.org/003-577-908-263-173,Patent Application,yes,6,0,5,5,0,G02F1/141;;G02F1/141;;G02F2202/01;;G16C10/00;;G16C20/20;;G02F1/0045;;G02F1/0136;;G02F1/1358;;G02F1/141;;G02F2202/01;;G21K1/00,G02F1/141;;G02F1/00;;G02F1/01;;G02F1/135;;G16C10/00;;G16C20/20;;G21K1/00,,0,0,,,,PENDING
532,AU,A1,AU 2015/358561 A1,003-277-048-321-913,2017-06-08,2017,AU 2015/358561 A,2015-12-02,US 201462097854 P;;US 201462086323 P;;US 2015/0063417 W,2014-12-02,Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment,"The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,,https://lens.org/003-277-048-321-913,Patent Application,no,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C321/28;;A61K31/10;;A61K31/166;;A61K31/167;;A61P31/00;;A61P31/12;;C07C321/30;;C07C323/62,,0,0,,,,DISCONTINUED
533,EP,A1,EP 3595648 A1,010-772-132-979-269,2020-01-22,2020,EP 18712555 A,2018-03-16,US 201762473232 P;;US 201715709262 A;;EP 2018056745 W,2017-03-17,GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF DISORDERS,,JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/010-772-132-979-269,Patent Application,yes,0,10,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61P25/00,,0,0,,,,PENDING
534,US,A1,US 2023/0129511 A1,025-859-400-344-929,2023-04-27,2023,US 202218146295 A,2022-12-23,US 202218146295 A,2022-12-23,"METHODS, SYSTEMS, ARTICLES OF MANUFACTURE AND APPARATUS TO IMPROVE DISTRIBUTED MACHINE LEARNING EFFICIENCY","Methods, apparatus, systems, and articles of manufacture are disclosed to improve distributed machine learning efficiency. An example apparatus includes train management circuitry to cause a first vector to be sent from a worker node to an in-network-aggregator (INA) after completion of a first processing iteration requested by a parameter server. The example apparatus also includes protocol configuration circuitry to prohibit a second processing iteration when an availability status of the INA is false, and permit the second processing iteration when (a) an acknowledgement (ACK) from the INA corresponding to the first vector is received and (b) the availability status of the INA is true.",INTEL CORP,MERWADAY ARVIND;;JHA SATISH;;ALAM S M IFTEKHARUL;;SHARMA BANJADE VESH RAJ;;CHEN KUILIN CLARK,INTEL CORPORATION (2022-12-22),https://lens.org/025-859-400-344-929,Patent Application,yes,0,0,1,1,0,G06N3/08;;G06N3/063;;G06N3/08,G06N3/08,,0,0,,,,PENDING
535,US,B2,US 7205011 B2,058-986-180-002-183,2007-04-17,2007,US 98987404 A,2004-11-15,US 98987404 A;;US 52002803 P,2003-11-14,Anti-inflammatory activity of a specific turmeric extract,"Disclosed herein are mixtures of turmeric extract oils. One mixture of turmeric oils is the hexane soluble fraction obtained by dissolving turmeric powder in hexane to form a hexane mixture, filtering the hexane mixture and evaporating the hexane from the turmeric oil mixture. A more refined turmeric oil combination is the oil left after the turmeric oil mixture is dissolved in hexane, placed on a silica gel/hexane chromatography column, and eluted with hexane into fractions that were then evaporated, thereby leaving the refined turmeric oil combination. Also disclosed are methods for treating inflammation, arthritis and rheumatoid arthritis and a pharmaceutical dosage form of the refined turmeric oil combination.",UNIV MICHIGAN,CHEN GUAN JIE;;LANTZ ROBERT CLARK;;SOLYOM ANIKO M;;TIMMERMANN BARBARA N;;JOLAD SHIVANAND D,ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF UNIVERSITY OF ARIZONA (2005-02-16),https://lens.org/058-986-180-002-183,Granted Patent,yes,8,17,2,2,0,A61K36/9066;;A61K36/9066,A61K36/906;;A61K36/00;;A61K36/9066,424/756;;514/825;;514/885;;514/886,21,20,072-782-764-055-863;;069-529-625-148-333;;030-551-422-044-118;;017-698-009-303-775;;020-724-301-555-886;;048-579-769-946-469;;004-616-567-506-960;;034-216-530-620-108;;024-650-462-255-856;;031-311-323-202-655;;018-336-777-823-552;;021-809-090-880-273;;084-295-990-602-420;;030-185-184-206-953;;041-508-198-584-069;;058-706-309-830-352;;100-364-899-785-363;;017-161-042-825-41X;;144-967-806-702-952;;085-859-433-176-77X,10.1006/phrs.1998.0404;;10051376;;12680238;;10.1016/s0006-2952(98)00114-2;;9714315;;10.1016/0006-2952(95)00171-u;;7786295;;9674701;;10.1038/sj.onc.1201941;;11566484;;10.1016/s0304-3835(01)00655-3;;12413723;;10.1016/s0378-8741(02)00205-2;;12094302;;10.1055/s-2002-32560;;10477620;;9397403;;10.1007/s11745-997-0151-8;;9154168;;11297823;;10.1016/s0304-3940(01)01677-9;;10.1615/jenvironpatholtoxicoloncol.v21.i2.70;;12086400;;11077049;;10.1016/s0006-2952(00)00489-5;;10557090;;10.1038/sj.onc.1202980;;10.1016/s0944-7113(00)80048-3;;10969724;;10.1016/0304-3835(95)03827-j;;7621448;;7559628;;10.1074/jbc.270.42.24995;;10.1016/s0731-7085(96)02024-9;;9278892;;10190560;;10.1093/carcin/20.3.445,"Abe et al., ""Curcumin inhibition of inflammatory cytokine production by human peripheral blood mono . . . "", Pharmacol. Res. 1999, 39: 41-47.;;Aggarwal et al., ""Anticancer potential of curcumin; preclinical and clinical studies."", Anticancer Res. 2003, 23: 363-398.;;Chan et al., ""In vivo inhibition of nitric oxide synthase gene expression by . . . "", Biochemical Pharmacology, 55:1995-1962, 1998.;;Chan, ""Inhibition of Tumor necrosis factor by curcumin"", Biochem Pharmacol, 49, pp. 1551-1556, 1995.;;Chen et al., ""Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin."", Oncogene. 1998, 17: 173-178.;;Gallin et al., ""Overview in inflammation: basic principles and clinical correlates"", 3rd Ed., Lippincott Williams & Wilkins, Philadelphia, 1999, pp. 1-3.;;Goel, et al., ""Specific inhibition of cyclooxygenase-1 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells."", Cancer Let., 2001, 172:111-118.;;Hong et al., ""Evaluation of natural products on inhibition of inducible cyclooxygenase . . . "", Ethnopharmacol. 2002 83:153-159.;;Hong et al., ""Inhibitory effects of natural sesquiterpenoids isolated from rhizomes of Curcuma zedoaria on prostaglandin E2 . . . "", Planta Medica 2002 68:545-547.;;Jobin et al., ""Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory . . . "", J Immunology, 1999, 163: 3474-3483.;;Joe et al., ""Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme . . . "", Lipids, 1997, 32: 1173-1180.;;Kelloff et al., ""Strategy and planning for chemopreventive drug development: clinical developmant plans II."", J. Cellular Biochem-Supplement, 1996, 26:54-71.;;Kim et al., ""Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat . . . "", Neurosci. Let., 2001 303:57-61.;;Lee et al., ""Suppressive effect of natural sesquiterpenoids on inducible cyclooxygenase . . . "", J. Environ. Pathol. Toxicol. Oncol., 2002, 21:141-148.;;Pan et al., ""Comparative studies on the suppression of nitric oxicd synthase by . . . "", Biochem. Pharmacol, 2002, 60:1665-1676.;;Plummer et al., ""Inhibition of cyclo-oxygenase 2 expression in colon cells by the . . . "", Oncogene, 1999, 18:6013-6020.;;Ramsewak et al., ""Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I-III from Curcuma longa. "", Phytomedicine, 2000, 7:303-308.;;Ruby et al., ""Anti-tumor and antioxidant activity of natural curcuminoids."", Cancer Letters, 1995, 94:79-83.;;Singh et al., ""Activation of transcription factor NF-kB is suppressed by curcumin (diferulolylmethane)."", 1995, J. Biol. Chem. 270: 24995-25000.;;Wang.J., et al., ""Stability of curcumin in buffer solutions and characterization of its degradation products."" J. Pharmaceut. Biomed. Anal., 1997, 15:1867-76.;;Zhang, ""Curcumin inhibits cyclooxygenase-2 transcription in bile acid-and phorbol ester . . . "", Carcinogenesis, 1999, 20:445-451.",ACTIVE
536,EP,B1,EP 3227262 B1,101-209-445-068-542,2020-05-13,2020,EP 15864386 A,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,,NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,NOVIRA THERAPEUTICS INC. (2019-04-10),https://lens.org/101-209-445-068-542,Granted Patent,yes,4,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C323/62;;A61K31/167;;A61K31/18;;A61K31/337;;A61K31/351;;A61K31/44;;A61K31/4453;;A61K31/498;;A61K31/5375;;A61P31/12;;C07D213/81;;C07D295/185;;C07D305/06;;C07D305/08;;C07D307/10;;C07D307/18;;C07D309/08,,2,0,,,"DATABASE REGISTRY [Online] Chemical Abstracts Service, Columbus, OH, US; 15 April 2011 (2011-04-15), ""Benzamide, N-(4-fluorophenyl)-3-[(2-thienylsulfonyl)a mino]-"", XP002781315, retrieved from STN Database accession no. 1280388-44-4;;MASARU OGATA ET AL.: 'Synthesis an Antiviral Activity of Sulfonamidobenzophen -one Oximes and Sulfonamidobenzamides' J. MED. CHEM. vol. 29, no. 3, 01 March 1986, pages 417 - 423, XP002096176 DOI: 10.1021/JM00153A018",ACTIVE
537,US,B1,US 10148662 B1,148-968-924-197-029,2018-12-04,2018,US 201514602251 A,2015-01-21,US 201514602251 A,2015-01-21,De-duplication of access control lists,"Described are methods, systems, and apparatus, including computer program products for de-duplicating access control lists (ACLs). A first ACL associated with a first computer file is received. A first checksum based at least in part on the first ACL is calculated. One or more directory entries based on the first checksum are retrieved from a de-duplication directory, wherein each directory entry of the one or more directory entries comprises a reference to an ACL and a name comprising the first checksum. A directory entry of the one or more directory entries is identified that references a second ACL that specifies the same permissions as the first ACL. A reference to the second ACL of the directory entry is added to the first computer file.",EMC IP HOLDING CO LLC,CLARK MORGAN A;;DAVENPORT WILLIAM C;;SCHOUTEN MICHAEL D;;MAO QI;;ZHOU YINGCHAO;;CHEN YUNFEI,EMC CORPORATION (2015-02-04);;EMC IP HOLDING COMPANY LLC (2016-09-06),https://lens.org/148-968-924-197-029,Granted Patent,yes,28,3,1,1,0,G06F16/113;;G06F16/137;;G06F16/152;;G06F16/164;;G06F16/174;;G06F16/174;;G06F16/2255;;G06F16/2291;;H04L63/101;;H04L63/101;;H04L63/20;;H04L63/20,G06F17/30;;G06F11/00;;G06F11/14;;H04L29/06,,0,0,,,,ACTIVE
538,TW,A,TW 202335663 A,028-600-937-202-310,2023-09-16,2023,TW 111146727 A,2018-03-16,US 201762473232 P;;US 201715709262 A,2017-03-17,Gamma-hydroxybutyrate compositions and their use for the treatment of disorders,"Provided herein are pharmaceutical compositions and formulations comprising mixed salts of gamma-hydroxybutyrate (GHB). Also provided herein are methods of making the pharmaceutical compositions and formulations, and methods of their use for the treatment of sleep disorders such as apnea, sleep time disturbances, narcolepsy, cataplexy, sleep paralysis, hypnagogic hallucination, sleep arousal, insomnia, and nocturnal myoclonus.",JAZZ PHARMACEUTICALS IRELAND LTD,ALLPHIN CLARK P;;JUNNARKAR GUNJAN;;SKOWRONSKI ROMAN;;CHEN CUIPING;;ZOMORODI KATAYOUN;;ELLER MARK;;MCGARRIGLE PHILIP,,https://lens.org/028-600-937-202-310,Patent of Addition,no,0,0,13,13,0,A61K31/19;;A61P25/00;;A61K31/19;;A61K2300/00,A61K31/19;;A61K9/08;;A61P25/00,,0,0,,,,ACTIVE
539,US,B1,US 11377120 B1,028-009-983-793-512,2022-07-05,2022,US 202016863341 A,2020-04-30,US 202016863341 A;;US 202062983204 P,2020-02-28,Autonomous vehicle control based on risk-based interactions,"Systems, methods, tangible non-transitory computer-readable media, and devices associated with vehicle control based on risk-based interactions are provided. For example, vehicle data and perception data can be accessed. The vehicle data can include the speed of an autonomous vehicle in an environment. The perception data can include location information and classification information associated with an object in the environment. A scenario exposure can be determined based on the vehicle data and perception data. Prediction data including predicted trajectories of the object can be accessed. Expected speed data can be determined based on hypothetical speeds and hypothetical distances between the vehicle and the object. A speed profile that satisfies a threshold criteria can be determining based on the scenario exposure, the prediction data, and the expected speed data, over a distance. A motion plan to control the autonomous vehicle can be generated based on the speed profile.",UATC LLC,DENG ERIC CHEN;;MARCHETTI-BOWICK MICOL;;CONCILIO YASMINE STRAKA;;HAYNES GALEN CLARK;;PHILLIPS MICHAEL LEE,UATC LLC (2020-12-17),https://lens.org/028-009-983-793-512,Granted Patent,yes,4,6,1,1,0,B60W30/0956;;B60W60/0027;;B60W2554/80;;B60W60/0015;;B60W2520/10;;B60W2720/103;;B60W30/0953;;B60W50/0097;;B60W2554/402;;B60W2556/50;;B60W60/0015;;B60W30/0956;;B60W30/16;;G08G1/20;;B60W2554/80;;B60W10/20;;B60W2520/10;;B60W2552/05;;B60W10/18;;B60W60/0027;;B60W2720/103,B60W60/00;;B60W10/18;;B60W10/20;;B60W30/095;;B60W30/16;;G08G1/00,,1,1,178-593-892-503-844,10.1109/cdc40024.2019.9030068,"Phan-Minh et al., :Towards Assume-Guarantee Profiles For Autonomous Vehicles, Conference on Decision and Control (CPC), 2019, 10 pages.",ACTIVE
540,CA,A1,CA 3082781 A1,114-146-036-339-301,2019-06-13,2019,CA 3082781 A,2017-12-07,US 2017/0065124 W,2017-12-07,REMOTE AUTOMATED DEPLOYMENT OF HVAC OPTIMIZATION SOFTWARE,"Computer-implemented methods and structures deploy a heating ventilation and air conditioning (HVAC) energy optimization program. A standard operating control platform (OCP) is deployed in an energy optimization control engine (EOCE) computing system communicatively coupled to a plurality of HVAC components via a building automation system (BAS). An energy optimization portal (EOP), which receives from the EOCE computing system a first data set identifying the plurality of HVAC components, a second data set including operational control parameters for each of the plurality of HVAC components, and a third data set including measured operations data associated with each of the plurality of HVAC components. The EOP generates an energy optimized operating control platform based on the first, second, and third data sets, which is automatically communicated from the EOP to the EOCE computing system.",OPTIMUM ENERGY LLC,MATTHYS CLARK RICHARD;;DEMPSTER IAN ROBERT;;CHEN PENG;;CARTER CHRIS;;BOSCOLO CHRIS;;LECHNER ANDREW ALEXANDER,,https://lens.org/114-146-036-339-301,Patent Application,no,0,0,6,6,0,G05B15/02;;H04L12/2803;;H04L12/4625;;G05B2219/2642;;F24F11/30;;F24F2110/00;;F24F2130/10;;F24F11/54;;F24F11/58;;F24F11/46;;F24F11/64;;F24F2130/10;;F24F11/46;;F24F11/65;;F24F2110/00;;F24F11/30;;F24F11/54;;F24F11/58;;G05B19/042;;G05B2219/2614,F24F11/30;;F24F11/46;;F24F11/54;;F24F11/58;;G05B15/02;;H04L12/28,,0,0,,,,PENDING
541,US,A1,US 2024/0054292 A1,035-623-443-235-708,2024-02-15,2024,US 202218266865 A,2022-01-05,NZ 77165921 A;;IB 2022050071 W,2021-01-05,CONVERSATION ORCHESTRATION IN INTERACTIVE AGENTS,"Embodiments described herein relate to methods and systems for animating (bringing to life) an Agent, which may be a virtual object, digital entity, and/or robot. A Router enables seamless interactions between a user and the Agent via multiple Skill Modules. Skill Modules may include conversation corpora and/or other applications. Embodiments described herein may improve Conversation Orchestration in Interactive Agents in the context of multi-modal human-computer interactions.",SOUL MACHINES LTD,CHEN JEREMY;;CLARK-YOUNGER HANNAH;;HASLAM ANDREW;;AYYAD NADER;;PLETKA JOHN;;MASSERINI MARUO;;POOL LIAM,,https://lens.org/035-623-443-235-708,Patent Application,yes,0,0,8,8,0,G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/35;;G06F40/284;;G10L15/22;;H04L51/02;;G06F40/30;;G06F16/3329;;G10L2015/223;;H04L51/02;;H04L51/214;;G06F40/35;;G06F16/3329;;G06F40/35,G06F40/35,,0,0,,,,PENDING
542,ES,T3,ES 2802412 T3,126-181-229-869-180,2021-01-19,2021,ES 15864386 T,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,"Compuestos de sulfonamida inversa a base de sulfuro, alquilo y piridilo para el tratamiento del VHB","compuesto de Fórmula IIIa: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo; en la que cada R1 se selecciona independientemente de H, halo y alquilo de C1-6; R2 se selecciona de halo, OH, CN, -alquilo de C1-6, -alcoxi de C1-6, halo-(alquilo de C1-6), di-halo-(alquilo de C1-6) y tri-halo-(alquilo de C1-6); R3 es halo; y R4 se selecciona de -alquilo de C1-6, -heteroalquilo de C1-6, -cicloalquilo de C3-7, -heterocicloalquilo de C3-7, (alquilo de C1-6)-(cicloalquilo de C3-7), -(cicloalquilo de C3-7)-(alquilo de C1-6), cicloalquilo de C7-8 con puente, - (alquilo de C1-6)-C(O)O-(alquilo de C1-6) y -(alquilo de C1-6)-(heterocicloalquilo de C3-7), cada uno de los cuales puede estar sustituido con 0, 1 o 2 grupos seleccionados independientemente de (=O), -OH, -alquilo de C1-6, - cicloalquilo de C3-7, halo-(alquilo de C1-6), di-halo-(alquilo de C1-6), tri-halo-(alquilo de C1-6), C(O)OH, fenilo y halo; o R4 se selecciona de (cicloalquilo de C3-7)-C(O)R5 y -(cicloalquilo de C7-8 con puente)-C(O)R5, y R5 se selecciona de N(CH3)2, NS(O)2CH3, y heterocicloalquilo de C3-7, en los que: ""alquilo"", por sí mismo o como parte de otro sustituyente, significa, a menos que se señale de otro modo, un hidrocarburo que tiene el número de átomos de carbono designado (es decir, C1-6 significa uno a seis átomos de carbono), e incluye grupos sustituyentes de cadena lineal, ramificada, o cíclicos; y ""cicloalquilo"" se refiere a un radical no aromático monocíclico o policíclico, en el que cada uno de los átomos que forman el anillo (es decir, átomos esqueléticos) es un átomo de carbono, y/o se refiere a grupos ""carbociclilo no aromático insaturado"" o ""carbociclilo insaturado no aromático"", opcionalmente en el que el grupo cicloalquilo comprende un anillo aromático condensado.",NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,,https://lens.org/126-181-229-869-180,Granted Patent,no,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C323/62;;A61K31/167;;A61K31/18;;A61K31/337;;A61K31/351;;A61K31/44;;A61K31/4453;;A61K31/498;;A61K31/5375;;A61P31/12;;C07D213/81;;C07D295/185;;C07D305/06;;C07D305/08;;C07D307/10;;C07D307/18;;C07D309/08,,0,0,,,,ACTIVE
543,EP,A4,EP 3227262 A4,067-273-527-861-195,2018-07-11,2018,EP 15864386 A,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDE ALKYL AND PYRIDYL REVERSE SULFONAMIDE COMPOUNDS FOR HBV TREATMENT,,NOVIRA THERAPEUTICS INC,CHEN AUSTIN;;BRAVO YALDA;;STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN,NOVIRA THERAPEUTICS INC. (2019-04-10),https://lens.org/067-273-527-861-195,Search Report,no,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C311/24;;A61K31/167;;A61K31/18;;A61K31/192;;A61K31/381;;A61K31/415;;A61K31/44;;A61K31/5375;;A61K45/06;;A61P31/12;;C07C323/62;;C07D213/81;;C07D231/18;;C07D333/34;;C07D487/10,,1,0,,,"DATABASE REGISTRY [online] Chemical Abstracts Service, Columbus, OH, US; 15 April 2011 (2011-04-15), ""Benzamide, N-(4-fluorophenyl)-3-[(2-thienylsulfonyl)amino]-"", XP002781315, retrieved from STN Database accession no. 1280388-44-4",ACTIVE
544,US,B2,US 6739877 B2,118-914-697-220-126,2004-05-25,2004,US 80010401 A,2001-03-06,US 80010401 A,2001-03-06,Distributive processing simulation method and system for training healthcare teams,"
    A simulation method and system based on a distributive processing model is used for training and educating healthcare teams. The system allows team members to be at the training facility or located remotely and connected via data communication links. The system allows multiple participants for individual team member roles at various connected simulation workstations. If simulation participants cannot man all the team roles, the system can provide virtual team members in their stead. The simulation server computer delivers to each workstation the particular programs and outputs required for any given simulation exercise. 
",MEDICAL SIMULATION CORP,BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,MENTICE AB A SWEDISH CORPORATION (2017-12-19),https://lens.org/118-914-697-220-126,Granted Patent,yes,27,85,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,434/262;;434/219,0,0,,,,EXPIRED
545,WO,A1,WO 2012/021712 A1,142-812-108-573-947,2012-02-16,2012,US 2011/0047428 W,2011-08-11,US 201161483025 P;;US 201061424552 P;;US 37319010 P,2010-08-12,TETRACYCLINE ANALOGS,"The present invention is directed to a compound represented by Structural Formula (I), or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.",TETRAPHASE PHARMACEUTICALS INC;;CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,,https://lens.org/142-812-108-573-947,Patent Application,yes,5,46,3,3,0,A01N43/90;;A01N43/36;;A01N43/40;;A01N43/60;;A01N43/80;;A01N43/84;;A61P31/04;;A61P31/06;;C07D205/04;;C07D207/09;;C07D207/12;;C07D207/20;;C07D209/52;;C07D211/26;;C07D211/38;;C07D213/73;;C07D223/04;;C07D231/12;;C07D233/64;;C07D241/04;;C07D261/20;;C07D265/30;;C07D413/04;;C07D471/08,A61K31/535;;A01N43/46;;A61K31/40;;C07D207/00;;C07D413/00;;C07D487/00,,0,0,,,,PENDING
546,DK,T3,DK 3227262 T3,185-405-505-335-266,2020-08-10,2020,DK 15864386 T,2015-12-02,US 201462086323 P;;US 201462097854 P;;US 2015/0063417 W,2014-12-02,SULFIDALKYL OG PYRIDYL-REVERS-SULFONAMIDFORBINDELSER TIL HBV-BEHANDLING,,NOVIRA THERAPEUTICS INC,STOCK NICHOLAS;;PEDRAM BIJAN;;JACINTHO JASON;;CLARK RYAN C;;TRUONG YEN;;CHEN AUSTIN;;BRAVO YALDA,,https://lens.org/185-405-505-335-266,Granted Patent,no,0,0,10,22,0,C07C311/03;;C07C311/29;;C07C321/28;;C07C321/30;;C07C323/62;;C07D211/46;;C07D213/81;;C07D231/18;;C07D295/185;;C07D305/06;;C07D307/10;;C07D307/18;;C07D309/04;;C07D333/26;;C07D333/34;;C07D333/48;;C07D405/12;;A61K31/167;;C07C323/62;;C07C311/03;;C07D295/185;;C07D213/81;;C07D309/04;;C07D231/18;;C07D333/34;;C07D333/48;;C07D405/12;;C07D211/46;;C07D305/06;;C07D307/10;;C07D307/18;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/18;;A61K45/06;;A61K31/18;;A61K31/192;;A61K31/341;;A61K31/381;;A61K31/397;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/4453;;A61K31/495;;A61K31/5375;;C07C311/24;;C07C2602/20;;A61P1/16;;A61P31/00;;A61P31/12;;A61P31/20,C07C323/62;;A61K31/167;;A61K31/18;;A61K31/337;;A61K31/351;;A61K31/44;;A61K31/4453;;A61K31/498;;A61K31/5375;;A61P31/12;;C07D213/81;;C07D295/185;;C07D305/06;;C07D305/08;;C07D307/10;;C07D307/18;;C07D309/08,,0,0,,,,ACTIVE
547,AU,A1,AU 2021/203458 A1,051-486-898-914-004,2021-06-24,2021,AU 2021/203458 A,2021-05-27,AU 2021/203458 A;;AU 2018/282451 A;;AU 2014/249224 A;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/051-486-898-914-004,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,PENDING
548,US,A1,US 2019/0233531 A1,116-898-028-506-338,2019-08-01,2019,US 201916238932 A,2019-01-03,US 201916238932 A;;US 201715417648 A;;US 201414203479 A;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2014-02-07),https://lens.org/116-898-028-506-338,Patent Application,yes,0,3,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,0,0,,,,ACTIVE
549,CN,A,CN 105228645 A,161-559-946-322-728,2016-01-06,2016,CN 201480014338 A,2014-03-10,US 2014/0022728 W;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/161-559-946-322-728,Patent Application,no,2,1,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K39/00;;C07K16/00,,5,2,136-414-621-541-929;;084-230-129-207-67X,pmc3464487;;10.1021/bc900103p;;19425533;;10.1021/bc1005416;;21417264,"ELIZABETH BOEGGEMAN ET AL: ""Site specific conjugation of fluoroprobes to the remodeled Fc Nglycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection"", 《BIOCONJUGATE CHEMISTRY》;;QUN ZHOU ET AL: ""Strategies for Neoglycan Conjugation to Human Acid r-Glucosidase"", 《AMERICAN CHEMICAL SOCIETY》;;林莉等: ""抗体药物偶联物及其在恶性血液系统肿瘤治疗中的应用"", 《药学学报》;;苗庆芳等: ""抗肿瘤抗体药物研究进展"", 《药学学报》;;SUN YU ET AL: ""Antibody-drug conjugates as targeted cancer therapeutics"", 《药学学报》",ACTIVE
550,EP,A3,EP 4063389 A3,087-251-856-811-197,2022-12-28,2022,EP 22151876 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;EP 14718808 A;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/087-251-856-811-197,Search Report,yes,1,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,9,7,136-414-621-541-929;;084-230-129-207-67X;;032-476-801-692-751;;003-338-632-019-904;;023-249-219-470-807;;075-192-332-107-331;;155-997-499-883-189,pmc3464487;;10.1021/bc900103p;;19425533;;10.1021/bc1005416;;21417264;;10.1021/bc400505q;;24533768;;10.1038/nbt.1480;;18641636;;10.1126/science.1129594;;16888140;;19036920;;10.1073/pnas.0810163105;;pmc2604916;;10.1007/s00253-011-3814-1;;22205442,"ELIZABETH BOEGGEMAN ET AL: ""Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection"", BIOCONJUGATE CHEMISTRY, vol. 20, no. 6, 17 June 2009 (2009-06-17), pages 1228 - 1236, XP055061205, ISSN: 1043-1802, DOI: 10.1021/bc900103p;;ZHOU Q ET AL: ""Strategies for Neoglycan conjugation to human acid [alpha]-glucosidase"", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 22, no. 4, 20 April 2011 (2011-04-20), pages 741 - 751, XP002727745, ISSN: 1043-1802, [retrieved on 20110318], DOI: 10.1021/BC1005416;;QUN ZHOU ET AL: ""Site-Specific Antibody–Drug Conjugation through Glycoengineering"", BIOCONJUGATE CHEMISTRY, vol. 25, no. 3, 19 March 2014 (2014-03-19), pages 510 - 520, XP055190282, ISSN: 1043-1802, DOI: 10.1021/bc400505q;;JUNUTULA J R ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index"", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 26, no. 8, 1 August 2008 (2008-08-01), pages 925 - 932, XP002499771, ISSN: 1087-0156, [retrieved on 20080720], DOI: 10.1038/NBT.1480;;RAMESH JASSAL ET AL: ""Sialylation of Human IgG-Fc Carbohydrate by Transfected Rat α2,6-Sialyltransferase"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, no. 2, 1 August 2001 (2001-08-01), Amsterdam NL, pages 243 - 249, XP055327703, ISSN: 0006-291X, DOI: 10.1006/bbrc.2001.5382;;ROCHE DIAGNOSTICS GMBH: ""alpha.-2,6, Sialyltransferase"", no. Version 2, 1 May 2013 (2013-05-01), pages 1 - 2, XP002727803, Retrieved from the Internet <URL:https://cssportal.roche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf>;;KANEKO Y ET AL: ""ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594;;R. M. ANTHONY ET AL: ""Inaugural Article: Identification of a receptor required for the anti-inflammatory activity of IVIG"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 50, 16 December 2008 (2008-12-16), pages 19571 - 19578, XP055053128, ISSN: 0027-8424, DOI: 10.1073/pnas.0810163105;;MASAYOSHI ONITSUKA ET AL: ""Enhancement of sialylation on humanized IgG-like bispecific antibody by overexpression of Î 2,6-sialyltransferase derived from Chinese hamster ovary cells"", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, SPRINGER, BERLIN, DE, vol. 94, no. 1, 29 December 2011 (2011-12-29), pages 69 - 80, XP035029858, ISSN: 1432-0614, DOI: 10.1007/S00253-011-3814-1",PENDING
551,EP,A2,EP 2235962 A2,108-214-885-592-701,2010-10-06,2010,EP 08869181 A,2008-12-17,US 2008/0087102 W;;US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,,MOTOROLA INC,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,"MOTOROLA MOBILITY, INC. (2011-03-02);;MOTOROLA MOBILITY LLC (2012-09-05)",https://lens.org/108-214-885-592-701,Patent Application,yes,0,0,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04R1/02;;H04M1/12;;H04R1/28,,0,0,,,,DISCONTINUED
552,US,B2,US 9580511 B2,135-602-004-207-070,2017-02-28,2017,US 201414203479 A,2014-03-10,US 201414203479 A;;US 201361776724 P;;US 201361776710 P;;US 201361776715 P,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2014-02-07),https://lens.org/135-602-004-207-070,Granted Patent,yes,72,11,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K38/00;;C07K16/28;;C07K16/32;;C07K16/40,,74,58,013-885-021-097-853;;048-510-345-009-61X;;058-543-894-773-905;;018-007-265-921-231;;045-974-352-776-610;;136-414-621-541-929;;136-414-621-541-929;;084-230-129-207-67X;;032-476-801-692-751;;003-338-632-019-904;;038-305-867-383-662;;013-795-151-218-458;;005-218-993-322-382;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;015-623-518-697-144;;076-152-531-431-484;;113-720-510-689-403;;047-364-936-221-939;;075-912-302-795-48X;;028-401-996-299-149;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X;;153-263-439-316-208;;025-805-731-142-930;;046-783-448-716-481;;033-955-564-406-161;;083-071-649-888-913;;062-544-695-545-247;;060-056-896-118-940;;011-629-800-752-356;;058-985-409-440-786;;032-870-057-378-750;;074-787-113-780-602;;013-977-769-158-191;;143-862-943-589-725;;028-456-569-502-585;;016-716-200-807-517;;042-233-175-582-26X;;036-975-782-541-190;;058-270-451-857-914;;106-158-572-918-727;;111-625-445-280-864;;013-157-274-165-126;;004-458-031-333-650;;004-272-966-072-139;;008-019-042-176-997;;002-771-789-858-985;;013-142-717-038-23X;;100-801-934-296-913,10.1021/ja00119a001;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;10.1039/b604391g;;16791327;;10.1002/anie.199612301;;10.1021/ja038545r;;14692737;;pmc3464487;;10.1021/bc900103p;;19425533;;pmc3464487;;10.1021/bc900103p;;19425533;;10.1021/bc1005416;;21417264;;10.1021/bc400505q;;24533768;;10.1038/nbt.1480;;18641636;;10.1006/bbrc.2001.5382;;11500028;;9780179;;10.4049/jimmunol.161.8.4083;;17041261;;10.1385/1-59745-187-8:95;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;389741;;10.1016/0378-1119(79)90029-5;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;388229;;10.1038/282039a0;;6248420;;10.1016/0378-1119(80)90133-x;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365;;1476621;;9930678;;10.1093/protein/11.12.1277;;18536555;;10.1097/ppo.0b013e318172d704;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;8623165;;10.1097/00007890-199603270-00018;;10.1097/00007890-199601270-00032;;8600649;;10.1002/bit.21598;;17680659;;10.4049/jimmunol.148.12.3768;;1376340;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;20805300;;10.1158/1078-0432.ccr-10-0987;;18577454;;10.1016/j.coi.2008.05.010;;10541351;;10.1111/j.1432-2277.2012.01456.x;;22420711;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;10.1097/00007890-199902270-00019;;10071034;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;10.1002/micr.20294;;17066409;;7879044;;10.4049/jimmunol.147.12.4366;;1836485;;11096108;;10.1074/jbc.m009483200;;10.1038/nbt832;;12778055;;15185369;;10.1002/cbic.200300806;;10.4049/jimmunol.165.8.4505;;11035090;;10556035;;10.1006/jmbi.1999.3141;;18234994;;10.1167/iovs.07-1175,"Shao et al. Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages. JACS, 1995. vol. 117, No. 14, pp. 3893-3899.;;Axup et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. PNAS, 2012. vol. 109, No. 40, pp. 16101-16106.;;Renaudet et al. On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides. Organic and Biomolecular Chemistry, 2006. vol. 4, pp. 2628-2636.;;Cervigni et al. Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation. Angew. Chem. Int. Ed. Engl. 1996, vol. 35, No. 11, pp. 1230-1232.;;Khidekel et al. A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications, J. Am. Chem. Soc., 2003. vol. 125, pp. 16162-16163.;;Boeggeman et al. Site specific conjugation of fluoroprobes to the remodeled Fc Nglycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection. Bioconjug Chem. Jun. 2009. vol. 20, No. 6, pp. 1228-1236.;;Boeggman, Elizabeth et al., ""Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection."" Bioconjugate Chemistry. 2009, 20(6):1228-1236.;;Zhou, Qun et al., ""Strategies for Neoglycan conjugation to human acid [alpha]-glucosidase."" Bioconjugate Chemistry. 2011, 22(4):741-751.;;Zhou, Qun et al., ""Site-specific antibody-drug conjugation through glycoengineering."" Bioconjugate Chemistry. 2014, 25(3):510-520.;;Junutula, Jagath R., et al., Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.: Nature Biotechnology. 2008, 26(8):925-932.;;Jassal, R. et al., ""Sialylation of human igG-Fc carbohydrate by transfected rat alpha2, 6-sialyltransferase."" Biochemical and Biophysical Research Communications. 2001, 286(2): 243-249.;;Anonymous, ""alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data Sheet)."" Roche Diagnostics. 2013, XP002727803 Retrieved from Internet: URL: https://cssportal.roche.com/LFR-PublicDocs/ras/07012250103-en-02.pdf [retrieved on Jul. 25, 2014].;;International Search Report from application No. PCT/US2014/022728 dated Oct. 13, 2014.;;Roux et al. 'Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, IgE, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry'. Journal of Immunology. 1998, vol. 161, No. 8, pp. 4083-4090.;;Koide et al. 'Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain'. Methods in Molecular Biology. 2007, vol. 352, pp. 95-109.;;Stumpp et al. 'DARPins: A New Generation of Protein Therpeutics'. Drug Discovery Today. 2008, vol. 13, No. 15-16, pp. 695-670.;;Nygren et al. 'Alternative Binding Proteins: Affibody Binding Proteins Devloped from a Small Three-helix Bundle Scaffold'. The FEBS Journal. 2008, vol. 275, No. 11, pp. 2668-2676.;;Skerra et al. 'Alternative Binding Proteins: Anticalins-Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activites'. The FEBS Journal. 2008, vol. 275, No. 11, pp. 2677-2683.;;Ebersbach et al. 'Affilin-Novel Binding Molecules Based on Humans gamma-B-Crystallin, an All beta-Sheet Protein'. Journal of Molecular Biology. 2007, vol. 372, No. 1, pp. 172-185.;;Krehenbrink et al. 'Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PuID'. Journal of Molecular Biology. 2008, vol. 383, No. 5, pp. 1058-1068.;;Silverman et al. 'Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains'. Nature Biotechnology. 2005, vol. 23, No. 12, pp. 1556-1561.;;Grabulovski et al. 'A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Proteins'. The Journal of Biological Chemistry. 2007, vol. 282, No. 5, pp. 3196-3204.;;Nixon et al. 'Engineered Protein Inhibitors of Proteases'. Current Opinion in Drug Discovery & Development. 2006, vol. 9, No. 2, pp. 261-268.;;Guan et al. 'Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization'. PNAS. 1998, vol. 95, No. 22, pp. 13206-13210.;;Kingsman et al. 'Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trpl Region'. Gene. 1979, vol. 7, pp. 141-152.;;Carrasquillo et al. Improved imaging of metastatic melanoma with high dose 9.2.27 In-11 1 monoclonal antibody'. J. Nuc. Med. 1985. vol. 26, pp. 67, Abstract No. 276.;;Cobos-Correa et. al. 'Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation'. Nature Chemical Biology. 2009, vol. 5, No. 9, pp. 628-663.;;Gehrig et.al. 'Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters'. Angewandte Chemie International Edition. 2012, vol. 51, No. 25, pp. 6258-6261.;;Stinchcomb et al. 'Isolation and Characterization of a Yeast Chromosomal Replicator'. Nature. 1979, vol. 282, pp. 39-43.;;Tschumper et al. 'Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene'. Gene. 1980, vol. 10, pp. 157-166.;;Jones. 'Proteinase Mutants of Saccharomyces cerevisiae'. Genetics. 1977, vol. 85, pp. 23-33.;;Kaneko et al. 'Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation'. Science. 2006, vol. 313, No. 5787, pp. 670-673.;;Wang et al. 'Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies'. Molecular Immunology. 2011, vol. 48, No. 6, pp. 860-866.;;Teicher. 'Antibody-drug conjugate targets'. Current Cancer Drug Targets. 2009, vol. 9, No. 8, pp. 982-1004.;;International Search Report and Written Opinion for International Application No. PCT/US2013/059481, dated Feb. 7, 2014, 11 pages.;;International Search Report and Written Opinion for International Application No. PCTUS2014/022623, mailed Jul. 31, 2014, 18 pages.;;International Search Report for International Application No. PCT/EP2012/003819, dated Jul. 17, 2013, 7 pages.;;Written Opinion for International Application No. PCT/EP2012/003819, dated Jul. 17, 2013, 13 pages.;;Wright et al. (1992) ""Genetically Engineered Antibodies: Progress and Prospects,"" Critical Reviews in Immunology. 12:125-168.;;Wang et al. (1998) ""Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules,"" Protein Engineering. 11:1277-1283.;;Carter et al. (2008) ""Antibody-drug conjugates for cancer therapy,"" Caner Journal. 14:154-169.;;Chan et al. (2010) ""Therapeutic antibodies for autoimmunity and inflammation,"" The Journal of Immunology. 10:301-316.;;Chari (2008) ""Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs,"" Accounts of Chemical Research. 41:98-107.;;Heidecke et al. (1996) ""Alpha-Beta T Cell Receptor-Directed Therapy in Rat Allograft Recipients,"" Transplantation. 61:948-956.;;Heidecke et al. (1996) ""Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-A/B-Targeted Therapy,"" Transplantation 61:336-339.;;Zhou et al. (2008) ""Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,"" Biotechnol. Bioeng. 99:652-665.;;Jung et al. (1992) ""Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta,"" Journal of Immunology. 148:3768-3775.;;Yoshino et al. (1992) ""Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats.,"" J. Exp. Med. 175:907-915.5-932.;;Junutula et al. (2010) ""Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer,"" Clin. Cancer Res. 16:4769-4778.;;Labrijn et al. (2008) ""When binding is enough: nonactivating antibody formats,"" Curr. Opin. Immunol. 20:479-485.;;Leung et al. (1999) ""The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments,"" Clin. Cancer Res. 5:3106s-3117s.;;Page et al. (2012) ""Biologics in Organ Transplant,"" Transplant International. 25:707-719.;;Polakis (2005) ""Arming antibodies for cancer therapy,"" Current Opinion in Pharmacology. 5:382-387.;;Qu et al. (1998) ""Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,"" Journal of Immunological Methods. 213:131-144.;;Yamagami et al. (1999) ""Suppression of Allograft Rejection with Anti-Abeta T Cell Receptor Antibody in Rat Corneal Transplantation,"" Transplantation. 67:600-604.;;Sazinsky et al. (2008) ""Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,"" Proc. Natl. Acad. Sci. USA. 105(51): 20167-20172.;;Scharpf et al. (2006) ""Immunomodulation with anti-alphabeta T-cell receptor monoclonal antibodies in combination with cyclosporine a improves regeneration in nerve allografts,"" Microsurgery. 26:599-607.;;Schorlemmer et al. (1995) ""Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats,"" Transplantation Proceedings. 27:414-416.;;Shearman et al. (1991) ""Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor,"" The Journal of Immunology. 147:4366-4373.;;Shields et al. (2001) ""High Resolution Mapping of the Binding Site on Human IgG1 for FcgammaRI, FcgammaRII, FcgammaRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcgammaR,"" J. Biol. Chem. 276:6591-6604.;;Doronina et al. (2003) ""Development of potent monoclonal antibody auristatin conjugates for cancer therapy,"" Nat. Biotechnol. 21(7):778-784.;;Patesi et al. (2004) ""Immunological optimization of a generic hydrophobic pocket for high affinity hapten binding and Diels-Alder activity,"" ChemBioChem. 5:460-466.;;Winkler et al. (2000) ""Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,"" J. Immunol. 165:4505-4514.;;Wu et al. (1999) ""Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues,"" J. Mol. Biol. 294:151-162.;;Yu et al. (2008) ""Interaction between bevacizumab and murine VEGF-A: a reassessment,"" Investigative Opthalmology and Visual Science. 49(2):522-527.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022728, mailed Oct. 9, 2014.;;U.S. Appl. No. 14/205,264, Mar. 11, 2014, Clark Pan.;;PCT/US2014/022623, Mar. 10, 2014, Clark Pan.;;U.S. Appl. No. 14/203,438, Mar. 10, 2014, Clark Pan.;;PCT/EP2012/003819, Sep. 12, 2012, Daniel Snell.;;U.S. Appl. No. 14/241,099, Feb. 26, 2014, Daniel Snell.;;PCT/US2013/059481, Sep. 12, 2013, Clark Pan.;;U.S. Appl. No. 14/203,479, Mar. 10, 2014, Clark Pan.;;U.S. Appl. No. 14/662,187, Mar. 18, 2015, Luis Avila.",ACTIVE
553,KR,A,KR 20100091232 A,134-020-743-057-401,2010-08-18,2010,KR 20107014230 A,2008-12-17,US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,,MOTOROLA INC,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,,https://lens.org/134-020-743-057-401,Patent Application,no,0,0,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04R1/02;;H04M1/12,,0,0,,,,DISCONTINUED
554,WO,A1,WO 2006/096906 A1,130-799-015-740-09X,2006-09-21,2006,AU 2006/000302 W,2006-03-08,AU 2005/901355 A,2005-03-18,INHALABLE DRUG,"A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.",NANOMATERIALS TECH PTE LTD;;CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,,https://lens.org/130-799-015-740-09X,Patent Application,yes,11,1,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61J3/02;;B01J13/00,,0,0,,,,PENDING
555,BR,A2,BR 112015020315 A2,023-025-876-292-083,2017-10-10,2017,BR 112015020315 A,2014-03-10,US 2014/0022728 W;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,conjugação de anticorpo-fármaco sítio-específica por glicoengenharia,"resumo patente de invenção: conjugação de anticorpo-fármaco sítio-específica por glicoengenharia. a presente descrição refere-se a polipeptídeos de ligação (por exemplo, anticorpos), e conjugados de porção efetora dos mesmos (por exemplo, conjugados de anticorpo-fármaco ou adcs), compreendendo uma ligação de fármaco-glicano construída especificamente por sítio dentro de glicanos nativos ou criados do polipetpídeo de ligação. a presente descrição também fornece ácidos nucleicos que codificam os polipeptídeos de ligação de antígeno, vetores de expressão recombinantes e células hospedeiras para preparar tais polipeptídeos de ligação de antígeno. métodos de usar os polipeptídeos de ligação de antígeno descritos aqui para tratar doença são, da mesma forma fornecidos.",GENZYME CORP,BO CHEN;;CLARK PAN;;DIEGO GIANOLIO;;HUAWEI QIU;;JAMES STEFANO;;PRADEEP DHAL;;QUN ZHOU;;ROBERT MILLER,,https://lens.org/023-025-876-292-083,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,DISCONTINUED
556,SG,A1,SG 52451 A1,044-839-588-649-476,1998-09-28,1998,SG 1996004696 A,1994-12-01,US 16194493 A;;US 27645294 A,1993-12-03,Plant arabinogalactan protein (agp) genes,,ALBRIGHT & WILSON AUSTRALIA,CLARK ADRIENNE E;;GANE ALISON M;;BACIC ANTHONY;;CCHAO-GUANG CHEN;;HE DU;;SHAIO-LIM MAU,,https://lens.org/044-839-588-649-476,Patent Application,no,0,0,13,13,0,A23J1/007;;A61K38/00;;C07K14/415;;C12N15/8241;;C07K14/415;;C12N15/8241;;A61K38/00;;A23J1/007,C12N15/09;;A23J1/00;;A61K38/00;;A61K47/48;;C07H21/04;;C07K14/415;;C07K16/16;;C12N5/10;;C12N15/82;;C12P21/02;;C12Q1/68;;C12R1/91,,0,0,,,,PENDING
557,WO,A3,WO 2014/164534 A3,048-008-028-744-975,2014-11-27,2014,US 2014/0022728 W,2014-03-10,US 201361776724 P;;US 201361776710 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/048-008-028-744-975,Search Report,yes,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,6,5,136-414-621-541-929;;084-230-129-207-67X;;032-476-801-692-751;;003-338-632-019-904;;038-305-867-383-662,pmc3464487;;10.1021/bc900103p;;19425533;;10.1021/bc1005416;;21417264;;10.1021/bc400505q;;24533768;;10.1038/nbt.1480;;18641636;;10.1006/bbrc.2001.5382;;11500028,"ELIZABETH BOEGGEMAN ET AL: ""Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection"", BIOCONJUGATE CHEMISTRY, vol. 20, no. 6, 17 June 2009 (2009-06-17), pages 1228 - 1236, XP055061205, ISSN: 1043-1802, DOI: 10.1021/bc900103p;;ZHOU QUN ET AL: ""Strategies for Neoglycan conjugation to human acid [alpha]-glucosidase."", BIOCONJUGATE CHEMISTRY, vol. 22, no. 4, 20 April 2011 (2011-04-20), pages 741 - 751, XP002727745, ISSN: 1520-4812;;ZHOU QUN ET AL: ""Site-specific antibody-drug conjugation through glycoengineering."", BIOCONJUGATE CHEMISTRY, vol. 25, no. 3, 19 March 2014 (2014-03-19), pages 510 - 520, XP002727746, ISSN: 1520-4812;;JUNUTULA JAGATH R ET AL: ""Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index."", NATURE BIOTECHNOLOGY, vol. 26, no. 8, August 2008 (2008-08-01), pages 925 - 932, XP002727747, ISSN: 1546-1696;;JASSAL R ET AL: ""Sialylation of human IgG-Fc carbohydrate by transfected rat alpha2,6-sialyltransferase"", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 286, no. 2, 17 August 2001 (2001-08-17), ACADEMIC PRESS INC. ORLANDO, FL, US, pages 243 - 249, XP002574380, ISSN: 0006-291X, DOI: 10.1006/BBRC.2001.5382;;ANONYMOUS: ""alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data sheet)"", May 2013 (2013-05-01), XP002727803, Retrieved from the Internet <URL:https://cssportal.roche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf> [retrieved on 20140725]",PENDING
558,IN,A,IN 2001KON2010 A,131-742-062-898-614,2015-04-17,2015,IN 2001KON2010 A,2010-06-01,US 96502207 A;;US 2008/0087102 W,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,"Disclosed are passive acoustic structures, portable audio devices configured for use with the passive acoustic structures and methods for enhancing the frequency output of a speaker of a portable device configured for use with a disclosed passive acoustic structure. The disclosed portable audio device may include an opening proximal a speaker cavity of the device, a shutter or door to open and close the opening so that the device interoperates with a docking station of a passive acoustic structure including a labyrinth or a transmission line system that may increase the frequency range of the system. For an end user to experience the music and multimedia features of a portable audio device, and in particular a mobile communication device, the above-described passive acoustic structure may provide a bass enhancement for the typically small loudspeaker of a portable audio device with no additional loudspeaker and therefore no additional circuitry.",MOTOROLA INC,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,,https://lens.org/131-742-062-898-614,Patent Application,no,0,0,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,G01S7/484,,0,0,,,,PENDING
559,US,A1,US 2022/0089763 A1,168-502-939-514-999,2022-03-24,2022,US 202117404412 A,2021-08-17,US 202117404412 A;;US 201916238932 A;;US 201715417648 A;;US 201414203479 A;;US 201361776710 P;;US 201361776715 P;;US 201361776724 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/168-502-939-514-999,Patent Application,yes,3,2,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,0,0,,,,PENDING
560,MX,A,MX 2019014833 A,187-427-720-916-856,2020-02-17,2020,MX 2019014833 A,2015-09-11,US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING.,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,HUAWEI QIU;;PRADEEP DHAL;;BO CHEN;;DIEGO GIANOLIO;;JAMES STEFANO;;CLARK PAN;;QUN SHOU;;ROBERT MILLER,,https://lens.org/187-427-720-916-856,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K38/00;;C07K16/28;;C07K16/32;;C07K16/40,,0,0,,,,PENDING
561,US,B2,US 8068459 B2,070-153-694-234-086,2011-11-29,2011,US 41595709 A,2009-03-31,US 41595709 A,2009-03-31,Adaptive frequency reuse method of radio resources management and allocation,"A method for managing and allocating radio resources (RRMA method) of multiple radio resource types to subscriber stations is disclosed. The RRMA method includes bandwidth partitioning, into parts comprising “slots” with a given reuse pattern, a selection rule, to select a “cell, reuse pattern” pair serving each user, and an allocation rule, for distributing to each user an appropriate number of bandwidth slots from the selected “cell, reuse pattern” pair. After an adaptation period, the method reaches a desired fairness, while simultaneously reaching a maximal mean throughput, possible under this fairness. For big networks, the method provides basically decentralized radio resource management. The RRMA method is useful to cellular networks having a single set of orthogonal sub-channels (frequency/time slots) being reused by all network cells, such as time division multiple access (TDMA), orthogonal frequency division multiple access (OFDMA), or OFDMA/TDMA cellular systems. Particularly, the method is applicable in fractional frequency reuse cellular networks.",KRAVTSOV VLADIMIR;;LOMNITZ YUVAL;;CHEN CLARK;;TALWAR SHILPA;;HIMAYAT NAGEEN;;LI LI;;YANG HUA;;SUN HOMGMEI;;INTEL CORP,KRAVTSOV VLADIMIR;;LOMNITZ YUVAL;;CHEN CLARK;;TALWAR SHILPA;;HIMAYAT NAGEEN;;LI LI;;YANG HUA;;SUN HOMGMEI,INTEL CORPORATION (2009-03-27),https://lens.org/070-153-694-234-086,Granted Patent,yes,6,11,2,2,0,H04W72/563;;H04W72/541;;H04W28/0861;;H04W72/563;;H04W72/541;;H04W28/0861,H04L5/22;;H04J3/00;;H04W72/00,370/329;;370/330;;370/336;;455/452.2;;455/451;;455/450,0,0,,,,INACTIVE
562,WO,A8,WO 2006/096906 A8,084-680-702-413-643,2007-11-29,2007,AU 2006/000302 W,2006-03-08,AU 2005/901355 A,2005-03-18,INHALABLE DRUG,"A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.",NANOMATERIALS TECH PTE LTD;;CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,,https://lens.org/084-680-702-413-643,Patent Application,no,0,0,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61J3/02;;B01J13/00,,0,0,,,,PENDING
563,US,B2,US 10214589 B2,124-023-367-843-273,2019-02-26,2019,US 201715417648 A,2017-01-27,US 201715417648 A;;US 201414203479 A;;US 201361776710 P;;US 201361776715 P;;US 201361776724 P,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2013-09-05),https://lens.org/124-023-367-843-273,Granted Patent,yes,118,5,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/68;;C07K16/32;;C07K16/40,,102,89,019-737-890-459-231;;018-007-265-921-231;;024-645-922-183-894;;038-611-663-646-681;;032-720-983-972-675;;075-192-332-107-331;;024-566-886-688-557;;010-673-495-194-66X;;012-014-436-857-578;;045-729-053-464-650;;042-810-773-450-504;;056-471-233-133-22X;;037-751-049-527-007;;093-834-126-228-444;;136-900-289-011-574;;026-844-281-977-583;;005-237-901-039-197;;060-802-427-932-669;;017-882-810-578-23X;;039-987-734-111-45X;;143-883-026-349-057;;021-635-324-390-465;;023-084-573-306-134;;001-738-124-789-726;;039-183-048-383-873;;103-031-843-607-684;;047-364-936-221-939;;039-331-124-493-196;;092-890-446-683-93X;;075-912-302-795-48X;;025-805-731-142-930;;050-877-021-901-567;;013-688-922-444-741;;002-771-789-858-985;;153-263-439-316-208;;013-142-717-038-23X;;036-975-782-541-190;;032-870-057-378-750;;100-801-934-296-913;;032-476-801-692-751;;011-629-800-752-356;;084-230-129-207-67X;;048-510-345-009-61X;;156-222-375-677-941;;136-414-621-541-929;;046-783-448-716-481;;018-007-265-921-231;;033-955-564-406-161;;083-071-649-888-913;;076-152-531-431-484;;004-272-966-072-139;;023-630-635-437-312;;113-720-510-689-403;;080-596-177-983-981;;001-329-438-412-588;;062-544-695-545-247;;060-056-896-118-940;;038-305-867-383-662;;028-401-996-299-149;;058-985-409-440-786;;003-338-632-019-904;;074-787-113-780-602;;023-249-219-470-807;;045-974-352-776-610;;015-623-518-697-144;;005-218-993-322-382;;015-458-200-457-953;;013-977-769-158-191;;143-862-943-589-725;;143-898-600-120-153;;043-016-539-897-20X;;028-456-569-502-585;;008-019-042-176-997;;016-716-200-807-517;;042-233-175-582-26X;;088-402-699-481-535;;058-543-894-773-905;;013-795-151-218-458;;058-270-451-857-914;;106-158-572-918-727;;111-625-445-280-864;;013-885-021-097-853;;013-157-274-165-126;;004-458-031-333-650;;079-000-142-364-026;;006-053-610-642-017;;066-847-171-955-046;;003-339-819-702-214;;087-412-910-091-181,22052803;;10.1002/psc.1415;;10.1002/anie.199612301;;17411062;;10.1021/ol0704946;;10.1021/bc9002019;;19769391;;10.1006/jmbi.1997.1354;;9367782;;19036920;;10.1073/pnas.0810163105;;pmc2604916;;pmc2409116;;18420934;;10.1126/science.1154315;;10.1023/a:1007533121682;;10870990;;pmc2890185;;10.1182/blood-2009-12-257386;;20181615;;pmc3197974;;10.3109/10428194.2011.604755;;21756025;;10.1016/j.jmb.2009.06.048;;19559712;;pmc3182912;;21980295;;10.1371/journal.ppat.1002281;;21632778;;10.1101/pdb.prot5633;;pmc3241764;;10.1073/pnas.1105057108;;22114188;;14695221;;20684602;;10.1021/jm100612r;;pmc3651435;;23610394;;10.1073/pnas.1219888110;;10.2210/pdb1h3v/pdb;;10.2210/pdb1h3w/pdb;;10.1016/s0022-2836(02)01250-0;;12527303;;10.1016/j.addr.2013.05.007;;23727341;;10.1002/anie.201402606;;24862406;;pmc4128391;;15791258;;10.1038/nature03408;;10.1007/s10719-013-9490-x;;23949787;;21429574;;10.1016/j.biomaterials.2010.11.068;;pmc3740328;;23787467;;pmc6557662;;10.1515/cclm-2013-0174;;pmc3065967;;21035459;;10.1016/j.jmb.2010.10.030;;23957305;;10.1021/ja407739y;;pmc3812917;;388229;;10.1038/282039a0;;10.1016/j.drudis.2008.04.013;;18621567;;20025606;;10.2174/156800909790192365;;6248420;;10.1016/0378-1119(80)90133-x;;9930678;;10.1093/protein/11.12.1277;;21256596;;10.1016/j.molimm.2010.12.009;;18771295;;pmc2628294;;10.1021/bi800874y;;10.4049/jimmunol.165.8.4505;;11035090;;1476621;;10556035;;10.1006/jmbi.1999.3141;;10.1097/00007890-199902270-00019;;10071034;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;18234994;;10.1167/iovs.07-1175;;10.1021/bc400505q;;24533768;;10.1002/bit.21598;;17680659;;10.1021/bc1005416;;21417264;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;17370997;;10.1021/bc060341n;;pmc3534963;;pmc3464487;;10.1021/bc900103p;;19425533;;18536555;;10.1097/ppo.0b013e318172d704;;10.1002/anie.199612301;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;10.1038/nchembio.196;;19648933;;10.1038/nbt832;;12778055;;17628592;;10.1016/j.jmb.2007.06.045;;10.1002/anie.201109226;;22555935;;10.1074/jbc.m609211200;;17130124;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;8623165;;10.1097/00007890-199603270-00018;;10.1097/00007890-199601270-00032;;8600649;;10.1006/bbrc.2001.5382;;11500028;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.4049/jimmunol.148.12.3768;;1376340;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;10.1126/science.1129594;;16888140;;10.1021/ja038545r;;14692737;;389741;;10.1016/0378-1119(79)90029-5;;17041261;;10.1385/1-59745-187-8:95;;18822295;;10.1016/j.jmb.2008.09.016;;18577454;;10.1016/j.coi.2008.05.010;;10541351;;16566296;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1432-2277.2012.01456.x;;22420711;;15185369;;10.1002/cbic.200300806;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;10.1021/bi010475i;;11467948;;10.1039/b604391g;;16791327;;9780179;;10.4049/jimmunol.161.8.4083;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;10.1002/micr.20294;;17066409;;7879044;;10.1021/ja00119a001;;10.4049/jimmunol.147.12.4366;;1836485;;11096108;;10.1074/jbc.m009483200;;10.1038/nbt1166;;16299519;;10.1111/j.1742-4658.2008.06439.x;;18435758;;520572;;10.1016/0014-5793(79)80559-1;;10.1021/bp050228w;;16321047;;10.1016/j.jim.2007.12.011;;18230399,"Zevgiti et al. Sialic acid and sialyl-lactose glyco-conjugates: design, synthesis and binding assays to lectins and swine influenza H1N1 virus. J Pep Sci: Nov. 3, 2011, vol. 18, pp. 52-58. (Year: 2011).;;Sakarellos-Kaitsiotis et al. Design, synthesis and binding assays of sialic acid and sialyl-saccharide conjugates to lectins and influenza H1N1 virus. J Pep Sci: Sep. 2012. vol. 18, Supp. 1, p. S52. Abstract No. 069. (Year: 2012).;;Cervigni et al. Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation. Angew Chem Ed Engl, 1996. vol. 35. No. 11, pp. 1230-1232. (Year: 1996).;;Hanashima et al. Synthesis of a Sialic Acid r(2-3) Galactose Building Block and Its Use in a Linear Synthesis of Sialyl Lewis X. Organic Letters, 2007. vol. 9, No. 9, pp. 1777-1779. (Year: 2007).;;Ducry et al. Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies. Bioconjugate Chem. 2010, vol. 21, pp. 5-13. (Year: 2010).;;Al-Lazikani et al. (1997) “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol. 273:927-948.;;Anthony et al. (2008) “Identification of a receptor required for the anti-inflammatory activity of IVIG,” Proc. Natl. Acad. Sci. USA. 105:19571-19578.;;Anthony et al. (2008) “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science. 320:373-376.;;Anwer et al. (2000) “Synthetic Glycopeptide-Based Delivery Systems for Systemic Gene Targeting to Hepatocytes,” Pharm. Res. 17:451-459.;;Chen et al. (2010) “In vivo targeting of B-cell lymphoma with glycan ligands of CD22,” Blood. 115:4778-4786.;;Chen et al. (2012) “Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22,” Leukemia and Lymphoma. 53:208-210.;;Feige et al. (2009) “Structure of the murine unglycosylated IgG1 Fc fragment,” J. Mol Biol. 391:599-608.;;Ganesan et al. (2011) “Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium,” PLoS Pathogens. 7(9):e1002281. pp. 1-11.;;Giudicelli et al. (2011) “IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences” In; Cold Spring Harb. Protoc. 2011(6):58-78.;;Hatekeyama et al. (2011) “Targeted Drug Delivery to Tumor Vasculature by a Carbohydrate Mimetic Peptide,” Proc. Natl. Acad. Sci. USA. 108:19587-19592.;;Hong et al. (2003) “Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells,” Cancer Res. 23:9023-9031.;;Hosoguchi (2010) “An efficient approach to the discovery of potent inhibitors against glycosyltransferases,” J. Med. Chem. 53:5607-5619.;;Kawasaki et al. (2013) “Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation,” Proc. Natl. Acad. Sci. USA. 110:7826-7831.;;Krapp et al. (2003) “Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity,” J. Mol. Biol. 325:979-998.;;Lepenies et al. (2013) “Targeting C-type lectin receptors with multivalent carbohydrate ligands,” Adv. Drug Delivery Rev. 65:1271-1281.;;Li et al.(May 23, 2014) “The Preparation of Well-Defined Antibody-Drug Conjugates Through Glycan Remodeling and Strain Promoted Azide-Alkyne Cycloadditions,” Angew. Chem., Int. Ed. 53(28):7179-7182.;;Martin (2010) “Protein Sequence and Structure Analysis of Antibody Variable Domains” Ch. 3 in; Antibody Engineenng. vol. 2. Eds: Kontermann et al. Springer-Verlag. pp. 33-51.;;Mattner et al. (2005) “Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections,” Nature. 434:525-529.;;McCarthy (Aug. 16, 2013) “Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates,” Glycoconj. J. 30:857-870.;;Medina et al. (2011) “N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers,” Biomaterials. 32:4118-4129.;;Monnier et al. (2014) “Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications,” Clin. Chem. Lab. Med. 52:21-32.;;Murray (1985) “Imaging Findings and Pharmacaokinetics of 111-Indium ZME-018 Monoclonal Antibodies,” J. Nuc. Med. 26:P16. Abstract No. 55.;;North et al. (2011) “A new clustering of antibody CDR loop conformations,” J. Mol. Biol. 406:228-256.;;Williams et al. (2010) “Humanising Antibodies by CDR Grafting” Ch. 21 in; Antibody Engineering. vol. 1. Eds.: Kontermann et al. Springer-Verlag. pp. 319-339.;;Zhou (Aug. 22, 2013) “Bioconjugation by native chemical tagging of C—H bonds.,” J. Am. Chem. Soc. 135:12994-12997.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/021342, dated Jun. 8, 2015.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/054651, dated Apr. 20, 2016.;;Stinchcomb et al. (1979) “Isolation and Characterization of a Yeast Chromosomal Replicator,” Nature. 282:39-43.;;Stumpp et al. (2008) “DARPins: A New Generation of Protein Therpeutics,” Drug Discovery Today. 13(15-16):695-670.;;Teicher (2009) “Antibody-drug conjugate targets,” Current Cancer Drug Targets. 9(8):982-1004.;;Tschumper et al. (1980) “Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene,” Gene. 10:157-166.;;Wang et al. (1998) “Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules,” Protein Engineering. 11:1277-1283.;;Wang et al. (2011) “Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies,” Molecular Immunology. 48(6):860-866.;;Wei et al. (2008) “Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and in Vitro Chemoenzymatic Glycosylation,” Biochem. 47(39):10294-10304.;;Winkler et al. (2000) “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,” J. Immunol. 165:4505-4514.;;Wright et al. (1992) “Genetically Engineered Antibodies: Progress and Prospects,” Critical Reviews in Immunology. 12:125-168.;;Wu et al. (1999) “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR Residues,” J. Mal. Biol. 294:151-162.;;Yamagami et al. (1999) “Suppression of Allograft Rejection with Anti-Anti-A(3T Cell Receptor Antibody in Rat Corneal Transplantation,” Transplantation. 67:600-604.;;Yoshino et al. (1992) “Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats,” J. Exp. Med. 175:907-915.;;Yu et al. (2008) “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Investigative Opthalmology and Visual Science. 49(2):522-527.;;Zhou (Feb. 17, 2014) “Site-specific antibody-drug conjugation through glycoengineering,” Bioconjugate Chemistry. 25(3):510-520.;;Zhou et al. (2008) “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,” Biotechnol. Bioeng. 99:652-665.;;Zhou et al. (2011) “Strategies for Neoglycan conjugation to human acid [alpha]-glucosidase,” Bioconjugate Chemistry. 22(4):741-751.;;Zhu et al. (2009) “Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease,” Mol. Ther. 17(6):954-963.;;Axup et al. (2012) “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids,” Proc. Natl. Acad. Sci. USA. 109(40)16101-16106.;;Boeggeman et al. (2007) “Direct Identification of Nonreducing GIcNAc Residues on N-Glycans of Glycoproteins Using a Novel Chemoenzymatic Method,” Bioconjugate Chemistry. 18(3):806-814.;;Boeggman et al. (2009) “Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection,” Bioconjugate Chemistry. 20(6):1228-1236.;;Carrasquillo et al. (1985) “Improved imaging of metastatic melanoma with high dose 9. 2. 27 In-111 monoclonal antibody,” J. Nuc. Med. vol. 26. No. 67. Abstract No. 276.;;Carter et al. (2008) “Antibody-drug conjugates for cancer therapy,” Caner Journal. 14:154-169.;;Cervigni et al. (1996) “Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation,” Angew. Chem. Int. Ed. 35(11):1230-1232.;;Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” The Journal of Immunology. 10:301-316.;;Chari (2008) “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs,” Accounts of Chemical Research. 41:98-107.;;Cobos-Correa et al. (2009) “Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation,” Nature Chemical Biology. 5(9):628-663.;;Doronina et al. (2003) “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nat. Biotechnol. 21(7):778-784.;;Ebersbach et al. (2007) “Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein,” Journal of Molecular Biology. 372(1):172-185.;;Gehrig et al. (2012) “Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters,” Angewandte Chemie International Edition. 51(25):6258-6261.;;Grabulovski et al. (2007) “A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Proteins,” The Journal of Biological Chemistry. 282(5):3196-3204.;;Guan et al. (1998) “Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization,” Proc. Natl. Acad. Sci. USA. 95(22):13206-13210.;;Heidecke et al. (1996) “Alpha-Beta T Cell Receptor-Directed Therapy in Rat Allograft Recipients,” Transplantation. 61:948-956.;;Heidecke et al. (1996) “Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-NB-Targeted Therapy,” Transplantation 61:336-339.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/003819, dated Jul. 17, 2013.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/059481, dated Feb. 7, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022623, dated Jul. 31, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022728, dated Oct. 9, 2014.;;Jassal et al. (2001) “Sialylation of human igG-Fc carbohydrate by transfected rat alpha2, 6-sialyltransferase,” Biochemical and Biophysical Research Communications. 286(2):243-249.;;Jones (1977) “Proteinase Mutants of Saccharomyces cerevisiae,” Genetics. 85:23-33.;;Jung et al. (1992) “Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta,” Journal of Immunology. 148:3768-3775.;;Junutula et al. (2008) “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” Nature Biotechnology. 26(8):925-929.;;Junutula et al. (2010) “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer,” Clin. Cancer Res. 16:4769-4778.;;Kaneko et al. (2006) “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science. 313(5787):670-673.;;Khidekel et al. (2003) “A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of 0-GlcNAc Posttranslational Modifications,” J. Am. Chem. Soc. 125:16162-16163.;;Kingsman et al. (1979) “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trpl Region,” Gene. 7:141-152.;;Koide et al. (2007) “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain,” Methods in Molecular Biology. 352:95-109.;;Krehenbrink et al. (2008) “Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PuID,” Journal of Molecular Biology. 383(5):1058-1068.;;Labrijn et al. (2008) “When binding is enough: nonactivating antibody formats,” Curr. Opin. Immunol. 20:479-485.;;Leung et al. (1999) “The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments,” Clin. Cancer Res. 5:3106s-3117s.;;Nixon et al. (2006) “Engineered Protein Inhibitors of Proteases,” Current Opinion in Drug Discovery & Development. 9(2):261-268.;;Nygren et al. (2008) “Alternative Binding Proteins: Affibody Binding Proteins Devloped from a Small Three-helix Bundle Scaffold,” The FEBS Journal. 275(11):2668-2676.;;Page et al. (2012) “Biologics in Organ Transplant,” Transplant International. 25:707-719.;;Piatesi et al. (2004) “Immunological optimization of a generic hydrophobic pocket for high affinity hapten binding and Diels-Alder activity,” ChemBioChem. 5:460-466.;;Polakis (2005) “Arming antibodies for cancer therapy,” Current Opinion in Pharmacology. 5:382-387.;;Qu et al. (1998) “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,” Journal of Immunological Methods. 213:131-144.;;Raju et al. (2011) “Glycoengineering of Therapeutic Glycoproteins: In Vitro Galactosylation and Sialylation of Glycoproteins with Terminal N-Acetylglucosamine and Galactose Residues,” Biochem. 40(30):8868-8876.;;Renaudet et al. (2006) “On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides,” Organic and Biomolecular Chemistry. 4:2628-2636.;;Roche Diagnostics (2013) “alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data Sheet),” Roche Diagnostics. Accessible on the Internet at URL: https://cssportal.roche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf [Last Accessed on on Jul. 25, 2014].;;Roux et al. (1998) “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, 19E, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” Journal of Immunology. 161(8):4083-4090.;;Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,” Proc. Natl. Acad. Sci. USA. 105(51): 20167-20172.—with Supplementary Information.;;Scharpf et al. (2006) “Immunomodulation with anti-anti-a(3T-cell receptor monoclonal antibodies in combination with cyclosporine a improves regeneration in nerve allografts,” Microsurgery. 26:599-607.;;Schorlemmer et al. (1995) “Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats,” Transplantation Proceedings. 27:414-416.;;Shao et al. (1995) “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages,” J. Am. Chem. Soc. 117(14):3893-3899.;;Shearman et al. (1991) “Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor,” The Journal of Immunology. 147:4366-4373.;;Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR,” J. Biol. Chem. 276:6591-6604.;;Silverman et al. (2005) “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains,” Nature Biotechnology. 23(12):1556-1561.;;Skerra et al. (2008) “Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activites,” The FEBS Journal. 275(11):2677-2683.;;Bause et al. (1979) “Primary structural requirements for N-glycosylation of peptides in rat liver,” FEBS Letters. 108(2):341-344.;;Hodoniczky et al. (2005) “Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro,” Biotechnol. Prog. 21:1644-1652.;;Junutula et al. (2008) “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs,” Journal of Immunological Methods. 332:41-52.",ACTIVE
564,KR,A,KR 20230020013 A,134-405-232-868-787,2023-02-09,2023,KR 20237003194 A,2014-03-10,US 201361776710 P;;US 201361776715 P;;US 201361776724 P;;KR 20217037637 A;;US 2014/0022728 W,2013-03-11,- - SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"본 개시내용은 결합 폴리펩티드의 천연 또는 조작된 글리칸 내에 부위-특이적으로 조작된 약물-글리칸 연결을 포함하는 결합 폴리펩티드 (예를 들어, 항체) 및 그의 이펙터 모이어티 접합체 (예를 들어, 항체-약물 접합체 또는 ADC)를 제공한다. 본 개시내용은 또한 항원-결합 폴리펩티드를 코딩하는 핵산, 상기 항원-결합 폴리펩티드를 제조하기 위한 재조합 발현 벡터 및 숙주 세포를 제공한다. 질환을 치료하기 위해 본원에 개시된 항원-결합 폴리펩티드를 사용하는 방법을 또한 제공한다.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/134-405-232-868-787,Patent Application,no,0,0,88,165,80,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,0,0,,,,DISCONTINUED
565,EP,A2,EP 4063389 A2,139-903-633-286-001,2022-09-28,2022,EP 22151876 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;EP 14718808 A;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/139-903-633-286-001,Patent Application,yes,55,0,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28,,27,19,013-795-151-218-458;;081-762-551-590-027;;005-218-993-322-382;;039-331-124-493-196;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;076-152-531-431-484;;113-720-510-689-403;;064-343-550-244-269;;047-364-936-221-939;;015-623-518-697-144;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X,9780179;;10.4049/jimmunol.161.8.4083;;10.1006/meth.1995.9996;;17041261;;10.1385/1-59745-187-8:95;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;3061521;;10.1016/b978-0-409-90042-2.50030-1;;388229;;10.1038/282039a0;;389741;;10.1016/0378-1119(79)90029-5;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365,"KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPT. HEALTH AND HUMAN SERVICES;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ASHKENAZI ET AL., METHODS, vol. 8, no. 2, 1995, pages 104 - 115;;KOIDE ET AL., METHODS MOL. BIOL., vol. 352, 2007, pages 95 - 109;;STUMPP, DRUG DISCOV. TODAY, vol. 13, no. 15-16, 2008, pages 695 - 701;;SKERRA ET AL., FEBS J, vol. 275, no. 11, 2008, pages 2677 - 83;;EBERSBACH ET AL., J. MOL. BIOL., vol. 372, no. 1, 2007, pages 172 - 85;;KREHENBRINK ET AL., J. MOL. BIOL., vol. 383, no. 5, 2008, pages 1058 - 68;;SILVERMAN ET AL., NAT. BIOTECHNOL., vol. 23, no. 12, 2005, pages 1556 - 61;;GRABULOVSKI ET AL., J BIOL CHEM, vol. 282, no. 5, 2007, pages 3196 - 3204;;NIXON ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, no. 2, 2006, pages 261 - 8;;DRICKAMER KTAYLOR ME, INTRODUCTION TO GLYCOBIOLOGY, 2006;;GUAN ET AL., PNAS, vol. 95, 1998, pages 13206 - 10;;CARRAGUILLO ET AL., J. NUC. MED., vol. 26, 1985, pages 3328;;A. COBOS-CORREA: ""Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation"", NATURE CHEMICAL BIOLOGY, vol. 5, no. 9, 2009, pages 628 - 63;;S. GEHRIG: ""Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters"", ANGEW. CHEM. INT. ED., vol. 51, 2012;;HERMANSON, G.T.: ""Bioconjugate Techniques"", 1996, ACADEMIC PRESS;;ARNOLD S. FREEDMANLEE M. NADLER ET AL.: ""HARRISON'S PRINCIPLES OF INTERNAL MEDICINE"", 1994, article ""Malignant Lymphomas"", pages: 1774 - 1788;;RIDGWAY, A. A. G.: ""Mammalian Expression Vectors"", 1988, BUTTERWORTHS, pages: 470 - 472;;STINCHCOMB ET AL., NATURE, vol. 282, 1979, pages 39;;KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141;;TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157;;JONES, GENETICS, vol. 85, 1977, pages 12;;KANEKO, Y.NIMMERJAHN, F.RAVETCH, J. V.: ""Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"", SCIENCE, vol. 313, 2006, pages 670 - 3, XP008076047, DOI: 10.1126/science.1129594;;WANG, W. ET AL.: ""Impact of methionine oxidation in human IgGl Fc on serum half-life of monoclonal antibodies"", MOL IMMUNOL, vol. 48, 2011, pages 860 - 6, XP028143840, DOI: 10.1016/j.molimm.2010.12.009;;STEFANO ET AL., METHODS IN MOLECULAR BIOLOGY, 2013;;TEICHER, B. A.: ""Antibody-drug conjugate targets"", CURR CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004",PENDING
566,WO,A2,WO 2009/085796 A2,117-177-822-921-391,2009-07-09,2009,US 2008/0087102 W,2008-12-17,US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,"Disclosed are passive acoustic structures, portable audio devices configured for use with the passive acoustic structures and methods for enhancing the frequency output of a speaker of a portable device configured for use with a disclosed passive acoustic structure. The disclosed portable audio device may include an opening proximal a speaker cavity of the device, a shutter or door to open and close the opening so that the device interoperates with a docking station of a passive acoustic structure including a labyrinth or a transmission line system that may increase the frequency range of the system. For an end user to experience the music and multimedia features of a portable audio device, and in particular a mobile communication device, the above-described passive acoustic structure may provide a bass enhancement for the typically small loudspeaker of a portable audio device with no additional loudspeaker and therefore no additional circuitry.",MOTOROLA INC;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,,https://lens.org/117-177-822-921-391,Patent Application,yes,1,1,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,,,0,0,,,,PENDING
567,SG,A,SG 10201809779R A,166-752-991-306-192,2018-12-28,2018,SG 10201809779R A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING 5 The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such 10 antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. [Figure 1]",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/166-752-991-306-192,Unknown,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,,,0,0,,,,PENDING
568,AU,A1,AU 2006/225066 A1,045-427-464-841-488,2006-09-21,2006,AU 2006/225066 A,2006-03-08,AU 2005/901355 A;;AU 2006/000302 W;;AU 2006/225066 A,2005-03-18,Inhalable drug,,NANOMATERIALS TECH PTE LTD,CHAN HAK-KIM;;HU TING TING;;YUN JIMMY SUNG LAI;;CHEN JIAN FENG;;CHIOU HERBERT CLARK,NMT PHARMACEUTICALS PTE LTD (2016-05-19),https://lens.org/045-427-464-841-488,Patent Application,no,0,0,2,9,0,,A61K9/14;;A61J3/02;;B01J13/00,,0,0,,,,INACTIVE
569,AU,A1,AU 2018/282451 A1,117-939-066-116-255,2019-01-24,2019,AU 2018/282451 A,2018-12-21,AU 2018/282451 A;;AU 2014/249224 A;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/117-939-066-116-255,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
570,US,A1,US 2009/0169040 A1,034-999-387-060-18X,2009-07-02,2009,US 96502207 A,2007-12-27,US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,"Disclosed are passive acoustic structures, portable audio devices configured for use with the passive acoustic structures and methods for enhancing the frequency output of a speaker of a portable device configured for use with a disclosed passive acoustic structure. The disclosed portable audio device may include an opening proximal a speaker cavity of the device, a shutter or door to open and close the opening so that the device interoperates with a docking station of a passive acoustic structure including a labyrinth or a transmission line system that may increase the frequency range of the system. For an end user to experience the music and multimedia features of a portable audio device, and in particular a mobile communication device, the above-described passive acoustic structure may provide a bass enhancement for the typically small loudspeaker of a portable audio device with no additional loudspeaker and therefore no additional circuitry.",MOTOROLA INC,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,MOTOROLA MOBILITY INC (2010-07-31);;MOTOROLA MOBILITY LLC (2012-06-22);;GOOGLE TECHNOLOGY HOLDINGS LLC (2014-10-28);;MOTOROLA INC (2008-03-20),https://lens.org/034-999-387-060-18X,Patent Application,yes,9,15,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04R1/02,381/345,0,0,,,,DISCONTINUED
571,KR,A,KR 20150126024 A,090-062-239-503-274,2015-11-10,2015,KR 20157027622 A,2014-03-10,US 201361776710 P;;US 201361776715 P;;US 201361776724 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"본 개시내용은 결합 폴리펩티드의 천연 또는 조작된 글리칸 내에 부위-특이적으로 조작된 약물-글리칸 연결을 포함하는 결합 폴리펩티드 (예를 들어, 항체) 및 그의 이펙터 모이어티 접합체 (예를 들어, 항체-약물 접합체 또는 ADC)를 제공한다. 본 개시내용은 또한 항원-결합 폴리펩티드를 코딩하는 핵산, 상기 항원-결합 폴리펩티드를 제조하기 위한 재조합 발현 벡터 및 숙주 세포를 제공한다. 질환을 치료하기 위해 본원에 개시된 항원-결합 폴리펩티드를 사용하는 방법을 또한 제공한다.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/090-062-239-503-274,Patent Application,no,1,0,88,165,80,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;C07K16/32;;C07K16/40,,2,0,,,"E. Boeggeman 등, Bioconjugate Chem., Vol.20, p.11228-1236 (2009)*;;Q. Zhou 등, Bioconjugate Chem., Vol.22, p.741-751 (2011)*",ACTIVE
572,WO,A3,WO 2009/085796 A3,171-232-243-084-290,2009-12-03,2009,US 2008/0087102 W,2008-12-17,US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,"Disclosed are passive acoustic structures, portable audio devices configured for use with the passive acoustic structures and methods for enhancing the frequency output of a speaker of a portable device configured for use with a disclosed passive acoustic structure. The disclosed portable audio device may include an opening proximal a speaker cavity of the device, a shutter or door to open and close the opening so that the device interoperates with a docking station of a passive acoustic structure including a labyrinth or a transmission line system that may increase the frequency range of the system. For an end user to experience the music and multimedia features of a portable audio device, and in particular a mobile communication device, the above-described passive acoustic structure may provide a bass enhancement for the typically small loudspeaker of a portable audio device with no additional loudspeaker and therefore no additional circuitry.",MOTOROLA INC;;CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,,https://lens.org/171-232-243-084-290,Search Report,yes,5,0,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04M1/12;;H04R1/02,,0,0,,,,PENDING
573,CN,A,CN 101919262 A,185-542-355-249-194,2010-12-15,2010,CN 200880122621 A,2008-12-17,US 2008/0087102 W;;US 96502207 A,2007-12-27,Devices and methods for enhancing the frequency output of a portable audio device,"Disclosed are passive acoustic structures, portable audio devices configured for use with the passive acoustic structures and methods for enhancing the frequency output of a speaker of a portable device configured for use with a disclosed passive acoustic structure. The disclosed portable audio device may include an opening proximal a speaker cavity of the device, a shutter or door to open and close the opening so that the device interoperates with a docking station of a passive acoustic structure including a labyrinth or a transmission line system that may increase the frequency range of the system. For an end user to experience the music and multimedia features of a portable audio device, and in particular a mobile communication device, the above-described passive acoustic structure may provide a bass enhancement for the typically small loudspeaker of a portable audio device with no additional loudspeaker and therefore no additional circuitry.",MOTOROLA INC,SHAOHAI CHEN;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;GILES DAVIS,"MOTOROLA MOBILE CO., LTD. (2011-01-07)",https://lens.org/185-542-355-249-194,Patent Application,no,2,2,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04R1/02;;H04M1/12,,0,0,,,,DISCONTINUED
574,MX,B,MX 370356 B,059-276-631-952-410,2019-12-10,2019,MX 2015012570 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING.,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,HUAWEI QIU;;CLARK PAN;;ROBERT MILLER;;PRADEEP DHAL;;BO CHEN;;DIEGO GIANOLIO;;QUN ZHOU;;JAMES STEFANO,,https://lens.org/059-276-631-952-410,Granted Patent,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K38/00;;C07K16/32;;C07K16/40,,0,0,,,,ACTIVE
575,JP,A,JP 2020000252 A,168-928-522-540-217,2020-01-09,2020,JP 2019165052 A,2019-09-11,US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"To provide binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide.SOLUTION: A binding polypeptide comprises at least one modified glycan, comprising at least one moiety of Formula (IV): -Gal-Sia-C(H)=N-Q-CON-X [In the formula, A) Q is NH or O; B) CON is a connector moiety; C) X is an effector moiety; D) Gal is a galactose-derived component; and E) Sia is a sialic acid-derived component, where Sia may be or not be present].SELECTED DRAWING: None",GENZYME CORP,CLARK PAN;;ZHOU QUN;;JAMES STEFANO;;PRADEEP DHAL;;CHEN BO;;DIEGO GIANOLIO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/168-928-522-540-217,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C12N15/13;;A61K45/00;;A61K47/61;;A61K47/62;;A61K47/68;;A61P43/00;;C07K16/18;;C07K16/46;;C12N1/15;;C12N1/19;;C12N1/21;;C12N5/10;;C12N15/63;;C12P21/08,,3,1,087-412-910-091-181,10.1016/j.jim.2007.12.011;;18230399,"BIOCONJUGATE CHEM., vol. 20, JPN6017050912, 2009, pages 1228 - 1236, ISSN: 0004529572;;MOLECULAR THERAPY, vol. 17, no. 6, JPN6017050914, 2009, pages 954 - 963, ISSN: 0004529573;;JOURNAL OF IMMUNOLOGICAL METHODS, vol. 332, JPN6017050917, 2008, pages 41 - 52, ISSN: 0004529574",ACTIVE
576,US,A1,US 2014/0294867 A1,059-766-038-599-54X,2014-10-02,2014,US 201414203479 A,2014-03-10,US 201414203479 A;;US 201361776724 P;;US 201361776710 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2014-02-07),https://lens.org/059-766-038-599-54X,Patent Application,yes,4,20,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K47/48,424/181.1;;530/391.9;;536/23.53;;435/320.1;;435/328;;435/252.33;;435/252.3;;435/252.31;;435/254.21;;435/419;;435/68.1,4,4,058-543-894-773-905;;018-007-265-921-231;;045-974-352-776-610;;136-414-621-541-929,10.1039/b604391g;;16791327;;10.1002/anie.199612301;;10.1021/ja038545r;;14692737;;pmc3464487;;10.1021/bc900103p;;19425533,"Renaudet et al. On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides. Organic and Biomolecular Chemistry, 2006. Vol. 4, pages 2628-2636.;;Cervigni et al. Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation. Angew. Chem. Int. Ed. Engl. 1996, Vol. 35, No. 11, pages 1230-1232..;;Khidekel et al. A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of O-GlcNAc Posttranslational Modifications, J. AM. CHEM. SOC., 2003. Vol 125, pages 16162-16163.;;Boeggeman et al. Site specific conjugation of fluoroprobes to the remodeled Fc Nglycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection. Bioconjug Chem. 2009 June. Vol. 20, No. 6, pages 1228â1236.",ACTIVE
577,US,B2,US 11130816 B2,148-192-822-468-523,2021-09-28,2021,US 201916238932 A,2019-01-03,US 201916238932 A;;US 201715417648 A;;US 201414203479 A;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2014-02-07),https://lens.org/148-192-822-468-523,Granted Patent,yes,134,3,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,101,88,038-611-663-646-681;;047-364-936-221-939;;039-331-124-493-196;;092-890-446-683-93X;;075-912-302-795-48X;;025-805-731-142-930;;050-877-021-901-567;;013-688-922-444-741;;002-771-789-858-985;;153-263-439-316-208;;013-142-717-038-23X;;036-975-782-541-190;;032-870-057-378-750;;100-801-934-296-913;;032-476-801-692-751;;011-629-800-752-356;;084-230-129-207-67X;;032-720-983-972-675;;075-192-332-107-331;;024-566-886-688-557;;010-673-495-194-66X;;012-014-436-857-578;;045-729-053-464-650;;042-810-773-450-504;;056-471-233-133-22X;;037-751-049-527-007;;093-834-126-228-444;;136-900-289-011-574;;026-844-281-977-583;;005-237-901-039-197;;060-802-427-932-669;;017-882-810-578-23X;;039-987-734-111-45X;;143-883-026-349-057;;021-635-324-390-465;;023-084-573-306-134;;001-738-124-789-726;;039-183-048-383-873;;103-031-843-607-684;;066-847-171-955-046;;003-339-819-702-214;;087-412-910-091-181;;019-737-890-459-231;;024-645-922-183-894;;048-510-345-009-61X;;156-222-375-677-941;;136-414-621-541-929;;046-783-448-716-481;;018-007-265-921-231;;033-955-564-406-161;;083-071-649-888-913;;076-152-531-431-484;;004-272-966-072-139;;023-630-635-437-312;;113-720-510-689-403;;080-596-177-983-981;;001-329-438-412-588;;062-544-695-545-247;;060-056-896-118-940;;038-305-867-383-662;;028-401-996-299-149;;058-985-409-440-786;;003-338-632-019-904;;074-787-113-780-602;;023-249-219-470-807;;045-974-352-776-610;;015-623-518-697-144;;005-218-993-322-382;;015-458-200-457-953;;013-977-769-158-191;;143-862-943-589-725;;143-898-600-120-153;;043-016-539-897-20X;;028-456-569-502-585;;008-019-042-176-997;;016-716-200-807-517;;042-233-175-582-26X;;088-402-699-481-535;;058-543-894-773-905;;013-795-151-218-458;;058-270-451-857-914;;106-158-572-918-727;;111-625-445-280-864;;013-885-021-097-853;;013-157-274-165-126;;004-458-031-333-650;;079-000-142-364-026;;006-053-610-642-017,10.1021/bc9002019;;19769391;;388229;;10.1038/282039a0;;10.1016/j.drudis.2008.04.013;;18621567;;20025606;;10.2174/156800909790192365;;6248420;;10.1016/0378-1119(80)90133-x;;9930678;;10.1093/protein/11.12.1277;;21256596;;10.1016/j.molimm.2010.12.009;;18771295;;pmc2628294;;10.1021/bi800874y;;10.4049/jimmunol.165.8.4505;;11035090;;1476621;;10556035;;10.1006/jmbi.1999.3141;;10.1097/00007890-199902270-00019;;10071034;;10.1084/jem.175.4.907;;1372648;;pmc2119191;;18234994;;10.1167/iovs.07-1175;;10.1021/bc400505q;;24533768;;10.1002/bit.21598;;17680659;;10.1021/bc1005416;;21417264;;10.1006/jmbi.1997.1354;;9367782;;19036920;;10.1073/pnas.0810163105;;pmc2604916;;pmc2409116;;18420934;;10.1126/science.1154315;;10.1023/a:1007533121682;;10870990;;pmc2890185;;10.1182/blood-2009-12-257386;;20181615;;pmc3197974;;10.3109/10428194.2011.604755;;21756025;;10.1016/j.jmb.2009.06.048;;19559712;;pmc3182912;;21980295;;10.1371/journal.ppat.1002281;;21632778;;10.1101/pdb.prot5633;;pmc3241764;;10.1073/pnas.1105057108;;22114188;;14695221;;20684602;;10.1021/jm100612r;;pmc3651435;;23610394;;10.1073/pnas.1219888110;;10.2210/pdb1h3v/pdb;;10.2210/pdb1h3w/pdb;;10.1016/s0022-2836(02)01250-0;;12527303;;10.1016/j.addr.2013.05.007;;23727341;;10.1002/anie.201402606;;24862406;;pmc4128391;;15791258;;10.1038/nature03408;;10.1007/s10719-013-9490-x;;23949787;;21429574;;10.1016/j.biomaterials.2010.11.068;;pmc3740328;;23787467;;pmc6557662;;10.1515/cclm-2013-0174;;pmc3065967;;21035459;;10.1016/j.jmb.2010.10.030;;23957305;;10.1021/ja407739y;;pmc3812917;;520572;;10.1016/0014-5793(79)80559-1;;10.1021/bp050228w;;16321047;;10.1016/j.jim.2007.12.011;;18230399;;22052803;;10.1002/psc.1415;;17411062;;10.1021/ol0704946;;22988081;;10.1073/pnas.1211023109;;pmc3479532;;17370997;;10.1021/bc060341n;;pmc3534963;;pmc3464487;;10.1021/bc900103p;;19425533;;18536555;;10.1097/ppo.0b013e318172d704;;10.1002/anie.199612301;;10.1038/nri2761;;20414204;;10.1021/ar700108g;;17705444;;10.1038/nchembio.196;;19648933;;10.1038/nbt832;;12778055;;17628592;;10.1016/j.jmb.2007.06.045;;10.1002/anie.201109226;;22555935;;10.1074/jbc.m609211200;;17130124;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;8623165;;10.1097/00007890-199603270-00018;;10.1097/00007890-199601270-00032;;8600649;;10.1006/bbrc.2001.5382;;11500028;;10.1093/genetics/85.1.23;;pmc1213617;;320092;;10.4049/jimmunol.148.12.3768;;1376340;;10.1038/nbt.1480;;18641636;;20805300;;10.1158/1078-0432.ccr-10-0987;;10.1126/science.1129594;;16888140;;10.1021/ja038545r;;14692737;;389741;;10.1016/0378-1119(79)90029-5;;17041261;;10.1385/1-59745-187-8:95;;18822295;;10.1016/j.jmb.2008.09.016;;18577454;;10.1016/j.coi.2008.05.010;;10541351;;16566296;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1432-2277.2012.01456.x;;22420711;;15185369;;10.1002/cbic.200300806;;10.1016/j.coph.2005.04.008;;15951239;;10.1016/s0022-1759(97)00192-0;;9692846;;10.1021/bi010475i;;11467948;;10.1039/b604391g;;16791327;;9780179;;10.4049/jimmunol.161.8.4083;;pmc2629253;;19074274;;10.1073/pnas.0809257105;;10.1002/micr.20294;;17066409;;7879044;;10.1021/ja00119a001;;10.4049/jimmunol.147.12.4366;;1836485;;11096108;;10.1074/jbc.m009483200;;10.1038/nbt1166;;16299519;;10.1111/j.1742-4658.2008.06439.x;;18435758,"Ducry et al., (2010) “Antibody-conjugates: Linking Cytotoxic to Monoclonal Antibodies,” Bioconjugate Chem., 21:5-13.;;Stinchcomb et al. (1979) “Isolation and Characterization of a Yeast Chromosomal Replicator,” Nature. 282:39-43.;;Stumpp et al. (2008) “DARPins: A New Generation of Protein Therpeutics,” Drug Discovery Today. 13 (15-16):695-670.;;Teicher (2009) “Antibody-drug conjugate targets,” Current Cancer Drug Targets. 9(8):982-1004.;;Tschumper et al. (1980) “Sequence of a Yeast DNA Fragment Containing a Chromosomal Replicator and the TRP1 Gene,” Gene. 10:157-166.;;Wang et al. (1998) “Single-chain Fv with manifold N-glycans as bifunctional scaffolds for immunomolecules,” Protein Engineering. 11:1277-1283.;;Wang et al. (2011) “Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies,” Molecular Immunology. 48(6):860-866.;;Wei et al. (2008) “Glycoengineering of Human IgG1-Fc through Combined Yeast Expression and in Vitro Chemoenzymatic Glycosylation,” Biochem. 47(39):10294-10304.;;Winkler et al. (2000) “Changing the antigen binding specificity by single point mutations of an anti-p24 (HIV-1) antibody,” J. Immunol. 165:4505-4514.;;Wright et al. (1992) “Genetically Engineered Antibodies: Progress and Prospects,” Critical Reviews in Immunology. 12:125-168.;;Wu et al. (1999) “Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR Residues,” J. Mal. Biol. 294:151-162.;;Yamagami et al. (1999) “Suppression of Allograft Rejection with Anti-Anti-A(3T Cell Receptor Antibody in Rat Corneal Transplantation,” Transplantation. 67:600-604.;;Yoshino et al. (1992) “Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in rats,” J. Exp. Med. 175:907-915.;;Yu et al. (2008) “Interaction between bevacizumab and murine VEGF-A: a reassessment,” Investigative Opthalmology and Visual Science. 49(2):522-527.;;Zhou (Feb. 17, 2014) “Site-specific antibody-drug conjugation through glycoengineering,” Bioconjugate Chemistry. 25(3):510-520.;;Zhou et al. (2008) “Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function,” Biotechnol. Bioeng. 99:652-665.;;Zhou et al. (2011) “Strategies for Neoglycan conjugation to human acid [alpha]-glucosidase,” Bioconjugate Chemistry. 22(4):741-751.;;Zhou et al. (2009) “Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease,” Mol. Ther. 17(6):954-963.;;Al-Lazikani et al. (1997) “Standard conformations for the canonical structures of immunoglobulins,” J. Mol. Biol. 273:927-948.;;Anthony et al. (2008) “Identification of a receptor required for the anti-inflammatory activity of IVIG,” Proc. Natl. Acad. Sci. USA. 105:19571-19578.;;Anthony et al. (2008) “Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc,” Science. 320:373-376.;;Anwer et al. (2000) “Synthetic Glycopeptide-Based Delivery Systems for Systemic Gene Targeting to Hepatocytes,” Pharm. Res. 17:451-459.;;Chen et al. (2010) “In vivo targeting of B-cell lymphoma with glycan ligands of CD22,” Blood. 115:4778-4786.;;Chen et al. (2012) “Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22,” Leukemia and Lymphoma. 53:208-210.;;Feige et al. (2009) “Structure of the murine unglycosylated IgG1 Fc fragment,” J. Mol Biol. 391:599-608.;;Ganesan et al. (2011) “Rapid and Efficient Clearance of Blood-borne Virus by Liver Sinusoidal Endothelium,” PLoS Pathogens. 7(9):e1002281. pp. 1-11.;;Giudicelli et al. (2011) “IMGT/V-QUEST: IMGT Standardized Analysis of the Immunoglobulin (IG) and T Cell Receptor (TR) Nucleotide Sequences” In; Cold Spring Harb. Protoc. 2011(6):58-78.;;Hatekeyama et al. (2011) “Targeted Drug Delivery to Tumor Vasculature by A Carbohydrate Mimetic Peptide,” Proc. Natl. Acad. Sci. USA. 108:19587-19592.;;Hong et al. (2003) “Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells,” Cancer Res. 23:9023-9031.;;Hosoguchi (2010) “An efficient approach to the discovery of potent inhibitors against glycosyltransferases,” J. Med. Chem. 53:5607-5619.;;Kawasaki et al. (2013) “Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation,” Proc. Natl. Acad. Sci. USA. 110:7826-7831.;;Krapp et al. (2003) “Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity,” J. Mol. Biol. 325:979-998.;;Lepenies et al. (2013) “Targeting C-type lectin receptors with multivalent carbohydrate ligands,” Adv. Drug Delivery Rev. 65:1271-1281.;;Li et al.(May 23, 2014) “The Preparation of Well-Defined Antibody-Drug Conjugates Through Glycan Remodeling and Strain Promoted Azide-Alkyne Cycloadditions,” Angew. Chem., Int. Ed. 53(28):7179-7182.;;Martin (2010) “Protein Sequence and Structure Analysis of Antibody Variable Domains” Ch. 3 In; Antibody Engineenng. vol. 2. Eds: Kontermann et al. Springer-Verlag. pp. 33-51.;;Mattner et al. (2005) “Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections,” Nature. 434:525-529.;;McCarthy (Aug. 16, 2013) “Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates,” Glycoconj. J. 30:857-870.;;Medina et al. (2011) “N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers,” Biomaterials. 32:4118-4129.;;Monnier et al. (2014) “Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications,” Clin. Chem. Lab. Med. 52:21-32.;;Murray (1985) “Imaging Findings and Pharmacaokinetics of 111-Indium ZME-018 Monoclonal Antibodies,” J. Nuc. Med. 26:P16. Abstract No. 55.;;North et al. (2011) “A new clustering of antibody CDR loop conformations,” J. Mol. Biol. 406:228-256.;;Williams et al. (2010) “Humanising Antibodies by CDR Grafting” Ch. 21 In; Antibody Engineering. vol. 1. Eds.: Kontermann et al. Springer-Verlag. pp. 319-339.;;Zhou (Aug. 22, 2013) “Bioconjugation by native chemical tagging of C-H bonds.,” J. Am. Chem. Soc. 135:12994-12997.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/021342, dated Jun. 8, 2015.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2015/054651, dated Apr. 20, 2016.;;Bause et al. (1979) “Primary structural requirements for N-glycosylation of peptides in rat liver,” FEBS Letters. 108(2):341-344.;;Hodoniczky et al. (2005) “Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro,” Biotechnol. Prog. 21:1644-1652.;;Junutula et al. (2008) “Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs,” Journal of Immunological Methods. 332:41-52.;;Zevgiti et al. (2011) “Sialic acid and sialyl-lactose glyco-conjugates: design, synthesis and binding assays to lectins and swine influenza H1N1 virus,” J. Pep. Sci., 18:52-58.;;Sakarellos-Kaitsiotisa et al., (2012) “Design, synthesis and binding assays of sialic acid and sialyl-saccharide conjugates to lectins and influenza H1N1 virus,” J. Pep. Sci., 18(Supp 1):S52, Abstract No. 069.;;Hanashima et al. (2007) “Syntheis of a Sialic Acid r(2-3) Galactose Building Block and Its Use in a Linear Synthesis of Sialyl Lewis X.,” Organic Letters, 9(9)1 777-1779.;;Axup et al. (2012) “Synthesis of site-specific antibody-drug conjugates using unnatural amino acids,” Proc. Natl. Acad. Sci. USA. 109(40)16101-16106.;;Boeggeman et al. (2007) “Direct Identification of Nonreducing GlcNAc Residues on N-Glycans of Glycoproteins Using a Novel Chemoenzymatic Method,” Bioconjugate Chemistry. 18(3):806-814.;;Boeggman et al. (2009) “Site Specific Conjugation of Fluoroprobes to the Remodeled Fc N-Glycans of Monoclonal Antibodies Using Mutant Glycosyltransferases: Application for Cell Surface Antigen Detection,” Bioconjugate Chemistry. 20(6):1228-1236.;;Carrasquillo et al. (1985) “Improved imaging of metastatic melanoma with high dose 9. 2.27 In-111 monoclonal antibody,” J. Nuc. Med. vol. 26. No. 67. Abstract No. 276.;;Carter et al. (2008) “Antibody-drug conjugates for cancer therapy,” Caner Journal. 14:154-169.;;Cervigni et al. (1996) “Synthesis of Glycopeptides and Lipopeptides by Chemoselective Ligation,” Angew. Chem. Int. Ed. 35(11):1230-1232.;;Chan et al. (2010) “Therapeutic antibodies for autoimmunity and inflammation,” The Journal of Immunology. 10:301-316.;;Chari (2008) “Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs,” Accounts of Chemical Research. 41:98-107.;;Cobos-Correa et al. (2009) “Membrane-bound FRET probe visualizes MMP12 activity in pulmonary inflammation,” Nature Chemical Biology. 5(9):628-663.;;Doronina et al. (2003) “Development of potent monoclonal antibody auristatin conjugates for cancer therapy,” Nat. Biotechnol. 21(7):778-784.;;Ebersbach et al. (2007) “Affilin-novel binding molecules based on human gamma-B-crystallin, an all beta-sheet protein,” Journal of Molecular Biology. 372(1):172-185.;;Gehrig et al. (2012) “Spatially resolved monitoring of neutrophil elastase activity with ratiometric fluorescent reporters,” Angewandte Chemie International Edition. 51(25):6258-6261.;;Grabulovski et al. (2007) “A Novel, Non-immunogenic Fyn SH3-derived Binding Protein with Tumor Vascular Targeting Proteins,” The Journal of Biological Chemistry. 282(5):3196-3204.;;Guan et al. (1998) “Homogeneous Immunoconjugates for Boron Neutron-capture Therapy: Design, Synthesis, and Preliminary Characterization,” Proc. Natl. Acad. Sci. USA. 95(22):13206-13210.;;Heidecke et al. (1996) “Alpha-Beta T Cell Receptor-Directed Therapy in Rat Allograft Recipients,” Transplantation. 61:948-956.;;Heidecke et al. (1996) “Induction of Long-Term Rat Renal Allograft Survival by Pretransplant T Cell Receptor-NB-Targeted Therapy,” Transplantation 61:336-339.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2012/003819, dated Jul. 17, 2013.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/059481, dated Feb. 7, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022623, dated Jul. 31, 2014.;;International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2014/022728, dated Oct. 9, 2014.;;Jassal et al. (2001) “Sialylation of human igG-Fc carbohydrate by transfected rat alpha2, 6-sialyltransferase,” Biochemical and Biophysical Research Communications. 286(2):243-249.;;Jones (1977) “Proteinase Mutants of Saccharomyces Cerevisiae,” Genetics. 85:23-33.;;Jung et al. (1992) “Prevention and therapy of experimental autoimmune neuritis by an antibody against T cell receptors-alpha/beta,” Journal of Immunology. 148:3768-3775.;;Junutula et al. (2008) “Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index,” Nature Biotechnology. 26(8):925-929.;;Junutula et al. (2010) “Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2—Positive Breast Cancer,” Clin. Cancer Res. 16:4769-4778.;;Kaneko et al. (2006) “Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation,” Science. 313 (5787):670-673.;;Khidekel et al. (2003) “A Chemoenzymatic Approach toward the Rapid and Sensitive Detection of 0-GlcNAc Posttranslational Modifications,” J. Am. Chem. Soc. 125:16162-16163.;;Kingsman et al. (1979) “Replication in Saccharomyces cerevisiae of Plasmid pBR313 Carrying DNA from the Yeast trpl Region,” Gene. 7:141-152.;;Koide et al. (2007) “Monobodies: Antibody Mimics Based on the Scaffold of the Fibronectin Type III Domain,” Methods in Molecular Biology. 352:95-109.;;Krehenbrink et al. (2008) “Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PuID,” Journal of Molecular Biology. 383(5):1058-1068.;;Labrijn et al. (2008) “When binding is enough: nonactivating antibody formats,” Curr. Opin. Immunol. 20:479-485.;;Leung et al. (1999) “The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments,” Clin. Cancer Res. 5:3106s-3117s.;;Nixon et al. (2006) “Engineered Protein Inhibitors of Proteases,” Current Opinion in Drug Discovery & Development. 9 (2):261-268.;;Nygren et al. (2008) “Alternative Binding Proteins: Affibody Binding Proteins Devloped from a Small Three-helix Bundle Scaffold,” The FEBS Journal. 275(11):2668-2676.;;Page et al. (2012) “Biologics in Organ Transplant,” Transplant International. 25:707-719.;;Piatesi et al. (2004) “Immunological optimization of a generic hydrophobic pocket for high affinity hapten binding and Diels-Alder activity,” ChemBioChem. 5:460-466.;;Polakis (2005) “Arming antibodies for cancer therapy,” Current Opinion in Pharmacology. 5:382-387.;;Qu et al. (1998) “Carbohydrates engineered at antibody constant domains can be used for site-specific conjugation of drugs and chelates,” Journal of Immunological Methods. 213:131-144.;;Raju et al. (2011) “Glycoengineering of Therapeutic Glycoproteins: In Vitro Galactosylation and Sialylation of Glycoproteins with Terminal N-Acetylglucosamine and Galactose Residues,” Biochem. 40(30):8868-8876.;;Renaudet et al. (2006) “On-bead synthesis and binding assay of chemoselectively template-assembled multivalent neoglycopeptides,” Organic and Biomolecular Chemistry. 4:2628-2636.;;Roche Diagnostics (2013) “alpha-2,6, Sialyltransferase Cat. No. 07 012 250 103 (Data Sheet),” Roche Diagnostics. Accessible on the Internet at URL: https://cssportalsoche.com/LFR_PublicDocs/ras/07012250103_en_02.pdf [Last Accessed on on Jul. 25, 2014].;;Roux et al. (1998) “Comparisons of the Ability of Human IgG3 Hinge Mutants, IgM, 19E, and IgA2, to Form Small Immune Complexes: A Role for Flexibility and Geometry,” Journal of Immunology. 161(8):4083-4090.;;Sazinsky et al. (2008) “Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors,” Proc. Natl. Acad. Sci. USA. 105(51): 20167-20172.—with Supplementary Information.;;Scharpf et al. (2006) “Immunomodulation with anti-anti-a(3T-cell receptor monoclonal antibodies in combination with cyclosporine a improves regeneration in nerve allografts,” Microsurgery. 26:599-607.;;Schorlemmer et al. (1995) “Synergistic effects of 15-deoxyspergualin with cyclosporine and the TCR-targeted monoclonal antibody R73 to induce specific unresponsiveness to skin allografts in rats,” Transplantation Proceedings. 27:414-416.;;Shao et al. (1995) “Unprotected Peptides as Building Blocks for the Synthesis of Peptide Dendrimers with Oxime, Hydrazone, and Thiazolidine Linkages,” J. Am. Chem. Soc. 117(14):3893-3899.;;Shearman et al. (1991) “Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor,” The Journal of Immunology. 147:4366-4373.;;Shields et al. (2001) “High Resolution Mapping of the Binding Site on Human IgG1 for FcyRl, FcyRll, FcyRlll, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR,” J. Biol. Chem. 276:6591-6604.;;Silverman et al. (2005) “Multivalent Avimer Proteins Evolved by Exon Shuffling of a Family of Human Receptor Domains,” Nature Biotechnology. 23(12):1556-1561.;;Skerra et al. (2008) “Alternative Binding Proteins: Anticalins—Harnessing the Structural Plasticity of the Lipocalin Ligand Pocket to Engineer Novel Binding Activites,” The FEBS Journal. 275(11):2677-2683.",ACTIVE
578,MY,A,MY 147476 A,043-438-978-523-154,2012-12-14,2012,MY PI20071581 A,2007-09-20,MY PI20071581 A,2007-09-20,INHALABLE DRUG,"INHALABLE DRUG A PROCESS FOR PREPARATION OF PARTICLES OF AN INHALABLE DRUG IS DESCRIBED. THE PROCESS COMPRISES COMBINING A FIRST LIQUID AND A SECOND LIQUID IN A REGION OF HIGH SHEAR, WHEREBY THE FIRST LIQUID AND THE SECOND LIQUID INTERACT TO FBINN THE PARTICLES OF THE DRUG. ONE OF THE FIRST AND SECOND LIQUIDS COMPRISES THE DRUG OR A PRECURSOR THEREOF. IN THE CASE WHERE ONE OF THE LIQUIDS COMPRISES THE PRECURSOR, THE OTHER OF THE FIRST AND SECOND LIQUIDS COMPRISES A REAGENT WHICH REACTS WITH THE PRECURSOR UNDER HIGH SHEAR CONDITIONS TO FORM PARTICLES OF THE DRUG. IN THE CASE WHERE ONE OF THE LIQUIDS COMPRISES THE DRUG, THE OTHER OF THE FIRST AND SECOND LIQUIDS COMPRISES A LIQUID WHICH, WHEN MIXED WITH THE LIQUID CONTAINING THE DRUG UNDER HIGH SHEAR, FORMS PARTICLES OF THE DRUG.",NANOMATERIALS TECH PTE LTD,HAK-KIM CHAN;;CLARK CHIOU HERBERT;;FENG CHEN JIAN;;TING HU TING;;LAI YUN JIMMY SUNG,,https://lens.org/043-438-978-523-154,Granted Patent,no,0,0,1,1,0,,A61K9/14,,0,0,,,,ACTIVE
579,CN,A,CN 110256560 A,168-726-529-253-039,2019-09-20,2019,CN 201910427632 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;CN 201480014338 A,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/168-726-529-253-039,Patent Application,no,4,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/61;;A61K47/68;;A61P35/00;;C07K16/32;;C12N15/13;;C12P21/08,,5,0,,,"苗庆芳 等: ""抗肿瘤抗体药物研究进展"", 《药学学报》;;ELIZABETH BOEGGEMAN 等: ""Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection"", 《BIOCONJUG CHEM》;;ELIZABETH BOEGGEMAN 等: ""Site specific conjugation of fluoroprobes to the remodeled Fc Nglycans of monoclonal antibodies using mutant glycosyltransferases: Application for cell surface antigen detection"", pages 1228;;苗庆芳 等: ""抗肿瘤抗体药物研究进展"", 《药学学报》, 12 October 2012 (2012-10-12), pages 1261 - 1268;;ELIZABETH BOEGGEMAN 等: ""Site specific conjugation of fluoroprobes to the remodeled Fc N-glycans of monoclonal antibodies using mutant glycosyltransferases: application for cell surface antigen detection"", 《BIOCONJUG CHEM》, 17 June 2009 (2009-06-17), pages 1228 - 1236, XP055061205, DOI: 10.1021/bc900103p",PENDING
580,US,A1,US 2017/0267774 A1,199-375-793-976-79X,2017-09-21,2017,US 201715417648 A,2017-01-27,US 201715417648 A;;US 201414203479 A;;US 201361776710 P;;US 201361776715 P;;US 201361776724 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2013-09-05),https://lens.org/199-375-793-976-79X,Patent Application,yes,0,11,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/32;;C07K16/28;;C07K16/40,,0,0,,,,ACTIVE
581,EP,A4,EP 2235962 A4,035-836-265-875-882,2011-05-18,2011,EP 08869181 A,2008-12-17,US 2008/0087102 W;;US 96502207 A,2007-12-27,DEVICES AND METHODS FOR ENHANCING THE FREQUENCY OUTPUT OF A PORTABLE AUDIO DEVICE,,MOTOROLA MOBILITY INC,CHEN SHAOHAI;;CLARK JOEL A;;STEUER PAUL R;;ZUREK ROBERT A;;ADY ROGER W;;DAVIS GILES,"MOTOROLA MOBILITY, INC. (2011-03-02);;MOTOROLA MOBILITY LLC (2012-09-05)",https://lens.org/035-836-265-875-882,Search Report,no,7,0,10,10,0,H04R1/2857;;H04R2205/021;;H04M1/12;;H04R1/02;;H04R1/2857;;H04R2205/021;;H04R1/2857;;H04R2205/021,H04R1/02;;H04M1/12;;H04R1/28,,1,0,,,See also references of WO 2009085796A2,DISCONTINUED
582,WO,A2,WO 2014/164534 A2,045-899-696-316-493,2014-10-09,2014,US 2014/0022728 W,2014-03-10,US 201361776724 P;;US 201361776710 P;;US 201361776715 P,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/045-899-696-316-493,Patent Application,yes,53,22,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K39/00,,31,19,013-795-151-218-458;;081-762-551-590-027;;039-331-124-493-196;;043-016-539-897-20X;;006-053-610-642-017;;023-630-635-437-312;;015-458-200-457-953;;079-000-142-364-026;;080-596-177-983-981;;143-898-600-120-153;;001-329-438-412-588;;076-152-531-431-484;;113-720-510-689-403;;064-343-550-244-269;;047-364-936-221-939;;015-623-518-697-144;;023-249-219-470-807;;050-877-021-901-567;;092-890-446-683-93X,9780179;;10.4049/jimmunol.161.8.4083;;10.1006/meth.1995.9996;;10.1016/j.drudis.2008.04.013;;18621567;;10.1111/j.1742-4658.2008.06438.x;;18435759;;10.1111/j.1742-4658.2008.06439.x;;18435758;;17628592;;10.1016/j.jmb.2007.06.045;;18822295;;10.1016/j.jmb.2008.09.016;;10.1038/nbt1166;;16299519;;10.1074/jbc.m609211200;;17130124;;16566296;;10.1073/pnas.95.22.13206;;9789066;;pmc23761;;10.1038/nchembio.196;;19648933;;10.1002/anie.201109226;;22555935;;3061521;;10.1016/b978-0-409-90042-2.50030-1;;388229;;10.1038/282039a0;;389741;;10.1016/0378-1119(79)90029-5;;10.1126/science.1129594;;16888140;;21256596;;10.1016/j.molimm.2010.12.009;;20025606;;10.2174/156800909790192365,"KABAT ET AL.: ""Sequences of Proteins of Immunological Interest"", 1991, U.S. DEPT. HEALTH AND HUMAN SERVICES;;ROUX ET AL., J. IMMUNOL., vol. 161, 1998, pages 4083;;ASHKENAZI ET AL., METHODS, vol. 8, no. 2, 1995, pages 104 - 115;;KOIDE ET AL., METHODS MOL. BIOI., vol. 352, 2007, pages 95 - 109;;STUMPP ET AL., DRUG DISCOV. TODAY, vol. 13, no. 15-16, 2008, pages 695 - 701;;NYGREN ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2668 - 76;;SKERRA ET AL., FEBS J., vol. 275, no. 11, 2008, pages 2677 - 83;;EBERSBACH ET AL., J. MOL. BIOD., vol. 372, no. 1, 2007, pages 172 - 85;;KREHENBRINK ET AL., J. MOL. BIOI., vol. 383, no. 5, 2008, pages 1058 - 68;;SILVERMAN ET AL., NAT. BIOTECHNOL., vol. 23, no. 12, 2005, pages 1556 - 61;;GRABULOVSKI ET AL., J BIOL CHEM, vol. 282, no. 5, 2007, pages 3196 - 3204;;NIXON ET AL., CURR OPIN DRUG DISCOV DEVEL, vol. 9, no. 2, 2006, pages 261 - 8;;DRICKAMER K; TAYLOR ME: ""Introduction to Glycobiology"", 2006;;GUAN ET AL., PNAS, vol. 95, 1998, pages 13206 - 10;;MURRAY, J. NUC. MED., vol. 26, 1985, pages 3328;;CARRAGUILLO ET AL., J. NUC. MED., vol. 26, 1985, pages 67;;A. COBOS-CORREA: ""Membrane-bound FRETprobe visualizes MMP12 activity in pulmonary inflammation"", NATURE CHEMICAL BIOLOGY, vol. 5, no. 9, 2009, pages 628 - 63;;S. GEHRIG: ""Spatially Resolved Monitoring of Neutrophil Elastase Activity with Ratiometric Fluorescent Reporters"", ANGEW. CHEM. INT. ED., vol. 51, 2012, pages 6258 - 6261;;HERMANSON, G.T.: ""Bioconjugate Techniques"", 1996, ACADEMIC PRESS;;ARNOLD S. FREEDMAN; LEE M. NADLER ET AL.: ""HARRISON'S PRINCIPLES OF INTERNAL MEDICINE"", 1994, article ""Malignant Lymphomas"", pages: 1774 - 1788;;BRUCE A CHABNER ET AL.: ""GOODMAN & GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS"", 1996, article ""Antineoplastic Agents"", pages: 1233 - 1287;;RIDGWAY, A. A. G: ""Mammalian Expression Vectors"", article ""Mammalian Expression Vectors"", pages: 470 - 472;;STINCHCOMB, NATURE, vol. 282, 1979, pages 39;;KINGSMAN ET AL., GENE, vol. 7, 1979, pages 141;;TSCHEMPER ET AL., GENE, vol. 10, 1980, pages 157;;JONES, GENETICS, vol. 85, 1977, pages 12;;KANEKO, Y.; NIMMERJAHN, F.; RAVETCH, J. V.: ""Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation"", SCIENCE, vol. 313, 2006, pages 670 - 3, XP008076047, DOI: doi:10.1126/science.1129594;;WANG, W. ET AL.: ""Impact of methionine oxidation in human IgGl Fc on serum half-life of monoclonal antibodies"", MOL IMMUNOL, vol. 48, 2011, pages 860 - 6, XP028143840, DOI: doi:10.1016/j.molimm.2010.12.009;;STEFANO ET AL., METHODS IN MOLECULAR BIOLOGY, 2013;;TEICHER, B. A: ""Antibody-drug conjugate targets"", CURR CANCER DRUG TARGETS, vol. 9, 2009, pages 982 - 1004;;See also references of EP 2983701A2",PENDING
583,AU,B2,AU 2018/282451 B2,090-751-650-610-524,2021-03-04,2021,AU 2018/282451 A,2018-12-21,AU 2018/282451 A;;AU 2014/249224 A;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/090-751-650-610-524,Granted Patent,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,2,1,136-414-621-541-929,pmc3464487;;10.1021/bc900103p;;19425533,"Qun Zhou et al, ""Strategies for Neoglycan Conjugation to Human Acid α-Glucosidase"", Bioconjugate Chemistry 2011, vol 22, 741-751.;;Boeggeman et al. Bioconjug Chem. 2009 June. Vol. 20, No. 6, pages 1228-1236.",ACTIVE
584,EP,A1,EP 1871344 A1,111-671-411-146-437,2008-01-02,2008,EP 06704975 A,2006-03-08,AU 2006/000302 W;;AU 2005/901355 A,2005-03-18,INHALABLE DRUG,,NANOMATERIALS TECH PTE LTD,CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,,https://lens.org/111-671-411-146-437,Patent Application,yes,0,0,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61J3/02;;B01J13/00,,0,0,,,,DISCONTINUED
585,AU,A1,AU 2014/249224 A1,198-687-038-320-531,2015-09-24,2015,AU 2014/249224 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/198-687-038-320-531,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
586,SG,A,SG 11201506086S A,073-240-557-868-714,2015-09-29,2015,SG 11201506086S A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,,GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/073-240-557-868-714,Unknown,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K39/00;;C07K16/00,,0,0,,,,PENDING
587,CA,C,CA 2902530 C,079-001-396-294-341,2023-05-09,2023,CA 2902530 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/079-001-396-294-341,Granted Patent,no,0,0,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K39/00;;C07K16/00,,0,0,,,,PENDING
588,US,A1,US 2024/0073143 A1,182-391-045-332-449,2024-02-29,2024,US 202318498940 A,2023-10-31,US 202318498940 A,2023-10-31,IN-NETWORK COMPUTATION AND CONTROL OF NETWORK CONGESTION BASED ON IN-NETWORK COMPUTATION DELAYS,"Systems, apparatus, articles of manufacture, and methods are disclosed for in-network computation and control of network congestion based on in-network computation delays. An example device includes interface circuitry to access a packet including a header having (1) a destination address field to identify a first network address of a destination device capable of performing an action and (2) a workload class field to identify a workload class associated with the action. The example device also includes programmable circuitry to utilize machine-readable instructions to perform the action at the device based on the workload class field, the device having a second network address that is different than the first network address. Additionally, the example programmable circuitry is to modify an indicator field of the packet to indicate that the action has been performed and cause the interface circuitry to forward the packet with the modified indicator field toward the destination device.",INTEL CORP,SHARMA BANJADE VESH RAJ;;ALAM S M IFTEKHARUL;;JHA SATISH CHANDRA;;MERWADAY ARVIND;;CHEN KUILIN CLARK,,https://lens.org/182-391-045-332-449,Patent Application,yes,0,0,1,1,0,H04L47/283;;H04L47/12,H04L47/283;;H04L47/12,,0,0,,,,PENDING
589,KR,A,KR 20210145294 A,183-922-321-908-691,2021-12-01,2021,KR 20217037637 A,2014-03-10,US 201361776710 P;;US 201361776715 P;;US 201361776724 P;;KR 20157027622 A;;US 2014/0022728 W,2013-03-11,- - SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"본 개시내용은 결합 폴리펩티드의 천연 또는 조작된 글리칸 내에 부위-특이적으로 조작된 약물-글리칸 연결을 포함하는 결합 폴리펩티드 (예를 들어, 항체) 및 그의 이펙터 모이어티 접합체 (예를 들어, 항체-약물 접합체 또는 ADC)를 제공한다. 본 개시내용은 또한 항원-결합 폴리펩티드를 코딩하는 핵산, 상기 항원-결합 폴리펩티드를 제조하기 위한 재조합 발현 벡터 및 숙주 세포를 제공한다. 질환을 치료하기 위해 본원에 개시된 항원-결합 폴리펩티드를 사용하는 방법을 또한 제공한다.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/183-922-321-908-691,Patent Application,no,1,0,88,165,80,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/28;;A61K47/54;;A61K47/68;;C07K16/32;;C07K16/40,,2,0,,,"E. Boeggeman 등, Bioconjugate Chem., Vol.20, p.11228-1236 (2009);;Q. Zhou 등, Bioconjugate Chem., Vol.22, p.741-751 (2011)",ACTIVE
590,AU,B2,AU 2006/225066 B2,014-519-396-858-782,2010-07-29,2010,AU 2006/225066 A,2006-03-08,AU 2005/901355 A;;AU 2006/000302 W;;AU 2006/225066 A,2005-03-18,Inhalable drug,,NANOMATERIALS TECH PTE LTD,CHAN HAK-KIM;;HU TING TING;;YUN JIMMY SUNG LAI;;CHEN JIAN FENG;;CHIOU HERBERT CLARK,NMT PHARMACEUTICALS PTE LTD (2016-05-19),https://lens.org/014-519-396-858-782,Granted Patent,no,1,0,2,9,0,,A61K9/14;;A61J3/02;;A61K9/72;;B01J13/00,,0,0,,,,INACTIVE
591,CA,A1,CA 2902530 A1,035-049-362-797-027,2014-10-09,2014,CA 2902530 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/035-049-362-797-027,Patent Application,no,0,0,88,165,40,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,A61K39/00;;C07K16/00,,0,0,,,,PENDING
592,US,A1,US 2009/0186088 A1,068-968-116-148-720,2009-07-23,2009,US 90875706 A,2006-03-08,AU 2005/901355 A;;AU 2006/000302 W,2005-03-18,INHALABLE DRUG,"A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and second liquids comprises the drug or a precursor thereof. In the case where one of the liquids comprises the precursor, the other of the first and second liquids comprises a reagent which reacts with the precursor under high shear conditions to form particles of the drug. In the case where one of the liquids comprises the drug, the other of the first and second liquids comprises a liquid which, when mixed with the liquid containing the drug under high shear, forms particles of the drug.",NANOMATERIALS TECH PTE LTD,CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,NANOMATERIALS TECHNOLOGY PTE LTD (2009-05-15),https://lens.org/068-968-116-148-720,Patent Application,yes,6,7,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61K31/137,424/484;;514/653,1,1,020-576-622-674-729,10.1016/j.ijpharm.2003.09.044;;14698598,"Chen et al 2004, Int. J. Pharmaceutics 269:267-274.",DISCONTINUED
593,US,A1,US 2010/0246538 A1,127-547-510-992-64X,2010-09-30,2010,US 41595709 A,2009-03-31,US 41595709 A,2009-03-31,ADAPTIVE FREQUENCY REUSE METHOD OF RADIO RESOURCES MANAGEMENT AND ALLOCATION,"A method for managing and allocating radio resources (RRMA method) of multiple radio resource types to subscriber stations is disclosed. The RRMA method includes bandwidth partitioning, into parts comprising “slots” with a given reuse pattern, a selection rule, to select a “cell, reuse pattern” pair serving each user, and an allocation rule, for distributing to each user an appropriate number of bandwidth slots from the selected “cell, reuse pattern” pair. After an adaptation period, the method reaches a desired fairness, while simultaneously reaching a maximal mean throughput, possible under this fairness. For big networks, the method provides basically decentralized radio resource management. The RRMA method is useful to cellular networks having a single set of orthogonal sub-channels (frequency/time slots) being reused by all network cells, such as time division multiple access (TDMA), orthogonal frequency division multiple access (OFDMA), or OFDMA/TDMA cellular systems. Particularly, the method is applicable in fractional frequency reuse cellular networks.",KRAVTSOV VLADIMIR;;LOMNITZ YUVAL;;CHEN CLARK;;TALWAR SHILPA;;HIMAYAT NAGEEN;;LI LI;;YANG HUA;;SUN HOMGMEI,KRAVTSOV VLADIMIR;;LOMNITZ YUVAL;;CHEN CLARK;;TALWAR SHILPA;;HIMAYAT NAGEEN;;LI LI;;YANG HUA;;SUN HOMGMEI,INTEL CORPORATION (2009-03-27),https://lens.org/127-547-510-992-64X,Patent Application,yes,6,16,2,2,0,H04W72/563;;H04W72/541;;H04W28/0861;;H04W72/563;;H04W72/541;;H04W28/0861,H04J3/00,370/336,0,0,,,,INACTIVE
594,EP,A4,EP 1871344 A4,174-373-266-106-948,2012-05-02,2012,EP 06704975 A,2006-03-08,AU 2006/000302 W;;AU 2005/901355 A,2005-03-18,INHALABLE DRUG,,NANOMATERIALS TECH PTE LTD,CHAN HAK-KIM;;CHIOU HERBERT CLARK;;CHEN JIAN FENG;;HU TING TING;;YUN JIMMY SUNG LAI,,https://lens.org/174-373-266-106-948,Search Report,no,1,0,7,9,0,A61K9/0075;;A61K9/14;;A61K9/1688;;A61P11/08;;A61K9/0075;;A61K9/1688;;A61K9/14,A61K9/14;;A61J3/02;;B01J13/00,,1,1,020-435-634-003-86X,10.1016/j.addr.2003.10.020;;14962582,"MORISSETTE SHERRY L ET AL: ""HIGH-THROUGHPUT CRYSTALLIZATION: POLYMORPHS, SALTS, CO-CRYSTALS AND SOLCATES OF PHARMACEUTICAL SOLIDS"", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, vol. 56, no. 3, 1 January 2004 (2004-01-01), pages 275 - 300, XP009072233, ISSN: 0169-409X, DOI: 10.1016/J.ADDR.2003.10.020",DISCONTINUED
595,EP,A2,EP 2983701 A2,024-982-004-934-465,2016-02-17,2016,EP 14718808 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING,,GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,GENZYME CORPORATION (2018-07-18),https://lens.org/024-982-004-934-465,Patent Application,yes,0,3,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,3,2,023-249-219-470-807;;075-192-332-107-331,10.1126/science.1129594;;16888140;;19036920;;10.1073/pnas.0810163105;;pmc2604916,"KANEKO Y ET AL: ""ANTI-INFLAMMATORY ACTIVITY OF IMMUNOGLOBULIN G RESULTING FROM FC SIALYLATION"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 313, no. 5787, 1 August 2006 (2006-08-01), pages 670 - 673, XP008076047, ISSN: 0036-8075, DOI: 10.1126/SCIENCE.1129594;;R. M. ANTHONY ET AL: ""Inaugural Article: Identification of a receptor required for the anti-inflammatory activity of IVIG"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 105, no. 50, 16 December 2008 (2008-12-16), pages 19571 - 19578, XP055053128, ISSN: 0027-8424, DOI: 10.1073/pnas.0810163105;;See also references of WO 2014164534A2",DISCONTINUED
596,AU,B2,AU 2014/249224 B2,102-597-936-508-403,2019-01-17,2019,AU 2014/249224 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,Site-specific antibody-drug conjugation through glycoengineering,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/102-597-936-508-403,Granted Patent,no,3,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,2,2,084-230-129-207-67X;;136-414-621-541-929,10.1021/bc1005416;;21417264;;pmc3464487;;10.1021/bc900103p;;19425533,"Qun Zhou et al, ""Strategies for Neoglycan Conjugation to Human Acid a-Glucosidase"", Bioconjugate Chemistry 2011, vol 22, 741-751.;;Boeggeman et al. Bioconjug Chem. 2009 June. Vol. 20, No. 6, pages 1228-1236.",ACTIVE
597,HK,A1,HK 1214501 A1,105-956-446-130-04X,2016-07-29,2016,HK 16102347 A,2016-03-01,US 2014/0022728 W;;US 201361776710 P;;US 201361776724 P;;US 201361776715 P,2013-03-11,SITE SPECIFIC ANTIBODY DRUG CONJUGATION THROUGH GLYCOENGINEERING,,GENZYME CORP,PAN CLARK;;ZHOU QUN;;STEFANO JAMES;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;MILLER ROBERT;;QIU HUAWEI,,https://lens.org/105-956-446-130-04X,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K/;;A61K/,,0,0,,,,PENDING
598,MX,A,MX 2015012570 A,194-989-585-581-077,2016-01-12,2016,MX 2015012570 A,2014-03-10,US 201361776710 P;;US 201361776724 P;;US 201361776715 P;;US 2014/0022728 W,2013-03-11,SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION THROUGH GLYCOENGINEERING.,"The current disclosure provides binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof (e.g., antibody-drug conjugates or ADCs), comprising a site- specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypetpide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.",GENZYME CORP,QIU HUAWEI;;PAN CLARK;;MILLER ROBERT;;DHAL PRADEEP;;CHEN BO;;GIANOLIO DIEGO;;ZHOU QUN;;STEFANO JAMES,,https://lens.org/194-989-585-581-077,Patent Application,no,0,0,88,165,0,C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6869;;A61K47/549;;C07K16/2893;;A61P35/00;;A61P43/00;;A61K47/68031;;A61K47/549;;A61K47/6889;;C07K2317/41;;C07K2317/522;;C07K2317/56;;C07K2319/00;;A61P35/00;;A61P43/00;;C07K16/2893;;C07K2317/76;;A61K47/6869;;C07K16/32;;C07K2317/71;;C07K16/28;;C07K2317/92;;C07K16/2851;;C07K16/2809;;C07K2317/40;;C07K2317/732;;C07K16/40;;C07K2317/94;;A61K47/68031;;C07K16/28;;C07K2317/41;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6869;;A61K47/6889;;A61K47/549;;C07K2317/94;;A61K47/68031;;A61K47/549;;A61K47/6869;;C07K16/28;;C07K16/2809;;C07K16/2851;;C07K16/2893;;C07K16/32;;C07K16/40;;A61K47/6889;;A61K47/68031;;C07K2317/40;;C07K2317/41;;C07K2317/522;;C07K2319/00;;C07K16/2809;;C07K16/2851;;C07K16/32;;C07K16/40;;C07K2317/56;;C07K2317/732;;C07K2317/92;;C07K2317/71;;C07K2317/94;;A61K47/6889;;A61K47/6803;;A61K47/6869;;A61K47/549;;C07K16/2893;;C07K16/28;;C07K2317/76,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
599,US,B2,US 11025520 B2,012-908-208-932-292,2021-06-01,2021,US 201916457435 A,2019-06-28,US 201916457435 A,2019-06-28,Quality-of-service in cellular information centric network,"Systems and techniques for quality-of-service (QoS) in cellular information centric network (ICN) are described herein. To this end, QoS characteristics may be obtained for an ICN packet. The QoS characteristics may then be applied to the ICN packet. The ICN packet may then be transmitted in accordance with the QoS characteristics.",INTEL CORP,ZHANG YI;;DING ZONGRUI;;ALAM S M IFTEKHARUL;;JHA SATISH CHANDRA;;ARROBO VIDAL GABRIEL;;CHEN KUILIN CLARK,INTEL CORPORATION (2019-07-11),https://lens.org/012-908-208-932-292,Granted Patent,yes,16,1,4,4,0,H04L41/5009;;H04L43/028;;H04W24/08;;H04L43/0894;;H04L41/5009,H04L12/26;;H04W24/08,,9,1,071-883-204-324-144,10.1109/mcom.2017.1600938,"“3GPP; TSG RAN; Evolved Universal Terrestrial Radio Access (E-UTRA) and Evolved Universal Terrestrial Radio Access Network (E-UTRAN); Overall description; Stage 2 (Release 13)”, 3GPP TS 36.300 V13.2.0, (Jan. 13, 2016), 299 pgs.;;“5G; Procedures for the 5G System”, 3GPP TS 23.502 version 15.2.0 Release 15 ETSI TS 123 502 V15.2.0, (Jun. 2018), 311 pgs.;;“Information-Centric Networking (icnrg)”, https: datatracker.ietf.org group icnrg about accessed on Jun. 20, 2019, (Accessed on Jun. 20, 2019), 5 pgs.;;“5G; NR; Overall description; Stage-2”, ETSI TS 138 300 V15.3.1 3GPP TS 38.300 version 15.3.1 Release 15, (Oct. 2018), 90 pgs.;;“3GPP TS 23.501 V15.2.0”, 3rd Generation Partnership Project;Technical Specification Group Services and System Aspects;System Architecture for the 5G System;Stage 2(Release 15), (Jun. 2018), 78 pgs.;;“3GPP TS 23.501 V15.2.0”, 5G;NR;Radio Resource Control (RRC);Protocol specification(3GPP TS 38.331 version 15.3.0 Release 15), (Oct. 2018), 441 pgs.;;“ETSI TS 136 331 V13.0.0”, LTE; Evolved Universal Terrestrial Radio Access (E-UTRA); Radio Resource Control (RRC); Protocol specification (3GPP TS 36.331 version 13.0.0 Release 13), (Jan. 2016), 670 pgs.;;Ravindran, R, “Enabling ICN in 3GPP's 5G NextGen Core Architecture”, Memo ICNRG, (Jul. 2, 2018), 26 pgs.;;Ravindran, Ravishankar, “5G-ICN Delivering ICN Services over 5G Using Network Slicing”, IEEE Communications Magazine, (May 2017), 101-107.",ACTIVE
600,CN,A,CN 115706285 A,089-318-528-046-349,2023-02-17,2023,CN 202210522577 A,2022-05-13,US 202117396245 A,2021-08-06,"Flame-retardant composition, manufacturing method thereof and battery comprising flame-retardant composition",Disclosed herein is a battery module including a plurality of battery cells encapsulated in an enclosure. The inner surface of the shell is provided with a flame-retardant layer containing expandable graphite. The expandable graphite expands during a thermal event that causes an increase in temperature of the battery module. Also disclosed herein is a method comprising disposing a flame retardant layer in a battery module; wherein the battery module includes a plurality of battery cells encapsulated in a housing. The inner surface of the shell is provided with a flame-retardant layer containing expandable graphite. The expandable graphite expands during a thermal event that causes an increase in temperature of the battery module.,GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;HAHN THOMAS;;CLARK DAVID R;;HAN SUH JOON;;CHEN KUO-HUEY;;CEBRIAN SALAZAR GABRIEL,,https://lens.org/089-318-528-046-349,Patent Application,no,0,1,3,3,0,C09K21/02;;H01M10/6554;;H01M50/204;;Y02E60/10;;H01M2200/00;;H01M50/367;;H01M50/375;;H01M50/213;;H01M50/231;;H01M50/222;;H01M50/233;;H01M50/143;;C09K21/02;;H01M10/6554;;H01M10/613;;H01M10/6551;;H01M50/204,H01M10/658;;C09K5/14;;C09K21/10;;C09K21/12;;H01M50/124;;H01M50/143,,0,0,,,,PENDING
601,PL,B1,PL 191453 B1,005-468-853-856-050,2006-05-31,2006,PL 34029098 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halogeno-6-0-substituted derivatives of ketolide,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/005-468-853-856-050,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,C07H17/08;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61P31/04,,0,0,,,,EXPIRED
602,US,A,US 6124269 A,049-103-572-780-015,2000-09-26,2000,US 15429498 A,1998-09-16,US 15429498 A;;US 6370097 P,1997-10-29,2-Halo-6-O-substituted ketolide derivatives,"Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a formula ##STR1## compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTER JACOB J;;CHEN YAN;;CLARK RICHARD F,ABBOTT LABORATORIES (1998-10-21),https://lens.org/049-103-572-780-015,Granted Patent,yes,12,94,1,1,0,A61K31/7048;;C07H17/08;;A61K31/7048;;C07H17/08,C07H17/08,514/29;;536/7.2;;536/7.3;;536/7.4,2,2,048-099-424-873-230;;032-247-084-573-135,10.7164/antibiotics.43.286;;2324013;;10.7164/antibiotics.37.187;;6706855,"Journal of Antibiotics, vol. 43, No. 3 (Mar. 1990), pp. 286 294, Morimoto et al., Chemical Modification of Erythromycins: II. Synthesis and Antibacterial Activity of O Alkyl Derivatives of Erythromycin A .;;Journal of Antibiotics, vol. 37, No. 2 (Feb. 1984), pp. 187 189, Morimoto, et al., Chemical Modifications of Erythromycins: I. Synthesis and Antibacterial Activity of 6 O Methylerythromycins A .",EXPIRED
603,US,B2,US 10915703 B2,149-074-178-402-206,2021-02-09,2021,US 201916512825 A,2019-07-16,US 201916512825 A;;CN 200810134072 A;;US 201514830491 A;;US 50726109 A,2008-07-24,Validating an XML document,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/149-074-178-402-206,Granted Patent,yes,19,0,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/18;;G06F16/25;;G06F16/84;;G06F16/957;;G06F17/00;;G06F40/14;;G06F40/143;;G06F40/154;;G06F40/166;;G06F40/189;;G06F40/221;;G06F40/226;;G06F40/55;;G06Q10/06;;G06Q10/10;;G16C20/70,,21,0,,,"Leigh Dodds, Schematron: Validating XML Using XSLT, Website/page, Printed from website on Oct. 6, 2008, pp. 1-21, Bath University, Published at: http://www.Idodds.com/papers/schematron_xsltuk.html.;;Eric Armstrong, A Simple Collaboration System (Proposal), Website/page, Printed from website on Oct. 6, 2008, pp. 1-13, Treelight Software, Published at: .ttp://www.treelight.com/software/collaboration/SimpleSystem.html.;;Author Unknown, Topologi Schema Documentation Tool, Website/page, Printed from website on Oct. 6, 2008, pp. 1-3, Topologi Pty. Limited, NSW, Australia, Published at. http://www.topologi.com.;;Author Unknown, Program (xml.php), Website/page, Printed from website on Oct. 6, 2008, pp. 1-191, World Wide Web Conference 2007, Canada, Published at: http://www2007.org/program/xml.php.;;Rick Jelliffe, The W3C XML Schema Specification in Context, Website/page, Printed from website on Oct. 6, 2008, pp. 1-4, O'Reilly Media, Inc., Published at: http://www.xml.com/pub/a/2001/01/10/schemasincontext.html? page=5.;;Eddie Robertsson, An Introduction to Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-10, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/1318.;;Chimezie Ogbuji, Validating XML with Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-6, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/687.;;Rick Jelliffe, The Schematron Assertion Language 1.6, The Schematron software project, Oct. 1, 2002, pp. 1-32, Academia Sinica Computing Centre, Published at: http://xml.ascc.net/resource/schematron/Schematron2000.html.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Apr. 10, 2012, pp. 1-29, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Dec. 14, 2012, pp. 1-21, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Aug. 22, 2013, pp. 1-23, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jan. 14, 2014, pp. 1-20, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jul. 31, 2014, pp. 1-31, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 12/507,261, dated May 20, 2015, pp. 1-18, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Aug. 28, 2017, pp. 1-33, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Feb. 28, 2018, pp. 1-36, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Advisory Action for U.S. Appl. No. 14/830,491, dated May 8, 2018, pp. 1-5, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Sep. 20, 2018, pp. 1-16, Alexandria, VA, USA.;;Quoc A. Tran, Examiner, United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 14/830,491, dated Mar. 27, 2019, pp. 1-6, Alexandria, VA, USA.;;“Schematron” A language for making assertions about patterns found in XML documents, web archive dated May 12, 2008, 2 pages, <https://web.archive.org/web/20080512085819/http://www.schematron.com/>.;;Hinkelman, Scott, “Business Information Conformance Statements for Java”, IBM, Date Posted Jan. 22, 2004, 1 page, <https://web.archive.org/web/20080515164011/http://www.alphaworks.ibm.com/tech/biics4j>.",ACTIVE
604,CA,C,CA 2307788 C,154-286-009-906-185,2008-05-20,2008,CA 2307788 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,"Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I) or (II), compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention , and processes for their preparation.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;CLARK RICHARD F;;CHEN YAN;;PLATTNER JACOB J,,https://lens.org/154-286-009-906-185,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,C07H17/08;;A61K31/70;;A61K31/7042;;A61K31/7048;;A61P31/04,,0,0,,,,EXPIRED
605,US,A1,US 2019/0340229 A1,002-280-592-509-750,2019-11-07,2019,US 201916512884 A,2019-07-16,US 201916512884 A;;CN 200810134072 A;;US 201514830491 A;;US 50726109 A,2008-07-24,VALIDATING AN XML DOCUMENT,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/002-280-592-509-750,Patent Application,yes,0,1,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/143;;G06F40/189,,0,0,,,,ACTIVE
606,CZ,B6,CZ 300063 B6,100-191-730-969-80X,2009-01-21,2009,CZ 20001525 A,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,"2-Halo-6-O-substituted ketolide derivatives, process of their preparation, their use and pharmaceutical composition in which the derivatives are comprised","In the present invention, there are disclosed 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having a general formula I, compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier: Further disclosed is a process for preparing the above-indicated ketolide derivatives, a pharmaceutical composition intended for the treatment of bacterial infections and containing a therapeutically-effective amount of a compound of the invention, as well as the use of such ketolide derivatives.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/100-191-730-969-80X,Granted Patent,no,2,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,C07H17/08;;A61K31/7042;;A61K31/7048;;A61P31/04,,0,0,,,,EXPIRED
607,US,B2,US 10929598 B2,133-091-065-496-238,2021-02-23,2021,US 201916512884 A,2019-07-16,US 201916512884 A;;CN 200810134072 A;;US 201514830491 A;;US 50726109 A,2008-07-24,Validating an XML document,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/133-091-065-496-238,Granted Patent,yes,19,0,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/18;;G06F16/25;;G06F16/84;;G06F16/957;;G06F17/00;;G06F40/14;;G06F40/143;;G06F40/154;;G06F40/166;;G06F40/189;;G06F40/221;;G06F40/226;;G06F40/55;;G06Q10/06;;G06Q10/10;;G16C20/70,,21,0,,,"“Schematron” A language for making assertions about patterns found in XML documents, web archive dated May 12, 2008, 2 pages, <https://web.archive.org/web/20080512085819/http://www.schematron.com/>.;;Hinkelman, Scott, “Business Information Conformance Statements for Java”, IBM, Date Posted Jan. 22, 2004, 1 page, <https://web.archive.org/web/20080515164011/http://www.alphaworks.ibm.com/tech/biics4j>.;;Leigh Dodds, Schematron: Validating XML Using XSLT, Website/page, Printed from website on Oct. 6, 2008, pp. 1-21, Bath University, Published at: http://www.ldodds.com/papers/schematron_xsltuk.html.;;Eric Armstrong, A Simple Collaboration System (Proposal), Website/page, Printed from website on Oct. 6, 2008, pp. 1-13, Treelight Software, Published at: .ttp://www.treelight.com/software/collaboration/SimpleSystem.html.;;Author Unknown, Topologi Schema Documentation Tool, Website/page, Printed from website on Oct. 6, 2008, pp. 1-3, Topologi Pty. Limited, NSW, Australia, Published at. http://www.topologi.com.;;Author Unknown, Program (xml.php), Website/page, Printed from website on Oct. 6, 2008, pp. 1-191, World Wide Web Conference 2007, Canada, Published at: http://www2007.org/program/xml.php.;;Rick Jelliffe, Yhe W3C XML Schema Specification in Context, Website/page, Printed from website on Oct. 6, 2008, pp. 1-4, O'Reilly Media, Inc., Published at: http://www.xml.com/pub/a/2001/01/10/schemasincontext.html?page=5.;;Eddie Robertsson, An Introduction to Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-10, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/1318.;;Chimezie Ogbuji, Validating XML with Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-6, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/687.;;Rick Jelliffe, The Schematron Assertion Language 1.6, The Schematron software project, Oct. 1, 2002, pp. 1-32, Academia Sinica Computing Centre, Published at: http://xml.ascc.net/resource/schematron/Schematron2000.html.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Apr. 10, 2012, pp. 1-29, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Dec. 14, 2012, pp. 1-21, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Aug. 22, 2013, pp. 1-23, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jan. 14, 2014, pp. 1-20, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jul. 31, 2014, pp. 1-31, Alexandria, VA, USA.;;United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 12/507,261, dated May 20, 2015, pp. 1-18, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Aug. 28, 2017, pp. 1-33, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Feb. 28, 2018, pp. 1-36, Alexandria, VA, USA.;;United States Patent and Trademark Office, Advisory Action for U.S. Appl. No. 14/830,491, dated May 8, 2018, pp. 1-5, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 14/830,491, dated Sep. 20, 2018, pp. 1-16, Alexandria, VA, USA.;;United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 14/830,491, dated Mar. 27, 2019, pp. 1-6, Alexandria, VA, USA.",ACTIVE
608,HU,A2,HU P0004282 A2,076-932-243-820-001,2001-04-28,2001,HU P0004282 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-0-SUBSTITUTED KETOLIDE DERIVATIVES,"A találmány (I) és (II) általános képletű új 2-halogén-6-O-szubsztituált ketolidszármazékokra és azok gyógyszerészetilegelfogadható sóira és észtereire vonatkozik, amelyek antibakteriálisaktivitással rendelkeznek. A találmány tárgykörébe tartoznak továbbá avegyületek előállítására szolgáló eljárások, valamint agyógyszerészetileg elfogadható hordozó mellett a vegyületek terápiásanhatékony mennyiségét tartalmazó gyógyszerkészítmények, amelyek emlősökbakteriális fertőzés elleni kezelésére alkalmazhatók. Ó",ABBOTT LAB,CHEN YAN;;CHU DANIEL T;;CLARK RICHARD F;;OR YAT SUN;;PHAN LY TAM;;PLATTNER JACOB J,,https://lens.org/076-932-243-820-001,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
609,WO,A1,WO 1999/021871 A1,090-207-893-221-807,1999-05-06,1999,US 9822989 W,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,"Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I) or (II), compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/090-207-893-221-807,Patent Application,yes,2,29,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,PATENTED
610,US,A1,US 2010/0023471 A1,133-833-529-460-680,2010-01-28,2010,US 50726109 A,2009-07-22,CN 200810134072 A,2008-07-24,METHOD AND SYSTEM FOR VALIDATING XML DOCUMENT,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Validation is performed in a corresponding execution context for the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-07-13),https://lens.org/133-833-529-460-680,Patent Application,yes,10,18,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06N5/02;;G06F40/143;;G06F40/189;;G06N7/00,706/47;;706/59;;715/234,1,0,,,"Rick Jelliffe ""The Schematron Assertion Language 1.6"" Published 10/01/2002 -pages 1-32",INACTIVE
611,US,B2,US 11570079 B2,193-288-711-512-737,2023-01-31,2023,US 202117246243 A,2021-04-30,US 202117246243 A;;US 201916457435 A,2019-06-28,Quality-of-service in cellular information centric network,"Systems and techniques for quality-of-service (QoS) in cellular information centric network (ICN) are described herein. An example system includes processing circuitry, and a memory that includes instructions, the instructions, when executed by the processing circuitry, cause the processing circuitry to obtain QoS characteristics for an ICN packet, apply the QoS characteristics to the ICN packet, and transmit the ICN packet over the cellular ICN in accordance with the QoS characteristics.",INTEL CORP,ZHANG YI;;DING ZONGRUI;;ALAM S M IFTEKHARUL;;JHA SATISH CHANDRA;;ARROBO VIDAL GABRIEL;;CHEN KUILIN CLARK,INTEL CORPORATION (2019-07-11),https://lens.org/193-288-711-512-737,Granted Patent,yes,23,0,4,4,0,H04L41/5009;;H04L43/028;;H04W24/08;;H04L43/0894;;H04L41/5009,H04L41/5009;;H04L43/0894;;H04W24/08,,13,1,071-883-204-324-144,10.1109/mcom.2017.1600938,"Hsu et al. Reflecting QoS Using SDAP Header Processing AS/NAS and Ensure the Re-mapping During Sequential Transmission Packet in a 5G Communication System. China Patent Document No. 109952773 A, translated by Clarivate Analytics. China, Jun. 28, 2019. (Year: 2019).;;Li et al. Method in a Wireless Communication System for Executing Reflects the Quality of Service (QoS) and Device Thereof. China Patent Document No. 110235463 A, translated by Clarivate Analytics. China, Sep. 13, 2019. (Year: 2019).;;3GPP; TSG RAN; LTE; Evolved Universal Terrestrial Radio Access (E-UTRA) and Evolved Universal Terrestrial Radio Access Network (E-UTRAN); Overall description; Stage 2 (Release 13), 3GPP TS 36.300 V13.2.0, (Jan. 13, 2016), 299 pages.;;5G; Procedures for the 5G System, 3GPP TS 23.502 version 15.2.0 Release 15, ETSI TS 123 502 V15.2.0, Jun. 2018), 311 pages.;;Information-Centric Networking (icnrg), https://datatracker.ietf.org/group/icnrg/about/, accessed on Jun. 20, 2019, 5 pages.;;5G; NR; Overall description; Stage-2, ETSI TS 138 300 V15.3.1, 3GPP TS 38.300 version 15.3.1 Release 15, Oct. 2018, 90 pages.;;3GPP TS 23.501 V15.2.0, 3rd Generation Partnership Project;Technical Specification Group Services and System Aspects; System Architecture for the 5G System;Stage 2 (Release 15), Jun. 2018, 78 pages.;;ETSI TS 138 331 V15.3 0 (Oct. 2018), 5G;NR;Radio Resource Control (RRC);Protocol specification (3GPP TS 38.331 version 15.3.0 Release 15), Oct. 2018, 441 pages.;;ETSI TS 136 331 V13.0.0, LTE; Evolved Universal Terrestrial Radio Access (E-UTRA); Radio Resource Control (RRC); Protocol specification (3GPP TS 36.331 version 13 0.0 Release 13), Jan. 2016, 670 pages.;;Ravindran, R., et al. “Enabling ICN in 3GPP's 5G NextGen Core Architecture”, Memo ICNRG, Jul. 2, 2018), 26 pages.;;Ravindran, et al., “5G-ICN: Delivering ICN Services over 5G Using Network Slicing”, IEEE Communications Magazine, May 2017, 7 pages.;;United States Patent and Trademark Office, “Notice of Allowance”, issued in connection with U.S. Appl. No. 16/457,435, dated Feb. 3, 2021, (9 pages).;;United States Patent and Trademark Office, “Non-Final Office Action”, issued in connection with U.S. Appl. No. 16/457,435, dated Jul. 20, 2020, (20 pages).",ACTIVE
612,SI,T1,SI 1027362 T1,017-766-893-370-013,2005-12-31,2005,SI 9830783 T,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W;;EP 98956338 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/017-766-893-370-013,Granted Patent,no,0,0,1,40,0,,C07H17/00;;A61K31/00,,0,0,,,,EXPIRED
613,US,A1,US 2015/0356069 A1,135-055-767-927-818,2015-12-10,2015,US 201514830491 A,2015-08-19,US 201514830491 A;;CN 200810134072 A;;US 50726109 A,2008-07-24,VALIDATING AN XML DOCUMENT,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/135-055-767-927-818,Patent Application,yes,1,6,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/143;;G06F40/189,,1,0,,,“The Schematron Assertion Language 1.6” Published 10/01/2002 –pages 1-32,ACTIVE
614,US,A1,US 2020/0012716 A1,134-410-882-789-614,2020-01-09,2020,US 201916512825 A,2019-07-16,US 201916512825 A;;CN 200810134072 A;;US 201514830491 A;;US 50726109 A,2008-07-24,VALIDATING AN XML DOCUMENT,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/134-410-882-789-614,Patent Application,yes,0,1,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/143;;G06F40/189,,0,0,,,,ACTIVE
615,PT,E,PT 1027362 E,178-527-141-066-190,2005-08-31,2005,PT 98956338 T,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,DERIVADOS DE CETOLIDOS 2-HALOGENO-6-O-SUBSTITUIDOS,,ABBOTT LAB,OR YAT SUN;;CHU DANIEL T;;CLARK RICHARD F;;PLATTNER JACOB J;;PHAN LY TAM;;YAN CHEN,,https://lens.org/178-527-141-066-190,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
616,ES,T3,ES 2244094 T3,199-230-765-635-368,2005-12-01,2005,ES 98956338 T,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,DERIVADOS DE KETLIDO 2-HALO-6-0-SUSTITUIDOS.,"Un compuesto que tiene la fórmula: o una sal farmacéuticamente aceptable del mismo, donde Rp es hidrógeno o un grupo hidroxi protector; X es F, Cl o Br; y R1 se selecciona entre el grupo compuesto por (1) -CH2-CH=CH-Y, en la que Y se selecciona entre el grupo compuesto por (a) H, (b) fenilo, (c) quinolinilo, (d) naftiridinilo, (e) heteroarilo sustituido, donde el heteroarilo es piridinilo, quinolinilo o tiofenilo sustituido con carboxamida, alquilamino, dialquilamino, carboxaldehído, nitro, -CN, -CH(=N-OH), -CH(=N-NH2), -CH(=N-N=C(CH3)2), piridilo, tiofenilo o pirimidinilo o amino N-protegido, donde el grupo N-protector es t- butiloxicarbonilo; (f) quinoxalinilo, y (g) (aril)oilo, donde el arilo es fenilo; y (2) -CH2-C=C-Y, en la que Y es como se ha definido anteriormente.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/199-230-765-635-368,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
617,CA,A1,CA 2307788 A1,007-937-283-438-958,1999-05-06,1999,CA 2307788 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,"Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formula (I) or (II), compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation.",ABBOTT LAB,PLATTNER JACOB J;;CHU DANIEL T;;OR YAT SUN;;CHEN YAN;;CLARK RICHARD F;;PHAN LY TAM,,https://lens.org/007-937-283-438-958,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
618,AU,B2,AU 751448 B2,104-483-973-252-619,2002-08-15,2002,AU 1999/012881 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halo-6-O-substituted ketolide derivatives,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/104-483-973-252-619,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
619,SK,B6,SK 286397 B6,145-361-157-230-739,2008-09-05,2008,SK 6332000 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,"2-Halo-6-O-substituted ketolide derivatives, their use, method for their preparation and pharmaceutical composition containing the same","2-Halo-6-O-substituted ketolide derivatives of general formula (I) and a pharmaceutically acceptable salt thereof, having antibacterial activity, method for their preparation and their use for manufacturing a medicament for treating bacteria infections. Thereinafter there are disclosed pharmaceutical compositions containing a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/145-361-157-230-739,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,C07H17/00;;A61K31/00;;A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
620,CZ,A3,CZ 20001525 A3,153-292-728-363-177,2000-10-11,2000,CZ 20001525 A,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,2-Halogen-6-O-substituted ketolide derivatives,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/153-292-728-363-177,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
621,ES,T3,ES 2300490 T3,194-803-809-025-689,2008-06-16,2008,ES 02786829 T,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,INHIBIDORES DE FOSFOLIPASA A2 CITOSOLICA.,"Compuesto de fórmula: (Ver fórmula) en la que: R se selecciona de entre las fórmulas -(CH2)n-A, -(CH2)n-S-A o -(CH2)n-O-A, en las que A se selecciona de entre las fracciones: (Ver fórmula) en las que B y C se seleccionan independientemente de entre grupos fenilo, piridinilo, pirimidinilo, furilo, tienilo o pirrolilo, cada uno sustituido opcionalmente con 1 a 3, preferentemente de 1 a 2, sustituyentes seleccionados independientemente de entre H, halógeno, -CN, -CHO, -CF3, -OCF3, -OH, alquilo C1-C6, alcoxilo C1-C6, -NH2, -N(alquilo C1-C6)2, -NH(alquilo C1-C6), -N-C(O)-(alquilo C1-C6), -NO2, o con un anillo heteroaromático o heterocíclico de 5 ó 6 miembros que contiene 1 ó 2 heteroátomos seleccionados de O, N o S; o n es un número entero de 0 a 3; n1 es un número entero de 1 a 3; n2 es un número entero de 0 a 4; n3 es un número entero de 0 a 3; n4 es un número entero de 0 a 2; X1 se selecciona de entre un enlace químico, -S-, -O-, -S(O)-, -S(O)2-, -NH-, -NHC(O)-, -C=C-...",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH,,https://lens.org/194-803-809-025-689,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;A61K31/404;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
622,NO,L,NO 20002190 L,131-078-707-395-318,2000-06-29,2000,NO 20002190 A,2000-04-27,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halo-6-O-substituerte ketolidderivater,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/131-078-707-395-318,Abstract,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
623,US,A1,US 2022/0094620 A1,019-665-027-407-940,2022-03-24,2022,US 202117246243 A,2021-04-30,US 202117246243 A;;US 201916457435 A,2019-06-28,QUALITY-OF-SERVICE IN CELLULAR INFORMATION CENTRIC NETWORK,"Systems and techniques for quality-of-service (QoS) in cellular information centric network (ICN) are described herein. An example system includes processing circuitry, and a memory that includes instructions, the instructions, when executed by the processing circuitry, cause the processing circuitry to obtain QoS characteristics for an ICN packet, apply the QoS characteristics to the ICN packet, and transmit the ICN packet over the cellular ICN in accordance with the QoS characteristics.",INTEL CORP,ZHANG YI;;DING ZONGRUI;;ALAM S M IFTEKHARUL;;JHA SATISH CHANDRA;;ARROBO VIDAL GABRIEL;;CHEN KUILIN CLARK,INTEL CORPORATION (2019-07-11),https://lens.org/019-665-027-407-940,Patent Application,yes,5,0,4,4,0,H04L41/5009;;H04L43/028;;H04W24/08;;H04L43/0894;;H04L41/5009,H04W24/08,,2,0,,,"Hsu et al. Reflecting QoS Using SDAP Header Processing AS/NAS And Ensure The Re-mapping During Sequential Transmission Packet In A 5G Communication System. China Patent Document No. 109952773 A, translated by Clarivate Analytics. China, 28 June 2019. (Year: 2019);;Li et al. Method In A Wireless Communication System For Executing Reflects The Quality Of Service (QoS) And Device Thereof. China Patent Document No. 110235463 A, translated by Clarivate Analytics. China, 13 September 2019. (Year: 2019)",ACTIVE
624,WO,A3,WO 2010/129057 A3,112-990-443-669-683,2011-01-06,2011,US 2010/0001350 W,2010-05-07,US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC;;CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,,https://lens.org/112-990-443-669-683,Search Report,yes,2,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,1,1,026-872-796-351-596,pmc2681267;;19053822;;10.1021/ja806629e,"JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,, vol. 130, 12 March 2008 (2008-03-12), pages 17913 - 17927, XP002604988",PENDING
625,NZ,A,NZ 503822 A,011-421-869-452-885,2002-12-20,2002,NZ 50382298 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,"2-halo-6-O-substituted erythromycin derivatives, a process for their preparation and pharmaceuticals thereof, useful for treating bacterial infections","A compound selected from the group consisting of (I) and (II), and pharmaceutically acceptable salts and esters thereof, wherein: RP is hydrogen or a hydroxy protecting group; X is F, Cl, Br, or I; and R1 is selected from the group consisting of: (1) Cl-C6-alkyl optionally substituted with one or more substituents selected from the group consisting of a) Aryl, b) Substituted aryl, c) Heteroaryl, d) Substituted heteroaryl, e) -NR3R4 wherein R3 and R4 are independently selected from hydrogen and Cl-C3-alkyl, or R3 and R4 are taken together with the atom to which they are attached form a 3-7 membered ring containing a moiety selected from the group consisting of-O-, -NH-, -N (CI-C6-alkyl-)-, -N (aryl-Cl-C6-alkyl-)-, -N (substituted aryl-Cl-C6-alkyl-)-, -N (heteroaryl-Cl-C6-alkyl-)-, and-N (substituted heteroaryl Cl-C6-alkyl-)- ; (2) -CH2-CH=CH-Y, wherein Y is selected from the group consisting of a) H; b) Aryl; c) Substituted aryl; d) Heteroaryl; e) Substituted heteroaryl; f) -CH=CH2; g) -CH=CH-aryl; h) -CH=CH-substituted aryl; i) -CH=CH-heteroaryl; and j) -CH=CH-substituted heteroaryl; k) (aryl) oyl; l) (substituted aryl) oyl; m) (heteroaryl) oyl; and n) (substituted heteroaryl) oyl; and (3) -CH2-C-=C-Y, wherein Y is as defined previously, with the proviso that in compounds of formula (II) wherein R1 is selected from option (1) the C1-C6-alkyl group must be substituted.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/011-421-869-452-885,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
626,DE,A1,DE 102022110595 A1,019-877-836-873-84X,2023-02-09,2023,DE 102022110595 A,2022-04-30,US 202117396245 A,2021-08-06,"FLAMMHEMMENDE ZUSAMMENSETZUNGEN FÜR ENERGIESPEICHERVORRICHTUNGEN, VERFAHREN ZU DEREN HERSTELLUNG UND BATTERIEN, DIE DIESELBEN ENTHALTEN","Hierin ist ein Batteriemodul offenbart, das eine Vielzahl von Batteriezellen umfasst, die in einer Außenhülle eingeschlossen sind. Auf der Innenseite der Außenhülle ist eine flammhemmende Schicht angeordnet, die expandierbaren Graphit umfasst. Der expandierbare Graphit ist in der Lage, sich während eines thermischen Ereignisses, das zu einem Anstieg der Temperatur des Batteriemoduls führt, auszudehnen. Außerdem ist hierin ein Verfahren offenbart, das das Anordnen einer flammhemmenden Schicht in einem Batteriemodul umfasst, wobei das Batteriemodul eine Vielzahl von Batteriezellen umfasst, die in einer Außenhülle eingeschlossen sind. Auf der Innenseite der Außenhülle ist eine flammhemmende Schicht angeordnet, die expandierbaren Graphit umfasst. Der expandierbare Graphit ist in der Lage, sich während eines thermischen Ereignisses, das zu einem Anstieg der Temperatur des Batteriemoduls führt, auszudehnen.",GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;HAN TAEYOUNG;;CLARK DAVID R;;HAN SU JUNG;;CHEN KUO-HUEY;;CIBRIAN SALAZAR GUSTAVO,,https://lens.org/019-877-836-873-84X,Patent Application,no,0,0,3,3,0,C09K21/02;;H01M10/6554;;H01M50/204;;Y02E60/10;;H01M2200/00;;H01M50/367;;H01M50/375;;H01M50/213;;H01M50/231;;H01M50/222;;H01M50/233;;H01M50/143;;C09K21/02;;H01M10/6554;;H01M10/613;;H01M10/6551;;H01M50/204,H01M50/383;;C08K3/016;;C08K3/04;;C08K7/24;;H01M50/30,,0,0,,,,PENDING
627,TW,A,TW 201245116 A,044-523-230-748-823,2012-11-16,2012,TW 100128656 A,2011-08-11,US 201161483025 P;;US 201061424552 P;;US 37319010 P,2010-08-12,Tetracycline analogs,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONG-HONG;;PLAMONDON LOUIS;;SUN CUI-XIANG;;XIAO XIAO-YI,,https://lens.org/044-523-230-748-823,Patent of Addition,no,0,0,3,3,0,A01N43/90;;A01N43/36;;A01N43/40;;A01N43/60;;A01N43/80;;A01N43/84;;A61P31/04;;A61P31/06;;C07D205/04;;C07D207/09;;C07D207/12;;C07D207/20;;C07D209/52;;C07D211/26;;C07D211/38;;C07D213/73;;C07D223/04;;C07D231/12;;C07D233/64;;C07D241/04;;C07D261/20;;C07D265/30;;C07D413/04;;C07D471/08,C07C237/26;;C07D205/04;;C07D207/09;;C07D209/52;;C07D211/34;;C07D213/56;;C07D223/04;;C07D231/12;;C07D233/04;;C07D241/04,,0,0,,,,PENDING
628,US,A1,US 2019/0394109 A1,141-287-123-198-066,2019-12-26,2019,US 201916457435 A,2019-06-28,US 201916457435 A,2019-06-28,QUALITY-OF-SERVICE IN CELLULAR INFORMATION CENTRIC NETWORK,"Systems and techniques for quality-of-service (QoS) in cellular information centric network (ICN) are described herein. To this end, QoS characteristics may be obtained for an ICN packet. The QoS characteristics may then be applied to the ICN packet. The ICN packet may then be transmitted in accordance with the QoS characteristics.",INTEL CORP,ZHANG YI;;DING ZONGRUI;;ALAM S M IFTEKHARUL;;JHA SATISH CHANDRA;;ARROBO VIDAL GABRIEL;;CHEN KUILIN CLARK,INTEL CORPORATION (2019-07-11),https://lens.org/141-287-123-198-066,Patent Application,yes,12,1,4,4,0,H04L41/5009;;H04L43/028;;H04W24/08;;H04L43/0894;;H04L41/5009,H04L12/26;;H04W24/08,,0,0,,,,ACTIVE
629,WO,A8,WO 2010/129057 A8,173-980-832-443-868,2011-02-24,2011,US 2010/0001350 W,2010-05-07,US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC;;CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,,https://lens.org/173-980-832-443-868,Amended Application,yes,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,PENDING
630,US,B2,US 9146908 B2,015-478-960-366-833,2015-09-29,2015,US 50726109 A,2009-07-22,CN 200810134072 A,2008-07-24,Validating an XML document,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Validation is performed in a corresponding execution context for the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN;;IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2009-07-13),https://lens.org/015-478-960-366-833,Granted Patent,yes,12,3,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F17/00;;G06F17/30;;G06F19/00;;G06F40/143;;G06F40/189,,8,0,,,"Rick Jelliffe ""The Schematron Assertion Language 1.6"" Published Oct. 1, 2002-pp. 1-32.;;Leigh Dodds, Schematron: Validating XML Using XSLT, Website/page http://www.ldodds.com/papers/schematron-xsltuk.html, Printed from website on Oct. 6, 2008, pp. 1-21, Bath University, Published on the World Wide Web.;;Eric Armstrong, A Simple Collaboration System (Proposal), Website/page http://www.treelight.com/software/collaboration/SimpleSystem.html, Printed from website on Oct. 6, 2008, pp. 1-13, Treelight Software, Published on the World Wide Web.;;Author Unknown, Topologi Schema Documentation Tool, Website/page http://www.topologi.com, Printed from website on Oct. 6, 2008, pp. 1-3, Topologi Pty. Limited, NSW, Australia, Published on the World Wide Web.;;Author Unknown, Program (xml.php), Website/page http://www2007.org/program/xml.php, Printed from website on Oct. 6, 2008, pp. 1-191, World Wide Web Conference 2007, Canada, Published on the World Wide Web.;;Rick Jelliffe, The W3C XML Schema Specification in Context, Website/page http://www.xml.com/pub/a/2001/01/10/schemasincontext.html?page=5, Printed from website on Oct. 6, 2008, pp. 1-4, O'Reilly Media, Inc., Published on the World Wide Web.;;Eddie Robertsson, An Introduction to Schematron, Website/page http://www.xml.com/lpt/a/1318, Printed from website on Oct. 6, 2008, pp. 1-10, O'Reilly Media, Inc., Published on the World Wide Web.;;Chimezie Ogbuji, Validating XML with Schematron, Website/page http://www.xml.com/lpt/a/687, Printed from website on Oct. 6, 2008, pp. 1-6, O'Reilly Media, Inc., Published on the World Wide Web.",INACTIVE
631,NO,D0,NO 20002190 D0,022-694-293-840-596,2000-04-27,2000,NO 20002190 A,2000-04-27,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halo-6-O-substituerte ketolidderivater,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/022-694-293-840-596,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
632,SK,A3,SK 6332000 A3,040-292-709-704-549,2000-09-12,2000,SK 6332000 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/040-292-709-704-549,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
633,TR,T2,TR 200001142 T2,063-536-456-513-279,2000-09-21,2000,TR 200001142 T,1998-10-29,US 95988197 A;;US 15423998 A,1997-10-29,2-Halo-6-O ile yer değiştirmiş ketolit türevleri.,"(I) veya (II) formülüne haiz anti bakteriyel etkinligi olan yeni 2-halo-6-O-ile degistirmis ketolit türevleri ve farmasötik olarak kabul edilebilir tuzlari ve esterleri, farmasötik olarak kabul edilebilir bir tasiyici ile birlikte terapötik olarak etkili miktarda bulusun terkibini ihtiva eden bilesimler, bir memeliye bulusun terkibinden terapötik olarak etkili bir miktarin uygulanmasi suretiyle bakteriyel enfeksiyonlari tedavi etme yöntemi ve bulusun terkiplerinin hazirlanmasi için islemler temin edilmistir.",ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATINER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/063-536-456-513-279,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,PENDING
634,EP,A1,EP 1027362 A1,045-391-097-041-670,2000-08-16,2000,EP 98956338 A,1998-10-29,US 9822989 W;;US 95988197 A;;US 15423998 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,ABBOTT LABORATORIES (2008-06-25),https://lens.org/045-391-097-041-670,Patent Application,yes,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
635,BR,A,BR 9813319 A,082-615-352-480-171,2000-08-22,2000,BR 9813319 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,"Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto","""COMPOSTO, COMPOSIçãO FARMACêUTICA PARA TRATAMENTO DE INFECçõES BACTERIANAS, E, PROCESSOS PARA TRATAR INFECçõES BACTERIANAS E PARA PREPARAR UM COMPOSTO"" Novos derivados 2-halo-6-O-substituídos e sais e ésteres farmaceuticamente aceitáveis dos mesmos tendo atividade antibacteriana de fórmula (I) ou (II): composições compreendendo uma quantidade terapeuticamente eficaz de um composto da invenção em combinação com um veículo farmaceuticamente aceitável, um processo para tratar infecções bacterianas pela administração a um mamífero de uma composição farmacêutica contendo uma quantidade terapeuticamente eficaz de um composto da invenção, e processos para sua preparação.",ABBOTT LAB,LY TAM PHAN;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/082-615-352-480-171,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
636,WO,A2,WO 2010/129057 A2,191-817-915-471-269,2010-11-11,2010,US 2010/0001350 W,2010-05-07,US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC;;CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI,,https://lens.org/191-817-915-471-269,Patent Application,yes,34,14,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,A61K31/65,,8,6,117-748-510-581-240;;079-199-434-691-089;;022-734-116-865-665;;038-187-505-836-252;;064-924-913-807-40X;;066-075-860-745-370,3180079;;10.1002/ana.410440110;;9667591;;10.1146/annurev.cb.09.110193.002545;;8280471;;2823896;;10.1016/0304-419x(87)90006-0;;10.1016/s8756-3282(97)00221-4;;9437511;;10.1097/00002281-199605000-00013;;8796985,"VAN DER BOZERT ET AL., CANCER RES., vol. 48, 1988, pages 6686 - 6690;;LIEDTKE ET AL., ANN. NEUROL., vol. 44, 1998, pages 35 - 46;;CHANDLER ET AL., J. NEUROIMMUNOL., vol. 72, 1997, pages 155 - 71;;STETLER-STEVENSON ET AL., ANNU. REV. CELL BIOL., vol. 9, 1993, pages 541 - 73;;TRYGGVASON ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 907, 1987, pages 191 - 217;;LI ET AL., MOL. CARCILLOG., vol. 22, 1998, pages 84 - 89;;GREENWALD ET AL., BONE, vol. 22, 1998, pages 33 - 38;;RYAN ET AL., CURR. OP. RHEUMATOL., vol. 8, 1996, pages 238 - 247",PENDING
637,HK,A1,HK 1031383 A1,182-732-311-669-558,2001-06-15,2001,HK 01100816 A,2001-02-05,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-Halo-5-o-substituted ketolide derivatives,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CLARK RICHARD F;;CHEN YAN,,https://lens.org/182-732-311-669-558,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
638,US,A1,US 2023/0057172 A1,057-247-416-119-13X,2023-02-23,2023,US 202117396245 A,2021-08-06,US 202117396245 A,2021-08-06,"FLAME-RETARDANT COMPOSITIONS FOR ENERGY STORAGE DEVICES, METHODS OF MANUFACTURE THEREOF AND BATTERIES CONTAINING THE SAME",Disclosed herein is a battery module comprising a plurality of battery cells encased in an outer shell. The outer shell has disposed on an inner surface a flame retardant layer that comprises expandable graphite. The expandable graphite is operative to expand during an thermal event that results in an increase in battery module temperature. Disclosed herein too is a method comprising disposing in a battery module a flame retardant layer; where the battery module comprises a plurality of battery cells encased in an outer shell. The outer shell has disposed on an inner surface a flame retardant layer that comprises expandable graphite. The expandable graphite is operative to expand during an thermal event that results in an increase in battery module temperature.,GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;HAN TAEYOUNG;;CLARK DAVID R;;HAN SU JUNG;;CHEN KUO-HUEY;;CIBRIAN SALAZAR GUSTAVO,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2021-07-27),https://lens.org/057-247-416-119-13X,Patent Application,yes,2,2,3,3,0,C09K21/02;;H01M10/6554;;H01M50/204;;Y02E60/10;;H01M2200/00;;H01M50/367;;H01M50/375;;H01M50/213;;H01M50/231;;H01M50/222;;H01M50/233;;H01M50/143;;C09K21/02;;H01M10/6554;;H01M10/613;;H01M10/6551;;H01M50/204,H01M50/143;;C09K21/02;;H01M10/613;;H01M10/6551;;H01M10/6554;;H01M50/204,,0,0,,,,PENDING
639,EP,B1,EP 1027362 B1,084-242-929-603-273,2005-06-29,2005,EP 98956338 A,1998-10-29,US 9822989 W;;US 95988197 A;;US 15423998 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,ABBOTT LABORATORIES (2008-06-25),https://lens.org/084-242-929-603-273,Granted Patent,yes,2,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
640,AU,A,AU 1999/012881 A,082-862-052-100-489,1999-05-17,1999,AU 1999/012881 A,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halo-6-o-substituted ketolide derivatives,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/082-862-052-100-489,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
641,DK,T3,DK 1027362 T3,199-688-020-980-655,2005-10-31,2005,DK 98956338 T,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-halogen-6-O-substituerede ketolidderivater,,ABBOTT LAB,OR YAT SUN;;CHU DANIEL T;;PHAN LY TAM;;PLATTNER JACOB J;;CLARK RICHARD F;;CHEN YAN,,https://lens.org/199-688-020-980-655,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
642,KR,A,KR 20100011912 A,031-939-062-983-441,2010-02-03,2010,KR 20090065913 A,2009-07-20,CN 200810134072 A,2008-07-24,METHOD AND SYSTEM FOR VALIDATING XML DOCUMENT,PURPOSE: A method and a system for validating an XML document are provided to parse at least one XML document and express XML data of the document as at least one data object model. CONSTITUTION: XML data of an XML document is expressed as one or more data object models(S10). One or more rule documents are parsed to generate a rule object model(S20). Partial data objects are extracted from the data object model. Partial rule objects are extracted from the rule object model(S25). The extracted data objects and rule objects are verified(S30).,IBM,WANG XI NING;;ZHOU YU CHEN;;LIU XIN PENG;;XUE LIANG;;CLARK DUNCAN G;;BALDWIN TIMOTHY JOHN,,https://lens.org/031-939-062-983-441,Patent Application,no,0,0,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F40/143;;G06F40/189,,0,0,,,,ACTIVE
643,ZA,B,ZA 989845 B,013-162-048-229-802,1999-04-29,1999,ZA 989845 A,1998-10-28,US 95988197 A,1997-10-29,2-halo-6-O-substituted ketolide derivatives,,ABBOTT LAB,PHAN LY T;;OR YAT S;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/013-162-048-229-802,Granted Patent,no,0,0,2,40,0,Y02P20/55,A61K/;;A61K31/70;;C07D/;;C07H17/08,,0,0,,,,EXPIRED
644,EP,A1,EP 4021052 A1,188-820-358-172-790,2022-06-29,2022,EP 21209076 A,2021-11-18,US 202017130631 A,2020-12-22,PATHLOSS DROP TRUSTED AGENT MISBEHAVIOR DETECTION,"V2X trusted agents provide technical solutions for technical problems facing falsely reported locations of connected vehicles within V2X systems. These trusted agents (e.g., trusted members) may be used to detect an abrupt physical attenuation of a wireless signal and determine whether the attenuation was caused by signal occlusion caused by the presence of an untrusted vehicle or other untrusted object. When the untrusted vehicle is sending a message received by trusted agents, these temporary occlusions allow trusted members to collaboratively estimate the positions of untrusted vehicles in the shared network, and to detect misbehavior by associating the untrusted vehicle with reported positions. Trusted agents may also be used to pinpoint specific mobile targets. Information about one or more untrusted vehicles may be aggregated and distributed as a service.
",INTEL CORP,GEISSLER FLORIAN;;ALAM S M IFTEKHARUL;;FOUAD YASER;;PAULITSCH MICHAEL;;ROSALES RAFAEL;;SIVANESAN KATHIRAVETPILLAI;;CHEN KUILIN CLARK,,https://lens.org/188-820-358-172-790,Patent Application,yes,4,0,3,3,0,H04W4/029;;H04W4/40;;H04W4/44;;H04W12/06;;H04W12/104;;H04W12/126;;H04B17/318;;H04W12/63;;H04W12/66;;H04W12/122;;H04W4/40;;H04W12/104;;H04W12/104;;H04W4/40;;H04W12/009,H04W12/122;;H04W4/40;;H04W12/104;;H04W12/60;;H04W12/63,,1,0,,,"INTEL CORPORATION: ""Channel Models for eV2X Evaluation Methodology"", vol. RAN WG1, no. Busan, Korea; 20180521 - 20180525, 20 May 2018 (2018-05-20), XP051441741, Retrieved from the Internet <URL:http://www.3gpp.org/ftp/Meetings%5F3GPP%5FSYNC/RAN1/Docs/> [retrieved on 20180520]",PENDING
645,AT,T1,AT E298760 T1,088-687-045-328-293,2005-07-15,2005,AT 98956338 T,1998-10-29,US 95988197 A;;US 15423998 A;;US 9822989 W,1997-10-29,2-HALO-6-0-SUBSTITUIERTE KETOLIDE DERIVATE,,ABBOTT LAB,PHAN LY TAM;;OR YAT SUN;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/088-687-045-328-293,Granted Patent,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,DISCONTINUED
646,BG,A,BG 104434 A,087-294-411-485-106,2001-01-31,2001,BG 10443400 A,2000-05-15,US 95988197 A;;US 15423998 A,1997-10-29,2-HALO-6-O-SUBSTITUTED KETOLIDE DERIVATIVES,"Novel 2-halo-6-O-substituted ketolide derivatives and pharmaceutically acceptable salts and esters thereof having antibacterial activity having formulae compositions comprising of a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by administering to a mammal a pharmaceutical composition containing a therapeutically-effective amount of a compound of the invention, and processes for their preparation. 14 claims",ABBOTT LAB,PHAN LY T;;OR YAT S;;CHU DANIEL T;;PLATTNER JACOB J;;CHEN YAN;;CLARK RICHARD F,,https://lens.org/087-294-411-485-106,Patent Application,no,0,0,37,40,0,C07H17/08;;Y02P20/55;;A61P31/04;;C07H17/08;;A61K31/7048,A61K31/7042;;A61K31/7048;;A61P31/04;;C07H17/08,,0,0,,,,EXPIRED
647,US,B2,US 10372809 B2,173-909-832-359-736,2019-08-06,2019,US 201514830491 A,2015-08-19,US 201514830491 A;;CN 200810134072 A;;US 50726109 A,2008-07-24,Validating an XML document,"At least one XML document to be validated is parsed, and XML data in the at least one XML document is represented as data objects in at least one data object model in a memory. At least one rule document is parsed and a rule object model that includes rule objects is created in the memory. At least part of the data objects are extracted from the at least one data object model and at least part of rule objects are extracted from the rule object model. Partial validation is performed in a corresponding execution context that validates the extracted at least part of the data objects based upon the extracted at least part of the rule objects.",IBM,BALDWIN TIMOTHY J;;CLARK DUNCAN G;;LIU XIN PENG;;WANG XI NING;;XUE LIANG;;ZHOU YU CHEN,INTERNATIONAL BUSINESS MACHINES CORPORATION (2015-08-12),https://lens.org/173-909-832-359-736,Granted Patent,yes,14,0,10,10,0,G06F16/258;;G06F16/9577;;G16C20/70;;G06Q10/10;;G06Q10/06;;G06F40/226;;G06F40/143;;G06F16/258;;G06F16/9577;;G16C20/70;;G06F16/86;;G06Q10/10;;G06Q10/06;;G06F40/18;;G06F40/226;;G06F40/55;;G06F40/154;;G06F40/166;;G06F40/221;;G06F40/143,G06F16/25;;G06F16/84;;G06F16/957;;G06F17/00;;G06F40/143;;G06F40/189;;G06Q10/06;;G06Q10/10;;G16C20/70,,15,0,,,"“The Schematron Assertion Language 1.6” Published Oct. 1, 2002—pp. 1-32.;;Leigh Dodds, Schematron: Validating XML Using XSLT, Website/page, Printed from website on Oct. 6, 2008, pp. 1-21, Bath University, Published at: http://www.ldodds.com/papers/schematron_xsltuk.html.;;Eric Armstrong, A Simple Collaboration System (Proposal), Website/page, Printed from website on Oct. 6, 2008, pp. 1-13, Treelight Software, Published at: .ttp://www.treelight.com/software/collaboration/SimpleSystem.html.;;Author Unknown, Topologi Schema Documentation Tool, Website/page, Printed from website on Oct. 6, 2008, pp. 1-3, Topologi Pty. Limited, NSW, Australia, Published at. http://www.topologi.com.;;Author Unknown, Program (xml.php), Website/page, Printed from website on Oct. 6, 2008, pp. 1-191, World Wide Web Conference 2007, Canada, Published at: http://www2007.org/program/xml.php.;;Rick Jelliffe, The W3C XML Schema Specification in Context, Website/page, Printed from website on Oct. 6, 2008, pp. 1-4, O'Reilly Media, Inc., Published at: http://www.xml.com/pub/a/2001/01/10/schemasincontext.html?page=5.;;Eddie Robertsson, An Introduction to Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-10, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/1318.;;Chimezie Ogbuji, Validating XML with Schematron, Website/page, Printed from website on Oct. 6, 2008, pp. 1-6, O'Reilly Media, Inc., Published at: http://www.xml.com/lpt/a/687.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Apr. 10, 2012, pp. 1-29, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Dec. 14, 2012, pp. 1-21, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Aug. 22, 2013, pp. 1-23, Alexandria, VA, USA.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jan. 14, 2014, pp. 1-20, Alexandria, VA, USA.;;Rick Jelliffe, The Schematron Assertion Language 1.6, The Schematron software project, Oct. 1, 2002, pp. 1-32, Academia Sinica Computing Centre, Published at: http://xml.ascc.net/resource/schematron/Schematron2000.html.;;United States Patent and Trademark Office, Office Action for U.S. Appl. No. 12/507,261, dated Jul. 31, 2014, pp. 1-31, Alexandria, VA, USA.;;United States Patent and Trademark Office, Notice of Allowance for U.S. Appl. No. 12/507,261, dated May 20, 2015, pp. 1-18, Alexandria, VA, USA.",ACTIVE
648,US,A1,US 2014/0019340 A1,070-805-668-604-89X,2014-01-16,2014,US 201313797390 A,2013-03-12,US 201313797390 A;;US 201261672228 P,2012-07-16,Storing and Forwarding Payment Transactions,"Method, systems, and apparatus for a method of processing a payment transaction using a mobile device of a merchant. In one aspect, determining the mobile device does not have a connection to an external network; receiving data indicating a payment transaction between a customer and the merchant; determining whether the payment transaction should be stored, where the determining is based on a risk heuristic model that considers one or more of the following: a number of already stored transactions, a value of the payment transaction, a total value, where the total value is a sum of the value of the payment transaction and values of one or more already stored transactions, and risk factors associated with the customer; and based at least on the determination, storing the payment transaction on the mobile device for future processing.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/070-805-668-604-89X,Patent Application,yes,46,16,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32,705/39,6,0,,,"""MasterCard and VeriFone Bring 'Tap & Go' Payments to Taxis"", Wireless News, Nov 15, 2006, ps 1-2.;;Anonymous, ""Suncorp and live TaxiEpay to provider Mobile Payment Terminals for Hypercom"", Wireless News, Jacksonville, June 20, 2010, pgs. 1-2.;;Ferguson, Boucher, Renee, ""Passenger Hacks NYC computer system; The problem is more significant than GPS objections, according to the sofware engineer who hacked the system"", eWeek, Dec 28, 2007, pgs 1-2.;;Anonymous, ""Suncorp and live TaxiEpay to provider Mobile Payment Terminals for Hypercom"", Wireless News, Jacksonville, June 20, 2010, pgs. 1-2.;;Ferguson, Boucher, Renee, ""Passenger Hacks NYC computer system; The problem is more significant than GPS objections, according to the sofware engineer who hacked the system"", eWeek, Dec 28, 2007, pgs 1-2.;;""MasterCard and VeriFone Bring 'Tap & Go' Payments to Taxis"", Wireless News, Nov 15, 2006, ps 1-2.",ACTIVE
649,US,A1,US 2015/0043770 A1,040-547-119-007-198,2015-02-12,2015,US 201313963117 A,2013-08-09,US 201313963117 A,2013-08-09,SPECKLE SENSING FOR MOTION TRACKING,"Speckle sensing for motion tracking is described, for example, to track a user's finger or head in an environment to control a graphical user interface, to track a hand-held device, to track digits of a hand for gesture-based control, and to track 3D motion of other objects or parts of objects in a real-world environment. In various examples a stream of images of a speckle pattern from at least one coherent light source illuminating the object, or which is generated by a light source at the object to be tracked, is used to compute an estimate of 3D position of the object. In various examples the estimate is transformed using information about position and/or orientation of the object from another source. In various examples the other source is a time of flight system, a structured light system, a stereo system, a sensor at the object, or other sources.",CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM,CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-08-04),https://lens.org/040-547-119-007-198,Patent Application,yes,5,39,4,4,0,G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647;;G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647,G06T7/00;;G06K9/00,382/103,0,0,,,,ACTIVE
650,AT,T1,AT E489364 T1,084-016-323-462-693,2010-12-15,2010,AT 06771540 T,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,HEMMER DER ZYTOSOLEN PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN;;LEE KATHERINE;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/084-016-323-462-693,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,,,0,0,,,,ACTIVE
651,TW,A,TW 201508561 A,123-361-562-728-188,2015-03-01,2015,TW 103124938 A,2014-07-21,US 201313963117 A,2013-08-09,Speckle sensing for motion tracking,"Speckle sensing for motion tracking is described, for example, to track a user's finger or head in an environment to control a graphical user interface, to track a hand-held device, to track digits of a hand for gesture-based control, and to track 3D motion of other objects or parts of objects in a real-world environment. In various examples a stream of images of a speckle pattern from at least one coherent light source illuminating the object, or which is generated by a light source at the object to be tracked, is used to compute an estimate of 3D position of the object. In various examples the estimate is transformed using information about position and/or orientation of the object from another source. In various examples the other source is a time of flight system, a structured light system, a stereo system, a sensor at the object, or other sources.",MICROSOFT CORP,CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM,,https://lens.org/123-361-562-728-188,Patent of Addition,no,0,2,4,4,0,G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647;;G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647,G06F3/0346,,0,0,,,,PENDING
652,US,B2,US 6960794 B2,040-022-070-317-571,2005-11-01,2005,US 33464902 A,2002-12-31,US 33464902 A,2002-12-31,Formation of thin channels for TFT devices to ensure low variability of threshold voltages,"A thin film transistor with a channel less than 100 angstroms thick, preferably less than 80 angstroms thick, preferably less than 60 angstroms thick. The very thin channel reduces variability of threshold voltage from one TFT to the next. This is particularly advantageous for TFT memory arrays. It is possible that an extremely thin channel restricts the size of grains, forcing many small grains to be formed.",MATRIX SEMICONDUCTOR INC,WALKER ANDREW J;;HERNER S BRAD;;MAHAJANI MAITREYEE;;CHEN EN-HSING;;SCHEUERLEIN ROY E;;NALLAMOTHU SUCHETA;;CLARK MARK,MATRIX SEMICONDUCTOR (2003-04-18);;SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2005-10-20),https://lens.org/040-022-070-317-571,Granted Patent,yes,8,8,2,2,0,H01L27/12;;H01L29/78675;;H01L29/78696;;H01L29/78696;;H01L29/78675;;H01L27/12,H01L27/12;;H01L29/786,257/213;;257/311;;257/411;;257/640;;257/649,2,1,029-894-914-121-473,10.1143/jjap.35.923,"Hodges et al., Analysis and Design of Digital Integrated circuits, 2 ed, p. 30-34.;;Miyasaka, Mitsutoshi.,et al. , ""Effects of Semiconductor Thickness on Poly-Crystalline Silicon Thin Film Transistors"", Jpn. J. Appl. Phys. vol. 35 (1996) Part 1, No. 2B, (Feb. 1996),923-929.",EXPIRED
653,EP,A1,EP 1374206 A1,089-581-831-710-861,2004-01-02,2004,EP 02748401 A,2002-03-06,US 0206781 W;;US 80010401 A,2001-03-06,DISTRIBUTIVE PROCESSING SIMULATION METHOD AND SYSTEM FOR TRAINING HEALTHCARE TEAMS,,MEDICAL SIMULATION CORP,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,,https://lens.org/089-581-831-710-861,Patent Application,yes,0,0,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B23/28;;G09B7/04,,0,0,,,,DISCONTINUED
654,WO,A1,WO 2017/192312 A1,117-405-534-327-664,2017-11-09,2017,US 2017/0029437 W,2017-04-25,US 201662332095 P,2016-05-05,PARASITIC CHARGE CONTROL FOR III-N MATERIALS ON SILICON,"A structure can include a substrate layer with an interface and a carrier concentration at the interface, a rare earth oxide barrier layer grown over the substrate layer, and a Group III layer grown over the rare earth oxide barrier layer. The carrier concentration at the interface can be different by more than an order of magnitude than the bulk carrier concentration. The rare earth oxide layer can include a rare earth oxide material and can prevent diffusion of Group III species into the substrate layer. The Group III layer can include a Group III element.",IQE PLC;;CLARK ANDREW;;DARGIS RYTIS;;MARCHAND HUGUES;;LABOUTIN OLEG;;KAO CHEN-KAI;;LO CHIEN-FONG;;LEBBY MICHAEL;;PELZEL RODNEY,CLARK ANDREW;;DARGIS RYTIS;;MARCHAND HUGUES;;LABOUTIN OLEG;;KAO CHEN-KAI;;LO CHIEN-FONG;;LEBBY MICHAEL;;PELZEL RODNEY,,https://lens.org/117-405-534-327-664,Patent Application,yes,3,0,2,2,0,H01L21/02381;;H01L21/02483;;H01L21/0254,H01L21/20,,0,0,,,,PENDING
655,WO,A1,WO 2015/021084 A1,153-674-039-882-629,2015-02-12,2015,US 2014/0049841 W,2014-08-06,US 201313963117 A,2013-08-09,SPECKLE SENSING FOR MOTION TRACKING,"Speckle sensing for motion tracking is described, for example, to track a user's finger or head in an environment to control a graphical user interface, to track a hand-held device, to track digits of a hand for gesture-based control, and to track 3D motion of other objects or parts of objects in a real-world environment. In various examples a stream of images of a speckle pattern from at least one coherent light source illuminating the object, or which is generated by a light source at the object to be tracked, is used to compute an estimate of 3D position of the object. In various examples the estimate is transformed using information about position and/or orientation of the object from another source. In various examples the other source is a time of flight system, a structured light system, a stereo system, a sensor at the object, or other sources.",MICROSOFT CORP,CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM,,https://lens.org/153-674-039-882-629,Patent Application,yes,3,1,4,4,0,G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647;;G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647,G06F3/03;;G06F3/01;;G06F3/0346,,0,0,,,,PENDING
656,CA,C,CA 2879290 C,183-266-501-201-682,2018-08-21,2018,CA 2879290 A,2013-07-12,US 201261672228 P;;US 201313797390 A;;US 2013/0050345 W,2012-07-16,STORING AND FORWARDING PAYMENT TRANSACTIONS,"Method, systems, and apparatus for a method of processing a payment transaction using a mobile device of a merchant. In one aspect, determining the mobile device does not have a connection to an external network; receiving data indicating a payment transaction between a customer and the merchant; determining whether the payment transaction should be stored, where the determining is based on a risk heuristic model that considers one or more of the following: a number of already stored transactions, a value of the payment transaction, a total value, where the total value is a sum of the value of the payment transaction and values of one or more already stored transactions, and risk factors associated with the customer; and based at least on the determination, storing the payment transaction on the mobile device for future processing.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,,https://lens.org/183-266-501-201-682,Granted Patent,no,0,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/38,,0,0,,,,ACTIVE
657,US,A1,US 2021/0112417 A1,186-891-663-054-892,2021-04-15,2021,US 202017130631 A,2020-12-22,US 202017130631 A,2020-12-22,PATHLOSS DROP TRUSTED AGENT MISBEHAVIOR DETECTION,"V2X trusted agents provide technical solutions for technical problems facing falsely reported locations of connected vehicles within V2X systems. These trusted agents (e.g., trusted members) may be used to detect an abrupt physical attenuation of a wireless signal and determine whether the attenuation was caused by signal occlusion caused by the presence of an untrusted vehicle or other untrusted object. When the untrusted vehicle is sending a message received by trusted agents, these temporary occlusions allow trusted members to collaboratively estimate the positions of untrusted vehicles in the shared network, and to detect misbehavior by associating the untrusted vehicle with reported positions. Trusted agents may also be used to pinpoint specific mobile targets. Information about one or more untrusted vehicles may be aggregated and distributed as a service.",GEISSLER FLORIAN;;ALAM S M IFTEKHARUL;;FOUAD YASER M;;PAULITSCH MICHAEL;;ROSALES RAFAEL;;SIVANESAN KATHIRAVETPILLAI;;CHEN KUILIN CLARK,GEISSLER FLORIAN;;ALAM S M IFTEKHARUL;;FOUAD YASER M;;PAULITSCH MICHAEL;;ROSALES RAFAEL;;SIVANESAN KATHIRAVETPILLAI;;CHEN KUILIN CLARK,INTEL CORPORATION (2021-01-17),https://lens.org/186-891-663-054-892,Patent Application,yes,0,5,3,3,0,H04W4/029;;H04W4/40;;H04W4/44;;H04W12/06;;H04W12/104;;H04W12/126;;H04B17/318;;H04W12/63;;H04W12/66;;H04W12/122;;H04W4/40;;H04W12/104;;H04W12/104;;H04W4/40;;H04W12/009,H04W12/104;;H04W4/40;;H04W12/00,,0,0,,,,PENDING
658,CN,A,CN 112840063 A,107-725-038-812-96X,2021-05-25,2021,CN 201980066362 A,2019-09-24,US 201862743582 P;;US 2019/0052697 W,2018-10-10,METHODS FOR DEPOSITING TUNGSTEN OR MOLYBDENUM FILMS,"Described are vapor deposition methods for depositing metal films or layers onto a substrate, wherein the metal is molybdenum or tungsten; the methods involve organometallic precursor compounds that contain the metal and one or more carbon-containing ligands, and include depositing a metal layer formed from the metal of the precursor, onto a substrate, followed by introducing oxidizer to the formed metal layer.",ENTEGRIS INC,WRIGHT ROBERT JR;;BAUM THOMAS H;;HENDRIX BRYAN CLARK;;NGUYEN SHAWN D;;WANG HAN;;CHEN PHILIP S H,,https://lens.org/107-725-038-812-96X,Patent Application,no,17,1,13,13,0,H01L21/28562;;C23C16/18;;C23C16/45534;;C23C16/56;;H01L21/28568;;H01L21/28556;;C23C16/18;;C23C16/56;;C23C16/45523;;C23C16/45553;;H01L21/28556;;C23C16/45534;;H01L21/0228;;C23C16/56;;C23C16/18,C23C16/18;;C23C16/455;;C23C16/56;;H01L21/285,,0,0,,,,PENDING
659,CN,A,CN 114666737 A,171-087-887-268-441,2022-06-24,2022,CN 202111387214 A,2021-11-22,US 202017130631 A,2020-12-22,Path loss reduction trusted proxy improper behavior detection,"The invention relates to path loss reduction trusted proxy improper behavior detection. The V2X trusted agent provides a technical solution for technical problems confronted by misreporting the location of the connected vehicle within the V2X system. These trusted agents (e.g., trusted members) may be used to detect sudden physical attenuation of wireless signals and determine whether the attenuation is caused by signal occlusion caused by the presence of untrusted vehicles or other untrusted objects. When an untrusted vehicle is sending a message received by a trusted agent, these temporary occlusions allow trusted members to cooperatively estimate the location of the untrusted vehicle in the shared network and detect improper behavior by associating the untrusted vehicle with the reported location. Trusted agents can also be used to accurately locate specific moving targets. Information related to one or more untrusted vehicles may be aggregated and distributed as a service.",INTEL COMPANY,GEISSLER FLORIAN;;ALAM S M IFTEKHARUL;;FORDE YOHANN M;;PAULITSCH MICHAEL;;ROSALES ROGELIO;;SIVANESAN KATHIRAVETPILLAI;;CHEN KUILIN CLARK,,https://lens.org/171-087-887-268-441,Patent Application,no,0,0,3,3,0,H04W4/029;;H04W4/40;;H04W4/44;;H04W12/06;;H04W12/104;;H04W12/126;;H04B17/318;;H04W12/63;;H04W12/66;;H04W12/122;;H04W4/40;;H04W12/104;;H04W12/104;;H04W4/40;;H04W12/009,H04W4/029;;H04B17/318;;H04W4/40;;H04W4/44;;H04W12/06;;H04W12/104;;H04W12/126,,0,0,,,,PENDING
660,US,B2,US 11669826 B2,166-292-008-355-840,2023-06-06,2023,US 202217900690 A,2022-08-31,US 202217900690 A;;US 201916681217 A;;US 201313797390 A;;US 201261672228 P,2012-07-16,Transaction processing by multiple devices,"Techniques associated with a customer-facing device and a merchant-facing device are described herein. In an example, a system can include a customer-facing device configured with a customer application that is executable on an operating system of the customer-facing device to (i) display information to a customer and (ii) receive input from the customer, wherein the customer-facing device includes a payment reader to read payment data from a payment instrument in association with a payment transaction between the customer and a merchant, and a merchant-facing device configured with a merchant application that is executable on an operating system of the merchant-facing device to (i) display information to the merchant and (ii) receive input from the merchant. In at least one example, the customer-facing device and the merchant-facing device can communicate to process, at least in part, the payment transaction associated with the payment instrument via a remote payment service system.",BLOCK INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE HUEY;;CLARK CHRISTOPHER;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/166-292-008-355-840,Granted Patent,yes,299,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/12;;G06Q20/40,,117,5,115-264-857-004-051;;075-820-403-616-614;;075-820-403-616-614;;030-415-006-904-231;;137-892-911-964-412,10.1109/wmcs.2005.16;;10.1109/aptc.2008.24;;10.1109/aptc.2008.24;;10.17487/rfc5280;;10.1109/mobiq.2004.1331708,"J. Gao, K. Edunuru, J. Cai and S. P. D. Shim, “P2P-Paid: A Peer-to-Peer Wireless Payment System,” Second IEEE International Workshop on Mobile Commerce and Services, 2005, pp. 102-111 (Year: 2005).;;Q. Li, X. Zhang, J.-P. Seifert and H. Zhong, “Secure Mobile Payment via Trusted Computing,” 2008 Third Asia-Pacific Trusted Infrastructure Technologies Conference, 2008, pp. 98-112. (Year: 2008).;;Non-Final Office Action dated Oct. 31, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non-Final Office Action dated Sep. 10, 2018, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non-Final Office dated Mar. 24, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Notice of Acceptance for Australian Patent Application No. 2014225973, dated Mar. 15, 2017.;;Notice of Allowance for Canadian Patent Application No. 2,879,290, dated Jan. 9, 2018.;;Notice of Allowance for Canadian Patent Application No. 2,892,511, dated May 26, 2017.;;Notice of Allowance for Canadian Patent Application No. 2,903,983, dated Oct. 24, 2018.;;Notice of Allowance dated Apr. 6, 2018, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Notice of Allowance dated Apr. 9, 2018, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Notice of Allowance dated Apr. 13, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Notice of Allowance dated Apr. 17, 2017, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Notice of Allowance dated Apr. 24, 2018, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Notice of Allowance dated Jul. 3, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Notice of Allowance dated Mar. 13, 2019, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Notice of Allowance dated May 31, 2022, for U.S. Appl. No. 16/681,217, of Ruder, E., et al., filed Nov. 12, 2019.;;Notice of Allowance dated Nov. 6, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Notice of Allowance dated Oct. 13, 2017, for U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed May 3, 2013.;;Notice of Allowance dated Oct. 22, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance dated Sep. 15, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Notification concerning the date of oral proceedings for European Patent Application No. 13819366.9, mailed Mar. 5, 2018.;;Office Action for Canadian Patent Application No. 2,903,983, dated Nov. 4, 2016.;;Summons to attend oral proceedings for European Patent Application No. 13859656.4, dated Nov. 2, 2017.;;Third Party Observation, for PCT Application No. PCT/US2013/050345 on May 30, 2014.;;Final Office Action dated Sep. 29, 2022, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Non-Final Office Action dated Sep. 27, 2022, for U.S. Appl. No. 16/936,381, of Quigley, O. S. C., et al., filed Jul. 22, 2020.;;Advisory Action dated Aug. 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Advisory Action dated Dec. 27, 2021, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Advisory Action dated Jan. 31, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Advisory Action dated May 24, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Advisory Action dated Nov. 30, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Advisory Action dated Sep. 13, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Advisory Action dated Sep. 21, 2020, for U.S. Appl. No. 16/681,217, of Ruder, E., et al., filed Nov. 12, 2019.;;Advisory Action dated Sep. 30, 2020, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Examination Report for European Patent Application No. 13819366.9, dated Nov. 2, 2016.;;Examination Report for European Patent Application No. 14760487.0, dated Jun. 28, 2017.;;Examiner's Requisition for Canadian Patent Application No. 2,879,290, dated Jan. 11, 2017.;;Examiner's Requisition for Canadian Patent Application No. 2,903,983, dated Nov. 6, 2017.;;Extended European Search Report for European Patent Application No. 13819366.9 dated Feb. 19, 2016.;;Extended European Search Report for European Patent Application No. 13859656.4, dated Sep. 4, 2015.;;Extended European Search Report for European Patent Application No. 14760487.0 dated Jul. 7, 2016.;;Final Office Action dated Dec. 29, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Final Office Action dated Feb. 1, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Final Office Action dated Feb. 20, 2020, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Final Office Action dated Jul. 9, 2020, for U.S. Appl. No. 16/681,217, of Ruder, E., et al., filed Nov. 12, 2019.;;Final Office Action dated Jul. 14, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Final Office Action dated Jul. 30, 2020, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Final Office Action dated Jun. 17, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Final Office Action dated Mar. 21, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Final Office Action dated May 9, 2017, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Final Office Action dated May 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Final Office Action dated Oct. 31, 2016, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Final Office Action dated Sep. 9, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Final Office Action dated Sep. 15, 2021, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/050345, dated Oct. 4, 2013.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/073302, dated Apr. 18, 2014.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2014/020389, dated Jun. 17, 2014.;;Non Final Office Action dated Apr. 10, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Non Final Office Action dated Aug. 7, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non Final Office Action dated Dec. 31, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Non Final Office Action dated Feb. 4, 2020, for U.S. Appl. No. 16/681,217, of Ruder, E., et al., filed Nov. 12, 2019.;;Non Final Office Action dated Feb. 14, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Non Final Office Action dated Mar. 3, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Non-Final Office Action dated Aug. 7, 2018, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non-Final Office Action dated Feb. 16, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non-Final Office Action dated Jan. 21, 2022, for U.S. Appl. No. 16/681,217, of Ruder, E., et al., filed Nov. 12, 2019.;;Non-Final Office Action dated Jul. 25, 2018, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Non-Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated May 25, 2022, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Non-Final Office Action dated May 7, 2021, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Non-Final Office Action dated Nov. 27, 2020, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Non-Final Office Action dated Oct. 4, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;“Advancing Payment Security: MasterCard Contactless Security Overview,” www.mastercard.com, retrieved from Internet URL: https://www.mastercard.com/contactless/doc/MasterCardContactless_SecurityFactSheet_2015.pdf, on Jun. 12, 2017, pp. 1-4.;;“Cryptography—PCI Encryption Key Management—Information Security Stack Exchange,” published Jan. 1, 2011, XP055415553, Retrieved from the Internet URL: https://security.stackexchange.com/questions/1412/pci-encryptionkey-management. Retrieved on Oct. 13, 2017, pp. 1-3.;;“MasterCard and VeriFone Bring ‘Tap & Go’ Payments to Taxis,” Wireless News, dated Nov. 15, 2006, Retrieved from the Internet URL: http://search.proquest.com/printviewfile?accountid=14753, on Apr. 24, 2017, pp. 1-2.;;“Mobile payment,” Wikipedia, dated Jul. 9, 2012. Retrieved from the Internet URL: https://en.wikipedia.org/w/index.php?title=Mobile_payment&oldid=501410747,on Feb. 27, 2018, pp. 1-8.;;“Offline DB Support for POS,” Stack Overflow, dated Jan. 24, 2013, Retrieved from the Internet URL: <http://stackoverflow.com/questions/14495935/offline-dbsupport-for-pos>, on Jun. 4, 2014, p. 1-2.;;“Payment Card Industry (PCI) Hardware Security Module (HSM),” Security Requirements Version 1.0, XP055168869, pp. 1-26 (Apr. 2009).;;“PCI DSS compliant Key Management,” published Jul. 31, 2011, XP055415555, Retrieved from the Internet URL: http://www.src-gmbh.de/pcinews/download/PCIWhitepaper-2011-07.pdf, on Oct. 13, 2017, pp. 1-3.;;“Suncorp and live TaxiEpay to provider Mobile Payment Terminals for Hypercom,” Anonymous Wireless News, dated Jun. 20, 2010, Retrieved from the Internet URL: http://search.pro quest. com/printviewfile?accountid=14753, on Apr. 21, 2017, pp. 1-2.;;“What is ‘Offline Mode’ and How Does It Work?,” Vend, dated Dec. 20, 2011, Retrieved from the Internet URL: <http://support.vendhq.com/hc/enus/articles/201379940-What -is-Offline-Mode-and-how-does-it-work>, on Jun. 4, 2014, pp. 1-3.;;“What is the Purpose of Retail Offline Sync Service and How Does It Work?,” Microsoft Dynamics, dated Apr. 12, 2012, Retrieved from the Internet URL: <http://community.dynamics.eom/ax/f/33/p/77 406/149851.aspx>, on Jun. 4, 2014, p. 1-3.;;Zhang et al., “Secure Mobile Payment via Trusted Computing,” 2008 Third Asia-Pacific Trusted Infrastructure Technologies Conference, (Year: 2008) pp. 98-112.;;Conkling, C., “General Credit Card (CC) Approval/Payment Process,” Figure 2, dated Jan. 17, 2011, Retrieved from the Internet: URL<http:/ /craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html>, on Jun. 6, 2014, p. 1-1.;;Conkling, C., “Mobile Trends Insight: NFC and the Mobile Payment Initiative—4,” dated Jan. 17, 2011, Retrieved from the Internet URL: http:/ /craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html, on Jun. 6, 2014, pp. 1-15.;;Cooper, D., et al., “Internet X.509 Public Key Infrastructure Certificate and Certificate Revocation List (CRL) Profile,” Standards Track, pp. 1-151 (May 2008).;;Denniswi, “How Can I change the Offline Mode Password in Microsoft Dynamice POS 2009?,” Microsoft Dynamics, dated Nov. 8, 2011, Retrieved from the Internet URL: <https://community.dynamics.eom/f/31/t/66698.aspx>, on Jun. 4, 2014, p. 1-1.;;Evans, D. L., et al., “Security Requirements for Cryptographic Modules,” Fips Pub 140-2 Change Notices, pp. 1-69 (May 25, 2001).;;Perez, S., “Revel Systems Debuts an iPad Point-of-Sale in a Box,” TechCrunch, dated Jun. 1, 2012, Retrieved from the Internet URL: <http://techcrunch.com/2012/06/27/revel-systems-debuts-an-ipad-point-of-sale-in-a-box>, on Jun. 4, 2014, pp. 1-5.;;Tanenbaum, A. S., “Distributed Systems: Principles and Paradigms (2nd Edition),” Pearson Prentice Hall, pp. 273-320 (2007).;;Labrou et al., “Wireless wallet,” The First Annual International Conference on Mobile andUbiquitous Systems: Networking and Services, 2004. MOBIQUITOUS 2004, pp. 32-41.;;Ferguson, R.B., “Passenger Hacks NYC computer system; The problem is more significant than GPS objections, according to the sotware engineer who hacked the system,” eWeek, dated Dec. 28, 2007, Retrieved from the Internet URL: http://search.pro quest. com/printviewfile?accountid=14753, on Apr. 24, 2017, pp. 1-2.;;Advisory Action dated Jun. 1, 2016, in U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed Mar. 5, 2013.;;Advisory Action dated Mar. 23, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Examination Report for European Patent Application No. 13859656.4, dated Jun. 22, 2016.;;Examination Report No. 1 for Australian Patent Application No. 2014225973, dated May 6, 2016.;;Examiner's Requisition for Canadian Patent Application No. 2,879,290, dated Nov. 9, 2015.;;Final Office Action dated Aug. 12, 2015, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Final Office Action dated Jan. 15, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Final Office Action dated Mar. 24, 2016, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Final Office Action dated Oct. 6, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Apr. 21, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Non-Final Office Action dated Aug. 16, 2016, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Non-Final Office Action dated Dec. 19, 2014, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Feb. 18, 2015, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non-Final Office Action dated Jul. 28, 2016, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non-Final Office Action dated Jun. 5, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Jun. 13, 2014, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Sep. 9, 2014, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Sep. 11, 2015, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non-Final Office Action dated Sep. 11, 2015, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Office Action for Canadian Patent Application No. 2,892,511, dated Jul. 19, 2016.",ACTIVE
661,US,A1,US 2023/0316255 A1,161-101-845-299-173,2023-10-05,2023,US 202318306964 A,2023-04-25,US 202318306964 A;;US 202217900690 A;;US 201916681217 A;;US 201313797390 A;;US 201261672228 P,2012-07-16,Transaction Processing by Multiple Devices,"In an example, a method can include receiving, at a merchant-facing portion of a payment system, data from a customer-facing portion of the payment system indicating a payment transaction between a merchant and a customer, wherein there is a physical connection between the portions; determining that the payment system is unable to access a remote payment service system via an external network; determining that the payment transaction is not preapproved for payment by the remote payment service system; storing the payment transaction on the merchant-facing portion even though the payment transaction is not preapproved; determining that the payment system is able to access the remote payment service system via the external network; and transmitting transaction information including the stored payment transaction to the remote payment service system, via the external network, for processing the stored payment transaction.",BLOCK INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE HUEY;;CLARK CHRISTOPHER;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/161-101-845-299-173,Patent Application,yes,0,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/12;;G06Q20/32;;G06Q20/40,,0,0,,,,PENDING
662,US,S,US D0972572 S,162-519-723-811-743,2022-12-13,2022,US 202129770066 F,2021-02-09,US 202129770066 F,2021-02-09,Protective information handling system case,,DELL PRODUCTS LP,CLARK PETER;;GUZMAN RICHARD W;;O'DONNELL SEAN P;;TODTENBIER GEORG;;COUTINHO OSCAR;;CHEN YUNG-CHUN;;LEE MING-CHIAO,DELL PRODUCTS L.P (2020-12-03),https://lens.org/162-519-723-811-743,Design Right,no,15,2,1,1,0,,,1402;;D14/440,1,0,,,"Pelican, “V-Series Medium Duty Rack Mount Case,” downloaded from https://www.pelican.com/us/en/professional/rack-mount-cases/v-series/ on Dec. 9, 2021, 6 pages.",ACTIVE
663,CA,A1,CA 2879290 A1,140-651-849-986-493,2014-01-23,2014,CA 2879290 A,2013-07-12,US 201261672228 P;;US 201313797390 A;;US 2013/0050345 W,2012-07-16,STORING AND FORWARDING PAYMENT TRANSACTIONS,"Method, systems, and apparatus for a method of processing a payment transaction using a mobile device of a merchant. In one aspect, determining the mobile device does not have a connection to an external network; receiving data indicating a payment transaction between a customer and the merchant; determining whether the payment transaction should be stored, where the determining is based on a risk heuristic model that considers one or more of the following: a number of already stored transactions, a value of the payment transaction, a total value, where the total value is a sum of the value of the payment transaction and values of one or more already stored transactions, and risk factors associated with the customer; and based at least on the determination, storing the payment transaction on the mobile device for future processing.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,,https://lens.org/140-651-849-986-493,Patent Application,no,0,6,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/38,,0,0,,,,ACTIVE
664,US,B2,US 6918771 B2,192-647-012-141-389,2005-07-19,2005,US 77883304 A,2004-02-13,US 77883304 A;;US 80010401 A,2001-03-06,Distributive processing simulation method and system for training healthcare teams,"A simulation method and system based on a distributive processing model is used for training and educating healthcare teams. The system allows team members to be at the training facility or located remotely and connected via data communication links. The system allows multiple participants for individual team member roles at various connected simulation workstations. If simulation participants cannot man all the team roles, the system can provide virtual team members in their stead. The simulation server computer delivers to each workstation the particular programs and outputs required for any given simulation exercise.",MEDICAL SIMULATION CORP,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,MENTICE AB A SWEDISH CORPORATION (2017-12-19),https://lens.org/192-647-012-141-389,Granted Patent,yes,17,61,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,434/262;;434/219,0,0,,,,EXPIRED
665,WO,A1,WO 2002/071370 A1,009-948-772-736-91X,2002-09-12,2002,US 0206781 W,2002-03-06,US 80010401 A,2001-03-06,DISTRIBUTIVE PROCESSING SIMULATION METHOD AND SYSTEM FOR TRAINING HEALTHCARE TEAMS,"A simulation method and system based on a distributive processing model is used for training and educating healthcare teams. The system (100) allows team members to be at the training facility or located remotely (164) and connected via data communication links (108)(162). The system allows multiple participants for individual team member roles at various connected simulation workstations (112). If simulation participants cannot man all the team role s, the system can provide virtual team members in their stead. The simulation server computer (162) delivers to each workstation the particular programs and outputs required for any given simulation exercise.",MEDICAL SIMULATION CORP,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,,https://lens.org/009-948-772-736-91X,Patent Application,yes,9,0,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,,1,0,,,See also references of EP 1374206A4,PENDING
666,US,A1,US 2020/0082376 A1,051-246-165-541-076,2020-03-12,2020,US 201916681217 A,2019-11-12,US 201916681217 A;;US 201313797390 A;;US 201261672228 P,2012-07-16,Storing and Forwarding Payment Transactions,"Techniques associated with a customer-facing device and a merchant-facing device are described herein. In an example, a system can include a customer-facing device configured with a customer application that is executable on an operating system of the customer-facing device to (i) display information to a customer and (ii) receive input from the customer, wherein the customer-facing device includes a payment reader to read payment data from a payment instrument in association with a payment transaction between the customer and a merchant, and a merchant-facing device configured with a merchant application that is executable on an operating system of the merchant-facing device to (i) display information to the merchant and (ii) receive input from the merchant. In at least one example, the customer-facing device and the merchant-facing device can communicate to process, at least in part, the payment transaction associated with the payment instrument via a remote payment service system.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/051-246-165-541-076,Patent Application,yes,40,1,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/12;;G06Q20/40,,1,0,,,"which priority provisional application 61/452 ,102",ACTIVE
667,ES,T3,ES 2627772 T3,065-886-928-912-407,2017-07-31,2017,ES 10765527 T,2010-05-07,US 21575709 P;;US 2010/0001350 W,2009-05-08,Compuestos de tetraciclina,"Un compuesto de Fórmula II:**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que: X se selecciona entre hidrógeno, bromo, flúor, cloro, alquilo C1-C6, -O-alquilo C1-C6, -S(O)m-alquilo C1-C6, 10 cicloalquilo C3-C7, -O-cicloalquilo C3-C7, -S(O)m-cicloalquilo C3-C7, -CN, -N(R4)(R5) y -NH-C(O)-(alquileno C1-C6)- N(R4)(R5), en donde cada alquilo, alquileno o cicloalquilo en el grupo representado por X está opcionalmente sustituido con flúor; R1a se selecciona entre hidrógeno, alquilo C1-C4 y carbociclilo C3-C10; R2 se selecciona entre hidrógeno, alquilo C1-C12, -alquilen C0-C6-carbociclilo C3-C10 y -alquilen C0-C6heterociclilo- (4-13 miembros); R3 se selecciona entre hidrógeno, alquilo C1-C8, -alquilen C0-C6-carbociclilo C3-C10, -alquilen C0-C6- heterociclilo(4-13 miembros), -C(O)-alquilo C1-C6, -alquilen C0-C6-C(O)N(R4)(R5), -C(O)-alquilen C1-C6-N(R4)(R5), -alquilen C2-C6-N(R4)(R5), -S(O)m-alquilo C1-C6, -S(O)m-carbociclilo C3-C10 y -S(O)m-heterociclilo (4-13 miembros), en donde cada alquilo, carbociclilo, alquileno o heterociclilo en el grupo representado por R2 o R3 está opcional e independientemente sustituido con uno o más sustituyentes seleccionados independientemente entre flúor, cloro, -OH, -O-alquilo C1-C4, alquilo C1-C4, -alquilo C1-C4 fluorosustituido, -N(R4)(R5), carbociclilo C3-C10 o un heterociclilo (4-13 miembros); o R2 y R3 tomados junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico monocíclico (4-7 miembros) o un anillo heterocíclico (6-13 miembros) bicíclico, espirocíclico o en forma de puente, en donde el anillo heterocíclico (4-7 miembros) monocíclico o el anillo heterocíclico (6-13 miembros) bicíclico, espirocíclico o en forma de puente comprenden opcionalmente de 1 a 4 heteroátomos seleccionados independientemente entre N, S y O; y en donde el anillo heterocíclico (4-7 miembros) monocíclico o el anillo heterocíclico (6-13 miembros) bicíclico, espirocíclico o en forma de puente están opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente entre carbociclilo C3-C10, heterociclilo (4-13 miembros), flúor, cloro, -OH, -fluoroalquilo C1-C4, -alquilo C1-C4, -O-carbociclilo C3-C10, -O-heterociclilo (4-13 miembros), -alquilen C0-C4-O-alquilo C1-C4, -alquilen C0-C4-O-fluoroalquilo C1-C4, >=O, -C(O)-alquilo C1-C4, -C(O)N(R4)(R5), -N(R4)- C(O)-alquilo C1-C4 y -alquileno C0-C4-N(R4)(R5) y en donde cada sustituyente carbociclilo o heterociclilo está opcionalmente sustituido con flúor, cloro, -OH, fluoroalquilo C1-C4, alquilo C1-C4, -O-alquilo C1-C4, -O-fluoroalquilo C1-C4, -NH2, -NH(alquilo C1-C4) o -N(alquilo C1-C4)2; cada uno de R4 y R5 se selecciona independientemente entre hidrógeno y alquilo C1-C4; o R4 y R5 tomados junto con el átomo de nitrógeno al que están unidos forman un anillo heterocíclico (4-7 miembros) que comprende opcionalmente un heteroátomo adicional seleccionado entre N, S y O, en donde el anillo heterocíclico (4-7 miembros) está opcionalmente sustituido con flúor, cloro, -OH, alquilo C1-C4 fluorosustituido, -alquilo C1-C4 o -alquilen C1-C4-O-alquilo C1-C4 y está opcionalmente condensado con fenilo; y cada m es independientemente 0, 1 o 2.",TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS,,https://lens.org/065-886-928-912-407,Granted Patent,no,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,ACTIVE
668,TW,A,TW 201807269 A,086-521-436-640-724,2018-03-01,2018,TW 106114779 A,2017-05-04,US 201662332095 P;;US 2017/0029437 W,2016-05-05,Structure grown epitaxially on substrate with a chemical barrier,"A structure can include a substrate layer with an interface and a carrier concentration at the interface, a rare earth oxide barrier layer grown over the substrate layer, and a Group III layer grown over the rare earth oxide barrier layer. The carrier concentration at the interface can be different by more than an order of magnitude than the bulk carrier concentration. The rare earth oxide layer can include a rare earth oxide material and can prevent diffusion of Group III species into the substrate layer. The Group III layer can include a Group III element.",IQE PLC,CLARK ANDREW;;DARGIS RYTIS;;MARCHAND HUGUES;;LABOUTIN OLEG;;KAO CHEN-KAI;;LO CHIEN-FONG;;LEBBY MICHAEL;;PELZEL RODNEY,,https://lens.org/086-521-436-640-724,Patent of Addition,no,0,0,2,2,0,H01L21/02381;;H01L21/02483;;H01L21/0254,C30B25/18;;C30B29/38,,0,0,,,,PENDING
669,WO,A1,WO 2023/004131 A1,033-403-946-975-065,2023-01-26,2023,US 2022/0038041 W,2022-07-22,US 202163203476 P,2021-07-23,ALUMINUM ALLOYS FOR BRAZABLE CASTING,Provided herein are aluminum alloy compositions having high conductivity. Low conductivity parent materials are also described.,TESLA INC,PATTINSON GRANT;;HAMILL QUINLIN;;PALANIVEL SIVANESH;;KOMAI RICARDO;;STUCKI JASON ROBERT;;CALDERONE JOHN DAVID;;CLARK TREVOR;;CHEN JIAJIE,,https://lens.org/033-403-946-975-065,Patent Application,yes,8,0,1,1,0,C22C21/00;;B23K35/286,B23K35/28;;C22C21/00,,1,1,007-460-786-036-322,10.1007/s11661-017-4369-2,"PANDEY P ET AL: ""Development of High-Strength High-Temperature Cast Al-Ni-Cr Alloys Through Evolution of a Novel Composite Eutectic Structure"", METALLURGICAL AND MATERIALS TRANSACTIONS A, SPRINGER US, NEW YORK, vol. 48, no. 12, 20 October 2017 (2017-10-20), pages 5940 - 5950, XP036368008, ISSN: 1073-5623, [retrieved on 20171020], DOI: 10.1007/S11661-017-4369-2",PENDING
670,US,A1,US 2004/0161731 A1,053-287-150-913-31X,2004-08-19,2004,US 77883304 A,2004-02-13,US 77883304 A;;US 80010401 A,2001-03-06,Distributive processing simulation method and system for training healthcare teams,"
   A simulation method and system based on a distributive processing model is used for training and educating healthcare teams. The system allows team members to be at the training facility or located remotely and connected via data communication links. The system allows multiple participants for individual team member roles at various connected simulation workstations. If simulation participants cannot man all the team roles, the system can provide virtual team members in their stead. The simulation server computer delivers to each workstation the particular programs and outputs required for any given simulation exercise. 
",ARINGTON MICHAEL L.;;BAILEY BRADFORD E.;;CLARK BILL B.;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E.,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,MENTICE AB A SWEDISH CORPORATION (2017-12-19),https://lens.org/053-287-150-913-31X,Patent Application,yes,18,36,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,434/262,0,0,,,,EXPIRED
671,US,A1,US 2004/0124415 A1,129-249-258-469-407,2004-07-01,2004,US 33464902 A,2002-12-31,US 33464902 A,2002-12-31,Formation of thin channels for TFT devices to ensure low variability of threshold voltages,"
   A thin film transistor with a channel less than 100 angstroms thick, preferably less than 80 angstroms thick, preferably less than 60 angstroms thick. The very thin channel reduces variability of threshold voltage from one TFT to the next. This is particularly advantageous for TFT memory arrays. It is possible that an extremely thin channel restricts the size of grains, forcing many small grains to be formed. 
",WALKER ANDREW J.;;HERNER S. BRAD;;MAHAJANI MAITREYEE;;CHEN EN-HSING;;SCHEUERLEIN ROY E.;;NALLAMOTHU SUCHETA;;CLARK MARK,WALKER ANDREW J;;HERNER S BRAD;;MAHAJANI MAITREYEE;;CHEN EN-HSING;;SCHEUERLEIN ROY E;;NALLAMOTHU SUCHETA;;CLARK MARK,MATRIX SEMICONDUCTOR (2003-04-18);;SANDISK TECHNOLOGIES LLC (2016-03-24);;SANDISK 3D LLC (2005-10-20),https://lens.org/129-249-258-469-407,Patent Application,yes,8,57,2,2,0,H01L27/12;;H01L29/78675;;H01L29/78696;;H01L29/78696;;H01L29/78675;;H01L27/12,H01L27/12;;H01L29/786,257/65,0,0,,,,EXPIRED
672,ES,T3,ES 2354908 T3,009-250-854-907-933,2011-03-21,2011,ES 06771540 T,2006-05-26,US 68556405 P,2005-05-27,INHIBIDORES DE FOSFOLIPASA A2 CITOSOLICA.,"Ácido 3-{4-[(2-{5-cloro-1-(difenilmetil)-2-[2-({[2-(trifluorometil)bencil]sulfonil}amino)etil]1H-indol-3-il}etil)sulfonil]fenil}-propanoico, o una sal farmacéuticamente aceptable del mismo.",WYETH LLC,MCKEW JOHN;;LEE KATHERINE;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/009-250-854-907-933,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
673,EP,A1,EP 2873040 A1,017-547-415-355-580,2015-05-20,2015,EP 13819366 A,2013-07-12,US 201261672228 P;;US 201313797390 A;;US 2013/0050345 W,2012-07-16,STORING AND FORWARDING PAYMENT TRANSACTIONS,,SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,,https://lens.org/017-547-415-355-580,Patent Application,yes,3,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/12;;G06Q20/32;;G06Q20/40,,5,0,,,"VEND TEAM: ""WHAT IS 'OFFLINE MODE' AND HOW DOES IT WORK?"", VEND LIMIT, 21 December 2011 (2011-12-21), pages 1 - 3, XP003035520, Retrieved from the Internet <URL:HTTP://SUPPORT.VENDHQ.COM/HC/EN-US/ARTICLES/201379940-WHAT-IS-OFFLINE-MODE-AND-HOW-DOES-IT-WORK->;;DENNISWI: ""HOW CAN I CHANGE THE OFFLINE MODE PASSWORD IN MICROSOFT DYNAMICE POS 2009?"", MICROSOFT, 8 November 2011 (2011-11-08), XP003035521, Retrieved from the Internet <URL:HTTPS://COMMUNITY.DYNAMICS.COM/F/31/T/66698>;;BRANISLAV PETKOVIC: ""WHAT IS THE PURPOSE OF RETAIL OFFLINE SYNC SERVICE AND HOW DOES IT WORK?"", MICROSOFT DYNAMICS AX COMMUNITY, MY, 12 April 2012 (2012-04-12), pages 1 - 2, XP003035522, DOI: BADGES;;SARAH PEREZ: ""REVEL SYSTEMS DEBUTS AN IPAD POINT-OF-SALE IN A BOX"", TECHCRUNCH, 27 June 2012 (2012-06-27), pages 1 - 6, XP003035523, Retrieved from the Internet <URL:HTTP://TECHCRUNCH.COM/2012/06/27/REVEL-SYSTEMS-DEBUTS-AN-IPAD-POINT-OF-SALE-IN-A-BOX/>;;""OFFLINE DB SUPPORT FOR POS"", STACK OVERFLOW, 24 January 2013 (2013-01-24), pages 1 - 2, XP003035524, Retrieved from the Internet <URL:HTTP://STACKOVERFLOW.COM/QUESTIONS/14495935/OFFLINE-DB-SUPPORT-FOR-POS>",DISCONTINUED
674,CN,C,CN 100503566 C,032-705-168-789-297,2009-06-24,2009,CN 02827611 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,Inhibitors of cytosolic phospholipase A2,,WYETH CORP,CAEDMON MCKEW JOHN;;DONALD CLARK JAMES;;LIN LEE KATHERINE;;LIHREN CHEN;;PARESH THAKKER;;LEO BEHNKE MARK;;BAIHUA HU,,https://lens.org/032-705-168-789-297,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
675,US,A1,US 2022/0414635 A1,052-837-852-339-102,2022-12-29,2022,US 202217900690 A,2022-08-31,US 202217900690 A;;US 201916681217 A;;US 201313797390 A;;US 201261672228 P,2012-07-16,Transaction Processing by Multiple Devices,"Techniques associated with a customer-facing device and a merchant-facing device are described herein. In an example, a system can include a customer-facing device configured with a customer application that is executable on an operating system of the customer-facing device to (i) display information to a customer and (ii) receive input from the customer, wherein the customer-facing device includes a payment reader to read payment data from a payment instrument in association with a payment transaction between the customer and a merchant, and a merchant-facing device configured with a merchant application that is executable on an operating system of the merchant-facing device to (i) display information to the merchant and (ii) receive input from the merchant. In at least one example, the customer-facing device and the merchant-facing device can communicate to process, at least in part, the payment transaction associated with the payment instrument via a remote payment service system.",BLOCK INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE HUEY;;CLARK CHRISTOPHER;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/052-837-852-339-102,Patent Application,yes,34,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/12;;G06Q20/40,,2,2,115-264-857-004-051;;075-820-403-616-614,10.1109/wmcs.2005.16;;10.1109/aptc.2008.24,"J. Gao, K. Edunuru, J. Cai and S. P. D. Shim, ""P2P-Paid: A Peer-to-Peer Wireless Payment System,"" Second IEEE International Workshop on Mobile Commerce and Services, 2005, pp. 102-111 (Year: 2005);;Q. Li, X. Zhang, J. -P. Seifert and H. Zhong, ""Secure Mobile Payment via Trusted Computing,"" 2008 Third Asia-Pacific Trusted Infrastructure Technologies Conference, 2008, pp. 98-112. (Year: 2008)",ACTIVE
676,WO,A1,WO 2014/014781 A1,028-751-224-017-009,2014-01-23,2014,US 2013/0050345 W,2013-07-12,US 201261672228 P;;US 201313797390 A,2012-07-16,STORING AND FORWARDING PAYMENT TRANSACTIONS,"Method, systems, and apparatus for a method of processing a payment transaction using a mobile device of a merchant. In one aspect, determining the mobile device does not have a connection to an external network; receiving data indicating a payment transaction between a customer and the merchant; determining whether the payment transaction should be stored, where the determining is based on a risk heuristic model that considers one or more of the following: a number of already stored transactions, a value of the payment transaction, a total value, where the total value is a sum of the value of the payment transaction and values of one or more already stored transactions, and risk factors associated with the customer; and based at least on the determination, storing the payment transaction on the mobile device for future processing.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,,https://lens.org/028-751-224-017-009,Patent Application,yes,5,5,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/00,,0,0,,,,PENDING
677,US,B2,US 11475431 B2,184-261-059-509-492,2022-10-18,2022,US 201916681217 A,2019-11-12,US 201916681217 A;;US 201313797390 A;;US 201261672228 P,2012-07-16,Transaction processing by multiple devices,"Techniques associated with a customer-facing device and a merchant-facing device are described herein. In an example, a system can include a customer-facing device configured with a customer application that is executable on an operating system of the customer-facing device to (i) display information to a customer and (ii) receive input from the customer, wherein the customer-facing device includes a payment reader to read payment data from a payment instrument in association with a payment transaction between the customer and a merchant, and a merchant-facing device configured with a merchant application that is executable on an operating system of the merchant-facing device to (i) display information to the merchant and (ii) receive input from the merchant. In at least one example, the customer-facing device and the merchant-facing device can communicate to process, at least in part, the payment transaction associated with the payment instrument via a remote payment service system.",BLOCK INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/184-261-059-509-492,Granted Patent,yes,275,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/12;;G06Q20/40,,108,4,075-820-403-616-614;;137-892-911-964-412;;030-415-006-904-231;;075-820-403-616-614,10.1109/aptc.2008.24;;10.1109/mobiq.2004.1331708;;10.17487/rfc5280;;10.1109/aptc.2008.24,"Q. Li, X. Zhang, J. Seifert and H. Zhong, “Secure Mobile Payment via Trusted Computing,” 2008 Third Asia-Pacific Trusted Infrastructure Technologies Conference, 2008, pp. 98-112 (Year: 2008).;;Y. Labrou, J. Agre, L. Ji, J. Molina and W. .-I. Chen, “Wireless wallet,” The First Annual International Conference on Mobile and Ubiquitous Systems: Networking and Services, 2004. MOBIQUITOUS 2004., 2004, pp. 32-41, (Year: 2004).;;“Advancing Payment Security: MasterCard Contactless Security Overview,” www.mastercard.com, retrieved from Internet URL: https://www.mastercard.com/contactless/doc/MasterCardContactless_SecurityFactSheet_2015.pdf, on Jun. 12, 2017, pp. 1-4.;;Conkling, C., “General Credit Card (CC) Approval/Payment Process,” Figure 2, dated Jan. 17, 2011, Retrieved from the Internet: URL<http:/ /craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html>, on Jun. 6, 2014, p. 1-1.;;Conkling, C., “Mobile Trends Insight: NFC and the Mobile Payment Initiative-4,” dated Jan. 17, 2011, Retrieved from the Internet URL: http:/ /craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html, on Jun. 6, 2014, pp. 1-15.;;Cooper, D , et al., “Internet X 509 Public Key Infrastructure Certificate and Certificate Revocation List (CRL) Profile,” Standards Track, pp. 1-151 (May 2008).;;“Cryptography—PCI Encryption Key Management—Information Security Stack Exchange,” published Jan. 1, 2011, XP055415553, Retrieved from the Internet URL: https://security.stackexchange.com/questions/1412/pci-encryptionkey-management. Retrieved on Oct. 13, 2017, pp. 1-3.;;Denniswi, “How Can I change the Offline Mode Password in Microsoft Dynamice POS 2009?,” Microsoft Dynamics, dated Nov. 8, 2011, Retrieved from the Internet URL: <https://community.dynamics.eom/f/31/t/66698.aspx>, on Jun. 4, 2014, p. 1-1.;;Evans, D. L., et al., “Security Requirements for Cryptographic Modules,” FIPS PUB 140-2 Change Notices, pp. 1-69 (May 25, 2001).;;Ferguson, R.B., “Passenger Hacks NYC computer system; The problem is more significant than GPS objections, according to the sofware engineer who hacked the system,” eWeek, dated Dec. 28, 2007, Retrieved from the Internet URL: http://search.pro quest. com/printviewfile?accountid=14753, on Apr. 24, 2017, pp. 1-2.;;“MasterCard and VeriFone Bring ‘Tap & Go’ Payments to Taxis,” Wireless News, dated Nov. 15, 2006, Retrieved from the Internet URL: http://search proquest.com/printviewfile?accountid=14753, on Apr. 24, 2017, pp. 1-2.;;“Mobile payment,” Wikipedia, dated Jul. 9, 2012. Retrieved from the Internet URL: https://en.wikipedia.org/w/index.php?title=Mobile_payment&oldid=501410747,on Feb. 27, 2018, pp. 1-8.;;“Offline DB Support for POS,” Stack Overflow, dated Jan. 24, 2013, Retrieved from the Internet URL: <http://stackoverflow.com/questions/14495935/offline-dbsupport-for-pos>, on Jun. 4, 2014, p. 1-2.;;“Payment Card Industry (PCI) Hardware Security Module (HSM),” Security Requirements Version 1.0, XP055168869, pp. 1-26 (Apr. 2009).;;Perez, S., “Revel Systems Debuts An iPad Point-Of- Sale In A Box,” TechCrunch, dated Jun. 1, 2012, Retrieved from the Internet URL: <http://techcrunch.com/2012/06/27/revel-systems-debuts-an-ipad-point-of-sale-in-a-box>, on Jun. 4, 2014, pp. 1-5.;;“PCI DSS compliant Key Management,” published Jul. 31, 2011, XP055415555, Retrieved from the Internet URL: http://www.src-gmbh.de/pcinews/download/PCIWhitepaper-2011-07.pdf, on Oct. 13, 2017, pp. 1-3.;;“Suncorp and live TaxiEpay to provider Mobile Payment Terminals for Hypercom,” Anonymous Wireless News, dated Jun. 20, 2010, Retrieved from the Internet URL: http://search.pro quest. com/printviewfile?accountid=14753, on Apr. 21, 2017, pp. 1-2.;;Tanenbaum, A. S., “Distributed Systems: Principles and Paradigms (2nd Edition),” Pearson Prentice Hall, pp. 273-320 (2007).;;“What is ‘Offline Mode’ and How Does It Work?,” Vend, dated Dec. 20, 2011, Retrieved from the Internet URL: <http://support.vendhq.com/hc/enus/articles/201379940-What -is-Offline-Mode-and-how-does-it-work>, on Jun. 4, 2014, pp. 1-3.;;“What is the Purpose of Retail Offline Sync Service and How Does It Work?,” Microsoft Dynamics, dated Apr. 12, 2012, Retrieved from the Internet URL: <http://community.dynamics.eom/ax/f/33/p/77 406/149851.aspx>, on Jun. 4, 2014, p. 1-3.;;Third Party Observation submitted, for PCT Application No. PCT/US2013/050345 on May 30, 2014.;;Non-Final Office Action dated Jun. 13, 2014, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Sep. 9, 2014, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Dec. 19, 2014, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Final Office Action dated Jan. 15, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Feb. 18, 2015, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Advisory Action dated Mar. 23, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Jun. 5, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Final Office Action dated Aug. 12, 2015, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non-Final Office Action dated Sep. 11, 2015, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non-Final Office Action dated Sep. 11, 2015, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Final Office Action dated Oct. 6, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Examiner's Requisition for Canadian Patent Application No. 2,879,290, mailed Nov. 9, 2015.;;Final Office Action dated Mar. 24, 2016, in U.S. Appl. No. 13/786,262, of Scott J.B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Apr. 21, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Examination Report No. 1 for Australian Patent Application No. 2014225973, dated May 6, 2016.;;Advisory Action dated Jun. 1, 2016, in U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed Mar. 5, 2013.;;Examination Report for European Patent Application No. 13859656.4, dated Jun. 22, 2016.;;Office Action for Canadian Patent Application No. 2,892,511, dated Jul. 19, 2016.;;Non-Final Office Action dated Jul. 28, 2016, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non-Final Office Action dated Aug. 16, 2016, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Final Office Action dated Oct. 31, 2016, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Examination Report for European Patent Application No. 13819366.9, dated Nov. 2, 2016.;;Office Action for Canadian Patent Application No. 2,903,983, dated Nov. 4, 2016.;;Final Office Action dated Dec. 29, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Examiner's Requisition for Canadian Patent Application No. 2,879,290, mailed Jan. 11, 2017.;;Non-Final Office Action dated Feb. 16, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non Final Office Action dated Mar. 3, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Notice of Acceptance for Australian Patent Application No. 2014225973, dated Mar. 15, 2017.;;Non-Final Office dated Mar. 24, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Final Office Action dated Feb. 20, 2020, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non Final Office Action dated Apr. 10, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Notice of Allowance dated Apr. 17, 2017, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Final Office Action dated May 9, 2017, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Notice of Allowance for Canadian Patent Application No. 2,892,511, dated May 26, 2017.;;Non-Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed on Mar. 5, 2013.;;Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Examination Report for European Patent Application No. 14760487.0, dated Jun. 28, 2017.;;Final Office Action dated Jul. 14, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Advisory Action dated Sep. 13, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance dated Sep. 15, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Non-Final Office Action dated Oct. 4, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Notice of Allowance dated Oct. 13, 2017, for U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed May 3, 2013.;;Non-Final Office Action dated Oct. 31, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Summons to attend oral proceedings for European Patent Application No. 13859656.4, mailed Nov. 2, 2017.;;Examiner's Requisition for Canadian Patent Application No. 2,903,983, mailed Nov. 6, 2017.;;Notice of Allowance for Canadian Patent Application No. 2,879,290, dated Jan. 9, 2018.;;Advisory Action dated Jan. 31, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Notification concerning the date of oral proceedings for European Patent Application No. 13819366.9, mailed Mar. 5, 2018.;;Notice of Allowance dated Apr. 6, 2018, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Notice of Allowance dated Apr. 9, 2018, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Notice of Allowance dated Apr. 13, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Notice of Allowance dated Apr. 24, 2018, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Final Office Action dated May 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non-Final Office Action dated Jul. 25, 2018, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Non-Final Office Action dated Aug. 7, 2018, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Advisory Action dated Aug. 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non-Final Office Action dated Sep. 10, 2018, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Notice of Allowance dated Oct. 22, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance for Canadian Patent Application No. 2,903,983, dated Oct. 24, 2018.;;Final Office Action dated Feb. 1, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non Final Office Action dated Feb. 14, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Notice of Allowance dated Mar. 13, 2019, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Final Office Action dated Mar. 21, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Advisory Action mailed May 24, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Final Office Action mailed Jun. 17, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., etaL, filed Augusi 20,2018.;;Notice of Allowance mailed Jul. 3, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non Final Office Action mailed Aug. 7, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Notice of Allowance mailed Nov. 6, 2019, for U.S. Appl. No. 13/797,390, of Ruder, E., et al., filed Mar. 12, 2013.;;Non Final Office Action mailed Dec. 31, 2019, for U.S. Appl. No. 16/105,918, ofChen, G.H., et al., filed Aug. 20, 2018.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/050345, mailed Oct. 4, 2013.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/073302, mailed Apr. 18, 2014.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2014/020389, mailed Jun. 17, 2014.;;Extended European Search Report for European Patent Application No. 13859656.4, mailed on Sep. 4, 2015.;;Extended European Search Report for European Patent Application No. 13819366.9 mailed Feb. 19, 2 016.;;Extended European Search Report for European Patent Application No. 14760487.0 dated Jul. 7, 2016.;;Final Office Action dated Jul. 30, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Advisory Action dated Sep. 30, 2020, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Final Office Action dated Sep. 9, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Zhang et al., “Secure Mobile Payment via Trusted Computing,” 2008 Third Asia-Pacific Trusted Infrastructure Technologies Conference, (Year: 2008) pp. 98-112.;;Non-Final Office Action dated Nov. 27, 2020, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Advisory Action dated Nov. 30, 2020, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Non-Final Office Action dated May 7, 2021, for U.S. Appl. No. 15/870,562, of White, M.W , et al., filed Jan. 12, 2018.;;Final Office Action dated Sep. 15, 2021, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.;;Advisory Action dated Dec. 27, 2021, for U.S. Appl. No. 15/870,562, of White, M.W., et al., filed Jan. 12, 2018.",ACTIVE
678,US,B2,US 9208566 B2,036-065-080-686-51X,2015-12-08,2015,US 201313963117 A,2013-08-09,US 201313963117 A,2013-08-09,Speckle sensing for motion tracking,"Speckle sensing for motion tracking is described, for example, to track a user's finger or head in an environment to control a graphical user interface, to track a hand-held device, to track digits of a hand for gesture-based control, and to track 3D motion of other objects or parts of objects in a real-world environment. In various examples a stream of images of a speckle pattern from at least one coherent light source illuminating the object, or which is generated by a light source at the object to be tracked, is used to compute an estimate of 3D position of the object. In various examples the estimate is transformed using information about position and/or orientation of the object from another source. In various examples the other source is a time of flight system, a structured light system, a stereo system, a sensor at the object, or other sources.",CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM;;MICROSOFT TECHNOLOGY LICENSING LLC,CHEN NICHOLAS YEN-CHERNG;;HODGES STEPHEN EDWARD;;FITZGIBBON ANDREW WILLIAM;;GORIS ANDREW CLARK;;HASTINGS BRIAN LEE;;IZADI SHAHRAM,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2013-08-04),https://lens.org/036-065-080-686-51X,Granted Patent,yes,17,13,4,4,0,G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647;;G06F3/011;;G06F3/0304;;G06F3/0346;;G06T7/73;;G06V20/647,G06K9/00;;G06F3/01;;G06F3/03;;G06F3/0346;;G06T7/00,,6,3,008-533-613-852-840;;050-223-209-674-236;;042-988-740-984-428,10.1145/2212776.2223782;;22695586;;10.1364/ao.51.003478;;10.1145/2047196.2047261,"Olwal, et al., ""SpeckleEye: Gestural Interaction for Embedded Electronics in Ubiquitous Computing"", In Proceedings of the ACM Annual Conference on Extended Abstracts on Human Factors in Computing Systems, May 5, 2012, 6 pages.;;Francis, et al., ""Objective Speckle Velocimetry for Autonomous Vehicle Odometry"", In Journal of Applied Optics, vol. 51, Issue 16, Jun. 2012, 13 pages.;;Zizka, et al., ""SpeckleSense: Fast, Precise, Low-Cost and Compact Motion Sensing Using Laser Speckle"", In Proceedings of the 24th Annual ACM Symposium on User Interface Software and Technology, Oct. 16, 2011, 10 pages.;;Dunmeyer., ""Laser Speckle Modeling for Three-Dimensional Metrology and LADAR"",M. Eng. dissertation Massachusetts Institute of Technology, Jan. 1, 2001.;;""International Search Report and Written Opinion issued for International Application No. PCT/US2014/049841"", Mailed Date: Nov. 21, 2014,12 pages.;;""Second Written Opinion Issued in PCT Application No. PCT/US2014/049841"", Mailed Date: Jul. 2, 2015, 7 pages.",ACTIVE
679,US,B2,US 10496977 B2,126-473-996-287-098,2019-12-03,2019,US 201313797390 A,2013-03-12,US 201313797390 A;;US 201261672228 P,2012-07-16,Storing and forwarding payment transactions,"Method, systems, and apparatus for a method of processing a payment transaction using a mobile device of a merchant. In one aspect, determining the mobile device does not have a connection to an external network; receiving data indicating a payment transaction between a customer and the merchant; determining whether the payment transaction should be stored, where the determining is based on a risk heuristic model that considers one or more of the following: a number of already stored transactions, a value of the payment transaction, a total value, where the total value is a sum of the value of the payment transaction and values of one or more already stored transactions, and risk factors associated with the customer; and based at least on the determination, storing the payment transaction on the mobile device for future processing.",SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,BLOCK INC (2013-03-01),https://lens.org/126-473-996-287-098,Granted Patent,yes,215,5,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/32;;G06Q20/12;;G06Q20/40,,85,1,030-415-006-904-231,10.17487/rfc5280,"Anonymous, “Suncorp and live TaxiEpay to provider Mobile Payment Terminals for Hypercom”, Wireless News, Jacksonville, Jun. 20, 2010, pp. 1-2.;;Ferguson, Boucher, Renee, “Passenger Hacks NYC computer system; The problem is more significant than GPS objections, according to the sofware engineer who hacked the system”, eWeek, Dec. 28, 2007, pp. 1-2.;;“MasterCard and VeriFone Bring ‘Tap & Go’ Payments to Taxis”, Wireless News, Nov. 15, 2006, ps 1-2.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/050345, filed Jul. 12, 2013. 15 Pages.;;PCT Third Party Observation for International Patent Application No. PCT/US2013/050345, filed Jul. 12, 2013. 6 Pages.;;How Can I change the Offline Mode Password in Microsoft Dynamice POS 2009? Microsoft Dynamics. Published on Nov. 8, 2011. Retrieved Jun. 4, 2014. Retrieved from the Internet: URL<https://community.dynamics.com/f/31/t/66698.aspx>. 1 page.;;What is ‘Offline Mode’ and How Does It Work? Vend. Published on Dec. 20, 2011. Retrieved on Jun. 4, 2014. Retrieved from the Internet: URL<http://support.vendhq.com/hc/en-us/articles/201379940-What-is-Offline-Mode-and-how-does-it-work>. 3 pages.;;What is the Purpose of Retail Offline Sync Service and How Does It Work? Microsoft Dynamics. Published on Apr. 12, 2012. Retrieved on Jun. 4, 2014. Retrieved from the Internet: URL<http://community.dynamics.com/ax/f/33/p/77406/149851.aspx>. 3 pages.;;Perez, Sarah. Revel Systems Debuts An iPad Point-Of-Sale In A Box. TechCrunch. Published Jun. 1, 2012. Retrieved on Jun. 4, 2014. Retrieved from the Internet: URL<http://techcrunch.com/2012/06/27/revel-systems-debuts-an-ipad-point-of-sale-in-a-box>. 5 pages.;;Offline DB Support for POS. Stack Overflow. Published on Jan. 24, 2013. Retrieved on Jun. 4, 2014. Retrieved from the Internet: URL<http://stackoverflow.com/questions/14495935/offline-db-support-for-pos >. 2 pages.;;Advisory Action dated Jun. 1, 2016, in U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed Mar. 5, 2013.;;Examination Report No. 1 for Australian Patent Application No. 2014225973, dated May 6, 2016.;;Conkling, C., “General Credit Card (CC) Approval/Payment Process,” Figure 2, dated Jan. 17, 2011, Retrieved from the Internet: URL<http://craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html>, on Jun. 6, 2014, p. 1-1.;;Conkling, C., “Mobile Trends Insight: NFC and the Mobile Payment Initiative-4,” dated Jan. 17, 2011, Retrieved from the Internet URL: http://craigconkling. blogspot.com/2011/01/nfc-and-mobile-payment-initiative-4.html, on Jun. 6, 2014, pp. 1-15.;;Non-Final Office Action dated Jun. 13, 2014, in U.S. Appl. No. 13/786,262, of Scott J. B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Dec. 19, 2014, in U.S. Appl. No. 13/786,262, of Scott J. B., et al., filed Mar. 5, 2013.;;Non-Final Office Action dated Sep. 11, 2015, in U.S. Appl. No. 13/786,262, of Scott J. B., et al., filed Mar. 5, 2013.;;Office Action dated Nov. 9, 2015, in Canadian Patent Application No. 2,879,290 of Ruder, E., et al.;;International Search Report and Written Opinion for PCT Application No. PCT/US2014/020389 dated Jun. 17, 2014.;;Extended European Search Report for European Patent Application No. 13819366.9 dated Feb. 19, 2016.;;Final Office Action dated Mar. 24, 2016, in U.S. Appl. No. 13/786,262, of Scott J. B., et al., filed Mar. 5, 2013.;;Examination Report for European Patent Application No. 13 819 366.9, dated Nov. 2, 2016.;;Office Action for Canadian Patent Application No. 2,903,983, dated Nov. 4, 2016.;;Extended European Search Report for European Patent Application No. 14760487.0 dated Jul. 7, 2016.;;Notice of Allowance for Canadian Patent Application No. 2,879,290, dated Jan. 9, 2018.;;Examiner's Requisition for Canadian Patent Application No. 2,879,290, dated Jan. 11, 2017.;;Notice of Acceptance for Australian Patent Application No. 2014225973, dated Mar. 15, 2017.;;Non-Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 13/786,262, of Scott, J. B., et al., filed Mar. 5, 2013.;;Examination Report for European Patent Application No. 14760487.0, dated Jun. 28, 2017.;;Notice of Allowance dated Oct. 13, 2017, for U.S. Appl. No. 13/786,262, of Scott, J.B., et al., filed May 3, 2013.;;Examiner's Requisition for Canadian Patent Application No. 2,903,983, dated Nov. 6, 2017.;;“Advancing Payment Security: MasterCard Contactless Security Overview,” www.mastercard.com, retrieved from Internet URL: https://www.mastercard.com/contactless/doc/MasterCardContactless_SecurityFactSheet_2015.pdf, on Jun. 12, 2017, pp. 1-4.;;Cooper, D., et al., “Internet X.509 Public Key Infrastructure Certificate and Certificate Revocation List (CRL) Profile,” Standards Track, pp. 1-151 (May 2008).;;“Cryptography—PCI Encryption Key Management-Information Security Stack Exchange,” published Jan. 1, 2011, XP055415553, Retrieved from the Internet URL: https://security.stackexchange.com/questions/1412/pci-encryptionkey-management, Retrieved on Oct. 13, 2017, pp. 1-3.;;Evans, D. L., et al., “Security Requirements for Cryptographic Modules,” FIPS PUB 140-2 Change Notices, pp. 1-69 (May 25, 2001).;;“Mobile payment,” Wikipedia, dated Jul. 9, 2012. Retrieved from the Internet URL: https://en.wikipedia.org/w/index.php?title=Mobile_payment&oldid=501410747,on Feb. 27, 2018, pp. 1-8.;;“Payment Card Industry (PCI) Hardware Security Module (HSM),” Security Requirements Version 1.0, XP055168869, pp. 1-26 (Apr. 2009).;;“PCI DSS compliant Key Management,” published Jul. 31, 2011, XP055415555, Retrieved from the Internet URL: http://www.src-gmbh.de/pcinews/download/PCIWhitepaper-2011-07.pdf, on Oct. 13, 2017, pp. 1-3.;;Tanenbaum, A. S., “Distributed Systems: Principles and Paradigms (2nd Edition),” Pearson Prentice Hall, pp. 273-320 (2007).;;Non-Final Office Action dated Sep. 9, 2014, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Final Office Action dated Jan. 15, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Advisory Action dated Mar. 23, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Jun. 5, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Sep. 11, 2015, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Final Office Action dated Oct. 6, 2015, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Non-Final Office Action dated Apr. 21, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Examination Report for European Patent Application No. 13859656A, dated Jun. 22, 2016.;;Office Action for Canadian Patent Application No. 2,892,511, dated Jul. 19, 2016.;;Non-Final Office Action dated Aug. 16, 2016, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Final Office Action dated Oct. 31, 2016, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Final Office Action dated Dec. 29, 2016, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Non-Final Office Action dated Feb. 16, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non Final Office Action dated Mar. 3, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Final Office Action dated Mar. 9, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Non-Final Office dated Mar. 24, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Non-Final Office Action dated Apr. 6, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Notice of Allowance dated Apr. 17, 2017, for U.S. Appl. No. 14/567,145, of White, M.W., et al., filed Dec. 11, 2014.;;Notice of Allowance for Canadian Patent Application No. 2,892,511, dated May 26, 2017.;;Final Office Action dated Jun. 2, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Final Office Action dated Jul. 14, 2017, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Advisory Action dated Sep. 13, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance dated Sep. 15, 2017, for U.S. Appl. No. 14/567,118, of White, M.W., et al., filed Dec. 11, 2014.;;Non-Final Office Action dated Oct. 4, 2017, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Non-Final Office Action dated Oct. 31, 2017, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Final Office Action dated Nov. 1, 2017, for U.S. Appl. No. 14/274,524, of Mocko, C.L., et al., filed May 9, 2014.;;Summons to attend oral proceedings for European Patent Application No. 13859656.4, dated Nov. 2, 2017.;;Advisory Action dated Jan. 31, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L, et al., filed May 9, 2014.;;Notification concerning the date of oral proceedings for European Patent Application No. 13819366.9, dated Mar. 5, 2018.;;Notice of Allowance dated Apr. 6, 2018, for U.S. Appl. No. 14/578,765, of Chi, Y., et al., filed Dec. 22, 2014.;;Notice of Allowance dated Apr. 9, 2018, for U.S. Appl. No. 14/495,390, of Botros, P.A., et al., filed Sep. 24, 2014.;;Notice of Allowance dated Apr. 13, 2018, for U.S. Appl. No. 14/274,524, of Mocko, C.L, et al., filed May 9, 2014.;;Notice of Allowance dated Apr. 24, 2018, for U.S. Appl. No. 14/284,125, of Chen, G.H., et al., filed May 21, 2014.;;Final Office Action dated May 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Non-Final Office Action dated Jul. 25, 2018, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Non-Final Office Action dated Aug. 7, 2018, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Advisory Action dated Aug. 31, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance dated Oct. 22, 2018, for U.S. Appl. No. 14/274,481, of Chen, G.H., et al., filed May 9, 2014.;;Notice of Allowance for Canadian Patent Application No. 2,903,983, dated Oct. 24, 2018.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2013/073302, dated Apr. 18, 2014.;;Extended European Search Report for European Patent Application No. 13859656.4, dated Sep. 4, 2015.;;Final Office Action dated Feb. 1, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.;;Non Final Office Action dated Feb. 14, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Notice of Allowance dated Mar. 13, 2019, for U.S. Appl. No. 15/199,466, of Han, K., et al., filed Jun. 30, 2016.;;Final Office Action dated Jun. 17, 2019, for U.S. Appl. No. 16/105,918, of Chen, G.H., et al., filed Aug. 20, 2018.;;Non Final Office Action dated Aug. 7, 2019, for U.S. Appl. No. 13/736,447, of Quigley, O.S.C., et al., filed Jan. 8, 2013.",ACTIVE
680,US,A1,US 2002/0127525 A1,127-194-752-652-997,2002-09-12,2002,US 80010401 A,2001-03-06,US 80010401 A,2001-03-06,Distributive processing simulation method and system for training healthcare teams,"
   A simulation method and system based on a distributive processing model is used for training and educating healthcare teams. The system allows team members to be at the training facility or located remotely and connected via data communication links. The system allows multiple participants for individual team member roles at various connected simulation workstations. If simulation participants cannot man all the team roles, the system can provide virtual team members in their stead. The simulation server computer delivers to each workstation the particular programs and outputs required for any given simulation exercise. 
",ARINGTON MICHAEL L.;;BAILEY BRADFORD E.;;CLARK BILL B.;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E.,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,MENTICE AB A SWEDISH CORPORATION (2017-12-19),https://lens.org/127-194-752-652-997,Patent Application,yes,1,58,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,434/262,0,0,,,,EXPIRED
681,EP,A4,EP 1374206 A4,166-358-250-413-104,2006-07-26,2006,EP 02748401 A,2002-03-06,US 0206781 W;;US 80010401 A,2001-03-06,DISTRIBUTIVE PROCESSING SIMULATION METHOD AND SYSTEM FOR TRAINING HEALTHCARE TEAMS,,MEDICAL SIMULATION CORP,ARINGTON MICHAEL L;;BAILEY BRADFORD E;;CLARK BILL B;;YUANMING CHEN;;GAO QIANG;;WILSON DAVE;;YOUNKES WILLIAM E,,https://lens.org/166-358-250-413-104,Search Report,no,2,0,7,7,0,G09B7/04;;G09B23/28;;G09B23/285;;G09B7/04;;G09B23/28;;G09B23/285,G09B7/04;;G09B23/28,,1,0,,,See also references of WO 02071370A1,DISCONTINUED
682,EP,A4,EP 2873040 A4,167-918-012-954-158,2016-03-23,2016,EP 13819366 A,2013-07-12,US 201261672228 P;;US 201313797390 A;;US 2013/0050345 W,2012-07-16,STORING AND FORWARDING PAYMENT TRANSACTIONS,,SQUARE INC,RUDER EDWARD;;PULS JAMES;;MULANI MEHDI;;MOREL SHAWN;;CHEN GRACE;;CLARK CHRISTOPHER R;;SCOTT J BRYAN;;MONTI ERIC,,https://lens.org/167-918-012-954-158,Search Report,no,6,0,12,12,0,G06Q20/12;;G06Q20/3223;;G06Q20/4016;;G06Q20/322;;G06Q20/3223;;G06Q20/4016;;G06Q20/12,G06Q20/12;;G06Q20/32;;G06Q20/40,,0,0,,,,DISCONTINUED
683,US,A1,US 2017/0165252 A1,055-537-014-858-004,2017-06-15,2017,US 201514965069 A,2015-12-10,US 201514965069 A,2015-12-10,PROTEIN-ENRICHED THERAPEUTIC COMPOSITION,"The present disclosure provides protein-enriched, nicotine-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one nicotinic compound, at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",NICONOVUM USA INC,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,NICONOVUM USA INC (2016-01-26),https://lens.org/055-537-014-858-004,Patent Application,yes,3,11,2,2,0,A61K9/0056;;A61K47/46;;A61K9/1623;;A61K9/1658;;A61K9/1664;;A61K9/2063;;A61K9/2068;;A61K36/81;;A61K45/06;;A61K31/465;;A61K9/0056;;A61K47/46;;A61K9/2068;;A61K36/81;;A61K47/61;;A61K9/2063;;A61K45/06;;A61K9/1658;;A61K9/1664;;A61K47/58;;A61K9/1623;;A61K31/465;;A61K9/0053;;A61K9/2018;;A61K47/10;;A61K47/26;;A61K47/36,A61K31/465;;A61K9/00;;A61K9/20;;A61K47/10;;A61K47/26;;A61K47/36;;A61K47/46,,1,0,,,"WILDMAN, “An Alternate Use for Tobacco Agriculture: Proteins for Food plus a Safer Smoking Material”, pages 63-77, 1996",DISCONTINUED
684,US,A1,US 2023/0189872 A1,181-484-324-078-806,2023-06-22,2023,US 202318110774 A,2023-02-16,US 202318110774 A;;US 201514965080 A,2015-12-10,PROTEIN-ENRICHED TOBACCO COMPOSITION,"The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",REYNOLDS TOBACCO CO R,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,,https://lens.org/181-484-324-078-806,Patent Application,yes,0,0,4,4,0,A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B15/32,A24B15/24;;A24B3/14;;A24B13/00;;A24B15/10;;A24B15/32,,0,0,,,,PENDING
685,US,A1,US 2021/0363152 A1,182-367-685-771-466,2021-11-25,2021,US 201917311144 A,2019-12-10,US 201917311144 A;;EP 2018084377 W;;US 201962939853 P;;US 2019/0065341 W,2018-12-11,AMINOAZINE AMIDES,"The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds.",HOFFMANN LA ROCHE,BACCEI JILL MELISSA;;BRAVO YALDA;;CHEN AUSTIN CHIH-YU;;CLARK RYAN CHRISTOPHER;;STEARNS BRIAN ANDREW;;TRUONG YEN PHAM HONG,,https://lens.org/182-367-685-771-466,Patent Application,yes,0,0,6,7,0,C07D491/10;;C07D403/06;;C07D471/10;;C07D471/04;;C07D487/10;;C07D495/10;;C07D491/048;;C07D491/107;;A61P1/16;;A61P11/00;;A61P3/00;;A61P9/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07D401/06;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D491/107;;C07D495/10,C07D401/06;;C07D491/107;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D495/10,,0,0,,,,PENDING
686,ES,T3,ES 2401454 T3,045-627-020-039-669,2013-04-19,2013,ES 07023208 T,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,Inhibidores de la fosfolipasa A2 citosólica,"Un compuesto de fórmula:**Fórmula** n1 es 1; n2 es un número entero de 0 a 4; n3 es un número entero de 0 a 3; n4 es un número entero de 0 a 2; X1 está seleccionado de un enlace químico o -S-; R1 está seleccionado de grupos alquilo C1-C6, alquilo C1-C6 fluorado, cicloalquilo C3-C6, fenilo, piridinilo, tienilo,morfolinilo, pirazolilo, piperidinilo, pirrolidinilo, imidazolilo, benzo [1,2,5] oxadiazol, 2-oxa-5-azabiciclo [2.2.1]heptano, cada uno opcionalmente sustituido por de 1 a 3, de preferencia 1 a 2, sustituyentes seleccionadosindependientemente de H, halógeno, -CN, -CHO, -CF3, OCF3, -OH, alquilo C1-C6, alcoxi C1-C6, -NH2, -N(alquilo C1-C6)2, -NH(alquilo C1-C6), -NC(O)-(alquilo C1-C6), -NO2, -SO2(alquilo C1-C3), -SO2NH2, -SO2NH(alquilo C1-C3), -SO2N(alquilo C1-C3)2, -COOH, -CH2-COOH, -CH2N(alquilo C1-C6), -CH2-N(alquilo C1-C6)2, -CH2-NH2, piridina, 2-metil-tiazol, morfolino, 1-cloro-2-metil-propilo, -tioalquilo C1-C6, fenilo(opcionalmente sustituido además con halógenos), benciloxi, (alquilo C1-C3)C(O)CH3, (alquilo C1-C3)OCH3,C(O)NH2; o 7-metoxi-2,1,3-benzoxadiazol-4-ilo o 7-cloro-2,1,3-benzoxadiazol-4-ilo cuando X1 es un enlace, n2 es O, n3 es1, X2 es -O- o CH2, R2 es 4-COOH-fenilo, n1 es 1 y R3 es Cl; o piperazinilo sustituido con 4-acetilo, 3,5-dimetilo, 3,5-dimetil-5-acetilo o 2-metil-3-oxo cuando X1 es un enlace,n2 es O, n3 es 1, X2 es -O-, R2 es 4-COOH-fenilo, n1 es 1 y R3 es Cl.",WYETH LLC,MCKEW JOHN;;TAM STEVE;;CLARK JAMES;;LEE KATHERINE;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA,,https://lens.org/045-627-020-039-669,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;A61K31/404;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/00;;C07D221/00;;C07D307/00;;C07D317/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
687,WO,A1,WO 2017/098443 A1,165-959-090-523-378,2017-06-15,2017,IB 2016057458 W,2016-12-09,US 201514965069 A,2015-12-10,PROTEIN-ENRICHED THERAPEUTIC COMPOSITION OF A NICOTINIC COMPOUND,"The present disclosure provides protein-enriched, nicotine-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one nicotinic compound, at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",NICONOVUM USA INC,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,,https://lens.org/165-959-090-523-378,Patent Application,yes,218,0,2,2,0,A61K9/0056;;A61K47/46;;A61K9/1623;;A61K9/1658;;A61K9/1664;;A61K9/2063;;A61K9/2068;;A61K36/81;;A61K45/06;;A61K31/465;;A61K9/0056;;A61K47/46;;A61K9/2068;;A61K36/81;;A61K47/61;;A61K9/2063;;A61K45/06;;A61K9/1658;;A61K9/1664;;A61K47/58;;A61K9/1623;;A61K31/465;;A61K9/0053;;A61K9/2018;;A61K47/10;;A61K47/26;;A61K47/36,A61K47/46;;A61K9/16;;A61K9/20;;A61K31/465,,21,8,094-717-857-085-735;;026-976-334-911-938;;112-651-582-273-375;;148-910-444-751-084;;035-248-158-677-935;;022-823-157-393-400;;120-581-125-812-803;;008-583-216-246-682,10.1517/13543776.10.10.1561;;10.1021/ja052681+;;16218635;;pmc3182463;;10.1016/j.bcp.2007.06.033;;17662959;;10.1016/j.bcp.2009.06.015;;19540210;;10.1248/cpb.50.501;;11963998;;12012171;;10.1007/s00216-002-1260-8;;10.1002/jsfa.2312;;10.1016/j.chroma.2008.09.078;;18849039,"DWOSKIN ET AL., EXP. OPIN. THER. PATENTS, vol. 10, 2000, pages 1561 - 1581;;SCHMITT ET AL., ANNUAL REPORTS IN MED. CHEM., vol. 35, 2000, pages 41 - 51;;HUANG ET AL., J. AM. CHEM. SOC., vol. 127, 2006, pages 14401 - 14414;;ARNERIC ET AL., BIOCHEM. PHARMACOL., vol. 74, 2007, pages 1092 - 1101;;MILLAR, BIOCHEM. PHARMACOL., vol. 78, 2009, pages 766 - 776;;BRANDT ET AL., LC-GC EUROPE, March 2002 (2002-03-01), pages 2 - 5;;WELLINGS: ""A Practical Handbook of Preparative HPLC"", 2006;;ISHIKAWA ET AL., CHEM. PHARM. BULL., vol. 50, 2002, pages 501 - 507;;TIENPONT ET AL., ANAL. BIOANAL. CHEM., vol. 373, 2002, pages 46 - 55;;OCHIAI, GERSTEL SOLUTIONS WORLDWIDE, vol. 6, 2006, pages 17 - 19;;COLEMAN, III ET AL., J. SCI. FOOD AND AGRIC., vol. 84, 2004, pages 1223 - 1228;;COLEMAN, III ET AL., J. SCI. FOOD AND AGRIC., vol. 85, 2005, pages 2645 - 2654;;PAWLISZYN: ""Applications of Solid Phase Microextraction, RSC Chromatography Monographs"", 1999, ROYAL SOCIETY OF CHEMISTRY;;SAHRAOUI ET AL., J. CHROM., vol. 1210, 2008, pages 229 - 233;;PERFETTI, BEITRAGE TABAKFORSCHUNG INT., vol. 12, 1983, pages 43 - 54;;WANG ET AL., J. PARENT. DRUG ASSN., vol. 34, no. 6, 1980, pages 452 - 462;;""Remington: The Science & Practice of Pharmacy, 21st ed.,"", 2006, LIPPINCOTT WILLIAMS & WILKINS;;""Physician's Desk Reference, 64th ed.,"", 2010, THOMSON PDR;;RAYMOND C. ROWE ET AL.,: ""Handbook of Pharmaceutical Excipients, 6th ed.,"", 2009, PHARMACEUTICAL PRESS;;LEFFINGWILL ET AL.: ""Tobacco Flavoring for Smoking Products"", 1972, R. J. REYNOLDS TOBACCO COMPANY;;""Remington's Pharmaceutical Sciences, 18th ed.;"", 1990, MACK PUBLISHING COMPANY",PENDING
688,CN,A,CN 113412113 A,169-768-370-224-675,2021-09-17,2021,CN 201980091724 A,2019-12-10,EP 2018084377 W;;US 201962939853 P;;US 2019/0065341 W,2018-12-11,AMINOAZINE AMIDES,"The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds.",HOFFMANN LA ROCHE,BACCEI JILL MELISSA;;BRAVO YALDA;;CHEN AUSTIN CHIH-YU;;CLARK RYAN CHRISTOPHER;;STEARNS BRIAN ANDREW;;TRUONG YEN PHAM HONG,,https://lens.org/169-768-370-224-675,Patent Application,no,8,0,6,7,0,C07D491/10;;C07D403/06;;C07D471/10;;C07D471/04;;C07D487/10;;C07D495/10;;C07D491/048;;C07D491/107;;A61P1/16;;A61P11/00;;A61P3/00;;A61P9/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07D401/06;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D491/107;;C07D495/10,A61K31/505;;A61K31/506;;C07D239/42,,0,0,,,,PENDING
689,US,B2,US 10420051 B2,011-135-958-683-434,2019-09-17,2019,US 201815936777 A,2018-03-27,US 201815936777 A,2018-03-27,Context aware synchronization methods for decentralized V2V networks,"In one example a system to manage inter-vehicle communication in a decentralized vehicle-to-vehicle network comprises a plurality of sensors to detect context information about driving conditions proximate a first vehicle; a communication interface to manage communications between the first vehicle and a second vehicle; and a controller communicatively coupled to the plurality of sensors and the communication interface and comprising processing circuitry, to receive context information from the plurality of sensors; determine, from the context information, when the first vehicle is approaching a dead zone in which contact with a communication network may be lost; and in response to a determination that the first vehicle is approaching a dead zone in which contact with a communication network may be lost, to activate a synchronization frame broadcast module to broadcast a synchronization frame via the communication interface. Other examples may be described.",INTEL CORP,MERWADAY ARVIND;;CHEN KUILIN CLARK;;DING ZONGRUI;;ZHANG YI;;ALAM S M IFTEKHARUL;;RAHMAN MEHNAZ;;LI QIAN;;LU LU,INTEL CORPORATION (2018-05-07),https://lens.org/011-135-958-683-434,Granted Patent,yes,36,0,3,3,0,H04W88/04;;H04W56/0025;;H04W4/46;;H04W56/002;;H04W4/023;;H04W4/46;;H04W88/04;;H04W56/0025,H04W56/00;;H04W4/02;;H04W4/46,,0,0,,,,ACTIVE
690,WO,A1,WO 2020/119896 A1,001-478-598-272-894,2020-06-18,2020,EP 2018084377 W,2018-12-11,EP 2018084377 W,2018-12-11,HETEROCYCLIC INHIBITORS OF ATX,"The disclosure provides novel compounds having the general formula (I) or a pharmaceutically acceptable salt, solvate or salt of the solvate thereof, compositions including the compounds and methods of using the compounds. The compounds of formula (I) are inhibitors of ATX and therefore useful in the treatment of various disorders (inflammatory, proliferative and others).",HOFFMANN LA ROCHE;;HOFFMANN LA ROCHE,BACCEI JILL MELISSA;;BRAVO YALDA;;AUSTIN CHIH-YU CHEN;;RYAN CHRISTOPHER CLARK;;STEARNS BRIAN ANDREW;;TRUONG YEN PHAM HONG,,https://lens.org/001-478-598-272-894,Patent Application,yes,7,2,1,7,0,A61P1/16;;A61P3/00;;A61P9/00;;A61P11/00;;A61P27/02;;A61P29/00;;A61P35/00;;C07D491/107;;C07D239/42;;C07D403/06;;C07D471/04;;C07D471/10;;C07D487/10;;C07D495/10,C07D403/06;;A61K31/4427;;A61K31/497;;A61K31/501;;A61K31/506;;A61P1/16;;A61P3/00;;A61P9/00;;A61P11/00;;A61P27/02;;A61P29/00;;A61P35/00;;C07D239/42;;C07D471/04;;C07D471/10;;C07D487/10;;C07D491/107;;C07D495/10,,19,14,025-641-933-592-19X;;021-533-051-688-014;;007-798-860-599-886;;002-763-045-071-020;;038-542-272-470-432;;066-120-478-215-707;;079-728-571-037-447;;108-296-141-884-121;;033-167-700-135-136;;003-749-131-464-854;;007-364-858-655-289;;034-806-045-611-689;;013-129-766-729-356;;011-128-409-385-244,27981605;;10.1002/hep.28973;;10.1053/j.gastro.2010.05.009;;20546739;;22867755;;10.1016/j.bbalip.2012.07.019;;10.1016/j.febslet.2014.02.009;;24560789;;24050723;;pmc3826286;;10.1164/rccm.201306-1014oc;;10.1038/labinvest.2013.45;;23478591;;10.1124/jpet.116.234013;;27516465;;20709140;;10.1016/j.biochi.2010.08.002;;10.1136/bjo.2010.194241;;pmc3711020;;21421650;;10.1210/en.2017-00035;;28324037;;10.1002/jps.2600660104;;833720;;10.1002/9783527632220;;4957125;;pmc8036247;;10.1021/ja202769t;;21553878,"KAFFE ET AL., HEPATOLOGY, vol. 65, no. 4, April 2017 (2017-04-01), pages 1369 - 1383;;KREMER ET AL., GASTROENTEROLOGY, vol. 139, 2010, pages 1008 - 1018;;BAIN ET AL., J PHARMACOL. EXP. THER., vol. 360, no. 1, 2017, pages 1 - 13;;SEVASTOU ET AL., BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1831, 2013, pages 42 - 60;;BENESCH M. ET AL., FEBS LETT, vol. 588, no. 16, 2014, pages 2712 - 2727;;PARK ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 188, 2013, pages 928 - 940;;HOZUMI ET AL., LAB. INVEST., vol. 93, 2013, pages 508 - 519;;THIRUNAVUKKARASU K. ET AL., J PHARMACOL EXP THER, vol. 359, no. 1, 2016, pages 207 - 14;;SAMADI ET AL., BIOCHIMIE, vol. 93, 2011, pages 61 - 70;;STAHL ET AL., BR J OPHTHALMOL, vol. 95, no. 11, 2011, pages 1496 - 15010;;D'SOUZA ET AL., ENDOCRINOLOGY, vol. 158, no. 4, 2017, pages 791 - 803;;BIOCHEM., vol. 11, 1972, pages 942 - 944;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;S. M. BERGE ET AL.: ""Pharmaceutical Salt"", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Pharmaceutical Salts: Properties, Selection, and Use. A Handbook"", 2002, VERLAG HELVETICA CHIMICA ACTA;;REICHARDT, C.; WELTON T.: ""Solvents and Solvent Effects in Organic Chemistry"", 2011, JOHN WILEY & SONS;;FREIREICH ET AL., CANCER CHEMOTHER. REP., vol. 50, 1966, pages 219 - 244;;""Scientific Tables"", 1970, GEIGY PHARMACEUTICALS, pages: 537;;J. AM. CHEM. SOC., vol. 133, 2011, pages 8478 - 8481",PENDING
691,PL,T3,PL 2427425 T3,045-438-443-434-094,2017-08-31,2017,PL 10765527 T,2010-05-07,US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS,,https://lens.org/045-438-443-434-094,Patent Application,no,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,PENDING
692,AU,A,AU 1997/038923 A,070-858-340-809-401,1998-02-10,1998,AU 1997/038923 A,1997-07-24,US 2257896 P;;US 2307796 P;;US 9712983 W,1996-07-24,"Protein engineering of glucoamylase to increase ph optimum, substrate specificity and thermostability",,UNIV IOWA STATE RES FOUND INC,ALLEN MARTIN;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;CLARK FORD,,https://lens.org/070-858-340-809-401,Patent Application,no,0,0,6,7,0,C12N9/2428,C12N15/09;;C12N1/21;;C12N9/34;;C12P19/04;;C12Q1/40;;C12R1/645,,0,0,,,,DISCONTINUED
693,EP,A4,EP 3873473 A4,177-530-728-850-858,2022-06-29,2022,EP 19895885 A,2019-12-10,EP 2018084377 W;;US 201962939853 P;;US 2019/0065341 W,2018-12-11,AMINOAZINE AMIDES,,HOFFMANN LA ROCHE,BACCEI JILL MELISSA;;BRAVO YALDA;;CHEN AUSTIN CHIH-YU;;CLARK RYAN CHRISTOPHER;;STEARNS BRIAN ANDREW;;TRUONG YEN PHAM HONG,,https://lens.org/177-530-728-850-858,Search Report,no,8,0,6,7,0,C07D491/10;;C07D403/06;;C07D471/10;;C07D471/04;;C07D487/10;;C07D495/10;;C07D491/048;;C07D491/107;;A61P1/16;;A61P11/00;;A61P3/00;;A61P9/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07D401/06;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D491/107;;C07D495/10,C07D403/06;;A61K31/4427;;A61K31/497;;A61K31/501;;A61K31/506;;A61P1/16;;A61P3/00;;A61P9/00;;A61P11/00;;A61P27/02;;A61P29/00;;A61P35/00;;A61P37/02;;C07D239/42;;C07D471/04;;C07D471/10;;C07D487/10;;C07D491/107;;C07D495/10,,1,0,,,See also references of WO 2020123426A1,PENDING
694,CN,A,CN 102459153 A,178-541-771-982-725,2012-05-16,2012,CN 201080031077 A,2010-05-07,US 2010/0001350 W;;US 21575709 P,2009-05-08,Tetracycline compounds,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHI-LI CHEN;;CLARK ROGER B;;YONGHONG DENG;;MINSHENG HE;;LOUIS PLAMONDON;;CUIXIANG SUN;;XIAO-YI XIAO;;MAGNUS ROENN,,https://lens.org/178-541-771-982-725,Patent Application,no,4,4,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,1,1,026-872-796-351-596,pmc2681267;;19053822;;10.1021/ja806629e,"CUIXIANG SUN ET AL.: ""A Robust Platform for the Synthesis of New Tetracycline Antibiotics"", 《J.AM.CHEM.SOC.》, vol. 130, 31 December 2008 (2008-12-31), pages 17913 - 17927, XP002604988, DOI: doi:10.1021/JA806629E",DISCONTINUED
695,PT,E,PT 1891006 E,058-967-431-337-559,2011-01-26,2011,PT 06771540 T,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH LLC,LEE KATHERINE LIN;;MCKEW JOHN C;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;PONG KEVIN,,https://lens.org/058-967-431-337-559,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
696,US,A1,US 2017/0164651 A1,095-716-195-478-688,2017-06-15,2017,US 201514965080 A,2015-12-10,US 201514965080 A,2015-12-10,PROTEIN-ENRICHED TOBACCO COMPOSITION,"The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",REYNOLDS TOBACCO CO R,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,R.J. REYNOLDS TOBACCO COMPANY (2016-01-26),https://lens.org/095-716-195-478-688,Patent Application,yes,24,19,4,4,0,A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B15/32,A24B15/24;;A24B3/14;;A24B13/00;;A24B15/32,,2,0,,,"English translations, provided by Espacenet and Google patents, for foreign patent documents;;STIC 1700 Search report",ACTIVE
697,EP,A2,EP 2427425 A2,000-841-913-811-139,2012-03-14,2012,EP 10765527 A,2010-05-07,US 2010/0001350 W;;US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;ROENN MAGNUS,,https://lens.org/000-841-913-811-139,Patent Application,yes,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,1,0,,,See references of WO 2010129057A2,ACTIVE
698,CA,A1,CA 2761241 A1,010-984-092-517-610,2010-11-11,2010,CA 2761241 A,2010-05-07,US 21575709 P;;US 2010/0001350 W,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;ROENN MAGNUS,,https://lens.org/010-984-092-517-610,Patent Application,no,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,INACTIVE
699,WO,A1,WO 1998/003639 A1,152-355-747-830-286,1998-01-29,1998,US 9712983 W,1997-07-24,US 2257896 P;;US 2307796 P,1996-07-24,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE pH OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY","A fungal glucoamylase including a mutation pair Asn20Cys coupled with Ala27Cys forming a disulfide bond between the two members of the pair. The mutation provides increased thermal stability and reduced isomaltose formation to the enzyme. A fungal glucoamylase including a 311-314Loop mutation, wherein reduced isomaltose formation is provided by the mutation, is also provided. A fungal glucoamylase, including a mutation Ser411Ala wherein increased pH optimum and reduced isomaltose formation is provided by the mutation, is also provided. Combinations of the mutations in engineered glucoamylases are also provided as are combinations with other glucoamylase mutations that provide increased thermal stability, increased pH optimum and reduced isomaltose formation for cumulative improvements in the engineered glucoamylases.",UNIV IOWA STATE RES FOUND INC;;ALLEN MARTIN;;FANG TSUEI YUN;;LI YUXING;;LIU HSUAN LIANG;;CHEN HSIU MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,ALLEN MARTIN;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/152-355-747-830-286,Patent Application,yes,0,30,6,7,0,C12N9/2428,C12N15/09;;C12N1/21;;C12N9/34;;C12P19/04;;C12Q1/40;;C12R1/645,,7,6,095-780-397-149-715;;083-279-939-512-570;;020-617-470-769-304;;000-151-312-534-318;;074-224-868-188-122;;031-446-433-102-047,10.31274/rtd-180813-10576;;10.31274/rtd-180813-12161;;10.1093/protein/9.6.499;;8862550;;10.1093/protein/10.1.81;;9051738;;10.1021/bi960241c;;8679632;;10.1093/protein/7.12.1479;;7716159,"DISSERTATION ABSTRACTS INTERNATIONAL, Abstract No. 97:24090, 1996, Vol. 57, No. 11B, LI, ""Genetic Construction and Biochemical Analysis of Thermostability Mutants of Glucoamylase from Aspergillus Awamori"", page 6761.;;DISSERTATION ABSTRACTS INTERNATIONAL, Abstract No. 95(03):B0023, 1994, Vol. 54, CHEN, ""Site-Directed Mutagenesis to Enhance Thermostability of Aspergillus Awamori Glucoamylase Expressed in Saccharomyces Cerevisiae"", page 5998.;;PROTEIN ENGINEERING, June 1996, Vol. 9, No. 6, CHEN et al., ""Effect of Replacing Helical Glycine Residues with Alanines on Reversible and Irreversible Stability and Production of Aspergillus Awamori Glucoamylase"", pages 499-505.;;PROTEIN ENGINEERING, January 1997, Vol. 10, No. 1, STOFFER et al., ""Glucoamylase Mutants in the Conserved Active-Site Segment Trp170-Tyr175 Located at a Distance from the Site of Catalysis"", pages 81-87.;;BIOCHEMISTRY, 02 July 1996, Vol. 35, No. 26, FIEROBE et al., ""Mutational Modulation of Substrate Bond-Type Specificity and Thermostability of Glucoamylase from Aspergillus Awamori by Replacement with Short Homologue Active Site Sequences and Thiol/Disulfide Engineering"", pages 8696-8704.;;PROTEIN ENGINEERING, December 1994, Vol. 7, No. 12, SIERCKS et al., ""Protein Engineering of the Relative Specificity of Glucoamylase from Aspergillus Awamori Based on Sequence Similarities Between Starch-Degrading Enzymes"", pages 1479-1484.;;PROTEIN ENGINEERING, Abstract No. 93-04739, March 1993, Vol. 6, BAKIR et al., ""Cassette Mutagenesis of the Active Site of Aspergillus Awamori Glucoamylase"", page 41.",PENDING
700,US,A1,US 2012/0135968 A1,125-104-384-495-961,2012-05-31,2012,US 201013319298 A,2010-05-07,US 201013319298 A;;US 21575709 P;;US 2010/0001350 W,2009-05-08,Tetracycline Compounds,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;ROENN MAGNUS,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;ROENN MAGNUS,TETRAPHASE PHARMACEUTICALS INC (2011-02-28),https://lens.org/125-104-384-495-961,Patent Application,yes,0,15,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,A61K31/65;;A61P31/04;;C07C237/26;;C07D205/04;;C07D207/09;;C07D207/14;;C07D209/42;;C07D209/44;;C07D209/52;;C07D211/14;;C07D211/58;;C07D211/62;;C07D213/56;;C07D217/20;;C07D221/20;;C07D223/08;;C07D223/14;;C07D223/16;;C07D225/02;;C07D241/08;;C07D279/12;;C07D295/155;;C07D295/185;;C07D295/26;;C07D307/16;;C07D307/22;;C07D401/04;;C07D471/10;;C07D487/08,514/152;;552/203;;548/528;;544/380;;546/195;;548/482;;548/950;;540/612;;548/515;;546/285;;548/952;;546/16;;549/480;;549/494;;544/154;;548/453;;546/146;;544/58.2;;540/450;;540/482;;540/593;;540/604;;540/594;;548/504,0,0,,,,ACTIVE
701,EP,A1,EP 3873473 A1,147-460-216-628-621,2021-09-08,2021,EP 19895885 A,2019-12-10,EP 2018084377 W;;US 201962939853 P;;US 2019/0065341 W,2018-12-11,AMINOAZINE AMIDES,,HOFFMANN LA ROCHE,BACCEI JILL MELISSA;;BRAVO YALDA;;CHEN AUSTIN CHIH-YU;;CLARK RYAN CHRISTOPHER;;STEARNS BRIAN ANDREW;;TRUONG YEN PHAM HONG,,https://lens.org/147-460-216-628-621,Patent Application,yes,0,0,6,7,0,C07D491/10;;C07D403/06;;C07D471/10;;C07D471/04;;C07D487/10;;C07D495/10;;C07D491/048;;C07D491/107;;A61P1/16;;A61P11/00;;A61P3/00;;A61P9/00;;A61P29/00;;A61P35/00;;A61P37/02;;C07D401/06;;C07D403/06;;C07D471/04;;C07D471/10;;C07D491/048;;C07D491/107;;C07D495/10,A61K31/505;;A61K31/506;;C07D239/42,,0,0,,,,PENDING
702,US,B2,US 9315451 B2,090-470-070-718-933,2016-04-19,2016,US 201013319298 A,2010-05-07,US 201013319298 A;;US 21575709 P;;US 2010/0001350 W,2009-05-08,Tetracycline compounds,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS;;TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS,TETRAPHASE PHARMACEUTICALS INC (2011-02-28),https://lens.org/090-470-070-718-933,Granted Patent,yes,82,9,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,A61K31/65;;C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/10;;C07D209/04;;C07D209/44;;C07D211/14;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/13;;C07D295/15;;C07D295/155,,38,8,026-872-796-351-596;;056-591-233-129-286;;002-078-829-796-489;;031-094-950-921-992;;160-925-493-776-604;;185-160-153-276-14X;;070-856-765-326-262;;109-552-349-845-005,pmc2681267;;19053822;;10.1021/ja806629e;;10.1128/mmbr.65.2.232-260.2001;;pmc99026;;11381101;;10.1016/j.coph.2008.08.001;;18761107;;15831754;;10.1126/science.1109755;;10.1021/jo01057a501;;10.1517/eotp.13.4.467.23118;;10.1517/13543776.18.1.69;;10.1021/ja01072a057,"Notice of Allowance, U.S. Appl. No. 13/570,837, Dated: Jun. 6, 2013.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, International Search Report and Written Opinion in International Application No. PCT/US2010/001350, 13 pages, date of mailing Nov. 23, 2010.;;Sun, C., et al., ""A Robust Platform for the Synthesis of New Tetracycline Antibiotics,"" J. Am. Chem. Soc., 130:17913-17927 (2008).;;Chopra, I. and Roberts, M., ""Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance,"" Microbiology and Molecular Biology Reviews, 65(2): 232-260 (2001).;;Office Action, U.S. Appl. No. 13/718,909, Dated: Jul. 9, 2013.;;Office Action, U.S. Appl. No. 12/462,795, Dated: Sep. 23, 2013.;;Abbanat, D., et al., ""New agents in development for the treatment of bacterial infections"", Current Opinion in Pharmacology, 8(5): 582-592 (available online Sep. 18, 2008).;;Charest, M.G., et al., ""A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics,"" Science, 308: 395-398 (2005).;;Hlavka, J.J., et al., ""The 6-Deoxytetracyclines. IV. A Photochemical Displacement of a Diazonium Group,"" Organic Chemical Research Section, vol. 27, pp. 3674-3675 (1962).;;Podlogar, B., L., et al ""Patents on tetracycline and tetracyline derivatives as antimicrobials"", Expert Opin. Ther. Patents, 13(4): 467-478 (2003).;;Sato, F., et al. ""Structure-Activity Relationship Investigation of Some New Tetracyclines by Electronic Index Methodology"", Los Alamos National Laboratory, Quantitative Biology, 1-18 (Aug. 21, 2007).;;Verma, A.K., et al., ""Antibiotic and non-antibiotic tetracycline patents"", Expert Opin. Ther. Patents, vol. 18, pp. 69-82 (2008).;;Written Opinion of the International Searching Authority for International Application No. PCT/US2009/053142; Date Mailed: Oct. 13, 2009.;;International Search Report for International Application No. PCT/US2009/053142; Date Mailed: Oct. 13, 2009.;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/053142 dated Feb. 17, 2011.;;Notification of Transmittal of International Search Report and the Written Opinion of the International Search Authority, or the Declaration, in International Application No. PCT/US2010/047035; Date mailed: Jul. 22, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2009/001350; Date Mailed: Nov. 9, 2011.;;Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration, in International Application No. PCT/US2011/047428, 4 pages, date of mailing Jan. 6, 2012.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/047035; Date Mailed: Feb. 28, 2012.;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2011/047428; Date Mailed: Feb. 21, 2013.;;Office Action, U.S. Appl. No. 12/462,795, Dated: Dec. 7, 2011.;;Office Action, U.S. Appl. No. 12/462,795, Dated: Jan. 24, 2012.;;Office Action, U.S. Appl. No. 12/462,795, Dated: Jul. 24, 2012.;;Office Action, U.S. Appl. No. 13/570,837, Dated: Feb. 4, 2013.;;Pre Appeal Brief Conference Decision, U.S. Appl. No. 12/462,795, Dated: Feb. 19, 2013.;;Office Action, U.S. Appl. No. 13/718,909, Dated: Feb. 5, 2013.;;Esse, R., et al., ""Tetracycloxides. II. Transformations at the C-4 Position"", Journal of the American Chemical Society, 86(18): 3875-3877 (Sep. 20, 1964).;;International Search Report for International Application No. PCT/US2013/057690, ""Tetracycline Compounds,"" Date of Mailing: Feb. 24, 2014.;;HCAPLUS, Accession No. 2005:99455, Document No. 142:197754 (Jun. 25, 2004).;;HCAPLUS, Accession No. 2004:1036703, Document No. 141:420412 (Apr. 24, 2002).;;Office Action dated Jan. 16, 2014 for U.S. Appl. No. 13/319,298, ""Tetracycline Compounds"".;;Office Action dated Jan. 17, 2014 for U.S. Appl. No. 12/462,795, ""C7-Fluoro Substituted Tetracycline Compounds."";;Office Action dated Feb. 14, 2014 for U.S. Appl. No. 13/391,407, ""Tetracycline Compounds."";;Notice of Allowance dated Jun. 5, 2014 for U.S. Appl. No. 13/718,909, ""Tetracycline Compounds."";;Martin, W., et al., ""Totalsynthese von d, 1-7-Chlor-6-desoxytetracyclinen und d, 1-7-Chlor-6-desmethy1-6-desoxytetracyclinen der naturlichen, der 5a-epi- und der 6-epi-Reihe"", Tetrahedron Letters, pp. 3513-3516, (Dec. 31, 1975).;;Extended Search Report for European Patent Application No. 13172357.9 dated May 16, 2014 ""C7-Fluoro Substituted Tetracycline Compounds"".;;Notice of Allowance, U.S. Appl. No. 12/462,795, Dated: Aug. 4, 2014.;;Final Office Action, U.S. Appl. No. 13/391,407, Dated: Oct. 1, 2014.",ACTIVE
703,AT,T1,AT E384045 T1,142-537-421-251-852,2008-02-15,2008,AT 02786829 T,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,INHIBITOREN VON CYTOSOLISCHEN PHOSPHOLIPASE A2,,WYETH CORP,MCKEW JOHN;;TAM STEVE;;CLARK JAMES;;LEE KATHERINE;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA,,https://lens.org/142-537-421-251-852,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
704,WO,A1,WO 2017/098439 A1,009-448-679-512-187,2017-06-15,2017,IB 2016057449 W,2016-12-08,US 201514965080 A,2015-12-10,PROTEIN-ENRICHED TOBACCO COMPOSITION,"The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",REYNOLDS TOBACCO CO R,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,,https://lens.org/009-448-679-512-187,Patent Application,yes,125,2,4,4,0,A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B15/32,A24B13/00;;A24B15/10;;A24B15/24,,1,0,,,"DAVIS ET AL.: ""Tobacco Production, Chemistry and Technology"", 1999",PENDING
705,CA,C,CA 2761241 C,047-825-731-692-55X,2018-02-27,2018,CA 2761241 A,2010-05-07,US 21575709 P;;US 2010/0001350 W,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically ac-ceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;ROENN MAGNUS,,https://lens.org/047-825-731-692-55X,Granted Patent,no,0,0,17,17,0,C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/14;;C07D209/14;;C07D209/44;;C07D209/52;;C07D211/14;;C07D211/18;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D221/20;;C07D241/04;;C07D261/20;;C07D295/108;;C07D295/155;;C07D295/26;;C07D307/22;;C07D401/04;;C07D487/10;;C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/10;;C07D209/04;;C07D209/44;;C07D211/14;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/13;;C07D295/15;;C07D295/155;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/08;;C07C2602/24;;C07C2602/42;;C07C2602/50;;C07C2603/46;;C07C2603/74;;C07D207/09;;C07D207/14;;C07D207/16;;C07D209/14;;C07D209/52;;C07D223/14;;C07D261/20;;C07D295/135;;C07D295/185;;C07D295/26;;C07D307/22;;C07D401/04;;C07D413/06;;C07D471/10;;A61P31/04;;A61P31/12;;C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/10;;C07D209/04;;C07D209/44;;C07D211/14;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/13;;C07D295/15;;C07D295/155;;C07C2601/02;;C07C2601/04;;C07C2601/08;;C07C2601/14;;C07C2601/18;;C07C2602/08;;C07C2602/24;;C07C2602/42;;C07C2602/50;;C07C2603/46;;C07C2603/74;;C07D207/09;;C07D207/14;;C07D207/16;;C07D209/14;;C07D209/52;;C07D223/14;;C07D261/20;;C07D295/135;;C07D295/185;;C07D295/26;;C07D307/22;;C07D401/04;;C07D413/06;;C07D471/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,INACTIVE
706,EP,B1,EP 2427425 B1,154-739-846-912-071,2017-03-08,2017,EP 10765527 A,2010-05-07,US 2010/0001350 W;;US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS,,https://lens.org/154-739-846-912-071,Granted Patent,yes,1,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,ACTIVE
707,AU,A,AU 2001/035130 A,034-131-493-363-882,2001-08-16,2001,AU 2001/035130 A,2001-04-12,AU 2001/035130 A,2001-04-12,"Protein engineering of glucoamylase to increase pH optimum, ubstrate specificity and thermostability",,UNIV IOWA STATE RES FOUND INC,ALLEN MARTIN;;LI YUXING;;FANG TSUEI-YUN;;LIUN HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/034-131-493-363-882,Patent Application,no,0,0,1,1,0,,C12N1/21;;C12N9/34;;C12N15/09;;C12N15/63,,0,0,,,,DISCONTINUED
708,CN,A,CN 107021887 A,034-393-817-373-164,2017-08-08,2017,CN 201710098748 A,2010-05-07,US 21575709 P;;CN 201080031077 A,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RONN MAGNUS,,https://lens.org/034-393-817-373-164,Patent Application,no,4,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;A61K31/65;;A61P31/04;;A61P31/12;;C07C231/10;;C07D205/04;;C07D207/06;;C07D207/14;;C07D209/14;;C07D209/44;;C07D209/52;;C07D211/14;;C07D211/18;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D221/20;;C07D241/04;;C07D295/108;;C07D295/155;;C07D295/26;;C07D307/22;;C07D401/04;;C07D487/10,,1,1,026-872-796-351-596,pmc2681267;;19053822;;10.1021/ja806629e,"CUIXIANG SUN，ET AL.: ""“A Robust Platform for the Synthesis of New Tetracycline Antibiotics”"", 《J. AM. CHEM. SOC.》",DISCONTINUED
709,US,A1,US 2019/0053178 A1,059-193-772-756-807,2019-02-14,2019,US 201815936777 A,2018-03-27,US 201815936777 A,2018-03-27,CONTEXT AWARE SYNCHRONIZATION METHODS FOR DECENTRALIZED V2V NETWORKS,"In one example a system to manage inter-vehicle communication in a decentralized vehicle-to-vehicle network comprises a plurality of sensors to detect context information about driving conditions proximate a first vehicle; a communication interface to manage communications between the first vehicle and a second vehicle; and a controller communicatively coupled to the plurality of sensors and the communication interface and comprising processing circuitry, to receive context information from the plurality of sensors; determine, from the context information, when the first vehicle is approaching a dead zone in which contact with a communication network may be lost; and in response to a determination that the first vehicle is approaching a dead zone in which contact with a communication network may be lost, to activate a synchronization frame broadcast module to broadcast a synchronization frame via the communication interface. Other examples may be described.",INTEL CORP,MERWADAY ARVIND;;CHEN KUILIN CLARK;;DING ZONGRUI;;ZHANG YI;;ALAM S M IFTEKHARUL;;RAHMAN MEHNAZ;;LI QIAN;;LU LU,INTEL CORPORATION (2018-05-07),https://lens.org/059-193-772-756-807,Patent Application,yes,35,12,3,3,0,H04W88/04;;H04W56/0025;;H04W4/46;;H04W56/002;;H04W4/023;;H04W4/46;;H04W88/04;;H04W56/0025,H04W56/00;;H04W4/02;;H04W4/46,,0,0,,,,ACTIVE
710,US,B2,US 11612183 B2,115-190-336-896-040,2023-03-28,2023,US 201514965080 A,2015-12-10,US 201514965080 A,2015-12-10,Protein-enriched tobacco composition,"The present disclosure provides protein-enriched, tobacco-containing products, suitable for use as oral formulations. Products of the present disclosure typically include at least one tobacco material (e.g., a particulate tobacco material or a tobacco-derived extract), at least one protein-enriched material (e.g., a tobacco-derived protein-enriched material), and at least one sugar alcohol.",REYNOLDS TOBACCO CO R,MUA JOHN-PAUL;;CHEN GONG;;JACKSON THADDEUS JUDE;;GERARDI ANTHONY RICHARD;;FORD KYLE;;FAGG BARRY SMITH;;CLARK MELISSA ANN,R.J. REYNOLDS TOBACCO COMPANY (2016-01-26),https://lens.org/115-190-336-896-040,Granted Patent,yes,98,0,4,4,0,A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B13/00;;A24B15/10;;A24B15/24;;A24B3/14;;A24B15/32,A24B13/00;;A24B3/14;;A24B15/10;;A24B15/24;;A24B15/32,,5,2,092-681-205-100-931;;021-359-682-168-065,10.1016/j.phytochem.2009.08.020;;19766275;;11725610;;10.1385/criai:21:2-3:93,"English translations, provided by Espacenet and Google patents, for foreign patent documents.;;STIC 1700 Search report.;;Krishnan et al., “A Rapid Method for Depletion of Rubisco From Soybean (Glycine Max) Leaf for Proteomic Analysis of Lower Abundance Proteins,” Phytochemistry, 2009, pp. 1958-1964, vol. 70.;;Siceloff, “A Revolutionary Upheaval? Tobacco for Protein” N.C. Insight, Jun. 1981, pp. 28-32. http://www.nccppr.org/drupal/content/insightarticle/918/tobacco-for-protein.;;Hauck et al., “The Manufacture of Allergenic Extracts in North America,” Clinical Review in Allergy and Immunology, 2001, pp. 93-110, vol. 21.",ACTIVE
711,US,A1,US 2017/0104031 A1,190-749-813-859-897,2017-04-13,2017,US 201615287091 A,2016-10-06,US 201615287091 A;;US 201562238519 P,2015-10-07,Selector Elements,"Provided are selector elements with active components comprising insulating matrices and mobile ions disposed within these insulating matrices. Also provided are methods of operating such selector elements. The insulating matrices and mobile ions may be formed from different combinations of materials. For example, the insulating matrix may comprise amorphous silicon or silicon oxide, while mobile ions may be silver ions. In another example, the active component comprises copper and germanium, selenium, or tellerium, e.g., Se 61 Cu 39 , Se 67 Cu 33 , or Se 56 Cu 44 . The active component may be a multilayered structure with a variable composition throughout the structure. For example, the concentration of mobile ions may be higher in a center of the structure, away from the electrode interfaces. In some embodiments, outer layers may be formed from Ge 33 Se 24 Cu 47 , while the middle layer may be formed from Ge 47 Se 29 Cu 24 .",INTERMOLECULAR INC,CLARK MARK;;PHATAK PRASHANT;;CHEN CHARLENE;;BODKE ASHISH;;MUJUMDAR SALIL;;NARDI FEDERICO;;KAHLON SATBIR;;BARABASH SERGEY V;;WANG FEIHU,INTERMOLECULAR INC (2016-12-16),https://lens.org/190-749-813-859-897,Patent Application,yes,3,14,1,1,0,G11C2213/53;;G11C2213/76;;G11C13/003;;G11C11/1659;;G11C2213/72;;H10B63/20;;H10B61/10;;H10N70/245;;H10N70/826;;H10N70/8416;;H10N70/8825;;H10N70/8828;;G11C13/003;;G11C11/1659;;G11C2213/72;;G11C2213/53;;G11C2213/76;;H10B61/10;;H10B63/20;;H10N70/245;;H10N70/826;;H10N70/8416;;H10N70/8825;;H10N70/8828,H01L27/24;;G11C11/16;;G11C13/00;;H01L27/22;;H01L45/00,,0,0,,,,DISCONTINUED
712,CA,A1,CA 2259958 A1,054-116-344-147-262,1998-01-29,1998,CA 2259958 A,1997-07-24,US 2257896 P;;US 2307796 P,1996-07-24,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE PH OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY","A fungal glucoamylase including a mutation pair Asn20Cys coupled with Ala27Cys forming a disulfide bond between the two members of the pair. The mutation provides increased thermal stability and reduced isomaltose formation to the enzyme. A fungal glucoamylase including a 311-314Loop mutation, wherein reduced isomaltose formation is provided by the mutation, is also provided. A fungal glucoamylase, including a mutation Ser411Ala wherein increased pH optimum and reduced isomaltose formation is provided by the mutation, is also provided. Combinations of the mutations in engineered glucoamylases are also provided as are combinations with other glucoamylase mutations that provide increased thermal stability, increased pH optimum and reduced isomaltose formation for cumulative improvements in the engineered glucoamylases.",UNIV IOWA STATE RES FOUND INC,FORD CLARK;;COUTINHO PEDRO;;CHEN HSIU-MEI;;FANG TSUEI-YUN;;ALLEN MARTIN;;LIU HSUAN-LIANG;;LI YUXING;;HONZATKO RICHARD,,https://lens.org/054-116-344-147-262,Patent Application,no,0,0,6,7,11,C12N9/2428,C12N15/09;;C12N1/21;;C12N9/34;;C12P19/04;;C12Q1/40;;C12R1/645,,0,0,,,,DISCONTINUED
713,EP,A1,EP 0970193 A1,041-843-414-537-434,2000-01-12,2000,EP 97936193 A,1997-07-24,US 2257896 P;;US 2307796 P;;US 9712983 W,1996-07-24,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE pH OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY",,UNIV IOWA STATE RES FOUND INC,ALLEN MARTIN;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/041-843-414-537-434,Patent Application,yes,0,0,6,7,12,C12N9/2428,C12N15/09;;C12N1/21;;C12N9/34;;C12P19/04;;C12Q1/40;;C12R1/645,,1,0,,,See references of WO 9803639A1,DISCONTINUED
714,DK,T3,DK 2427425 T3,003-364-802-742-61X,2017-06-12,2017,DK 10765527 T,2010-05-07,US 21575709 P;;US 2010/0001350 W,2009-05-08,TETRACYCLINFORBINDELSER,,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RÖNN MAGNUS,,https://lens.org/003-364-802-742-61X,Granted Patent,no,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D209/04;;C07D211/34;;C07D221/20;;C07D223/04;;C07D223/32;;C07D295/03,,0,0,,,,ACTIVE
715,WO,A1,WO 2023/091299 A1,016-457-720-940-895,2023-05-25,2023,US 2022/0048629 W,2022-11-01,US 202163279901 P,2021-11-16,SILICON ETCH WITH ORGANOCHLORIDE,"A method of etching recessed features in a stack with a silicon containing layer over a wafer on a substrate support is provided. The substrate support is maintained at a temperature below about 30° C. An etch ga, comprising an organochloride source selected from the group consisting of carbon tetrachloride (CCl 4 ), C x H y Cl z (where x>0 and z > 0), and combinations thereof, a carbon source, a fluorine source, and a hydrogen source is flowed. The etch gas is formed into a plasma. The stack is exposed to the plasma to etch recessed features into the stack.",LAM RES CORP,PISKUN ILYA;;VEBER GREGORY CLINTON;;AGARWAL DAKSH;;OZEL TANER;;MUKHOPADHYAY AMIT;;CHEN CHEN;;SERINO ANDREW CLARK;;HUDSON ERIC;;RALSTON WALTER THOMAS;;XU QING;;WONG MERRETT,,https://lens.org/016-457-720-940-895,Patent Application,yes,5,0,1,1,0,H01L21/3065;;H01L21/31116,H01L21/311;;H01L21/3213,,0,0,,,,PENDING
716,WO,A1,WO 2020/091988 A1,150-823-435-452-468,2020-05-07,2020,US 2019/0056193 W,2019-10-15,EP 18290127 A,2018-10-29,FABRIC CARE COMPOSITION WITH SILICONE,"A fabric care composition is provided including water; a cleaning surfactant; a fabric softening silicone; and a modified carbohydrate polymer having a weight average molecular weight of < 500,000 Daltons and a Kjeldahl nitrogen content corrected for ash and volatiles, TKN, of ≥ 0.5 wt%; wherein the modified carbohydrate polymer is a carbohydrate polymer functionalized with quaternary ammonium moieties; wherein the quaternary ammonium moieties on the modified carbohydrate polymer include: trimethyl ammonium moieties having formula (I) and dimethyl(alkyl) ammonium moieties having formula (II) wherein each R is independently selected from a C 8‑22 alkyl group.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR;;MIGLIORE ALINE;;CHEN YUNSHEN;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN;;TODD JENNIFER P;;LESLIE CYNTHIA,,https://lens.org/150-823-435-452-468,Patent Application,yes,6,2,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D3/37,,3,0,,,"W. W. YAUJ. J. KIRKLANDD. D. BLY: ""Modem Size Exclusion Chromatography"", 1979, WILEY-LNTERSCIENCE;;J. P. SIBILIA: ""A Guide to Materials Characterization and Chemical Analysis"", 1988, VCH, pages: 81 - 84;;""The Encyclopedia of Polymer Science"", vol. 11, pages: 765",PENDING
717,US,A1,US 2017/0044160 A1,173-418-149-702-740,2017-02-16,2017,US 201615079926 A,2016-03-24,US 201615079926 A;;US 201213319298 A;;US 2010/0001350 W;;US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RONN MAGNUS P,TETRAPHASE PHARMACEUTICALS INC (2011-02-28),https://lens.org/173-418-149-702-740,Patent Application,yes,0,4,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07D471/10;;C07C237/26;;C07D205/04;;C07D207/09;;C07D207/14;;C07D207/16;;C07D209/14;;C07D209/44;;C07D209/52;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/14;;C07D261/20;;C07D295/135;;C07D295/185;;C07D295/26;;C07D307/22;;C07D401/04;;C07D413/06,,0,0,,,,INACTIVE
718,AU,A1,AU 2013/203348 A1,115-692-438-239-586,2013-05-02,2013,AU 2013/203348 A,2013-04-10,AU 2012/203813 A;;AU 2013/203348 A,2012-06-28,Site-directed modification of FVIII,"H:\fmt\Intenvovcn\NRPottbl\DCC\FM-I4427591_l.doc-6/042013 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/115-692-438-239-586,Patent Application,no,0,0,2,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,0,0,,,,ACTIVE
719,WO,A1,WO 2000/043504 A1,048-073-824-272-578,2000-07-27,2000,US 0000532 W,2000-01-10,US 23606399 A,1999-01-22,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE pH OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY","A fungal glucoamylase including a mutation pair Asn20Cys coupled with Ala27Cys forming a disulfide bond between the two members of the pair. The mutation provides increased thermal stability and reduced isomaltose formation to the enzyme. A fungal glucoamylase including a 311-314Loop mutation wherein reduced isomaltose formation is provided by the mutation is also provided. A fungal glucoamylase including a mutation Ser411Ala wherein increased pH optimum and reduced isomaltose formation is provided by the mutation is also provided. Combinations of the mutations in engineered glucoamylases are also provided as are combinations with other glucoamylase mutations that provide increased thermal stability, increased pH optimum and reduced isomaltose formation for cumulative improvements in the engineered glucoamylases. Also provided is a fungal glucoamylase including a mutation of Ser30Pro coupled with at least two stabilizing mutations forming a disulfide bond between the two stabilizing members. A fungal glucoamylase including a Ser30Pro/Gly137Ala/311-314 Loop is provided. A fungal glucoamylase including a mutation Ser30Pro/Glu137Ala/Ser411Ala is also provided.",UNIV IOWA STATE RES FOUND INC;;ALLEN MARTIN J;;FANG TSUEI YUN;;LI YUXING;;LIU HSUAN LIANG;;CHEN HSIU MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,ALLEN MARTIN J;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/048-073-824-272-578,Patent Application,yes,1,6,4,4,0,C12N9/2428;;C12N9/2428,C12N1/21;;C12N9/34,,10,9,095-780-397-149-715;;083-279-939-512-570;;020-617-470-769-304;;000-151-312-534-318;;074-224-868-188-122;;031-446-433-102-047;;008-011-081-630-72X;;025-692-352-779-116;;063-388-031-611-736,10.31274/rtd-180813-10576;;10.31274/rtd-180813-12161;;10.1093/protein/9.6.499;;8862550;;10.1093/protein/10.1.81;;9051738;;10.1021/bi960241c;;8679632;;10.1093/protein/7.12.1479;;7716159;;10.1093/protein/11.9.783;;9796827;;9605546;;10.1093/protein/11.2.119;;10.1093/protein/11.2.127;;9605547,"DATABASE DIALOG LI, YUXING: ""Genetic Construction and Biochemical Analysis of Thermostability mutants of Glucoamylase from Aspergillus Awamori"", XP002931801;;DATABASE DIALOG CHEN, HSIU-MEI: ""Site-Directed Mutagenesis to Enhance Thermostability of Aspergillus Awamori Glucoamylase Expressed in Sacharomyces Cerevisiae"", XP002931802;;CHEN ET AL.: ""Effect of replacing helical glycine residues with alanines on reversible and irreversible stability and production of Aspergillus awamori glucoamylase"", PROTEIN ENGINEERING,, vol. 9, no. 6, June 1996 (1996-06-01), pages 499 - 505, XP002926723;;STOFFER ET AL.: ""Glucoamylase mutants in the conserved active-site segment Trp170-Tyr175 located at a distance from the site of catalysis"", PROTEIN ENGINEERING,, vol. 10, no. 1, January 1997 (1997-01-01), pages 81 - 87, XP002927866;;FIEROBE ET AL.: ""Mutational modulation of substrate bond-type specificity and thermostability of glucoamylase from Aspergillus awamori by replacement with short homologue active site sequences and thiol/disulfide engineering"", BIOCHEMISTRY,, vol. 35, no. 26, 2 July 1996 (1996-07-02), pages 8696 - 8704, XP002927867;;SIERKS ET AL.: ""Protein engineering of the relative specificity of glucoamylase from Aspergillus awamori based on sequence similarities between starch-degrading enzymes"", PROTEIN ENGINEERING,, vol. 7, no. 12, December 1994 (1994-12-01), pages 1479 - 1484, XP002927868;;BAKIR ET AL: ""Cassette Mutagenesis of the Active Site of Aspergillus Awamori Glucoamylase"", PROTEIN ENGINEERING, vol. 6, no. SUPPL, March 1993 (1993-03-01), pages 41, XP002931803;;ALLEN ET AL.: ""Stabilization of Aspergillus awamori glucoamylase by proline substitution and combining stabilizing mutations"", PROTEIN ENGINEERING,, vol. 11, no. 9, September 1998 (1998-09-01), pages 783 - 788, XP002927869;;FANG ET AL.: ""Mutations to alter Aspergillus awamori glucoamylase selectivity. I. Tyr48Phe49-Trp, Tyr116-Trp, Tyr175-Phe, Arg241-Lys, Ser411-Ala and Ser411-Gly"", PROTEIN ENGINEERING,, vol. 11, no. 2, February 1998 (1998-02-01), pages 119 - 126, XP002927878;;FANG ET AL.: ""Mutations to alter Aspergillus awamori glucoamylase selectivity. II. Mutation of residues 119 and 121"", PROTEIN ENGINEERING,, vol. 11, no. 2, February 1998 (1998-02-01), pages 127 - 133, XP002927870",PENDING
720,US,B1,US 6537792 B1,123-115-885-568-154,2003-03-25,2003,US 23606399 A,1999-01-22,US 23606399 A;;US 9712983 W;;US 2257896 P;;US 2307796 P,1996-07-24,"Protein engineering of glucoamylase to increase pH optimum, substrate specificity and thermostability","
    A fungal glucoamylase including a mutation pair Asn20Cys coupled with Ala27Cys forming a disulfide bond between the two members of the pair. The mutation provides increased thermal stability and reduced isomaltose formation to the enzyme. A fungal glucoamylase including a 311-314Loop mutation wherein reduced isomaltose formation is provided by the mutation is also provided. A fungal glucoamylase including a mutation Ser411Ala wherein increased pH optimum and reduced isomaltose formation is provided by the mutation is also provided. Combinations of the mutations in engineered glucoamylases are also provided as are combinations with other glucoamylase mutations that provide increased thermal stability, increased pH optimum and reduced isomaltose froamtion for cumulative improvements in the engineered glucoamylases. Also provided is a fungal glucoamylase including a mutation of Ser30Pro coupled with at least two stabilizing mutations forming a disulfide bond between the two stabilizing members. A fungal glucoamylase including a Ser30Pro/Gly137Ala/311-314 Loop is provided. A fungal glucoamylase including a mutation Ser30Pro/Glu137Ala/Ser411Ala is also provided. 
",UNIV IOWA STATE,ALLEN MARTIN J;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,IOWA STATE UNIVERSITY (1999-04-20),https://lens.org/123-115-885-568-154,Granted Patent,yes,0,19,4,4,12,C12N9/2428;;C12N9/2428,C12N1/21;;C12N9/34,435/200;;435/183;;435/440;;530/350,41,33,095-780-397-149-715;;074-224-868-188-122;;091-792-077-863-533;;096-558-345-321-594;;002-129-848-383-652;;001-889-361-290-978;;005-219-796-109-392;;057-962-914-275-592;;025-692-352-779-116;;063-388-031-611-736;;079-970-875-125-257;;109-400-442-936-494;;051-228-795-510-793;;120-239-137-265-786;;006-148-472-168-549;;063-460-415-904-574;;052-544-852-171-750;;016-491-235-554-834;;045-659-767-208-949;;054-788-284-607-408;;137-119-117-187-873;;006-377-126-676-03X;;063-906-726-112-148;;088-211-236-191-361;;015-708-846-554-33X;;022-716-513-472-962;;086-581-999-679-66X;;073-256-143-760-689;;027-421-489-292-796;;000-151-312-534-318;;060-871-002-059-525;;004-319-692-848-678;;071-662-572-799-750,10.31274/rtd-180813-10576;;10.1021/bi960241c;;8679632;;3896127;;10.1146/annurev.biochem.54.1.597;;10.1146/annurev.bi.54.070185.003121;;6488318;;10.1016/0092-8674(84)90278-2;;2516317;;10.1002/prot.340060306;;9365988;;10.1002/(sici)1097-0134(199711)29:3<334::aid-prot7>3.0.co;2-a;;3334089;;10.1093/protein/1.4.319;;9681871;;10.1093/protein/11.5.383;;9605546;;10.1093/protein/11.2.119;;10.1093/protein/11.2.127;;9605547;;10.1021/bi00032a009;;7640270;;10.1006/jmbi.1996.0557;;8890914;;10.1002/prot.340010108;;3449850;;10.1016/0003-9861(69)90518-9;;5391475;;4225394;;10.1093/oxfordjournals.jbchem.a128330;;10.1107/s0021889891004399;;9488144;;10.1093/protein/10.10.1199;;pmc322906;;10.1073/pnas.83.3.576;;3003740;;9681872;;10.1093/protein/11.5.389;;8952477;;10.1021/bi961355r;;10.1002/bit.260340514;;18588154;;10.1021/bi00444a012;;2684274;;10.1016/s0008-6215(00)80194-9;;10.1016/s0008-6215(00)83415-1;;334366;;10.1002/star.19880400503;;10.1038/328496a0;;3302724;;10.1016/0022-2836(68)90237-4;;5760450;;2296288;;10.1038/343038a0;;10.1038/nbt0490-308;;1369261;;10.1093/protein/10.1.81;;9051738;;10.1002/star.19690210106;;10.1002/star.19690210204;;10.1073/pnas.84.5.1219;;pmc304398;;3547407,"Li et al., Genetic Construction and Biochemical Analysis of Thermostability Mutants of Glucoamylase from Aspergillus awamori, Dissertation Abstracts vol. 57/11-B p. 6761, 1996.*;;Fierobe et al., Mutational Modulation of Substrate Bond-Type Specificity and Thermostability of Glucoamylase from Aspergillus awamori by Replacement with Short Homologue Active Site Sequences and Thiol/Disulfide Engineering, Biochemistry 35:8696-8704, 19.*;;Ackers, G.K. and Smith, F.R. (1985) Annu. Rev. Biochem., 54, 597-629.;;Allen, M., Coutinho, P.M. and Ford, C. (1998) Protein Eng., accepted for publication.;;Carter, P.J. Winter, G., Wilkinson, A.J. and Fersht, A.R. (1984) Cell, 38, 835-840.;;Carter, P., Nilsson, B. Burnier, J.P., Burdick, D. and Wells, J.A. (1989) Proteins: Struct. Funct. Genet., 6, 240-248.;;Corn Annual (1998) Corn Refiners Association, Inc., Washington, D.C.;;Coutinho, P.M. (1996) Ph.D. Dissertation, Iowa State University, Ames, Ia.;;Coutinho, P.M. and Reilly, P.J. (1997) Proteins: Struct. Funct Genet., 29, 334-347.;;Cunningham, B.C. and Wells, J.A. (1987) Protein Eng., 1, 319-325.;;Fang, T.-Y and Ford, C. (1998) Protein Eng., 11, 383-388.;;Fang, T.-Y., Coutinho, P.M. Reilly, P.J. and Ford, C. (1988a) Protein Eng., 11, 119-126.;;Fang, T.-Y., Honzatko, R.B., Reilly, P.J. and Ford, C. (1998b) Protein Eng., 11, 127-133.;;Frandsen, T.P., Christensen, T., Stoffer, B. Lehmbeck, J., Dupont, C., Honzatko, R.B. and Svensson, B. (1995) Biochemistry, 34, 10162-10169.;;Frandsen, T.P., Stoffer, B., Palcic, M.M. Hof, S. and Svensson, B. (1996) J. Mol. Biol., 263, 79-89.;;Hecht, M.H., Sturtevant, J.M. and Sauer, R.T. (1986) Proteins: Struct. Funct. Genet., 1, 43-46.;;Hehre, E.J., Okada, G. and Genghof, D.S. (1969) Arch. Biochem. Biophys., 135, 74-89.;;Hiromi, K., Kawai, M. and Ono, S. (1966b) J. Biochem., 59, 476-480.;;Kraulis, P.J. (1991) J. Appl. Crystallogr. 34, 946-950.;;Li, Y., Reilly, P.J. and Ford, C (1997) Protein Eng., 10, 1199-1204.;;Li, Y., Coutinho, P.M. and Ford, C. (1998) Protein Eng., accepted for publication.;;Liao, H. McKenzie, T. and Hageman, R. (1986) Proc. Natl. Acad Sci. U.S.A., 83, 576-580.;;Liu, H.-L., Coutinho, P.M., Ford, C. and Reilly, P.J. (1998) Protein Eng., 11, 389-398.;;Natarajan, S. and Sierks, M.R. (1996) Biochemistry, 35, 15269-15279.;;Nikolov, Z.L., Meagher, M.M. and Reilly, P.J. (1989) Biotechnol. Bioeng., 34, 694-704.;;O'Rourke, T., Bentley, I.S. and Williams, E.C. (1996) Godfrey, T. and West, S. (eds). Industrial Enzymology, Secton edition. Stockton Press, New York.;;Pantoiiano, M.W., Whitlow, M., Wood, J.F., Dodd, S.W., Hardman, K.D., Rollence, M.L. and Bryan, P.N. (1989) Biochemistry, 28, 7205-7213.;;Pazur, J.H. and Okada, S. (1967) Charbohydr. Res., 4, 371-379.;;Pazur, J.H. Cepure, A., Okada, S. and Forsberg, L.S. (1977) Carbohydr. Res., 58, 193-202.;;Przybyt, M. and Sugier, H. (1988) Starch/Starke, 40, 171-174.;;Russell, A.J. and Fersht, A.R. (1987) Nature, 328, 496-500.;;Schimmel, P.R. and Flory, P.J. (1968) J. Mol. Biiol., 34, 105-120.;;Scrutton, N.S., Berry A. and Perham, R.N. (1990) Nature, 343, 38-43.;;Shein, C.H. (1990) Bio-Technology, 8, 308-317.;;Sinitsyn, A.P. Klibanov, A.M., Klesov, A.A. and Martiek, K. (1978) Prikl, Biokhim. Mikrobiol., 14, 236-243.;;Stoffer, B.B., Dupont, C., Frandsen, T.P., Lehmbeck, J. and Svensson, B. (1997) Protein Eng., 10, 81-87.;;Svensson, B. Brandsen, T.P., Matsui, I., Juge, N., Fierobe, H.-P., Stoffer, B. and Rodenburg, K.W. (1995) Carbohydrate Bioengineering, Petersen, S.B., Svensson, B. and Pedersen, S., eds., Elsevier, Amsterdam, pp. 125-145.;;Teague, W.M. and Brumm, P.J. (1992) Starch Hydrolysis Products: Woldwide Technology, Production, and Applications, Schenck, F.W. and Hebeda, R.E., eds., VCH, New York, p. 45-77.;;Watanabe, T. Kawamura, S., Sasaki, S. and Matsuda, K. (1969a) Starke, 21, 18-21.;;Watanabe, T., Kawamura, S., Sasaki, S. and Matsuda, K. (1969b) Starke, 21, 44-47.;;Wells, J.A., Cunningham, B.C., Graycar, T.P. and Estell, D.A. (1987a) Proc. Natl, Acad. Sci. U.S.A., 84, 1219-1223.",EXPIRED
721,CN,A,CN 113745729 A,146-548-282-366-383,2021-12-03,2021,CN 202110340021 A,2021-03-30,US 202016888304 A,2020-05-29,DIRECT TEMPERATURE REGULATION OF BATTERIES,"A temperature regulation system for a battery is provided. The temperature regulation system includes an electrochemical cell, which may be in the form of a battery. The electrochemical cell includes a housing having a first side surface that extends from a first end to a second end, and a first temperature control chamber containing a dielectric fluid. The first temperature control chamber is located along the first side surface of the housing or along at least one of the first end or the second end of the housing. The dielectric fluid is in direct contact with the housing at the first side surface or at the first end or the second end.",GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;CLARK DAVID R;;SWIFT MATTHEW;;HAN TAO;;CHEN KUO-HUEY;;KHALIGHI BAHRAM;;TAMAI GORO;;HSU CHIH-CHENG,,https://lens.org/146-548-282-366-383,Patent Application,no,8,0,3,3,0,H01M10/613;;H01M10/625;;H01M10/635;;H01M10/6551;;H01M10/6568;;H01M10/6568;;H01M10/6554;;H01M10/625;;Y02E60/10;;H01M10/6568;;H01M2220/20;;H01M10/625;;H01M10/613,H01M50/211;;H01M10/613;;H01M10/625;;H01M10/635;;H01M10/6551;;H01M10/6568;;H01M50/249,,0,0,,,,PENDING
722,AU,A1,AU 2018/267653 A1,007-230-109-068-569,2018-12-13,2018,AU 2018/267653 A,2018-11-22,AU 2018/267653 A;;AU 2016/203693 A;;AU 2013/203348 A;;AU 2012/203813 A,2012-06-28,Site-directed modification of FVIII,"This invention relates to Factor Vill muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/007-230-109-068-569,Patent Application,no,0,0,4,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,0,0,,,,DISCONTINUED
723,WO,A1,WO 2021/178587 A1,019-634-347-227-453,2021-09-10,2021,US 2021/0020741 W,2021-03-03,US 202062984739 P,2020-03-03,DEVICES INCLUDING FERROELECTRIC NEMATIC MATERIAL AND METHODS OF FORMING AND USING SAME,"Devices including nematic liquid crystal-forming molecules are disclosed. The molecules include one or more dipoles and exist in a ferroelectric nematic state. Exemplary devices can further include an electrode for applying an electric field in, for example, and in-plane direction.",UNIV COLORADO REGENTS;;UNIV UTAH RES FOUND,CLARK NOEL;;CHEN XI;;SHAO REN;;KORBLOVA EVA;;GLASER MATTHEW;;MACLENNAN JOSEPH;;RADZIHOVSKY LEO;;WEI MICHAEL;;DONG DENGPAN;;BEDROV DIMITRY,,https://lens.org/019-634-347-227-453,Patent Application,yes,5,1,5,5,0,G02F1/141;;G02F1/141;;G02F2202/01;;G16C10/00;;G16C20/20;;G02F1/0045;;G02F1/0136;;G02F1/1358;;G02F1/141;;G02F2202/01;;G21K1/00,G02F1/141;;G02F1/1337,,1,1,004-135-642-456-91X,17930554;;10.1103/physrevlett.99.127802,"PISHNYAK ET AL.: ""Levitation, Lift, and Bidirectional Motion of Colloidal Particles in an Electrically Driven Nematic Liquid Crystal"", PHYS. REV. LETT., vol. 99, 21 September 2007 (2007-09-21), pages 127802, XP055855184, Retrieved from the Internet <URL:https://journais.aps.org/pri/abstract/10.1103/PhysRevLett.99.127802>",PENDING
724,WO,B1,WO 2000/043504 B1,045-770-947-066-912,2000-09-14,2000,US 0000532 W,2000-01-10,US 23606399 A,1999-01-22,"PROTEIN ENGINEERING OF GLUCOAMYLASE TO INCREASE pH OPTIMUM, SUBSTRATE SPECIFICITY AND THERMOSTABILITY","A fungal glucoamylase including a mutation pair Asn20Cys coupled with Ala27Cys forming a disulfide bond between the two members of the pair. The mutation provides increased thermal stability and reduced isomaltose formation to the enzyme. A fungal glucoamylase including a 311-314Loop mutation wherein reduced isomaltose formation is provided by the mutation is also provided. A fungal glucoamylase including a mutation Ser411Ala wherein increased pH optimum and reduced isomaltose formation is provided by the mutation is also provided. Combinations of the mutations in engineered glucoamylases are also provided as are combinations with other glucoamylase mutations that provide increased thermal stability, increased pH optimum and reduced isomaltose formation for cumulative improvements in the engineered glucoamylases. Also provided is a fungal glucoamylase including a mutation of Ser30Pro coupled with at least two stabilizing mutations forming a disulfide bond between the two stabilizing members. A fungal glucoamylase including a Ser30Pro/Gly137Ala/311-314 Loop is provided. A fungal glucoamylase including a mutation Ser30Pro/Glu137Ala/Ser411Ala is also provided.",UNIV IOWA STATE RES FOUND INC;;ALLEN MARTIN J;;FANG TSUEI YUN;;LI YUXING;;LIU HSUAN LIANG;;CHEN HSIU MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,ALLEN MARTIN J;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/045-770-947-066-912,Patent Application,no,0,0,4,4,0,C12N9/2428;;C12N9/2428,C12N1/21;;C12N9/34,,0,0,,,,PENDING
725,US,B2,US 10072007 B2,094-764-489-152-544,2018-09-11,2018,US 201615079926 A,2016-03-24,US 201615079926 A;;US 201213319298 A;;US 2010/0001350 W;;US 21575709 P,2009-05-08,Tetracycline compounds,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RONN MAGNUS P,TETRAPHASE PHARMACEUTICALS INC (2011-02-28),https://lens.org/094-764-489-152-544,Granted Patent,yes,127,5,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,A61K31/65;;C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/09;;C07D207/10;;C07D207/14;;C07D207/16;;C07D209/04;;C07D209/14;;C07D209/44;;C07D209/52;;C07D211/14;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/14;;C07D223/32;;C07D261/20;;C07D295/13;;C07D295/135;;C07D295/15;;C07D295/155;;C07D295/185;;C07D295/26;;C07D307/22;;C07D401/04;;C07D413/06;;C07D471/10,,79,17,002-078-829-796-489;;027-016-309-206-450;;049-052-217-161-423;;031-094-950-921-992;;111-747-637-151-165;;056-591-233-129-286;;109-552-349-845-005;;160-925-493-776-604;;004-978-144-379-582;;185-160-153-276-14X;;034-050-731-202-167;;100-766-722-392-398;;148-332-819-466-078;;026-872-796-351-596;;049-605-096-220-403;;070-856-765-326-262;;034-236-283-566-228,10.1016/j.coph.2008.08.001;;18761107;;10.1139/v65-187;;6874826;;10.1016/s0378-4347(00)84428-x;;15831754;;10.1126/science.1109755;;10.1016/j.jhazmat.2011.07.039;;21835543;;10.1128/mmbr.65.2.232-260.2001;;pmc99026;;11381101;;10.1021/ja01072a057;;10.1021/jo01057a501;;6124399;;10.1517/eotp.13.4.467.23118;;10.1002/jps.2600510118;;14491416;;10.1007/978-3-642-70304-1_5;;10.1021/jm00027a023;;8289194;;pmc2681267;;19053822;;10.1021/ja806629e;;pmc3108469;;21500832;;10.1021/jm1015395;;10.1517/13543776.18.1.69;;10744327;;10.1016/s0378-4347(99)00477-6,"Final Office Action dated Aug. 25, 2014 for U.S. Appl. No. 13/319,298 “Tetracycline Compounds”.;;Final Office Action, U.S. Appl. No. 13/391,407, dated Oct. 1, 2014.;;Final Rejection for U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated Feb. 20, 2015.;;Final Rejection for U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated Nov. 7, 2013.;;Final Rejection for U.S. Appl. No. 13/391,401, “Tetracycline Compounds,” dated May 18, 2016.;;Non-Final Rejection for U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated Mar. 22, 2013.;;Non-Final Rejection for U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated May 22, 2014.;;Non-Final Rejection for U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated Nov. 24, 2015.;;Non-Final Rejection for U.S. Appl. No. 13/391,401, “Tetracycline Compounds,” dated Jul. 29, 2015.;;Non-Final Rejection for U.S. Appl. No. 14/532,882, “C7-Fluoro Substituted Tetracycline Compounds,” dated May 9, 2016.;;Non-Final Rejection for U.S. Appl. No. 15/079,926, “Tetracycline Compounds,” dated May 10, 2017.;;Non-Final Rejection for U.S. Appl. No. 15/164,183 “Polycyclic Tetracycline Compounds,” dated Jul. 24, 2017.;;Non-Final Rejection for U.S. Appl. No. 15/347,352, “C7-Fluoro Substituted Tetracycline Compounds,” dated Jul. 28, 2017.;;Notice of Allowance dated Dec. 1, 2015 for U.S. Appl. No. 13/319,298 entitled “Tetracycline Compounds”.;;Notice of Allowance dated Jun. 5, 2014 for U.S. Appl. No. 13/718,909, entitled “C7-Fluro Substituted Tetracycline Compounds”.;;Notice of Allowance dated Jun. 6, 2013 for U.S. Appl. No. 13/570,837.;;Notice of Allowance for U.S. Appl. No. 13/391,401, “Tetracycline Compounds,” dated Dec. 1, 2016.;;Notice of Allowance for U.S. Appl. No. 14/424,765, “Tetracycline Compounds,” dated Oct. 7, 2016.;;Notice of Allowance, U.S. Appl. No. 12/462,795, dated Aug. 4, 2014.;;Notice of Allowance, U.S. Appl. No. 13/319,307, dated Sep. 19, 2012.;;Notice of Allowance, U.S. Appl. No. 13/731,753, dated May 1, 2014.;;Notice of Allowancefor U.S. Appl. No. 13/075,886, “Polycyclic Tetracycline Compounds,” dated Feb. 22, 2016.;;Office Action dated Dec. 7, 2011 for U.S. Appl. No. 12/462,795.;;Office Action dated Feb. 14, 2014 for U.S. Appl. No. 13/391,407, “Tetracycline Compounds”.;;Office Action dated Feb. 4, 2013 for U.S. Appl. No. 13/570,837.;;Office Action dated Feb. 5, 2013 for U.S. Appl. No. 13/718,909.;;Office Action dated Jan. 16, 2014 for U.S. Appl. No. 13/319,298, “Tetracycline Compounds”.;;Office Action dated Jan. 17, 2014 for U.S. Appl. No. 12/462,795, “C7-Fluoro Substituted Tetracycline Compounds”.;;Office Action dated Jan. 24, 2012 for U.S. Appl. No. 12/462,795.;;Office Action dated Jul. 24, 2012 for U.S. Appl. No. 12/462,795.;;Office Action dated Jul. 9, 2013 for U.S. Appl. No. 13/718,909.;;Office Action dated Sep. 23, 2013 for U.S. Appl. No. 12/462,795.;;Office Action, U.S. Appl. No. 13/319,298; dated Apr. 27, 2015.;;Requirement for Restriction/Election for U.S. Appl. No. 13/391,401, “Tetracycline Compounds,” dated Jun. 25, 2013.;;Requirement for Restriction/Election for U.S. Appl. No. 14/424,765, “Tetracycline Compounds,” dated Apr. 8, 2016.;;Requirement for Restriction/Election for U.S. Appl. No. 15/446,831, “Tetracycline Compounds,” dated Aug. 31, 2017.;;Abbanat, D., et al., “New agents in development for the treatment of bacterial infections”, Curr Opin Pharmacol, 8(5):582-592 (Oct. 1, 2008).;;Bhattacharyya et al., “Studies on Hydrofluorene Derivatives. Part II. Synthesis of 1,1a,1b,2,3,4,4a,5,6,6a-Decaydro-la-methyl-3-oxochrysofluorene,” Journal of the Indian Chemical Society, 41(7): 479-495 (1964).;;Blackwood et al., “Some Transformations of Tetracycline at the 4-Position,” Can J Chem, 43(5): 1382-1388 (1965).;;Bocker, “Analysis and Quantitation of a Metabolite of Doxycycline in Mice, Rats, and Humans by High-Performance Liquid Chromatography,” J Chromatogr-Biomed, 274: 255-262 (1983).;;Charest, M.G., et al., “A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics”, Science, 308:395-398 (Apr. 15, 2005).;;Chen et al., “Oxidative Degradation Kinetics and Products of Chlortetracycline by Manganese Dioxide,” J Hazard Mater, 193: 128-138 (2011).;;Chopra, I. and Roberts, M., “Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance,” Microbiol Mol Biol R, 65(2):232-260 (2001).;;Esse, R., et al., “Tetracycloxides. II. Transformations at the C-4 Position”, J Am Chem Soc, 86(18): 3875-3877 (Sep. 20, 1964).;;Extended Search Report for European Patent Application No. 13172357.9 dated May 16, 2014 “C7-Fluoro Substituted Tetracycline Compounds”.;;HCAPLUS, Accession No. 2004:1036703, Document No. 141:420412 (Apr. 24, 2002).;;HCAPLUS, Accession No. 2005:99455, Document No. 142:197754 (Jun. 25, 2004).;;Hlavka, J.J., et al., “The 6-Deoxytetracyclines. IV. A Photochemical Displacement of a Diazonium Group,” Organic Chemical Research Section, 27:3674-3675 (1962).;;Huel, Christiane, et al., “Synthesis of 1-Functionalized-6-hydroxy-4-methyl and 6,11-Dihydroxy-4-methylnaphtho[2,3-g]isoquinoline-5,12-quinoes,” J. Heterocyclic Chem., 28:67-71 (1991).;;International Preliminary Report on Patentability for International Application No. PCT/US2010/001350; dated Nov. 9, 2011.;;International Preliminary Report on Patentability for International Application No. PCT/US2010/047035; dated Feb. 28, 2012.;;International Preliminary Report on Patentability for International Application No. PCT/US2011/047428; dated Feb. 12, 2013.;;International Preliminary Report on Patentability for International Application No. PCT/US2013/057690, “Tetracycline Compounds”, dated Mar. 3, 2015.;;International Preliminary Report on Patentability for International Patent Application No. PCT/US2010/034718 dated Nov. 15, 2011.;;International Preliminary Report on Patentability for International Patent Application No. PCT/US2011/030532 dated Oct. 11, 2012.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2010/034718 dated Nov. 9, 2010.;;International Search Report and Written Opinion for International Patent Application No. PCT/US2011/030532 dated Jul. 12, 2011.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2010/001348, dated Jul. 19, 2010.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2010/001350, dated Nov. 23, 2010.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2010/047035; dated Jul. 22, 2011.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2011/047428, dated Jan. 6, 2012.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2013/057690; dated Feb. 24, 2014.;;International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/US2009/053142; dated Oct. 13, 2009.;;Martin, W., et al., “Totalsynthese von d, 1-7-Chlor-6-desoxytetracyclinen und d, 1-7-Chlor-6-desmethyl-6-desoxytetracyclinen der naturlichen, der 5a-epi-und der 6-epi-Reihe”, Tetrahedron Lett, pp. 3513-3516, (Dec. 31, 1975).;;Nelis et al., “Metabolism of Minocycline in Humans,” Drug Metab Dispos, 10(2): 142-146 (1982).;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2009/053142 dated Feb. 17, 2011.;;Notification Concerning Transmittal of International Preliminary Report on Patentability for International Application No. PCT/US2010/001348, dated Nov. 17, 2011.;;Plakunov, “Relation Between Chemical-Structure of Tetracyclines and Their Analogs and Specific Features of Transport and Mechanism of Antibacterial Effect,” Antibiotiki, 18(12): 1069-1073 (1973).;;Podlogar, B., L., et al., “Patents on tetracycline and tetracycline derivatives as antimicrobials”, Expert Opin. Ther. Patents, 13(4):467-478 (2003).;;Pre-appeal Conference Decision dated Feb. 19, 2013 for U.S. Appl. No. 12/462,795.;;Remmers et al., “New Alkaline-Stable Species for Selected Members of the Tetracycline Family,” J Pharm Sci, 51(1): 86-87 (1962).;;Rogalski, “Chemical Modifications of Tetracyclines,” in Hlvaka et al., “The Tetracyclines,” Berlin, Spring-Verlag, pp. 179-316 (1985).;;Sato, F., et al. “Structure-Activity Relationship Investigation of Some New Tetracyclines by Electronic Index Methodology”, Los Alamos National Laboratory, Quantitative Biology, 1-18 (Aug. 21, 2007).;;Sum et al., “Glycylcyclines. 1. A New Generation of Potent Antibacterial Agents Through Modification of 9-Aminotetracyclines,” J Med Chem, 37: 184-188 (1994).;;Sun, C., et al., “A Robust Platform for the Synthesis of New Tetracycline Antibiotics,”, J. Am. Chem.Soc., 130:17913-17927 (2008).;;Sun. C. et al., Synthesis and Antibacterial Activity of Pentacyclines: A Novel Class of Tetracycline Analogs. J. Med. Chem., Apr. 18, 2011, vol. 54, No. 11, pp. 3704-3731.;;Verma, A.K., et al., “Antibiotic and non-antibiotic tetracycline patents”, Expert Opin. Ther. Patents, vol. 18, pp. 69-82 (2008).;;Zurhelle et al., “Automated Residue Analysis of Tetracyclines and Their Metabolites in Whole Egg, Egg White, Egg Yolk and Hen's Plasma Utilizing a Modified ASTED System,” Journal of Chromatography B: Biomedical Sciences and Applications, 739(1): 191-203 (2000).;;Examination Report for New Zealand Patent Application No. 705849, dated Aug. 7, 2017.",INACTIVE
726,AU,A,AU 2000/024102 A,002-347-726-714-041,2000-08-07,2000,AU 2000/024102 A,2000-01-10,US 23606399 A;;US 0000532 W,1999-01-22,"Protein engineering of glucoamylase to increase ph optimum, substrate specificity and thermostability",,UNIV IOWA STATE RES FOUND INC,ALLEN MARTIN J;;FANG TSUEI-YUN;;LI YUXING;;LIU HSUAN-LIANG;;CHEN HSIU-MEI;;COUTINHO PEDRO;;HONZATKO RICHARD;;FORD CLARK,,https://lens.org/002-347-726-714-041,Patent Application,no,0,0,4,4,0,C12N9/2428;;C12N9/2428,C12N1/21;;C12N9/34,,0,0,,,,DISCONTINUED
727,US,A1,US 2019/0077803 A1,072-541-442-335-224,2019-03-14,2019,US 201815969537 A,2018-05-02,US 201815969537 A;;US 201615079926 A;;US 201213319298 A;;US 2010/0001350 W;;US 21575709 P,2009-05-08,TETRACYCLINE COMPOUNDS,The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.,TETRAPHASE PHARMACEUTICALS INC,CHEN CHI-LI;;CLARK ROGER B;;DENG YONGHONG;;HE MINSHENG;;PLAMONDON LOUIS;;SUN CUIXIANG;;XIAO XIAO-YI;;RONN MAGNUS P,,https://lens.org/072-541-442-335-224,Patent Application,yes,0,0,17,17,0,A61P31/04;;A61P31/12;;C07C237/26;;C07D471/10;;C07D471/10;;C07C51/353;;C07C67/08;;C07C67/307;;C07C67/31;;C07C67/313;;C07C67/317;;C07C231/10;;C07C237/26;;C07C237/26;;C07C275/24;;C07C275/24;;C07C311/06;;C07C311/06;;C07C311/19;;C07C311/19;;C07C2601/02;;C07C2601/02;;C07C2601/04;;C07C2601/04;;C07C2601/08;;C07C2601/08;;C07C2601/14;;C07C2601/14;;C07C2601/18;;C07C2601/18;;C07C2602/08;;C07C2602/08;;C07C2602/24;;C07C2602/24;;C07C2602/42;;C07C2602/42;;C07C2602/50;;C07C2602/50;;C07C2603/46;;C07C2603/46;;C07C2603/74;;C07C2603/74;;C07D205/04;;C07D205/04;;C07D205/04;;C07D207/06;;C07D207/06;;C07D207/06;;C07D207/08;;C07D207/08;;C07D207/08;;C07D207/09;;C07D207/09;;C07D207/10;;C07D207/10;;C07D207/14;;C07D207/14;;C07D207/14;;C07D207/16;;C07D207/16;;C07D209/04;;C07D209/04;;C07D209/14;;C07D209/14;;C07D209/14;;C07D209/44;;C07D209/44;;C07D209/44;;C07D209/52;;C07D209/52;;C07D209/52;;C07D211/14;;C07D211/14;;C07D211/14;;C07D211/18;;C07D211/34;;C07D211/34;;C07D211/46;;C07D211/58;;C07D211/62;;C07D213/74;;C07D213/74;;C07D213/74;;C07D221/20;;C07D221/20;;C07D221/20;;C07D223/04;;C07D223/04;;C07D223/14;;C07D223/14;;C07D223/32;;C07D223/32;;C07D241/04;;C07D261/20;;C07D261/20;;C07D261/20;;C07D295/108;;C07D295/13;;C07D295/13;;C07D295/135;;C07D295/135;;C07D295/15;;C07D295/15;;C07D295/155;;C07D295/155;;C07D295/155;;C07D295/185;;C07D295/185;;C07D295/26;;C07D295/26;;C07D295/26;;C07D307/22;;C07D307/22;;C07D307/22;;C07D401/04;;C07D401/04;;C07D401/04;;C07D413/06;;C07D413/06;;C07D487/10,C07D471/10;;C07C237/26;;C07C275/24;;C07C311/06;;C07C311/19;;C07D205/04;;C07D207/06;;C07D207/08;;C07D207/09;;C07D207/10;;C07D207/14;;C07D207/16;;C07D209/04;;C07D209/14;;C07D209/44;;C07D209/52;;C07D211/14;;C07D211/34;;C07D213/74;;C07D221/20;;C07D223/04;;C07D223/14;;C07D223/32;;C07D261/20;;C07D295/13;;C07D295/135;;C07D295/15;;C07D295/155;;C07D295/185;;C07D295/26;;C07D307/22;;C07D401/04;;C07D413/06,,0,0,,,,DISCONTINUED
728,US,A1,US 2021/0376411 A1,003-557-685-082-077,2021-12-02,2021,US 202016888304 A,2020-05-29,US 202016888304 A,2020-05-29,DIRECT TEMPERATURE REGULATION OF BATTERIES,"A temperature regulation system for a battery is provided. The temperature regulation system includes an electrochemical cell, which may be in the form of a battery. The electrochemical cell includes a housing having a first side surface that extends from a first end to a second end, and a first temperature control chamber containing a dielectric fluid. The first temperature control chamber is located along the first side surface of the housing or along at least one of the first end or the second end of the housing. The dielectric fluid is in direct contact with the housing at the first side surface or at the first end or the second end.",GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;CLARK DAVID R;;SWIFT MATTHEW;;HAN TAEYOUNG;;CHEN KUO-HUEY;;KHALIGHI BAHRAM;;TAMAI GORO;;HSU CHIH-CHENG,GM GLOBAL TECHNOLOGY OPERATIONS LLC (2020-05-29),https://lens.org/003-557-685-082-077,Patent Application,yes,2,1,3,3,0,H01M10/613;;H01M10/625;;H01M10/635;;H01M10/6551;;H01M10/6568;;H01M10/6568;;H01M10/6554;;H01M10/625;;Y02E60/10;;H01M10/6568;;H01M2220/20;;H01M10/625;;H01M10/613,H01M10/6568;;H01M10/613;;H01M10/625,,0,0,,,,DISCONTINUED
729,US,B1,US 10856532 B1,042-677-033-568-881,2020-12-08,2020,US 201815909957 A,2018-03-01,US 201815909957 A;;US 201762466939 P,2017-03-03,Method for producing an RNAi resistant colony of an insect pest species from a field-derived population,The present invention is directed to a method for producing an RNAi resistant insect pest species colony from an insect pest species isolated from an agricultural field. The invention is also directed to methods for determining the inheritance of resistance to the RNAi and determining the allele frequency of resistance in an agricultural field.,MONSANTO TECHNOLOGY LLC,CHEN MAO;;CLARK THOMAS L;;FLAGEL LEX E;;JENSEN PETER D;;KHAJURIA CHITVAN;;MCNULTY BRIAN C;;MOAR WILLIAM;;VAZQUEZ CARA,,https://lens.org/042-677-033-568-881,Granted Patent,yes,2,0,1,1,7,A01K67/033;;A01K67/033,A01K67/033,,14,13,103-032-541-898-329;;020-327-117-600-49X;;031-358-248-495-432;;086-957-149-507-864;;039-674-874-576-26X;;001-177-911-057-463;;047-400-654-088-848;;066-190-716-875-959;;039-409-753-411-154;;025-693-541-408-319;;047-376-901-003-403;;051-724-802-048-895;;010-060-030-527-530,17982443;;10.1038/nbt1359;;10.1002/ps.2086;;21472969;;10.1016/j.plaphy.2010.04.001;;20451401;;16985000;;pmc1570184;;10.1073/pnas.0604698103;;21370391;;10.1002/ps.2124;;10.1038/nbt1352;;17982444;;28060922;;10.1371/journal.pone.0169175;;pmc5217956;;21998682;;10.1371/journal.pone.0025709;;pmc3187792;;10.1093/jmedent/45.3.414;;10.1603/0022-2585(2008)45[414:taadrk]2.0.co;2;;18533434;;10.1093/jxb/ern289;;pmc3071771;;19015219;;23752438;;10.1038/nbt.2597;;10.1007/s12038-011-9009-1;;21451256;;19815067;;10.1016/j.ibmb.2009.09.007,"Bolognesi et al. (2012, PLOS One, vol. 7(10), pp. 1-11). (Year: 2012).;;Baum, J.A., et al., “Control of Coleopteran Insect Pests Through RNA Interference,” Nature Biotechnology 25(11):13-22-1326, 2007.;;Gong, L., et al., “Silencing of Rieske Iron-Sulfur Protein Using Chemically Synthesised siRNA as a Potential Biopesticide Against Plutella xylostella,” Pest Management Science 67:514-520, 2011.;;Hu, Y., et al., “High Efficiency Transport of Quantum Dots Into Plant Roots With the Aid of silwet L-77,” Plant Physiology and Biochemistry 48(8):703-709, 2010.;;Huang, G., et al., “Engineering Broad Root-Knot Resistance in Transgenic Plant by RNAi Silencing of a Conserved and Essential Root-Knot Nematode Parasitism Gene,” Proceedings of the National Academy of Sciences of the United States of America 103(39), 14302-14306, 2006.;;Li, J., et al., “RNA Interference in Nilaparvata lugens (Homoptera: Delphacidae) Based on dsRNA Ingestion,” Pest Management Science 67:852-859, 2011.;;Mao, Y.B., et al., “Silencing a Cotton Bollworm P450 Monooxygenase Gene by Plant-Mediated RNAi Impairs Larval Tolerance of Gossypol,” Nature Biotechnology 25(11):1307-1313, Nov. 2007.;;Moar, W., et al., “Cry3Bb1-Resistant Western Corn Rootworm, Diabrotica virgifera (LeConte) Does Not Exhibit Cross Resistance to SvSnf7 dsRNA,” PloS One 12(1):e0169175, 2017.;;Pitino, M., et al., “Silencing of Aphid Genes by dsRNA Feeding From Plants,” PLoS One 6(10):325709, 2011.;;Pridgeon, J.W., et al., “Topically Applied AaelAP1 Double-Stranded RNA Kills Female Adults of Aedes aegypti,” Journal of Medical Entomolology 45(3):414-420, 2008.;;Sindhu, A.S., et al., “Effective and Specific in Planta RNAi in Cyst Nematodes: Expression Interference of Four Parasitism Genes Reduces Parasitic Success,” Journal of Experimental Botany 60(1):315-324, 2008.;;Tabashnik, B.E., et al., “Insect Resistance to BT Crops: Lessons From the First Billion Acres,” Nature Biotechnology 31(6):510-521, 2013.;;Upadhyay, S.K., et al., “RNA Interference for the Control of Whiteflies (Bemisia tabaci) by Oral Route,” Journal of Biosciences 36(1):153-161, 2011.;;Whyard, S., et al., “Ingested Double-Stranded RNAs Can Act as Species-Specific Insecticides,” Insect Biochemistry and Molecular Biology 39(11):8224-832, 2009.",ACTIVE
730,CN,A,CN 105148287 A,191-985-573-760-054,2015-12-16,2015,CN 201510612184 A,2005-11-14,US 62727704 P;;CN 200580046469 A,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN;;HENDRI TJANDRA;;CHEN JIANMIN;;THOMAS BARNETT;;TANG LIANG;;WANG DEQIAN,,https://lens.org/191-985-573-760-054,Patent Application,no,3,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K47/48;;A61K38/37;;A61P7/04,,0,0,,,,ACTIVE
731,DE,A1,DE 102021107347 A1,026-083-356-653-329,2021-12-02,2021,DE 102021107347 A,2021-03-24,US 202016888304 A,2020-05-29,DIREKTE TEMPERATURREGELUNG VON BATTERIEN,"Ein Temperaturregelungssystem für eine Batterie wird bereitgestellt. Das Temperaturregelungssystem umfasst eine elektrochemische Zelle, die als Batterie ausgeführt sein kann. Die elektrochemische Zelle umfasst ein Gehäuse mit einer ersten Seitenfläche, die sich von einem ersten Ende zu einem zweiten Ende erstreckt, und eine erste Temperatursteuerkammer, die ein dielektrisches Fluid enthält. Die erste Temperatursteuerkammer befindet sich entlang der ersten Seitenfläche des Gehäuses oder entlang mindestens eines der ersten oder zweiten Enden des Gehäuses. Das dielektrische Fluid ist an der ersten Seitenfläche oder am ersten Ende oder am zweiten Ende in direktem Kontakt mit dem Gehäuse.",GM GLOBAL TECH OPERATIONS LLC,YEN CHIH-HUNG;;CLARK DAVID R;;SWIFT MATTHEW;;HAN TAEYOUNG;;CHEN KUO-HUEY;;KHALIGHI BAHRAM;;TAMAI GORO;;HSU CHIH-CHENG,,https://lens.org/026-083-356-653-329,Patent Application,no,0,0,3,3,0,H01M10/613;;H01M10/625;;H01M10/635;;H01M10/6551;;H01M10/6568;;H01M10/6568;;H01M10/6554;;H01M10/625;;Y02E60/10;;H01M10/6568;;H01M2220/20;;H01M10/625;;H01M10/613,H01M10/655;;H01M10/656,,0,0,,,,PENDING
732,AU,B2,AU 2013/203348 B2,183-472-967-915-676,2016-03-03,2016,AU 2013/203348 A,2013-04-10,AU 2012/203813 A;;AU 2013/203348 A,2012-06-28,Site-directed modification of FVIII,"H:\fmt\Intenvovcn\NRPottbl\DCC\FM-I4427591_l.doc-6/042013 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/183-472-967-915-676,Granted Patent,no,3,0,2,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,2,1,019-730-797-612-199,10821655;;10.1021/bc990137i,"Sakuragawa, N. et al. ""Studies On The Stability Of Factor VIII Modified By Polyethylene Glycol"" Acta Medica et Biologica (1998) 36(1): 1-5;;Rostin J. et al. ""B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol"" Bioconjugate Chem. (2000) 11: 387-396",ACTIVE
733,HK,A1,HK 1182121 A1,026-608-635-590-278,2013-11-22,2013,HK 13109463 A,2013-08-13,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/026-608-635-590-278,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K/;;A61K/;;A61P/,,0,0,,,,PENDING
734,LT,T,LT 1824988 T,025-187-060-273-896,2017-10-25,2017,LT 05849392 T,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/025-187-060-273-896,Unknown,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,PENDING
735,US,B2,US 11509745 B2,049-233-221-686-620,2022-11-22,2022,US 201916457704 A,2019-06-28,US 201916457704 A,2019-06-28,Efficient remote function execution in an information centric network,"Systems and techniques for efficient remote function execution in an information centric network (ICN) are described herein. For example, a requestor node may transmit an admission probe interest packet. Here, the admission probe interest packet includes a name that includes a function. The admission probe interest packet also includes a metric of a parameter of the function. In response, the requestor node may receive a manifest data packet. The manifest includes a metric of function execution at a node that created the manifest data packet. The manifest also includes a name of an implementation of the function. The requestor node may then determine that the metric of function execution meets a threshold and transmit an interest packet that includes the name of the implementation of the function.",INTEL CORP,ALAM S M IFTEKHARUL;;ZHANG YI;;JHA SATISH CHANDRA;;CHEN KUILIN CLARK;;SIVANESAN KATHIRAVETPILLAI;;KARPENKO STEPAN;;SRIKANTESWARA SRIKATHYAYANI;;NALLAMPATTI EKAMBARAM VENKATESAN,,https://lens.org/049-233-221-686-620,Granted Patent,yes,5,0,2,2,0,H04L43/14;;H04L43/16;;H04L67/568;;H04L67/63;;H04L43/16;;H04L43/12;;H04L67/63;;H04L67/568;;H04L67/10;;H04L43/08,H04L43/16;;H04L43/08;;H04L43/12;;H04L67/10;;H04L67/568;;H04L67/63,,5,3,065-103-708-235-471;;127-810-498-630-210;;068-358-835-682-681,10.1145/3125719.3125727;;10.1109/nof.2017.8251219;;10.1109/ccnc.2014.6940518,"Krol, Michal, “NFaaS: named function as a service”, In Proceedings of the 4th ACM Conference on Information-Centric Networking. ACM, (2017), 11 pgs.;;Krol, Michal, “Rice: Remote method invocation in icn”, Network Systems Research and Design, (2018), 39 pgs.;;Shakeri, Sara, “Proactive Admission Control and Dynamic Resource Management in SDN-based Virtualized Networks”, 2017 8th International Conference on the Network of the Future (NOF), (2017), 7 pgs.;;Tschundin, Christian, “Named functions and cached computations”, . In IEEE Consumer Communications and Networking Conference, (2014), 7 pgs.;;Wissingh, B, “Information-Centric Networking (ICN): CCN and NDN Terminology”, [Online]. Retrieved from the Internet: URL: https: tools.ietf.org html draft-irtf-icnrg-terminology-01, (Oct. 22, 2018), 36 pgs.",ACTIVE
736,KR,A,KR 20180110192 A,058-689-478-620-83X,2018-10-08,2018,KR 20187027821 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"본 발명은 N-말단이 아닌 소정의 부위에서 폴리에틸렌 글리콜과 같은 1종 이상의 생체적합성 중합체에 공유적으로 결합되는 제VIII 인자에 관한 것이다. 이 뮤테인 컨쥬게이트는 FVIII 응고촉진 활성을 유지하고, 향상된 약물동태학적 특성을 갖는다.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/058-689-478-620-83X,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00,,0,0,,,,DISCONTINUED
737,NI,A,NI 200700287 A,071-150-372-242-908,2008-05-27,2008,NI 200700287 A,2007-11-09,US 68556405 P,2005-05-27,INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA,"La invención provee inhibidores químicos de la actividad de diversas enzimas fosfolipasa, particularmente de las enzimas fosfolipasa A2 citosólica (cPLA2), más particularmente incluyendo inhibidores de las enzimas fosfolipasa A2 alfa citosólica (cPLA2alfa). En algunas modalidades, los inhibidores poseen la fórmula I: donde las variables constituyentes son como se han definido aquí.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/071-150-372-242-908,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00;;C07D209/14,,0,0,,,,ACTIVE
738,US,A1,US 2007/0004719 A1,086-674-140-712-685,2007-01-04,2007,US 44219906 A,2006-05-26,US 44219906 A;;US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZAN;;PONG KEVIN,WYETH (2006-09-18);;NOVARTIS AG (2021-12-03);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/086-674-140-712-685,Patent Application,yes,41,16,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/5377;;A61K31/405;;A61K31/496;;C07D209/18;;C07D403/02;;C07D413/02,514/233.2;;514/254.09;;514/419;;544/143;;544/373;;548/495,0,0,,,,ACTIVE
739,CN,B,CN 101184729 B,099-911-924-009-603,2011-02-16,2011,CN 200680018646 A,2006-05-26,US 2006/0020847 W;;US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase a2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA 2 alpha). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,LIHREN CHEN;;CLARK JAMES D;;SUZAN MARUSIC;;MCKEW JOHN C;;VALERIE CLERIN;;CARA WILLIAMS;;LEE KATHERINE L;;RICHARD VARGAS;;KEVIN PONG,,https://lens.org/099-911-924-009-603,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
740,HR,B1,HR P20180481 B1,115-392-514-629-689,2022-02-18,2022,HR P20180481 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE DIRECTED MODIFICATION OF FVIII,"Ovaj izum se odnosi na muteine faktora VIII koji su kovalentno vezani, na predodređenom mjestu koje nije N-terminalni amin, za jedan ili više biokompatibilnih polimera kao što je polietilen glikol. Mutein konjugati zadržavaju prokoagulantno djelovanje faktora VIII te imaju poboljšane farmakokinetičke značajke.This invention relates F VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain procoagulant activity of F VIII and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,Q PAN CLARK;;E MURPHY JOHN;;MEI BAISONG;;S STRAUSS JONATHAN;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/115-392-514-629-689,Granted Patent,no,5,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61K38/37;;A61K47/60;;A61P7/04;;C07K14/755;;C12P21/00,,3,2,022-092-946-978-595;;029-944-973-758-653,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"SAKURAGAWA N. ET AL., ""Studies on the Stability of Factor VIII modified by Polyethylene Glycol"", Acta Medica et Biologica, (1988), vol. 36, no. 1, str. 1 – 6;;VERONESE F M, ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, (20010301), vol. 22, no. 5, ISSN 0142-9612, str. 405 – 417; US6753165 B1 (BOLDER BIOTECHNOLOGY INC [US]) 22.06.2004;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, vol. 03, no. 08, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598, DOI: 10.1517/eobt.3.8.1253.21285",ACTIVE
741,CA,C,CA 2607857 C,126-519-157-821-772,2014-02-11,2014,CA 2607857 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA.alpha.). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/126-519-157-821-772,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
742,PH,A1,PH 12014500352 A1,156-031-389-365-891,2015-07-20,2015,PH 12014500352 A,2014-02-12,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;BAISONG MEI;;STRAUSS JONATHAN S;;HENDRI TJANDRA;;JIANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/156-031-389-365-891,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
743,JP,A,JP 2017105773 A,154-209-697-674-699,2017-06-15,2017,JP 2016234757 A,2016-12-02,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"PROBLEM TO BE SOLVED: To provide an isolated conjugate comprising entire factor VIII covalently bonded to one or more biocompatible polymers at B domain.SOLUTION: The invention relates to a conjugate having factor VIII procoagulant activity comprising a functional factor VIII polypeptide covalently attached to one or more biocompatible polymers at one or more predetermined sites on the polypeptide wherein the predetermined site is not an N-terminal amine. In certain embodiments, the conjugate is an isolated polypeptide conjugate whose biocompatible polymer is a polyalkylene oxide, preferably a polyethylene glycol, more preferably a methoxypolyethylene glycol of 3-100 kD, preferably 5-64 kD, more preferably 5-43 kD in size. The invention also provides a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable additive, and a method for treating hemophilia administering a therapeutically effective amount of the pharmaceutical composition to a patient in need.SELECTED DRAWING: None",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/154-209-697-674-699,Patent Application,no,7,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/46;;A61K47/50;;A61P7/04;;C07K19/00,,0,0,,,,ACTIVE
744,US,A1,US 2019/0215695 A1,167-555-585-693-063,2019-07-11,2019,US 201816230971 A,2018-12-21,US 201816230971 A,2018-12-21,METHODS AND APPARATUS FOR DETECTING ATTACKS IN V2X NETWORKS,"Methods, apparatus, systems, and articles of manufacture are disclosed to detect attacks in V2X networks. An example apparatus includes a challenge handler to (a) transmit a first challenge packet to a first vehicle to request a transmission of a first response, (b) instruct a second challenge packet to be transmitted to a second vehicle to request a transmission of a second response, (c) increment a first counter when the first response is not obtained, (d) increment a second counter when the second response is not obtained, and (e) after repeating (a)-(d), determine that the first and second vehicles are phantom vehicles associated with an attacker with a half-duplex radio when at least one of the first or second counters satisfy a threshold, and a network interface to instruct a third vehicle associated with the V2X network to ignore future messages from the phantom vehicles based on the determination.",YANG LIUYANG;;CHOUDHURY DEBABANI;;SHARMA SRIDHAR;;SIVANESAN KATHIRAVETPILLAI;;GOTTSCHLICH JUSTIN;;ZHANG ZHENG;;YONA YAIR;;LIU XIRUO;;AMBROSIN MORENO;;CHEN KUILIN CLARK,YANG LIUYANG;;CHOUDHURY DEBABANI;;SHARMA SRIDHAR;;SIVANESAN KATHIRAVETPILLAI;;GOTTSCHLICH JUSTIN;;ZHANG ZHENG;;YONA YAIR;;LIU XIRUO;;AMBROSIN MORENO;;CHEN KUILIN CLARK,INTEL CORPORATION (2018-01-02),https://lens.org/167-555-585-693-063,Patent Application,yes,0,12,4,4,0,H04L9/3271;;H04W4/40;;H04W4/80;;H04W12/122;;H04W12/12;;H04W4/40;;H04W12/06;;H04L9/3271;;H04W12/122,H04W12/12;;H04W4/40;;H04W12/06,,0,0,,,,ACTIVE
745,US,B1,US 6743894 B1,011-538-522-261-675,2004-06-01,2004,US 72325400 A,2000-11-27,US 72325400 A;;US 33722799 A;;US 5288898 A;;US 82585297 A,1997-04-04,Insulin-like growth factor agonist molecules,"
    Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. 
",GENENTECH INC,CHEN YVONNE MAN-YEE;;CLARK ROSS G;;COCHRAN ANDREA G;;LOWMAN HENRY B;;ROBINSON IAIN C A F;;SKELTON NICHOLAS J,GENENTECH INC (2002-02-12),https://lens.org/011-538-522-261-675,Granted Patent,yes,67,3,8,8,51,A61K38/30;;C07K7/08;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61P5/00;;A61K38/00;;C07K7/08;;A61K38/30;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61K38/00,A61K38/00;;A61K38/30;;C07K7/08;;C07K14/47;;C07K14/65,530/324;;530/317;;530/326;;530/327,100,90,014-125-367-031-231;;017-264-804-459-877;;017-350-602-958-513;;026-623-017-714-89X;;053-508-442-408-581;;050-719-958-572-148;;035-756-231-423-984;;045-964-465-312-91X;;091-854-753-933-770;;009-317-840-275-65X;;044-898-403-939-670;;020-803-531-740-687;;114-552-109-070-862;;121-192-711-498-551;;122-544-263-077-018;;048-188-266-680-461;;028-244-774-323-223;;051-762-247-693-584;;027-889-828-130-366;;097-785-885-745-976;;044-885-448-085-960;;055-029-284-594-570;;044-015-018-025-600;;066-564-168-992-217;;069-485-915-823-577;;036-028-618-959-354;;014-911-901-153-035;;032-236-672-104-294;;020-582-523-460-582;;038-260-426-123-957;;146-171-107-846-251;;009-186-473-238-939;;009-069-193-386-694;;098-441-778-398-080;;070-740-676-932-821;;093-658-600-554-037;;020-411-130-368-703;;020-510-267-061-589;;030-081-590-114-687;;026-720-717-926-994;;127-616-834-120-73X;;042-682-434-812-597;;167-040-741-674-313;;029-966-690-919-75X;;040-185-536-258-128;;105-560-205-533-971;;013-303-631-864-631;;096-718-408-234-974;;116-645-290-887-265;;010-645-653-539-638;;004-678-657-001-505;;019-984-077-132-656;;140-584-552-918-775;;035-483-585-582-64X;;116-157-636-951-170;;089-677-859-786-645;;003-137-931-754-668;;021-449-779-524-07X;;084-363-781-757-911;;000-613-056-275-938;;008-721-226-627-596;;063-088-702-691-710;;046-072-043-619-455;;078-655-932-195-328;;112-994-384-334-733;;007-717-236-970-533;;044-071-530-416-412;;016-758-022-635-876;;097-011-248-396-364;;044-051-728-567-349;;086-111-078-062-01X;;029-286-680-248-885;;007-489-225-495-51X;;045-838-528-482-83X;;147-661-590-433-69X;;015-768-700-460-036;;023-036-715-680-660;;016-796-441-670-243;;060-413-390-113-504;;025-059-951-768-239;;026-190-764-535-624;;150-639-968-778-276;;039-038-656-451-824;;076-444-264-945-863;;081-838-471-410-493;;028-701-201-701-662;;022-281-660-192-32X;;035-594-330-696-292;;070-680-873-937-056;;015-653-151-970-972,7680510;;10.1016/s0083-6729(08)60444-6;;10.1210/endo-127-6-3243;;2174349;;8171331;;10.1126/science.8171331;;10.1002/prot.340080405;;1708882;;2443135;;10.1016/s0006-291x(87)80136-5;;10.1016/s0021-9258(18)48458-x;;1370451;;2424282;;10.1016/s0065-2423(08)60124-9;;10.1016/0305-0491(88)90137-x;;2461835;;10.1016/s0021-9258(18)68777-0;;2966152;;2472386;;10.1016/s0021-9258(18)60418-1;;10.1016/s0021-9258(18)55447-8;;2168421;;10.1002/j.1460-2075.1989.tb08386.x;;pmc401241;;2479552;;6998350;;10.7326/0003-4819-120-7-199404010-00011;;8116999;;8374685;;10.1515/jpem.1993.6.1.21;;2315699;;10.1126/science.2315699;;7631865;;10.1152/ajpheart.1995.269.1.h326;;10.1016/s0006-291x(88)80425-x;;2454104;;10.1002/j.1460-2075.1988.tb03087.x;;2461294;;pmc457109;;10.1677/joe.0.1220661;;2681500;;10.1007/978-1-4615-2988-0_4;;7514345;;10.1021/bi00409a016;;2839228;;2536701;;10.1016/s0021-9258(18)94162-1;;3193048;;10.1677/joe.0.1190051;;8187319;;10.1111/j.1365-2265.1994.tb02492.x;;10.1007/bf00404081;;8359587;;10.1007/bf03000203;;21153160;;10.1007/bf03021409;;21153178;;10.1007/978-3-642-67986-5_5;;1379166;;10.1210/en.131.2.890;;10.1210/endo.131.2.1379166;;10.1016/s0021-9258(19)38332-2;;1695626;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;2143033;;10.1126/science.2143033;;10.1021/bi990089p;;10350456;;10.1172/jci117706;;pmc295527;;7860746;;10.1210/endo.137.5.8612531;;10.1210/en.137.5.1913;;8612531;;9124404;;10.1152/ajprenal.1997.272.2.f257;;10.1159/000184148;;7959637;;10.1210/endo.135.5.7956938;;7956938;;10.1210/en.135.5.2144;;10.1016/0161-5890(86)90081-7;;2432410;;9032099;;10.2337/diabetes.46.3.433;;10.2337/diab.46.3.433;;10.1021/bi00047a006;;7492543;;2220389;;pmc287020;;10.1073/pnas.86.8.2868;;2649897;;2741635;;10.1530/acta.0.1210101;;3387445;;10.1073/pnas.85.13.4889;;pmc280542;;3299085;;10.1056/nejm198707163170303;;10.1152/ajprenal.1993.265.1.f1;;8393619;;7948775;;10.1681/asn.v511;;10.1016/s0021-9258(19)47281-5;;2553732;;10.1172/jci116480;;pmc443305;;8514857;;7593439;;10.1210/jc.80.11.3284;;10.1210/jcem.80.11.7593439;;8662901;;10.1074/jbc.271.24.13948;;10.1038/ki.1993.57;;8441234;;1668800;;10.1111/j.1432-1033.1990.tb15595.x;;2197088;;8314009;;10.2337/diab.43.3.369;;10.2337/diabetes.43.3.369;;2237405;;10.1126/science.2237405;;10.1210/er.16.1.3;;10.1210/edrv-16-1-3;;7758431;;8762727;;10.1046/j.1365-2265.1996.711531.x;;10.1016/0378-1119(93)90153-t;;8508960;;pmc330007;;8423214;;10.1172/jci116163;;1538716;;7679407;;pmc287936;;10.1172/jci116212;;8482426;;10.2337/diab.42.5.696;;10.2337/diabetes.42.5.696;;10.1074/jbc.271.34.20458;;8702785;;2407519;;10.1210/endo-126-3-1593;;10.1210/mend-2-5-404;;2458522;;10.3181/00379727-204-43630;;7690486;;10.1038/330537a0;;2825030;;1718795;;10.1016/0303-7207(91)90086-8;;7691582;;10.1210/endo.133.4.7691582;;10.1210/en.133.4.1797;;10.1210/endo-129-4-2254;;1717244;;7508949;;10.1210/jc.78.2.404;;10.1210/jcem.78.2.7508949;;1377706;;10.1210/jc.75.1.30;;10.1210/jcem.75.1.1377706;;8662530;;10.1126/science.273.5274.464;;9465113;;10.1073/pnas.95.4.1894;;pmc19209;;9636028;;10.1021/bi980426e;;10.1146/annurev.biophys.26.1.401;;9241425;;9523276;;10.1385/0-89603-392-9:249;;2823385;;10.1126/science.2823385;;3722172;;10.1016/s0021-9258(19)84446-0;;10.1016/0378-1119(93)90149-w;;8508957;;10.1038/ki.1994.260;;7933838;;1438188;;10.1002/prot.340140411;;10.1681/asn.v32157;;1391716;;8498545;;10.1152/ajprenal.1993.264.5.f917;;10.1210/en.132.3.1337;;7679979;;10.1210/endo.132.3.7679979;;8939990;;10.1074/jbc.271.48.30322;;10.1073/pnas.89.12.5393;;1608948;;pmc49298,"Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*;;Alberts et al. Molecular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. p. 119 (1994).;;Bach and Rechler, ""Insulin-like Growth Factor Binding Proteins"" Diabetes Reviews 3:38-61 (1995).;;Ballard et al., ""Does IGF-I Ever Act Through the Insulin Receptor?"" The Insulin-like Growth Factors and Their Regulatory Proteins, Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).;;Bar et al., ""Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I"" Endocrinology 127 (6) : 3243-3245 (1990).;;Barinaga, M., ""Neurotrophic factors enter the clinic [news]"" Science 264: 772-774 (1994).;;Bass et al., ""Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties"" Proteins: Structure, Function, and Genetics8(4) :309-314 (1990).;;Baxter & Martin, ""Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison with Other Human and Rat Binding Proteins"" Biochem. & Biophys. Res. Comm. 147 (1) :408-415 (1987).;;Baxter et al., ""Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding proteins-3"" Journal of Biological Chemistry 267 (1) :60-65 (Jan. 5, 1992).;;Baxter, ""Physiological Roles of IGF Binding Proteins"" Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).;;Baxter, ""The somatomedins: insulin-like growth factors"" Advance in Clinical Chemistry 25:49-115 (1986).;;Baxter, R., ""The Insulin-Like Growth Factors and Their Binding Proteins"" Comp. Biochem. Physiol. 91B (2) :229-235 (1988).;;Bayne et al., ""Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor"" Journal of Biological Chemistry 263:6233-6239 (1988).;;Bayne et al., ""The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor"" Journal of Biological Chemistry 264 (19) :11004-11008 (Jul. 5, 1989).;;Bayne et al., ""The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor"" Journal of Biological Chemistry 265 (26) : 15648-15652 (Sep. 15, 1990).;;Binkert et al., ""Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)"" EMBO Journal 8 :2497-2502 (1989).;;Binoux, M., ""Donnees recentes sur les somatomedines (Insulin-like growth factors)"" Annales d'Endocrinologie 41:157-192 (1980).;;Bondy, C., ""Clinical uses of insulin-like growth factor I"" Annals of Internal Medicine 120:593-601 (1994).;;Bowers, C. Y., ""GH Releasing Peptides-Structure and Kinetics"" J. Pediatr. Endocrinology 6 (1) :21-31 (1993).;;Bowie et al., ""Deciphering the Message in Protein Sequences: Tolerance to Amio Acid Substitutions"" Science 247:1306-1310 (1990).;;Brandt et al., ""Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide"" American Journal of Physiology 269 (1 Pt 2) :H326-H331 (Jul. 1995).;;Brewer et al., ""Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein"" Biochem. & Biophys. Res. Comm. 152 (3) :1289-1297 (1988).;;Brinkman et al., ""Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)"" The EMBO J. 7:2417-2423 (1988).;;Carlsson et al., ""Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions"" J. Endocrinol. 122:661-670 (1989).;;Cascieri et al., ""Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins"" Advances in Experimental Medicine & Biology 343:33-40 (1993).;;Cascieri et al., ""Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor"" Biochemistry 27 (9) :3229-3233 (May 3, 1988).;;Cascieri et al., ""Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors"" Journal of Biological Chemistry 264:2199-2202 (1989).;;Charlton et al., ""Growth hormone-deficient dwarfism in the rat: a new mutation"" J. of Endocrinology 119:51-58 (1988).;;Cheetham et al., ""The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus"" Clin. Endocrinol. 40:515-522 (1994).;;Cheetham et al., ""The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus"" Diabetologia 36:678-681 (1993).;;Chen et al., ""Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation"" US Endocrine Meeting (Abstract 1596) p. 449 (1993).;;Clark et al., ""Growth-Responses to Patterned GH Delivery"" Endocrine 3:717-723 (1995).;;Clark et al., ""Insulin-Like Growth Factor-1 and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats"" Endocrine 3:297-304 (1995).;;Clemmons and Van Wyk, ""Somatomedin: physiological control and effects on cell proliferation"" Handbook Exp. Pharmacol. 57:161-208 (1981).;;Clemmons et al., ""Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs"" Endocrinology 131 (2) :890-895 (Aug. 1992).;;Clemmons et al., ""Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity"" Journal of Biological Chemistry 265 (21) :12210-12216 (1990).;;Cwirla et al., ""Peptides on phage: a vast library of peptides for identifying ligands"" Proc. Natl. Acad. Sci. USA 87 (16) :6378-6382 (1990).;;Devlin et al., ""Random peptide libraries: a source of specific protein binding molecules"" Science 249:404-406 (1990).;;Dubaquie et al., ""Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3"" Biochemistry 38 (20) :6386-6396 (1999).;;Duerr et al., ""Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure"" J. Clin. Invest. 95:619-627 (1995).;;Elahi et al., ""Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men"" Modern Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).;;Fielder et al., ""Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats"" Endocrinology 137:1913-1920 (1996).;;Franklin et al., ""Insulin-Like Growth Factor I Preserves Renal Function Postoperatively"" Am. J. Physiol. 272:F257-F259 (1997).;;Froesch et al., ""Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I"" Horm. Res. 42:66-71 (1994).;;Furnsinn et al., ""Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats"" Endocrinology 135 (5) :2144-2149 (1994).;;Geysen et al., ""A priori delineation of a peptide which mimics a discontinuous antigentic determinant"" Molecular Immunology 23 (7) : 709-715 (1986).;;Ghazzi et al., ""Cardiac and glycemic benefits of troglitazone treatment in NIDDM"" Diabetes 46:433-439 (1997).;;Giebel et al., ""Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities"" Biochemistry 34:15430-15435 (1995).;;Guler et al., ""Effects of Insulin-like Growth Factor I in Man"" Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).;;Guler et al., ""Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects"" Proc. Natl. Acad. Sci. USA 86:2868-2872 (Apr. 1989).;;Guler et al., ""Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man"" Acta Endocrinologica 121:101-106 (1989).;;Guler et al., ""Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats"" Proc. Natl. Acad. Sci. USA 85:4889-4893 (1988).;;Guler et al., ""Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults"" New England J. of Medicine 317 (3) :137-140 (1987).;;Hammerman and Miller, ""The growth hormone insulin-like factor axis in kidney revisited"" Am. J. Physiol. 265:F1-F14 (1993).;;Hammerman and Miller, ""Therapeutic use of growth factors in renal failure"" J. Am. Soc. Nephrol. 5:1-11 (1994).;;Hampton et al., ""Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma"" Journal of Biological Chemistry 264 (32) :19155-19160 (Nov. 15, 1989).;;Hartman et al., ""A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans"" J. Clin. Invest. 91:2453-2462 (1993).;;Hasegawa et al., ""The free form of insulin-like growth factor I increases in circulation during normal human pregnancy"" J. Clin. Endocrinol. Metabol. 80:3284-3286 (1995).;;Heding et al., ""Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3"" Journal of Biological Chemistry 271 (24) :13948-13952 (Jun. 14, 1996).;;Hirschberg et al., ""Effects of insulin-like growth factor I on renal function in normal men"" Kidney International 43:387-397 (1993).;;Hizuka et al., ""Measurement of free form of insulin-like growth factor I in human plasma"" Growth Regulation 1:51-55 (1991).;;Humbel, ""Insulin-like growth factors I and II"" European Journal of Biochemistry 190:445-462 (1990).;;Jabri et al., ""Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients"" Diabetes 43:369-374 (1994).;;Johnson et al., ""Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes"" Science 250:546-549 (1990).;;Jones et al., ""Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions"" Endocrine Reviews 16 (1) :3-34 (1995).;;Juul et al., ""Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty"" Clin. Endocrinology 44:515-523 (1996).;;Kay et al., ""An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets"" Gene 128: 59-65 (1993).;;Kerr et al., ""Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia"" Diabetes: American Diabetes Association (ADA) , San Antonio, Texas, Jun. 20-23, 1992 (abstract #225) , 52nd Annual Meeting edition 41 (supp 1) : 60A (Jun. 1992).;;Kerr et al., ""Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans"" J. Clin. Invest. 91:141-147 (1993).;;Kletzien et al., ""Enhancement of adipocyte differentiation by an insulin-sensitizing agent"" Molecular Pharmacology 41 (2) :393-398 (Feb. 1992).;;Kupfer et al., ""Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously"" J. Clin Invest. 91:391-396 (1993).;;Kuzuya et al., ""Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes"" Diabetes 42:696-705 (1993).;;Lassalle et al., ""ESM-1 is a novel human edothelial cell-specific molecule expressed in lung and regulated by cytokines"" Journal of Biological Chemistry 271:20458-20464 (1996).;;Leahy et al., ""Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion"" Endocrinology 126 (3):1593-1598 (1990).;;Lee et al., ""Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors"" Mol. Endocrinol. 2 (5) :404-411 (1988).;;Lee et al., ""Regulation and function of insulin-like growth factor-binding protein-1"" Proc. Soc. Exp. Biol. & Med. 204:4-29 (1993).;;Leung et al., ""Growth hormone receptor and serum binding protein: purification, cloning and expression"" Nature 330:537-543 (1987).;;Lewitt and Baxter, ""Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?"" Mol. Cell. Endocrinology 79 (1-3) :C147-C152 (1991).;;Lewitt et al., ""Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3"" Endocrinology 133:1797-1802 (1993).;;Lewitt et al., ""Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels"" Endocrinology 129 (4) :2254-2256 (1991).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia"" US Endocrine Meeting (Abstract 1664) p. 466 (1993).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome"" J. Clin. Endocrinol. and Metab. 78 (2) :404-410 (1994).;;Lieberman et al., ""Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans"" J. Clin. Endocrinol. and Metab. 75(1) :30-36 (1992).;;Livnah et al., ""Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A "" Science 273 (5274) :464-471 (Jul. 26, 1996).;;Loddick et al., ""Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke"" Proc. Natl. Acad. Sci. USA 95 (4) :1894-1898 (Feb. 17, 1998).;;Lowman et al., ""Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions"" Biochemistry 37 (25) :8870-8878 (1998).;;Lowman et al., ""Peptides that displace IGFs from their BPS as potential novel treatment modalities of growth orders-basic aspects"" (Abstract presented at the Intl. Pediatric Nephrology Assn.'s 6th Symposium on Growth and Development in Children with Chronic Renal Failure held in NY on Mar. 11-13, 1999).;;Lowman, H. , ""Bacteriophage display and discovery of peptide leads for drug development"" Annual Review of Biophysics and Biomolecular Structure 26:401-424 (1997).;;Lowman, H., ""Phage display of peptide libraries on protein scaffolds"" Methods in Molecular Biology , Chapter 24, 87:249-264 (1998).;;Maack et al., ""Physiological Role of Silent Receptors of Atrial Natriuretic Factor"" Science 238:675-678 (Oct. 30, 1987).;;Martin & Baxter, ""Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characteriztion"" Journal of Biological Chemistry 261(19) :8754-8760 (1986).;;McLafferty et al., ""M13 bacteriophage displaying disulfide-constrained microproteins"" Gene 128:29-36 (1993).;;Miller et al., ""Effects of IGF-I on renal function in end-stage chronic renal failure"" Kidney International 46:201-207 (1994).;;Morrow et al., ""Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance"" Diabetes-53rd Annual Meeting, Jun. 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993).;;O'Neil et al., ""Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library"" Proteins: Structure, Function, and Genetics 14:509-515 (1992).;;O'Shea and Layish, ""Growth hormone and the kidney: a case presentation and review of the literature"" J. Am. Soc. Nephrol. 3:157-161 (1992).;;O'Shea et al., ""Effects of IGF-I on renal function in patients with chronic renal failure"" Am. J. Physiol. 264:F917-F922 (1993).;;Oh et al., ""Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs"" Endocrinology 132:1337-1344 (1993).;;Oh et al., ""Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II"" Journal of Biological Chemistry 271:30322-30325 (1996).;;Oldenburg et al., ""Peptide ligands for a sugar-binding protein isolated from a random peptide library"" Proc. Natl. Acad. Sci. 89:5393-5397 (1992).",EXPIRED
746,EP,A1,EP 3130601 A1,037-889-791-721-148,2017-02-15,2017,EP 16186901 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to B-domain deleted Factor VIII muteins that are covalently bound, at position 1804 site to one PEG polymers. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/037-889-791-721-148,Patent Application,yes,10,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00,,45,41,022-092-946-978-595;;029-944-973-758-653;;098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;050-112-382-936-584;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;16233987;;10.1016/j.cbpa.2005.10.007;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCANDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 551;;HARRIS ET AL., CLIN PHARMACOKINETICS, vol. 40, no. 7, 2001, pages 539 - 551;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL., 2005;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE, S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23",ACTIVE
747,EP,B1,EP 3130601 B1,025-938-001-569-560,2020-07-15,2020,EP 16186901 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/025-938-001-569-560,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,3,0,,,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01) , pages 1253-1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1-05, XP009011547, ISSN: 0567-7734",ACTIVE
748,BR,B1,BR 122016022033 B1,063-537-477-095-517,2021-03-02,2021,BR 122016022033 A,2005-11-14,US 2005/0041205 W;;US 62727704 P;;BR PI0517795 A,2004-11-12,"conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica","conjugado polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica. a presente invenção refere-se a muteínas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteína conservam atividade pró-coagulante de fviii e têm propriedades farmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,BAISONG MEI;;CLARK Q PAN;;DEQIAN WANG;;HENDRI TJANDRA;;JIANMIN CHEN;;JOHN E MURPHY;;JONATHAN S STRAUSS;;LIANG TANG;;THOMAS BARNETT,,https://lens.org/063-537-477-095-517,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
749,PL,T3,PL 2371856 T3,091-472-259-107-680,2022-08-22,2022,PL 11153297 T,2005-11-14,US 62727704 P,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,,https://lens.org/091-472-259-107-680,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K14/755,,0,0,,,,PENDING
750,HK,A1,HK 1113680 A1,100-885-111-966-139,2008-10-10,2008,HK 08109102 A,2008-08-15,US 2006/0020847 W;;US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/100-885-111-966-139,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K/;;A61P/;;C07D/,,0,0,,,,DISCONTINUED
751,SI,T1,SI 2371856 T1,135-635-457-673-665,2022-09-30,2022,SI 200532309 T,2005-11-14,US 62727704 P;;EP 11153297 A,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,TANG JIANG;;PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;WAMG DEQIAN,,https://lens.org/135-635-457-673-665,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K47/00;;A61K38/00;;C07K14/00,,0,0,,,,ACTIVE
752,CY,T1,CY 1111151 T1,141-178-456-507-565,2015-06-11,2015,CY 101101135 T,2010-12-09,EP 06771540 A;;US 68556405 P,2005-05-27,ΑΝΑΣΤΟΛΕΙΣ ΦΩΣΦΟΛΙΠΑΣΗΣ Α2 ΤΟΥ ΚΥΤΤΑΡΟΔΙΑΛΥΜΑΤΟΣ,"Η εφεύρεση αυτή παρέχει χημικούς αναστολείς της δραστικότητας διαφόρων ενζύμων φωσφολιπάσης, ιδιαιτέρως ενζύμων φωσφολιπάσης Α2 του κυτταροδιαλύματος (cPLA2), ειδικότερα συμπεριλαμβάνοντας αναστολείς φωσφολιπάσης Α2 άλφα ενζύμων του κυτταροδιαλύματος (cPLAα). Σε μερικές πραγματοποιήσεις, οι αναστολείς έχουν τον Τύπο I: όπου οι μεταβλητές σύνταξης είναι όπως ορίζεται εδώ.",WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/141-178-456-507-565,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
753,EP,B1,EP 3323829 B1,173-677-054-626-462,2020-07-15,2020,EP 17201672 A,2005-11-14,US 62727704 P;;EP 17166910 A;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/173-677-054-626-462,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,3,0,,,"SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLO, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1-05, XP009011547, ISSN: 0567-7734;;VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01) , pages 1253-1261, XP008036528, ISSN: 1471-2598",ACTIVE
754,MY,A,MY 151329 A,032-848-655-680-289,2014-05-15,2014,MY PI20070790 A,2007-05-18,MY PI20070790 A,2007-05-18,SITE-DIRECTED MODIFICATION OF FVIII,"THIS INVENTION RELATES TO FACTOR VIII MUTEINS THAT ARE COVALENTLY BOUND, AT A PREDEFINED SITE THAT IS NOT AN N-TERMINAL AMINE, TO ONE OR MORE BIOCOMPATIBLE POLYMERS SUCH AS POLYETHYLENE GLYCOL. THE MUTEIN CONJUGATES RETAIN VIII PROCOAGULANT ACTIVITY AND HAVE IMPROVED PHARMACOKINETIC PROPERTIES.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;BAISONG MEI;;STRAUSS JONATHAN S;;HENDRI TJANDRA;;JIANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/032-848-655-680-289,Granted Patent,no,0,0,1,1,0,,C07K14/755,,0,0,,,,ACTIVE
755,CN,A,CN 103214569 A,039-808-838-682-138,2013-07-24,2013,CN 201310125428 A,2005-11-14,US 62727704 P;;CN 200580046469 A,2004-11-12,Site-directed modification of fviii,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,CLARK Q PAN;;JOHN E MURPHY;;BAISONG MEI;;JONATHAN S STRAUSS;;HENDRI TJANDRA;;JLANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/039-808-838-682-138,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/37;;A61P31/02,,0,0,,,,ACTIVE
756,EP,B1,EP 2363414 B1,038-607-490-125-746,2022-05-18,2022,EP 11153300 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-04-27),https://lens.org/038-607-490-125-746,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;C07K17/08,,3,0,,,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01) , pages 1253-1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1-05, XP009011547, ISSN: 0567-7734",ACTIVE
757,KR,A,KR 20070110260 A,033-533-460-818-110,2007-11-16,2007,KR 20077013131 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/033-533-460-818-110,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
758,PL,T3,PL 1824988 T3,128-032-628-340-616,2018-01-31,2018,PL 05849392 T,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/128-032-628-340-616,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,PENDING
759,AU,B2,AU 2006/251946 B2,112-506-392-783-162,2011-05-12,2011,AU 2006/251946 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,Inhibitors of cytosolic phospholipase A2,,NOVARTIS AG,PONG KEVIN;;CLERIN VALERIE;;WILLIAMS CARA;;LEE KATHERINE L;;CLARK JAMES D;;CHEN LILHREN;;MCKEW JOHN C;;VARGAS RICHARD;;MARUSIC SUZANA,"NOVARTIS AG (2022-08-25);;ZIARCO, INC. (2016-11-03)",https://lens.org/112-506-392-783-162,Granted Patent,no,1,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,INACTIVE
760,US,A1,US 2010/0022536 A1,136-002-609-772-491,2010-01-28,2010,US 48818209 A,2009-06-19,US 48818209 A;;US 44219906 A;;US 68556405 P,2005-05-27,Inhibitors of Cytosolic Phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,NOVARTIS AG (2021-12-03);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/136-002-609-772-491,Patent Application,yes,49,2,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/5377;;A61K31/405;;A61K31/497;;A61P7/02;;A61P11/06;;A61P19/02;;A61P25/00;;A61P25/16;;A61P29/00,514/235.2;;514/415;;514/254.09,0,0,,,,ACTIVE
761,EP,A2,EP 1824988 A2,142-824-792-728-236,2007-08-29,2007,EP 05849392 A,2005-11-14,US 2005/0041205 W;;US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,"BAYER HEALTHCARE LLC, WHIPPANY, US (2018-12-10);;BAYER HEALTHCARE LLC (2017-11-01)",https://lens.org/142-824-792-728-236,Patent Application,yes,0,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,ACTIVE
762,HN,A,HN 2006019513 A,140-197-456-869-803,2011-03-02,2011,HN 2006019513 A,2006-05-26,US 68556405 P,2005-05-27,INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA,LA PRESENTE INVENCION SE REFIERE A INHIBIDORES QUIMICOS PARA LA ACTIVIDAD DE VARIAS ENZIMAS FOSFOLIPASA,WYETH CORP,JOHN C MCKEW;;KATHERINE L LEE;;LIHREN CHEN;;RICHARD VARGAS;;JAMES D CLARK;;CARA WILLIAMS;;VALERIE CLERIN;;SUZANA MARUSIC;;KEVIN PONG,,https://lens.org/140-197-456-869-803,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,,,0,0,,,,PENDING
763,US,A1,US 2021/0099799 A1,157-144-853-868-714,2021-04-01,2021,US 202017019778 A,2020-09-14,US 202017019778 A;;US 201962923391 P;;US 201962907315 P,2019-09-27,HEADPHONE ACOUSTIC NOISE CANCELLATION AND SPEAKER PROTECTION OR DYNAMIC USER EXPERIENCE PROCESSING,A method for audio signal processing of microphone signals of a headphone. An audio signal from a first microphone of a headphone is filtered by an ANC system to produce a first filtered signal. Dynamic range control is performed upon the first filtered signal to produce a first dynamic range adjusted signal that drives a speaker of the headphone. Other aspects are also described and claimed.,APPLE INC,SAUX TOM-DAVY W;;CLARK BRIAN D;;CHEN HANCHI;;CHIU VICTORIA;;BAJIC VLADAN;;MASSIE DANA;;BRIGHT ANDREW P;;JENSEN THOMAS M,APPLE INC (2020-08-04),https://lens.org/157-144-853-868-714,Patent Application,yes,0,7,2,4,0,G10K11/17833;;G10K11/17881;;G10K2210/1081;;G10K2210/3039;;G10K2210/3056;;G10L21/0224;;H04R1/1083;;H04R3/04;;H04R1/1016;;H04R1/1016;;H04R1/406;;H04R3/005;;H04R3/005;;H04R3/007;;H04R5/033;;H04R5/04;;H04R29/004,H04R3/04;;G10L21/0224;;H04R1/10;;H04R3/00;;H04R5/033;;H04R5/04;;H04R29/00,,0,0,,,,ACTIVE
764,MX,A,MX 2007005466 A,037-843-720-797-264,2007-10-19,2007,MX 2007005466 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII.,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,BARNETT THOMAS;;MURPHY JOHN E;;PAN CLARK Q;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;WANG DEQIAN;;TANG LIANG,,https://lens.org/037-843-720-797-264,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;A61K35/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
765,US,B2,US 8283373 B2,030-124-449-921-356,2012-10-09,2012,US 48818209 A,2009-06-19,US 48818209 A;;US 44219906 A;;US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN;;PFIZER,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,NOVARTIS AG (2021-12-03);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/030-124-449-921-356,Granted Patent,yes,81,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404,514/415,45,26,026-226-062-873-479;;096-665-121-074-620;;088-873-608-648-063;;017-119-380-043-243;;068-228-387-549-08X;;151-879-670-237-214;;007-737-889-206-944;;027-226-226-568-670;;017-773-555-337-136;;049-360-904-961-611;;110-574-808-894-379;;067-576-826-353-21X;;012-599-148-844-832;;009-130-865-367-745;;001-844-539-881-363;;057-913-407-111-808;;095-914-469-028-092;;031-766-076-467-920;;036-877-450-775-805;;020-654-176-077-967;;124-150-239-256-308;;006-389-760-792-212;;128-362-223-519-855;;023-381-831-996-846;;096-484-982-426-875;;007-306-546-814-126,10.1517/13543770903463905;;20021282;;10.1016/j.drudis.2008.03.026;;18954804;;10.1186/1479-5876-2-44;;15610560;;pmc544857;;10.1016/0040-4020(95)00809-m;;10.1517/13543776.14.7.937;;10.1002/ddr.430100404;;9005255;;10.1021/jm960485v;;8978843;;10.1021/jm960486n;;5069781;;10.1021/jm00280a027;;8978844;;10.1021/jm960487f;;10.1021/ja00137a021;;2925633;;10.1016/s0021-9258(18)83616-x;;11310603;;10.1016/s0968-0896(00)00286-8;;3143418;;10.1016/0005-2760(88)90316-5;;16102039;;10.1111/j.1538-7836.2005.01488.x;;7174067;;10.1038/nsb0695-458;;pmc7097651;;7664108;;10.1016/s0021-9258(18)83549-9;;2925608;;11377176;;10.1016/s0968-0896(00)00345-x;;10.1038/nrd985;;12509756;;2888113;;10.1073/pnas.84.18.6374;;pmc299078;;3300655;;10.1016/0006-2952(87)90512-0;;2655580;;10.1042/bj2590315;;pmc1138513;;10.1038/37622;;9403692;;3053741;;10.1080/21548331.1988.11703580;;10.1021/jo9909913,"Magrioti et al. Expert Opin. Ther. Patents 2010, 10(1), 1-18.;;Schafer et al. (Drug Discovery Today 2008, 13 (21/22), 913-916).;;Horig et al. Journal of Translational Medicine 2004, 2(44).;;International Search Report for PCT/US/2006/020847, 5 pages Nov. 20, 2006).;;Written Opinion of the International Searching Authority for PCT/US2006/020847, 7 pages (Nov. 20, 2006).;;Clark, James D., ""Discovery of Anti-Inflammatory cPLA2alpha Inhibitors"" FASEB Conference Phospholipid Metabolism, (Jul. 21, 2008).;;""Discovery of Anti-Inflammatory cPLA2alpha inhibitors"", Inflammation & Immune Diseases Drug Discovery & Development Summit, (Mar. 14-15, 2005).;;Lee, Katherine L. et al., Indole Phenyl Sulfonamide cPLA2alpha inhibitors for the Treatment of Inflammation (Mar. 30, 2006).;;Lee, Katherine L. et al., ""The Discovery of cPLA2alpha Inhibitors with Efficacy in Animal Models of Arthritis, Asthma, Multiple Sclerosis, Thrombosis and Atherosclerosis"", (Aug. 2007).;;McKew, John C., et al., ""Discovery of New Class of Anti-Inflammatory: Indole cPLA2alpha Inhibitors"", (May 2004).;;McKew, John C. et al., ""Indole Benzyl Sulfonamide CPLA2alpha Inhibitors: Optimization and Efficacy in Inflammatory Models"", (2006).;;McKew, John C. et al, ""The Discovery CPLA2alpha Inhibitors that are Efficacious in in Vivo Models of Arthritis, Stroke, and Atherothrombosis"", (2007).;;McKew, John, Discovery & Characterization of Giripladib: A first in Class cPLA2alpha Inhibitor, (Feb. 20, 2008).;;Ramarao, Manjunath, ""Characterization of cPLAalpha Inhibitors by Microcalorimetry"", (2007).;;Behnke, Marck L., et al., ""Indole Based Inhibitors of cPLAalpha: Phenylsulfonamides"", (2005).;;Chung et al., Synthesis of 3-Fluoro-2-substituted amino-5,12-dihydro-5-oxobenzoxazolo[3,2-.alpha.] quinoline-6-carboxylic Acids Employing the Tandem Double Ring Closure Reaction of N-Acetyl-N-(2-hydroxyphenyl)anthranilic Acid as the Key Step, Tetrahedron vol. 51, No. 46, pp. 12549-12562, 1995, Elsevier Science Ltd, printed in Great Britain.;;Clark et al., ""Potential therapeutic uses of phospholipase A2 inhibitors,"" Expert Opin. Ther. Pat., 14:937-950 (2004).;;Dennis, Drug Devel. Res., 10:205-220 (1987).;;Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp. 5119-5136.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 2. Indole-3-acetamides with Additional Functionality, J. Med.chem. 1996, vol. 39, No. 26, pp. 5137-5158.;;Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp. 1081-1082.;;Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp. 5159-5175.;;Goodman et al., Self-Assembling, Chromogenic Receptors for the Recognition of Dicarboxylic Acid, J. Am. Chem. Soc., 1995, 117, pp. 8447-8455.;;Jackson et al., Nature Reviews, Drug Discovery vol. 2, 1-15, Oct. 2003.;;Kando et al, Biochem. Biophys, Res. Comm., 163:42-48 (1989).;;Kramer et al, J. Biol. Chem., 264:5768-5775 (1989).;;Langer et al., Synthesis of High-specific-radioactivity 4- and 6-[.sup.18F]fluorometaraminol- PET Tracers for the Adrenergic Nervous System of the Heart, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 677-694.;;Leslie et al, Biochem. Biophys. Acta., 963:476-492 (1988).;;Nieswandt et al., J. Thrombosis and Haemostasis, 3: 1725-1736 (2005).;;Roy et al., Further Studies on Anti-Inflammatory Activity of Two Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp. 207-214.;;Samuelson et al., Science, 237:1171-76 (1987).;;Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp. 458-465.;;Seilhamer et al, J. Biol. Chem., 264:5335-5338 (1989).;;Adediran et al., The Synthesis and Evaluation of Benzofuranones as .beta.-Lactamase Substrates, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 1175-1183.;;Bhatt et al., Nature Reviews, Drug Discovery vol. 2, 15-28, Jan. 2003.;;Bonventure et al., et al., Nature 1997, 390: 622-625.;;Burch et al., Proc. Natl. Acad. Sci. U.S.A., 84:6374-6378 (1989).;;Chang et al, Biochem. Pharmacol., 36:2429-2436 (1987).;;Chemical Abstract Service Registry No. 865200-20-0, ""Benzoic acid, 4-[3-[5-chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]-(9CI),"" 1 page (Oct. 13, 2005).;;Smith, Biochem. J., 259:315-324 (1989).;;Uozumi et al. Role of Cytosolic Phospholipase A2 in Allergic Response and Parturition, Nature, 390:618-622, (Dec. 11, 1997).;;Wasserman, Hospital Practice, 15:49-58 (1988).;;Xi et al., Functionalized Deep-Cavity Cavitands, J. Org. Chem. 1999, 64, pp. 9286-9288.;;Written Opinion of the International Searching Authority and International Search Report for PCT/US2006/020847, 14 pages (Nov. 20, 2006).;;Notification Concerning Transmittal of International Preliminary Report on Patentability for PCT/US2006/020847, 9 pages (Dec. 13, 2007).",ACTIVE
766,CY,T1,CY 1119292 T1,079-348-969-880-747,2018-02-14,2018,CY 171100753 T,2017-07-14,US 2005/0041205 W;;US 62727704 P,2004-11-12,ΚΑΤΕΥΘΥΝΟΜΕΝΗ ΑΠΟ ΘΕΣΗ ΤΡΟΠΟΠΟΙΗΣΗ TOY FVIII,"Η παρούσα εφεύρεση σχετίζεται με μουτεΐνες του παράγοντα VIII οι οποίες είναι ομοιοπολικά δεσμευμένες, σε μια προκαθορισμένη θέση η οποία δεν είναι μια Ν-τελική αμίνη, με ένα ή περισσότερα βιοσυμβατά πολυμερή, όπως πολυαιθυλενογλυκόλη. Τα προϊόντα σύζευξης μουτεΐνης διατηρούν την προ-πηκτική δραστικότητα του FVIII και έχουν βελτιωμένες φαρμακοκινητικές ιδιότητες.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/079-348-969-880-747,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,ACTIVE
767,AU,A1,AU 2006/251946 A1,079-318-657-257-158,2006-11-30,2006,AU 2006/251946 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,Inhibitors of cytosolic phospholipase A2,,WYETH CORP,PONG KEVIN;;CLERIN VALERIE;;WILLIAMS CARA;;LEE KATHERINE L;;CLARK JAMES D;;CHEN LILHREN;;MCKEW JOHN C;;VARGAS RICHARD;;MARUSIC SUZANA,"NOVARTIS AG (2022-08-25);;ZIARCO, INC. (2016-11-03)",https://lens.org/079-318-657-257-158,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,INACTIVE
768,DK,T3,DK 2363414 T3,095-217-339-363-817,2022-08-08,2022,DK 11153300 T,2005-11-14,US 62727704 P;;EP 05849392 A,2004-11-12,Stedstyret modifikation af FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;WAMG DEQIAN;;MEI BAISONG;;TANG LIANG,,https://lens.org/095-217-339-363-817,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;C07K17/08,,0,0,,,,ACTIVE
769,DK,T3,DK 1891006 T3,093-863-939-031-449,2011-01-24,2011,DK 06771540 T,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,Inhibitorer af cytosolisk phospholipase A2,,WYETH LLC,LEE KATHERINE L;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN;;MCKEW JOHN C;;CHEN LIHREN;;VARGAS RICHARD,,https://lens.org/093-863-939-031-449,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
770,GT,A,GT 200700040 A,129-135-832-717-183,2008-12-18,2008,GT 200700040 A,2007-05-11,GT 200700040 A,2007-05-11,MODIFICACION DIRIGIDA AL SITIO DEL FVIII,"LA INVENCIÓN SE RELACIONA CON MUTEÍNAS DEL FACTOR VIII QUE ESTÁN LIGADAS COVALENTEMENTE, EN UN SITIO PREDEFINIDO QUE NO ES UNA AMINA DE TERMINAL N, A UNO O MÁS POLÍMEROS BIOCOMPATIBLES TALES COMO POLIETILENGLICOL. LOS CONJUGADOS DE LA MUTEÍNA RETIENEN LA ACTIVIDAD PROCOAGULANTE DEL FVIII Y TIENEN PROPIEDADES FARMACOCINÉTICAS MEJORADAS. T2007",,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/129-135-832-717-183,Amended Application,no,0,0,1,1,0,,A61P7/00;;A61P37/00;;C07K14/745;;C12P21/06,,0,0,,,,PENDING
771,HR,A2,HR P20180481 A2,154-436-640-452-438,2018-06-29,2018,HR P20180481 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE DIRECTED MODIFICATION OF FVIII,"Ovaj izum se odnosi na muteine faktora VIII koji su kovalentno vezani, na predodređenom mjestu koje nije N-terminalni amin, za jedan ili više biokompatibilnih polimera kao što je polietilen glikol. Mutein konjugati zadržavaju prokoagulantno djelovanje faktora VIII te imaju poboljšane farmakokinetičke značajke.",BAYER HEALTHCARE LLC,Q PAN CLARK;;E MURPHY JOHN;;MEI BAISONG;;S STRAUSS JONATHAN;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/154-436-640-452-438,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61K38/37;;A61K47/60;;A61P7/04;;C07K14/755;;C12P21/00,,0,0,,,,ACTIVE
772,NO,A1,NO 20210454 A1,155-999-430-799-308,2007-06-27,2007,NO 20210454 A,2021-04-13,US 62727704 P;;US 2005/0041205 W,2004-11-12,Setedirigert modifikasjon av FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/155-999-430-799-308,Unknown,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K47/60;;A61P7/00;;A61P7/04;;A61P31/02;;C07K14/00;;C07K14/755;;C07K17/08,,0,0,,,,PENDING
773,EP,A1,EP 3153181 A1,168-557-496-463-560,2017-04-12,2017,EP 16186902 A,2005-11-14,US 62727704 P;;EP 05849392 A,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII BDD,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2021-11-03),https://lens.org/168-557-496-463-560,Patent Application,yes,11,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K47/50;;A61K38/00;;C07K14/755,,54,47,022-092-946-978-595;;029-944-973-758-653;;098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220;;040-121-810-358-365;;037-918-429-248-167;;098-674-577-477-126;;040-121-810-358-365;;037-918-429-248-167;;098-674-577-477-126,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361;;7613471;;10.1002/pro.5560040413;;pmc2143093;;18400180;;10.1016/j.str.2008.03.001;;10.1016/s0378-5173(97)00155-5;;7613471;;10.1002/pro.5560040413;;pmc2143093;;18400180;;10.1016/j.str.2008.03.001;;10.1016/s0378-5173(97)00155-5,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612, DOI: 10.1016/S0142-9612(00)00193-9;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, ASHLEY, LONDON; GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598, DOI: 10.1517/EOBT.3.8.1253.21285;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;THOMPSON: ""Semin. Hematol."", vol. 29, 2003, pages: 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATI. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAEHKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCARIDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA. D. ET AL., THROMB HAEMOST, vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDEHBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL. 2005, 15 October 2005 (2005-10-15);;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN, PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE. S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., vol. 4, 1999, pages 269 - 275;;MCMULLEN, ET AL: ""Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)"", PROTEIN SCIENCE, vol. 4, 1 January 1995 (1995-01-01), pages 740 - 746, XP055666938, DOI: 10.1002/pro.5560040413;;NGO, J.C.K. ; HUANG, M. ; ROTH, D.A. ; FURIE, B.C. ; FURIE, B.: ""Crystal Structure of Human Factor VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex"", STRUCTURE, vol. 16, no. 4, 8 April 2008 (2008-04-08), AMSTERDAM, NL , pages 597 - 606, XP022588339, ISSN: 0969-2126, DOI: 10.1016/j.str.2008.03.001;;HERMANSON GREG T.: ""FUNCTIONAL TARGETS FOR BICCONJUGATON"", BIOCONJUGATE TECHNIQUES THIRD EDITION, 1 January 2013 (2013-01-01), pages 178 - 184, XP093055789;;FATOUROS ANGELICA, OESTERBERG THOMAS, MIKAELSSON MARIANNE: ""Recombinant factor VIII SQ: Influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 155, no. 1, 1 January 1997 (1997-01-01), NL , pages 121 - 131, XP002475005, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00155-5;;MCMULLEN, ET AL: ""Locations of disulfide bonds and free cysteines in the heavy and light chains of recombinant human factor VIII (antihemophilic factor A)"", PROTEIN SCIENCE, vol. 4, 1 January 1995 (1995-01-01), pages 740 - 746, XP055666938, DOI: 10.1002/pro.5560040413;;NGO, J.C.K. ; HUANG, M. ; ROTH, D.A. ; FURIE, B.C. ; FURIE, B.: ""Crystal Structure of Human Factor VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex"", STRUCTURE, vol. 16, no. 4, 8 April 2008 (2008-04-08), AMSTERDAM, NL , pages 597 - 606, XP022588339, ISSN: 0969-2126, DOI: 10.1016/j.str.2008.03.001;;FATOUROS ANGELICA, OESTERBERG THOMAS, MIKAELSSON MARIANNE: ""Recombinant factor VIII SQ: Influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution"", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 155, no. 1, 1 January 1997 (1997-01-01), NL , pages 121 - 131, XP002475005, ISSN: 0378-5173, DOI: 10.1016/S0378-5173(97)00155-5",DISCONTINUED
774,SG,A,SG 11201504622P A,001-583-409-984-433,2015-07-30,2015,SG 11201504622P A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER;;STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/001-583-409-984-433,Unknown,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,PENDING
775,KR,A,KR 20130036780 A,019-862-038-480-652,2013-04-12,2013,KR 20137007423 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/019-862-038-480-652,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61P7/04;;C07K14/755;;C12P21/00,,0,0,,,,ACTIVE
776,AU,A1,AU 2016/203693 A1,027-818-026-868-74X,2016-06-23,2016,AU 2016/203693 A,2016-06-03,AU 2016/203693 A;;AU 2013/203348 A;;AU 2012/203813 A,2012-06-28,Site-directed modification of FVIII,"H:\ft\interwoven\NRPortbl\DCC\FMT\I 0258723_l.docx-3/06/2016 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/027-818-026-868-74X,Patent Application,no,0,0,4,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,0,0,,,,ACTIVE
777,HK,A1,HK 1152710 A1,040-586-779-386-498,2012-03-09,2012,HK 11106893 A,2011-07-05,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/040-586-779-386-498,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K/;;A61P/;;C07D/,,0,0,,,,DISCONTINUED
778,HU,T2,HU E059193 T2,077-007-016-112-484,2022-10-28,2022,HU E11153297 A,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,,https://lens.org/077-007-016-112-484,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00,,0,0,,,,PENDING
779,MY,A,MY 173864 A,078-509-739-875-027,2020-02-25,2020,MY PI2013000709 A,2007-05-18,MY PI2013000709 A,2007-05-18,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain VIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;CHEN JIANMIN;;BARNETT THOMAS;;TJANDRA HENDRI;;TANG LIANG;;WANG DEQIAN,,https://lens.org/078-509-739-875-027,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,ACTIVE
780,BR,B8,BR PI0517795 B8,090-360-178-973-795,2021-05-25,2021,BR PI0517795 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,"conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica","modificação sítio-dirigida de fviii. esta invenção se refere a muteinas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteina conservam atividade pró-coagulante de eviii e têm propriedades fa rmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,BAISONG MEI;;CLARK Q PAN;;DEQIAN WANG;;HENDRI TJANDRA;;JIANMIN CHEN;;JOHN E MURPHY;;JONATHAN S STRAUSS;;LIANG TANG;;THOMAS BARNETT,,https://lens.org/090-360-178-973-795,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
781,PT,T,PT 1824988 T,102-915-504-348-742,2017-07-21,2017,PT 05849392 T,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,CLARK Q PAN;;JOHN E MURPHY;;BAISONG MEI;;JONATHAN S STRAUSS;;HENDRI TJANDRA;;JIANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/102-915-504-348-742,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,PENDING
782,MA,B1,MA 29663 B1,107-042-536-530-516,2008-08-01,2008,MA 29972 A,2007-06-06,US 62727704 P,2004-11-12,MODIFICATION DU FACTEUR FVIII EN FONCTION DU SITE,"Cette invention concerne des mutéines du facteur VIII qui sont liées de manière covalente, sur un site prédéfini autre qu'un N-terminal aminé, à un ou plusieurs polymères biocompatibles tels que le polyéthylène glycol. Les conjugués de mutéine maintiennent l'activité procoagulante du facteur FVIII et possèdent des propriétés pharmacocinétiques améliorées.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/107-042-536-530-516,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,,,0,0,,,,ACTIVE
783,US,A1,US 2013/0274445 A1,121-673-175-511-704,2013-10-17,2013,US 201313748983 A,2013-01-24,US 201313748983 A;;US 54070309 A;;US 27389605 A;;US 62727704 P,2004-11-12,FACTOR VIII CONJUGATES,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/121-673-175-511-704,Patent Application,yes,1,2,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08,530/383,0,0,,,,ACTIVE
784,EP,A2,EP 2371856 A2,184-173-507-024-06X,2011-10-05,2011,EP 11153297 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
 
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-03-16),https://lens.org/184-173-507-024-06X,Patent Application,yes,7,6,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K47/48;;A61K38/00;;C07K14/755,,44,41,098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;050-112-382-936-584;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220,10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;16233987;;10.1016/j.cbpa.2005.10.007;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361,"THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCANDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL., 2005;;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE, S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., vol. 19994, pages 269 - 275",ACTIVE
785,CA,A1,CA 2586379 A1,193-375-772-631-284,2006-05-18,2006,CA 2586379 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,WANG DEQIAN;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;STRAUSS JONATHAN S;;PAN CLARK Q;;MEI BAISONG;;TJANDRA HENDRI;;MURPHY JOHN E,,https://lens.org/193-375-772-631-284,Patent Application,no,0,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,0,0,,,,ACTIVE
786,AU,A1,AU 2012/203813 A1,002-844-627-534-050,2012-07-19,2012,AU 2012/203813 A,2012-06-28,AU 2005/304622 A;;AU 2012/203813 A,2005-11-14,Site-directed modification of FVIII,"C:\NRPortb\DCCKXC\4427591 - DOC.2(16/21112 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;CHEN JIANMIN;;MURPHY JOHN E;;MEI BAISONG;;TANG LIANG;;STRAUSS JONATHAN S;;WANG DEQIAN;;TJANDRA HENDRI;;BARNETT THOMAS,,https://lens.org/002-844-627-534-050,Patent Application,no,0,0,2,2,0,,C07K14/755;;C07H21/04;;C12P21/06,,0,0,,,,ACTIVE
787,KR,A,KR 20140019489 A,006-799-772-664-033,2014-02-14,2014,KR 20147002721 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/006-799-772-664-033,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;C07K14/755,,0,0,,,,ACTIVE
788,EP,B1,EP 3243833 B1,012-394-400-993-524,2020-06-17,2020,EP 17166910 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/012-394-400-993-524,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,3,0,,,"SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLO, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1-05, XP009011547, ISSN: 0567-7734;;VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01) , pages 1253-1261, XP008036528, ISSN: 1471-2598",ACTIVE
789,ES,T3,ES 2633916 T3,032-240-563-792-050,2017-09-26,2017,ES 05849392 T,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,Modificación de FVIII dirigida al sitio,"Un conjugado que tiene actividad procoagulante del factor VIII que comprende un factor VIII polipeptídico funcional que está mutado de manera que al menos un resto no cisteína se ha remplazado con un resto de cisteína de manera que existe un resto de cisteína mutante, en el que el factor VIII polipeptídico funcional está unido covalentemente a un polímero biocompatible en el resto de cisteína mutante, en el que el polímero biocompatible está unido covalentemente al polipéptido en uno de los aminoácidos del factor VIII de las posiciones 81, 129, 377, 378, 468, 487, 491, 504, 556, 570, 1648, 1795, 1796, 1803, 1804, 1808, 1810, 1812, 1813, 1815, 1864, 1911, 2091, 2118 y 2284.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/032-240-563-792-050,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,ACTIVE
790,US,A1,US 2010/0081615 A1,048-663-437-507-509,2010-04-01,2010,US 54070309 A,2009-08-13,US 54070309 A;;US 27389605 A;;US 62727704 P,2004-11-12,CONTINUATION - SITE DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2006-01-04),https://lens.org/048-663-437-507-509,Patent Application,yes,41,20,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/37;;C12P21/02,514/12;;530/383;;435/69.6,0,0,,,,ACTIVE
791,LT,T,LT 2371856 T,057-349-877-075-843,2022-08-25,2022,LT 11153297 T,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,,https://lens.org/057-349-877-075-843,Unknown,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;A61K38/37;;A61K47/60;;A61P7/00;;A61P7/04;;A61P31/02;;C07K14/755,,0,0,,,,PENDING
792,PH,B1,PH 12014500352 B1,109-027-759-992-969,2015-07-20,2015,PH 12014500352 A,2014-02-12,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/109-027-759-992-969,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;A61K38/37;;A61P7/04;;C07K14/755;;C07K17/08,,0,0,,,,ACTIVE
793,US,B2,US 7557135 B2,106-609-387-451-088,2009-07-07,2009,US 44219906 A,2006-05-26,US 44219906 A;;US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,WYETH (2006-09-18);;NOVARTIS AG (2021-12-03);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/106-609-387-451-088,Granted Patent,yes,73,12,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404,514/415;;548/507,44,24,036-877-450-775-805;;020-654-176-077-967;;124-150-239-256-308;;006-389-760-792-212;;128-362-223-519-855;;023-381-831-996-846;;096-484-982-426-875;;007-306-546-814-126;;017-119-380-043-243;;068-228-387-549-08X;;151-879-670-237-214;;007-737-889-206-944;;027-226-226-568-670;;017-773-555-337-136;;049-360-904-961-611;;110-574-808-894-379;;067-576-826-353-21X;;012-599-148-844-832;;009-130-865-367-745;;001-844-539-881-363;;057-913-407-111-808;;095-914-469-028-092;;031-766-076-467-920;;068-228-387-549-08X,11377176;;10.1016/s0968-0896(00)00345-x;;10.1038/nrd985;;12509756;;2888113;;10.1073/pnas.84.18.6374;;pmc299078;;3300655;;10.1016/0006-2952(87)90512-0;;2655580;;10.1042/bj2590315;;pmc1138513;;10.1038/37622;;9403692;;3053741;;10.1080/21548331.1988.11703580;;10.1021/jo9909913;;10.1016/0040-4020(95)00809-m;;10.1517/13543776.14.7.937;;10.1002/ddr.430100404;;9005255;;10.1021/jm960485v;;8978843;;10.1021/jm960486n;;5069781;;10.1021/jm00280a027;;8978844;;10.1021/jm960487f;;10.1021/ja00137a021;;2925633;;10.1016/s0021-9258(18)83616-x;;11310603;;10.1016/s0968-0896(00)00286-8;;3143418;;10.1016/0005-2760(88)90316-5;;16102039;;10.1111/j.1538-7836.2005.01488.x;;7174067;;10.1038/nsb0695-458;;pmc7097651;;7664108;;10.1016/s0021-9258(18)83549-9;;2925608;;10.1517/13543776.14.7.937,"Adediran et al., The Synthesis and Evaluation of Benzofuranones as .beta.-Lactamase Substrates, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 1175-1183.;;Bhatt et al., Nature Reviews, Drug Discovery vol. 2, 15-28, Jan. 2003.;;Bonventure et al., et al., Nature 1997, 390: 622-625.;;Burch et al., Proc. Natl. Acad. Sci. U.S.A., 84:6374-6378 (1989).;;Chang et al, Biochem. Pharmacol., 36:2429-2436 (1987).;;Chemical Abstract Service Registry No. 865200-20-0, ""Benzoic acid, 4-[3-[5-chloro-1-(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]-(9CI),"" 1 page (Oct. 13, 2005).;;Smith, Biochem. J., 259:315-324 (1989).;;Uozumi et al. Role of Cytosolic Phospholipase A2 in Allergic Response and Parturition, Nature, 390:618-622, (Dec. 11, 1997).;;Wasserman, Hospital Practice, 15:49-58 (1988).;;Xi et al., Functionalized Deep-Cavity Cavitands, J. Org. Chem. 1999, 64, pp. 9286-9288.;;Written Opinion of the International Searching Authority and International Search Report for PCT/US2006/020847, 14 pages (Nov. 20, 2006).;;Notification Concerning Transmittal of Copy of International Preliminary Report on Patentability for PCT/US2006/020847, 9 pages (Dec. 13, 2007).;;Chung et al., Synthesis of 3-Fluoro-2-substituted amino-5,12-dihydro-5-oxobenzoxazolo[3,2-.alpha.]quinoline-6-carboxylic Acids Employing the Tandem Double Ring Closure Reaction of N-Acetyl-N-(2-hydroxyphenyl)anthranilic Acid as the Key Step, Tetrahedron vol. 51, No. 46, pp. 12549-12562, 1995, Elsevier Science Ltd, printed in Great Britain.;;Clark et al., ""Potential therapeutic uses of phospholipase A2 inhibitors,"" Expert Opin. Ther. Pat., 14:937-950 (2004).;;Dennis, Drug Devel. Res., 10:205-220 (1987).;;Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp. 5119-5136.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 2. Indole-3-acetamides with Additional Functionality, J. Med.chem. 1996, vol. 39, No. 26, pp. 5137-5158.;;Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp. 1081-1082.;;Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A.sub.2. 3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp. 5159-5175.;;Goodman et al., Self-Assembling, Chromogenic Receptors for the Recognition of Dicarboxylic Acid, J. Am. Chem. Soc., 1995, 117, pp. 8447-8455.;;Jackson et al., Nature Reviews, Drug Discovery vol. 2, 1-15, Oct. 2003.;;Kando et al, Biochem. Biophys. Res. Comm., 163:42-48 (1989).;;Kramer et al, J. Biol. Chem., 264:5768-5775 (1989).;;Langer et al., Synthesis of High-specific-radioactivity 4- and 6-[.sup.18F]fluorometaraminol-PET Tracers for the Adrenergic Nervous System of the Heart, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 677-694.;;Leslie et al, Biochem. Biophys. Acta., 963:476-492 (1988).;;Nieswandt et al., J. Thrombosis and Haemostasis, 3: 1725-1736 (2005).;;Roy et al., Further Studies on Anti-Inflammatory Activity of Two Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp. 207-214.;;Samuelson et al., Science, 237:1171-76 (1987).;;Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp. 458-465.;;Seilhamer et al, J. Biol. Chem., 264:5335-5338 (1989).;;Clark, James D. et al., ""Potential therapeutic uses of phospholipase A2 inhibitors,"" Expert Opin. Ther. Pat., 14:937-950 (2004).;;International Search Report for PCT/US2006/020847, 5 pages (Nov. 20, 2006).;;Written Opinion of the International Searching Authority for PCT/US2006/020847, 7 pages (Nov. 20, 2006).;;Behnke, Mark L. et al., ""Indole Based Inhibitors of cPLA2alpha: Phenylsulfonamides"", (2005).;;Clark, James D., ""Discovery of Anti-Inflammatory cPLA2alpha Inhibitors"" FASEB Conference Phospholipid Metabolism, (Jul. 21, 2008).;;""Discovery of Anti-Inflammaotry cPLA2alpha Inhibitors"", Inflammation & Immune Diseases Drug Discovery & Development Summit, (Mar. 14-15, 2005).;;Lee, Katherine L. et al., ""Indole Phenyl Sulfonamide CPLA2alpha Inhibitors for the Treatment of Inflammation"" Mar. 30, 2006).;;Lee, Katherine L. et al., ""The Discovery of cPLA2alpha Inhibotors with Efficacy in Animal Models of Arthritis, Asthma, Multiple Sclerosis, Thrombosis and Atherosclerosis"", (Aug. 2007).;;McKew, John C. et al., ""Discovery of a New Class of Anti-Inflammatory: Indole cPLA2alpha Inhibitors"", (May 2004).;;McKew, John C. et al., ""Indole Benzyl Sulfonamide cPLA2alpha Inhibitors: Optimization and Efficacy in Inflammatory Models"", (2006).;;McKew, John et al., ""The Discovery cPLA2alpha Inhibitors that are Efficacious in In Vivo Models of Arthritis, Stroke, and Atherothrombosis"", (2007).;;McKew, John, ""Discovery & Characterization of Giripladib: A first in Class cPLA<sub/>alpha Inhibitor"", (Nov. 2, 2007).;;McKew, John, ""Discovery & Characterization of Giripladib: A first in Class cPLA2alpha Inhibitor"", (Feb. 20, 2008).;;Ramarao, Manjunath, ""Characterization of cPLA2alpha Inhibitors by Microcalorimetry"", (2007).",ACTIVE
794,EP,B1,EP 2371856 B1,163-790-336-900-951,2022-05-18,2022,EP 11153297 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,TANG JIANG;;PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-03-16),https://lens.org/163-790-336-900-951,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K14/755,,3,0,,,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01) , pages 1253-1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1-05, XP009011547, ISSN: 0567-7734",ACTIVE
795,WO,A8,WO 2006/128142 A8,014-116-598-531-722,2007-12-27,2007,US 2006/0020847 W,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A<SUB>2</SUB> enzymes (cPLA<SUB>2</SUB>), more particularly including inhibitors of cytosolic phospholipase A<SUB>2</SUB> alpha enzymes (cPLA<SUB>2</SUB>a). In some embodiments, the inhibitors have the Formula (I): wherein the constituent variables are as defined herein.",WYETH CORP;;MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/014-116-598-531-722,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,PENDING
796,SV,A,SV 2007002756 A,023-750-289-047-261,2010-01-05,2010,SV 2007002756 A,2007-05-18,SV 2007002756 A,2007-05-18,MODIFICACION DIRIGIDA AL SITIO DEL FVIII,"ESTA INVENCIÓN SE RELACIONA CON MUTEÍNAS DEL FACTOR VIII QUE ESTÁN LIGADAS COVALENTEMENTE, EN UN SITIO PREDEFINIDO QUE NO ES UNA AMINA DE TERMINAL N, A UNO O MÁS POLÍMEROS BIOCOMPATIBLES TALES COMO POLIETILENGLICOL. LOS CONJUGADOS DE LA MUTEÍNA RETIENEN LA ACTIVIDAD PROCOAGULANTE DEL FVIII Y TIENEN PROPIEDADES FARMACOCINÉTICAS MEJORADAS",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JUANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/023-750-289-047-261,Patent Application,no,0,0,1,1,0,,A61K31/00,,0,0,,,,PENDING
797,JP,A,JP 2017101028 A,024-960-968-302-182,2017-06-08,2017,JP 2016234756 A,2016-12-02,US 62727704 P,2004-11-12,SITE DIRECTED MODIFICATION OF FVIII,PROBLEM TO BE SOLVED: To provide a biocompatible polymer-conjugated functional FVIII polypeptide having improved pharmacokinetic characteristics and therapeutic characteristics.SOLUTION: An isolated polypeptide conjugate having factor VIII procoagulant activity comprises a functional factor VIII polypeptide having heavy and light chains. The functional factor VIII polypeptide is covalently bound to one or more biocompatible polymers only in the heavy chain.SELECTED DRAWING: None,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/024-960-968-302-182,Patent Application,no,3,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/43;;A61K47/34;;A61K47/50;;A61P7/04;;C07K17/08,,0,0,,,,ACTIVE
798,LT,T,LT 2363414 T,039-795-427-353-17X,2022-10-25,2022,LT 11153300 T,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,,https://lens.org/039-795-427-353-17X,Unknown,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60;;A61P7/00;;A61P7/04;;A61P31/02;;C07K17/08,,0,0,,,,PENDING
799,NO,B1,NO 344606 B1,090-687-107-586-389,2020-02-10,2020,NO 20072997 A,2007-06-12,US 62727704 P;;US 2005/0041205 W,2004-11-12,"Konjugat som har faktor VIII prokoagulant aktivitet, fremgangsmåte for fremstilling av slike ved setedirigert modifikasjon, farmasøytisk sammensetning og anvendelse for behandling av hemofili.",,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/090-687-107-586-389,Granted Patent,no,1,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08,,1,0,,,"SAKURAGAWA NOBUO ET AL., ""Studies on the stability of factor VIII modified by polyethylene glycol"", Acta Medica et Biologica, vol. 36, nr. 1, 1988, side 1-5, Dated: 01.01.0001",ACTIVE
800,AU,B2,AU 2016/203693 B2,088-576-189-054-47X,2018-08-23,2018,AU 2016/203693 A,2016-06-03,AU 2016/203693 A;;AU 2013/203348 A;;AU 2012/203813 A,2012-06-28,Site-directed modification of FVIII,"H:\ft\interwoven\NRPortbl\DCC\FMT\I 0258723_l.docx-3/06/2016 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/088-576-189-054-47X,Granted Patent,no,5,0,4,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,2,1,019-730-797-612-199,10821655;;10.1021/bc990137i,J. Röstin et al. “B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol” Bioconjugate Chemistry (2000) 11(3): 387–396;;N. Sakuragawa et al. “Studies on the Stability of Factor VIII Modified by Polyethylene Glycol” Acta Medica et Biologica (1988) 36(1): 1-5,ACTIVE
801,MY,A,MY 181129 A,106-710-076-827-558,2020-12-18,2020,MY PI2016001404 A,2007-05-18,MY PI2016001404 A,2007-05-18,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain VIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC;;BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;CHEN JIANMIN;;BARNETT THOMAS;;TJANDRA HENDRI;;TANG LIANG;;WANG DEQIAN,,https://lens.org/106-710-076-827-558,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,ACTIVE
802,CN,B,CN 103102406 B,107-648-931-326-511,2015-05-27,2015,CN 201210455152 A,2005-11-14,US 62727704 P,2004-11-12,Continuation - site directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/107-648-931-326-511,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/37;;A61K47/48;;A61P7/04;;C07K1/107,,0,0,,,,ACTIVE
803,KR,A,KR 20120136413 A,153-654-621-999-568,2012-12-18,2012,KR 20127028644 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/153-654-621-999-568,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;C12P21/00,,0,0,,,,DISCONTINUED
804,CY,T1,CY 1123384 T1,150-168-366-891-839,2021-12-31,2021,CY 201100928 T,2020-10-05,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,ΚΑΤΕΥΘΥΝΟΜΕΝΗ ΑΠΟ ΘΕΣΗ ΤΡΟΠΟΠΟΙΗΣΗ TOY FVIII,"Αυτή η εφεύρεση σχετίζεται με μουτεΐνες του παράγοντα VIII, με απαλοιφή της επικράτειας Β, οι οποίες είναι ομοιοπολικά δεσμευμένες, στην θέση 1804 σε ένα πολυμερές PEG. Τα προϊόντα σύζευξης μουτεΐνης διατηρούν την προ-πηκτική δραστικότητα του FVIII και έχουν βελτιωμένες φαρμακοκινητικές ιδιότητες.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/150-168-366-891-839,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,0,0,,,,ACTIVE
805,PH,A1,PH 12019501613 A1,159-232-430-236-945,2020-09-14,2020,PH 12019501613 A,2019-07-09,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/159-232-430-236-945,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07H21/04;;C07K14/745;;C12P21/06,,0,0,,,,PENDING
806,HU,T2,HU E060016 T2,183-423-958-450-079,2023-01-28,2023,HU E11153300 A,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,,https://lens.org/183-423-958-450-079,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K17/08,,0,0,,,,PENDING
807,SI,T1,SI 3130601 T1,185-691-130-159-496,2020-11-30,2020,SI 200532283 T,2005-11-14,US 62727704 P;;EP 16186901 A,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/185-691-130-159-496,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/00;;A61K38/00;;A61K47/00,,0,0,,,,ACTIVE
808,EP,A3,EP 2371856 A3,007-343-968-724-238,2012-03-14,2012,EP 11153297 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
 
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-03-16),https://lens.org/007-343-968-724-238,Search Report,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755,,3,2,022-092-946-978-595;;029-944-973-758-653,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734",ACTIVE
809,NO,L,NO 20072997 L,019-974-171-100-918,2007-06-27,2007,NO 20072997 A,2007-06-12,US 62727704 P;;US 2005/0041205 W,2004-11-12,Posisjonsstyrt omdanning av FVIII,"Denne oppfinnelse relaterer til Faktor VIII muteiner som er kovalent bundet, ved et predefinert sete som ikke er et N-terminalt amin, til en eller flere biokompatible polymerer slik som polyetylenglykol. Muteinkonjugatene bibeholder FVIII prokoagulantaktivitet og har forbedrede farmakokinetiske egenskaper.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/019-974-171-100-918,Abstract,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K14/755;;A61P7/00,,0,0,,,,ACTIVE
810,EP,A1,EP 3243834 A1,022-347-614-373-292,2017-11-15,2017,EP 17170687 A,2005-11-14,US 62727704 P;;EP 17166910 A;;EP 05849392 A,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to native Factor VIII that is covalently bound, at the B-domain, to one or more biocompatible polymers such as polyethylene glycol. The conjugates retain FVIII procoagulant activity -and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2022-03-09),https://lens.org/022-347-614-373-292,Patent Application,yes,8,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,12,9,022-092-946-978-595;;029-944-973-758-653;;098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;023-871-188-490-96X;;006-217-492-680-01X;;105-215-317-030-407;;076-459-195-524-871,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1046/j.1365-2516.2003.00769.x;;12694514,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLO, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN, SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURRO OPIN. CHEM. BIOL., 15 October 2005 (2005-10-15);;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260",PENDING
811,US,A1,US 2019/0327340 A1,025-747-183-878-193,2019-10-24,2019,US 201916457704 A,2019-06-28,US 201916457704 A,2019-06-28,EFFICIENT REMOTE FUNCTION EXECUTION IN AN INFORMATION CENTRIC NETWORK,"Systems and techniques for efficient remote function execution in an information centric network (ICN) are described herein. For example, a requestor node may transmit an admission probe interest packet. Here, the admission probe interest packet includes a name that includes a function. The admission probe interest packet also includes a metric of a parameter of the function. In response, the requestor node may receive a manifest data packet. The manifest includes a metric of function execution at a node that created the manifest data packet. The manifest also includes a name of an implementation of the function. The requestor node may then determine that the metric of function execution meets a threshold and transmit an interest packet that includes the name of the implementation of the function.",ALAM S M IFTEKHARUL;;ZHANG YI;;JHA SATISH CHANDRA;;CHEN KUILIN CLARK;;SIVANESAN KATHIRAVETPILLAI;;KARPENKO STEPAN;;SRIKANTESWARA SRIKATHYAYANI;;NALLAMPATTI EKAMBARAM VENKATESAN,ALAM S M IFTEKHARUL;;ZHANG YI;;JHA SATISH CHANDRA;;CHEN KUILIN CLARK;;SIVANESAN KATHIRAVETPILLAI;;KARPENKO STEPAN;;SRIKANTESWARA SRIKATHYAYANI;;NALLAMPATTI EKAMBARAM VENKATESAN,INTEL CORPORATION (2019-07-11),https://lens.org/025-747-183-878-193,Patent Application,yes,0,0,2,2,0,H04L43/14;;H04L43/16;;H04L67/568;;H04L67/63;;H04L43/16;;H04L43/12;;H04L67/63;;H04L67/568;;H04L67/10;;H04L43/08,H04L29/08;;H04L12/26,,0,0,,,,ACTIVE
812,HU,T2,HU E033776 T2,033-433-078-263-814,2018-01-29,2018,HU E05849392 A,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/033-433-078-263-814,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,PENDING
813,ES,T3,ES 2821832 T3,073-376-955-885-790,2021-04-27,2021,ES 16186901 T,2005-11-14,US 62727704 P,2004-11-12,Modificación de FVIII dirigida al sitio,"Un conjugado que tiene actividad procoagulante del factor VIII que comprende un factor VIII polipeptídico funcional con el dominio B eliminado que está mutado de manera que el resto de lisina en la posición de aminoácido 1804 se sustituye por un resto de cisteína de manera que exista un resto de cisteína mutante, en el que el factor VIII polipeptídico con el dominio B eliminado está unido covalentemente a un polímero biocompatible en el resto de cisteína mutante en la posición de aminoácido 1804.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/073-376-955-885-790,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,0,0,,,,ACTIVE
814,US,A1,US 2010/0029645 A1,109-680-660-901-184,2010-02-04,2010,US 48802009 A,2009-06-19,US 48802009 A;;US 44219906 A;;US 68556405 P,2005-05-27,Inhibitors of Cytosolic Phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A 2 alpha enzymes (cPLA 2 α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,WYETH LLC (2009-11-09),https://lens.org/109-680-660-901-184,Patent Application,yes,7,2,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/5377;;A61K31/405;;A61K31/497;;A61P7/02;;A61P19/02;;A61P25/00;;A61P29/00;;C07D209/04;;C07D403/02;;C07D413/02,514/235.2;;548/491;;544/373;;544/143;;514/415;;514/254.09,0,0,,,,DISCONTINUED
815,KR,A,KR 20160105928 A,137-139-885-799-686,2016-09-07,2016,KR 20167023706 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"본 발명은 N-말단이 아닌 소정의 부위에서 폴리에틸렌 글리콜과 같은 1종 이상의 생체적합성 중합체에 공유적으로 결합되는 제VIII 인자에 관한 것이다. 이 뮤테인 컨쥬게이트는 FVIII 응고촉진 활성을 유지하고, 향상된 약물동태학적 특성을 갖는다.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/137-139-885-799-686,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;C07K17/08;;C07K19/00,,0,0,,,,ACTIVE
816,US,B1,US 6420518 B1,137-162-565-952-595,2002-07-16,2002,US 33722799 A,1999-06-22,US 33722799 A;;US 5288898 A;;US 82585297 A,1997-04-04,Insulin-like growth factor agonist molecules,"
    Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. 
",GENENTECH INC;;ROBINSON IAIN C A F,CHEN YVONNE MAN-YEE;;CLARK ROSS G;;COCHRAN ANDREA G;;LOWMAN HENRY B;;ROBINSON IAIN C A F;;SKELTON NICHOLAS J,GENENTECH INC (1999-08-05),https://lens.org/137-162-565-952-595,Granted Patent,yes,66,11,8,8,51,A61K38/30;;C07K7/08;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61P5/00;;A61K38/00;;C07K7/08;;A61K38/30;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61K38/00,A61K38/00;;A61K38/30;;C07K7/08;;C07K14/47;;C07K14/65,530/317;;530/300;;530/324;;530/326;;530/327;;930/260;;930/270,100,90,017-350-602-958-513;;060-413-390-113-504;;025-059-951-768-239;;108-079-960-807-110;;016-265-697-674-181;;014-125-367-031-231;;017-264-804-459-877;;026-623-017-714-89X;;053-508-442-408-581;;050-719-958-572-148;;035-756-231-423-984;;045-964-465-312-91X;;091-854-753-933-770;;009-317-840-275-65X;;044-898-403-939-670;;020-803-531-740-687;;114-552-109-070-862;;121-192-711-498-551;;122-544-263-077-018;;048-188-266-680-461;;028-244-774-323-223;;051-762-247-693-584;;027-889-828-130-366;;097-785-885-745-976;;044-885-448-085-960;;055-029-284-594-570;;044-015-018-025-600;;066-564-168-992-217;;069-485-915-823-577;;036-028-618-959-354;;014-911-901-153-035;;032-236-672-104-294;;020-582-523-460-582;;038-260-426-123-957;;146-171-107-846-251;;009-186-473-238-939;;009-069-193-386-694;;098-441-778-398-080;;070-740-676-932-821;;093-658-600-554-037;;020-411-130-368-703;;020-510-267-061-589;;030-081-590-114-687;;026-720-717-926-994;;127-616-834-120-73X;;042-682-434-812-597;;167-040-741-674-313;;029-966-690-919-75X;;040-185-536-258-128;;105-560-205-533-971;;013-303-631-864-631;;096-718-408-234-974;;116-645-290-887-265;;010-645-653-539-638;;004-678-657-001-505;;019-984-077-132-656;;140-584-552-918-775;;035-483-585-582-64X;;116-157-636-951-170;;089-677-859-786-645;;003-137-931-754-668;;021-449-779-524-07X;;084-363-781-757-911;;000-613-056-275-938;;008-721-226-627-596;;063-088-702-691-710;;046-072-043-619-455;;078-655-932-195-328;;112-994-384-334-733;;007-717-236-970-533;;044-071-530-416-412;;016-758-022-635-876;;097-011-248-396-364;;044-051-728-567-349;;086-111-078-062-01X;;029-286-680-248-885;;007-489-225-495-51X;;045-838-528-482-83X;;147-661-590-433-69X;;015-768-700-460-036;;023-036-715-680-660;;016-796-441-670-243;;026-190-764-535-624;;150-639-968-778-276;;039-038-656-451-824;;076-444-264-945-863;;081-838-471-410-493;;028-701-201-701-662;;022-281-660-192-32X;;035-594-330-696-292,8171331;;10.1126/science.8171331;;10.1146/annurev.biophys.26.1.401;;9241425;;9523276;;10.1385/0-89603-392-9:249;;10.1021/ja9611654;;10.1021/bi00489a001;;2271534;;7680510;;10.1016/s0083-6729(08)60444-6;;10.1210/endo-127-6-3243;;2174349;;10.1002/prot.340080405;;1708882;;2443135;;10.1016/s0006-291x(87)80136-5;;10.1016/s0021-9258(18)48458-x;;1370451;;2424282;;10.1016/s0065-2423(08)60124-9;;10.1016/0305-0491(88)90137-x;;2461835;;10.1016/s0021-9258(18)68777-0;;2966152;;2472386;;10.1016/s0021-9258(18)60418-1;;10.1016/s0021-9258(18)55447-8;;2168421;;10.1002/j.1460-2075.1989.tb08386.x;;pmc401241;;2479552;;6998350;;10.7326/0003-4819-120-7-199404010-00011;;8116999;;8374685;;10.1515/jpem.1993.6.1.21;;2315699;;10.1126/science.2315699;;7631865;;10.1152/ajpheart.1995.269.1.h326;;10.1016/s0006-291x(88)80425-x;;2454104;;10.1002/j.1460-2075.1988.tb03087.x;;2461294;;pmc457109;;10.1677/joe.0.1220661;;2681500;;10.1007/978-1-4615-2988-0_4;;7514345;;10.1021/bi00409a016;;2839228;;2536701;;10.1016/s0021-9258(18)94162-1;;3193048;;10.1677/joe.0.1190051;;8187319;;10.1111/j.1365-2265.1994.tb02492.x;;10.1007/bf00404081;;8359587;;10.1007/bf03000203;;21153160;;10.1007/bf03021409;;21153178;;10.1007/978-3-642-67986-5_5;;1379166;;10.1210/en.131.2.890;;10.1210/endo.131.2.1379166;;10.1016/s0021-9258(19)38332-2;;1695626;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;2143033;;10.1126/science.2143033;;10.1021/bi990089p;;10350456;;10.1172/jci117706;;pmc295527;;7860746;;10.1210/endo.137.5.8612531;;10.1210/en.137.5.1913;;8612531;;9124404;;10.1152/ajprenal.1997.272.2.f257;;10.1159/000184148;;7959637;;10.1210/endo.135.5.7956938;;7956938;;10.1210/en.135.5.2144;;10.1016/0161-5890(86)90081-7;;2432410;;9032099;;10.2337/diabetes.46.3.433;;10.2337/diab.46.3.433;;10.1021/bi00047a006;;7492543;;2220389;;pmc287020;;10.1073/pnas.86.8.2868;;2649897;;2741635;;10.1530/acta.0.1210101;;3387445;;10.1073/pnas.85.13.4889;;pmc280542;;3299085;;10.1056/nejm198707163170303;;10.1152/ajprenal.1993.265.1.f1;;8393619;;7948775;;10.1681/asn.v511;;10.1016/s0021-9258(19)47281-5;;2553732;;10.1172/jci116480;;pmc443305;;8514857;;7593439;;10.1210/jc.80.11.3284;;10.1210/jcem.80.11.7593439;;8662901;;10.1074/jbc.271.24.13948;;10.1038/ki.1993.57;;8441234;;1668800;;10.1111/j.1432-1033.1990.tb15595.x;;2197088;;8314009;;10.2337/diab.43.3.369;;10.2337/diabetes.43.3.369;;2237405;;10.1126/science.2237405;;10.1210/er.16.1.3;;10.1210/edrv-16-1-3;;7758431;;8762727;;10.1046/j.1365-2265.1996.711531.x;;10.1016/0378-1119(93)90153-t;;8508960;;pmc330007;;8423214;;10.1172/jci116163;;1538716;;7679407;;pmc287936;;10.1172/jci116212;;8482426;;10.2337/diab.42.5.696;;10.2337/diabetes.42.5.696;;10.1074/jbc.271.34.20458;;8702785;;2407519;;10.1210/endo-126-3-1593;;10.1210/mend-2-5-404;;2458522;;10.3181/00379727-204-43630;;7690486;;10.1038/330537a0;;2825030;;1718795;;10.1016/0303-7207(91)90086-8;;7691582;;10.1210/endo.133.4.7691582;;10.1210/en.133.4.1797;;10.1210/endo-129-4-2254;;1717244;;7508949;;10.1210/jc.78.2.404;;10.1210/jcem.78.2.7508949;;1377706;;10.1210/jc.75.1.30;;10.1210/jcem.75.1.1377706;;8662530;;10.1126/science.273.5274.464;;9465113;;10.1073/pnas.95.4.1894;;pmc19209;;9636028;;10.1021/bi980426e;;2823385;;10.1126/science.2823385;;3722172;;10.1016/s0021-9258(19)84446-0;;10.1016/0378-1119(93)90149-w;;8508957;;10.1038/ki.1994.260;;7933838;;1438188;;10.1002/prot.340140411;;10.1681/asn.v32157;;1391716;;8498545;;10.1152/ajprenal.1993.264.5.f917;;10.1210/en.132.3.1337;;7679979;;10.1210/endo.132.3.7679979,"Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*;;Barinaga, M., ""Neurotrophic factors enter the clinic [news]"" Science 264:772-774 (1994).;;Lowman et al., ""Peptides that displace IGFs from their BPS as potential novel treatment modalities of growth orders-basic aspects"" (Abstract presented at the Intl. Pediatric Nephrology Assn.'s 6th Symposium on Growth and Development in Children with Chronic Renal Failure held in NY on Mar. 11-13, 1999).;;Lowman, H., ""Bacteriophage display and discovery of peptide leads for drug development"" Annual Review of Biophysics and Biomolecular Structure 26:401-424 (1997).;;Lowman, H., ""Phage display of peptide libraries on protein scaffolds"" Methods in Molecular Biology, Chapter 24, 87:249-264 (1998).;;Phelan et al., ""A General Method for Constraining Short Peptides to an alpha-Helical Conformation"" J. Am. Chem. Soc. 119(3):455-460 (Jan. 22, 1997).;;Wells, J. A., ""Additivity of Mutational Effects in Proteins"" Biochemistry 29(37):8509-8517 (Sep. 18, 1990).;;Alberts et al. Molecular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. pp. 119 (1994).;;Bach and Rechler, ""Insulin-like Growth Factor Binding Proteins"" Diabetes Reviews 3:38-61 (1995).;;Ballard et al., ""Does IGF-I Ever Act Through the Insulin Receptor?"" The Insulin-like Growth Factors and Their Regulatory Proteins, Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).;;Bar et al., ""Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I"" Endocrinology 127(6):3243-3245 (1990).;;Bass et al., ""Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties"" Proteins: Structure, Function, and Genetics 8(4):309-314 (1990).;;Baxter & Martin, ""Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins"" Biochem. & Biophys. Res. Comm. 147(1):408-415 (1987).;;Baxter et al., ""Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF I) and IGF binding protein-3"" Journal of Biological Chemistry 267(1):60-65 (Jan. 5, 1992).;;Baxter, ""Physiological Roles of IGF Binding Proteins"" Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).;;Baxter, ""The somatomedins: insulin-like growth factors"" Advances in Clinical Chemistry 25:49-115 (1986).;;Baxter, R., ""The Insulin-Like Growth Factors and Their Binding Proteins"" Comp. Biochem. Physiol. 91B(2):229-235 (1988).;;Bayne et al., ""Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor"" Journal of Biological Chemistry 263:6233-6239 (1988).;;Bayne et al., ""The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor"" Journal of Biological Chemistry 264(19):11004-11008 (Jul. 5, 1988).;;Bayne et al., ""The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor"" Journal of Biological Chemistry 265(26):15648-15652 (Sep. 15, 1990).;;Binkert et al., ""Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)"" EMBO Journal 8:2497-2502 (1989).;;Binoux, M., ""Donnees recentes sur les somatomedines (Insulin-like growth factors)"" Annales d'Endocrinologie 41:157-192 (1980).;;Bondy, C., ""Clinical uses of insulin-like growth factor I"" Annals of Internal Medicine 120:593-601 (1994).;;Bowers, C. Y., ""GH Releasing Peptides-Structure and Kinetics"" J. Pediatr. Endocrinology 6(1):21-31 (1993).;;Bowie et al., ""Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions"" Science 247:1306-1310 (1990).;;Brandt et al., ""Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide"" American Journal of Physiology 269(1 Pt 2):H326-H331 (Jul. 1995).;;Brewer et al., ""Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein"" Biochem. & Biophys. Res. Comm. 152(3):1289-1297 (1988).;;Brinkman et al., ""Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)"" The EMBO J. 7:2417-2423 (1988).;;Carlsson et al., ""Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions"" J. Endocrinol. 122:661-670 (1989).;;Cascieri et al., ""Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins"" Advanced in Experimental Medicine & Biology 343:33-40 (1993).;;Cascieri et al., ""Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor"" Biochemistry 27(9):3229-3233 (May 3, 1988).;;Cascieri et al., ""Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors"" Journal of Biological Chemistry 264:2199-2202 (1989).;;Charlton et al., ""Growth hormone-deficient dwarfism in the rat: a new mutation"" J. of Endocrinology 119:51-58 (1988).;;Cheetham et al., ""The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus"" Clin. Endocrinol. 40:515-522 (1994).;;Cheetham et al., ""The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus"" Diabetologia 36:678-681 (1993).;;Chen et al., ""Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation"" US Endocrine Meeting (Abstract 1596) pp. 449 (1993).;;Clark et al., ""Growth-Responses to Patterned GH Delivery"" Endocrine 3:717-723 (1995).;;Clark et al., ""Insulin-Like Growth Factor-1 and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats"" Endocrine 3:297-304 (1995).;;Clemmons and Van Wyk, ""Somatomedin: physiological control and effects on cell proliferation"" Handbook Exp. Pharmacol. 57:161-208 (1981).;;Clemmons et al., ""Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs"" Endocrinology 131(2):890-895 (Aug. 1992).;;Clemmons et al., ""Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity"" Journal of Biological Chemistry 265(21):12210-12216 (1990).;;Cwirla et al., ""Peptides on phage: a vast library of peptides for identifying ligands"" Proc. Natl. Acad. Sci. USA 87(16):6378-6382 (1990).;;Devlin et al., ""Random peptide libraries: a source of specific protein binding molecules"" Science 249:404-406 (Jul. 27, 1990).;;Dubaquie et al., ""Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor 1 (IGF-1) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3"" Biochemistry 38(20):6386-6396 (1999).;;Duerr et al., ""Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure"" J. Clin. Invest. 95:619-627 (1995).;;Elahi et al., ""Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men"" Modern Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).;;Fielder et al., ""Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats"" Endocrinology 137:1913-1920 (1996).;;Franklin et al., ""Insulin-Like Growth Factor I Preserves Renal Function Postoperatively"" Am. J. Physiol. 272:F257-F259 (1997).;;Froesch et al., ""Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I"" Horm. Res. 42:66-71 (1994).;;Furnsinn et al., ""Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats"" Endocrinology 135(5):2144-2149 (1994).;;Geysen et al., ""A priori delineation of a peptide which mimics a discontinuous antigenic determinant"" Molecular Immunology 23(7):709-715 (1986).;;Ghazzi et al., ""Cardiac and glycemic benefits of troglitazone treatment in NIDDM"" Diabetes 46:433-439 (1997).;;Giebel et al., ""Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities"" Biochemistry 34:15430-15435 (1995).;;Guler et al., ""Effects of Insulin-like Growth Factor I in Man"" Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).;;Guler et al., ""Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects"" Proc. Natl. Acad. Sci. USA 86:2868-2872 (Apr. 1989).;;Guler et al., ""Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man"" Acta Endocrinologica 121:101-106 (1989).;;Guler et al., ""Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats"" Proc. Natl. Acad. Sci. USA 85:4889-4893 (1988).;;Guler et al., ""Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults"" New England J. of Medicine 317(3):137-140 (1987).;;Hammerman and Miller, ""The growth hormone insulin-like factor axis in kidney revisited"" Am. J. Physiol. 265:F1-F14 (1993).;;Hammerman and Miller, ""Therapeutic use of growth factors in renal failure"" J. Am. Soc. Nephrol. 5:1-11 (1994).;;Hampton et al., ""Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma"" Journal of Biological Chemistry 264(32):19155-19160 (Nov. 15, 1989).;;Hartman et al., ""A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans"" J. Clin. Invest. 91:2453-2462 (1993).;;Hasegawa et al., ""The free form of insulin-like growth factor I increases in circulation during normal human pregnancy"" J. Clin. Endocrinol. Metabol. 80:3284-3286 (1995).;;Heding et al., ""Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3"" Journal of Biological Chemistry 271(24):13948-13952 (Jun. 14, 1996).;;Hirschberg et al., ""Effects of insulin-like growth factor I on renal function in normal men"" Kidney International 43:387-397 (1993).;;Hizuka et al., ""Measurement of free form of insulin-like growth factor I in human plasma"" Growth Regulation 1:51-55 (1991).;;Humbel, ""Insulin-like growth factors I and II"" European Journal of Biochemistry 190:445-462 (1990).;;Jabri et al., ""Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients"" Diabetes 43:369-374 (1994).;;Johnson et al., ""Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes"" Science 250:546-549 (1990).;;Jones et al., ""Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions"" Endocr. Rev. 16:3-34 (1995).;;Juul et al., ""Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty"" Clin. Endocrinology 44:515-523 (1996).;;Kay et al., ""An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets"" Gene 128:59-65 (1993).;;Kerr et al., ""Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia"" Diabetes: American Diabetes Association (ADA), San Antonio, Texas, Jun. 20-23, 1992 (abstract #225), 52nd Annual Meeting edition 41(supp 1):60A (Jun. 1992).;;Kerr et al., ""Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans"" J. Clin. Invest. 91:141-147 (1993).;;Kletzien et al., ""Enhancement of adipocyte differentiation by an insulin-sensitizing agent"" Molecular Pharmacology 41(2):393-398 (Feb. 1992).;;Kupfer et al., ""Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously"" J. Clin Invest. 91:391-396 (1993).;;Kuzuya et al., ""Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes"" Diabetes 42:696-705 (1993).;;Lassalle et al., ""ESM-1 is a novel human endothelial cell-specific molecular expressed in lung and regulated by cytokines"" Journal of Biological Chemistry 271:20458-20464 (1996).;;Leahy et al., ""Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion"" Endocrinology 126(3):1593-1598 (1990).;;Lee et al., ""Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors"" Mol. Endocrinol. 2(5):404-411 (1988).;;Lee et al., ""Regulation and function of insulin-like growth factor-binding protein-1"" Proc. Soc. Exp. Biol. & Med. 204:4-29 (1993).;;Leung et al., ""Growth hormone receptor and serum binding protein: purification, cloning and expression"" Nature 330:537-543 (1987).;;Lewitt and Baxter, ""Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?"" Mol. Cell. Endocrinology 79(1-3):C147-C152 (1991).;;Lewitt et al., ""Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3"" Endocrinology 133:1797-1802 (1993).;;Lewitt et al., ""Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels"" Endocrinology 129(4):2254-2256 (1991).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia"" US Endocrine Meeting (Abstract 1664) pp. 466 (1993).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome"" J. Clin. Endocrinol. and Metab. 78(2):404-410 (1994).;;Lieberman et al., ""Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans"" J. Clin. Endocrinol. and Metab. 75(1):30-36 (1992).;;Livnah et al., ""Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A"" Science 273:464-471 (1996).;;Loddick et al., ""Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke"" Proc. Natl. Acad. Sci. USA 95(4):1894-1898 (Feb. 17, 1998).;;Lowman et al., ""Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions"" Biochemistry 37(25):8870-8878 (Jun. 23, 1998).;;Maack et al., ""Physiological Role of Silent Receptors of Atrial Natriuretic Factor"" Science 238:675-678 (Oct. 30, 1987).;;Martin & Baxter, ""Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characterization"" Journal of Biological Chemistry 261(19):8754-8760 (1986).;;McLafferty et al., ""M13 bacteriophage displaying disulfide-constrained microproteins"" Gene 128:29-36 (1993).;;Miller et al., ""Effects of IGF-I on renal function in end-stage chronic renal failure"" Kidney International 46:201-207 (1994).;;Morrow et al., ""Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance"" Diabetes-53rd Annual Meeting, Jun. 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993).;;O'Neil et al., ""Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library"" Proteins: Structure, Function, and Genetics 14:509-515 (1992).;;O'Shea and Layish, ""Growth hormone and the kidney: a case presentation and review of the literature"" J. Am. Soc. Nephrol. 3:157-161 (1992).;;O'Shea et al., ""Effects of IGF-I on renal function in patients with chronic renal failure"" Am. J. Physiol. 264:F917-F922 (1993).;;Oh et al., ""Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs"" Endocrinology 132:1337-1344 (1993).",EXPIRED
817,PL,T3,PL 1891006 T3,163-401-520-447-614,2011-05-31,2011,PL 06771540 T,2006-05-26,US 68556405 P;;EP 06771540 A;;US 2006/0020847 W,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/163-401-520-447-614,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,PENDING
818,JP,A,JP 2015134780 A,165-792-622-671-266,2015-07-27,2015,JP 2015022993 A,2015-02-09,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"PROBLEM TO BE SOLVED: To provide a biocompatible polymer-conjugated functional FVIII polypeptide having improved pharmacokinetic characteristics and therapeutic characteristics, having reduced binding to inhibitory antibodies against the related protein, possessing greater duration of action in vivo, and is a homogeneous product and product material, and to provide a pharmaceutical composition thereof.SOLUTION: The invention provides a pharmaceutical composition which comprises a conjugate having a factor VIII procoagulant activity comprising a functional factor VIII polypeptide which is covalently attached to one or more biocompatible polymers at one or more predefined sites on the polypeptide, and a pharmaceutically acceptable additive. In the conjugate, the biocompatible polymer contains polyethylene glycol comprising a methoxy polyethylene glycol. The pharmaceutical composition is used for the treatment of hemophilia A.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/165-792-622-671-266,Patent Application,no,4,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61K38/43;;A61K47/48;;A61P7/04;;C07K14/755;;C12N15/09,,10,0,,,JPN6013059710; Ａｃｔａ ｍｅｄｉｃａ ｅｔ ｂｉｏｌｏｇｉｃａ． １９８８， Ｖｏｌ．３６， Ｎｏ．１， ｐ．１-５;;JPN6014013664; Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ａｎｄ ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ． ２００３， Ｖｏｌ．８２， Ｎｏ．２， ｐ．２００-２０６;;JPN6011030740; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ， ｖｏｌ． ９７， ｐａｇｅｓ ８５４８-８５５３ （２０００）;;JPN6011030743; Ｐｒｏｔｅｉｎ Ｅｎｇ．， ｖｏｌ． １６， ｐａｇｅｓ ７６１-７７０ （２００３）;;JPN6011030746; Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， ｖｏｌ． ２６９， ｐａｇｅｓ １３３９８-１３４０４ （１９９４）;;JPN6013059710; Ａｃｔａ ｍｅｄｉｃａ ｅｔ ｂｉｏｌｏｇｉｃａ． １９８８， Ｖｏｌ．３６， Ｎｏ．１， ｐ．１-５;;JPN6014013664; Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ａｎｄ ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ． ２００３， Ｖｏｌ．８２， Ｎｏ．２， ｐ．２００-２０６;;JPN6011030740; Ｐｒｏｃ． Ｎａｔｌ． Ａｃａｄ． Ｓｃｉ． ＵＳＡ， ｖｏｌ． ９７， ｐａｇｅｓ ８５４８-８５５３ （２０００）;;JPN6011030743; Ｐｒｏｔｅｉｎ Ｅｎｇ．， ｖｏｌ． １６， ｐａｇｅｓ ７６１-７７０ （２００３）;;JPN6011030746; Ｊ． Ｂｉｏｌ． Ｃｈｅｍ．， ｖｏｌ． ２６９， ｐａｇｅｓ １３３９８-１３４０４ （１９９４）,ACTIVE
819,US,B2,US 9096656 B2,195-839-717-757-226,2015-08-04,2015,US 201313748983 A,2013-01-24,US 201313748983 A;;US 54070309 A;;US 27389605 A;;US 62727704 P,2004-11-12,Factor VIII conjugates,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/195-839-717-757-226,Granted Patent,yes,68,3,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61K38/00;;A61K47/48;;C07K14/755,,65,54,015-358-777-456-041;;113-937-719-001-259;;024-100-889-350-661;;110-266-842-977-819;;048-391-899-819-148;;054-090-919-783-575;;050-914-567-218-321;;014-404-528-569-22X;;021-691-529-972-457;;023-461-551-285-468;;064-356-470-690-00X;;082-011-579-838-812;;167-656-547-020-741;;057-935-502-781-436;;073-064-348-159-030;;036-303-431-596-016;;061-013-622-187-304;;049-936-640-346-832;;007-068-453-274-860;;010-356-395-170-813;;036-657-079-582-704;;038-992-740-792-079;;083-448-995-704-379;;010-347-158-675-450;;040-121-810-358-365;;032-960-531-047-473;;056-927-333-742-99X;;071-881-515-349-948;;076-459-195-524-871;;031-219-178-479-524;;095-248-606-612-120;;105-215-317-030-407;;050-112-382-936-584;;118-803-283-877-249;;019-730-797-612-199;;066-146-798-965-262;;022-092-946-978-595;;029-944-973-758-653;;055-003-061-629-507;;007-822-064-014-928;;044-737-094-103-978;;038-049-676-284-899;;084-834-810-821-651;;038-371-868-499-013;;065-668-968-707-947;;066-370-603-911-042;;067-722-407-233-179;;034-467-759-984-977;;081-336-200-295-868;;017-912-258-241-514;;004-277-641-273-568;;063-199-306-025-70X;;013-464-612-745-677;;010-050-083-518-268,15119576;;10.1093/ajhp/61.7.695;;10.1016/0169-409x(91)90037-d;;10.1002/bit.10561;;12584761;;10.1074/jbc.274.53.37685;;10608826;;10.1016/s0021-9258(18)31537-0;;1902833;;10.1074/jbc.m212053200;;12522143;;10.1182/blood.v96.3.958;;10910910;;10.1182/blood.v95.2.564;;10627463;;8626729;;10.1074/jbc.271.8.3982;;10446132;;10.1074/jbc.274.34.23734;;8567641;;10.1074/jbc.271.4.1935;;9374501;;10.1074/jbc.272.48.30191;;10.1074/jbc.m104732200;;11698391;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1074/jbc.m008046200;;11278379;;15073030;;10.1182/blood-2003-11-3891;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1074/jbc.m400568200;;14764590;;10.1073/pnas.85.8.2429;;pmc280010;;3128786;;7540171;;10.1074/jbc.270.24.14505;;10.1073/pnas.82.22.7728;;2415970;;pmc391407;;7613471;;10.1002/pro.5560040413;;pmc2143093;;10.1016/s0021-9258(17)32024-0;;8051150;;10.1074/jbc.m409389200;;15471879;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;15840700;;10.1182/blood-2004-11-4230;;11510630;;10.2165/00003088-200140070-00005;;12787631;;10.1016/s0378-5173(03)00227-8;;16233987;;10.1016/j.cbpa.2005.10.007;;10.1055/s-0038-1648520;;1509407;;10821655;;10.1021/bc990137i;;1366535;;10.1038/nbt0490-343;;11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;10.1006/bbrc.1998.8301;;9514953;;8175770;;10.1016/s0021-9258(17)36846-1;;10890891;;pmc26985;;10.1073/pnas.140210597;;10.1093/protein/gzg093;;14600206;;10.1182/blood.v92.11.3983.423k51_3983_3996;;9834200;;10.1182/blood.v92.11.3983;;10.1016/s0024-3205(99)00048-x;;10210259;;8125985;;10.1016/s0021-9258(17)37331-3;;3936044;;10.1073/pnas.82.24.8752;;pmc391515;;15946216;;10.1111/j.1538-7836.2005.01389.x;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1111/j.1538-7933.2004.00614.x;;15009451;;10.1038/312337a0;;6438527;;10.1056/nejmoa075760;;19369668;;pmc2761028;;6438528;;10.1038/312342a0,"Adair F, et al. ""The immunogenicity of Therapeutic Proteins,"" BioPharm, vol. 15, No. 2, 2002, pp. 30-36.;;Dalborg J, et al. ""Bioavailability of B-Domain Deleted Recombinant Factor VIII Conjugated with Monomethoxy polyethylene glycol,"" XXIII International Congress of the World Federation of Hemophilia. The Hague, The Netherlands, May 17-21, 1998. Abstracts. Haemophilia, vol. 4, No. 3, 1998, p. 163.;;Ferreira J, Therapeutic Proteins: Present and Future Perspectives, Revista Portuguesa de Farmacia, vol. 49, No. 3, 1999, pp. 131-140. Abst.;;Kleinberg M, et al., ""Current and Future Considerations for the New Classes of Biologicals,"" American Journal of Health-System Pharmacy, vol. 61, No. 7, pp. 695-708.;;Nucci ML, et al. ""The Therapeutic Value of Poly(ethylene glycol)-Modified Proteins,"" Advanced Drug Delivery Reviews, vol. 6, No. 2, 1991, pp. 133-151.;;Oguma Y, et al. ""Studies on the Stability and Oral Administration of the Factor VIII and IX Concentrates,"" The Japanese Journal of Clinical Hematology, vol. 29, No. 5, 1988, pp. 655-661.;;Sakuragawa N, et al. ""Stability of Modified Factor-VIII Concentrate by Polyethylene Glycol,"" Ricerca in Clinica e in Laboratorio, vol. 16, No. 1, 1986, p. 113.;;Sakuragawa N, et al. ""Absorbability of Factor VIII or IX Concentrates Preparation Using Beagles,"" Acta Medica et Biologica, vol. 34, No. 3, 1986, pp. 77-84.;;Schellekens H, et al., ""Biopharmaceutical Molecules are Not Created Equally,"" The Pharmaceutical Journal, vol. 268, No. 7187, 2002, pp. 300-301.;;Throm S, ""Activities of the CPMP,"" Pharmazeutische Industrie, vol. 64, No. 8, 2002, pp. 757-763 (translation not available).;;Fee C, ""Size-Exclusion Reaction . . . Protein PEGylation"", in Biotechnology and Bioengineering, vol. 82, No. 2. Apr. 20, 2003, Publisher: Wiley Periodicals, pp. 200-206.;;Saenko, E., et al., ""Role of the Low Density Lipoprotein-Related Protein Receptor in Mediation of Factor VIII Catabolism"", The Journal of Biological Chemistry, vol. 274, No. 53, 1999, pp. 37685-37692.;;Fay, P. J., et al., ""Human Factor VIIIa Subunit Structure"", The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8957-8962.;;Bovenschen, N., et al., ""Low Density Lipoprotein Receptor-Related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII"", The Journal of Biological Chemistry, vol. 278, No. 11, 2003, pp. 9370-9377.;;Jacquemin, M., et al., ""A Novel Cause of Mild/Moderate Hemophilia A: Mutations Scattered in the Factor VIII C1 Domain Reduce Factor VIII Binding to von Willebrand Factor"", Blood, vol. 96, No. 3, 2000, pp. 958-965.;;Barrow, R., et al, ""Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules"", Blood, vol. 95, No. 2, 2000, pp. 564-568.;;Regan, L., et al., ""Activated Protein C-Catalyzed Proteolysis of Factor VIIIa Alters Its Interactions Within Factor Xase"", The Journal of Biological Chemistry, vol. 271, No. 8, 1996, pp. 3982-3987.;;Lenting, P., et al., ""The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 274, No. 34, 1999, pp. 23734-23739.;;Lenting, P. , et al., ""The Sequence Glu811-Lys1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX"", The Journal of Biological Chemistry, vol. 271, No. 4, 1996, pp. 1935-1940.;;Lubin, I., et al., ""Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis"", The Journal of Biological Chemistry, vol. 272, No. 48, 1997, pp. 30191-30195.;;Gilbert, G., et al., ""Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-Binding and von Willebrand Factor-Binding Motifs"", The Journal of Biological Chemistry, vol. 277, No. 8, 2002, pp. 6374-6381.;;Scandella, D., et al., ""Localization of Epitopes for Human Factor VIII Inhibitor Antitodies by Immunoblotting and Antibody Neutralization"", Blood, vol. 74, No. 5, 1989, pp. 1618-1626.;;Foster, P., et al., ""An Immunogenic Region within Residues Val1670-Glu1684 of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding of Factor VIII to von Willebrand Factor"", The Journal of Biological Chemistry, vol. 263, No. 11, 1988, pp. 5230-5234.;;Lubin, I., et al., ""Elimination of a Major Inhibitor Epitope in Factor VIII"", The Journal of Biological Chemistry, vol. 269, No. 12, 1994, pp. 8639-8641.;;Scandella, D., et al., ""A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2"", Blood, vol. 82, No. 6, 1993, pp. 1767-1775.;;Sarafanov, A., ""Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 276, No. 15, 2001, pp. 11970-11979.;;Parker, E., at al., ""Reduction of the Inhibitory Antibody Response to Human Factor VIII in Hemophilia A Mice by Mutagenesis of the A2 Domain B-Cell Epitope"", Blood, vol. 104, No, 3, 2004, pp. 704-710.;;Scandella, D., et al., ""Epitope Mapping of Human Factor VIII Inhibitor Antibodies by Deletion Analysis of Factor VIII Fragments Expressed in Escherichia coli"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 6152-6156.;;Nogami, K., et al., ""Identification of a Factor Xa-Interactive Site Within Residues 337-372 of the Factor VIII Heavy Chain"", The Journal of Biological Chemistry, vol. 279, No. 16, 2004, pp. 15763-15771.;;Pittman, D., et al., ""Proteolytic Requirements for Thrombin Activation of Anti-Hemophilic Factor (Factor VIII)"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 2429-2433.;;Healy, J., et al., ""Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII"", The Journal of Biological Chemistry, vol. 270, No. 24, 1995, pp. 14505-14509.;;Fulcher, C., et al., ""Localization of Human Factor FVIII Inhibitor Epitopes to Two Polypeptide Fragments"", Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 7728-7732.;;McMullen, B., et al., ""Locations of Disulfide Bonds and Free Cysteines in the Heavy and Light Chains of Recombinant Human Factor VIII (Antihemophilic Factor A)"", Protein Science, vol. 4, 1995, pp. 740-746.;;Fay, P. , et al., ""Factor VIIIa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site"", The Journal of Biological Chemistry, vol. 269, No. 32, 1994, pp. 20522-20527.;;Spiegel. P. C., et al., ""Surface-Exposed Hemophilic Mutations Across the Factor VIII C2 Domain Have Variable Effects on Stability and Binding Activities"", The Journal of Biological Chemistry, vol. 279, No. 51. 2004, pp. 56391-56398.;;Stoilova-McPhie, S., et al., ""3-Dimensional Structure of Membrane-Bound Coagulation Factor VII: Modeling of the Factor VIII Heterodimer Within a 3-Dimensional Density Map Derived by Electron Crystallography"", Blood, vol. 99, No. 4, 2002, pp. 1215-1223.;;Gruppo, R.A. et al. ""Comparative effectiveeness of full-length and B-domain deleted factor VIII for prophylaxis-a meta analysis"", Haemophilia, vol. 4 2003, pp. 251-260.;;Bovenschen, N. et al. ""LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo"", Blood, vol. 106, No. 3, 2005, pp. 906-912.;;Harris, J., et al., ""Pegylation a Novel Process for Modifying Pharmacokinetics"", Clin Pharmacokinet, vol. 40, No. 7, 2001, pp. 539-551.;;Wang, W. et al., ""Coagulation factor VIII: structure and stability"", International Journal of Pharaceulics, vol. 259, 2003, pp. 1-15.;;Kochendoerfer, G., "" Site-specific polymer modification of therapeutic proteins"", Current Opinion in Chemical Biology, vol. 9, 2005, pp. 555-560.;;Scandella, D., at al, ""A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting"", Thrombosis and Haemostasis, vol. 67, No. 6, 1992, pp. 665-671.;;Rostin, J., et al., ""B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol"", Bioconjugate Chem., vol. 11, 2000, pp. 387-396.;;Goodson, R.et al., ""Site-Directed Peglation of Recombinant Interleukin-2 at its Glycosylation Site"", Bio/Technology, vol. 8, 1900, pp. 343-346.;;Sakuragawa, N. et al. Studies on the Stability of Factor VIII Modified by Polyethylene Glycol. Acta Medica et Biologica, 36(1), pp. 1-6 (1988). (Abstract only).;;Veronese, F. M., ""Peptide and Protein PEGylation-a Review of Problems and Solutions"", Biomaterials, Elsevier Science Publishers BV, Barking, GB (2001), No. 5, vol. 22, p. 405-417.;;Kochendoerfer, G., ""Chemical and Biological Properties of Polymer-Modified Proteins"", Expert Opinion on Biological Therapy, (2003), vol. 3, No. 8, pp. 1253-1261.;;Extended European Search Report (including suppl. European Search Report and the European search opinion) for EP App. 05849392.5 dated Dec. 1, 2008 (5 pages).;;Guo et al., ""Protein Tolerance to Random Amino Acid Change"", Prox. Natl. Acad. Sci. USA, (2004), vol. 101, pp. 9205-9210.;;Lazar, et al., Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol., (1998), vol. 8, pp. 1247-1252.;;Hill et al., Functional Analysis of Conserved Histidines in ADP-Glucose Pyrophosphorylase from Escherichia coli, Biochem, Biophys, Res. Comm., (1998), vol. 244, pp. 573-577.;;Benhar, I., et al., ""Pseudomonas Exotoxin A Mutants: Replacement of Surface-Exposed Residues in Domain III with Cysteine Residues That Can Be Modified with Polyethylene Glycol in a Site-Specific Manner,"" The Journal of Biological Chemistry, (May 6, 1994), vol. 109, No. 18, pp. 13398-13404.;;Tsutsumi, Y., et al., ""Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity,"" PNAS, (Jul. 18, 2000), vol. 97, No. 15, pp. 8548-8553.;;Yang, K., et al., ""Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,"" Protein Engineering. (2003), vol. 16, No. 10,-pp. 761-770.;;Lenting, P., et al., ""The Life Cycle of Coagulation Factor VIII in View of its Structure and Function"", Blood, 1998, vol. 92, No. 11, pp. 3983-3996.;;He et al., ""Site-Directed Polyethylene Glycol Modification of Trichosanthin: Effects on its Biological Activities, Pharmacokinetics, and Antigenicity"", Life Sciences, 1999, vol. 64, No. 14, pp. 1163-1175.;;Kuan et al ""Pseudomonas Exotoxin A Mutants: Replacement of Surface Exposed Residues in Domain II with Cysteine Residues that can be Modified with Polyethylene Glycol in a Site-Directed Manner"", The Journal of Biological Chemistry, 1994, vol. 269, No. 10, Issue of Mar. 11, pp. 7610-7616.;;Brinkhous et al., ""Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs"", Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 8752-8756.;;Bovenschen et al., ""The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor"", Journal of Thrombosis and Haemostasis, 2005, vol. 3, pp. 1257-1265.;;Lind et al., ""Novel forms of B-domain-deleted recombinant factor VIII molecules"", Construction and biochemical characterization, Eur. J. Biochem, 1995, vol. 232, pp. 19-27.;;Gitshier et al., ""Remembrances of factor VIII. Part 1: The race to the gene"", Journal of Thrombosis and Haemostatsis, 2004, vol. 2, pp. 383-387.;;Vehar et al., ""Structure of human factor VIII"", Nature, 1984, vol. 312, pp. 337-342.;;Howard at al., ""African-Americans Express Multiple Haplotypic Forms of the Wildtype Factor VIII (FVIII) Protein: A Possible Role for Pharmacogentics in FVIII Inhibitor Development?"", Blood, vol. 104, 2004, Abstract 384.;;Viel et al., ""Inhibitors of Factor VIII in Black Patients with Hemophilia"", The New England Journal of Medicine, 2009, vol. 360, pp. 1618-1627.;;Toole et al., ""Molecular cloning of a cDNA encoding human antihaemophilic factor"", Nature, 1984, vol. 312, pp. 342-347.",ACTIVE
820,LT,T,LT 3130601 T,006-134-639-517-548,2020-09-10,2020,LT 16186901 T,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/006-134-639-517-548,Unknown,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,0,0,,,,PENDING
821,MX,A,MX 2007014589 A,015-152-367-381-346,2008-01-21,2008,MX 2007014589 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2.,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPL????). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,WILLIAMS CARA;;MARUSIC SUZANA;;PONG KEVIN;;MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;CLERIN VALERIE,,https://lens.org/015-152-367-381-346,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
822,EP,A1,EP 3243833 A1,031-389-455-615-806,2017-11-15,2017,EP 17166910 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor Vill muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/031-389-455-615-806,Patent Application,yes,10,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,47,42,022-092-946-978-595;;029-944-973-758-653;;098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361,"SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLO, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATI. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCARIDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. ,CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL., 15 October 2005 (2005-10-15);;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE. S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., vol. 4, 1999, pages 269 - 275",ACTIVE
823,EP,A1,EP 2772500 A1,050-052-205-424-156,2014-09-03,2014,EP 14165736 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/050-052-205-424-156,Patent Application,yes,10,1,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K47/48;;C07K17/08,,47,42,022-092-946-978-595;;029-944-973-758-653;;098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCANDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL., 15 October 2005 (2005-10-15);;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE, S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., vol. 4, 1999, pages 269 - 275",INACTIVE
824,NO,L,NO 20075627 L,079-393-789-809-161,2008-01-03,2008,NO 20075627 A,2007-11-06,US 68556405 P;;US 2006/0020847 W,2005-05-27,Inhibitorer av cytosolisk fosfolipase A2,"Den foreliggende oppfinnelse angår nye forbindelser valgt fra substituerte oksazolderivater med formel (I) som selektivt modulerer, regulerer, og/eller inhiberer signaltransduksjon mediert av visse native og/eller mutante tyrosinkinaser implisert i et utvalg av humane og dyresykdommer så som celleprolifererende, metabolske, allergiske og degenerative lidelser. Mer spesielt er disse forbindelsene kraftige og selektive c-kit, bcr-abl- og Fit-3-inhibitorer.",WYETH CORP,MCKEW JOHN CAEDMON;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;WILLIAMS CARA;;MARUSIC SUZANA;;PONG KEVIN;;CHEN LIHREN;;VARGAS RICHARD;;CLERIN VALERIE,,https://lens.org/079-393-789-809-161,Abstract,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14,,0,0,,,,DISCONTINUED
825,ES,T3,ES 2930159 T3,149-625-659-440-076,2022-12-07,2022,ES 11153300 T,2005-11-14,US 62727704 P,2004-11-12,Modificación de FVIII dirigida al sitio,"Esta invención se refiere a muteínas del Factor VIII que están unidas covalentemente, en un sitio predefinido que no es una amina N-terminal, a uno o más polímeros biocompatibles tales como polietilenglicol. Los conjugados de muteína retienen la actividad procoagulante de FVIII y tienen propiedades farmacocinéticas mejoradas. (Traducción automática con Google Translate, sin valor legal)",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,,https://lens.org/149-625-659-440-076,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;C07K17/08,,0,0,,,,ACTIVE
826,ES,T3,ES 2930143 T3,134-799-158-618-302,2022-12-07,2022,ES 11153297 T,2005-11-14,US 62727704 P,2004-11-12,Modificación de FVIII dirigida al sitio,"Esta invención se refiere a muteínas del Factor VIII que están unidas covalentemente, en un sitio predefinido que no es una amina N-terminal, a uno o más polímeros biocompatibles tales como polietilenglicol. Los conjugados de muteína retienen la actividad procoagulante de FVIII y tienen propiedades farmacocinéticas mejoradas. (Traducción automática con Google Translate, sin valor legal)",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG JIANG;;WAMG DEQIAN,,https://lens.org/134-799-158-618-302,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K14/755,,0,0,,,,ACTIVE
827,AU,B2,AU 2005/304622 B2,159-903-069-810-401,2012-03-29,2012,AU 2005/304622 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;CHEN JIANMIN;;MURPHY JOHN E;;WANG DEQIAN;;STRAUSS JONATHAN S;;TANG LIANG;;BARNETT THOMAS;;TJANDRA HENDRI;;MEI BAISONG,,https://lens.org/159-903-069-810-401,Granted Patent,no,2,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;C07H21/04;;C12P21/06,,2,1,019-730-797-612-199,10821655;;10.1021/bc990137i,"N. Sakuragawa et al. Acta Medica et Biologica, 1988, 36 (1), 1-5.;;J. Rostin et al. Bioconjugate Chemistry, 2000, 11 (3), 387- 396.",ACTIVE
828,PL,T3,PL 2363414 T3,154-581-222-716-104,2022-09-05,2022,PL 11153300 T,2005-11-14,US 62727704 P,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,,https://lens.org/154-581-222-716-104,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;C07K17/08,,0,0,,,,PENDING
829,EP,A4,EP 1824988 A4,025-127-316-248-05X,2008-12-31,2008,EP 05849392 A,2005-11-14,US 2005/0041205 W;;US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,"BAYER HEALTHCARE LLC, WHIPPANY, US (2018-12-10);;BAYER HEALTHCARE LLC (2017-11-01)",https://lens.org/025-127-316-248-05X,Search Report,no,2,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/745,,2,2,022-092-946-978-595;;029-944-973-758-653,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598",ACTIVE
830,WO,A3,WO 2006/053299 A3,077-488-714-701-809,2006-08-24,2006,US 2005/0041205 W,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC;;PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/077-488-714-701-809,Search Report,yes,2,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,1,0,,,"DATABASE BIOSIS [online] 13 April 2006 (2006-04-13), SAKURAGAWA N. ET AL.: ""Studies on the Stability of Factor VIII modified by Polyethylene Glycol"", XP008114276, Database accession no. (PREV198886083867)",PENDING
831,EP,A1,EP 2248801 A1,082-539-959-395-916,2010-11-10,2010,EP 10172388 A,2006-05-26,EP 06771540 A;;US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase a2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2  enzymes (cPLA 2 ). Of particular interest is 4-(3-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzy]sulfonyl}amino)ethyl]-1 H -indol-3-yl}propyl) benzoic acid, or a pharmaceutically acceptable salt thereof. The compounds of the invention are indicated,  inter alia,  in the treatment of inflammation.",WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/082-539-959-395-916,Patent Application,yes,11,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,45,40,068-228-387-549-08X;;128-362-223-519-855;;096-484-982-426-875;;006-389-760-792-212;;151-879-670-237-214;;031-766-076-467-920;;067-576-826-353-21X;;124-150-239-256-308;;009-130-865-367-745;;020-654-176-077-967;;001-844-539-881-363;;065-566-847-220-924;;006-158-813-986-806;;064-131-759-907-41X;;013-584-224-630-938;;043-220-138-399-064;;019-564-929-326-776;;012-095-611-363-936;;015-326-638-070-37X;;000-544-219-628-464;;103-122-158-249-923;;140-060-865-263-725;;001-010-429-114-293;;069-493-236-977-89X;;014-254-720-413-443;;006-520-269-590-144;;001-953-398-419-02X;;147-687-216-433-476;;042-137-679-682-475;;008-090-551-141-559;;001-292-892-348-399;;033-296-096-749-641;;086-438-450-009-51X;;049-258-866-657-721;;053-355-331-660-00X;;053-355-331-660-00X;;013-650-979-277-426;;117-167-590-216-378;;026-314-977-913-387;;059-961-965-631-102,10.1517/13543776.14.7.937;;2655580;;10.1042/bj2590315;;pmc1138513;;3053741;;10.1080/21548331.1988.11703580;;3300655;;10.1016/0006-2952(87)90512-0;;10.1002/ddr.430100404;;10.1016/s0021-9258(18)83549-9;;2925608;;2925633;;10.1016/s0021-9258(18)83616-x;;2888113;;10.1073/pnas.84.18.6374;;pmc299078;;3143418;;10.1016/0005-2760(88)90316-5;;10.1038/nrd985;;12509756;;16102039;;10.1111/j.1538-7836.2005.01488.x;;10.1055/s-1988-27471;;10.1016/s0040-4020(98)00362-7;;10.1021/jm051060o;;16392788;;10.1161/01.cir.87.6.1873;;8504499;;11205894;;10.1016/s0024-3205(00)00950-4;;10.1161/01.cir.0000027816.54430.96;;12208806;;11248083;;pmc30658;;10.1073/pnas.061607398;;11956125;;10.1161/01.cir.0000014927.74465.7f;;10894809;;10.1161/01.atv.20.7.1724;;10.1161/hq0302.105593;;11884288;;10.1161/01.res.85.4.311;;10455059;;9351398;;10.1161/01.atv.17.10.2257;;10.1046/j.1471-4159.1997.69030986.x;;9282920;;14001233;;10.3181/00379727-111-27849;;3244721;;10.1016/0091-3057(88)90372-3;;10.1007/bf02342223;;8951503;;10.1038/35093019;;11557989;;10.1126/science.288.5472.1765;;10846153;;11165666;;10.1016/s0165-6147(00)01602-3;;10.1124/jpet.103.053819;;12954795;;10.1046/j.1365-2222.2003.01615.x;;12614451;;9067325;;8879219;;10.1084/jem.184.4.1483;;pmc2192843;;10.1159/000195777;;2557658;;10.1159/000195777;;2557658;;1330588;;10.1016/0014-2999(92)90829-s;;10.1139/y95-028;;7621356;;3204511;;10.1152/jappl.1989.66.5.2351;;2745300,"CLARK J D ET AL: ""Potential therapeutic uses of phospholipase A2 inhibitors"", EXPERT OPINION ON THERAPEUTIC PATENTS 2004 UNITED KINGDOM, vol. 14, no. 7, 2004, pages 937 - 950, XP002405708, ISSN: 1354-3776;;B. SAMUELSON ET AL., SCIENCE, vol. 237, 1987, pages 1171 - 76;;W. L. SMITH, BIOCHEM. J., vol. 259, 1989, pages 315 - 324;;S. I. WASSERMAN, HOSPITAL PRACTICE, vol. 15, 1988, pages 49 - 58;;J. CHANG, BIOCHEM. PHARMACOL., vol. 36, 1987, pages 2429 - 2436;;E. A. DENNIS, DRUG DEVEL. RES., vol. 10, 1987, pages 205 - 220;;J. J. SEILHAMER ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5335 - 5338;;R. M. KRAMER ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5768 - 5775;;A. KANDO ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 163, 1989, pages 42 - 48;;R. BURCH; J. AXELROD, PROC. NATL. ACAD. SCI. U.S.A., vol. 84, 1989, pages 6374 - 6378;;C. C. LESLIE ET AL., BIOCHEM. BIOPHYS. ACTA., vol. 963, 1988, pages 476 - 492;;S. P. JACKSON; S. M. SCHOENWAELDER, NATURE REVIEWS, DRUG DISCOVERY, vol. 2, October 2003 (2003-10-01), pages 1 - 15;;D.L. BHATT; E.J. TOPOL, NATURE REVIEWS, DRUG DISCOVERY, vol. 2, January 2003 (2003-01-01), pages 15 - 28;;B. NIESWANDT ET AL., J. THROMBOSIS AND HAEMOSTASIS, vol. 3, 2005, pages 1725 - 1736;;LI, J. P.; NEWLANDER, K. A.; YELLIN, T. O., SYNTHESIS, 1988, pages 73 - 76;;GILCHRIST, T. L.; ROBERTS, T. G., J. CHEM. SOC. PERKIN. TRANS, vol. 11983, pages 1283 - 1292;;W. DMOWSKI; K. PIASECKA-MACIEJEWSKA, TETRAHEDRON LETT., vol. 54, 1998, pages 6781 - 6792;;R.V. SOMU, J. MED. CHEM., vol. 49, 2006, pages 31 - 34;;RANKE ET AL., CIRCULATION, vol. 87, no. 6, 1993, pages 1873 - 1879;;PAUL ET AL., LIFE SCIENCES, vol. 68, no. 4, 2000, pages 457 - 465;;CYRUS ET AL., CIRCULATION, vol. 106, no. 10, 2002, pages 1282 - 1287;;PRATICO ET AL., PNAS, vol. 98, no. 6, 2001, pages 3358 - 3363;;BURLEIGH ET AL., CIRCULATION, vol. 105, no. 15, 2002, pages 1816 - 1823;;CAYATTE ET AL., ATVB, vol. 20, no. 7, 2000, pages 1724 - 1728;;AIELLO ET AL., ATVB, vol. 22, no. 3, 2002, pages 443 - 449;;SUBBANAGOUNDER ET AL., CIRC. RES., vol. 85, no. 4, 1999, pages 311 - 318;;SCHAFER ELINDER, ATVB, vol. 17, no. 10, 1997, pages 2257 - 2263;;PONG K. ET AL., J. NEUROCHEM., vol. 69, 1997, pages 986 - 994;;WINTER, C.A. ET AL., PROC SOC EXP BIOL MED, vol. 111, 1962, pages 544 - 547;;TRENTHAM, D.E. ET AL., J EXP. MED, vol. 146, pages 828 - 833;;STEIN C ET AL., PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, vol. 31, 1988, pages 445 - 451;;MUKHERJEE A ET AL., INFLAMM RES., vol. 45, 1996, pages 531 - 540;;JULIUS, D. ET AL., NATURE, vol. 413, 2001, pages 203;;WOOLF, C.J. ET AL., SCIENCE, vol. 288, 2000, pages 1765;;PIOMELLI D., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 22, no. 1, January 2001 (2001-01-01), pages 17 - 29;;KUMAR, R.K., J PHARMACOL EXP THER., vol. 307, 2003, pages 349 - 355;;WU, A.Y. ET AL., CLIN EXP ALLERGY., vol. 33, 2003, pages 359 - 366;;BELL, R.L. ET AL., J PHARMACOL EXP THER, vol. 280, 1997, pages 1366 - 1373;;HENDERSON, W.R., JR. ET AL., J EXP MED., vol. 184, 1996, pages 1483 - 1494;;ABRAHAM, W.M., RESPIRATION, vol. 56, 1989, pages 48 - 56;;ABRAHAM, W.M. ET AL., RESPIRATION, vol. 56, 1989, pages 48 - 56;;ABRAHAM, W.M. ET AL., EUR J PHARMACOL, vol. 217, 1992, pages 119 - 126;;JONES, T.R. ET AL., CAN J PHYSIOL PHARMACOL., vol. 73, 1995, pages 191 - 201;;ABRAHAM, W.M. ET AL., J PHARMACOL EXP THER., vol. 247, 1988, pages 1004 - 1011;;ABRAHAM, W.M., J APPL PHYSIOL., vol. 66, 1989, pages 2351 - 2357",DISCONTINUED
832,CN,A,CN 107082806 A,102-445-929-584-798,2017-08-22,2017,CN 201610838893 A,2005-11-14,US 62727704 P;;CN 200580046469 A,2004-11-12,Site-directed modification of FVIII,"The invention relates to site-directed modification of FVIII, and also relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;CHEN JIANMIN;;MURPHY JOHN E;;WANG DEQIAN;;STRAUSS JONATHAN S;;TANG LIANG;;BARNETT THOMAS;;TJANDRA HENDRI;;MEI BAISONG,,https://lens.org/102-445-929-584-798,Patent Application,no,2,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K47/60;;C07K1/107,,1,0,,,"NOBUO SAKURAGAWA,ET AL.: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", 《ACTA MEDICA ET BIOLOGICA》",DISCONTINUED
833,MX,B,MX 350293 B,119-410-164-534-410,2017-09-04,2017,MX 2014005051 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII.,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,CLARK Q PAN;;JOHN E MURPHY;;BAISONG MEI;;JONATHAN S STRAUSS;;HENDRI TJANDRA;;JIANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/119-410-164-534-410,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K14/755;;C07K17/08,,0,0,,,,ACTIVE
834,SI,T1,SI 2363414 T1,158-378-088-368-496,2022-09-30,2022,SI 200532308 T,2005-11-14,US 62727704 P;;EP 11153300 A,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,,https://lens.org/158-378-088-368-496,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/00;;A61K38/00;;A61K47/00;;C07K17/00,,0,0,,,,ACTIVE
835,CN,B,CN 101124331 B,174-218-503-351-761,2013-04-24,2013,CN 200580046469 A,2005-11-14,US 2005/0041205 W;;US 62727704 P,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;TJANDRA HENDRI;;MURPHY JOHN E;;BARNETT THOMAS;;STRAUSS JONATHAN S;;TANG LIANG;;MEI BAISONG;;CHEN JIANMIN;;WANG DEQIAN,,https://lens.org/174-218-503-351-761,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,0,0,,,,ACTIVE
836,EP,A2,EP 1891006 A2,181-974-443-647-591,2008-02-27,2008,EP 06771540 A,2006-05-26,US 2006/0020847 W;;US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,"ZIARCO PHARMA LIMITED; GB (2023-11-21);;NOVARTIS AG, CH (2024-01-10)",https://lens.org/181-974-443-647-591,Patent Application,yes,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
837,HK,A1,HK 1218718 A1,196-270-930-994-485,2017-03-10,2017,HK 16106727 A,2016-06-13,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/196-270-930-994-485,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61P/;;A61K/,,0,0,,,,PENDING
838,UA,C2,UA 91053 C2,012-977-759-736-983,2010-06-25,2010,UA A200713220 A,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,", (I)This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase Aenzymes (cPLA) more particularly including inhibitors of cytosolic phospholipase Aalpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/012-977-759-736-983,Limited Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,EXPIRED
839,EP,B1,EP 2772500 B1,096-206-384-805-832,2019-12-25,2019,EP 14165736 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/096-206-384-805-832,Granted Patent,yes,6,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,19,14,065-668-968-707-947;;040-121-810-358-365;;125-439-449-787-91X;;022-092-946-978-595;;016-713-024-796-711;;066-146-798-965-262;;038-049-676-284-899;;067-722-407-233-179;;015-058-913-193-123;;118-141-021-040-457;;065-507-326-783-764;;048-173-766-063-724;;059-832-677-948-024;;026-307-785-052-863,10.1182/blood.v92.11.3983.423k51_3983_3996;;9834200;;10.1182/blood.v92.11.3983;;7613471;;10.1002/pro.5560040413;;pmc2143093;;10.1038/nrd1033;;12612647;;11214751;;10.1016/s0142-9612(00)00193-9;;10.2174/1381612023393242;;12369859;;1366535;;10.1038/nbt0490-343;;8175770;;10.1016/s0021-9258(17)36846-1;;8125985;;10.1016/s0021-9258(17)37331-3;;12052713;;10.1016/s0169-409x(02)00026-1;;10.1182/blood-2009-11-254755;;20194895;;12821324;;10.1016/s1046-5928(03)00055-x;;14499707;;10.1016/s0169-409x(03)00109-1;;10.1074/mcp.m800108-mcp200;;18653768;;12816898;;10.1373/49.7.1041,"LENTING ET AL., BLOOD, vol. 92, no. 11, 1998, pages 3983 - 3996, XP002333863;;MCMULLEN ET AL., PROTEIN SCIENCE, vol. 4, no. 4, 1995, pages 740 - 6, XP055666938;;PASUT ET AL., EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 14, no. 6, 2005, pages 859 - 894, XP001202106;;COPY OF EXTRACTS FROM THE EXPERT OPINION JOURNAL CONTAINING D5, June 2004 (2004-06-01);;COPY OF ENTRY FROM EMBASE SEARCHING DATABASE SHOWING THAT D5 WAS AVAILABLE TO SEARCH IN THIS PUBLIC DATABASE, July 2004 (2004-07-01);;HARRIS ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 2, 2003, pages 214 - 221, XP009042217;;VERONESE, BIOMATERIALS, vol. 22, 2001, pages 405 - 417, XP004227886;;YOUNGSTER ET AL., CURRENT PHARMACEUTICAL DESIGN, vol. 8, no. 24, 2002, pages 2139 - 2157, XP008064341;;GOODSON ET AL., BIOTECHNOLOGY, vol. 8, 1990, pages 343 - 346, XP002949248;;BENHAR ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 18, 1994, pages 13398 - 13404, XP055213946;;KUAN ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 10, 1994, pages 7610 - 7616, XP055666928;;CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 531 - 545, XP002300924;;MEI ET AL., BLOOD, vol. 116, no. 2, pages 270 - 279, XP002618133;;FOSER ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 30, 2003, pages 78 - 87, XP004432807;;LEE ET AL., PHARMACEUTICAL RESEARCH, vol. 19, no. 6, June 2002 (2002-06-01), XP002904848;;ESPOSITO ET AL., ADVANCED DRUG DELIVERY REVIEWS, vol. 55, 2003, pages 1279 - 1291, XP008040600;;DECLARATION OF PROFESSOR MICHAEL PRZYBYLSKI;;SZAJLI ET AL., MOLECULAR & CELLULAR PROTEOMICS, 12 July 2008 (2008-07-12), pages 2410 - 2418, XP055260168;;ANNESLEY, CLINICAL CHEMISTRY, vol. 49, no. 7, 2003, pages 1041 - 1044, XP055153860",INACTIVE
840,HK,A1,HK 1117875 A1,097-165-942-508-401,2009-01-23,2009,HK 08107795 A,2008-07-15,US 2005/0041205 W;;US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/097-165-942-508-401,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P/;;A61K/;;C07K/,,0,0,,,,PENDING
841,EP,A3,EP 2363414 A3,125-334-449-117-19X,2012-03-21,2012,EP 11153300 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
 
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-04-27),https://lens.org/125-334-449-117-19X,Search Report,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755,,3,2,022-092-946-978-595;;029-944-973-758-653,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598;;SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLOGICA, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734",ACTIVE
842,HU,T2,HU E050542 T2,154-753-720-398-768,2020-12-28,2020,HU E16186901 A,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/154-753-720-398-768,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;A61K38/37;;A61K47/60,,0,0,,,,PENDING
843,CR,A,CR 9520 A,188-671-491-584-798,2008-02-20,2008,CR 9520 A,2007-11-14,US 68556405 P,2005-05-27,INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA,"La invencion provee inhibidores quimicos de la actividad de diversas enzimas fosfolipasa, particularmente de las enzimas fosfolipasa A2 citosolica (cpla2), mas particularmente incluyendo inhibidores de las enzimas fosfolipasa A2 alfa citosolica (cpla2a)",WYETH CORP,JOHN C MCKEW;;KATHERINE L LEE;;LILHREN CHEN;;RICHARD VARGAS;;JAMES D CLARK;;CARA WILLIAMS;;VALERIE CLERIN;;SUZANA MARUSIC;;KEVIN PONG,,https://lens.org/188-671-491-584-798,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00;;C07D209/14,,0,0,,,,DISCONTINUED
844,US,B2,US 9364520 B2,195-128-056-817-066,2016-06-14,2016,US 54070309 A,2009-08-13,US 54070309 A;;US 27389605 A;;US 62727704 P,2004-11-12,Factor VIII conjugates,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN;;BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2006-01-04),https://lens.org/195-128-056-817-066,Granted Patent,yes,59,2,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K38/00;;A61K47/48;;C07K14/755;;C07K17/08,,50,48,034-467-759-984-977;;081-336-200-295-868;;017-912-258-241-514;;066-370-603-911-042;;067-722-407-233-179;;110-266-842-977-819;;048-391-899-819-148;;054-090-919-783-575;;050-914-567-218-321;;014-404-528-569-22X;;021-691-529-972-457;;023-461-551-285-468;;064-356-470-690-00X;;082-011-579-838-812;;167-656-547-020-741;;057-935-502-781-436;;073-064-348-159-030;;036-303-431-596-016;;061-013-622-187-304;;049-936-640-346-832;;007-068-453-274-860;;010-356-395-170-813;;036-657-079-582-704;;038-992-740-792-079;;083-448-995-704-379;;010-347-158-675-450;;040-121-810-358-365;;032-960-531-047-473;;056-927-333-742-99X;;071-881-515-349-948;;092-185-025-573-894;;076-459-195-524-871;;031-219-178-479-524;;095-248-606-612-120;;105-215-317-030-407;;050-112-382-936-584;;118-803-283-877-249;;019-730-797-612-199;;066-146-798-965-262;;022-092-946-978-595;;029-944-973-758-653;;055-003-061-629-507;;007-822-064-014-928;;044-737-094-103-978;;038-049-676-284-899;;084-834-810-821-651;;038-371-868-499-013;;065-668-968-707-947,3936044;;10.1073/pnas.82.24.8752;;pmc391515;;15946216;;10.1111/j.1538-7836.2005.01389.x;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1016/s0024-3205(99)00048-x;;10210259;;8125985;;10.1016/s0021-9258(17)37331-3;;10.1074/jbc.274.53.37685;;10608826;;10.1016/s0021-9258(18)31537-0;;1902833;;10.1074/jbc.m212053200;;12522143;;10.1182/blood.v96.3.958;;10910910;;10.1182/blood.v95.2.564;;10627463;;8626729;;10.1074/jbc.271.8.3982;;10446132;;10.1074/jbc.274.34.23734;;8567641;;10.1074/jbc.271.4.1935;;9374501;;10.1074/jbc.272.48.30191;;10.1074/jbc.m104732200;;11698391;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1074/jbc.m008046200;;11278379;;15073030;;10.1182/blood-2003-11-3891;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1074/jbc.m400568200;;14764590;;10.1073/pnas.85.8.2429;;pmc280010;;3128786;;7540171;;10.1074/jbc.270.24.14505;;10.1073/pnas.82.22.7728;;2415970;;pmc391407;;7613471;;10.1002/pro.5560040413;;pmc2143093;;10.1016/s0021-9258(17)32024-0;;8051150;;10.1074/jbc.m409389200;;15471879;;11830468;;10.1182/blood.v99.4.1215;;10.1111/j.1365-2516.2004.01005.x;;15479386;;10.1046/j.1365-2516.2003.00769.x;;12694514;;15840700;;10.1182/blood-2004-11-4230;;11510630;;10.2165/00003088-200140070-00005;;12787631;;10.1016/s0378-5173(03)00227-8;;16233987;;10.1016/j.cbpa.2005.10.007;;10.1055/s-0038-1648520;;1509407;;10821655;;10.1021/bc990137i;;1366535;;10.1038/nbt0490-343;;11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;10.1006/bbrc.1998.8301;;9514953;;8175770;;10.1016/s0021-9258(17)36846-1;;10890891;;pmc26985;;10.1073/pnas.140210597;;10.1093/protein/gzg093;;14600206;;10.1182/blood.v92.11.3983.423k51_3983_3996;;9834200;;10.1182/blood.v92.11.3983,"Brinkhous et al., Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs., Proc. Natl. Acad. Sci. USA, 1985, vol. 82, pp. 8752-8756.;;Bovenschen et al., The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor, Journal of Thrombosis and Haemostasis, vol. 3, pp. 1257-1265.;;Lind et al., Novel froms of B-doamin-deleted recobminant factor VIII molecules, Eru. J. Biochem, 1995, vol. 232, pp. 19-27.;;He et al., ""Site-Directed Polyethylene Glycol Modificatio of Trichosanthin: Effects on its Biological Activities, Pharmacokinetics, and Antigenicity"", Life Sciences, 1999, vol. 64, No. 14, pp. 1163-1175.;;Kuan et al., ""Pseudomonas Exotoxin A Mutants: Replacement of Surface Exposed Residues in Domain II with Cysteine Residues that can be Modified with Polyethylene Glycol in a Site-Directed Manner"", The Journal of Biological Chemistry, 1994, vol. 269, No. 10, Issue of Mar. 11, pp. 7610-7616.;;Saenko, E., et al., ""Role of the Low Density Lipoprotein-Related Protein Receptor in Mediation of Factor VIII Catabolism"", The Journal of Biological Chemistry, vol. 274, No. 53, 1999, pp. 37685-37692.;;Fay, P. J., et al., ""Human Factor VIIIa Subunit Structure"", The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8957-8962.;;Bovenschen, N., et al., ""Low Density Lipoprotein Receptor-Related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII"", The Journal of Biological Chemistry, vol. 278, No. 11, 2003, pp. 9370-9377.;;Jacquemin, M., et al., ""A Novel Cause of Mild/Moderate Hemophilia A: Mutations Scattered in the Factor VIII C1 Domain Reduce Factor VIII Binding to von Willebrand Factor"", Blood, vol. 96, No. 3, 2000, pp. 958-965.;;Barrow, R., et al., ""Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules"", Blood, vol. 95, No. 2, 2000, pp. 564-568.;;Regan, L., et al., ""Activated Protein C-Catalyzed Proteolysis of Factor VIIIa Alters Its Interactions Within Factor Xase"", The Journal of Biological Chemistry, vol. 271, No. 8, 1996, pp. 3982-3987.;;Lenting, P., et al., ""The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 274, No. 34, 1999, pp. 23734-23739.;;Lenting, P. , et al., ""The Sequence Glu1811-Lys1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX"", The Journal of Biological Chemistry, vol. 271, No. 4, 1996, pp. 1935-1940.;;Lubin, I., et al., ""Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis"", The Journal of Biological Chemistry, vol. 272, No. 48, 1997, pp. 30191-30195.;;Gilbert, G., et al., ""Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-Binding and von Willebrand Factor-Binding Motifs"", The Journal of Biological Chemistry, vol. 277, No. 8, 2002, pp. 6374-6381.;;Scandella, D., et al., ""Localization of Epitopes for Human Factor VIII Inhibitor Antitodies by Immunoblotting and Antibody Neutralization"", Blood, vol. 74, No. 5, 1989, pp. 1618-1626.;;Foster, P., et al., ""An Immunogenic Region within Residues Val1670-Glu1684 of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding of Factor VIII to von Willebrand Factor"", The Journal of Biological Chemistry, vol. 263, No. 11, 1988, pp. 5230-5234.;;Lubin, I., et al., ""Elimination of a Major Inhibitor Epitope in Factor VIII"", The Journal of Biological Chemistry, vol. 269, No. 12, 1994, pp. 8639-8641.;;Scandella, D., et al., ""A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2"", Blood, vol. 82, No. 6, 1993, pp. 1767-1775.;;Sarafanov, A., ""Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 276, No. 15, 2001, pp. 11970-11979.;;Parker, E., et al., ""Reduction of the Inhibitory Antibody Response to Human Factor VIII in Hemophilia A Mice by Mutagenesis of the A2 Domain B-Cell Epitope"", Blood, vol. 104, No. 3, 2004, pp. 704-710.;;Scandella, D., et al., ""Epitope Mapping of Human Factor VIII Inhibitor Antibodies by Deletion Analysis of Factor VIII Fragments Expressed in Escherichia coli"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 6152-6156.;;Nogami, K., at al., ""Identification of a Factor Xa-Interactive Site Within Residues 337-372 of the Factor VIII Heavy Chain"", The Journal of Biological Chemistry, vol. 279, No. 16, 2004, pp. 15763-15771.;;Pittman, D., at al., ""Proteolytic Requirements for Thrombin Activation of Anti-Hemophilic Factor (Factor VIII)"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 2429-2433.;;Healy, J., et al., ""Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII"", The Journal of Biological Chemistry, vol. 270, No. 24, 1995, pp. 14505-14509.;;Fulcher, C., et al., ""Localization of Human Factor FVIII Inhibitor Epitopes to Two Polypeptide Fragments"", Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 7728-7732.;;McMullen, B., at al., ""Locations of Disulfide Bonds and Free Cysteines in the Heavy and Light Chains of Recombinant Human Factor VIII (Antihemophilic Factor A)"", Protein Science, vol. 4, 1995, pp. 740-746.;;Fay P. , et al., ""Factor VILLa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site"", The Journal of Biological Chemistry, vol. 269, No. 32, 1994, pp. 20522-20527.;;Spiegel. P. C., et al., ""Surface-Exposed Hemophilic Mutations Across the Factor VIII C2 Domain Have Variable Effects on Stability and Binding Activities"", The Journal of Biological Chemistry, vol. 279, No. 51. 2004, pp. 56391-56398.;;Stoilova-McPhie, S., et al., ""3-Dimensional Structure of Membrane-Bound Coagulation Factor VII: Modeling of the Factor VIII Heterodimer Within a 3-Dimensional Density Map Derived by Electron Crystallography"", Blood, vol. 99, No. 4, 2002, pp. 1215-1223.;;Oldenburg, J. at al., ""Molecular basis of haemophilia A"", Haemophilia, vol. 10, No. 4, 2004, pp. 133-139.;;Gruppo, R.A. at al. ""Comparative effectiveeness of full-length and B-domain deleted factor VIII for prophylaxis-a meta analysis"", Haemophilia, vol. 4 2003, pp. 251-260.;;Bovenschen, N. et al. ""LDL receptor cooperates with LDL receptor- related protein in regulating plasma levels of coagulation factor VIII in vivo"", Blood, vol. 106, No. 3, 2005, pp. 906-912.;;Harris, J., et al., ""Pegylation A Novel Process for Modifying Pharmacokinetics"", Clin Pharmacokinet, vol. 40, No. 7, 2001, pp. 539-551.;;Wang, W. et al., ""Coagulation factor VIII: structure and stability"", International Journal of Pharaceutics, vol. 259, 2003, pp. 1-15.;;Kochendoerfer, G., ""Site-specific polymer modification of therapeutic proteins"", Current Opinion in Chemical Biology, vol. 9, 2005, pp. 555-560.;;Scandella, D., at al., ""A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting"", Thrombosis and Haemostasis, vol. 67, No. 6, 1992, pp. 665-671.;;Rostin, J., at al., ""B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol"", Bioconjugate Chem., vol. 11, 2000, pp. 387-396.;;Goodson, R.et al., ""Site-Directed Peglation of Recombinant Interleukin-2 at its Glycosylation Site"", Bio/Technology, vol. 8, 1900, pp. 343-346.;;Sakuragawa, N. et al. Studies on the Stability of Factor VIII Modified by Polyethylene Glycol, Acta Medica et Biologica, 36(1), pp. 1-6 (1988). (Abstract only).;;Veronese, F. M., ""Peptide and Protein PEGylation-a Review of Problems and Solutions"", Biomaterials, Elsevier Science Publishers BV, Barking, GB (2001), No. 5, vol. 22, p. 405-417.;;Kochendoerfer, G., ""Chemical and Biological Properties of Polymer-Modified Proteins"", Expert Opinion on Biological Therapy, (2003), vol. 3, No. 8, pp. 1253-1261.;;Extended European Search Report (including suppl. European Search Report and the European search opinion) for EP App. 05849392.5 dated Dec. 1, 2008 (5 pages).;;Guo et al., ""Protein Tolerance to Random Amino Acid Change"", Prox. Natl. Acad. Sci. USA, (2004), vol. 101, pp. 9205-9210.;;Lazar, at al., Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, Mol. Cell. Biol., (1998), vol. 8, pp. 1247-1252.;;Hill et al., Functional Analysis of Conserved Histidines in ADP-Glucose Pyrophosphorylase from Escherichia coli, Biochem, Biophys, Res. Comm., (1998), vol. 244, pp. 573-577.;;Benhar, I., et al., ""Pseudomonas Exotoxin A Mutants: Replacement of Surface-Exposed Residues in Domain III with Cysteine Residues That Can Be Modified with Polyethylene Glycol in a Site-Specific Manner,"" The Journal of Biological Chemistry, (May 6, 1994), vol. 109, No. 18, pp. 13398-13404.;;Tsutsumi, Y., et al., ""Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity,"" PNAS, (Jul. 18, 2000), vol. 97, No. 15, pp. 8548-8553.;;Yang, K., et al., ""Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation,"" Protein Engineering, (2003), vol. 16, No. 10, pp. 761-770.;;Lenting, P., et al., ""The Life Cycle of Coagulation Factor VIII in View of its Structure and Function"", Blood, 1998, vol. 92, No. 11, pp. 3983-3996.",ACTIVE
845,ZA,B,ZA 200703696 B,001-504-778-303-21X,2008-08-27,2008,ZA 200703696 A,2007-05-08,US 62727704 P,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;BAISON MEI;;STRAUSS JONATHAN S;;HENDRI TJANDRA;;JIANMIN CHEN;;THOMAS BARNETT;;LIANG TANG;;DEQIAN WANG,,https://lens.org/001-504-778-303-21X,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K/;;C07K/;;C12P/,,0,0,,,,ACTIVE
846,SI,T1,SI 1824988 T1,013-786-081-490-944,2017-11-30,2017,SI 200532158 T,2005-11-14,US 62727704 P;;US 2005/0041205 W;;EP 05849392 A,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/013-786-081-490-944,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K17/00,,0,0,,,,ACTIVE
847,MY,A,MY 144672 A,062-466-755-227-11X,2011-10-31,2011,MY PI20062443 A,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"THIS INVENTION PROVIDES CHEMICAL INHIBITORS OF THE ACTIVITY OF VARIOUS PHOSPHOLIPASE ENZYMES, PARTICULARLY CYTOSOLIC PHOSPHOLIPASE A2 ENZYMES (CPLA2), MORE PARTICULARLY INCLUDING INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 ALPHA ENZYMES (CPLA2A). IN SOME EMBODIMENTS, THE INHIBITORS HAVE THE FORMULA I: WHEREIN THE CONSTITUENT VARIABLES ARE AS DEFINED HEREIN.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/062-466-755-227-11X,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14,,0,0,,,,ACTIVE
848,US,B1,US 6608028 B1,073-297-356-066-085,2003-08-19,2003,US 72325100 A,2000-11-27,US 72325100 A;;US 33722799 A;;US 5288898 A;;US 82585297 A,1997-04-04,Insulin-like growth factor agonist molecules,"
    Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. 
",GENENTECH INC,CHEN YVONNE MAN-YEE;;CLARK ROSS G;;COCHRAN ANDREA G;;LOWMAN HENRY B;;ROBINSON IAIN C A F;;SKELTON NICHOLAS J,GENENTECH INC (2002-02-12),https://lens.org/073-297-356-066-085,Granted Patent,yes,67,3,8,8,51,A61K38/30;;C07K7/08;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61P5/00;;A61K38/00;;C07K7/08;;A61K38/30;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61K38/00,A61K38/00;;A61K38/30;;C07K7/08;;C07K14/47;;C07K14/65,514/11;;514/12;;514/13;;514/14;;514/3;;514/4;;530/317;;530/324;;530/326;;530/327;;530/303;;930/120;;930/260,99,90,014-125-367-031-231;;017-264-804-459-877;;017-350-602-958-513;;026-623-017-714-89X;;053-508-442-408-581;;050-719-958-572-148;;035-756-231-423-984;;045-964-465-312-91X;;091-854-753-933-770;;009-317-840-275-65X;;044-898-403-939-670;;020-803-531-740-687;;114-552-109-070-862;;121-192-711-498-551;;122-544-263-077-018;;048-188-266-680-461;;028-244-774-323-223;;051-762-247-693-584;;027-889-828-130-366;;097-785-885-745-976;;044-885-448-085-960;;055-029-284-594-570;;044-015-018-025-600;;066-564-168-992-217;;069-485-915-823-577;;036-028-618-959-354;;014-911-901-153-035;;032-236-672-104-294;;020-582-523-460-582;;038-260-426-123-957;;146-171-107-846-251;;009-186-473-238-939;;009-069-193-386-694;;098-441-778-398-080;;070-740-676-932-821;;093-658-600-554-037;;020-411-130-368-703;;020-510-267-061-589;;030-081-590-114-687;;026-720-717-926-994;;127-616-834-120-73X;;042-682-434-812-597;;167-040-741-674-313;;029-966-690-919-75X;;040-185-536-258-128;;105-560-205-533-971;;013-303-631-864-631;;096-718-408-234-974;;116-645-290-887-265;;010-645-653-539-638;;004-678-657-001-505;;019-984-077-132-656;;140-584-552-918-775;;035-483-585-582-64X;;116-157-636-951-170;;089-677-859-786-645;;003-137-931-754-668;;021-449-779-524-07X;;084-363-781-757-911;;000-613-056-275-938;;008-721-226-627-596;;063-088-702-691-710;;046-072-043-619-455;;078-655-932-195-328;;112-994-384-334-733;;007-717-236-970-533;;044-071-530-416-412;;016-758-022-635-876;;097-011-248-396-364;;044-051-728-567-349;;086-111-078-062-01X;;029-286-680-248-885;;007-489-225-495-51X;;045-838-528-482-83X;;147-661-590-433-69X;;015-768-700-460-036;;023-036-715-680-660;;016-796-441-670-243;;060-413-390-113-504;;025-059-951-768-239;;026-190-764-535-624;;150-639-968-778-276;;039-038-656-451-824;;076-444-264-945-863;;081-838-471-410-493;;028-701-201-701-662;;022-281-660-192-32X;;035-594-330-696-292;;070-680-873-937-056;;015-653-151-970-972,7680510;;10.1016/s0083-6729(08)60444-6;;10.1210/endo-127-6-3243;;2174349;;8171331;;10.1126/science.8171331;;10.1002/prot.340080405;;1708882;;2443135;;10.1016/s0006-291x(87)80136-5;;10.1016/s0021-9258(18)48458-x;;1370451;;2424282;;10.1016/s0065-2423(08)60124-9;;10.1016/0305-0491(88)90137-x;;2461835;;10.1016/s0021-9258(18)68777-0;;2966152;;2472386;;10.1016/s0021-9258(18)60418-1;;10.1016/s0021-9258(18)55447-8;;2168421;;10.1002/j.1460-2075.1989.tb08386.x;;pmc401241;;2479552;;6998350;;10.7326/0003-4819-120-7-199404010-00011;;8116999;;8374685;;10.1515/jpem.1993.6.1.21;;2315699;;10.1126/science.2315699;;7631865;;10.1152/ajpheart.1995.269.1.h326;;10.1016/s0006-291x(88)80425-x;;2454104;;10.1002/j.1460-2075.1988.tb03087.x;;2461294;;pmc457109;;10.1677/joe.0.1220661;;2681500;;10.1007/978-1-4615-2988-0_4;;7514345;;10.1021/bi00409a016;;2839228;;2536701;;10.1016/s0021-9258(18)94162-1;;3193048;;10.1677/joe.0.1190051;;8187319;;10.1111/j.1365-2265.1994.tb02492.x;;10.1007/bf00404081;;8359587;;10.1007/bf03000203;;21153160;;10.1007/bf03021409;;21153178;;10.1007/978-3-642-67986-5_5;;1379166;;10.1210/en.131.2.890;;10.1210/endo.131.2.1379166;;10.1016/s0021-9258(19)38332-2;;1695626;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;2143033;;10.1126/science.2143033;;10.1021/bi990089p;;10350456;;10.1172/jci117706;;pmc295527;;7860746;;10.1210/endo.137.5.8612531;;10.1210/en.137.5.1913;;8612531;;9124404;;10.1152/ajprenal.1997.272.2.f257;;10.1159/000184148;;7959637;;10.1210/endo.135.5.7956938;;7956938;;10.1210/en.135.5.2144;;10.1016/0161-5890(86)90081-7;;2432410;;9032099;;10.2337/diabetes.46.3.433;;10.2337/diab.46.3.433;;10.1021/bi00047a006;;7492543;;2220389;;pmc287020;;10.1073/pnas.86.8.2868;;2649897;;2741635;;10.1530/acta.0.1210101;;3387445;;10.1073/pnas.85.13.4889;;pmc280542;;3299085;;10.1056/nejm198707163170303;;10.1152/ajprenal.1993.265.1.f1;;8393619;;7948775;;10.1681/asn.v511;;10.1016/s0021-9258(19)47281-5;;2553732;;10.1172/jci116480;;pmc443305;;8514857;;7593439;;10.1210/jc.80.11.3284;;10.1210/jcem.80.11.7593439;;8662901;;10.1074/jbc.271.24.13948;;10.1038/ki.1993.57;;8441234;;1668800;;10.1111/j.1432-1033.1990.tb15595.x;;2197088;;8314009;;10.2337/diab.43.3.369;;10.2337/diabetes.43.3.369;;2237405;;10.1126/science.2237405;;10.1210/er.16.1.3;;10.1210/edrv-16-1-3;;7758431;;8762727;;10.1046/j.1365-2265.1996.711531.x;;10.1016/0378-1119(93)90153-t;;8508960;;pmc330007;;8423214;;10.1172/jci116163;;1538716;;7679407;;pmc287936;;10.1172/jci116212;;8482426;;10.2337/diab.42.5.696;;10.2337/diabetes.42.5.696;;10.1074/jbc.271.34.20458;;8702785;;2407519;;10.1210/endo-126-3-1593;;10.1210/mend-2-5-404;;2458522;;10.3181/00379727-204-43630;;7690486;;10.1038/330537a0;;2825030;;1718795;;10.1016/0303-7207(91)90086-8;;7691582;;10.1210/endo.133.4.7691582;;10.1210/en.133.4.1797;;10.1210/endo-129-4-2254;;1717244;;7508949;;10.1210/jc.78.2.404;;10.1210/jcem.78.2.7508949;;1377706;;10.1210/jc.75.1.30;;10.1210/jcem.75.1.1377706;;8662530;;10.1126/science.273.5274.464;;9465113;;10.1073/pnas.95.4.1894;;pmc19209;;9636028;;10.1021/bi980426e;;10.1146/annurev.biophys.26.1.401;;9241425;;9523276;;10.1385/0-89603-392-9:249;;2823385;;10.1126/science.2823385;;3722172;;10.1016/s0021-9258(19)84446-0;;10.1016/0378-1119(93)90149-w;;8508957;;10.1038/ki.1994.260;;7933838;;1438188;;10.1002/prot.340140411;;10.1681/asn.v32157;;1391716;;8498545;;10.1152/ajprenal.1993.264.5.f917;;10.1210/en.132.3.1337;;7679979;;10.1210/endo.132.3.7679979;;8939990;;10.1074/jbc.271.48.30322;;10.1073/pnas.89.12.5393;;1608948;;pmc49298,"Alberts et al. Molecular Biology of the Cell, 3RD edition, New York:Garland Publishing, Inc. pp. 119 (1994).;;Bach and Rechler, ""Insulin-like Growth Factor Binding Proteins"" Diabetes Reviews 3:38-61 (1995).;;Ballard et al., ""Does IGF-I Ever Act Through the Insulin Receptor?"" The Insulin-like Growth Factors and Their Regulatory Proteins, Baxter, eds., Amsterdam: Elsevier pp. 131-138 (1994).;;Bar et al., ""Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I"" Endocrinology 127(6):3243-3245 (1990).;;Barinaga, M., ""Neurotrophic factors enter the clinic [news]"" Science 264:772-774 (1994).;;Bass et al., ""Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties"" Proteins: Structure, Function, and Genetics 8(4):309-314 (1990).;;Baxter & Martin, ""Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins"" Biochem. & Biophys. Res. Comm. 147(1):408-415 (1987).;;Baxter et al., ""Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3"" Journal of Biological Chemistry 267(1):60-65 (Jan. 5, 1992).;;Baxter, ""Physiological Roles of IGF Binding Proteins"" Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).;;Baxter, ""The somatomedins: insulin-like growth factors"" Advances in Clinical Chemistry 25:49-115 (1986).;;Baxter, R., ""The Insulin-Like Growth Factors and Their Binding Proteins"" Comp. Biochem. Physiol. 91B(2):229-235 (1988).;;Bayne et al., ""Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor"" Journal of Biological Chemistry 263:6233-6239 (1988).;;Bayne et al., ""The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor"" Journal of Biological Chemistry 264(19):11004-11008 (Jul. 5, 1989).;;Bayne et al., ""The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor"" Journal of Biological Chemistry 265(26):15648-15652 (Sep. 15, 1990).;;Binkert et al., ""Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)"" EMBO Journal 8:2497-2502 (1989).;;Binoux, M., ""Donnees recentes sur les somatomedines (Insulin-like growth factors)"" Annales d'Endocrinologie 41:157-192 (1980).;;Bondy, C., ""Clinical uses of insulin-like growth factor I"" Annals of Internal Medicine 120:593-601 (1994).;;Bowers, C. Y., ""GH Releasing Peptides-Structure and Kinetics"" J. Pediatr. Endocrinology 6(1):21-31 (1993).;;Bowie et al., ""Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions"" Science 247:1306-1310 (1990).;;Brandt et al., ""Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide"" American Journal of Physiology 269(1 Pt 2):H326-H331 (Jul. 1995).;;Brewer et al., ""Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein"" Biochem. & Biophys. Res. Comm. 152(3):1289-1297 (1988).;;Brinkman et al., ""Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)"" The EMBO J. 7:2417-2423 (1988).;;Carlsson et al., ""Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions"" J. Endocrinol. 122:661-670 (1989).;;Cascieri et al., ""Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins"" Advances in Experimental Medicine & Biology 343:33-40 (1993).;;Cascieri et al., ""Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor"" Biochemistry 27(9):3229-3233 (May 3, 1988).;;Cascieri et al., ""Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors"" Journal of Biological Chemistry 264:2199-2202 (1989).;;Charlton et al., ""Growth hormone-deficient dwarfism in the rat: a new mutation"" J. of Endocrinology 119:51-58 (1988).;;Cheetham et al., ""The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependant Diabetes Mellitus"" Clin. Endocrinol. 40:515-522 (1994).;;Cheetham et al., ""The Effects of Recombinant Insulin-like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus"" Diabetologia 36:678-681 (1993).;;Chen et al., ""Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation"" US Endocrine Meeting (Abstract 1596) pp. 449 (1993).;;Clark et al., ""Growth-Responses to Patterned GH Delivery"" Endocrine 3:717-723 (1995).;;Clark et al., ""Insulin-Like Growth Factor-1 and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats"" Endocrine 3:297-304 (1995).;;Clemmons and Van Wyk, ""Somatomedin: physiological control and effects on cell proliferation"" Handbook Exp. Pharmacol. 57:161-208 (1981).;;Clemmons et al., ""Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs"" Endocrinology 131(2):890-895 (Aug. 1992).;;Clemmons et al., ""Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity"" Journal of Biological Chemistry 265(21):12210-12216 (1990).;;Cwirla et al., ""Peptides on phage: a vast library of peptides for identifying ligands"" Proc. Natl. Acad. Sci. USA 87(16):6378-6382 (1990).;;Devlin et al., ""Random peptide libraries: a source of specific protein binding molecules"" Science 249:404-406 (1990).;;Dubaquie et al., ""Total Alanine-Scanning Mutagenesis of Insulin-Like Growth Factor I (IGF-I) Identifies Differential Binding Epitopes for IGFBP-1 and IGFBP-3"" Biochemistry 38(20):6386-6396 (1999).;;Duerr et al., ""Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure"" J. Clin. Invest. 95:619-627 (1995).;;Elahi et al., ""Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men"" Modern Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York:Elsevier Science Publ. Co. pp. 219-224 (1991).;;Fiedler et al., ""Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats"" Endocrinology 137:1913-1920 (1996).;;Franklin et al., ""Insulin-Like Growth Factor I Preserves Renal Function Postoperatively"" Am. J. Physiol. 272:F257-F259 (1997).;;Froesch et al., ""Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I"" Horm. Res. 42:66-71 (1994).;;Furnsinn et al., ""Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats"" Endocrinology 135(5):2144-2149 (1994).;;Geysen et al., ""A priori delineation of a peptide which mimics a discontinuous antigenic determinant"" Molecular Immunology 23(7):709-715 (1986).;;Ghazzi et al., ""Cardiac glycemic benefits of troglitazone treatment in NIDDM"" Diabetes 46:433-439 (1997).;;Giebel et al. ""Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities"" Biochemistry 34:15430-15435 (1995).;;Guler et al., ""Effects of Insulin-like Growth Factor I in Man"" Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).;;Guler et al., ""Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects"" Proc. Natl. Acad. Sci. USA 86:2868-2872 (Apr. 1989).;;Guler et al., ""Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man"" Acta Endocrinologica 121:101-106 (1989).;;Guler et al., ""Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats"" Proc. Natl. Acad. Sci. USA 85:4889-4893 (1988).;;Guler et al., ""Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults"" New England J. of Medicine 317(3):137-140 (1987).;;Hammerman and Miller, ""The growth hormone insulin-like factor axis in kidney revisited"" Am. J. Physiol. 265:F1-F14 (1993).;;Hammerman and Miller, ""Therapeutic use of growth factors in renal failure"" J. Am. Soc. Nephrol. 5:1-11 (1994).;;Hampton et al., ""Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma"" Journal of Biological Chemistry 264(32):19155-19160 (Nov. 15, 1989).;;Hartman et al., ""A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans"" J. Clin. Invest. 91:2453-2462 (1993).;;Hasegawa et al., ""The free form of insulin-like growth factor I increases in circulation during normal human pregnancy"" J. Clin. Endocrinol. Metabol. 80:3284-3286 (1995).;;Heding et al., ""Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3"" Journal of Biological Chemistry 271(24):13948-13952 (Jun. 14, 1996).;;Hirschberg et al., ""Effects of insulin-like growth factor I on renal function in normal men"" Kidney International 43:387-397 (1993).;;Hizuka et al., ""Measurement of free form of insulin-like growth factor I in human plasma"" Growth Regulation 1:51-55 (1991).;;Humbel, ""Insulin-like growth factors I an II"" European Journal of Biochemistry 190:445-462 (1990).;;Jabri et al., ""Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients"" Diabetes 43:369-374 (1994).;;Johnson et al., ""Underexpression of betacell high Km glucose transporters in noninsulin-dependent diabetes"" Science 250:546-549 (1990).;;Jones et al., ""Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions"" Endocrine Reviews 16(1):3-34 (1995).;;Juul et al., ""Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty"" Clin. Endocrinology 44:515-523 (1996).;;Kay et al., ""An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets"" Gene 128:59-65 (1993).;;Kerr et al., ""Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia"" Diabetes: American Diabetes Association (ADA), San Antonio, Texas, Jun. 20-23, 1992 (abstract #225), 52nd Annual Meeting edition 41(supp 1):60A (Jun. 1992).;;Kerr et al., ""Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans"" J. Clin. Invest. 91:141-147 (1993).;;Kletzien et al., ""Enhancement of adipocyte differentiation by an insulin-sensitizing agent"" Molecular Pharmacology 41(2):393-398 (Feb. 1992).;;Kupfer et al., ""Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously"" J. Clin Invest. 91:391-396 (1993).;;Kuzuya et al., ""Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes"" Diabetes 42:696-705 (1993).;;Lassalle et al., ""ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines"" Journal of Biological Chemistry 271:20458-20464 (1996).;;Leahy et al., ""Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion"" Endocrinology 126(3):1593-1598 (1990).;;Lee et al., ""Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors"" Mol. Endocrinol. 2(5):404-411 (1988).;;Lee et al., ""Regulation and function of insulin-like growth factor-binding protein-1"" Proc. Soc. Exp. Biol. & Med. 204:4-29 (1993).;;Leung et al., ""Growth hormone receptor and serum binding protein: purification, cloning and expression"" Nature 330:537-543 (1987).;;Lewitt and Baxter, ""Insulin-like growth factor-binding prote4in-1: a role in glucose counterregulation?"" Mol. Cell. Endocrinology 79(1-3):C147-C152 (1991).;;Lewitt et al., ""Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3"" Endocrinology 133:1797-1802 (1993).;;Lewitt et al., ""Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels"" Endocrinology 129(4):2254-2256 (1991).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia"" US Endocrine Meeting (Abstract 1664) pp. 466 (1993).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome"" J. Clin. Endocrinol. and Metab. 78(2):404-410 (1994).;;Lieberman et al., ""Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans"" J. Clin. Endocrinol. and Metab. 75(1):30-36 (1992).;;Livnah et al., ""Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A"" Science 273(5274):464-471 (Jul. 26, 1996).;;Loddick et al., ""Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke"" Proc. Natl. Acad. Sci. USA 95(4):1894-1898 (Feb. 17, 1998).;;Lowman et al., ""Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions"" Biochemistry 37(25):8870-8878 (1998).;;Lowman et al., ""Peptides that displace IGFs from their BPS as potential novel treatment modalities of growth orders-basic aspects"" (Abstract presented at the Intl. Pediatric Nephrology Assn.'s 6th Symposium on Growth and Development in Children with Chronic Renal Failure held in NY on Mar. 11-13, 1999).;;Lowman, H., ""Bacteriophage display and discovery of peptide leads for drug development"" Annual Review of Biophysics and Biomolecular Structure 26:401-424 (1997).;;Lowman, H., ""Phage display of peptide libraries on protein scaffolds"" Methods in Molecular Biology, Chapter 24, 87:249-264 (1998).;;Maack et al., ""Physiological Role of Silent Receptors of Atrial Natriuretic Factor"" Science 238:675-678 (Oct. 30, 1987).;;Martin & Baxter, ""Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characterization"" Journal of Biological Chemistry 261(19):8754-8760 (1986).;;McLafferty et al., ""M13 bacteriophage displaying disulfide-constrained microproteins"" Gene 128:29-36 (1993).;;Miller et al., ""Effects of IGF-I on renal function in end-stage chronic renal failure"" Kidney International 46:201-207 (1994).;;Morrow et al., ""Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance"" Diabetes-53rd Annual Meeting, Jun. 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993).;;O'Neil et al., ""Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library"" Proteins: Structure, Function, and Genetics 14:509-515 (1992).;;O'Shea and Layish, ""Growth hormone and the kidney: a case presentation and review of the literature"" J. Am. Soc. Nephrol. 3:157-161 (1992).;;O'Shea et al., ""Effects of IGF-I on renal function in patients with chronic renal failure"" Am. J. Physiol. 264:F917-F922 (1993).;;Oh et al., ""Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs"" Endocrinology 132:1337-1344 (1993).;;Oh et al., ""Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II"" Journal of Biological Chemistry 271:30322-30325 (1996).;;Oldenburg et al., ""Peptide ligands for a sugar-binding protein isolated from a random peptide library"" Proc. Natl. Acad. Sci. 89:5393-5397 (1992).",EXPIRED
849,WO,A2,WO 2006/053299 A2,086-033-091-439-79X,2006-05-18,2006,US 2005/0041205 W,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC;;PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/086-033-091-439-79X,Patent Application,yes,6,76,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/06;;C07H21/04;;C07K14/745,,44,41,098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;050-112-382-936-584;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220,10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;16233987;;10.1016/j.cbpa.2005.10.007;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361,"THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCANDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL., 2005;;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE, S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., vol. 4, 1999, pages 269 - 275",PENDING
850,WO,A3,WO 2006/128142 A3,080-896-123-023-226,2007-03-29,2007,US 2006/0020847 W,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A 2 enzymes (cPLA 2 ), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAα). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP;;MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/080-896-123-023-226,Search Report,yes,1,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,2,1,068-228-387-549-08X,10.1517/13543776.14.7.937,"CLARK J D ET AL: ""Potential therapeutic uses of phospholipase A2 inhibitors"", EXPERT OPINION ON THERAPEUTIC PATENTS 2004 UNITED KINGDOM, vol. 14, no. 7, 2004, pages 937 - 950, XP002405708, ISSN: 1354-3776;;DATABASE REGISTRY Chemical Abstract Service, Columbus, Ohio, US; 13 October 2005 (2005-10-13), XP002405672",PENDING
851,JP,A,JP 2013067621 A,141-438-802-126-481,2013-04-18,2013,JP 2012231926 A,2012-10-19,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,PROBLEM TO BE SOLVED: To provide a biocompatible polymer-conjugated functional FVIII polypeptide having improved pharmacokinetic characteristics and therapeutic characteristics.SOLUTION: An isolated conjugate comprises a full-length factor VIII that is covalently bound at a B domain to one or more biocompatible polymers. The conjugate is formed by: mutating a nucleotide sequence that encodes for a functional factor VIII polypeptide to substitute the sequence with a coding sequence for a cysteine residue at a predefined site; expressing the mutated nucleotide sequence to produce a cysteine-enhanced mutein; purifying the mutein; and reacting the mutein with the biocompatible polymer that has been activated to react with polypeptides at substantially introduced cysteine residues only.,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/141-438-802-126-481,Patent Application,no,2,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/43;;A61K47/34;;A61K47/48;;A61P7/04;;C12N15/09,,2,0,,,JPN6013059710; Ａｃｔａ ｍｅｄｉｃａ ｅｔ ｂｉｏｌｏｇｉｃａ． １９８８， Ｖｏｌ．３６， Ｎｏ．１， ｐ．１-５;;JPN6014013664; Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ａｎｄ ｂｉｏｅｎｇｉｎｅｅｒｉｎｇ． ２００３， Ｖｏｌ．８２， Ｎｏ．２， ｐ．２００-２０６,ACTIVE
852,BR,B8,BR 122016022033 B8,127-113-924-505-241,2021-05-25,2021,BR 122016022033 A,2005-11-14,US 2005/0041205 W;;US 62727704 P;;BR PI0517795 A,2004-11-12,"conjugados de polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica","conjugado polipeptídeo isolado apresentando atividade pró-coagulante de fator viii, seu uso e composição farmacêutica. a presente invenção refere-se a muteínas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteína conservam atividade pró-coagulante de fviii e têm propriedades farmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,BAISONG MEI;;CLARK Q PAN;;DEQIAN WANG;;HENDRI TJANDRA;;JIANMIN CHEN;;JOHN E MURPHY;;JONATHAN S STRAUSS;;LIANG TANG;;THOMAS BARNETT,,https://lens.org/127-113-924-505-241,Amended Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
853,CN,A,CN 103102406 A,179-100-853-565-346,2013-05-15,2013,CN 201210455152 A,2005-11-14,US 62727704 P,2004-11-12,Continuation - site directed modification of FVIII ?,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/179-100-853-565-346,Patent Application,no,2,1,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/37;;A61K47/48;;A61P7/04;;C07K1/107,,0,0,,,,ACTIVE
854,WO,A2,WO 2006/128142 A2,003-637-006-083-757,2006-11-30,2006,US 2006/0020847 W,2006-05-26,US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2&alpha;). In some embodiments, the inhibitors have the Formula (I): wherein the constituent variables are as defined herein.",WYETH CORP;;MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/003-637-006-083-757,Patent Application,yes,0,22,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404;;C07D209/14;;A61P11/00;;A61P19/00;;A61P25/00,,36,31,128-362-223-519-855;;096-484-982-426-875;;006-389-760-792-212;;031-766-076-467-920;;067-576-826-353-21X;;124-150-239-256-308;;064-131-759-907-41X;;013-584-224-630-938;;043-220-138-399-064;;019-564-929-326-776;;012-095-611-363-936;;015-326-638-070-37X;;000-544-219-628-464;;103-122-158-249-923;;140-060-865-263-725;;001-010-429-114-293;;069-493-236-977-89X;;014-254-720-413-443;;006-520-269-590-144;;001-953-398-419-02X;;147-687-216-433-476;;008-090-551-141-559;;001-292-892-348-399;;033-296-096-749-641;;086-438-450-009-51X;;049-258-866-657-721;;053-355-331-660-00X;;013-650-979-277-426;;117-167-590-216-378;;026-314-977-913-387;;059-961-965-631-102,2655580;;10.1042/bj2590315;;pmc1138513;;3053741;;10.1080/21548331.1988.11703580;;3300655;;10.1016/0006-2952(87)90512-0;;10.1016/s0021-9258(18)83549-9;;2925608;;2925633;;10.1016/s0021-9258(18)83616-x;;2888113;;10.1073/pnas.84.18.6374;;pmc299078;;10.1021/jm051060o;;16392788;;10.1161/01.cir.87.6.1873;;8504499;;11205894;;10.1016/s0024-3205(00)00950-4;;10.1161/01.cir.0000027816.54430.96;;12208806;;11248083;;pmc30658;;10.1073/pnas.061607398;;11956125;;10.1161/01.cir.0000014927.74465.7f;;10894809;;10.1161/01.atv.20.7.1724;;10.1161/hq0302.105593;;11884288;;10.1161/01.res.85.4.311;;10455059;;9351398;;10.1161/01.atv.17.10.2257;;10.1046/j.1471-4159.1997.69030986.x;;9282920;;14001233;;10.3181/00379727-111-27849;;3244721;;10.1016/0091-3057(88)90372-3;;10.1007/bf02342223;;8951503;;10.1038/35093019;;11557989;;11165666;;10.1016/s0165-6147(00)01602-3;;10.1124/jpet.103.053819;;12954795;;10.1046/j.1365-2222.2003.01615.x;;12614451;;9067325;;8879219;;10.1084/jem.184.4.1483;;pmc2192843;;10.1159/000195777;;2557658;;1330588;;10.1016/0014-2999(92)90829-s;;10.1139/y95-028;;7621356;;3204511;;10.1152/jappl.1989.66.5.2351;;2745300,"B. SAMUELSON ET AL., SCIENCE, vol. 237, 1987, pages 1171 - 76;;W. L. SMITH, BIOCHEM. J., vol. 259, 1989, pages 315 - 324;;S. I. WASSERMAN, HOSPITAL PRACTICE, vol. 15, 1988, pages 49 - 58;;J. CHANG ET AL., BIOCHEM. PHARMACOL., vol. 36, 1987, pages 2429 - 2436;;CHANG; E. A. DENNIS ET AL., DRUG DEVEL. RES., vol. 10, 1987, pages 205 - 220;;J. J. SEILHAMER, J. BIOL. CHEM., vol. 264, 1989, pages 5335 - 5338;;R. M. KRAMER ET AL., J. BIOL. CHEM., vol. 264, 1989, pages 5768 - 5775;;A. KANDO ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 163, 1989, pages 42 - 48;;R. BURCH; J. AXELROD, PROC. NATL. ACAD. SCI. U.S.A., vol. 84, 1989, pages 6374 - 6378;;R.V. SOMU, J. MED. CHEM., vol. 49, 2006, pages 31 - 34;;RANKE ET AL., CIRCULATION, vol. 87, no. 6, 1993, pages 1873 - 1879;;PAUL ET AL., LIFE SCIENCES, vol. 68, no. 4, 2000, pages 457 - 465;;CYRUS ET AL., CIRCULATION, vol. 106, no. 10, 2002, pages 1282 - 1287;;PRATICO ET AL., PNAS, vol. 98, no. 6, 2001, pages 3358 - 3363;;BURLEIGH ET AL., CIRCULATION, vol. 105, no. 15, 2002, pages 1816 - 1823;;CAYATTE ET AL., ATVB, vol. 20, no. 7, 2000, pages 1724 - 1728;;AIELLO ET AL., ATVB, vol. 22, no. 3, 2002, pages 443 - 449;;SUBBANAGOUNDER ET AL., CIRC. RES., vol. 85, no. 4, 1999, pages 311 - 318;;SCHAFER ELINDER ET AL., ATVB, vol. 17, no. 10, 1997, pages 2257 - 2263;;PONG K. ET AL., J. NEUROCHEM., vol. 69, 1997, pages 986 - 994;;WINTER, C.A. ET AL., PROC SOC EXP BIOL MED, vol. 111, 1962, pages 544 - 547;;TRENTHAM, D.E. ET AL., J EXP. MED, vol. 146, pages 828 - 833;;STEIN C ET AL., PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR, vol. 31, 1988, pages 445 - 451;;MUKHERJEE A ET AL., INFLAMM RES., vol. 45, 1996, pages 531 - 540;;JULIUS, D. ET AL., NATURE., 2001, pages 413 - 203;;WOOLF, C.J. ET AL., SCIENCE., vol. 200, no. 288, pages 1765;;PIOMELLI D., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 22, no. 1, January 2001 (2001-01-01), pages 17 - 29;;KUMAR, R.K. ET AL., J PHARMACOL EXP THER., vol. 307, 2003, pages 349 - 355;;WU, A.Y. ET AL., CLIN EXP ALLERGY., vol. 33, 2003, pages 359 - 366;;BELL, R.L. ET AL., J PHARMACOL EXP THER, vol. 280, 1997, pages 1366 - 1373;;HENDERSON, W.R., JR. ET AL., J EXP MED., vol. 184, 1996, pages 1483 - 1494;;ABRAHAM, W.M. ET AL., RESPIRATION., vol. 56, 1989, pages 48 - 56;;ABRAHAM, W.M. ET AL., EUR J PHARMACOL, vol. 217, 1992, pages 119 - 126;;JONES, T.R ET AL., CAN J PHYSIOL PHARMACOL., vol. 73, 1995, pages 191 - 201;;ABRAHAM, W.M. ET AL., J PHARMACOL EXP THER., vol. 247, 1988, pages 1004 - 1011;;ABRAHAM, W.M., J APPL PHYSIOL., vol. 66, 1989, pages 2351 - 2357",PENDING
855,HR,B1,HR P20070268 B1,013-325-810-704-42X,2018-04-20,2018,HR P20070268 A,2007-06-08,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"Ovaj izum se odnosi na muteine faktora VIII koji su kovalentno vezani, na predodređenom mjestu koje nije N-terminalni amin, za jedan ili više biokompatibilnih polimera kao što je polietilen glikol. Mutein konjugati zadržavaju prokoagulantno djelovanje faktora VIII te imaju poboljšane farmakokinetičke značajke.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,"BAYER HEALTHCARE LLC, US (2018-06-12)",https://lens.org/013-325-810-704-42X,Granted Patent,no,5,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K17/08;;A61K38/37;;A61K47/60;;A61P7/04;;C07K14/755;;C12P21/00,,0,0,,,,ACTIVE
856,HR,A2,HR P20070268 A2,024-188-988-903-398,2007-09-30,2007,HR P20070268 A,2007-06-08,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"Ovaj izum se odnosi na muteine faktora VIII koji su kovalentno vezani, na predodređenom mjestu kojenije N-terminalni amin, za jedan ili više biokompatibilnih polimera kao što je polietilen glikol. Mutein konjugati zadržavaju prokoagulantno djelovanje faktora VIII te imaju poboljšane farmakokinetičke značajke.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,"BAYER HEALTHCARE LLC, US (2018-06-12)",https://lens.org/024-188-988-903-398,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,0,0,,,,ACTIVE
857,UA,C2,UA 95225 C2,066-709-090-583-855,2011-07-25,2011,UA A200706559 A,2005-11-14,US 62727704 P,2004-11-12,MODIFIED WITH POLYMER FACTOR VIII FOR THE TREATMENT OF HAEMOPHILIA AND PROCESS FOR THE PREPARATION THEREOF,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/066-709-090-583-855,Limited Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K47/48;;A61P7/04,,0,0,,,,EXPIRED
858,NZ,A,NZ 563736 A,082-112-373-055-524,2010-11-26,2010,NZ 56373606 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,Inhibitors of cytosolic phospholipase A2,"3-{4-[(2-{5-chloro-1-(diphenylmethyl)-2-[2-({[2-(trifluoromethyl)benzyl]sulfonyl}amino)ethyl]-1H-indol-3-yl}ethyl)sulfonyl]phenyl}propanoic acid, and a pharmaceutically acceptable salt thereof is disclosed. Also disclosed is the use of said compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating inflammation or pain caused or potentiated by prostaglandins, leukotrienes, or platelet activation factor in a mammal. This compound is particularly suitable for treating asthma, rheumatoid arthritis, osteoarthritis, juvenile arthritis, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, and central nervous system damage resulting from trauma.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/082-112-373-055-524,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,DISCONTINUED
859,AU,A1,AU 2005/304622 A1,080-579-212-494-477,2006-05-18,2006,AU 2005/304622 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;CHEN JIANMIN;;MURPHY JOHN E;;WANG DEQIAN;;STRAUSS JONATHAN S;;TANG LIANG;;BARNETT THOMAS;;TJANDRA HENDRI;;MEI BAISONG,,https://lens.org/080-579-212-494-477,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/06;;C07H21/04;;C07K14/745,,0,0,,,,ACTIVE
860,EP,B1,EP 1824988 B1,088-480-259-348-62X,2017-04-19,2017,EP 05849392 A,2005-11-14,US 2005/0041205 W;;US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,"BAYER HEALTHCARE LLC, WHIPPANY, US (2018-12-10);;BAYER HEALTHCARE LLC (2017-11-01)",https://lens.org/088-480-259-348-62X,Granted Patent,yes,4,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,3,0,,,"VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"" BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405-417, XP004227886 ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"" EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253-1261, XP008036528 ISSN: 1471-2598;;DATABASE BIOSIS [Online] 13 April 2006 SAKURAGAWA N. ET AL.: 'Studies on the Stability of Factor VIII modified by Polyethylene Glycol', XP008114276 Database accession no. (PREV198886083867) & ACTA MEDICA ET BIOLOGICA vol. 36, no. 1, 1988, pages 1 - 6",ACTIVE
861,DK,T3,DK 2371856 T3,108-158-777-302-064,2022-08-08,2022,DK 11153297 T,2005-11-14,US 62727704 P;;EP 05849392 A,2004-11-12,Site-directed modifikation af FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;WAMG DEQIAN;;TANG JIANG;;MEI BAISONG;;STRAUSS JONATHAN S,,https://lens.org/108-158-777-302-064,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/00;;C07K14/755,,0,0,,,,ACTIVE
862,US,B1,US 6750321 B1,124-119-794-389-200,2004-06-15,2004,US 72318500 A,2000-11-27,US 72318500 A;;US 33722799 A;;US 5288898 A;;US 82585297 A,1997-04-04,Insulin-like growth factor agonist molecules,"
    Peptides are provided that inhibit the interaction of an IGF with any one of its binding proteins and not to a human IGF receptor. These IGF agonist peptides are useful to increase serum and tissue levels of active IGFs in a mammal. 
",GENENTECH INC,CHEN YVONNE MAN-YEE;;CLARK ROSS G;;COCHRAN ANDREA G;;LOWMAN HENRY B;;ROBINSON IAIN C A F;;SKELTON NICOLAS J,GENENTECH INC (2002-02-12),https://lens.org/124-119-794-389-200,Granted Patent,yes,67,28,8,8,50,A61K38/30;;C07K7/08;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61P5/00;;A61K38/00;;C07K7/08;;A61K38/30;;C07K14/4743;;C07K14/65;;C07K2319/00;;Y10S930/12;;Y10S930/26;;Y10S930/27;;A61K38/00,A61K38/00;;A61K38/30;;C07K7/08;;C07K14/47;;C07K14/65,530/317;;530/328;;930/270,101,91,095-621-966-646-140;;014-125-367-031-231;;017-264-804-459-877;;026-623-017-714-89X;;053-508-442-408-581;;050-719-958-572-148;;035-756-231-423-984;;045-964-465-312-91X;;091-854-753-933-770;;009-317-840-275-65X;;044-898-403-939-670;;020-803-531-740-687;;114-552-109-070-862;;121-192-711-498-551;;122-544-263-077-018;;048-188-266-680-461;;028-244-774-323-223;;051-762-247-693-584;;027-889-828-130-366;;097-785-885-745-976;;044-885-448-085-960;;055-029-284-594-570;;044-015-018-025-600;;066-564-168-992-217;;069-485-915-823-577;;036-028-618-959-354;;014-911-901-153-035;;032-236-672-104-294;;020-582-523-460-582;;038-260-426-123-957;;146-171-107-846-251;;009-186-473-238-939;;009-069-193-386-694;;070-740-676-932-821;;093-658-600-554-037;;020-411-130-368-703;;020-510-267-061-589;;030-081-590-114-687;;026-720-717-926-994;;127-616-834-120-73X;;042-682-434-812-597;;167-040-741-674-313;;029-966-690-919-75X;;040-185-536-258-128;;105-560-205-533-971;;013-303-631-864-631;;096-718-408-234-974;;116-645-290-887-265;;010-645-653-539-638;;004-678-657-001-505;;019-984-077-132-656;;140-584-552-918-775;;035-483-585-582-64X;;116-157-636-951-170;;089-677-859-786-645;;003-137-931-754-668;;021-449-779-524-07X;;084-363-781-757-911;;000-613-056-275-938;;008-721-226-627-596;;063-088-702-691-710;;046-072-043-619-455;;078-655-932-195-328;;112-994-384-334-733;;007-717-236-970-533;;044-071-530-416-412;;016-758-022-635-876;;097-011-248-396-364;;044-051-728-567-349;;086-111-078-062-01X;;029-286-680-248-885;;007-489-225-495-51X;;045-838-528-482-83X;;147-661-590-433-69X;;015-768-700-460-036;;023-036-715-680-660;;016-796-441-670-243;;060-413-390-113-504;;025-059-951-768-239;;026-190-764-535-624;;150-639-968-778-276;;039-038-656-451-824;;076-444-264-945-863;;081-838-471-410-493;;028-701-201-701-662;;022-281-660-192-32X;;035-594-330-696-292;;070-680-873-937-056;;015-653-151-970-972;;001-736-861-875-625;;108-079-960-807-110,9111295;;10.1021/jm960753p;;7680510;;10.1016/s0083-6729(08)60444-6;;10.1210/endo-127-6-3243;;2174349;;10.1002/prot.340080405;;1708882;;2443135;;10.1016/s0006-291x(87)80136-5;;10.1016/s0021-9258(18)48458-x;;1370451;;2424282;;10.1016/s0065-2423(08)60124-9;;10.1016/0305-0491(88)90137-x;;2461835;;10.1016/s0021-9258(18)68777-0;;2966152;;2472386;;10.1016/s0021-9258(18)60418-1;;10.1016/s0021-9258(18)55447-8;;2168421;;10.1002/j.1460-2075.1989.tb08386.x;;pmc401241;;2479552;;6998350;;10.7326/0003-4819-120-7-199404010-00011;;8116999;;8374685;;10.1515/jpem.1993.6.1.21;;2315699;;10.1126/science.2315699;;7631865;;10.1152/ajpheart.1995.269.1.h326;;10.1016/s0006-291x(88)80425-x;;2454104;;10.1002/j.1460-2075.1988.tb03087.x;;2461294;;pmc457109;;10.1677/joe.0.1220661;;2681500;;10.1007/978-1-4615-2988-0_4;;7514345;;10.1021/bi00409a016;;2839228;;2536701;;10.1016/s0021-9258(18)94162-1;;3193048;;10.1677/joe.0.1190051;;8187319;;10.1111/j.1365-2265.1994.tb02492.x;;10.1007/bf00404081;;8359587;;10.1007/bf03000203;;21153160;;10.1007/bf03021409;;21153178;;10.1007/978-3-642-67986-5_5;;1379166;;10.1210/en.131.2.890;;10.1210/endo.131.2.1379166;;10.1016/s0021-9258(19)38332-2;;1695626;;10.1073/pnas.87.16.6378;;2201029;;pmc54537;;2143033;;10.1126/science.2143033;;10.1172/jci117706;;pmc295527;;7860746;;10.1210/endo.137.5.8612531;;10.1210/en.137.5.1913;;8612531;;9124404;;10.1152/ajprenal.1997.272.2.f257;;10.1159/000184148;;7959637;;10.1210/endo.135.5.7956938;;7956938;;10.1210/en.135.5.2144;;10.1016/0161-5890(86)90081-7;;2432410;;9032099;;10.2337/diabetes.46.3.433;;10.2337/diab.46.3.433;;10.1021/bi00047a006;;7492543;;2220389;;pmc287020;;10.1073/pnas.86.8.2868;;2649897;;2741635;;10.1530/acta.0.1210101;;3387445;;10.1073/pnas.85.13.4889;;pmc280542;;3299085;;10.1056/nejm198707163170303;;10.1152/ajprenal.1993.265.1.f1;;8393619;;7948775;;10.1681/asn.v511;;10.1016/s0021-9258(19)47281-5;;2553732;;10.1172/jci116480;;pmc443305;;8514857;;7593439;;10.1210/jc.80.11.3284;;10.1210/jcem.80.11.7593439;;8662901;;10.1074/jbc.271.24.13948;;10.1038/ki.1993.57;;8441234;;1668800;;10.1111/j.1432-1033.1990.tb15595.x;;2197088;;8314009;;10.2337/diab.43.3.369;;10.2337/diabetes.43.3.369;;2237405;;10.1126/science.2237405;;10.1210/er.16.1.3;;10.1210/edrv-16-1-3;;7758431;;8762727;;10.1046/j.1365-2265.1996.711531.x;;10.1016/0378-1119(93)90153-t;;8508960;;pmc330007;;8423214;;10.1172/jci116163;;1538716;;7679407;;pmc287936;;10.1172/jci116212;;8482426;;10.2337/diab.42.5.696;;10.2337/diabetes.42.5.696;;10.1074/jbc.271.34.20458;;8702785;;2407519;;10.1210/endo-126-3-1593;;10.1210/mend-2-5-404;;2458522;;10.3181/00379727-204-43630;;7690486;;10.1038/330537a0;;2825030;;1718795;;10.1016/0303-7207(91)90086-8;;7691582;;10.1210/endo.133.4.7691582;;10.1210/en.133.4.1797;;10.1210/endo-129-4-2254;;1717244;;7508949;;10.1210/jc.78.2.404;;10.1210/jcem.78.2.7508949;;1377706;;10.1210/jc.75.1.30;;10.1210/jcem.75.1.1377706;;8662530;;10.1126/science.273.5274.464;;9465113;;10.1073/pnas.95.4.1894;;pmc19209;;9636028;;10.1021/bi980426e;;10.1146/annurev.biophys.26.1.401;;9241425;;9523276;;10.1385/0-89603-392-9:249;;2823385;;10.1126/science.2823385;;3722172;;10.1016/s0021-9258(19)84446-0;;10.1016/0378-1119(93)90149-w;;8508957;;10.1038/ki.1994.260;;7933838;;1438188;;10.1002/prot.340140411;;10.1681/asn.v32157;;1391716;;8498545;;10.1152/ajprenal.1993.264.5.f917;;10.1210/en.132.3.1337;;7679979;;10.1210/endo.132.3.7679979;;8939990;;10.1074/jbc.271.48.30322;;10.1073/pnas.89.12.5393;;1608948;;pmc49298;;1706259;;10.1210/endo-128-4-1769;;10.1021/ja9611654,"Ngo et al., in The Protein Folding Problem and Tertiary Structure Prediction, Merz and Le Grand (Eds), Aug. 1994, Springer Verlag, pp. 433 and 492-495.*;;Arttamangkul et al. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the ""address"" sequence. Journal of Medicinal Chemistry, (Apr. 11, 1997) 40(8) 1211-8.*;;Alberts et al. Molecular Biology of the Cell, 3RD edition, New York: Garland Publishing, Inc. pp. 119 (1994).;;Bach and Rechler, ""Insulin-like Growth Factor Binding Proteins"" Diabetes Reviews 3:38-61 (1995).;;Ballard et al., ""Does IGF-Ever Act Through the Insulin Receptor?"" The Insulin-like Growth Factors and Their Regulatory Proteins, Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994).;;Bar et al., ""Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I"" Endocrinology 127(6):3243-3245 (1990).;;Bass et al., ""Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties"" Proteins: Structure, Function, and Genetics 8(4):309-314 (1990).;;Baxter & Martin, ""Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins"" Biochem. & Biophys. Res. Comm. 147(1):408-415 (1987).;;Baxter et al., ""Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3"" Journal of Biological Chemistry 267(1):60-65 (Jan. 5, 1992).;;Baxter, ""Physiological Roles of IGF Binding Proteins"" Modern Concepts of Insulin-like Growth Factors, Spencer, eds., Elsevier, New York pp. 371-380 (1991).;;Baxter, ""The somatomedins: insulin-like growth factors"" Advances in Clinical Chemistry 25:49-115 (1986).;;Baxter, R., ""The Insulin-Like Growth Factors and Their Binding Proteins"" Comp. Biochem. Physiol. 91B(2):229-235 (1988).;;Bayne et al., ""Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor"" Journal of Biological Chemistry 263:6233-6239 (1988).;;Bayne et al., ""The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor"" Journal of Biological Chemistry 264(19):11004-11008 (Jul. 5, 1989).;;Bayne et al., ""The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor"" Journal of Biological Chemistry 265(26):15648-15652 (Sep. 15, 1990).;;Binkert et al., ""Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)"" EMBO Journal 8:2497-2502 (1989).;;Binoux, M., ""Donnees recentes sur les somatomedines (Insulin-like growth factors)"" Annales d'Endocrinologie 41:157-192 (1980).;;Bondy, C., ""Clinical uses of insulin-like growth factor I"" Annals of Internal Medicine 120:593-601 (1994).;;Bowers, C. Y., ""GH Releasing Peptides-Structure and Kinetics"" J. Pediatr. Endocrinology 6(1):21-31 (1993).;;Bowie et al., ""Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions"" Science 247:1306-1310 (1990).;;Brandt et al., ""Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide"" American Journal of Physiology 269 (1 Pt 2): H326-H331 (Jul. 1995).;;Brewer et al., ""Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein"" Biochem. & Biophys. Res. Comm. 152(3):1289-1297 (1988).;;Brinkman et al., ""Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)"" The EMBO J. 7:2417-2423 (1988).;;Carlsson et al., ""Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions"" J. Endocrinol. 122:661-670 (1989).;;Cascieri et al., ""Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins"" Advances in Experimental Medicine & Biology 343:33-40 (1993).;;Cascieri et al., ""Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor"" Biochemistry 27(9):3229-3233 (May 3, 1988).;;Cascieri et al., ""Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors"" Journal of Biological Chemistry 264:2199-2202 (1989).;;Charlton et al., ""Growth hormone-deficient dwarfism in the rat: a new mutation"" J. of Endocrinology 119:51-58 (1988).;;Cheetham et al., ""The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus"" Clin. Endocrinol. 40:515-522 (1994).;;Cheetham et al., ""The Effects of Recombinant Insulin-like Growth Factor I Adminstration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus"" Diabetologia 36:678-681 (1993).;;Chen et al., ""Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation"" US Endocrine Meeting (Abstract 1596) pp. 449 (1993).;;Clark et al., ""Growth-Responses to Patterned GH Delivery"" Endocrine 3:717-723 (1995).;;Clark et al., ""Insulin-Like Growth Factor-1 and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats"" Endocrine 3:297-304 (1995).;;Clemmons and Van Wyk, ""Somatomedin: physiological control and effects on cell proliferation"" Handbook Exp. Pharmacol. 57:161-208 (1981).;;Clemmons et al., ""Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs"" Endocrinology 131(2):890-895 (Aug. 1992).;;Clemmons et al., ""Discrete Alterations of the Insulin-like Growth Factor I Molecular Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity"" Journal of Biological Chemistry 265(21):12210-12216 (1990).;;Cwirla et al., ""Peptides on phage: a vast library of peptides for identifying ligands"" Proc. Natl. Acad. Sci. USA 87(16):6378-6382 (1990).;;Devlin et al., ""Random peptide libraries: a source of specific protein binding molecules"" Science 249:404-406 (1990).;;Duerr et al., ""Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure"" J. Clin. Invest. 95:619-627 (1995).;;Elahi et al., ""Hemodynamic and metabolic responses to human Insulin-like growth factor I (IGF-I) in men"" Modern Concepts of Insulin-Like Growth Factors, Spencer, EM, ed., New York: Elsevier Science Publ. Co. pp. 219-224 (1991).;;Fielder et al., ""Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats"" Endocrinology 137:1913-1920 (1996).;;Franklin et al., ""Insulin-Like Growth Factor I Preserves Renal Function Postoperatively"" Am. J. Physiol. 272:F257-F259 (1997).;;Froesch et al., ""Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I"" Horm. Res. 42:66-71 (1994).;;Furnsinn et al., ""Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats"" Endocrinology 135(5):2144-2149 (1994).;;Geysen et al., ""A priori delineation of a peptide which mimics a discontinuous antigenic determinant"" Molecular Immunology 23(7):709-715 (1986).;;Ghazzi et al., ""Cardiac and glycemic benefits of troglitazone treatment in NIDDM"" Diabetes 46:433-439 (1997).;;Giebel et al., ""Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities"" Biochemistry 34:15430-15435 (1995).;;Guler et al., ""Effects of Insulin-like Growth Factor I in Man"" Acta Paediatr. Scand. 367:52-54 (Suppl. 1990).;;Guler et al., ""Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects"" Proc. Natl. Acad. Sci. USA 86:2868-2872 (Apr. 1989).;;Guler et al., ""Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man"" Acta Endocrinologica 121:101-106 (1989).;;Guler et al., ""Recombinant human insulin-like growth factor 1 stimulates growth and has distinct effects on organ size in hypophysectomized rats"" Proc. Natl. Acad. Sci. USA 85:4889-4893 (1988).;;Guler et al., ""Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults"" New England J. of Medicine 317(3):137-140 (1987).;;Hammerman and Miller, ""The growth hormone insulin-like factor axis in kidney revisited"" Am. J. Physiol. 265:F1-F14 (1993).;;Hammerman and Miller, ""Therapeutic use of growth factors in renal failure"" J. Am. Soc. Nephrol. 5:1-11 (1994).;;Hampton et al., ""Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma"" Journal of Biological Chemistry 264(32):19155-19160 (Nov. 15, 1989).;;Hartman et al., ""A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans"" J. Clin. Invest. 91:2453-2462 (1993).;;Hasegawa et al., ""The free form of insulin-like growth factor I increases in circulation during normal human pregnancy"" J. Clin. Endocrinol. Metabol. 80:3284-3286 (1995).;;Heding et al., ""Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3"" Journal of Biological Chemistry 271(24):13948-13952 (Jun. 14, 1996).;;Hirschberg et al., ""Effects of insulin-like growth factor I on renal function in normal men"" Kidney International 43:387-397 (1993).;;Hizuka et al., ""Measurement of free form of insulin-like growth factor I in human plasma"" Growth Regulation 1:51-55 (1991).;;Humbel, ""Insulin-like growth factors I and II"" European Journal of Biochemistry 190:445-462 (1990).;;Jabri et al., ""Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients"" Diabetes 43:369-374 (1994).;;Johnson et al., ""Underexpression of beta cell high Km glucose transporters in noninsulin-dependent diabetes"" Science 250:546-549 (1990).;;Jones et al., ""Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions"" Endocrine Reviews 16(1):3-34 (1995).;;Juul et al., ""Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty"" Clin. Endocrinology 44:515-523 (1996).;;Kay et al., ""An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets"" Gene 128:59-65 (1993).;;Kerr et al., ""Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia"" Diabetes: American Diabetes Association (ADA), San Antonio, Texas, Jun. 20-23, 1992 (abstract #225), 52nd Annual Meeting edition 41(supp 1):60A (Jun. 1992).;;Kerr et al., ""Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans"" J. Clin. Invest. 91:141-147 (1993).;;Kletzien et al., ""Enhancement of adipocyte differentiation by an insulin-sensitizing agent"" Molecular Pharmacology 41(2):393-398 (Feb. 1992).;;Kupfer et al., ""Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously"" J. Clin Invest. 91:391-396 (1993).;;Kuzuya et al., ""Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes"" Diabetes 42:696-705 (1993).;;Lassalle et al., ""ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines"" Journal of Biological Chemistry 271:20458-20464 (1996).;;Leahy et al., ""Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion"" Endocrinology 126(3):1593-1598 (1990).;;Lee et al., ""Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors"" Mol. Endocrinol. 2(5):404-411 (1988).;;Lee et al., ""Regulation and function of insulin-like growth factor-binding protein-1"" Proc. Soc. Exp. Biol. & Med. 204:4-29 (1993).;;Leung et al., ""Growth hormone receptor and serum binding protein: purification, cloning and expression"" Nature 330:537-543 (1987).;;Lewitt and Baxter, ""Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?"" Mol. Cell. Endocrinology 79(1-3):C147-C152 (1991).;;Lewitt et al., ""Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3"" Endocrinology 133:1797-1802 (1993).;;Lewitt et al., ""Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels"" Endocrinology 129(4):2254-2256 (1991).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia"" US Endocrine Meeting (Abstract 1664) pp. 466 (1993).;;Lieberman et al., ""Anabolic effects of recombinant insulin-like growth factor I in cachectic patients with the acquired immunodeficiency syndrome"" J. Clin. Endocrinol. and Metab. 78(2):404-410 (1994).;;Lieberman et al., ""Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans"" J. Clin. Endocrinol. and Metabl. 75(1):30-36 (1992).;;Livnah et al., ""Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A"" Science 273(5274):464-471 (Jul. 26, 1996).;;Loddick et al., ""Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke"" Proc. Natl. Acad. Sci. USA 95(4):1894-1898 (Feb. 17, 1998).;;Lowman et al., ""Molecular mimics of insulin-like growth factor 1 (IGF-I) for inhibiting IGF-I: IGF-binding protein interactions"" Biochemistry 37(25):8870-8878 (1998).;;Lowman et al., ""Peptide that displace IGFs from their BPS as potential novel treament modalities of growth orders-basic aspects"" (Abstract presented at the Intl. Pediatric Nephrology Assn.'s 6th Symposium on Growth and Development in Children with Chronic Renal Failure held in NY on Mar. 11-13, 1999).;;Lowman, H., ""Bacteriophage display and discovery of peptide leads for drug development"" Annual Review of Biophysics and Biomolecular Structure 26:401-424 (1997).;;Lowman, H., ""Phage display of peptide libraries on protein scaffolds"" Methods in Molecular Biology, Chapter 24, 87:249-264 (1998).;;Maack et al., ""Physiological Role of Silent Receptors of Atrial Natriuretic Factor"" Science 238:675-678 (Oct. 30, 1987).;;Martin & Baxter, ""Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characterization"" Journal of Biological Chemistry 261(19):8754-8760 (1986).;;McLafferty et al., ""M13 bacteriophage displaying disulfide-constrained microproteins"" Gene 128:29-36 (1993).;;Miller et al., ""Effects of IGF-I on renal function in end-stage chronic renal failure"" Kidney International 46:201-207 (1994).;;Morrow et al., ""Recombinant Human (rh) IGF-I Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance"" Diabetes-53rd Annual Meeting, Jun. 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993).;;O'Neil et al., ""Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library"" Proteins: Structure, Function, and Genetics 14:509-515 (1992).;;O'Shea and Layish, ""Growth hormone and the kidney: a case presentation and review of the literature"" J. Am. Soc. Nephrol. 3:157-161 (1992).;;O'Shea et al., ""Effects of IGF-I on renal function in patients with chronic renal failure"" Am. J. Physiol. 264:F917-F922 (1993).;;Oh et al., ""Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II IGF-I/insulin hybrid, and IGF-I analogs"" Endocrinology 132:1337-1344 (1993).;;Oh et al., ""Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II"" Journal of Biological Chemistry 271:30322-30325 (1996).;;Oldenburg et al., ""Peptide ligands for a sugar-binding protein isolated from a random peptide library"" Proc. Natl. Acad. Sci. 89:5393-5397 (1992).;;Peterkofsky et al., ""Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs"" Endocrinology 128(4):1769-1779 (1991).;;Phelan et al., ""A General Method for Constraining Short Peptides to an alpha-Helical Conformation"" J. Am. Chem. Soc. 119(3):455-460 (Jan. 22, 1997).",EXPIRED
863,US,A1,US 2006/0115876 A1,129-657-811-877-047,2006-06-01,2006,US 27389605 A,2005-11-14,US 27389605 A;;US 62727704 P,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2006-01-04),https://lens.org/129-657-811-877-047,Patent Application,yes,7,55,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/06;;C07H21/04;;C07K14/745,435/69.1;;435/320.1;;435/325;;530/383;;536/23.2,0,0,,,,ACTIVE
864,EP,A1,EP 3323829 A1,185-808-515-442-467,2018-05-23,2018,EP 17201672 A,2005-11-14,US 62727704 P;;EP 17166910 A;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/185-808-515-442-467,Patent Application,yes,4,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K38/37;;A61K47/60,,3,2,022-092-946-978-595;;029-944-973-758-653,11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"SAKURAGAWA N ET AL: ""STUDIES ON THE STABILITY OF FACTOR VIII MODIFIED BY POLYETHYLENE GLYCOL"", ACTA MEDICA BIOLO, NIIGATA DAIGAKU IGAKUBU, NIIGATA, JP, vol. 36, no. 1, 1 January 1988 (1988-01-01), pages 1 - 05, XP009011547, ISSN: 0567-7734;;VERONESE F M: ""Peptide and protein PEGylation - a review of problems and solutions"", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 22, no. 5, 1 March 2001 (2001-03-01), pages 405 - 417, XP004227886, ISSN: 0142-9612;;KOCHENDOERFER G: ""CHEMICAL AND BIOLOGICAL PROPERTIES OF POLYMER-MODIFIED PROTEINS"", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 3, no. 8, 1 January 2003 (2003-01-01), pages 1253 - 1261, XP008036528, ISSN: 1471-2598",ACTIVE
865,PE,A1,PE 20061426 A1,110-426-690-982-597,2007-01-24,2007,PE 2006000559 A,2006-05-26,US 68556405 P,2005-05-27,DERIVADOS DE INDOL COMO INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA,"REFERIDA A UN COMPUESTO DERIVADO DE INDOL DE FORMULA (I), DONDE n1 ES 1 O 2; n2 ES 1 O 2; n3 ES 1 O 2; n5 ES 0, 1 O 2; X2 ES UN ENLACE, O, CH2, SO2; R5 ES H O ALQUILO C1-C3; R6 ES H O ALQUILO C1-C6; R7 ES OH, BENCILOXI, CH3, CF3, ENTRE OTROS; R8 ES H, OH, NO2, CF3, OCF3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO 4-{2-[2-[2-({[2-(BENCILOXI)BENCIL]-SULFONIL}AMINO)ETIL]-5-CLORO-1-(DIFENIL-METIL)-1H-INDOL-3-IL]-ETOXI}BENZOICO, ACIDO 4-{2-[5-CLORO-1-(DIFENILMETIL)-2-(2-{[(2-HIDROXIBENCIL)SULFONIL]AMINO}ETIL)-1H-INDOL-3-IL]ETOXI}-BENZOICO, ACIDO 4-{2-[5--CLORO-2-(2-{[(2,6-DIBROMO-BENCIL)SULFONIL]AMINO}ETIL)-1-(DIFENILMETIL)-1H-INDOL-3-IL]-ETOXI}BENZOICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LAS FOSFOLIPASAS, PARTICULARMENTE, FOSFOLIPASA A2 CITOSOLICA (cPLA2), Y MAS PARTICULARMENTE DE LA ENZIMA FOSFOLIPASA A2 ALFA CITOSOLICA Y SON UTILES EN EL TRATAMIENTO DE LA INFLAMACION, DOLOR, ASMA, INFARTO, ENTRE OTROS",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;VARGAS RICHARD;;WILLIAMS CARA;;MARUSIC SUZANA;;PONG KEVIN;;CLERIN VALERIE;;CLARK JAMES D;;CHEN LIHREN,,https://lens.org/110-426-690-982-597,Patent Application,no,0,1,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404;;C07D209/14,,0,0,,,,ACTIVE
866,US,A1,US 2016/0051633 A1,118-569-336-038-447,2016-02-25,2016,US 201514803677 A,2015-07-20,US 201514803677 A;;US 201313748983 A;;US 54070309 A;;US 27389605 A;;US 62727704 P,2004-11-12,METHODS OF TREATING HEMOPHILIA IN PATIENTS HAVING DEVELOPED INHIBITORY ANTIBODIES,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/118-569-336-038-447,Patent Application,yes,0,2,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K47/48,,1,0,,,Antibody-and-Antigen (last viewed on 5-9-2017).,DISCONTINUED
867,CN,B,CN 102040550 B,134-713-534-727-108,2012-10-03,2012,CN 201010535530 A,2006-05-26,US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"The present invention relates to inhibitors of cytosolic phospholipase A2. Concretely, the invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2alpha). In some embodiments, the inhibitors have the Formula (I): whereinthe constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;LIHREN CHEN;;RICHARD VARGAS;;CLARK JAMES D;;CARA WILLIAMS;;VALERIE CLERIN;;SUZANA MARUSIC;;KEVIN PONG,,https://lens.org/134-713-534-727-108,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/4045;;A61P7/02;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00,,0,0,,,,ACTIVE
868,SV,A,SV 2008002551 A,135-225-653-805-002,2008-07-23,2008,SV 2006002551 A,2006-05-26,US 68556405 P,2005-05-27,INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA REF.: WYTH0122-503/AM101816(187007),"LA INVENCIÓN PROVEE INHIBIDORES QUÍMICOS DE LA ACTIVIDAD DE DIVERSAS ENZIMAS FOSFOLIPASA, PARTICULARMENTE DE LAS ENZIMAS FOSFOLIPASA A2 CITOSÓLICA (CPLA2), MÁS PARTICULARMENTE INCLUYENDO INHIBIDORES DE LAS ENZIMAS FOSFOLIPASA A2 ALFA CITOSÓLICA (CPLA2 BETA). EN ALGUNAS MODALIDADES, LOS INHIBIDORES POSEEN LA FORMULA I: (VER FORMULA); DONDE LAS VARIABLES CONSTITUYENTES SON COMO SE HAN DEFINIDO AQUÍ: (VER FORMULA); DONDE LAS VARIABLES CONSTITUYENTES SON COMO SE HAN DEFINIDO AQUÍ",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/135-225-653-805-002,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61P3/00;;C07D263/22,,0,0,,,,PENDING
869,BR,B1,BR PI0517795 B1,136-253-721-395-821,2020-03-31,2020,BR PI0517795 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,"conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica","modificação sítio-dirigida de fviii. esta invenção se refere a muteinas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteina conservam atividade pró-coagulante de eviii e têm propriedades fa rmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,BAISONG MEI;;CLARK Q PAN;;DEQIAN WANG;;HENDRI TJANDRA;;JIANMIN CHEN;;JOHN E MURPHY;;JONATHAN S STRAUSS;;LIANG TANG;;THOMAS BARNETT,,https://lens.org/136-253-721-395-821,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
870,CA,A1,CA 2607857 A1,181-229-162-305-798,2006-11-30,2006,CA 2607857 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,CLERIN VALERIE;;WILLIAMS CARA;;MARUSIC SUZANA;;MCKEW JOHN C;;PONG KEVIN;;CHEN LIHREN;;LEE KATHERINE L;;VARGAS RICHARD;;CLARK JAMES D,,https://lens.org/181-229-162-305-798,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
871,DE,D1,DE 602006018451 D1,032-759-451-915-82X,2011-01-05,2011,DE 602006018451 T,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,HEMMER DER ZYTOSOLEN PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/032-759-451-915-82X,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
872,GT,A,GT 200600228 A,082-320-079-239-839,2006-12-26,2006,GT 200600228 A,2006-05-25,US 68556405 P,2005-05-27,INHIBIDORES DE LA FOSFOLIPASA A2 CITOSOLICA,"LA INVENCIÓN PROVEE INHIBIDORES QUÍMICOS DE LA ACTIVIDAD DE DIVERSAS ENZIMAS FOSFOLIPASAS, PARTICULARMENTE DE LAS ENZIMAS FOSFOLIPASAS A2, CITOSÓLICA (CPLA2), MÁS PARTICULARMENTE INCLUYENDO INHIBIDORES DE LAS ENZIMAS FOSFOLIPASAS A2, ALFA CITOSÓLICA (CPLA2ALFA). EN ALGUNAS MODALIDADES, LOS INHIBIDORES POSEEN LA FÓRMULA I. T2006",,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/082-320-079-239-839,Amended Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/30;;A61P29/00;;C07D209/18,,0,0,,,,PENDING
873,AU,B2,AU 2012/203813 B2,082-214-018-394-107,2013-10-24,2013,AU 2012/203813 A,2012-06-28,AU 2005/304622 A;;AU 2012/203813 A,2005-11-14,Site-directed modification of FVIII,"C:\NRPortb\DCCKXC\4427591 - DOC.2(16/21112 This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;CHEN JIANMIN;;MURPHY JOHN E;;BARNETT THOMAS;;MEI BAISONG;;TANG LIANG;;STRAUSS JONATHAN S;;WANG DEQIAN;;TJANDRA HENDRI,,https://lens.org/082-214-018-394-107,Granted Patent,no,3,0,2,2,0,,C07K14/755;;C07H21/04;;C12P21/06,,2,0,,,"Sakuragawa, N. et al., ""Studies On The Stability Of Factor VIII Modified By Polyethylene Glycol"", Acta Medica et Biologica, 1998, 36 (1), 1-5;;Genbank Accession No. AAA52484, 8 November 1994",ACTIVE
874,CN,A,CN 102040550 A,111-811-647-206-186,2011-05-04,2011,CN 201010535530 A,2006-05-26,US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"The present invention relates to inhibitors of cytosolic phospholipase A2. Concretely, the invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2alpha). In some embodiments, the inhibitors have the Formula (I): wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;LIHREN CHEN;;RICHARD VARGAS;;CLARK JAMES D;;CARA WILLIAMS;;VALERIE CLERIN;;SUZANA MARUSIC;;KEVIN PONG,,https://lens.org/111-811-647-206-186,Patent Application,no,0,1,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/4045;;A61P7/02;;A61P9/10;;A61P11/06;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00,,0,0,,,,ACTIVE
875,KR,A,KR 20140091618 A,094-916-069-196-954,2014-07-21,2014,KR 20147018134 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/094-916-069-196-954,Patent Application,no,0,0,135,135,70,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61P7/04;;A61K38/37;;C07K14/755;;C07K17/08,,1,1,019-730-797-612-199,10821655;;10.1021/bc990137i,"Bioconjug Chem. 2000 May-Jun,11(3):387-96.",ACTIVE
876,BR,A8,BR PI0517795 A8,139-761-358-188-544,2018-12-26,2018,BR PI0517795 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,modificação sítio-dirigida de fviii,"modificação sítio-dirigida de fviii. esta invenção se refere a muteinas de fator viii que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de n-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. os conjugados de muteina conservam atividade pró-coagulante de eviii e têm propriedades fa rmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,BAISONG MEI;;CLARK Q PAN;;DEQIAN WANG;;HENDRI TJANDRA;;JIANMIN CHEN;;JOHN E MURPHY;;JONATHAN S STRAUSS;;LIANG TANG;;THOMAS BARNETT,,https://lens.org/139-761-358-188-544,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00;;C12P21/00,,0,0,,,,ACTIVE
877,EP,B1,EP 1891006 B1,145-115-513-487-386,2010-11-24,2010,EP 06771540 A,2006-05-26,US 2006/0020847 W;;US 68556405 P,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,"ZIARCO PHARMA LIMITED; GB (2023-11-21);;NOVARTIS AG, CH (2024-01-10)",https://lens.org/145-115-513-487-386,Granted Patent,yes,1,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,2,0,,,"CLARK J D ET AL: ""Potential therapeutic uses of phospholipase A2 inhibitors"" EXPERT OPINION ON THERAPEUTIC PATENTS 2004 UNITED KINGDOM, vol. 14, no. 7, 2004, pages 937-950, XP002405708 ISSN: 1354-3776;;DATABASE REGISTRY Chemical Abstract Service, Columbus, Ohio, US; RN 865200-20-0 13 October 2005 (2005-10-13), XP002405672",ACTIVE
878,SI,T1,SI 1891006 T1,047-462-111-696-496,2011-02-28,2011,SI 200630865 T,2006-05-26,US 68556405 P;;US 2006/0020847 W;;EP 06771540 A,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH LLC,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LIHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/047-462-111-696-496,Granted Patent,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/00;;A61K31/403;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,ACTIVE
879,US,B2,US 11166099 B2,060-913-801-179-147,2021-11-02,2021,US 202017019778 A,2020-09-14,US 202017019778 A;;US 201962923391 P;;US 201962907315 P,2019-09-27,Headphone acoustic noise cancellation and speaker protection or dynamic user experience processing,A method for audio signal processing of microphone signals of a headphone. An audio signal from a first microphone of a headphone is filtered by an ANC system to produce a first filtered signal. Dynamic range control is performed upon the first filtered signal to produce a first dynamic range adjusted signal that drives a speaker of the headphone. Other aspects are also described and claimed.,APPLE INC,SAUX TOM-DAVY W;;CLARK BRIAN D;;CHEN HANCHI;;CHIU VICTORIA;;BAJIC VLADAN;;MASSIE DANA;;BRIGHT ANDREW P;;JENSEN THOMAS M,APPLE INC (2020-08-04),https://lens.org/060-913-801-179-147,Granted Patent,yes,24,0,2,4,0,G10K11/17833;;G10K11/17881;;G10K2210/1081;;G10K2210/3039;;G10K2210/3056;;G10L21/0224;;H04R1/1083;;H04R3/04;;H04R1/1016;;H04R1/1016;;H04R1/406;;H04R3/005;;H04R3/005;;H04R3/007;;H04R5/033;;H04R5/04;;H04R29/004,H04R3/04;;G10L21/0224;;H04R1/10;;H04R3/00;;H04R5/033;;H04R5/04;;H04R29/00,,4,0,,,"“Bose QuietComfort Earbuds”, Retrieved from the Internet <https://www.bose.com/en_us/products/headphones/earbuds/quietcomfort-earbuds.html#v=qc_earbuds_black, Sep. 10, 2020, 15 pages.;;Bristow-Johnson, Robert, “Cookbook formulae for audio equalizer biquad filter coefficients”, Retrieved from the Internet <https://www.w3.org/2011/audio/audio-eq-cookbook.html>, May 29, 2020, 7 pages.;;Notice of Allowance for U.S. Appl. No. 17/023,340 dated Aug. 19, 2021, 8 pages.;;Non-Final Office Action for U.S. Appl. No. 17/023,314 dated Sep. 16, 2021, 26 pages.",ACTIVE
880,KR,A,KR 20080021618 A,073-441-667-790-402,2008-03-07,2008,KR 20077027672 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLAE). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein. ® KIPO & WIPO 2008",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/073-441-667-790-402,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,A61K31/404;;A61P29/00;;C07D209/18,,0,0,,,,ACTIVE
881,AU,A1,AU 2020/256332 A1,092-345-656-473-785,2020-11-12,2020,AU 2020/256332 A,2020-10-13,AU 2020/256332 A;;AU 2018/267653 A;;AU 2016/203693 A;;AU 2013/203348 A;;AU 2012/203813 A,2012-06-28,Site-directed modification of FVIII,"This invention relates to Factor Vill muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/092-345-656-473-785,Patent Application,no,0,0,4,6,0,,C07K14/755;;C07H21/04;;C12P21/06,,0,0,,,,DISCONTINUED
882,NO,A1,NO 20200044 A1,117-678-553-532-624,2007-06-27,2007,NO 20200044 A,2020-01-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,Setedirigert modifikasjon av FVIII,,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/117-678-553-532-624,Unknown,no,1,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08,,1,0,,,"D2: SAKURAGAWA NOBUO ET AL., ""Studies on the stability of factor VIII modified by polyethylene glycol"", Acta Medica et Biologica, vol. 36, nr. 1, 1988, side 1-5 , Dated: 01.01.0001",ACTIVE
883,BR,A2,BR PI0610049 A2,136-309-179-317-988,2010-05-25,2010,BR PI0610049 A,2006-05-26,US 68556405 P;;US 2006/0020847 W,2005-05-27,inibidores de fosfolipase a2 citosólica,"INIBIDORES DE FOSFOLIPASE A~ 2~ CITOSóLICA. A presente invenção provê inibidores químicos da atividade de várias enzimas fosfolipase, particularmente enzimas fosfolipase A~ 2~ citosólica (CPLA~ 2~), mais particularmente incluindo inibidores de enzimas fosfolipase A~ 2~ alfa citosólica (cPLA<244>). Em algumas modalidades, os inibidores têm a fórmula I; em que as variáveis constituintes são como aqui definidas",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LILHREN;;VARGAS RICHARD;;CLARK JAMES D;;CLERIN VALERIE;;WILLIAMS CARA;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/136-309-179-317-988,Patent Application,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/404;;A61P11/00;;A61P19/00;;A61P25/00,,0,0,,,,DISCONTINUED
884,US,B2,US 7632921 B2,127-393-606-824-967,2009-12-15,2009,US 27389605 A,2005-11-14,US 27389605 A;;US 62727704 P,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at one or more predefined sites that are not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity, are capable of correcting human factor VIII deficiencies and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,BAYER HEALTHCARE LLC (2006-01-04),https://lens.org/127-393-606-824-967,Granted Patent,yes,51,59,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/04,530/383;;435/70.1,42,40,019-730-797-612-199;;055-003-061-629-507;;007-822-064-014-928;;044-737-094-103-978;;110-266-842-977-819;;048-391-899-819-148;;054-090-919-783-575;;050-914-567-218-321;;014-404-528-569-22X;;021-691-529-972-457;;023-461-551-285-468;;064-356-470-690-00X;;082-011-579-838-812;;167-656-547-020-741;;057-935-502-781-436;;073-064-348-159-030;;036-303-431-596-016;;061-013-622-187-304;;049-936-640-346-832;;007-068-453-274-860;;010-356-395-170-813;;036-657-079-582-704;;038-992-740-792-079;;083-448-995-704-379;;010-347-158-675-450;;040-121-810-358-365;;032-960-531-047-473;;056-927-333-742-99X;;071-881-515-349-948;;092-185-025-573-894;;076-459-195-524-871;;031-219-178-479-524;;095-248-606-612-120;;105-215-317-030-407;;050-112-382-936-584;;118-803-283-877-249;;019-730-797-612-199;;066-146-798-965-262;;022-092-946-978-595;;029-944-973-758-653,10821655;;10.1021/bc990137i;;10.1073/pnas.0403255101;;pmc438954;;15197260;;10.1128/mcb.8.3.1247-1252.1988;;10.1128/mcb.8.3.1247;;pmc363269;;3285178;;10.1006/bbrc.1998.8301;;9514953;;10.1074/jbc.274.53.37685;;10608826;;10.1016/s0021-9258(18)31537-0;;1902833;;10.1074/jbc.m212053200;;12522143;;10.1182/blood.v96.3.958;;10910910;;10.1182/blood.v95.2.564;;10627463;;8626729;;10.1074/jbc.271.8.3982;;10446132;;10.1074/jbc.274.34.23734;;8567641;;10.1074/jbc.271.4.1935;;9374501;;10.1074/jbc.272.48.30191;;10.1074/jbc.m104732200;;11698391;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1074/jbc.m008046200;;11278379;;15073030;;10.1182/blood-2003-11-3891;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1074/jbc.m400568200;;14764590;;10.1073/pnas.85.8.2429;;pmc280010;;3128786;;7540171;;10.1074/jbc.270.24.14505;;10.1073/pnas.82.22.7728;;2415970;;pmc391407;;7613471;;10.1002/pro.5560040413;;pmc2143093;;10.1016/s0021-9258(17)32024-0;;8051150;;10.1074/jbc.m409389200;;15471879;;11830468;;10.1182/blood.v99.4.1215;;10.1111/j.1365-2516.2004.01005.x;;15479386;;10.1046/j.1365-2516.2003.00769.x;;12694514;;15840700;;10.1182/blood-2004-11-4230;;11510630;;10.2165/00003088-200140070-00005;;12787631;;10.1016/s0378-5173(03)00227-8;;16233987;;10.1016/j.cbpa.2005.10.007;;10.1055/s-0038-1648520;;1509407;;10821655;;10.1021/bc990137i;;1366535;;10.1038/nbt0490-343;;11214751;;10.1016/s0142-9612(00)00193-9;;14640951;;10.1517/14712598.3.8.1253;;10.1517/eobt.3.8.1253.21285,"Rostin et al. (2000) Bioconjugate Chem, vol. 11, 387-396.;;Guo et al., Protein tolerance to random amino acid change, (2004) Proc. Natl. Acad. Sci. USA 101: 9205-9210.;;Lazar et al., Trnasforming Growth Factor alpha: Mutation of aspartic Acid 47 and Leucine 48 Results in Different Biological Activities, (1988) Mol. Cell. Biol. 8:1247-1252.;;Hill et al., Functional Analysis of Conserved Histidines in ADP-Glucose Pyrophosphorylase from Escherichia coli, (1998) Biochem. Biophys. Res. Comm. 244:573-577.;;Sakuragawa, N. et al. Studies on the Stability of Factor VIII Modified by Polyethylene Glycol. Acta Medica et Biologica, 36(1), pp. 1-6 (1988). (Abstract only).;;Saenko, E., et al., ""Role of the Low Density Lipoprotein-Related Protein Receptor in Mediation of Factor VIII Catabolism"", The Journal of Biological Chemistry, vol. 274, No. 53, 1999, pp. 37685-37692.;;Fay, P. J., et al., ""Human Factor VIIIa Subunit Structure"", The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8957-8962.;;Bovenschen, N., et al., ""Low Density Lipoprotein Receptor-Related Protein and Factor IXa Share Structural Requirements for Binding to the A3 Domain of Coagulation Factor VIII"", The Journal of Biological Chemistry, vol. 278, No. 11, 2003, pp. 9370-9377.;;Jacquemin, M., et al., ""A Novel Cause of Mild/Moderate Hemophilia A: Mutations Scattered in the Factor VIII C1 Domain Reduce Factor VIII Binding to von Willebrand Factor"", Blood, vol. 96, No. 3, 2000, pp. 958-965.;;Barrow, R., et al., ""Reduction of the Antigenicity of Factor VIII Toward Complex Inhibitory Antibody Plasmas Using Multiply-Substituted Hybrid Human/Porcine Factor VIII Molecules"", Blood, vol. 95, No. 2, 2000, pp. 564-568.;;Regan, L., et al., ""Activated Protein C-Catalyzed Proteolysis of Factor Villa Alters Its Interactions Within Factor Xase"", The Journal of Biological Chemistry, vol. 271, No. 8, 1996, pp. 3982-3987.;;Lenting, P., et al., ""The Light Chain of Factor VIII Comprises a Binding Site for Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 274, No. 34, 1999, pp. 23734-23739.;;Lenting, P. , et al., ""The Sequence Glu1811-Lys1818 of Human Blood Coagulation Factor VIII Comprises a Binding Site for Activated Factor IX"", The Journal of Biological Chemistry, vol. 271, No. 4, 1996, pp. 1935-1940.;;Lubin, I., et al., ""Analysis of the Human Factor VIII A2 Inhibitor Epitope by Alanine Scanning Mutagenesis"", The Journal of Biological Chemistry, vol. 272, No. 48, 1997, pp. 30191-30195.;;Gilbert, G., et al., ""Four Hydrophobic Amino Acids of the Factor VIII C2 Domain Are Constituents of Both the Membrane-Binding and von Willebrand Factor-Binding Motifs"", The Journal of Biological Chemistry, vol. 277, No. 8, 2002, pp. 6374-6381.;;Scandella, D., et al., ""Localization of Epitopes for Human Factor VIII Inhibitor Antitodies by Immunoblotting and Antibody Neutralization"", Blood, vol. 74, No. 5, 1989, pp. 1618-1626.;;Foster, P., et al., ""An Immunogenic Region within Residues Val1670-Glu1684 of the Factor VIII Light Chain Induces Antibodies Which Inhibit Binding of Factor VIII to von Willebrand Factor"", The Journal of Biological Chemistry, vol. 263, No. 11, 1988, pp. 5230-5234.;;Lubin, I., et al., ""Elimination of a Major Inhibitor Epitope in Factor VIII"", The Journal of Biological Chemistry, vol. 269, No. 12, 1994, pp. 8639-8641.;;Scandella, D., et al., ""A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2"", Blood, vol. 82, No. 6, 1993, pp. 1767-1775.;;Sarafanov, A., ""Cell Surface Heparan Sulfate Proteoglycans Participate in Factor VIII Catabolism Mediated by Low Density Lipoprotein Receptor-Related Protein"", The Journal of Biological Chemistry, vol. 276, No. 15, 2001, pp. 11970-11979.;;Parker, E., et al., ""Reduction of the Inhibitory Antibody Response to Human Factor VIII in Hemophilia A Mice by Mutagenesis of the A2 Domain B-Cell Epitope"", Blood, vol. 104, No. 3, 2004, pp. 704-710.;;Scandella, D., et al., ""Epitope Mapping of Human Factor VIII Inhibitor Antibodies by Deletion Analysis of Factor VIII Fragments Expressed in Escherichia coli"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 6152-6156.;;Nogami, K., et al., ""Identification of a Factor Xa-Interactive Site Within Residues 337-372 of the Factor VIII Heavy Chain"", The Journal of Biological Chemistry, vol. 279, No. 16, 2004, pp. 15763-15771.;;Pittman, D., et al., ""Proteolytic Requirements for Thrombin Activation of Anti-Hemophilic Factor (Factor VIII)"", Proc. Natl. Acad. Sci. USA, vol. 85, 1988, pp. 2429-2433.;;Healy, J., et al., ""Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII"", The Journal of Biological Chemistry, vol. 270, No. 24, 1995, pp. 14505-14509.;;Fulcher, C., et al., ""Localization of Human Factor FVIII Inhibitor Epitopes to Two Polypeptide Fragments"", Proc. Natl. Acad. Sci. USA, vol. 82, 1985, pp. 7728-7732.;;McMullen, B., et al., ""Locations of Disulfide Bonds and Free Cysteines in the Heavy and Light Chains of Recombinant Human Factor VIII (Antihemophilic Factor A)"", Protein Science, vol. 4, 1995, pp. 740-746.;;Fay, P. , et al., ""Factor VIIIa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site"", The Journal of Biological Chemistry, vol. 269, No. 32, 1994, pp. 20522-20527.;;Spiegel. P. C., et al., ""Surface-Exposed Hemophilic Mutations Across the Factor VIII C2 Domain Have Variable Effects on Stability and Binding Activities"", The Journal of Biological Chemistry, vol. 279, No. 51. 2004, pp. 56391-56398.;;Stoilova-McPhie, S., et al., ""3-Dimensional Structure of Membrane-Bound Coagulation Factor VII: Modeling of the Factor VIII Heterodimer Within a 3-Dimensional Density Map Derived by Electron Crystallography"", Blood, vol. 99, No. 4, 2002, pp. 1215-1223.;;Oldenburg, J. et al., ""Molecular basis of haemophilia A"", Haemophilia, vol. 10, No. 4, 2004, pp. 133-139.;;Gruppo, R.A. et al. ""Comparative effectiveeness of full-length and B-domain deleted factor VIII for prophytaxis-a meta analysis"", Haemophilia, vol. 4 2003, pp. 251-260.;;Boynschen, N. et al. ""LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo"", Blood, vol. 106, No. 3, 2005, pp. 906-912.;;Harris, J., et al., ""Pegylation A Novel Process for Modifying Pharmacokinetics"", Clin Pharmacokinet, vol. 40, No. 7, 2001, pp. 539-551.;;Wang, W. et al., ""Coagulation factor VIII: structure and stability"", International Journal of Pharaceutics, vol. 259, 2003, pp. 1-15.;;Kochendoerfer, G., ""Site-specific polymer modification of therapeutic proteins"", Current Opinion in Chemical Biology, vol. 9, 2005, pp. 555-560.;;Scandella, D., et al., ""A Soluble Recombinant Factor VIII Fragment Containing the A2 Domain Binds to Some Human Anti-Factor VIII Antibodies that Are not Detected by Immunoblotting"", Thrombosis and Haemostasis, vol. 67, No. 6, 1992, pp. 665-671.;;Rostin, J., et al., ""B-Domain Deleted Recombinant Coagulation Factor VIII Modified with Monomethoxy Polyethylene Glycol"", Bioconjugate Chem., vol. 11, 2000, pp. 387-396.;;Goodson, R., et al., ""Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site"", Bio/Technology, vol. 8, 1900, pp. 343-346.;;Veronese, F. M., ""Peptide and Protein PEGylation-a Review of Problems and Solutions"", Biomaterials, Elsevier Science Publishers BV, Barking, GB (2001), No. 5, vol. 22, p. 405-417.;;Kochendoerfer, G., ""Chemical and Biological Properties of Polymer-Modified Proteins"", Expert Opinion on Biological Therapy, (2003), vol. 3, No. 8, pp. 1253-1261.;;Extended European Search Report (including suppl. European Search Report and the European search opinion) for EP App. 05849392.5 dated Dec. 1, 2008 (5 pages).",ACTIVE
885,NO,B1,NO 345800 B1,139-227-575-963-586,2021-08-09,2021,NO 20200044 A,2020-01-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,"Isolert konjugat omfattende full-lengde faktor VIII kovalent festet ved B-domenet til en eller flere biokompatible polymerer, farmasøytisk sammensetning og anvendelse for behandling av hemofili.",,BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/139-227-575-963-586,Granted Patent,no,1,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K47/60;;A61K38/37;;A61P7/00;;A61P7/04;;A61P31/02;;C07K14/00;;C07K14/745;;C07K14/755;;C07K17/08;;C07K19/00,,1,0,,,"D2: SAKURAGAWA NOBUO ET AL., ""Studies on the stability of factor VIII modified by polyethylene glycol"", Acta Medica et Biologica, vol. 36, nr. 1, 1988, side 1-5 , Dated: 01.01.0001",ACTIVE
886,CN,A,CN 105753968 A,163-532-714-333-666,2016-07-13,2016,CN 201610201090 A,2005-11-14,US 62727704 P,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JLANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/163-532-714-333-666,Patent Application,no,5,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/37;;A61K47/48;;A61P7/04,,1,0,,,"NOGAMI,K. 等: ""coagulation factor VIII isoform a precursor; procoagulant component; coagulation factor VIIIc; Factor VIII F8B [Homo sapiens]"", 《GENBANK DATABASE》",PENDING
887,CA,C,CA 2586379 C,195-937-809-308-435,2012-04-03,2012,CA 2586379 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,SITE-DIRECTED MODIFICATION OF FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/195-937-809-308-435,Granted Patent,no,0,0,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,0,0,,,,ACTIVE
888,EP,A2,EP 2363414 A2,198-111-967-487-887,2011-09-07,2011,EP 11153300 A,2005-11-14,US 62727704 P;;EP 05849392 A;;US 2005/0041205 W,2004-11-12,Site-directed modification of FVIII,"This invention relates to Factor VIII muteins that are covalently bound, at a predefined site that is not an N-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain FVIII procoagulant activity and have improved pharmacokinetic properties.
 
",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;BARNETT THOMAS;;TANG LIANG;;WAMG DEQIAN,BAYER HEALTHCARE LLC (2022-04-27),https://lens.org/198-111-967-487-887,Patent Application,yes,7,3,135,135,35,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C07K14/755;;A61K38/00;;A61K47/48;;C07K17/08,,44,40,098-019-938-261-435;;061-189-356-139-957;;014-900-809-767-452;;028-454-885-541-982;;061-013-622-187-304;;010-356-395-170-813;;057-935-502-781-436;;036-303-431-596-016;;118-803-283-877-249;;083-448-995-704-379;;014-404-528-569-22X;;082-011-579-838-812;;007-068-453-274-860;;092-185-025-573-894;;031-219-178-479-524;;049-936-640-346-832;;110-266-842-977-819;;054-090-919-783-575;;023-461-551-285-468;;073-064-348-159-030;;050-914-567-218-321;;056-927-333-742-99X;;167-656-547-020-741;;032-960-531-047-473;;064-356-470-690-00X;;036-657-079-582-704;;021-691-529-972-457;;048-391-899-819-148;;095-248-606-612-120;;023-871-188-490-96X;;006-217-492-680-01X;;105-215-317-030-407;;017-912-258-241-514;;054-090-919-783-575;;040-121-810-358-365;;071-881-515-349-948;;076-459-195-524-871;;071-881-515-349-948;;118-803-283-877-249;;092-480-703-645-220,10.1016/s0021-9258(18)68793-9;;3129422;;10.1073/pnas.83.9.2979;;pmc323430;;3085106;;10.1016/s0037-1963(04)00017-4;;15071785;;11886458;;10.1046/j.1365-2516.2002.00579.x;;10.1182/blood.v82.6.1767.1767;;7691236;;10.1073/pnas.85.16.6152;;2457907;;pmc281923;;10.1182/blood.v74.5.1618.1618;;2477082;;10.1016/s0021-9258(17)37014-x;;7510693;;10.1055/s-0038-1648520;;1509407;;7540171;;10.1074/jbc.270.24.14505;;10.1182/blood.v95.2.564;;10627463;;9374501;;10.1074/jbc.272.48.30191;;15073030;;10.1182/blood-2003-11-3891;;10.1111/j.1365-2516.2004.01005.x;;15479386;;15840700;;10.1182/blood-2004-11-4230;;10.1074/jbc.m008046200;;11278379;;10.1074/jbc.274.53.37685;;10608826;;10.1074/jbc.m212053200;;12522143;;10446132;;10.1074/jbc.274.34.23734;;10.1016/s0021-9258(18)60704-5;;2895765;;10.1182/blood.v96.3.958;;10910910;;10.1074/jbc.m409389200;;15471879;;10.1074/jbc.m104732200;;11698391;;10.1016/s0021-9258(17)32024-0;;8051150;;8567641;;10.1074/jbc.271.4.1935;;10.1074/jbc.m400568200;;14764590;;8626729;;10.1074/jbc.271.8.3982;;10.1016/s0021-9258(18)31537-0;;1902833;;11510630;;10.2165/00003088-200140070-00005;;11520253;;10.2165/00063030-200115070-00001;;10.1021/bi000617t;;10978146;;12787631;;10.1016/s0378-5173(03)00227-8;;10.1111/j.1432-1033.1995.tb20776.x;;7556150;;10.1074/jbc.m212053200;;12522143;;7613471;;10.1002/pro.5560040413;;pmc2143093;;11830468;;10.1182/blood.v99.4.1215;;10.1046/j.1365-2516.2003.00769.x;;12694514;;11830468;;10.1182/blood.v99.4.1215;;10.1055/s-0038-1648520;;1509407;;10231888;;10.1081/pdt-100101361,"THOMPSON, SEMIN. HEMATOL., vol. 29, 2003, pages 11 - 22;;KAUFMAN ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 6352;;ANDERSSON ET AL., PROC. NATL. ACAD. SCI., vol. 83, 1986, pages 2979;;EWENSTEIN ET AL., SEMIN. HEMATOL., vol. 41, 2004, pages 1 - 16;;SAENKO ET AL., HAEMOPHILIA, vol. 8, 2002, pages 1 - 11;;FULCHER, C. ET AL., PROC. NATL. ACAD. SCI., vol. 2, no. 22, 1985, pages 7728 - 32;;SCANDELLA, D. ET AL., BLOOD, vol. 82, no. 6, 1993, pages 1767 - 75;;SCANDELLA, D. ET AL., PROC. NATL. ACAD. SCI., vol. 85, no. 16, 1988, pages 6152 - 6;;SCANDELLA, D. ET AL., BLOOD, vol. 74, no. 5, 1989, pages 1618 - 26;;LUBIN, I. ET AL., J. BIOL. CHEM., vol. 269, no. 12, 1994, pages 8639 - 41;;SCANDELLA, D. ET AL., THROMB HAEMOST., vol. 67, no. 6, 1992, pages 665 - 71;;HEALEY, J. ET AL., J. BIOL. CHEM., vol. 270, no. 24, 1995, pages 14505 - 9;;BARROW, R. ET AL., BLOOD, vol. 95, no. 2, 2000, pages 564 - 8;;LUBIN, I., J. BIOL. CHEM., vol. 272, no. 48, pages 30191 - 5;;PARKER, E. ET AL., BLOOD, vol. 104, no. 3, 2004, pages 704 - 10;;OLDENBURG ET AL., HAEMOPHILIA, vol. 10, no. 4, 2004, pages 133 - 139;;BOVENSCHEN ET AL., BLOOD, vol. 106, 2005, pages 906 - 910;;SARAFANOV ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 11970 - 11979;;SAENKO ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 37685 - 37692;;BOVENSCHEN ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 9370 - 9377;;LENTING ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 23734 - 23739;;FOSTER ET AL., J. BIOL. CHEM., vol. 263, 1988, pages 5230 - 5234;;JACQUEMIN ET AL., BLOOD, vol. 96, 2000, pages 958 - 965;;SPIEGEL, P. ET AL., J. BIOL. CHEM., vol. 279, no. 51, 2004, pages 53691 - 8;;PITTMAN ET AL., PROC. NATL. ACAD. SCI., vol. 276, 2001, pages 12434 - 12439;;GILBERT ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6374 - 6381;;FAY ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 20522 - 20527;;LENTING ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 1935 - 1940;;NOGAMI ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 15763 - 15771;;REGAN ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 3982 - 3987;;FAY ET AL., J. BIOL. CHEM., vol. 266, 1991, pages 8957 - 8962;;HARRIS ET AL., CLINICAL PHARMACOKINETICS, vol. 40, 2001, pages 539 - 51;;KOZLOWSKI ET AL., BIODRUGS, vol. 15, 2001, pages 419 - 429;;WANG ET AL., BIOCHEMISTRY, vol. 39, 2000, pages 10634 - 10640;;KOCHENDOERFER, G., CURR. OPIN. CHEM. BIOL. 2005, 15 October 2005 (2005-10-15);;WANG ET AL., INTERNATIONAL J. PHARMACEUTICS, vol. 259, 2003, pages 1 - 15;;LIND, P. ET AL., EUR. J. BIOCHEM., vol. 232, 1995, pages 19 - 27;;BOVENSCHEN N. ET AL., J. BIOL. CHEM., vol. 278, no. 11, 2003, pages 9370 - 7;;MCMULLEN ET AL., PROTEIN SCI., vol. 4, 1995, pages 740 - 746;;STOLIOVA-MCPHIE ET AL., BLOOD, vol. 99, 2002, pages 1215 - 1223;;GRUPPO ET AL., HAEMOPHILIA, vol. 9, 2003, pages 251 - 260;;STOILOVA-MCPHIE, S. ET AL., BLOOD, vol. 99, no. 4, 2002, pages 1215 - 23;;SCANDELLA ET AL., THROMB. HAEMOST., vol. 67, 1992, pages 665 - 71;;LEE ET AL., PHARM DEV TECHNOL., 1999, pages 269 - 275",ACTIVE
889,BR,A,BR PI0517795 A,195-565-233-054-860,2008-10-21,2008,BR PI0517795 A,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,modificação sìtio-dirigida de fviii,"MODIFICAçãO SìTIO-DIRIGIDA DE FVIII. Esta invenção se refere a muteinas de Fator VIII que são ligadas de modo covalente, em um sítio predefinido que não é uma amina de N-terminal, a um ou mais polímeros biocompatíveis tais como polietileno glicol. Os conjugados de muteina conservam atividade pró-coagulante de EVIII e têm propriedades fa rmacocinéticas aperfeiçoadas.",BAYER HEALTHCARE LLC,PAN CLARK Q;;MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JLANMIN;;BARNETT THOMAS;;TANG LIANG;;WANG DEQIAN,,https://lens.org/195-565-233-054-860,Patent Application,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,C12P21/00;;A61K35/14;;A61K35/16;;A61K38/00;;C07K1/00,,0,0,,,,ACTIVE
890,WO,A1,WO 2003/026666 A1,197-192-884-808-922,2003-04-03,2003,US 0230984 W,2002-09-26,US 32511001 P,2001-09-26,"2-PHENYLAMINO-4- (5-PYRAZOLYLAMINO)-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS, IN PARTICULAR, AS SRC KINASE INHIBITORS","The invention provides novel substituted 2,4-diaminopyrimidine compounds (I), in which L is a linker selected from: -O-(CH2)1-4- ; s(O)0-2-(CH2)1-4- ; -N(R1)-(CH2)1-4-(CH2)1-4-O-(CH2)1-4- ; -N(R1)-C(O)-(CH¿2?)1-4- ; (I) and (I) G represents: Alternatively, L may represent (I) or (I), and in this event, G represents (I) and pharmaceutical compositions thereof. The invention also provides methods of use of the novel substituted 2,4-diaminopyrimidine compounds and pharmaceutical compositions thereof as inhibitors of src kinase enzymes. Exemplary diseases that can be treated by the compounds of the invention include cell proliferative diseases, such as cancer and non-malignant cell proliferative diseases, osteoporosis and inflammatory diseases. Also provided are methods for preparing the compounds of the present invention.",BAYER AG;;DIXON JULIE;;DUMAS JACQUES;;BRENNAN CATHERINE;;HATOUM-MOKDAD HOLIA;;LEE WENDY;;SIBLEY ROBERT;;BEAR BRIAN;;CHANDLER BRENT;;MIRANDA KARL;;CHEN GANG;;CHEN ZHI;;BRITTELLI DAVID;;CLARK ROGER B,DIXON JULIE;;DUMAS JACQUES;;BRENNAN CATHERINE;;HATOUM-MOKDAD HOLIA;;LEE WENDY;;SIBLEY ROBERT;;BEAR BRIAN;;CHANDLER BRENT;;MIRANDA KARL;;CHEN GANG;;CHEN ZHI;;BRITTELLI DAVID;;CLARK ROGER B,,https://lens.org/197-192-884-808-922,Patent Application,yes,6,0,3,3,0,A61P35/00;;C07D231/12;;C07D233/56;;C07D249/08;;C07D401/14;;C07D403/12;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14,A61P35/00;;C07D401/14;;C07D403/12;;C07D403/14;;C07D405/14;;C07D409/14;;C07D413/14;;C07D417/14;;C07D521/00,,0,0,,,,PENDING
891,KR,A,KR 20230043044 A,034-582-574-919-101,2023-03-30,2023,KR 20220105482 A,2022-08-23,US 202117448689 A,2021-09-23,METHODS AND APPARATUS FOR DIGITAL TWIN AIDED RESILIENCY,"디지털 트윈 보조 회복성을 위한 방법들, 장치들, 시스템들, 및 제조 물품들이 개시된다. 예시적인 방법은 하나 이상의 물리적 엔티티에 대응하는 운영 통계에 액세스하는 단계 - 하나 이상의 물리적 엔티티는 사용자 장비 및 네트워크 장비를 포함함 - ; 운영 통계로 하나 이상의 물리적 엔티티에 각각 대응하는 가상 환경 내의 하나 이상의 가상 엔티티를 업데이트하는 단계; 운영 통계에 기초하여 가상 환경에 대한 변경을 시뮬레이션하는 단계; 시뮬레이션된 변경에 기초하여 네트워크 장비가 태스크를 수행하기 위한 추천을 생성하는 단계; 및 추천의 신뢰성이 임계 신뢰성을 충족시킨다고 결정하는 것에 응답하여, 추천을 네트워크 장비에 제공하는 단계를 포함한다.",INTEL CORP,MERWADAY ARVIND;;SIVANESAN KATHIRAVETPILLAI;;JHA SATISH;;SHARMA BANJADE VESH RAJ;;SEHRA SUMAN;;ALAM S M IFTEKHARUL;;GOMES BALTAR LEONARDO;;CHEN KUILIN CLARK,,https://lens.org/034-582-574-919-101,Patent Application,no,0,0,3,3,0,H04W16/22;;H04W76/15;;G06N3/08;;G06N3/063;;H04B7/0695;;H04W24/04;;H04W36/08;;H04W16/22;;H04W76/15;;H04W76/19;;H04W24/10;;H04W36/08;;H04W36/24;;H04W24/04;;G06N5/04;;H04W76/15;;H04W76/19;;H04W36/165,H04W16/22;;H04W24/10;;H04W36/08;;H04W36/24;;H04W76/15;;H04W76/19,,0,0,,,,PENDING
892,AU,A1,AU 2013/363398 A1,090-920-105-694-00X,2015-07-23,2015,AU 2013/363398 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC. (2020-09-24)",https://lens.org/090-920-105-694-00X,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
893,EP,B1,EP 2935228 B1,115-148-581-166-78X,2017-08-02,2017,EP 13863783 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC.; US (2022-10-19);;TEMPEST THERAPEUTICS, US (2022-06-27);;TEMPEST THERAPEUTICS, INC. (N.D.GES.D.STAATES , US (2023-03-10);;TEMPEST THERAPEUTICS, INC. (2023-03-17)",https://lens.org/115-148-581-166-78X,Granted Patent,yes,6,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
894,CA,A1,CA 3214756 A1,164-780-967-658-505,2022-10-13,2022,CA 3214756 A,2022-04-07,US 202163172617 P;;US 2022/0023861 W,2021-04-08,ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN,"Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.",CHDI FOUNDATION INC,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/164-780-967-658-505,Patent Application,no,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,C07D401/14,,0,0,,,,PENDING
895,US,A1,US 2022/0014946 A1,060-644-386-334-089,2022-01-13,2022,US 202117448689 A,2021-09-23,US 202117448689 A,2021-09-23,METHODS AND APPARATUS FOR DIGITAL TWIN AIDED RESILIENCY,"Methods, apparatus, systems, and articles of manufacture for digital twin aided resiliency are disclosed. An example method includes accessing operational statistics corresponding to one or more physical entities, the one or more physical entities including user equipment and network equipment; updating one or more virtual entities within a virtual environment that correspond, respectively, to the one or more physical entities with the operational statistics; simulating a change to the virtual environment based on the operational statistics; generating a recommendation for the network equipment to perform a task based on the simulated change; and in response to determining a confidence of the recommendation meets a threshold confidence, provide the recommendation to the network equipment.",INTEL CORP,MERWADAY ARVIND;;SIVANESAN KATHIRAVETPILLAI;;JHA SATISH;;SHARMA BANJADE VESH RAJ;;SEHRA SUMAN;;ALAM S M IFTEKHARUL;;GOMES BALTAR LEONARDO;;CHEN KUILIN CLARK,INTEL CORPORATION (2021-09-22),https://lens.org/060-644-386-334-089,Patent Application,yes,0,5,3,3,0,H04W16/22;;H04W76/15;;G06N3/08;;G06N3/063;;H04B7/0695;;H04W24/04;;H04W36/08;;H04W16/22;;H04W76/15;;H04W76/19;;H04W24/10;;H04W36/08;;H04W36/24;;H04W24/04;;G06N5/04;;H04W76/15;;H04W76/19;;H04W36/165,H04W24/04;;G06N5/04;;H04W36/16;;H04W76/15;;H04W76/19,,0,0,,,,PENDING
896,US,B2,US 11252567 B2,074-253-985-230-150,2022-02-15,2022,US 201816230971 A,2018-12-21,US 201816230971 A,2018-12-21,Methods and apparatus for detecting attacks in V2X networks,"Methods, apparatus, systems, and articles of manufacture are disclosed to detect attacks in V2X networks. An example apparatus includes a challenge handler to (a) transmit a first challenge packet to a first vehicle to request a transmission of a first response, (b) instruct a second challenge packet to be transmitted to a second vehicle to request a transmission of a second response, (c) increment a first counter when the first response is not obtained, (d) increment a second counter when the second response is not obtained, and (e) after repeating (a)-(d), determine that the first and second vehicles are phantom vehicles associated with an attacker with a half-duplex radio when at least one of the first or second counters satisfy a threshold, and a network interface to instruct a third vehicle associated with the V2X network to ignore future messages from the phantom vehicles based on the determination.",INTEL CORP,YANG LIUYANG LILY;;CHOUDHURY DEBABANI;;SHARMA SRIDHAR;;SIVANESAN KATHIRAVETPILLAI;;GOTTSCHLICH JUSTIN;;ZHANG ZHENG;;YONA YAIR;;LIU XIRUO;;AMBROSIN MORENO;;CHEN KUILIN CLARK,INTEL CORPORATION (2018-01-02),https://lens.org/074-253-985-230-150,Granted Patent,yes,16,2,4,4,0,H04L9/3271;;H04W4/40;;H04W4/80;;H04W12/122;;H04W12/12;;H04W4/40;;H04W12/06;;H04L9/3271;;H04W12/122,H04W12/12;;H04L9/32;;H04W4/40;;H04W12/06;;H04W12/122,,5,4,162-782-575-071-349;;017-668-647-489-677;;082-931-521-179-879;;119-329-382-992-112,10.1145/1409944.1409959;;10.1109/cjece.2007.364330;;10.1145/1161289.1161297;;10.1109/cns.2014.6997522,"Brik et al., “Wireless Device Identification with Radiometric Signatures,” MobiCom '08, Sep. 14-19, 2008. Retrieved from the Internet on Jun. 27, 2019, <URL: http://www.winlab.rutgers.edu/˜gruteser/papers/brik_paradis.pdf> (13 pages).;;Ureten et al., “Wireless Security through RF Fingerprinting,” Canadian Journal of Electrical Engineering, vol. 32, No. 1, 2007 (7 pages).;;Li et al., “Securing Wireless Systems via Lower Layer Enforcements,” WiSe '06, Sep. 29, 2006 (10 pages).;;Mathur et al., “Exploiting the Physical Layer for Enhanced Security,” IEEE Wireless Communications, Oct. 2010 (8 pages).;;Rehman et al., “Radio Frequency Fingerprinting and its Challenges,” IEEE CNS 2014 (2 pages).",ACTIVE
897,ES,T3,ES 2660249 T3,111-085-897-812-361,2018-03-21,2018,ES 13863783 T,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,Compuestos de tipo triazolona y sus usos,"Un compuesto de fórmula I**Fórmula** o una sal farmacéuticamente aceptable de este donde: A1 es un anillo fenilo o un anillo heteroaromático de 6 miembros que tiene 1, 2 o 3 N en el anillo heteroaromático; A2 se selecciona entre A2a o A2b**Fórmula** donde A2a es un anillo fenilo o un anillo heteroaromático de 6 miembros que tiene 1, 2 o 3 N en el anillo heteroaromático, y A2b es un anillo heteroaromático de 5 miembros que tiene 1, 2 o 3 heteroátomos seleccionados de manera independiente entre O, S y N; X se selecciona a partir del grupo constituido por -(CH2)2-, -(CH2)3-, -(CH2)4-, y -(CH2)m-O-(CH2)n-, mono- o disustituido de manera opcional con halógeno, donde m y n son de manera independiente 0, 1, 2, 3 o 4, siempre que m+n sea 2, 3 o 4; Y es O; R1 y R2 se seleccionan cada uno de manera independiente a partir del grupo constituido por: (a) hidrógeno, (b) halógeno, (c) CN, (d) CF3, (e) -alquilo C1-6, (f) -(alquilo C1-6)-C(>=O)OH, (g) -O-(R7), (h) -S(>=O)oR7, (i) -N(R7)(R8), (j) -N(R7)-C(>=O)-(R8), (k) -N(R7)-C(>=O)-O-(R8), (l) -N(R7)S(>=O)2(R8), (m) -(cicloalquilo C3-6), (n) -C(>=O)(R7), (o) arilo, (p) heteroarilo, (q) -OC(>=O)N(R7)(R8), (r) -S(>=O)2N(R7)(R8), (s) -C(>=O)N(R7)(R8) y (t) -C(R7)(R8)OH, donde la porción alquilo de las opciones (e) y (f), y la porción cicloalquilo de la opción (m) están sustituidas de manera opcional con halógeno, y donde el arilo de la opción (o) y el heteroarilo de la opción (p) están mono- o disustituidos de manera opcional con sustituyentes seleccionados entre halógeno, nitro, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, cicloalquilo C3-6, cicloalcoxi C3-6, -NH(alquilo C1-6), -NH(cicloalquilo C3-6), -N(alquilo C1-6)2, -N(cicloalquilo C3-6)2, -S(>=O)o(alquilo C1-6), - S(>=O)o(cicloalquilo C3-6) y CN; R3 se selecciona a partir del grupo constituido por: (a) hidrógeno, (b) halógeno, (c) CN, (d) CF3, (e) -alquilo C1-6, (f) -(alquilo C1-6)-C(>=O)OH, (g) -O-(R7), (h) -S(>=O)oR7 (i) -N(R7)(R8), (j) -N(R7)-C(>=O)-(R8), (k) -N(R7)-C(>=O)-O-(R8), (l) -N(R7)S(>=O)2(R8), (m) -(cicloalquilo C3-6), (n) -C(>=O)(R7), (o) arilo, (p) heteroarilo, (q) -OC(>=O)N(R7)(R8), (r) -S(>=O)2N(R7)(R8), (s) -C(>=O)N(R7)(R8), (t) -C(R7)(R8)OH, (u) -NHC(>=O)-N(R7)(R8), (v) -(cicloalquil C3-6)-COOH, (w) heterociclo y (x) -(alquil C1-6)C(>=O)-N(R7)(R8), donde la porción alquilo de las opciones (e), (f) y (x), y la porción cicloalquilo de las opciones (m) y (v) están sustituidas de manera opcional con halógeno o hidroxilo, y",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/111-085-897-812-361,Granted Patent,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
898,US,A1,US 2020/0138790 A1,168-425-303-231-401,2020-05-07,2020,US 201916722773 A,2019-12-20,US 201916722773 A;;US 201715590766 A;;US 201514654225 A;;US 2013/0074197 W;;US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",TEMPEST THERAPEUTICS INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,INCEPTION SCIENCES INC (2014-01-06);;TEMPEST THERAPEUTICS INC (2014-01-30),https://lens.org/168-425-303-231-401,Patent Application,yes,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;A61K31/4439;;A61K31/506;;C07D249/12;;C07D401/06;;C07D401/10;;C07D403/06;;C07D403/10,,1,1,045-878-114-197-621,10.2174/092986711798347243;;22172067,"Nevin, D.K., ""Rational targeting of peroxisome proliferating activated receptor subtypes."" Current medicinal chemistry 18.36 (2011): 5598-5623.",ACTIVE
899,MX,A,MX 2015007433 A,026-670-672-210-761,2015-12-07,2015,MX 2015007433 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF.,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER;;STOCK NICHOLAS SIMON;;JACINTHO JASON DUARTE,ALCON INC. (2022-04-13),https://lens.org/026-670-672-210-761,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
900,EA,B9,EA 027986 B9,123-558-267-668-88X,2018-01-31,2018,EA 201590909 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The present invention disclosed herein is directed to compounds of Formula Iand pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/123-558-267-668-88X,Amended Patent,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
901,EA,B1,EA 027986 B1,123-005-963-309-67X,2017-09-29,2017,EA 201590909 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The present invention disclosed herein is directed to compounds of Formula Iand pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/123-005-963-309-67X,Granted Patent,no,4,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
902,WO,A1,WO 2014/099503 A1,128-135-154-193-969,2014-06-26,2014,US 2013/0074197 W,2013-12-10,US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/128-135-154-193-969,Patent Application,yes,5,4,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,23,13,066-381-130-805-736;;085-942-045-626-422;;021-226-204-429-540;;052-997-668-168-924;;021-137-110-683-500;;019-231-006-288-884;;011-376-698-117-168;;063-901-802-479-900;;123-451-751-800-555;;118-413-674-329-713;;048-913-421-594-66X;;002-629-807-147-902;;013-129-766-729-356,20038799;;10.1172/jci38942;;pmc2799198;;10.1621/nrs.08002;;20414453;;pmc2858266;;22037646;;pmc4157349;;10.1038/nm.2492;;10.1038/sj.pcan.4500879;;16683009;;pmc3191041;;10.1074/jbc.m110.184697;;21757690;;19208810;;pmc2651311;;10.1073/pnas.0802864106;;21576264;;pmc3093120;;10.1101/gad.1987211;;10.1038/415813a;;11845213;;pmc1221919;;11389700;;10.1042/0264-6021:3560899;;pmc2712082;;10.1038/nature07016;;18469801;;10.1172/jci62129;;22886304;;pmc3433768;;10.1016/j.chembiol.2005.10.006;;16426968;;4957125,"WANG ET AL.: ""Small mitochondrial-targeting molecules as anti-cancer agents"", MOL. ASPECTS MED., vol. 31, no. 1, February 2010 (2010-02-01), pages 75 - 92, XP026941757, DOI: doi:10.1016/j.mam.2009.12.003;;SAMUDIO ET AL., J. CLIN. INVEST., vol. 120, 2010, pages 142 - 156;;PYPER ET AL., NUCL. RECEPT. SIGNAL., vol. 8, 2010, pages E002;;LINHER-MELVILLE ET AL., BMC, vol. 4, no. 11, 2011, pages 56;;NIEMAN ET AL., NAT MED., vol. 17, no. 11, 30 October 2011 (2011-10-30), pages 1498 - 503;;LIU, PROSTATE CANCER PROSTATIC DIS., vol. 9, no. 3, 2006, pages 230 - 4;;HOLLA ET AL., JCB, vol. 286, no. 34, 2011, pages 30003 - 30009;;KHASAWNEH ET AL., PNAS, vol. 106, no. 9, 2009, pages 3354 - 3359;;ZAUGG ET AL., GENES AND DEVELOPMENT, vol. 25, 2011, pages 1041 - 1051;;XU ET AL., NATURE, vol. 415, 2002, pages 813 - 817;;KEHRER ET AL., BIOCHEM. J., vol. 356, 2001, pages 899 - 906;;NATURE, vol. 453, no. 7198, 19 June 2008 (2008-06-19), pages 1072 - 1078;;NATURE MEDICINE;;J. CLIN. INVEST., vol. 122, no. 9, 2012, pages 3088 - 3100;;RAKIC ET AL., CHEM. & BIOL., vol. 13, January 2006 (2006-01-01), pages 23 - 30;;CAPEAU ET AL., PPAR RESEARCH, vol. 2009, pages 2;;""Remington's Pharmaceutical Sciences"", 1985, MACK PUBLISHING COMPANY, pages: 1418;;JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2;;""Pharmaceutical Salts: Properties, Selection, and Use A Handbook"", 2002, VERLAG HELVETICA CHIMICA ACTA;;FREIREICH ET AL., CANCER CHEMOTHER. REP., vol. 50, 1966, pages 219;;""Scientific Tables, Geigy Pharmaceuticals"", 1970, ARDSLEY, pages: 537;;BRADEN, T. M. ET AL., ORG. PROCESS RES. DEV., vol. 11, 2007, pages 431 - 440;;See also references of EP 2935228A4",PENDING
903,HK,A1,HK 1212680 A1,151-211-979-271-007,2016-06-17,2016,HK 16100494 A,2016-01-18,US 2013/0074197 W;;US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU -;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/151-211-979-271-007,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D/;;A61K/;;A61P/,,0,0,,,,PENDING
904,EP,A2,EP 2571999 A2,181-685-159-267-208,2013-03-27,2013,EP 11722037 A,2011-05-19,US 34704910 P;;EP 2011058102 W,2010-05-21,SYSTEM AND METHOD FOR TAILORING NUCLEOTIDE CONCENTRATION TO ENZYMATIC EFFICIENCIES IN DNA SEQUENCING TECHNOLOGIES,,ROCHE DIAGNOSTICS GMBH;;HOFFMANN LA ROCHE,BRUNELLE JULIE MARIE;;CAPRIO AMANDA DE ASIS;;CHEN YI-JU;;CLARK SHAUNA MARY;;GOMES XAVIER V;;MAKHIJANI VINOD;;WONG CHIU TAI ANDREW,,https://lens.org/181-685-159-267-208,Patent Application,yes,0,0,7,7,0,C12Q1/6869;;C12Q1/6869,C12Q1/68,,1,0,,,See references of WO 2011144682A2,DISCONTINUED
905,CA,A1,CA 2894281 A1,055-354-019-883-581,2014-06-26,2014,CA 2894281 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/055-354-019-883-581,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
906,CA,A1,CA 2796309 A1,088-895-173-991-862,2011-11-24,2011,CA 2796309 A,2011-05-19,US 34704910 P;;EP 2011058102 W,2010-05-21,SYSTEM AND METHOD FOR TAILORING NUCLEOTIDE CONCENTRATION TO ENZYMATIC EFFICIENCIES IN DNA SEQUENCING TECHNOLOGIES,"An embodiment of a method for optimizing sequencing performance is described that comprises the steps of calculating a nucleotide species specific degradation rate of an apyrase enzyme for a plurality of nucleotide species; determining a concentration for each of the nucleotide species using the nucleotide species specific degradation rate; iteratively providing the concentration of each of the nucleotide species in a reaction environment comprising a polymerase enzyme and a species of template nucleic acid molecule, wherein one or more molecules of the nucleotide species are incorporated into a nascent molecule in a sequencing reaction and the apyrase enzyme is introduced to the reaction environment to degrade unincorporated nucleotide species molecules; and detecting a signal in response to the incorporation of the nucleotide species.",HOFFMANN LA ROCHE;;ROCHE DIAGNOSTICS GMBH,BRUNELLE JULIE MARIE;;CAPRIO AMANDA DE ASIS;;CHEN YI-JU;;CLARK SHAUNA MARY;;GOMES XAVIER V;;MAKHIJANI VINOD;;WONG CHIU TAI ANDREW,,https://lens.org/088-895-173-991-862,Patent Application,no,0,0,7,7,0,C12Q1/6869;;C12Q1/6869,C12Q1/68,,0,0,,,,DISCONTINUED
907,WO,A1,WO 2022/216947 A1,118-809-448-961-658,2022-10-13,2022,US 2022/0023861 W,2022-04-07,US 202163172617 P,2021-04-08,ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN,"Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.",CHDI FOUNDATION INC,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/118-809-448-961-658,Patent Application,yes,2,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,C07D401/14;;A61P25/00,,16,9,003-567-080-482-309;;053-165-937-011-306;;046-927-273-365-367;;073-732-789-484-526;;043-480-107-380-257;;050-247-819-044-289;;000-392-592-353-198;;011-081-798-244-318;;003-567-080-482-309,32662649;;10.1021/acs.jmedchem.0c00955;;10.1016/0165-6147(84)90534-0;;18988199;;10.1002/anie.200800222;;pmc4306521;;10.1021/bc500475e;;25473848;;10.1002/anie.201805501;;30054961;;pmc6405341;;10.1002/0470053488;;10.1016/s0092-8674(00)80514-0;;9267034;;23651455;;10.3410/f.718019201.793478478;;10.1021/jm400312y;;32662649;;10.1021/acs.jmedchem.0c00955,"LIU LONGBIN ET AL: ""Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 15, 14 July 2020 (2020-07-14), US, pages 8608 - 8633, XP055848455, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c00955;;FOSTER: ""Deuterium Isotope Effects in Studies of Drug Metabolism"", TRENDS PHARMACOL. SCI., vol. 5, no. 12, 1984, pages 524 - 527, XP025943358, DOI: 10.1016/0165-6147(84)90534-0;;T. HIGUCHIV. STELLA: ""Design of Prodrugs"", vol. 14, 1985, ELSEVIER, article ""Pro-drugs as Novel Delivery Systems"";;""Bioreversible Carriers in Drug Design"", 1987, PERGAMON PRESS;;MILLER ET AL., ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 47, 2008, pages 8998 - 9033;;JACOBSON, O. ET AL., BIOCONJUGATE CHEM., vol. 26, 2015, pages 1 - 18;;DENG, X. ET AL., ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 58, no. 9, 2019, pages 2580 - 2605;;GENNARO, A. R.: ""Remington's Pharmaceutical Sciences"", 15 December 2000, LIPPINCOTT WILLIAMS & WILKINS;;WUTS, P. G. M.GREENE, T. W.GREENE, T. W.: ""Hoboken, N.J."", 2006, WILEY-INTERSCIENCE, article ""Greene's protective groups in organic synthesis"";;FIESER: ""Fieser's Reagents for Organic Synthesis"", vol. 1, 1991, JOHN WILEY, AND SONS;;""Larock's Comprehensive Organic Transformations"", vol. 1, 1989, ELSEVIER SCIENCE PUBLISHERS;;""March's Advanced Organic Chemistry"", 2001, JOHN WILEY, AND SONS;;SCHERZINGER ET AL., CELL, vol. 90, 8 August 1997 (1997-08-08), pages 549 - 558;;WAXMAN A.D. ET AL., SOCIETY OF NUCLEAR MEDICINE PROCEDURE GUIDELINE FOR FDG PET BRAIN IMAGING, 8 February 2009 (2009-02-08);;ZHANG ET AL.: ""Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand"", J MED CHEM, vol. 56, no. 11, 2013, pages 4568 - 79, XP055123423, DOI: 10.1021/jm400312y;;LIU ET AL.: ""Imaging Mutant Huntingtin Aggregates: Development of a Potential PET Ligand"", J MED CHEM, vol. 63, no. 15, 2020, pages 8608 - 8633, XP055848455, DOI: 10.1021/acs.jmedchem.0c00955",PENDING
908,PE,A1,PE 20151521 A1,029-592-167-121-07X,2015-11-25,2015,PE 2015001031 A,2013-12-10,US 201261739906 P,2012-12-20,COMPUESTOS DE TRIAZOLONA Y USOS DE LOS MISMOS,"SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOLONA DE FORMULA I Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, CARACTERIZADOS PORQUE A1 ES FENILO O UN ANILLO HETEROAROMATICO DE 6 MIEMBROS CONTENIENDO 1, 2 o 3 ATOMOS DE N; A2 ES A2a O A2b, DONDE A2a ES FENILO O UN ANILLO HETEROAROMATICO DE 6 MIEMBROS CONTENIENDO 1, 2 o 3 ATOMOS DE N; Y A2b ES UN ANILLO HETEROAROMATICO DE 5 MIEMBROS CONTENIENDO 1, 2 o 3 HETEROATOMOS SELECCIONADOS INDEPENDIENTEMENTE ENTRE O, S y N; X ES -(CH2)m-, -(CH2)m-O-(CH2)n-, -(CH2)m-NH-(CH2)n-, -(CH2)m-S(O)2-(CH2)n-, ENTRE OTROS, DONDE m Y n SON INDEPENDIENTEMENTE 0, 1, 2, 3 o 4; Y ES O u S; R1 Y R2 SON INDEPENDIENTEMENTE H, HALOGENO, CN, CF3, ALQUILO C1-6, OH, SO2H, NH2, NHC(O)OH, NHS(O)2H, CICLOALQUILO C3-6, SO2NH2, CONH2, ENTRE OTROS; R5 ES H, ALQUILO C1-6, ARILO, HETEROARILO, CICLOALQUILO C3-6, ENTRE OTROS; Y R6 ES H, ALQUILO C1-6, ALQUILARILO C1-6, ALQUILHETEROARILO C1-6, ENTRE OTROS. LOS COMPUESTOS DE FORMULA I SON ANTAGONISTAS DE PPAR-ALFA Y POR TANTO, UTILES EN EL TRATAMIENTO DE CANCERES DE PROSTATA, MAMA, COLON, PANCREAS, LEUCEMIA LINFOCITICA HUMANA CRONICA, MELANOMA, ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN UN COMPUESTO DE FORMULA I O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES. LOS PRODUCTOS DE LA INVENCION TAMBIEN SON UTILES EN EL TRATAMIENTO DE INFECCIONES VIRALES, TALES COMO INFECCIONES POR VHC O VIH",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/029-592-167-121-07X,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,DISCONTINUED
909,WO,A2,WO 2011/144682 A2,084-461-509-958-836,2011-11-24,2011,EP 2011058102 W,2011-05-19,US 34704910 P,2010-05-21,SYSTEM AND METHOD FOR TAILORING NUCLEOTIDE CONCENTRATION TO ENZYMATIC EFFICIENCIES IN DNA SEQUENCING TECHNOLOGIES,"An embodiment of a method for optimizing sequencing performance is described that comprises the steps of calculating a nucleotide species specific degradation rate of an apyrase enzyme for a plurality of nucleotide species; determining a concentration for each of the nucleotide species using the nucleotide species specific degradation rate; iteratively providing the concentration of each of the nucleotide species in a reaction environment comprising a polymerase enzyme and a species of template nucleic acid molecule, wherein one or more molecules of the nucleotide species are incorporated into a nascent molecule in a sequencing reaction and the apyrase enzyme is introduced to the reaction environment to degrade unincorporated nucleotide species molecules; and detecting a signal in response to the incorporation of the nucleotide species.",ROCHE DIAGNOSTICS GMBH;;HOFFMANN LA ROCHE,BRUNELLE JULIE MARIE;;CAPRIO AMANDA DE ASIS;;CHEN YI-JU;;CLARK SHAUNA MARY;;GOMES XAVIER V;;MAKHIJANI VINOD;;WONG CHIU TAI ANDREW,,https://lens.org/084-461-509-958-836,Patent Application,yes,28,0,7,7,0,C12Q1/6869;;C12Q1/6869,,,3,3,045-492-909-706-539;;058-835-243-495-555;;033-268-481-657-382,10.1101/gr.150601;;10.1101/gr.11.1.3;;11156611;;pmc307455;;8524672;;10.1093/nar/23.22.4742;;10.1021/bi00897a032;;14229685,"RONAGHI, M.: ""Pyrosequencing sheds light on DNA sequencing"", GENOME RES., vol. 11, 2001, pages 3 - 11, XP000980886, DOI: doi:10.1101/gr.11.1.3;;DEANGELIS, MARGARET M. ET AL.: ""Solid-Phase Reversible Immobilization for the Isolation of PCR Products"", NUCLEIC ACIDS RES, vol. 23, no. 22, 1995, pages 4742 - 4743, XP001153688;;MERRIFIELD, BIOCHEMISTRY, vol. 3, 1964, pages 1385 - 1390",PENDING
910,EP,A1,EP 2935228 A1,149-883-454-464-885,2015-10-28,2015,EP 13863783 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC.; US (2022-10-19);;TEMPEST THERAPEUTICS, US (2022-06-27);;TEMPEST THERAPEUTICS, INC. (N.D.GES.D.STAATES , US (2023-03-10);;TEMPEST THERAPEUTICS, INC. (2023-03-17)",https://lens.org/149-883-454-464-885,Patent Application,yes,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
911,AU,B2,AU 2013/363398 B2,162-443-619-534-258,2017-06-01,2017,AU 2013/363398 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",TEMPEST THERAPEUTICS INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC. (2020-09-24)",https://lens.org/162-443-619-534-258,Granted Patent,no,2,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
912,AU,A1,AU 2022/253897 A1,175-503-760-210-168,2023-10-19,2023,AU 2022/253897 A,2022-04-07,US 202163172617 P;;US 2022/0023861 W,2021-04-08,ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN,"Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.",CHDI FOUNDATION INC,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/175-503-760-210-168,Patent Application,no,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,C07D401/14;;A61P25/00,,0,0,,,,PENDING
913,BR,A2,BR 112015013350 A2,197-528-975-353-229,2017-07-11,2017,BR 112015013350 A,2013-12-10,US 2013/0074197 W;;US 201261739906 P,2012-12-20,compostos de triazolona e usos dos mesmos,"compostos de triazolona e usos dos mesmos resumo a invenção divulgada aqui é direcionada a compostos da fórmula i i e sais farmaceuticamente aceitáveis dos mesmos, que são úteis no tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção compreende ainda composições farmacêuticas que compreendem uma quantidade terapeuticamente eficiente de composto da fórmula i ou um sal farmaceuticamente aceitável do mesmo. a invenção divulgada aqui também se direciona a processos de tratamento de câncer de próstata, mama, ovariano, fígado, rim, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção divulgada aqui é adicionalmente direcionada a processos de tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica, melanoma e outros cânceres que compreendem a administração de uma quantidade terapeuticamente eficiente de um antagonista de ppar? seletivo. os compostos e as composições farmacêuticas da invenção também são úteis no tratamento de infecções virais, tais como infecções com hcv e infecções com hiv. 1/1",INCEPTION 2 INC,AUSTIN CHIH-YU CHEN;;BRIAN ANDREW STEARNS;;JASON DUARTE JACINTHO;;JILL MELISSA BACCEI;;NICHOLAS SIMON STOCK;;RYAN CHRISTOPHER CLARK;;YALDA MOSTOFI BRAVO,"TEMPEST THERAPEUTICS, INC. (US) (2020-10-13)",https://lens.org/197-528-975-353-229,Patent Application,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
914,US,A1,US 2022/0124503 A1,102-699-482-161-536,2022-04-21,2022,US 202117545721 A,2021-12-08,US 202117545721 A;;US 201816230971 A,2018-12-21,METHODS AND APPARATUS FOR DETECTING ATTACKS IN V2X NETWORKS,"Methods, apparatus, systems, and articles of manufacture are disclosed to detect attacks in V2X networks. An example apparatus includes a challenge handler to (a) transmit a first challenge packet to a first vehicle to request a transmission of a first response, (b) instruct a second challenge packet to be transmitted to a second vehicle to request a transmission of a second response, (c) increment a first counter when the first response is not obtained, (d) increment a second counter when the second response is not obtained, and (e) after repeating (a)-(d), determine that the first and second vehicles are phantom vehicles associated with an attacker with a half-duplex radio when at least one of the first or second counters satisfy a threshold, and a network interface to instruct a third vehicle associated with the V2X network to ignore future messages from the phantom vehicles based on the determination.",INTEL CORP,YANG LIUYANG LILY;;CHOUDHURY DEBABANI;;SHARMA SRIDHAR;;SIVANESAN KATHIRAVETPILLAI;;GOTTSCHLICH JUSTIN;;ZHANG ZHENG;;YONA YAIR;;LIU XIRUO;;AMBROSIN MORENO;;CHEN KUILIN CLARK,INTEL CORPORATION (2018-01-02),https://lens.org/102-699-482-161-536,Patent Application,yes,3,0,4,4,0,H04L9/3271;;H04W4/40;;H04W4/80;;H04W12/122;;H04W12/12;;H04W4/40;;H04W12/06;;H04L9/3271;;H04W12/122,H04W12/12;;H04L9/32;;H04W4/40;;H04W12/06;;H04W12/122,,0,0,,,,ACTIVE
915,US,B2,US 9676754 B2,113-990-763-049-789,2017-06-13,2017,US 201314654225 A,2013-12-10,US 201314654225 A;;US 201261739906 P;;US 2013/0074197 W,2012-12-20,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,INCEPTION SCIENCES INC (2014-01-06);;TEMPEST THERAPEUTICS INC (2013-01-30),https://lens.org/113-990-763-049-789,Granted Patent,yes,139,2,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D403/06;;C07D249/12;;C07D401/06;;C07D401/10;;C07D403/10,,27,14,049-932-762-286-948;;051-557-225-802-425;;056-408-192-066-881;;002-115-236-048-709;;083-860-889-470-294;;139-248-440-904-768;;067-827-227-854-569;;058-495-863-605-294;;010-146-155-505-826;;034-176-252-756-14X;;067-117-598-067-277;;114-295-506-012-872;;046-117-273-487-917;;072-113-796-200-30X,10.1016/j.tetlet.2005.09.073;;10.2174/1568026033451673;;14683520;;10.1007/bf00945649;;pmc2968207;;10.1107/s1600536809002840;;21581982;;21582015;;10.1107/s1600536809002815;;pmc2968336;;21581039;;10.1107/s1600536808033990;;pmc2959665;;10.1016/j.ejmech.2006.12.038;;17418454;;10.1002/jlcr.1395;;10.1002/ardp.201000002;;20803621;;10.1007/s10593-007-0176-9;;10.3987/com-08-11478;;10.1007/s00706-009-0210-y;;10.1021/jm034173l;;14613314;;10.1002/jctb.280630207,"Bravo et al., Identification of the first potent, selective and bioavailable PPARα antagonist, Bioorganic & Medicinal Chemistry Letters, 24:2267-2272, 2014.;;Messmer et al., Dec. 8-11, 2012, 3879 Inhibition of fatty acid oxidation leads to apoptosis of resting and proliferating chronic lymphocytic leukemia cells in vitro, 54th ASH Annual Meeting and Exposition, Atlanta, GA, Oral and Poster Abstracts, 1 p.;;Extended European Search report dated Apr. 6, 2016 in patent application No. 13863783.0.;;International Search Report and Written Opinion dated Mar. 31, 2014 in PCT/US13/074197.;;Ammazzalorso et al., 2011, Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists, Bioorg. Med. Chem. Lett. 21:4869-4872.;;Argentine et al., 2009, The Role of New Technologies in Defining a Manufacturing Process for PPARα Agonist LY518674, Organic Process Research & Development, 13(2):131-143.;;Braden et al., 2007, A Convergent Kilogram-Scale Synthesis of the PPARα Agonist LY518674: Discovery of a Novel Acid-Mediated Triazolone Synthesis, Organic Process Research & Development, 11(3):431-440.;;Deng et al., 2005, A novel and efficient synthesis of 2,5-substituted 1,2,4-triazol-3-ones. Tetrahedron Letters 46(46):7993-7996.;;Etgen et al., 2003, PPAR ligands for metabolic disorders, Current Topics in Medicinal Chemistry, 3:1649-1661.;;Girard, 1941, Tautomeric oxotriazoles and hydroxytriazoles. A new method for the preparation of hydroxy-1,2,4-triazoles, Compt rend. 212:547-549.;;Goldin et al., 1974, Synthesis of triazolones and c-aminotriazoles by thermal condensation of carbamidoamidrazones. Chemistry of Heterocyclic Compounds 10(4):489-490.;;Hanif et al., 2009, 4-(3-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-one, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o387, sup-1-sup-11.;;Hanif et al., 2009, 4-(4-Methoxyphenyl)-3-[2-(2-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-one, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o429, sup-1-sup-8.;;Hanif et al., 2008, 5-(3-Methoxyphenethyl)-4-(2-methoxyphenyl)-4H-1,2,4-triazol-3-ol, Acta Crystallographica, Section E: Structure Reports Online, E64(11):o2180, sup-1-sup-9.;;Kuecuekguezel et al., 2007, Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents, European Journal of Medicinal Chemistry, 42:893-901.;;Kuo et al., 2007, The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist, Journal of Labelled Compounds and Radiopharmaceuticals, 50(8):693-701.;;Millar et al., 2009, Potent and selective PPARα agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, 29(1):140-146.;;Moenes et al., Feb. 1996, Synthesis and antimicrobial activity of certain pyradazines, Alex. J. 146 Pharm. Sci., 10(1):35-38.;;Rao et al., 2010, Synthesis of substituted 2,4-dihydro[1,2,4,]-triazol-3-ones, Indian Journal of Heterocyclic Chemistry 20(1):9-12.;;Rashad et al., 2010, Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth. Archiv der Pharmazie (Weinheim, Germany) 343(8):440-448.;;Soliman et al., 2007, Heterocyclic synthesis with biologically active S-(6-aryl pyridazin 3-yl) thioglycollic acid hydrazides, Egypt. J. Chem. 50(4):443-453.;;Tumosiene et al., 2007, Synthesis of azoles from 3,3′-(arylimino)bis[propanoyl hydrazides]. Chemistry of Heterocyclic Compounds (New York, NY, United States) 43(9):1148-1153.;;Tumosiene et al., 2009, Synthesis of azole derivatives from 3-phenylaminopropanohydrazide and evaluation of their antimicrobial efficacy, Heterocycles, 78(1):59-70.;;Tumosiene et al., 2009, Synthesis of azoles from 3,3′-[(4-alkoxyphenyl)imino]bis(propanoic acid hydrazides), Monatshefte fuer Chemie, 140(12):1523-1528.;;Tutoveanu et al., 1973, New semi- and thiosemicarbazides and cyclization products, Revistade Chimie (Bucharest, Romania) 24(3):155-158.;;Xu et al., 2003, Journal of Medicinal Chemistry 46:5121-5124.;;Abd Ei-Samii et al. 1995, Synthesis of some new 3-mercapto-5-substituted-1,2,4-triazine-s-triazoles for evaluation as antimicrobial agents. Journal of Chemical Technology and Biotechnology 63(2)135-140.",ACTIVE
916,US,B2,US 10568871 B2,167-330-469-436-062,2020-02-25,2020,US 201715590766 A,2017-05-09,US 201715590766 A;;US 201514654225 A;;US 2013/0074197 W;;US 201261739906 P,2012-12-20,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",TEMPEST THERAPEUTICS INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,TEMPEST THERAPEUTICS INC (2013-01-30);;INCEPTION SCIENCES INC (2013-12-13),https://lens.org/167-330-469-436-062,Granted Patent,yes,143,1,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;A61K31/4439;;A61K31/506;;C07D249/12;;C07D401/06;;C07D401/10;;C07D403/06;;C07D403/10,,35,20,029-742-983-481-795;;072-113-796-200-30X;;008-626-626-600-450;;142-741-599-093-036;;147-149-448-374-286;;036-259-871-752-187;;049-932-762-286-948;;051-557-225-802-425;;056-408-192-066-881;;002-115-236-048-709;;083-860-889-470-294;;139-248-440-904-768;;067-827-227-854-569;;058-495-863-605-294;;091-619-184-876-795;;010-146-155-505-826;;067-117-598-067-277;;114-295-506-012-872;;034-176-252-756-14X;;046-117-273-487-917,10.1126/science.286.5439.531;;10521349;;10.1002/jctb.280630207;;21742490;;10.1016/j.bmcl.2011.06.028;;10.1021/op8002486;;10.1021/op700040v;;10.1016/j.bmcl.2014.03.090;;24745969;;10.1016/j.tetlet.2005.09.073;;10.2174/1568026033451673;;14683520;;10.1007/bf00945649;;pmc2968207;;10.1107/s1600536809002840;;21581982;;21582015;;10.1107/s1600536809002815;;pmc2968336;;21581039;;10.1107/s1600536808033990;;pmc2959665;;10.1016/j.ejmech.2006.12.038;;17418454;;10.1002/jlcr.1395;;10.1182/blood.v120.21.3879.3879;;10.1002/ardp.201000002;;20803621;;10.3987/com-08-11478;;10.1007/s00706-009-0210-y;;10.1007/s10593-007-0176-9;;10.1021/jm034173l;;14613314,"Golub, Science, 1999, vol. 286, p. 531-537. (Year: 1999).;;Target Cancer Therapies Fact Sheet, retrieved from http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet on Dec. 8, 2015. (Year: 2015).;;Abd Ei-Samii et al. Synthesis of some new 3-mercapto-5-substituted-1,2,4-triazine-s-triazoles for evaluation as antimicrobial agents. J Chem Technol Biotechnol 63(2)135-140 (1995).;;Ammazzalorso et al. Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPAR.alpha. antagonists. Bioorg Med Chem Lett 21:4869-4872 (2011).;;Argentine et al. The Role of New Technologies in Defining a Manufacturing Process for PPAR.alpha. Agonist LY518674. Organic Process Research & Development 3(2):131-143 (2009).;;Braden et al. A Convergent Kilogram-Scale Synthesis of the PPAR.alpha. Agonist LY518674: Discovery of a Novel Acid-Mediated Triazolone Synthesis. Organic Process Research & Development 11(3):431-440 (2007).;;Bravo et al. Identification of the first potent, selective and bioavailable PPAR.alpha. antagonist. Bioorg Med Chem Let 24:2267-2272 (2014).;;Deng et al. A novel and efficient synthesis of 2,5-substituted 1,2,4-triazol-3-ones. Tetrahedron Letters 46(46):7993-7996 (2005).;;Etgen et al. PPAR ligands for metabolic disorders. Current Topics in Medicinal Chemistry 3:1649-1661 (2003).;;Girard. Tautomeric oxotriazoles and hydroxytriazoles. A new method for the preparation of hydroxy-1,2,4-triazoles. Compt rend. 212:547-549 (1941) (English Abstract).;;Gol 'Din et al. Synthesis of triazolones and c-aminotriazoles by thermal condensation of carbamidoamidrazones. Chemistry of Heterocyclic Compounds 10(4):489-490 (1974).;;Hanif et al. 4-(3-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-o- ne, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o387, sup-1-sup-11 (2009).;;Hanif et al. 4-(4-Methoxyphenyl)-3-[2-(2-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-o- ne, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o429, sup-1-sup-8 (2009).;;Hanif et al. 5-(3-Methoxyphenethyl)-4-(2-methoxyphenyl)-4H-1,2,4-triazol-3-ol, Acta Crystallographica, Section E: Structure Reports Online, E64(11):o2180, sup-1-sup-9 (2008).;;Kucukguzel et al. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. European Journal of Medicinal Chemistry 42:893-901 (2007).;;Kuo et al. The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol—3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist. Journal of Labelled Compounds and Radiopharmaceuticals 50(8):693-701 (2007).;;Messmer et al. Abstract No. 3879 Inhibition of fatty acid oxidation leads to apoptosis of resting and proliferating chronic lymphocytic leukemia cells in vitro, 54th ASH Annual Meeting and Exposition, Atlanta, GA, Oral and Poster Abstracts. (Dec. 8-11, 2012) (1 pg.).;;Millar et al. Potent and selective PPARα agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Throm Vasc Biol 29(1):140-146 (2009).;;Moenes et al. Synthesis and antimicrobial activity of certain pyradazines. Alex J Pharm Sci 10(1):35-38 (1996).;;PCT/US2013/029713 International Preliminary Report on Patentability dated Sep. 9, 2014.;;PCT/US2013/029713 International Search Report and Written Opinion dated Jun. 28, 2013.;;PCT/US2013/074197 International Search Report and Written Opinion dated Mar. 31, 2014.;;PCT/US2014/054108 International Search Report and Written Opinion dated Dec. 26, 2014.;;Rao et al. Synthesis of substituted 2,4-dihydro[1,2,4,]-triazol-3-ones. Indian Journal of Heterocyclic Chemistry 20(1):9-12 (2010).;;Rashad et al. Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth. Archiv der Pharmazie 343(8):440-448 (2010).;;Soliman et al. Heterocyclic synthesis with biologically active S-(6-aryl pyridazin 3-yl) thioglycollic acid hydrazides. Egypt J Chem 50(4):443-453 (2007).;;Tumosiene et al. Synthesis of azole derivatives from 3-phenylaminopropanohydrazide and evaluation of their antimicrobial efficacy. Heterocycles 78(1):59-70 (2009).;;Tumosiene et al. Synthesis of azoles from 3,3′-[(4-alkoxyphenyl)imino]bis(propanoic acid hydrazides). Monatsh Chem 140(12):1523-1528 (2009).;;Tumosiene et al. Synthesis of azoles from 3,3′-(arylimino)bis[propanoyl hydrazides]. Chemistry of Heterocyclic Compounds 43(9):1148-1153 (2007).;;Tutoveanu et al. New semi—and thiosemicarbazides and cyclization products. Revistade Chimie 24(3):155-158 (1973) (English Abstract).;;U.S. Appl. No. 14/383,096 Office Action dated Dec. 17, 2015.;;U.S. Appl. No. 14/383,096 Office Action dated May 3, 2016.;;U.S. Appl. No. 14/654,225 Office Action dated Oct. 7, 2016.;;U.S. Appl. No. 14/916,860 Office Action dated Dec. 29, 2016.;;Xu et al. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. J Med Chem 46:5121-5124 (2003).",ACTIVE
917,CA,C,CA 2894281 C,192-579-748-430-579,2021-04-20,2021,CA 2894281 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/192-579-748-430-579,Granted Patent,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
918,EP,A1,EP 4320114 A1,097-497-997-747-232,2024-02-14,2024,EP 22720147 A,2022-04-07,US 202163172617 P;;US 2022/0023861 W,2021-04-08,ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN,,CHDI FOUNDATION INC,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/097-497-997-747-232,Patent Application,yes,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,C07D401/14;;A61P25/00,,0,0,,,,PENDING
919,DK,T3,DK 2935228 T3,153-833-683-537-16X,2017-10-30,2017,DK 13863783 T,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONFORBINDELSER OG ANVENDELSER DERAF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/153-833-683-537-16X,Granted Patent,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
920,EP,A1,EP 3874019 A1,021-214-464-542-71X,2021-09-08,2021,EP 19795429 A,2019-10-15,EP 18290127 A;;US 2019/0056193 W,2018-10-29,FABRIC CARE COMPOSITION WITH SILICONE,,DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III EMMETT M;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR MICHAEL B;;MIGLIORE ALINE;;CHEN YUNSHEN;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN;;TODD JENNIFER P;;LESLIE CYNTHIA,,https://lens.org/021-214-464-542-71X,Patent Application,yes,0,0,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D3/37,,0,0,,,,ACTIVE
921,BR,A2,BR 112023020857 A2,085-892-890-403-370,2023-12-12,2023,BR 112023020857 A,2022-04-07,US 2022/0023861 W;;US 202163172617 P,2021-04-08,Compostos de isoindolinona e agentes de imaginologia para imaginologia da proteína huntingtina,"compostos de isoindolinona e agentes de imaginologia para imaginologia da proteína huntingtina. são fornecidos no presente documento certos compostos de isoindolinona e agentes de imaginologia úteis para detectar uma doença ou condição associada à agregação de proteínas, composições dos mesmos e métodos de seu uso.",CHDI FOUNDATION INC,DOMINGUEZ CELIA;;CHRISTOPHER JOHN BROWN;;CLARK-FREW DANIEL;;GADOULEAU ELISE;;BARD JONATHAN;;LIU LONGBIN;;MATTHEW ROBERT MILLS;;PETER DAVID JOHNSON;;CHEN XUEMEI,,https://lens.org/085-892-890-403-370,Patent Application,no,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,C07D401/14;;A61P25/00,,0,0,,,,PENDING
922,US,A1,US 2015/0344446 A1,070-863-221-617-526,2015-12-03,2015,US 201314654225 A,2013-12-10,US 201314654225 A;;US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,INCEPTION SCIENCES INC (2014-01-06);;TEMPEST THERAPEUTICS INC (2013-01-30),https://lens.org/070-863-221-617-526,Patent Application,yes,0,1,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;C07D401/10;;C07D403/10,,0,0,,,,ACTIVE
923,US,A1,US 2024/0041837 A1,138-631-051-163-666,2024-02-08,2024,US 202318304815 A,2023-04-21,US 202318304815 A;;US 201916722773 A;;US 201715590766 A;;US 201514654225 A;;US 2013/0074197 W;;US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",TEMPEST THERAPEUTICS INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,INCEPTION SCIENCES INC (2014-01-06);;TEMPEST THERAPEUTICS INC (2014-01-30),https://lens.org/138-631-051-163-666,Patent Application,yes,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;A61K31/41;;A61K31/4439;;A61K31/506;;A61P35/00;;A61P35/02;;C07D249/12;;C07D401/06;;C07D401/10;;C07D403/06;;C07D403/10,,0,0,,,,PENDING
924,US,A1,US 2017/0239223 A1,196-735-108-434-253,2017-08-24,2017,US 201715590766 A,2017-05-09,US 201715590766 A;;US 201514654225 A;;US 2013/0074197 W;;US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,TEMPEST THERAPEUTICS INC (2013-01-30);;INCEPTION SCIENCES INC (2013-12-13),https://lens.org/196-735-108-434-253,Patent Application,yes,0,1,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;A61K31/4439;;A61K31/506,,2,1,029-742-983-481-795,10.1126/science.286.5439.531;;10521349,"Golub, Science, 1999, Vol. 286, p. 531-537. (Year: 1999);;Target Cancer Therapies Fact Sheet, retrieved from http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet on 12/8/2015. (Year: 2015)",ACTIVE
925,EP,A4,EP 2935228 A4,083-622-759-935-651,2016-05-04,2016,EP 13863783 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC.; US (2022-10-19);;TEMPEST THERAPEUTICS, US (2022-06-27);;TEMPEST THERAPEUTICS, INC. (N.D.GES.D.STAATES , US (2023-03-10);;TEMPEST THERAPEUTICS, INC. (2023-03-17)",https://lens.org/083-622-759-935-651,Search Report,no,2,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,1,0,,,See also references of WO 2014099503A1,ACTIVE
926,TW,A,TW 200718687 A,187-495-482-524-391,2007-05-16,2007,TW 95118534 A,2006-05-25,US 68556405 P,2005-05-27,Inhibitors of cytosolic phospholipase A2,"This invention provides chemical inhibitors of the activity of various phospholipase enzymes, particularly cytosolic phospholipase A2 enzymes (cPLA2), more particularly including inhibitors of cytosolic phospholipase A2 alpha enzymes (cPLA2α). In some embodiments, the inhibitors have the Formula I: wherein the constituent variables are as defined herein.",WYETH CORP,MCKEW JOHN C;;LEE KATHERINE L;;CHEN LI-HREN;;VARGAS RICHARD;;CLARK JAMES D;;WILLIAMS CARA;;CLERIN VALERIE;;MARUSIC SUZANA;;PONG KEVIN,,https://lens.org/187-495-482-524-391,Patent of Addition,no,0,0,51,51,0,C07D209/14;;C07D209/18;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P25/00;;A61P25/16;;A61P25/28;;A61P29/00;;A61P3/00;;A61P43/00;;A61P7/02;;A61P9/10;;C07D209/14;;C07D209/18;;A61K31/404;;C07D209/14;;C07D209/18,C07D209/14;;A61K31/405;;A61P11/00;;A61P19/00;;A61P25/00;;C07D209/18,,0,0,,,,PENDING
927,WO,A3,WO 2011/144682 A3,036-037-692-819-207,2012-09-20,2012,EP 2011058102 W,2011-05-19,US 34704910 P,2010-05-21,SYSTEM AND METHOD FOR TAILORING NUCLEOTIDE CONCENTRATION TO ENZYMATIC EFFICIENCIES IN DNA SEQUENCING TECHNOLOGIES,"An embodiment of a method for optimizing sequencing performance is described that comprises the steps of calculating a nucleotide species specific degradation rate of an apyrase enzyme for a plurality of nucleotide species; determining a concentration for each of the nucleotide species using the nucleotide species specific degradation rate; iteratively providing the concentration of each of the nucleotide species in a reaction environment comprising a polymerase enzyme and a species of template nucleic acid molecule, wherein one or more molecules of the nucleotide species are incorporated into a nascent molecule in a sequencing reaction and the apyrase enzyme is introduced to the reaction environment to degrade unincorporated nucleotide species molecules; and detecting a signal in response to the incorporation of the nucleotide species.",ROCHE DIAGNOSTICS GMBH;;HOFFMANN LA ROCHE,BRUNELLE JULIE MARIE;;CAPRIO AMANDA DE ASIS;;CHEN YI-JU;;CLARK SHAUNA MARY;;GOMES XAVIER V;;MAKHIJANI VINOD;;WONG CHIU TAI ANDREW,,https://lens.org/036-037-692-819-207,Search Report,yes,1,0,7,7,0,C12Q1/6869;;C12Q1/6869,C12Q1/68,,1,1,009-110-302-070-560,15576673;;10.1093/nar/gnh159;;pmc535692,"A. AGAH ET AL: ""A multi-enzyme model for pyrosequencing"", NUCLEIC ACIDS RESEARCH, vol. 32, no. 21, 29 November 2004 (2004-11-29), pages E166 - E166, XP055032817, ISSN: 0305-1048, DOI: 10.1093/nar/gnh159",PENDING
928,BR,B1,BR 112015013350 B1,136-928-305-395-331,2022-04-05,2022,BR 112015013350 A,2013-12-10,US 2013/0074197 W;;US 201261739906 P,2012-12-20,"Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos","compostos de triazolona e usos dos mesmos a invenção divulgada aqui é direcionada a compostos da fórmula i i e sais farmaceuticamente aceitáveis dos mesmos, que são úteis no tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção compreende ainda composições farmacêuticas que compreendem uma quantidade terapeuticamente eficiente de composto da fórmula i ou um sal farmaceuticamente aceitável do mesmo. a invenção divulgada aqui também se direciona a processos de tratamento de câncer de próstata, mama, ovariano, fígado, rim, cólon, pancreático, leucemia linfocítica crônica humana, melanoma e outros cânceres. a invenção divulgada aqui é adicionalmente direcionada a processos de tratamento de câncer de próstata, mama, cólon, pancreático, leucemia linfocítica crônica, melanoma e outros cânceres que compreendem a administração de uma quantidade terapeuticamente eficiente de um antagonista de ppar(alfa) seletivo. os compostos e as composições farmacêuticas da invenção também são úteis no tratamento de infecções virais, tais como infecções com hcv e infecções com hiv.",INCEPTION 2 INC;;TEMPEST THERAPEUTICS INC,AUSTIN CHIH-YU CHEN;;BRIAN ANDREW STEARNS;;JASON DUARTE JACINTHO;;JILL MELISSA BACCEI;;NICHOLAS SIMON STOCK;;RYAN CHRISTOPHER CLARK;;YALDA MOSTOFI BRAVO,"TEMPEST THERAPEUTICS, INC. (US) (2020-10-13)",https://lens.org/136-928-305-395-331,Granted Patent,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
929,US,A1,US 2022/0339302 A1,148-349-948-009-739,2022-10-27,2022,US 202217715661 A,2022-04-07,US 202217715661 A;;US 202163172617 P,2021-04-08,ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN,"Provided herein are certain isoindolinone compounds and imaging agents useful for detecting a disease or condition associated with protein aggregation, compositions thereof, and methods of their use.",CHDI FOUNDATION INC,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/148-349-948-009-739,Patent Application,yes,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,A61K51/04;;A61P25/28;;C07D401/14,,0,0,,,,PENDING
930,IL,A,IL 307507 A,136-366-978-661-241,2023-12-01,2023,IL 30750723 A,2023-10-05,US 202163172617 P;;US 2022/0023861 W,2021-04-08,Isoindolinone compounds and imaging agents for imaging huntingtin protein,,CHDI FOUNDATION INC;;LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,LIU LONGBIN;;DOMINGUEZ CELIA;;BARD JONATHAN;;BROWN CHRISTOPHER JOHN;;CHEN XUEMEI;;CLARK-FREW DANIEL;;MILLS MATTHEW ROBERT;;JOHNSON PETER DAVID;;GADOULEAU ELISE,,https://lens.org/136-366-978-661-241,Patent Application,no,0,0,8,8,0,C07D401/14;;A61K51/0455;;C07B2200/05;;C07D401/14;;A61K51/0459;;A61P25/28;;A61P25/28;;A61K51/0455;;A61K51/0459;;C07B2200/05;;C07D401/14,A61K51/04;;A61P25/28,,0,0,,,,PENDING
931,US,B2,US 11666557 B2,196-081-433-832-28X,2023-06-06,2023,US 201916722773 A,2019-12-20,US 201916722773 A;;US 201715590766 A;;US 201514654225 A;;US 2013/0074197 W;;US 201261739906 P,2012-12-20,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",TEMPEST THERAPEUTICS INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,INCEPTION SCIENCES INC (2014-01-06);;TEMPEST THERAPEUTICS INC (2014-01-30),https://lens.org/196-081-433-832-28X,Granted Patent,yes,145,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;A61K31/41;;A61K31/4439;;A61K31/506;;A61P35/00;;A61P35/02;;C07D249/12;;C07D401/06;;C07D401/10;;C07D403/06;;C07D403/10,,42,23,029-742-983-481-795;;001-863-314-362-574;;045-878-114-197-621;;072-113-796-200-30X;;008-626-626-600-450;;142-741-599-093-036;;147-149-448-374-286;;036-259-871-752-187;;049-932-762-286-948;;051-557-225-802-425;;056-408-192-066-881;;029-742-983-481-795;;002-115-236-048-709;;083-860-889-470-294;;139-248-440-904-768;;067-827-227-854-569;;058-495-863-605-294;;091-619-184-876-795;;010-146-155-505-826;;067-117-598-067-277;;114-295-506-012-872;;034-176-252-756-14X;;046-117-273-487-917,10.1126/science.286.5439.531;;10521349;;10.1038/nature03095;;15549090;;10.2174/092986711798347243;;22172067;;10.1002/jctb.280630207;;21742490;;10.1016/j.bmcl.2011.06.028;;10.1021/op8002486;;10.1021/op700040v;;10.1016/j.bmcl.2014.03.090;;24745969;;10.1016/j.tetlet.2005.09.073;;10.2174/1568026033451673;;14683520;;10.1007/bf00945649;;10.1126/science.286.5439.531;;10521349;;pmc2968207;;10.1107/s1600536809002840;;21581982;;21582015;;10.1107/s1600536809002815;;pmc2968336;;21581039;;10.1107/s1600536808033990;;pmc2959665;;10.1016/j.ejmech.2006.12.038;;17418454;;10.1002/jlcr.1395;;10.1182/blood.v120.21.3879.3879;;10.1002/ardp.201000002;;20803621;;10.3987/com-08-11478;;10.1007/s00706-009-0210-y;;10.1007/s10593-007-0176-9;;10.1021/jm034173l;;14613314,"Golub, T.R.,“Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.” science 286.5439 (1999): 531-537.;;Sawyers, C., “Targeted cancer therapy.” Nature 432.7015 (2004): 294-297.;;Nevin, D.K., “Rational targeting of peroxisome proliferating activated receptor subtypes.” Current medicinal chemistry 18.36 (2011): 5598-5623.;;Abd Ei-Samii et al. Synthesis of some new 3-mercapto-5-substituted-1,2,4-triazine-s-triazoles for evaluation as antimicrobial agents. J Chem Technol Biotechnol 63(2)135-140 (1995).;;Ammazzalorso et al. Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPAR.alpha, antagonists. Bioorg Med Chem Lett 21:4869-4872 (2011).;;Argentine et al. The Role of New Technologies in Defining a Manufacturing Process for PPAR.alpha. Agonist LY518674. Organic Process Research & Development 3(2):131-143 (2009).;;Braden et al. A Convergent Kilogram-Scale Synthesis of the PPAR.alpha. Agonist LY518674: Discovery of a Novel Acid-Mediated Triazolone Synthesis. Organic Process Research & Development 11(3):431-440 (2007).;;Bravo et al. Identification of the first potent, selective and bioavailable PPAR.alpha. antagonist. Bioorg Med Chem Let 24:2267-2272 (2014).;;Deng et al. A novel and efficient synthesis of 2,5-substituted 1,2,4-triazol-3-ones. Tetrahedron Letters 46(46):7993-7996 (2005).;;Etgen et al. PPAR ligands for metabolic disorders. Current Topics in Medicinal Chemistry 3:1649-1661 (2003).;;Girard. Tautomeric oxotriazoles and hydroxytriazoles. A new method for the preparation of hydroxy-1,2,4-triazoles. Compt rend. 212:547-549 (1941) (English Abstract).;;Gol'Din et al. Synthesis of triazoIones and c-aminotriazoles by thermal condensation of carbamidoamidrazones. Chemistry of Heterocyclic Compounds 10(4):489-490 (1974).;;Golub et al. Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring. Science 286:531-537 (1999).;;Hanif et al. 4-(3-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-o-ne, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o387, sup-1-sup-11 (2009).;;Hanif et al. 4-(4-Methoxyphenyl)-3-[2-(2-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-o-ne, Acta Crystallographica, Section E: Structure Reports Online, E65(2):o429, sup-1-sup-8 (2009).;;Hanif et al. 5-(3-Methoxyphenethyl)-4-(2-methoxyphenyl)-4H-1,2,4-triazol-3-ol, Acta Crystallographica, Section E: Structure Reports Online, E64(11):o2180, sup-1-sup-9 (2008).;;Kucukguzel et al. Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. European Journal of Medicinal Chemistry 42:893-901 (2007).;;Kuo et al. The synthesis of three isotopomers of2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-- 3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist. Journal of Labelled Compounds and Radiopharmaceuticals 50(8):693-701 (2007).;;Messmer et al. Abstract No. 3879 Inhibition of fatty acid oxidation leads to apoptosis of resting and proliferating chronic lymphocytic leukemia cells in vitro, 54th ASH Annual Meeting and Exposition, Atlanta, GA, Oral and Poster Abstracts. (Dec. 8-11, 2012) (1 pg.).;;Millar et al. Potent and selective PPARα agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome. Arterioscler Throm Vasc Biol 29(1):140-146 (2009).;;Moenes et al. Synthesis and antimicrobial activity of certain pyradazines. Alex J Pharm Sci 10(1):35-38 (1996).;;PCT/US2013/029713 International Search Report and Written Opinion dated Jun. 28, 2013.;;PCT/US2013/074197 International Search Report and Written Opinion dated Mar. 31, 2014.;;PCT/US2014/054108 International Search Report and Written Opinion dated Dec. 26, 2014.;;Rao et al. Synthesis of substituted 2,4-dihydro[1,2,4,]-triazol-3-ones. Indian Journal of Heterocyclic Chemistry 20(1):9-12 (2010).;;Rashad et al. Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth. Archiv der Pharmazie 343(8):440-448 (2010).;;Soliman et al. Heterocyclic synthesis with biologically active S-(6-aryl pyridazin 3-yl) thioglycollic acid hydrazides. Egypt J Chem 50(4):443-453 (2007).;;Targeted Cancer Therapies Fact Sheet—National Cancer Institute. Retrieved from http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/ targeted-therapies-fact-sheet on Dec. 8, 2015 (6 pgs.).;;Tumosiene et al. Synthesis of azole derivatives from 3-phenylaminopropanohydrazide and evaluation of their antimicrobial efficacy. Heterocycles 78(1):59-70 (2009).;;Tumosiene et al. Synthesis of azoles from 3,3′-[(4-alkoxyphenyl)imino]bis(propanoic acid hydrazides). Monatsh Chem 140(12):1523-1528 (2009).;;Tumosiene et al. Synthesis of azoles from 3,3′-(arylimino)bis[propanoyl hydrazides]. Chemistry of Heterocyclic Compounds 43(9):1148-1153 (2007).;;Tutoveanu et al. New semi- and thiosemicarbazides and cyclization products. Revistade Chimie 24(3):155-158 (1973) (English Abstract).;;U.S. Appl. No. 14/383,096 Office Action dated Dec. 17, 2015.;;U.S. Appl. No. 14/383,096 Office Action dated May 3, 2016.;;U.S. Appl. No. 14/654,225 Office Action dated Oct. 7, 2016.;;U.S. Appl. No. 14/916,860 Office Action dated Dec. 29, 2016.;;U.S. Appl. No. 15/590,766 Office Action dated Dec. 12, 2018.;;U.S. Appl. No. 15/590,766 Office Action dated Dec. 26, 2017.;;U.S. Appl. No. 15/590,766 Office Action dated Jul. 1, 2019.;;U.S. Appl. No. 15/590,766 Office Action dated Mar. 28, 2019.;;U.S. Appl. No. 15/590,766 Office Action dated May 17, 2018.;;Xu et al. Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist. J Med Chem 46:5121-5124 (2003).",ACTIVE
932,US,B2,US 11902785 B2,044-519-788-203-265,2024-02-13,2024,US 202117545721 A,2021-12-08,US 202117545721 A;;US 201816230971 A,2018-12-21,Methods and apparatus for detecting attacks in V2X networks,"Methods, apparatus, systems, and articles of manufacture are disclosed to detect attacks in V2X networks. An example apparatus includes a challenge handler to (a) transmit a first challenge packet to a first vehicle to request a transmission of a first response, (b) instruct a second challenge packet to be transmitted to a second vehicle to request a transmission of a second response, (c) increment a first counter when the first response is not obtained, (d) increment a second counter when the second response is not obtained, and (e) after repeating (a)-(d), determine that the first and second vehicles are phantom vehicles associated with an attacker with a half-duplex radio when at least one of the first or second counters satisfy a threshold, and a network interface to instruct a third vehicle associated with the V2X network to ignore future messages from the phantom vehicles based on the determination.",INTEL CORP,YANG LIUYANG LILY;;CHOUDHURY DEBABANI;;SHARMA SRIDHAR;;SIVANESAN KATHIRAVETPILLAI;;GOTTSCHLICH JUSTIN;;ZHANG ZHENG;;YONA YAIR;;LIU XIRUO;;AMBROSIN MORENO;;CHEN KUILIN CLARK,,https://lens.org/044-519-788-203-265,Granted Patent,yes,21,0,4,4,0,H04L9/3271;;H04W4/40;;H04W4/80;;H04W12/122;;H04W12/12;;H04W4/40;;H04W12/06;;H04L9/3271;;H04W12/122,H04W12/12;;H04L9/32;;H04W4/40;;H04W12/06;;H04W12/122,,8,0,,,"Brik et al., “Wireless Device Identification with Radiometric Signatures,” MobiCom '08, Sep. 14-19, 2008. Retrieved from the Internet on Jun. 27, 2019, <URL: http://www.winlab.rutgers.edu/˜gruteser/papers/brik_paradis.pdf> (13 pages).;;Ureten et al., “Wireless Security through RF Fingerprinting,” Canadian Journal of Electrical Engineering, vol. 32, No. 1, 2007 (7 pages).;;Li et al., “Securing Wireless Systems via Lower Layer Enforcements,” WiSe '06, Sep. 29, 2006 (10 pages).;;Mathur et al., “Exploiting the Physical Layer for Enhanced Security,” IEEE Wireless Communications, Oct. 2010 (8 pages).;;Rehman et al., “Radio Frequency Fingerprinting and its Challenges,” IEEE CNS 2014 (2 pages).;;United States Patent and Trademark Office, “Non-final Office Action,” mailed in connection with U.S. Appl. No. 16/230,971, dated Jan. 22, 2021, 40 pages.;;United States Patent and Trademark Office, “Final Office Action,” mailed in connection with U.S. Appl. No. 16/230,971, dated Jul. 22, 2021, 61 pages.;;United States Patent and Trademark Office, “Notice of Allowance,” mailed in connection with U.S. Appl. No. 16/230,971, dated Oct. 6, 2021, 38 pages.",ACTIVE
933,KR,A,KR 20150099537 A,053-309-426-234-428,2015-08-31,2015,KR 20157017924 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/053-309-426-234-428,Patent Application,no,2,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,A61K31/4196;;C07D401/06;;C07D403/06,,1,1,067-827-227-854-569,10.1016/j.ejmech.2006.12.038;;17418454,"European Journal of Medicinal Chemistry, 2007, Vol. 42, pp. 893-901*",ACTIVE
934,US,S,US D0857665 S,143-694-519-917-283,2019-08-27,2019,US 201829646142 F,2018-05-02,US 201829646142 F,2018-05-02,Computer accessory device,,HEWLETT PACKARD DEVELOPMENT CO,YOUNG ERIC;;CLARK MATTHEW B;;CHEN CATHY YACHUAN;;HARPER PIERRE;;FRANE STEVEN M;;PIETZ GREG P;;OGAMI SAMUEL YUICHI;;STANTON NASH STEVEN,HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2018-05-01),https://lens.org/143-694-519-917-283,Design Right,no,23,7,1,1,0,,,1403;;D14/218,1,0,,,"HP AJ652AA Notebook—Newegg.com, website 2019, ste visited Mar. 9, 2019, https://www.newegg.com/...00&gclid=Cj0KCQiA5Y3kBRDwARIsAEwloL4kzA2HiAG0-UWY1GDuMG25XUqdU2BBlm7XGzNPZz2Y6IWpp88sh14aAgR-EALw_wcB&gclsrc=aw.ds.",ACTIVE
935,CN,A,CN 103038365 A,181-945-610-266-671,2013-04-10,2013,CN 201180025207 A,2011-05-19,EP 2011058102 W;;US 34704910 P,2010-05-21,System and method for tailoring nucleotide concentration to enzymatic efficiencies in DNA sequencing technologies,"An embodiment of a method for optimizing sequencing performance is described that comprises the steps of calculating a nucleotide species specific degradation rate of an apyrase enzyme for a plurality of nucleotide species; determining a concentration for each of the nucleotide species using the nucleotide species specific degradation rate; iteratively providing the concentration of each of the nucleotide species in a reaction environment comprising a polymerase enzyme and a species of template nucleic acid molecule, wherein one or more molecules of the nucleotide species are incorporated into a nascent molecule in a sequencing reaction and the apyrase enzyme is introduced to the reaction environment to degrade unincorporated nucleotide species molecules; and detecting a signal in response to the incorporation of the nucleotide species.",ROCHE DIAGNOSTICS GMBH,BRUNELLE JULIE MARIE;;CAPRIO AMANDA DE ASIS;;CHEN YI-JU;;CLARK SHAUNA MARY;;GOMES XAVIER V;;MAKHIJANI VINOD;;WONG CHIU TAI ANDREW,,https://lens.org/181-945-610-266-671,Patent Application,no,1,1,7,7,0,C12Q1/6869;;C12Q1/6869,C12Q1/68,,1,1,009-110-302-070-560,15576673;;10.1093/nar/gnh159;;pmc535692,"ALI AGAH ET AL.: ""A multi-enzyme model for pyrosequencing"", 《NUCLEIC ACIDS RESEARCH》, 2 December 2004 (2004-12-02)",DISCONTINUED
936,DK,T3,DK 1824988 T3,027-341-851-437-32X,2017-08-07,2017,DK 05849392 T,2005-11-14,US 62727704 P;;US 2005/0041205 W,2004-11-12,STEDSPECIFIK MODIFICERING AF FVIII,,BAYER HEALTHCARE LLC,MURPHY JOHN E;;MEI BAISONG;;STRAUSS JONATHAN S;;TJANDRA HENDRI;;CHEN JIANMIN;;TANG LIANG;;PAN CLARK Q;;BARNETT THOMAS;;WANG DE QIAN,,https://lens.org/027-341-851-437-32X,Granted Patent,no,0,0,135,135,0,C07K14/755;;A61K38/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;A61K38/37;;A61P31/02;;A61P7/00;;A61P7/04;;C07K14/00;;C07K14/755;;C07K17/08;;C07K19/00;;A61K38/37;;A61K47/60;;C07K14/00;;C07K14/755;;C07K17/08;;C07K2319/00;;A61P7/00;;A61P7/04;;A61P31/02;;C07K19/00;;A61K38/00;;C07K14/755;;C07K2319/00;;A61K47/60;;C07K17/08;;A61K38/37,A61K38/37;;C07K17/08,,0,0,,,,ACTIVE
937,IL,B,IL 239372 B,099-743-746-330-09X,2018-08-30,2018,IL 23937215 A,2015-06-11,US 201261739906 P;;US 2013/0074197 W,2012-12-20,Triazolone compounds and uses thereof,,INCEPTION 2 INC;;NICHOLAS SIMON STOCK;;AUSTIN CHIH YU CHEN;;YALDA MOSTOFI BRAVO;;JASON DUARTE JACINTHO;;JILL MELISSA BACCEI;;BRIAN ANDREW STEARNS;;RYAN CHRISTOPHER CLARK,NICHOLAS SIMON STOCK;;AUSTIN CHIH-YU CHEN;;YALDA MOSTOFI BRAVO;;JASON DUARTE JACINTHO;;JILL MELISSA BACCEI;;BRIAN ANDREW STEARNS;;RYAN CHRISTOPHER CLARK,,https://lens.org/099-743-746-330-09X,Unknown,no,0,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,,,0,0,,,,ACTIVE
938,EP,B9,EP 2935228 B9,116-460-716-689-418,2017-12-06,2017,EP 13863783 A,2013-12-10,US 201261739906 P;;US 2013/0074197 W,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,"TEMPEST THERAPEUTICS, INC.; US (2022-10-19);;TEMPEST THERAPEUTICS, US (2022-06-27);;TEMPEST THERAPEUTICS, INC. (N.D.GES.D.STAATES , US (2023-03-10);;TEMPEST THERAPEUTICS, INC. (2023-03-17)",https://lens.org/116-460-716-689-418,Amended Patent,yes,6,0,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,0,0,,,,ACTIVE
939,CN,A,CN 104918922 A,152-958-741-116-068,2015-09-16,2015,CN 201380070398 A,2013-12-10,US 2013/0074197 W;;US 201261739906 P,2012-12-20,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER,,https://lens.org/152-958-741-116-068,Patent Application,no,4,1,36,36,0,C07D249/12;;C07D401/06;;C07D403/06;;C07D401/06;;C07D249/12;;C07D401/10;;C07D403/10;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506;;A61P3/00;;A61P31/12;;A61P35/00;;A61P35/02;;C07D401/10;;C07D403/10;;C07D401/06;;C07D249/12;;A61K31/41;;A61P35/02;;A61P35/00;;C07D403/06;;A61K31/4196;;A61K31/4439;;A61K31/506,C07D249/12;;A61K31/4196;;A61P31/12;;A61P35/00;;C07D401/06,,1,0,,,"S. GUENIZ KUECUEKGUEZEL，等: ""Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 42, no. 7, 25 February 2007 (2007-02-25), pages 893 - 901, XP 022117511, DOI: doi:10.1016/j.ejmech.2006.12.038",ACTIVE
940,EP,B1,EP 3874019 B1,182-467-300-774-585,2022-07-27,2022,EP 19795429 A,2019-10-15,EP 18290127 A;;US 2019/0056193 W,2018-10-29,FABRIC CARE COMPOSITION WITH SILICONE,,DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III EMMETT M;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR MICHAEL B;;MIGLIORE ALINE;;CHEN YUNSHEN;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN;;TODD JENNIFER P;;LESLIE CYNTHIA,,https://lens.org/182-467-300-774-585,Granted Patent,yes,4,0,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D3/37,,0,0,,,,ACTIVE
941,BR,A2,BR 112021005656 A2,195-926-817-679-435,2021-06-22,2021,BR 112021005656 A,2019-10-15,US 2019/0056193 W;;EP 18290127 A,2018-10-29,"composição de cuidado de tecido, e, detergente de lavanderia.","trata-se de uma composição de cuidado de tecido que inclui água; um tensoativo de limpeza; um silicone de amaciamento de tecido; um polímero de carboidrato modificado que tem um peso molecular médio ponderal de <500.000 daltons e um teor de nitrogênio kjeldahl corrigido para cinzas e voláteis, tkn, de =0,5% em peso; em que o polímero de carboidrato modificado é um polímero de carboidrato funcionalizado com porções químicas de amônio quaternário; em que as porções químicas de amônio quaternário no polímero de carboidrato modificado incluem: porções químicas de trimetil amônio que têm a fórmula (i); e porções químicas de dimetil(alquil)amônio que têm a fórmula (ii) em que cada r é independentemente selecionado a partir de um grupo c8-22 alquila.",DOW GLOBAL TECHNOLOGIES LLC;;DOW SILICONES CORP;;ROHM & HAAS,ALINE MIGLIORE;;ASGHAR A PEERA;;CYNTHIA LESLIE;;DANIEL S MILLER;;EMMETT M PARTAIN III;;JAN E SHULMAN;;JENNIFER P TODD;;JOHN HAYES;;LEON MARTEAUX;;MARIANN CLARK;;MICHAEL B CLARK JR;;PEILIN YANG;;RANDARA PULUKKODY;;STEPHEN DONOVAN;;YUNSHEN CHEN,,https://lens.org/195-926-817-679-435,Patent Application,no,0,0,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D3/37,,0,0,,,,PENDING
942,CN,A,CN 112805360 A,162-217-288-362-301,2021-05-14,2021,CN 201980064806 A,2019-10-15,EP 18290127 A;;US 2019/0056193 W,2018-10-29,FABRIC CARE COMPOSITION WITH SILICONE,"A fabric care composition is provided including water; a cleaning surfactant; a fabric softening silicone; and a modified carbohydrate polymer having a weight average molecular weight of < 500,000 Daltons and a Kjeldahl nitrogen content corrected for ash and volatiles, TKN, of >= 0.5 wt%; wherein the modified carbohydrate polymer is a carbohydrate polymer functionalized with quaternary ammonium moieties; wherein the quaternary ammonium moieties on the modified carbohydrate polymer include: trimethyl ammonium moieties having formula (I) and dimethyl(alkyl) ammonium moieties having formula (II) wherein each R is independently selected from a C8-22 alkyl group.",DOW GLOBAL TECHNOLOGIES INC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III E M;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR MICHAEL B;;MIGLIORE ALINE;;CHEN YIYOU;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MICHAEL;;DONOVAN STEPHEN;;TODD JENNIFER P;;LESLIE CYNTHIA,,https://lens.org/162-217-288-362-301,Patent Application,no,8,0,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D3/37,,1,0,,,"裘炳毅等, 中国轻工业出版社",PENDING
943,US,A1,US 2021/0348085 A1,189-194-029-515-925,2021-11-11,2021,US 201917272847 A,2019-10-15,EP 18290127 A;;US 2019/0056193 W,2018-10-29,FABRIC CARE COMPOSITION WITH SILICONE,"A fabric care composition is provided including water; a cleaning surfactant; a fabric softening silicone; and a modified carbohydrate polymer having a weight average molecular weight of <500,000 Daltons and a Kjeldahl nitrogen content corrected for ash and volatiles, TKN, of ≥0.5 wt %; wherein the modified carbohydrate polymer is a carbohydrate polymer functionalized with quaternary ammonium moieties; wherein the quaternary ammonium moieties on the modified carbohydrate polymer include: trimethyl ammonium moieties having formula (I) and dimethyl(alkyl) ammonium moieties having formula (II) wherein each R is independently selected from a C 8-22 alkyl group.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III EMMETT M;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR MICHAEL B;;MIGLIORE ALINE;;CHEN YUNSHEN;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN J;;TODD JENNIFER P;;LESLIE CYNTHIA,DOW FRANCE S.A.S (2019-01-04);;UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC (2018-12-05);;DOW GLOBAL TECHNOLOGIES LLC (2018-12-05);;THE DOW CHEMICAL COMPANY (2019-01-22);;DOW SILICONES CORPORATION (2019-01-16);;ROHM AND HAAS COMPANY (2018-12-05);;DOW SILICONES BELGIUM S.P.R.L (2019-01-04),https://lens.org/189-194-029-515-925,Patent Application,yes,4,1,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D3/22;;C11D1/83;;C11D3/00;;C11D3/37;;C11D11/00,,0,0,,,,ACTIVE
944,US,B2,US 11814608 B2,114-058-575-448-208,2023-11-14,2023,US 201917272847 A,2019-10-15,EP 18290127 A;;US 2019/0056193 W,2018-10-29,Fabric care composition comprising silicone and quaternary ammonium-functionalized carbohydrate polymer,"A fabric care composition is provided including water; a cleaning surfactant; a fabric softening silicone; and a modified carbohydrate polymer having a weight average molecular weight of <500,000 Daltons and a Kjeldahl nitrogen content corrected for ash and volatiles, TKN, of ≥0.5 wt %; wherein the modified carbohydrate polymer is a carbohydrate polymer functionalized with quaternary ammonium moieties; wherein the quaternary ammonium moieties on the modified carbohydrate polymer include: trimethyl ammonium moieties having formula (I) and dimethyl(alkyl) ammonium moieties having formula (II) wherein each R is independently selected from a C 8-22 alkyl group.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;DOW SILICONES CORP,PARTAIN III EMMETT M;;SHULMAN JAN E;;MARTEAUX LEON;;CLARK JR MICHAEL B;;MIGLIORE ALINE;;CHEN YUNSHEN;;PULUKKODY RANDARA;;MILLER DANIEL S;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN J;;TODD JENNIFER P;;LESLIE CYNTHIA,DOW FRANCE S.A.S (2019-01-04);;UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC (2018-12-05);;DOW GLOBAL TECHNOLOGIES LLC (2018-12-05);;THE DOW CHEMICAL COMPANY (2019-01-22);;DOW SILICONES CORPORATION (2019-01-16);;ROHM AND HAAS COMPANY (2018-12-05);;DOW SILICONES BELGIUM S.P.R.L (2019-01-04),https://lens.org/114-058-575-448-208,Granted Patent,yes,23,0,9,9,0,C11D3/227;;C11D3/373;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/0015;;C11D3/227;;C11D3/373;;C11D2111/12,C11D9/36;;C11D1/14;;C11D1/22;;C11D1/72;;C11D1/83;;C11D3/00;;C11D3/22;;C11D3/37;;C11D11/00,,2,0,,,"Sibilia., “A Guide to Materials Characterization and Chemical Analysis.” 1988, p. 81-84.;;Office Action from corresponding Japanese Application No. 2021-518871 dated Aug. 15, 2023.",ACTIVE
945,US,A1,US 2003/0166649 A1,072-512-262-351-11X,2003-09-04,2003,US 30208702 A,2002-11-22,US 30208702 A;;US 33459101 P,2001-12-03,Methods for treating arthritic disorders,"
    This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: 

    and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A ₂ enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVE Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-12),https://lens.org/072-512-262-351-11X,Patent Application,yes,20,16,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D405/12;;C07D409/12;;C07D209/14;;C07D413/14;;C07D487/08;;C07D417/14;;C07D413/12;;C07D491/10;;C07D403/12;;C07D417/12,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/228.2;;514/232.8;;514/253.09;;514/254.09;;514/278;;514/323;;514/365;;514/397;;514/374;;514/375;;514/414;;514/419;;514/256,0,0,,,,EXPIRED
946,US,A1,US 2013/0339334 A1,032-112-184-679-748,2013-12-19,2013,US 201213656481 A,2012-10-19,US 201213656481 A;;US 201261660224 P,2012-06-15,PERSONALIZED SEARCH ENGINE RESULTS,"A user can selectively customize what data is provided to a search engine to influence a degree of personalization of search results. Personalized search engine results can thereby be provided to one or more applications on a client device, such as a mobile phone. The data provided to the search engine can include any of a variety of user preferences stored on the client device (e.g., music, music ratings, search queries, search results selected, etc.), or other user information, such as current location or the location of the user when applications were downloaded. Social networking websites can also be used for supplying data to the search engine.",MICROSOFT CORP,BROWN JARED;;CLARK LEE DICKS;;LIN SHERRY PEI-CHEN;;WONG HOUSTON;;NESBIT NATHAN ELDON;;KIRK ELLIOT WILLIAM;;DEAKINS JASON;;CUNNINGHAM JOANNE;;GOPALKRISHNAN PRATEEP,MICROSOFT TECHNOLOGY LICENSING LLC (2014-10-14);;MICROSOFT CORPORATION (2012-10-15),https://lens.org/032-112-184-679-748,Patent Application,yes,23,23,1,1,0,G06F16/9535;;G06F16/9535;;G06F16/9536,G06F17/30,707/706;;X707E17108,0,0,,,,DISCONTINUED
947,TW,A,TW 200800369 A,146-365-167-543-848,2008-01-01,2008,TW 96105108 A,2007-02-12,US 77231706 P;;US 86534706 P,2006-02-11,Methods and apparatus for PFC abatement using a CDO chamber,"In at least one aspect, a controlled decomposition oxidation (CDO) system is provided for abating perfluorocarbons (PFCs) that includes (1) an upstream portion including a first conduit adapted to convey a gaseous waste stream; (2) a thermal reaction chamber having an inlet coupled to the first conduit, a catalyst bed adapted to abate PFCs, and an outlet; and (3) a downstream portion including a second conduit having a first end coupled to the outlet of the thermal reaction chamber and having a portion, downstream from the first end, positioned proximate to the first conduit. The second conduit is adapted to convey a gaseous waste stream heated within the thermal reaction chamber to enable a transfer of heat energy from the second conduit to the first conduit so as to pre-heat the gaseous waste stream in the first conduit. Numerous other aspects are provided.",APPLIED MATERIALS INC,RAOUX SEBASTIEN;;LIN KUO-CHEN;;VERMEULEN ROBBERT M;;CLARK DANIEL O;;TSU STEPHEN;;MOALEM MEHRAN;;FOX ALLEN;;MCINTOSH MONIQUE;;PUTZ JOSHUA;;RIESKE ERIC,,https://lens.org/146-365-167-543-848,Patent of Addition,no,0,0,18,18,0,B01D53/8662;;B01D53/8662;;B01D2257/2066;;B01D2257/2066;;C01B7/20;;C01B7/20;;Y02C20/30;;Y02C20/30;;Y02P20/151;;Y02P20/151,B01D53/68;;B01D53/86;;H01L21/00,,0,0,,,,PENDING
948,TW,A,TW 200802519 A,192-074-450-440-527,2008-01-01,2008,TW 96105126 A,2007-02-12,US 77231706 P;;US 86534706 P,2006-02-11,Methods and apparatus for PFC abatement using a CDO chamber,"In certain aspects, a system is provided for abating perfluorocarbons (PFCs) from a gaseous waste stream that includes (1) a wet scrubber adapted to scrub a gaseous waste stream and having an outlet adapted to discharge a scrubbed gaseous waste stream; and (2) a controlled decomposition oxidation (CDO) system. The CDO system includes a CDO thermal reaction chamber that includes (a) an inlet coupled to the outlet of the wet scrubber; (b) a catalyst bed adapted to abate PFCs within the CDO thermal reaction chamber; and (c) an outlet. Numerous other aspects are provided.",APPLIED MATERIALS INC,RAOUX SEBASTIEN;;LIN KUO-CHEN;;VERMEULEN ROBBERT M;;CLARK DANIEL O;;TSU STEPHEN;;MOALEM MEHRAN;;FOX ALLEN;;MCINTOSH MONIQUE;;PUTZ JOSHUA;;RIESKE ERIC,,https://lens.org/192-074-450-440-527,Patent of Addition,no,0,0,18,18,0,B01D53/8662;;B01D53/8662;;B01D2257/2066;;B01D2257/2066;;C01B7/20;;C01B7/20;;Y02C20/30;;Y02C20/30;;Y02P20/151;;Y02P20/151,H01L21/00,,0,0,,,,PENDING
949,EP,B1,EP 3274425 B1,151-198-561-839-669,2021-06-16,2021,EP 16711943 A,2016-03-10,US 201562136692 P;;US 2016/0021756 W,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,,EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-06-03),https://lens.org/151-198-561-839-669,Granted Patent,yes,6,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G65/12;;C10G47/14;;C10G47/16,,0,0,,,,ACTIVE
950,CN,A,CN 112997572 A,092-493-006-280-898,2021-06-18,2021,CN 201980073164 A,2019-11-18,US 201862769694 P;;US 2019/0062055 W,2018-11-20,SENSING-BASED DISTRIBUTED SCHEDULING OF EVENT-BASED MISSION CRITICAL (MC) VEHICLE-TO-EVERYTHING (V2X) TRAFFIC,"Technology is disclosed for a vehicle-capable user equipment (vUE) operable for sensing-based distributed scheduling 5 of event-based mission critical (MC) vehicle-toeverything (V2X) traffic. The vUE can sense sidelink control information (SCI) for semipersistent scheduling (SPS) resource selection from one or more SCI messages received in one or more physical sidelink control channels (PSCCHs) from one or more neighboring vUEs. The vUE can identify: a number of MC resources to transmit event10 based MC data with a selected number of repetitions within a latency budget, wherein the MC resources include one or more of MC-SCI or MC data with the selected number of repetitions; and a number of available resources to transmit event-based MC data within the latency budget. The vUE can select revocable resources from one or more scheduled low-priority resources based on the sensed SCI for SPS resource selection.",APPLE INC,JHA SATISH;;SIVANESAN KATHIRAVETPILLAI;;SHARMA BANJADE VESH RAJ;;FOUAD YASER;;MERWADAY ARVIND;;LU LU;;ALAM S M IFTEKHARUL;;CHEN KUILIN CLARK;;ZHANG YI,,https://lens.org/092-493-006-280-898,Patent Application,no,10,0,3,3,0,H04W92/18;;H04W72/02;;H04W4/40;;H04W4/44;;H04W4/46;;H04W4/70;;H04W4/10;;H04W4/027;;H04W4/80;;H04W36/0009;;H04W36/0007;;H04W72/02;;H04W72/0446;;H04W72/20;;H04W72/51;;H04W72/542,H04W72/12;;H04W4/40;;H04W72/02;;H04W92/18,,2,0,,,"INTEL CORPORATION: """"Sidelink Resource Allocation Mechanisms for NR V2X Communication"""", 《3GPP TSG RAN WG1 MEETING #94BIS R1-1810775》;;FUJITSU: ""“Resource Allocation for NR V2X Sidelink Communication”"", 《3GPP TSG RAN WG1 MEETING #95 R1-1812410》, pages 1 - 9",PENDING
951,US,B2,US 6797708 B2,089-316-721-700-155,2004-09-28,2004,US 30263602 A,2002-11-22,US 30263602 A;;US 33458801 P,2001-12-03,Inhibitors of cytosolic phospholipase A2,"
    This invention provides substituted indole compounds of the general formula: 

    and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A _{ 2 } enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVEN Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-15);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/089-316-721-700-155,Granted Patent,yes,34,67,5,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P29/00;;C07D209/14;;C07D409/12;;C07D401/12;;C07D413/14;;C07D403/12;;C07D417/14;;C07D405/12;;C07D413/12;;C07D417/12;;C07D487/08;;C07D491/10,A61P29/00;;C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/228.2;;514/374;;514/375;;514/381;;514/386;;514/406;;514/414;;514/233.5;;514/254.09;;514/256;;514/365;;514/278;;514/364;;514/326;;514/357;;514/327;;514/350;;514/339;;514/345;;544/58.2;;544/143;;544/333;;544/373;;546/16;;546/201;;546/277.4;;546/115;;548/125;;548/126;;548/181;;548/235;;548/236;;548/254;;548/364.7;;548/407;;548/454;;548/455;;548/504;;548/311.4,6,6,057-913-407-111-808;;049-360-904-961-611;;027-226-226-568-670;;007-737-889-206-944;;095-914-469-028-092;;017-773-555-337-136,7174067;;8978844;;10.1021/jm960487f;;8978843;;10.1021/jm960486n;;9005255;;10.1021/jm960485v;;10.1038/nsb0695-458;;pmc7097651;;7664108;;5069781;;10.1021/jm00280a027,"Roy et al., Further Studies on Anti-Inflammatory Activity of Tw Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp 207-214.;;Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp 5159-5175.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 2. -Indole-3-acetamides with Additional Functionality, J. Med. chem. 1996, vol. 39, No. 26, pp 5137-5158.;;Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp 5119-5136.;;Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp 458-465.;;Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp. 1081-1082.",EXPIRED
952,TW,A,TW 200800368 A,162-363-822-584-349,2008-01-01,2008,TW 96105105 A,2007-02-12,US 77231706 P;;US 86534706 P,2006-02-11,Methods and apparatus for PFC abatement using a CDO chamber,"In some aspects, an apparatus is provided for abating perfluorocarbons (PFCs) in a controlled decomposition oxidation (CDO) thermal reaction chamber. The apparatus includes (1) a cartridge insertable into the thermal reaction chamber having gas-permeable first and second ends and including a catalyst material; and (2) thermally-conductive fixtures positioned within the cartridge. Numerous other aspects are provided.",APPLIED MATERIALS INC,RAOUX SEBASTIEN;;LIN KUO-CHEN;;VERMEULEN ROBBERT M;;CLARK DANIEL O;;TSU STEPHEN;;MOALEM MEHRAN;;FOX ALLEN;;MCINTOSH MONIQUE;;PUTZ JOSHUA;;RIESKE ERIC,,https://lens.org/162-363-822-584-349,Patent of Addition,no,0,0,18,18,0,B01D53/8662;;B01D53/8662;;B01D2257/2066;;B01D2257/2066;;C01B7/20;;C01B7/20;;Y02C20/30;;Y02C20/30;;Y02P20/151;;Y02P20/151,B01D53/68;;B01D53/86;;H01L21/00,,0,0,,,,PENDING
953,DE,A1,DE 102022208684 A1,152-709-393-196-331,2023-03-23,2023,DE 102022208684 A,2022-08-22,US 202117448689 A,2021-09-23,VERFAHREN UND EINRICHTUNG FÜR RESILIENZ MITHILFE DIGITALER ZWILLINGE,"Verfahren, Einrichtungen, Systeme und Herstellungsartikel für Resilienz mithilfe digitaler Zwillinge sind offenbart. Ein beispielhaftes Verfahren beinhaltet Zugreifen auf Betriebsstatistiken, die einer oder mehreren physischen Entitäten entsprechen, wobei die eine oder die mehreren physischen Entitäten Benutzergeräte und Netzwerkausrüstung beinhalten; Aktualisieren einer oder mehrerer virtueller Entitäten innerhalb einer virtuellen Umgebung, die der einen bzw. den mehreren physischen Entitäten entsprechen, mit den Betriebsstatistiken; Simulieren einer Änderung der virtuellen Umgebung basierend auf den Betriebsstatistiken; Erzeugen einer Empfehlung für die Netzwerkausrüstung zum Durchführen einer Aufgabe basierend auf der simulierten Änderung; und Bereitstellen der Empfehlung an die Netzwerkausrüstung in Reaktion auf Bestimmen, dass eine Konfidenz der Empfehlung eine Schwellenkonfidenz erfüllt.",INTEL CORP,MERWADAY ARVIND;;SIVANESAN KATHIRAVETPILLAI;;JHA SATISH CHANDRA;;SHARMA BANJADE VESH RAJ;;ALAM S M IFTEKHARUL;;GOMES BALTAR LEONARDO;;CHEN KUILIN CLARK;;SEHRA SUMAN,,https://lens.org/152-709-393-196-331,Patent Application,no,0,0,3,3,0,H04W16/22;;H04W76/15;;G06N3/08;;G06N3/063;;H04B7/0695;;H04W24/04;;H04W36/08;;H04W16/22;;H04W76/15;;H04W76/19;;H04W24/10;;H04W36/08;;H04W36/24;;H04W24/04;;G06N5/04;;H04W76/15;;H04W76/19;;H04W36/165,H04W28/02,,0,0,,,,PENDING
954,US,B2,US 7101875 B2,044-502-267-744-903,2006-09-05,2006,US 30208702 A,2002-11-22,US 30208702 A;;US 33459101 P,2001-12-03,Methods for treating arthritic disorders,"This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,MCKEW JOHN C;;TAM STEVE Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-12),https://lens.org/044-502-267-744-903,Granted Patent,yes,35,13,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D405/12;;C07D409/12;;C07D209/14;;C07D413/14;;C07D487/08;;C07D417/14;;C07D413/12;;C07D491/10;;C07D403/12;;C07D417/12,A61K31/404;;A61K31/40;;A61K31/41;;A61K31/42;;A61K31/54;;C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/228.2;;514/374;;514/375;;514/381;;514/386;;514/406;;514/414;;514/233.5;;514/254.09;;514/256;;514/365;;514/278;;514/364;;514/326;;514/357;;514/327;;514/350;;514/339;;514/345,6,6,057-913-407-111-808;;049-360-904-961-611;;027-226-226-568-670;;007-737-889-206-944;;095-914-469-028-092;;017-773-555-337-136,7174067;;8978844;;10.1021/jm960487f;;8978843;;10.1021/jm960486n;;9005255;;10.1021/jm960485v;;10.1038/nsb0695-458;;pmc7097651;;7664108;;5069781;;10.1021/jm00280a027,"Roy et al., Further Studies on Anti-Inflammatory Activity of Two Potent Indian-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp. 207-214.;;Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A<SUB>2. </SUB>3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp. 5159-5175.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A<SUB>2- </SUB>2. Indole-3-acetamides with Additional Functionality, J. Med.chem. 1996, vol. 39, No. 26, pp. 5137-5158.;;Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A<SUB>2- </SUB>1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp. 5119-5136.;;Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp. 458-465.;;Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp. 1081-1082.",EXPIRED
955,SG,A,SG 11201705643W A,021-085-481-077-890,2017-10-30,2017,SG 11201705643W A,2016-03-10,US 201562136692 P;;US 2016/0021756 W,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,,EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,,https://lens.org/021-085-481-077-890,Unknown,no,0,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G65/12;;C10G47/14;;C10G47/16,,0,0,,,,PENDING
956,US,A1,US 2003/0149029 A1,078-582-944-659-391,2003-08-07,2003,US 30217102 A,2002-11-22,US 30217102 A;;US 33460501 P,2001-12-03,Methods for treating asthmatic conditions,"
    This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: 

    and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A ₂ enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVE Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-12),https://lens.org/078-582-944-659-391,Patent Application,yes,44,27,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D409/12;;C07D491/10;;C07D487/08;;C07D405/12;;C07D417/14;;C07D417/12;;C07D413/14;;C07D403/12;;C07D209/14;;C07D413/12,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/227.8;;514/233.5;;514/278;;514/323;;514/414;;514/419,0,0,,,,EXPIRED
957,EP,A1,EP 3274425 A1,172-470-529-974-723,2018-01-31,2018,EP 16711943 A,2016-03-10,US 201562136692 P;;US 2016/0021756 W,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,,EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-06-03),https://lens.org/172-470-529-974-723,Patent Application,yes,0,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G65/12;;C10G47/14;;C10G47/16,,0,0,,,,ACTIVE
958,US,B2,US 7713964 B2,061-741-881-004-563,2010-05-11,2010,US 30217102 A,2002-11-22,US 30217102 A;;US 33460501 P,2001-12-03,Methods for treating asthmatic conditions,"This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH LLC,MCKEW JOHN C;;TAM STEVEN Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-12),https://lens.org/061-741-881-004-563,Granted Patent,yes,74,5,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D409/12;;C07D491/10;;C07D487/08;;C07D405/12;;C07D417/14;;C07D417/12;;C07D413/14;;C07D403/12;;C07D209/14;;C07D413/12,A61K31/54;;A61K31/40;;A61K31/41;;A61K31/415;;A61K31/425;;A61K31/44;;A61K31/497;;A61K31/535;;C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/228.2;;514/374;;514/375;;514/381;;514/406;;514/414;;514/233.5;;514/254.09;;514/365;;514/278;;514/339;;514/826,30,25,095-914-469-028-092;;017-773-555-337-136;;049-360-904-961-611;;027-226-226-568-670;;007-737-889-206-944;;057-913-407-111-808;;023-381-831-996-846;;036-877-450-775-805;;020-654-176-077-967;;124-150-239-256-308;;006-389-760-792-212;;017-119-380-043-243;;068-228-387-549-08X;;151-879-670-237-214;;110-574-808-894-379;;020-654-176-077-967;;143-971-559-309-349;;067-576-826-353-21X;;012-599-148-844-832;;009-130-865-367-745;;001-844-539-881-363;;031-766-076-467-920;;128-362-223-519-855;;096-484-982-426-875;;007-306-546-814-126,10.1038/nsb0695-458;;pmc7097651;;7664108;;5069781;;10.1021/jm00280a027;;8978844;;10.1021/jm960487f;;8978843;;10.1021/jm960486n;;9005255;;10.1021/jm960485v;;7174067;;10.1038/37622;;9403692;;11377176;;10.1016/s0968-0896(00)00345-x;;10.1038/nrd985;;12509756;;2888113;;10.1073/pnas.84.18.6374;;pmc299078;;3300655;;10.1016/0006-2952(87)90512-0;;10.1016/0040-4020(95)00809-m;;10.1517/13543776.14.7.937;;10.1002/ddr.430100404;;10.1021/ja00137a021;;10.1038/nrd985;;12509756;;10.1016/0006-291x(89)92096-2;;2775276;;2925633;;10.1016/s0021-9258(18)83616-x;;11310603;;10.1016/s0968-0896(00)00286-8;;3143418;;10.1016/0005-2760(88)90316-5;;16102039;;10.1111/j.1538-7836.2005.01488.x;;10.1016/s0021-9258(18)83549-9;;2925608;;2655580;;10.1042/bj2590315;;pmc1138513;;3053741;;10.1080/21548331.1988.11703580;;10.1021/jo9909913,"Schevitz et al., Structure-Based Design of the First Potent and Selective Inhibitor of Human non-Pancreatic Secretory Phospholipase A2, Nature Structural Biology , vol. 2, No. 6, Jun. 1995, pp. 458-465.;;Doebel et al., Derivatives of Indole-1-acetic Acid as Antiinflammatory Agents, Journal of Medicinal Chemistry, 1972, vol. 15, No. 10, pp. 1081-1082.;;Draheim, et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 3. Indole-3-glyoxamides, Journal of Medicinal Chemistry, 1996, vol. 39, No. 26, pp. 5159-5175.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2. 2. Indole-3-acetamides with Additional Functionality, Journal of Medicinal Chemistry, 1996, vol. 39, No. 26, pp. 5137-5158.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospolipase A2. 1. Indole-3-acetamides, Journal of Medicinal Chemistry, 1996, vol. 39, No. 26, pp. 5119-5136.;;Roy, et al., Further Studies on Anti-inflammatory Activity of Two Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 26, No. 3, pp. 207-214.;;Uozumi, N., et al., ""Role of cytosolic phospholipase A2 in allergic response and parturition,"" Nature, 390:618-622, (Dec. 11, 1997).;;Adediran et al., The Synthesis and Evaluation of Benzofuranones as .beta.-Lactamase Substrates, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 1175-1183.;;Bhatt et al., Nature Reviews, Drug Discovery vol. 2, Jan. 15-28, 2003.;;Bonventure et al., et al., Nature 1997, 390: 622-625.;;Burch et al., Proc. Natl. Acad. Sci. U.S.A., 84:6374-6378 (1989).;;Chang et al, Biochem. Pharmacol., 36:2429-2436 (1987).;;Chemical Abstract Service Registry No. 865200-20-0, ""Benzoic acid, 4-[3-[5-chloro-1(diphenylmethyl)-2-[2-[[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]-(9C1),"" 1 page (Oct. 13, 2005).;;Chung et al., Synthesis of 3-Fluoro-2-substituted amino-5,12-dihydro-5-oxobenzoxazolo[3,2-.alpha.] quinoline-6-carboxylic Acids Employing the Tandem Double Ring Closure Reaction of N-Acetyl-N-(2-hydroxyphenyl)anthranilic Acid as the Key Step, Tetrahedron vol. 51, No. 46, pp. 12549-12562, 1995, Elsevier Science Ltd, printed in Great Britain.;;Clark et al., ""Potential therapeutic uses of phospholipase A2 inhibitors,"" Expert Opin. Ther. Pat., 14:937-950 (2004).;;Dennis, Drug Devel. Res., 10:205-220 (1987).;;Goodman et al., Self-Assembling, Chromogenic Receptors for the Recognition of Dicarboxylic Acid, J. Am. Chem. Soc., 1995, 117, pp. 8447-8455.;;Jackson et al., Nature Reviews, Drug Discovery vol. 2, Oct. 1-15, 2003.;;Kanda et al, Biochem. Biophys. Res. Comm., 163:42-48 (1989).;;Kramer et al, J. Biol. Chem., 264:5768-5775 (1989).;;Langer et al., Synthesis of High-specific-radioactivity 4- and 6-[.sup.18F]fluorometaraminol-PET Tracers for the Adrenergic Nervous System of the Heart, Bioorganic & Medicinal Chemistry, 9, 2001, pp. 677-694.;;Leslie et al, Biochem. Biophys. Acta., 963:476-492 (1988).;;Nieswandt et al., J. Thrombosis and Haemostasis, 3: 1725-1736 (2005).;;Samuelson et al., Science, 237:1171-76 (1987).;;Seilhamer et al, J. Biol. Chem., 264:5335-5338 (1989).;;Smith, Biochem. J., 259:315-324 (1989).;;Wasserman, Hospital Practice, 15:49-58 (1988).;;Xi et al., Functionalized Deep-Cavity Cavitands, J. Org. Chem. 1999, 64, pp. 9286-9288.;;Written Opinion of the International Searching Authority for PCT/US2006/020847, 7 pp. (Nov. 20, 2006).;;International Search Report for PCT/US2006/020847, 5 pages (Nov. 20, 2006).",INACTIVE
959,US,A1,US 2022/0022167 A1,060-763-558-880-521,2022-01-20,2022,US 201917295146 A,2019-11-18,US 201917295146 A;;US 201862769694 P;;US 2019/0062055 W,2018-11-20,SENSING-BASED DISTRIBUTED SCHEDULING OF EVENT-BASED MISSION CRITICAL (MC) VEHICLE-TO-EVERYTHING (V2X) TRAFFIC,"Technology is disclosed for a vehicle-capable user equipment (vUE) operable for sensing-based distributed scheduling 5 of event-based mission critical (MC) vehicle-to everything (V2X) traffic. The vUE can sense sidelink control information (SCI) for semi persistent scheduling (SPS) resource selection from one or more SCI messages received in one or more physical sidelink control channels (PSCCHs) from one or more neighboring vUEs. The vUE can identify: a number of MC resources to transmit event10 based MC data with a selected number of repetitions within a latency budget, wherein the MC resources include one or more of MC-SCI or MC data with the selected number of repetitions; and a number of available resources to transmit event-based MC data within the latency budget. The vUE can select revocable resources from one or more scheduled low-priority resources based on the sensed SCI for SPS resource selection.",APPLE INC,JHA SATISH;;SIVANESAN KATHIRAVETPILLAI;;SHARMA BANJADE VESH RAJ;;FOUAD YASER;;MERWADAY ARVIND;;LU LU;;ALAM S M IFTEKHARUL;;CHEN KUILIN CLARK;;ZHANG YI,,https://lens.org/060-763-558-880-521,Patent Application,yes,1,2,3,3,0,H04W92/18;;H04W72/02;;H04W4/40;;H04W4/44;;H04W4/46;;H04W4/70;;H04W4/10;;H04W4/027;;H04W4/80;;H04W36/0009;;H04W36/0007;;H04W72/02;;H04W72/0446;;H04W72/20;;H04W72/51;;H04W72/542,H04W72/02;;H04W36/00;;H04W72/04;;H04W72/12,,1,0,,,"FUJITSU,“Resource Allocation for NR V2X Sidelink Communication’,R1-1812410, 3GPP TSG RAN WGI Meeting#95, Spokane, US, 02November2018. (Year: 2018)",PENDING
960,US,A1,US 2003/0158405 A1,181-690-899-400-541,2003-08-21,2003,US 30263402 A,2002-11-22,US 30263402 A;;US 41966402 P;;US 33458801 P,2001-12-03,N-BENZHYDRYL INDOLE COMPOUNDS,"
    Compounds of the formula 

    in which R, R, R ₇ -R ₁₁ , X, n ₁ and n ₃ are as defined herein. These compounds are useful as intermediates for preparing pharmaceutical compounds having pharmacological activity as chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A ₂ enzymes. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVE Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-15);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/181-690-899-400-541,Patent Application,yes,0,15,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D209/14;;C07D413/12;;C07D409/12;;C07D413/14;;C07D491/10;;C07D417/14;;C07D487/08;;C07D405/12;;C07D417/12;;C07D403/12,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,544 6;;544/143;;544/333;;544/373;;546/201;;546/277.7;;548/181;;548/235;;548/312.1;;548/465;;548/509,0,0,,,,EXPIRED
961,WO,A1,WO 2020/106643 A1,032-887-066-664-637,2020-05-28,2020,US 2019/0062055 W,2019-11-18,US 201862769694 P,2018-11-20,SENSING-BASED DISTRIBUTED SCHEDULING OF EVENT-BASED MISSION CRITICAL (MC) VEHICLE-TO-EVERYTHING (V2X) TRAFFIC,"Technology is disclosed for a vehicle-capable user equipment (vUE) operable for sensing-based distributed scheduling 5 of event-based mission critical (MC) vehicle-toeverything (V2X) traffic. The vUE can sense sidelink control information (SCI) for semipersistent scheduling (SPS) resource selection from one or more SCI messages received in one or more physical sidelink control channels (PSCCHs) from one or more neighboring vUEs. The vUE can identify: a number of MC resources to transmit event10 based MC data with a selected number of repetitions within a latency budget, wherein the MC resources include one or more of MC-SCI or MC data with the selected number of repetitions; and a number of available resources to transmit event-based MC data within the latency budget. The vUE can select revocable resources from one or more scheduled low-priority resources based on the sensed SCI for SPS resource selection.",INTEL CORP,JHA SATISH;;SIVANESAN KATHIRAVETPILLAI;;SHARMA BANJADE VESH RAJ;;FOUAD YASER;;MERWADAY ARVIND;;LU LU;;ALAM S M IFTEKHARUL;;CHEN KUILIN CLARK;;ZHANG YI,,https://lens.org/032-887-066-664-637,Patent Application,yes,1,6,3,3,0,H04W92/18;;H04W72/02;;H04W4/40;;H04W4/44;;H04W4/46;;H04W4/70;;H04W4/10;;H04W4/027;;H04W4/80;;H04W36/0009;;H04W36/0007;;H04W72/02;;H04W72/0446;;H04W72/20;;H04W72/51;;H04W72/542,H04W72/12;;H04W4/40;;H04W72/02;;H04W92/18,,4,0,,,"FUJITSU: ""Resource Allocation for NR V2X Sidelink Communication"", R1-1812410, 3GPP TSG RAN WG1 MEETING #95, 2 November 2018 (2018-11-02), Spokane, US, XP051478610;;FRAUNHOFER HHI ET AL.: ""Physical Layer Procedures for Unicast and Groupcast"", R1-1812401, 3GPP TSG RAN WG1 MEETING #95, SPOKANE, 2 November 2018 (2018-11-02), US, XP051478601;;""Uu-based enhancements to control NR sidelink"", R1-1810456, 3GPP TSG RANI WG1 MEETING #94BIS, 29 September 2018 (2018-09-29), Chengdu, XP051517865;;HUAWEI ET AL.: ""Potential RAN2 impacts on gNB scheduled resource allocation for NR V2X"", R2-1816518, 3GPP TSG RAN WG2 #104, 2 November 2018 (2018-11-02), Spokane, USA, XP051480472",PENDING
962,US,A1,US 2003/0144282 A1,057-439-768-082-605,2003-07-31,2003,US 30263602 A,2002-11-22,US 30263602 A;;US 33458801 P,2001-12-03,Inhibitors of cytosolic phospholipase A2,"
    This invention provides substituted indole compounds of the general formula: 

    and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A ₂ enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVE Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-15);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/057-439-768-082-605,Patent Application,yes,19,35,5,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P29/00;;C07D209/14;;C07D409/12;;C07D401/12;;C07D413/14;;C07D403/12;;C07D417/14;;C07D405/12;;C07D413/12;;C07D417/12;;C07D487/08;;C07D491/10,A61P29/00;;C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,514/228.2;;X544 6;;544/143;;X54436;;544/333;;544/295;;544/373;;546/16;;546/201;;548/132;;548/252;;544/405;;548/465;;548/312.1;;548/364.7;;514/232.8;;514/255.05;;514/254.09;;514/256;;514/278;;514/339;;514/397;;514/406;;514/414;;514/419,0,0,,,,EXPIRED
963,US,B2,US 6635771 B2,091-578-105-100-246,2003-10-21,2003,US 30263402 A,2002-11-22,US 30263402 A;;US 41966402 P;;US 33458801 P,2001-12-03,N-benzhydryl indole compounds,"
    Compounds of the formula 

    in which R, R, R _{ 7 } -R _{ 11 } , X, n _{ 1 } and n _{ 3 } are as defined herein. These compounds are useful as intermediates for preparing pharmaceutical compounds having pharmacological activity as chemical inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A _{ 2 } enzymes. 
",WYETH CORP,MCKEW JOHN C;;TAM STEVEN Y;;LEE KATHERINE L;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK;;HU BAIHUA;;CLARK JAMES D,WYETH (2002-11-15);;WYETH LLC (2009-11-09);;ZIARCO INC (2016-09-15),https://lens.org/091-578-105-100-246,Granted Patent,yes,35,29,2,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D401/12;;C07D209/14;;C07D413/12;;C07D409/12;;C07D413/14;;C07D491/10;;C07D417/14;;C07D487/08;;C07D405/12;;C07D417/12;;C07D403/12,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,548/491;;546/277.4;;546/201;;544/61;;544/62;;544/143;;548/146;;548/217;;548/250;;548/255;;548/312.1;;548/364.7;;548/469,6,6,057-913-407-111-808;;049-360-904-961-611;;027-226-226-568-670;;007-737-889-206-944;;095-914-469-028-092;;017-773-555-337-136,7174067;;8978844;;10.1021/jm960487f;;8978843;;10.1021/jm960486n;;9005255;;10.1021/jm960485v;;10.1038/nsb0695-458;;pmc7097651;;7664108;;5069781;;10.1021/jm00280a027,"Roy et al., Further Studies on Anti-Inflammatory Activity of Two Potent Indan-1-Acetic Acids, Ind. J. Physiol. Pharmac., Jul.-Sep. 1982, vol. 28, No. 3, pp 207-214.;;Draheim et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2+ 3 Indole-3-glyoxamides, J. Med. Chem 1996, vol. 39, No. 26, pp 5159-5175.;;Dillard et al., Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2+ 2. Indole-3-acetamides with Additional Functionality, J. Med.chem. 1996, vol. 39, No. 26, pp 5137-5158.;;Dillard et al, Indole Inhibitors of Human Nonpancreatic Secretory Phospholipase A2+ 1. Indole-3-acetamides, J. Med. Chem., 1996, vol. 39, No. 26, pp 5119-5136.;;Schevitz et al., Nature Structural Biology, vol. 2, No. 2, Jun. 1995, pp 458-465.;;Doebel et al., J. Med. Chem., 1972, vol. 15, No. 10, pp 1081-1082.",EXPIRED
964,US,B2,US 9809764 B2,163-044-371-466-463,2017-11-07,2017,US 201615066251 A,2016-03-10,US 201615066251 A;;US 201562136692 P,2015-03-23,Hydrocracking process for high yields of high quality lube products,"A process for producing high yields of higher quality (API Group II, Group III′) lubricating oil basestock fractions which allows the production of two or more types of high quality lubes in continuous mode (no blocked operation mode) without transition times and feed or intermediate product tankage segregation. Two consecutive hydroprocessing steps are used: the first step processes a wide cut feed at a severity needed to match heavy oil lube properties. The second step hydroprocesses a light oil after fractionation of the liquid product from the first step at a severity higher than for the heavy oil fraction. The two hydroprocessing steps will normally be carried out in separate reactors but they may be combined in a single reactor which allows for the two fractions to be processed with different degrees of severity.",EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECK-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2016-06-03),https://lens.org/163-044-371-466-463,Granted Patent,yes,23,2,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G47/12;;C10G47/14;;C10G47/16;;C10G65/12;;C10G67/02;;C10M101/02,,2,1,013-106-266-318-313,10.1021/ie00008a008,"S. T. Sie, Acid-Catalyzed Cracking of Paraffinic Hydrocarbons, 31 Ind. Eng. Chem. Res. 1881-1889 (1992).;;The International Search Report and Written Opinion of PCT/US2016/021756 dated Jun. 6, 2016.",ACTIVE
965,WO,A1,WO 2016/153803 A1,024-717-251-162-776,2016-09-29,2016,US 2016/0021756 W,2016-03-10,US 201562136692 P,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,"A process for producing high yields of higher quality (API Group II, Group ΙΙI`) lubricating oil basestock fractions which allows the production of two or more types of high quality lubes in continuous mode (no blocked operation mode) without transition times and feed or intermediate product tankage segregation. Two consecutive hydroprocessing steps are used: the first step processes a wide cut feed at a severity needed to match heavy oil lube properties. The second step hvdroprocesses a light oil after fractionation of the liquid product from the first step at a severity higher than for the heavy oil fraction. The two hydroprocessing steps will normally be carried out in separate reactors but they may be combined in a single reactor which allows for the two fractions to be processed with different degrees of severity.",EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,,https://lens.org/024-717-251-162-776,Patent Application,yes,10,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G47/14;;C10G65/12;;C10G47/16,,0,0,,,,PENDING
966,EP,B1,EP 3561024 B1,001-422-272-013-486,2022-10-12,2022,EP 19181009 A,2016-03-10,US 201562136692 P;;EP 16711943 A;;US 2016/0021756 W,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,,EXXONMOBIL TECHNOLOGY & ENGINEERING COMPANY,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-07-06);;EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-06-03),https://lens.org/001-422-272-013-486,Granted Patent,yes,6,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G65/12;;C10G47/14;;C10G47/16;;C10G67/02,,0,0,,,,ACTIVE
967,TW,A,TW 200800366 A,061-167-373-406-642,2008-01-01,2008,TW 96105122 A,2007-02-12,US 77231706 P;;US 86534706 P,2006-02-11,Methods and apparatus for PFC abatement using a CDO chamber,"In some aspects, a method is provided for abating perfluorocarbons (PFCs) in a gaseous waste abatement system having a pre-installed controlled decomposition oxidation (CDO) thermal reaction chamber. The method that includes (1) providing a catalyst bed within the CDO thermal reaction chamber; and (2) introducing a gaseous waste stream into the CDO thermal reaction chamber so as to expose the gaseous waste stream to the catalyst bed. Numerous other aspects are provided.",APPLIED MATERIALS INC,RAOUX SEBASTIEN;;LIN KUO-CHEN;;VERMEULEN ROBBERT M;;CLARK DANIEL O;;TSU STEPHEN;;MOALEM MEHRAN;;FOX ALLEN;;MCINTOSH MONIQUE;;PUTZ JOSHUA;;RIESKE ERIC,,https://lens.org/061-167-373-406-642,Patent of Addition,no,0,0,18,18,0,B01D53/8662;;B01D53/8662;;B01D2257/2066;;B01D2257/2066;;C01B7/20;;C01B7/20;;Y02C20/30;;Y02C20/30;;Y02P20/151;;Y02P20/151,B01D53/00;;H01L21/00,,0,0,,,,PENDING
968,US,A1,US 2016/0298038 A1,128-209-657-600-262,2016-10-13,2016,US 201615066251 A,2016-03-10,US 201615066251 A;;US 201562136692 P,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,"A process for producing high yields of higher quality (API Group II, Group III′) lubricating oil basestock fractions which allows the production of two or more types of high quality lubes in continuous mode (no blocked operation mode) without transition times and feed or intermediate product tankage segregation. Two consecutive hydroprocessing steps are used: the first step processes a wide cut feed at a severity needed to match heavy oil lube properties. The second step hydroprocesses a light oil after fractionation of the liquid product from the first step at a severity higher than for the heavy oil fraction. The two hydroprocessing steps will normally be carried out in separate reactors but they may be combined in a single reactor which allows for the two fractions to be processed with different degrees of severity.",EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECK-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2016-06-03),https://lens.org/128-209-657-600-262,Patent Application,yes,1,7,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G67/02;;C10M101/02,,1,1,013-106-266-318-313,10.1021/ie00008a008,"S. T. Sie, Acid-Catalyzed Cracking of Paraffinic Hydrocarbons, 31 Ind. Eng. Chem. Res. 1881-1889 (1992)",ACTIVE
969,EP,A1,EP 3561024 A1,055-705-809-173-973,2019-10-30,2019,EP 19181009 A,2016-03-10,US 201562136692 P;;EP 16711943 A;;US 2016/0021756 W,2015-03-23,HYDROCRACKING PROCESS FOR HIGH YIELDS OF HIGH QUALITY LUBE PRODUCTS,"A process for producing high yields of higher quality (API Group II, Group III') lubricating oil basestock fractions which allows the production of two or more types of high quality lubes in continuous mode (no blocked operation mode) without transition times and feed or intermediate product tankage segregation. Two consecutive hydroprocessing steps are used: the first step processes a wide cut feed at a severity needed to match heavy oil lube properties. The second step hydroprocesses a light oil after fractionation of the liquid product from the first step at a severity higher than for the heavy oil fraction. The two hydroprocessing steps will normally be carried out in separate reactors but they may be combined in a single reactor which allows for the two fractions to be processed with different degrees of severity.
",EXXONMOBIL RES & ENG CO,UMANSKY BENJAMIN S;;HOO TECH-MUI;;DEMMIN RICHARD A;;CHEN FENGRONG;;GLEESON JAMES W;;DOU SUISHENG M;;MELLI TOMAS R;;CLARK MICHAEL C,EXXONMOBIL TECHNOLOGY AND ENGINEERING COMPANY (2022-07-06);;EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (2020-06-03),https://lens.org/055-705-809-173-973,Patent Application,yes,10,0,8,8,0,C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10G47/14;;C10G47/16;;C10G65/12;;C10G2300/301;;C10G2300/302;;C10G2300/304;;C10G2400/10;;C10G67/02;;C10M101/02,C10G65/12;;C10G47/14;;C10G47/16;;C10G67/02,,0,0,,,,ACTIVE
970,US,A1,US 2023/0351235 A1,150-484-924-000-741,2023-11-02,2023,US 202318140813 A,2023-04-28,US 202318140813 A;;US 202263336873 P,2022-04-29,SYSTEMS AND METHODS FOR PIEZOELECTRIC CONTROL OF SPIN QUANTUM MEMORIES,"A method for controlling a qubit encoded in an atom-like defect in a solid-state host may comprise applying an electrical signal to a piezoelectric cantilever that is mechanically coupled to a photonic waveguide comprising one or more embedded point defect sites. The photonic waveguide may be optically coupled to a photonic chip. Applying the electrical signal to the piezoelectric cantilever may induce movement in the piezoelectric cantilever, which may induce a strain in the photonic waveguide. The applied electrical signal may be determined by a defect site with excitation light, measuring a frequency of a photon emitted by the excited defect site, determining a frequency shift based on the measured frequency of the emitted photon, and determining the electrical signal to be applied to the piezoelectric cantilever based on the frequency shift.",MITRE CORP;;NATIONAL TECH & ENGINEERING SOLUTION OF SANDIA LLC;;MIT MASSACHUSETTS INSTITUTE OF TECH,CLARK GENEVIEVE;;KOPPA MATTHEW;;CHEN KEVIN;;LEENHEER ANDREW;;LI LINSEN;;DOMINQUEZ DANIEL;;DONG MARK;;SAHA MATTHEW;;GOLTER ANDREW;;GILBERT GERALD;;EICHENFIELD MATTHEW;;ENGLUND DIRK,,https://lens.org/150-484-924-000-741,Patent Application,yes,0,0,1,1,0,G02F1/0128;;G02F1/011;;G02F1/0102;;G06N10/40;;G06N10/20;;G02F1/0128;;G02F2202/32;;G02F1/0102;;G06E3/005;;G02F1/011,G06N10/20;;G02F1/01;;G06E3/00,,0,0,,,,PENDING
971,US,S,US D0624928 S,184-962-901-598-960,2010-10-05,2010,US 34548909 F,2009-10-16,US 34548909 F,2009-10-16,Graphic user interface for a display screen,,MICROSOFT CORP,AGNETTA BRYAN T;;ASTORT ALFRED;;CHEN LIANG;;TURPIN MATT CLARK;;HULBERT MATTHEW STIEG;;SPEIGHT BRIAN;;BRANTLEY JOSH JEREMIAH;;BALLEW MATT CHRISTOPHER;;BRIGHT ASHLEY ALEXANDER,MICROSOFT CORPORATION (2009-10-12),https://lens.org/184-962-901-598-960,Design Right,no,0,49,1,1,0,,,3200;;D14/487;;D14/491,0,0,,,,ACTIVE
972,US,S,US D0624930 S,147-899-447-855-478,2010-10-05,2010,US 34549209 F,2009-10-16,US 34549209 F,2009-10-16,Graphic user interface for a display screen,,MICROSOFT CORP,AGNETTA BRYAN T;;ASTORT ALFRED;;CHEN LIANG;;TURPIN MATT CLARK;;HULBERT MATTHEW STIEG;;SPEIGHT BRIAN;;BRANTLEY JOSH JEREMIAH;;BALLEW MATT CHRISTOPHER;;BRIGHT ASHLEY ALEXANDER,MICROSOFT CORPORATION (2009-10-12),https://lens.org/147-899-447-855-478,Design Right,no,0,65,1,1,0,,,3200;;D14/487,0,0,,,,ACTIVE
973,US,S,US D0624929 S,165-650-393-129-25X,2010-10-05,2010,US 34549109 F,2009-10-16,US 34549109 F,2009-10-16,Graphic user interface for a display screen,,MICROSOFT CORP,AGNETTA BRYAN T;;ASTORT ALFRED;;CHEN LIANG;;TURPIN MATT CLARK;;HULBERT MATTHEW STIEG;;SPEIGHT BRIAN;;BRANTLEY JOSH JEREMIAH;;BALLEW MATT CHRISTOPHER;;BRIGHT ASHLEY ALEXANDER,MICROSOFT CORPORATION (2009-10-12),https://lens.org/165-650-393-129-25X,Design Right,no,0,26,1,1,0,,,3200;;D14/487;;D14/491,0,0,,,,ACTIVE
974,US,B1,US 6261813 B1,199-798-576-365-946,2001-07-17,2001,US 19809698 A,1998-11-23,US 19809698 A;;US 10270398 P;;US 366195 P,1995-09-11,Two step enzymatic acylation,A method for derivatizing a compound having a hydroxyl group by back to back acylation is provided. The compound is acylated with a bifunctional acyl donor in the presence of a hydrolase to form an activated acyl ester or carbonate. Preferably the bifunctional acylating donor is a di(vinyl) ester or carbonate. The activated acyl ester or carbonate is then used to acylate a nucleophile in the presence of a lipase. The method of the invention provides regioselective enzymatic acylation of the base compound.,ALBANY MOLECULAR RES INC,KHMELNITSKY YURI L;;BUDDE CHERYL L;;ARNOLD JOHN M;;RICH JOSEPH O;;CHEN SHARON S;;USYATINSKY ALEXANDER YA;;CLARK DOUGLAS S;;DORDICK JONATHAN S,ENZYMED INC (1998-12-22);;AMR TECHNOLOGY INC (2004-07-07);;ALBANY MOLECULAR RESEARCH INC (2008-12-11),https://lens.org/199-798-576-365-946,Granted Patent,yes,2,10,1,9,0,C07H13/06;;C07H13/06;;C07D305/14;;C07D305/14;;C07H13/08;;C07H13/08;;C07H13/10;;C07H13/10;;C07H15/18;;C07H15/18;;C07H15/26;;C07H15/26;;C07H17/04;;C07H17/04;;C07H17/08;;C07H17/08;;C07H19/16;;C07H19/16;;G11C5/143;;G11C5/143;;G11C11/401;;G11C11/401;;G11C29/028;;G11C29/028;;G11C29/50;;G11C29/50;;G11C29/50012;;G11C29/50012,C07D305/14;;C07H13/06;;C07H13/08;;C07H13/10;;C07H15/18;;C07H15/26;;C07H17/04;;C07H17/08;;C07H19/16;;G11C5/14;;G11C29/50,435/135;;435/136;;435/117;;435/123;;435/72,64,54,081-288-693-423-835;;163-949-322-559-459;;070-024-634-398-74X;;067-897-580-324-300;;043-429-425-406-113;;048-097-747-920-557;;029-803-125-483-109;;078-394-872-777-197;;189-226-996-516-927;;054-413-514-072-146;;052-221-435-272-685;;022-617-463-894-417;;047-889-876-581-829;;070-024-634-398-74X;;126-842-090-765-074;;003-846-246-017-362;;096-110-239-479-042;;026-837-534-613-521;;063-609-427-435-317;;103-151-579-029-585;;029-803-125-483-109;;107-197-606-900-76X;;155-005-879-122-627;;011-086-175-349-140;;088-121-563-822-125;;126-928-253-561-584;;058-820-558-166-906;;037-267-588-207-964;;055-271-416-424-254;;122-974-213-361-846;;076-656-956-960-954;;044-640-549-079-572;;029-400-858-850-387;;021-852-445-100-277;;070-023-444-628-829;;015-729-566-575-630;;163-949-322-559-459;;144-613-995-367-808;;102-120-956-640-032;;030-065-661-437-580;;038-005-989-364-959;;065-256-322-869-866;;054-552-846-647-102;;067-897-580-324-300;;073-224-042-022-816;;029-074-371-988-463;;032-005-116-883-006;;041-027-996-169-911;;005-488-326-684-865;;067-467-754-425-209;;019-802-756-155-69X;;117-261-637-755-960;;010-880-636-193-743;;016-518-972-217-499,10.1021/ja973103z;;10.1021/jm00079a019;;1346275;;10.1021/jm00124a011;;2564894;;10.1038/364464a0;;8101355;;10.1021/np50078a018;;10.1021/ar00172a004;;7915279;;10.1016/s0021-9258(17)31767-2;;10.1016/0141-0229(88)90115-9;;10.1007/bf01021662;;10.1039/p19940002385;;10.1002/anie.198906951;;10.1021/np50082a002;;1355110;;10.1002/recl.19931121102;;10.1021/jm00124a011;;2564894;;10.1055/s-1995-3882;;10.1016/0008-6215(93)87045-t;;8342077;;8102018;;10.1021/jm00100a031;;1359143;;10.1016/s0960-894x(01)80411-x;;10.1021/ar00028a005;;7915279;;10.1016/s0021-9258(17)31767-2;;10.1055/s-1993-22364;;10.1021/ja00083a067;;10.1021/ja00083a066;;10.1021/np50046a018;;2878063;;18613114;;10.1002/bit.260420616;;10.1016/s0040-4020(01)87306-3;;10.1002/chin.199406054;;10.1021/ja00085a066;;10.1016/s0040-4039(00)60706-2;;7765351;;10.1016/0167-7799(94)90120-1;;10.1016/s0957-4166(00)86021-8;;10.1007/bf01020845;;10.1080/07328309308021267;;2898009;;10.1021/np50056a017;;7636751;;10.1021/jm00079a019;;1346275;;10.1021/cr60232a004;;2569287;;10.7326/0003-4819-111-4-273;;6548627;;10.1016/0006-291x(84)91557-2;;10.1055/s-1993-25798;;10.1002/anie.199415811;;10.1021/ja00107a006;;10.1038/364464a0;;8101355;;10.1016/s0040-4020(01)91210-4;;10.1080/07328309308018546;;2886648;;10.1093/jnci/82.15.1247;;1973737;;1361079;;10.1038/277665a0;;423966;;10.1007/bf00131554;;10.1007/bf00131205;;10.1021/ja00278a053;;10.1016/0960-894x(95)00018-o,"J. Am. Chem. Soc. 119(47):11554-11555 (Khmelnitsky et al), 1997.*;;Mathew et al, ""Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity,"" J. Med. Chem., 1992, 35, 145-151.;;Deutsch et al., ""Synthesis of Congeners and Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity,"" J. Med. Chem., 1989, 32, 788-792.;;Ueda, et al. ""Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel-2'-Carbonates),"" Bioorg. Med. Chem. Lttrs., 1994, 4, 1861-1864.;;Nicolaou et al., ""Design, synthesis and biological activity of protaxols,"" Nature, Jul. 29, 1993, 364, 464-466.;;Zhao et al., ""Modified Taxols, 6. 1Preparation of Water-Soluble Prodrugs of Taxol,"" J. Nat. Prod., Nov.-Dec. 1991, 54, 1607-1611.;;Klibanov, ""Asymmetric Transformations Catalyzed by Enzymes in Organic Solvents,"" Acc. Chem. Res., 1990, 23, 114-120.;;Hanson et al., ""Site-specific Enzymatic Hydrolysis of Taxanes of C-10 and C-13,"" J. Biol. Chem., Sep. 2, 1994, 269, 22145-22149.;;Khmelnitsky et al., ""Engineering biocatalytic systems in organic media with low water content,"" Enzyme Microb. Technol., Dec. 1988,10, 710-724.;;Lambusta, Daniela, et al., ""Lipase catalyzed acylation of phenols in organic solvents,"" Indian Journal of Chemistry, vol. 32B, Jan. 1993, pp. 58-60.;;Athawale, V.D. and Gaonkar, S.R., ""Enzymatic Synthesis of Polyesters by Lipase Catalysed Polytransesterification,"" Biotechnology Letters, vol. 16, No. 2 (Feb. 1994), pp. 149-154.;;Baldessari, Alicia et al., ""Regioselective Acylation of 3-Mercaptopropane-1,2-diol by Lipase-catalysed Transesterification,"" J. Chem. Research (S), 1993, pp. 382-383.;;Bianchi, Daniele et al., ""Enzymatic preparation of optically active fungicide intermediates in aqueous and in organic media,"" Indian Journal of Chemistry, vol. 32B, Jan. 1993, pp. 176-180.;;Bunnage, Mark E. et al., ""Asymmetric Synthesis of the Taxol and Taxotère C-13 Side Chains,"" J. Chem. Soc. Perkin Trans. 1, 1994, pp. 238 239.;;Chen, Ching-Shih and Sih, Charles J., ""General Aspects and Optimization of Enantioselective Biocatalysis in Organic Solvents: The Use of Lipases,"" Angew. Chem. Int. Ed. Engl. 28 (1989), pp. 695-707.;;Chmurney, Gwendolyn N. et al., ""1H- and 13C-NMR Assignments for Taxol, 7-epi-Taxol, and Cephalomannine,"" Journal of Natural Products, vol. 55, No. 4, Apr. 1992, pp. 414-423.;;de Goede, A.T.J.W. et al., ""Selective lipase-catalyzed 6-0-acylation of alkyl alpha-D-glucopyranosides using functionalized ethyl esters,"" Recueil des Travaux Chimiques des Pays-Bas, 112/11, Nov. 1993. pp 567-672.;;Deutsch, H.M. et al., ""Synthesis of Congeners and Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity,"" Journal of Medicinal Chemistry, 1989, vol. 32, No. 4, pp. 792.;;Dondoni, Alessandro et al., ""Synthesis of Taxol and Taxotere Side chains by 2-(Trimethylsilyl)thiazole Based Homologation of L-Phenylglycine,"" Synthesis, Fab. 1995, pp. 181-186.;;Fabre, Jean et al., ""Regiospecific enzymic acylation of butyl alpha-D-glucopyranoside,"" Carbohydr. Res. 243 (1993) pp. 407-411.;;Forastiere, Arlene A., ""Use of Paclitaxel (TAXOL(R)) in Squamous Cell Carcinoma of the Head and Neck,"" Seminars in Oncology, vol. 20, No. 4, Suppl. 3 (Aug.), 1993, pp. 56-60.;;Georg, Gunda I., ""Synthesis of Biologically Active Taxol Analogues with Modified Phenylisoserine Side Chains,"" J. Med. Chem., 1982, vol. 35, No. 22.;;Greenwald, Richard B. et al., ""Highly Water Soluble Taxol Derivatives: 2'-Polyethyleneglycol Esters as Potential Prodrugs,"" Bioorganic & Medical Chemistry Letters, vol. 4, No. 20 (1994),pp. 2465-2470.;;Guenard, Daniel et al., ""Taxol and Taxotere: Discovery, Chemistry, and Structure-Activity Relationships,"" Acc. Chem. Res. 1993, 26, pp. 160-167.;;Hanson, Ronald L. et al., ""Site-specific Enzymatic Hydrolysis of Taxanes at C-10 and C-13,"" J. Biological Chemistry, vol. 269, No. 35, Issue of Sep. 2, pp. 22145-22148, 1994.;;Herradon, Bernardo, ""Biocatalytic Synthesis of Chiral Polyoxgenated Compounds: Effect of the Solvent on the Enantioselectivity of Lipase Catalyzed Transesterifications in Organic Solvents,"" SYNLETT, Feb. 1993, pp. 108-110.;;Holton, Robert A., ""First Total Synthesis of Taxol. 2. Completion of the C and D Rings,"" J. Am. Chem. Soc. 1994, 116, pp. 1599-1600.;;Holton, Robert A., ""First Total Synthesis of Taxol. 1. Functionalization of the B Ring,"" J. Am. Chem. Soc. 1994, 116, pp. 1597-1598.;;Huang, C.H. Oliver et al., ""New Taxanes from Taxus Brevifolia. 2.,"" J. Natural Products, vol. 49, No. 4, pp. 665-669, Jul.-Aug. 1986.;;Ikeda, Isao and Klibanov, Alexander M., ""Lipase-Catalyzed Acylation of Sugars Solubilized in Hydrophobic Solvents by Complexation,"" Biotechnology and bioengineering, vol. 42, pp. 788-791 (1993).;;Jones, J. Bryan, ""Enzymes in Organic Synthesis,"" Tetrahedron, vol. 42, No. 13, pp. 3351-3403, 1986.;;Kanerva, Liisa T. and Sundholm, Oskari, ""Enzymatic Acylation in the Resolution of Methyl threo-2-Hydroxy-3-(4-methoxyphenyl)-3-(2-X-phenylthio)propionates in Organic Solvents,"" J. chem. Soc. Perkins Trans. 1, 1993.;;Kanerva, Liisa and Sundholm, Oskari, ""Lipase Catalysis in the Resolution of Recemic Intermediates of Diltiazem Synthesis in Organic Solvents,"" J. Chem. Soc. Perkin Trans. 1., 1993.;;Khmelnitsky, Yuri L., ""Salts Dramatically Enhance Activity of Enzymes Suspended in Organic Solvents,"" J. Am. Chem. Soc., 1994, 116.;;Khmelnitsky, Yu. L., ""Engineering biocatalytic systems in organic media with low water contents,"" Enzyme Microb. Technol., 1988, vol. 10, Dec., pp. 710-724.;;Kingston, David G.I. et al., ""The Chemistry of Taxol, a Clinically Useful Anticancer Agent,"" J. Natural Products, vol. 53, No. 1, pp. 1-12, Jan.-Feb. 1990.;;Kingston, David G.I. et al., ""Synthesis of Taxol from Baccatin III via an Oxazoline Intermediate,"" Tetrahedron Letters, vol. 35, No. 26, pp. 4483-4484, 1994.;;Kingston, David G.I., ""The Chemistry of Taxol,"" Pharmac. Ther., vol. 52, pp. 1034, 1991.;;Kingston, David G.I., ""Taxol: the chemistry and structure-activity relationships of a novel anticancer agent,"" Tib. Tech. 12(6), 1994, pp 222-227.;;Yong-Fu Li and Hammerschmidt, Friederich, ""alpha-(Acyloxy)phosphonates by Esterolytic Enzymes,"" Tetrahedron:Asymmetry, vol. 4, No. 1, pp. 109-120, 1993.;;Ljunger, Gudrun et al., ""Lipase Catalyzed Acylation of Glucose,"" Biotechnology Letters, vol. 16, No. 11 (Nov. 1994), p. 1167-1172.;;Lopez, Rosa et al., ""Enzymatic Transesterification of Alkyl 2,3,4-Tri-O-Acyl-beta-D-Xylopyranosides,"" J. Carbohydrate Chemistry, 12(2), 165-171 (193).;;Magri, Neal F. and Kingston, David G.I., ""Modified Taxols, 4.Synthesis and Biological Activity of Taxols Modified in the Side Chain,"" J. Natural Products, vol. 51, No. 2, pp. 298-306, Mar.-Apr. 1988.;;Mamber, Stephen W. et al., ""Tubulin Polymerization by Paclitaxel (Taxol) Phosphate Prodrugs after Metabolic Activation with Alkaline Phosphatase,"" J. Pharmacology and Experimental Therapeutics, vol. 274, No. 2, 1995, pp. 877-883.;;Mathew, Abraham E., ""Synthesis and Evaluation of Some Water-Soluble Prodrugs and Derivatives of Taxol with Antitumor Activity,"" J. Med. Chem. 1992, 35, 145-151.;;Matzner, Markus et al., ""The Chemistry of Chloroformates,"" Chemical Reviews, vol. 64, No. 6, Dec. 1964, 645-687.;;McGuire, William P. et al., ""Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms,"" Annals of Internal Medicine, vol. 111, No. 4, 273-280.;;Mellado, Wilfredo et al., ""Preparation and Biological Activity of Taxol Acetates,"" Biochemical and biophysical Research Communications, vol. 124, No. 2, 1984, pp. 329-336.;;Menendez, Emma and Gotor, Vicente, Acylation and Alkoxycarbonylation of Oximes Through an Enzymatic Oximolysis Reaction, Synthesis, Jul. 1993, 72-74.;;Nicolaou, Kyriacos Costa et al., ""Synthesis of C-2 Taxol Analogues,"" Angew. Chem. Int. Ed. Engl. 1994, 33, No. 15.16, pp. 1581-1582.;;Nicolaou, K.C. et al., ""Total Synthesis of Taxol. 1. Retrosynthesis, Degradation, and Reconstitution,"" J. Am. Chem. Soc. 1995, 117, 624-633.;;Nicolaou, K.C. et al., ""Design, synthesis and biological activity of protaxols,"" Nature, vol. 364, Jul. 29, 1993, 464-466.;;Ojima, Iwao et al., ""New and Efficient Approaches to the Semisynthesis of Taxol and its C-13 Side Chain Analogs by Means of beta-Lactam Synthon Method,"" Tetrahedron, vol. 48, No. 34, pp. 6985-7012, 1992.;;Panza, Luigi et al., ""Selective Acylation of 4,6-O-Benzylidene Glycopyranosides by Enzymatic catalysis,"" J. Carbohydrate Chemistry, 12(1), 125-130 (1993).;;Ringel, Israel and Horwitz, Susan Band, ""Taxol is Converted to 7-Epitaxol, a Biologically Active Isomer, in Cell Culture Medium,"" The Journal Pharmacology and Experimental Therapeutics, vol. 242, 1987, pp. 692-698.;;Rowinsky, Eric K. et al., ""Taxol: A Novel Investigational Antimicrotubule Agent,"" J. Nat. Cancer Inst., vol. 82, No. 15, Aug. 1, 1990, pp. 1247-1250.;;Rowinsky, Eric K. et al., ""Taxol: The First of the Taxanes, an Important New Class of Antitumor Agents,"" Seminars In Oncology, vol. 19, No. 6 (Dec.), 1992, pp. 646-662.;;Schiff, Peter B. et al., ""Promotion of microtubule assembly in vitro by taxol,"" Nature, vol. 277, Feb. 22, 1979, p. 665-667.;;Schlotterbeck, Andrea et al., ""Lipase-Catalyzed Monoacylation of Fructose,"" Biotechnology Letters, vol. 15, No. 1 (Jan. 1993) pp. 61-64.;;Sharma, A. and Chattopadhyay, S., ""Lipase Catalysed Acetylation of Carbohydrates,"" Biotechnology Letters, vol. 15, No. 11 (Nov. 1993), pp. 1145-1146.;;Sih, Charles J. and Rosazza, John P., ""Microbial Transformations in Organic Synthesis,"" Techniques of Chemistry, vol. X-Applications of Biochemical Systems in Organic Chemistry, 1976, pp. 69-106.;;Therisod, Michel and Klibanov, Alexander M., ""Facile Enzymatic Preparation of Monoacylated Sugars in Pyridine,"" J. Am. Chem. Soc., vol. 108, No. 18, 1986, pp 5638-5640.;;Ueda, Yasutsugu et al., Synthesis and Antitumor Evaluation of 2'-Oxycarbonylpaclitaxels (Paclitaxel-2'-Carbonates), Biorganic & Medicinal Chemistry Letters, vol. 4, No. 15, pp. 1861-1864. (1994).;;Ueda, Yasutsugu et al., ""Novel, Water-soluble Phosphate Derivatives of 2'-Ethoxy Carbonylpaclitaxel as Potential Prodrugs of Paclitaxel: Synthesis and Antitumor Evaluation,"" Biorganic & Medicinal Chemistry Letters, vol. 5, No. 3, pp. 247-252, 1995.",EXPIRED
975,EP,A1,EP 4156745 A1,097-914-602-445-673,2023-03-29,2023,EP 22188476 A,2022-08-03,US 202117482773 A,2021-09-23,UNLICENSED SPECTRUM HARVESTING WITH COLLABORATIVE SPECTRUM SENSING IN NEXT GENERATION NETWORKS,"A computing node includes interface circuitry and processing circuitry. To implement a spectrum harvesting entity in a wireless network configured for crowdsource-based unlicensed spectrum harvesting, the processing circuitry is configured to select a set of crowdsourcing nodes from a plurality of crowdsourcing nodes available in the wireless network. A plurality of spectrum occupancy reports (SORs) is received from the set of crowdsourcing. Each of the plurality of SORs indicates a channel occupancy status of a communication channel in the unlicensed spectrum sensed by a corresponding crowdsourcing node of the set and geolocation associated with the corresponding crowdsourcing node. A spectrum occupancy map of the unlicensed spectrum is generated based on the channel occupancy status and the geolocation provided in the plurality of SORs by each crowdsourcing node of the set of crowdsourcing nodes.
",INTEL CORP,YANG LIUYANG;;MACIOCCO CHRISTIAN;;SMITH NED;;DOSHI KSHITIJ;;GUIM BERNAT FRANCESC;;JHA SATISH;;SHARMA BANJADE VESH RAJ;;ALAM S M IFTEKHARUL;;CHEN KUILIN CLARK,,https://lens.org/097-914-602-445-673,Patent Application,yes,0,0,3,3,0,H04W16/14;;H04W4/38;;G06N20/00;;H04W16/14,H04W16/14;;G05D1/00,,6,6,084-288-379-094-286;;066-185-544-818-635;;116-873-068-203-541;;114-054-579-913-252;;167-217-419-350-805;;012-927-090-521-298,10.1109/access.2019.2901200;;10.1109/access.2019.2949202;;10.1007/978-3-030-29959-0_27;;10.17487/rfc7231;;10.17487/rfc3986;;10.17487/rfc8820,"LI XIAOHUI ET AL: ""Privacy-Aware Crowdsourced Spectrum Sensing and Multi-User Sharing Mechanism in Dynamic Spectrum Access Networks"", IEEE ACCESS, vol. 7, 22 February 2019 (2019-02-22), pages 32971 - 32988, XP011716062, DOI: 10.1109/ACCESS.2019.2901200;;QIU XINYU ET AL: ""Cost-Minimized Crowdsourced Spectrum Sensing"", IEEE ACCESS, vol. 7, 23 October 2019 (2019-10-23), pages 154640 - 154648, XP011756000, DOI: 10.1109/ACCESS.2019.2949202;;CURRAN MAX ET AL: ""ProCSA: Protecting Privacy in Crowdsourced Spectrum Allocation"", 15 September 2019, ADVANCES IN DATABASES AND INFORMATION SYSTEMS; [LECTURE NOTES IN COMPUTER SCIENCE; LECT.NOTES COMPUTER], SPRINGER INTERNATIONAL PUBLISHING, CHAM, PAGE(S) 556 - 576, ISBN: 978-3-319-10403-4, XP047521417;;FIELDING ET AL.: ""Hypertext Transfer Protocol (HTTP/1.1): Semantics and Content"", IETF RFC 7231, June 2014 (2014-06-01);;BERNERS-LEE ET AL.: ""Uniform Resource Identifier (URI): Generic Syntax"", RFC 3986, January 2005 (2005-01-01);;NOTTINGHAM: ""URI Design and Ownership"", IETF RFC 8820, June 2020 (2020-06-01)",PENDING
976,US,S,US D0624931 S,190-618-061-890-460,2010-10-05,2010,US 34549309 F,2009-10-16,US 34549309 F,2009-10-16,Graphic user interface for a display screen,,MICROSOFT CORP,AGNETTA BRYAN T;;ASTORT ALFRED;;CHEN LIANG;;TURPIN MATT CLARK;;HULBERT MATTHEW STIEG;;SPEIGHT BRIAN;;BRANTLEY JOSH JEREMIAH;;BALLEW MATT CHRISTOPHER;;BRIGHT ASHLEY ALEXANDER,MICROSOFT CORPORATION (2009-10-12),https://lens.org/190-618-061-890-460,Design Right,no,0,19,1,1,0,,,3200;;D14/487;;D14/491,0,0,,,,ACTIVE
977,WO,A1,WO 2020/051049 A1,072-092-423-289-487,2020-03-12,2020,US 2019/0048693 W,2019-08-29,EP 18290101 A,2018-09-06,FABRIC CARE COMPOSITION,"A fabric care composition is provided including water; a modified carbohydrate polymer having a weight average molecular weight of < 500,000 Daltons and a Kjeldahl nitrogen content corrected for ash and volatiles, TKN, of ≥ 0.5 wt%; and a cleaning surfactant; wherein the modified carbohydrate polymer is a carbohydrate polymer functionalized with quaternary ammonium moieties; wherein the quaternary ammonium moieties on the modified carbohydrate polymer include: trimethyl ammonium moieties having formula (I) and dimethyl(alkyl) ammonium moieties having formula (II) wherein each R is independently selected from a C 8‑22 alkyl group.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS,PARTAIN III;;SHULMAN JAN E;;MIGLIORE ALINE;;CHEN YUNSHEN;;HAYES JOHN;;PEERA ASGHAR A;;YANG PEILIN;;CLARK MARIANN;;DONOVAN STEPHEN;;TODD JENNIFER;;LESLIE CYNTHIA,,https://lens.org/072-092-423-289-487,Patent Application,yes,4,4,9,9,0,C11D3/0015;;C11D3/0036;;C11D3/227;;C11D1/146;;C11D1/22;;C11D1/72;;C11D1/831;;C11D3/0015;;C11D3/0036;;C11D3/227;;C11D2111/12,C11D3/00;;C11D3/22,,2,0,,,"W. W. YAUJ. J. KIRKLANDD. D. BLY: ""Modem Size Exclusion Chromatography"", 1979, WILEY-LNTERSCIENCE;;J. P. SIBILIA: ""A Guide to Materials Characterization and Chemical Analysis"", 1988, VCH, pages: 81 - 84",PENDING
978,US,A1,US 2019/0130762 A1,036-953-930-437-639,2019-05-02,2019,US 201816234495 A,2018-12-27,US 201816234495 A,2018-12-27,METHODS AND APPARATUS TO VALIDATE DATA COMMUNICATED BY A VEHICLE,"Methods, apparatus, systems and articles of manufacture are disclosed to validate data communicated by a vehicle. An example apparatus an anomaly detector to, in response to data communicated by a vehicle, at least one of compare an estimated speed with a reported speed or compare a location of the vehicle with a reported location. The apparatus including the anomaly detector further to generate an indication of the vehicle in response to the comparison. The apparatus further includes a notifier to discard data sent by the vehicle and notify surrounding vehicles of the data communicated by the vehicle.",INTEL CORP,YANG LIUYANG;;YONA YAIR;;AMBROSIN MORENO;;LIU XIRUO;;NIKOPOUR HOSEIN;;TALWAR SHILPA;;SIVANESAN KATHIRAVETPILLAI;;SHARMA SRIDHAR;;CHOUDHURY DEBABANI;;CHEN KUILIN CLARK;;OTA JEFFREY;;GOTTSCHLICH JUSTIN,INTEL CORPORATION (2018-12-17),https://lens.org/036-953-930-437-639,Patent Application,yes,3,12,5,5,0,H04W12/12;;H04W4/40;;G01S5/0072;;G01S11/10;;H04K3/20;;G08G1/163;;H04K3/65;;H04K2203/22;;G01S5/0244;;G01S5/0246;;G08G1/20;;G01S5/14;;H04W4/40;;G08G1/052;;H04W12/12;;G01S5/0246;;G01S5/0244,G01S5/14;;G08G1/00;;G08G1/052;;H04W4/40,,0,0,,,,ACTIVE
979,US,A1,US 2015/0080412 A1,077-946-431-277-812,2015-03-19,2015,US 201314383096 A,2013-03-07,US 201314383096 A;;US 201261608961 P;;US 2013/0029713 W,2012-03-09,TRIAZOLONE COMPOUNDS AND USES THEREOF,"The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER;;TRUONG YEN PHAM,INCEPTION SCIENCES INC (2014-09-15);;TEMPEST THERAPEUTICS INC (2014-09-16),https://lens.org/077-946-431-277-812,Patent Application,yes,0,3,6,6,0,A61K31/4196;;A61K31/4439;;A61P31/14;;A61P35/00;;C07D249/12;;C07D249/12;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/12;;C07D401/12;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/10;;C07D405/10;;C07D405/14;;C07D405/14;;C07D409/06;;C07D409/06;;C07D409/10;;C07D409/10;;C07D413/10;;C07D413/10;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14,C07D249/12;;C07D401/10;;C07D401/14;;C07D403/10;;C07D405/10;;C07D409/10;;C07D413/10;;C07D417/14,514/255.05;;548/263.2;;514/384;;546/272.4;;514/340;;548/233;;514/377;;548/253;;514/381;;514/333;;546/256;;544/327;;514/256;;544/405,0,0,,,,INACTIVE
980,HU,A2,HU P0402577 A2,162-981-784-485-742,2005-03-29,2005,HU P0402577 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,"INDOLE DERIVATIVES AS INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2, PROCESS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM","A találmány tárgyát az (I) általános képletű helyettesítettindolszármazékok és gyógyászati szempontból elfogadható sóik képezik,valamint ezen vegyületek alkalmazása olyan betegségek kezeléséreszolgáló gyógyászati készítmények előállítására, amelyeknél különfélefoszfolipáz enzimek, különösen foszfolipáz A2 enzimek gátlásaszükséges, különösen gyulladás és fájdalom kezelésére, megelőzésérevagy gátlására szolgáló gyógyszerek előállítására. Ó",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/162-981-784-485-742,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,A61K31/4045;;C07D491/113;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,DISCONTINUED
981,US,B2,US 11024180 B2,062-038-977-225-995,2021-06-01,2021,US 201816234495 A,2018-12-27,US 201816234495 A,2018-12-27,Methods and apparatus to validate data communicated by a vehicle,"Methods, apparatus, systems and articles of manufacture are disclosed to validate data communicated by a vehicle. An example apparatus an anomaly detector to, in response to data communicated by a vehicle, at least one of compare an estimated speed with a reported speed or compare a location of the vehicle with a reported location. The apparatus including the anomaly detector further to generate an indication of the vehicle in response to the comparison. The apparatus further includes a notifier to discard data sent by the vehicle and notify surrounding vehicles of the data communicated by the vehicle.",INTEL CORP,YANG LIUYANG;;YONA YAIR;;AMBROSIN MORENO;;LIU XIRUO;;NIKOPOUR HOSEIN;;TALWAR SHILPA;;SIVANESAN KATHIRAVETPILLAI;;SHARMA SRIDHAR;;CHOUDHURY DEBABANI;;CHEN KUILIN CLARK;;OTA JEFFREY;;GOTTSCHLICH JUSTIN,INTEL CORPORATION (2018-12-17),https://lens.org/062-038-977-225-995,Granted Patent,yes,6,2,5,5,0,H04W12/12;;H04W4/40;;G01S5/0072;;G01S11/10;;H04K3/20;;G08G1/163;;H04K3/65;;H04K2203/22;;G01S5/0244;;G01S5/0246;;G08G1/20;;G01S5/14;;H04W4/40;;G08G1/052;;H04W12/12;;G01S5/0246;;G01S5/0244,H04W4/40;;G01S5/14;;G08G1/00;;G08G1/052;;H04W12/12,,9,5,108-977-653-255-672;;173-208-681-897-083;;030-264-726-451-28X;;029-139-169-930-668;;009-260-518-556-731,10.14722/ndss.2018.23222;;10.1109/milcom.2008.4753538;;10.1109/tac.2014.2303233;;10.1109/isit.2015.7282993;;10.1109/msp.2004.26,"SAE, “Dedicated short range communications (DSRC) message set dictionary support page,” [https://www.sae.org/standards/content/j2735_201603/] Tech. Rep. SAE J2735, Mar. 2016, retrieved on Feb. 21, 2017, 267 pages (Uploaded as NPL1-A, NPL1-B, NPL1-C).;;ETSI, “Intelligent transport systems (ITS); vehicular communications; basic set of applications; part 2: Specification of cooperative awareness basic service,” [https://www.etsi.org/deliver/etsi_en/302600_302699/30263702/01.03.02_60/en_30263702v010302p.pdf], Final draft ETSI EN 302 637-2 V1.3.1, Sep. 2014, 44 pages.;;Chen et al., . “Exposing Congestion Attack on Emerging Connected Vehicle based Traffic Signal Control.” [https://www.ndss-symposium.org/wp-content/uploads/2018/02/ndss2018_01B-2_Chen_paper.pdf], Network and Distributed Systems Security (NDSS) Symposium 2018, 15 pages.;;Zhou et al., “A Novel method of Doppler shift estimation for OFDM systems,” [https://www.researchgate.net/publication/224372655_A_novel_method_of_Doppler_shift_estimation_for_OFDM_systems], pp. 1-7, MILCOM 2008-2008 IEEE Military Communications Conference, Dec. 2008, 8 pages.;;Fawzi et al., “Secure Estimation and Control for Cyber-Physical Systems Under Adversarial Attacks,” [https://arxiv.org/pdf/1205.5073.pdf], IEEE Transactions on Automatic Control, May 24, 2014, 32 pages.;;Mishra et al., “Secure state estimation: optimal guarantees against sensor attacks in the presence of noise,” [http://licos.ee.ucla.edu/lib/exe/fetch.php/papers:sse_mskdt.pdf?cache=], 2015 IEEE International Symposium on Information Theory (ISIT), pp. 2929-2933, Apr. 23, 2015, 5 pages.;;Capkun et al., “Secure Positioning in Wireless Networks,” IEEE Journal on Selected Areas in Communications, vol. 24, Issue 2, Feb. 2006, 13 pages.;;Rasmussen et al., “Realization of RF Distance Bounding,” [https://www.researchgate.net/publication/221260527], Proceedings of the USENIX Security Symposium, Sep. 2010, pp. 389-402, 14 pages.;;Hubaux et al., “The Security and Privacy of Smart Vehicles,” [https://www.researchgate.net/publication/3437601_The_Security_and_Privacy_of_Smart_Vehicles], IEEE Security & Privacy May/Jun. 2004, pp. 49-55, 7 pages.",ACTIVE
982,EP,B1,EP 2822931 B1,083-508-869-913-964,2017-05-03,2017,EP 13758171 A,2013-03-07,US 201261608961 P;;US 2013/0029713 W,2012-03-09,TRIAZOLONE COMPOUNDS AND USES THEREOF,,INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER;;TRUONG YEN PHAM,,https://lens.org/083-508-869-913-964,Granted Patent,yes,4,0,6,6,0,A61K31/4196;;A61K31/4439;;A61P31/14;;A61P35/00;;C07D249/12;;C07D249/12;;C07D401/06;;C07D401/06;;C07D401/10;;C07D401/10;;C07D401/12;;C07D401/12;;C07D401/14;;C07D401/14;;C07D403/10;;C07D403/10;;C07D405/10;;C07D405/10;;C07D405/14;;C07D405/14;;C07D409/06;;C07D409/06;;C07D409/10;;C07D409/10;;C07D413/10;;C07D413/10;;C07D417/10;;C07D417/10;;C07D417/14;;C07D417/14,C07D249/12;;A61K31/4196;;A61P31/14;;A61P35/00;;C07D401/10;;C07D401/12;;C07D409/06;;C07D417/10,,4,0,,,"ALAA A. MOENES ET AL: ""Synthesis and antimicrobial activity of certain pyridazines"", ALEXANDRIA JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 10, 2007, pages 35-38, XP009184966, ISSN: 1110-1792;;SOLIMAN F: ""Heterocyclic synthesis with biologically active S-(6-aryl pyridazin 3-yl) thioglycollic acid hydrazides"", EGYPTIAN JOURNAL OF CHEMISTRY, NATIONAL INFORMATION AND DOCUMENTATION CENTRE (NIDOC), CAIRO; EG, vol. 50, no. 4, 1 January 2007 (2007-01-01), pages 443-453, XP009184917, ISSN: 0449-2285;;AMMAZZALORSO, A. ET AL.: 'Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARa antagonist' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 21, 2011, pages 4869 - 4872, XP028247205;;XU, Y. ET AL.: 'Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor alpha agonist' JOURNAL OF MEDICINAL CHEMISTRY vol. 46, 2003, pages 5121 - 5124, XP002299289",ACTIVE
983,AU,A1,AU 2002/351182 A1,084-608-999-481-818,2003-06-17,2003,AU 2002/351182 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,BEHNKE MARK LEO;;HU BAIHUA;;MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH,"NOVARTIS AG (2022-08-25);;ZIARCO, INC. (2016-11-03)",https://lens.org/084-608-999-481-818,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
984,TW,B,TW I334778 B,114-247-583-342-289,2010-12-21,2010,TW 91134928 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,Inhibitors of cytosolic phospholipase a2,,WYETH CORP,JOHN CAEDMON MCKEW;;STEVE YIK-KAI TAM;;JAMES DONALD CLARK;;KATHERINE LIN LEE;;LIHREN CHEN;;PARESH THAKKER;;FUK-WAH SUM;;MARK LEO BEHNKE;;HU BAIHUA,,https://lens.org/114-247-583-342-289,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,A61K31/4045;;C07D491/113;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
985,EP,A2,EP 1451154 A2,074-046-604-701-00X,2004-09-01,2004,EP 02786829 A,2002-12-02,US 0238311 W;;US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,"ZIARCO PHARMA LTD., GB (2019-11-13);;ZIARCO PHARMA LIMITED; GB (2020-03-27)",https://lens.org/074-046-604-701-00X,Patent Application,yes,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;C07D491/113;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
986,CA,C,CA 2469138 C,094-776-862-232-648,2012-04-17,2012,CA 2469138 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides substituted indole compounds of the general formula: (I) and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/094-776-862-232-648,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;C07D491/113;;A61K31/404;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/00;;C07D221/00;;C07D307/00;;C07D317/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
987,DE,A1,DE 102020204476 A1,162-701-584-758-153,2020-12-31,2020,DE 102020204476 A,2020-04-07,US 201916456864 A,2019-06-28,NOTFALLDATENSAMMLUNG IN EINEM INFORMATIONSZENTRISCHEN NETZWERK,"Es werden hier Systeme und Techniken zur Notfall-Datensammlung in informationszentrischen Netzwerken (ICN) beschrieben. Zum Beispiel kann ein Ereignis-Abdeckungsgebiet gemessen werden. Es kann ein Interessepaket gesendet werden, um Knoten in dem Abdeckungsgebiet abzubilden. In einem Beispiel spezifiziert das Interessepaket einen Gruppenpräfix. Eine Gruppe von Knoten, die auf das Interessepaket antworten, kann als Ereignisdetektionsknoten ausgewählt werden. Dann kann ein Ereignissubskriptions-Interessepaket zu den Ereignisdetektionsknoten gesendet werden.",INTEL CORP,SIVANESAN KATHIRAVETPILLAI;;CHEN KUILIN CLARK;;SMITH NED M;;VANNITHAMBY RATH;;ALAM S M IFTEKHARUL;;JHA SATISH;;SRIKANTESWARA SRIKATHYAYANI;;NALLAMPATTI EKAMBARAM VENKATESAN;;ZHANG YI;;DING ZONGRUI,,https://lens.org/162-701-584-758-153,Patent Application,no,0,1,4,4,0,H04W4/44;;H04W4/46;;H04W4/06;;H04W4/90;;H04W40/02;;H04W40/20;;H04W40/22;;H04W4/44;;H04W4/90;;H04L41/0803;;H04L41/0893;;H04L67/12;;H04L41/0803;;H04L47/82;;H04L43/08;;H04L67/55,G06F16/9537,,0,0,,,,PENDING
988,TW,A,TW 200301695 A,038-387-288-436-354,2003-07-16,2003,TW 91134928 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,Inhibitors of cytosolic phospholipase A2,"This invention provides substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;PARESH THAKKER;;FUK-WAH SUM;;MARK LEO BEHNKE;;HU BAIHUA,,https://lens.org/038-387-288-436-354,Patent of Addition,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
989,CA,A1,CA 2469138 A1,078-254-193-738-482,2003-06-12,2003,CA 2469138 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides substituted indole compounds of the general formula: (I) and pharmaceutically acceptable salt forms thereof, and methods for usin g the compounds as inhibitors of the activity of various phospholipase enzymes , particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,THAKKER PARESH;;TAM STEVE YIK-KAI;;MCKEW JOHN CAEDMON;;BEHNKE MARK LEO;;SUM FUK-WAH;;LEE KATHERINE LIN;;CLARK JAMES DONALD;;CHEN LIHREN;;HU BAIHUA,,https://lens.org/078-254-193-738-482,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
990,DK,T3,DK 1451154 T3,088-730-451-007-98X,2008-05-19,2008,DK 02786829 T,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,Inhibitorer af cytosolisk phospholipase A2,,WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;THAKKER PARESH;;BEHNKE MARK LEO;;HU BAIHUA;;SUM FUK-WAH;;CHEN LIHREN,,https://lens.org/088-730-451-007-98X,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;A61K31/404;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
991,WO,A2,WO 2003/048122 A2,161-580-084-214-251,2003-06-12,2003,US 0238311 W,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,"This invention provides substituted indole compounds of the general formula: (I) and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/161-580-084-214-251,Patent Application,yes,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,A61K31/4045;;C07D491/113;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,PATENTED
992,US,B2,US 9505728 B2,165-875-927-341-114,2016-11-29,2016,US 201314383096 A,2013-03-07,US 201314383096 A;;US 201261608961 P;;US 2013/0029713 W,2012-03-09,Triazolone compounds and uses thereof,"The invention disclosed herein is directed to compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein is also directed to a methods of preventing the onset of and/or recurrence of acute and chronic myeloid leukemia, as well as other cancers, comprising administration of a of a therapeutically effective amount of a selective PPARα antagonist.",INCEPTION 2 INC,STOCK NICHOLAS SIMON;;CHEN AUSTIN CHIH-YU;;BRAVO YALDA MOSTOFI;;JACINTHO JASON DUARTE;;BACCEI JILL MELISSA;;STEARNS BRIAN ANDREW;;CLARK RYAN CHRISTOPHER;;TRUONG YEN PHAM,INCEPTION SCIENCES INC (2014-09-15);;TEMPEST THERAPEUTICS INC (2013-03-07),https://lens.org/165-875-927-341-114,Granted Patent,yes,99,2,6,6,0,C07D401/10;;C07D401/14;;C07D405/14;;C07D401/06;;C07D403/10;;C07D405/10;;C07D409/10;;C07D413/10;;C07D417/14;;C07D401/12;;C07D409/06;;C07D417/10;;C07D249/12;;A61P31/14;;A61P35/00;;A61K31/4196;;A61K31/4439;;C07D401/12;;C07D409/06;;C07D417/10;;C07D401/10;;C07D401/14;;C07D405/14;;C07D401/06;;C07D403/10;;C07D405/10;;C07D409/10;;C07D413/10;;C07D417/14;;C07D249/12,A61K31/4196;;A61K31/4439;;C07D249/12;;C07D401/06;;C07D401/10;;C07D401/12;;C07D401/14;;C07D403/10;;C07D405/10;;C07D405/14;;C07D409/06;;C07D409/10;;C07D413/10;;C07D417/10;;C07D417/14,,27,17,008-626-626-600-450;;142-741-599-093-036;;147-149-448-374-286;;058-495-863-605-294;;002-115-236-048-709;;083-860-889-470-294;;139-248-440-904-768;;013-832-054-656-210;;067-117-598-067-277;;114-295-506-012-872;;046-117-273-487-917;;051-557-225-802-425;;049-932-762-286-948;;056-408-192-066-881;;010-146-155-505-826;;034-176-252-756-14X;;036-259-871-752-187,21742490;;10.1016/j.bmcl.2011.06.028;;10.1021/op8002486;;10.1021/op700040v;;10.1002/jlcr.1395;;pmc2968207;;10.1107/s1600536809002840;;21581982;;21582015;;10.1107/s1600536809002815;;pmc2968336;;21581039;;10.1107/s1600536808033990;;pmc2959665;;pmc2746746;;10.1161/atvbaha.108.171223;;18988892;;10.3987/com-08-11478;;10.1007/s00706-009-0210-y;;10.1021/jm034173l;;14613314;;10.2174/1568026033451673;;14683520;;10.1016/j.tetlet.2005.09.073;;10.1007/bf00945649;;10.1002/ardp.201000002;;20803621;;10.1007/s10593-007-0176-9;;10.1016/j.bmcl.2014.03.090;;24745969,"Ammazzalorso et al., Bioorg. Med. Chem. Lett. 21:4869-4872 (2011).;;Argentine et al., The Role of New Technologies in Defining a Manufacturing Process for PPARalpha Agonist LY518674, Organic Process Research & Development, 13(2):131-143 (2009).;;Braden et al., A Convergent Kilogram-Scale Synthesis of the PPARalpha Agonist LY518674: Discovery of a Novel Acid-Mediated Triazolone Synthesis, Organic Process Research & Development, 11(3):431-440 (2007).;;Kuo et al., The synthesis of three isotopomers of 2-methyl-2-(4-[3-[1-(4-methylbenzyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]propyl]phenoxy)propionic acid, a potent and selective peroxisome proliferator-activated receptor alpha agonist, Journal of Labelled Compounds and Radiopharmaceuticals, 50(8):693-701 (2007).;;Girard, Tautomeric oxotriazoles and hydroxytriazoles. A new method for the preparation of hydroxy-1,2,4-triazoles, Compt rend. 212:547-549 (1941).;;Hanif et al., 4-(3-Methoxyphenyl)-3-[2-(4-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-one, Acta Crystallographica, Section E: Structure Reports Online, 2009, E65(2), o387.;;Hanif et al., 4-(4-Methoxyphenyl)-3-[2-(2-methoxyphenyl)ethyl]-1H-1,2,4-triazol-5(4H)-one, Acta Crystallographica, Section E: Structure Reports Online, 2009, E65(2), o429.;;Hanif et al., 5-(3-Methoxyphenethyl)-4-(2-methoxyphenyl)-4H-1,2,4-triazol-3-ol, Acta Crystallographica, Section E: Structure Reports Online, 2008, E64(11), o2180, o2180/1-o2180/9.;;Millar et al., Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome, Arteriosclerosis, Thrombosis, and Vascular Biology, 29(1):140-146 (2009).;;Rao et al., Synthesis of substituted 2,4-dihydro[1,2,4]-triazol-3-ones, Indian Journal of Heterocyclic Chemistry 20(1):9-12 (2010).;;Tumosiene et al., Synthesis of azole derivatives from 3-phenylaminopropanohydrazide and evaluation of their antimicrobial efficacy, Heterocycles, 78(1):59-70 (2009).;;Tumosiene et al., Synthesis of azoles from 3,3'-[(4-alkoxyphenyl)imino]bis(propanoic acid hydrazides), Monatshefte fuer Chemie, 140(12):1523-1528 (2009).;;Tutoveanu et al., New semi- and thiosemicarbazides and cyclization products, Revistade Chimie (Bucharest, Romania) 24(3):155-158 (1973).;;Xu et al., Journal of Medicinal Chemistry 46:5121-5124 (2003).;;Etgen et al., 2003, PPAR ligands for metabolic disorders, Current Topics in Medicinal Chemistry, 3:1649-1661.;;Moenes et al., Feb. 1996, Synthesis and antimicrobial activity of certain pyridazines, Alex. J. Pharm. Sci., 10(1):35-38.;;Soliman et al., 2007, Heterocyclic synthesis with biologically active S-(6-aryl pyridazin 3-yl) thioglycollic acid hydrazides, Egypt. J. Chem. 50(4):443-453.;;Extended European Search report dated Jul. 16, 2015 in patent application No. 13758171.6.;;Deng et al. A novel and efficient synthesis of 2,5-substituted 1,2,4-triazol-3-ones. Tetrahedron Letters 46(46):7993-7996 (2005).;;Goldin et al. Synthesis of triazolones and c-aminotriazoles by thermal condensation of carbamidoamidrazones. Chemistry of Heterocyclic Compounds 10(4):489-490 (1974).;;PCT/US2013/029713 International Preliminary Report on Patentability dated Sep. 9, 2014.;;PCT/US2013/029713 International Search Report dated Jun. 28, 2013.;;Rashad et al. Synthesis of new quinoline derivatives as inhibitors of human tumor cells growth. Archiv der Pharmazie (Weinheim, Germany) 343(8):440-448 (2010).;;Tumosiene et al. Synthesis of azoles from 3,3'-(arylimino)bis[propanoyl hydrazides]. Chemistry of Heterocyclic Compounds (New York, NY, United States) 43(9):1148-1153 (2007).;;Zakaria et al. Synthesis of some new 3-mercapto-5-substituted-1,2,4-triazine-s-triazoles for evaluation as antimicrobial agents. Journal of Chemical Technology and Biotechnology 63(2):135-140 (1995).;;Bravo et al., Identification of the first potent, selective and bioavailable PPARalpha antagonist, Bioorg. Med. Chem. Lett. 24:2267-2272 (2014).;;Messmer et al., Abstract of Papers, 54th Meeting of the American Society of Hematology, Atlanta, GA, 2012; Abstract 3879.",INACTIVE
993,US,A1,US 2021/0304613 A1,088-650-578-638-017,2021-09-30,2021,US 202117227191 A,2021-04-09,US 202117227191 A;;US 201816234495 A,2018-12-27,METHODS AND APPARATUS TO VALIDATE DATA COMMUNICATED BY A VEHICLE,"Methods, apparatus, systems and articles of manufacture are disclosed to validate data communicated by a vehicle. An example apparatus an anomaly detector to, in response to data communicated by a vehicle, at least one of compare an estimated speed with a reported speed or compare a location of the vehicle with a reported location. The apparatus including the anomaly detector further to generate an indication of the vehicle in response to the comparison. The apparatus further includes a notifier to discard data sent by the vehicle and notify surrounding vehicles of the data communicated by the vehicle.",INTEL CORP,YANG LIUYANG;;YONA YAIR;;AMBROSIN MORENO;;LIU XIRUO;;NIKOPOUR HOSEIN;;TALWAR SHILPA;;SIVANESAN KATHIRAVETPILLAI;;SHARMA SRIDHAR;;CHOUDHURY DEBABANI;;CHEN KUILIN CLARK;;OTA JEFFREY;;GOTTSCHLICH JUSTIN,INTEL CORPORATION (2018-12-17),https://lens.org/088-650-578-638-017,Patent Application,yes,10,0,5,5,0,H04W12/12;;H04W4/40;;G01S5/0072;;G01S11/10;;H04K3/20;;G08G1/163;;H04K3/65;;H04K2203/22;;G01S5/0244;;G01S5/0246;;G08G1/20;;G01S5/14;;H04W4/40;;G08G1/052;;H04W12/12;;G01S5/0246;;G01S5/0244,G08G1/00;;G01S5/14;;G08G1/052;;H04W4/40,,0,0,,,,ACTIVE
994,AU,B2,AU 2002/351182 B2,164-025-219-410-716,2009-01-15,2009,AU 2002/351182 A,2002-12-02,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P;;US 0238311 W,2001-12-03,Inhibitors of cytosolic phospholipase A2,,NOVARTIS AG,CHEN LIHREN;;MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;LEE KATHERINE LIN;;SUM FUK-WAH;;HU BAIHUA;;CLARK JAMES DONALD;;BEHNKE MARK LEO;;THAKKER PARESH,"NOVARTIS AG (2022-08-25);;ZIARCO, INC. (2016-11-03)",https://lens.org/164-025-219-410-716,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
995,EC,A,EC SP045131 A,012-515-320-563-389,2004-07-23,2004,EC SP045131 A,2004-06-03,US 33458801 P;;US 33459101 P;;US 33460501 P;;US 41966402 P,2001-12-03,INHIBIDORES DE FOSFOLIPASA A2 CITOSÓLICA,"Esta invención proporciona compuestos de indol sustituidos de la fórmula general: (I) y formas de sal farmacéuticamente aceptables de la misma, y un método para usar los compuestos como inhibidores de la actividad de varias enzimas fosfolipasa, particularmente enzimas fosfolipasa A2 y para el tratamiento médico, prevención e inhibición de dolor e inflamación.",LEE KATHERINE LIN,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/012-515-320-563-389,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,A61K31/4045;;C07D491/113;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,PENDING
996,CN,A,CN 101628888 A,046-841-164-267-947,2010-01-20,2010,CN 200910140888 A,2002-12-02,US 33460501 P;;US 33459101 P;;US 33458801 P;;US 41966402 P,2001-12-03,Inhibitors of cytosolic phospholipase a2,"This invention provides substituted indole compounds of the general formula: (I) and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,CAEDMON MCKEW JOHN;;VIK-KAI TAM STEVE;;DONALD CLARK JAMES;;LIN LEE KATHERINE;;LIHREN CHEN;;OARESH THAKKER;;FUK-WAH SUM;;LEO BEHNKE MARK;;BAIHUA HU,,https://lens.org/046-841-164-267-947,Patent Application,no,0,3,5,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P29/00;;C07D209/14;;C07D409/12;;C07D401/12;;C07D413/14;;C07D403/12;;C07D417/14;;C07D405/12;;C07D413/12;;C07D417/12;;C07D487/08;;C07D491/10,C07D209/14;;A61P29/00;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10,,0,0,,,,EXPIRED
997,EP,B1,EP 1451154 B1,092-992-991-356-923,2008-01-16,2008,EP 02786829 A,2002-12-02,US 0238311 W;;US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,"ZIARCO PHARMA LTD., GB (2019-11-13);;ZIARCO PHARMA LIMITED; GB (2020-03-27)",https://lens.org/092-992-991-356-923,Granted Patent,yes,2,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;A61K31/404;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
998,IN,A,IN 312KO2005 A,105-726-361-773-798,2015-08-14,2015,IN 312KO2005 A,2005-04-12,US 33458801 P;;US 33460501 P;;US 33459101 P;;US 41966402 P,2001-12-03,A PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOUND,"This invention provides substituted indole compounds of the general formula: (I) and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/105-726-361-773-798,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;C12P21/06;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,PENDING
999,PT,E,PT 1451154 E,134-134-832-598-862,2008-04-21,2008,PT 02786829 T,2002-12-02,US 33458801 P;;US 33459101 P;;US 33460501 P;;US 41966402 P,2001-12-03,INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2,,WYETH CORP,SUM FUK-WAH;;MCKEW JOHN CAEDMON;;TAM STEVE YIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER PARESH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/134-134-832-598-862,Granted Patent,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D209/14;;A61K31/404;;C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/08;;C07D491/10;;C07D498/18,,0,0,,,,EXPIRED
1000,BR,A,BR 0214672 A,172-637-226-838-46X,2004-10-19,2004,BR 0214672 A,2002-12-02,US 33458801 P;;US 33459101 P;;US 33460501 P;;US 41966402 P;;US 0238311 W,2001-12-03,Inibidores de fosfolipase citosólica a2,"""INIBIDORES DE FOSFOLIPASE CITOSóLICA A2"". A presente invenção refere-se a compostos indol substituídos de fórmula geral (I) (I) e formas de sal farmaceuticamente aceitáveis do mesmo e métodos para usar os compostos como inibidores da atividade de várias enzimas fosfolipase, particularmente enzimas fosfolipase A~ 2~ e para o tratamento médico, prevenção e inibição de dor e inflamação.",WYETH CORP,MCKEW JOHN CAEDMON;;TAM STEVE VIK-KAI;;CLARK JAMES DONALD;;LEE KATHERINE LIN;;CHEN LIHREN;;THAKKER OARESH;;SUM FUK-WAH;;BEHNKE MARK LEO;;HU BAIHUA,,https://lens.org/172-637-226-838-46X,Patent Application,no,0,0,40,64,0,C07D209/14;;C07D401/12;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;A61P11/00;;A61P11/06;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D209/16;;C07D403/12;;C07D413/14;;C07D401/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D417/12;;A61K31/404,C07D491/113;;A61K31/4045;;A61K31/41;;A61K31/4155;;A61K31/417;;A61K31/4178;;A61K31/4192;;A61K31/4196;;A61K31/4245;;A61K31/427;;A61K31/438;;A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/537;;A61K31/5377;;A61K31/541;;A61P11/06;;A61P19/02;;A61P25/04;;A61P29/00;;A61P43/00;;C07D209/14;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/12;;C07D409/12;;C07D413/12;;C07D413/14;;C07D417/12;;C07D417/14;;C07D487/08;;C07D491/10;;C07D498/18,,0,0,,,,DISCONTINUED
